ObjId,DocumentType,DocId,DocketId,Title
09000064816b083a,Other,FDA-2013-N-0590-0002,FDA-2013-N-0590,"Memo to DDM Re. on Implementation of the Food and Drug Administration Food Safety Modernization Act Amendments to the Reportable Food Registry Provisions of the Federal Food, Drug, and Cosmetic Act"
0900006481681990,Proposed Rule,FDA-2013-N-0590-0001,FDA-2013-N-0590,"Implementation of the Food and Drug Administration Food Safety
Modernization Act Amendments to the Reportable Food Registry Provisions of the Federal Food, Drug, and Cosmetic Act"
090000648174fb4f,Proposed Rule,FDA-2013-N-0590-0003,FDA-2013-N-0590,"Implementation of the Food and Drug Administration Food Safety
Modernization Act Amendments to the Reportable Food Registry Provisions of the Federal Food, Drug, and Cosmetic Act; Reopening of Comment Period"
0900006482581c20,Notice,FDA-2017-N-1393-0001,FDA-2017-N-1393,Government-Owned Inventions; Availability for Licensing
090000648214c3fa,Supporting & Related Material,FDA-2011-F-0171-0279,FDA-2011-F-0171,Reference 3 - FDA FRIA July 2016 FINAL re Food Labeling; Calorie Labeling of Articles of Food in Vending Machines; Extension of Compliance Date
0900006482178a99,Notice,FDA-2011-F-0171-0280,FDA-2011-F-0171,"Calorie Labeling of Articles of Food in Vending Machines: Guidance for
Industry; Small Entity Compliance Guide; Availability"
0900006481951d17,Supporting & Related Material,FDA-2011-F-0171-0200,FDA-2011-F-0171,"Reference - 6 “2012 Census of the Industry,” Vending Times, 2012; 52(12) re Food Labeling; Calorie Labeling of Articles of Food in Vending Machines"
090000648217ac1b,Other,FDA-2011-F-0171-0283,FDA-2011-F-0171,Calorie Labeling of Articles of Food in Vending Machines: Guidance for Industry; Draft Guidance
0900006480c1cfbc,Proposed Rule,FDA-2011-F-0171-0001,FDA-2011-F-0171,Food Labeling: Calorie Labeling of Articles of Food in Vending Machines
0900006480fac182,Other,FDA-2011-F-0171-0251,FDA-2011-F-0171,"FDA/OC/OP to Division of Dockets Management - OMB Review, Executive Order 12866, Food Labeling; Calorie Labeling of Articles of Food in Vending Machines, Proposed Rule Published 4/6/2011 - Memorandum"
09000064819516e4,Supporting & Related Material,FDA-2011-F-0171-0193,FDA-2011-F-0171,"Reference 1- FDA/CFSAN, “Food Labeling: Calorie Labeling of Articles of Food in Vending Machines, Regulatory Impact Analysis,” 2014 re Food Labeling; Calorie Labeling of Articles of Food in Vending Machines"
09000064819516e5,Supporting & Related Material,FDA-2011-F-0171-0194,FDA-2011-F-0171,"Reference 2- FDA/CFSAN, “Food Labeling: Calorie Labeling of Articles of Food in Vending Machines NPRM, Preliminary Regulatory Impact Analysis,”  re Food Labeling; Calorie Labeling of Articles of Food in Vending Machines"
09000064819516e7,Supporting & Related Material,FDA-2011-F-0171-0196,FDA-2011-F-0171,"Reference 4 - Memo to File. Correspondence with Eric Dell of the National Automatic Merchandising Association. April 13, 2013 re Food Labeling; Calorie Labeling of Articles of Food in Vending Machines"
0900006481951d18,Supporting & Related Material,FDA-2011-F-0171-0198,FDA-2011-F-0171,"Reference 7- ""2012 State of the Vending Industry Report, 2013,” Automatic Merchandiser re Food Labeling; Calorie Labeling of Articles of Food in Vending Machines"
0900006481951d19,Supporting & Related Material,FDA-2011-F-0171-0199,FDA-2011-F-0171,Reference 8 - National Automatic Merchandising Association. Comments of: The National Automatic Merchandising Association. Docket No. FDA-2010-N-0298. 2010 re Food Labeling; Calorie Labeling of Articles of Food in Vending Machines
0900006481973980,Supporting & Related Material,FDA-2011-F-0171-0207,FDA-2011-F-0171,"Tab C Final Rule Impact Analysis, Final Regulatory Action as Cleared by OIRA re Food Labeling; Calorie Labeling of Articles of Food in Vending Machines (Final Rule); Publication Date: December 1, 2014"
0900006480c19867,Supporting & Related Material,FDA-2011-F-0171-0005,FDA-2011-F-0171,"Reference 2 -  ""Food and Drug Administration, Food Labeling Guide"" - [Food Labeling; Food Labeling; Calorie Labeling of Articles of Food in Vending Machines; Proposed Rule] re FDA-2011-F-0171-0001"
0900006480c19ccc,Supporting & Related Material,FDA-2011-F-0171-0011,FDA-2011-F-0171,"Reference List - [Preliminary Regulatory Impact Analysis, March 2011, Food Labeling; Food Labeling; Calorie Labeling of Articles of Food in Vending Machines; Proposed Rule, re FDA-2011-F-0171-0001]"
0900006480c1a0ec,Supporting & Related Material,FDA-2011-F-0171-0020,FDA-2011-F-0171,"Reference 39 - ""U.S. Census Bureau, Statistical Abstract of the United States: 2011"" - [Preliminary Regulatory Impact Analysis, March 2011, Food Labeling; Food Labeling; Calorie Labeling of Articles of Food in Vending Machines; Proposed Rule, re FDA-2011-F-0171-0001]"
090000648214c3f7,Supporting & Related Material,FDA-2011-F-0171-0276,FDA-2011-F-0171,"Reference 1 - Letter from Karin F. R. Moore from GMA March 2016 re Food Labeling; Calorie Labeling of Articles of Food in Vending Machines;
Extension of Compliance Date"
090000648217a73b,Other,FDA-2011-F-0171-0282,FDA-2011-F-0171,Guidance for Industry Calorie Labeling of Articles of Food in Vending Machines - Small Entity Compliance Guide
090000648197397f,Supporting & Related Material,FDA-2011-F-0171-0206,FDA-2011-F-0171,"Tab B Final Rule Impact Analysis (FRIA) Substantive Changes Between the Draft Submitted to OIRA for Review and the Regulatory Action Subsequently Cleared by OIRA re Food Labeling; Calorie Labeling of Articles of Food in Vending Machines (Final Rule); Publication Date: December 1, 2014"
090000648214c3f9,Supporting & Related Material,FDA-2011-F-0171-0278,FDA-2011-F-0171,"Reference 2a - Attachment to Letter from Karin Moore of GMA June 2016 re Food Labeling; Calorie Labeling of Articles of Food in Vending Machines;
Extension of Compliance Date"
0900006482178bd6,Notice,FDA-2011-F-0171-0281,FDA-2011-F-0171,"Calorie Labeling of Articles of Food in Vending Machines; Draft Guidance for
Industry; Availability"
0900006480c19866,Supporting & Related Material,FDA-2011-F-0171-0004,FDA-2011-F-0171,"Reference 1 -  ""Merriam Webster Collegiate Dictionary, Tenth Edition, 1993"" - [Food Labeling; Food Labeling; Calorie Labeling of Articles of Food in Vending Machines; Proposed Rule] re FDA-2011-F-0171-0001"
0900006480c19865,Supporting & Related Material,FDA-2011-F-0171-0003,FDA-2011-F-0171,"Reference List - ""Vending Machine Labeling"" - [Food Labeling; Food Labeling; Calorie Labeling of Articles of Food in Vending Machines; Proposed Rule] re FDA-2011-F-0171-0001"
0900006480c19881,Supporting & Related Material,FDA-2011-F-0171-0009,FDA-2011-F-0171,"Reference 28 - ""Eastern Research Group, Inc., Evaluation of Recordkeeping Costs for Food Manufacturers, Final Report” "" - [Food Labeling; Food Labeling; Calorie Labeling of Articles of Food in Vending Machines; Proposed Rule] re FDA-2011-F-0171-0001"
0900006480c19ccb,Supporting & Related Material,FDA-2011-F-0171-0010,FDA-2011-F-0171,"Preliminary Regulatory Impact Analysis, March 2011, Food Labeling; Food Labeling; Calorie Labeling of Articles of Food in Vending Machines; Proposed Rule, re FDA-2011-F-0171-0001"
0900006480c1a0c8,Supporting & Related Material,FDA-2011-F-0171-0013,FDA-2011-F-0171,"Reference 3 - ""U.S. Small Business Administration, Table of Small Business Size Standards Matched to North American Industry Classification System Codes,” Effective November 5, 2010"" - [Preliminary Regulatory Impact Analysis, March 2011, Food Labeling; Food Labeling; Calorie Labeling of Articles of Food in Vending Machines; Proposed Rule, re FDA-2011-F-0171-0001]"
0900006481fdeb39,Supporting & Related Material,FDA-2012-N-1210-0900,FDA-2012-N-1210,Reference Index for Revision of the Nutrition and Supplement Facts labels final rule re Food Labeling: Revision of the Nutrition and Supplement Facts Labels
0900006481fded9a,Supporting & Related Material,FDA-2012-N-1210-0953,FDA-2012-N-1210,Reference 17 Lifestyle Interventions to Reduce Cardiovascular Risk re Food Labeling: Revision of the Nutrition and Supplement Facts Labels
0900006481fdeda1,Supporting & Related Material,FDA-2012-N-1210-0946,FDA-2012-N-1210,"Reference 24 IOM DRI for Energy, Chapter 5 re Food Labeling: Revision of the Nutrition and Supplement Facts Labels"
0900006481fdeda2,Supporting & Related Material,FDA-2012-N-1210-0945,FDA-2012-N-1210,Reference 25 IOM DRIs - Guiding Principles for Nutrition re Food Labeling: Revision of the Nutrition and Supplement Facts Labels
0900006481fdee0a,Supporting & Related Material,FDA-2012-N-1210-0979,FDA-2012-N-1210,Reference 47 Association between omega-3 fatty a re Food Labeling: Revision of the Nutrition and Supplement Facts Labels
0900006481fdee0b,Supporting & Related Material,FDA-2012-N-1210-0978,FDA-2012-N-1210,Reference 48 Seafood Omega-3 Intake and risk of Coronary He re Food Labeling: Revision of the Nutrition and Supplement Facts Labels
0900006481fdee0e,Supporting & Related Material,FDA-2012-N-1210-0975,FDA-2012-N-1210,Reference 51 Long-chain omega-3 fatty acids eic re Food Labeling: Revision of the Nutrition and Supplement Facts Labels
0900006481fdee0f,Supporting & Related Material,FDA-2012-N-1210-0974,FDA-2012-N-1210,Reference 52 Scientific opinion Labelling reference intake re Food Labeling: Revision of the Nutrition and Supplement Facts Labels
0900006481fdee11,Supporting & Related Material,FDA-2012-N-1210-0972,FDA-2012-N-1210,"Reference 54 Dietary cholesterol from eggs increases the ratio of total cholesterol to high-density lipoprotein cholesterol in humans, a meta-analysis re Food Labeling: Revision of the Nutrition and Supplement Facts Labels"
0900006481fdee63,Supporting & Related Material,FDA-2012-N-1210-1028,FDA-2012-N-1210,Reference 110 Expert memo no1_5_11_16 re Food Labeling: Revision of the Nutrition and Supplement Facts Labels
0900006481fdf075,Supporting & Related Material,FDA-2012-N-1210-1148,FDA-2012-N-1210,Reference 162 Anthropometric reference data for c re Food Labeling: Revision of the Nutrition and Supplement Facts Labels
0900006481fdf07e,Supporting & Related Material,FDA-2012-N-1210-1140,FDA-2012-N-1210,Reference 170 FDA 2004 and 2005 Health and Diet Survey re Food Labeling: Revision of the Nutrition and Supplement Facts Labels
0900006481fdf131,Supporting & Related Material,FDA-2012-N-1210-0882,FDA-2012-N-1210,Reference 016-02 Reformulation Cost Model re Food Labeling: Revision of the Nutrition and Supplement Facts Labels
0900006481fdf135,Supporting & Related Material,FDA-2012-N-1210-0878,FDA-2012-N-1210,Reference 016-06 Out of Control: Visceral Influences on Behavior re Food Labeling: Revision of the Nutrition and Supplement Facts Labels
0900006481fdf13a,Supporting & Related Material,FDA-2012-N-1210-0926,FDA-2012-N-1210,"Reference 16-11 Do dietary intakes affect search for nutrient information
on food labels? re Food Labeling: Revision of the Nutrition and Supplement Facts Labels"
0900006481fdf141,Supporting & Related Material,FDA-2012-N-1210-0919,FDA-2012-N-1210,"Reference 16-18 Attention Capture and Transfer in Advertising: Brand, Pictorial, and Text-Size Effects re Food Labeling: Revision of the Nutrition and Supplement Facts Labels"
0900006481fdf18d,Supporting & Related Material,FDA-2012-N-1210-0911,FDA-2012-N-1210,Reference 16-26 Health with Special Feature on Socioeconomic Status and Health re Food Labeling: Revision of the Nutrition and Supplement Facts Labels
0900006481fdf190,Supporting & Related Material,FDA-2012-N-1210-0908,FDA-2012-N-1210,Reference 16-29 Status of Nutrition Labeling re Food Labeling: Revision of the Nutrition and Supplement Facts Labels
0900006481fdf5ba,Supporting & Related Material,FDA-2012-N-1210-1099,FDA-2012-N-1210,Reference 155 Ileal and faecal protein digesti re Food Labeling: Revision of the Nutrition and Supplement Facts Labels
0900006481fdf6b2,Supporting & Related Material,FDA-2012-N-1210-1157,FDA-2012-N-1210,Reference 208-The Requirement of Magnesium by the Normal Adu re Food Labeling: Revision of the Nutrition and Supplement Facts Labels
0900006481fdf6b6,Supporting & Related Material,FDA-2012-N-1210-1153,FDA-2012-N-1210,"Reference 212-Magnesium, nature's physiologic calcium blocke re Food Labeling: Revision of the Nutrition and Supplement Facts Labels"
0900006481fdf6b8,Supporting & Related Material,FDA-2012-N-1210-1207,FDA-2012-N-1210,Reference 214-Dorup-1993-Correlation between magnesium and p re Food Labeling: Revision of the Nutrition and Supplement Facts Labels
0900006481fdf6c0,Supporting & Related Material,FDA-2012-N-1210-1199,FDA-2012-N-1210,Reference 222-USDA_Labeling re Food Labeling: Revision of the Nutrition and Supplement Facts Labels
0900006481fdf6f3,Supporting & Related Material,FDA-2012-N-1210-1183,FDA-2012-N-1210,"Reference 238-IOM_DRI for Folate, Chapter 8 re Food Labeling: Revision of the Nutrition and Supplement Facts Labels"
0900006481fdf6f4,Supporting & Related Material,FDA-2012-N-1210-1182,FDA-2012-N-1210,"Reference 239-The Calcium Quandary, How Consumers Use Nutrit re Food Labeling: Revision of the Nutrition and Supplement Facts Labels"
090000648172d7b5,Supporting & Related Material,FDA-1995-N-0063-0140,FDA-1995-N-0063,Reference 52 Summary of Findings
090000648172d7c4,Supporting & Related Material,FDA-1995-N-0063-0145,FDA-1995-N-0063,Reference 57 Jensen and Jensen Invited Review Specialty Lipids for Infant Nutrition I. Milks and Formulas
090000648172d766,Supporting & Related Material,FDA-1995-N-0063-0114,FDA-1995-N-0063,Reference 26 No Material Submitted
090000648172d769,Supporting & Related Material,FDA-1995-N-0063-0117,FDA-1995-N-0063,Reference 29 Ronald F Tetzlaff GMP Documentation Requirements for Automated Systems Part 1
090000648172d770,Supporting & Related Material,FDA-1995-N-0063-0121,FDA-1995-N-0063,Reference 33 Salmonella Ealing Inspections Associated with Consumption of Infant Dired Milk
090000648172d7a2,Supporting & Related Material,FDA-1995-N-0063-0125,FDA-1995-N-0063,Reference 37 Farber and Peterkin Listeria Monocytogenes A Food Borne Pathogen
090000648172d7aa,Supporting & Related Material,FDA-1995-N-0063-0133,FDA-1995-N-0063,Reference 45 Jackson et al Control of Salmonellosis and Similar Foodborne Infections
090000648056cbdb,Supporting & Related Material,FDA-1995-N-0063-0007,FDA-1995-N-0063,Background Material from Unknown Submitter
090000648056cbe4,Supporting & Related Material,FDA-1995-N-0063-0008,FDA-1995-N-0063,Background Material from Unknown Submitter
090000648172d767,Supporting & Related Material,FDA-1995-N-0063-0115,FDA-1995-N-0063,Reference 27 IEEE Standard Glossary of Software Engineering Terminology
090000648172d76e,Supporting & Related Material,FDA-1995-N-0063-0119,FDA-1995-N-0063,"Reference 31 Ronald F Tetzlaff GMP Documentation Requirements for Automated Systems Part 3, FDA Inspections of Computerized Laboratory Systems"
090000648172de15,Supporting & Related Material,FDA-1995-N-0063-0155,FDA-1995-N-0063,Reference 69 Shenai et al Nutritional Balance Studies in Very Low-Birth- Weight Infants: Role of Soy Formula
090000648172de16,Supporting & Related Material,FDA-1995-N-0063-0156,FDA-1995-N-0063,Reference 70 Lindroth et al Rickets in Very Low Birthweight Infants
090000648174e748,Supporting & Related Material,FDA-1995-N-0063-0169,FDA-1995-N-0063,Reference 81 Minton et al Bone Mineral Content in Term and Preterm Appropriate-for-Gestational-Age Infants
090000648174e74f,Supporting & Related Material,FDA-1995-N-0063-0176,FDA-1995-N-0063,"Reference 88 Memorandum of Telephone Conversation between Ed puro, FDA, and Mary Hudtloff Dated March 15, 1994"
09000064817368eb,Supporting & Related Material,FDA-1995-N-0063-0051,FDA-1995-N-0063,"Reference 1 - FDA. Current Good Manufacturing Practices, Quality Control Procedures, Quality Factors, Notification Requirements, and Records and Reports, for Infant Formula. Regulatory Impact Analysis for Final Rule - Current Good Manufacturing Practices, Quality Control Procedures, Quality Factors, Notification Requirements, and Records and Reports, for Infant Formula"
090000648172d7c5,Supporting & Related Material,FDA-1995-N-0063-0159,FDA-1995-N-0063,Reference 58 Ziegler et al Cow Milk Feeding in Infancy: Further Observations on Blood Loss from the Gastrointestinal Tract
090000648172d7c7,Supporting & Related Material,FDA-1995-N-0063-0147,FDA-1995-N-0063,Reference 60 Infant Formula Act of 1980 Report by the Committee on Labor and Human Resources United States Senate
090000648056cb0f,Notice,FDA-1995-N-0063-0041,FDA-1995-N-0063,Agency Information Collection Activities: Proposed Collection; Extension
090000648056cb1b,Other,FDA-1995-N-0063-0045,FDA-1995-N-0063,Request for Extension of Comment Period from International Formula Council
090000648056cb75,Supporting & Related Material,FDA-1995-N-0063-0096,FDA-1995-N-0063,Attachment on Basis and Context  of Sample Growth Trial Protocol Comment from International Formula Council
090000648056cb73,Supporting & Related Material,FDA-1995-N-0063-0095,FDA-1995-N-0063,Attachment G Guidelines Concerning Notification and Testing of  Infant Formulas Comment from International Formula Council
090000648056cc22,Supporting & Related Material,FDA-1995-N-0063-0107,FDA-1995-N-0063,Appendix A3 Comment from International Formula Council
090000648056cbd5,Supporting & Related Material,FDA-1995-N-0063-0005,FDA-1995-N-0063,Background Material from Unknown Submitter
090000648172de12,Supporting & Related Material,FDA-1995-N-0063-0160,FDA-1995-N-0063,Reference 66 Koletzko et al Intestinal Milk - Bolus Obstruction in Formula-Fed Premature Infants Given High Doses of Calcium
0900006481822218,Notice,FDA-2008-N-0334-0012,FDA-2008-N-0334,"Postmarketing Safety Reports for Human Drug and Biological Products;
Electronic Submission Requirements; Correction"
0900006482c21dfe,Notice,FDA-2008-N-0334-0016,FDA-2008-N-0334,Agency Information Collection Activities; Proposed Collection; Comment Request; Postmarketing Safety Reports for Human Drug and Biological Products: Electronic Submission Requirements
09000064817358ac,Other,FDA-2008-N-0334-0010,FDA-2008-N-0334,Guidance for Industry Providing Submissions in Electronic Format - Postmarketing Safety Reports-Postmarketing Safety Reports for Human Drug and Biological Products; Electronic Submission Requirements
090000648186336a,Rule,FDA-2008-N-0334-0014,FDA-2008-N-0334,"Postmarketing Safety Reports for Human Drug and Biological Products;
Electronic Submission Requirements; Corrections"
09000064817358ae,Supporting & Related Material,FDA-2008-N-0334-0011,FDA-2008-N-0334,Reference 1 Postmarketing Safety Reports for Human Drug and Biological Products; Electronic Submission Requirements; Final Rule - Administrative Practices and Procedures; Drugs; Labeling; Medical Devices; Reporting and Recordkeeping Requirements; Confidential Business Information; Over-the-counter Drugs; Biologics
09000064818633f4,Rule,FDA-2008-N-0334-0013,FDA-2008-N-0334,"Postmarketing Safety Reports for Human Drug and Biological Products;
Electronic Submission Requirements; Correction"
0900006481734bb1,Rule,FDA-2008-N-0334-0009,FDA-2008-N-0334,"Postmarketing Safety Reports for Human Drug and Biological Products;
Electronic Submission Requirements"
0900006482f06070,Notice,FDA-2008-N-0334-0017,FDA-2008-N-0334,"Agency Information Collection Activities; Submission for Office of
Management and Budget Review; Comment Request; Postmarketing
Safety Reports for Human Drug and Biological Products: Electronic
Submission Requirements"
0900006481b04f02,Rule,FDA-2008-N-0334-0015,FDA-2008-N-0334,"Postmarketing Safety Reports for Human Drug and Biological Products;
Electronic Submission Requirements; Delay of Compliance Date; Safety
Reporting Portal of Electronic Submission of Postmarketing Safety
Reports for Human Drugs and Nonvaccine Biological Products"
0900006480a0f0ed,Proposed Rule,FDA-2008-N-0334-0001,FDA-2008-N-0334,Postmarketing Safety Reports for Human Drug and Biological Products; Electronic Submission Requirements
0900006481fac540,Proposed Rule,FDA-2011-F-0172-0613,FDA-2011-F-0172,"A Labeling Guide for Restaurants and Retail Establishments Selling Away-
From-Home Foods—Part II (Menu Labeling Requirements in Accordance
With the Patient Protection Affordable Care Act of 2010); Guidance for
Industry; Availability"
090000648290aa13,Supporting & Related Material,FDA-2011-F-0172-1762,FDA-2011-F-0172,Article C Flexibility in Font Size re: Comment from Publix
09000064826abbd7,Other,FDA-2011-F-0172-0725,FDA-2011-F-0172,Final Regulatory Impact Analysis on Food Labeling; Nutrition Labeling of Standard Menu Items in Restaurants and Similar Retail Food Establishments; Extension of Compliance Date and Request for Comments
0900006482963502,Supporting & Related Material,FDA-2011-F-0172-2281,FDA-2011-F-0172,Reference Letter from P. Larkin of NGA concerning pending  Nutrition R 2017-1614...
090000648323dcc8,Rule,FDA-2011-F-0172-2905,FDA-2011-F-0172,Menu Labeling: Supplemental Guidance for Industry; Availability
09000064827b3d3d,Other,FDA-2011-F-0172-1175,FDA-2011-F-0172,Letter Menu Extension to NRA dtd 6-28-2017
0900006480c1aa11,Supporting & Related Material,FDA-2011-F-0172-0049,FDA-2011-F-0172,"Reference 67 - ""U.S. Census Bureau, Sectors 44-45: Sub: Single Unit & Multiunit Firms for the U.S:2007"" - [Preliminary Regulatory Impact Analysis, March 2011, Food Labeling:Nutrition Labeling of Standard Menu Items in Restaurants and Similar Retail Food Establishments Notice of Proposed Rulemaking re FDA-2011-F-0172-0001]"
0900006480c1aa4a,Supporting & Related Material,FDA-2011-F-0172-0055,FDA-2011-F-0172,"Reference 75 - ""Bureau of Transportation Statistics, Appendix D – Modal Profiles, Rail Profile"" - [Preliminary Regulatory Impact Analysis, March 2011, Food Labeling:Nutrition Labeling of Standard Menu Items in Restaurants and Similar Retail Food Establishments Notice of Proposed Rulemaking re FDA-2011-F-0172-0001]"
0900006480c197bf,Supporting & Related Material,FDA-2011-F-0172-0024,FDA-2011-F-0172,"Reference List - [Preliminary Regulatory Impact Analysis, March 2011, Food Labeling:Nutrition Labeling of Standard Menu Items in Restaurants and Similar Retail Food Establishments Notice of Proposed Rulemaking re FDA-2011-F-0172-0001]"
0900006480c1a599,Supporting & Related Material,FDA-2011-F-0172-0017,FDA-2011-F-0172,"Reference 35 - ""Ogden, et al., Prevalence of Overweight, Obesity, and Extreme Obesity Among Adults: United States, Trends 1976–1980 Through 2007–2008"" - [Food Labeling: Nutrition Labeling of Standard Menu Items in Restaurants and Similar Retail re FDA-2011-F-0172-0001]"
0900006480c1a5a4,Supporting & Related Material,FDA-2011-F-0172-0018,FDA-2011-F-0172,"Reference 44 - ""USDA, ERS, Table 1: Food and Alcoholic Beverages: Total Expenditures,  Food CPI and Expenditures: Food Expenditure Tables"" - [Food Labeling: Nutrition Labeling of Standard Menu Items in Restaurants and Similar Retail re FDA-2011-F-0172-0001]"
0900006480c1a5aa,Supporting & Related Material,FDA-2011-F-0172-0022,FDA-2011-F-0172,"Reference 50 - ""NPD Group, FDA Report, ReCount Restaurant Census, Spring 2010"" - [Food Labeling: Nutrition Labeling of Standard Menu Items in Restaurants and Similar Retail re FDA-2011-F-0172-0001]"
0900006480c1a9b5,Supporting & Related Material,FDA-2011-F-0172-0025,FDA-2011-F-0172,"Reference 2 - ""US Census Bureau, County Business Patterns, United States NAICS 722 2000-2008"" - [Preliminary Regulatory Impact Analysis, March 2011, Food Labeling:Nutrition Labeling of Standard Menu Items in Restaurants and Similar Retail Food Establishments Notice of Proposed Rulemaking re FDA-2011-F-0172-0001]"
0900006480c1a9c7,Supporting & Related Material,FDA-2011-F-0172-0027,FDA-2011-F-0172,"Reference 20 - ""U.S. Department of Health and Human Services and U.S. Department of Agriculture, 2010 Dietary Guidelines for Americans"" - [Preliminary Regulatory Impact Analysis, March 2011, Food Labeling:Nutrition Labeling of Standard Menu Items in Restaurants and Similar Retail Food Establishments Notice of Proposed Rulemaking re FDA-2011-F-0172-0001]"
0900006480c1a9f3,Supporting & Related Material,FDA-2011-F-0172-0039,FDA-2011-F-0172,"Reference 37 - ""Technomic Inc., FDA Report"" - [Preliminary Regulatory Impact Analysis, March 2011, Food Labeling:Nutrition Labeling of Standard Menu Items in Restaurants and Similar Retail Food Establishments Notice of Proposed Rulemaking re FDA-2011-F-0172-0001]"
0900006482441831,Supporting & Related Material,FDA-2011-F-0172-0620,FDA-2011-F-0172,"Food Labeling:Nutrition Labeling of Standard Menu Items in Restaurants and Similar Retail Food Establishments Final Regulatory Impact Analysis
FDA–2011–F–0172"
0900006482590936,Rule,FDA-2011-F-0172-0621,FDA-2011-F-0172,"Food Labeling; Nutrition Labeling of Standard Menu Items in 
Restaurants and Similar Retail Food Establishments; Extension of 
Compliance Date; Request for Comments"
09000064824412de,Rule,FDA-2011-F-0172-0619,FDA-2011-F-0172,Food Labeling: Nutrition Labeling of Standard Menu Items in Restaurants and Similar Retail Food Establishments; Extension of Compliance Date
0900006482963506,Supporting & Related Material,FDA-2011-F-0172-2285,FDA-2011-F-0172,Reference LTR to Sec Price re 040717 Menu Labling
090000648197401a,Other,FDA-2011-F-0172-0547,FDA-2011-F-0172,"OMB Executive Order 12866 Regulatory Planning and Review re Food Labeling; Nutrition Labeling of Standard Menu Items in Restaurants and Similar Retail Food Establishments (Final Rule); Publication Date: December 1, 2014"
0900006480c1cf20,Proposed Rule,FDA-2011-F-0172-0001,FDA-2011-F-0172,Food Labeling: Nutrition Labeling of Standard Menu Items in Restaurants and Similar Retail Food Establishments
090000648197401f,Supporting & Related Material,FDA-2011-F-0172-0551,FDA-2011-F-0172,"Tab A Menu (FRIA), Draft Regulatory Action as Submitted to the Office of Management and Budget's (OMB) Office of Information and Regulatory Affairs (OIRA) for Review re OMB Executive Order 12866 Regulatory Planning and Review re Food Labeling; Nutrition Labeling of Standard Menu Items in Restaurants and Similar Retail Food Establishments (Final Rule); Publication Date: December 1, 2014"
0900006481974020,Supporting & Related Material,FDA-2011-F-0172-0552,FDA-2011-F-0172,"Tab B Menu Final Rule Impact Analysis (FRIA) Substantive Changes Between the Draft Submitted to OIRA for Review and the Regulatory Action Subsequently Cleared by OIRA re OMB Executive Order 12866 Regulatory Planning and Review re Food Labeling; Nutrition Labeling of Standard Menu Items in Restaurants and Similar Retail Food Establishments (Final Rule); Publication Date: December 1, 2014"
090000648195229f,Supporting & Related Material,FDA-2011-F-0172-0537,FDA-2011-F-0172,"Reference 39- FDA, ""Regulatory Procedures Manual,"" chapter 4. re Food Labeling; Nutrition Labeling of Standard Menu Items in Restaurants and Similar Retail Food Establishments."
09000064819522a0,Supporting & Related Material,FDA-2011-F-0172-0538,FDA-2011-F-0172,"Reference 40 - FDA, ""Regulatory Procedures Manual,"" chapter 6, section 5. re Food Labeling; Nutrition Labeling of Standard Menu Items in Restaurants and Similar Retail Food Establishments."
0900006480aabaa3,Other,FDA-2008-N-0115-0003,FDA-2008-N-0115,"OMB Review, Executive Order 12866 Published 2/19/2010 - [Reporting Information Regarding Falsification of Data] - Reference"
090000648378011d,Proposed Rule,FDA-2008-N-0115-0050,FDA-2008-N-0115,Use of Materials Derived From Cattle in Medical Products Intended for Use in Humans and Drugs Intended for Use in Ruminants; Reporting Information Regarding Falsification of Data
0900006480aa8374,Proposed Rule,FDA-2008-N-0115-0001,FDA-2008-N-0115,Reporting Information Regarding Falsification of Data
09000064805d46ca,Supporting & Related Material,FDA-1997-D-0494-0001,FDA-1997-D-0494,See FDA-1997-D-0494-0002
0900006480900aec,Notice,FDA-1997-D-0494-0002,FDA-1997-D-0494,Guidance for FDA and Industry: Direct Final Rule Procedures
0900006480900ab4,Other,FDA-1997-D-0494-0003,FDA-1997-D-0494,Guidance for FDA Industry Direct Final Rule Procedures; Guidance Document
0900006480ead32d,Supporting & Related Material,FDA-2010-N-0568-0266,FDA-2010-N-0568,"Reference 38 - ""Farber, et at, ""Secondhand Tobacco Smoke in Children With Asthma: Sources of and Parental Perceptions About Exposure in Children and Parental Readiness to Change"" - [Required Warnings for Cigarette Packages and Advertisements; Final Rule]"
0900006480eb4ab6,Supporting & Related Material,FDA-2010-N-0568-0693,FDA-2010-N-0568,"Reference 66 - ""Fiore, M.C., Jaen C.R., Baker T.R, et al., Treating Tobacco Use and Dependence: 2008 Update, Rockville, MD: U.S. Department of Health and Human Services, Public Health Service"" - [Required Warnings for Cigarette Packages and Advertisements; Final Rule]"
0900006480eb61e0,Supporting & Related Material,FDA-2010-N-0568-0735,FDA-2010-N-0568,"Reference 167 - ""U.S. Department of the Treasury, Daily Treasury Long-Term Rate Data, Daily Treasury Real Long- Term Rates"" - [Required Warnings for Cigarette Packages and Advertisements; Final Rule]"
0900006480eb5d6a,Supporting & Related Material,FDA-2010-N-0568-0708,FDA-2010-N-0568,"Reference 128 - ""National Center for Health Statistics (U.S. Department of Health and Human Services), National Health Interview Survey: Questionnaires, Datasets and Related Documentation, 1997 to the Present"" - [Required Warnings for Cigarette Packages and Advertisements; Final Rule]"
0900006480eb5da1,Supporting & Related Material,FDA-2010-N-0568-0712,FDA-2010-N-0568,"Reference 136 - ""Arias, E., United States Life Tables, 2006, National Vital Statistics Reports, 58(21); June 28, 2010"" - [Required Warnings for Cigarette Packages and Advertisements; Final Rule]"
0900006480eb5dc7,Supporting & Related Material,FDA-2010-N-0568-0714,FDA-2010-N-0568,"Reference 142 - ""U.S. Department ofCommerce, Census Bureau 2008, National Cancer Institute and Centers for Disease Control and Prevention co-sponsored Tobacco Use Supplement to the Current Population Survey 2006-2007"" - [Required Warnings for Cigarette Packages and Advertisements; Final Rule]"
0900006480b87423,Proposed Rule,FDA-2010-N-0568-0001,FDA-2010-N-0568,Required Warnings for Cigarette Packages and Advertisements
0900006480eb555a,Supporting & Related Material,FDA-2010-N-0568-0697,FDA-2010-N-0568,"Reference 89 - ""U.S. Department of Health and Human Services, Ending the Tobacco Epidemic: A Tobacco Control Strategic Action Plan for the U.S. Department of Health and Human Services, Nov. 10, 2010"" - [Required Warnings for Cigarette Packages and Advertisements; Final Rule]"
0900006480e9ea5d,Supporting & Related Material,FDA-2010-N-0568-0261,FDA-2010-N-0568,"Reference 17 - ""U.S. Department of Health and Human Services, The Health Consequences of Involuntary Exposure to Tobacco Smoke,  A Report of the Surgeon General; 2006"" - [Required Warnings for Cigarette Packages and Advertisements; Final Rule]"
0900006480bb0be7,Notice,FDA-2010-N-0568-0006,FDA-2010-N-0568,Required Warnings for Cigarette Packages and Advertisements; Research Report
0900006480bad0e1,Supporting & Related Material,FDA-2010-N-0568-0008,FDA-2010-N-0568,"(1) Experimental Study of Graphic Cigarette Warning Labels, Final Results Report, December 2010 - [Required Warnings for Cigarette Packages and Advertisements; Research Report] re FDA-2010-N-0568-0006"
0900006480eb555d,Supporting & Related Material,FDA-2010-N-0568-0700,FDA-2010-N-0568,"Reference 92 - ""NTlA Research Preview, Digital Nation: Expanding Internet Usage, U.S. Department of Commerce: National Telecommunications and Information Administration, February 2011"" - [Required Warnings for Cigarette Packages and Advertisements; Final Rule]"
0900006480eb556c,Supporting & Related Material,FDA-2010-N-0568-0702,FDA-2010-N-0568,"Reference 102 - ""U.S. Census Bureau, Language Use and English-Speaking Ability: 2000,"" October 2003"" - [Required Warnings for Cigarette Packages and Advertisements; Final Rule]"
0900006480eb61de,Supporting & Related Material,FDA-2010-N-0568-0733,FDA-2010-N-0568,"Reference 165- ""Tax Foundation, State Sales, Gasoline, Cigarette and Alcohol Tax Rates by State, 2000-2010"" - [Required Warnings for Cigarette Packages and Advertisements; Final Rule]"
0900006480eb61e3,Supporting & Related Material,FDA-2010-N-0568-0738,FDA-2010-N-0568,"Reference 170 - ""U.S Department of Agriculture, Foreign Agricultural Service, Global Agricultural Trade System"" - [Required Warnings for Cigarette Packages and Advertisements; Final Rule]"
0900006480eb63b6,Supporting & Related Material,FDA-2010-N-0568-0744,FDA-2010-N-0568,"Reference 178 - ""Jamison, N., et al., Federal and State Cigarette Excise Taxes--United States, 1995-2009, Morbidity and Mortality Weekly Report"" - [Required Warnings for Cigarette Packages and Advertisements; Final Rule]"
0900006480eb63b7,Supporting & Related Material,FDA-2010-N-0568-0745,FDA-2010-N-0568,"Reference 179 - ""U.S. Census Bureau Population Division, Table CO-EST2001-12-00--Time Series of Intercensal State Population Estimates: April 1, 1990 to April 1, 2000, April 11, 2002,"" - [Required Warnings for Cigarette Packages and Advertisements; Final Rule]"
0900006480bad0e0,Supporting & Related Material,FDA-2010-N-0568-0007,FDA-2010-N-0568,List of Documents for the Notice of Availability and Request for Comments - [Required Warnings for Cigarette Packages and Advertisements; Research Report] re FDA-2010-N-0568-0006
0900006480eb5da9,Supporting & Related Material,FDA-2010-N-0568-0713,FDA-2010-N-0568,"Reference 140 - ""U.S. Department of Labor, Bureau of Labor Statistics. Consumer Price Index Detailed Report"" - [Required Warnings for Cigarette Packages and Advertisements; Final Rule]"
0900006480eb5dd4,Supporting & Related Material,FDA-2010-N-0568-0716,FDA-2010-N-0568,"Reference 145 - ""National Fire Protection Association, News Release, July 16, 2004."" - [Required Warnings for Cigarette Packages and Advertisements; Final Rule]"
0900006480eb619c,Supporting & Related Material,FDA-2010-N-0568-0721,FDA-2010-N-0568,"Reference 151 - ""U.S. Census Bureau, Nonemployer Statistics, U.S., All Industries, 2008, Retail Trade, Accommodation and Food Services"" - [Required Warnings for Cigarette Packages and Advertisements; Final Rule]"
0900006480eb61bd,Supporting & Related Material,FDA-2010-N-0568-0729,FDA-2010-N-0568,"Reference 160 - ""U.S. Census Bureau, American FactFinder, 2006 Annual Survey of Manufacturers,"" 2008"" - [Required Warnings for Cigarette Packages and Advertisements; Final Rule]"
0900006480e9996b,Supporting & Related Material,FDA-2010-N-0568-0257,FDA-2010-N-0568,"Reference 6 - ""Centers for Disease Control and Prevention, ""Tobacco Use Among Middle and High School Students--United States, 2000-2009"" - [Required Warnings for Cigarette Packages and Advertisements; Final Rule]"
0900006480eb3f88,Supporting & Related Material,FDA-2010-N-0568-0691,FDA-2010-N-0568,"Reference 64 - ""U.S. Food and Drug Administration, Cigarette Required Warnings, June 2011""  - [Required Warnings for Cigarette Packages and Advertisements; Final Rule]"
0900006480e9996e,Supporting & Related Material,FDA-2010-N-0568-0258,FDA-2010-N-0568,"Reference 7 - ""Substance Abuse and Mental Health Services Administration, ""Results from the 2008 National Survey on Drug Use and Health: National Findings"" - [Required Warnings for Cigarette Packages and Advertisements; Final Rule]"
0900006482a3ef61,Other,FDA-1992-S-0039-0064,FDA-1992-S-0039,CBER Memo to the Division of Dockets Management
090000648052882e,Notice,FDA-1992-S-0039-0001,FDA-1992-S-0039,Electronic Submissions; Establishment of Public Docket
0900006480528898,Supporting & Related Material,FDA-1992-S-0039-0019,FDA-1992-S-0039,"CDER, CFR 314(50) New Drug Applications Memo 6 - Memorandum"
09000064805288b7,Supporting & Related Material,FDA-1992-S-0039-0027,FDA-1992-S-0039,"CVM, CFR 11.2(b)(2) Final Disposition of Memo 11 - Memorandum"
09000064805288bb,Supporting & Related Material,FDA-1992-S-0039-0028,FDA-1992-S-0039,CDER to the Division of Docket Postmarketing Expedited Safety Reports – “15-day Alert Reports Memo 12 - Memorandum
0900006481e620b5,Other,FDA-1992-S-0039-0062,FDA-1992-S-0039,"Letter from Epic Pharma, LLC to FDA re: Information Request Product Quality Reference #206770"
09000064828d4c21,Supporting & Related Material,FDA-1992-S-0039-0063,FDA-1992-S-0039,FDA/CVM Memo to the Division of Dockets Management Using the
09000064814a18df,Supporting & Related Material,FDA-1992-S-0039-0060,FDA-1992-S-0039,"FDA/CDRH Memo to the Division of Dockets Management Submission of Device Information (DI) record to the Global Unique Device Identification Database (GUDID), in compliance with the Unique Device Identification Rule - Memorandum"
0900006480552d61,Supporting & Related Material,FDA-1992-S-0039-0054,FDA-1992-S-0039,FDA Center fo Devices and Radiological Health to the Division of Dockets Management - Memorandum
090000648052890d,Other,FDA-1992-S-0039-0050,FDA-1992-S-0039,CBER Blood Establishment Registration - Memo 25
090000648052892a,Supporting & Related Material,FDA-1992-S-0039-0010,FDA-1992-S-0039,CDER to the Division of Dockets Management Orphan-Drug Designation Requests Memo 33 - Memorandum
09000064805288a0,Supporting & Related Material,FDA-1992-S-0039-0022,FDA-1992-S-0039,"CBER, Biologics License Applications (BLA)Product License Applications (PLA) Establishment License Applications (ELA) New Drug Applications - Memo 8 - Supplement"
09000064805288d1,Other,FDA-1992-S-0039-0040,FDA-1992-S-0039,CBER Advertisements and Promotional Labeling - Memo 20
09000064805288d4,Other,FDA-1992-S-0039-0041,FDA-1992-S-0039,CBER Advertisements and Promotional Labeling - Memo 20
0900006480f43469,Supporting & Related Material,FDA-1992-S-0039-0058,FDA-1992-S-0039,FDA/CVM Memo to the Division of Dockets Management Using the eSubmitter Tool Instead of Adobe Acrobat PDF SmartForms - Memorandum
0900006480528922,Supporting & Related Material,FDA-1992-S-0039-0003,FDA-1992-S-0039,CDER Investigational New Drug Applications  New Drug Applications Abbreviated NewDrug Applications Master Files Annual Reports Promotional Material Memo 27 - Memorandum
09000064805288a4,Other,FDA-1992-S-0039-0023,FDA-1992-S-0039,"CBER, CFR 601.2, 314.50 Biologics Marketing Applications - Memo 9"
09000064805288dc,Other,FDA-1992-S-0039-0043,FDA-1992-S-0039,CBER Investigational NDA - Memo 21
090000648052889b,Supporting & Related Material,FDA-1992-S-0039-0020,FDA-1992-S-0039,"CDER to the Division of Dockets Management, Withdrawal of Case Report Forms, Memo 2 and Case Report Tabulations Memo 3 - Memorandum"
09000064805288c8,Supporting & Related Material,FDA-1992-S-0039-0038,FDA-1992-S-0039,CDER Advertisements and Promotional Labeling Memo 18 - Memorandum
090000648066936b,Supporting & Related Material,FDA-1992-S-0039-0055,FDA-1992-S-0039,"FDA Center for Drug Evaluation and Research, et al to the Division of Dockets Management - Memorandum"
09000064805288ac,Supporting & Related Material,FDA-1992-S-0039-0025,FDA-1992-S-0039,"CVM, CFR 11.2(b)(2) Final Disposition of Memo 10"
09000064805288bd,Supporting & Related Material,FDA-1992-S-0039-0029,FDA-1992-S-0039,CVM CFR 11.2(b) (2) Guidance for Indudstry Memo 13 - Memorandum
09000064805288e7,Supporting & Related Material,FDA-1992-S-0039-0046,FDA-1992-S-0039,CDER Abbreviated New Drug Applications Memo 24 - Memorandum re FDA-1992-S-0039-0047
090000648052891c,Other,FDA-1992-S-0039-0051,FDA-1992-S-0039,CBER Blood Establishment Registration - Memo 26
090000648294f0f0,Other,FDA-2017-D-4359-0002,FDA-2017-D-4359,"Guidance for Industry 68 on Small Entites Compliance Guide for Protein Blenders, Feed Manufacturers, and Distributors"
090000648294f0ee,Other,FDA-2017-D-4359-0001,FDA-2017-D-4359,Guidance for Industry on Small Entitles Compliance Guide for Renderers
090000648294f0f2,Other,FDA-2017-D-4359-0003,FDA-2017-D-4359,Guidance for Industry on Small Entities Compliance Guide for Feeders of Ruminant Animals with On-Farm Feed Mixing Operations
090000648294fa11,Other,FDA-2017-D-4359-0005,FDA-2017-D-4359,Guidance for Industry on Questions and Answers BSE Feed Regulation
090000648294fa0f,Other,FDA-2017-D-4359-0004,FDA-2017-D-4359,Guidance for Industry on Small Entities Compliance Guide for Feeders of Ruminant Animals without On-Farm Feed Mixing Operations
090000648094efb0,Other,FDA-2002-N-0031-0154,FDA-2002-N-0031,Form Letter Sample #10 - [Multiple Submitters=4] - Form Letter Comment (C507)
090000648094ec3e,Other,FDA-2002-N-0031-0148,FDA-2002-N-0031,Form Letter Sample #4 - [Multiple Submitters=7] - Form Letter Comment (EMC45)
090000648053331a,Supporting & Related Material,FDA-2002-N-0031-0128,FDA-2002-N-0031,Findings of No Significant Impact
0900006480533338,Supporting & Related Material,FDA-2002-N-0031-0129,FDA-2002-N-0031,Environmental Assessment
09000064805239b5,Supporting & Related Material,FDA-2002-N-0031-0111,FDA-2002-N-0031,Substances Prohibited From Use in Animal Food or Feed - References
09000064805239d2,Supporting & Related Material,FDA-2002-N-0031-0112,FDA-2002-N-0031,Reference 1 - Opinion of the Scientific Steering Committee on the Human Exposure Risk (HER) via Food With Respect to BSE
09000064805239f4,Supporting & Related Material,FDA-2002-N-0031-0114,FDA-2002-N-0031,"Reference 3 - An Estimate of the Prevalence of BSE in the United States, USDA"
0900006480523b2e,Supporting & Related Material,FDA-2002-N-0031-0121,FDA-2002-N-0031,Reference 14 - OIG Report No. 50601-10-KC - Audit Report
090000648048a5ef,Other,FDA-2002-N-0031-0094,FDA-2002-N-0031,The Honorable Paul E. Kanjorski to the Food and Drug Administration - Letter
090000648048a62a,Other,FDA-2002-N-0031-0100,FDA-2002-N-0031,The Honorable P. Sarbanes to the Food and Drug Administration - Letter
0900006480523b1d,Supporting & Related Material,FDA-2002-N-0031-0118,FDA-2002-N-0031,"Reference 9 - ""Opinion on The Safety of Ruminant Blood with Respect to TSE Risks"
0900006480523b37,Supporting & Related Material,FDA-2002-N-0031-0120,FDA-2002-N-0031,"Reference 16 - ""Economic Impacts of FDA Regulatory Changes Due to Risk of Bovine Spongiform Encephalopathy"""
0900006480523baf,Supporting & Related Material,FDA-2002-N-0031-0124,FDA-2002-N-0031,"Reference 23 - ""An Economic Chronology of Bovine Spongiform Encephalopathy in North America"""
0900006480523bcb,Supporting & Related Material,FDA-2002-N-0031-0126,FDA-2002-N-0031,"Reference 26 - ""Economic Impacts of Proposed Changes to Livestock Feed Regulations"""
0900006480523bf8,Supporting & Related Material,FDA-2002-N-0031-0127,FDA-2002-N-0031,"Reference 28 - National Agricultural Statistics Service, USDA"
09000064804896b9,Notice,FDA-2002-N-0031-0002,FDA-2002-N-0031,Substances Prohibited From Use in Animal Food or Feed; Animal Proteins Prohibited in Ruminant Feed; Correction
090000648094bc24,Proposed Rule,FDA-2002-N-0031-0132,FDA-2002-N-0031,Substances Prohibited From Use in Animal Food or Feed; Final Rule: Proposed Delay of Effective Date
090000648094f00a,Other,FDA-2002-N-0031-0156,FDA-2002-N-0031,Form Letter Sample #12 - [Multiple Submitters=3] - Form Letter Comment (C531)
090000648048a4b5,Other,FDA-2002-N-0031-0063,FDA-2002-N-0031,The Honorable Jim Bunning to the Food and Drug Administration - Letter
090000648048a608,Other,FDA-2002-N-0031-0099,FDA-2002-N-0031,The Honorable Barbara A. Mikulski to the Food and Drug Administration - Letter
090000648048a52f,Supporting & Related Material,FDA-2002-N-0031-0072,FDA-2002-N-0031,Facsimile Sheet - [The Honorable John E. Peterson - Comment]
090000648048a633,Other,FDA-2002-N-0031-0102,FDA-2002-N-0031,Nate Berry to the Food and Drug Administration - Letter
0900006480523b71,Supporting & Related Material,FDA-2002-N-0031-0123,FDA-2002-N-0031,"Reference 19 - United Kingdom, Department for Environment, Food and Rural Affairs, 2007"
090000648094eaa8,Other,FDA-2002-N-0031-0146,FDA-2002-N-0031,Form Letter Sample#2 - [Multiple Submitters=13] - Form Letter Comment (C52)
090000648094ee6a,Other,FDA-2002-N-0031-0151,FDA-2002-N-0031,Form Letter Sample #7 - [Multiple Submitters=10] - Form Letter Comment (C92)
0900006481304148,Proposed Rule,FDA-2012-N-0920-0001,FDA-2012-N-0920,"Tobacco Products, User Fees, Requirements for the Submission of Data Needed to Calculate User Fees for Domestic Manufacturers and Importers of Tobacco Products"
0900006481fbd96d,Rule,FDA-2012-N-0920-0016,FDA-2012-N-0920,"Requirements for the Submission of Data Needed To Calculate User Fees
for Domestic Manufacturers and Importers of Cigars and Pipe Tobacco"
0900006481fbea5b,Supporting & Related Material,FDA-2012-N-0920-0019,FDA-2012-N-0920,Reference 2 Form FDA 3825 re Requirements for the Submission of Data Needed To Calculate User Fees for Domestic Manufacturers and Importers of Cigars and Pipe Tobacco
0900006481fbea5a,Supporting & Related Material,FDA-2012-N-0920-0018,FDA-2012-N-0920,"Reference 1 Regulatory Impact Analysis re Requirements for the Submission of Data Needed to Calculate User Fees for Domestic Manufacturers and Importers of Cigars and Pipe Tobacco re Requirements for the Submission of Data Needed To Calculate User Fees
for Domestic Manufacturers and Importers of Cigars and Pipe Tobacco"
090000648179c7c3,Supporting & Related Material,FDA-2012-N-0920-0014,FDA-2012-N-0920,"Reference 1 FDA-3852 re Tobacco Products, User Fees, Requirements for the Submission of Data Needed To Calculate User Fees for Domestic Manufacturers and Importers of Tobacco Products"
090000648132f28b,Other,FDA-2012-N-0920-0002,FDA-2012-N-0920,"OMB Review, Executive Order 12866, Tobacco Products, User Fees, Requirements for the Submission of Data Needed to Calculate User Fees for Domestic Manufacturers and Importers of Tobacco Products (May 31, 2013) - Memorandum"
0900006481fbe15c,Supporting & Related Material,FDA-2012-N-0920-0017,FDA-2012-N-0920,User Fee Rule References
090000648179c80d,Supporting & Related Material,FDA-2012-N-0920-0015,FDA-2012-N-0920,"Reference 2 - Regulatory Impact Analysis re Tobacco Products, User Fees, Requirements for the Submission of Data Needed To Calculate User Fees for Domestic Manufacturers and Importers of Tobacco Products"
090000648179ccd9,Rule,FDA-2012-N-0920-0013,FDA-2012-N-0920,"Tobacco Products, User Fees, Requirements for the Submission of
Data Needed To Calculate User Fees for Domestic Manufacturers and
Importers of Tobacco Products"
09000064804a0a95,Supporting & Related Material,FDA-2002-N-0323-0110,FDA-2002-N-0323,See: FDA-2002-N-0323-0164
09000064804a090d,Notice,FDA-2002-N-0323-0026,FDA-2002-N-0323,"Interim Final Regulations Implementing Title III, Subtitle A, of the Public Health Security and Bioterrorism Preparedness and Response Act of 2002 Section 305: Registration of Food Facilities and Section 307: Prior Notice of Imported Food Shipments; Notice of Public Meeting"
09000064804a0963,Other,FDA-2002-N-0323-0045,FDA-2002-N-0323,"Memphis, TN BT Downsite 10/28/2003"
09000064804a089b,Other,FDA-2002-N-0323-0006,FDA-2002-N-0323,FDA and Formatta Corporation
09000064804a0996,Other,FDA-2002-N-0323-0069,FDA-2002-N-0323,New York District registration list from 10/28 Downlink
09000064804a0994,Other,FDA-2002-N-0323-0068,FDA-2002-N-0323,List that attended the 10/28/03 Satellite Downlink in Cincinnati District
09000064804a098b,Other,FDA-2002-N-0323-0063,FDA-2002-N-0323,"BT downlink list of attendees in Baton Rouge, LA"
09000064804a0981,Other,FDA-2002-N-0323-0058,FDA-2002-N-0323,"List of attendees for 10/28th Conference in Portland, Oregon"
09000064804a0a9d,Other,FDA-2002-N-0323-0115,FDA-2002-N-0323,New FDA Bioterrorism Act Registration and Prior Notice Interim Final Rules
09000064804a0989,Other,FDA-2002-N-0323-0062,FDA-2002-N-0323,"BT downlink list of attendees in Baton Rouge, LA"
09000064804a0986,Other,FDA-2002-N-0323-0061,FDA-2002-N-0323,"BT downlink list of attendees in Baton Rouge, LA"
09000064804a099c,Other,FDA-2002-N-0323-0073,FDA-2002-N-0323,List for BT Downlink held in Washington
09000064804a0b31,Other,FDA-2002-N-0323-0156,FDA-2002-N-0323,"Meeting Held in Fresno California on March 4, 2004"
09000064804a097f,Other,FDA-2002-N-0323-0057,FDA-2002-N-0323,List of Wisconsin Dowlink
09000064804a0959,Other,FDA-2002-N-0323-0039,FDA-2002-N-0323,Participant List for the Houston BT Downlink
09000064821f9c22,Notice,FDA-2002-N-0323-0248,FDA-2002-N-0323,Agency Information Collection Activities; Announcement of Office of  Management and Budget Approvals
09000064820adbef,Supporting & Related Material,FDA-2002-N-0323-0240,FDA-2002-N-0323,Reference 6 Guidance for Industry Questions and Answers Regarding Food Facility Registration (Sixth Edition) re Amendments to Registration of Food Facilities
09000064820adc7c,Supporting & Related Material,FDA-2002-N-0323-0242,FDA-2002-N-0323,"Reference 8 Specification of the Unique Facility Identifier (UFI) System for Drug Establishment Registration, Guidance for Industry re Amendments to Registration of Food Facilities"
09000064820adc7e,Supporting & Related Material,FDA-2002-N-0323-0244,FDA-2002-N-0323,Reference 10 GAO Memo Government Is Analyzing Alternatives for Contractor Identification Numbers re Amendments to Registration of Food Facilities
0900006481a975de,Supporting & Related Material,FDA-2002-N-0323-0175,FDA-2002-N-0323,"Reference 4-2 U.S. Department of Labor, Bureau of Labor Statistics, Consumer Price Index (CPI) History Tables. CPI- All Urban Consumers- Series ID CUUR0000SA0 re Amendments to Registration of Food Facilities"
0900006481a975e0,Supporting & Related Material,FDA-2002-N-0323-0177,FDA-2002-N-0323,"Reference 4-4 U.S. Department of Labor, Bureau of Labor Statistics, National Compensation Survey: Occupation Wages in the United States, 2000 re Amendments to Registration of Food Facilities"
0900006481a975e1,Supporting & Related Material,FDA-2002-N-0323-0178,FDA-2002-N-0323,"09 Reference 4-5 - FDA Center for Food Safety and Applied Nutrition -Division of Field Programs and Guidance, “Guidance for Industry: Necessity of the Use of Food Product Categories in Food Facility Registrations and Updates to Food Product Categories.” re Amendments to Registration of Food Facilities"
0900006481a970fb,Supporting & Related Material,FDA-2002-N-0323-0172,FDA-2002-N-0323,"Reference 3 Guidance for Industry: Necessity of the Use of Food Product Categories in Food Facility Registrations and Updates to Food Product Categories,"" re Amendments to Registration of Food Facilities"
09000064804a045b,Notice,FDA-2002-N-0323-0002,FDA-2002-N-0323,FDA
09000064804a045e,Notice,FDA-2002-N-0323-0003,FDA-2002-N-0323,Registration of Food Facilities Under the Public Health Security and Bioterrorism Preparedness and Response Act of 2002; Notice of Proposed Rulemaking
0900006481f0eacb,Supporting & Related Material,FDA-2016-N-0543-0007,FDA-2016-N-0543,Reference 5 - A FDA Track re Food and Drug Administration Review and Action on Over-the-Counter Time and Extent Applications
09000064823b9aa7,Rule,FDA-2016-N-0543-0013,FDA-2016-N-0543,Food and Drug Administration Review and Action on Over-the-Counter Time and Extent Applications
0900006481f0eac9,Supporting & Related Material,FDA-2016-N-0543-0005,FDA-2016-N-0543,Reference 3 2009 GAO Report on Federal Rulemaking re Food and Drug Administration Review and Action on Over-the-Counter Time and Extent Applications
0900006481f0eaca,Supporting & Related Material,FDA-2016-N-0543-0006,FDA-2016-N-0543,Reference 4 Content and Format of Sunscreen Data Submissions Draft Guidance re Food and Drug Administration Review and Action on Over-the-Counter Time and Extent Applications
0900006481f2331f,Proposed Rule,FDA-2016-N-0543-0001,FDA-2016-N-0543,Food and Drug Administration Review and Action on Over-the-Counter Time and Extent Applications
0900006481f0eac8,Supporting & Related Material,FDA-2016-N-0543-0004,FDA-2016-N-0543,Reference 2 OFR Guide to the Rulemaking Process re Food and Drug Administration Review and Action on Over-the-Counter Time and Extent Applications
0900006481f0eacc,Supporting & Related Material,FDA-2016-N-0543-0008,FDA-2016-N-0543,Reference 5B Sunscreen Innovation Act (SIA) Website re Food and Drug Administration Review and Action on Over-the-Counter Time and Extent Applications
0900006481f24068,Supporting & Related Material,FDA-2016-N-0543-0002,FDA-2016-N-0543,References List for Food and Drug Administration Review and Action on Over-the-Counter Time and Extent Applications
09000064823ba8d7,Supporting & Related Material,FDA-2016-N-0543-0014,FDA-2016-N-0543,Nonprescription Sunscreen Drug Products  Format and Content of Data Submissions Guidance for Industry
0900006481f0eac7,Supporting & Related Material,FDA-2016-N-0543-0003,FDA-2016-N-0543,Reference 1 TEA Guidance re Food and Drug Administration Review and Action on Over-the-Counter Time and Extent Applications
0900006481f0eacd,Supporting & Related Material,FDA-2016-N-0543-0009,FDA-2016-N-0543,Reference 5C - Rulemaking History for OTC Time and Extent Applications re Food and Drug Administration Review and Action on Over-the-Counter Time and Extent Applications
090000648062ec5d,Notice,FDA-2008-N-0297-0001,FDA-2008-N-0297,Status of Certain Additional Over-the-Counter Drug Category II Active Ingredients
090000648070dcb3,Supporting & Related Material,FDA-2008-N-0297-0007,FDA-2008-N-0297,"Buchanan Ingersoll  Rooney, PC [re FDA-2008-N-0297-0010]"
0900006480a5cd06,Proposed Rule,FDA-2009-N-0025-0001,FDA-2009-N-0025,Animal Food Labeling; Declaration of Certifiable Color Additives
0900006481a8572a,Notice,FDA-2009-N-0025-0008,FDA-2009-N-0025,"Agency Information Collection Activities; Proposed Collection;
Comment Request; Animal Food Labeling; Declaration of Certifiable 
Color Additives"
0900006481b5dc20,Notice,FDA-2009-N-0025-0009,FDA-2009-N-0025,"Agency Information Collection Activities; Submission for Office of
Management and Budget Review; Comment Request; Animal Food
Labeling; Declaration of Certifiable Color Additives"
0900006484a5e2e5,Notice,FDA-2009-N-0025-0015,FDA-2009-N-0025,"Agency Information Collection Activities; Proposed Collection; Comment Request; Animal Food
Labeling; Declaration of Certified and Non-Certified Color Additives"
0900006484bdf2db,Notice,FDA-2009-N-0025-0038,FDA-2009-N-0025,"Agency Information Collection Activities; Submission for Office of Management and Budget Review; 
Comment Request; Animal Food Labeling; Declaration of Certified and Non-Certified Color Additives"
0900006484db6edd,Notice,FDA-2009-N-0025-0039,FDA-2009-N-0025,Agency Information Collection Activities; Announcement of Office of Management and Budget Approvals
0900006481c88529,Notice,FDA-2009-N-0025-0010,FDA-2009-N-0025,"Agency Information Collection Activities; Announcement of Office of
Management and Budget Approval; Animal Food Labeling; Declaration of Certifiable Color Additives"
0900006480f6e620,Rule,FDA-2009-N-0025-0007,FDA-2009-N-0025,Animal Food Labeling; Declaration of Certifiable Color Additives
0900006483478ab4,Notice,FDA-2009-N-0025-0013,FDA-2009-N-0025,"Agency Information Collection Activities; Submission for Office of
Management and Budget Review; Comment Request; Animal Food
Labeling; Declaration of Certifiable Color Additives"
090000648378024c,Notice,FDA-2009-N-0025-0014,FDA-2009-N-0025,Agency Information Collection Activities; Announcement of Office of Management and Budget Approvals
0900006482f45a02,Notice,FDA-2009-N-0025-0011,FDA-2009-N-0025,"Agency Information Collection Activities; Proposed Collection;
Comment Request; Animal Food Labeling; Declaration of Certifiable
Color Additives"
0900006483478999,Notice,FDA-2012-N-0447-0112,FDA-2012-N-0447,"Antimicrobial Animal Drug Sales and Distribution Reporting; Small Entity
Compliance Guide; Availability"
0900006481fc35b3,Rule,FDA-2012-N-0447-0108,FDA-2012-N-0447,Antimicrobial Animal Drug Sales and Distribution Reporting
0900006481fc3b77,Supporting & Related Material,FDA-2012-N-0447-0109,FDA-2012-N-0447,Congresswoman Slaughter's Letter to FDA
0900006481fc3bca,Supporting & Related Material,FDA-2012-N-0447-0110,FDA-2012-N-0447,Antimicrobial Animal Drug Sales and Distribution Reporting Final Regulatory Impact Analysis
0900006481128b32,Proposed Rule,FDA-2012-N-0447-0006,FDA-2012-N-0447,Antimicrobial Animal Drug Sales and Distribution Reporting: Extension of Comment Period
09000064810b436c,Proposed Rule,FDA-2012-N-0447-0001,FDA-2012-N-0447,Antimicrobial Animal Drug Sales and Distribution Reporting
0900006481b9c266,Supporting & Related Material,FDA-2012-N-0447-0069,FDA-2012-N-0447,FDA PRIA Antimicrobial Animal Drug Sales and Distribution Reporting
090000648209c0b3,Notice,FDA-2012-N-0447-0111,FDA-2012-N-0447,"Agency Information Collection Activities; Announcement of Office 
of Management and Budget Approvals"
0900006481aeb0af,Proposed Rule,FDA-2012-N-0447-0066,FDA-2012-N-0447,Antimicrobial Animal Drug Sales and Distribution Reporting
090000648346cca1,Other,FDA-2012-N-0447-0113,FDA-2012-N-0447,Antimicrobial Animal Drug Sales and Distribution Reporting; Guidance for Industry; Small Entity Compliance Guide #252
090000648143b90d,Proposed Rule,FDA-2012-N-0447-0028,FDA-2012-N-0447,Antimicrobial Animal Drug Sales and Distribution Annual Summary Report Data Tables
0900006482f4ca35,Rule,FDA-2013-N-0080-0015,FDA-2013-N-0080,Human Subject Protection; Acceptance of Data From Clinical Investigations for Medical Devices
09000064816addac,Other,FDA-2013-N-0080-0014,FDA-2013-N-0080,"Minutes of Meeting between FDA and AdvaMed, Marh 3, 2014"
090000648342fb0e,Notice,FDA-2013-N-0080-0016,FDA-2013-N-0080,"Agency Information Collection Activities; Announcement of Office of
Management and Budget Approvals"
0900006481206965,Proposed Rule,FDA-2013-N-0080-0001,FDA-2013-N-0080,Human Subject Protection: Acceptance of Data from Clinical Studies for Medical Devices
09000064843fe841,Other,FDA-2013-N-0080-0017,FDA-2013-N-0080,"Acceptance of Clinical Data to Support Medical Device Applications and Submissions Frequently Asked Questions; Guidance for Industry and
Food and Drug Administration Staff"
09000064804c2749,Proposed Rule,FDA-2000-N-0108-0007,FDA-2000-N-0108,Safety Reporting Requirements for Human Drug and Biological Products; Extension of Comment Period
09000064804c2954,Supporting & Related Material,FDA-2000-N-0108-0013,FDA-2000-N-0108,"Tab B - ""OMB Review March 14, 2003, Executive Order 12866, Changes in the Regulatory Action Made by OIRA"" - (Safety Reporting Requirements for Human Drug and Biological Products), re FDA-2000-N-0108-0006 - Reference (Pages 377-464)"
09000064804c2967,Supporting & Related Material,FDA-2000-N-0108-0018,FDA-2000-N-0108,"Tab A - ""OMB Review March 14, 2003, Executive Order 12866, Substantive Changes Between the Draft Submitted to OIRA and Action Subsequently Announced"" - (Safety Reporting Requirements for Human Drug and Biological Products), re FDA-2000-N-0108-0006 - Reference (Pages 308-406)"
0900006480b627c7,Supporting & Related Material,FDA-2000-N-0108-0074,FDA-2000-N-0108,"Reference 4.  Occupational Employment and Wage Estimates  May 2008  [Investigational New Drug Safety Reporting Requirements for Human Drug and Biological Products and Safety Reporting Requirements for Bioavailability and Bioequivalence Studies in Humans, Final Rule]"
09000064804c26bc,Supporting & Related Material,FDA-2000-N-0108-0027,FDA-2000-N-0108,"Reference 25 - ""Eastern Research Group, Inc., “Cost of Implementing MedDRA Terminology for Pharmaceutical and Biologics Companies,”2000"" - [Safety Reporting Requirements for Human Drug and Biological Products; NPR1] re FDA-2000-N-0108-0006"
09000064804c26ba,Supporting & Related Material,FDA-2000-N-0108-0021,FDA-2000-N-0108,"Reference List - ""V.G. References"" - [Safety Reporting Requirements for Human Drug and Biological Products; NPR1] re FDA-2000-N-0108-0006"
09000064804c26f7,Supporting & Related Material,FDA-2000-N-0108-0002,FDA-2000-N-0108,See FDA-2000-N-0108-0006
09000064804c26fb,Proposed Rule,FDA-2000-N-0108-0003,FDA-2000-N-0108,See FDA-2000-N-0108-0006
0900006480b63055,Rule,FDA-2000-N-0108-0071,FDA-2000-N-0108,Final Rule re Investigational New Drug Safety Reporting Requirements for Human Drug and Biological Products: Safety Reporting Requirements for Bioavailability and Bioequivalence Studies in Humans
09000064804c26d1,Supporting & Related Material,FDA-2000-N-0108-0026,FDA-2000-N-0108,"Reference 17 - ""General Accounting Office, Adverse Drug Events The Magnitude of Health Risk Is Uncertain Because of Limited Incidence Data, GAO/HEHS-00-21, January, 2000"" - [Safety Reporting Requirements for Human Drug and Biological Products; NPR1] re FDA-2000-N-0108-0006"
09000064804c26ed,Supporting & Related Material,FDA-2000-N-0108-0022,FDA-2000-N-0108,"Reference 10 - ""Institute of Medicine, edited by Kohn et al., To Err is Human: Building a Safer Health System, National Academy Press, 1999 "" - [Safety Reporting Requirements for Human Drug and Biological Products; NPR1] re FDA-2000-N-0108-0006"
09000064804c26f1,Supporting & Related Material,FDA-2000-N-0108-0023,FDA-2000-N-0108,"Reference 12 - ""Department of Health and Human Services, Office of the Inspector General, Review of the Food and Drug Administration’s Handling of Adverse Drug Reaction Reports, Report No. A-15-98-50001, 1999"" - [Safety Reporting Requirements for Human Drug and Biological Products; NPR1] re FDA-2000-N-0108-0006"
09000064804c26fd,Supporting & Related Material,FDA-2000-N-0108-0004,FDA-2000-N-0108,See FDA-2000-N-0108-0006
0900006480b627cb,Supporting & Related Material,FDA-2000-N-0108-0075,FDA-2000-N-0108,"Reference 5.  U.S. Department of Commerce, Bureau of the Census, Economic Census, Manufacturing Industry Series  [Investigational New Drug Safety Reporting Requirements for Human Drug and Biological Products and Safety Reporting Requirements for Bioavailability and Bioequivalence Studies in Humans, Final Rule]"
09000064804c2946,Supporting & Related Material,FDA-2000-N-0108-0008,FDA-2000-N-0108,"Tab B - ""OMB Review March 14, 2003, Executive Order 12866, Changes in the Regulatory Action Made by OIRA"" - (Safety Reporting Requirements for Human Drug and Biological Products), re FDA-2000-N-0108-0006 - Reference (Pages 79-174)"
09000064804c2951,Supporting & Related Material,FDA-2000-N-0108-0012,FDA-2000-N-0108,"Tab A - ""OMB Review March 14, 2003, Executive Order 12866, Substantive Changes Between the Draft Submitted to OIRA and Action Subsequently Announced"" - (Safety Reporting Requirements for Human Drug and Biological Products), re FDA-2000-N-0108-0006 - Reference (Pages 200-307)"
09000064804c26ad,Supporting & Related Material,FDA-2000-N-0108-0025,FDA-2000-N-0108,"Reference 15  - ""Agency for Health Care Policy and Research, “National Medical Expenditure Survey: Annual Expenses and Sources of Payment for Health Care Services, Research Findings 14,” p.7, 1995"" - [Safety Reporting Requirements for Human Drug and Biological Products; NPR1] re FDA-2000-N-0108-0006"
09000064804c26f5,Supporting & Related Material,FDA-2000-N-0108-0024,FDA-2000-N-0108,"Reference 14 -""Statistical Abstract of the United States: The National Data Book, p.137-138, 1999"" - [Safety Reporting Requirements for Human Drug and Biological Products; NPR1] re FDA-2000-N-0108-0006"
09000064804c265e,Proposed Rule,FDA-2000-N-0108-0001,FDA-2000-N-0108,Notice of Proposed Rulemaking re Safety Reporting Requirements for Human Drug and Biological Products See FDA-2000-N-0108-0006
09000064804c2961,Supporting & Related Material,FDA-2000-N-0108-0016,FDA-2000-N-0108,"Tab B - ""OMB Review March 14, 2003, Executive Order 12866, Changes in the Regulatory Action Made by OIRA"" - (Safety Reporting Requirements for Human Drug and Biological Products), re FDA-2000-N-0108-0006 - Reference (Pages 175-277)"
09000064804c2964,Supporting & Related Material,FDA-2000-N-0108-0017,FDA-2000-N-0108,"Tab B - ""OMB Review March 14, 2003, Executive Order 12866, Changes in the Regulatory Action Made by OIRA"" - (Safety Reporting Requirements for Human Drug and Biological Products), re FDA-2000-N-0108-0006 - Reference (Pages 278-376)"
0900006480b62574,Supporting & Related Material,FDA-2000-N-0108-0073,FDA-2000-N-0108,"Reference 1.  ""Detailed Guidance on the Collection, Verification and Presentation of Adverse Reaction Reports Arising From Clinical Trials on Medicinal Products for Human Use"" [Investigational New Drug Safety Reporting Requirements for Human Drug and Biological Products and Safety Reporting Requirements for Bioavailability and Bioequivalence Studies in Humans, Final Rule]"
09000064804c294a,Supporting & Related Material,FDA-2000-N-0108-0009,FDA-2000-N-0108,"Reference Regulations Policy Management Staff to the Docket, OMB Review March 14, 2003, Executive Order 12866"" - (Safety Reporting Requirements for Human Drug and Biological Products), re FDA-2000-N-0108-0006"
0900006480b62025,Supporting & Related Material,FDA-2000-N-0108-0072,FDA-2000-N-0108,"List of References re Investigational New Drug Safety Reporting Requirements for Human Drug and Biological Products and Safety Reporting Requirements for Bioavailability and Bioequivalence Studies in Humans, Final Rule"
09000064804c294e,Supporting & Related Material,FDA-2000-N-0108-0011,FDA-2000-N-0108,"Tab A - ""OMB Review March 14, 2003, Executive Order 12866, Substantive Changes Between the Draft Submitted to OIRA and Action Subsequently Announced"" - (Safety Reporting Requirements for Human Drug and Biological Products), re FDA-2000-N-0108-0006 - Reference (Pages 100-199)"
0900006480bf6619,Other,FDA-2009-P-0298-0008,FDA-2009-P-0298,"FDA/CFSAN Response to OVOS Natural Health, Inc. (Ullman, Shapiro & Ullman, LLP) - Petition Denial"
09000064809e3560,Other,FDA-2009-P-0298-0001,FDA-2009-P-0298,"OVOS Natural Health, Inc. (Ullman, Shapiro & Ullman, LLP) - Citizen Petition"
0900006480ebc94f,Other,FDA-2009-P-0298-0009,FDA-2009-P-0298,Council for Responsible Nutrition (CRN) - Letter
0900006480a69fe6,Other,FDA-2009-P-0298-0007,FDA-2009-P-0298,"FDA/CFSAN Interim Response to OVOS Natural Health, Inc. (Ullman, Shapiro & Ullman, LLP) - Letter"
09000064809ebbaf,Other,FDA-2009-P-0298-0003,FDA-2009-P-0298,"Acknowledgement Letter to Ullman, Shapiro & Ullman, LLP - Correction"
09000064809e3561,Other,FDA-2009-P-0298-0002,FDA-2009-P-0298,"Acknowledgement Letter to OVOS Natural Health, Inc. (Ullman, Shapiro & Ullman, LLP)"
09000064821f9e0f,Notice,FDA-2014-N-0189-83201,FDA-2014-N-0189,Agency Information Collection Activities; Announcement of Office of  Management and Budget Approvals
0900006481ff9d65,Supporting & Related Material,FDA-2014-N-0189-83195,FDA-2014-N-0189,TAB C 2014-850 Deeming Final Rule as Cleared by OMB
0900006481fbf51a,Supporting & Related Material,FDA-2014-N-0189-83021,FDA-2014-N-0189,"Reference 113 Intentions to Smoke Cigarettes Among re Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and
Cosmetic Act, as Amended by the Family Smoking Prevention and
Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco
Products and Required Warning Statements for Tobacco Product"
0900006481fbf539,Supporting & Related Material,FDA-2014-N-0189-83052,FDA-2014-N-0189,"Reference 144 Acute Effects of Electronic and Tobacco Cigarette re Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and
Cosmetic Act, as Amended by the Family Smoking Prevention and
Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco
Products and Required Warning Statements for Tobacco Product"
0900006481fbf5bd,Supporting & Related Material,FDA-2014-N-0189-83082,FDA-2014-N-0189,"Reference 178 Electronic Nicotine Delivery Systems International Tobacco re Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco
Products and Required Warning Statements for Tobacco Product"
0900006481fbf644,Supporting & Related Material,FDA-2014-N-0189-83088,FDA-2014-N-0189,"Reference 184 Electronic Cigarettes for Smoking Cessation A re Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and
Cosmetic Act, as Amended by the Family Smoking Prevention and
Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco
Products and Required Warning Statements for Tobacco Product"
0900006481fbf647,Supporting & Related Material,FDA-2014-N-0189-83091,FDA-2014-N-0189,"Reference 187 E-Cigarettes and Smoking Cessation Evidence re Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and
Cosmetic Act, as Amended by the Family Smoking Prevention and
Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco
Products and Required Warning Statements for Tobacco Product"
0900006481fbf3fa,Supporting & Related Material,FDA-2014-N-0189-82978,FDA-2014-N-0189,"Reference 73 Alcohol and Tobacco Tax and Trade Bureau re Deeming Tobacco Products To Be Subject to the Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Regulations on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products"
0900006481fbf3fb,Supporting & Related Material,FDA-2014-N-0189-82979,FDA-2014-N-0189,"Reference 73a  Dec 2013 Dept of Treasury Statistical Report - Tobacco re Deeming Tobacco Products To Be Subject to the Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Regulations on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products"
0900006481fbf4bd,Supporting & Related Material,FDA-2014-N-0189-83063,FDA-2014-N-0189,"Reference 159 Characterization of Chemicals Released to the Env re Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and
Cosmetic Act, as Amended by the Family Smoking Prevention and
Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco
Products and Required Warning Statements for Tobacco Product"
0900006481fbf4d1,Supporting & Related Material,FDA-2014-N-0189-83072,FDA-2014-N-0189,"Reference 168 2012 Annual Report of the American Association of Poison re Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and
Cosmetic Act, as Amended by the Family Smoking Prevention and
Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco
Products and Required Warning Statements for Tobacco Product"
0900006481fbf515,Supporting & Related Material,FDA-2014-N-0189-83016,FDA-2014-N-0189,"Reference 108 Electronic Cigarette Use Among Middle and HS Students re Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products"
0900006481fbf516,Supporting & Related Material,FDA-2014-N-0189-83017,FDA-2014-N-0189,"Reference 109 Characteristics Perceived Side Effects and Benefits of Electronic Cigarette Use re Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products"
0900006481fbf65c,Supporting & Related Material,FDA-2014-N-0189-83112,FDA-2014-N-0189,"Reference 208 The Adolescent Brain and Age Related Behavioral Manifestations re Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Product"
0900006481fbf661,Supporting & Related Material,FDA-2014-N-0189-83117,FDA-2014-N-0189,"Reference 213 Curbing the Epidemic Governments and the Economics of Tobacco Control re Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Product"
0900006481fbf666,Supporting & Related Material,FDA-2014-N-0189-83122,FDA-2014-N-0189,"Reference 218 Tobacco Specific Nitrosamines re Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and
Cosmetic Act, as Amended by the Family Smoking Prevention and
Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco
Products and Required Warning Statements for Tobacco Product"
0900006481fbf691,Supporting & Related Material,FDA-2014-N-0189-83127,FDA-2014-N-0189,"Reference 224 Hookah Use Among US College Students re Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and
Cosmetic Act, as Amended by the Family Smoking Prevention and
Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco
Products and Required Warning Statements for Tobacco Product"
0900006481fbf693,Supporting & Related Material,FDA-2014-N-0189-83129,FDA-2014-N-0189,"Reference 226 Waterpipe Smoking The Role of Humectants in the Relesase of Toxic Carbonyls re Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Product"
0900006481fbf695,Supporting & Related Material,FDA-2014-N-0189-83131,FDA-2014-N-0189,"Reference 228 Change in Carbon Monoxide Exposure Among Waterpipe Bar Patrons re Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Product"
0900006481fbf696,Supporting & Related Material,FDA-2014-N-0189-83132,FDA-2014-N-0189,"Reference 229 Polycyclic Aromatic Hydrocarbons, Carbon Monoxide Tar and Nicotine re Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Product"
0900006481fbf69c,Supporting & Related Material,FDA-2014-N-0189-83138,FDA-2014-N-0189,"Reference 235 In Vitro Cytotoxicity and Mutagencity of Mainstream Waterpipe Smoke re Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Product"
0900006481fbf039,Supporting & Related Material,FDA-2014-N-0189-82934,FDA-2014-N-0189,"Reference 24 Electronic Cigarette Use Among Adults re Deeming Tobacco Products To Be Subject to the Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Regulations on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products"
0900006481fbf03a,Supporting & Related Material,FDA-2014-N-0189-82933,FDA-2014-N-0189,"Reference 25 Prevalence and Correlates of Waterpipe Tobacco Smoking by College Students in NC re Deeming Tobacco Products To Be Subject to the Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Regulations on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products"
0900006481fbf03f,Supporting & Related Material,FDA-2014-N-0189-82928,FDA-2014-N-0189,"Reference 30 Growing Up Tobacco Free Preventing Nicotine Addiction re Deeming Tobacco Products To Be Subject to the Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Regulations on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products"
0900006481fbf042,Supporting & Related Material,FDA-2014-N-0189-82925,FDA-2014-N-0189,"Reference 33 Deposition of Cigar Smoke Particles in the Lung re Deeming Tobacco Products To Be Subject to the Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Regulations on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products"
0900006480478037,Other,FDA-1989-P-0124-0001,FDA-1989-P-0124,"Sonnenreich & Reccograndi, P.C. - Citizen Petition"
090000648047804b,Other,FDA-1989-P-0124-0007,FDA-1989-P-0124,"Sonnenreich & Roccograndi, PC to FDA/CDER February 23, 1993 - Letter"
0900006480478047,Other,FDA-1989-P-0124-0005,FDA-1989-P-0124,"FDA/CDER Interim Response to Sonnenreich & Roccograndi, PC"
0900006481119c33,Other,FDA-1989-P-0124-0002,FDA-1989-P-0124,"Acknowledgement Letter to Sonnenreich & Roccograndi, PC"
090000648047804d,Other,FDA-1989-P-0124-0008,FDA-1989-P-0124,"Sonnenreich & Roccograndi, PC to FDA/CDER March 25 1993 - Letter"
0900006481113d00,Other,FDA-1989-P-0124-0011,FDA-1989-P-0124,FDA/CDER to Division of Dockets Management - Memorandum
09000064811130f8,Other,FDA-1989-P-0124-0010,FDA-1989-P-0124,FDA/CDER to Sonnenreich Roccograndi and Woo PC - Letter
0900006480478045,Other,FDA-1989-P-0124-0004,FDA-1989-P-0124,FDA/CDER to Health Industry Manufacturers Association (HIMA) - Letter
0900006480478049,Other,FDA-1989-P-0124-0006,FDA-1989-P-0124,"Sonnenreich & Roccograndi, PC to FDA/CDER January 2 1993 - Letter"
090000648047804f,Other,FDA-1989-P-0124-0009,FDA-1989-P-0124,"FDA/CDER to Sonnenreich, Roccograndi, & Woo, PC"
0900006481e6a698,Other,FDA-2015-D-4848-0002,FDA-2015-D-4848,Draft Guidance for Industry and FDA Staff Human Factors Studies and Related Clinical Study Considerations in Combination Product Design and Development
0900006481e49f90,Notice,FDA-2015-D-4848-0001,FDA-2015-D-4848,"Human Factors Studies and Related Clinical Study Considerations in
Combination Product Design and Development; Draft Guidance for
Industry and Food and Drug Administration Staff; Availability"
0900006481f93448,Supporting & Related Material,FDA-2014-N-1021-0557,FDA-2014-N-1021,"Attachment A-6 Janssen G, et al (2015) Ineffective Degradation of Immunogenic Gluten Epitopes by Currently Available Digestive Enzyme Supplements. PLoS One, Jun 1;10(6):e0128065. doi: 10.1371 journal.pone.0128065 re: Comment from Craft Brew Alliance"
0900006481e13eda,Other,FDA-2014-N-1021-0073,FDA-2014-N-1021,Request for Extension from Beer Institute
0900006481e620b0,Other,FDA-2014-N-1021-0232,FDA-2014-N-1021,Request to Extend Comment Period from Celiac Support Association (CSA)
0900006481e5d9e4,Other,FDA-2014-N-1021-0231,FDA-2014-N-1021,"Request to Extend Comment Period from New Belgium Brewing Company, Inc."
0900006481d38c33,Supporting & Related Material,FDA-2014-N-1021-0003,FDA-2014-N-1021,Reference 1.  Ciclitira - Clinical Testing of Gliadin re Food Labeling; Gluten-Free Labeling of Fermented or Hydrolyzed Foods
0900006481d3929c,Supporting & Related Material,FDA-2014-N-1021-0009,FDA-2014-N-1021,"Reference 7.  Köhler, et al., Immunochemical Determination of Partially Hydrolyzed Gluten re Food Labeling; Gluten-Free Labeling of Fermented or Hydrolyzed Foods"
09000064847f996f,Rule,FDA-2014-N-1021-0560,FDA-2014-N-1021,Food Labeling; Gluten-Free Labeling of Fermented or Hydrolyzed Foods
09000064847fe93e,Supporting & Related Material,FDA-2014-N-1021-0564,FDA-2014-N-1021,Reference 10 Using mass spectrometry to detect hydrolysed gluten in beer that isresponsible for false negatives by ELISA re: Food Labeling; Gluten-Free Labeling of Fermented or Hydrolyzed Foods
0900006481d38ea2,Supporting & Related Material,FDA-2014-N-1021-0002,FDA-2014-N-1021,References Index re Food Labeling; Gluten-Free Labeling of Fermented or Hydrolyzed Foods
0900006481d39621,Supporting & Related Material,FDA-2014-N-1021-0010,FDA-2014-N-1021,Reference 8.  Codex - Foods for Special Dietary Use Standard 118-1979 re Food Labeling; Gluten-Free Labeling of Fermented or Hydrolyzed Foods
0900006481d39623,Supporting & Related Material,FDA-2014-N-1021-0011,FDA-2014-N-1021,Reference 9.  Garber - ELISA Methods Used to Detect Gluten in Foods re Food Labeling; Gluten-Free Labeling of Fermented or Hydrolyzed Foods
0900006481d39704,Supporting & Related Material,FDA-2014-N-1021-0014,FDA-2014-N-1021,Reference 12. Fellows - Chapter 14- Evaporation and Distillation in Food Processing and Technology re Food Labeling; Gluten-Free Labeling of Fermented or Hydrolyzed Foods
0900006481d3979b,Supporting & Related Material,FDA-2014-N-1021-0018,FDA-2014-N-1021,Reference 16. FDA - PRIA of Gluten-Free Labeling of Fermented or Hydrolyzed Foods re Food Labeling; Gluten-Free Labeling of Fermented or Hydrolyzed Foods
0900006481d38c93,Supporting & Related Material,FDA-2014-N-1021-0005,FDA-2014-N-1021,Reference 3.  Food Essentials - Product Label Database re Food Labeling; Gluten-Free Labeling of Fermented or Hydrolyzed Foods
0900006481d3956a,Supporting & Related Material,FDA-2014-N-1021-0006,FDA-2014-N-1021,Reference 4.  Belitz - Enzyme Immunoassay in Food Chemistry re Food Labeling; Gluten-Free Labeling of Fermented or Hydrolyzed Foods
0900006481d3956d,Supporting & Related Material,FDA-2014-N-1021-0007,FDA-2014-N-1021,Reference 5.  Ciccocioppo - Immune Recognition of Gluten in Coeliac Disease re Food Labeling; Gluten-Free Labeling of Fermented or Hydrolyzed Foods
090000648485d18e,Supporting & Related Material,FDA-2014-N-1021-0575,FDA-2014-N-1021,FDA tab B - Gluten F-H - RIA (OMB redline compare 2-7-20 to 7-16-20) re FDA - Gluten F-H Memo to DMS
090000648485d18d,Supporting & Related Material,FDA-2014-N-1021-0574,FDA-2014-N-1021,FDA tab B - Gluten F-H - Final Rule (OMB redline compare 2-7-20 to 7-16-20) re FDA - Gluten F-H Memo to DMS
09000064847fe8e7,Supporting & Related Material,FDA-2014-N-1021-0568,FDA-2014-N-1021,Reference 16 2010 NATIONWIDE SURVEY OF FOOD INDUSTRY SAFETY PRACTICES re: Food Labeling; Gluten-Free Labeling of Fermented or Hydrolyzed Foods
0900006481f93339,Supporting & Related Material,FDA-2014-N-1021-0556,FDA-2014-N-1021,Exhibit 1 Sample Omission Labeling re: Comment from Craft Brew Alliance
0900006481e6bc04,Other,FDA-2014-N-1021-0254,FDA-2014-N-1021,Request for Extension from Charles Bamforth
0900006481e2e464,Other,FDA-2014-N-1021-0149,FDA-2014-N-1021,Request for Extension from Brewers Association
09000064847fe93d,Supporting & Related Material,FDA-2014-N-1021-0563,FDA-2014-N-1021,"Reference 9 Effects of a Proline Endopeptidase on the Detection and
Quantitation of Gluten by Antibody-Based Methods during the
Fermentation of a Model Sorghum Beer re: Food Labeling; Gluten-Free Labeling of Fermented or Hydrolyzed Foods"
09000064847fea2f,Supporting & Related Material,FDA-2014-N-1021-0566,FDA-2014-N-1021,Reference 12 Improving wheat to remove coeliac epitopes but retain functionality re: Food Labeling; Gluten-Free Labeling of Fermented or Hydrolyzed Foods
090000648485d18c,Supporting & Related Material,FDA-2014-N-1021-0573,FDA-2014-N-1021,FDA tab A - Gluten F-H - RIA (2-7-20 to OMB) re FDA - Gluten F-H Memo to DMS
090000648111a7db,Other,FDA-1995-P-0043-0006,FDA-1995-P-0043,FDA/CDER to Division of Dockets Management - Memorandum
0900006480561371,Other,FDA-1995-P-0043-0004,FDA-1995-P-0043,"FDA/CDER to Sonnenreich Roccograndi & Woo P.C., October 5, 1995 - Letter"
090000648056133f,Other,FDA-1995-P-0043-0001,FDA-1995-P-0043,"Acknowledgement Letter to Sonnenreich, Roccograndi & Woo"
090000648111a7d9,Other,FDA-1995-P-0043-0005,FDA-1995-P-0043,FDA/CDER to Sonnenreich Roccograndi and Woo PC - Letter re FDA-1995-P-0043-0002
0900006480561361,Other,FDA-1995-P-0043-0002,FDA-1995-P-0043,"Sonnenreich, Roccograndi & Woo, P.C. - Citizen Petition"
090000648056136f,Other,FDA-1995-P-0043-0003,FDA-1995-P-0043,"FDA/CDER to Sonnenreich Roccograndi & Woo P.C., June 21, 1995 - Letter"
09000064813823a9,Proposed Rule,FDA-2011-N-0146-0024,FDA-2011-N-0146,Accreditation of Third-Party Auditors/Certification Bodies to Conduct Food Safety Audits and to Issue Certifications
090000648152c733,Other,FDA-2011-N-0146-0112,FDA-2011-N-0146,Record of Outreach Sessions from FDA/CFSAN
090000648152c5de,Other,FDA-2011-N-0146-0104,FDA-2011-N-0146,Record of Outreach Sessions from FDA/CFSAN
09000064824074c7,Rule,FDA-2011-N-0146-0241,FDA-2011-N-0146,Amendments to Accreditation of Third-Party Certification Bodies to Conduct Food Safety Audits and to Issue Certifications to Provide for User Fee Program
0900006481453f5b,Other,FDA-2011-N-0146-0038,FDA-2011-N-0146,"OMB Review of Proposed Rule re Executive Order 12866 Accreditation of Third-Party Auditors/Certification Bodies to Conduct Food Safety Audits and to Issue Certifications (Proposed Rule); July 29, 2013 - Memorandum"
0900006482408b4f,Supporting & Related Material,FDA-2011-N-0146-0242,FDA-2011-N-0146,List of References re Amendments to Accreditation of Third-Party Certification Bodies to Conduct Food Safety Audits and to Issue Certifications to Provide for User Fee Program
0900006482408b52,Supporting & Related Material,FDA-2011-N-0146-0245,FDA-2011-N-0146,Reference 03 Regulatory Impact Analysis for Third-Party Final Rule re Amendments to Accreditation of Third-Party Certification Bodies to Conduct Food Safety Audits and to Issue Certifications to Provide for User Fee Program
0900006481d5be76,Supporting & Related Material,FDA-2011-N-0146-0204,FDA-2011-N-0146,"Reference 8: International Organization for Standardization, ISO 19011:2011 Guidelines for Auditing Management Systems,” re Accreditation of Third-Party Certification Bodies To Conduct Food Safety Audits and To Issue Certifications"
0900006481d5be77,Supporting & Related Material,FDA-2011-N-0146-0205,FDA-2011-N-0146,"Reference 10: International Organization for Standardization/International Electrotechnical Commission, “ISO/IEC 17020:2012 Conformity Assessment--Requirements for the Operation of Various Types of Bodies Performing Inspection,” re Accreditation of Third-Party Certification Bodies To Conduct Food Safety Audits and To Issue Certifications"
0900006481d5bf1a,Supporting & Related Material,FDA-2011-N-0146-0206,FDA-2011-N-0146,"Reference 11: Global Food Safety Initiative, “Enhancing Food Safety Through Third-Party Certification,” March 2011 re Accreditation of Third-Party Certification Bodies To Conduct Food Safety Audits and To Issue Certifications"
0900006481d5bf1c,Supporting & Related Material,FDA-2011-N-0146-0208,FDA-2011-N-0146,"Reference 13: International Accreditation Forum, “IAF Endorsed Normative Documents, Issue 4 (IAF PR 4:2007),” re Accreditation of Third-Party Certification Bodies To Conduct Food Safety Audits and To Issue Certifications"
0900006481d5bf1d,Supporting & Related Material,FDA-2011-N-0146-0209,FDA-2011-N-0146,"Reference 14: Codex Alimentarius Commission, “Principles for Food Import and Export Inspection and Certification (CAC/GL 20-1995)” re Accreditation of Third-Party Certification Bodies To Conduct Food Safety Audits and To Issue Certifications"
0900006481b9da54,Notice,FDA-2011-N-0146-0179,FDA-2011-N-0146,Third-Party Auditor/Certification Body Accreditation for Food Safety Audits: Model Accreditation Standards; Draft Guidance for Industry and Food and Drug Administration Staff; Availability
0900006481ba7aa4,Supporting & Related Material,FDA-2011-N-0146-0182,FDA-2011-N-0146,List of References re User Fee Program To Provide for Accreditation of Third-Party Auditors/Certification Bodies To Conduct Food Safety Audits and To Issue Certifications
0900006481ba7aa6,Supporting & Related Material,FDA-2011-N-0146-0184,FDA-2011-N-0146,Reference 2  MDUF Small Business Guidance re User Fee Program To Provide for Accreditation of Third-Party Auditors/Certification Bodies To Conduct Food Safety Audits and To Issue Certifications
0900006481ba7aa7,Supporting & Related Material,FDA-2011-N-0146-0185,FDA-2011-N-0146,Reference 3 User Fee Waivers Guidance re User Fee Program To Provide for Accreditation of Third-Party Auditors/Certification Bodies To Conduct Food Safety Audits and To Issue Certifications
09000064823e6ef0,Notice,FDA-2011-N-0146-0239,FDA-2011-N-0146,Third-Party Certification Body Accreditation for Food Safety Audits:  Model Accreditation Standards; Guidance for Industry and Food and Drug Administration Staff; Availability
0900006481d76139,Rule,FDA-2011-N-0146-0198,FDA-2011-N-0146,Accreditation of Third-Party Certification Bodies To Conduct Food Safety Audits and To Issue Certifications
090000648152db2a,Other,FDA-2011-N-0146-0173,FDA-2011-N-0146,Transcript from FDA/CFSAN
090000648152c676,Other,FDA-2011-N-0146-0106,FDA-2011-N-0146,Record of Outreach Sessions from FDA/CFSAN
090000648152cc1f,Other,FDA-2011-N-0146-0132,FDA-2011-N-0146,Record of Outreach Sessions from FDA/CFSAN
0900006482408b50,Supporting & Related Material,FDA-2011-N-0146-0243,FDA-2011-N-0146,Reference 01 ISO IEC 17011-2004_copyright re Amendments to Accreditation of Third-Party Certification Bodies to Conduct Food Safety Audits and to Issue Certifications to Provide for User Fee Program
0900006482408b51,Supporting & Related Material,FDA-2011-N-0146-0244,FDA-2011-N-0146,Reference 02 Preliminary Regulatory Impact Analysis for Third-Party Proposed Rule re Amendments to Accreditation of Third-Party Certification Bodies to Conduct Food Safety Audits and to Issue Certifications to Provide for User Fee Program
0900006481b9dfd9,Other,FDA-2011-N-0146-0180,FDA-2011-N-0146,Third-Party Auditor/Certification Body Accreditation for Food Safety Audits: Model Accreditation Standards; Draft Guidance for Industry and Food and Drug Administration Staff
090000648148bc0e,Proposed Rule,FDA-2011-N-0146-0039,FDA-2011-N-0146,Accreditation of Third-Party Auditors/Certification Bodies to Conduct Food Safety Audits and to Issue Certifications; Extension of Comment Periods
0900006480c08cba,Notice,FDA-2010-N-0122-0003,FDA-2010-N-0122,"Agency Information Collection Activities; Proposals, Submissions, and Approvals: Focus Groups About Drug Products as Used by the Food and Drug Administration"
0900006480ac4803,Notice,FDA-2010-N-0122-0001,FDA-2010-N-0122,"Agency Information Collection Activities; Proposals, Submissions, and Approvals: Focus Groups About Drug Products, as Used by the Food and Drug Administration"
0900006480b15f89,Notice,FDA-2010-N-0122-0002,FDA-2010-N-0122,"Agency Information Collection Activities; Proposals, Submissions, and Approvals: Focus Groups About Drug Products, as Used by the Food and Drug Administration"
09000064824a31a6,Supporting & Related Material,FDA-2013-P-0735-0012,FDA-2013-P-0735,06 Reference 4-Fed Register PDUFA Patient-focused Drug Development - Request for Comments
090000648132d33d,Other,FDA-2013-P-0735-0001,FDA-2013-P-0735,Acknowledgement Letter to Mario Morais
0900006481832502,Other,FDA-2013-P-0735-0003,FDA-2013-P-0735,Petition Response from FDA/CDRH to Mario Morais
090000648132d1e2,Other,FDA-2013-P-0735-0002,FDA-2013-P-0735,Citizen Petition from Mario Morais
090000648187a97b,Other,FDA-2013-P-0735-0004,FDA-2013-P-0735,Appeal From Mario Morais
09000064824a31a1,Supporting & Related Material,FDA-2013-P-0735-0008,FDA-2013-P-0735,01 Reference  1-Safety Communications _ Chronic Cerebrospinal Venous Insufficiency Treatment in Multiple Sclerosis Patients_ FDA Safety Communication - Copy
09000064824a31a2,Supporting & Related Material,FDA-2013-P-0735-0009,FDA-2013-P-0735,02 Guidance for Industry 1-Expanded Access to Investigational Drugs for Treatment Use — Questions and Answers - Copy
09000064824a31a0,Supporting & Related Material,FDA-2013-P-0735-0007,FDA-2013-P-0735,Reference List for 0735
09000064824a25ed,Other,FDA-2013-P-0735-0006,FDA-2013-P-0735,FDA Response to joint appeal in FDA-2012-P-0119 and FDA-2013-P-0735
090000648187a97d,Other,FDA-2013-P-0735-0005,FDA-2013-P-0735,Redacted Appeal From Mario Morais
090000648250c0fb,Other,FDA-2013-P-0735-0016,FDA-2013-P-0735,Mario Morais Email March 15 2017
09000064824a31a3,Supporting & Related Material,FDA-2013-P-0735-0010,FDA-2013-P-0735,03 Guidance for Industry 2-Individual Patient Expanded Access Applications_ Form FDA 3926 - Copy
09000064824a31a5,Supporting & Related Material,FDA-2013-P-0735-0013,FDA-2013-P-0735,05 Reference 3-PDUFA _ Enhancing Benefit-Risk Assessment in Regulatory Decision-Making - Copy
09000064824a31a7,Supporting & Related Material,FDA-2013-P-0735-0011,FDA-2013-P-0735,07 Reference 5-Prescription Drug User Fee Act (PDUFA) _ Patient-Focused Drug Development_ Disease Area Meetings Planned for Fiscal Years 2013-2017 - Copy
09000064824a31a8,Supporting & Related Material,FDA-2013-P-0735-0015,FDA-2013-P-0735,08 Reference 6-PDUFA Reauthorization Performance Goals and Procedures FY18-22
09000064824a31a4,Supporting & Related Material,FDA-2013-P-0735-0014,FDA-2013-P-0735,04 - Reference 2-PDUFA _ The Voice of the Patient_ A Series of Reports from FDA's Patient-Focused Drug Development Initiative - Copy
0900006481856a04,Other,FDA-2014-P-0748-0006,FDA-2014-P-0748,Citizen Petition Approval Letter from FDA/CVM to Piedmont Animal Health
09000064817282ac,Supporting & Related Material,FDA-2014-P-0748-0004,FDA-2014-P-0748,Reference 1 Proposed Revised Labeling Citizen Petition from Piedmont Animal Health
0900006481728104,Other,FDA-2014-P-0748-0001,FDA-2014-P-0748,Citizen Petition From Piedmont Animal Health
0900006481728108,Other,FDA-2014-P-0748-0002,FDA-2014-P-0748,Acknowledgement Letter from FDA DDM to Piedmont Animal Health
090000648174dd39,Other,FDA-2014-P-0748-0005,FDA-2014-P-0748,Amendment from Piedmont Animal Health
09000064817282ab,Supporting & Related Material,FDA-2014-P-0748-0003,FDA-2014-P-0748,Reference 1 Current Labeling Citizen Petition From Piedmont Animal Health
0900006480475d50,Notice,FDA-1988-N-0019-0001,FDA-1988-N-0019,FDA
0900006481527db3,Proposed Rule,FDA-1988-N-0019-0028,FDA-1988-N-0019,Semiannual Regulatory Agenda
09000064807410a4,Notice,FDA-2005-N-0345-0002,FDA-2005-N-0345,"Distribution of Certain Drug Products by Registered Blood Establishments and Comprehensive Hemophilia Diagnostic Treatment Centers That Qualify as Health Care Entities; Prescription Drug Marketing Act of 1987; Prescription Drug Amendments of 1992; Policies, Requirements and Administrative Procedures"
0900006481527db7,Proposed Rule,FDA-2005-N-0345-0006,FDA-2005-N-0345,Semiannual Regulatory Agenda
0900006480449864,Proposed Rule,FDA-2005-N-0345-0001,FDA-2005-N-0345,"Distribution of Blood Derivatives by Registered Blood Establishments that Qualify as Health Care Entities; Prescription Drug Marketing Act of 1987; Prescription Drug Amendments of 1992; Policies, Requirements and Administrative Procedures; Proposed Rule"
0900006481527db8,Proposed Rule,FDA-1992-N-0407-0001,FDA-1992-N-0407,Semiannual Regulatory Agenda
0900006481f94d20,Rule,FDA-2011-N-0143-0388,FDA-2011-N-0143,Foreign Supplier Verification Programs for Importers of Food for Humans and Animals; Technical Amendment
0900006481d7fc9e,Supporting & Related Material,FDA-2011-N-0143-0373,FDA-2011-N-0143,Reference 5 - Model for Local Federal_State Planning and Coordination of Field Operations and Training re Foreign Supplier Verification Programs for Importers of Food for Humans and Animals
0900006481d7fca1,Supporting & Related Material,FDA-2011-N-0143-0374,FDA-2011-N-0143,Reference 6 - Guidelines for Food Import Control Systems re Foreign Supplier Verification Programs for Importers of Food for Humans and Animals
0900006481d7fced,Supporting & Related Material,FDA-2011-N-0143-0375,FDA-2011-N-0143,Reference 7 - HACCP System and Guidelines for Its Application re Foreign Supplier Verification Programs for Importers of Food for Humans and Animals
0900006481d7fec8,Supporting & Related Material,FDA-2011-N-0143-0377,FDA-2011-N-0143,Reference 9 - General Standard for the Labelling of Prepackaged Food re Foreign Supplier Verification Programs for Importers of Food for Humans and Animals
0900006481d7ff97,Supporting & Related Material,FDA-2011-N-0143-0383,FDA-2011-N-0143,Reference 16 - Information for Foreign Governments  Frequently Asked Questions on Systems Recognition re Foreign Supplier Verification Programs for Importers of Food for Humans and Animals
0900006481d7ff9c,Supporting & Related Material,FDA-2011-N-0143-0385,FDA-2011-N-0143,Reference 18 - WTO Ministerial Conference Implementaion-Related Issues and Concerns re Foreign Supplier Verification Programs for Importers of Food for Humans and Animals
0900006481d801a1,Supporting & Related Material,FDA-2011-N-0143-0381,FDA-2011-N-0143,Reference 14 - Reportable Food Registry Guidance for Industry re Foreign Supplier Verification Programs for Importers of Food for Humans and Animals
090000648152dbed,Other,FDA-2011-N-0143-0240,FDA-2011-N-0143,Record of Outreach Session from FDA/CFSAN
0900006481525692,Supporting & Related Material,FDA-2011-N-0143-0255,FDA-2011-N-0143,Record of Outreach Sessions on FDA Proposed Rules IFT Members Webinar August 14 2013 re Form FDA 3876
090000648152daa4,Other,FDA-2011-N-0143-0234,FDA-2011-N-0143,Record of Outreach Session from FDA/CFSAN
0900006482e6458d,Proposed Rule,FDA-2011-N-0143-0400,FDA-2011-N-0143,"Foreign Supplier Verification Programs for Importers of Food for Humans and Animals: What You Need To Know About the Food and Drug
Administration Regulation; Small Entity Compliance Guide; Availability"
09000064814411b7,Other,FDA-2011-N-0143-0036,FDA-2011-N-0143,"OMB Review of Proposed Rule re Executive Order 12866, Foreign Supplier Verification Programs for Importers of Food for Humans and Animals, July 29, 2013 - Memorandum"
09000064818cdcbc,Supporting & Related Material,FDA-2011-N-0143-0253,FDA-2011-N-0143,"Tab C Final Regulatory Action as Cleared by OMB  (Suppl NPRM) OMB Executive Order 12866 Regulatory Planning and Review re Foreign Supplier Verification Programs for Importers of Food for Humans and Animals (Supplemental Proposed Rule); Publication Date: September 29, 2014 see FDA-2011-N-0143-0248"
09000064818cdcbd,Supporting & Related Material,FDA-2011-N-0143-0254,FDA-2011-N-0143,"Tab C Finall Regulatoy Action as Cleared by OMB  (Suppl PRIA) OMB Executive Order 12866 Regulatory Planning and Review re Foreign Supplier Verification Programs for Importers of Food for Humans and Animals (Supplemental Proposed Rule); Publication Date: September 29, 2014 see FDA-2011-N-0143-0248"
090000648143cc64,Other,FDA-2011-N-0143-0029,FDA-2011-N-0143,Testimony from Pew Charitable Trusts
0900006482550a24,Supporting & Related Material,FDA-2011-N-0143-0391,FDA-2011-N-0143,List of references re The Food and Drug Administration Food Safety Modernization Act; Extension and Clarification of Compliance Dates for Certain Provisions of Four Implementing Rules
0900006482550a25,Supporting & Related Material,FDA-2011-N-0143-0392,FDA-2011-N-0143,Reference 1 GMA Industry Impacts from Disclosure and Written Assurance Requirements re The Food and Drug Administration Food Safety Modernization Act; Extension and Clarification of Compliance Dates for Certain Provisions of Four Implementing Rules
0900006482550a26,Supporting & Related Material,FDA-2011-N-0143-0393,FDA-2011-N-0143,Reference 2 United Fresh Produce Association Letter April 19 2016 re The Food and Drug Administration Food Safety Modernization Act; Extension and Clarification of Compliance Dates for Certain Provisions of Four Implementing Rules
0900006482550a29,Supporting & Related Material,FDA-2011-N-0143-0396,FDA-2011-N-0143,Reference 5 Part 117 FSMA Final Rulemaking for CGMP and HAPC for Human Food RIA re The Food and Drug Administration Food Safety Modernization Act; Extension and Clarification of Compliance Dates for Certain Provisions of Four Implementing Rules
09000064814a2afc,Other,FDA-2011-N-0143-0244,FDA-2011-N-0143,Transcript from FDA Food Safety  Modernization Act Imports Rules  September 19 2013 Day One
09000064818f824b,Proposed Rule,FDA-2011-N-0143-0259,FDA-2011-N-0143,Food and Drug Administration Food Safety Modernization Act: Meetings on Rule Revisions
0900006481898ff6,Proposed Rule,FDA-2011-N-0143-0247,FDA-2011-N-0143,Foreign Supplier Verification Programs for Importers of Food for Humans and Animals
0900006483007e46,Other,FDA-2011-N-0143-0402,FDA-2011-N-0143,"Compliance with Providing an Acceptable Unique Facility Identifier for
the Foreign Supplier Verification Programs Regulation: Guidance for
Industry"
090000648188d030,Other,FDA-2011-N-0143-0246,FDA-2011-N-0143,"Comparison Redlined Version of the Codified Sections Published on July 29, 2013 and September 29, 2014"
09000064807072de,Other,FDA-2008-P-0511-0001,FDA-2008-P-0511,"Citizen Petition from Claxton Bakery et al (Bell, Boyd & Lloyd LLP)"
090000648070735f,Other,FDA-2008-P-0511-0002,FDA-2008-P-0511,"Acknowledgment Letter from FDA DDM to Bell, Boyd & Lloyd LLP"
0900006482e1fcb2,Other,FDA-2008-P-0511-0003,FDA-2008-P-0511,"Letter from FDA CSFAN to K&L Gates (formerly Bell, Boyd & Lloyd LLP)"
0900006480c0eca4,Proposed Rule,FDA-2011-N-0029-0001,FDA-2011-N-0029,Medical Devices Ovarian Adnexal Mass Assessment Score Test System; Labeling; Black Box Restrictions
09000064811626df,Supporting & Related Material,FDA-2011-N-0090-0218,FDA-2011-N-0090,GS1 US - Comment
09000064811626e2,Supporting & Related Material,FDA-2011-N-0090-0219,FDA-2011-N-0090,GS1 US - Comment
0900006481082634,Proposed Rule,FDA-2011-N-0090-0001,FDA-2011-N-0090,Unique Device Identification System
090000648115ee5a,Other,FDA-2011-N-0090-0107,FDA-2011-N-0090,GS1® and the GS1 US™ - Supplement re FDA-2011-N-0090-0080
09000064811df0d0,Supporting & Related Material,FDA-2011-N-0090-0273,FDA-2011-N-0090,Alphatec Spine - Supplement
09000064811196ad,Proposed Rule,FDA-2011-N-0090-0019,FDA-2011-N-0090,Agency Information Collection Activities; Proposed Collection; Unique Device Identification System; Extension of Comment Period
09000064811626e4,Supporting & Related Material,FDA-2011-N-0090-0220,FDA-2011-N-0090,GS1 US - Comment
0900006481ea0935,Rule,FDA-2011-N-0090-0276,FDA-2011-N-0090,Unique Device Identification System; Editorial Provisions; Technical  Amendment
09000064814340dc,Rule,FDA-2011-N-0090-0274,FDA-2011-N-0090,Unique Device Identification System
09000064810871a6,Other,FDA-2011-N-0090-0022,FDA-2011-N-0090,National Council for Prescription Drug Programs (NCPDP) to FDA\CDRH -  Letter
090000648108723e,Other,FDA-2011-N-0090-0023,FDA-2011-N-0090,Advancing Patient Safety Coalition to Office of Management and Budget  -  Letter
090000648145cdfb,Other,FDA-2011-N-0090-0275,FDA-2011-N-0090,FDA/OC to Dockets Management - Memorandum
090000648116ca95,Proposed Rule,FDA-2011-N-0090-0222,FDA-2011-N-0090,Unique Device Identification System; Amendment
09000064810a3278,Other,FDA-2011-N-0090-0002,FDA-2011-N-0090,"Unique Device Identification System - OMB Review, Executive Order 12866  July 10,2012 - Reference"
090000648186845f,Notice,FDA-2014-D-1182-0001,FDA-2014-D-1182,"Unique Device Identification System: Small Entity Compliance Guide;
Guidance for Industry; Availability"
090000648186916c,Other,FDA-2014-D-1182-0002,FDA-2014-D-1182,Small Entity Compliance Guide: Unique Device Identification System; Availability
0900006481babb41,Other,FDA-2015-N-2713-0001,FDA-2015-N-2713,Dear Applicant Letter from FDA Center for Drug Evaluation and Research re Cyclosporine Ophthalmic Emulsion ANDA Applicant
0900006481854cf7,Other,FDA-2014-P-0404-0004,FDA-2014-P-0404,"Response from FDA/CDER Partial Approval and Denial Letter to Teva Pharmaceutical Industries, LTD (Teva Respiratory, LLC)"
09000064816a1ee3,Other,FDA-2014-P-0404-0002,FDA-2014-P-0404,Acknowledgement letter from FDA/DDM to Teva Pharmaceutical Industries LTD (Teva Respiratory LLC)
090000648169f67b,Other,FDA-2014-P-0404-0001,FDA-2014-P-0404,"Citizen Petition From Teva Pharmaceutical Industries, LTD (Teva Respiratory, LLC)"
090000648171fbc5,Supporting & Related Material,FDA-2013-N-0500-0078,FDA-2013-N-0500,"Attachment 3 Revised Virilon Package Insert with Changes Highlighted Supplement from Star Pharmaceuticals, Inc."
090000648171fd33,Other,FDA-2013-N-0500-0075,FDA-2013-N-0500,"Supplement from Star Pharmaceuticals, Inc."
09000064839949a4,Supporting & Related Material,FDA-2013-N-0500-0143,FDA-2013-N-0500,"03- Reference 02- U.S. Department of Health and Human Services, Food and Drug Administration, “Fiscal Year 2019 Justification of Estimates for Appropriations Committees"
09000064814bc8a9,Other,FDA-2013-N-0500-0005,FDA-2013-N-0500,"OMB Review Proposed Rule re Executive Order 12866, Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products 11-13-2013 - Memorandum"
09000064814c6d0a,Other,FDA-2013-N-0500-0010,FDA-2013-N-0500,Request for Extension from Biotechnology Industry Organization (BIO) and Pharmaceutical Research and Manufacturers of America (PhRMA)
09000064814c5e12,Other,FDA-2013-N-0500-0009,FDA-2013-N-0500,Request for Extension from Mylan
0900006481ab9bdf,Other,FDA-2013-N-0500-0111,FDA-2013-N-0500,Agenda for March 27 2015 Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products Public Meeting
0900006481a078f5,Proposed Rule,FDA-2013-N-0500-0081,FDA-2013-N-0500,"Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products; Public Meeting; Request for Comments;
Reopening of the Comment Period"
0900006481a0854b,Supporting & Related Material,FDA-2013-N-0500-0082,FDA-2013-N-0500,"Reference 1 - Joint GPhA PhRMA Letter to Dr Hamburg re Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products; Public Meeting; Request for Comments;
Reopening of the Comment Period"
0900006481f8f7d2,Supporting & Related Material,FDA-2013-N-0500-0139,FDA-2013-N-0500,"Attachment 1 Record of Comments from March 13, 2014 re: Supplemental Comment from Washington Legal Foundation"
090000648149a218,Other,FDA-2013-N-0500-0004,FDA-2013-N-0500,Generic Pharmaceutical Association (GPhA) - Request for Extension of Comment Period
09000064814c4f5c,Other,FDA-2013-N-0500-0008,FDA-2013-N-0500,Request for Extension from Academy of Managed Care Pharmacy (AMCP) et al
09000064814ca396,Other,FDA-2013-N-0500-0011,FDA-2013-N-0500,Request for Extension from Perrigo
090000648147a982,Proposed Rule,FDA-2013-N-0500-0001,FDA-2013-N-0500,Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products
090000648171fbc4,Supporting & Related Material,FDA-2013-N-0500-0077,FDA-2013-N-0500,"Attachment 2 Revised Virilon Package Insert re Supplement from Star Pharmaceuticals, Inc."
090000648171fad3,Supporting & Related Material,FDA-2013-N-0500-0076,FDA-2013-N-0500,"Attachment 1 Virilon Drug Listing re Supplement from Star Pharmaceuticals, Inc."
09000064839949a2,Supporting & Related Material,FDA-2013-N-0500-0141,FDA-2013-N-0500,01-List of References Withdrawal of Proposed Rule on Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products
090000648148e9e1,Other,FDA-2013-N-0500-0002,FDA-2013-N-0500,"OMB Review Proposed Rule re Executive Order 12866, Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products 11-13-2013 - Memorandum"
0900006481a8b7a5,Supporting & Related Material,FDA-2013-N-0500-0105,FDA-2013-N-0500,"Briefs Submitted in Teva Pharmaceuticals USA, Inc. v. Superior Court of Orange County"
0900006481aba131,Other,FDA-2013-N-0500-0112,FDA-2013-N-0500,Transcript of March 27 2015 Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products Public Meeting
0900006481abfea0,Other,FDA-2013-N-0500-0136,FDA-2013-N-0500,Slide Presentations from the March 27 2015 Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products Public Meeting Redacted
09000064814debad,Proposed Rule,FDA-2013-N-0500-0006,FDA-2013-N-0500,Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products; Correction and Extension of Comment Period
09000064839936bc,Proposed Rule,FDA-2013-N-0500-0140,FDA-2013-N-0500,"Withdrawal of Proposed Rule on Supplemental Applications Proposing
Labeling Changes for Approved Drugs and Biological Products"
09000064839949a3,Supporting & Related Material,FDA-2013-N-0500-0142,FDA-2013-N-0500,"02- Reference 01- Draft guidance for industry, “Updating ANDA Labeling After the Marketing Application for the Reference Listed Drug Has Been Withdrawn,”"
09000064814b4789,Other,FDA-2013-N-0500-0007,FDA-2013-N-0500,Request for Extension from Perrigo
0900006481ecead0,Supporting & Related Material,FDA-2004-N-0188-0067,FDA-2004-N-0188,Reference 1 BSE - A Decade On - Part I re Use of Materials Derived From Cattle in Human Food and Cosmetics
0900006481ecec4b,Supporting & Related Material,FDA-2004-N-0188-0079,FDA-2004-N-0188,Reference 15 Article 11.4.14 Bovine Spongiform Encephalopathy re Use of Materials Derived From Cattle in Human Food and Cosmetics
0900006481ecec59,Supporting & Related Material,FDA-2004-N-0188-0090,FDA-2004-N-0188,"Reference 23 BSE infectivity in jejunum, ileum and ileocaecal junction of incubating cattle re Use of Materials Derived From Cattle in Human Food and Cosmetics"
09000064804708da,Supporting & Related Material,FDA-2004-N-0188-0032,FDA-2004-N-0188,See FDA-2004-N-0188-0050
09000064804702ff,Other,FDA-2004-N-0188-0004,FDA-2004-N-0188,BSE Stakeholders Conference Calls
0900006480a4c757,Supporting & Related Material,FDA-2004-N-0188-0050,FDA-2004-N-0188,FDA/Regulations Policy and Management Staff (RPMS) to the Division of Dockets Management - E.O. 12866 Review - [Use of Materials Derived From Cattle in Human Food and Cosmetics - Interim Final Rules and Request for Comments ] - Reference 2 [See FDA-2004-N-0188-0023]
0900006481ecef4b,Supporting & Related Material,FDA-2004-N-0188-0073,FDA-2004-N-0188,Reference 7 Article 11.4.1 Bovine Spongiform Encephalopathy re Use of Materials Derived From Cattle in Human Food and Cosmetics
0900006481ecead3,Supporting & Related Material,FDA-2004-N-0188-0070,FDA-2004-N-0188,Reference 4 Confirmed Variant Creutzfeldt-Jakob Disease (variant CJD) Case in Texas re Use of Materials Derived From Cattle in Human Food and Cosmetics
0900006481ecec4c,Supporting & Related Material,FDA-2004-N-0188-0083,FDA-2004-N-0188,Reference 16 BSE Ongoing Surveillance Plan final 71406 re Use of Materials Derived From Cattle in Human Food and Cosmetics
0900006481ecec52,Supporting & Related Material,FDA-2004-N-0188-0088,FDA-2004-N-0188,Reference 21 Prevalence BSE (Bovine Spongiform Encephalopathy) re Use of Materials Derived From Cattle in Human Food and Cosmetics
0900006481ecec5a,Supporting & Related Material,FDA-2004-N-0188-0091,FDA-2004-N-0188,Reference 24 Detection of disease-specific PrP in the distal ileum of cattle exposed orally to the agent of bovine spongiform encephalopathy re Use of Materials Derived From Cattle in Human Food and Cosmetics
0900006481ecec5e,Supporting & Related Material,FDA-2004-N-0188-0099,FDA-2004-N-0188,Reference 28 vCJD Surveillance Data - CJD International Surveillance Network re Use of Materials Derived From Cattle in Human Food and Cosmetics
09000064804708d9,Supporting & Related Material,FDA-2004-N-0188-0031,FDA-2004-N-0188,See FDA-2004-N-0188-0050
0900006481ecef4c,Supporting & Related Material,FDA-2004-N-0188-0074,FDA-2004-N-0188,Reference 8 Inactivation of the BSE Agent by the Heat and Pressure Process for Manufacturing Gelatine re Use of Materials Derived From Cattle in Human Food and Cosmetics
0900006481ecef4e,Supporting & Related Material,FDA-2004-N-0188-0076,FDA-2004-N-0188,Reference 9 Article 11.4.15 Bovine Spongiform Encephalopathy re Use of Materials Derived From Cattle in Human Food and Cosmetics
0900006481ecef49,Supporting & Related Material,FDA-2004-N-0188-0071,FDA-2004-N-0188,Reference 5 Variant CJD Cases Worldwide re Use of Materials Derived From Cattle in Human Food and Cosmetics
0900006481ecef4a,Supporting & Related Material,FDA-2004-N-0188-0072,FDA-2004-N-0188,Reference 6 Recognition of BSE Risk Status of Member Countries -D12483 re Use of Materials Derived From Cattle in Human Food and Cosmetics
0900006481ecead2,Supporting & Related Material,FDA-2004-N-0188-0069,FDA-2004-N-0188,Reference 3 A Novel Progressive Spongiform Encephalopathy in Cattle re Use of Materials Derived From Cattle in Human Food and Cosmetics
0900006481ecec5b,Supporting & Related Material,FDA-2004-N-0188-0092,FDA-2004-N-0188,Reference 25 Scientific Opinion on BSE risk in bovine intestines and mesentery EFSA Panel on Biological Hazards (BIOHAZ) re Use of Materials Derived From Cattle in Human Food and Cosmetics
0900006481ecec5f,Supporting & Related Material,FDA-2004-N-0188-0095,FDA-2004-N-0188,Reference 29 vCJD Key Facts re Use of Materials Derived From Cattle in Human Food and Cosmetics
0900006481ecec61,Supporting & Related Material,FDA-2004-N-0188-0097,FDA-2004-N-0188,Reference 31 Report of the OIE Scientific Commission for Animal Diseases re Use of Materials Derived From Cattle in Human Food and Cosmetics
0900006481ece21a,Rule,FDA-2004-N-0188-0065,FDA-2004-N-0188,Use of Materials Derived From Cattle in Human Food and Cosmetics
0900006481ecec4a,Supporting & Related Material,FDA-2004-N-0188-0078,FDA-2004-N-0188,Reference 14 Long-Term Subclinical Carrier State Precedes Scrapie Replication and Adaptation in a Resistant Species: Analogies to Bovine Spongiform Encephalopathy and Variant Creutzfeldt-Jakob Disease in Humans re Use of Materials Derived From Cattle in Human Food and Cosmetics
0900006481ecec5c,Supporting & Related Material,FDA-2004-N-0188-0093,FDA-2004-N-0188,Reference 26 GMIA Gelatin Handbook 2012 re Use of Materials Derived From Cattle in Human Food and Cosmetics
0900006481ecef50,Supporting & Related Material,FDA-2004-N-0188-0080,FDA-2004-N-0188,Referemce 11 The Sourcing and Processing of Gelatin to Reduce the Potential Risk Posed by Bovine Spongiform Encephalopathy (BSE) in FDA-Regulated Products for Human Use re Use of Materials Derived From Cattle in Human Food and Cosmetics
09000064804843c8,Supporting & Related Material,FDA-2003-N-0103-0017,FDA-2003-N-0103,BACKGROUND
09000064804843c5,Supporting & Related Material,FDA-2003-N-0103-0014,FDA-2003-N-0103,BACKGROUND
09000064804843c4,Supporting & Related Material,FDA-2003-N-0103-0013,FDA-2003-N-0103,BACKGROUND
09000064804843c2,Supporting & Related Material,FDA-2003-N-0103-0011,FDA-2003-N-0103,GUIDANCE
09000064804843d1,Supporting & Related Material,FDA-2003-N-0103-0026,FDA-2003-N-0103,BACKGROUND
09000064804843cc,Supporting & Related Material,FDA-2003-N-0103-0021,FDA-2003-N-0103,BACKGROUND
09000064804843cb,Supporting & Related Material,FDA-2003-N-0103-0020,FDA-2003-N-0103,BACKGROUND
09000064804843e6,Supporting & Related Material,FDA-2003-N-0103-0035,FDA-2003-N-0103,BACKGROUND
0900006480484409,Supporting & Related Material,FDA-2003-N-0103-0048,FDA-2003-N-0103,BACKGROUND
0900006480484406,Supporting & Related Material,FDA-2003-N-0103-0047,FDA-2003-N-0103,BACKGROUND
09000064804843f5,Supporting & Related Material,FDA-2003-N-0103-0041,FDA-2003-N-0103,BACKGROUND
0900006480484436,Other,FDA-2003-N-0103-0059,FDA-2003-N-0103,Task Force Final Report July 2003
0900006480484430,Other,FDA-2003-N-0103-0057,FDA-2003-N-0103,Task Force Final Report July 2003
0900006480484424,Other,FDA-2003-N-0103-0054,FDA-2003-N-0103,Task Force Final Report July 2003
0900006480484428,Other,FDA-2003-N-0103-0055,FDA-2003-N-0103,Task Force Final Report July 2003
09000064804843e9,Supporting & Related Material,FDA-2003-N-0103-0036,FDA-2003-N-0103,BACKGROUND
09000064804843c3,Notice,FDA-2003-N-0103-0012,FDA-2003-N-0103,Number not used
09000064804843b8,Supporting & Related Material,FDA-2003-N-0103-0007,FDA-2003-N-0103,GUIDANCE
09000064804843c6,Supporting & Related Material,FDA-2003-N-0103-0015,FDA-2003-N-0103,BACKGROUND
09000064804843c9,Supporting & Related Material,FDA-2003-N-0103-0018,FDA-2003-N-0103,BACKGROUND
09000064804843bf,Supporting & Related Material,FDA-2003-N-0103-0009,FDA-2003-N-0103,GUIDANCE
09000064804843bb,Supporting & Related Material,FDA-2003-N-0103-0008,FDA-2003-N-0103,GUIDANCE
09000064804843d0,Supporting & Related Material,FDA-2003-N-0103-0025,FDA-2003-N-0103,BACKGROUND
09000064804843cf,Supporting & Related Material,FDA-2003-N-0103-0024,FDA-2003-N-0103,BACKGROUND
09000064804843e4,Supporting & Related Material,FDA-2003-N-0103-0034,FDA-2003-N-0103,BACKGROUND
090000648042b1cb,Supporting & Related Material,FDA-2007-D-0258-0002,FDA-2007-D-0258,Guidance
090000648042b1ca,Notice,FDA-2007-D-0258-0001,FDA-2007-D-0258,FDA
09000064805994b4,Proposed Rule,FDA-1978-N-1254-0001,FDA-1978-N-1254,Bioresearch Monitoring Program
09000064805994d2,Notice,FDA-1978-N-1254-0002,FDA-1978-N-1254,Withdrawal of Certain Pre-1986 Proposed Rules; Opportunity for Public Comment
09000064805994d6,Notice,FDA-1978-N-1254-0003,FDA-1978-N-1254,Withdrawal of Certain Pre-1986 Proposed Rules; Final Action
0900006480599f66,Other,FDA-1995-P-0355-0001,FDA-1995-P-0355,Citizen Petition from Washington Legal Foundation
09000064824aa669,Other,FDA-1995-P-0355-0002,FDA-1995-P-0355,Acknowledgment Letter from FDA DDM to Washington Legal Foundation
0900006480599f67,Other,FDA-1995-P-0355-0003,FDA-1995-P-0355,Petition Denial Letter from FDA OC to Washington
0900006480599f68,Other,FDA-1995-P-0355-0004,FDA-1995-P-0355,Letter from FDA OC to Washington Legal Foundation
0900006481507600,Other,FDA-2013-D-1622-0002,FDA-2013-D-1622,"Draft Guidance for Industry: Submitting Food Canning Establishment Registration Form and Food Process Filing Forms to the Food
and Drug Administration in Electronic or Paper Format"
0900006481505eae,Notice,FDA-2013-D-1622-0001,FDA-2013-D-1622,"Draft Guidance for Industry: Submitting Food Canning Establishment Registration Form and Food Process Filing Forms to the Food
and Drug Administration in Electronic or Paper Format; Availability"
0900006481cbbb85,Other,FDA-2013-D-1622-0008,FDA-2013-D-1622,"Submitting Form FDA 2541 (Food Canning Establishment Registration) and Forms FDA 2541d, FDA 2541e, FDA 2541f, and FDA 2541g (Food Process Filing Forms) to FDA in Electronic or Paper Format: Guidance for Industry"
0900006481cba00c,Notice,FDA-2013-D-1622-0007,FDA-2013-D-1622,"Submitting Food Canning Establishment Registration Form and
Food Process Filing Forms to the Food and Drug Administration in Electronic or Paper Format: Guidance for Industry; Availability"
090000648118f830,Other,FDA-1995-S-0036-0135,FDA-1995-S-0036,"Resuscitation Outcomes Consortium (ROC) re IND 110280, British Columbia, Canada Public Disclosure Material Report 63 - Report"
0900006480e373e5,Other,FDA-1995-S-0036-0112,FDA-1995-S-0036,"Advanced Circulatory Systems, Inc., to the Division of Dockets Management re: IDE G080169, ResQpro Clinical Trial, Community Consultation Plan - Report 41"
0900006481113f5e,Other,FDA-1995-S-0036-0126,FDA-1995-S-0036,Resuscitation Outcomes Consortium (ROC) British Columbia Public Disclosure Materials re IND 110699 Report 54 - Report
0900006481159613,Other,FDA-1995-S-0036-0129,FDA-1995-S-0036,"University of Texas Health Science Center at Houston, Site University of Southern California Los Angeles, Public Disclosure Material Report 58 - Report"
0900006481cefe33,Other,FDA-1995-S-0036-0167,FDA-1995-S-0036,Public Disclosure Report from Resuscitation Outcomes Consortium (ROC)  Dallas Site re IND 119858 - Report 86
09000064822299f5,Other,FDA-1995-S-0036-0170,FDA-1995-S-0036,"Public Disclosure Material from Resuscitation Outcomes Consortium (ROC) Hennepin County Medical Center, Minneapolis Site re IND 119858 Report 89"
0900006481cefe31,Other,FDA-1995-S-0036-0165,FDA-1995-S-0036,Public Disclosure Report from Resuscitation Outcomes Consortium (ROC)  Milwaukee Site re IND 119858 - Report 84
0900006481cefe2e,Other,FDA-1995-S-0036-0162,FDA-1995-S-0036,Public Disclosure Report from Resuscitation Outcomes Consortium (ROC) Alabama Site re IND 119858 - Report 81
09000064823bc263,Other,FDA-1995-S-0036-0176,FDA-1995-S-0036,"ESETT, Neurological Emergencies Treatment Trials (NETT) & PECARN Networks Public Disclosure Docket Report IND# 119,756"
09000064823bc294,Other,FDA-1995-S-0036-0177,FDA-1995-S-0036,"ESETT, Neurological Emergencies Treatment Trials (NETT) Network Summary Report of Public Disclosures IND# 119,756"
0900006482337a8c,Other,FDA-1995-S-0036-0171,FDA-1995-S-0036,"Annual Report from ProTECT III Emory University School of Medicine Public Disclosure IND 104,188 Report 91"
0900006482337ad9,Other,FDA-1995-S-0036-0173,FDA-1995-S-0036,"Resuscitation Outcomes Consortium (ROC) Milwaukee Site, Public Disclosure for Emergency Research Study of Cardiac Arrest, Report 93"
09000064818679be,Other,FDA-1995-S-0036-0143,FDA-1995-S-0036,Correspondence from Baroness Lady Sonia McMorris Query
09000064818679bd,Other,FDA-1995-S-0036-0142,FDA-1995-S-0036,"Neuren Pharmaceuticals Ltd, IND 111724, Site Wayne State University
Detroit Receiving and Sinai-Grace Hospitals and The Queen's Medical Center, Honolulu, HI Exception From Informed Consent Requirements For Emergency Research  Report 68"
09000064818679c1,Other,FDA-1995-S-0036-0148,FDA-1995-S-0036,"Eunice Kennedy Shriver National Institute of Child Health and Human Development, IND 79,010, Lorazepam, Sites Listed in Abstract, Public Disclosure Material Report 69"
0900006481868114,Other,FDA-1995-S-0036-0152,FDA-1995-S-0036,"Ben Taub General Hospital and Baylor College of Medicine, IND 100681, Effects of Erythropoietin on Cerebral Vascular Dysfunction and Anemia in Traumatic Brain Injury, Public Disclosure Material Report 71"
0900006483d2bc1d,Other,FDA-1995-S-0036-0178,FDA-1995-S-0036,"Public Disclosure Report from Kelly Hoy, Diffusion Pharmaceuticals Inc"
09000064818679c0,Other,FDA-1995-S-0036-0145,FDA-1995-S-0036,Correspondence from Baroness Lady Sonia McMorris Query Follow-up to Query
09000064818679c3,Other,FDA-1995-S-0036-0146,FDA-1995-S-0036,Correspondence from Baroness Lady Sonia McMorris Query Follow-up
090000648186ae53,Other,FDA-1995-S-0036-0147,FDA-1995-S-0036,Correspondence from Baroness Lady Sonia McMorris Query Follow-up Request
090000648108a994,Other,FDA-1995-S-0036-0122,FDA-1995-S-0036,"Resuscitation Outcomes Consortium (ROC) re IND 110699, Milwaukee Public Disclosure Material Report 50 - Report"
0900006482228931,Other,FDA-1995-S-0036-0168,FDA-1995-S-0036,"Public Disclosure Report from Penn Medicine, Hospital of the University of Pennsylvania re IND 110314 Report 87"
0900006481ab145c,Other,FDA-1995-S-0036-0161,FDA-1995-S-0036,Public Disclosure Report from Resuscitation Outcomes Consortium Houston Site re Tranexamic Acid Report 80
0900006480b1a4c4,Other,FDA-1995-S-0036-0110,FDA-1995-S-0036,"Report 39 - ""Immediate Trial  for Public Disclosure, Saint Paul Minnesota Area, IND 70,376,"""
0900006481159612,Other,FDA-1995-S-0036-0128,FDA-1995-S-0036,Resuscitation Outcomes Consortium (ROC) Pittsburgh Public Disclosure Materials Report 57 - Report
0900006481b94e74,Notice,FDA-2014-N-0411-0002,FDA-2014-N-0411,"Cooperative Agreement for Research, Education, and Outreach in Support of the Food and Drug Administration Food Safety Modernization Act"
09000064816d165c,Notice,FDA-2014-N-0411-0001,FDA-2014-N-0411,"Cooperative Agreement To Support the Illinois Institute of Technology’s
National Center for Food Safety and Technology"
090000648157676a,Notice,FDA-2014-N-0006-0001,FDA-2014-N-0006,"Report on the Performance of Drug and Biologics Firms in Conducting
Postmarketing Requirements and Commitments; Availability"
0900006483e11c81,Notice,FDA-2019-N-0006-0001,FDA-2019-N-0006,Advisory Committees; Filing of Closed Meeting Reports
090000648046324b,Other,FDA-2006-N-0485-0001,FDA-2006-N-0485,Independent Evaluation of FDA's First Cycle Review Performance Retrospective Analysis Final Report
0900006480463238,Notice,FDA-2006-N-0485-0002,FDA-2006-N-0485,FDA
0900006480471148,Other,FDA-2004-P-0215-0017,FDA-2004-P-0215,"Hill Dermaceuticals, Inc. - Amendment"
0900006480471169,Other,FDA-2004-P-0215-0007,FDA-2004-P-0215,"FDA Division of Dockets Management to Hill Dermaceuticals, Inc. - Letter"
0900006480471146,Other,FDA-2004-P-0215-0009,FDA-2004-P-0215,"Hill Dermaceuticals, Inc. to the Division of Dockets Management - Letter"
0900006480471165,Other,FDA-2004-P-0215-0012,FDA-2004-P-0215,"Hill Dermaceuticals, Inc. - Supplement"
0900006480471159,Other,FDA-2004-P-0215-0010,FDA-2004-P-0215,"Hill Dermaceuticals, Inc. - Supplement"
0900006480471158,Supporting & Related Material,FDA-2004-P-0215-0026,FDA-2004-P-0215,"Affidavit of Ralph Harkins, Ph.D. - [Hill Dermaceuticals Inc. - Supplement] re FDA-2004-P-0215-0010"
090000648047114b,Supporting & Related Material,FDA-2004-P-0215-0034,FDA-2004-P-0215,"Appendix E - ""Summary of Contact Urticaria (by Howard I. Maibach, MD)"" - [Hill Dermaceuticals, Inc. - Supplement]"
0900006480471168,Other,FDA-2004-P-0215-0006,FDA-2004-P-0215,"FDA/DDM to Hill Dermaceuticals, Inc."
090000648047114e,Supporting & Related Material,FDA-2004-P-0215-0036,FDA-2004-P-0215,"Appendix G - ""Contact Urticaria Syndrome"" - (Cover Page)  [Hill Dermaceuticals, Inc. - Supplement]"
0900006480471160,Supporting & Related Material,FDA-2004-P-0215-0020,FDA-2004-P-0215,Attachment A - [Hill Dermaceuticals Inc. - Supplement] re FDA-2004-P-0215-0010
090000648047113d,Other,FDA-2004-P-0215-0001,FDA-2004-P-0215,"Acknowledgement Letter to Hill Dermaceuticals, Inc."
0900006480471170,Other,FDA-2004-P-0215-0019,FDA-2004-P-0215,"Hill Dermaceuticals, Inc. - Amendment"
090000648047116f,Supporting & Related Material,FDA-2004-P-0215-0029,FDA-2004-P-0215,DERMA-SMOOTHE/FS[Scalp Oil] - Product Description - [Hill Dermaceuticals Inc. - Amendment] re FDA-2004-P-0215-0019
0900006480471161,Other,FDA-2004-P-0215-0011,FDA-2004-P-0215,Hill Dermaceuticals Inc. - Supplement
0900006480471157,Supporting & Related Material,FDA-2004-P-0215-0025,FDA-2004-P-0215,Affidavit of Howard I. Maibach. M.D - [Hill Dermaceuticals Inc. - Supplement] re FDA-2004-P-0215-0010
090000648047116b,Other,FDA-2004-P-0215-0013,FDA-2004-P-0215,"Hill Dermaceuticals, Inc. to the Division of Dockets Management - Letter"
090000648047115f,Supporting & Related Material,FDA-2004-P-0215-0021,FDA-2004-P-0215,Attachment B - [Hill Dermaceuticals Inc. - Supplement] re FDA-2004-P-0215-0010
0900006480471167,Other,FDA-2004-P-0215-0005,FDA-2004-P-0215,"FDA/CDER to Hill Dermaceuticals, Inc. - Letter"
090000648047114c,Supporting & Related Material,FDA-2004-P-0215-0035,FDA-2004-P-0215,"Appendix F - ""Reference List: Bibliography of Howard I. Maibach, M.D."" - [Hill Dermaceuticals, Inc. - Supplement] re  FDA-2004-P-0215-0037 (Part 1 of 2)"
0900006480471155,Supporting & Related Material,FDA-2004-P-0215-0024,FDA-2004-P-0215,"Bibliography of Howard I. Maibach, M.D. - [Hill Dermaceuticals Inc. - Supplement] re FDA-2004-P-0215-0010"
0900006480471154,Supporting & Related Material,FDA-2004-P-0215-0022,FDA-2004-P-0215,Attachment C - [Hill Dermaceuticals Inc. - Supplement] re FDA-2004-P-0215-0010
0900006480471149,Supporting & Related Material,FDA-2004-P-0215-0033,FDA-2004-P-0215,"Appendix D - ""Data presented to the Advisory Committee PowerPoint Presentation"" - [Hill Dermaceuticals, Inc. - Supplement] reFDA-2004-P-0215-0037"
090000648047114d,Supporting & Related Material,FDA-2004-P-0215-0030,FDA-2004-P-0215,"Appendix A - ""Dr. Howard I. Maibach Letter on Bioequivalence and Safety Issues Pertaining to Generic Versions of Derma-Smoothe/FSO"" - [Hill Dermaceuticals, Inc. - Supplement] re FDA-2004-P-0215-0037"
0900006480471144,Other,FDA-2004-P-0215-0004,FDA-2004-P-0215,See FDA-2004-P-0215-0007
0900006480471142,Supporting & Related Material,FDA-2004-P-0215-0002,FDA-2004-P-0215,See FDA-2004-P-0215-0001
090000648058b295,Other,FDA-1998-N-0155-0007,FDA-1998-N-0155,Joint Commission on Accreditation of Healthcare Organizations - Testimony
090000648058b280,Notice,FDA-1998-N-0155-0002,FDA-1998-N-0155,FDA - Notice of Hearing
090000648058b259,Other,FDA-1998-N-0155-0003,FDA-1998-N-0155,SAMSAH to FDA - Memo
090000648058b2b4,Other,FDA-1998-N-0155-0013,FDA-1998-N-0155,"LAARC, Matrix Institute on Addictions - Testimony"
090000648058b29b,Supporting & Related Material,FDA-1998-N-0155-0015,FDA-1998-N-0155,Sign-In List - [Joint Commission on Accreditation of Healthcare Organizations-Testimony]
090000648058b2a3,Other,FDA-1998-N-0155-0009,FDA-1998-N-0155,American Methadone Treatment Association - Testimony
090000648058b30b,Other,FDA-1998-N-0155-0014,FDA-1998-N-0155,Transcript - 11-1-99 Public Hearing on Methadone-LAAM Proposed RUle (pages 1 - 100)
090000648058b2a4,Other,FDA-1998-N-0155-0010,FDA-1998-N-0155,"College on Problems of Drug Dependence, Inc. - Testimony"
090000648058b2b2,Other,FDA-1998-N-0155-0012,FDA-1998-N-0155,Medical College of Virginia - Testimony
090000648058b294,Supporting & Related Material,FDA-1998-N-0155-0004,FDA-1998-N-0155,Agenda for Public Hearing on Methadone/LAAM Proposed Rule - List
090000648058b2a1,Other,FDA-1998-N-0155-0008,FDA-1998-N-0155,Research Triangle Institute - Letter
090000648058b224,Proposed Rule,FDA-1998-N-0155-0001,FDA-1998-N-0155,Narcotic Drugs in Maintenance and Detoxification Treatment of Narcotic
090000648058b293,Other,FDA-1998-N-0155-0006,FDA-1998-N-0155,SAMSHA - Testimony
090000648058b25e,Supporting & Related Material,FDA-1998-N-0155-0005,FDA-1998-N-0155,OMB Review - Reference (1a)
090000648058b2a5,Other,FDA-1998-N-0155-0011,FDA-1998-N-0155,"Nat Assn of State Alcohol and Drug Abuse Director's, Inc. - Testimony"
0900006481ed6d6f,Other,FDA-2005-P-0191-0006,FDA-2005-P-0191,Citizen Petition Partial Approval and Denial Response from FDA CDER to Pine Grove Behavioral Health & Addiction Services
0900006480440e27,Other,FDA-2005-P-0191-0001,FDA-2005-P-0191,HFA-305 to Pine Grove Behavioral Health & Addiction Services
0900006480440e2a,Other,FDA-2005-P-0191-0004,FDA-2005-P-0191,Citizen Petition from Pine Grove Behavioral Health & Addiction Services
0900006480440e2f,Other,FDA-2005-P-0191-0003,FDA-2005-P-0191,FDA/CDER to Pine Grove Recovery Center
0900006480440e2e,Other,FDA-2005-P-0191-0002,FDA-2005-P-0191,HFA-305 to Pine Grove Behavioral Health & Addiction Services
0900006480484621,Notice,FDA-2003-N-0105-0001,FDA-2003-N-0105,FDA
09000064804876d8,Notice,FDA-2002-D-0010-0001,FDA-2002-D-0010,FDA
090000648048771d,Notice,FDA-2002-D-0010-0002,FDA-2002-D-0010,FDA
090000648048771f,Supporting & Related Material,FDA-2002-D-0010-0003,FDA-2002-D-0010,Notifying FDA of Fatalities Related to Blood Collection or Transfusion
0900006480487721,Supporting & Related Material,FDA-2002-D-0010-0004,FDA-2002-D-0010,GUIDANCE
0900006484dcc28b,Other,FDA-2002-D-0010-0005,FDA-2002-D-0010,Notifying-FDA-of-Fatalities-Related-to-Blood-Collection-or-Transfusion - L2 Update - Aug 2021 FINAL
0900006481e65c6c,Other,FDA-2016-P-0541-0002,FDA-2016-P-0541,"Acknowledgement Letter from FDA DDM to Gordon Johnston Regulatory Consultants, LLC"
0900006481e65ff7,Other,FDA-2016-P-0541-0001,FDA-2016-P-0541,"Citizen Petition from Gordon Johnston Regulatory Consultants, LLC"
0900006481e66137,Supporting & Related Material,FDA-2016-P-0541-0003,FDA-2016-P-0541,"Attachment A Electronic Orange Book Listing for Sodium Chloride 0.45% re Citizen Petition from Gordon Johnston Regulatory Consultants, LLC"
0900006482195e50,Other,FDA-2016-P-0541-0004,FDA-2016-P-0541,"Petition Approval Letter from FDA CDER to Gordon Johnston Regulatory Consultants, LLC"
09000064804dfe07,Notice,FDA-2001-D-0163-0001,FDA-2001-D-0163,FDA
09000064804dfe68,Supporting & Related Material,FDA-2001-D-0163-0002,FDA-2001-D-0163,Corrected Final Guidance
090000648050733d,Notice,FDA-1996-D-0405-0001,FDA-1996-D-0405,Exports: Certificates and Other Assurance that Products Meet FDA Requirements; Availability
0900006484bfad1a,Supporting & Related Material,FDA-1996-D-0405-0002,FDA-1996-D-0405,Compliance Policy Guide Section 110.100 Certification for Exports re: Exports: Certificates and Other Assurance that Products Meet FDA Requirements; Availability
0900006484e23a7d,Notice,FDA-1996-D-0405-0010,FDA-1996-D-0405,Compliance Policy Guide Sec. 110.100; Withdrawal of Guidance
0900006481e65830,Other,FDA-2016-P-0540-0001,FDA-2016-P-0540,"Citizen Petition from Gordon Johnston Regulatory Consultants, LLC"
0900006481e65e6f,Other,FDA-2016-P-0540-0002,FDA-2016-P-0540,"Acknowledgement Letter from FDA DDM to Gordon Johnston Regulatory Consultants, LLC"
0900006481e65ec5,Supporting & Related Material,FDA-2016-P-0540-0003,FDA-2016-P-0540,"Attachment A Electronic Orange Book Listing for Sodium Chloride 3% re Citizen Petition from Gordon Johnston Regulatory Consultants, LLC"
0900006482195e42,Other,FDA-2016-P-0540-0004,FDA-2016-P-0540,"Petition Approval Letter from FDA CDER to Gordon Johnston Regulatory Consultants, LLC"
0900006481edf359,Other,FDA-2016-P-1085-0002,FDA-2016-P-1085,Acknowledgement Letter from FDA DDM to Frontage Laboratories Inc
0900006484e0c23b,Other,FDA-2016-P-1085-0004,FDA-2016-P-1085,Agency Response from FDA CDER to Beijing Health Life Pharm Tech Co Ltd
0900006481edf35b,Supporting & Related Material,FDA-2016-P-1085-0003,FDA-2016-P-1085,Attachment A Product Inserts re Citizen Petiton from Frontage Laboratories
0900006481edf1d5,Other,FDA-2016-P-1085-0001,FDA-2016-P-1085,"Citizen Petition from Frontage Laboratories, Inc."
0900006480ed4122,Other,FDA-2010-P-0491-0156,FDA-2010-P-0491,"The Honorable Charles E. Grassley, et al., to the Commissioner for Food and Drugs - Letter"
0900006480b506a0,Supporting & Related Material,FDA-2010-P-0491-0058,FDA-2010-P-0491,"Appendix A (6) - ""Jones, Dietary Sweeteners Containing Fructose: Overview of a Workshop on the State of the Science"" - [Corn Refiners Association - Citizen Petition] re FDA-2010-P-0491-0001"
0900006480b50d75,Supporting & Related Material,FDA-2010-P-0491-2158,FDA-2010-P-0491,"Appendix C  (7 ) Jessica M. Scott, A Sticky Subject, Richmond.com [Corn Refiners Association - Citizen Petition] re FDA-2010-P-0491-0001"
0900006480b50d90,Supporting & Related Material,FDA-2010-P-0491-2171,FDA-2010-P-0491,"Appendix C (21) Dangers of sweetener fructose, The Capital-HometownAnnapolis.com  [Corn Refiners Association - Citizen Petition] re FDA-2010-P-0491-0001"
0900006480b50db7,Supporting & Related Material,FDA-2010-P-0491-2167,FDA-2010-P-0491,"Appendix  C  (17) Phil Lempert, Is this the End ofHigh Fructose Com Syrup?,  Supermarket Guru   [Corn Refiners Association - Citizen Petition] re FDA-2010-P-0491-0001"
0900006480f89deb,Other,FDA-2010-P-0491-1064,FDA-2010-P-0491,Sugar Association (Wenable LLP) - Supplement
0900006480bfc8d2,Supporting & Related Material,FDA-2010-P-0491-0085,FDA-2010-P-0491,"Tab 23 - ""Report of the Dietary Guidelines Advisory Committee on the Dietary Guidelines for Americans, 2010"" - [The Sugar Association (Venable, LLP) - Comment] re: FDA-2010-P-0491-0082"
0900006480b50664,Supporting & Related Material,FDA-2010-P-0491-0002,FDA-2010-P-0491,"Appendix A - ""List of References"" - [Corn Refiners Association - Citizen Petition] re FDA-2010-P-0491-0001"
0900006480c260bb,Supporting & Related Material,FDA-2010-P-0491-0094,FDA-2010-P-0491,Withdrawn Public Submission
0900006480b5100d,Supporting & Related Material,FDA-2010-P-0491-2179,FDA-2010-P-0491,Appendix C (31) Book Revised to Account for Rise in Sugar Love [Corn Refiners Association - Citizen Petition] re FDA-2010-P-0491-0001
0900006480b51012,Supporting & Related Material,FDA-2010-P-0491-2182,FDA-2010-P-0491,"Appendix C (34) Sophia Ahmad, Your Health: Become a label reader,  DesMoinesRegister.com [The Corn Refiners Association Citizen Petition]"
0900006480b51013,Supporting & Related Material,FDA-2010-P-0491-2183,FDA-2010-P-0491,"Appendix C (35) Don Colburn & Joe Rojas-Burke, The skinny on big bellies,  OregonLive.com  [The Corn Refiners Association Citizen Petition]"
0900006480b51081,Supporting & Related Material,FDA-2010-P-0491-2187,FDA-2010-P-0491,"Appendix C (39) The You Docs: Gut trouble? The sneaky culprit, Seattle Post-Intelligencer  [The Corn Refiners Association Citizen Petition]"
0900006480b51104,Supporting & Related Material,FDA-2010-P-0491-2189,FDA-2010-P-0491,"Appendix C (43) Gailon Totheroh, Fructose:' Sugar-Coated Danger, CBN.com  [The Corn Refiners Association Citizen Petition]"
0900006480b50d77,Supporting & Related Material,FDA-2010-P-0491-2160,FDA-2010-P-0491,"Appendix C  (9) Merri Rosenberg, In The Schools; Refilling Lunch Trays: Less Junk, More Veggies, The New York Times [Corn Refiners Association - Citizen Petition] re FDA-2010-P-0491-0001"
0900006480b50d78,Supporting & Related Material,FDA-2010-P-0491-2161,FDA-2010-P-0491,"Appendix C  (10 ) Janet Helm., Link between obesity, high fructose com syrup?,  SouthBendTribune.com [Corn Refiners Association - Citizen Petition] re FDA-2010-P-0491-0001"
0900006480b50d7a,Supporting & Related Material,FDA-2010-P-0491-2163,FDA-2010-P-0491,"Appendix C  (12) Gabriella Boston, Eating small; The French connection to food and weight, The Washington Times [Corn Refiners Association - Citizen Petition] re FDA-2010-P-0491-0001"
0900006480b50d7b,Supporting & Related Material,FDA-2010-P-0491-2164,FDA-2010-P-0491,"Appendix C  (13) Transcripts, Healthwatch; Elisa Zied, author of""So What Can I Eat,"" discusses nutrition for teenage girls, CBS The Early Show [Corn Refiners Association - Citizen Petition] re FDA-2010-P-0491-0001"
0900006480b50d8d,Supporting & Related Material,FDA-2010-P-0491-2168,FDA-2010-P-0491,"Appendix C (18) Nicholas D. Kristoff, Hazardous to Your Health, The New York Times  [Corn Refiners Association - Citizen Petition] re FDA-2010-P-0491-0001"
0900006480b50d8e,Supporting & Related Material,FDA-2010-P-0491-2169,FDA-2010-P-0491,"Appendix C (19) Study Links Soft Drinks With Obesity, consumeraffairs.com  [Corn Refiners Association - Citizen Petition] re FDA-2010-P-0491-0001"
0900006480ed13cc,Other,FDA-2010-P-0491-0155,FDA-2010-P-0491,"FDA/OC Office of Legislation to The Honorable Tom Hankin, May 24, 2011 - Answer"
0900006480b50662,Other,FDA-2010-P-0491-0001,FDA-2010-P-0491,Corn Refiners Association - Citizen Petition
090000648102314a,Other,FDA-2010-P-0491-2181,FDA-2010-P-0491,FDA/CFSAN Response to Corn Refiners Association - Petition Denial Letter
0900006480c22255,Other,FDA-2010-P-0491-0088,FDA-2010-P-0491,FDA/CFSAN Interim Response to Corn Refiners Association
0900006480ed412a,Other,FDA-2010-P-0491-0157,FDA-2010-P-0491,"FDA/OC Office of Legislation to the Honorable Charles E. Grassley, et al, August 1, 2011 - Answer"
090000648042db08,Other,FDA-2007-D-0424-0005,FDA-2007-D-0424,FDA/OP
09000064806aed12,Notice,FDA-2007-D-0424-0006,FDA-2007-D-0424,"Guidance for the Public, FDA Advisory Committee Members, and FDA Staff on Procedures for Determining Conflict of Interest and Eligibility for Participation in FDA Advisory Committees; Availability"
090000648042daf5,Supporting & Related Material,FDA-2007-D-0424-0002,FDA-2007-D-0424,Draft Guidance
090000648042daf6,Supporting & Related Material,FDA-2007-D-0424-0003,FDA-2007-D-0424,Draft Guidance
09000064806af196,Other,FDA-2007-D-0424-0007,FDA-2007-D-0424,"Guidance for the Public, FDA Advisory Committee Members, and FDA Staff on Procedures for Determining Conflict of Interest and Eligibility for Participation in FDA Advisory Committees"
090000648042daf1,Notice,FDA-2007-D-0424-0001,FDA-2007-D-0424,FDA
0900006480499798,Notice,FDA-2003-D-0378-0001,FDA-2003-D-0378,FDA
09000064804997f3,Supporting & Related Material,FDA-2003-D-0378-0002,FDA-2003-D-0378,Guideline
09000064809edb4d,Other,FDA-2009-P-0321-0002,FDA-2009-P-0321,"Acknowledgement Letter to Ferdic, Incorporated"
09000064809edb4a,Other,FDA-2009-P-0321-0001,FDA-2009-P-0321,"Ferdic, Incorporated - Citizen Petition"
090000648048162a,Other,FDA-2003-D-0033-0003,FDA-2003-D-0033,Guidance for Industry and Food and Drug Administration Staff: Food and Drug Administration and Industry Actions on Premarket Notification Submissions: Effect on Food and Drug Administration Review Clock and Performance Assessment
090000648116e889,Notice,FDA-2003-D-0033-0004,FDA-2003-D-0033,Guidance for Industry and Food and Drug Administration Staff: Food and Drug Administration and Industry Actions on Premarket Notification Submissions: Effect on Food and Drug Administration Review Clock and Performance Assessment; Availability see FDA-2003-D_0033-0001
0900006480481625,Notice,FDA-2003-D-0033-0001,FDA-2003-D-0033,Guidance for Industry and Food and Drug Administration Staff: Food and Drug Administration and Industry Actions on Premarket Notification Submissions: Effect on Food and Drug Administration Review Clock and Performance Assessment; Availability
0900006480481629,Supporting & Related Material,FDA-2003-D-0033-0002,FDA-2003-D-0033,See FDA-2003-D-0033-0003
09000064823c8959,Other,FDA-2016-P-1398-0003,FDA-2016-P-1398,Interim Response Letter from CDRH to Dr. Hooman Noorchashm - Redacated
09000064849d263b,Other,FDA-2016-P-1398-0004,FDA-2016-P-1398,Citizen Petition Response to Dr. Hooman Noorchashm
0900006482001383,Other,FDA-2016-P-1398-0001,FDA-2016-P-1398,Citizen Petition from Dr. Hooman Noorchashm
0900006482001385,Other,FDA-2016-P-1398-0002,FDA-2016-P-1398,Acknowledgement Letter from FDA DDM to Dr. Hooman Noorchashm
0900006484acfd31,Other,FDA-2021-P-0427-0002,FDA-2021-P-0427,Acknowledgment Letter from FDA DMS to Pet Schooled
0900006484acfd2d,Other,FDA-2021-P-0427-0001,FDA-2021-P-0427,Citizen Petition from Pet Schooled
0900006484986177,Other,FDA-2019-D-4739-0017,FDA-2019-D-4739,Requesting FDA Feedback on Combination Products Guidance for Industry and FDA Staff
09000064842503f0,Other,FDA-2019-D-4739-0002,FDA-2019-D-4739,Requesting Food and Drug Administration Feedback on Combination Products; Draft Guidance for Industry and Food and Drug Administration Staff
0900006484985b24,Notice,FDA-2019-D-4739-0016,FDA-2019-D-4739,"Requesting FDA Feedback on Combination Products; Guidance for
Industry and FDA Staff; Availability"
090000648424ff26,Notice,FDA-2019-D-4739-0001,FDA-2019-D-4739,Requesting Food and Drug Administration Feedback on Combination Products; Draft Guidance for Industry and Food and Drug Administration Staff; Availability
09000064805529eb,Other,FDA-2007-P-0418-0005,FDA-2007-P-0418,FDA/Center for Drug Evaluation and Research - Final Response Letter
090000648042da5d,Other,FDA-2007-P-0418-0001,FDA-2007-P-0418,FDA/DDM to Cobalt Laboratories Inc. and Cobalt Pharmaceuticals Inc.
090000648042da5e,Other,FDA-2007-P-0418-0003,FDA-2007-P-0418,"Cobalt Laboratories, Inc. and Cobalt Pharmaceuticals, Inc. - Citizen Petition"
090000648042da64,Other,FDA-2007-P-0418-0002,FDA-2007-P-0418,FDA/DDM to Cobalt Laboratories Inc. and Cobalt Pharmaceuticlas Inc
090000648042da65,Other,FDA-2007-P-0418-0004,FDA-2007-P-0418,Cobalt Laboratories Inc. and Cobalt Pharmaceuticlas Inc - Petition for Stay of Action
09000064804efcc2,Other,FDA-2001-P-0524-0003,FDA-2001-P-0524,"FDA/CDER Interim Response to Lawrence D. Bernhardt & Arnold Liebman (Milberg, Weiss, Bershad, Hynes, and Lerach LLP) - Letter"
09000064804efcc7,Other,FDA-2001-P-0524-0008,FDA-2001-P-0524,"Between FDA/CDER HFD110 and Milberg, Weiss, Bershad Hynes, & Lerach LLP April 17 2001 re Minutes of April 4 2001 - Memorandum of Telephone Conversation"
09000064804efcc0,Other,FDA-2001-P-0524-0002,FDA-2001-P-0524,"Acknowledgement Letter to (Milberg, Weiss, Bershad Hynes, and Lerach LLP)"
09000064804efcc5,Other,FDA-2001-P-0524-0006,FDA-2001-P-0524,Between FDA/CDER HFD110 and Pfizer March 6 2001 re Minutes of February 28 2001 - Memorandum of Telephone Conversation
09000064804efcc6,Other,FDA-2001-P-0524-0007,FDA-2001-P-0524,Between FDA/CDER HFD110 and Pfizer March 20 2001 re Minutes of March 16 2001 - Memorandum of Telephone Conversation
09000064804efcc4,Other,FDA-2001-P-0524-0005,FDA-2001-P-0524,Between FDA/CDER HFD110 and Milberg Weiss Bershad Hynes & Lerach LLP - Memorandum of Telephone Conversation
09000064804efcba,Other,FDA-2001-P-0524-0001,FDA-2001-P-0524,"Lawrence D. Bernhardt & Arnold Liebman (Milberg, Weiss, Bershad, Hynes, and Lerach LLP) - Citizen Petition"
090000648105ffbb,Other,FDA-2001-P-0524-0010,FDA-2001-P-0524,"FDA/CDER to the Division of Dockets Management re Involuntarily Closure of Lawrence D Bernhardt and Arnold Liebman (Salvatore J. Graziano, Esq. of Milberg, LLP) June 22, 2012 - Memorandum"
09000064804efcc8,Other,FDA-2001-P-0524-0009,FDA-2001-P-0524,Between FDA/CDER HFD110 and Pfizer April 17 2001 re Minutes of April 3 2001 - Memorandum of Telephone Conversation
0900006484a930dd,Notice,FDA-2021-N-0262-0001,FDA-2021-N-0262,Food and Drug Administration Science Forum 2021; Public Workshop
09000064804e2531,Other,FDA-2001-P-0190-0001,FDA-2001-P-0190,FDA/DDM to Washington Legal Foundation
09000064804e2582,Other,FDA-2001-P-0190-0002,FDA-2001-P-0190,FDA/OC to Washington Legal Foundation
090000648070f519,Rule,FDA-2008-N-0423-0002,FDA-2008-N-0423,FDA Regulations; Technical Amendment; Correction
09000064806d80ba,Notice,FDA-2008-N-0423-0001,FDA-2008-N-0423,FDA Regulations; Technical Amendment
0900006482416a9e,Other,FDA-2015-D-4361-0008,FDA-2015-D-4361,Gifts to FDA-Evaluation and Acceptance-Final Guidance with updated reference for the Public and FDA Personnel
0900006482414334,Notice,FDA-2015-D-4361-0005,FDA-2015-D-4361,Gifts to the Food and Drug Administration: Evaluation and Acceptance; Guidance for the Public and Food and Drug Administration; Availability
0900006482079351,Other,FDA-2015-D-4361-0002,FDA-2015-D-4361,Gifts to FDA: Evaluation and Acceptance: Draft Guidance for the Public and FDA Staff DRAFT GUIDANCE
090000648241485e,Other,FDA-2015-D-4361-0006,FDA-2015-D-4361,Gifts to FDA: Evaluation and Acceptance: Draft Guidance for the Public and FDA Staff
09000064820786ba,Notice,FDA-2015-D-4361-0001,FDA-2015-D-4361,Gifts to the Food and Drug Administration: Evaluation and Acceptance: Draft Guidance for the Public and Food and Drug Administration Staff; Availability
0900006482416647,Other,FDA-2015-D-4361-0007,FDA-2015-D-4361,Gifts to FDA-Evaluation and Acceptance-Final Guidance for the Public and...
090000648208001c,Other,FDA-2015-D-4361-0003,FDA-2015-D-4361,Gifts to FDA: Evaluation and Acceptance: Draft Guidance for the Public and FDA Staff
0900006482c3799b,Notice,FDA-2017-N-6129-0001,FDA-2017-N-6129,Assessment of Food and Drug Administration Hiring and Retention; Public Meeting; Request for Comments
0900006481e91e0b,Other,FDA-2016-N-0586-0003,FDA-2016-N-0586,U. S DEPARTMENT OF HEALTH AND HUMAN SERVICES TRIBAL CONSULTATION POLICY
0900006481e91e06,Other,FDA-2016-N-0586-0002,FDA-2016-N-0586,U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION TRIBAL CONSULTATION POLICY (DRAFT)
0900006481e8f960,Notice,FDA-2016-N-0586-0001,FDA-2016-N-0586,"Draft Food and Drug Administration Tribal Consultation Policy; Availability;
Request for Comments"
090000648244bfec,Notice,FDA-2016-N-0586-0010,FDA-2016-N-0586,Food and Drug Administration Tribal Consultation Policy; Availability
0900006481fb4c08,Supporting & Related Material,FDA-2016-N-0586-0004,FDA-2016-N-0586,Transcript from the All Tribes Call 04-21-16  NWX-FDA OC
090000648244c995,Other,FDA-2016-N-0586-0011,FDA-2016-N-0586,FDA Tribal Consultation Policy (FINAL)_508ed_1
0900006480481746,Notice,FDA-2003-N-0041-0004,FDA-2003-N-0041,FDA
0900006480481747,Supporting & Related Material,FDA-2003-N-0041-0005,FDA-2003-N-0041,SUPPORTING STATEMENT
0900006480481736,Notice,FDA-2003-N-0041-0002,FDA-2003-N-0041,FDA
0900006480481748,Notice,FDA-2003-N-0041-0006,FDA-2003-N-0041,FDA
090000648048171f,Notice,FDA-2003-N-0041-0001,FDA-2003-N-0041,FDA
0900006480481745,Other,FDA-2003-N-0041-0003,FDA-2003-N-0041,HFZ-510 to Dockets Management Branch
0900006481f56d85,Other,FDA-2016-P-1128-0001,FDA-2016-P-1128,Citizen Petition from Melissa Schilling
0900006481f57020,Other,FDA-2016-P-1128-0002,FDA-2016-P-1128,Acknowledgement Letter from FDA DDM to Melissa Schilling
09000064804d0de7,Other,FDA-2000-N-0143-0007,FDA-2000-N-0143,Answer from FDA/CDER to Honorable Rosa L. DeLauro
09000064804d0dc5,Proposed Rule,FDA-2000-N-0143-0001,FDA-2000-N-0143,Notice of Proposed Rule from FDA/CDER
09000064804d0dec,Notice,FDA-2000-N-0143-0002,FDA-2000-N-0143,Notice of Final Rule from FDA/CDER
0900006480ac9fd4,Supporting & Related Material,FDA-2009-N-0582-0007,FDA-2009-N-0582,"Reference 12 - ""IMS Health, Total U.S. Promotional Spend By Type, 2008"" - Background"
0900006480ac9fd9,Supporting & Related Material,FDA-2009-N-0582-0008,FDA-2009-N-0582,"Reference 13 - ""IMS Health, Integrated Promotional Services™, Year 2008, Data Extracted on September 2009"" - Background"
0900006480ac9ffb,Supporting & Related Material,FDA-2009-N-0582-0009,FDA-2009-N-0582,"Reference 15 - ""Office of Management and Budget, Circular A-4, Setember 17, 2003"" - Background"
0900006480aca060,Supporting & Related Material,FDA-2009-N-0582-0013,FDA-2009-N-0582,"Reference 19 - ""Scientific Literature on Direct to Consumer Advertising of Precription Pharmaceuticals, 2004-2008; Eastern Research Group, Inc., Literature Review"" - Background"
0900006480ac9f70,Supporting & Related Material,FDA-2009-N-0582-0003,FDA-2009-N-0582,"Reference 1 - ""FDA Guidance for Industry, ""Consumer-Directed Broadcast Advertisements,"" - Background"
0900006480fa7047,Proposed Rule,FDA-2009-N-0582-0040,FDA-2009-N-0582,"Direct-to-Consumer Prescription Drug Advertisements; Presentation of the Major Statement in Television and Radio Advertisements in a Clear, Conspicuous, and Neutral Manner; Notice of Availability of Study Data"
0900006480ae15c4,Other,FDA-2009-N-0582-0017,FDA-2009-N-0582,"OMB Changes, Executive Order 12866 (E.O.)[Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in Television and Radio Advertisements in a Clear, Conspicuous, and Neutral Manner ] - Reference"
0900006480aca825,Proposed Rule,FDA-2009-N-0582-0001,FDA-2009-N-0582,"Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in Television and Radio Advertisements in a Clear, Conspicuous, and Neutral Manner"
0900006480aca03c,Supporting & Related Material,FDA-2009-N-0582-0010,FDA-2009-N-0582,"Reference 16 - ""Prescription Drugs: FDA Oversight of Direct-to-Consumer Advertising Has Limitations, GAO"" - Background"
0900006480aca149,Supporting & Related Material,FDA-2009-N-0582-0002,FDA-2009-N-0582,DDMAC References -  [Note for MONDAY 3/29/2010 - POST THIS DOCUMENT FIRST BUT AFTER THE FR DOCUMENT AND Please Insert the Title of the FR Notice Here]
0900006480ac9f89,Supporting & Related Material,FDA-2009-N-0582-0006,FDA-2009-N-0582,"Reference 4 - ""FDA Draft Guidance for Industry, ""Presenting Risk Information in Prescription Drug and Medical Device Promotion,"" - Background"
0900006480aca044,Supporting & Related Material,FDA-2009-N-0582-0012,FDA-2009-N-0582,"Reference 18 - ""Patient and Physician Attitudes and Behaviors Associated With DTC Promotion of Prescription Drugs--Summary of FDA Survey Research Results, Final Report, November 19, 2004"" - Background"
0900006480ac9f86,Supporting & Related Material,FDA-2009-N-0582-0004,FDA-2009-N-0582,"Reference 2 - ""CCH Trade Regulation Reporter, Paragraph 7569.09 ""Clear and Conspicous Disclosure,"" Ocober 21, 1970 - Background"
0900006480ac9f87,Supporting & Related Material,FDA-2009-N-0582-0005,FDA-2009-N-0582,"Reference 3 - ""See H. Rept. No. 102-839, August 11, 1992"" - Background"
0900006480aca040,Supporting & Related Material,FDA-2009-N-0582-0011,FDA-2009-N-0582,"Reference 17 - ""PhRMA Guiding Priniciples; Direct to Consumer Advertisements About Prescription Medicines, Revised December 2008"" - Background"
0900006480fdf3d2,Proposed Rule,FDA-2009-N-0582-0055,FDA-2009-N-0582,"Direct-to-Consumer Prescription Drug Advertisements; Presentation of the Major Statement in Television and Radio Advertisements in a Clear, Conspicuous, and Neutral Manner; Reopening of the Comment Period"
0900006480a23f8b,Other,FDA-2008-N-0163-0290,FDA-2008-N-0163,Acknowledgement Letter to Swankin & Turner
0900006480537ef9,Proposed Rule,FDA-2008-N-0163-0001,FDA-2008-N-0163,Dental Devices: Classification of Encapsulated Amalgam Alloy and Dental Mercury and Reclassification of Dental Mercury; Issuance of Special Controls for Amalgam Alloy; Reopening of Comment Period
0900006481220d56,Other,FDA-2008-N-0163-0304,FDA-2008-N-0163,"Moms Against Mercury, et al. - Supplement"
0900006480a23fa2,Supporting & Related Material,FDA-2008-N-0163-0297,FDA-2008-N-0163,"Reference 1 - Mundy, New FDA Chief Must Divest Several Stock, Fund Holdings - [Citizens for Health, et al (Swankin & Turner) - Petition for Reconsideration]"
09000064805f1545,Supporting & Related Material,FDA-2008-N-0163-0269,FDA-2008-N-0163,Reference 3 - [FDA-2008-N-0163-0004] FDA Update/Review of Potential Adverse Health Risks Associated With Exposure to Mercury in Dental Amalgam
090000648175888c,Other,FDA-2008-N-0163-0305,FDA-2008-N-0163,"Letter from Titus Hills Reynolds Love Dickman & McCalmon re Conversion to Citizen Petition of the September 3, 2009 Petition for Reconsideration"
09000064809ff65c,Supporting & Related Material,FDA-2008-N-0163-0253,FDA-2008-N-0163,"Reference 4 - ""Update Statement by the U. S. Public Health Service on the Safety of Dental Amalgam"" - [Dental Devices: Classification of Encapsulated Amalgam Alloy and Dental Mercury and Reclassification of Dental Mercury; Issuance of Special Controls for Amalgam Alloy; Final Rule]"
09000064809ff68e,Supporting & Related Material,FDA-2008-N-0163-0258,FDA-2008-N-0163,"Reference 13 - ""Life Science Research Office Report: The Potential Health Effects of Dental Amalgam, July 2004"" - [Dental Devices: Classification of Encapsulated Amalgam Alloy and Dental Mercury and Reclassification of Dental Mercury; Issuance of Special Controls for Amalgam Alloy; Final Rule]"
09000064809ff691,Supporting & Related Material,FDA-2008-N-0163-0259,FDA-2008-N-0163,"Reference 14 - ""Toxicological Profile for Mercury "" - [Dental Devices: Classification of Encapsulated Amalgam Alloy and Dental Mercury and Reclassification of Dental Mercury; Issuance of Special Controls for Amalgam Alloy; Final Rule]"
0900006480a24910,Supporting & Related Material,FDA-2008-N-0163-0303,FDA-2008-N-0163,"Reference 2 - Richardson, et al, Mercury Vapour (Hgº): Continuing Toxicological Uncertainties, and Establishing a Canadian Reference Exposure Level - [Mom's Against Mercury, et al. - Petition for Reconsideration]"
0900006480a244fa,Supporting & Related Material,FDA-2008-N-0163-0300,FDA-2008-N-0163,"Reference 4 - Henry Schein Inc. Q2 2009 Earnings Call Transcript - [Citizens for Health, et al. - Petition for Reconsideration]"
0900006480b002a6,Rule,FDA-2008-N-0163-0294,FDA-2008-N-0163,"Dental Devices: Classification of Dental Amalgam, Reclassification of Dental Mercury, Designation of Special Controls for Dental Amalgam, Mercury, and Amalgam Alloy; Technical Amendment"
09000064809ff76b,Supporting & Related Material,FDA-2008-N-0163-0260,FDA-2008-N-0163,"Reference 15a - ""Integrated Risk Information System (IRIS) Screening-Level Literature Review"" - [Dental Devices: Classification of Encapsulated Amalgam Alloy and Dental Mercury and Reclassification of Dental Mercury; Issuance of Special Controls for Amalgam Alloy; Final Rule]"
09000064809ff76e,Supporting & Related Material,FDA-2008-N-0163-0261,FDA-2008-N-0163,"Reference 15b - ""Measurement of Hand Tremor Induced by Industrial Exposure to Metallic Mercury"" - [Dental Devices: Classification of Encapsulated Amalgam Alloy and Dental Mercury and Reclassification of Dental Mercury; Issuance of Special Controls for Amalgam Alloy; Final Rule]"
0900006480a003c2,Supporting & Related Material,FDA-2008-N-0163-0267,FDA-2008-N-0163,"Reference 86 - ""Estimated Pregnancy Rates by Outcome for the United States, 1990-2004, National Vital Statistics Reports, CDC, April 14, 2008 "" - [Dental Devices: Classification of Encapsulated Amalgam Alloy and Dental Mercury and Reclassification of Dental Mercury; Issuance of Special Controls for Amalgam Alloy; Final Rule]"
0900006480a003c8,Supporting & Related Material,FDA-2008-N-0163-0268,FDA-2008-N-0163,"Reference 88 - ""Preliminary Estimates: Labeling and Related Testing Costs for Medical Glove Manufacturers, Eastern Research Group Memorandum, January 18, 1999"" - [Dental Devices: Classification of Encapsulated Amalgam Alloy and Dental Mercury and Reclassification of Dental Mercury; Issuance of Special Controls for Amalgam Alloy; Final Rule]"
0900006480a24613,Supporting & Related Material,FDA-2008-N-0163-0280,FDA-2008-N-0163,"Reference 13 - Mundy, FDA Chief Eyes Device Group - [Citizens for Health, et al. - Petition for Reconsideration]"
0900006480a24784,Supporting & Related Material,FDA-2008-N-0163-0288,FDA-2008-N-0163,"Reference 21 - Dickinson, FDA Amalgam Science Called 'Absurd' in New Experts Attack, August 5, 2009 - [Citizens for Health, et al. - Petition for Reconsideration]"
09000064809ff68b,Supporting & Related Material,FDA-2008-N-0163-0257,FDA-2008-N-0163,"Reference 12 - ""Dental Amalgam and Alternative Restorative Materials: An Update Report to the Environment Health Policy Committee, September 1997"" - [Dental Devices: Classification of Encapsulated Amalgam Alloy and Dental Mercury and Reclassification of Dental Mercury; Issuance of Special Controls for Amalgam Alloy; Final Rule]"
09000064809ffa77,Supporting & Related Material,FDA-2008-N-0163-0262,FDA-2008-N-0163,"Reference 52 - U.S. Environmental Protection Agency (EPA) - ""Integrated Risk Information System (IRIS) Screening-Level Literature Review--Mercuric Chloride, 2002"" - [Dental Devices: Classification of Encapsulated Amalgam Alloy and Dental Mercury and Reclassification of Dental Mercury; Issuance of Special Controls for Amalgam Alloy; Final Rule]"
0900006480a2452b,Supporting & Related Material,FDA-2008-N-0163-0273,FDA-2008-N-0163,"Reference 5 - Consumers for Dental Choice FDA, June 9, 2009 re: Concerns About Mercury Amalgam Regulation and Your Henry Schein Board Membership - [Citizens for Health, et al. - Petition for Reconsideration]"
0900006480a24534,Supporting & Related Material,FDA-2008-N-0163-0275,FDA-2008-N-0163,"Reference 7 - Consumers for Dental Choice Acting FDA Chief Counsel, July 9, 2009 - [Citizens for Health, et al. - Petition for Reconsideration]"
0900006480a2460e,Supporting & Related Material,FDA-2008-N-0163-0278,FDA-2008-N-0163,"Reference 10 - Landers, American Medical News, Jan. 14, 2008, Questioning Kids - [Citizens for Health, et al. - Petition for Reconsideration]"
0900006480a24611,Supporting & Related Material,FDA-2008-N-0163-0279,FDA-2008-N-0163,"Reference 11 - Janis, Baltimore City Paper, Feb. 8, 2006, Q+A, Dr. Joshua Sharfstein - [Citizens for Health, et al. - Petition for Reconsideration]"
0900006480a24614,Supporting & Related Material,FDA-2008-N-0163-0281,FDA-2008-N-0163,"Reference 14 - Dickinson, A 'Shocking' Decision - Bias Seen in Dental Amalgams Rule  - [Citizens for Health, et al. - Petition for Reconsideration]"
0900006482d3c6c6,Supporting & Related Material,FDA-2017-P-6918-0007,FDA-2017-P-6918,Reference 2 - Standardizing terms for clinical pharmacogenetic test results re Citizen Petition from St. Jude Children's Research Hospital
0900006482d3c6c7,Supporting & Related Material,FDA-2017-P-6918-0006,FDA-2017-P-6918,Reference 3 - Clinical practice guideline: tonsillectomy in children re Citizen Petition from St. Jude Children's Research Hospital
0900006482d3c6c8,Supporting & Related Material,FDA-2017-P-6918-0005,FDA-2017-P-6918,Reference 4 - Recurrent hypoxemia in young children with obstructive sleep apnea is associated with reduced opioid requirement for analgesia re Citizen Petition from St. Jude Children's Research Hospital
0900006482d3c9a0,Supporting & Related Material,FDA-2017-P-6918-0015,FDA-2017-P-6918,Table 1 Cases of Toxicity in Children after Receiving Codeine re Citizen Petition from St. Jude Children's Research Hospital re Citizen Petition from St. Jude Children's Research Hospital
0900006482d3c998,Supporting & Related Material,FDA-2017-P-6918-0003,FDA-2017-P-6918,Reference 8 - Clinical Pharmacogenetics Implementation Consortium guideline for cytochrome P450 2D6 genotype and codeine therapy re Citizen Petition from St. Jude Children's Research Hospital
0900006482d3c99e,Supporting & Related Material,FDA-2017-P-6918-0009,FDA-2017-P-6918,Reference 17 - Systematic evaluation of commercial pharmacogenetic testing in psychiatry re Citizen Petition from St. Jude Children's Research Hospital
0900006482d3c99f,Supporting & Related Material,FDA-2017-P-6918-0016,FDA-2017-P-6918,Reference 18 - Pharmacogenetics for safe codeine use in sickle cell disease re Citizen Petition from St. Jude Children's Research Hospital
0900006482d3c99b,Supporting & Related Material,FDA-2017-P-6918-0012,FDA-2017-P-6918,Reference 10 - Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication re Citizen Petition from St. Jude Children's Research Hospital
0900006482d3c6c1,Other,FDA-2017-P-6918-0001,FDA-2017-P-6918,Citizen Petition from St. Jude Children's Research Hospital
0900006482d3c6c5,Supporting & Related Material,FDA-2017-P-6918-0008,FDA-2017-P-6918,Reference List re Citizen Petition from St. Jude Children's Research Hospital
0900006482d3c999,Supporting & Related Material,FDA-2017-P-6918-0014,FDA-2017-P-6918,Reference 8(suppl) - Clinical Pharmacogenetics Implementation Consortium guideline for cytochrome P450 2D6 genotype and codeine therapy re Citizen Petition from St. Jude Children's Research Hospital
0900006482d3c99c,Supporting & Related Material,FDA-2017-P-6918-0011,FDA-2017-P-6918,Reference 11 - Preemptive clinical pharmacogenetics implementation current programs in five United States medical centers re Citizen Petition from St. Jude Children's Research Hospital
0900006482d3c99d,Supporting & Related Material,FDA-2017-P-6918-0010,FDA-2017-P-6918,Reference 15 - Challenges in ordering and interpreting pharmacogenomic tests in clinical practice re Citizen Petition from St. Jude Children's Research Hospital
0900006482d3c6c3,Other,FDA-2017-P-6918-0002,FDA-2017-P-6918,Acknowledgment Letter from FDA DDM to St. Jude Children’s Research Hospital
0900006482d3c997,Supporting & Related Material,FDA-2017-P-6918-0004,FDA-2017-P-6918,Reference 6 - Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation re Citizen Petition from St. Jude Children's Research Hospital
0900006482d3c99a,Supporting & Related Material,FDA-2017-P-6918-0013,FDA-2017-P-6918,Reference 9 - Codeine use among children in the United States_a nationally representative study from 1996 to 2013 re Citizen Petition from St. Jude Children's Research Hospital
0900006483f2093e,Other,FDA-2017-D-5712-0002,FDA-2017-D-5712,FDA and Industry Actions on De Novo Classification Requests: Effect on FDA Review Clock and Goals; Guidance for Industry and Food and Drug Administration Staff
0900006484dbaf21,Other,FDA-2017-D-5712-0003,FDA-2017-D-5712,FDA and Industry Actions on De Novo Classification Requests: Effect on FDA Review Clock and Goals; Guidance for Industry and Food and Drug Administration Staff
0900006482b92175,Other,FDA-2017-D-5712-0001,FDA-2017-D-5712,Guidance for Industry on FDA and Industry Actions on De Novo Classification Requests Effect on FDA Review Clock and Goals
090000648207861c,Notice,FDA-2016-D-1399-0001,FDA-2016-D-1399,"Procedures for Evaluating Appearance Issues and Granting  Authorizations for Participation in Food and Drug Administration Advisory Committees; Draft Guidance for the Public, Food and Drug Administration Advisory Committee Members, and Food and Drug Administration Staff; Availability"
090000648225ad97,Notice,FDA-2016-D-1399-0003,FDA-2016-D-1399,"Procedures for Evaluating Appearance Issues and Granting  Authorizations for Participation in Food and Drug Administration  Advisory Committees; Draft Guidance for the Public, Food and Drug Administration Advisory Committee Members, and Food and Drug Administration Staff; Availability; Extension of Comment Period"
090000648207942c,Other,FDA-2016-D-1399-0002,FDA-2016-D-1399,"Procedures for Evaluating Appearance Issues and Granting Authorizations for Participation in FDA Advisory Committees; Guidance for the Public, FDA Advisory Committee Members, and FDA Staff; Draft Guidance"
0900006482131cd2,Other,FDA-2016-D-1853-0002,FDA-2016-D-1853,Unique Device Identification System: Form and Content of the Unique Device Identifier (UDI); Draft Guidance for Industry and Food and Drug Administration Staff
0900006484bd5e43,Notice,FDA-2016-D-1853-0029,FDA-2016-D-1853,Unique Device Identification System: Form and Content of the Unique Device Identifier; Guidance for Industry and Food and Drug Administration Staff; Availability
0900006484bd83cc,Other,FDA-2016-D-1853-0030,FDA-2016-D-1853,Unique Device Identification System: Form and Content of the Unique Device Identifier (UDI); Guidance for Industry and Food and Drug Administration Staff
09000064822183e6,Notice,FDA-2016-D-1853-0012,FDA-2016-D-1853,"Agency Information Collection Activities; Proposed Collection; 
Comment Request; Unique Device Identification System"
09000064821222de,Notice,FDA-2016-D-1853-0001,FDA-2016-D-1853,"Unique Device Identification System: Form and Content of the Unique
Device Identifier; Draft Guidance for Industry and Food and Drug
Administration Staff; Availability and Request for Comments"
0900006482611b63,Notice,FDA-2016-D-1853-0026,FDA-2016-D-1853,"Agency Information Collection Activities; Announcement of Office of
Management and Budget Approvals"
09000064804dfc8f,Notice,FDA-2001-D-0162-0001,FDA-2001-D-0162,FDA
0900006482d56c24,Notice,FDA-2017-N-6395-0001,FDA-2017-N-6395,Request for Nominations of Members for the Clinical Trials Transformation Initiative/Food and Drug Administration Patient  Engagement Collaborative
0900006484c0a30f,Notice,FDA-2017-N-6395-0002,FDA-2017-N-6395,"Request for Applications for New Members of the Clinical Trials 
Transformation Initiative/Food and Drug Administration Patient 
Engagement Collaborative"
09000064804f5fb5,Other,FDA-1999-N-4096-0002,FDA-1999-N-4096,CDRH Teleconference For FDA Stakeholders on 4/28/99  - Agenda
09000064804f5fc0,Other,FDA-1999-N-4096-0007,FDA-1999-N-4096,Paul G King Consulting - Comment
09000064804f5fb7,Other,FDA-1999-N-4096-0003,FDA-1999-N-4096,CryoGen Inc - Testimony
09000064804f5fb8,Other,FDA-1999-N-4096-0004,FDA-1999-N-4096,Chemically Associated Neurological Disorders - Testimony
09000064804f5fb4,Other,FDA-1999-N-4096-0001,FDA-1999-N-4096,CDRH Teleconference For FDA Stakeholders on 4/28/99  - Transcript
09000064804f5fb9,Other,FDA-1999-N-4096-0005,FDA-1999-N-4096,Health Industries Manufacturers Association (HIMA)  - Testimony
09000064837ae186,Other,FDA-2018-P-1880-0005,FDA-2018-P-1880,Response Letter from FDA CDER to Louis Morris Aledort Md
0900006483266230,Other,FDA-2018-P-1880-0002,FDA-2018-P-1880,"Acknowledgment Letter from FDA DDM to Louis Morris Aledort, MD"
09000064832654b0,Other,FDA-2018-P-1880-0001,FDA-2018-P-1880,Citizens Petition from Louis Morris Aledort MD
0900006484e66067,Notice,FDA_FRDOC_0001-11009,FDA_FRDOC_0001,Notice to Public of Website Location of Center for Devices and Radiological Health Fiscal Year 2022 Proposed Guidance Development
0900006481703679,Supporting & Related Material,FDA-2008-N-0176-0020,FDA-2008-N-0176,"Reference 6-Tables 1-5, 1-9, 1-10, 1-14, 1-20, 1-24, 2-8, 2-9, 2-22, 2-23, 2-46 & 2-47 from U. S. Pet Ownership & Demographics Sourcebook 2012 Edition, reproduced by permission of the America - Defining Small Numbers of Animals for Minor Use Designation; Periodic Reassessment"
090000648170367a,Supporting & Related Material,FDA-2008-N-0176-0014,FDA-2008-N-0176,List of References
090000648170367b,Supporting & Related Material,FDA-2008-N-0176-0015,FDA-2008-N-0176,"Reference 1- Sheep and Goats – Sheep and Lamb Inventory by Class, National Agricultural Statistics Service (NASS), United States Department of Agriculture (USDA), February 1, 2013-Defining Small Numbers of Animals for Minor Use Designation; Periodic Reassessment"
090000648170375e,Supporting & Related Material,FDA-2008-N-0176-0017,FDA-2008-N-0176,"Reference 3- Brakke Consulting, Inc., “Update of Population Estimates, Disease Incidence Rates, Drug Development Costs and Treatment Costs for Companion Animals,” September 6, 2013 - Defining Small Numbers of Animals for Minor Use Designation; Periodic Reassessment"
090000648170375f,Supporting & Related Material,FDA-2008-N-0176-0018,FDA-2008-N-0176,"Reference 4- Figures 8, 15, & 27 from U. S. Pet Ownership & Demographics Sourcebook 2002 Edition, reproduced by permission of the American Veterinary Medical Association - Defining Small Numbers of Animals for Minor Use Designation; Periodic Reassessment"
09000064809fbaec,Supporting & Related Material,FDA-2008-N-0176-0010,FDA-2008-N-0176,"Reference List and Reference 1 - ""Brakke Consulting, Inc., ‘‘Disease Incidence Rates, Drug Development and Treatment Costs,’’ September 2005"" - [Defining Small Number of Animals for Minor Use Designation]"
09000064803f6f8d,Supporting & Related Material,FDA-2008-N-0176-0002,FDA-2008-N-0176,Defining Small Number of Animals for Minor Use Designation - References
0900006481703760,Supporting & Related Material,FDA-2008-N-0176-0019,FDA-2008-N-0176,"Reference 5- Tables 1-5, 1-10, & 1-20 from U. S. Pet Ownership & Demographics Sourcebook 2007 Edition, reproduced by permission of the American Veterinary Medical Association - Defining Small Numbers of Animals for Minor Use Designation; Periodic Reassessment"
0900006480a12f05,Rule,FDA-2008-N-0176-0009,FDA-2008-N-0176,"Defining ""Small Number of Animals"" for Minor Use Designation"
090000648170367c,Supporting & Related Material,FDA-2008-N-0176-0016,FDA-2008-N-0176,"Reference 2- Brakke Consulting, Inc., “Disease Incidence Rates, Drug
Development and Treatment Costs,” September, 2005 - Defining Small Numbers of Animals for Minor Use Designation; Periodic Reassessment"
09000064803fc39d,Proposed Rule,FDA-2008-N-0176-0001,FDA-2008-N-0176,Defining Small Number of Animals for Minor Use Designation
09000064809fbaee,Supporting & Related Material,FDA-2008-N-0176-0012,FDA-2008-N-0176,"Reference 3 - ""American Veterinary Medical Association, ‘‘U.S. Pet Ownership & Demographics Sourcebook,’’ 2002"" - [Defining Small Number of Animals for Minor Use Designation]"
09000064809fbaed,Supporting & Related Material,FDA-2008-N-0176-0011,FDA-2008-N-0176,"Reference 2 - ""Brakke Consulting, Inc., Pharmaceutical Pricing for Companion Animal Products, December 1, 2008"" - [Defining Small Number of Animals for Minor Use Designation]"
0900006481702f42,Notice,FDA-2008-N-0176-0013,FDA-2008-N-0176,"Defining Small Numbers of Animals for Minor Use Designation; Periodic
Reassessment"
0900006481fd113b,Proposed Rule,FDA-2016-D-1164-0001,FDA-2016-D-1164,Qualified Facility Attestation Using Form FDA 3942a (for Human Food) or Form FDA 3942b (for Animal Food); Draft Guidance for Industry; Availability; Agency Information Collection Activities; Proposed Collection; Comment Request
09000064839957e8,Other,FDA-2016-D-1164-0010,FDA-2016-D-1164,Form FDA 3942a from Hillside Creamery
09000064837008bf,Other,FDA-2016-D-1164-0008,FDA-2016-D-1164,"Determination of Status as a Qualified Facility Under Part 117: Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food And Part 507: Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Food for Animals; Guidance for Industry"
09000064837801b3,Notice,FDA-2016-D-1164-0009,FDA-2016-D-1164,Agency Information Collection Activities; Announcement of Office of Management and Budget Approvals
09000064833ed951,Notice,FDA-2016-D-1164-0005,FDA-2016-D-1164,"Agency Information Collection Activities; Proposals, Submissions, and Approvals: Qualified Facility Attestation"
09000064839ac383,Other,FDA-2016-D-1164-0011,FDA-2016-D-1164,Form FDA 3942a from Natural Ice Fruits Inc
0900006481fd0b06,Other,FDA-2016-D-1164-0002,FDA-2016-D-1164,Guidance for Qualified Facility Attestation Using Form FDA 3942a (for Human Food) and Form FDA 3942b (for Animal Food) Draft Guidance for Industry
09000064836fe3e4,Notice,FDA-2016-D-1164-0007,FDA-2016-D-1164,"Determination of Status as a Qualified Facility Under Part 117: Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food And Part 507: Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Food for Animals; Guidance for Industry"
0900006484a71bd3,Other,FDA-2021-P-0305-0001,FDA-2021-P-0305,Citizen Petition from Donavan Melton
0900006484c03bd7,Other,FDA-2021-P-0305-0003,FDA-2021-P-0305,Final Response to  Donavan Melton from FDA CVM
0900006484a71bd6,Other,FDA-2021-P-0305-0002,FDA-2021-P-0305,Acknowledgment Letter from FDA DMS to Donavan Melton
090000648203f737,Supporting & Related Material,FDA-2013-N-0125-0018,FDA-2013-N-0125,Reference 1 Frequently Asked Questions Guidance re Use of Symbols in Labeling
090000648203f738,Supporting & Related Material,FDA-2013-N-0125-0019,FDA-2013-N-0125,Reference 2 National Technology Transfer  Act re Use of Symbols in Labeling
090000648203df63,Supporting & Related Material,FDA-2013-N-0125-0017,FDA-2013-N-0125,Index List of References re Use of Symbols in Labeling
09000064820f48bd,Supporting & Related Material,FDA-2013-N-0125-0023,FDA-2013-N-0125,Reference 6 Final Regulatory Impact Analysis re Use of Certain Symbols in Labeling
090000648203d414,Rule,FDA-2013-N-0125-0016,FDA-2013-N-0125,Use of Symbols in Labeling
090000648203f739,Supporting & Related Material,FDA-2013-N-0125-0020,FDA-2013-N-0125,Reference 3 Circular A119 re Use of Symbols in Labeling
090000648203f73a,Supporting & Related Material,FDA-2013-N-0125-0021,FDA-2013-N-0125,Reference 4 IVD Symbols Guidance re Use of Symbols in Labeling
0900006484635b8a,Other,FDA-2013-N-0125-0025,FDA-2013-N-0125,Guidance for Industry Alternative to Certain Prescription Device Labeling Requirements
090000648129c6c1,Proposed Rule,FDA-2013-N-0125-0001,FDA-2013-N-0125,Use of Certain Symbols in Labeling
090000648203f73b,Supporting & Related Material,FDA-2013-N-0125-0022,FDA-2013-N-0125,06 Reference 5 Alternative to Prescription Device Labeling Guidance re Use of Symbols in Labeling
09000064824264d3,Notice,FDA-2013-N-0125-0024,FDA-2013-N-0125,"Agency Information Collection Activities; Proposals, Submissions, and Approvals: Announcement of Office of Management and Budget Approvals"
09000064849f870c,Other,FDA-2021-P-0084-0001,FDA-2021-P-0084,Citizen Petition from Peggy Lillis Foundation for C. diff Education & Advocacy
09000064849f870f,Other,FDA-2021-P-0084-0002,FDA-2021-P-0084,Acknowledgement Letter from FDA DMS to Peggy Lillis Foundation for C. diff Education & Advocacy
0900006484bdfa80,Other,FDA-2021-P-0084-0005,FDA-2021-P-0084,Interim Response Letter from FDA CBER to Peggy Lillis Foundation for C. diff Education & Advocacy
0900006481fbdc65,Other,FDA-2015-P-1279-0021,FDA-2015-P-1279,Acknowledgement Letter from FDA DDM to Cigar Rights of America
0900006481fbaa04,Other,FDA-2015-P-1279-0013,FDA-2015-P-1279,Citizen Petition Final Response from FDA CTP to Cigar Rights of America
0900006481fbae1d,Other,FDA-2015-P-1279-0016,FDA-2015-P-1279,Citizen Petition Final Response from FDA CTP to Cigar Rights of America
0900006481cef120,Other,FDA-2015-P-1279-0008,FDA-2015-P-1279,Citizen Petition from Cigar Rights of America
0900006481fadea8,Other,FDA-2015-P-1279-0018,FDA-2015-P-1279,Citizen Petition from Cigar Rights of America
0900006481aac5ef,Other,FDA-2015-P-1279-0002,FDA-2015-P-1279,Acknowledgement Letter from FDA DDM to Cigar Rights of America
0900006481f866c2,Other,FDA-2015-P-1279-0012,FDA-2015-P-1279,Acknowledgement Letter from FDA DDM to Cigar Rights of America
0900006481aac52a,Other,FDA-2015-P-1279-0001,FDA-2015-P-1279,Citizen Petition from Cigar Rights of America
0900006481ad2702,Other,FDA-2015-P-1279-0004,FDA-2015-P-1279,Second Acknowledgement Letter From FDA DDM to Cigar Rights of America
0900006481ad2700,Other,FDA-2015-P-1279-0003,FDA-2015-P-1279,Citizen Petition From Cigar Rights of America Regarding HPHC (petition 2)
0900006481cef2b5,Other,FDA-2015-P-1279-0009,FDA-2015-P-1279,Acknowledgement Letter from FDA DDM to Cigar Rights of America
0900006481faf43a,Supporting & Related Material,FDA-2015-P-1279-0022,FDA-2015-P-1279,Appendix: Coggins Report on Health Effects of Cigar Smoking
0900006482354c53,Other,FDA-2015-P-1279-0023,FDA-2015-P-1279,Final Response from FDA CDER to Cigar Rights of America
0900006481f86124,Other,FDA-2015-P-1279-0011,FDA-2015-P-1279,Citizen Petition 5 from Cigar Rights of America
0900006481fbae17,Other,FDA-2015-P-1279-0015,FDA-2015-P-1279,Citizen Petition Final Response from FDA CTP to Cigar Rights of America
0900006481bcc3f5,Other,FDA-2015-P-1279-0006,FDA-2015-P-1279,Acknowledgment Letter from FDA DDM to Cigar Rights of America
0900006481fae367,Other,FDA-2015-P-1279-0019,FDA-2015-P-1279,Acknowledgement Letter from FDA DDM to Cigar Rights of America
0900006481f82d09,Other,FDA-2015-P-1279-0010,FDA-2015-P-1279,Interim Response from FDA CTP to Cigar Rights of America - Tentative - Signed
0900006481fbaec2,Other,FDA-2015-P-1279-0017,FDA-2015-P-1279,Citizen Petition Final Response from FDA CTP to Cigar Rights of America
0900006481bcc3f2,Other,FDA-2015-P-1279-0005,FDA-2015-P-1279,Citizen Petition from Cigar Rights of America
0900006481fbdc60,Other,FDA-2015-P-1279-0020,FDA-2015-P-1279,Citizen Petition from Cigar Rights of America
0900006481fbaa07,Other,FDA-2015-P-1279-0014,FDA-2015-P-1279,Citizen Petition Final Response from FDA CTP to Cigar Rights of America
0900006481c7a70e,Other,FDA-2015-P-1279-0007,FDA-2015-P-1279,Interim Response Letter from FDA CTP to Cigar Rights of America
0900006484a9d360,Other,FDA-2021-P-0350-0002,FDA-2021-P-0350,Acknowledgement Letter from FDA DMS  to Donavan Melton
0900006484a9d1dd,Other,FDA-2021-P-0350-0001,FDA-2021-P-0350,Citizen Petition from Donavan Melton
0900006484c03bdc,Other,FDA-2021-P-0350-0003,FDA-2021-P-0350,Final Response to  Donavan Melton from FDA CVM
0900006484db14eb,Other,FDA-2021-P-1048-0001,FDA-2021-P-1048,Citizen Petition from Pet Schooled
0900006484db1932,Other,FDA-2021-P-1048-0002,FDA-2021-P-1048,Acknowledgment Letter from FDA DMS to Pet Schooled
09000064849796b2,Other,FDA-2020-P-2237-0002,FDA-2020-P-2237,Acknowledgment Letter from FDA DMS to Dr. S. Albert Edwards
0900006484c2caa4,Other,FDA-2020-P-2237-0004,FDA-2020-P-2237,Response to Citizen Petition from FDA OC to Dr. S. Albert Edwards
0900006484ba90d1,Other,FDA-2020-P-2237-0003,FDA-2020-P-2237,Interim Response Letter from FDA CBER to Dr. S. Albert Edwards
09000064849796b1,Other,FDA-2020-P-2237-0001,FDA-2020-P-2237,Citizen Petition from Dr. S. Albert Edwards
09000064804a59ca,Notice,FDA-1999-D-0009-0001,FDA-1999-D-0009,"Guidance for Industry on the Disclosure of Materials Provided to Advisory
Committees in Connection with Open Advisory Committee Meetings Convened by the Center for Drug Evaluation and Research Beginning on January 1, 2000; Availability"
09000064804a59d0,Notice,FDA-1999-D-0009-0002,FDA-1999-D-0009,"Draft Guidance for Industry on Disclosing Information Provided to Advisory Committees in Connection With Open Advisory Committee Meetings Related to the Testing or Approval of New Drugs and Convened by the Center for Drug Evaluation and Research, Beginning on January 1, 2000; Availability"
09000064804a59cf,Other,FDA-1999-D-0009-0004,FDA-1999-D-0009,"Draft Guidance for Industry Disclosure of Materials Provided to Advisory Committees in Connection with Open Advisory Committee Meetings Convened by the Center for Drug Evaluation and Research Beginning on January 1, 2000"
09000064804a59ce,Other,FDA-1999-D-0009-0003,FDA-1999-D-0009,"Guidance for Industry Disclosure of Materials Provided to Advisory Committees in Connection with Open Advisory Committee Meetings Convened by the Center for Drug Evaluation and Research Beginning on January 1, 2000"
09000064804ed710,Notice,FDA-2000-N-1088-0002,FDA-2000-N-1088,Codex Alimentarius: Meeting of the Codex Committee on General Principles; Organization for Economic Cooperation and Development: Meeting of the Ad Hoc Group on Food Safety
09000064804ed707,Notice,FDA-2000-N-1088-0001,FDA-2000-N-1088,"Codex Alimentarius: Meeting of the Codex Committee on General Principles, Organization for Economic Cooperation and Development: Meeting of the Ad Hoc Group on Food Safety"
09000064807d2748,Other,FDA-2008-P-0630-0001,FDA-2008-P-0630,The Prescription Project of Community Catalyst - Citizen Petition
0900006480f67983,Other,FDA-2008-P-0630-0003,FDA-2008-P-0630,Interim Response to The Prescription Project of Community Catalyst - Letter
09000064807d277c,Other,FDA-2008-P-0630-0002,FDA-2008-P-0630,Acknowledgement Letter to The Prescription Project of Community Catalyst
0900006481394eec,Notice,FDA-2013-N-0779-0001,FDA-2013-N-0779,Retrospective Review of Draft Guidance Documents Issued Before 2010; Withdrawal of Guidances
090000648049e6c6,Supporting & Related Material,FDA-2002-N-0279-0016,FDA-2002-N-0279,"Tab 4 - [Reference (FDA to Lord, Bissell & Brook on Behalf of Apotex, Inc. Citizen Petition)] - Background Material"
090000648049e6c9,Supporting & Related Material,FDA-2002-N-0279-0024,FDA-2002-N-0279,"Tab 14 - [Reference (Congressional Budget Office ""How Increased Competition from Generic Drugs has Affected Prices and Returns in the Pharmaceutical Industry"" (July 1998))] - Background Material"
090000648049e6cc,Supporting & Related Material,FDA-2002-N-0279-0027,FDA-2002-N-0279,Tab 20 - [Reference (Drug Expenditure Tables)] - Background Material
090000648049e7bb,Notice,FDA-2002-N-0279-0011,FDA-2002-N-0279,FDA [Technical Amendment] - Notice of Final Rule
090000648049e6bf,Supporting & Related Material,FDA-2002-N-0279-0020,FDA-2002-N-0279,"Tab 8 - [Reference ""Congressional House"" (Page H 6916 thru H 6921 (9/13/1982))] - Background Material"
090000648049e6bd,Supporting & Related Material,FDA-2002-N-0279-0012,FDA-2002-N-0279,Reference Listing - [Tab 1 thru 19 Reference Title List] - Background Material
090000648049e6bc,Supporting & Related Material,FDA-2002-N-0279-0013,FDA-2002-N-0279,"Tab 1 - [Reference ""FTC Citizen Petiton""] - Background Material"
090000648049e6c7,Supporting & Related Material,FDA-2002-N-0279-0017,FDA-2002-N-0279,"Tab 5 - [Reference (Guidance for Industry ""Q7A Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients"")] - Background Material"
090000648049e7b6,Supporting & Related Material,FDA-2002-N-0279-0009,FDA-2002-N-0279,Tab A - OMB Review (6/18/2000) [Final Rule page 1 thru 99] - Reference
090000648049e7ae,Supporting & Related Material,FDA-2002-N-0279-0006,FDA-2002-N-0279,Tab B - [OMB Review ([Notice of Final Rule page 99 thru 121 and FDA3542a) (6/18/2003)] - Reference
090000648049e6cd,Supporting & Related Material,FDA-2002-N-0279-0019,FDA-2002-N-0279,"Tab 7 - [Reference Andrx Pharmaceuticals, Inc. v. Biovail Corporation International and Tommy Thompson, Secretary DHHS] - Background Material"
090000648049e6cb,Supporting & Related Material,FDA-2002-N-0279-0026,FDA-2002-N-0279,"Tab 19 - [Reference ""National Health Care Expenditures Projections: 2001-2011"" (Centers for Medicare & Medicaid Services - Office of the Actuary)] - Background Material"
090000648049e7a5,Notice,FDA-2002-N-0279-0002,FDA-2002-N-0279,FDA - Notice of Final Rule
090000648049e7b9,Supporting & Related Material,FDA-2002-N-0279-0010,FDA-2002-N-0279,Cover Page - OMB Review (6/18/2003)  - Reference
090000648049e7b1,Supporting & Related Material,FDA-2002-N-0279-0007,FDA-2002-N-0279,Tab B - [OMB Review ([Notice of Final Rule page 1 thru 98)  (6/18/2003)] - Reference
090000648049e7ac,Supporting & Related Material,FDA-2002-N-0279-0005,FDA-2002-N-0279,OMB INFORMATION COLLECTION - SUPPORTING STATEMENT
090000648049e6c3,Supporting & Related Material,FDA-2002-N-0279-0022,FDA-2002-N-0279,"Tab 10 - [Reference ""The Patent Term Restoration Act of 1983""] (page 48, 56 and 57  Lewis A. Engman Comment)] - Background Material"
090000648049e6ba,Notice,FDA-2002-N-0279-0001,FDA-2002-N-0279,FDA - Notice of Proposed Rule-Making
090000648049e6c4,Supporting & Related Material,FDA-2002-N-0279-0015,FDA-2002-N-0279,Tab 3 - [Reference (FDA to Biovail Laboratories Inc.)]  - Background Material
090000648049e6c8,Supporting & Related Material,FDA-2002-N-0279-0018,FDA-2002-N-0279,"Tab 6 - [Reference (FDA to Beers, Korn, Arnold & Porter, McNichol, Scheineson, Frisch, Smith (Petiton Denial))] - Background Material"
090000648049e6ca,Supporting & Related Material,FDA-2002-N-0279-0025,FDA-2002-N-0279,"Tab 16 - [Reference  ""The Pediatric Exclusivity Provision - January 2001 Status Report to Congress"" [DHHS/FDA]] - Background Material"
090000648049e7aa,Supporting & Related Material,FDA-2002-N-0279-0004,FDA-2002-N-0279,OMB INFORMATION COLLECTION - SUPPORTING STATEMENT
090000648049e7a9,Notice,FDA-2002-N-0279-0003,FDA-2002-N-0279,FDA - Notice of Approval
090000648049e6c1,Supporting & Related Material,FDA-2002-N-0279-0021,FDA-2002-N-0279,"Tab 9 - [Reference ""Congressional House"" (Page H 6922 thru H 6924 (9/13/1982))] - Background Material"
090000648049e6c0,Supporting & Related Material,FDA-2002-N-0279-0014,FDA-2002-N-0279,"Tab 2 - [Reference ""Generic Drug Entry Prior to Patent Expiration"" (An FTC Study (July 2002))] - Background Material"
090000648049c9a4,Other,FDA-2002-N-0265-0055,FDA-2002-N-0265,FDC Reports - Electronic Request for Appearance
090000648049c92b,Other,FDA-2002-N-0265-0032,FDA-2002-N-0265,"FlowMedica, Inc. - Electronic Request for Appearance"
090000648049c96d,Other,FDA-2002-N-0265-0039,FDA-2002-N-0265,Inhale Therapeutic Systems - Electronic Request for Appearance
090000648049c90c,Other,FDA-2002-N-0265-0023,FDA-2002-N-0265,Tom Steinke Research Company - Electronic Request for Appearance
090000648049c8e0,Other,FDA-2002-N-0265-0004,FDA-2002-N-0265,PAREXEL International Corporation - Electronic Request for Appearance
090000648049c925,Other,FDA-2002-N-0265-0029,FDA-2002-N-0265,"VIVUS, Inc. - Electronic Request for Appearance"
090000648049c992,Other,FDA-2002-N-0265-0046,FDA-2002-N-0265,Johnson & Johnson Pharmaceutical R&D - Electronic Request for Appearance
090000648049c973,Other,FDA-2002-N-0265-0042,FDA-2002-N-0265,"Wyeth Pharmaceuticals, Inc. - Electronic Request for Appearance"
090000648049c9c1,Other,FDA-2002-N-0265-0057,FDA-2002-N-0265,"Coley Pharmaceutical Group, Inc. - Electronic Request for Appearance"
090000648049c9e4,Other,FDA-2002-N-0265-0063,FDA-2002-N-0265,Alpine Group - Electronic Request for Appearance
090000648049c9a0,Other,FDA-2002-N-0265-0053,FDA-2002-N-0265,Hogan & Hartson LLP - Electronic Request for Appearance
090000648049c9c7,Other,FDA-2002-N-0265-0060,FDA-2002-N-0265,Carnegie Mellon University - Electronic Request for Appearance
090000648049ca11,Other,FDA-2002-N-0265-0074,FDA-2002-N-0265,Ethicon Endo-Surgery - Electronic Request for Appearance
090000648049c99a,Other,FDA-2002-N-0265-0049,FDA-2002-N-0265,"Alquest, Inc. - Electronic Request for Appearance"
090000648049c99b,Other,FDA-2002-N-0265-0050,FDA-2002-N-0265,Wyeth Pharmaceuticals - Electronic Request for Appearance
090000648049c922,Other,FDA-2002-N-0265-0027,FDA-2002-N-0265,EMBSI - Electronic Request for Appearance
090000648049c8de,Other,FDA-2002-N-0265-0003,FDA-2002-N-0265,"Medtronic, Inc. - Electronic Request for Appearance"
090000648049c8ff,Other,FDA-2002-N-0265-0016,FDA-2002-N-0265,Patton Boggs LLP - Electronic Request for Appearance
090000648049c8fd,Other,FDA-2002-N-0265-0015,FDA-2002-N-0265,Merck Research Laboratories - Electronic Request for Appearance
090000648049c934,Other,FDA-2002-N-0265-0037,FDA-2002-N-0265,"Medtronic, Inc. - Electronic Request for Appearance"
090000648049c9e6,Other,FDA-2002-N-0265-0064,FDA-2002-N-0265,Abbott Laboratories - Electronic Request for Appearance
090000648049c9c5,Other,FDA-2002-N-0265-0059,FDA-2002-N-0265,American Medical Systems - Electronic Request for Appearance
090000648049c99e,Other,FDA-2002-N-0265-0052,FDA-2002-N-0265,Biomerix - Electronic Request for Appearance
090000648049c9ee,Other,FDA-2002-N-0265-0068,FDA-2002-N-0265,Iomai Corporation - Electronic Request for Appearance
090000648049c9ea,Other,FDA-2002-N-0265-0066,FDA-2002-N-0265,BonScience - Electronic Request for Appearance
090000648049cbdd,Notice,FDA-2002-D-0266-0005,FDA-2002-D-0266,FDA
090000648049cb29,Notice,FDA-2002-D-0266-0001,FDA-2002-D-0266,FDA
090000648049cbdc,Supporting & Related Material,FDA-2002-D-0266-0004,FDA-2002-D-0266,Guidance
090000648049cbd8,Supporting & Related Material,FDA-2002-D-0266-0002,FDA-2002-D-0266,Guidance
090000648049cbda,Supporting & Related Material,FDA-2002-D-0266-0003,FDA-2002-D-0266,Guidance
090000648044cc1a,Notice,FDA-2005-N-0396-0001,FDA-2005-N-0396,FDA
090000648044cc23,Notice,FDA-2005-N-0396-0002,FDA-2005-N-0396,FDA
090000648044cc24,Notice,FDA-2005-N-0396-0003,FDA-2005-N-0396,FDA
090000648044cc29,Notice,FDA-2005-N-0396-0004,FDA-2005-N-0396,FDA
09000064804b49f5,Notice,FDA-2001-D-0012-0001,FDA-2001-D-0012,FDA
09000064804b4a3f,Notice,FDA-2001-D-0012-0002,FDA-2001-D-0012,FDA
090000648056e80f,Notice,FDA-1998-N-0050-0017,FDA-1998-N-0050,Quarterly List of Guidance Documents at the Food and Drug Administration; Notice
090000648056e820,Notice,FDA-1998-N-0050-0005,FDA-1998-N-0050,Annual Comprehensive List of Guidance Documents at the Food and Drug Administration; Notice
090000648056e809,Notice,FDA-1998-N-0050-0011,FDA-1998-N-0050,Quarterly List of Guidance Documents at the Food and Drug Administration; Notice
090000648056e80a,Notice,FDA-1998-N-0050-0012,FDA-1998-N-0050,Quarterly List of Guidance Documents at the Food and Drug Administration; Notice
090000648056e80b,Other,FDA-1998-N-0050-0013,FDA-1998-N-0050,"Letter from The Weinberg Group, Inc to FDA DDM"
090000648457a7fb,Other,FDA-1998-N-0050-0022,FDA-1998-N-0050,CPG Sec. 540.375 Canned Salmon - Adulteration Involving Decomposition Withdrawn 3-22-2010
0900006480b2c09d,Notice,FDA-1998-N-0050-0007,FDA-1998-N-0050,Comprehensive List of Guidance Documents at Food and Drug Administration; Notice
090000648056e80c,Notice,FDA-1998-N-0050-0014,FDA-1998-N-0050,Annual Comprehensive List of Guidance Documents at the Food and Drug Administration; Notice
090000648056e813,Notice,FDA-1998-N-0050-0002,FDA-1998-N-0050,Annual Comprehensive List of Guidance Documents at the Food and Drug Administration
0900006480ac4727,Notice,FDA-1998-N-0050-0006,FDA-1998-N-0050,Compliance Policy Guide Section 540-375 Canned Salmon-Adulteration Involving Decomposition; Withdrawal of Guidance
090000648056e817,Notice,FDA-1998-N-0050-0003,FDA-1998-N-0050,Annual Comprehensive List of Guidance Documents at the Food and Drug Administration; Notice
090000648056e81c,Notice,FDA-1998-N-0050-0004,FDA-1998-N-0050,Annual Comprehensive List of Guidance Documents at the Food and Drug Administration; Correction
090000648056e807,Notice,FDA-1998-N-0050-0009,FDA-1998-N-0050,Comprehensive List of Current Guidance Documents at the Food and Drug Administration; Notice
090000648056e80d,Notice,FDA-1998-N-0050-0015,FDA-1998-N-0050,Update of Guidance Documents at the Food and Drug Administration; Notice
090000648056e810,Notice,FDA-1998-N-0050-0018,FDA-1998-N-0050,Quarterly List of Guidance Documents at the Food and Drug Administration; Notice
090000648056e808,Notice,FDA-1998-N-0050-0010,FDA-1998-N-0050,Comprehensive List of Current Guidance Documents at the Food and Drug Administration; Correction
090000648056e7f4,Notice,FDA-1998-N-0050-0001,FDA-1998-N-0050,Annual Comprehensive List of Guidance Documents at the Food and Drug Administration; Notice
09000064846bd37f,Other,FDA-2020-D-1444-0001,FDA-2020-D-1444,Drug Safety Information - FDA's Communication to the Public
09000064804efd60,Other,FDA-2000-N-1247-0001,FDA-2000-N-1247,FDA Concept Paper: Drug Products That Present Demonstrable Difficulties - Report
09000064805b3a4e,Supporting & Related Material,FDA-1985-D-0012-0003,FDA-1985-D-0012,Guidance
09000064805b3a4d,Notice,FDA-1985-D-0012-0002,FDA-1985-D-0012,FDA
09000064805b3a4a,Notice,FDA-1985-D-0012-0001,FDA-1985-D-0012,FDA
09000064805b3a4f,Supporting & Related Material,FDA-1985-D-0012-0004,FDA-1985-D-0012,Guidance
090000648056e4f5,Supporting & Related Material,FDA-1998-D-0039-0002,FDA-1998-D-0039,Guidance
090000648056e4fd,Notice,FDA-1998-D-0039-0003,FDA-1998-D-0039,FDA
090000648056e4ed,Notice,FDA-1998-D-0039-0001,FDA-1998-D-0039,FDA
0900006480b214bb,Supporting & Related Material,FDA-2009-N-0247-0256,FDA-2009-N-0247,Blue Cross Blue Shield Association (BCBSA) re FDA-2009-N-0247-0222
0900006480bc6d30,Notice,FDA-2009-N-0247-0260,FDA-2009-N-0247,FDA Transparency Initiative: Improving Transparency to Regulated Industry
09000064809e7abb,Other,FDA-2009-N-0247-0070,FDA-2009-N-0247,"Public Meeting FDA Transparency Task Force, June 24, 2009 - Transcript"
09000064809e5664,Supporting & Related Material,FDA-2009-N-0247-0056,FDA-2009-N-0247,See FDA-2009-N-0247-0094
0900006480fab1d4,Notice,FDA-2009-N-0247-0301,FDA-2009-N-0247,Transparency Initiative: Exploratory Program to Increase Access to Compliance and Enforcement Data
09000064809e5699,Other,FDA-2009-N-0247-0066,FDA-2009-N-0247,"Medical Device Safety Institute - ""FDA Transparency:Suggestions for Improving Public Health (W.Maisel)"" - [Public Meeting FDA Transparency Task Force, June 24, 2009] - Testimony"
09000064809e563c,Other,FDA-2009-N-0247-0054,FDA-2009-N-0247,"Breast Cancer Fund - ""Testimony for the FDA Transparency Task Force (E.Napalo)"" - [Public Meeting FDA Transparency Task Force, June 24, 2009] - Testimony"
09000064809e5639,Other,FDA-2009-N-0247-0053,FDA-2009-N-0247,"IDSN (International Document Solutions Network) - ""Technology Improves Food Safety Communication (B.Kelser)"" - [Public Meeting FDA Transparency Task Force, June 24, 2009] - Testimony"
09000064809e5666,Other,FDA-2009-N-0247-0071,FDA-2009-N-0247,"Milford Medical Laboratory (S.Lee) - [Public Meeting FDA Transparency Task Force, June 24, 2009] - Testimony"
0900006480a51ccd,Supporting & Related Material,FDA-2009-N-0247-0158,FDA-2009-N-0247,"Final Versions - Three Hypothetical Case Studies, Presentation Date November 3, 2009 (Food and Drug Administration Transparency Task Force; Public Meeting;Request for Comments) - Reference"
0900006480f8b7c2,Notice,FDA-2009-N-0247-0300,FDA-2009-N-0247,Report on Good Guidance Practices Improving Efficiency and Transparency; Availability
09000064816c39bd,Notice,FDA-2009-N-0247-0310,FDA-2009-N-0247,"Food and Drug Administration Transparency Initiative: Increasing
Public Access to the Food and Drug Administration’s Compliance and
Enforcement Data; Availability"
0900006480f4b7a6,Other,FDA-2009-N-0247-0282,FDA-2009-N-0247,Food and Drug Administration Transparency Initiative: Draft Proposals for Public Comment to Increase Transparency By Promoting Greater Access to the Agency’s Compliance and Enforcement Data - Report
09000064809e5b20,Other,FDA-2009-N-0247-0064,FDA-2009-N-0247,"The Senior Citizens League ""Statement of S.Benton"" [Public Meeting FDA Transparency Task Force, June 24, 2009] - Testimony"
09000064809e5b15,Other,FDA-2009-N-0247-0061,FDA-2009-N-0247,"Bray Patrick-Lake - ""Enhancing Transparency via Patient Advocacy in FDA Regulated Clinical Research Trials"" [Public Meeting FDA Transparency Task Force, June 24, 2009] - Testimony"
09000064809e5b11,Other,FDA-2009-N-0247-0060,FDA-2009-N-0247,"Medical Device Manufacturers Association (MDMA) - ""Recommendations to Promote Predictability and Transparency (M.Leahy)"" - [Public Meeting FDA Transparency Task Force, June 24, 2009] - Testimony"
09000064809e630b,Other,FDA-2009-N-0247-0067,FDA-2009-N-0247,"The Tatia Oden French Memorial Foundation - "" Recommendations to the Transparency Task Force (K.Oden)"" - [Public Meeting FDA Transparency Task Force, June 24, 2009] - Testimony"
09000064809e630d,Other,FDA-2009-N-0247-0068,FDA-2009-N-0247,"David Lim, Ph.D. RAC - ""Transparencey 101""-  [Public Meeting FDA Transparency Task Force, June 24, 2009] - Testimony"
0900006480a0367a,Other,FDA-2009-N-0247-0124,FDA-2009-N-0247,American Association for Health Freedom (AAHF) to the Division of Dockets Management - [Multiple Submitters=801] - Letter
0900006480abb6c5,Other,FDA-2009-N-0247-0183,FDA-2009-N-0247,Summary of Listening Sessions with Industry - Reference
09000064809e5b0d,Other,FDA-2009-N-0247-0059,FDA-2009-N-0247,"Genetic Alliance - ""Transforming Health Through Genetics Promoting an Environment of Openness (K.Zonno)"" [Public Meeting FDA Transparency Task Force, June 24, 2009] - Testimony"
09000064809e563e,Other,FDA-2009-N-0247-0051,FDA-2009-N-0247,"Microsoft® - ""Enabling Transparent Goverance With Gov 2.0 (C.Brubaker)""  [Public Meeting FDA Transparency Task Force, June 24, 2009] - Testimony"
0900006480a0c1f1,Notice,FDA-2009-N-0247-0128,FDA-2009-N-0247,Food and Drug Administration Transparency Task Force; Reopening Comment Period
0900006480a3ba54,Notice,FDA-2009-N-0247-0136,FDA-2009-N-0247,Food and Drug Administration Transparency Task Force; Public Meeting; Request for Comments
09000064809c3c29,Notice,FDA-2009-N-0247-0001,FDA-2009-N-0247,Food and Drug Administration Transparency Task Force; Public Meeting
0900006480a517a4,Notice,FDA-2009-N-0526-0001,FDA-2009-N-0526,Safe Use Initiative; Availability of Information
0900006484c3d0c8,Other,FDA-2021-P-0882-0001,FDA-2021-P-0882,Citizen Petition from Chelsea Kent
0900006484c3dada,Other,FDA-2021-P-0882-0002,FDA-2021-P-0882,Acknowledgement Letter from FDA DMS to Chelsea Kent
0900006484c3dae3,Other,FDA-2021-P-0884-0002,FDA-2021-P-0884,Acknowledgement Letter from FDA DMS to Ronald Brock
0900006484c3dec4,Other,FDA-2021-P-0884-0001,FDA-2021-P-0884,Citizen Petition from Ronald Brock
0900006484c3dae1,Other,FDA-2021-P-0883-0001,FDA-2021-P-0883,Citizen Petition from Wanda Brock
0900006484c3dec1,Other,FDA-2021-P-0883-0002,FDA-2021-P-0883,Acknowledgement Letter from FDA DMS to Wanda Brock
0900006484c6c5aa,Other,FDA-2021-P-0912-0002,FDA-2021-P-0912,Acknowledgment Letter from FDA DMS to Harry Duty
0900006484c6c1d8,Other,FDA-2021-P-0912-0001,FDA-2021-P-0912,Citizen Petition from Harry Duty
0900006484dcafe8,Other,FDA-2021-P-1126-0001,FDA-2021-P-1126,Citizen Petition from Harry Duty
0900006484dcb3d2,Other,FDA-2021-P-1126-0002,FDA-2021-P-1126,Acknowledgment Letter from FDA DMS to Harry Duty
0900006483d7dcb2,Supporting & Related Material,FDA-2019-P-1236-0005,FDA-2019-P-1236,Risk-Based Licensing of Biosimilars re Memorandum of Meeting - Listening Meeting with Dr. Sarfaraz Niazi regarding biosimilars
0900006483ae80ed,Other,FDA-2019-P-1236-0002,FDA-2019-P-1236,Acknowledgment Letter from FDA DDM to Sarfaraz Niazi
0900006483ae11e2,Other,FDA-2019-P-1236-0001,FDA-2019-P-1236,Citizen Petition from Sarfaraz K. Niazi
0900006483d7dcaf,Other,FDA-2019-P-1236-0004,FDA-2019-P-1236,Memorandum of Meeting - Listening Meeting with Dr. Sarfaraz Niazi regarding biosimilars
0900006483f86af3,Other,FDA-2019-P-1236-0006,FDA-2019-P-1236,Interim Response Letter from FDA CDER to Sarfaraz Niazi
0900006483bf2bd6,Other,FDA-2019-P-1236-0003,FDA-2019-P-1236,Testimony from Sarfaraz Niazi
090000648248bee8,Other,FDA-2017-P-0428-0001,FDA-2017-P-0428,Citizen Petition From Mucodel Pharma LLC
090000648248c2ff,Other,FDA-2017-P-0428-0002,FDA-2017-P-0428,Acknowledgment Letter from FDA DDM to Mucodel Pharma LLC
09000064824b85e1,Other,FDA-2017-P-0428-0003,FDA-2017-P-0428,MEMORANDUM requesting closure of FDA-P-2017-0428
0900006484b47a5b,Supporting & Related Material,FDA-2021-P-0521-0004,FDA-2021-P-0521,References 09 to 16 re Citizen Petition from Linda Wastila
0900006484b47bb7,Supporting & Related Material,FDA-2021-P-0521-0008,FDA-2021-P-0521,References 19 to 23 re Citizen Petition from Linda Wastila
0900006484b5d34f,Other,FDA-2021-P-0521-0072,FDA-2021-P-0521,Press Release from Anonymous
0900006484b5c50b,Other,FDA-2021-P-0521-0069,FDA-2021-P-0521,Press Release from Anonymous
0900006484bdf9bd,Other,FDA-2021-P-0521-1533,FDA-2021-P-0521,Amended Citizen Petition for e Coalition Advocating for Adequately  Licensed Medicines
0900006484b47a56,Other,FDA-2021-P-0521-0001,FDA-2021-P-0521,Citizen Petition from Linda Wastila
0900006484b47bbc,Supporting & Related Material,FDA-2021-P-0521-0009,FDA-2021-P-0521,References 37 to 47 re Citizen Petition from Linda Wastila
0900006484b47a58,Other,FDA-2021-P-0521-0002,FDA-2021-P-0521,Acknowledgment Letter from FDA DMS to Linda Wastila
0900006484c0b1d2,Other,FDA-2021-P-0521-1560,FDA-2021-P-0521,Withdrawal letter from Linda Wastila et. al
0900006484b58f29,Other,FDA-2021-P-0521-0020,FDA-2021-P-0521,Press release from Petitioner
0900006484b47a5a,Supporting & Related Material,FDA-2021-P-0521-0003,FDA-2021-P-0521,References 01 to 08 re Citizen Petition from Linda Wastila
0900006484b47a5c,Supporting & Related Material,FDA-2021-P-0521-0007,FDA-2021-P-0521,References 17 to 18 re Citizen Petition from Linda Wastila
0900006484b47bba,Supporting & Related Material,FDA-2021-P-0521-0005,FDA-2021-P-0521,References 24 to 32 re Citizen Petition from Linda Wastila
0900006484b47bbb,Supporting & Related Material,FDA-2021-P-0521-0006,FDA-2021-P-0521,References 33 to 36 re Citizen Petition from Linda Wastila
0900006480633542,Other,FDA-2007-P-0184-0003,FDA-2007-P-0184,Judy Slome Cohain - Supplement
09000064806c06a7,Other,FDA-2007-P-0184-0005,FDA-2007-P-0184,FDA Response to Judy Slome Cohain - Citizen Petition Denial
09000064806a9660,Other,FDA-2007-P-0184-0004,FDA-2007-P-0184,Judy Slome Cohain - Supplement
090000648042a728,Other,FDA-2007-P-0184-0001,FDA-2007-P-0184,Acknowledgement Letter to Judy Slome Cohain
090000648042a72b,Other,FDA-2007-P-0184-0002,FDA-2007-P-0184,Judy Slome Cohain - Citizen Petition
0900006484dc2081,Other,FDA-2021-P-1090-0002,FDA-2021-P-1090,Acknowledgment Letter from FDA DMS to Pet Schooled
0900006484dc24dc,Other,FDA-2021-P-1090-0001,FDA-2021-P-1090,Citizen Petition from Pet Schooled
0900006484c944b7,Other,FDA-2021-P-0927-0001,FDA-2021-P-0927,Citizen Petition from Donavan Melton
0900006484c95375,Other,FDA-2021-P-0927-0002,FDA-2021-P-0927,Acknowledgment Letter from FDA DMS to Donavan Melton
0900006482afddc3,Other,FDA-2017-D-3716-0002,FDA-2017-D-3716,Low-Acid Foods Packaged in Hermetically Sealed Containers (LACF) Regulation and the FDA Food Safety Modernization Act: Guidance for Industry
0900006482afddc4,Other,FDA-2017-D-3716-0003,FDA-2017-D-3716,"Seafood HACCP and the FDA Food Safety Modernization Act: Guidance for
Industry"
0900006482afddc2,Other,FDA-2017-D-3716-0001,FDA-2017-D-3716,Juice HACCP and the FDA Food Safety Modernization Act Guidance
0900006481c40270,Other,FDA-2015-P-1404-0004,FDA-2015-P-1404,Supplement from Allergan
0900006481ab97c2,Other,FDA-2015-P-1404-0002,FDA-2015-P-1404,"Acknowledgement Letter from FDA DDM to Physical Pharmaceutica, LLC"
0900006481e66e2d,Other,FDA-2015-P-1404-0007,FDA-2015-P-1404,"Citizen Petition Denial Response Letter from FDA CDER to (Allergan, Inc.) and Physical Pharmaceutica, LLC"
0900006481ab97be,Other,FDA-2015-P-1404-0001,FDA-2015-P-1404,"Citizen Petition from Physical Pharmaceutica, LLC"
0900006484c1c40a,Other,FDA-2021-P-0850-0001,FDA-2021-P-0850,Citizen Petition from Donavan Melton
0900006484c1c411,Other,FDA-2021-P-0850-0002,FDA-2021-P-0850,Acknowledgement Letter from FDA DMS to Donavan Melton
09000064836b0ed1,Supporting & Related Material,FDA-2018-P-3372-0006,FDA-2018-P-3372,"Attachment 4 Biofeedback Treatment for Headache Disorders:
A Comprehensive Efficacy Review Re: Citizen Petition from Ohio State University"
09000064836b0ed2,Supporting & Related Material,FDA-2018-P-3372-0007,FDA-2018-P-3372,"Attachment 5 Evidence-based guideline update: Pharmacologic
treatment for episodic migraine prevention in adults Re: Citizen Petition from Ohio State University"
09000064836b0ecc,Other,FDA-2018-P-3372-0002,FDA-2018-P-3372,Acknowledgement Letter from FDA DDM to Ohio State University
0900006484ab1d70,Other,FDA-2018-P-3372-0008,FDA-2018-P-3372,Final response from FDA CDRH to Ohio State University
09000064836b0ece,Supporting & Related Material,FDA-2018-P-3372-0003,FDA-2018-P-3372,Attachment 1 Cochran Library Virtual reality for stroke rehabilitation (Review) Re: Citizen Petition from Ohio State University
09000064836b0ecf,Supporting & Related Material,FDA-2018-P-3372-0004,FDA-2018-P-3372,Attachment 2 Cochrane Library  Virtual reality for stroke rehabilitation (Review) Re: Citizen Petition from Ohio State University
09000064836b0ed0,Supporting & Related Material,FDA-2018-P-3372-0005,FDA-2018-P-3372,"Attachment 3 Virtual Reality Therapy for Adults Post-Stroke: A
Systematic Review and Meta-Analysis Exploring Virtual
Environments and Commercial Games in Therapy Re: Citizen Petition from Ohio State University"
09000064836b03f4,Other,FDA-2018-P-3372-0001,FDA-2018-P-3372,Citizen Petition from Ohio State University
090000648048975d,Other,FDA-2003-P-0175-0001,FDA-2003-P-0175,"HF-22 to Olsson, Frank and Weeda, PC"
0900006481013ec6,Notice,FDA-2012-N-0471-0001,FDA-2012-N-0471,Agency Information Collection Activities; Proposed Collection; Comment Request; User Fee Cover Sheet; Form FDA 3397
090000648114ada8,Notice,FDA-2012-N-0471-0002,FDA-2012-N-0471,"Agency Information Collection Activities; Proposals, Submissions, and Approvals: Prescription Drug User Fee Cover Sheet"
0900006481aa6828,Notice,FDA-2012-N-0471-0004,FDA-2012-N-0471,"Agency Information Collection Activities: Proposed Collection;
Comment Request; User Fee Cover Sheet; Form FDA 3397"
0900006481cd46f5,Notice,FDA-2012-N-0471-0005,FDA-2012-N-0471,"Agency Information Collection Activities; Submission for Office 
of Management and Budget Review; Comment Request; User Fee Cover Sheet; Form FDA 3397"
09000064813a8677,Notice,FDA-2012-N-0471-0003,FDA-2012-N-0471,Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; Prescription Drug User Fee Cover Sheet; Form FDA 3397
0900006480444c25,Other,FDA-2005-N-0281-0013,FDA-2005-N-0281,"December 8, 2005 Transcript"
0900006480444c22,Other,FDA-2005-N-0281-0010,FDA-2005-N-0281,"December 7, 2005 Transcript"
0900006480444bec,Other,FDA-2005-N-0281-0005,FDA-2005-N-0281,Embassy of France / Economic Department
0900006480444b44,Notice,FDA-2005-N-0281-0001,FDA-2005-N-0281,FDA
0900006480444b85,Other,FDA-2005-N-0281-0002,FDA-2005-N-0281,"Mettler, Erik"
0900006480444c24,Other,FDA-2005-N-0281-0012,FDA-2005-N-0281,"December 8, 2005 Transcript"
0900006480444bc0,Other,FDA-2005-N-0281-0004,FDA-2005-N-0281,"Gallagher, Maryann"
0900006480444c01,Other,FDA-2005-N-0281-0007,FDA-2005-N-0281,"Agenda for December 7-8, 2005 Hearing"
0900006480444c23,Other,FDA-2005-N-0281-0011,FDA-2005-N-0281,"December 7, 2005 Transcript"
0900006480444c17,Other,FDA-2005-N-0281-0009,FDA-2005-N-0281,List of Attendees for 12/7-8/2005 Public Meeting
0900006480444b8f,Other,FDA-2005-N-0281-0003,FDA-2005-N-0281,"Frank, Lesley"
0900006480444c00,Other,FDA-2005-N-0281-0006,FDA-2005-N-0281,"Agenda for December 7-8, 2005 Hearing"
0900006480444c02,Other,FDA-2005-N-0281-0008,FDA-2005-N-0281,"Director, Center for Drugs Evaluation and Research, FDA"
09000064804b7e85,Notice,FDA-2000-N-0079-0001,FDA-2000-N-0079,FDA
09000064804e742d,Other,FDA-2001-P-0321-0001,FDA-2001-P-0321,Washington Legal Foundation - Citizen Petition
09000064804e7433,Other,FDA-2001-P-0321-0003,FDA-2001-P-0321,FDA/Associate Commissioner for Policy Response to the Washington Legal Foundation - Petition Denial
09000064804e7432,Other,FDA-2001-P-0321-0002,FDA-2001-P-0321,Acknowledgement Letter to the Washington Legal Foundation
09000064804d2a37,Other,FDA-2000-P-0183-0001,FDA-2000-P-0183,HFC-1 to Robert Cohen
0900006480526fc1,Notice,FDA-1992-D-0021-0001,FDA-1992-D-0021,FDA
0900006480b09be6,Other,FDA-2010-N-0233-0023,FDA-2010-N-0233,Meeting Attendees - List
0900006480b09be3,Other,FDA-2010-N-0233-0022,FDA-2010-N-0233,Transcript
0900006480aea319,Notice,FDA-2010-N-0233-0001,FDA-2010-N-0233,The National Institutes of Health and Food and Drug Administration Joint Leadership Council; Stakeholders
0900006482cd4273,Notice,FDA-2017-N-6475-0001,FDA-2017-N-6475,"Food and Drug Administration Fiscal Year 2017 Performance Review Board
Members"
09000064816bd871,Other,FDA-2014-P-0497-0001,FDA-2014-P-0497,Citizen Petition From Ken Surprenant
090000648213be67,Other,FDA-2014-P-0497-0009,FDA-2014-P-0497,Partial Approval Final Response
09000064818a859f,Other,FDA-2014-P-0497-0003,FDA-2014-P-0497,Interim Response from FDA/CDER to Ken Surprenant
09000064816be10a,Other,FDA-2014-P-0497-0002,FDA-2014-P-0497,Acknowledgement Letter From FDA DDM to Ken Surprenant
090000648043f7eb,Notice,FDA-2005-N-0098-0001,FDA-2005-N-0098,FDA
0900006480739101,Notice,FDA-2005-N-0098-0004,FDA-2005-N-0098,Agency InformationCollection Activities; Announcement of Office of Management and Budget Approval; Survey of Current Manufacturing Practices in the Food Industry
090000648043f807,Notice,FDA-2005-N-0098-0002,FDA-2005-N-0098,FDA
090000648043f808,Notice,FDA-2005-N-0098-0003,FDA-2005-N-0098,FDA
09000064804a5a1f,Notice,FDA-1999-D-0012-0006,FDA-1999-D-0012,Enforcement Policy: Electronic Records; Electronic Signatures--Compliance Policy Guide; Guidance for FDA Personnel - Notice of Correction
09000064804a5a23,Notice,FDA-1999-D-0012-0004,FDA-1999-D-0012,FDA
09000064804a5a1e,Notice,FDA-1999-D-0012-0005,FDA-1999-D-0012,Enforcement Policy: Electronic Records; Electronic Signatures--Compliance Policy Guide; Guidance for FDA Personnel - Notice of Availability
09000064804a5a20,Supporting & Related Material,FDA-1999-D-0012-0007,FDA-1999-D-0012,"Draft Guidance for Industry: Part 11, Electronic Records; Electronic Signatures--Scope and Application - [Draft Guidance for Industry on ""Part 11, Electronic Records, Electronic Signatures--Scope and Application;"" Availability of Draft Guidance and Withdrawal of Draft Part 11 Guidance Documents and a Compliance Policy Guide]"
09000064804a5a21,Notice,FDA-1999-D-0012-0002,FDA-1999-D-0012,FDA
09000064804a5a1d,Notice,FDA-1999-D-0012-0001,FDA-1999-D-0012,FDA
09000064804a5a22,Notice,FDA-1999-D-0012-0003,FDA-1999-D-0012,FDA
09000064807e8734,Other,FDA-2008-N-0523-0005,FDA-2008-N-0523,Plasma Protein Therapeutics Association (PPTA) - Request for Extension Comment Due Date
09000064807d5bdd,Other,FDA-2008-N-0523-0004,FDA-2008-N-0523,American Dental Association (ADA) - Council's Statement [re FDA-2008-N-0523-0003]
090000648075c348,Notice,FDA-2008-N-0523-0001,FDA-2008-N-0523,FDA-Regulated Products that Contain Bisphenol-A; Request for Information
0900006484db48cb,Other,FDA-2021-N-0859-0028,FDA-2021-N-0859,FDA Virtual Listening Session on the Oversight of Pet Food - Agenda
0900006484db94dc,Other,FDA-2021-N-0859-0038,FDA-2021-N-0859,FDA Virtual Listening Session on the Oversight of Pet Food- Pet Food Contaminants
0900006484db9943,Other,FDA-2021-N-0859-0040,FDA-2021-N-0859,FDA Virtual Listening Session on the Oversight of Pet Food- Center -Slides for FDA SA Center Copper Canine Dog Food for Video Final Video Removed
0900006484db9d15,Other,FDA-2021-N-0859-0042,FDA-2021-N-0859,FDA Virtual Listening Session on the Oversight of Pet Food- Connors - FDA Presentation Slides DEC 17SEP21
0900006484db48cd,Other,FDA-2021-N-0859-0029,FDA-2021-N-0859,FDA Virtual Listening Session on the Oversight of Pet Food - CVM Presentation - 9-24-21
0900006484db4d21,Other,FDA-2021-N-0859-0030,FDA-2021-N-0859,FDA Virtual Listening Session on the Oversight of Pet Food - Transcript - 9-24-21
0900006484db9d17,Other,FDA-2021-N-0859-0043,FDA-2021-N-0859,FDA Virtual Listening Session on the Oversight of Pet Food- Thixton - FDA presentation Sept 2021
0900006484db9d19,Other,FDA-2021-N-0859-0044,FDA-2021-N-0859,FDA Virtual Listening Session on the Oversight of Pet Food-  Castonguay - DietAssociatedDCMEdAlliance_The-Impact-of-DCM-Related-FDA-Messaging
0900006484c4320b,Other,FDA-2021-N-0859-0001,FDA-2021-N-0859,Listening Session Announcement
0900006484db9941,Other,FDA-2021-N-0859-0039,FDA-2021-N-0859,FDA Virtual Listening Session on the Oversight of Pet Food-Greenacre - FDA ferret diet
0900006484db9945,Other,FDA-2021-N-0859-0041,FDA-2021-N-0859,FDA Virtual Listening Session on the Oversight of Pet Food- Smedley - FDA's ROLE IN INGREDIENT DEFINITION DEVELOPMENT
0900006482b74fbb,Notice,FDA-2017-N-4952-0001,FDA-2017-N-4952,"Food and Drug Administration Clinical Trial Requirements, Regulations, Compliance, and Good Clinical Practice; Public Workshop"
090000648259fb21,Notice,FDA-2017-D-2497-0001,FDA-2017-D-2497,Draft Revisions to the Food and Drug Administration Blueprint for Prescriber Education for Extended-Release and Long-Acting Opioids; Availability
0900006482e789bf,Other,FDA-2017-D-2497-0683,FDA-2017-D-2497,Opioid Analgesic REMS Education Blueprint
0900006481578a5a,Other,FDA-2012-D-0530-0025,FDA-2012-D-0530,"Requests for Feedback on Medical Device Submissions: The Pre-
Submission Program and Meetings With Food and Drug Administration
Staff; Guidance for Industry and Food and Drug Administration Staff"
090000648146a1b7,Notice,FDA-2012-D-0530-0022,FDA-2012-D-0530,Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Guidance on Medical Devices: The Pre-Submission Program and Meetings with FDA Staff
090000648118589b,Notice,FDA-2012-D-0530-0019,FDA-2012-D-0530,"Agency Information Collection Activities; Proposals, Submissions, and Approvals: Guidance on Medical Devices; Pre-Submission Program and Meetings with FDA Staff"
090000648151ce06,Notice,FDA-2012-D-0530-0023,FDA-2012-D-0530,"Agency Information Collection ctivities; Announcement of Office of
Management and Budget Approval; equests for Feedback on Medical
Device Submissions"
0900006483e3c11b,Notice,FDA-2012-D-0530-0032,FDA-2012-D-0530,Agency Information Collection Activities; Proposed Collection; Comment Request; Q-Submission Program for Medical Devices
09000064826680d8,Notice,FDA-2012-D-0530-0030,FDA-2012-D-0530,"Agency Information Collection Activities; Announcement of Office of
Management and Budget Approvals"
09000064821349fc,Notice,FDA-2012-D-0530-0028,FDA-2012-D-0530,Agency Information Collection Activities; Proposed Collection; Comment Request; Pre-Submission Program for Medical Devices
0900006484161392,Notice,FDA-2012-D-0530-0033,FDA-2012-D-0530,Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Q-Submission Program for Medical Devices
0900006481094e0c,Other,FDA-2012-D-0530-0002,FDA-2012-D-0530,Draft Guidance for Industry and Food and Drug Administration Staff Medical Devices The Pre-Submission Program and Meetings with FDA Staff
0900006481576953,Notice,FDA-2012-D-0530-0024,FDA-2012-D-0530,"Requests for Feedback on Medical Device Submissions: The Pre-
Submission Program and Meetings With Food and Drug Administration
Staff; Guidance for Industry and Food and Drug Administration Staff;
Availability"
09000064810934d0,Notice,FDA-2012-D-0530-0001,FDA-2012-D-0530,Draft Guidance for Industry and Food and Drug Administration Staff; Medical Devices: The Pre-Submission Program and Meetings With FDA Staff; Availability
09000064811aa8e8,Notice,FDA-2012-D-0530-0021,FDA-2012-D-0530,Agency Information Collection Activities; Submission for Office of Management and Budge Review; Comment Request; Guidance on Medical Devices; Pre-Submission Program and Meetings with FDA Staff; Withdrawal
090000648232063e,Notice,FDA-2012-D-0530-0029,FDA-2012-D-0530,"Agency Information Collection Activities; Submission for Office of
Management and Budget Review; Comment Request; Pre-Submission
Program for Medical Devices"
0900006482b95aad,Other,FDA-2012-D-0530-0031,FDA-2012-D-0530,Guidance for Industry on Requests for Feedback on Medical Device Submissions The Pre-Submission Program and Meetings with Food and Drug Administration Staff
0900006481e84b42,Other,FDA-2012-D-0530-0027,FDA-2012-D-0530,Requests for Feedback on Medical Device Submissions: The Pre-Submission Program and Meetings with Food and Drug Administration Staff Guidance for Industry and Food and Drug Administration Staff
090000648430cf52,Notice,FDA-2012-D-0530-0035,FDA-2012-D-0530,"Agency Information Collection Activities; Announcement of Office of
Management and Budget Approvals"
0900006481e837da,Notice,FDA-2012-D-0530-0026,FDA-2012-D-0530,"Request for Expressions of Interest From Coverage Organizations;
Coverage Organizations Interested in Providing Input Regarding Private
Payer Coverage to Medical Device Sponsors Who Request Their
Participation in a Pre-Submission Meeting With the Food and Drug
Administration"
09000064849823d2,Other,FDA-2019-D-3904-0001,FDA-2019-D-3904,Compliance Policy Guide CPG Sec. 110.650 Weekly Entry Filing Guidance for Industry and FDA Staff
09000064844ab694,Notice,FDA-2017-N-0366-0008,FDA-2017-N-0366,"Agency Information Collection Activities; Submission for Office of
Management and Budget Review; Comment Request; Advisory
Committee Nomination Applications"
090000648473bb59,Notice,FDA-2017-N-0366-0009,FDA-2017-N-0366,"Agency Information Collection Activities; Proposals, Submissions, and Approvals"
09000064824ad378,Notice,FDA-2017-N-0366-0001,FDA-2017-N-0366,Agency Information Collection Activities: Proposed Collection; Comment Request; Collection of Nominations for Candidates To Serve on the Food and Drug Administration's Advisory Committees
0900006484275aef,Notice,FDA-2017-N-0366-0005,FDA-2017-N-0366,Agency Information Collection Activities; Proposed Collection; Comment Request; Advisory Committee Nomination Applications
0900006482600398,Notice,FDA-2017-N-0366-0003,FDA-2017-N-0366,Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Advisory Committee Nomination Applications
0900006482a9e338,Notice,FDA-2017-N-0366-0004,FDA-2017-N-0366,"Agency Information Collection Activities; Announcement of Office of
Management and Budget Approvals"
09000064825c5090,Notice,FDA-2017-N-1067-0001,FDA-2017-N-1067,"Request for Comments on Food and Drug Administration 
Accreditation Scheme for Conformity Assessment Pilot Program"
09000064820816a5,Supporting & Related Material,FDA-2016-N-1487-0005,FDA-2016-N-1487,"Reference 3 FDA Draft Guidance for Industry: Implementation of the ""Deemed to be a License"" Provision re Submission of FDA Import Data in the Automated Commercial Environment"
09000064821636fe,Other,FDA-2016-N-1487-0008,FDA-2016-N-1487,Request for Extension from American Association of Exporters and Importers
09000064820816a2,Supporting & Related Material,FDA-2016-N-1487-0002,FDA-2016-N-1487,E.O. 13659 re Submission of FDA Import Data in the Automated Commercial Environment
09000064820816a3,Supporting & Related Material,FDA-2016-N-1487-0003,FDA-2016-N-1487,Reference 1 Automated Commercial System and ABI CATAIR re Submission of FDA Import Data in the Automated Commercial Environment
09000064820816a4,Supporting & Related Material,FDA-2016-N-1487-0004,FDA-2016-N-1487,Reference 2 FDA Guidance for Industry: Submitting Form FDA 2541 re Submission of FDA Import Data in the Automated Commercial Environment
0900006482080496,Proposed Rule,FDA-2016-N-1487-0001,FDA-2016-N-1487,Submission of Food and Drug Administration Import Data in the Automated Commercial Environment
0900006484a92f39,Rule,FDA-2016-N-1487-0024,FDA-2016-N-1487,Electronic Import Entries; Technical Amendments
090000648208ccb9,Supporting & Related Material,FDA-2016-N-1487-0006,FDA-2016-N-1487,Reference 4 re Submission of FDA Import Data in the Automated Commercial Environment
09000064823c749b,Supporting & Related Material,FDA-2016-N-1487-0023,FDA-2016-N-1487,"Reference 1 Final Regulatory Flexibility Analysis, and Final Unfunded Mandates Reform Act Analysis for Submission of Food and Drug Administration Import Data in the Automated Commercial Environment"
09000064823c5ff3,Rule,FDA-2016-N-1487-0022,FDA-2016-N-1487,Submission of Food and Drug Administration Import Data in the  Automated Commercial Environment
090000648218d4a4,Other,FDA-2016-N-1487-0014,FDA-2016-N-1487,FDA Response to Request for Extension from American Association of Exporters and Importers
090000648050da5e,Other,FDA-1986-P-0015-0001,FDA-1986-P-0015,HFA-305 to Pharmaceutical Manufacturers Assn.
09000064825ebcfc,Supporting & Related Material,FDA-2017-P-3202-0003,FDA-2017-P-3202,Attachment 1 Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations
09000064825ebcfa,Other,FDA-2017-P-3202-0002,FDA-2017-P-3202,Acknowledgment Letter from FDA DDM to Foley & Lardner LLP
0900006482b2f8df,Other,FDA-2017-P-3202-0004,FDA-2017-P-3202,Withdrawal Letter from Foley & Lardner LLP
09000064825ebb42,Other,FDA-2017-P-3202-0001,FDA-2017-P-3202,Citizen Petition from Foley & Lardner LLP
09000064804295f2,Notice,FDA-2007-N-0039-0001,FDA-2007-N-0039,FDA
0900006483cdd6ed,Other,FDA-2018-P-4661-0004,FDA-2018-P-4661,"Letter from FDA CDER to Hyman, Phelps & McNamara, P.C."
090000648395abc1,Other,FDA-2018-P-4661-0001,FDA-2018-P-4661,"Citizen Petition from Hyman, Phelps & McNamara, P.C."
090000648395b816,Other,FDA-2018-P-4661-0002,FDA-2018-P-4661,"Acknowledgment Letter from FDA DDM to Hyman,  Phelps, & McNamara PC"
09000064840a9595,Other,FDA-2018-P-4661-0005,FDA-2018-P-4661,"Letter from FDA CDER to Hyman, Phelps & McNamara, P.C."
090000648395bd2f,Supporting & Related Material,FDA-2018-P-4661-0003,FDA-2018-P-4661,"Exhibit 1 Prescription Drug Product List from Orange Book re: Citizen Petition from Hyman, Phelps, and McNamara PC"
0900006484db19d6,Other,FDA-2021-P-1049-0002,FDA-2021-P-1049,Acknowledgment Letter from FDA DMS to Pet Schooled
0900006484db19b9,Other,FDA-2021-P-1049-0001,FDA-2021-P-1049,Citizen Petition from Pet Schooled
09000064835c3bbb,Other,FDA-2018-P-2997-0003,FDA-2018-P-2997,Citizen Petition from New Civil Liberties Alliance
09000064835af2cf,Other,FDA-2018-P-2997-0002,FDA-2018-P-2997,Acknowledgment Letter from FDA DDM to New Civil Liberties Alliance
0900006483a4dd59,Other,FDA-2018-P-2997-0006,FDA-2018-P-2997,Interim Response from FDA OP to New Civil Liberties Alliance
09000064835af2cb,Other,FDA-2018-P-2997-0001,FDA-2018-P-2997,Citizen Petition from New Civil Liberties Alliance
09000064825eafd0,Other,FDA-2017-P-3201-0001,FDA-2017-P-3201,Citizen Petition from Foley & Lardner LLP
09000064825ebb3c,Other,FDA-2017-P-3201-0002,FDA-2017-P-3201,Acknowledgment Letter from FDA DDM to  Foley & Lardner LLP
0900006482b2f77e,Other,FDA-2017-P-3201-0004,FDA-2017-P-3201,Withdrawal Letter from Foley & Lardner LLP
09000064825eb986,Supporting & Related Material,FDA-2017-P-3201-0003,FDA-2017-P-3201,Attachment 1 Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations re Citizen Petition from Foley & Lardner LLP
0900006484c63c28,Other,FDA-2021-P-0909-0002,FDA-2021-P-0909,Acknowledgement Letter from FDA DMS to Donavan Melton
0900006484c63c26,Other,FDA-2021-P-0909-0001,FDA-2021-P-0909,Citizen Petition from Donavan Melton
0900006481224a02,Other,FDA-2013-P-0280-0001,FDA-2013-P-0280,"R.J. Reynolds Tobacco Company, American Snuff Company, Santa Fe Natural Tobacco Company, Inc. (RAI Services Company) - Citizen Petition"
0900006481224a49,Other,FDA-2013-P-0280-0002,FDA-2013-P-0280,"Acknowledgement Letter to R.J. Reynolds Tobacco Company, American Snuff Company, Santa Fe Natural Tobacco Company, Inc. (RAI Services Company)"
090000648136111a,Other,FDA-2013-P-0280-0003,FDA-2013-P-0280,"FDA/OC to R.J. Reynolds Tobacco Company, American Snuff Company, Santa Fe Natural Tobacco Company, Inc. (RAI Services Company) - Petition Approval"
090000648048bb7b,Notice,FDA-2003-N-0207-0001,FDA-2003-N-0207,FDA
090000648048bbb6,Notice,FDA-2003-N-0207-0002,FDA-2003-N-0207,FDA
090000648048bbdd,Supporting & Related Material,FDA-2003-N-0207-0004,FDA-2003-N-0207,Supporting Statement
090000648048bbdb,Notice,FDA-2003-N-0207-0003,FDA-2003-N-0207,FDA
0900006481aaebfb,Supporting & Related Material,FDA-2015-P-1296-0006,FDA-2015-P-1296,Attachment 6 FDA Inspection Report re Citizen Petition From LeClairRyan PC
0900006481aaebfc,Supporting & Related Material,FDA-2015-P-1296-0007,FDA-2015-P-1296,Attachment 7 Letter from FDA to Florida Board of Pharmacy re Citizen Petition from LeClairRyan PC
0900006481aaec00,Supporting & Related Material,FDA-2015-P-1296-0010,FDA-2015-P-1296,Attachment 11 Drugs Marketed by Anazao Health re Citizen Petition from LeClairRyan PC
0900006481aaec05,Supporting & Related Material,FDA-2015-P-1296-0012,FDA-2015-P-1296,Attachment 15 FDA Guidance for Staff and Industry Compliance Policy Guides Manual re Citizen Petition From LeClairRyan PC
0900006481aaec0a,Supporting & Related Material,FDA-2015-P-1296-0015,FDA-2015-P-1296,"Attachment 20 Memorandum of Understanding Between the U.S. Nuclear Regulatory Commission and the U.S. Department of Health and Human Services, FDA, Federal Register Notice, March 31, 2015 re Citizen Petition From LeClairRyan PC"
0900006481aaebfa,Supporting & Related Material,FDA-2015-P-1296-0005,FDA-2015-P-1296,Attachment 5 Unapproved Prescription Drugs Drugs Marketed in the United States That Do Not Have Required FDA Approval re Citizen Petition From LeClairRyan PC
0900006481aaebfd,Supporting & Related Material,FDA-2015-P-1296-0008,FDA-2015-P-1296,"Attachment 8 FDA Warning Letter to International Isotopes, Inc. re Citizen Petition from LeClairRyan PC"
0900006481aaec0b,Supporting & Related Material,FDA-2015-P-1296-0016,FDA-2015-P-1296,Attachment 21 Nuclear Pharmacy Guideline Criteria for Determining When to Register as a Drug Establishment re Citizen Petition from LeClairRyan PC
0900006481aaec0c,Supporting & Related Material,FDA-2015-P-1296-0017,FDA-2015-P-1296,Attachment 22 Letter from FDA to Florida Board of Pharmacy re Citizen Petition from LeClairRyan PC
0900006481aaeeeb,Supporting & Related Material,FDA-2015-P-1296-0002,FDA-2015-P-1296,Attachment 1 Compounded Drugs re Citizen Petition From LeClairRyan PC
0900006481aaeeec,Supporting & Related Material,FDA-2015-P-1296-0003,FDA-2015-P-1296,Attachment 2 Letter from CORAR to FDA Regarding Proposed Compliance Policy Guide on Radiopharmaceutical Compounding re Citizen Petition From LeClairRyan PC
0900006481adbd4a,Other,FDA-2015-P-1296-0019,FDA-2015-P-1296,Letter from LeClairRyan PC Jubilant DraxImage to FDA DDM
0900006481aaec09,Supporting & Related Material,FDA-2015-P-1296-0014,FDA-2015-P-1296,"Attachment 19 Regulations for In Vivo Readiopharmaceuticals Used for Diagnosis and Monitoring, Federal Register Notice dated  May 17, 1999 re Citizen Petition From LeClairRyan PC"
09000064823ba54c,Other,FDA-2015-P-1296-0024,FDA-2015-P-1296,Letter from Robinson and Cole to FDA DDM
0900006481aaea28,Other,FDA-2015-P-1296-0001,FDA-2015-P-1296,Citizen Petition From LeClairRyan PC Jubilant DraxImage
0900006481aaec01,Supporting & Related Material,FDA-2015-P-1296-0011,FDA-2015-P-1296,Attachment 12  Letter from FDA CDER to Lantheus Medical Imaging re Citizen Petition from LeClairRyan PC
0900006481aaeeed,Supporting & Related Material,FDA-2015-P-1296-0004,FDA-2015-P-1296,Attachment 3 National Association of Nuclear Pharmacies Position Statement on Appropriate Compounding re Citizen Petition From LeClairRyan PC
0900006481aaea91,Other,FDA-2015-P-1296-0018,FDA-2015-P-1296,"Acknowledgement Letter from FDA DDM to LeClairRyan, PC"
0900006481cca42c,Other,FDA-2015-P-1296-0022,FDA-2015-P-1296,"Interim Response Letter from FDA CDER to LeClairRyan, PC"
0900006481aaebfe,Supporting & Related Material,FDA-2015-P-1296-0009,FDA-2015-P-1296,Attachment 9 FDA Letter and Establishment Inspection Report re Citizen Petition from LeClairRyan PC
0900006481aaec08,Supporting & Related Material,FDA-2015-P-1296-0013,FDA-2015-P-1296,Attachment 18 Anazao Health Ad Citizen Petition from LeClairRyan PC
0900006482bec8ae,Other,FDA-2015-P-1296-0025,FDA-2015-P-1296,Response Letter from FDA to Jubilant DraxImage
09000064837408da,Notice,FDA-2018-D-0787-0001,FDA-2018-D-0787,"Civil Money Penalties Relating to the ClinicalTrials.gov Data Bank; Draft
Guidance for Food and Drug Administration Staff, Responsible Parties, and Submitters of Certain Applications and Submissions to the Food and Drug Administration; Availability"
0900006483741e84,Other,FDA-2018-D-0787-0002,FDA-2018-D-0787,"Civil Money Penalties Relating to the ClinicalTrials.gov Data Bank; Guidance for FDA Staff, Responsible Parties, and Submitters of Certain Applications and Submissions to FDA; Draft Guidance"
0900006484807b92,Other,FDA-2018-D-0787-0067,FDA-2018-D-0787,"Civil Money Penalties Relating to the ClinicalTrials.gov Data Bank;  Guidance for Responsible Parties, Submitters of Certain Applications and Submissions to the Food and Drug Administration, and Food and Drug Administration Staff"
0900006484807e88,Notice,FDA-2018-D-0787-0066,FDA-2018-D-0787,"Civil Money Penalties Relating to the ClinicalTrials.gov Data Bank;  Guidance for Responsible Parties, Submitters of Certain Applications and Submissions to the Food and Drug Administration, and Food and Drug Administration Staff; Availability"
0900006480e32bcb,Notice,FDA-2010-D-0153-0003,FDA-2010-D-0153,"Agency Information Collection Activities; Proposals, Submissions, and Approvals: Procedures for Requests for Information Under the Federal Food, Drug, and Cosmetic Act"
0900006480ae353c,Other,FDA-2010-D-0153-0002,FDA-2010-D-0153,"Draft Guidance for Industry and Food and Drug Administration Staff: Procedures for Section 513(g) Requests for Information Under the Federal Food, Drug, and Cosmetic Act; Guidance Document"
0900006480fea98a,Notice,FDA-2010-D-0153-0004,FDA-2010-D-0153,"Guidance for Industry and Staff; Procedures for Section 513(g) Requests for Information under the Federal Food, Drug, and Cosmetic Act: Availability"
0900006480feaa00,Other,FDA-2010-D-0153-0005,FDA-2010-D-0153,"Guidance for Industry and Staff; Procedures for Section 513(g) Requests for Information under the Federal Food, Drug, and Cosmetic Act"
090000648421eba6,Other,FDA-2010-D-0153-0006,FDA-2010-D-0153,Guidance on FDA and Industry Procedures for Section 513(g) Requests for Info under FD&C Act (2019)
0900006480ae3a4d,Notice,FDA-2010-D-0153-0001,FDA-2010-D-0153,"Draft Guidance for Industry and Food and Drug Administration Staff: Procedures for Section 513(g) Requests for Information Under the Federal Food, Drug, and Cosmetic Act"
090000648424119a,Other,FDA-2010-D-0153-0007,FDA-2010-D-0153,"FDA and Industry Procedures for Section 513(g) Requests for Information under the Federal Food, Drug, and Cosmetic Act; Guidance for Industry and Food and Drug Administration Staff"
090000648215c3d7,Notice,FDA-2016-N-0566-0002,FDA-2016-N-0566,"Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Survey of Alumni 
Commissioner's Fellowship Program Fellows"
0900006481e83d1d,Notice,FDA-2016-N-0566-0001,FDA-2016-N-0566,Agency Information Collection Activities; Proposed Collection; Comment Request; Outcomes Evaluation Survey for Graduates of the Food and Drug Administration Commissioner’s Fellowship Program
09000064819e127e,Notice,FDA-2012-N-0194-0005,FDA-2012-N-0194,"Agency Information Collection Activities; Proposed Collection;
Comment Request; Biosimilars User Fee Cover Sheet; Form FDA 3792"
0900006480fd5d39,Notice,FDA-2012-N-0194-0001,FDA-2012-N-0194,"Agency Information Collection Activities; Proposals, Submissions, and Approvals: Biosimilars User Fee Cover Sheet"
090000648104fb38,Notice,FDA-2012-N-0194-0004,FDA-2012-N-0194,"Agency Information Collection Activities; Proposals, Submissions, and Approvals: Biosimilars User Fee Cover Sheet"
0900006481e4a0e2,Notice,FDA-2012-N-0194-0007,FDA-2012-N-0194,"Agency Information Collection Activities; Announcement of Office of
Management and Budget Approval; Biosimilar User Fee Cover Sheet;  Form
FDA 3792"
0900006481b17b76,Notice,FDA-2012-N-0194-0006,FDA-2012-N-0194,"Agency Information Collection Activities; Submission for Office of
Management and Budget Review; Comment Request; Biosimilars User
Fee Cover Sheet; Form FDA 3792"
0900006481817faa,Notice,FDA-2014-N-1069-0001,FDA-2014-N-1069,"Agency Information Collection Activities; Proposed Collection;
Comment Request; Blood Establishment Registration and
Product Listing"
09000064830dd30c,Notice,FDA-2014-N-1069-0005,FDA-2014-N-1069,"Agency Information Collection Activities; Submission for Office of
Management and Budget Review; Comment Request; Blood  Establishment Registration and Product Listing, Form FDA 2830"
0900006483582378,Notice,FDA-2014-N-1069-0007,FDA-2014-N-1069,"Agency Information Collection Activities; Announcement of Office of
Management and Budget Approvals"
0900006481b1cc3e,Notice,FDA-2014-N-1069-0003,FDA-2014-N-1069,"Agency Information Collection Activities; Announcement of Office of
Management and Budget Approval; Blood Establishment Registration and Product Listing, Form FDA 2830"
09000064819e628b,Notice,FDA-2014-N-1069-0002,FDA-2014-N-1069,"Agency Information Collection Activities; Submission for Office of
Management and Budget Review; Comment Request; Blood
Establishment Registration and Product Listing"
0900006482d728a4,Notice,FDA-2014-N-1069-0004,FDA-2014-N-1069,"Agency Information Collection Activities; Proposed Collection; Comment Request; Blood Establishment Registration and Product Listing, Form FDA 2830"
0900006481f5d523,Notice,FDA-2015-N-0797-0036,FDA-2015-N-0797,"Agency Information Collection Activities; Announcement of Office of
Management and Budget Approvals"
0900006481fb6feb,Proposed Rule,FDA-2015-N-0797-0037,FDA-2015-N-0797,"The Food and Drug Administration Food Safety Modernization Act: Focus
on Strategic Implementation of Prevention-Oriented Import Safety  Programs; Public Meetings"
0900006481a5cfc1,Notice,FDA-2015-N-0797-0001,FDA-2015-N-0797,"The Food and Drug Administration Food Safety Modernization Act: Focus
on Implementation Strategy for Prevention-Oriented Food Safety
Standards; Public Meeting and Establishment of Docket"
0900006481e8a4f4,Notice,FDA-2015-N-0797-0035,FDA-2015-N-0797,"The Food and Drug Administration Food Safety Modernization Act:
Prevention-Oriented Import System Regulations and Implementation;
Public Meeting"
0900006484a60d80,Other,FDA-2021-P-0272-0002,FDA-2021-P-0272,Acknowledgment Letter from FDA DMS to North Carolina Masks LLC
0900006484a60d14,Other,FDA-2021-P-0272-0001,FDA-2021-P-0272,Citizen Petition from North Carolina Masks LLC
0900006480449386,Supporting & Related Material,FDA-2005-N-0341-0004,FDA-2005-N-0341,Supporting Statement
0900006480449346,Notice,FDA-2005-N-0341-0001,FDA-2005-N-0341,FDA
0900006480449374,Notice,FDA-2005-N-0341-0002,FDA-2005-N-0341,FDA
0900006480449384,Supporting & Related Material,FDA-2005-N-0341-0003,FDA-2005-N-0341,Supporting Statement
0900006480449388,Notice,FDA-2005-N-0341-0005,FDA-2005-N-0341,FDA
090000648048eac1,Notice,FDA-2002-N-0102-0003,FDA-2002-N-0102,FDA
090000648048eab8,Notice,FDA-2002-N-0102-0002,FDA-2002-N-0102,FDA
090000648048ea72,Notice,FDA-2002-N-0102-0001,FDA-2002-N-0102,FDA
0900006480a7f223,Other,FDA-2010-V-0018-0003,FDA-2010-V-0018,FDA/CDRH to GE Healthcare - Approval for Variance
0900006480a78fca,Other,FDA-2010-V-0018-0001,FDA-2010-V-0018,GE Healthcare Services - Application for Variance
0900006481158ba7,Other,FDA-2010-V-0018-0004,FDA-2010-V-0018,GE Healthcare - Request for Extension
0900006482cd8a1a,Other,FDA-2010-V-0018-0005,FDA-2010-V-0018,GE Healthcare - Request for Extension Approval
0900006480a78ff4,Other,FDA-2010-V-0018-0002,FDA-2010-V-0018,Acknowledgement Letter to GE Healthcare Services
0900006482234230,Notice,FDA-2016-D-2730-0001,FDA-2016-D-2730,"Food and Drug Administration’s Application of Statutory Factors in
Determining When a Risk Evaluation and Mitigation Strategy Is Necessary; Draft Guidance for Industry; Availability"
0900006483b6917d,Notice,FDA-2016-D-2730-0009,FDA-2016-D-2730,Risk Evaluation and Mitigation Strategy: The Food and Drug Administration’s Application of Statutory Factors in Determining When a Risk Evaluation and Mitigation Strategy Is Necessary; Guidance for Industry; Availability
0900006483b69efa,Other,FDA-2016-D-2730-0010,FDA-2016-D-2730,REMS: FDA's Application of Statutory Factors in Determining When a REMS Is Necessary Guidance for Industry
0900006482226a98,Other,FDA-2016-D-2730-0002,FDA-2016-D-2730,Draft Guidance for Industry on FDA's Application of Statutory Factors in Determining When a REMS Is Necessary
0900006480f89877,Notice,FDA-2011-D-0790-0004,FDA-2011-D-0790,"Draft Guidance for Industry, Clinical Investigators, Institutional Review Boards, and Staff; Availability: Decisions for Investigational Device Exemption Clinical Investigations"
0900006480f69c13,Notice,FDA-2011-D-0790-0001,FDA-2011-D-0790,"Draft Guidance for Industry, Clinical Investigators, Institutional Review Boards, and Staff; Availability: Decisions for Investigational Device Exemption Clinical Investigations"
0900006480f69b65,Other,FDA-2011-D-0790-0002,FDA-2011-D-0790,"Draft Guidance for Industry, Clinical Investigators, Institutional Review Boards, and Food and Drug Administration Staff, FDA Decisions for Investigational Device Exemption Clinical Investigations"
0900006481830756,Other,FDA-2011-D-0790-0036,FDA-2011-D-0790,Guidance for Sponsors Clinical Investigators Institutional Review Boards and Food and Drug Administration Staff
090000648182f7fb,Notice,FDA-2011-D-0790-0035,FDA-2011-D-0790,"Food and Drug Administration Decisions for Investigational Device
Exemption Clinical Investigations: Guidance for Sponsors, Clinical
Investigators, Institutional Review Boards, and Food and Drug
Administration Staff; Availability"
090000648131ff08,Notice,FDA-2011-D-0790-0018,FDA-2011-D-0790,Food and Drug Administration Decisions for Investigational Device Exemption Clinical Investigations; Draft Guidance for Industry and Food and Drug Administration Staff; Availability
0900006481320322,Other,FDA-2011-D-0790-0019,FDA-2011-D-0790,Content of Premarket Submissions for Management of Cybersecurity in Medical Devices; Draft Guidance for Industry and Food and Drug Administration Staff
0900006481319c52,Other,FDA-2013-P-0695-0002,FDA-2013-P-0695,Acknowledgement Letter to Steven A Zecola
0900006481319be2,Other,FDA-2013-P-0695-0001,FDA-2013-P-0695,Steven A. Zecola - Citizen Petition
09000064814a5f5b,Other,FDA-2013-P-0695-0003,FDA-2013-P-0695,FDA/CDER Interim Response to Steven A Zecola - Letter
09000064817ea191,Other,FDA-2013-P-0695-0004,FDA-2013-P-0695,Citizen Petition Denial Response from FDA CDER to Steven A. Zecola
090000648188c8c6,Notice,FDA-2014-N-1287-0001,FDA-2014-N-1287,"Announcement of Requirements and Registration for the 2014 Food and
Drug Administration Food Safety Challenge"
090000648379096a,Other,FDA-2018-P-1876-0004,FDA-2018-P-1876,Additional Commmunication from Dr. Niazi 01 OCT-2018
09000064836af0e4,Other,FDA-2018-P-1876-0003,FDA-2018-P-1876,Letter re Biosimilars from Dr. S. Niazi
0900006483d7dc3e,Other,FDA-2018-P-1876-0008,FDA-2018-P-1876,Memorandum of Meeting - Listening Meeting with Dr. Sarfaraz Niazi Regarding Biosilmilars
0900006483d7dc3f,Supporting & Related Material,FDA-2018-P-1876-0009,FDA-2018-P-1876,Risk-Based Licensing of Biosimilars re Memorandum of Meeting - Listening Meeting with Dr. Sarfaraz Niazi Regarding Biosilmilars
0900006483264231,Other,FDA-2018-P-1876-0002,FDA-2018-P-1876,Acknowledgment Letter from FDA DDM to UIC College of Pharmacy
0900006483796c3b,Other,FDA-2018-P-1876-0005,FDA-2018-P-1876,FDA Summary_August 15 2018 mtg with Sarfaraz Niazi
090000648326422a,Other,FDA-2018-P-1876-0001,FDA-2018-P-1876,Citizen Petition from UIC College of Pharmacy
09000064838e18e1,Other,FDA-2018-P-1876-0007,FDA-2018-P-1876,Letter from FDA CDER to Sarfaraz K. Niazi
09000064838d7dbc,Other,FDA-2018-P-1876-0006,FDA-2018-P-1876,"Letter from Sarfaraz K. Niazi, UIC"
0900006483d7dd6f,Other,FDA-2018-P-1876-0010,FDA-2018-P-1876,Testimony from Sarfaraz Niazi
09000064845544fe,Other,FDA-2020-D-1336-0001,FDA-2020-D-1336,Guidance for Industry and FDA Staff Dental Cements - Premarket
090000648410ba23,Other,FDA-2019-P-5069-0002,FDA-2019-P-5069,Acknowledgment Letter from FDA DMS to Ontario Ginseng Growers Association
090000648410c5fa,Supporting & Related Material,FDA-2019-P-5069-0003,FDA-2019-P-5069,Attachment 1 re: Citizen Petition from Ontario Ginseng Growers Association
0900006484749e81,Other,FDA-2019-P-5069-0005,FDA-2019-P-5069,Final Response letter from FDA CFSAN to Ms. Rebecca Coates
090000648448cb4f,Other,FDA-2019-P-5069-0004,FDA-2019-P-5069,Interim Response Letter from FDA CFSAN to Ontario Ginseng Growers Association
090000648410ba22,Other,FDA-2019-P-5069-0001,FDA-2019-P-5069,Citizen Petition from Ontario Ginseng Growers Association
090000648049faf9,Notice,FDA-2002-N-0311-0002,FDA-2002-N-0311,FDA
090000648049fafd,Notice,FDA-2002-N-0311-0003,FDA-2002-N-0311,FDA
090000648049faab,Notice,FDA-2002-N-0311-0001,FDA-2002-N-0311,FDA
09000064804963c5,Other,FDA-2003-P-0338-0001,FDA-2003-P-0338,"HFD-005 to Frommer Lawrence &amp; Haug, LLP"
0900006480496459,Other,FDA-2003-P-0338-0002,FDA-2003-P-0338,HFD-1 to Frommer Lawrence &amp; Haug LLP
09000064804c599c,Notice,FDA-1999-N-0758-0003,FDA-1999-N-0758,Agency Information Collection Activities; Announcement of OMB Approval; FDA Safety Alert/Public Health Advisory Readership Survey
09000064804c5985,Notice,FDA-1999-N-0758-0001,FDA-1999-N-0758,Agency Information Collection Activities: Proposed Collection; Comment Request; FDA Safety Alert/ Public Health Advisory Readership Survey
09000064804c5997,Notice,FDA-1999-N-0758-0002,FDA-1999-N-0758,Agency Information Collection Activities; Submission for OMB Review; Comment Request; FDA Safety Alert/Public Health Advisory Readership Survey
09000064825f5e64,Supporting & Related Material,FDA-1999-N-0758-0004,FDA-1999-N-0758,Sample Document of FDA Safety Alert/Public Health Advisory Readership Survey
09000064813ba8e3,Other,FDA-1996-P-0056-0001,FDA-1996-P-0056,"FDA/CVM to Luitpold Pharmaceuticals, Inc. - Letter"
09000064806bf381,Notice,FDA-2008-N-0439-0001,FDA-2008-N-0439,"Agency Information Collection Activities; Proposed Collection; Comment Request; Blood Establishment Registration and Product Listing, Form FDA 2830"
09000064807defa6,Notice,FDA-2008-N-0439-0002,FDA-2008-N-0439,"Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Blood Establishment Registration and Product Listing, Form FDA 2830"
090000648222d97d,Notice,FDA-2016-N-2648-0001,FDA-2016-N-2648,"Announcement of Requirements and Registration for the 2016 Food and
Drug Administration Naloxone App Competition"
0900006480f87cba,Notice,FDA-2011-N-0508-0002,FDA-2011-N-0508,"Agency Information Collection Activities; Proposals, Submissions, and Approvals: Blood Establishment Registration and Product Listing"
0900006480fe7888,Notice,FDA-2011-N-0508-0003,FDA-2011-N-0508,"Agency Information Collection Activities; Proposals, Submissions, and Approvals: Blood Establishment Registration and Product Listing, Form FDA 2830"
0900006480ed9e3e,Notice,FDA-2011-N-0508-0001,FDA-2011-N-0508,"Agency Information Collection Activities; Proposals, Submissions, and Approvals: Blood Establishment Registration and Product Listing"
0900006481c29f72,Notice,FDA-2015-N-2817-0001,FDA-2015-N-2817,Medical Devices; Export Certificates; Food and Drug Administration Export Reform and Enhancement Act of 1996; Certification Fees
090000648266b120,Other,FDA-2017-P-3330-0003,FDA-2017-P-3330,Acknowledgement Letter from FDA DDM_Redacted
0900006482c99dfb,Other,FDA-2017-P-3330-0005,FDA-2017-P-3330,Interim Response from FDA
09000064843084fe,Other,FDA-2017-P-3330-0006,FDA-2017-P-3330,Dental Laser CP Final Response
0900006482617d8e,Other,FDA-2017-P-3330-0002,FDA-2017-P-3330,Acknowledgement Letter from FDA DDM
0900006482617d8c,Other,FDA-2017-P-3330-0001,FDA-2017-P-3330,Citizen Petition Regarding PMA K151763
090000648450bca9,Notice,FDA-2019-N-5799-0003,FDA-2019-N-5799,"Modernizing the Food and Drug Administration’s Data Strategy; Public
Meeting; Extension of Comment Period"
09000064844c936b,Other,FDA-2019-N-5799-0002,FDA-2019-N-5799,"Request for Extension from Regeneron Pharmaceuticals, Inc."
090000648427bfca,Notice,FDA-2019-N-5799-0001,FDA-2019-N-5799,Modernizing the Food and Drug Administration’s Data Strategy; Public Meeting; Request for Comments
0900006484825f8b,Other,FDA-2019-N-5799-0042,FDA-2019-N-5799,Letter from Symmetric Health Solutions to FDA OC
0900006480b08e16,Notice,FDA-2006-D-0298-0014,FDA-2006-D-0298,See FDA 2006-D-0298-0001
0900006480b0967a,Supporting & Related Material,FDA-2006-D-0298-0019,FDA-2006-D-0298,"Exhibit 2b - ""Whole Grain Half Truths"" - [Kellogg Company - Comment]"
0900006480ec0939,Other,FDA-2006-D-0298-0027,FDA-2006-D-0298,AACC International Task Force - Correction re FDA-2006-D-0298-0026
0900006480458e57,Other,FDA-2006-D-0298-0005,FDA-2006-D-0298,Draft Guidance for Industry and FDA Staff: Whole Grain Label Statements
0900006480b095b4,Supporting & Related Material,FDA-2006-D-0298-0018,FDA-2006-D-0298,"Exhibit 2a - ""Use of Whole Grain Claims: 2005 to April 2010"" - [Kellogg Company - Comment]"
0900006480458e35,Supporting & Related Material,FDA-2006-D-0298-0002,FDA-2006-D-0298,Background Information
0900006480458e3f,Supporting & Related Material,FDA-2006-D-0298-0004,FDA-2006-D-0298,Background Information
0900006480458e3d,Supporting & Related Material,FDA-2006-D-0298-0003,FDA-2006-D-0298,Background Information
0900006480b08d9c,Notice,FDA-2006-D-0298-0013,FDA-2006-D-0298,N
0900006480458e10,Notice,FDA-2006-D-0298-0001,FDA-2006-D-0298,Draft Guidance for Industry and FDA Staff Whole Grains Label Statement Availability
0900006480458e59,Supporting & Related Material,FDA-2006-D-0298-0006,FDA-2006-D-0298,Guidance
0900006480b095b2,Supporting & Related Material,FDA-2006-D-0298-0016,FDA-2006-D-0298,"Exhibit 1a - ""A Survey of Consumers Whole Grain & Fiber Consumption Behaviors, and the Perception of Whole GrainFoods as a Source od Dietary Fiber"" - [Kellogg Company - Comment]"
0900006480b095b3,Supporting & Related Material,FDA-2006-D-0298-0017,FDA-2006-D-0298,"Exhibit 1b - ""The American: ""Whole"" Lot of Fiber Confusion"" - [Kellogg Company - Comment]"
0900006480b0967b,Supporting & Related Material,FDA-2006-D-0298-0020,FDA-2006-D-0298,"Exhibit 3 - ""Review of the Whole Grain Council's 2009""Whole Grain Research Summary"" Prepared for the Kellogg Company 11/12/09 Fulgoni, VL. 3rd"" - [Kellogg Company - Comment]"
0900006480486d78,Supporting & Related Material,FDA-2003-D-0147-0002,FDA-2003-D-0147,Guidance
0900006480486d3d,Notice,FDA-2003-D-0147-0001,FDA-2003-D-0147,FDA
090000648044914e,Supporting & Related Material,FDA-2005-D-0339-0003,FDA-2005-D-0339,Guidance
0900006480449112,Notice,FDA-2005-D-0339-0001,FDA-2005-D-0339,FDA
09000064804491a0,Notice,FDA-2005-D-0339-0006,FDA-2005-D-0339,FDA
0900006480fd2752,Notice,FDA-2005-D-0339-0022,FDA-2005-D-0339,"Draft Guidance; Drug Safety Information, FDA's Communication to the Public: Availability"
090000648044919e,Supporting & Related Material,FDA-2005-D-0339-0004,FDA-2005-D-0339,Guidance
0900006480fd2bfc,Other,FDA-2005-D-0339-0023,FDA-2005-D-0339,"Guidance; Drug Safety Information, FDA's Communication to the Public"
090000648044914d,Supporting & Related Material,FDA-2005-D-0339-0002,FDA-2005-D-0339,Guidance
090000648044919f,Supporting & Related Material,FDA-2005-D-0339-0005,FDA-2005-D-0339,Guidance
0900006480447b09,Other,FDA-2005-P-0315-0005,FDA-2005-P-0315,Pfizer Global Research and Development - Citizen Petition
0900006480447b17,Other,FDA-2005-P-0315-0002,FDA-2005-P-0315,Acknowledgement Letter to Pfizer Inc.
0900006480447b1b,Other,FDA-2005-P-0315-0003,FDA-2005-P-0315,FDA/CDER to Pfizer Global Research and Development
0900006480447b20,Other,FDA-2005-P-0315-0006,FDA-2005-P-0315,Pfizer - Amendment
0900006480447aeb,Other,FDA-2005-P-0315-0001,FDA-2005-P-0315,HFA-305 to Pfizer Inc.
0900006480f78eec,Other,FDA-2005-P-0315-0004,FDA-2005-P-0315,FDA/CDER  to Pfizer Global Research and Development - Petition Denial
090000648049a36b,Notice,FDA-2003-N-0384-0002,FDA-2003-N-0384,FDA
090000648049a32f,Notice,FDA-2003-N-0384-0001,FDA-2003-N-0384,FDA
09000064825e9728,Supporting & Related Material,FDA-2017-P-3196-0020,FDA-2017-P-3196,"Reference 17 FAQ Fisheries and Aquaculture Report No, 978 re Citizen Petition from Philip Spiller et. al."
09000064825e972e,Supporting & Related Material,FDA-2017-P-3196-0026,FDA-2017-P-3196,Reference 23 FDA Strategic Plan for Risk Communication as updated in 2012 re Citizen Petition from Philip Spiller et. al.
09000064825e9747,Supporting & Related Material,FDA-2017-P-3196-0048,FDA-2017-P-3196,Reference 44 Fetal Methylmercury Poisoning re Citizen Petition from Philip Spiller et. al.
09000064825e974d,Supporting & Related Material,FDA-2017-P-3196-0054,FDA-2017-P-3196,Reference 50 Associations of maternal fish intake during pregnancy re Citizen Petition from Philip Spiller et. al.
09000064825e975a,Supporting & Related Material,FDA-2017-P-3196-0063,FDA-2017-P-3196,Reference 59 Letter from Michael Taylor to Dr John Kaneko re Citizen Petition from Philip Spiller et. al.
09000064825e9bcb,Supporting & Related Material,FDA-2017-P-3196-0018,FDA-2017-P-3196,Reference 15 EPA Study Mercury Levels in Women of Childbearing Age Drop 34 re Citizen Petition from Philip Spiller et. al.
09000064837b7fe5,Other,FDA-2017-P-3196-0074,FDA-2017-P-3196,Reconsideration Denial CP Response to Philip Spiller
0900006482c74b46,Other,FDA-2017-P-3196-0072,FDA-2017-P-3196,Citizen Petition for Reconsideration from  Philip Spiller et. al.
09000064825e972f,Supporting & Related Material,FDA-2017-P-3196-0027,FDA-2017-P-3196,Reference 24 New Advice Pregnant Women and Young re Citizen Petition from Philip Spiller et. al.
09000064825e9742,Supporting & Related Material,FDA-2017-P-3196-0045,FDA-2017-P-3196,Reference 41 Prenatal Exposure to Mercury and Infant re Citizen Petition from Philip Spiller et. al.
09000064825e9745,Supporting & Related Material,FDA-2017-P-3196-0046,FDA-2017-P-3196,Reference 42 Prenatal exposure to mercury and re Citizen Petition from Philip Spiller et. al.
09000064825e974b,Supporting & Related Material,FDA-2017-P-3196-0052,FDA-2017-P-3196,"Reference 48 Maternal Fish Consumption , Hair Mercury , and Infant Cognition re Citizen Petition from Philip Spiller et. al."
09000064825e9754,Supporting & Related Material,FDA-2017-P-3196-0057,FDA-2017-P-3196,Reference 53 Workshop on DHA as a required nutrient Overview re Citizen Petition from Philip Spiller et. al.
09000064825e9ba8,Supporting & Related Material,FDA-2017-P-3196-0005,FDA-2017-P-3196,Reference 2 Suggested Servings from Each Food Group re Citizen Petition from Philip Spiller et. al.
09000064825e9baa,Supporting & Related Material,FDA-2017-P-3196-0007,FDA-2017-P-3196,Reference 4 A qualitative study of fish consumption during pregnancy re Citizen Petition from Philip Spiller et. al.
09000064825e9bc3,Supporting & Related Material,FDA-2017-P-3196-0010,FDA-2017-P-3196,Reference 7 A Quantitative Analysis o f Prenatal Intake of n-3 re Citizen Petition from Philip Spiller et. al.
09000064825e9bc6,Supporting & Related Material,FDA-2017-P-3196-0013,FDA-2017-P-3196,Reference 10 Fish Intake During Pregnancy re Citizen Petition from Philip Spiller et. al.
09000064825e9bc7,Supporting & Related Material,FDA-2017-P-3196-0014,FDA-2017-P-3196,Reference 11 Report of the Dietary re Citizen Petition from Philip Spiller et. al.
09000064825e9bc9,Supporting & Related Material,FDA-2017-P-3196-0016,FDA-2017-P-3196,Reference 13 Reference Dose RfD Description and Use in re Citizen Petition from Philip Spiller et. al.
09000064825e9c24,Supporting & Related Material,FDA-2017-P-3196-0030,FDA-2017-P-3196,Reference 27 Fish What Pregnant Women and Parents Should Know re Citizen Petition from Philip Spiller et. al.
09000064825e9c26,Supporting & Related Material,FDA-2017-P-3196-0032,FDA-2017-P-3196,Reference 29 Quantitative Approach for Incorporating Methymercury Risks and Omega-3 re Citizen Petition from Philip Spiller et. al.
09000064825e9c27,Supporting & Related Material,FDA-2017-P-3196-0033,FDA-2017-P-3196,"Reference 30 Goyer, R.A. (2000) letter to Levitt, J. Not submitted to the docket re Citizen Petition from Philip Spiller et. al."
09000064825e9ba4,Other,FDA-2017-P-3196-0002,FDA-2017-P-3196,Acknowledgment Letter from FDA DDM to Philip Spiller et. al.
09000064825e96e0,Other,FDA-2017-P-3196-0001,FDA-2017-P-3196,Citizen Petition from Philip Spiller et. al.
09000064825e972a,Supporting & Related Material,FDA-2017-P-3196-0022,FDA-2017-P-3196,Reference 19 FDA fish consumption advice to pregnant women issued in 2001 re Citizen Petition from Philip Spiller et. al.
09000064832a4ddd,Supporting & Related Material,FDA-2018-P-1966-0003,FDA-2018-P-1966,"Attachment 3 Celebrex PI- re Suitability Petition from McNeely, Hare & War, LLP."
09000064832a4dde,Supporting & Related Material,FDA-2018-P-1966-0004,FDA-2018-P-1966,"Attachment 2 Highlights of proposed PI- re Suitability Petition from McNeely, Hare & War, LLP."
09000064832a4722,Other,FDA-2018-P-1966-0001,FDA-2018-P-1966,"Suitability Petition from McNeely, Hare & War, LLP."
09000064832a521c,Other,FDA-2018-P-1966-0002,FDA-2018-P-1966,"Acknowledgment Letter from FDA DDM to McNeely, Hare & War, LLP."
09000064832a4ddf,Supporting & Related Material,FDA-2018-P-1966-0005,FDA-2018-P-1966,"Attachment 1 Orange Book Listing- re Suitability Petition from McNeely, Hare & War, LLP."
09000064832b108b,Supporting & Related Material,FDA-2018-P-1980-0003,FDA-2018-P-1980,Attachment 1- Excerpts from FDA’s Orange Book re: Citizen Petition from Foley& Lardner LLP
09000064832b0b39,Other,FDA-2018-P-1980-0001,FDA-2018-P-1980,Citizen Petition  from Foley & Lardner LLP
09000064839ac1f2,Other,FDA-2018-P-1980-0005,FDA-2018-P-1980,"Letter from FDA CDER to Akorn Pharmaceuticals, Mylan Pharmaceuticals, Inc., Gland Pharma Limited, Foley & Lardner LLP"
09000064838e0b6c,Other,FDA-2018-P-1980-0004,FDA-2018-P-1980,Letter from FDA CDER to Foley & Lardner LLP
09000064832b0f3d,Other,FDA-2018-P-1980-0002,FDA-2018-P-1980,Acknowledgment Letter from FDA DDM to Foley & Lardner LLP
090000648175ee75,Other,FDA-2014-P-0861-0002,FDA-2014-P-0861,Acknowledgement Letter From FDA DDM to Clinipace Worldwide
09000064818270ee,Other,FDA-2014-P-0861-0005,FDA-2014-P-0861,Citizen Petition Response from FDA CDER to Clinipace Worldwide
090000648175ee7a,Supporting & Related Material,FDA-2014-P-0861-0004,FDA-2014-P-0861,Attachment 2 Orange Book Relevant Section Citizen Petition From Clinipace Worldwide
090000648175e888,Other,FDA-2014-P-0861-0001,FDA-2014-P-0861,Citizen Petition From Clinipace Worldwide
090000648175ee79,Supporting & Related Material,FDA-2014-P-0861-0003,FDA-2014-P-0861,Attachment 1 Orange Book Supplement Citizen Petition From Clinipace Worldwide
090000648268d631,Other,FDA-2017-P-3484-0001,FDA-2017-P-3484,Citizen Petition from Glasshouse Pharmaceuticals Limited Canada
090000648268e53b,Other,FDA-2017-P-3484-0002,FDA-2017-P-3484,Acknowledgement Letter from FDA DDM to Glasshouse Pharmaceuticals Limited Canada
0900006482cc69e0,Other,FDA-2017-P-3484-0003,FDA-2017-P-3484,Interim Response Letter from FDA CDER to Glasshouse Pharmaceuticals Limited Canada
090000648314769f,Other,FDA-2017-P-3484-0004,FDA-2017-P-3484,Petition Approval Letter from FDA CDER
0900006480b4fc45,Supporting & Related Material,FDA-2010-P-0489-0006,FDA-2010-P-0489,"Attachment 5 - ""Copy of Citizen Petition to Ansell Limited, One of the Leading Manufacturers of Powdered and Powder-Free Surgical Gloves..., July 15, 2010"" - [Richard F. Edlich, M.D., Ph.D. - Citizen Petition] re FDA-2010-P-0489-0001"
0900006480b4fbe2,Supporting & Related Material,FDA-2010-P-0489-0003,FDA-2010-P-0489,"Attachment 2 - ""FDA/CDRH March 9, 2009, Interim Response to Citizen Petition Dated September 24, 2008""  - [Richard F. Edlich, M.D., Ph.D. - Citizen Petition] re FDA-2010-P-0489-0001"
0900006480b4fbe7,Supporting & Related Material,FDA-2010-P-0489-0005,FDA-2010-P-0489,"Attachment 4 - ""Copy of Citizen Petition to Revise the Device Classification of Cornstarch Powdered Examination and Surgical Gloves and Powder, Dusting, Surgical, June 30, 2010 - [Richard F. Edlich, M.D., Ph.D. - Citizen Petition] re FDA-2010-P-0489-0001"
0900006480b4fc47,Other,FDA-2010-P-0489-0007,FDA-2010-P-0489,"Acknowledgement Letter to Richard F. Edlich, MD, PhD"
0900006480b4f2b1,Other,FDA-2010-P-0489-0001,FDA-2010-P-0489,"Richard F. Edlich, M.D., Ph.D. - Citizen Petition"
0900006480b4fbe0,Supporting & Related Material,FDA-2010-P-0489-0002,FDA-2010-P-0489,"Attachment 1 - ""Copy of Citizen Petition to Ban Cornstarch Powder on Medical Gloves Maltese Cross Birefringence, September 24, 2008 - [Richard F. Edlich, M.D., Ph.D. - Citizen Petition] re FDA-2010-P-0489-0001"
0900006480b4fbe4,Supporting & Related Material,FDA-2010-P-0489-0004,FDA-2010-P-0489,"Attachment 3 - ""Copy of Citizen Petition to Remove the Consumer Report""Medical Glove Powder Report"" from the FDA Website, January 19, 2010 - [Richard F. Edlich, M.D., Ph.D. - Citizen Petition] re FDA-2010-P-0489-0001"
0900006483093645,Other,FDA-2010-P-0489-0024,FDA-2010-P-0489,Memo and Combined Responses to Dr Edlich Citizen Petitions_Redacted
0900006484dc2c15,Other,FDA-2021-P-1098-0001,FDA-2021-P-1098,Citizen Petition from Pet Schooled
0900006484dc2c17,Other,FDA-2021-P-1098-0002,FDA-2021-P-1098,Acknowledgment Letter from FDA DMS to Pet Schooled
09000064847f49e4,Notice,FDA-2014-N-1027-0009,FDA-2014-N-1027,"Agency Information Collection Activities; Proposals, Submissions, and Approvals: Infant Formula Recall Regulations"
0900006481999d89,Notice,FDA-2014-N-1027-0003,FDA-2014-N-1027,Agency Information Collection Activities; Announcement of Office of Management and Budget Approval Infant Formula Recall Regulations
09000064844f5593,Notice,FDA-2014-N-1027-0008,FDA-2014-N-1027,Agency Information Collection Activities; Proposed Collection; Comment Request; Infant Formula Recall Regulations
0900006482c60655,Notice,FDA-2014-N-1027-0006,FDA-2014-N-1027,"Agency Information Collection Activities; Submission for Office of
Management and Budget Review; Comment Request; Infant Formula
Recall Regulations"
090000648303ec1d,Notice,FDA-2014-N-1027-0007,FDA-2014-N-1027,"Agency Information Collection Activities; Announcement of Office of
Management and Budget Approvals"
09000064818e8278,Notice,FDA-2014-N-1027-0002,FDA-2014-N-1027,"Agency Information Collection Activities; Submission for Office of
Management and Budget Review; Comment Request; Infant Formula
Recall Regulations"
090000648180bb14,Notice,FDA-2014-N-1027-0001,FDA-2014-N-1027,"Agency Information Collection Activities; Proposed Collection;
Comment Request; Infant Formula Recall Regulations"
09000064826dbb94,Notice,FDA-2014-N-1027-0004,FDA-2014-N-1027,Agency Information Collection Activities; Proposed Collection; Comment Request; Infant Formula Recall Regulations
0900006484a3c81d,Notice,FDA-2014-N-1027-0010,FDA-2014-N-1027,Agency Information Collection Activities; Announcement of Office of Management and Budget Approvals
0900006480add0fe,Notice,FDA-2002-D-0094-0007,FDA-2002-D-0094,"Draft Guidance for the Public, Food and Drug Administration Advisory Committee Members, and FDA Staff: Public Availability of Advisory Committee Members Financial Interest Information and Waivers; Availability"
0900006480fd2859,Notice,FDA-2002-D-0094-0031,FDA-2002-D-0094,"Guidance for the Public, Advisory Committee Members, and Staff;  Advisory Committee Members' Financial Interest Information and Waivers: Availability"
09000064806aed88,Notice,FDA-2002-D-0094-0004,FDA-2002-D-0094,"Guidance for the Public, FDA Advisory Committee Members, and FDA Staff: Public Availability of Advisory Committee Members' Financial Interest Information and Waivers; Availability"
0900006481691d05,Other,FDA-2002-D-0094-0034,FDA-2002-D-0094,"Guidance for the Public, Food and Drug Administration Advisory
Committee Members, and Food and Drug Administration Staff: Public
Availability of Advisory Committee Members’ Financial Interest
Information and Waivers"
09000064806af63a,Other,FDA-2002-D-0094-0005,FDA-2002-D-0094,"Guidance for the Public, FDA Advisory Committee Members, and FDA Staff:  Public Availability of Advisory Committee Members' Financial Interest Information and Waivers, August 2008"
0900006480fd2db6,Other,FDA-2002-D-0094-0032,FDA-2002-D-0094,"Guidance for the Public, Advisory Committee Members, and Staff;  Advisory Committee Members' Financial Interest Information and Waivers"
0900006480b6d38d,Supporting & Related Material,FDA-2002-D-0094-0022,FDA-2002-D-0094,"Appendix A - "" RJReynolds Letter to FDA, June 30, 2010"" - [R.J. Reynolds Tobacco Company - Comment] re FDA-2002-D-0094-0018"
0900006480add437,Other,FDA-2002-D-0094-0008,FDA-2002-D-0094,"Guidance for the Public, Food and Drug Administration Advisory Committee Members, and FDA Staff: Public Availability of Advisory Committee Members Financial Interest Information and Waivers; Draft Guidance"
090000648048e44e,Notice,FDA-2002-D-0094-0001,FDA-2002-D-0094,Draft Guidance on Disclosure of Conflicts of Interest for Special Government Employees Participating in FDA Product Specific Advisory Committees; Availability
090000648048e47c,Other,FDA-2002-D-0094-0006,FDA-2002-D-0094,"Draft Guidance on Disclosure of Conflicts of Interest for Special Gqvernment Employees Participating in FDA Product Specific Advisory Committees, January 2002"
090000648048e4a2,Other,FDA-2002-D-0094-0002,FDA-2002-D-0094,"Guidance for the Public, FDA Advisory Committee Members, and FDA Staff: Public Availability of Advisory Committee Members' Financial Interest Information and Waivers, October 2007"
09000064816912ef,Notice,FDA-2002-D-0094-0033,FDA-2002-D-0094,"Guidance for the Public, Food and Drug Administration Advisory
Committee Members, and Food and Drug Administration Staff: Public
Availability of Advisory Committee Members’ Financial Interest
Information and Waivers; Availability"
090000648048e4a5,Notice,FDA-2002-D-0094-0003,FDA-2002-D-0094,"Draft Guidance for the Public, Food and Drug Administration Advisory Committee Members, and Food and Drug Administration Staff: Public Availability of Advisory Committee Members Financial Interest Information and Waivers; Availability"
0900006480b82f6d,Supporting & Related Material,FDA-2002-D-0094-0023,FDA-2002-D-0094,"Appendix C - ""FDAAC August 30, 2010"" - [R.J. Reynolds Tobacco Company - Comment] re FDA-2002-D-0094-0018"
090000648048b832,Notice,FDA-2003-D-0201-0001,FDA-2003-D-0201,FDA
09000064804b807c,Notice,FDA-2001-D-0060-0001,FDA-2001-D-0060,FDA
09000064843baa63,Other,FDA-2015-P-1674-0007,FDA-2015-P-1674,WITHDRAWAL OF CITIZEN PETITION FROM Globus Medical Inc
0900006481adc1b3,Supporting & Related Material,FDA-2015-P-1674-0004,FDA-2015-P-1674,Attachment C Unique Device Identification System Final Rule re Citizen Petition from Globus Medical Inc
0900006481adc19a,Supporting & Related Material,FDA-2015-P-1674-0002,FDA-2015-P-1674,Attachment A FDA Guidance for Industry Bar Code Label Requirements Questions and Answers re Citizen Petition from Globus Medical Inc
0900006481adc19b,Supporting & Related Material,FDA-2015-P-1674-0003,FDA-2015-P-1674,Attachment B - Bar Code Label Requirement for Human Drug Products and Biological Products Final Rule re Citizen Petition from Globus Medical Inc
0900006481adbc9a,Other,FDA-2015-P-1674-0001,FDA-2015-P-1674,Citizen Petition from Globus Medical Inc
0900006481adc182,Other,FDA-2015-P-1674-0005,FDA-2015-P-1674,"Acknowledgement Letter from FDA DDM to Globus Medical, Inc."
0900006481d4dde1,Other,FDA-2015-P-1674-0006,FDA-2015-P-1674,"Interim Response Letter from FDA CDRH to Globus Medical, Inc."
090000648446ced7,Other,FDA-2019-P-2074-0004,FDA-2019-P-2074,Final Response from FDA CDER to Encube Ethicals Private Limited
090000648412624d,Other,FDA-2019-P-2074-0003,FDA-2019-P-2074,Interim Response from FDA CDER to Encube Ethicals Private Limited
0900006483c1df0b,Other,FDA-2019-P-2074-0002,FDA-2019-P-2074,Acknowledgment Letter from FDA DDM to Encube Ethicals Private Limited
0900006483c1cf9b,Other,FDA-2019-P-2074-0001,FDA-2019-P-2074,Citizen Petition from Encube Ethicals Private Limited
09000064843ef00b,Other,FDA-2019-P-4261-0003,FDA-2019-P-4261,"Interim Response Letter from FDA CDER to Hyman, Phelps & McNamara, P.C."
0900006483f44ee0,Other,FDA-2019-P-4261-0001,FDA-2019-P-4261,"Citizen Petition from Hyman, Phelps & McNamara, P.C."
09000064845fd284,Other,FDA-2019-P-4261-0004,FDA-2019-P-4261,"Approval Letter from FDA CDER to Hyman, Phelps & McNamara, P.C."
0900006483f44ee1,Other,FDA-2019-P-4261-0002,FDA-2019-P-4261,"Acknowledgment Letter from FDA DMS to Hyman, Phelps & McNamara, P.C."
0900006481ee4819,Other,FDA-2016-P-1090-0001,FDA-2016-P-1090,"Acknowledgement Letter from FDA DDM to Lachman Consultant Services, Inc."
0900006481ee4816,Supporting & Related Material,FDA-2016-P-1090-0003,FDA-2016-P-1090,"Attachment 2 Support for Co-prescribing Naloxone Alongside Opioids re Citizen Petition from Lachman Consultant Services, Inc. (Adapt Pharma Ltd.)"
0900006481ee49fc,Other,FDA-2016-P-1090-0004,FDA-2016-P-1090,"Citizen Petition from Lachman Consultant Services, Inc. (Adapt Pharma Ltd.)"
090000648479d285,Other,FDA-2016-P-1090-0022,FDA-2016-P-1090,"Letter from FDA CDER to Lachman Consultant Services, Inc."
090000648223fd50,Other,FDA-2016-P-1090-0020,FDA-2016-P-1090,"Interim Response to Lachman Consulting Services, Inc. from FDA CDER"
0900006481ee49fd,Supporting & Related Material,FDA-2016-P-1090-0002,FDA-2016-P-1090,"Attachment 1 Narcan Nasal Spray Indication and Important Safety  Information re Citizen Petition from Lachman Consultant Services, Inc. (Adapt Pharma Ltd.)"
090000648169a421,Notice,FDA-2014-D-0261-0001,FDA-2014-D-0261,"The Meaning of ‘‘Spouse’’ and ‘‘Family’’ in the Food and Drug
Administration’s Regulations After the Supreme Court’s Ruling in United
States v. Windsor—Questions and Answers: Guidance for Industry,
Consumers, and Food and Drug Administration Staff; Availability"
090000648169aef8,Other,FDA-2014-D-0261-0002,FDA-2014-D-0261,"The Meaning of ‘‘Spouse’’ and ‘‘Family’’ in the Food and Drug
Administration’s Regulations After the Supreme Court’s Ruling in United
States v. Windsor—Questions and Answers: Guidance for Industry,
Consumers, and Food and Drug Administration Staff"
0900006484de2a28,Supporting & Related Material,FDA-2021-P-1144-0005,FDA-2021-P-1144,Appendix C Third Example of Methodology for Establishing Interim Proposed Action Levels Described in Attorneys General Petition to FDA RE: Citizen Petition from STATE OF NEW YORK OFFICE OF THE ATTORNEY GENERAL
0900006484de2a26,Supporting & Related Material,FDA-2021-P-1144-0003,FDA-2021-P-1144,Appendix A Appendix A – First Example of Methodology for Establishing Interim Proposed Action Levels Described in Attorneys General Petition to FDA RE: Citizen Petition from STATE OF NEW YORK OFFICE OF THE ATTORNEY GENERAL
0900006484de32ed,Other,FDA-2021-P-1144-0002,FDA-2021-P-1144,Acknowledgment Letter from FDA DMS to State of New York Office of the Attorney General
0900006484de3228,Other,FDA-2021-P-1144-0001,FDA-2021-P-1144,Citizen Petition from STATE OF NEW YORK OFFICE OF THE ATTORNEY GENERAL
0900006484de2a27,Supporting & Related Material,FDA-2021-P-1144-0004,FDA-2021-P-1144,Appendix B Second Example of Methodology for Establishing Interim Proposed Action Levels Described in Attorneys General Petition to FDA RE: Citizen Petition from STATE OF NEW YORK OFFICE OF THE ATTORNEY GENERAL
0900006484de2a29,Supporting & Related Material,FDA-2021-P-1144-0006,FDA-2021-P-1144,"Appendix D Results of NYSOAG Infant Rice Cereal Inorganic Arsenic Sampling (4 manufacturers, 7 products, 21 total samples)RE: Citizen Petition from STATE OF NEW YORK OFFICE OF THE ATTORNEY GENERAL"
09000064803a22f3,Notice,FDA-2008-P-0059-0001,FDA-2008-P-0059,"Determination That SEROQUEL (Quetiapine Fumarate) Tablets, 150 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
09000064803a4720,Other,FDA-2008-P-0059-0002,FDA-2008-P-0059,"Response Letter to Lachman Consultant Services, Inc - Letter"
090000648117e684,Other,FDA-2012-D-0080-0005,FDA-2012-D-0080,Guidance on Oversight of Positron Emission Tomography Drug Products - Questions and Answers
090000648117e3df,Notice,FDA-2012-D-0080-0004,FDA-2012-D-0080,Guidance on Oversight of Positron Emission Tomography Drug Products - Questions and Answers
0900006480fc30a5,Notice,FDA-2012-D-0080-0001,FDA-2012-D-0080,Draft Guidance; Availability: Oversight of Positron Emission Tomography Drug Products
0900006480fc3894,Other,FDA-2012-D-0080-0002,FDA-2012-D-0080,Draft Guidance; Oversight of Positron Emission Tomography Drug Products
0900006483435981,Other,FDA-2018-P-0343-0003,FDA-2018-P-0343,Petition Response Letter from FDA CDER to Fish & Richardson PC
0900006482e544f3,Other,FDA-2018-P-0343-0002,FDA-2018-P-0343,Acknowledgment Letter from FDA DDM to Fish & Richardson PC
0900006482e544ec,Other,FDA-2018-P-0343-0001,FDA-2018-P-0343,Citizen Petition from Fish & Richardson PC
090000648126db16,Notice,FDA-2013-N-0345-0001,FDA-2013-N-0345,Food and Drug Administration/National Institutes of Health/National Science Foundation Public Workshop on Computer Methods for Medical Devices
0900006481c61c16,Proposed Rule,FDA-2015-N-0540-7641,FDA-2015-N-0540,"Homeopathic Product Regulation: Evaluating the Food and Drug
Administration’s Regulatory Framework After a Quarter-Century;
Reopening of the Comment Period"
0900006481aaa3e7,Other,FDA-2015-N-0540-0486,FDA-2015-N-0540,"Testimony from Nancy Peplinsky, Holistic Moms Network"
0900006481aaa2e6,Other,FDA-2015-N-0540-0474,FDA-2015-N-0540,Presentation from Paramesh Banerji Life Sciences LLC
0900006481aaa308,Other,FDA-2015-N-0540-0475,FDA-2015-N-0540,Presentation from the American Institute of Homeopathy
0900006481aaa012,Other,FDA-2015-N-0540-0479,FDA-2015-N-0540,"Testimony from Amy Rothenberg, American Association of Naturopathic Physicians"
0900006481aaa014,Other,FDA-2015-N-0540-0481,FDA-2015-N-0540,Presentation from Luana Colloca MD PhD
0900006481aabe06,Other,FDA-2015-N-0540-0639,FDA-2015-N-0540,Presentation from the Homoeopathic Pharmacopoeia Convention of the United States
0900006481aaa010,Other,FDA-2015-N-0540-0478,FDA-2015-N-0540,Presentation from Alvin Lorman
0900006481b0e9ff,Other,FDA-2015-N-0540-2177,FDA-2015-N-0540,"Testimony of Alyssa Wostrel, Integrative Health Policy Consortium"
0900006481b0ea02,Other,FDA-2015-N-0540-2179,FDA-2015-N-0540,"Transcript of the Homeopathic Product Regulation: Evaluating the Food and Drug Administration's Regulatory Framework After a Quarter Century Part 15 Public Hearing Day 2 April 21, 2015"
0900006481c18831,Other,FDA-2015-N-0540-4429,FDA-2015-N-0540,"Presentation from Edward P. Krenzelok, Rocky Mountain Poison and Drug Center"
0900006481aaa2e0,Other,FDA-2015-N-0540-0472,FDA-2015-N-0540,Presentation from Peter Fisher
0900006481aabb05,Other,FDA-2015-N-0540-0640,FDA-2015-N-0540,"Testimony from Will Woodlee, AHPA"
0900006481aaf1f8,Other,FDA-2015-N-0540-0995,FDA-2015-N-0540,"Testimony from Terry Cotter, Terra-Medica Inc"
0900006481ab2814,Other,FDA-2015-N-0540-1302,FDA-2015-N-0540,"Testimony from Youngran Chung, MD"
0900006481aa9f74,Other,FDA-2015-N-0540-0471,FDA-2015-N-0540,Testimony from the Homeopathic Academy of Naturopathic Physicians
0900006481aaa150,Other,FDA-2015-N-0540-0467,FDA-2015-N-0540,"Presentation from Gary Kracoff, Johnson Compounding and Wellness Center"
0900006481aaa14c,Other,FDA-2015-N-0540-0466,FDA-2015-N-0540,Testimony from Yale Martin
0900006481aaa016,Other,FDA-2015-N-0540-0482,FDA-2015-N-0540,"Testimony from Alison Teitelbaum, National Center for Homeopathy"
0900006481aaf2a0,Other,FDA-2015-N-0540-0998,FDA-2015-N-0540,Presentation from American Association of Homeopathic Pharmacists
0900006481aaf2a1,Other,FDA-2015-N-0540-0999,FDA-2015-N-0540,Presentation from Emerson Healthcare Group
0900006481ab20ea,Other,FDA-2015-N-0540-1293,FDA-2015-N-0540,"Testimony from Robert Dumont, Raby Institute for Integrative Medicine at Northwestern, LLC"
0900006481ab6695,Other,FDA-2015-N-0540-1501,FDA-2015-N-0540,Presentation from Materia Medica Holding
0900006481b291fb,Proposed Rule,FDA-2015-N-0540-2724,FDA-2015-N-0540,"Homeopathic Product Regulation: Evaluating the Food and Drug
Administration’s Regulatory Framework After a Quarter-Century;
Extension of Comment Period"
0900006481aabb0a,Other,FDA-2015-N-0540-0641,FDA-2015-N-0540,Testimony from Adriane Fugh-Berman MD
09000064837ab57c,Supporting & Related Material,FDA-2018-P-3825-0003,FDA-2018-P-3825,Pei Wei Clean Label Study Report Final Report
09000064837ab574,Other,FDA-2018-P-3825-0002,FDA-2018-P-3825,"Acknowledgment Letter from FDA to Pei Wei Asian Diner, LLC."
09000064837ab3f7,Other,FDA-2018-P-3825-0001,FDA-2018-P-3825,"Citizen Petition from Pei Wei Asian Diner, LLC."
0900006483becaeb,Other,FDA-2018-P-3825-0004,FDA-2018-P-3825,"180 Day Interim Response Letter from FDA CFSAN to Pei Wei Asian Diner, LLC"
090000648056e98e,Supporting & Related Material,FDA-1998-D-0052-0005,FDA-1998-D-0052,Guidance
090000648056e961,Notice,FDA-1998-D-0052-0001,FDA-1998-D-0052,FDA
090000648056e979,Notice,FDA-1998-D-0052-0002,FDA-1998-D-0052,FDA
090000648056e98c,Notice,FDA-1998-D-0052-0003,FDA-1998-D-0052,FDA
090000648056e98d,Supporting & Related Material,FDA-1998-D-0052-0004,FDA-1998-D-0052,Guidance
090000648052823a,Other,FDA-1992-P-0030-0001,FDA-1992-P-0030,Helen K. Harris
09000064805232ba,Other,FDA-2008-P-0255-0002,FDA-2008-P-0255,Acknowledgement Letter to K.S. Trading Company
090000648052328c,Other,FDA-2008-P-0255-0001,FDA-2008-P-0255,K.S. Trading Company - Petition for Stay of Action
0900006480a3ed9c,Other,FDA-2009-P-0500-0001,FDA-2009-P-0500,"Ferdic, Incorporated - Citizen Petition"
0900006480a3ed9d,Other,FDA-2009-P-0500-0002,FDA-2009-P-0500,"Acknowledgement Letter to Ferdic, Incorporated"
09000064813ee373,Other,FDA-2009-P-0500-0003,FDA-2009-P-0500,"FDA/Office of Policy Response to FERDIC, Inc. - Petition Denial"
090000648464315d,Other,FDA-2020-D-1398-0001,FDA-2020-D-1398,Guidance for Industry; FDA Approval of New Animal Drugs For Minor Uses and for Minor Species; #61
0900006481607d97,Other,FDA-2014-P-0283-0001,FDA-2014-P-0283,Citizen Petition From Leroy L. Hamilton
09000064817168f0,Other,FDA-2014-P-0283-0003,FDA-2014-P-0283,Citizen Petition Denial Response from FDA CDRH to Leroy Leslie Hamilton
0900006481607d9b,Other,FDA-2014-P-0283-0002,FDA-2014-P-0283,Acknowledgement Letter From FDA/DDM to Leroy L. Hamilton
0900006480483def,Notice,FDA-2003-N-0100-0003,FDA-2003-N-0100,Agency Information Collection Activities; Announcement of OMB Approval; Medical Device User Fee Cover Sheet; Form FDA 360
0900006480483dea,Notice,FDA-2003-N-0100-0002,FDA-2003-N-0100,Agency Information Collection Activities; Submission for OMB Review; Comment Request; Medical Device User Fee Cover Sheet; Form FDA 3601
0900006480483da1,Notice,FDA-2003-N-0100-0001,FDA-2003-N-0100,Agency Information Collection Activities; Proposed Collection; Comment Request; Medical Device User Fee Cover Sheet; Form FDA 3601
0900006480483ded,Supporting & Related Material,FDA-2003-N-0100-0005,FDA-2003-N-0100,Supporting Statement re Medical Device User Fee Cover Sheet - Form FDA 3601 OMB Control 0910-0511
09000064804736ff,Notice,FDA-2004-D-0371-0004,FDA-2004-D-0371,FDA
09000064804736fe,Supporting & Related Material,FDA-2004-D-0371-0003,FDA-2004-D-0371,Guideline
09000064804736ec,Notice,FDA-2004-D-0371-0001,FDA-2004-D-0371,FDA
09000064804736ed,Supporting & Related Material,FDA-2004-D-0371-0002,FDA-2004-D-0371,Guidance
0900006480481418,Notice,FDA-2003-N-0027-0003,FDA-2003-N-0027,FDA
0900006480481411,Notice,FDA-2003-N-0027-0001,FDA-2003-N-0027,FDA
0900006480481414,Notice,FDA-2003-N-0027-0002,FDA-2003-N-0027,FDA
0900006480bb387e,Notice,FDA-2005-D-0072-0005,FDA-2005-D-0072,"Guidance for Public, FDA Advisory Committee Members, and FDA Staff; Availability: The Open Public Hearing at FDA Advisory Committee Meetings;Availability"
090000648043f30b,Other,FDA-2005-D-0072-0002,FDA-2005-D-0072,Guidance on the Open Public Hearing; Food and Drug Administration Advisory Committee Meetings; Draft Guidance
090000648043f30a,Notice,FDA-2005-D-0072-0001,FDA-2005-D-0072,Draft Guidance on the Open Public Hearing; Food and Drug Administration Advisory Committee Meetings; Availability
0900006480bb3e0d,Other,FDA-2005-D-0072-0006,FDA-2005-D-0072,"Guidance for the Public, FDA Advisory Committee Members, and FDA Staff: The Open Public Hearing at FDA Advisory Committee Meeting; Final Guidance"
0900006481f5cca0,Notice,FDA-2012-N-0536-0006,FDA-2012-N-0536,"Agency Information Collection Activities; Submission for Office of
Management and Budget Review; Comment Request; Medical Device
User Fee Cover Sheet, Form FDA 3601"
09000064846e88f5,Notice,FDA-2012-N-0536-0012,FDA-2012-N-0536,"Agency Information Collection Activities; Proposed Collection;
Comment Request; Medical Device User Fee Cover Sheet, Form FDA 3601
and Device Facility User Fee Cover Sheet, Form FDA 3601a"
0900006481037d8e,Notice,FDA-2012-N-0536-0001,FDA-2012-N-0536,"Agency Information Collection Activities; Proposals, Submissions, and Approvals: Medical Device User Fee Cover Sheet"
0900006483d98f1c,Notice,FDA-2012-N-0536-0010,FDA-2012-N-0536,"Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Medical Device User Fee Cover Sheet, Form FDA 3601"
090000648138cdc9,Notice,FDA-2012-N-0536-0004,FDA-2012-N-0536,"Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; Medical Device User Fee Cover Sheet, Form FDA 3601"
0900006481cdc9e1,Notice,FDA-2012-N-0536-0005,FDA-2012-N-0536,"Agency Information Collection Activities; Proposed Collection;
Comment Request; Medical Device User Fee Cover Sheet, Form FDA 3601"
0900006484d4a040,Notice,FDA-2012-N-0536-0015,FDA-2012-N-0536,"Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Medical Device User Fee Cover Sheet, Form FDA 3601 and Device Facility User Fee Cover Sheet, Form FDA 3601a"
09000064821f9725,Notice,FDA-2012-N-0536-0007,FDA-2012-N-0536,Agency Information Collection Activities; Announcement of Office of  Management and Budget Approvals
09000064840beec8,Notice,FDA-2012-N-0536-0011,FDA-2012-N-0536,"Agency Information Collection Activities; Announcement of Office of
Management and Budget Approvals"
09000064811e88b8,Notice,FDA-2012-N-0536-0003,FDA-2012-N-0536,"Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Medical Device User Fee Cover Sheet, Form FDA 3601"
09000064839cc098,Notice,FDA-2012-N-0536-0008,FDA-2012-N-0536,"Agency Information Collection Activities; Proposed Collection; Comment Request; Medical Device User Fee Cover Sheet, Form FDA 3601"
09000064849672c9,Other,FDA-2020-P-2213-0001,FDA-2020-P-2213,Citizen Petition from Kenneth E. Surprenant
0900006484969130,Supporting & Related Material,FDA-2020-P-2213-0003,FDA-2020-P-2213,Attachments A - L - re: Citizen Petition from Kenneth E. Surprenant
09000064849677cb,Other,FDA-2020-P-2213-0002,FDA-2020-P-2213,Acknowledgment Letter from FDA DMS to Kenneth E. Surprenant
0900006484b07dc8,Other,FDA-2020-P-2213-0031,FDA-2020-P-2213,Interim Response Letter from FDA CDER to Kenneth E. Surprenant
0900006484969131,Supporting & Related Material,FDA-2020-P-2213-0004,FDA-2020-P-2213,Attachments M-Z  re: Citizen Petition from Kenneth E. Surprenant
0900006480c25e9d,Notice,FDA-2011-N-0251-0001,FDA-2011-N-0251,"Food Safety Modernization Act, Focus on Preventive Controls for Facilities; Notice of Public Meeting"
0900006480c3c137,Supporting & Related Material,FDA-2011-N-0251-0004,FDA-2011-N-0251,See FDA-2011-N-0251-0008
0900006480e32c3d,Notice,FDA-2011-N-0366-0001,FDA-2011-N-0366,"FDA Food Safety Modernization Act, Focus on Inspections and Compliance"
09000064818a7e52,Other,FDA-2011-D-0357-0002,FDA-2011-D-0357,"Draft Guidance for Industry, Food and Drug Administration Staff, and Clinical Laboratories; FDA Notification and Medical Device Reporting for Laboratory Developed Tests (LDTs)"
09000064818a6838,Notice,FDA-2011-D-0357-0001,FDA-2011-D-0357,"Food and Drug Administration Notification and Medical Device Reporting for Laboratory Developed Tests; Draft Guidance for Industry,
Food and Drug Administration Staff, and Clinical Laboratories; Availability"
09000064819425ac,Notice,FDA-2011-D-0357-0003,FDA-2011-D-0357,"Framework for Regulatory Oversight of Laboratory Developed Tests; Public
Workshop; Request for Comments"
0900006484745b3c,Notice,FDA-2020-N-1500-0001,FDA-2020-N-1500,"Food and Drug Administration Hiring and Retention Interim Assessment;
Public Meeting; Request for Comments"
090000648046e8a7,Notice,FDA-2004-N-0049-0001,FDA-2004-N-0049,FDA
090000648046e8aa,Notice,FDA-2004-N-0049-0004,FDA-2004-N-0049,FDA
090000648046e8a8,Supporting & Related Material,FDA-2004-N-0049-0002,FDA-2004-N-0049,Supporting Statement
090000648046e8a9,Supporting & Related Material,FDA-2004-N-0049-0003,FDA-2004-N-0049,Supporting Statement
0900006481757759,Supporting & Related Material,FDA-2014-P-0831-0004,FDA-2014-P-0831,Attachment B FDA Guidance for Industry Citizen Petition from Orthofix Inc.
0900006481757758,Supporting & Related Material,FDA-2014-P-0831-0003,FDA-2014-P-0831,Attachment A List of Instrumentation Citizen Petition from Orthofix Inc.
090000648175775c,Supporting & Related Material,FDA-2014-P-0831-0006,FDA-2014-P-0831,Attachment D Bar Code Labeling Requirement Citizen Petition from Orthofix Inc.
0900006481d1c0fc,Other,FDA-2014-P-0831-0008,FDA-2014-P-0831,Supplement from Orthofix Inc.
0900006481cf4505,Other,FDA-2014-P-0831-0009,FDA-2014-P-0831,Amendment from Orthofix Inc.
090000648197f38e,Other,FDA-2014-P-0831-0007,FDA-2014-P-0831,Interim Response Letter from FDA CDRH to Orthofix Inc
09000064817576b3,Other,FDA-2014-P-0831-0002,FDA-2014-P-0831,Acknowledgement Letter from FDA DDM to Orthofix Inc.
09000064817576b1,Other,FDA-2014-P-0831-0001,FDA-2014-P-0831,Citizen Petition From Orthofix Inc.
090000648175775a,Supporting & Related Material,FDA-2014-P-0831-0005,FDA-2014-P-0831,Attachment C Unique Device ID System Citizen Petition from Orthofix Inc.
0900006483d9c6f8,Other,FDA-2014-P-0831-0010,FDA-2014-P-0831,Withdrawal of Citizen Petition Letter from Orthofix to FDA DDM
090000648367bd32,Supporting & Related Material,FDA-2018-P-3325-0012,FDA-2018-P-3325,Tab 10_Pfizer Report 2 re Citizen Petition from Pfizer Inc
090000648367bd37,Supporting & Related Material,FDA-2018-P-3325-0017,FDA-2018-P-3325,Tab 15_Woodcock Letter re Citizen Petition from Pfizer Inc
090000648367baca,Supporting & Related Material,FDA-2018-P-3325-0005,FDA-2018-P-3325,Tab 3_Manson et al re Citizen Petition from Pfizer Inc
090000648367bd30,Supporting & Related Material,FDA-2018-P-3325-0010,FDA-2018-P-3325,Tab 8_Levy et al re Citizen Petition from Pfizer Inc
090000648367bd36,Supporting & Related Material,FDA-2018-P-3325-0016,FDA-2018-P-3325,Tab 14_Bhavnani et al re Citizen Petition from Pfizer Inc
0900006483a0ceee,Other,FDA-2018-P-3325-0018,FDA-2018-P-3325,Citizen Petition Denial Response  from FDA CDER to  Pfizer Inc
090000648367bac8,Supporting & Related Material,FDA-2018-P-3325-0003,FDA-2018-P-3325,Tab 1_1997 Woodcock Memo re Citizen Petition from Pfizer Inc
090000648367b8d0,Other,FDA-2018-P-3325-0002,FDA-2018-P-3325,Acknowledgment Letter from FDA DDM to Pfizer Inc
090000648367b8cd,Other,FDA-2018-P-3325-0001,FDA-2018-P-3325,Citizen Petition from Pfizer Inc
090000648367bacb,Supporting & Related Material,FDA-2018-P-3325-0006,FDA-2018-P-3325,Tab 4_Gurney et al re Citizen Petition from Pfizer Inc
090000648367bd34,Supporting & Related Material,FDA-2018-P-3325-0014,FDA-2018-P-3325,Tab 12_Pfizer Report 4 re Citizen Petition from Pfizer Inc
090000648367bacc,Supporting & Related Material,FDA-2018-P-3325-0007,FDA-2018-P-3325,Tab 5_Lacey et al re Citizen Petition from Pfizer Inc
090000648367bd35,Supporting & Related Material,FDA-2018-P-3325-0015,FDA-2018-P-3325,Tab 13_Pfizer Report 5 re Citizen Petition from Pfizer Inc
090000648367bacd,Supporting & Related Material,FDA-2018-P-3325-0008,FDA-2018-P-3325,Tab 6_FDA Letter to USP re Citizen Petition from Pfizer Inc
090000648367bd2f,Supporting & Related Material,FDA-2018-P-3325-0009,FDA-2018-P-3325,Tab 7_2000 Draft Guidance re Citizen Petition from Pfizer Inc
090000648367bd33,Supporting & Related Material,FDA-2018-P-3325-0013,FDA-2018-P-3325,Tab 11_Pfizer Report 3 re Citizen Petition from Pfizer Inc
090000648367bac9,Supporting & Related Material,FDA-2018-P-3325-0004,FDA-2018-P-3325,Tab 2_Anderson et al re Citizen Petition from Pfizer Inc
090000648367bd31,Supporting & Related Material,FDA-2018-P-3325-0011,FDA-2018-P-3325,Tab 9_Pfizer Report 1 re Citizen Petition from Pfizer Inc
09000064836efb08,Other,FDA-2018-P-1197-0003,FDA-2018-P-1197,Interim Response from FDA CDER to Exela Pharma Sciences
090000648302b1df,Other,FDA-2018-P-1197-0002,FDA-2018-P-1197,Acknowledgment Letter from FDA DDM to Exela Pharma Sciences
090000648302b1dd,Other,FDA-2018-P-1197-0001,FDA-2018-P-1197,Citizen Petition from Exela Pharma Sciences
0900006481249279,Other,FDA-2012-N-1153-0011,FDA-2012-N-1153,National Sustainable Agriculture Coalition (NSAC) - Request for Extension
0900006481258f14,Notice,FDA-2012-N-1153-0002,FDA-2012-N-1153,Improvement of Tracking and Tracing of Food; Establishment of Pilot Projects and Congressional Report
0900006481218171,Notice,FDA-2012-N-1153-0001,FDA-2012-N-1153,Improvement of Tracking and Tracing of Food; Establishment of Pilot Projects and Congressional Report
090000648494b7cb,Other,FDA-2020-P-1369-0003,FDA-2020-P-1369,"Interim Response Letter from FDA CDER to Hyman, Phelps & McNamara, P.C."
09000064845b7087,Other,FDA-2020-P-1369-0002,FDA-2020-P-1369,"Acknowledgment Letter from FDA DMS to Hyman, Phelps & McNamara, P.C."
09000064845b7086,Other,FDA-2020-P-1369-0001,FDA-2020-P-1369,"Citizen Petition from Hyman, Phelps & McNamara, P.C."
0900006484c2475f,Other,FDA-2021-P-0476-0002,FDA-2021-P-0476,Acknowledgment Letter from FDA DMS to Marianne English
0900006484c2475d,Other,FDA-2021-P-0476-0001,FDA-2021-P-0476,Citizen Petition from Marianne English
0900006484c8da6f,Other,FDA-2021-P-0924-0001,FDA-2021-P-0924,Citizen Petition from Nancy Tanner
0900006484c8daba,Other,FDA-2021-P-0924-0002,FDA-2021-P-0924,Acknowledgment Letter from FDA DMS to Nancy Tanner
090000648053d428,Notice,FDA-2008-N-0222-0001,FDA-2008-N-0222,Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Orphan Drugs; Common European Medicines Agency/Food and Drug Administration Application Form for Orphan Medicinal Product Designation (Form FDA 3671)
0900006480bcfb66,Notice,FDA-2011-N-0015-0001,FDA-2011-N-0015,"Agency Information Collection Activities; Proposals, Submissions, and Approvals Form for Orphan Medicinal Product Designation (Form FDA 3671)"
0900006480f6bb8e,Notice,FDA-2011-N-0015-0003,FDA-2011-N-0015,"Agency Information Collection Activities; Proposals, Submissions, and Approvals: Application Form for Orphan Medicinal Product Designation"
09000064830e0589,Notice,FDA-2011-N-0015-0006,FDA-2011-N-0015,"Agency Information Collection Activities; Proposals, Submissions, and Approvals"
090000648322b662,Notice,FDA-2011-N-0015-0007,FDA-2011-N-0015,"Agency Information Collection Activities; Announcement of Office of
Management and Budget Approvals; Correction"
0900006480c79eda,Notice,FDA-2011-N-0015-0002,FDA-2011-N-0015,"Agency Information Collection Activities; Proposals, Submissions, and Approvals: Orphan Drugs; Common EMA/FDA Application formfor Orphan Medicinal Product Designation"
09000064826ece9f,Notice,FDA-2011-N-0015-0004,FDA-2011-N-0015,Agency Information Collection Activities; Proposed Collection; Comment Request; Orphan Drugs; Common European Medicines Agency/Food and Drug Administration Application Form for Orphan Drug Medicinal Product Designation
0900006482cfd0ff,Notice,FDA-2011-N-0015-0005,FDA-2011-N-0015,"Agency Information Collection Activities; Submission for Office of
Management and Budget Review; Comment Request; Orphan Products
Development; Food and Drug Administration Orphan Drug Designation Request Form and The Common European Medicines Agency/
Food and Drug Administration Form for Orphan Medicinal Product
Designation"
090000648216209e,Other,FDA-2016-P-2467-0001,FDA-2016-P-2467,Citizen Petition from Actavis LLC
090000648216209f,Other,FDA-2016-P-2467-0002,FDA-2016-P-2467,Acknowledgement Letter from FDA DDM to Actavis LLC
09000064826c7114,Other,FDA-2016-P-2467-0003,FDA-2016-P-2467,Withdrawal letter from Actavis LLC to FDA
09000064845e677c,Other,FDA-2020-D-1378-0001,FDA-2020-D-1378,"Guidance for Industry, FDA Staff, and Third Parties; Inspection by Accredited Persons Under The Medical Device User Fee and Modernization Act of 2002 and the FDA Amendments Act of 2007; Accreditation Criteria"
0900006483d6738a,Other,FDA-2019-P-3266-0002,FDA-2019-P-3266,"Acknowledgment Letter from FDA DDM to Medical Research Collaborative, LLC"
09000064842b394a,Other,FDA-2019-P-3266-0014,FDA-2019-P-3266,Interim Response letter to  Medical Research Collaborative LLC
0900006483d672b4,Other,FDA-2019-P-3266-0001,FDA-2019-P-3266,Citizen Petition from Medical Research Collaborative LLC
0900006484a6fb3c,Supporting & Related Material,FDA-2021-P-0301-0013,FDA-2021-P-0301,Reference 10 re Citizen Petition from Adrienne Samuels
0900006484a6fb5d,Supporting & Related Material,FDA-2021-P-0301-0017,FDA-2021-P-0301,Reference 14 re Citizen Petition from Adrienne Samuels
0900006484a6fb26,Supporting & Related Material,FDA-2021-P-0301-0004,FDA-2021-P-0301,Reference 1 re Citizen Petition from Adrienne Samuels
0900006484a6fb37,Supporting & Related Material,FDA-2021-P-0301-0009,FDA-2021-P-0301,Reference 6 re Citizen Petition from Adrienne Samuels
0900006484a6fb25,Supporting & Related Material,FDA-2021-P-0301-0003,FDA-2021-P-0301,Cover Letter for Citizen Petition from Adrienne Samuels
0900006484a6fb27,Supporting & Related Material,FDA-2021-P-0301-0005,FDA-2021-P-0301,Reference 2 re Citizen Petition from Adrienne Samuels
0900006484a6fb28,Supporting & Related Material,FDA-2021-P-0301-0006,FDA-2021-P-0301,Reference 3 re Citizen Petition from Adrienne Samuels
0900006484a6fb3e,Supporting & Related Material,FDA-2021-P-0301-0015,FDA-2021-P-0301,Reference 12 re Citizen Petition from Adrienne Samuels
0900006484a6fb35,Supporting & Related Material,FDA-2021-P-0301-0007,FDA-2021-P-0301,Reference 4 re Citizen Petition from Adrienne Samuels
0900006484a6fb3a,Supporting & Related Material,FDA-2021-P-0301-0011,FDA-2021-P-0301,Reference 8 re Citizen Petition from Adrienne Samuels
0900006484a6fb3d,Supporting & Related Material,FDA-2021-P-0301-0014,FDA-2021-P-0301,Reference 11 re Citizen Petition from Adrienne Samuels
0900006484a6fb3b,Supporting & Related Material,FDA-2021-P-0301-0012,FDA-2021-P-0301,Reference 9 re Citizen Petition from Adrienne Samuels
0900006484a6fb5f,Supporting & Related Material,FDA-2021-P-0301-0019,FDA-2021-P-0301,Reference 16 re Citizen Petition from Adrienne Samuels
0900006484a6fb5e,Supporting & Related Material,FDA-2021-P-0301-0018,FDA-2021-P-0301,Reference 15 re Citizen Petition from Adrienne Samuels
0900006484a6fb0b,Other,FDA-2021-P-0301-0001,FDA-2021-P-0301,Citizen Petition from Adrienne Samuels
0900006484d57afc,Other,FDA-2021-P-0301-0022,FDA-2021-P-0301,180 Letter from FDA CFSAN to Adrienne Samuels
0900006484a6fb36,Supporting & Related Material,FDA-2021-P-0301-0008,FDA-2021-P-0301,Reference 5 re Citizen Petition from Adrienne Samuels
0900006484a6fb22,Other,FDA-2021-P-0301-0002,FDA-2021-P-0301,Acknowledgment Letter from FDA DMS to Adrienne Samuels
0900006484a6fb39,Supporting & Related Material,FDA-2021-P-0301-0010,FDA-2021-P-0301,Reference 7 re Citizen Petition from Adrienne Samuels
0900006484a6fb5c,Supporting & Related Material,FDA-2021-P-0301-0016,FDA-2021-P-0301,Reference 13 re Citizen Petition from Adrienne Samuels
09000064834ca81a,Other,FDA-2018-N-1558-0002,FDA-2018-N-1558,Request for Extension from Animal Health Institute
09000064836373a5,Notice,FDA-2018-N-1558-0008,FDA-2018-N-1558,Food and Drug Administration’s Evaluation of Approaches To Demonstrate Effectiveness of Heart worm Preventatives for Dogs; Extension of Comment Period
09000064832d8bb3,Notice,FDA-2018-N-1558-0001,FDA-2018-N-1558,Food and Drug Administration’s Evaluation of Approaches To  Demonstrate Effectiveness of Heartworm Preventatives for Dogs; Request for Comments
09000064834d2fd0,Other,FDA-2018-N-1558-0003,FDA-2018-N-1558,Request for Extension from Animal Health Institute
0900006481807bd5,Other,FDA-2011-D-0215-0038,FDA-2011-D-0215,In Vitro Companion Diagnostic Devices; Guidance for Industry and Food and Drug Administration Staff
0900006481807376,Notice,FDA-2011-D-0215-0037,FDA-2011-D-0215,"In Vitro Companion Diagnostic Devices; Guidance for Industry and
FDA Staff; Availability"
0900006480ee570e,Notice,FDA-2011-D-0215-0003,FDA-2011-D-0215,Draft Guidance for Industry and Staff; Availability: In Vitro Companion Diagnostic Devices
0900006480ec350b,Other,FDA-2011-D-0215-0002,FDA-2011-D-0215,Draft Guidance for Industry and Food and Drug Administration Staff In Vitro Compaion Diagnostic Devices
0900006480ec1bf8,Notice,FDA-2011-D-0215-0001,FDA-2011-D-0215,Draft Guidance for Industry and FDA Staff; Availability In Vitro Companion Diagnostic Devices
0900006482f6513d,Supporting & Related Material,FDA-2018-P-0876-0005,FDA-2018-P-0876,"Attachment 3 re Citizen Petition from Hyman, Phelps _ McNamara, P_C-1"
0900006482f65024,Supporting & Related Material,FDA-2018-P-0876-0004,FDA-2018-P-0876,"Attachment 2 re Citizen Petition from Hyman, Phelps _ McNamara, P_C-1"
0900006482f649f9,Other,FDA-2018-P-0876-0001,FDA-2018-P-0876,"Citizen Petition from Hyman, Phelps & McNamara, P.C."
0900006482f649fb,Other,FDA-2018-P-0876-0002,FDA-2018-P-0876,"Acknowledgment Letter from FDA DDM to Hyman, Phelps & McNamara P.C."
0900006482f65023,Supporting & Related Material,FDA-2018-P-0876-0003,FDA-2018-P-0876,"Attachment 1 re Citizen Petition from Hyman, Phelps _ McNamara, P_C-1"
0900006482cc3c66,Supporting & Related Material,FDA-2017-N-6529-0002,FDA-2017-N-6529,List of References re The Food and Drug Administration’s Approach To Evaluating Nicotine Replacement Therapies; Public Hearing; Request for Comments
0900006482cc3c67,Supporting & Related Material,FDA-2017-N-6529-0003,FDA-2017-N-6529,Reference 1 Quitting smoking among adults - United States 2000-2015 re The Food and Drug Administration’s Approach To Evaluating Nicotine Replacement Therapies; Public Hearing; Request for Comments
0900006482cc0a02,Proposed Rule,FDA-2017-N-6529-0001,FDA-2017-N-6529,"The Food and Drug Administration’s Approach To Evaluating Nicotine
Replacement Therapies; Public Hearing; Request for Comments"
0900006482cc3c68,Supporting & Related Material,FDA-2017-N-6529-0004,FDA-2017-N-6529,Reference 2 Nicotine replacement therapty for long term smoking cessation a meta-analysis (1) re The Food and Drug Administration’s Approach To Evaluating Nicotine Replacement Therapies; Public Hearing; Request for Comments
0900006482cc3c69,Supporting & Related Material,FDA-2017-N-6529-0005,FDA-2017-N-6529,Reference 3 Meta-analysis on efficacy of nicotine replacement therapies in smoking cessation re The Food and Drug Administration’s Approach To Evaluating Nicotine Replacement Therapies; Public Hearing; Request for Comments
0900006484864851,Other,FDA-2020-D-1937-0001,FDA-2020-D-1937,Guidance for Industry: Frequently Asked Questions about FDA's Regulation of Infant Formula
090000648486484b,Other,FDA-2020-D-1930-0001,FDA-2020-D-1930,Guidance for Industry and FDA: Dear Manufacturer Letter Regarding Sugar Free Claims
090000648208827c,Other,FDA-2015-D-1839-0005,FDA-2015-D-1839,FDA’s Policy on Declaring Small Amounts of Nutrients and Dietary Ingredients on Nutrition Labels: Guidance for Industry
090000648208061e,Notice,FDA-2015-D-1839-0004,FDA-2015-D-1839,Guidance: Policy on Declaring Small Amounts of Nutrients and Dietary Ingredients on Nutrition Labels
0900006481bb0c28,Proposed Rule,FDA-2015-D-1839-0001,FDA-2015-D-1839,The Food and Drug Administration’s Policy on Declaring Small Amounts of Nutrients and Dietary Ingredients on Nutrition Labels; Draft Guidance for Industry; Availability
0900006481bb1fb9,Other,FDA-2015-D-1839-0002,FDA-2015-D-1839,FDA’s Policy on Declaring Small Amounts of Nutrients and Dietary Ingredients on Nutrition Labels Draft Guidance
0900006482e2a276,Other,FDA-2017-P-4409-0006,FDA-2017-P-4409,"Interim Response Letter from FDA CDER to Hyman, Phelps & McNamara, PC"
0900006484a15d24,Other,FDA-2017-P-4409-0007,FDA-2017-P-4409,"Response Letter from FDA CDER to Hyman, Phelps & McNamara, PC"
0900006482963dcd,Other,FDA-2017-P-4409-0002,FDA-2017-P-4409,"Acknowledgement Letter from FDA DDM to Hyman, Phelps & McNamara, PC"
0900006482963dcb,Other,FDA-2017-P-4409-0001,FDA-2017-P-4409,"Citizen Petition from Hyman, Phelps & McNamara, PC"
0900006482bcf132,Other,FDA-2017-P-4409-0004,FDA-2017-P-4409,Response  from  Synergy Pharmaceuticals to CDER
0900006481e131e7,Supporting & Related Material,FDA-2016-P-0147-0005,FDA-2016-P-0147,"Attachment 3 Consumer Study of Drained Weight re Citizen Petition from Bumble Bee Foods, LLC, et al."
0900006482c8d940,Other,FDA-2016-P-0147-0007,FDA-2016-P-0147,"Interim Response from FDA CFSAN to Bumble Bee Foods, LLC"
0900006481e131e5,Supporting & Related Material,FDA-2016-P-0147-0003,FDA-2016-P-0147,"Attachment 1 Existing Standard of Identity for 'Canned Tuna' re Citizen Petition from Bumble Bee Foods, LLC, et al."
0900006481e131e8,Supporting & Related Material,FDA-2016-P-0147-0006,FDA-2016-P-0147,"Attachment 4 AOAC Official Method 968.30 re Citizen Petition from Bumble Bee Foods, LLC, et al."
0900006481e131e6,Supporting & Related Material,FDA-2016-P-0147-0004,FDA-2016-P-0147,"Attachment 2 Proposed Amended Standard of Identity for 'Canned Tuna' re Citizen Petition from Bumble Bee Foods, LLC, et al."
0900006481e12d81,Other,FDA-2016-P-0147-0002,FDA-2016-P-0147,"Acknowledgement Letter from FDA DDM to Bumble Bee Foods, LLC"
0900006481e09695,Other,FDA-2016-P-0147-0001,FDA-2016-P-0147,"Citizen Petition from Bumble Bee Foods, LLC, et al."
0900006484b34ace,Other,FDA-2021-P-0497-0002,FDA-2021-P-0497,Acknowledgment Letter from FDA DMS to Valisure LLC
0900006484b34acc,Other,FDA-2021-P-0497-0001,FDA-2021-P-0497,Citizen Petition from Valisure LLC
0900006484b34b5a,Supporting & Related Material,FDA-2021-P-0497-0004,FDA-2021-P-0497,Attachment B - ACC Resolution - Chemical Variability in Pharmaceutical Products re Citizen Petition from Valisure LLC
0900006484e719ab,Other,FDA-2021-P-0497-0005,FDA-2021-P-0497,Interim Response Letter from FDA CDER to Valisure LLC
0900006484b34ad1,Supporting & Related Material,FDA-2021-P-0497-0003,FDA-2021-P-0497,Attachment A - Table 5  Product description of various batches of sunscreen for which benzene was not detected through initial analysis of at least one sample from each batch re Citizen Petition from Valisure LLC
090000648054bf90,Other,FDA-2006-P-0150-0004,FDA-2006-P-0150,"Lachman Consultant Services, Inc. - Amendment to Citizen Petition"
090000648045050e,Other,FDA-2006-P-0150-0001,FDA-2006-P-0150,"Acknowledgement Letter to Lachman Consultant Services, Inc."
0900006480450517,Other,FDA-2006-P-0150-0003,FDA-2006-P-0150,"Lachman Consultant Services, Inc. - Citizen Petition"
0900006480450518,Supporting & Related Material,FDA-2006-P-0150-0002,FDA-2006-P-0150,See: FDA-2006-P-0150-0001
0900006480bb6370,Other,FDA-2006-P-0150-0005,FDA-2006-P-0150,"FDA/CDER to Lachman Consultant Services, Inc. - Petition Approval"
0900006480a800a8,Other,FDA-2010-P-0045-0001,FDA-2010-P-0045,"Richard F. Edlich, M.D., Ph.D., et al - Citizen Petition"
0900006483093531,Other,FDA-2010-P-0045-0038,FDA-2010-P-0045,Memo and Combined Responses to Dr Edlich Citizen Petitions_Redacted
0900006480a800ac,Supporting & Related Material,FDA-2010-P-0045-0002,FDA-2010-P-0045,"Reference 1 - ""For Consumers, Medical Glove Powder Report of the Food and Drug Administration"" - [Richard F. Edlich, M.D., Ph.D., et al - Citizen Petition]"
0900006480a804b8,Other,FDA-2010-P-0045-0003,FDA-2010-P-0045,"Acknowledgement Letter to Richard F. Edlich, M.D., Ph.D., et al"
0900006483478bc3,Proposed Rule,FDA-2018-N-2309-0001,FDA-2018-N-2309,The Food and Drug Administration Predictive Toxicology Roadmap and Its Implementation; Public Hearing; Request for Comments
0900006483988d4b,Other,FDA-2018-D-4267-0002,FDA-2018-D-4267,"Draft Guidance for Industry, Biomarker Qualification Evidentiary Framework"
090000648398820d,Notice,FDA-2018-D-4267-0001,FDA-2018-D-4267,"Biomarker Qualification: Evidentiary Framework; Draft Guidance for
Industry and Food and Drug Administration Staff; Availability"
0900006481905189,Notice,FDA-2014-N-1575-0001,FDA-2014-N-1575,"Best Practices for Communication Between the Food and Drug
Administration and Investigational New Drug Sponsors During Drug
Development; Request for Comments"
09000064815fb451,Notice,FDA-2014-N-0225-0001,FDA-2014-N-0225,Announcement of Center for Biologics Evaluation and Research’s Move to the Food and Drug Administration’s White Oak Campus
0900006483b7b1c8,Other,FDA-2018-N-4751-0030,FDA-2018-N-4751,Request for Extension from Medical Imaging & Technology Alliance (MITA)
09000064839fff9c,Other,FDA-2018-N-4751-0002,FDA-2018-N-4751,Instructions for Submitting Comments - FDA-2018-N-4751
09000064839ffaca,Other,FDA-2018-N-4751-0001,FDA-2018-N-4751,Modernizing the Food and Drug Administration's 510(k) Program Request for Comments
09000064832ed3fe,Other,FDA-2018-P-2025-0002,FDA-2018-P-2025,Acknowledgement Letter from FDA DDM to Center for Biological Diversity
09000064833126ce,Other,FDA-2018-P-2025-0003,FDA-2018-P-2025,Acknowledgement letter from FDA DDM to the Center for Biological Diversity - correction
09000064838f5e71,Other,FDA-2018-P-2025-0013,FDA-2018-P-2025,Interim Response from FDA/CDER to Center for Biological Diversity
09000064832ed3f9,Other,FDA-2018-P-2025-0001,FDA-2018-P-2025,Citizen Petition from Center for Biological Diversity
0900006483d0e49f,Other,FDA-2019-P-2869-0001,FDA-2019-P-2869,"Citizen Petition from Valisure, LLC."
0900006483d0e922,Supporting & Related Material,FDA-2019-P-2869-0004,FDA-2019-P-2869,"Attachment B - ACC Resolution - Chemical Variability in Pharmaceutical Products re: Citizen Petition from Valisure, LLC"
09000064842659d0,Other,FDA-2019-P-2869-0006,FDA-2019-P-2869,"Interim Response Letter from FDA CDER to Valisure, LLC"
0900006483d0e9be,Other,FDA-2019-P-2869-0002,FDA-2019-P-2869,"Acknowledgment Letter from FDA DDM to Valisure, LLC"
0900006483d0e921,Supporting & Related Material,FDA-2019-P-2869-0003,FDA-2019-P-2869,"Attachment A - WHO and IARC classification of DMF 061119 re: Citizen Petition from  Valisure, LLC"
090000648457de9f,Other,FDA-2020-D-1353-0001,FDA-2020-D-1353,"Draft Guidance for Industry; Regulatory Submissions to OFAS, Part IX FDA References"
0900006484704a4c,Other,FDA-2019-P-4448-0004,FDA-2019-P-4448,Interim Response Letter from FDA CFSAN to Samuel A Gonzalez
0900006483fbd297,Other,FDA-2019-P-4448-0001,FDA-2019-P-4448,Citizen Petition from Samuel A. Gonzalez
0900006483fbd298,Other,FDA-2019-P-4448-0002,FDA-2019-P-4448,Acknowledgment Letter from FDA DMS to Samuel A. Gonzalez
0900006484121492,Supporting & Related Material,FDA-2019-P-5191-0010,FDA-2019-P-5191,Appendix 8 - Making a commitment to EVOO quality and achieving a consumer focus re: Citizen Petition from American Olive Oil Producers Association
09000064841240ba,Supporting & Related Material,FDA-2019-P-5191-0008,FDA-2019-P-5191,Appendix 5 OOCC Quality Database 2014-15 to 2018-19 re: Citizen Petition from American Olive Oil Producers Association
090000648412146f,Supporting & Related Material,FDA-2019-P-5191-0009,FDA-2019-P-5191,Appendix 7 - Informe analisis campañas 2017-2018 y 2018-2019 re: Citizen Petition from American Olive Oil Producers Association
09000064849f2e3b,Other,FDA-2019-P-5191-0017,FDA-2019-P-5191,Interim response letter from FDA CFSAN
0900006484121493,Supporting & Related Material,FDA-2019-P-5191-0011,FDA-2019-P-5191,Appendix 9 Olive Oil Chemistry in Argentina re: Citizen Petition from American Olive Oil Producers Association
090000648497d915,Other,FDA-2019-P-5191-0016,FDA-2019-P-5191,Letter from CFSAN to The Meriam Hospital
090000648412146d,Supporting & Related Material,FDA-2019-P-5191-0005,FDA-2019-P-5191,Appendix 3 Testing Project 2015-2019 US Market Data (v2) re: Citizen Petition from American Olive Oil Producers Association
090000648412146e,Supporting & Related Material,FDA-2019-P-5191-0006,FDA-2019-P-5191,Appendix 6 Theoretical and Practical Aspects of the Determination of Pyropheophythins and Isomeric Diacylglycerols re: Citizen Petition from American Olive Oil Producers Association
0900006484121494,Supporting & Related Material,FDA-2019-P-5191-0012,FDA-2019-P-5191,Appendix 10 Southern Hemisphere Olive Oil re: Citizen Petition from American Olive Oil Producers Association
09000064841240b9,Supporting & Related Material,FDA-2019-P-5191-0007,FDA-2019-P-5191,Appendix 4 Australian Oils Database re: Citizen Petition from American Olive Oil Producers Association
0900006484120fdb,Other,FDA-2019-P-5191-0001,FDA-2019-P-5191,Citizen Petition from American Olive Oil Producers Association
0900006484121469,Other,FDA-2019-P-5191-0002,FDA-2019-P-5191,Acknowledgment Letter from DMS to American Olive Oil Producers Association
090000648412146b,Supporting & Related Material,FDA-2019-P-5191-0003,FDA-2019-P-5191,Appendix 1 Proposed Regulations re: Citizen Petition from American Olive Oil Producers Association
0900006484121495,Supporting & Related Material,FDA-2019-P-5191-0013,FDA-2019-P-5191,Appendix 11 Presentation Minor Components to Determine Oil Authenticity-2 re: Citizen Petition from American Olive Oil Producers Association
09000064846d5e31,Other,FDA-2019-P-5191-0015,FDA-2019-P-5191,Amended Citizen Petition for Standards of Identity for Olive Oil and Olive-Pomace Oil and Apendix 1 from American Olive Oil Producers Association
090000648412146c,Supporting & Related Material,FDA-2019-P-5191-0004,FDA-2019-P-5191,Appendix 2 TECHNICAL SUPPORT DOCUMENT re: Citizen Petition from American Olive Oil Producers Association
090000648100a472,Other,FDA-1989-D-0191-0002,FDA-1989-D-0191,FDA Guide to Acceptance Market Names for Food Fish Sold in Interstate Commerce; Guidance
0900006480479290,Notice,FDA-1989-D-0191-0001,FDA-1989-D-0191,FDA Guide to Acceptance Market Names for Food Fish Sold in Interstate Commerce; Availability
09000064808094f2,Other,FDA-2008-P-0380-0004,FDA-2008-P-0380,FDA/CDER Interim Response to National Association of Chain Drug Stores - Letter
0900006480651815,Other,FDA-2008-P-0380-0001,FDA-2008-P-0380,"National Consumers League, et al - Citizen Petition"
09000064812c413d,Other,FDA-2008-P-0380-0008,FDA-2008-P-0380,"National Consumers League, et al (Olson, Frank, Weeda) - Withdrawal of Petition"
090000648065ae0d,Other,FDA-2008-P-0380-0002,FDA-2008-P-0380,Acknowledgement Letter  to National Consumers League
0900006480810eae,Other,FDA-2008-P-0380-0006,FDA-2008-P-0380,Memo to the File
090000648239c58b,Other,FDA-2016-P-3823-0002,FDA-2016-P-3823,Acknowledgment Letter from FDA DDM to Jennifer A. Osler
090000648239c589,Other,FDA-2016-P-3823-0001,FDA-2016-P-3823,Citizen Petition from Jennifer A. Osler
090000648380e931,Other,FDA-2016-P-3823-0003,FDA-2016-P-3823,Agency Response Letter from FDA CFSAN to Jennifer A. Osler
09000064820052bb,Other,FDA-2016-P-0618-0004,FDA-2016-P-0618,Letter from Emily Connor
09000064820066a3,Other,FDA-2016-P-0618-0003,FDA-2016-P-0618,Interim Response Letter from FDA CFSAN to Emily Connor
0900006481e7649a,Other,FDA-2016-P-0618-0001,FDA-2016-P-0618,Citizen Petition from Emily Connor
0900006481e766e6,Other,FDA-2016-P-0618-0002,FDA-2016-P-0618,Acknowledgement Letter from FDA DDM to Emily Connor
0900006484324f91,Notice,FDA-2019-N-6050-0001,FDA-2019-N-6050,Food and Drug Administration/Federal Trade Commission Workshop on a Competitive Marketplace for Biosimilars; Public Workshop; Request for Comments
0900006484459679,Other,FDA-2019-N-6050-0002,FDA-2019-N-6050,FDA FTC Public Workshop Slides
090000648466456d,Other,FDA-2019-D-1163-0001,FDA-2019-D-1163,Release of ORA Laboratory Analytical Results to the Responsible Party:  Guidance for Food and Drug Administration Staff
090000648390cf2c,Other,FDA-2017-D-5928-0008,FDA-2017-D-5928,Post-Complete Response Letter Meetings Between FDA and ANDA Applicants Under GDUFA Guidance for Industry
0900006483939624,Notice,FDA-2017-D-5928-0007,FDA-2017-D-5928,"Post-Complete Response Letter Meetings Between the Food and Drug
Administration and Abbreviated New Drug Application Applicants Under
Generic Drug User Fee Amendments; Guidance for Industry; Availability"
0900006482bcd99e,Notice,FDA-2017-D-5928-0001,FDA-2017-D-5928,"Post-Complete Response Letter Meetings Between the Food and Drug 
Administration and Abbreviated New Drug Application Applicants Under 
the Generic Drug User Fee Act; Draft Guidance for Industry; Availability"
0900006482bcddde,Other,FDA-2017-D-5928-0002,FDA-2017-D-5928,Guidance for Industry on Response Letter Meetings Between FDA and ANDA Applicants Under GDUFA
0900006484b2edd2,Other,FDA-2021-P-0495-0002,FDA-2021-P-0495,Acknowledgment Letter from FDA DMS to Hyman Phelps McNamara PC
0900006484b2edd5,Supporting & Related Material,FDA-2021-P-0495-0003,FDA-2021-P-0495,Attachment 1- Prescription Drug Product List  re Suitability Petition from HYMAN PHELPS MCNAMARA P.C.
0900006484b2edd6,Supporting & Related Material,FDA-2021-P-0495-0004,FDA-2021-P-0495,Attachment 2- HIGHLIGHTS OF PRESCRIBING INFORMATION for ZANAFLEX re Suitability Petition from HYMAN PHELPS MCNAMARA P.C.
0900006484b2ea55,Other,FDA-2021-P-0495-0001,FDA-2021-P-0495,Suitability Petition from HYMAN PHELPS MCNAMARA P.C.
0900006484b2ee3d,Supporting & Related Material,FDA-2021-P-0495-0005,FDA-2021-P-0495,Attachment 3 - TIZANIDINE HYDROCHLORIDE CAPSULES - tizanidine hydrochloride capsule re Suitability Petition from HYMAN PHELPS MCNAMARA P.C.
09000064849e89f4,Notice,FDA-2014-N-1031-0004,FDA-2014-N-1031,"Agency Information Collection Activities; Proposals, Submissions, and Approvals: Recall Regulations"
0900006484b63c15,Notice,FDA-2014-N-1031-0006,FDA-2014-N-1031,"Agency Information Collection 
Activities; Announcement of Office of 
Management and Budget Approvals"
0900006481ae0264,Notice,FDA-2014-N-1031-0003,FDA-2014-N-1031,"Agency Information Collection Activities; Announcement of Office of
Management and Budget Approval; FDA Recall Regulations"
09000064819fe9fd,Notice,FDA-2014-N-1031-0002,FDA-2014-N-1031,"Agency Information Collection Activities; Submission for Office of
Management and Budget Review; Comment Request; Food and Drug
Administration Recall Regulations"
0900006484aa1304,Notice,FDA-2014-N-1031-0005,FDA-2014-N-1031,"Agency Information Collection Activities; Proposals, Submissions, and Approvals: Food and Drug Administration Recall Regulations"
09000064817fdc07,Notice,FDA-2014-N-1031-0001,FDA-2014-N-1031,"Agency Information Collection Activities; Proposed Collection;
Comment Request; Food and Drug Administration Recall Regulations"
09000064824c02e7,Supporting & Related Material,FDA-2017-P-0867-0049,FDA-2017-P-0867,Attachment 47 - Kim2016  re Citizen Petition from Public Citizen
09000064824c02f7,Supporting & Related Material,FDA-2017-P-0867-0058,FDA-2017-P-0867,Attachment 56 - Meybohm2013-HES-Doseclaim  re Citizen Petition from Public Citizen
09000064824c02f8,Supporting & Related Material,FDA-2017-P-0867-0059,FDA-2017-P-0867,Attachment 57 - Muller2015-PostHocOfPerner2012  re Citizen Petition from Public Citizen
09000064824c02fc,Supporting & Related Material,FDA-2017-P-0867-0063,FDA-2017-P-0867,Attachment 61 - Myburgh2012_CHEST-SuppAppendix  re Citizen Petition from Public Citizen
09000064824c0300,Supporting & Related Material,FDA-2017-P-0867-0067,FDA-2017-P-0867,Attachment 65 - Myburgh2012_CHEST-Table2corrected2016  re Citizen Petition from Public Citizen
09000064824c0301,Supporting & Related Material,FDA-2017-P-0867-0068,FDA-2017-P-0867,Attachment 66 - Ozturk2015-CoronarySurgery  re Citizen Petition from Public Citizen
09000064824c0305,Supporting & Related Material,FDA-2017-P-0867-0072,FDA-2017-P-0867,Attachment 70 - Patel2013-Meta-analysis HES sepsis-supp  re Citizen Petition from Public Citizen
09000064824c0307,Supporting & Related Material,FDA-2017-P-0867-0074,FDA-2017-P-0867,Attachment 72 - Perel_Cochrane 2013  re Citizen Petition from Public Citizen
09000064824c0309,Supporting & Related Material,FDA-2017-P-0867-0076,FDA-2017-P-0867,Attachment 74 - Rioux2009  re Citizen Petition from Public Citizen
09000064824c0310,Supporting & Related Material,FDA-2017-P-0867-0083,FDA-2017-P-0867,Attachment 81 - van der Linden2013- Postmark Comm children HES vs Alb  re Citizen Petition from Public Citizen
09000064824c0311,Supporting & Related Material,FDA-2017-P-0867-0084,FDA-2017-P-0867,Attachment 82 - Urology Surgery  re Citizen Petition from Public Citizen
09000064824c031a,Supporting & Related Material,FDA-2017-P-0867-0093,FDA-2017-P-0867,Attachment 91 - Wiedermann2014-Systreview  re Citizen Petition from Public Citizen
09000064824c00ea,Supporting & Related Material,FDA-2017-P-0867-0003,FDA-2017-P-0867,Attachment 1 - Alexander1975-PlasmaExpanders re Citizen Petition from Public Citizen
09000064824c00ed,Supporting & Related Material,FDA-2017-P-0867-0006,FDA-2017-P-0867,Attachment 4 - Alexander1975-PlasmaExpanders-1 re Citizen Petition from Public Citizen
09000064824c00ef,Supporting & Related Material,FDA-2017-P-0867-0008,FDA-2017-P-0867,Attachment 6 - Allen_2014_TraumaPtxs  re Citizen Petition from Public Citizen
09000064824c00f6,Supporting & Related Material,FDA-2017-P-0867-0011,FDA-2017-P-0867,Attachment 9 - Allison1999-Randomized Trial of Hydroxyethyl Starch versus Gelatine for Trauma Resuscitation  re Citizen Petition from Public Citizen
09000064824c00fa,Supporting & Related Material,FDA-2017-P-0867-0015,FDA-2017-P-0867,Attachment 13 - Brunkhorst2008  re Citizen Petition from Public Citizen
09000064824c00ff,Supporting & Related Material,FDA-2017-P-0867-0020,FDA-2017-P-0867,Attachment 18 - EMA Assessment Report_reversal of ban  re Citizen Petition from Public Citizen
09000064824c02d1,Supporting & Related Material,FDA-2017-P-0867-0029,FDA-2017-P-0867,Attachment 27 - FDA Voluven Med Review  re Citizen Petition from Public Citizen
09000064824c02d2,Supporting & Related Material,FDA-2017-P-0867-0030,FDA-2017-P-0867,Attachment 28 - Gattas2013-v39-p558  re Citizen Petition from Public Citizen
09000064824c02d9,Supporting & Related Material,FDA-2017-P-0867-0035,FDA-2017-P-0867,Attachment 33 - Finfer2010-surveyICUs  re Citizen Petition from Public Citizen
09000064824c02da,Supporting & Related Material,FDA-2017-P-0867-0036,FDA-2017-P-0867,Attachment 34 - Haase2013-Meta-analysisSepsis-supp2  re Citizen Petition from Public Citizen
09000064824c02de,Supporting & Related Material,FDA-2017-P-0867-0040,FDA-2017-P-0867,Attachment 38 - Hartog_Natanson_coreviewBMJ2014  re Citizen Petition from Public Citizen
09000064824c02e0,Supporting & Related Material,FDA-2017-P-0867-0042,FDA-2017-P-0867,Attachment 40 - Haynes 2004  re Citizen Petition from Public Citizen
09000064824c02e2,Supporting & Related Material,FDA-2017-P-0867-0044,FDA-2017-P-0867,Attachment 42 - Hextend - 2014-11  re Citizen Petition from Public Citizen
090000648048b8b1,Supporting & Related Material,FDA-2003-D-0203-0002,FDA-2003-D-0203,Guidance
090000648048b8ac,Notice,FDA-2003-D-0203-0001,FDA-2003-D-0203,FDA
090000648048b8b2,Supporting & Related Material,FDA-2003-D-0203-0003,FDA-2003-D-0203,Guidance
090000648049879e,Supporting & Related Material,FDA-2003-D-0367-0005,FDA-2003-D-0367,GUIDANCE
090000648049879b,Notice,FDA-2003-D-0367-0004,FDA-2003-D-0367,FDA
0900006480498779,Supporting & Related Material,FDA-2003-D-0367-0002,FDA-2003-D-0367,Guidance
0900006480498740,Notice,FDA-2003-D-0367-0001,FDA-2003-D-0367,FDA
0900006480498786,Supporting & Related Material,FDA-2003-D-0367-0003,FDA-2003-D-0367,Guidance
09000064804994a5,Notice,FDA-2003-D-0376-0001,FDA-2003-D-0376,FDA
09000064804994dd,Supporting & Related Material,FDA-2003-D-0376-0002,FDA-2003-D-0376,Guideline
090000648046eb38,Other,FDA-2004-N-0058-0002,FDA-2004-N-0058,Draft Drug-Diagnostic Co-Development Concept Paper
090000648046eb30,Notice,FDA-2004-N-0058-0001,FDA-2004-N-0058,FDA
090000648457a822,Other,FDA-2004-D-0124-0006,FDA-2004-D-0124,"Saline, Silicone Gel, and Alternative Breast Implants  Guidance for Industry and FDA Staff"
090000648046fc25,Supporting & Related Material,FDA-2004-D-0124-0003,FDA-2004-D-0124,Guidance
090000648046fc8c,Supporting & Related Material,FDA-2004-D-0124-0005,FDA-2004-D-0124,Guidance
090000648046fc8b,Notice,FDA-2004-D-0124-0004,FDA-2004-D-0124,FDA
090000648046fc24,Supporting & Related Material,FDA-2004-D-0124-0002,FDA-2004-D-0124,Guidance
090000648046fc18,Notice,FDA-2004-D-0124-0001,FDA-2004-D-0124,FDA
090000648045648a,Supporting & Related Material,FDA-2006-D-0232-0002,FDA-2006-D-0232,Guidance
09000064804564ac,Notice,FDA-2006-D-0232-0003,FDA-2006-D-0232,FDA
09000064804564ad,Supporting & Related Material,FDA-2006-D-0232-0004,FDA-2006-D-0232,Guidance
0900006480456466,Notice,FDA-2006-D-0232-0001,FDA-2006-D-0232,FDA
09000064804b501a,Supporting & Related Material,FDA-2001-N-0017-0005,FDA-2001-N-0017,"OMB Information Collection Supporting Statement re General Licensing Provisions; Biologics License Application, Changes to an Approved Application, Labeling; and Revocation and Suspension 0910-0338"
09000064804b501d,Notice,FDA-2001-N-0017-0004,FDA-2001-N-0017,"Agency Information Collection Activities; Submission for OMB Review; Comment Request; General Licensing Provisions: Biologics License Application, Changes to an Approved Application, Labeling Forms FDA 356h and 2567; and Revocation and Suspension"
09000064804b4fc7,Notice,FDA-2001-N-0017-0001,FDA-2001-N-0017,"Agency Information Collection Activities; Proposed Collection; Comment Request; General Licensing Provisions: Biologics License Application, Changes to an Approved Application, Labeling Forms FDA 356h and 2567; and Revocation and Suspension"
09000064804b5017,Notice,FDA-2001-N-0017-0002,FDA-2001-N-0017,"Agency Information Collection Activities; Submission for OMB Review; Comment Request; General Licensing Provisions: Biologics License Application, Changes to an Approved Application, Labeling Forms FDA 356h and 2567; and Revocation and Suspension"
09000064806af2a4,Other,FDA-2008-D-0417-0002,FDA-2008-D-0417,Guidance for the Public and FDA Staff on Convening Advisory Committee Meetings - Draft Guidance
09000064806aed1d,Notice,FDA-2008-D-0417-0001,FDA-2008-D-0417,Draft Guidance for the Public and the Food and Drug Administration Staff on Convening Advisory Committee Meetings; Availability
0900006480b644b8,Notice,FDA-2010-N-0506-0001,FDA-2010-N-0506,Office of the Commissioner; Request for Comments: Food and Drug Administration Fiscal Year 2011-2015 Strategic Priorities Document; Requests for Comments
0900006480b95eb8,Other,FDA-2010-N-0506-0035,FDA-2010-N-0506,Jerome R. Schindler Food Regulatory Consultant - Letter re FDA-2010-N-0506-0034
0900006480b072f9,Other,FDA-2010-P-0322-0001,FDA-2010-P-0322,Amgen Inc. - Citizen Petition
0900006480b072fa,Other,FDA-2010-P-0322-0002,FDA-2010-P-0322,Acknowledgement Letter to Amgen Inc.
0900006480b51a1e,Other,FDA-2010-P-0322-0003,FDA-2010-P-0322,"Amgen, Inc. - Withdrawal"
0900006484dc2c2d,Other,FDA-2021-P-1099-0002,FDA-2021-P-1099,Acknowledgment Letter from FDA DMS to Pet Schooled
0900006484dc28b7,Other,FDA-2021-P-1099-0001,FDA-2021-P-1099,Citizen Petition from Pet Schooled
0900006483792a60,Supporting & Related Material,FDA-2018-P-3770-0004,FDA-2018-P-3770,Exhibit 2 Proposed Package Insert for Levocarnitine Injection re Citizen Petition from Luitpold Pharmaceuticals Inc
090000648379280a,Other,FDA-2018-P-3770-0001,FDA-2018-P-3770,Citizen Petition from Luitpold Pharmaceuticals Inc
0900006484921274,Other,FDA-2018-P-3770-0007,FDA-2018-P-3770,Letter from FDA CDER to Luitpold Pharmaceuticals Inc.
0900006483792a5f,Supporting & Related Material,FDA-2018-P-3770-0003,FDA-2018-P-3770,Exhibit 1 Package Insert for Leadiant Biosciences re Citizen Petition from Luitpold Pharmaceuticals Inc
090000648379722a,Other,FDA-2018-P-3770-0006,FDA-2018-P-3770,Corrected Acknowledgment Letter from FDA DDM to Luitpold Pharmaceuticals Inc
090000648379280c,Other,FDA-2018-P-3770-0002,FDA-2018-P-3770,Acknowledgment Letter from FDA DDM to Luitpold Pharmaceuticals Inc
0900006483792a61,Supporting & Related Material,FDA-2018-P-3770-0005,FDA-2018-P-3770,Exhibit 3 Side by Side Comparison re Citizen Petition from Luitpold Pharmaceuticals Inc
09000064838c243a,Other,FDA-2018-P-3545-0005,FDA-2018-P-3545,Letter from Arnall Golden Gregory LLP to FDA DDM
090000648425436d,Other,FDA-2018-P-3545-0008,FDA-2018-P-3545,Withdrawal from Arnall Golden Gregory LLP
0900006483c11f5a,Other,FDA-2018-P-3545-0007,FDA-2018-P-3545,Letter from ARNALL GOLDEN GREORY LLP to FDA DDM
0900006483723670,Other,FDA-2018-P-3545-0002,FDA-2018-P-3545,"Acknowledgment Letter from FDA DDM to Arnall Golden Gregory, LLP"
0900006483b01dc9,Other,FDA-2018-P-3545-0006,FDA-2018-P-3545,"Letter from FDA CDER to Arnall Golden Gregory, LLP"
09000064837235fa,Other,FDA-2018-P-3545-0001,FDA-2018-P-3545,"Citizen Petition from Arnall Golden Gregory, LLP"
0900006483723673,Supporting & Related Material,FDA-2018-P-3545-0004,FDA-2018-P-3545,"Attachment B re Citizen Petition from Arnall Golden Gregory, LLP"
0900006483723672,Supporting & Related Material,FDA-2018-P-3545-0003,FDA-2018-P-3545,"Attachment A re Citizen Petition from Arnall Golden Gregory, LLP"
0900006481e6622a,Other,FDA-2016-P-0542-0002,FDA-2016-P-0542,"Acknowledgement Letter from FDA DDM to Gordon Johnston Regulatory Consultants, LLC"
0900006481e6622e,Supporting & Related Material,FDA-2016-P-0542-0003,FDA-2016-P-0542,"Attachment A Electronic Orange Book Listing for Calcium Chloride; Potassium Chloride; Sodium Chloride; Sodium Lactate re Citizen Petition from Gordon Johnston Regulatory Consultants, LLC"
0900006482195e52,Other,FDA-2016-P-0542-0004,FDA-2016-P-0542,"Petition Approval Letter from FDA CDER to Gordon Johnston Regulatory Consultants, LLC"
0900006481e66579,Other,FDA-2016-P-0542-0001,FDA-2016-P-0542,"Citizen Petition from Gordon Johnston Regulatory Consultants, LLC"
090000648447bea9,Supporting & Related Material,FDA-2020-P-1236-0003,FDA-2020-P-1236,Attachment 1 re: Citizen Petition from Foley & Lardner LLP
090000648447b542,Other,FDA-2020-P-1236-0002,FDA-2020-P-1236,Acknowledgment Letter from FDA DMS to Foley & Lardner LLP
090000648447b48f,Other,FDA-2020-P-1236-0001,FDA-2020-P-1236,Citizen Petition from Foley & Lardner LLP
090000648488ff89,Other,FDA-2020-P-1236-0004,FDA-2020-P-1236,Denial Letter from FDA CDER to Foley & Lardner LLP
09000064840f11fe,Other,FDA-2018-P-2962-16596,FDA-2018-P-2962,Petition Response Letter from FDA CDER to Americans for Homeopathy Choice
0900006483996110,Supporting & Related Material,FDA-2018-P-2962-1922,FDA-2018-P-2962,Homeopathys Role in Addressing the Over-Medication Epidemic AFHC re:Citizen Petition from Americans for Homeopathy Choice
09000064838bc56b,Supporting & Related Material,FDA-2018-P-2962-0827,FDA-2018-P-2962,Homeopathy in Reducing Pain Medications AFHC FDA Paper re:Citizen Petition from Americans for Homeopathy Choice
09000064838bc57f,Supporting & Related Material,FDA-2018-P-2962-0828,FDA-2018-P-2962,Antibiotics AFHC FDA Paper re;Citizen Petition from Americans for Homeopathy Choice
090000648358625a,Other,FDA-2018-P-2962-0002,FDA-2018-P-2962,Acknowledgment Letter from FDA DDM to Americans for Homeopathy Choice
0900006483995cc3,Supporting & Related Material,FDA-2018-P-2962-1924,FDA-2018-P-2962,The Use of Homeopathy in European Hospitals- AFHC re:Citizen Petition from Americans for Homeopathy Choice
0900006483a69b53,Other,FDA-2018-P-2962-16090,FDA-2018-P-2962,Letter from FDA CDER to Americans for Homeopathy Choice
0900006483582faa,Other,FDA-2018-P-2962-0001,FDA-2018-P-2962,Citizen Petition from Americans for Homeopathy Choice
0900006483995cc4,Supporting & Related Material,FDA-2018-P-2962-1923,FDA-2018-P-2962,Homeopathys Role in Addressing the Healthcare Costs - AFHC re:Citizen Petition from Americans for Homeopathy Choice
0900006483c8eef4,Other,FDA-2018-P-2962-16529,FDA-2018-P-2962,Memorandum of Meeting - AFHC meeting with FDA CDER
09000064821533b7,Other,FDA-2016-P-0656-0004,FDA-2016-P-0656,Interim response
09000064843ee819,Other,FDA-2016-P-0656-0005,FDA-2016-P-0656,Citizen Petition Denial Response Letter from FDA CDER to Steven A. Zecola
0900006481e8071a,Other,FDA-2016-P-0656-0002,FDA-2016-P-0656,Acknowledgement Letter from FDA DDM to Steven Zecola
0900006481e80716,Other,FDA-2016-P-0656-0001,FDA-2016-P-0656,Citizen Petition from Steven Zecola
0900006484cac78d,Other,FDA-2021-P-0950-0001,FDA-2021-P-0950,Citizen Petition from Donna Duty
0900006484cace14,Other,FDA-2021-P-0950-0002,FDA-2021-P-0950,Acknowledgment Letter from FDA DMS to Donna Duty
0900006482ef93ad,Other,FDA-2018-P-0599-0002,FDA-2018-P-0599,"Acknowledgment Letter from FDA DDM to National Pediculosis Association, Inc"
0900006483779102,Other,FDA-2018-P-0599-0018,FDA-2018-P-0599,Interim Response from FDA OC to National Pediculosis Association
0900006482ef93ab,Other,FDA-2018-P-0599-0001,FDA-2018-P-0599,"Citizen Petition from National Pediculosis Association, Inc"
09000064842bb398,Other,FDA-2018-P-0599-0020,FDA-2018-P-0599,Final Response from FDA OC to National Pediculosis Association
0900006481a7a987,Other,FDA-2013-P-1378-0004,FDA-2013-P-1378,Supplement from William Schwemer
090000648172cf5e,Other,FDA-2013-P-1378-0003,FDA-2013-P-1378,Citizen Petition Interim Response from FDA CDER to  William L. Schwemer
0900006481486a0b,Other,FDA-2013-P-1378-0002,FDA-2013-P-1378,Acknowledgement Letter to William L. Schwemer
0900006484605e35,Other,FDA-2013-P-1378-0005,FDA-2013-P-1378,Denial Letter from FDA CDER  to William L. Schwemer
090000648148697d,Other,FDA-2013-P-1378-0001,FDA-2013-P-1378,William L. Schwemer - Citizen Petition
0900006484a3874c,Other,FDA-2021-P-0191-0002,FDA-2021-P-0191,Acknowledgment Letter from FDA DMS to Foley & Lardner LLP
0900006484c03d8f,Other,FDA-2021-P-0191-0005,FDA-2021-P-0191,Petition Response to Foley & Lardner LLP from FDA CDER
0900006484a38743,Other,FDA-2021-P-0191-0001,FDA-2021-P-0191,Citizen Petition from Foley & Lardner LLP
0900006484a38750,Supporting & Related Material,FDA-2021-P-0191-0003,FDA-2021-P-0191,Attachment re Citizen Petition from Foley & Lardner LLP
0900006484befc3e,Notice,FDA-2021-P-0191-0004,FDA-2021-P-0191,"Determination That STROMECTOL (Ivermectin) Tablets, 6 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
0900006484cac0e1,Other,FDA-2021-P-0949-0002,FDA-2021-P-0949,Acknowledgment Letter from FDA DMS to Harry Duty
0900006484cac06b,Other,FDA-2021-P-0949-0001,FDA-2021-P-0949,Citizen Petition from Harry Duty
0900006484dacd95,Other,FDA-2021-P-1044-0002,FDA-2021-P-1044,Acknowledgment Letter from FDA DMS to Dr. Laurie Coger
0900006484dab8f7,Other,FDA-2021-P-1044-0001,FDA-2021-P-1044,Citizen Petition from Dr. Laurie Coger
0900006484dfd49d,Other,FDA-2021-P-1178-0001,FDA-2021-P-1178,Citizen Petition from Pet Schooled
0900006484dfd49f,Other,FDA-2021-P-1178-0002,FDA-2021-P-1178,Acknowledgment Letter from FDA DMS to Pet Schooled
09000064843b6afe,Other,FDA-2020-P-0947-0001,FDA-2020-P-0947,"Citizen Petition from Hyman, Phelps and McNamara, P.C."
0900006484816f41,Other,FDA-2020-P-0947-0003,FDA-2020-P-0947,"Interim Response from FDA CDER to Hyman, Phelps &McNamara, P.C."
09000064843b6827,Other,FDA-2020-P-0947-0002,FDA-2020-P-0947,"Acknowledgment Letter from FDA DMS to Hyman, Phelps and Mcnamara, P.C."
0900006484865b86,Other,FDA-2020-P-0947-0004,FDA-2020-P-0947,"Letter from FDA CDER to Hyman, Phelps & McNamara, P.C."
0900006483e6dc27,Other,FDA-2019-P-3903-0002,FDA-2019-P-3903,"Acknowledgment Letter from FDA DMS to Hyman, Phelps & McNamara P.C."
0900006483e6dc26,Other,FDA-2019-P-3903-0001,FDA-2019-P-3903,"Citizen Petition from Hyman, Phelps & McNamara P.C."
09000064847c538b,Other,FDA-2019-P-3903-0004,FDA-2019-P-3903,"Approval Letter from FDA CDER to Hyman, Phelps & McNamara P C"
0900006484363105,Other,FDA-2019-P-3903-0003,FDA-2019-P-3903,"Interim Response Letter from FDA CDER to Hyman, Phelps & McNamara P C"
0900006484bf3afe,Other,FDA-2021-P-0700-0002,FDA-2021-P-0700,Acknowledgement Letter from FDA DMS to Eric Nault
0900006484bf3543,Other,FDA-2021-P-0700-0001,FDA-2021-P-0700,Citizen Petition from Eric Nault
0900006484ad442e,Other,FDA-2021-P-0436-0002,FDA-2021-P-0436,Acknowledgment Letter from FDA DMS to Pet Schooled
0900006484dfdec4,Other,FDA-2021-P-0436-0003,FDA-2021-P-0436,Response Letter from FDA CVM to Pet Schooled
0900006484ad4539,Other,FDA-2021-P-0436-0001,FDA-2021-P-0436,Citizen Petition from Pet Schooled
0900006481f7cc81,Other,FDA-2016-P-1171-0002,FDA-2016-P-1171,"Acknowledgement Letter from FDA DDM to  Breast Cancer Fund, Center for Food Safety, Center for Environmental Health, Center for Science in the Public Interest, Consumer Federation of America, Earthjustice Environmental Defense Fund, Improving Kids’ Environment (IKE), Learning Disabilities Association of America, Natural Resources Defense Council"
090000648238c887,Other,FDA-2016-P-1171-0004,FDA-2016-P-1171,Interim Response Letter from FDA CFSAN to Breast Cancer Fund
0900006481f7ca25,Other,FDA-2016-P-1171-0001,FDA-2016-P-1171,"Citizen Petition from Breast Cancer Fund, Center for Food Safety, Center for Environmental Health, Center for Science in the Public Interest, Consumer Federation of America, Earthjustice, Environmental Defense Fund, Improving Kids’ Environment (IKE), Learning Disabilities Association of America, Natural Resources Defense Council"
0900006481f7cc83,Supporting & Related Material,FDA-2016-P-1171-0003,FDA-2016-P-1171,"Attachment 1 – Natural Resources Defense Council, et al To Dr. Nennis Keefe  re Citizen petition requesting that FDA remove its prior sanction of five ortho-phthalates and ban eight ortho-phthalates"
09000064832de824,Other,FDA-2014-P-1256-0004,FDA-2014-P-1256,Response Letter from FDA CDER to Public Citizen's Health Research Group
09000064817e6157,Other,FDA-2014-P-1256-0001,FDA-2014-P-1256,Citizen Petition from Public Citizen
0900006481e4518d,Other,FDA-2014-P-1256-0003,FDA-2014-P-1256,Interim Response Letter from FDA CDER to Public Citizen's Health Research Group
090000648185aee6,Other,FDA-2014-P-1256-0002,FDA-2014-P-1256,Acknowledgement Letter from FDA DDM to Public Citizen
0900006481b0a63e,Other,FDA-2015-P-1903-0002,FDA-2015-P-1903,"Acknowledgement Letter from FDA DDM to Matawan Pharmaceuticals, LLC"
0900006481b0a162,Other,FDA-2015-P-1903-0001,FDA-2015-P-1903,"Citizen Petition from Matawan Pharmaceuticals, LLC"
0900006481c3bc5a,Other,FDA-2015-P-3139-0001,FDA-2015-P-3139,Citizen Petition from Kimberly Kideckel
0900006482374277,Other,FDA-2015-P-3139-0003,FDA-2015-P-3139,Interim Response Letter from CFSAN to Kimberly Kideckel
0900006483b695c9,Other,FDA-2015-P-3139-0004,FDA-2015-P-3139,Letter from FDA CFSAN to Kimberly Kideckel
0900006481c3cdb2,Other,FDA-2015-P-3139-0002,FDA-2015-P-3139,Acknowledgement Letter from FDA DDM to Kimberly Kideckel
090000648346cd26,Other,FDA-2018-P-2506-0002,FDA-2018-P-2506,Acknowledgment Letter from FDA DDM to K&L Gates LLP
090000648346c846,Other,FDA-2018-P-2506-0001,FDA-2018-P-2506,Citizen Petition from K&L Gates LLP
09000064838cf132,Other,FDA-2018-P-2506-0004,FDA-2018-P-2506,Letter from FDA CDER to K&L Gates LLP re Citizen Petition
09000064838bb374,Notice,FDA-2018-P-2506-0003,FDA-2018-P-2506,"Determination That AXIRON (Testosterone) Transdermal Metered
Solution, 30 Milligrams/1.5 Milliliter Actuation, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
0900006483603a26,Supporting & Related Material,FDA-2018-P-3139-0003,FDA-2018-P-3139,"Attachment 1 re Citizen Petition from Hyman, Phelps & McNamara, P C"
0900006483603a28,Supporting & Related Material,FDA-2018-P-3139-0005,FDA-2018-P-3139,"Attachment 3 re Citizen Petition from Hyman, Phelps & McNamara, P C"
09000064836039fd,Other,FDA-2018-P-3139-0001,FDA-2018-P-3139,"Citizen Petition from Hyman, Phelps & McNamara, P C"
09000064836039ff,Other,FDA-2018-P-3139-0002,FDA-2018-P-3139,"Acknowledgment Letter from FDA DDM to Hyman, Phelps & McNamara"
0900006483603a27,Supporting & Related Material,FDA-2018-P-3139-0004,FDA-2018-P-3139,"Attachment 2 re Citizen Petition from Hyman, Phelps & McNamara, P C"
09000064846b5c82,Other,FDA-2020-D-1434-0001,FDA-2020-D-1434,CPG Sec. 130.300  FDA Access to Results of Quality Assurance Program Audits and Inspections
0900006484a469be,Other,FDA-2018-P-0884-0005,FDA-2018-P-0884,Response Letter from FDA CDER to Buchanan Ingersoll & Rooney PC ( on behalf of Synergy Pharmaceuticals  Inc.)
0900006482f68335,Other,FDA-2018-P-0884-0002,FDA-2018-P-0884,Acknowledgment Letter from FDA DDM to Buchanan Ingersoll & Rooney PC ( on behalf of Synergy Pharmaceuticals  Inc.)
0900006483642f4d,Other,FDA-2018-P-0884-0004,FDA-2018-P-0884,Interim Response Letter from FDA CDER to Buchanan Ingersoll & Rooney PC
0900006482f68292,Other,FDA-2018-P-0884-0001,FDA-2018-P-0884,Citizen Petition from Buchanan Ingersoll & Rooney PC ( on behalf of Synergy Pharmaceuticals  Inc.)
0900006484a2ca76,Other,FDA-2020-P-2225-0012,FDA-2020-P-2225,Reply from Siri & Glimstad LLP
0900006484974012,Other,FDA-2020-P-2225-0001,FDA-2020-P-2225,Citizen Petition from Siri & Glimstad LLP on behalf of Dr Sin Hang Lee
090000648499c481,Other,FDA-2020-P-2225-0008,FDA-2020-P-2225,SOA Denial Letter from FDA CBER  to Siri & Glimstad LLP
09000064849740da,Supporting & Related Material,FDA-2020-P-2225-0003,FDA-2020-P-2225,All Resources re Citizen Petition from Siri & Glimstad LLP on behalf of Dr Sin Hang Lee
0900006484974013,Other,FDA-2020-P-2225-0002,FDA-2020-P-2225,Acknowledgment Letter from FDA DMS to Siri & Glimstad LLP on behalf of Dr Sin Hang Lee
090000648497923f,Other,FDA-2020-P-2225-0004,FDA-2020-P-2225,Stay of Action Petition from Siri & Glimstad LLP on behalf of Dr Sin Hang Lee
0900006484a9aa03,Supporting & Related Material,FDA-2018-P-3354-0025,FDA-2018-P-3354,References from International Contrast Ultrasound Society (ICUS) part 6 of 7
0900006484a9a90e,Supporting & Related Material,FDA-2018-P-3354-0022,FDA-2018-P-3354,References from International Contrast Ultrasound Society (ICUS) part 3 of 7
09000064836a76ee,Supporting & Related Material,FDA-2018-P-3354-0003,FDA-2018-P-3354,Attachment re Citizen Petition from International Contrast Ultrasound Society
0900006484a9a8f2,Supporting & Related Material,FDA-2018-P-3354-0021,FDA-2018-P-3354,References from International Contrast Ultrasound Society (ICUS) part 2 of 7
0900006484a9a9c9,Supporting & Related Material,FDA-2018-P-3354-0024,FDA-2018-P-3354,References from International Contrast Ultrasound Society (ICUS) part 5 of 7
09000064836a76ec,Other,FDA-2018-P-3354-0002,FDA-2018-P-3354,Acknowledgment Letter from FDA DDM to International Contrast Ultrasound Society
0900006484a9a980,Supporting & Related Material,FDA-2018-P-3354-0023,FDA-2018-P-3354,References from International Contrast Ultrasound Society (ICUS) part 4 of 7
0900006484a9a837,Supporting & Related Material,FDA-2018-P-3354-0020,FDA-2018-P-3354,References from International Contrast Ultrasound Society (ICUS) part 1 of 7
0900006484a9aace,Supporting & Related Material,FDA-2018-P-3354-0026,FDA-2018-P-3354,References from International Contrast Ultrasound Society (ICUS) part 7 of 7
0900006484862c7c,Other,FDA-2018-P-3354-0018,FDA-2018-P-3354,Citizen Petition from International Contrast Ultrasound Society
09000064836a76d1,Other,FDA-2018-P-3354-0001,FDA-2018-P-3354,Citizen Petition from International Contrast Ultrasound Society
090000648486323e,Other,FDA-2018-P-3354-0019,FDA-2018-P-3354,Acknowledgment Letter from FDA DMS to International Contrast Ultrasound Society
0900006483b134d4,Other,FDA-2018-P-3354-0017,FDA-2018-P-3354,"Letter from FDA CDER to RUSH UNIVERSITY MEDICAL CENTER, MID-AMERICA HEART INSTITUTE/SAINT LUKE'S HEALTH SYSTEM, UNIVERSITY OF MICHIGAN HEALTH SYSTEM, UNIVERSITY OF SOUTHERN CALIFORNIA"
0900006484b35c8b,Supporting & Related Material,FDA-2021-P-0510-0003,FDA-2021-P-0510,"Attachment 1 - ATACAND - Prescription Drug Product List RE Suitability Petition from Hyman, Phelps & McNamara, P.C."
0900006484b384f1,Other,FDA-2021-P-0510-0002,FDA-2021-P-0510,"Acknowledgment Letter from FDA DMS to Hyman, Phelps & McNamara, P.C."
0900006484b384ef,Other,FDA-2021-P-0510-0001,FDA-2021-P-0510,"Suitability Petition from Hyman, Phelps & McNamara, P.C."
0900006484b35c8c,Supporting & Related Material,FDA-2021-P-0510-0004,FDA-2021-P-0510,"Attachment 2 - ATACAND PI - ATACAND- candes artan cilexetil tablet RE Suitability Petition from Hyman, Phelps & McNamara, P.C."
0900006484b35c8d,Supporting & Related Material,FDA-2021-P-0510-0005,FDA-2021-P-0510,"Attachment 3 - Candesartan Cilexetil PI - HIGHLIGHTS OF PRESCRIBING INFORMATION RE Suitability Petition from Hyman, Phelps & McNamara, P.C."
090000648049a9bb,Other,FDA-2002-P-0245-0007,FDA-2002-P-0245,Acknowledgment Letter From FDA DDM to Lachman Consultant Services
090000648049a9c6,Other,FDA-2002-P-0245-0003,FDA-2002-P-0245,"Final Response from FDA CDER to Lachman Consultant Services, Inc."
090000648049a96d,Other,FDA-2002-P-0245-0001,FDA-2002-P-0245,"Interim Response From FDA CDER to Lachman Consultant Services, Inc."
090000648049a9a8,Other,FDA-2002-P-0245-0005,FDA-2002-P-0245,"Citizen Petition From Lachman Consultant Services, Inc. SHIPPING LABEL"
090000648049a9b6,Other,FDA-2002-P-0245-0006,FDA-2002-P-0245,"Citizen Petition From Lachman Consultant Services, Inc."
090000648049a9c3,Notice,FDA-2002-P-0245-0002,FDA-2002-P-0245,FDA Determination that Wydase (Hyaluronidase) Inj. was not Withdrawn for Safety or Effectiveness Reasons 68 FR 62810
0900006481f94776,Other,FDA-1993-P-0060-0003,FDA-1993-P-0060,Letter from CVM to DDM to Close Docket
0900006481f94774,Other,FDA-1993-P-0060-0002,FDA-1993-P-0060,Letter from CVM to United Animal Owners Association
09000064804fc7a6,Other,FDA-1993-P-0060-0001,FDA-1993-P-0060,FDA/CVM Interim Response to United Animal Owners Association - Letter
0900006480b10748,Other,FDA-2010-N-0218-0021,FDA-2010-N-0218,"Ernest Dummann, National MPS Society - Testimony"
0900006480b03705,Other,FDA-2010-N-0218-0009,FDA-2010-N-0218,OC/FDA - Agenda
0900006480b1079e,Other,FDA-2010-N-0218-0025,FDA-2010-N-0218,"Art Kessler, Dystonia Medical Research Foundation - Testimony"
0900006480b10710,Other,FDA-2010-N-0218-0016,FDA-2010-N-0218,"Tracy VanHoutan, Batten Disease Support and Research Association (BDSRA) - Testimony"
0900006480b107ad,Other,FDA-2010-N-0218-0028,FDA-2010-N-0218,"Amy Waterhouse, BioMarin Pharmaceutical Inc. - Testimony"
0900006480b1fa30,Other,FDA-2010-N-0218-0035,FDA-2010-N-0218,FDA/Rare Disease Review Group - Roster
0900006480b10738,Other,FDA-2010-N-0218-0019,FDA-2010-N-0218,"Emil D. Kakkis, M.D., Ph.D., Kakkis EveryLife Foundation - Testimony"
0900006480b1072d,Other,FDA-2010-N-0218-0017,FDA-2010-N-0218,"Mary Gustafson, PPTA - Testimony"
0900006480b107d0,Other,FDA-2010-N-0218-0029,FDA-2010-N-0218,"Miriam O'Day, Alpha-1 Foundation - Testimony"
0900006480b1070a,Other,FDA-2010-N-0218-0013,FDA-2010-N-0218,"Diane Edquist Dorman, NORD - Testimony"
0900006480b1070c,Other,FDA-2010-N-0218-0014,FDA-2010-N-0218,"John L. P. (Seamus) Thompson, PhD et al, Columbia University - Testimony"
0900006480ae4437,Notice,FDA-2010-N-0218-0001,FDA-2010-N-0218,"Considerations Regarding Food and Drug Administration Review and Regulation of Articles, for the Treatment of Rare Diseases; Public Hearing"
0900006480b10750,Other,FDA-2010-N-0218-0024,FDA-2010-N-0218,"Chris Hempel, Addi & Cassi Fund - Testimony"
0900006480b1074c,Other,FDA-2010-N-0218-0022,FDA-2010-N-0218,"Sharon F. Terry, MA, Genetic Alliance - Testimony"
0900006480b107a3,Other,FDA-2010-N-0218-0027,FDA-2010-N-0218,"Ferdinand Massari, MD, Shire Human Genetic Therapies - Testimony"
0900006480b1070e,Other,FDA-2010-N-0218-0015,FDA-2010-N-0218,"Teresa Hickman, MDJunction.com - Testimony"
0900006480b1f9ce,Other,FDA-2010-N-0218-0034,FDA-2010-N-0218,FDA - Transcript
0900006480b0310c,Other,FDA-2010-N-0218-0007,FDA-2010-N-0218,OC/FDA - Agenda
0900006480b10733,Other,FDA-2010-N-0218-0018,FDA-2010-N-0218,"Jonathan Jacoby, R.A.R.E. - Testimony"
0900006480b107a1,Other,FDA-2010-N-0218-0026,FDA-2010-N-0218,"Susan Alpert, AdvaMed - Testimony"
0900006480b1074e,Other,FDA-2010-N-0218-0023,FDA-2010-N-0218,"Mark Weinberg, M.D., Lundbeck, Inc - Testimony"
0900006480b10746,Other,FDA-2010-N-0218-0020,FDA-2010-N-0218,"Dayton T. Reardan, PhD. RAC - Testimony"
09000064811a0d33,Other,FDA-2011-P-0768-0007,FDA-2011-P-0768,"Acknowledgement Letter to Physicians for Integrity in Medical Research, Inc."
090000648115f177,Other,FDA-2011-P-0768-0005,FDA-2011-P-0768,"FDA/CDER to Physicians for Integrity in Medical Research, Inc. - Denial"
09000064811a0d03,Other,FDA-2011-P-0768-0006,FDA-2011-P-0768,"Physicians for Integrity in Medical Research, Inc. - Petition for Reconsideration"
0900006480f5a19e,Other,FDA-2011-P-0768-0002,FDA-2011-P-0768,"Acknowledgement Letter to Physicians for Integrity in Medical Research, Inc."
0900006480f5a19c,Other,FDA-2011-P-0768-0001,FDA-2011-P-0768,"Physicians for Integrity in Medical Research, Inc. - Citizen Petition"
0900006480ff3387,Other,FDA-2011-P-0768-0003,FDA-2011-P-0768,"FDA/CDER to Physicians for Integrity in Medical Research, Inc. - Letter"
090000648124f7fe,Other,FDA-2011-P-0768-0009,FDA-2011-P-0768,"Physicians for Integrity in Medical Research, Inc. Response to FDA/CDER - Letter"
0900006481360c6b,Other,FDA-2011-P-0768-0010,FDA-2011-P-0768,"FDA/CDER to Physicians for Integrity in Medical Research, Inc. - Denial of Reconsideration Petition"
09000064830e8c05,Other,FDA-2018-P-1448-0002,FDA-2018-P-1448,"Acknowledgment Letter from FDA DDM to Hyman, Phelps & McNamara on behalf of Collegium Pharmaceutical, Inc"
09000064830e8633,Other,FDA-2018-P-1448-0001,FDA-2018-P-1448,"Citizen Petition from Hyman, Phelps & McNamara, PC on behalf of Collegium Pharmaceutical, Inc"
09000064836b458b,Other,FDA-2018-P-1448-0004,FDA-2018-P-1448,"Letter from FDA CDER to Hyman, Phelps & McNamara, P.C."
090000648342ddad,Supporting & Related Material,FDA-2018-P-2362-0005,FDA-2018-P-2362,"Attachment 3 - Proposed Labeling re: Citizen Petition from Lachman Consultant Services, Inc."
090000648342dda8,Supporting & Related Material,FDA-2018-P-2362-0003,FDA-2018-P-2362,"Attachment 1-Orange Book details re: Citizen Petition from Lachman Consultant Services, Inc."
090000648342d88d,Other,FDA-2018-P-2362-0002,FDA-2018-P-2362,Acknowledgement Letter from FDA DDM to Lachman Consultant Services
090000648342d990,Other,FDA-2018-P-2362-0001,FDA-2018-P-2362,"Citizen Petition from Lachman Consultant Services, Inc."
090000648342ddab,Supporting & Related Material,FDA-2018-P-2362-0004,FDA-2018-P-2362,"Attachment 2-Approved labeling for the RLD, VOTRIENT (pazopanib) Tablets re: Citizen Petition from Lachman Consultant Services, Inc."
0900006481f57013,Notice,FDA-2013-N-0519-0003,FDA-2013-N-0519,"Agency Information Collection Activities; Proposals, Submissions, and Approvals: Guidance for Industry on How To Submit Information in Electronic Format to the Center for Veterinary Medicine Using the FDA Electronic Submission Gateway"
0900006482407453,Notice,FDA-2013-N-0519-0006,FDA-2013-N-0519,"Agency Information Collection Activities; Announcement of Office of
Management and Budget Approvals"
09000064813d23c6,Notice,FDA-2013-N-0519-0002,FDA-2013-N-0519,"Agency Information Collection Activities; Proposals, Submissions, and Approvals: Guidance for Industry No. 108 on How to Submit Information in Electronic Format to the Center for Veterinary Medicine, etc."
09000064812e7501,Notice,FDA-2013-N-0519-0001,FDA-2013-N-0519,Agency Information Collection Activities; Proposed Collection; Comment Request; Guidance for Industry on How To Submit Information in Electronic Format to Center for Veterinary Medicine Using the Food and Drug Administration’s Electronic Submission Gateway
09000064822911d9,Notice,FDA-2013-N-0519-0005,FDA-2013-N-0519,"Agency Information Collection Activities; Submission for Office of
Management and Budget Review; Comment Request; Guidance for
Industry on How To Submit Information in Electronic Format to the
Center for Veterinary Medicine Using the Food and Drug Administration
Electronic Submission Gateway"
0900006482d5085f,Other,FDA-2014-P-0862-0004,FDA-2014-P-0862,Final Response From CDER to The Alliance for Natural Health USA
090000648175f69b,Other,FDA-2014-P-0862-0001,FDA-2014-P-0862,Citizen Petition from the Alliance for Natural Health USA
090000648175f69d,Other,FDA-2014-P-0862-0002,FDA-2014-P-0862,Acknowledgement Letter from FDA DDM to the Alliance for Natural Health USA
0900006481986da3,Other,FDA-2014-P-0862-0003,FDA-2014-P-0862,Interim Response From CDER to The Alliance for Natural Health USA
0900006481167317,Notice,FDA-2012-N-0911-0001,FDA-2012-N-0911,Privacy Act; Systems of Records
0900006481fc9f0b,Other,FDA-2014-P-0856-0011,FDA-2014-P-0856,Final Response Petition Denial FDA-2014-P-0856
0900006481af2964,Other,FDA-2014-P-0856-0008,FDA-2014-P-0856,Memorandum from FDA CDER dated 4-23-2015
0900006481af2966,Other,FDA-2014-P-0856-0010,FDA-2014-P-0856,FDA Conference Call April 2015 Presentation Redacted
090000648175d779,Other,FDA-2014-P-0856-0002,FDA-2014-P-0856,Acknowledgement Letter from FDA DDM to the Southern Network on Adverse Reactions (SONAR)
0900006481981de8,Other,FDA-2014-P-0856-0007,FDA-2014-P-0856,Interim Response From CDER to SONAR
0900006481af2965,Other,FDA-2014-P-0856-0009,FDA-2014-P-0856,FDA Conference Call April 2015 Presentation
090000648175d777,Other,FDA-2014-P-0856-0001,FDA-2014-P-0856,Citizen Petition from the Southern Network on Adverse Reactions
09000064812394ce,Other,FDA-2013-P-0335-0002,FDA-2013-P-0335,Acknowledgement Letter to Foley & Lardner LLP
090000648133c1a9,Other,FDA-2013-P-0335-0003,FDA-2013-P-0335,Foley & Lardner LLP - Withdrawal of Petition
0900006481239487,Other,FDA-2013-P-0335-0001,FDA-2013-P-0335,Foley & Lardner LLP - Citizen Petition
0900006481a426c3,Notice,FDA-2015-D-0198-0004,FDA-2015-D-0198,"Current Good Manufacturing Practice Requirements for Combination
Products; Draft Guidance for Industry and Food and Drug Administration
Staff; Extension of Comment Period"
09000064819e13e4,Notice,FDA-2015-D-0198-0001,FDA-2015-D-0198,"Current Good Manufacturing Practice Requirements for Combination
Products; Draft Guidance for Industry and Food and Drug Administration
Staff; Availability"
090000648245ba0b,Other,FDA-2015-D-0198-0028,FDA-2015-D-0198,Guidance for Industry and FDA Staff: Current Good Manufacturing Practice Requirements for Combination Products FINAL GUIDANCE
09000064819e1c14,Other,FDA-2015-D-0198-0002,FDA-2015-D-0198,"Current Good Manufacturing Practice Requirements for Combination
Products; Draft Guidance for Industry and Food and Drug Administration
Staff"
090000648245af31,Notice,FDA-2015-D-0198-0027,FDA-2015-D-0198,"Current Good Manufacturing Practice Requirements for Combination
Products; Guidance for Industry and Food and Drug Administration Staff;
Availability"
0900006481a3b4a1,Other,FDA-2015-D-0198-0005,FDA-2015-D-0198,Request for Extension from Parenteral Drug Association
0900006481a02c53,Other,FDA-2015-D-0198-0003,FDA-2015-D-0198,Request for an Extension from Combination Products Coalition CPC
0900006482158c55,Supporting & Related Material,FDA-2016-N-1678-0002,FDA-2016-N-1678,Reference 01 - FVM SP 2016-2025 re The Food and Drug Administration Foods and Veterinary Medicine Program’s Strategic Plan for Fiscal Years 2016–2025
09000064820ad167,Notice,FDA-2016-N-1678-0001,FDA-2016-N-1678,"The Food and Drug Administration Foods and Veterinary Medicine
Program’s Strategic Plan for Fiscal Years 2016–2025"
0900006482158c56,Supporting & Related Material,FDA-2016-N-1678-0003,FDA-2016-N-1678,Reference 02 - Partnership for Food Protection Strategic Plan re The Food and Drug Administration Foods and Veterinary Medicine Program’s Strategic Plan for Fiscal Years 2016–2025
09000064849200f4,Supporting & Related Material,FDA-2020-P-2096-0003,FDA-2020-P-2096,Cover letter from Siri & Glimstad LLP on behalf of Informed Consent Action Network
0900006484a577a1,Other,FDA-2020-P-2096-0009,FDA-2020-P-2096,Denial of Citizen Petition for Siri & Glimstad LLP
0900006484973e70,Supporting & Related Material,FDA-2020-P-2096-0008,FDA-2020-P-2096,Footnotes 2 through 37 re Citizen Petition from Siri & Glimstad LLP on behalf of Informed Consent Action Network
090000648491ff67,Other,FDA-2020-P-2096-0002,FDA-2020-P-2096,Acknowledgment Letter from FDA DMS to Siri & Glimstad LLP on behalf of Informed Consent Action Network
09000064849200f5,Other,FDA-2020-P-2096-0001,FDA-2020-P-2096,Citizen Petition from Siri & Glimstad LLP on behalf of Informed Consent Action Network
0900006484a8899a,Other,FDA-2020-P-2096-0011,FDA-2020-P-2096,Acknowledgment Letter from FDA DMS to  Siri & Glimstad LLP on behalf of Informed Consent Action Network
0900006484a88935,Other,FDA-2020-P-2096-0010,FDA-2020-P-2096,Petition for Reconsideration from Siri & Glimstad LLP on behalf of Informed Consent Action Network
0900006484921475,Supporting & Related Material,FDA-2020-P-2096-0004,FDA-2020-P-2096,Footnotes 2 through 37 re Citizen Petition from Siri & Glimstad LLP on behalf of Informed Consent Action Network
0900006484bfdd1b,Other,FDA-2021-P-0761-0002,FDA-2021-P-0761,Acknowledgment Letter from FDA DMS to International Maple Syrup Institute
0900006484bfdd19,Other,FDA-2021-P-0761-0001,FDA-2021-P-0761,Citizen Petition from International Maple Syrup Institute
0900006480ec7053,Other,FDA-2005-P-0136-0003,FDA-2005-P-0136,"FDA/OC Commissioner for Policy, Planning and Budget Response to Public Citizen - Petition Denial"
090000648043fe3e,Other,FDA-2005-P-0136-0002,FDA-2005-P-0136,HFA-305 to Public Citizen's Health Research Group
090000648043fe3b,Other,FDA-2005-P-0136-0001,FDA-2005-P-0136,HFA-305 to Public Citizen's Health Research Group
0900006480b0a919,Other,FDA-2007-D-0076-0004,FDA-2007-D-0076,Guidance for Industry and Food and Drug Administration Staff: In Vitro Diagnostic Studies; Frequently Asked Questions
09000064804298a4,Supporting & Related Material,FDA-2007-D-0076-0002,FDA-2007-D-0076,FDA/CDRH/CBER
090000648042989f,Notice,FDA-2007-D-0076-0001,FDA-2007-D-0076,FDA
0900006480b0a038,Notice,FDA-2007-D-0076-0003,FDA-2007-D-0076,Guidance for Industry and Food and Drug Administration Staff: In Vitro Diagnostic Studies; Frequently Asked Questions; Availability
09000064804565b8,Notice,FDA-2006-D-0233-0004,FDA-2006-D-0233,FDA
09000064804565c3,Notice,FDA-2006-D-0233-0006,FDA-2006-D-0233,FDA
0900006480456723,Other,FDA-2006-D-0233-0008,FDA-2006-D-0233,Transcript of the 2/8/07 Public Meeting
090000648045656b,Supporting & Related Material,FDA-2006-D-0233-0002,FDA-2006-D-0233,Guidance
0900006480456727,Other,FDA-2006-D-0233-0010,FDA-2006-D-0233,FDA and 21st Century Medicine Coalition
0900006480456740,Other,FDA-2006-D-0233-0013,FDA-2006-D-0233,FDA to Personalized Medicine Coalition
0900006480456754,Other,FDA-2006-D-0233-0015,FDA-2006-D-0233,FDA
0900006480456574,Supporting & Related Material,FDA-2006-D-0233-0003,FDA-2006-D-0233,Guidance
090000648045651d,Notice,FDA-2006-D-0233-0001,FDA-2006-D-0233,FDA
09000064804565b9,Notice,FDA-2006-D-0233-0005,FDA-2006-D-0233,FDA
0900006480456734,Notice,FDA-2006-D-0233-0011,FDA-2006-D-0233,FDA
0900006480456736,Supporting & Related Material,FDA-2006-D-0233-0012,FDA-2006-D-0233,Guidance
0900006480456752,Other,FDA-2006-D-0233-0014,FDA-2006-D-0233,FDA
0900006480456738,Other,FDA-2006-D-0233-0019,FDA-2006-D-0233,21st Century Medicine - Request for Extension of Comment Due Date
09000064804567f8,Notice,FDA-2006-D-0233-0017,FDA-2006-D-0233,FDA
0900006480456722,Other,FDA-2006-D-0233-0007,FDA-2006-D-0233,Transcript of the 2/8/07 Public Meeting
090000648045673c,Other,FDA-2006-D-0233-0020,FDA-2006-D-0233,"NANOGEN, Inc - Request for Extension Comment Due Date"
09000064804565b0,Other,FDA-2006-D-0233-0018,FDA-2006-D-0233,"Aureon Laboratories, Inc. - Request Extension of Comment Due Date"
0900006480456757,Other,FDA-2006-D-0233-0016,FDA-2006-D-0233,FDA
0900006480456725,Other,FDA-2006-D-0233-0009,FDA-2006-D-0233,Transcript of the 2/8/07 Public Meeting
0900006484e03fb8,Supporting & Related Material,FDA-2021-P-1180-0003,FDA-2021-P-1180,"Attachment 1 re Suitability Petition from HYMAN, PHELPS & MCNAMARA, P.C."
0900006484e03fb9,Supporting & Related Material,FDA-2021-P-1180-0004,FDA-2021-P-1180,"Attachment 2 re Suitability Petition from HYMAN, PHELPS & MCNAMARA, P.C."
0900006484e03f89,Supporting & Related Material,FDA-2021-P-1180-0005,FDA-2021-P-1180,"Attachment 3 re Suitability Petition from HYMAN, PHELPS & MCNAMARA, P.C."
0900006484e02648,Other,FDA-2021-P-1180-0002,FDA-2021-P-1180,Acknowledgment Letter from FDA DMS to HYMAN PHELPS and MCNAMARA P.C.
0900006484e01d26,Other,FDA-2021-P-1180-0001,FDA-2021-P-1180,"Suitability Petition from HYMAN, PHELPS & MCNAMARA, P.C."
090000648179b470,Other,FDA-2012-P-1160-0004,FDA-2012-P-1160,Citizen Petition Denial Response from FDA CDER to Steven A. Zecola
09000064812bbe64,Other,FDA-2012-P-1160-0003,FDA-2012-P-1160,FDA/CDER Interim Response to Steven A. Zecola - Letter
0900006481171dfe,Other,FDA-2012-P-1160-0002,FDA-2012-P-1160,Acknowledgement Letter to Steven A. Zecola
0900006481171dfc,Other,FDA-2012-P-1160-0001,FDA-2012-P-1160,Steven A. Zecola - Citizen Petition
0900006482f6501b,Supporting & Related Material,FDA-2018-P-0878-0004,FDA-2018-P-0878,"Attachment 2 re Citizen Petition from Hyman, Phelps & McNamara, P.C"
0900006482f64bb0,Supporting & Related Material,FDA-2018-P-0878-0005,FDA-2018-P-0878,"Attachment 1 Orange Book re Citizen Petition from Hyman, Phelps & McNamara, P.C"
0900006482f64ba7,Other,FDA-2018-P-0878-0002,FDA-2018-P-0878,"Acknowledgment Letter from FDA DDM to Hyman, Phelps & McNamara"
0900006482f64ee7,Other,FDA-2018-P-0878-0001,FDA-2018-P-0878,"Citizen Petition from Hyman, Phelps & McNamara, P.C"
0900006482f6501c,Supporting & Related Material,FDA-2018-P-0878-0003,FDA-2018-P-0878,"Attachment 3 re Citizen Petition from Hyman, Phelps & McNamara, P.C"
0900006481a185e1,Other,FDA-2015-P-0613-0001,FDA-2015-P-0613,"Citizen Petition From Qilu Pharma, Inc."
0900006481a185e3,Other,FDA-2015-P-0613-0002,FDA-2015-P-0613,"Acknowledgement Letter From FDA DDM to Qilu Pharma, Inc."
0900006481c30b27,Other,FDA-2015-P-0613-0003,FDA-2015-P-0613,"Interim Response Letter from FDA CDER to Qilu Pharmaceutical Co., Ltd."
0900006481fd177a,Other,FDA-2015-P-0613-0004,FDA-2015-P-0613,Final Petition Response Partial Approval Partial Denial
0900006481b2d702,Other,FDA-2015-P-2142-0004,FDA-2015-P-2142,Acknowledgement Letter from FDA DDM to Public Citizen
0900006481b2d7d8,Supporting & Related Material,FDA-2015-P-2142-0002,FDA-2015-P-2142,Appendix A Proposed Indication for Tasimelteon as Stated in FDA Reviews and Memos re Citizen Petition from Public Citizen
09000064842f8fc6,Other,FDA-2015-P-2142-0006,FDA-2015-P-2142,Response Letter from FDA CDER to Public Citizen
0900006481d8b21a,Other,FDA-2015-P-2142-0005,FDA-2015-P-2142,Interim Response Letter from FDA CDER to Public Citizen
0900006481b2e4b8,Supporting & Related Material,FDA-2015-P-2142-0003,FDA-2015-P-2142,Appendix B Proposed Label Changes re Citizen Petition from Public Citizen
0900006481b2d700,Other,FDA-2015-P-2142-0001,FDA-2015-P-2142,Citizen Petition from Public Citizen
0900006481fe88de,Other,FDA-2016-P-1314-0001,FDA-2016-P-1314,Citizen Petition from Center for Responsible Science (CRS)
0900006481fe969e,Supporting & Related Material,FDA-2016-P-1314-0003,FDA-2016-P-1314,Attachment 1 Skin and Eye Irritation Testing for Topically Applied Products: Questions and Answers Draft Guidance for Industry re Citizen Petition from Center for Responsible Science (CRS)
09000064823547de,Other,FDA-2016-P-1314-0004,FDA-2016-P-1314,Interim Response from FDA CDER to Center for Responsible Science
0900006481fe969c,Other,FDA-2016-P-1314-0002,FDA-2016-P-1314,Acknowledgement Letter from FDA DDM to  Center for Responsible Science (CRS)
0900006484a39012,Other,FDA-2021-N-0175-0001,FDA-2021-N-0175,Virtual Public Meeting: FDA Rare Disease Day 2021
0900006484b35c14,Other,FDA-2021-P-0509-0001,FDA-2021-P-0509,"Suitability Petition from Hyman, Phelps & McNamara, P.C."
0900006484b35c8a,Supporting & Related Material,FDA-2021-P-0509-0005,FDA-2021-P-0509,"Attachment 3 - Diclofenac Potassium PI - Diclofenac Potassium Tablets, USP 25 mg, 50 mg and 75 mg RE Suitability Petition from Hyman, Phelps & McNamara, P.C."
0900006484b35c88,Supporting & Related Material,FDA-2021-P-0509-0003,FDA-2021-P-0509,"Attachment 1 - CATAFLAM - Discontinued Drug Product List RE Suitability Petition from Hyman, Phelps & McNamara, P.C."
0900006484b35c89,Supporting & Related Material,FDA-2021-P-0509-0004,FDA-2021-P-0509,"Attachment 2 - CATAFLAM PI (diclofenac potassium immediate-release tablets) RE Suitability Petition from Hyman, Phelps & McNamara, P.C."
0900006484b35c16,Other,FDA-2021-P-0509-0002,FDA-2021-P-0509,"Acknowledgement Letter from FDA DMS to Hyman, Phelps & McNamara, P.C."
0900006484c96090,Supporting & Related Material,FDA-2021-P-0928-0003,FDA-2021-P-0928,"Attachment 1 re Suitability Petition from HYMAN, PHELPS & MCNAMARA, P.C."
0900006484c971e8,Supporting & Related Material,FDA-2021-P-0928-0005,FDA-2021-P-0928,"Attachment 2 re Suitability Petition from HYMAN, PHELPS & MCNAMARA, P.C."
0900006484c96432,Other,FDA-2021-P-0928-0001,FDA-2021-P-0928,"Suitability Petition from HYMAN, PHELPS & MCNAMARA, P.C."
0900006484c96d08,Other,FDA-2021-P-0928-0002,FDA-2021-P-0928,"Acknowledgment Letter from FDA DMS to HYMAN, PHELPS & MCNAMARA, P.C."
0900006484c96092,Supporting & Related Material,FDA-2021-P-0928-0004,FDA-2021-P-0928,"Attachment 3 re Suitability Petition from HYMAN, PHELPS & MCNAMARA, P.C."
0900006484285be9,Supporting & Related Material,FDA-2020-P-0158-0003,FDA-2020-P-0158,Attachments 1-10 re: Citizen Petition from Sidley Austin LLP on behalf of Vifor Pharma
0900006484285be3,Other,FDA-2020-P-0158-0001,FDA-2020-P-0158,Citizen Petition from Sidley Austin LLP on behalf of Vifor Pharma
09000064842862c7,Other,FDA-2020-P-0158-0002,FDA-2020-P-0158,"Acknowledgment Letter from FDA DMS to Sidley Austin, LLP on behalf of Vifor Pharma"
0900006484285beb,Supporting & Related Material,FDA-2020-P-0158-0005,FDA-2020-P-0158,Attachments 21-27 re: Citizen Petition from Sidley Austin LLP on behalf of Vifor Pharma
0900006484285bea,Supporting & Related Material,FDA-2020-P-0158-0004,FDA-2020-P-0158,Attachments 11-20 re: Citizen Petition from Sidley Austin LLP on behalf of Vifor Pharma
0900006484286114,Supporting & Related Material,FDA-2020-P-0158-0006,FDA-2020-P-0158,Attachments 28-32 re: Citizen Petition from Sidley Austin LLP on behalf of Vifor Pharma
0900006481e88ebd,Other,FDA-2016-P-0713-0002,FDA-2016-P-0713,Acknowledgement Letter from FDA DDM to Pernix Therapeutics
0900006481e88eb9,Other,FDA-2016-P-0713-0001,FDA-2016-P-0713,Citizen Petition from Pernix Therapeutics
090000648211dc50,Other,FDA-2016-P-0713-0003,FDA-2016-P-0713,Citizen Petition Denial Letter to Pernix Therapeutics
0900006481755911,Other,FDA-2014-P-0825-0001,FDA-2014-P-0825,Citizen Petition from Orthofix Inc.
09000064817559a5,Supporting & Related Material,FDA-2014-P-0825-0005,FDA-2014-P-0825,Attachment D Bar Code Label Requirement Citizen Petition From Orthofix Inc.
0900006481d1c0f9,Other,FDA-2014-P-0825-0007,FDA-2014-P-0825,Supplement from Orthofix Inc.
090000648197f2df,Other,FDA-2014-P-0825-0006,FDA-2014-P-0825,Interim Response Letter from FDA/CDRH to Orthofix Inc
0900006483d9cd8c,Other,FDA-2014-P-0825-0009,FDA-2014-P-0825,Withdrawal of Citizen Petition Letter from Orthofix to FDA DDM
090000648175591e,Other,FDA-2014-P-0825-0002,FDA-2014-P-0825,Acknowledgement Letter from FDA DDM to Orthofix Inc.
09000064817559a3,Supporting & Related Material,FDA-2014-P-0825-0004,FDA-2014-P-0825,Attachment B FDA Guidance for Industry Citizen Petition From Orthofix Inc.
0900006481755924,Supporting & Related Material,FDA-2014-P-0825-0003,FDA-2014-P-0825,Attachment A List of Implants Citizen Petition From Orthofix Inc.
0900006481cf4287,Other,FDA-2014-P-0825-0008,FDA-2014-P-0825,"Amendment from Orthofix, Inc."
0900006484485cc3,Other,FDA-2020-P-1247-0002,FDA-2020-P-1247,"Acknowledgment Letter from FDA DMS to Belcher Pharmaceuticals, LLC"
09000064844861c7,Supporting & Related Material,FDA-2020-P-1247-0003,FDA-2020-P-1247,"Attachment 1 Tacrolimus_cap_50708_RV12-12 BE guidances re Citizen Petition from Belcher Pharmaceuticals, LLC"
0900006484485cc2,Other,FDA-2020-P-1247-0001,FDA-2020-P-1247,"Citizen Petition from Belcher Pharmaceuticals, LLC"
09000064848745fe,Other,FDA-2020-P-1247-0005,FDA-2020-P-1247,"Interim Response Letter from FDA CDER to Belcher Pharmaceuticals, LLC"
0900006483262ddd,Rule,FDA-2018-D-1378-0001,FDA-2018-D-1378,The Food and Drug Administration Food Safety Modernization Act; Extension and Clarification of Compliance Dates for Certain Provisions of Four Implementing Rules: What You Need To Know About the Food and Drug Administration Regulation; Small Entity Compliance Guide; Availibility
09000064832695b0,Other,FDA-2018-D-1378-0002,FDA-2018-D-1378,The FDA Food Safety Modernization Act; Extension and Clarification of Compliance Dates for Certain Provisions of Four Implementing Rules: What You Need to Know About the FDA Regulation: Guidance for Industry - Small Entity Compliance Guide
09000064845e6be2,Other,FDA-2020-D-1379-0001,FDA-2020-D-1379,"Guidance for  Industry, FDA Staff, and FDA-Acredited Third Parties; Manufacturer’s Notification of the Intent to Use an Accredited Person under the Accredited Persons Inspection Program Authorized by Section 228 of the Food and Drug Administration Amendments Act of
2007 (FDAAA"
09000064831abb50,Supporting & Related Material,FDA-2018-P-1593-0013,FDA-2018-P-1593,Djousse et al_ 2016-1 Egg consumption and risk of type 2 diabetes: a meta-analysis of prospective studies re Citizen Petition from Pete and Gerry’s Organics LLC
09000064831ac42d,Supporting & Related Material,FDA-2018-P-1593-0026,FDA-2018-P-1593,O'Neil et al_ 2012_Supplement re Citizen Petition from Pete and Gerry’s Organics LLC
09000064831ac42e,Supporting & Related Material,FDA-2018-P-1593-0027,FDA-2018-P-1593,Richard et al_ 2017 re Citizen Petition from Pete and Gerry’s Organics LLC
09000064831ac432,Supporting & Related Material,FDA-2018-P-1593-0031,FDA-2018-P-1593,Speeches by FDA Officials _ Reducing the Burden of Chronic Disease re Citizen Petition from Pete and Gerry’s Organics LLC
09000064831ac4a1,Supporting & Related Material,FDA-2018-P-1593-0037,FDA-2018-P-1593,"USDA_National Nutrient Database for Standard Reference_ 01123, Egg, whole, raw, fresh_2018 re Citizen Petition from Pete and Gerry’s Organics LLC"
09000064831ac4a2,Supporting & Related Material,FDA-2018-P-1593-0038,FDA-2018-P-1593,Use of the Term _Healthy_ in the Labeling of Human Food Products_Request for Information and Comments-1 re Citizen Petition from Pete and Gerry’s Organics LLC
09000064831ac4a5,Supporting & Related Material,FDA-2018-P-1593-0041,FDA-2018-P-1593,Wallace and Fulgoni 2017 Usual Choline Intakes Are Associated with Egg and Protein Food Consumption in the United Statesre Citizen Petition from Pete and Gerry’s Organics LLC
09000064831ab9ec,Supporting & Related Material,FDA-2018-P-1593-0003,FDA-2018-P-1593,"Alexander et al_ 2016 Meta-analysis of Egg Consumption and Risk of
Coronary Heart Disease and Stroke re Citizen Petition from Pete and Gerry’s Organics LLC"
09000064831ab0d0,Other,FDA-2018-P-1593-0002,FDA-2018-P-1593,Acknowledgment Letter from FDA DDM to Pete and Gerry's Organics LLC
09000064831ab0cc,Other,FDA-2018-P-1593-0001,FDA-2018-P-1593,Citizen Petition from Pete and Gerry's Organics LLC
09000064831abb48,Supporting & Related Material,FDA-2018-P-1593-0007,FDA-2018-P-1593,"Blesso and Fernandez 2018 Dietary Cholesterol, Serum Lipids, and Heart Disease: Are Eggs Working for or Against You? re Citizen Petition from Pete and Gerry’s Organics LLC"
09000064831abc89,Supporting & Related Material,FDA-2018-P-1593-0021,FDA-2018-P-1593,IOM Food and Nutrition Board 1998 re Citizen Petition from Pete and Gerry’s Organics LLC
09000064831ac2e7,Supporting & Related Material,FDA-2018-P-1593-0014,FDA-2018-P-1593,Eckel et al_ 2013_Erratum 2014 re Citizen Petition from Pete and Gerry’s Organics LLC
09000064831ac2ec,Supporting & Related Material,FDA-2018-P-1593-0019,FDA-2018-P-1593,FDA_Labeling and Nutrition _ Changes to the Nutrition Facts Label re Citizen Petition from Pete and Gerry’s Organics LLC
09000064831ac434,Supporting & Related Material,FDA-2018-P-1593-0033,FDA-2018-P-1593,"The Australian Heart Foundation, Eggs re Citizen Petition from Pete and Gerry’s Organics LLC"
09000064831ac436,Supporting & Related Material,FDA-2018-P-1593-0035,FDA-2018-P-1593,"Tian et al_ 2017_compressed Dietary Protein Consumption and the Risk of Type 2 Diabetes: A Systematic Review and Meta-Analysis of
Cohort Studies re Citizen Petition from Pete and Gerry’s Organics LLC"
09000064831ac2e9,Supporting & Related Material,FDA-2018-P-1593-0016,FDA-2018-P-1593,Egg Nutrition Center_Nutrients in Eggs 2018 re Citizen Petition from Pete and Gerry’s Organics LLC
09000064831ac430,Supporting & Related Material,FDA-2018-P-1593-0029,FDA-2018-P-1593,Scientific Report of the 2015 Dietary Guidelines Advisory Committee 2015_Appendix-E-3_7 re Citizen Petition from Pete and Gerry’s Organics LLC
09000064831ac433,Supporting & Related Material,FDA-2018-P-1593-0032,FDA-2018-P-1593,"Tamez et al_ 2016 Egg consumption and risk of incident type 2 diabetes:
a dose–response meta-analysis of prospective cohort studies re Citizen Petition from Pete and Gerry’s Organics LLC"
09000064831ac435,Supporting & Related Material,FDA-2018-P-1593-0034,FDA-2018-P-1593,"The New Zealand Heart Foundation, Eggs and the Heart 2017 re Citizen Petition from Pete and Gerry’s Organics LLC"
09000064831ac4a3,Supporting & Related Material,FDA-2018-P-1593-0039,FDA-2018-P-1593,"Van Horn et al_ 2016 Recommended Dietary Pattern to Achieve Adherence to the American Heart Association/American College
of Cardiology (AHA/ACC) Guidelinesre Citizen Petition from Pete and Gerry’s Organics LLC"
09000064831abb49,Supporting & Related Material,FDA-2018-P-1593-0008,FDA-2018-P-1593,"British Heart Foundation, Healthy eating re Citizen Petition from Pete and Gerry’s Organics LLC"
09000064831abb4d,Supporting & Related Material,FDA-2018-P-1593-0010,FDA-2018-P-1593,Dietary Guidelines for Americans 2010 re Citizen Petition from Pete and Gerry’s Organics LLC
09000064831abb4e,Supporting & Related Material,FDA-2018-P-1593-0011,FDA-2018-P-1593,Dietary Guidelines for Americans 2015-2020-ilovepdf-compressed re Citizen Petition from Pete and Gerry’s Organics LLC
09000064831abb4f,Supporting & Related Material,FDA-2018-P-1593-0012,FDA-2018-P-1593,Djousse et al_ 2016 Egg consumption and risk of type 2 diabetes: a meta-analysis of prospective studies re Citizen Petition from Pete and Gerry’s Organics LLC
0900006483638781,Other,FDA-2018-P-3222-0002,FDA-2018-P-3222,Acknowledgment Letter from FDA DDM to Foley & Lardner LLP
09000064836385c0,Other,FDA-2018-P-3222-0001,FDA-2018-P-3222,Citizen Petition from Foley & Lardner LLP
09000064839b46fb,Other,FDA-2018-P-3222-0003,FDA-2018-P-3222,Citizen Petition Withdrawal Letter from Foley & Lardner LLP
090000648435335d,Supporting & Related Material,FDA-2020-P-0745-0003,FDA-2020-P-0745,Appendix 1 re Citizen Petition from Fox Rothschild LLP
0900006484353359,Other,FDA-2020-P-0745-0001,FDA-2020-P-0745,Citizen Petition from Fox Rothschild LLP
090000648435335a,Other,FDA-2020-P-0745-0002,FDA-2020-P-0745,Acknowledgment Letter from FDA DMS to Fox Rothschild LLP
09000064845fd281,Other,FDA-2020-P-0745-0004,FDA-2020-P-0745,Approval Letter from FDA CDER to Fox Rothschild LLP
0900006482a52426,Other,FDA-2017-P-5027-0002,FDA-2017-P-5027,Acknowledgement Letter from FDA DDM to Wilson Disease Association
0900006482a5242e,Supporting & Related Material,FDA-2017-P-5027-0009,FDA-2017-P-5027,Tab 7_Schilsky Costly Choices for Treating Wilson's Disease re Citizen Petition from Wilson Disease Association
0900006482a52429,Supporting & Related Material,FDA-2017-P-5027-0004,FDA-2017-P-5027,Tab 2_FDA Approval Information for NDA 019194 re Citizen Petition from Wilson Disease Association
0900006482a5242d,Supporting & Related Material,FDA-2017-P-5027-0008,FDA-2017-P-5027,Tab 6_OGD Annual Report 2016 re Citizen Petition from Wilson Disease Association
0900006482f2df3c,Other,FDA-2017-P-5027-0010,FDA-2017-P-5027,Response Letter from FDA CDER to Wilson Disease Association
0900006482a5242a,Supporting & Related Material,FDA-2017-P-5027-0005,FDA-2017-P-5027,Tab 3_Syprine Prescribing Information re Citizen Petition from Wilson Disease Association
0900006482a5242b,Supporting & Related Material,FDA-2017-P-5027-0006,FDA-2017-P-5027,Tab_4 Senate Special Committee on Aging_Drug Pricing Report re Citizen Petition from Wilson Disease Association
0900006482a5242c,Supporting & Related Material,FDA-2017-P-5027-0007,FDA-2017-P-5027,Tab 5_Orange Book Information for NDA 019194 re Citizen Petition from Wilson Disease Association
0900006482a52428,Supporting & Related Material,FDA-2017-P-5027-0003,FDA-2017-P-5027,Tab 1_Kadmon Press Releases re Citizen Petition from Wilson Disease Association
0900006482a52c84,Other,FDA-2017-P-5027-0001,FDA-2017-P-5027,Citizen Petition from Wilson Disease Association
0900006483a521ed,Other,FDA-2019-P-0622-0002,FDA-2019-P-0622,Acknowledgment Letter
0900006483c36c00,Other,FDA-2019-P-0622-0004,FDA-2019-P-0622,Response Letter re Citizen Petition from FDA OC
0900006483a521eb,Other,FDA-2019-P-0622-0001,FDA-2019-P-0622,Citizen Petition
0900006484961504,Supporting & Related Material,FDA-2020-P-2193-0005,FDA-2020-P-2193,"Exhibits 11-20 A Phase 3, Randomized, Open-Label, Active-Controlled Study to Evaluate the Efficacy and Safety of Roxadustat in the
Maintenance Treatment of Anemia in End Stage Renal Disease
Subjects on Stable Dialysis re: Citizen Petition from Epstein, Becker and Green, P.C."
0900006484961502,Supporting & Related Material,FDA-2020-P-2193-0003,FDA-2020-P-2193,"Exhibits 1-09 Chronic Kidney Disease in the United States, 2019 re: Citizen Petition from Epstein, Becker and Green, P.C."
0900006484961500,Other,FDA-2020-P-2193-0002,FDA-2020-P-2193,"Acknowledgment Letter from FDA DMS to Epstein, Becker and Green, P.C."
0900006484af40b3,Other,FDA-2020-P-2193-0007,FDA-2020-P-2193,"Interim Response from FDA CDER to Epstein Becker and Green, P.C."
0900006484961503,Supporting & Related Material,FDA-2020-P-2193-0004,FDA-2020-P-2193,"Exhibit 10 A Phase 3, Randomized, Open-Label, Active-Controlled Study to Evaluate the Efficacy and Safety of Roxadustat in the Maintenance Treatment of Anemia in End Stage Renal Disease Patients on Stable Dialysis re: Citizen Petition from Epstein, Becker and Green, P.C."
0900006484960dc9,Other,FDA-2020-P-2193-0001,FDA-2020-P-2193,"Citizen Petition from Epstein, Becker and Green, P.C."
090000648083e92f,Other,FDA-2009-P-0038-0002,FDA-2009-P-0038,Acknowlegdement Letter to Covington & Burling LLP
0900006480920098,Other,FDA-2009-P-0038-0006,FDA-2009-P-0038,"FDA/CDER Response to Mayne Pharma International Pty Ltd., and Warner Chilcott  Company, Inc. - Petition Denial"
090000648083e8c2,Other,FDA-2009-P-0038-0001,FDA-2009-P-0038,"Mayne Pharma International Pty Ltd., and Warner Chilcott (US), LLC, Warner Chilcott Laboratories Ireland, Ltd., and Warner Chilcott Company, Inc.  (Covington & Burling, LLP) - Citizen Petition"
0900006484aa38c8,Other,FDA-2021-P-0374-0001,FDA-2021-P-0374,Citizen Petition from Pet Schooled
0900006484dbfdc1,Other,FDA-2021-P-0374-0003,FDA-2021-P-0374,Final Response to Pet Schooled from FDA CVM
0900006484aa38dc,Other,FDA-2021-P-0374-0002,FDA-2021-P-0374,Acknowledgment Letter to Pet Schooled from FDA DMS
0900006483e33573,Other,FDA-2019-P-3800-0001,FDA-2019-P-3800,"Citizen Petition from Hyman, Phelps & McNamara P.C."
090000648423d3cc,Other,FDA-2019-P-3800-0003,FDA-2019-P-3800,"Petition Response Letter from FDA CDER to Hyman, Phelps & McNamara PC"
0900006483e3417c,Other,FDA-2019-P-3800-0002,FDA-2019-P-3800,"Acknowledgment Letter from FDA DMS to Hyman, Phelps & McNamara P.C."
09000064843f9ace,Notice,FDA-2019-N-3768-0009,FDA-2019-N-3768,Best Practices in Drug and Biological Product Postmarket Safety Surveillance for Food and Drug Administration Staff; Draft Document; Reopening of Comment Period
09000064845c0ad0,Other,FDA-2019-N-3768-0011,FDA-2019-N-3768,Best Practices in Drug and Biological Product Postmarket Safety Surveillance for FDA Staff - DRAFT
0900006484127411,Notice,FDA-2019-N-3768-0001,FDA-2019-N-3768,Best Practices in Drug and Biological Product Postmarket Safety Surveillance for Food and Drug Administration Staff; Draft Document; Availability; Establishment of Public Docket; Request for Comments
090000648420ddba,Other,FDA-2019-N-3768-0004,FDA-2019-N-3768,Request for Extension from Pharmaceutical Research and Manufacturers of America (PhRMA)
0900006482f7bbf3,Other,FDA-2017-P-5396-1001,FDA-2017-P-5396,Interim Response from FDA to Physicians for Responsible Opioid Prescribing
0900006482b0317a,Other,FDA-2017-P-5396-0002,FDA-2017-P-5396,Acknowledgement Letter from FDA DDM to Physicians for Responsible Opioid Prescribing
0900006482b02c71,Other,FDA-2017-P-5396-0001,FDA-2017-P-5396,Citizen Petition from Physicians for Responsible Opioid Prescribing
09000064812b1c2a,Notice,FDA-2013-N-0294-0001,FDA-2013-N-0294,Submission of New Drug Application/Abbreviated New Drug Application Field Alert Reports: Automated Form Pilot Program
0900006482198b58,Supporting & Related Material,FDA-2014-P-0687-0009,FDA-2014-P-0687,EPFX 2004 User Manual
0900006482198b5a,Supporting & Related Material,FDA-2014-P-0687-0011,FDA-2014-P-0687,EPFX YouTube video
0900006481714cad,Supporting & Related Material,FDA-2014-P-0687-0006,FDA-2014-P-0687,Exhibit D FDA Registration Approval Citizen Petition From Margaret Moline
0900006481ab47af,Other,FDA-2014-P-0687-0007,FDA-2014-P-0687,Interim Response Letter from FDA CDRH to Margaret Moline
0900006481714cab,Supporting & Related Material,FDA-2014-P-0687-0004,FDA-2014-P-0687,Exhibit B FDA Information Requests Citizen Petition From Margaret Moline
0900006482198b59,Supporting & Related Material,FDA-2014-P-0687-0010,FDA-2014-P-0687,EPFX 2008 User manual
0900006482198ac6,Other,FDA-2014-P-0687-0008,FDA-2014-P-0687,Letter from FDA CDRH  to Margaret Moline
090000648170d0f1,Other,FDA-2014-P-0687-0001,FDA-2014-P-0687,Citizen Petition From Margaret Moline
0900006481714cac,Supporting & Related Material,FDA-2014-P-0687-0005,FDA-2014-P-0687,Exhibit C Device Studies Citizen Petition From Margaret Moline
0900006481714caa,Supporting & Related Material,FDA-2014-P-0687-0003,FDA-2014-P-0687,Exhibit A FDA Import Alerts Citizen Petition From Margaret Moline
090000648171212e,Other,FDA-2014-P-0687-0002,FDA-2014-P-0687,Acknowledgement Letter From FDA DDM to Margaret Moline
0900006482d01f46,Notice,FDA-2017-N-5925-0011,FDA-2017-N-5925,21st Century Cures Act: Announcing the Establishment of the Susceptibility Test Interpretive Criteria Website
0900006482c21694,Notice,FDA-2017-N-5925-0001,FDA-2017-N-5925,"Standard Development Organizations Whose Susceptibility Test Interpretive Criteria Standards May Be Recognized by the Food and Drug 
Administration; Request for Information"
0900006483c2d8ac,Notice,FDA-2017-N-5925-0016,FDA-2017-N-5925,21st Century Cures Act: Annual Compilation of Notices of Updates From the Susceptibility Test Interpretive Criteria Web Page; Request for Comments
0900006482f7a3ab,Notice,FDA-2017-N-5925-0012,FDA-2017-N-5925,"Susceptibility Test Interpretive Criteria Recognized and Listed on the
Susceptibility Test Interpretive Web Page; Reopening of a Public Docket;
Request for Comments"
0900006484925e34,Notice,FDA-2017-N-5925-0026,FDA-2017-N-5925,21st Century Cures Act: Annual Compilation of Notices of Updates From the Susceptibility Test Interpretive Criteria Web Page; Request for Comments
09000064843b7f11,Other,FDA-2020-P-0945-0002,FDA-2020-P-0945,Acknowledgment Letter from DMS to  Dr. Ernest C. Chisena and Dr. Jahangir S. Rastegar
090000648478754c,Other,FDA-2020-P-0945-0012,FDA-2020-P-0945,Interim Response letter from FDA CDRH to Dr. Ernest C. Chisena and Dr. Jahangir S. Rastegar
09000064843b7057,Supporting & Related Material,FDA-2020-P-0945-0008,FDA-2020-P-0945,Reference 5 - Ultrasound for fracture healing: current evidence  RE: Citizen Petition from Dr. Ernest C. Chisena and Dr. Jahangir S. Rastegar
09000064843b6dfa,Other,FDA-2020-P-0945-0001,FDA-2020-P-0945,Citizen Petition from Dr. Ernest C. Chisena and Dr. Jahangir S. Rastegar
09000064843b7054,Supporting & Related Material,FDA-2020-P-0945-0005,FDA-2020-P-0945,Reference 2 - Local Soft Tissue Compression Enhances Fracture Healing in a Rabbit Fibula  RE: Citizen Petition from Dr. Ernest C. Chisena and Dr. Jahangir S. Rastegar
09000064843b7056,Supporting & Related Material,FDA-2020-P-0945-0007,FDA-2020-P-0945,"Reference 4 - Low intensity pulsed ultrasonography for fractures:
systematic review of randomised controlled trials  RE: Citizen Petition from Dr. Ernest C. Chisena and Dr. Jahangir S. Rastegar"
090000648449849c,Supporting & Related Material,FDA-2020-P-0945-0010,FDA-2020-P-0945,References 7 - Comparative Evaluation of the Angiogenic Potential of Hypoxia Preconditioned Blood-Derived Secretomes and Platelet-Rich re: Citizen Petition from Dr. Ernest C. Chisena and Dr. Jahangir S. Rastegar
09000064843b7053,Supporting & Related Material,FDA-2020-P-0945-0004,FDA-2020-P-0945,"Reference 1- Acceleration of Tibial Fracture-Healing by Non-Invasive, Low Intensity Pulsed Ultrasound Heckman J.D., et al JBJS 76-A, NO 1  JANUARY  1994 -  RE: Citizen Petition from Dr. Ernest C. Chisena and Dr. Jahangir S. Rastegar"
09000064843b7055,Supporting & Related Material,FDA-2020-P-0945-0006,FDA-2020-P-0945,Reference 3 - Re-evaluation of low intensity pulsed ultrasound in treatment of tibial fractures (TRUST): randomized clinical trial  RE: Citizen Petition from Dr. Ernest C. Chisena and Dr. Jahangir S. Rastegar
09000064846dfaf3,Supporting & Related Material,FDA-2020-P-0945-0011,FDA-2020-P-0945,Enclosure 1997 Letter
09000064843b7015,Supporting & Related Material,FDA-2020-P-0945-0003,FDA-2020-P-0945,"Attachment  A -  Bulletin of Joint Disease - A Specialized Orthosis for Suppressing Bony Destruction from Multiple Myeloma and to
Enhance Healing of a Pathologic Fracture in an Appendicular Lesion RE: Citizen Petition from Dr. Ernest C. Chisena and Dr. Jahangir S. Rastegar"
09000064843ba662,Supporting & Related Material,FDA-2020-P-0945-0009,FDA-2020-P-0945,Reference 6 - Low intensity pulsed ultrasound for bone healing: systematic review of randomized controlled trials  RE: Citizen Petition from Dr. Ernest C. Chisena and Dr. Jahangir S. Rastegar
090000648478754e,Other,FDA-2020-P-0945-0013,FDA-2020-P-0945,Interim Response letter from FDA CDRH to Dr. Ernest C. Chisena and Dr. Jahangir S. Rastegar - Redacted
0900006484a1ea02,Supporting & Related Material,FDA-2021-P-0157-0008,FDA-2021-P-0157,Exhibit E- Email Correspondence from FDA CTP to Fresh Farms E-Liquid re Citizen's Petition and Stay Petition
0900006484a1ea39,Other,FDA-2021-P-0157-0003,FDA-2021-P-0157,"Acknowledgement Letter from FDA DMS to Keller and Heckman LLP on behalf of Fresh Farms E-Liquid, LLC"
0900006484a1cbb2,Other,FDA-2021-P-0157-0001,FDA-2021-P-0157,Citizen's Petition from Keller and Heckman LLP on behalf of Fresh Farms E-Liquid LLC
0900006484a1cc50,Other,FDA-2021-P-0157-0002,FDA-2021-P-0157,Stay of Action Petition from Keller and Heckman LLP on behalf of Fresh Farms E-Liquid LLC
0900006484a1e9cd,Supporting & Related Material,FDA-2021-P-0157-0007,FDA-2021-P-0157,Exhibit D- Email Correspondence from Azim Chowdhury re Citizen's Petition and Stay Petition
0900006484c210f9,Other,FDA-2021-P-0157-0010,FDA-2021-P-0157,Letter from FDA CTP to Keller and Heckman LLP
0900006484a1e651,Supporting & Related Material,FDA-2021-P-0157-0004,FDA-2021-P-0157,Exhibit A- Refuse to Accept Letter re Citizen's Petition and Stay Petition from Keller and Heckman LLP on behalf of Fresh Farms E-Liquid LLC
0900006484a1e6ab,Supporting & Related Material,FDA-2021-P-0157-0006,FDA-2021-P-0157,Exhibit C- Declaration of Monica Schick re Citizen's Petition and Stay Petition
0900006484a859b5,Other,FDA-2021-P-0157-0009,FDA-2021-P-0157,"Fresh Farms E-Liquid, LLC Amended Petition For Stay of Action Regarding  Refuse- To- Accept Letter"
0900006484a1e6a7,Supporting & Related Material,FDA-2021-P-0157-0005,FDA-2021-P-0157,Exhibit B- Declaration of Anthony Devincentis re Citizen's Petition and Stay Petition
0900006480450459,Other,FDA-2006-P-0143-0004,FDA-2006-P-0143,Public Citizen Request to Center for Medicare & Medicaid Services (CMS) - Letter
0900006483669348,Other,FDA-2006-P-0143-0006,FDA-2006-P-0143,Interim response from FDA CDRH to Public Citizen
09000064846b2f43,Other,FDA-2006-P-0143-0007,FDA-2006-P-0143,Denial of Petition from FDA CDRH to Public Citizen's Health Research Group
0900006480450475,Other,FDA-2006-P-0143-0005,FDA-2006-P-0143,Public Citizen - Supplement
0900006480450455,Other,FDA-2006-P-0143-0002,FDA-2006-P-0143,Acknowledgment letter from FDA DDM to Public Citizen
090000648045044e,Other,FDA-2006-P-0143-0003,FDA-2006-P-0143,Public Citizen - Citizen Petition
0900006480450444,Other,FDA-2006-P-0143-0001,FDA-2006-P-0143,FDA DDM to Public Citizen
09000064804767f0,Supporting & Related Material,FDA-2004-D-0499-0006,FDA-2004-D-0499,GUIDANCE
09000064804767f1,Notice,FDA-2004-D-0499-0007,FDA-2004-D-0499,FDA
0900006480476709,Notice,FDA-2004-D-0499-0001,FDA-2004-D-0499,FDA
0900006480476713,Supporting & Related Material,FDA-2004-D-0499-0002,FDA-2004-D-0499,Guidance
0900006480ade142,Other,FDA-2010-P-0223-0007,FDA-2010-P-0223,Acknowledgement Letter to Genzyme Corporation (Covington & Burling LLP)
0900006480b77de8,Other,FDA-2010-P-0223-0010,FDA-2010-P-0223,FDA/CDER to Covington & Burling LLP (Genzyme Corporation) - Petition Approval
0900006480ade141,Other,FDA-2010-P-0223-0001,FDA-2010-P-0223,Genzyme Corporation (Covington & Burling LLP) - Citizen Petition
0900006480ade147,Supporting & Related Material,FDA-2010-P-0223-0004,FDA-2010-P-0223,"Exhibit B (Exhibit A) - ""United States Patent No. 2,602,116""  - [Genzyme Corporation (Covington & Burling LLP) - Citizen Petition]"
0900006480ade143,Supporting & Related Material,FDA-2010-P-0223-0002,FDA-2010-P-0223,"Exhibit A - ""Cobrek's First Notice Letter"" - [Genzyme Corporation (Covington & Burling LLP) - Citizen Petition]"
0900006480ade1fc,Supporting & Related Material,FDA-2010-P-0223-0008,FDA-2010-P-0223,"Exhibit B (Exhibit C) - ""Cobrek's Second Notice Letter""  - [Genzyme Corporation (Covington & Burling LLP) - Citizen Petition]"
0900006480ade1fb,Supporting & Related Material,FDA-2010-P-0223-0005,FDA-2010-P-0223,"Exhibit B (Exhibit B) - ""United States Patent No. 6,903,083 B2""  - [Genzyme Corporation (Covington & Burling LLP) - Citizen Petition]"
0900006480ade1fd,Supporting & Related Material,FDA-2010-P-0223-0006,FDA-2010-P-0223,"Exhibit B (Exhibit D) - ""Genzyme Corporation v. Cobrek Pharmaceuticals, Inc., No. 1:10-cv-00112 (N.D. III.) Complaint"" - [Genzyme Corporation (Covington & Burling LLP) - Citizen Petition]"
0900006480ade145,Supporting & Related Material,FDA-2010-P-0223-0003,FDA-2010-P-0223,"Exhibit B - ""Bone Care International LLC et al. v. Pentech Pharmaceuticals, Inc., 08-cv-1083(N.D. III.) Complaint"" - [Genzyme Corporation (Covington & Burling LLP) - Citizen Petition]"
0900006484dacd3b,Supporting & Related Material,FDA-2021-P-1045-0003,FDA-2021-P-1045,Exhibit A RE: Citizen Petition from Siri and Glimstad LLP on behalf of Informed Consent Action Network
0900006484dacd38,Other,FDA-2021-P-1045-0002,FDA-2021-P-1045,Acknowledgment Letter from FDA DMS to Siri and Glimstad LLP on behalf of Informed Consent Action Network
0900006484dd630f,Other,FDA-2021-P-1045-0004,FDA-2021-P-1045,Petition Response Letter from FDA CDER to Siri & Glimstad LLP
0900006484dacd00,Other,FDA-2021-P-1045-0001,FDA-2021-P-1045,Citizen Petition from Siri and Glimstad LLP on behalf of Informed Consent Action Network
0900006484d56737,Notice,FDA-2021-N-0929-0001,FDA-2021-N-0929,Food and Drug Administration New Era of Smarter Food Safety Summit on E-Commerce; Public Meeting; Request for Comments
0900006482af58ca,Other,FDA-2017-P-5335-0001,FDA-2017-P-5335,Citizen Petition from ANDA Consultants
0900006482af68ce,Supporting & Related Material,FDA-2017-P-5335-0004,FDA-2017-P-5335,Attachment 2 - Drugs@FDA Prescribing Information for Nexiclon XR Tablets
0900006482af58cc,Other,FDA-2017-P-5335-0002,FDA-2017-P-5335,Acknowledgement Letter from FDA DDM to ANDA Consultants
0900006482af68cd,Supporting & Related Material,FDA-2017-P-5335-0003,FDA-2017-P-5335,Attachment 1 - Orange Bood Drug Products Listing re
0900006482bb809f,Other,FDA-2017-P-6101-0001,FDA-2017-P-6101,Citizen Petition from Strides Pharma Inc.
0900006483094cae,Other,FDA-2017-P-6101-0004,FDA-2017-P-6101,Interim Response Letter from FDA CDER to Strides Pharma Inc.
090000648367eeaf,Other,FDA-2017-P-6101-0005,FDA-2017-P-6101,Agency Response Letter from FDA CDER to Strides Pharma Inc.
0900006482bb8745,Supporting & Related Material,FDA-2017-P-6101-0003,FDA-2017-P-6101,Annexure I - The declaration report for product (A074655) unavailability in the US market re Citizen Petition from Strides Pharma Inc.
0900006482bb80a1,Other,FDA-2017-P-6101-0002,FDA-2017-P-6101,Acknowledgement Letter from FDA DDM to Strides Pharma Inc.
09000064821a4ee7,Supporting & Related Material,FDA-2016-P-2558-0004,FDA-2016-P-2558,Exhibit 2  Choosing Wisely antibiotics for pink eye re Citizen Petition from Similasan Corporation
09000064821a4ee9,Supporting & Related Material,FDA-2016-P-2558-0006,FDA-2016-P-2558,Exhibit 4 CDC Pink Eye Usually Mild and Easy to Treat re Citizen Petition from Similasan Corporation
09000064821a51c0,Supporting & Related Material,FDA-2016-P-2558-0012,FDA-2016-P-2558,Exhibit 10 Remco P. Rietveld et al re Citizen Petition from Similasan Corporation
09000064821a51c1,Supporting & Related Material,FDA-2016-P-2558-0013,FDA-2016-P-2558,Exhibit 11 FDA antibiotic resistance re Citizen Petition from Similasan Corporation
09000064821a51c2,Supporting & Related Material,FDA-2016-P-2558-0014,FDA-2016-P-2558,Exhibit 12 FDA combating antibiotic resistance re Citizen Petition from Similasan Corporation
09000064821a51c4,Supporting & Related Material,FDA-2016-P-2558-0016,FDA-2016-P-2558,Exhibit 14 TRP Pink Eye Relief re Citizen Petition from Similasan Corporation
09000064821a4ee4,Other,FDA-2016-P-2558-0001,FDA-2016-P-2558,Citizen Petition from Similasan Corporation
09000064821ab135,Other,FDA-2016-P-2558-0002,FDA-2016-P-2558,Acknowledgment Letter from FDA DDM to Similasan Corporation
09000064821a4eea,Supporting & Related Material,FDA-2016-P-2558-0007,FDA-2016-P-2558,Exhibit 5 WebMD pink eye re Citizen Petition from Similasan Corporation
09000064824d13ba,Other,FDA-2016-P-2558-0018,FDA-2016-P-2558,Interim Response Letter from CDER to Similasan Corporation
09000064821a4ee6,Supporting & Related Material,FDA-2016-P-2558-0003,FDA-2016-P-2558,Exhibit 1 Hazel A Everitt et al re Citizen Petition from Similasan Corporation
09000064821a4ee8,Supporting & Related Material,FDA-2016-P-2558-0005,FDA-2016-P-2558,Exhibit 3 CDC conjunctivitis treatment re Citizen Petition from Similasan Corporation
09000064821a51bd,Supporting & Related Material,FDA-2016-P-2558-0009,FDA-2016-P-2558,Exhibit 7 Joanna Jefferis et al re Citizen Petition from Similasan Corporation
09000064821a51be,Supporting & Related Material,FDA-2016-P-2558-0010,FDA-2016-P-2558,Exhibit 8 Google pink eye re Citizen Petition from Similasan Corporation
09000064821a4eeb,Supporting & Related Material,FDA-2016-P-2558-0008,FDA-2016-P-2558,Exhibit 6  Azari & Barney re Citizen Petition from Similasan Corporation
09000064821a51c3,Supporting & Related Material,FDA-2016-P-2558-0015,FDA-2016-P-2558,Exhibit 13 Shirley Dang re Citizen Petition from Similasan Corporation
09000064821a51bf,Supporting & Related Material,FDA-2016-P-2558-0011,FDA-2016-P-2558,Exhibit 9 Peter W. Rose et al re Citizen Petition from Similasan Corporation
09000064821b8b43,Supporting & Related Material,FDA-2016-P-2558-0017,FDA-2016-P-2558,Exhibit 15 Kari Lee Visscher et al re Citizen Petition from Similasan Corporation
0900006482cfe790,Other,FDA-2017-P-6649-0004,FDA-2017-P-6649,Withdrawal from Greenberg Traurig LLP
0900006482cbc0d4,Other,FDA-2017-P-6649-0002,FDA-2017-P-6649,"Acknowledgment Letter from FDA DDM to Greenberg Traurig, LLP ( on behalf of Bracco Diagnostics Inc. )"
0900006482cbc01f,Other,FDA-2017-P-6649-0001,FDA-2017-P-6649,Citizen Petition from Greenberg Traurig LLP ( on behalf of Bracco Diagnostics Inc)
0900006482cbdbc4,Other,FDA-2017-P-6649-0003,FDA-2017-P-6649,Response in Opposition to Citizen Petition FDA-2017-P-1297
0900006480fecb83,Notice,FDA-2011-N-0439-0004,FDA-2011-N-0439,"Agency Information Collection Activities; Proposals, Submissions, and Approvals: Food and Drug Administration Recall Regulations"
0900006480eb644a,Notice,FDA-2011-N-0439-0001,FDA-2011-N-0439,"Agency Information Collection Activities; Proposals, Submissions, and Approvals: FDA Recall Regulations"
0900006480f7209a,Notice,FDA-2011-N-0439-0003,FDA-2011-N-0439,"Agency Information Collection Activities; Proposals, Submissions, and Approvals: Recall Regulations"
090000648197ba94,Notice,FDA-2014-N-1697-0002,FDA-2014-N-1697,"Privacy Act of 1974; Report of a New System of Records; Food and 
Drug Administration Commissioning of State and Local Officials; 
Correction"
090000648196402c,Notice,FDA-2014-N-1697-0001,FDA-2014-N-1697,"Privacy Act of 1974; Report of a New System of Records; Food and 
Drug Administration Commissioning of State and Local Officials"
0900006481966730,Supporting & Related Material,FDA-2014-P-2140-0004,FDA-2014-P-2140,Attachment 2 Citizen Petition From Lachman Consultat Services Inc.
0900006481966731,Supporting & Related Material,FDA-2014-P-2140-0005,FDA-2014-P-2140,Attachment 3 Citizen Petition From Lachman Consultat Services Inc.
090000648196672e,Supporting & Related Material,FDA-2014-P-2140-0003,FDA-2014-P-2140,Attachment 1 Citizen Petition From Lachman Consultat Services Inc.
09000064819669ac,Other,FDA-2014-P-2140-0002,FDA-2014-P-2140,"Acknowledgement Letter From FDA DDM to Lachman Consultant Services, Inc."
090000648196672b,Other,FDA-2014-P-2140-0001,FDA-2014-P-2140,"Citizen Petition From Lachman Consulting Services, Inc."
0900006481966732,Supporting & Related Material,FDA-2014-P-2140-0006,FDA-2014-P-2140,Attachment 4 Citizen Petition From Lachman Consultat Services Inc.
0900006484873c71,Supporting & Related Material,FDA-2020-P-2005-0005,FDA-2020-P-2005,"ATTACHMENT 1 Orange Book: Approved Drug Products
with Therapeutic Equivalence Evaluations RE: Suitability Petition from HYMAN, PHELPS & MCNAMARA, P.C."
0900006484873c02,Other,FDA-2020-P-2005-0002,FDA-2020-P-2005,"Acknowledgment Letter from FDA DMS to Hyman, Phelps & McNamara, P.C."
0900006484873c01,Other,FDA-2020-P-2005-0001,FDA-2020-P-2005,"Suitability Petition from HYMAN, PHELPS & MCNAMARA, P.C."
0900006484873c72,Supporting & Related Material,FDA-2020-P-2005-0004,FDA-2020-P-2005,"ATTACHMENT 2 HIGHLIGHTS OF PRESCRIBING INFORMATION K-TAB (potassium chloride) extended-release tablets RE: Suitability Petition from HYMAN, PHELPS & MCNAMARA, P.C."
0900006484873c73,Supporting & Related Material,FDA-2020-P-2005-0003,FDA-2020-P-2005,"ATTACHMENT 3 HIGHLIGHTS OF PRESCRIBING INFORMATION POTASSIUM CHLORIDE extended-release tablets RE: Suitability Petition from HYMAN, PHELPS & MCNAMARA, P.C."
09000064846f92ba,Other,FDA-2020-P-1423-0039,FDA-2020-P-1423,SOI CORRECTION LETTER to Citizen Petition from North American Olive Oil Association
09000064846ad90b,Supporting & Related Material,FDA-2020-P-1423-0003,FDA-2020-P-1423,Appendix 1 Proposed Regulation re Citizen Petition from North American Olive Oil Association
09000064846ad925,Supporting & Related Material,FDA-2020-P-1423-0012,FDA-2020-P-1423,Appendix 5 IOC Standard November 2019 re Citizen Petition from North American Olive Oil Association
09000064846ad93a,Supporting & Related Material,FDA-2020-P-1423-0021,FDA-2020-P-1423,Appendix 11b Oct 2019-”7-STIGMASTENOL DECISIONAL TREE IN REFINED OO re Citizen Petition from North American Olive Oil Association
09000064846ad557,Supporting & Related Material,FDA-2020-P-1423-0028,FDA-2020-P-1423,Appendix 15 Oct 2015 - K270 and decision trees PROPOSALS re Citizen Petition from North American Olive Oil Association
09000064846ad55b,Supporting & Related Material,FDA-2020-P-1423-0032,FDA-2020-P-1423,Appendix 16b Scientific papers on FAEEs re Citizen Petition from North American Olive Oil Association
09000064846ad558,Supporting & Related Material,FDA-2020-P-1423-0029,FDA-2020-P-1423,Appendix 15a IOC Report Presentation K270 re Citizen Petition from North American Olive Oil Association
09000064846ad939,Supporting & Related Material,FDA-2020-P-1423-0020,FDA-2020-P-1423,Appendix 11a Oct 2011-Study delta 7-stigmastenol +campesterol re Citizen Petition from North American Olive Oil Association
09000064846ad927,Supporting & Related Material,FDA-2020-P-1423-0014,FDA-2020-P-1423,Appendix 7 NAOOA Consumer Study March 2020 - Read-Only re Citizen Petition from North American Olive Oil Association
09000064846ad93e,Supporting & Related Material,FDA-2020-P-1423-0025,FDA-2020-P-1423,"Appendix 12b Oct 2012 annex 2 alkyl esters, waxes and stigmastadiene re Citizen Petition from North American Olive Oil Association"
09000064846ad92d,Supporting & Related Material,FDA-2020-P-1423-0018,FDA-2020-P-1423,Appendix 10 Oct 2006 linolenic acid limit re Citizen Petition from North American Olive Oil Association
09000064846ad564,Supporting & Related Material,FDA-2020-P-1423-0038,FDA-2020-P-1423,Appendix 18-Olive Oil Blend Labels and Amazon com Comments re Citizen Petition from North American Olive Oil Association
09000064846ad559,Supporting & Related Material,FDA-2020-P-1423-0030,FDA-2020-P-1423,Appendix 16 Fatty acid methyl and ethyl esters as well as wax esters re Citizen Petition from North American Olive Oil Association
09000064846ad55f,Supporting & Related Material,FDA-2020-P-1423-0034,FDA-2020-P-1423,Appendix 16d Gomez Coca et Al 2016 re Citizen Petition from North American Olive Oil Association
09000064846ad563,Supporting & Related Material,FDA-2020-P-1423-0037,FDA-2020-P-1423,Appendix 17a Li and Wang Shelf Life 2018 re Citizen Petition from North American Olive Oil Association
09000064846ad539,Supporting & Related Material,FDA-2020-P-1423-0010,FDA-2020-P-1423,Appendix 3b NAOOA Withdrawal of 2012 Petition re Citizen Petition from North American Olive Oil Association
09000064846ad55a,Supporting & Related Material,FDA-2020-P-1423-0031,FDA-2020-P-1423,Appendix 16a Di Serio Food Chem 2017 re Citizen Petition from North American Olive Oil Association
09000064846ad55c,Supporting & Related Material,FDA-2020-P-1423-0033,FDA-2020-P-1423,Appendix 16c April 2008 detection of admixures of deodorised oo with EVOO re Citizen Petition from North American Olive Oil Association
09000064846ad536,Supporting & Related Material,FDA-2020-P-1423-0007,FDA-2020-P-1423,Appendix 2c Codex Redline re Citizen Petition from North American Olive Oil Association
09000064846ad929,Supporting & Related Material,FDA-2020-P-1423-0016,FDA-2020-P-1423,"Appendix 9 April 2016 heptadecanoic, heptadecenoic, eicosenoic acids content re Citizen Petition from North American Olive Oil Association"
09000064846ad535,Supporting & Related Material,FDA-2020-P-1423-0006,FDA-2020-P-1423,Appendix 2b CCFO Proposed Revisions to Codex Standard November 2018 re Citizen Petition from North American Olive Oil Association
09000064846ad905,Other,FDA-2020-P-1423-0002,FDA-2020-P-1423,Acknowledgment Letter from FDA DMS to North American Olive Oil Association
090000648497d917,Other,FDA-2020-P-1423-0057,FDA-2020-P-1423,Letter from CFSAN to The Meriam Hospital
09000064846ad555,Supporting & Related Material,FDA-2020-P-1423-0026,FDA-2020-P-1423,Appendix 13 Oct 2012 reduction of stigmastadiene limit annex 6 re Citizen Petition from North American Olive Oil Association
09000064846ad93c,Supporting & Related Material,FDA-2020-P-1423-0023,FDA-2020-P-1423,Appendix 12 Oct 2012 reduction of wax limit annex 7 re Citizen Petition from North American Olive Oil Association
09000064804a255a,Notice,FDA-2003-N-0448-0002,FDA-2003-N-0448,FDA
09000064804a2555,Notice,FDA-2003-N-0448-0001,FDA-2003-N-0448,FDA
09000064804a255b,Notice,FDA-2003-N-0448-0003,FDA-2003-N-0448,FDA
09000064804943ae,Supporting & Related Material,FDA-2003-D-0305-0003,FDA-2003-D-0305,GUIDANCE
0900006480494337,Notice,FDA-2003-D-0305-0001,FDA-2003-D-0305,FDA
09000064804943b3,Notice,FDA-2003-D-0305-0005,FDA-2003-D-0305,FDA
090000648049437e,Supporting & Related Material,FDA-2003-D-0305-0002,FDA-2003-D-0305,Guideline
09000064804943b1,Supporting & Related Material,FDA-2003-D-0305-0004,FDA-2003-D-0305,GUIDANCE
090000648045143a,Other,FDA-2006-P-0206-0001,FDA-2006-P-0206,HFA-305  to The Sugar Association
0900006480451488,Other,FDA-2006-P-0206-0002,FDA-2006-P-0206,HFA-305  to The Sugar Association
09000064804514ca,Other,FDA-2006-P-0206-0007,FDA-2006-P-0206,"FDA/CFSAN to The Sugar Association, Inc."
09000064804e780c,Other,FDA-2001-N-0348-0004,FDA-2001-N-0348,"Supporting Statement OMB 910-0032 New Animal Drug Applications, Form FDA 356V and Supporting Regulations"
09000064804e780b,Notice,FDA-2001-N-0348-0002,FDA-2001-N-0348,"Agency Information Collection Activities; Submission for OMB Review; Comment Request;  New Animal Drug Application, Form FDA 356 V"
09000064804e780a,Notice,FDA-2001-N-0348-0001,FDA-2001-N-0348,"Agency Information Collection Activities; Proposed Collection; Comment Request; New Animal Drug Application, Form FDA 356 V, 21 CFR Part 514"
09000064804e780d,Notice,FDA-2001-N-0348-0003,FDA-2001-N-0348,"Agency Information Collection Activities; Announcement of OMB Approval; New Animal Drug Application, Form FDA 356  V"
0900006484a87f06,Supporting & Related Material,FDA-2021-P-0338-0013,FDA-2021-P-0338,Attachment C H205-H229 re Citizen Petition from Valisure
0900006484a87e89,Supporting & Related Material,FDA-2021-P-0338-0002,FDA-2021-P-0338,Attachment A - Valisure Citizen Petition on Hand Sanitizer Products re Citizen Petition from Valisure
0900006484a87f03,Supporting & Related Material,FDA-2021-P-0338-0012,FDA-2021-P-0338,Attachment C H178-H204 re Citizen Petition from Valisure
0900006484a87e91,Supporting & Related Material,FDA-2021-P-0338-0007,FDA-2021-P-0338,Attachment C H077-H091 re Citizen Petition from Valisure
0900006484a87f02,Supporting & Related Material,FDA-2021-P-0338-0011,FDA-2021-P-0338,Attachment C H153-H177 re Citizen Petition from Valisure
0900006484a87f53,Supporting & Related Material,FDA-2021-P-0338-0015,FDA-2021-P-0338,Attachment C H258-H267 re Citizen Petition from Valisure
0900006484a87bde,Other,FDA-2021-P-0338-0001,FDA-2021-P-0338,Citizen Petition from Valisure LLC
0900006484a87e8c,Supporting & Related Material,FDA-2021-P-0338-0004,FDA-2021-P-0338,Attachment C H001-H025 re Citizen Petition from Valisure
0900006484a87e8f,Supporting & Related Material,FDA-2021-P-0338-0006,FDA-2021-P-0338,Attachment C H052-H076 re Citizen Petition from Valisure
0900006484a87f01,Supporting & Related Material,FDA-2021-P-0338-0010,FDA-2021-P-0338,Attachment C H128-H152 re Citizen Petition from Valisure
0900006484a87be0,Other,FDA-2021-P-0338-0016,FDA-2021-P-0338,Acknowledgment Letter from FDA DMS to Valisure LLC
0900006484a87e8e,Supporting & Related Material,FDA-2021-P-0338-0005,FDA-2021-P-0338,Attachment C H026-H051 re Citizen Petition from Valisure
0900006484d93faf,Other,FDA-2021-P-0338-0018,FDA-2021-P-0338,"Interim Response Letter from FDA CDER to Valisure, LLC"
0900006484a87e8a,Supporting & Related Material,FDA-2021-P-0338-0003,FDA-2021-P-0338,Attachment B - ACC Resolution - Chemical Variability in Pharmaceutical Products re Citizen Petition from Valisure
0900006484a87efd,Supporting & Related Material,FDA-2021-P-0338-0008,FDA-2021-P-0338,Attachment C H092-H102 re Citizen Petition from Valisure
0900006484a87efe,Supporting & Related Material,FDA-2021-P-0338-0009,FDA-2021-P-0338,Attachment C H103-H127 re Citizen Petition from Valisure
0900006484a87f4e,Supporting & Related Material,FDA-2021-P-0338-0014,FDA-2021-P-0338,Attachment C H230-H257 re Citizen Petition from Valisure
0900006480e303cd,Supporting & Related Material,FDA-2011-N-0134-0015,FDA-2011-N-0134,See FDA-2011-N-0134-0010
0900006480c0723d,Notice,FDA-2011-N-0134-0001,FDA-2011-N-0134,FDA Food Safety Modernization Act: Title III--A New Paradigm for Importers; Public Meeting
0900006480f09138,Notice,FDA-2011-N-0607-0001,FDA-2011-N-0607,Public Database of Products With Orphan-Drug Designations: Replacing Non-Informative Code Names With Descriptive Identifiers
09000064824e16d5,Other,FDA-2017-P-1252-0002,FDA-2017-P-1252,Acknowledgement Letter from FDA DDM to Xiromed LLC on behalf of LifePharma FZE
0900006483670954,Other,FDA-2017-P-1252-0004,FDA-2017-P-1252,Response Letter from FDA CDER to  VKT Pharma Private Limeted and Xiromed LLC
0900006482aba1ee,Other,FDA-2017-P-1252-0003,FDA-2017-P-1252,Interim Response Letter from FDA CDER to Xiromed LLC
09000064824e16d3,Other,FDA-2017-P-1252-0001,FDA-2017-P-1252,"Citizen Petition from Xiromed, LLC on behalf of LifePharma FZE"
0900006481e78581,Notice,FDA-2014-N-1698-0056,FDA-2014-N-1698,"Food and Drug Administration Activities for Patient Participation in
Medical Product Discussions; Report on Stakeholder Views; Availability"
0900006481912c75,Notice,FDA-2014-N-1698-0001,FDA-2014-N-1698,"Food and Drug Administration Activities for Patient Participation in
Medical Product Discussions; Establishment of a Public Docket"
0900006481ee871c,Supporting & Related Material,FDA-2014-P-0814-0018,FDA-2014-P-0814,"Exhibit 20 O'Riordan, M. After Patient's Death, Study Shows HCV Drug Cardiotoxic in 14 of 34 Treated Patients Source: www.medscape.com/viewarticle/832251_print September 24, 2014 re: Amendment from Center for Responsible Science"
0900006481ee839d,Supporting & Related Material,FDA-2014-P-0814-0009,FDA-2014-P-0814,Exhibit 5 Online News Articles from Different Organizations re: Amendment from Center for Responsible Science
0900006481ee871a,Supporting & Related Material,FDA-2014-P-0814-0016,FDA-2014-P-0814,"Exhibit 18 Lerman, R. FDA halts trial of cancer drug by Seattle's CTI BioPharma after patients die, Source http://www.seattletimes.com/business/fda-halts-cti-biopharma-drug-trial-for-detrimental-effect-on-survival/ February 10, 2016 re: Amendment from Center for Responsible Science"
0900006481752b03,Other,FDA-2014-P-0814-0001,FDA-2014-P-0814,Citizen Petition from the Center for Responsible Science
0900006481752b05,Other,FDA-2014-P-0814-0002,FDA-2014-P-0814,Acknowledgement Letter from FDA DDM to the Center for Responsible Science
0900006481ee83a1,Supporting & Related Material,FDA-2014-P-0814-0012,FDA-2014-P-0814,"Exhibit 9 The Pharmaletter, ANSM continues investigations into Bial clinical trial death, March 10, 2016 re: Amendment from Center for Responsible Science"
0900006481979bbc,Other,FDA-2014-P-0814-0007,FDA-2014-P-0814,Interim Response From FDA CDER to the Center for Responsible Science
09000064818adec0,Other,FDA-2014-P-0814-0006,FDA-2014-P-0814,Amendment from the Center For Responsible Science
0900006481ee8651,Other,FDA-2014-P-0814-0008,FDA-2014-P-0814,Amendment from the Center For Responsible Science
0900006481ee83a2,Supporting & Related Material,FDA-2014-P-0814-0013,FDA-2014-P-0814,"Exhibit 10 Minutes of the Temporary Specialist Scientific Committee (TSSC) meeting on ""FAAH (Fatty Add Amide Hydrolase) Inhibitors"" of 15 February 2016. re: Amendment from Center for Responsible Science"
0900006481ee871b,Supporting & Related Material,FDA-2014-P-0814-0017,FDA-2014-P-0814,"Exhibit 19 Lougheed, K. Hepatitis C drug trial halted after patient death August 24, 2012 re: Amendment from Center for Responsible Science"
0900006481ee8445,Supporting & Related Material,FDA-2014-P-0814-0020,FDA-2014-P-0814,"Exhibit 22 Hogan, A. Failure to Report A STAT Investigation December 13, 2015 re: Amendment from Center for Responsible Science"
0900006481ee839f,Supporting & Related Material,FDA-2014-P-0814-0011,FDA-2014-P-0814,"Exhibit 7 The Guardian Man who died in French drug trial had 'unprecedented' reaction, say experts. March 2016 re: Amendment from Center for Responsible Science"
0900006481ee83a3,Supporting & Related Material,FDA-2014-P-0814-0014,FDA-2014-P-0814,"Exhibit 11 Brennan EMA Will Assess ANSM Review of Botched Clinical Trial in France, January 19, 2016 re: Amendment from Center for Responsible Science"
0900006482552ffb,Other,FDA-2014-P-0814-0021,FDA-2014-P-0814,Letter from CDER to Center for Responsible Science
0900006481752b07,Supporting & Related Material,FDA-2014-P-0814-0003,FDA-2014-P-0814,Exhibit 1 Declaration of John Tessmer Citizen Petition from The Center for Responsible Science
0900006481752b09,Supporting & Related Material,FDA-2014-P-0814-0005,FDA-2014-P-0814,Exhibit 3-55 Attached Literature Citizen Petition From The Center for Responsible Science
0900006481ee839e,Supporting & Related Material,FDA-2014-P-0814-0010,FDA-2014-P-0814,"Exhibit 6 Business Insider, Feb 5, 2016 Authorities are rapping up their investigation of a deadly drug trial that left one dead and several others in hospital re: Amendment from Center for Responsible Science"
0900006481ee83d2,Supporting & Related Material,FDA-2014-P-0814-0015,FDA-2014-P-0814,"Exhibit 14 Scientific Bloggging Science 2.0 Blood Test Predicts Cytokine Storm Drug Reaction In Humans March 9, 2015 re: Amendment from Center for Responsible Science"
0900006481ee8444,Supporting & Related Material,FDA-2014-P-0814-0019,FDA-2014-P-0814,"Exhibit 21 Earley, Lau and Uhlig Haphazard reporting of deaths in clinical trials: a review of cases of ClinicalTrials.gov records and matched publications-a cross-sectional study BMJ Open Access re: Amendment from Center for Responsible Science"
0900006481752b08,Supporting & Related Material,FDA-2014-P-0814-0004,FDA-2014-P-0814,Exhibit 2 Declaration of Hal Garcia-Smith Citizen Petition from The Center for Responsible Science
0900006481a8b599,Supporting & Related Material,FDA-2015-P-1094-0017,FDA-2015-P-1094,"Exhibit H, Guidance for Industry Regulation of Genetically Engineered Animals Containing Heritable Recombinant DNA Constructs, Citizen Petition From Food and Water Watch"
0900006481a8b5a1,Supporting & Related Material,FDA-2015-P-1094-0024,FDA-2015-P-1094,"Exhibit L, 21 USCS § 321, Citizen Petition from Food and Water Watch"
0900006481a8b5a4,Supporting & Related Material,FDA-2015-P-1094-0027,FDA-2015-P-1094,"Exhibit MM, 78 FR 43093, Citizen Petition from Food and Water Watch"
0900006481a8b5b1,Supporting & Related Material,FDA-2015-P-1094-0039,FDA-2015-P-1094,"Exhibit Y, Veterinary Medicine Advisory Committee Meeting AquAdvantage Salmon, Citizen Petition from Food and Water Watch"
0900006481a8b323,Other,FDA-2015-P-1094-0001,FDA-2015-P-1094,Citizen Petition from Food and Water Watch
0900006481a8b327,Other,FDA-2015-P-1094-0002,FDA-2015-P-1094,Acknowledgement Letter from FDA DDM to Food and Water Watch
0900006481a8b591,Supporting & Related Material,FDA-2015-P-1094-0009,FDA-2015-P-1094,"Exhibit D, 21 CFR 170.30, Citizen Petition from Food and Water Watch"
0900006481a8b596,Supporting & Related Material,FDA-2015-P-1094-0014,FDA-2015-P-1094,"Exhibit FF, Phenotypic Characterization, D. Prather DVM, Citizen Petition from Food and Water Watch"
0900006481a8b5a6,Supporting & Related Material,FDA-2015-P-1094-0029,FDA-2015-P-1094,"Exhibit O, Background Document: Public Hearing on the Labeling of Food Made from the AquAdvantage Salmon, Citizen Petition from Food and Water Watch"
0900006481a8b5b2,Supporting & Related Material,FDA-2015-P-1094-0040,FDA-2015-P-1094,"Exhibit Z, Idetification of a Brazil-Nut Allergen in Transgenic Soybeans, Citizen Petition from Food and Water Watch"
0900006481a8b5a9,Supporting & Related Material,FDA-2015-P-1094-0032,FDA-2015-P-1094,"Exhibit R, 21 USCS § 334, Citizen Petition from Food and Water Watch"
0900006481a8b5b0,Supporting & Related Material,FDA-2015-P-1094-0038,FDA-2015-P-1094,"Exhibit X, Potential Public Health Impacts of the Use of Recombinant Bovine Somatotropin In Dairy Production, Citizen Petition from Food and Water Watch"
0900006481a8b58c,Supporting & Related Material,FDA-2015-P-1094-0004,FDA-2015-P-1094,"Exhibit AA, J. Agric. Food Chern. 2005, 53, 9023-9030, Citizen Petition from Food and Water Watch"
0900006481a8b58e,Supporting & Related Material,FDA-2015-P-1094-0006,FDA-2015-P-1094,"Exhibit BB, 21 CFR 171.1, Citizen Petition from Food and Water Watch"
0900006481a8b329,Supporting & Related Material,FDA-2015-P-1094-0003,FDA-2015-P-1094,"Exhibit A, Veterinary Medicine Advisory Committee Briefing, Citizen Petition from Food and Water Watch"
0900006481a8b58f,Supporting & Related Material,FDA-2015-P-1094-0007,FDA-2015-P-1094,"Exhibit C, 21 CFR 10.115, Citizen Petition from Food and Water Watch"
0900006481a8b590,Supporting & Related Material,FDA-2015-P-1094-0008,FDA-2015-P-1094,"Exhibit CC, Agriculture: A Glossary of Terms, Programs, and Laws, 2005 Edition, Citizen Petition from Food and Water Watch"
0900006481a8b5aa,Supporting & Related Material,FDA-2015-P-1094-0033,FDA-2015-P-1094,"Exhibit S, Role of the Insulin-Like Growth Factor Family in Cancer Development and Progression, Citizen Petition from Food and Water Watch"
0900006481a8b598,Supporting & Related Material,FDA-2015-P-1094-0016,FDA-2015-P-1094,"Exhibit GG, Comment from Elizabeth Colantuoni, Citizen Petition from Food and Water Watch"
0900006481a8b5a7,Supporting & Related Material,FDA-2015-P-1094-0030,FDA-2015-P-1094,"Exhibit P, 21 USCS § 342, Citizen Petition from Food and Water Watch"
0900006481a8b58d,Supporting & Related Material,FDA-2015-P-1094-0005,FDA-2015-P-1094,"Exhibit B, AquAdvantage® Fish growth chart, Citizen Petition from Food and Water Watch"
0900006481a8b593,Supporting & Related Material,FDA-2015-P-1094-0011,FDA-2015-P-1094,"Exhibit E, 21 CFR 170.38, Citizen Petition from Food and Water Watch"
0900006481a8b5ae,Supporting & Related Material,FDA-2015-P-1094-0036,FDA-2015-P-1094,"Exhibit V, Gastrointestinal Absorption of Recombinant Human Insulin-Like Growth Factor-1 in Rats, Citizen Petition From Food and Water Watch"
0900006481a8b59e,Supporting & Related Material,FDA-2015-P-1094-0021,FDA-2015-P-1094,"Exhibit JJ, Environmental and Indirect Human Health Risk Assessment of the AquAdvantage® Salmon, Citizen Petition from Food and Water Watch"
0900006481a8b59a,Supporting & Related Material,FDA-2015-P-1094-0018,FDA-2015-P-1094,"Exhibit HH, Letter from CFSAN to Food and Water Watch, Citizen Petition from Food and Water Watch"
090000648483908e,Supporting & Related Material,FDA-2020-P-1831-0007,FDA-2020-P-1831,Reference 05- Teperino - (HH partial agonism drives Warburg-like metabolism in muscle and brown fat) re Citizen Petition from Meenal Kheterpal
0900006484839089,Supporting & Related Material,FDA-2020-P-1831-0006,FDA-2020-P-1831,Reference 04- Jacobsen_JAMA Derm - systematic review and pooled analysis) re Citizen Petition from Meenal Kheterpal
0900006484839eeb,Supporting & Related Material,FDA-2020-P-1831-0013,FDA-2020-P-1831,Reference 11 - (Variations of serum CK and prevalance of persistent hyperCK) re Citizen Petition from Meenal Kheterpal
0900006484839ee6,Supporting & Related Material,FDA-2020-P-1831-0010,FDA-2020-P-1831,Reference 08 -  (Correlation of alpha smooth muscle actin in BCC) re Citizen Petition from Meenal Kheterpal
090000648483a6bd,Supporting & Related Material,FDA-2020-P-1831-0028,FDA-2020-P-1831,Reference 26 - Lilleng Neuromusc Disorders 2011 re Citizen Petition from Meenal Kheterpal
090000648483a782,Supporting & Related Material,FDA-2020-P-1831-0037,FDA-2020-P-1831,Reference 28 - Thompson 2006 Horm Res re Citizen Petition from Meenal Kheterpal
090000648483a101,Supporting & Related Material,FDA-2020-P-1831-0021,FDA-2020-P-1831,Reference 19 - Dummer BJD 2019 re Citizen Petition from Meenal Kheterpal
0900006484839cf9,Supporting & Related Material,FDA-2020-P-1831-0018,FDA-2020-P-1831,Reference 16 - Sekulic BMC Cancer 2017 re Citizen Petition from Meenal Kheterpal
090000648483a6bc,Supporting & Related Material,FDA-2020-P-1831-0027,FDA-2020-P-1831,Reference 25 - Lev 1999 Clinica Chimica Act re Citizen Petition from Meenal Kheterpal
090000648483493e,Other,FDA-2020-P-1831-0002,FDA-2020-P-1831,Acknowledgment Letter FDA DMS to Meenal Kheterpal
090000648483a0be,Supporting & Related Material,FDA-2020-P-1831-0024,FDA-2020-P-1831,Reference 22 - Bohlmeyer Rheum Dis Clin North Am 1994 re Citizen Petition from Meenal Kheterpal
0900006484839eea,Supporting & Related Material,FDA-2020-P-1831-0012,FDA-2020-P-1831,Reference 10 - (Lab guide to diagnosing myositis) re Citizen Petition from Meenal Kheterpal
0900006484839eec,Supporting & Related Material,FDA-2020-P-1831-0014,FDA-2020-P-1831,Reference 12 - Brewster 2006 Circulation re Citizen Petition from Meenal Kheterpal
090000648483a783,Supporting & Related Material,FDA-2020-P-1831-0030,FDA-2020-P-1831,Reference 29 - Amelink 1990 ACta Physiologca re Citizen Petition from Meenal Kheterpal
0900006484838f88,Supporting & Related Material,FDA-2020-P-1831-0004,FDA-2020-P-1831,Reference 02- Odomzo PI NEW with Sun re: Citizen Petition from Meenal Kheterpal
0900006484839eee,Supporting & Related Material,FDA-2020-P-1831-0016,FDA-2020-P-1831,Reference 14 - Totsuka J Appl Physiol 2002 re Citizen Petition from Meenal Kheterpal
090000648483a100,Supporting & Related Material,FDA-2020-P-1831-0020,FDA-2020-P-1831,Reference 18 - Migden Lancet Oncol 2015 re Citizen Petition from Meenal Kheterpal
090000648483a789,Supporting & Related Material,FDA-2020-P-1831-0033,FDA-2020-P-1831,Reference 32 - Duyff J Neurol Neurosurg Psychiatry 2000 re Citizen Petition from Meenal Kheterpal
090000648483a781,Supporting & Related Material,FDA-2020-P-1831-0029,FDA-2020-P-1831,Reference 27 - Kyriakides Euro J Neurol 2010 re Citizen Petition from Meenal Kheterpal
0900006484839090,Supporting & Related Material,FDA-2020-P-1831-0008,FDA-2020-P-1831,Reference 06- Xiao (hedgehog signaling regulates E-cadherin expression) re Citizen Petition from Meenal Kheterpal
0900006484a57751,Other,FDA-2020-P-1831-0038,FDA-2020-P-1831,Interim Response for the Hedgehog Inhibitor
0900006484835d2b,Supporting & Related Material,FDA-2020-P-1831-0003,FDA-2020-P-1831,Reference 01- Erivedge (Vismodegib) capsules re: Citizen Petition from Meenal Kheterpal
0900006484839088,Supporting & Related Material,FDA-2020-P-1831-0005,FDA-2020-P-1831,Reference 03- Daurismo (glasdegib) re: Citizen Petition from Meenal Kheterpal
0900006484839eed,Supporting & Related Material,FDA-2020-P-1831-0015,FDA-2020-P-1831,Reference 13 - Sayers Med Sci Sports Exerc 2003 re Citizen Petition from Meenal Kheterpal
0900006484839eef,Supporting & Related Material,FDA-2020-P-1831-0017,FDA-2020-P-1831,Reference 15 - Sekulic New Eng J Med 2012 re Citizen Petition from Meenal Kheterpal
0900006484bc8cf7,Other,FDA-2021-P-0653-0001,FDA-2021-P-0653,Citizen Petition from Environmental Defense Fund
0900006484bc935e,Other,FDA-2021-P-0653-0002,FDA-2021-P-0653,Acknowledgment Letter from FDA DMS to Environmental Defense Fund
0900006484bd7015,Supporting & Related Material,FDA-2021-P-0677-0003,FDA-2021-P-0677,"Attachment 1 (Diltiazem HCl ER Capsules ANDA SP) PRESCRIPTION DRUG PRODUCT LIST  re: Citizen Petition from Hyman, Phelps & McNamara, P.C."
0900006484bd7017,Supporting & Related Material,FDA-2021-P-0677-0005,FDA-2021-P-0677,"Attachment 3 (Diltiazem HCl ER Capsules ANDA SP) Diltiazem Hydrochloride Extended-Release Capsules re: Citizen Petition from Hyman, Phelps & McNamara, P.C."
0900006484bd7a4a,Other,FDA-2021-P-0677-0001,FDA-2021-P-0677,"Suitability Petition from Hyman, Phelps & McNamara, P.C."
0900006484bd7a4c,Other,FDA-2021-P-0677-0002,FDA-2021-P-0677,"Acknowledgement Letter from FDA DMS to Hyman, Phelps & McNamara, P.C."
0900006484bd7016,Supporting & Related Material,FDA-2021-P-0677-0004,FDA-2021-P-0677,"Attachment 2 (Diltiazem HCl ER Capsules ANDA SP) CARDIZEM CD- diltiazem hydrochloride capsule, coated, extended release Bausch Health US LLC. re: Citizen Petition from Hyman, Phelps & McNamara, P.C."
090000648391d086,Other,FDA-2018-P-4591-0001,FDA-2018-P-4591,Citizen Petition from International Maple Syrup Institute
090000648404daca,Other,FDA-2018-P-4591-0003,FDA-2018-P-4591,Interim Response Letter from FDA CFSAN to International Maple Syrup Institute
090000648391d088,Other,FDA-2018-P-4591-0002,FDA-2018-P-4591,Acknowledgment Letter from FDA DDM to International Maple Syrup Institute
0900006480472821,Notice,FDA-2004-D-0286-0001,FDA-2004-D-0286,FDA
0900006480472822,Supporting & Related Material,FDA-2004-D-0286-0002,FDA-2004-D-0286,"FDA Review of Vaccine Labeling Requirements for Warnings, Use Instructions, and Precautionary Information"
0900006480681e56,Supporting & Related Material,FDA-2008-P-0049-0009,FDA-2008-P-0049,Exhibit D (3) [FDA-2008-P-0049-0006.1] - So You Sow [Invoice] - Comment
0900006480838fca,Other,FDA-2008-P-0049-0013,FDA-2008-P-0049,"Swanson Health Products, Inc. - Supplement Petition"
09000064803a2c0e,Supporting & Related Material,FDA-2008-P-0049-0003,FDA-2008-P-0049,Exhibit 1 - [FDA-2008-P-0049-0001]
0900006480681ec2,Supporting & Related Material,FDA-2008-P-0049-0007,FDA-2008-P-0049,Exhibit D(1) [FDA-2008-P-0049-0006.1] - So You Sow - [Invioce] - Comment
09000064808393de,Supporting & Related Material,FDA-2008-P-0049-0015,FDA-2008-P-0049,"Exhibit B - ""State of California Department of Justice"" - [Swanson Health Products, Inc. - Supplement Petition]"
09000064808391e3,Supporting & Related Material,FDA-2008-P-0049-0014,FDA-2008-P-0049,"Exhibit A - ""Superior Court of the State of California County of Alameda"" - [Swanson Health Products, Inc. - Supplement Petition]"
09000064803a0fba,Other,FDA-2008-P-0049-0001,FDA-2008-P-0049,"Swanson Health Products, Inc. - Citizen Petition"
0900006480681eb6,Supporting & Related Material,FDA-2008-P-0049-0008,FDA-2008-P-0049,Exhibit D(2) [FDA-2008-P-0049-0006.1] - So You Sow [Invoice] - Comment
09000064803a0ffe,Other,FDA-2008-P-0049-0002,FDA-2008-P-0049,"Acknowledgement Letter to Sedgewick, Detert, Moran & Arnold LLP [Swanson Health Products, Inc.]"
09000064819a9719,Other,FDA-2015-P-0059-0002,FDA-2015-P-0059,Supplement from CSPI
09000064819a9717,Other,FDA-2015-P-0059-0003,FDA-2015-P-0059,Citizen Petition from the Center for Science in the Public Interest (CSPI)
090000648318fdb3,Other,FDA-2015-P-0059-0013,FDA-2015-P-0059,Denial response letter from FDA CFSAN to Center for Science in the Public Interest
0900006481b38ce3,Other,FDA-2015-P-0059-0004,FDA-2015-P-0059,Interim Response Letter from FDA CFSAN to CSPI
0900006481f93ba2,Other,FDA-2015-P-0059-0011,FDA-2015-P-0059,Supplement from Center for Science in the Public Interest (CSPI)
0900006481badf23,Other,FDA-2015-P-0059-0006,FDA-2015-P-0059,Letter from Center for Science in the Public Interest to FDA CFSAN
0900006481bae1c0,Supporting & Related Material,FDA-2015-P-0059-0007,FDA-2015-P-0059,"Attachment 1 Law Banning the Sale of Powdered Caffeine in Ohio, Passed in June 2015 re Letter from Center for Science in the Public Interest to FDA CFSAN"
0900006481bae1c1,Supporting & Related Material,FDA-2015-P-0059-0008,FDA-2015-P-0059,"Attachment 2 Law Banning the Sale of Powdered Caffeine to Minors in Illinois, Passed in July 2015 re Letter from Center for Science in the Public Interest to FDA CFSAN"
09000064819a971b,Other,FDA-2015-P-0059-0001,FDA-2015-P-0059,Acknowledgement Letter from FDA DDM to CSPI
0900006481b75ed3,Other,FDA-2014-P-2035-0014,FDA-2014-P-2035,"Interim Response Letter from FDA CFSAN to Dr. Carla Davis, Texas Children's Hospital"
090000648322b058,Other,FDA-2014-P-2035-0292,FDA-2014-P-2035,Supplement from Center for Science in the Public Interest (CSPI)
09000064833f76b7,Other,FDA-2014-P-2035-0296,FDA-2014-P-2035,04.16.2018 CSPI and FARE Memorandum of Meeting
0900006481945409,Other,FDA-2014-P-2035-0002,FDA-2014-P-2035,Acknowledgement Letter From FDA DDM to Dr. Carla Davis
0900006481945892,Other,FDA-2014-P-2035-0001,FDA-2014-P-2035,"Citizen Petition From Dr. Carla M. Davis, et al."
0900006484e03f23,Other,FDA-2021-P-1181-0002,FDA-2021-P-1181,Acknowledgment Letter from FDA DMS to Pet Schooled
0900006484e03f21,Other,FDA-2021-P-1181-0001,FDA-2021-P-1181,Citizen Petition from Pet Schooled
0900006481ecaba7,Supporting & Related Material,FDA-2016-P-0974-0003,FDA-2016-P-0974,Attachment A Electronic Orange Book TOLVAPTAN TABLET; ORAL 15MG 30MG SAMSCA OTSUKA AMERICA PHARM re Citizen Petition from Gordon Johnston Regulatory Consultants LLC
090000648214c5e4,Notice,FDA-2016-P-0974-0005,FDA-2016-P-0974,"Determination That SAMSCA (Tolvaptan) Tablets, 60 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
0900006481ecaba8,Supporting & Related Material,FDA-2016-P-0974-0004,FDA-2016-P-0974,Attachment B Electronic Orange Book for Tolvaptan 60 MG Samsca Otsuka America Pharm re Citizen Petition from Gordon Johnston Regulatory Consultants LLC
0900006481ec9df8,Other,FDA-2016-P-0974-0002,FDA-2016-P-0974,"Acknowledgement Letter from FDA DDM to Gordon Johnston Regulatory Consultants, LLC"
0900006481ec8ff4,Other,FDA-2016-P-0974-0001,FDA-2016-P-0974,Citizen Petition from Gordon Johnston Regulatory Consultants LLC
0900006483411229,Other,FDA-2017-P-3832-0004,FDA-2017-P-3832,FDA-2017-P-3832 - NPA Response Letter
09000064826f02fa,Other,FDA-2017-P-3832-0001,FDA-2017-P-3832,"Citizen Petition for Reconsideration from Porzio, Bromberg & Newman PC (Natural Products Association)"
09000064826f03e3,Other,FDA-2017-P-3832-0002,FDA-2017-P-3832,"Acknowledgement Letter from FDA DDM to Porzio, Bromberg & Newman, PC (Natural Products Association)"
0900006482d3fb14,Other,FDA-2017-P-3832-0003,FDA-2017-P-3832,"Interim Response from FDA to Porzio, Bromberg & Newman, P.C."
0900006484dd10a8,Other,FDA-2021-P-1141-0002,FDA-2021-P-1141,Acknowledgment Letter from FDA DMS to Harry Duty
0900006484dd10b9,Other,FDA-2021-P-1141-0001,FDA-2021-P-1141,Citizen Petition from Harry Duty
0900006483d68217,Other,FDA-2019-P-3265-0002,FDA-2019-P-3265,"Acknowledgment Letter from FDA DDM to Medical Research Collaborative, LLC"
0900006483d6729f,Other,FDA-2019-P-3265-0001,FDA-2019-P-3265,Citizen Petition from Medical Research Collaborative LLC
09000064841b9ebe,Other,FDA-2019-P-3265-0003,FDA-2019-P-3265,"Letter from FDA CDER to Medical Research Collaborative, LLC"
0900006483410777,Other,FDA-2016-P-1674-0008,FDA-2016-P-1674,FDA-2016-P-1674 TateLyle Granting Response
090000648204be6b,Supporting & Related Material,FDA-2016-P-1674-0003,FDA-2016-P-1674,Attachment 1 Summary of Beneficial Physiological Effects June 15 2016 re Citizen Petition from Tate & Lyle Ingredients Americas LLC
09000064820486c7,Other,FDA-2016-P-1674-0002,FDA-2016-P-1674,Acknowledgement Letter from FDA DDM to Tate & Lyle Ingredients Americas LLC
090000648204829d,Other,FDA-2016-P-1674-0001,FDA-2016-P-1674,Citizen Petition from Tate & Lyle Ingredients Americas LLC
09000064822f1c2a,Other,FDA-2016-P-1674-0005,FDA-2016-P-1674,Letter from General Mills supporting Tate & Lyle's petition
090000648204be6c,Supporting & Related Material,FDA-2016-P-1674-0004,FDA-2016-P-1674,Attachment 3 Citizen Petition B References June 15 2016 re Citizen Petition from Tate & Lyle Ingredients Americas LLC
0900006482548ee1,Other,FDA-2016-P-1674-0007,FDA-2016-P-1674,Interim Response Letter from CFSAN to Tate & Lyle Ingredients Americas LLC
0900006482286036,Other,FDA-2016-P-3070-0002,FDA-2016-P-3070,Acknowledgement Letter from FDA DDM to DuPont Nutrition & Health
090000648252ec87,Other,FDA-2016-P-3070-0010,FDA-2016-P-3070,Interim Response Letter from CFSAN to DuPont Nutrition & Health
090000648228603c,Supporting & Related Material,FDA-2016-P-3070-0005,FDA-2016-P-3070,Appendix Table 2a - POSTPRANDIAL GLUCOSE CONTROL - Human Clinical Studies with Soy Fiber re Citizen Petition from DuPont Nutrition & Health
090000648228603b,Supporting & Related Material,FDA-2016-P-3070-0004,FDA-2016-P-3070,Appendix Table 1b - LAXATION - Human Clinical Studies with Soy Fiber - Institutionalized Subjects re Citizen Petition from DuPont Nutrition & Health
090000648228603a,Supporting & Related Material,FDA-2016-P-3070-0003,FDA-2016-P-3070,Appendix Table 1a - LAXATION - Human Clinical Studies with Soy Fiber - Healthy re Citizen Petition from DuPont Nutrition & Health
090000648228603d,Supporting & Related Material,FDA-2016-P-3070-0006,FDA-2016-P-3070,Appendix Table 2b - POSTPRANDIAL GLUCOSE CONTROL - Human Clinical Studies with Soy Fiber (Diabetic) re Citizen Petition from DuPont Nutrition & Health
090000648228603e,Supporting & Related Material,FDA-2016-P-3070-0007,FDA-2016-P-3070,Appendix Table 3 - CHOLESTEROL REDUCTION - Human Clinical Studies with Soy Fiber re Citizen Petition from DuPont Nutrition & Health
0900006482285e13,Other,FDA-2016-P-3070-0001,FDA-2016-P-3070,Citizen's Petition from DuPont Nutrition & Health
0900006483410f07,Other,FDA-2016-P-3070-0011,FDA-2016-P-3070,FDA-2016-P-3070-DuPont Nutrition and Health Granting Response
0900006482060aa9,Notice,FDA-2016-D-1280-0001,FDA-2016-D-1280,"International Conference on Harmonisation: Electronic Transmission of International Conference on Harmonisation; Electronic Transmission of Postmarket Individual Case Safety Reports for Drugs and Biologics, Excluding Vaccines; Availability of FDA Regional Implementation Specifications for ICH E2B(R3) Reporting to the Food and Drug Administration Adverse Event Reporting System"
0900006484da73e7,Other,FDA-2021-P-1040-0002,FDA-2021-P-1040,Acknowledgment Letter from FDA DMS to PetSchooled
0900006484da75c6,Other,FDA-2021-P-1040-0001,FDA-2021-P-1040,Citizen Petition from Pet Schooled
0900006482500c0e,Other,FDA-2016-P-2533-0003,FDA-2016-P-2533,Interim Response Letter from CVM to American Feed Industry Association
090000648219f0f7,Other,FDA-2016-P-2533-0002,FDA-2016-P-2533,Acknowledgment Letter from FDA DDM American Feed Industry Association and National Grain and Feed Association
090000648219e1f3,Other,FDA-2016-P-2533-0001,FDA-2016-P-2533,Citizen Petition from American Feed Industry Association and National Grain and Feed Association
0900006480ed9b2b,Other,FDA-2011-D-0579-0001,FDA-2011-D-0579,Guidance for Industry; Availability of FDA’s eSubmitter Program for Regulatory Submissions from Licensed Blood Establishments
090000648171f410,Supporting & Related Material,FDA-2014-P-0724-0006,FDA-2014-P-0724,Exhibit 4 Conformer Classification Citizen Petition From Barbara Spohn-Lillo
090000648171f411,Supporting & Related Material,FDA-2014-P-0724-0007,FDA-2014-P-0724,Exhibit 5 Misc. Definitions Citizen Petition From Barbara Spohn-Lillo
09000064821bf430,Other,FDA-2014-P-0724-0014,FDA-2014-P-0724,Citizen Petition Denial from CDRH
090000648171f413,Supporting & Related Material,FDA-2014-P-0724-0009,FDA-2014-P-0724,Exhibit 7 Misc. Definitions Citizen Petition From Barbara Spohn-Lillo
0900006481910e7b,Supporting & Related Material,FDA-2014-P-0724-0012,FDA-2014-P-0724,Exhibit 5c FDA Case Report Citizen Petition From Barbara Spohn-Lillo
090000648171f1e1,Supporting & Related Material,FDA-2014-P-0724-0003,FDA-2014-P-0724,Exhibit 1 Petitioner's Certification Citizen Petition From Barbara Spohn-Lillo
0900006481b03f3a,Other,FDA-2014-P-0724-0013,FDA-2014-P-0724,Interim Response Letter from FDA CDRH to Rocky Mountain Anaplastology Inc.
090000648171f40f,Supporting & Related Material,FDA-2014-P-0724-0005,FDA-2014-P-0724,Exhibit 3 Artificial Eye Classification Citizen Petition From Barbara Spohn-Lillo
090000648171f414,Supporting & Related Material,FDA-2014-P-0724-0010,FDA-2014-P-0724,Exhibit 8 FDA Prosthesis vs. Implant Citizen Petition From Barbara Spohn-Lillo
0900006481910e81,Other,FDA-2014-P-0724-0002,FDA-2014-P-0724,Acknowledgement Letter From FDA DDM to Barbara Spohn-Lillo November 2014
0900006481910e5b,Supporting & Related Material,FDA-2014-P-0724-0011,FDA-2014-P-0724,Exhibit 5b FDA Prosthesis vs. Implant Citizen Petition From Barbara Spohn-Lillo
090000648171f40e,Supporting & Related Material,FDA-2014-P-0724-0004,FDA-2014-P-0724,Exhibit 2 Supporting Precedent Citizen Petition From Barbara Spohn-Lillo
0900006481910e31,Other,FDA-2014-P-0724-0001,FDA-2014-P-0724,Citizen Petition From Barbara Spohn-Lillo
090000648171f412,Supporting & Related Material,FDA-2014-P-0724-0008,FDA-2014-P-0724,Exhibit 6 Scleral Shell Definition Citizen Petition From Barbara Spohn-Lillo
0900006481922a01,Other,FDA-2014-P-1883-0001,FDA-2014-P-1883,Citizen Petition From Lannett Holdings Inc.
0900006481922a09,Other,FDA-2014-P-1883-0002,FDA-2014-P-1883,Acknowledgement Letter From FDA DDM to Lannett Holdings Inc.
09000064819b10b3,Other,FDA-2014-P-1883-0006,FDA-2014-P-1883,Response Letter from FDA CDER to Lannett Holdings Inc.
0900006481922a07,Supporting & Related Material,FDA-2014-P-1883-0004,FDA-2014-P-1883,Exhibit 2 Drug Product List Citzen Petition From Lannett Holdings Inc.
0900006481922a06,Supporting & Related Material,FDA-2014-P-1883-0003,FDA-2014-P-1883,Exhibit 1 Orange Book Information Citzen Petition From Lannett Holdings Inc.
0900006481922a08,Supporting & Related Material,FDA-2014-P-1883-0005,FDA-2014-P-1883,Exhibit 3 Medicare Part D Information Citzen Petition From Lannett Holdings Inc.
0900006481763f61,Other,FDA-2014-P-0878-0001,FDA-2014-P-0878,Citizen Petition from Amarin Pharma Inc.
0900006481763f63,Other,FDA-2014-P-0878-0002,FDA-2014-P-0878,Acknowledgement Letter From FDA DDM to Amarin Pharma Inc.
0900006481949658,Other,FDA-2014-P-0878-0006,FDA-2014-P-0878,"Denial Petition Response Letter from FDA CDER  to Amarin Pharma, Inc."
090000648235df5e,Proposed Rule,FDA-2016-D-2841-0001,FDA-2016-D-2841,"Describing a Hazard That Needs Control in Documents Accompanying 
the Food, as Required by Four Rules Implementing the FDA Food Safety 
Modernization Act: Guidance for Industry; Availability"
0900006482357f82,Supporting & Related Material,FDA-2016-D-2841-0003,FDA-2016-D-2841,"Reference 1 - Grocery Manufacturers Association 21 CFR 117.136 Industry Impacts from Disclosure and Written Assurance Requirements re Describing a Hazard That Needs Control in Documents Accompanying the Food, as Required by Four Rules Implementing the FDA Food Safety Modernization Act: Guidance for Industry; Availability"
0900006482357e58,Other,FDA-2016-D-2841-0002,FDA-2016-D-2841,"Draft Guidance for Draft Guidance for Describing a Hazard That Needs Control in Documents Accompanying the Food, as Required by Four Rules Implementing the FDA Food Safety Modernization Act"
0900006482470618,Notice,FDA-2017-N-0086-0001,FDA-2017-N-0086,"Suggestions, Recommendations, and Comments for Topics That May Be 
Considered by the Food and Drug Administration Combination Product 
Policy Council; Establishment of a Docket"
090000648253d819,Other,FDA-2017-P-2131-0002,FDA-2017-P-2131,Acknowledgment Letter from FDA DDM to Menn Law Firm LTD
090000648253db62,Other,FDA-2017-P-2131-0001,FDA-2017-P-2131,Citizen Petition from Menn Law Firm LTD
0900006482a8cc80,Other,FDA-2017-P-2131-0003,FDA-2017-P-2131,Citizen Petition Withdrawal Letter
09000064841e7fa5,Other,FDA-2019-P-3855-0026,FDA-2019-P-3855,"Amendment to Citizen Petition from Latham & Watkins, LLP on behalf of Genus Lifesciences, Inc"
0900006483e531e0,Other,FDA-2019-P-3855-0001,FDA-2019-P-3855,"Citizen Petition from Latham & Watkins, LLP on behalf of Genus Lifesciences, Inc"
0900006484289a14,Other,FDA-2019-P-3855-0027,FDA-2019-P-3855,Petition Response Letter from FDA CDER to Latham Watkins LLP
0900006483e55590,Other,FDA-2019-P-3855-0002,FDA-2019-P-3855,"Acknowledgment Letter from FDA DMS to Latham & Watkins, LLP on behalf of Genus Lifesciences, Inc"
0900006483e5322c,Supporting & Related Material,FDA-2019-P-3855-0014,FDA-2019-P-3855,"Exhibit 012 - Aug  20, 2013 Pre-IND Meeting Request - Written Responses-  re: Citizen Petition from Latham & Watkins, LLP on behalf of Genus Lifesciences, Inc"
0900006483e53234,Supporting & Related Material,FDA-2019-P-3855-0016,FDA-2019-P-3855,"Exhibit 014 - May 7, 2019 Lannett Form 10-Q- re: Citizen Petition from Latham & Watkins, LLP on behalf of Genus Lifesciences, Inc"
0900006483e531e4,Supporting & Related Material,FDA-2019-P-3855-0003,FDA-2019-P-3855,"Exhibit 001 - June 15, 2015 Meeting Preliminary Comments from FDA to Genus- re: Citizen Petition from Latham & Watkins, LLP on behalf of Genus Lifesciences, Inc"
0900006483e53237,Supporting & Related Material,FDA-2019-P-3855-0019,FDA-2019-P-3855,"Exhibit 017 - Jan 6, 2019 Lannett (LCI) Q2 2019 - Results Earnings Call Transcript - re: Citizen Petition from Latham & Watkins, LLP on behalf of Genus Lifesciences, Inc"
0900006483e53228,Supporting & Related Material,FDA-2019-P-3855-0010,FDA-2019-P-3855,"Exhibit 008 - Feb 1, 2019 Citizen Petition from K L Gates on behalf of Genus-  re: Citizen Petition from Latham & Watkins, LLP on behalf of Genus Lifesciences, Inc"
0900006483e53236,Supporting & Related Material,FDA-2019-P-3855-0018,FDA-2019-P-3855,"Exhibit 016 - Aug 20, 2018 Special Investor Conference Call, Verbatim Report of Webcast by Lannett - re: Citizen Petition from Latham & Watkins, LLP on behalf of Genus Lifesciences, Inc"
0900006483e53238,Supporting & Related Material,FDA-2019-P-3855-0020,FDA-2019-P-3855,"Exhibit 018 - July 1, 2019 Response to Citizen Petition from FDA to K L Gates on behalf of Genus - re: Citizen Petition from Latham & Watkins, LLP on behalf of Genus Lifesciences, Inc"
0900006483e53224,Supporting & Related Material,FDA-2019-P-3855-0006,FDA-2019-P-3855,"Exhibit 004 - Nov_ 7, 2018 Lannett (LCI) Q1 2019 Results - Earnings Call Transcript- re: Citizen Petition from Latham & Watkins, LLP on behalf of Genus Lifesciences, Inc"
0900006483e531e5,Supporting & Related Material,FDA-2019-P-3855-0004,FDA-2019-P-3855,"Exhibit 002 - July 10, 2015 Response to Preliminary Comments from Genus to FDA-  re: Citizen Petition from Latham & Watkins, LLP on behalf of Genus Lifesciences, Inc"
0900006483e5322d,Supporting & Related Material,FDA-2019-P-3855-0015,FDA-2019-P-3855,"Exhibit 013 - Unapproved Labeling for Lannett's Cocaine Hydrochloride Product - re: Citizen Petition from Latham & Watkins, LLP on behalf of Genus Lifesciences, Inc"
0900006483e53235,Supporting & Related Material,FDA-2019-P-3855-0017,FDA-2019-P-3855,"Exhibit 015 - Nov 8, 2018 Lannett Form 10-Q - re: Citizen Petition from Latham & Watkins, LLP on behalf of Genus Lifesciences, Inc"
0900006483e531e6,Supporting & Related Material,FDA-2019-P-3855-0005,FDA-2019-P-3855,"Exhibit 003 - July 15, 2015 Meeting Minutes from FDA to Genus-  re: Citizen Petition from Latham & Watkins, LLP on behalf of Genus Lifesciences, Inc"
0900006483e5323a,Supporting & Related Material,FDA-2019-P-3855-0022,FDA-2019-P-3855,"Exhibit 020 - June 24, 2004 Response to Citizen Petition from FDA to Genpharm - re: Citizen Petition from Latham & Watkins, LLP on behalf of Genus Lifesciences, Inc"
0900006483e53225,Supporting & Related Material,FDA-2019-P-3855-0007,FDA-2019-P-3855,"Exhibit 005 - Dec_ 1, 2017 Press Release, Lannett Co-  re: Citizen Petition from Latham & Watkins, LLP on behalf of Genus Lifesciences, Inc"
0900006483e5322a,Supporting & Related Material,FDA-2019-P-3855-0012,FDA-2019-P-3855,"Exhibit 010 - Feb 24, 2012 Citizen Petition from Lannettet -  re: Citizen Petition from Latham & Watkins, LLP on behalf of Genus Lifesciences, Inc"
0900006483e53229,Supporting & Related Material,FDA-2019-P-3855-0011,FDA-2019-P-3855,"Exhibit 009 - July 3, 2019 Press Release, Lannett Co-  re: Citizen Petition from Latham & Watkins, LLP on behalf of Genus Lifesciences, Inc"
0900006483e5322b,Supporting & Related Material,FDA-2019-P-3855-0013,FDA-2019-P-3855,"Exhibit 011 - Nov 12, 2015 Response to Citizen Petition from FDA to Lannett- re: Citizen Petition from Latham & Watkins, LLP on behalf of Genus Lifesciences, Inc"
09000064841d8190,Other,FDA-2019-P-3855-0025,FDA-2019-P-3855,"Amendment to Citizen Petition from Latham & Watkins, LLP on behalf of Genus Lifesciences, Inc"
0900006483e53226,Supporting & Related Material,FDA-2019-P-3855-0008,FDA-2019-P-3855,"Exhibit 006 - NCT02500836- Clinical Trials -  re: Citizen Petition from Latham & Watkins, LLP on behalf of Genus Lifesciences, Inc"
0900006483e53227,Supporting & Related Material,FDA-2019-P-3855-0009,FDA-2019-P-3855,"Exhibit 007 - NCT01746940- Clinical Trials -  re: Citizen Petition from Latham & Watkins, LLP on behalf of Genus Lifesciences, Inc"
0900006483e53239,Supporting & Related Material,FDA-2019-P-3855-0021,FDA-2019-P-3855,"Exhibit 019 - May 25, 2011 Response to Citizen Petition from FDA to Mutual - re: Citizen Petition from Latham & Watkins, LLP on behalf of Genus Lifesciences, Inc"
09000064848d3167,Other,FDA-2019-P-5440-0003,FDA-2019-P-5440,Interim response letter from FDA CDER to Diane Kramer
0900006484176411,Other,FDA-2019-P-5440-0001,FDA-2019-P-5440,Citizen Petition from Diane Kramer
0900006484a34ada,Other,FDA-2019-P-5440-0004,FDA-2019-P-5440,Response Letter from FDA CDER to Diane Kramer
0900006484176412,Other,FDA-2019-P-5440-0002,FDA-2019-P-5440,Acknowledgement Letter from FDA DMS to Diane Kramer
0900006484be4b08,Other,FDA-2019-D-1997-0002,FDA-2019-D-1997,"FDA Oversight of Food Products Covered by Systems Recognition Arrangements: 
Guidance for Food and Drug Administration Staff DRAFT GUIDANCE"
0900006484be41db,Notice,FDA-2019-D-1997-0001,FDA-2019-D-1997,Food and Drug Administration Oversight of Food Products Covered by Systems Recognition Arrangements; Draft Guidance for Food and Drug Administration Staff; Availability
09000064824e9e20,Other,FDA-1998-P-0257-0005,FDA-1998-P-0257,Nisin Citizen Petition Response Letter
090000648253dc0b,Other,FDA-1998-P-0257-0006,FDA-1998-P-0257,2017-03-02 Nisin Citizen Petition Response Letter
0900006480594b7b,Other,FDA-1998-P-0257-0002,FDA-1998-P-0257,Acknowledgement Letter from FDA DDM to Stephaine Brown
0900006480594b6a,Other,FDA-1998-P-0257-0001,FDA-1998-P-0257,Citizen Petition from Stephanie Heather Brown
0900006480594b7e,Other,FDA-1998-P-0257-0003,FDA-1998-P-0257,Interim letter from CFSAN to Stephanie Heather Brown
09000064824c6b63,Supporting & Related Material,FDA-1998-P-0257-0004,FDA-1998-P-0257,Exibit 1 re Cititzen Petition from Stephaine Brown
0900006484a87a8f,Other,FDA-2021-P-0337-0002,FDA-2021-P-0337,Acknowledgment Letter from FDA DMS to Siri and Glimstad LLP on behalf of Informed Consent Action Network
0900006484a87a8d,Other,FDA-2021-P-0337-0001,FDA-2021-P-0337,Citizen Petition from Siri and Glimstad LLP on behalf of Informed Consent Action Network
0900006484d9ce93,Other,FDA-2021-P-0337-0004,FDA-2021-P-0337,"Interim Response from FDA CBER to Siri & Glimstad, LLP"
0900006484a87a91,Supporting & Related Material,FDA-2021-P-0337-0003,FDA-2021-P-0337,Cover Letter from Siri and Glimstad LLP on behalf of Informed Consent Action Network
09000064835d813f,Other,FDA-2018-P-3076-0001,FDA-2018-P-3076,Citizen Petition from Dr. Joseph Purita
09000064835d82cf,Other,FDA-2018-P-3076-0002,FDA-2018-P-3076,Acknowledgment Letter from FDA DDM to Dr. Joseph Purita
0900006483a3152a,Other,FDA-2018-P-3076-0003,FDA-2018-P-3076,Interim Response Letter from FDA CDER to Dr. Joseph Purita
0900006483df5d6c,Other,FDA-2018-P-3076-0004,FDA-2018-P-3076,Response Letter from FDA CDER to Dr. Joseph Purita
0900006480f4d339,Other,FDA-2011-D-0721-0002,FDA-2011-D-0721,Guidance for Industry Implementation of the Fee Provisions of Section 107 of the FDA Food Safety Modernization Act
0900006480f4d3c5,Notice,FDA-2011-D-0721-0001,FDA-2011-D-0721,Guidance for Industry on Implementation of the Fee Provisions of the FDA Food Safety Modernization Act; Availability
090000648290df41,Supporting & Related Material,FDA-2017-P-4145-0004,FDA-2017-P-4145,"Attachment 2 Draft Insert Labeling Proposed for Azacitidine for Injection re Citizen Petition from Mylan Pharmaceuticals, Inc"
090000648290dc10,Other,FDA-2017-P-4145-0001,FDA-2017-P-4145,"Citizen Petition from Mylan Pharmaceuticals, Inc"
090000648290dc12,Other,FDA-2017-P-4145-0002,FDA-2017-P-4145,Acknowledgement Letter from FDA DDM to Mylan Pharmaceuticals Inc
090000648290df42,Supporting & Related Material,FDA-2017-P-4145-0005,FDA-2017-P-4145,"Attachment 3 Labeling for Reference Listed Drug Vidaza re Citizen Petition from Mylan Pharmaceuticals, Inc"
090000648290df40,Supporting & Related Material,FDA-2017-P-4145-0003,FDA-2017-P-4145,"Attachment 1 Approved Drug Products with Therapeutic Equivalence Evaluations re Citizen Petition from Mylan Pharmaceuticals, Inc"
09000064810109e1,Supporting & Related Material,FDA-2012-D-0140-0008,FDA-2012-D-0140,See FDA-2012-D-0140-0006
0900006480fc306a,Notice,FDA-2012-D-0140-0001,FDA-2012-D-0140,Draft Guidance for Industry on Notification to Food and Drug Administration of Issues That May Result in a Prescription Drug Shortage; Availability
0900006480fc3d57,Other,FDA-2012-D-0140-0002,FDA-2012-D-0140,Notification to FDA of Issues that May Result in a Prescription Drug or Biological Product Shortage
0900006481d93908,Other,FDA-2015-A-4705-0001,FDA-2015-A-4705,"Advisory Opinion Petition from Luedeka Neely Group, P.C. on behalf of Consorzio del Formaggio Parmigiano-Reggiano"
0900006481d93bc4,Other,FDA-2015-A-4705-0002,FDA-2015-A-4705,"Acknowledgement Letter from FDA DDM to Luedeka Neely Group, P.C. on behalf of Consorzio del Formaggio Parmigiano-Reggiano"
09000064825833c8,Other,FDA-2015-A-4705-0003,FDA-2015-A-4705,FDA-2015-A-4705 Withdrawal of Petition
09000064815b0f68,Notice,FDA-2013-D-1600-0001,FDA-2013-D-1600,"Draft Guidance for Industry and Tobacco Retailers; Enforcement Policy
for Certain (Provisional) Tobacco Products That the Food and Drug
Administration Finds Not Substantially Equivalent; Availability"
0900006481c6c25e,Notice,FDA-2013-D-1600-0007,FDA-2013-D-1600,"Enforcement Policy for Certain (Provisional) Tobacco Products That
the Food and Drug Administration Finds Not Substantially Equivalent;
Guidance for Industry and Tobacco Retailers; Availability"
0900006481c6cf3b,Other,FDA-2013-D-1600-0008,FDA-2013-D-1600,Enforcement Policy for Certain (Provisional) Tobacco Products that FDA Finds Not Substantially Equivalent; Guidance for Industry and Tobacco Retailers
09000064815b2337,Other,FDA-2013-D-1600-0002,FDA-2013-D-1600,"Draft Guidance for Industry and Tobacco Retailers; Enforcement Policy
for Certain (Provisional) Tobacco Products That the Food and Drug
Administration Finds Not Substantially Equivalent"
0900006481953f5c,Notice,FDA-2013-D-0295-0010,FDA-2013-D-0295,"Guidance for Industry on Scale-Up Post-Approval Changes:
Manufacturing Equipment Addendum; Availability"
0900006481251f6d,Other,FDA-2013-D-0295-0002,FDA-2013-D-0295,"Draft Guidance for Industry; Scale-Up and Post-Approval Changes, Manufacturing Equipment Addendum"
0900006481252361,Notice,FDA-2013-D-0295-0001,FDA-2013-D-0295,"Draft Guidance for Industry; Availability: Scale-Up and Post-Approval Changes, Manufacturing Equipment Addendum"
0900006481954f47,Other,FDA-2013-D-0295-0011,FDA-2013-D-0295,"Guidance for Industry on Scale-Up Post-Approval Changes:
Manufacturing Equipment Addendum"
0900006484145cee,Other,FDA-2019-P-2239-0008,FDA-2019-P-2239,Interim Response Letter from FDA to BioNeutra North America Inc
0900006483c4568b,Supporting & Related Material,FDA-2019-P-2239-0003,FDA-2019-P-2239,Appendix A -  re Citizen Petition from BioNeutra North America Inc
0900006483c4568c,Supporting & Related Material,FDA-2019-P-2239-0004,FDA-2019-P-2239,Appendix A - FDA re Citizen Petition from BioNeutra North America Inc
0900006483c45614,Other,FDA-2019-P-2239-0001,FDA-2019-P-2239,Citizen Petition from BioNeutra North America Inc
0900006483c45689,Other,FDA-2019-P-2239-0002,FDA-2019-P-2239,Acknowledgement Letter from FDA DDM to BioNeutra North America Inc
0900006484291e7a,Other,FDA-2019-P-2239-0009,FDA-2019-P-2239,Final Response Letter from FDA to BioNeutra North America Inc
0900006482af743c,Other,FDA-2017-P-1298-0091,FDA-2017-P-1298,Interim Response Letter from FDA CFSAN to The Good Food Institute
090000648445b23c,Other,FDA-2017-P-1298-0302,FDA-2017-P-1298,Supplement from The Good Food Institute
09000064824e6abe,Other,FDA-2017-P-1298-0001,FDA-2017-P-1298,Citizen Petition from The Good Food Institute
09000064824e6b25,Supporting & Related Material,FDA-2017-P-1298-0004,FDA-2017-P-1298,Attachment B Orders from Federal Court Cases - Gitson and Ang re Citizen Petition from The Good Food Institute
09000064824e6ac0,Other,FDA-2017-P-1298-0002,FDA-2017-P-1298,Acknowledgement Letter from FDA DDM to The Good Food Institute
0900006482aed82e,Other,FDA-2017-P-1298-0064,FDA-2017-P-1298,Supplement from The Good Food Institute
09000064824e6b24,Supporting & Related Material,FDA-2017-P-1298-0003,FDA-2017-P-1298,"Attachment A Soyfoods Association of North America, Summary of Consumer Research re Citizen Petition from The Good Food Institute"
090000648243acf7,Supporting & Related Material,FDA-2016-P-4388-0003,FDA-2016-P-4388,"Baker, a Pharmacological Review 2007 Re. Citizen Petition from S. Varghese"
090000648243acf8,Supporting & Related Material,FDA-2016-P-4388-0004,FDA-2016-P-4388,Citizen Petition Reference List Re. Citizen Petition from S. Varghese
09000064826f191b,Other,FDA-2016-P-4388-0009,FDA-2016-P-4388,Interim Response Letter from FDA CDER to Dr. S. Varghese
0900006482b249b2,Other,FDA-2016-P-4388-0010,FDA-2016-P-4388,CHPA response to Citizen Petition Loperamide OTC to Rx 090517 FINAL
090000648243acf9,Supporting & Related Material,FDA-2016-P-4388-0005,FDA-2016-P-4388,Loperamide Abuse and Dependence 2015 Re. Citizen Petition from S. Varghese
090000648243acfa,Supporting & Related Material,FDA-2016-P-4388-0006,FDA-2016-P-4388,"Loperamide Induced TDP, Re. Citizen Petition from S. Varghese"
090000648240c140,Other,FDA-2016-P-4388-0002,FDA-2016-P-4388,Acknowledgment Letter from FDA DDM to Dr. S. Varghese
090000648243acfb,Supporting & Related Material,FDA-2016-P-4388-0007,FDA-2016-P-4388,"Poor man's Methadone, Re. Citizen Petition from S. Varghese"
090000648240c13d,Other,FDA-2016-P-4388-0001,FDA-2016-P-4388,Citizen Petition from Dr. S. Varghese
090000648499895d,Other,FDA-2016-P-4388-0013,FDA-2016-P-4388,Response Letter from FDA CDER to Dr. S. Varghese
09000064849a9a01,Supporting & Related Material,FDA-2020-P-2312-0002,FDA-2020-P-2312,Memo from FDA DMS to Phibro
09000064849a887b,Other,FDA-2020-P-2312-0001,FDA-2020-P-2312,Petition from Covington & Burling LLP
09000064835e8806,Other,FDA-2018-P-0673-0009,FDA-2018-P-0673,Interim Response from FDA CDER to Justice for Jake
0900006484a3b7c6,Other,FDA-2018-P-0673-0011,FDA-2018-P-0673,Response Letter from FDA CDER to Justice for Jake
0900006482f1adff,Other,FDA-2018-P-0673-0001,FDA-2018-P-0673,Citizen Petition from Justice for Jake
0900006482f1ae53,Supporting & Related Material,FDA-2018-P-0673-0003,FDA-2018-P-0673,"Attachment One, 239 signed form letters re Citizen Petition from Justice for Jake"
0900006482f1ae01,Other,FDA-2018-P-0673-0002,FDA-2018-P-0673,Acknowledgment Letter from FDA DDM to Justice for Jake
0900006484be90d7,Other,FDA-2021-P-0714-0002,FDA-2021-P-0714,Acknowledgment Letter from FDA DMS to Lassman Law + Policy
0900006484be90da,Supporting & Related Material,FDA-2021-P-0714-0003,FDA-2021-P-0714,Exhibits re Citizen Petition from Lassman Law + Policy
0900006484be90d5,Other,FDA-2021-P-0714-0001,FDA-2021-P-0714,Citizen Petition from Lassman Law + Policy
090000648436075f,Supporting & Related Material,FDA-2020-P-0763-0003,FDA-2020-P-0763,Doubts about the efficacy of tolvaptan for polycystic kidney disease RE Citizen Petition from Clark Anderson
0900006484c02749,Other,FDA-2020-P-0763-0005,FDA-2020-P-0763,Response Letter from FDA CDER to Clark Anderson
09000064847e402a,Other,FDA-2020-P-0763-0004,FDA-2020-P-0763,Interim Response from FDA CDER to Clark Anderson
090000648435c5b7,Other,FDA-2020-P-0763-0002,FDA-2020-P-0763,Acknowledgment Letter from FDA DMS to Clark Anderson
090000648435c1d7,Other,FDA-2020-P-0763-0001,FDA-2020-P-0763,Citizen Petition from Clark Anderson
0900006484aa7666,Other,FDA-2021-P-0389-0001,FDA-2021-P-0389,Citizen Petition from IDRS Labs Private Limited
0900006484ca5f9e,Other,FDA-2021-P-0389-0003,FDA-2021-P-0389,Response Letter from FDA CDER to IDRS Labs Private Limited
0900006484aa7668,Other,FDA-2021-P-0389-0002,FDA-2021-P-0389,Acknowledgement Letter from FDA DMS to IDRS Labs Private Limited
0900006482054403,Other,FDA-2005-P-0198-0003,FDA-2005-P-0198,Petition Closure Memorandum from FDA CFSAN
09000064804410e5,Other,FDA-2005-P-0198-0002,FDA-2005-P-0198,Interim Response Letter from FDA CFSAN to Perricone Juices
09000064804410c3,Other,FDA-2005-P-0198-0001,FDA-2005-P-0198,Acknowledgment Letter from FDA DDM to Perricone Juices
09000064809b8f1e,Notice,FDA-2008-D-0253-0001,FDA-2008-D-0253,Draft Guidance for Industry on Presenting Risk Information in Prescription Drug and Medical Device Promotion; Availability
09000064809b8fbb,Other,FDA-2008-D-0253-0002,FDA-2008-D-0253,Presenting Risk Information in Prescription Drug and Medical Device Promotion
0900006482f0221b,Other,FDA-2018-P-0625-0002,FDA-2018-P-0625,Acknowledgment Letter from FDA DDM to Made in the USA Foundation
0900006482f0221f,Supporting & Related Material,FDA-2018-P-0625-0005,FDA-2018-P-0625,Exhibit 3 re Citizen Petition from Made in the USA Foundation-2
0900006482f0221e,Supporting & Related Material,FDA-2018-P-0625-0004,FDA-2018-P-0625,Exhibit 2 re Citizen Petition from Made in the USA Foundation-2
09000064835e5aca,Other,FDA-2018-P-0625-0007,FDA-2018-P-0625,Interim Response from FDA CDER to Made in the USA Foundation
0900006482f02219,Other,FDA-2018-P-0625-0001,FDA-2018-P-0625,Citizen Petition from Made in the USA Foundation
0900006482f0221d,Supporting & Related Material,FDA-2018-P-0625-0003,FDA-2018-P-0625,Exhibit 1 re Citizen Petition from Made in the USA Foundation
0900006483dd0f53,Other,FDA-2018-P-0625-0008,FDA-2018-P-0625,Letter from FDA CDER to Made in the USA Foundation
0900006483e655e2,Other,FDA-2019-P-3886-0002,FDA-2019-P-3886,Acknowledgment Letter from FDA DMS to Turner Scientific
0900006483e65647,Supporting & Related Material,FDA-2019-P-3886-0003,FDA-2019-P-3886,Attachment 1 Guidance Document Submission - Ototoxicity - Nonclinical Evaluation During Drug Development re Citizen Petition from Turner Scientific
0900006483eadcce,Other,FDA-2019-P-3886-0004,FDA-2019-P-3886,Citizen Petition Withdrawal Request from Turner Scientific LLC to FDA DMS
0900006483e655e1,Other,FDA-2019-P-3886-0001,FDA-2019-P-3886,Citizen Petition from Turner Scientific
09000064813b64a7,Other,FDA-2013-P-0425-0003,FDA-2013-P-0425,"FDA/CDER to Rhodes Technologies (Kleinfeld, Kaplan and Becker, LLP) - Denial of Petition"
09000064812921cf,Other,FDA-2013-P-0425-0002,FDA-2013-P-0425,"Acknowledgement Letter to Rhodes Technologies (Kleinfeld, Kaplan and Becker, LLP)"
0900006481292188,Other,FDA-2013-P-0425-0001,FDA-2013-P-0425,"Rhodes Technologies (Kleinfeld, Kaplan and Becker, LLP) - Citizen Petition"
0900006483a73d13,Supporting & Related Material,FDA-2019-P-0726-0004,FDA-2019-P-0726,Attachment 2 Insert- FXT 60mg-ALVOGEN re Suitability Citizen Petition from Sunny Pharmtech Inc
0900006483a73d14,Supporting & Related Material,FDA-2019-P-0726-0005,FDA-2019-P-0726,Attachment 3 Draft labeling text-0212bm re Suitability Citizen  Petition from Sunny Pharmtech Inc
0900006483a73d15,Supporting & Related Material,FDA-2019-P-0726-0006,FDA-2019-P-0726,Attachment 4 Annotated comparison with listed drug-0212-bm re Suitability Citizen Petition from Sunny Pharmtech Inc
0900006483a73a87,Other,FDA-2019-P-0726-0001,FDA-2019-P-0726,Suitability Citizen Petition from Sunny Pharmtech Inc
0900006483a73a89,Other,FDA-2019-P-0726-0002,FDA-2019-P-0726,Acknowledgment Letter from FDA DDM to Sunny Pharmtech Inc
0900006483a73d12,Supporting & Related Material,FDA-2019-P-0726-0003,FDA-2019-P-0726,Attachment 1 Orange Book Approved Drug Products with Therapeutic Equivalence Evaluations re Suitability Citizen  Petition from Sunny Pharmtech Inc
0900006482e530d5,Supporting & Related Material,FDA-2018-P-0339-0004,FDA-2018-P-0339,"Attachment 2 Labeling for Listed Drug, TREANDA Cephalon, Inc. re: Citizen Petition from Hahn Loeser & Parks LLP"
0900006482e530d6,Supporting & Related Material,FDA-2018-P-0339-0005,FDA-2018-P-0339,Attachment 3 Draft Insert Labeling Proposed for Bendamustine Hydrochloride for Injection (200 mg) re: Citizen Petition from Hahn Loeser & Parks LLP
0900006482e4f7a1,Other,FDA-2018-P-0339-0001,FDA-2018-P-0339,Citizen Petition from Hahn Loeser and Parks LLP
0900006482e530d4,Supporting & Related Material,FDA-2018-P-0339-0003,FDA-2018-P-0339,"Attachment 1 Approved Drug Products with Therapeutic Equivalence Evaluations, November 13, 2017 accessed.  re: Citizen Petition from  Hahn Loeser & Parks LLP"
09000064837ec68a,Other,FDA-2018-P-0339-0006,FDA-2018-P-0339,Letter from Hahn Loeser & Parks LLP to FDA CDER-OGD
0900006482e4f7a5,Other,FDA-2018-P-0339-0002,FDA-2018-P-0339,Acknowledgment Letter from FDA DDM Hahn Loeser & Parks LLP
090000648183b320,Notice,FDA-2013-N-0745-0053,FDA-2013-N-0745,"Reopening of Docket and Request for Comments on the Food and Drug
Administration Safety and Innovation Act Action Plan"
09000064815f6b9f,Proposed Rule,FDA-2013-N-0745-0022,FDA-2013-N-0745,"Action Plan for the Collection, Analysis, and Availability of Demographic Subgroup Data in Applications for Approval of Food and Drug Administration-Regulated Medical Products; Notice of Public
Hearing; Request for Comments"
09000064813bf052,Notice,FDA-2013-N-0745-0001,FDA-2013-N-0745,Request for Comments on the Food and Drug Administration Safety and Innovation Act Section 907 Report
0900006482b0317c,Other,FDA-2015-P-0578-0005,FDA-2015-P-0578,Letter from FDA to Public Citizen's Health Research Group
0900006481a12b71,Other,FDA-2015-P-0578-0001,FDA-2015-P-0578,Citizen Petition From Public Citizen's Health Research Group
0900006481e04f0b,Other,FDA-2015-P-0578-0004,FDA-2015-P-0578,Interim Response from FDA CDER to Public Citizen's Health Research Group
0900006481a14d83,Other,FDA-2015-P-0578-0002,FDA-2015-P-0578,Acknowledgement Letter From FDA DDM to Public Citizen's Health Research Group
0900006481a12b74,Supporting & Related Material,FDA-2015-P-0578-0003,FDA-2015-P-0578,Background Material From Public Citizen Citizen Petition From Public Citizen's Health Research Group
0900006482cf38d4,Other,FDA-2017-N-6313-0002,FDA-2017-N-6313,Prescription Drug User Fee Act VI Commitment to Assess Current Practices of the Food and Drug Administration and Sponsors in Communicating During Investigational New Drug Development; Establishment of a Public Docket; Request for Comments
0900006482cf28d9,Notice,FDA-2017-N-6313-0001,FDA-2017-N-6313,"Prescription Drug User Fee Act VI Commitment To Assess Current  Practices of the Food and Drug Administration and Sponsors in
Communicating During Investigational New Drug Development; Establishment of a Public Docket; Request for Comments"
0900006482548a0e,Other,FDA-2017-P-2230-0002,FDA-2017-P-2230,"Acknowledgment Letter from FDA DDM to Kleinfeld, Kaplan and Becker, LLP  (Purdue Pharma L.P.)"
0900006482548946,Other,FDA-2017-P-2230-0001,FDA-2017-P-2230,"Citizen Petition from Kleinfeld, Kaplan and Becker, LLP  (Purdue Pharma L.P.)"
0900006482b15e2c,Other,FDA-2017-P-2230-0005,FDA-2017-P-2230,"Citizen Petition Response Letter from FDA CDER to Kleinfeld, Kaplan and Becker, LLP"
0900006481756b2b,Other,FDA-2014-P-0830-0002,FDA-2014-P-0830,"Acknowledgement Letter from FDA DDM to Merz North America (Buchanan, Ingersoll and Rooney PC)"
090000648235806c,Other,FDA-2014-P-0830-0006,FDA-2014-P-0830,"Denial letter from FDA CDER to Merz North America (Buchanan, Ingersoll and Rooney PC)"
09000064819f250c,Other,FDA-2014-P-0830-0004,FDA-2014-P-0830,Interim Response
0900006481756b28,Other,FDA-2014-P-0830-0001,FDA-2014-P-0830,"Citizen Petition From Merz North America (Buchanan, Ingersoll and Rooney PC)"
09000064836b2b36,Other,FDA-2018-P-3355-0003,FDA-2018-P-3355,Citizen Petition from Oregon Pain Guidance
0900006483ab67ae,Other,FDA-2018-P-3355-0017,FDA-2018-P-3355,Interim Response from FDA CDER
09000064836a7fbf,Other,FDA-2018-P-3355-0002,FDA-2018-P-3355,Acknowledgment Letter from FDA DDM to Oregon Pain Guidance
09000064836a816f,Other,FDA-2018-P-3355-0001,FDA-2018-P-3355,Citizen Petition from Oregon Pain Guidance
09000064836b2beb,Supporting & Related Material,FDA-2018-P-3355-0004,FDA-2018-P-3355,Attachments re Citizen Petition from Oregon Pain Guidance
09000064836e1b92,Other,FDA-2018-P-3355-0005,FDA-2018-P-3355,Acknowledgment Letter from FDA DDM to Oregon Pain Guidance
09000064848f91dd,Other,FDA-2020-P-2067-0001,FDA-2020-P-2067,"Suitability Petition from Hyman, Phelps & McNamara, PC"
09000064848f91e2,Supporting & Related Material,FDA-2020-P-2067-0004,FDA-2020-P-2067,"Attachment 2 re Suitability Petition from Hyman, Phelps & McNamara, PC"
09000064848f91de,Other,FDA-2020-P-2067-0002,FDA-2020-P-2067,"Acknowledgment Letter from FDA DMS to Hyman, Phelps & McNamara, PC"
09000064848f91e3,Supporting & Related Material,FDA-2020-P-2067-0005,FDA-2020-P-2067,"Attachment 3 re Suitability Petition from Hyman, Phelps & McNamara, PC"
09000064848f91e1,Supporting & Related Material,FDA-2020-P-2067-0003,FDA-2020-P-2067,"Attachment 1 re Suitability Petition from Hyman, Phelps & McNamara, PC"
09000064846f6807,Other,FDA-2020-P-1582-0002,FDA-2020-P-1582,Acknowledgment Letter from FDA DMS to Council for Responsible Nutrition
09000064849717c4,Other,FDA-2020-P-1582-0004,FDA-2020-P-1582,180 Day Interim Response Letter to the Council for Response Nutrition from FDA CFSAN
09000064846f66ef,Other,FDA-2020-P-1582-0001,FDA-2020-P-1582,Citizen Petition from The Council for Responsible Nutrition
0900006482f64093,Supporting & Related Material,FDA-2018-P-0870-0003,FDA-2018-P-0870,"Attachment 1 Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations re: Citizen Petition from  Lachman Consultant Services, Inc."
0900006482f64095,Supporting & Related Material,FDA-2018-P-0870-0005,FDA-2018-P-0870,"Attachment 3-POTASSIUM CHLORIDE EXTENDED RELEASE TABLET PROPOSED GERIATRIC AND OVERDOSAGE LABELING re:  Citizen Petition from Lachman Consultant Services, Inc."
09000064849224ac,Other,FDA-2018-P-0870-0006,FDA-2018-P-0870,"Letter from Lachman Consultant Services, Inc."
0900006482f63aee,Other,FDA-2018-P-0870-0001,FDA-2018-P-0870,"Citizen Petition from Lachman Consultant Services, Inc."
0900006482f64091,Other,FDA-2018-P-0870-0002,FDA-2018-P-0870,"Acknowledgment Letter from FDA DDM to LACHMAN CONSULTANT SERVICES, INC."
0900006482f64094,Supporting & Related Material,FDA-2018-P-0870-0004,FDA-2018-P-0870,"Attachment 2- Prescription Drug Product List Re: Citizen Petition from Lachman Consultant Services, Inc."
0900006483e2d63e,Notice,FDA-2019-N-3453-0001,FDA-2019-N-3453,Promoting Effective Drug Development Programs: Opportunities and Priorities for the Food and Drug Administration’s Office of New Drugs
0900006483b69f9f,Other,FDA-2019-P-1640-0002,FDA-2019-P-1640,"Acknowledgment Letter from FDA DDM to Top Health Ingredients, Inc"
0900006483b69fa4,Supporting & Related Material,FDA-2019-P-1640-0004,FDA-2019-P-1640,"Appendix 2 re Citizen Petition from Top Health Ingredients, Inc"
0900006484109bf5,Other,FDA-2019-P-1640-0008,FDA-2019-P-1640,"Interim Response Letter from FDA CFSAN to Top Health Ingredients, Inc"
09000064842ea5b1,Other,FDA-2019-P-1640-0011,FDA-2019-P-1640,"Letter from FDA CFSAN to Top Health Ingredients, Inc."
0900006484291eca,Other,FDA-2019-P-1640-0010,FDA-2019-P-1640,"Final Response Letter from FDA CFSAN to Top Health Ingredients, Inc"
0900006483b69fa3,Supporting & Related Material,FDA-2019-P-1640-0003,FDA-2019-P-1640,"Appendix 1 re Citizen Petition from Top Health Ingredients, Inc"
0900006483b69f92,Other,FDA-2019-P-1640-0001,FDA-2019-P-1640,"Citizen Petition from Top Health Ingredients, Inc."
09000064849a9202,Other,FDA-2020-P-2313-0002,FDA-2020-P-2313,Petition for Stay of Action from Covington & Burling LLP
09000064849a9a02,Supporting & Related Material,FDA-2020-P-2313-0001,FDA-2020-P-2313,Memo from FDA DMS to Phibro
0900006484ad87e3,Supporting & Related Material,FDA-2021-P-0438-0003,FDA-2021-P-0438,Attachment 1-  National Toxicology Program technical report re: Citizen Petition from Joe DiNardo
0900006484ad87e4,Supporting & Related Material,FDA-2021-P-0438-0004,FDA-2021-P-0438,Attachment 2- Per and Polyfluoroalkyl Substances (PFAS)  FDA re: Citizen Petition from Joe DiNardo
0900006484ad56b5,Other,FDA-2021-P-0438-0002,FDA-2021-P-0438,Acknowledgment  Letter from FDA DMS  to  Joe DiNardo
0900006484ad55fe,Other,FDA-2021-P-0438-0001,FDA-2021-P-0438,Citizen Petition from Joe DiNardo
0900006484ad87e6,Supporting & Related Material,FDA-2021-P-0438-0006,FDA-2021-P-0438,Attachment 4 Safer Chemicals Healthy Families. McDonalds re: Citizen Petition from Joe DiNardo
0900006484ad87e7,Supporting & Related Material,FDA-2021-P-0438-0007,FDA-2021-P-0438,Attachment 5- Detroit MetroTimes. Some Michigan cows  re: Citizen Petition from Joe DiNardo
0900006484ad87e5,Supporting & Related Material,FDA-2021-P-0438-0005,FDA-2021-P-0438,Attachment 3- FDA.gov- Testing Food for PFAS and Assessing Dietary Exposure re: Citizen Petition from Joe DiNardo
09000064849bae17,Other,FDA-2020-P-2322-0002,FDA-2020-P-2322,Acknowledgment Letter from FDA DMS to Covington & Burling LLP on behalf of Pharmaceutical Research and Manufacturers of America
09000064849bae16,Other,FDA-2020-P-2322-0001,FDA-2020-P-2322,Citizen Petition from Covington & Burling LLP on behalf of Pharmaceutical Research and Manufacturers of America
0900006484bac316,Other,FDA-2020-P-2322-0003,FDA-2020-P-2322,Interim Response to Covington & Burling LLP from FDA CDER
090000648048b7c7,Supporting & Related Material,FDA-2003-D-0198-0002,FDA-2003-D-0198,Guidance
090000648048b7c2,Notice,FDA-2003-D-0198-0001,FDA-2003-D-0198,FDA
0900006482b9515d,Other,FDA-2003-D-0198-0003,FDA-2003-D-0198,User Fees and Refunds for Premarket Notification Submissions (510(k)s) :  Guidance for Industry and Food and Drug Administration Staff
090000648044a08f,Notice,FDA-2005-N-0351-0002,FDA-2005-N-0351,FDA
090000648044a0c4,Notice,FDA-2005-N-0351-0001,FDA-2005-N-0351,FDA
09000064804816fa,Notice,FDA-2003-N-0039-0003,FDA-2003-N-0039,FDA
09000064804816fc,Notice,FDA-2003-N-0039-0004,FDA-2003-N-0039,FDA
09000064804816f8,Notice,FDA-2003-N-0039-0001,FDA-2003-N-0039,FDA
09000064804816f9,Notice,FDA-2003-N-0039-0002,FDA-2003-N-0039,FDA
09000064804816fe,Supporting & Related Material,FDA-2003-N-0039-0006,FDA-2003-N-0039,Supporting Statement
09000064804816fd,Supporting & Related Material,FDA-2003-N-0039-0005,FDA-2003-N-0039,Supporting Statement
090000648046fb73,Notice,FDA-2004-D-0120-0001,FDA-2004-D-0120,FDA
0900006480b3e098,Notice,FDA-2010-N-0445-0001,FDA-2010-N-0445,Request for Applications: Supplemental Funding Under the Emergency Response Laboratory Network Microbiological Cooperative Agreement Program
0900006484dcf02d,Other,FDA-2020-D-1380-0004,FDA-2020-D-1380,Regulatory Requirements for Hearing Aid Devices and Personal Sound Amplification Products Draft Guidance for Industry and Food and Drug Administration Staff
0900006484dd6df9,Other,FDA-2020-D-1380-0005,FDA-2020-D-1380,Regulatory Requirements for Hearing Aid Devices and Personal Sound Amplification Products; Draft Guidance for Industry and Food and Drug Administration Staff
09000064845e6c3e,Other,FDA-2020-D-1380-0001,FDA-2020-D-1380,Guidance for Industry and FDA Staff; Regulatory Requirements for Hearing Aid Devices and Personal Sound Amplification Products
0900006484dce4ff,Notice,FDA-2020-D-1380-0003,FDA-2020-D-1380,Regulatory Requirements for Hearing Aid Devices and Personal Sound Amplification Products; Draft Guidance for Industry and Food and Drug Administration Staff; Availability
0900006484936fce,Supporting & Related Material,FDA-2020-P-2132-0003,FDA-2020-P-2132,"Attachment 1:  Drug Shortage Detail Oral Suspension re Citizen Petition from HYMAN, PHELPS & MCNAMARA, P.C."
0900006484981cf4,Other,FDA-2020-P-2132-0004,FDA-2020-P-2132,"Withdrawal from HYMAN, PHELPS & MCNAMARA, P.C."
0900006484936ab3,Other,FDA-2020-P-2132-0002,FDA-2020-P-2132,"Acknowledgement Letter from FDA DMS to HYMAN, PHELPS & MCNAMARA, P.C."
0900006484936aad,Other,FDA-2020-P-2132-0001,FDA-2020-P-2132,"Citizen Petition from HYMAN, PHELPS & MCNAMARA, P.C."
09000064827c2b7f,Other,FDA-2017-P-0663-0003,FDA-2017-P-0663,"Petition Denial Letter from FDA CDER to Mucodel Pharma, LLC"
09000064824a56a9,Other,FDA-2017-P-0663-0001,FDA-2017-P-0663,"Citizen Petition from Mucodel Pharma, LLC"
09000064824a579a,Other,FDA-2017-P-0663-0002,FDA-2017-P-0663,"Acknowledgment Letter from FDA DDM to Mucodel Pharma, LLC"
09000064824d2340,Other,FDA-2017-P-1104-0002,FDA-2017-P-1104,"Acknowledgment Letter from FDA DDM to Gator Pharmaceuticals, Inc."
09000064840780d6,Other,FDA-2017-P-1104-0008,FDA-2017-P-1104,Dismissal of Citizen Petition  from FDA CDER to Gator Pharmaceuticals Inc
0900006482a63cd5,Other,FDA-2017-P-1104-0007,FDA-2017-P-1104,"Interim Response Letter from CDER to Gator Pharmaceuticals, Inc."
09000064824d1d3f,Supporting & Related Material,FDA-2017-P-1104-0003,FDA-2017-P-1104,"Attachment 1 COLPREP KIT- sodium sulfate, potassium sulfate, and magnesium sulfate for oral solution powder, for solution re Citizen Petition from Gator Pharmaceuticals, Inc."
09000064824d1d3d,Other,FDA-2017-P-1104-0001,FDA-2017-P-1104,"Citizen Petition from Gator Pharmaceuticals, Inc."
09000064824d1d40,Supporting & Related Material,FDA-2017-P-1104-0004,FDA-2017-P-1104,"Attachment 2 SUPREP BOWEL PREP- sodium suHate, potassium suHate, magnesium suHate solution, concentrate re Citizen Petition from Gator Pharmaceuticals, Inc."
0900006481dcf113,Other,FDA-2014-P-0594-0012,FDA-2014-P-0594,"Withdrawal from Hyman, Phelps & McNamara, P.C."
090000648190ddd0,Other,FDA-2014-P-0594-0010,FDA-2014-P-0594,Interim Response Letter from FDA/CDER to Hyman Phelps McNamara P.C.
090000648170efe2,Supporting & Related Material,FDA-2014-P-0594-0005,FDA-2014-P-0594,Exhibit 1 Letter from FDA CDER to Ranbaxy Inc Supplement from Teva Pharmaceuticals USA Inc Goodwin Procter LLP
09000064816e42cd,Other,FDA-2014-P-0594-0001,FDA-2014-P-0594,Citizen Petition from Hyman Phelps McNamara P.C.
09000064816e5151,Other,FDA-2014-P-0594-0002,FDA-2014-P-0594,Acknowledgement Letter from FDA DDM to Hyman Phelps McNamara PC
090000648170efe1,Supporting & Related Material,FDA-2014-P-0594-0004,FDA-2014-P-0594,Exhibit A Letter from Teva Pharmaceuticals USA Inc Supplement from Teva Pharmaceuticals USA Inc Goodwin Procter LLP
09000064816fc98e,Other,FDA-2014-P-0594-0003,FDA-2014-P-0594,"Supplement from Teva Pharmaceuticals USA, Inc. Goodwin Procter LLP"
09000064818c2423,Supporting & Related Material,FDA-2014-P-1615-0002,FDA-2014-P-1615,Exhibit Tabs 1 through 13
0900006481a14fa0,Other,FDA-2014-P-1615-0004,FDA-2014-P-1615,Petition Denial Response Letter
09000064818bbf25,Other,FDA-2014-P-1615-0001,FDA-2014-P-1615,Citizen Petition from Spectrum Pharmaceuticals Inc
09000064818c2425,Other,FDA-2014-P-1615-0003,FDA-2014-P-1615,Acknowledgment Letter from FDA DDM to Spectrum Pharmaceuticals Inc
0900006482538af9,Supporting & Related Material,FDA-2017-P-2043-0003,FDA-2017-P-2043,"Attachment 1 Status of inv 45244 - re Citizen Petition from Yiling Pharmaceutical, Ltd"
0900006482538a12,Other,FDA-2017-P-2043-0002,FDA-2017-P-2043,"Acknowledgment Lette from FDA DDM to Yiling Pharmaceutical, Ltd"
0900006482b847c0,Other,FDA-2017-P-2043-0005,FDA-2017-P-2043,"Interim Response Letter to Yiling Pharmaceutical, Ltd"
0900006482be0d27,Other,FDA-2017-P-2043-0006,FDA-2017-P-2043,Response Letter from FDA to Yiling Pharmaceuticals
0900006482538448,Other,FDA-2017-P-2043-0001,FDA-2017-P-2043,"Citizen Petition from Yiling Pharmaceutical, Ltd"
0900006482538afa,Supporting & Related Material,FDA-2017-P-2043-0004,FDA-2017-P-2043,"Attachment 2 RE-QUOTE re Citizen Petition from Yiling Pharmaceutical, Ltd"
0900006482214e24,Supporting & Related Material,FDA-2016-P-2781-0003,FDA-2016-P-2781,"Exhibit A Nanotherapies for the treatment of ocular diseases re Citizen Petition from Alcon Pharmaceuticals, Ltd. Novartis Pharmaceuticals Corporation"
0900006482214e22,Other,FDA-2016-P-2781-0002,FDA-2016-P-2781,"Acknowledgement Letter from FDA DDM to Alcon Pharmaceuticals, Ltd."
0900006482214e25,Supporting & Related Material,FDA-2016-P-2781-0004,FDA-2016-P-2781,"Exhibit B Generic medications in ophthalmology re Citizen Petition from Alcon Pharmaceuticals, Ltd. Novartis Pharmaceuticals Corporation"
0900006482214e27,Supporting & Related Material,FDA-2016-P-2781-0005,FDA-2016-P-2781,"Exhibit C Drug delivery to the ocular posterior segment using lipid emulsion via eye drop administration: Effect of emulsion formulations and surface modification re Citizen Petition from Alcon Pharmaceuticals, Ltd. Novartis Pharmaceuticals Corporation"
0900006482214643,Other,FDA-2016-P-2781-0001,FDA-2016-P-2781,"Citizen Petition from Alcon Pharmaceuticals, Ltd. Novartis Pharmaceuticals Corporation"
09000064824ba546,Other,FDA-2016-P-2781-0006,FDA-2016-P-2781,Citizen Petition Partial Approval and Denial Response from FDA CDER to  Novartis Pharmaceuticals Corporation
0900006481f84dcf,Supporting & Related Material,FDA-2016-P-1180-0007,FDA-2016-P-1180,Appendix 4 Nondigestible Oligosaccharides re AdvantaFiber FDA Citizen Petition
0900006481f84dff,Supporting & Related Material,FDA-2016-P-1180-0018,FDA-2016-P-1180,Appendix 15 The capacity of Nondigestible Carbohydrates to Stimulate Fecal Bifidobacteria in Healthy Humans re AdvantaFiber FDA Citizen Petition
0900006481f84d1e,Supporting & Related Material,FDA-2016-P-1180-0005,FDA-2016-P-1180,Appendix 2 Will Isomalto-Oligosaccharides A Well-Established Functional Food in Asia Break through the European and American Market re AdvantaFiber FDA Citizen Petition
0900006481f84dd5,Supporting & Related Material,FDA-2016-P-1180-0013,FDA-2016-P-1180,Appendix 10 Effects of Isomaltooligosaccharides with Different Degrees of Polymerization on Human Fecal Bifidobacteria re AdvantaFiber FDA Citizen Petition
0900006481f84dd7,Supporting & Related Material,FDA-2016-P-1180-0015,FDA-2016-P-1180,Appendix 12 Dose-Response Test of Isomaltooligosaccharides for Increasing Fecal Bifidobacteria re AdvantaFiber FDA Citizen Petition
0900006481f84dfe,Supporting & Related Material,FDA-2016-P-1180-0017,FDA-2016-P-1180,Appendix 14 Study on the Regulative effect of Isomalto-Oligosaccharides on Human Intestinal Flora re AdvantaFiber FDA Citizen Petition
0900006481f84e06,Supporting & Related Material,FDA-2016-P-1180-0025,FDA-2016-P-1180,"Appendix 22 An In Vitro Study of the Effect of Probiotics, Prebiotics and Synbiotics on the Elderly Faecal Microbiota re AdvantaFiber FDA Citizen Petition"
09000064823e9b98,Supporting & Related Material,FDA-2016-P-1180-0033,FDA-2016-P-1180,Appendix 2 Qiang - Health Benefits Carbohydrate Polymers re APPENDIX TABLE OF CONTENTS re AdvantaFiber (Top Health Inc.) FDA Citizen Petition Submission in Response to FDA Guidance Final
09000064823e9b9a,Supporting & Related Material,FDA-2016-P-1180-0035,FDA-2016-P-1180,Appendix 4 Gloria - Harmful Effects of Chronic Long Term Constpn re APPENDIX TABLE OF CONTENTS re AdvantaFiber (Top Health Inc.) FDA Citizen Petition Submission in Response to FDA Guidance Final
0900006481f84d1d,Supporting & Related Material,FDA-2016-P-1180-0004,FDA-2016-P-1180,Appendix 1 Nondigestible Oligo- and Polysaccharides Dietary Fiber re AdvantaFiber FDA Citizen Petition
0900006481f84dd0,Supporting & Related Material,FDA-2016-P-1180-0008,FDA-2016-P-1180,Appendix 5 The Definition of Dietary Fiber re AdvantaFiber FDA Citizen Petition
0900006481f84dd1,Supporting & Related Material,FDA-2016-P-1180-0009,FDA-2016-P-1180,Appendix 6 Long-Term Supplementation of Isomalto-Oligosaccharides Improved Colonic Microflora Profile re AdvantaFiber FDA Citizen Petition
0900006482af5748,Other,FDA-2016-P-1180-0044,FDA-2016-P-1180,"Supplement to Citizens Petition from Top Health Ingredients, Inc."
09000064823e9b9f,Supporting & Related Material,FDA-2016-P-1180-0040,FDA-2016-P-1180,Appendix 9 - Kaneko 1993 ENG Translation Jrnl of Home Ec Japan re APPENDIX TABLE OF CONTENTS re AdvantaFiber (Top Health Inc.) FDA Citizen Petition Submission in Response to FDA Guidance Final
09000064834109e2,Other,FDA-2016-P-1180-0046,FDA-2016-P-1180,Letter from FDA CFSAN to Top Health Ingredients Inc.
09000064823e94a8,Supporting & Related Material,FDA-2016-P-1180-0032,FDA-2016-P-1180,Appendix 1 Schmidt - Prevalence of_Constipation_in_the_General_Adult re APPENDIX TABLE OF CONTENTS re AdvantaFiber (Top Health Inc.) FDA Citizen Petition Submission in Response to FDA Guidance Final
09000064823e94a7,Supporting & Related Material,FDA-2016-P-1180-0031,FDA-2016-P-1180,APPENDIX TABLE OF CONTENTS re AdvantaFiber (Top Health Inc.) FDA Citizen Petition Submission in Response to FDA Guidance Final
090000648234522b,Other,FDA-2016-P-1180-0029,FDA-2016-P-1180,Interim Response Letter from CFSAN to Top Health Ingredients Inc
0900006481f847b4,Other,FDA-2016-P-1180-0001,FDA-2016-P-1180,Citizen Petition from Top Health Ingredients Inc
0900006481f84dce,Supporting & Related Material,FDA-2016-P-1180-0006,FDA-2016-P-1180,Appendix 3 Health Benefits of Non-Digestible Oligosaccharidesre AdvantaFiber FDA Citizen Petition
0900006481f84e00,Supporting & Related Material,FDA-2016-P-1180-0019,FDA-2016-P-1180,Appendix 16 The Effect of  a Commercial High-Fibre Diet and an Iso-Malto-Oligosaccharide-Supplemented Diet on Post Prandial Glucose Concentrations in Dogs re AdvantaFiber FDA Citizen Petition
0900006481f84e04,Supporting & Related Material,FDA-2016-P-1180-0023,FDA-2016-P-1180,Appendix 20 Effect of Prebiotic Oligosaccharides on Growth of Lactobacillus Strains Used as a Probiotic for Chickens re AdvantaFiber FDA Citizen Petition
0900006481f84e05,Supporting & Related Material,FDA-2016-P-1180-0024,FDA-2016-P-1180,"Appendix 21 Carbohydrate Preference, Acid Tolerance and Bile Tolerance in Five Strains of Befidobacterium re AdvantaFiber FDA Citizen Petition"
0900006481f84e29,Supporting & Related Material,FDA-2016-P-1180-0026,FDA-2016-P-1180,"Appendix 23 Panose, A New Prebiotic Candidate re AdvantaFiber FDA Citizen Petition"
0900006481f84d1c,Supporting & Related Material,FDA-2016-P-1180-0003,FDA-2016-P-1180,Appendix Table of Contents re AdvantaFiber FDA Citizen Petition
0900006484a5b471,Other,FDA-2019-P-1678-0004,FDA-2019-P-1678,"Withdrawal from Hyman, Phelps & McNamara, P.C. on behalf Exela Pharma Sciences, LLC"
0900006483b723a8,Other,FDA-2019-P-1678-0002,FDA-2019-P-1678,"Acknowledgment Letter from FDA DDM to Exela Pharma Sciences, LLC."
0900006483fe291b,Other,FDA-2019-P-1678-0003,FDA-2019-P-1678,"Interim Response Letter from FDA CDER to Exela Pharma Sciences, LLC"
0900006483b7253f,Other,FDA-2019-P-1678-0001,FDA-2019-P-1678,"Citizen Petition from Exela Pharma Sciences, LLC."
0900006482449613,Notice,FDA-2016-N-4232-0001,FDA-2016-N-4232,"Battery Safety Concerns in Electronic Nicotine Delivery Systems; Public
Workshop; Establishment of a Public Docket; Request for Comments"
09000064825d591d,Other,FDA-2016-N-4232-0035,FDA-2016-N-4232,Testimony from American Academy of Pediatrics
0900006482592a4d,Other,FDA-2017-P-2836-0002,FDA-2017-P-2836,Acknowledgment Letter from FDA DDM to VKT Pharma Private Limited
09000064836709ec,Other,FDA-2017-P-2836-0004,FDA-2017-P-2836,Response Letter from FDA CDER to  VKT Pharma Private Limeted and Xiromed LLC
0900006482c0d2f1,Other,FDA-2017-P-2836-0003,FDA-2017-P-2836,Interim Response Letter from FDA CDER to VKT Pharma Private Limited
0900006482592a46,Other,FDA-2017-P-2836-0001,FDA-2017-P-2836,Citizen Petition from VKT Pharma Private Limited
0900006481c66539,Other,FDA-2015-P-0711-0004,FDA-2015-P-0711,Interim Response Letter from FDA CBER to Larry Garner
0900006481dcbfa5,Other,FDA-2015-P-0711-0005,FDA-2015-P-0711,Citizen Petition Partial Approval and Denial Response from FDA CBER to Larry M. Garner
0900006481a2e7f8,Other,FDA-2015-P-0711-0001,FDA-2015-P-0711,Citizen Petition From L. Garner
0900006481a2e7fb,Other,FDA-2015-P-0711-0002,FDA-2015-P-0711,Acknowledgment Letter From FDA DDM to Larry Garner
090000648423c428,Other,FDA-2019-P-4101-0003,FDA-2019-P-4101,Petition Response Letter from FDA CDER to IQVIA RDS Inc
0900006483ee2f1d,Other,FDA-2019-P-4101-0002,FDA-2019-P-4101,Acknowledgment Letter from FDA DMS to IQVIA RDS Inc.
0900006483ee2f1c,Other,FDA-2019-P-4101-0001,FDA-2019-P-4101,Citizen Petition from IQVIA RDS Inc.
0900006480bb8002,Other,FDA-2010-P-0641-0001,FDA-2010-P-0641,Washington Action For Safe Water - Citizen Petition
090000648252c3fa,Other,FDA-2017-P-1911-0002,FDA-2017-P-1911,"Acknowledgment Letter from FDA DDM to Kleinfeld, Kaplan and Becker, LLP  (Purdue Pharma L.P.)"
090000648252bfb9,Other,FDA-2017-P-1911-0001,FDA-2017-P-1911,"Citizen Petition from Kleinfeld, Kaplan and Becker, LLP  (Purdue Pharma L.P.)"
0900006482547d99,Other,FDA-2017-P-1911-0003,FDA-2017-P-1911,"Withdrawal Letter from Kleinfeld, Kaplan & Becker LLP (Purdue Pharma L.P.)"
09000064846bd381,Other,FDA-2020-D-1445-0001,FDA-2020-D-1445,"Guidance for Industry and FDA; Letter to Industry, State and Local Food Regulators and Inspectors Regarding  Web-based ALERT Training"
0900006482ef8d71,Supporting & Related Material,FDA-2018-P-0597-0003,FDA-2018-P-0597,Attachment1- Pew letter to House Approps Jun_2017(1)
0900006482ef8d2d,Other,FDA-2018-P-0597-0001,FDA-2018-P-0597,Citizen Petition from the Alliance for Natural Health USA
0900006482ef8d6e,Other,FDA-2018-P-0597-0002,FDA-2018-P-0597,Acknowledgment Letter from FDA DDM to Alliance for Natural Health USA
0900006483553734,Other,FDA-2018-P-0597-0004,FDA-2018-P-0597,Interim Response from FDA CDER re FDA-2018-P-0597
0900006483d5d7d2,Other,FDA-2018-P-0597-0008,FDA-2018-P-0597,Letter from FDA CDER to Alliance for Natural Health USA
0900006484976f03,Other,FDA-2020-P-2234-0002,FDA-2020-P-2234,"Acknowledgment Letter from FDA DMS to Ray Law Firm, PLLC"
0900006484976dac,Other,FDA-2020-P-2234-0001,FDA-2020-P-2234,"Suitability Petition from Ray Law Firm, PLLC"
0900006484a3b795,Other,FDA-2020-P-2234-0003,FDA-2020-P-2234,"Final Suitability Petition Approval Letter from FDA CVM to Ray Law Firm, PLLC"
0900006481fc11da,Supporting & Related Material,FDA-2016-P-1251-0004,FDA-2016-P-1251,"Attachment 2 Approved labeling for the RLD, BUSULFEX (Busulfan) Injection 6 mg/mL in 60 mg/10mL approved re Citizen Petition from Lachman Consultant Services, Inc."
0900006481fc11db,Supporting & Related Material,FDA-2016-P-1251-0005,FDA-2016-P-1251,"Attachment 3 Proposed Prescribing Information for Busulfan Injection, 6 mg/mL in 30 mg/5 mL strength re Citizen Petition from Lachman Consultant Services, Inc."
0900006481fc0e7f,Other,FDA-2016-P-1251-0001,FDA-2016-P-1251,"Citizen Petition from Lachman Consultant Services, Inc."
0900006481fc11d9,Supporting & Related Material,FDA-2016-P-1251-0003,FDA-2016-P-1251,"Attachment 1 Approved Drug Products with Therapeutic Equivalence Evaluations, Electronic Orange Book accessed May 6, 2016 re Citizen Petition from Lachman Consultant Services, Inc."
0900006481fc11d7,Other,FDA-2016-P-1251-0002,FDA-2016-P-1251,"Acknowledgement Letter from FDA DDM to Lachman Consultant Services, Inc."
0900006484b64ea1,Other,FDA-2016-P-1251-0006,FDA-2016-P-1251,"Agency Response from FDA CDER to Lachman Consultant Services, Inc."
090000648046e914,Notice,FDA-2004-N-0054-0009,FDA-2004-N-0054,FDA
090000648046e8f7,Supporting & Related Material,FDA-2004-N-0054-0002,FDA-2004-N-0054,Background
090000648046e8f4,Notice,FDA-2004-N-0054-0001,FDA-2004-N-0054,FDA
090000648046e8f8,Supporting & Related Material,FDA-2004-N-0054-0003,FDA-2004-N-0054,Background
090000648046e912,Supporting & Related Material,FDA-2004-N-0054-0007,FDA-2004-N-0054,Supporting Statement
090000648046e910,Notice,FDA-2004-N-0054-0005,FDA-2004-N-0054,FDA
090000648046e913,Notice,FDA-2004-N-0054-0008,FDA-2004-N-0054,FDA
090000648046e911,Supporting & Related Material,FDA-2004-N-0054-0006,FDA-2004-N-0054,Supporting Statement
09000064804990be,Notice,FDA-2003-D-0373-0001,FDA-2003-D-0373,FDA
09000064804990fe,Supporting & Related Material,FDA-2003-D-0373-0002,FDA-2003-D-0373,Guidance
0900006480472efd,Notice,FDA-2004-N-0310-0002,FDA-2004-N-0310,FDA
0900006480472f02,Supporting & Related Material,FDA-2004-N-0310-0005,FDA-2004-N-0310,Supporting Statement
0900006480472ef5,Notice,FDA-2004-N-0310-0001,FDA-2004-N-0310,FDA
0900006480472f03,Notice,FDA-2004-N-0310-0006,FDA-2004-N-0310,FDA
0900006480472f01,Supporting & Related Material,FDA-2004-N-0310-0004,FDA-2004-N-0310,Supporting Statement
0900006480472f00,Supporting & Related Material,FDA-2004-N-0310-0003,FDA-2004-N-0310,Supporting Statement
09000064809f010c,Notice,FDA-2009-N-0284-0001,FDA-2009-N-0284,"Meetings: Food and Drug Administration Regulation and Licensure of Whole Blood and Blood Components, Including Source Plasma"
0900006483915990,Notice,FDA-2018-N-4131-0001,FDA-2018-N-4131,"Agency Information Collection Activities; Proposed Collection; Comment Request; Food and Drug Administration Adverse Event Reports;
Electronic Submissions"
0900006483e06883,Notice,FDA-2018-N-4131-0007,FDA-2018-N-4131,Agency Information Collection Activities; Announcement of Office of Management and Budget Approvals
0900006483cd0bd5,Notice,FDA-2018-N-4131-0004,FDA-2018-N-4131,"Agency Information Collection Activities; Submission for Office of
Management and Budget Review; Comment Request; Food and Drug
Administration Adverse Event Reports; Electronic Submissions"
0900006482291406,Rule,FDA-2016-P-1026-0006,FDA-2016-P-1026,"Medical Devices; Exemption From Premarket Notification: Method,
Metallic Reduction, Glucose (Urinary, Nonquantitative) Test System in a
Reagent Tablet Format"
090000648204fcd6,Notice,FDA-2016-P-1026-0003,FDA-2016-P-1026,"Medical Devices; Exemption from Premarket Notification: Method, Metallic Reduction, Glucose (Urinary, Non-Quantitative) Test System in a Reagent Tablet Format; Republication"
0900006481ed6723,Other,FDA-2016-P-1026-0002,FDA-2016-P-1026,"Acknowledgement Letter from FDA DDM to Germaine Laboratories, Inc."
0900006482295b63,Supporting & Related Material,FDA-2016-P-1026-0007,FDA-2016-P-1026,Reference 1 - Guidance - Procedures for Class II Device Exemptions from Premarket Notification 1998
090000648204943e,Supporting & Related Material,FDA-2016-P-1026-0004,FDA-2016-P-1026,Reference 1 - Guidance for Industry and CDRH Staff on Procedures for Class II Device Exemptions from Premarket Notification
0900006481ed61cd,Other,FDA-2016-P-1026-0001,FDA-2016-P-1026,"Citizen Petition from Germaine Laboratories, Inc."
09000064821fad0d,Other,FDA-2016-P-1026-0005,FDA-2016-P-1026,Letter from CDRH to Germaine Laboratories Inc
0900006482ef8d48,Other,FDA-2018-P-0598-0002,FDA-2018-P-0598,"Acknowledgment Letter from FDA DDM to Hyman, Phelps & McNamara"
0900006482ef8d4a,Supporting & Related Material,FDA-2018-P-0598-0003,FDA-2018-P-0598,"Tab 1 - ISO 27427, Anaesthetic and respiratory equipment _ Nebulizing systems and components (2010) re Citizen Petition from Hyman, Phelps & McNamara, PC on behalf of United Therapeutics Corporation"
0900006482ef913c,Supporting & Related Material,FDA-2018-P-0598-0007,FDA-2018-P-0598,"Tab 5 - Dean Hess et al_, Medication nebulizer performance effects of diluent volume, nebulizer flow, and nebulizer brand, 110 CHE re Citizen Petition from Hyman, Phelps & McNamara, PC on behalf of United Therapeutics Corporation"
0900006482ef9142,Supporting & Related Material,FDA-2018-P-0598-0012,FDA-2018-P-0598,"Tab 10 - Lawrence X_ Yu, Quality by Design for Orally Inhaled Drug Products, PQRI Workshop on Demonstrating Bioequivalence of Loca re Citizen Petition from Hyman, Phelps & McNamara, PC on behalf of United Therapeutics Corporation"
0900006482ef913a,Supporting & Related Material,FDA-2018-P-0598-0005,FDA-2018-P-0598,"Tab 3 - Andrew M_ Wilson et al_, Importance of drug-device interaction in determining systemic effects of inhaled corticosteroids re Citizen Petition from Hyman, Phelps & McNamara, PC on behalf of United Therapeutics Corporation"
0900006482ef9140,Supporting & Related Material,FDA-2018-P-0598-0010,FDA-2018-P-0598,"Tab 8 - Christopher OCallaghan Peter W_ Barry The science of nebulised drug delivery 52 Suppl 2 THORAX S31 S36 (1997) re Citizen Petition from Hyman, Phelps & McNamara, PC on behalf of United Therapeutics Corporation"
0900006482ef913b,Supporting & Related Material,FDA-2018-P-0598-0006,FDA-2018-P-0598,"Tab 4 - AH Kendrick et al_, Selecting and using nebulizer equipment re Citizen Petition from Hyman, Phelps & McNamara, PC on behalf of United Therapeutics Corporation"
0900006482ef913f,Supporting & Related Material,FDA-2018-P-0598-0009,FDA-2018-P-0598,"Tab 7 - JG Hardy et al_, Lung deposition from four nebulizers, 87 RESPIR MED 461 (1993) re Citizen Petition from Hyman, Phelps & McNamara, PC on behalf of United Therapeutics Corporation"
0900006482ef913e,Supporting & Related Material,FDA-2018-P-0598-0008,FDA-2018-P-0598,"Tab 6 - D_ Todd Loffert et al_, A comparison of commercial jet nebulizers, 106 CHEST 1788 (1994) re Citizen Petition from Hyman, Phelps & McNamara, PC on behalf of United Therapeutics Corporation"
09000064834b6ea1,Other,FDA-2018-P-0598-0014,FDA-2018-P-0598,Petition Denial Letter from FDA CDER to Kurt Karst 07-06-2018
0900006482ef8d46,Other,FDA-2018-P-0598-0001,FDA-2018-P-0598,"Citizen Petition from Hyman, Phelps & McNamara, PC on behalf of United Therapeutics Corporation"
0900006482ef8d69,Supporting & Related Material,FDA-2018-P-0598-0013,FDA-2018-P-0598,"Tab 11 - Wallace P_ Adams et al_, Demonstrating Bioequivalence of Locally Acting Orally Inhaled Drug Products, 23 J AEROSOL MED PU re Citizen Petition from Hyman, Phelps & McNamara, PC"
0900006482ef9141,Supporting & Related Material,FDA-2018-P-0598-0011,FDA-2018-P-0598,"Tab 9 - T_ Gessler et al_, Ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension, 17 EUR RESPIR J 14, 16 re Citizen Petition from Hyman, Phelps & McNamara, PC on behalf of United Therapeutics Corporation"
0900006482ef9139,Supporting & Related Material,FDA-2018-P-0598-0004,FDA-2018-P-0598,"Tab 2 - Food and Drug Administration Respiratory Drug Delivery Devices A CDRH Perspective (Nov_ 2 2010) re Citizen Petition from Hyman, Phelps & McNamara, PC on behalf of United Therapeutics Corporation"
09000064830e239d,Other,FDA-2018-P-1441-0002,FDA-2018-P-1441,Acknowledgment Letter from FDA DDM to Patients for Access to Advanced Hemophilia Therapy
090000648379e6c4,Other,FDA-2018-P-1441-0009,FDA-2018-P-1441,Response Letter from FDA CDER to Mr. Antell and Mr. Dattoli
09000064830e1b85,Other,FDA-2018-P-1441-0001,FDA-2018-P-1441,Citizen Petition from Patients for Access to Advanced Hemophilia Therapy
090000648151d50f,Other,FDA-2014-P-0112-0002,FDA-2014-P-0112,Acknowledgement Letter From FDA DDM to NadaChair
0900006483b5a4e9,Other,FDA-2014-P-0112-0003,FDA-2014-P-0112,Letter from FDA CDRH to NadaChair
090000648151ccc4,Other,FDA-2014-P-0112-0001,FDA-2014-P-0112,Citizen Petition From NadaChair
0900006482505d56,Notice,FDA-2017-N-0455-0001,FDA-2017-N-0455,Enhancing Patient Engagement Efforts Across the Food and Drug Administration; Establishment of a Public Docket; Request for Comments
09000064847d12f9,Other,FDA-2020-P-1728-0001,FDA-2020-P-1728,Citizen Petition from Tenshi Kaizen Private Limited
09000064847d0fe1,Supporting & Related Material,FDA-2020-P-1728-0003,FDA-2020-P-1728,Attachment 4 RE: Citizen Petition from Tenshi Kaizen Private Limited
09000064847d0fde,Supporting & Related Material,FDA-2020-P-1728-0006,FDA-2020-P-1728,Attachment 1 RE: Citizen Petition from Tenshi Kaizen Private Limited
09000064847d0fe0,Supporting & Related Material,FDA-2020-P-1728-0004,FDA-2020-P-1728,Attachment 3 RE: Citizen Petition from Tenshi Kaizen Private Limited
09000064847d0fdf,Supporting & Related Material,FDA-2020-P-1728-0005,FDA-2020-P-1728,Attachment 2 RE: Citizen Petition from Tenshi Kaizen Private Limited
09000064847d0fdc,Other,FDA-2020-P-1728-0002,FDA-2020-P-1728,Acknowledgment Letter from FDA DMS to Tenshi Kaizen Private Limited
0900006482b94e1d,Other,FDA-2017-D-5739-0002,FDA-2017-D-5739,Formal Meetings Between FDA and ANDA Applicants of Complex Products Under GDUFA Guidance for Industry; Draft Guidance
09000064849761b3,Other,FDA-2017-D-5739-0008,FDA-2017-D-5739,"Formal Meetings Between the Food and Drug Administration and
Abbreviated New Drug Application Applicants of Complex Products Under Generic Drug User Fee Amendments; Guidance for Industry"
0900006484985c2a,Notice,FDA-2017-D-5739-0009,FDA-2017-D-5739,"Formal Meetings Between the Food and Drug Administration and
Abbreviated New Drug Application Applicants of Complex Products Under Generic Drug User Fee Amendments; Guidance for Industry; Availability; Correction"
0900006482b9370d,Notice,FDA-2017-D-5739-0001,FDA-2017-D-5739,"Formal Meetings Between the Food and Drug Administration and
Abbreviated New Drug Application Applicants of Complex Products Under Generic Drug User Fee Act; Draft Guidance for Industry;  Availability"
0900006484975d73,Notice,FDA-2017-D-5739-0007,FDA-2017-D-5739,"Formal Meetings Between the Food and Drug Administration and
Abbreviated New Drug Application Applicants of Complex Products Under Generic Drug User Fee Amendments; Guidance for Industry; Availability"
0900006484986175,Other,FDA-2017-D-5739-0010,FDA-2017-D-5739,Formal Meetings Between FDA and ANDA Applicants of Complex Products Under GDUFA Guidance for Industry
0900006483fabf25,Other,FDA-2019-D-3679-0002,FDA-2019-D-3679,Interacting with the FDA on Complex Innovative Trial Designs for Drugs and Biological Products Draft Guidance for Industry
09000064849a443c,Notice,FDA-2019-D-3679-0014,FDA-2019-D-3679,Interacting With the Food and Drug Administration on Complex Innovative Trial Designs for Drugs and Biological Products; Guidance for Industry; Availability
09000064849a5c00,Other,FDA-2019-D-3679-0015,FDA-2019-D-3679,Interacting with the FDA on Complex Innovative Trial Designs for Drugs and Biological Products; Guidance for Industry
0900006483fab277,Notice,FDA-2019-D-3679-0001,FDA-2019-D-3679,Interacting With the Food and Drug Administration on Complex Innovative Clinical Trial Designs for Drugs and Biological Products; Draft Guidance for Industry; Availability
0900006482d58cb9,Other,FDA-2017-P-6968-0002,FDA-2017-P-6968,"Acknowledgment Letter from FDA DDM to Ceva Animal Health, LLC"
0900006483018aaa,Other,FDA-2017-P-6968-0005,FDA-2017-P-6968,"Response Letter from FDA to Ceva Animal Health, LLC"
0900006482f08015,Other,FDA-2017-P-6968-0004,FDA-2017-P-6968,"Amendment from Ceva Animal Health, LLC"
0900006482d58e60,Other,FDA-2017-P-6968-0001,FDA-2017-P-6968,"Suitability Petition from Ceva Animal Health, LLC"
0900006482d58cbb,Supporting & Related Material,FDA-2017-P-6968-0003,FDA-2017-P-6968,"Appendices for Suitability Petition from Ceva Animal Health, LLC"
090000648207e576,Supporting & Related Material,FDA-2016-P-1852-0009,FDA-2016-P-1852,Milk and Milk Products: Microbiology of Cream and Butter
090000648207e5b5,Supporting & Related Material,FDA-2016-P-1852-0016,FDA-2016-P-1852,MICROBIOLOGICAL QUALITY AND SAFETY ISSUES IN CHEESEMAKING
090000648207e5d7,Supporting & Related Material,FDA-2016-P-1852-0052,FDA-2016-P-1852,"A review of the microbiological hazards of dairy products made from
raw milk"
090000648207e5db,Supporting & Related Material,FDA-2016-P-1852-0056,FDA-2016-P-1852,Understanding Potential Intervention Measures To Reduce the Risk of Foodborne Illness From Consumption of Cheese Manufactured From Unpasteurized Milk
0900006482081b61,Other,FDA-2016-P-1852-0002,FDA-2016-P-1852,Acknowledgement Letter from FDA DDM to Farm-to-Consumer Legal Defense Fund
090000648207e433,Supporting & Related Material,FDA-2016-P-1852-0026,FDA-2016-P-1852,"Microbiology of Cream, Butter, Ice Cream and Related Products"
090000648207e436,Supporting & Related Material,FDA-2016-P-1852-0029,FDA-2016-P-1852,FACTORS INFLUENCING BACTERIAL GROWTH IN BUTTER
090000648207e44d,Supporting & Related Material,FDA-2016-P-1852-0034,FDA-2016-P-1852,"Prevalence of Listeria monocytogenes and Other Listeria Species in Butter from United Kingdom Production, Retail, and Catering Premises"
090000648207e486,Supporting & Related Material,FDA-2016-P-1852-0050,FDA-2016-P-1852,"2013 REPORT TO THE NATURAL RESOURCES, AGRICULTURE & ENVIRONMENT INTERIM COMMITTEE and the HEALTH & HUMAN SERVICES INTERIM COMMITTEES"
090000648207e571,Supporting & Related Material,FDA-2016-P-1852-0004,FDA-2016-P-1852,"Milk for Manufacturing Purposes and its Production and Processing
Recommended Requirements"
090000648207e575,Supporting & Related Material,FDA-2016-P-1852-0008,FDA-2016-P-1852,Queso Fresco: Cheese with a Reputation
090000648207e577,Supporting & Related Material,FDA-2016-P-1852-0010,FDA-2016-P-1852,§ 11380. Required Health Warning on Labels of Raw Milk and Raw Milk Products
090000648207e42f,Supporting & Related Material,FDA-2016-P-1852-0022,FDA-2016-P-1852,Quantitative Assessment of Relative Risk to Public Health From Food borne Listeria monocytogenes Among Selected Categories of Ready-to-Eat Foods
090000648207e437,Supporting & Related Material,FDA-2016-P-1852-0030,FDA-2016-P-1852,IDAPA 02.04.13.007 007. DEFINITIONS
090000648207e451,Supporting & Related Material,FDA-2016-P-1852-0038,FDA-2016-P-1852,Exposure of Listeria monocytogenes within an epidemic caused by butter in Finland
090000648207e482,Supporting & Related Material,FDA-2016-P-1852-0046,FDA-2016-P-1852,Molecular approaches to analysing the microbial composition of raw milk and raw milk cheese
090000648207e485,Supporting & Related Material,FDA-2016-P-1852-0049,FDA-2016-P-1852,"UT Admin Code R70330. Raw Milk for Retail. June 1, 2016"
09000064843c8d4f,Other,FDA-2016-P-1852-0061,FDA-2016-P-1852,Citizen Petition Denial Response Letter from FDA CFSAN to to Pete Kennedy - Mark McAfee
090000648242a392,Other,FDA-2016-P-1852-0059,FDA-2016-P-1852,Interim Response Letter from CFSAN to Organic Pastures Dairy Company & Organic Pastures Dairy Company
090000648207e574,Supporting & Related Material,FDA-2016-P-1852-0007,FDA-2016-P-1852,"Sale of milk, milk products, raw milk and raw milk..., AZ ST § 3-606"
090000648207e5b1,Supporting & Related Material,FDA-2016-P-1852-0012,FDA-2016-P-1852,"The human milk microbiome changes over lactation and is shaped by
maternal weight and mode of delivery"
090000648207e5b9,Supporting & Related Material,FDA-2016-P-1852-0019,FDA-2016-P-1852,"Food and Drug Administration (FDA), U.S. Department of Health and Human Services. (2011). Section I: Definitions. Grade “A” Pasteurized Milk Ordinance (pp. 6-7). Rev. 2011."
090000648207e5ba,Supporting & Related Material,FDA-2016-P-1852-0020,FDA-2016-P-1852,Quantitative Assessment of Relative Risk to Public Health From Foodborne Listeria monocytogenes Among Selected Categories of Ready-to-Eat Foods
090000648207e5d5,Supporting & Related Material,FDA-2016-P-1852-0051,FDA-2016-P-1852,Microbiota of Human Breast Tissue
090000648207e5b2,Supporting & Related Material,FDA-2016-P-1852-0013,FDA-2016-P-1852,Impact of Microbial Ecology of Meat and Poultry Products on Predictions from Exposure Assessment Scenarios for Refrigerated Storage
0900006483d47844,Supporting & Related Material,FDA-2019-P-3109-0004,FDA-2019-P-3109,"Appendix 2. Draft labels of the proposed generic soft chew: Label for small dogs and puppies (6-25 lbs.) and medium to large dogs (25.1-200 lbs.) re Citizen Petition from Noble Pharma, LLC"
0900006483d47994,Other,FDA-2019-P-3109-0002,FDA-2019-P-3109,"Acknowledgment Letter from FDA DDM to Noble Pharma, LLC"
0900006483d476e8,Other,FDA-2019-P-3109-0001,FDA-2019-P-3109,"Citizen Petition from Noble Pharma, LLC"
0900006483d47795,Supporting & Related Material,FDA-2019-P-3109-0003,FDA-2019-P-3109,"Appendix 1. Pioneer Product Labels for small dogs and puppies (6-25 lbs.) and medium to large (25.1-200 lbs.) dogs re Citizen Petition from Noble Pharma, LLC"
0900006483f08086,Other,FDA-2019-P-3109-0006,FDA-2019-P-3109,"Approval Letter from FDA CVM to Noble Pharma, LLC"
0900006483be9a70,Notice,FDA-2019-N-1468-0001,FDA-2019-N-1468,"Characterizing the Food and Drug Administration’s Approach to Benefit-
Risk Assessment Throughout the Medical Product Life Cycle; Public
Meeting; Request for Comments"
0900006483c912d7,Supporting & Related Material,FDA-2019-P-2407-0003,FDA-2019-P-2407,Attachment 1 Declaration of Rubicon re Citizen Petition from Kratz & Barry LLP on behalf of Rubicon Research Private Limited
0900006483c91512,Other,FDA-2019-P-2407-0001,FDA-2019-P-2407,Citizen Petition from Kratz & Barry LLP on behalf of Rubicon Research Private Limited
0900006483c91518,Other,FDA-2019-P-2407-0002,FDA-2019-P-2407,Acknowledgment Letter from FDA DDM to Kratz & Barry LLP
0900006483c912d8,Supporting & Related Material,FDA-2019-P-2407-0004,FDA-2019-P-2407,Attachment 2 Declaration of George J. Barry III re Citizen Petition from Kratz & Barry LLP on behalf of Rubicon Research Private Limited
09000064841bfc80,Other,FDA-2019-P-2407-0005,FDA-2019-P-2407,Letter from FDA CDER to Kratz & Barry LLP and Yiling Pharmaceutical Ltd.
090000648190d1af,Notice,FDA-2014-N-1072-0002,FDA-2014-N-1072,"Agency Information Collection Activities; Proposals, Submissions, and Approvals: Application for Participation in the Food and Drug Administration Commissioner's Fellowship Program"
09000064830e0b16,Notice,FDA-2014-N-1072-0007,FDA-2014-N-1072,"Agency Information Collection Activities; Proposals, Submissions, and Approvals"
090000648380ac38,Notice,FDA-2014-N-1072-0008,FDA-2014-N-1072,Agency Information Collection Activities; Proposed Collection; Comment Request; Application for Participation in Food and Drug Administration Fellowship and Traineeship Programs
090000648432061c,Notice,FDA-2014-N-1072-0010,FDA-2014-N-1072,"Agency Information Collection Activities; Submission for Office of
Management and Budget Review; Comment Request; Application for
Participation in Food and Drug Administration Fellowship and
Traineeship Programs"
09000064826f5b96,Notice,FDA-2014-N-1072-0003,FDA-2014-N-1072,Agency Information Collection Activities; Proposed Collection; Comment Request; Application for Participation in Food and Drug Administration Fellowship Programs
09000064849a75bd,Notice,FDA-2014-N-1072-0011,FDA-2014-N-1072,"Agency Information Collection
Activities; Submission for Office of
Management and Budget Review; Comment Request; Application for Participation in Food and Drug Administration Fellowship and Traineeship Programs"
09000064817fdb35,Notice,FDA-2014-N-1072-0001,FDA-2014-N-1072,"Agency Information Collection Activities; Proposed Collection;
Comment Request; Application for Participation in the Food and Drug
Administration Commissioner’s Fellowship Program"
0900006482cf739c,Notice,FDA-2014-N-1072-0005,FDA-2014-N-1072,"Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Application for 
Participation in Food and Drug Administration Fellowship Programs"
090000648322b860,Notice,FDA-2014-N-1072-0006,FDA-2014-N-1072,"Agency Information Collection Activities; Announcement of Office of
Management and Budget Approvals; Correction"
0900006484a7ec7d,Notice,FDA-2014-N-1072-0012,FDA-2014-N-1072,Agency Information Collection Activities; Announcement of Office of Management and Budget Approvals
0900006484a37db7,Notice,FDA-2020-N-2030-0002,FDA-2020-N-2030,Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Application for Food and Drug Administration Approval To Market a New Drug
0900006484960494,Notice,FDA-2020-N-2030-0001,FDA-2020-N-2030,Agency Information Collection Activities; Proposed Collection; Comment Request; Application for Food and Drug Administration Approval To Market a New Drug
0900006484ae14ab,Notice,FDA-2020-N-2030-0003,FDA-2020-N-2030,Agency Information Collection Activities; Announcement of Office of Management and Budget Approvals
0900006484b1a994,Notice,FDA-2021-N-0431-0001,FDA-2021-N-0431,Food and Drug Administration Public Meeting on Financial Efficiency of Human Drug User Fee Programs; Public Meeting; Request for Comments
0900006482f7cca2,Other,FDA-2018-P-0945-0001,FDA-2018-P-0945,Citizen Petition from Scott Beach
09000064842cba2b,Supporting & Related Material,FDA-2018-P-0945-0026,FDA-2018-P-0945,Beach CP - footnote 4 re Agency Response Letter from FDA CBER to Scott Beach
09000064842cba56,Supporting & Related Material,FDA-2018-P-0945-0018,FDA-2018-P-0945,Beach CP - footnote 12 re Agency Response Letter from FDA CBER to Scott Beach
09000064842cba5b,Supporting & Related Material,FDA-2018-P-0945-0039,FDA-2018-P-0945,Beach CP - footnote 19 re Agency Response Letter from FDA CBER to Scott Beach
0900006483631c26,Other,FDA-2018-P-0945-0010,FDA-2018-P-0945,Interim Response Letter from FDA CBER to Scott Beach
09000064842cb40a,Other,FDA-2018-P-0945-0012,FDA-2018-P-0945,Agency Response Letter from FDA CBER to Scott Beach
09000064842cb4f7,Supporting & Related Material,FDA-2018-P-0945-0034,FDA-2018-P-0945,Beach CP - footnote 31 re Agency Response Letter from FDA CBER to Scott Beach
09000064842cb4f9,Supporting & Related Material,FDA-2018-P-0945-0032,FDA-2018-P-0945,Beach CP - footnote 34 re Agency Response Letter from FDA CBER to Scott Beach
09000064842cb4fc,Supporting & Related Material,FDA-2018-P-0945-0029,FDA-2018-P-0945,Beach CP footnote 17 re Agency Response Letter from FDA CBER to Scott Beach
09000064842cb4fe,Supporting & Related Material,FDA-2018-P-0945-0027,FDA-2018-P-0945,Beach CP- footnote 29 re Agency Response Letter from FDA CBER to Scott Beach
09000064842cba2a,Supporting & Related Material,FDA-2018-P-0945-0014,FDA-2018-P-0945,Beach CP - footnote 2 re Agency Response Letter from FDA CBER to Scott Beach
09000064842cba2c,Supporting & Related Material,FDA-2018-P-0945-0025,FDA-2018-P-0945,Beach CP - footnote 5 re Agency Response Letter from FDA CBER to Scott Beach
09000064842cba30,Supporting & Related Material,FDA-2018-P-0945-0021,FDA-2018-P-0945,Beach CP - footnote 9 re Agency Response Letter from FDA CBER to Scott Beach
09000064842cba5c,Supporting & Related Material,FDA-2018-P-0945-0038,FDA-2018-P-0945,Beach CP - footnote 20 re Agency Response Letter from FDA CBER to Scott Beach
09000064842cb4fd,Supporting & Related Material,FDA-2018-P-0945-0028,FDA-2018-P-0945,Beach CP- footnote 24 re Agency Response Letter from FDA CBER to Scott Beach
09000064842cba57,Supporting & Related Material,FDA-2018-P-0945-0017,FDA-2018-P-0945,Beach CP - footnote 13 re Agency Response Letter from FDA CBER to Scott Beach
09000064842cba2f,Supporting & Related Material,FDA-2018-P-0945-0022,FDA-2018-P-0945,Beach CP - footnote 8 re Agency Response Letter from FDA CBER to Scott Beach
09000064842cb4fb,Supporting & Related Material,FDA-2018-P-0945-0030,FDA-2018-P-0945,Beach CP - footnote 39 re Agency Response Letter from FDA CBER to Scott Beach
09000064842cba55,Supporting & Related Material,FDA-2018-P-0945-0019,FDA-2018-P-0945,Beach CP - footnote 11 re Agency Response Letter from FDA CBER to Scott Beach
09000064842cba5a,Supporting & Related Material,FDA-2018-P-0945-0040,FDA-2018-P-0945,Beach CP - footnote 16 re Agency Response Letter from FDA CBER to Scott Beach
0900006482f7cca4,Other,FDA-2018-P-0945-0002,FDA-2018-P-0945,Acknowledgment Letter from FDA DDM to Scott Beach
09000064842cb4f8,Supporting & Related Material,FDA-2018-P-0945-0033,FDA-2018-P-0945,Beach CP - footnote 33 re Agency Response Letter from FDA CBER to Scott Beach
09000064842cba58,Supporting & Related Material,FDA-2018-P-0945-0016,FDA-2018-P-0945,Beach CP - footnote 14 re Agency Response Letter from FDA CBER to Scott Beach
09000064842cba5e,Supporting & Related Material,FDA-2018-P-0945-0036,FDA-2018-P-0945,Beach CP - footnote 23 re Agency Response Letter from FDA CBER to Scott Beach
09000064842cba5d,Supporting & Related Material,FDA-2018-P-0945-0037,FDA-2018-P-0945,Beach CP - footnote 21 re Agency Response Letter from FDA CBER to Scott Beach
09000064803b01dc,Notice,FDA-2008-N-0077-0001,FDA-2008-N-0077,Agency Information Collection Activities; Proposed Collection; Comment Request; MedWatch: The Food and Drug Administration Medical Products Reporting Program
0900006480a0e0b6,Notice,FDA-2008-N-0077-0006,FDA-2008-N-0077,Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; MedWatch: Food and Drug Administration Medical Products Reporting Program
0900006480720344,Notice,FDA-2008-N-0077-0005,FDA-2008-N-0077,Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; MedWatch: Food and Drug Administration Medical Products Reporting Program
0900006480a68b1b,Other,FDA-2006-P-0518-0005,FDA-2006-P-0518,"George Washington University Medical Center to FDA, December 3, 2009 - Letter re FDA-2006-P-0518-0001"
0900006480463a6c,Other,FDA-2006-P-0518-0004,FDA-2006-P-0518,National Jewish Medical and Research Center to FDA - Letter
0900006480463a67,Other,FDA-2006-P-0518-0001,FDA-2006-P-0518,The George Washington University Medical Center  - Citizen Petiion
0900006480463a6a,Other,FDA-2006-P-0518-0003,FDA-2006-P-0518,FDA Interim Response to George Washington University -  Letter
0900006480463a56,Other,FDA-2006-P-0518-0002,FDA-2006-P-0518,Acknowledgement Letter  to The George Washington University Medical Center
0900006484b5157d,Other,FDA-2021-P-0529-0002,FDA-2021-P-0529,Acknowledgment Letter from FDA DMS to SIRI  & GLIMSTAD LLP on behalf of Informed Consent Action Network
0900006484b604b1,Supporting & Related Material,FDA-2021-P-0529-0005,FDA-2021-P-0529,Combined FNs Part 3 of 7 Re Citizen Petition from SIRI  & GLIMSTAD LLP on behalf of Informed Consent Action Network
0900006484b604b2,Supporting & Related Material,FDA-2021-P-0529-0009,FDA-2021-P-0529,Combined FNs Part 7 of 7 re Re Citizen Petition from SIRI  & GLIMSTAD LLP on behalf of Informed Consent Action Network
0900006484b5179c,Supporting & Related Material,FDA-2021-P-0529-0008,FDA-2021-P-0529,Combined FNs Part 6 of 7 Re Citizen Petition from SIRI  & GLIMSTAD LLP on behalf of Informed Consent Action Network
0900006484b51584,Supporting & Related Material,FDA-2021-P-0529-0006,FDA-2021-P-0529,Combined FNs Part 4 of 7 Re Citizen Petition from SIRI  & GLIMSTAD LLP on behalf of Informed Consent Action Network
0900006484b5157f,Supporting & Related Material,FDA-2021-P-0529-0257,FDA-2021-P-0529,Combined FNs Part 1 of 7 Re Citizen Petition from SIRI  & GLIMSTAD LLP on behalf of Informed Consent Action Network
0900006484b51b03,Other,FDA-2021-P-0529-0001,FDA-2021-P-0529,Citizen Petition from SIRI & GLIMSTAD LLP on behalf of Informed Consent Action Network
0900006484b51580,Supporting & Related Material,FDA-2021-P-0529-0004,FDA-2021-P-0529,Combined FNs Part 2 of 7 Re Citizen Petition from SIRI  & GLIMSTAD LLP on behalf of Informed Consent Action Network
0900006484b51bda,Supporting & Related Material,FDA-2021-P-0529-0007,FDA-2021-P-0529,Combined FNs Part 5 of 7 Re Citizen Petition from SIRI  & GLIMSTAD LLP on behalf of Informed Consent Action Network
0900006484bdf677,Other,FDA-2021-P-0529-1053,FDA-2021-P-0529,Petition for Stay of Action from Siri & Glimstad LLP (on behalf of Informed Consent Action Network)
0900006484c9d6a7,Other,FDA-2021-P-0529-1077,FDA-2021-P-0529,Response Letter to Citizen Petition from FDA CBER to Siri & Glimstad LLP
0900006484be012a,Other,FDA-2021-P-0529-1054,FDA-2021-P-0529,Acknowledgment Letter from FDA DMS to Siri & Glimstad LLP (on behalf of Informed Consent Action Network)
0900006484b604b0,Supporting & Related Material,FDA-2021-P-0529-0003,FDA-2021-P-0529,Combined FNs Part 1 of 7 Re Citizen Petition from SIRI  & GLIMSTAD LLP on behalf of Informed Consent Action Network
0900006483c4b908,Other,FDA-2019-D-1263-0002,FDA-2019-D-1263,"Submitting Documents Using Real-World Data and Real-World Evidence
to FDA for Drugs and Biologics; Guidance for Industry; Draft Guidance"
0900006483c4aeb5,Notice,FDA-2019-D-1263-0001,FDA-2019-D-1263,"Submitting Documents Using Real-World Data and Real-World Evidence
to the Food and Drug Administration for Drugs and Biologics; Draft Guidance for Industry; Availability"
0900006484dc7319,Other,FDA-2021-P-1114-0001,FDA-2021-P-1114,Citizen Petition from Lewis Katz School of Medicine of Temple University
0900006484dc731d,Other,FDA-2021-P-1114-0002,FDA-2021-P-1114,Acknowledgment Letter from FDA DMS to Lewis Katz School of Medicine of Temple University
09000064846c8516,Other,FDA-2016-P-2532-0004,FDA-2016-P-2532,30 Day Response Letter from FDA CFSAN  to Dr. Cundiff
09000064825df8be,Other,FDA-2016-P-2532-0003,FDA-2016-P-2532,Response letter from FDA to David K. Cundiff
090000648219f0fd,Other,FDA-2016-P-2532-0002,FDA-2016-P-2532,Acknowledgment Letter from FDA DDM David K. Cundiff
090000648219e1f5,Other,FDA-2016-P-2532-0001,FDA-2016-P-2532,Citizen Petition from David K. Cundiff
0900006483b8bb74,Other,FDA-2014-P-0823-0013,FDA-2014-P-0823,Agency Response Letter From FDA CDER to Richard D. Burk
0900006481752bc0,Other,FDA-2014-P-0823-0001,FDA-2014-P-0823,Citizen Petition From Richard D. Burk
09000064828cd79d,Other,FDA-2014-P-0823-0009,FDA-2014-P-0823,Letter from Richard D. Burk to FDA CDER
0900006481948b54,Other,FDA-2014-P-0823-0003,FDA-2014-P-0823,Letter from Richard Burk
0900006482033f82,Other,FDA-2014-P-0823-0006,FDA-2014-P-0823,Letter from Richard D. Burk to FDA CDER
0900006482cc69f0,Other,FDA-2014-P-0823-0011,FDA-2014-P-0823,Letter from Richard D. Burk to FDA DDM
0900006482912544,Other,FDA-2014-P-0823-0010,FDA-2014-P-0823,Letter from Richard D. Burk to FDA CDER
09000064831affdc,Other,FDA-2014-P-0823-0012,FDA-2014-P-0823,Letter from Richard D. Burk to FDA CDER
090000648175334a,Other,FDA-2014-P-0823-0002,FDA-2014-P-0823,Acknowledgement Letter From FDA DDM to Richard D. Burk
0900006481e4cafa,Other,FDA-2014-P-0823-0004,FDA-2014-P-0823,Interim Response Letter from FDA CDER to Richard D. Burk
0900006481edc3b8,Other,FDA-2014-P-0823-0005,FDA-2014-P-0823,Letter from Richard D. Burk to FDA CDER
0900006481a1e058,Other,FDA-2015-P-0633-0001,FDA-2015-P-0633,Citizen Petition From Jonathan Smith
0900006482d48e64,Other,FDA-2015-P-0633-0020,FDA-2015-P-0633,Final Response Letter from FDA to Jonathan Smith
0900006481c35409,Other,FDA-2015-P-0633-0003,FDA-2015-P-0633,Interim Response from FDA CDER to University of Kentucky College of Medicine
0900006481a1e3e1,Other,FDA-2015-P-0633-0002,FDA-2015-P-0633,"Acknowledgement Letter From FDA DDM to Jonathan Smith, M.D."
0900006483398895,Notice,FDA-2018-N-0529-0031,FDA-2018-N-0529,Draft Concept Paper: Illicit Trade in Tobacco Products After Implementation of a Food and Drug Administration Product Standard; Extension of Comment Period
090000648301d52e,Supporting & Related Material,FDA-2018-N-0529-0002,FDA-2018-N-0529,508-Illicit Trade in Tobacco Products after Implementation of an FDA Pro...
090000648301be26,Notice,FDA-2018-N-0529-0001,FDA-2018-N-0529,Draft Concept Paper: Illicit Trade in Tobacco Products After Implementation of a Food and Drug Administration Product Standard; Availability; Request for Comments
09000064830e0568,Other,FDA-2018-N-0529-0023,FDA-2018-N-0529,Request for Extension from Altria Client Services LLC
090000648379e78f,Other,FDA-2018-P-3806-0002,FDA-2018-P-3806,Acknowledgment Letter from FDA DDM to Greg Grillo
0900006483b588b0,Other,FDA-2018-P-3806-0003,FDA-2018-P-3806,Letter from FDA CDER to Greg Grillo
090000648379e789,Other,FDA-2018-P-3806-0001,FDA-2018-P-3806,Citizen Petition from Greg Grillo
0900006484954f8f,Other,FDA-2018-P-3806-0004,FDA-2018-P-3806,Response letter from FDA CDER to Greg Grillo
0900006484a08072,Other,FDA-2021-P-0124-0002,FDA-2021-P-0124,"Acknowledgement Letter from FDA DMS to Hyman, Phelps & McNamara, P.C."
0900006484a08074,Supporting & Related Material,FDA-2021-P-0124-0003,FDA-2021-P-0124,"Attachment 1 re Suitability Petition from Hyman, Phelps & McNamara P.C."
0900006484a08294,Supporting & Related Material,FDA-2021-P-0124-0006,FDA-2021-P-0124,"Attachment 4 re Suitability Petition from Hyman, Phelps & McNamara P.C."
0900006484a08070,Other,FDA-2021-P-0124-0001,FDA-2021-P-0124,"Suitability Petition from Hyman, Phelps & McNamara P.C."
0900006484a08293,Supporting & Related Material,FDA-2021-P-0124-0004,FDA-2021-P-0124,"Attachment 2 re Suitability Petition from Hyman, Phelps & McNamara P.C."
0900006484a08295,Supporting & Related Material,FDA-2021-P-0124-0005,FDA-2021-P-0124,"Attachment 3 re Suitability Petition from Hyman, Phelps & McNamara P.C."
0900006484a145cf,Supporting & Related Material,FDA-2021-P-0137-0005,FDA-2021-P-0137,"Attachment 3 re Suitability Petition from Hyman, Phelps & McNamara, P.C."
0900006484a1454d,Other,FDA-2021-P-0137-0002,FDA-2021-P-0137,"Acknowledgment Letter from FDA DMS to Hyman, Phelps & McNamara, P.C."
0900006484a14552,Supporting & Related Material,FDA-2021-P-0137-0003,FDA-2021-P-0137,"Attachment 1 re Suitability Petition from Hyman, Phelps & McNamara, P.C."
0900006484a145ce,Supporting & Related Material,FDA-2021-P-0137-0004,FDA-2021-P-0137,"Attachment 2 re Suitability Petition from Hyman, Phelps & McNamara, P.C."
0900006484a1454b,Other,FDA-2021-P-0137-0001,FDA-2021-P-0137,"Suitability Petition from Hyman, Phelps & McNamara, P.C."
0900006484a5b473,Other,FDA-2018-P-4769-0004,FDA-2018-P-4769,"Withdrawal from Hyman, Phelps & McNamara, P.C."
0900006483d11b5c,Other,FDA-2018-P-4769-0003,FDA-2018-P-4769,"Letter from FDA CDER to Exela Pharma Sciences, LLC"
090000648399e454,Other,FDA-2018-P-4769-0001,FDA-2018-P-4769,"CITIZEN PETITION  FROM EXELA PHARMA SCIENCES, LLC."
090000648399e9b8,Other,FDA-2018-P-4769-0002,FDA-2018-P-4769,"Acknowledgment Letter from FDA DDM to Exela Pharma Sciences, LLC"
090000648320c32f,Other,FDA-2017-P-4335-0003,FDA-2017-P-4335,Interim response from FDA CDRH to William Bonificio
0900006482941359,Other,FDA-2017-P-4335-0002,FDA-2017-P-4335,Acknowledgement Letter from FDA DDM to William Bonificio
0900006482940f49,Other,FDA-2017-P-4335-0001,FDA-2017-P-4335,Citizen Petition from William Bonificio
0900006484b3ab07,Other,FDA-2017-P-4335-0004,FDA-2017-P-4335,Response Letter from FDA CDRH to William Bonificio
090000648045040e,Other,FDA-2005-P-0434-0002,FDA-2005-P-0434,HFA-305 to Ms. Elizabeth M. Trevino
09000064804503ea,Other,FDA-2005-P-0434-0001,FDA-2005-P-0434,HFA-305 to Ms. Elizabeth M. Trevino
0900006482073c10,Other,FDA-2005-P-0434-0003,FDA-2005-P-0434,Petition Closure Memorandum from FDA CFSAN
0900006480a6b578,Other,FDA-2003-P-0127-0004,FDA-2003-P-0127,"The Weinberg Group, Inc.  - Petition Withdrawal re FDA-2003-P-0127-0003"
0900006480486267,Other,FDA-2003-P-0127-0003,FDA-2003-P-0127,"The Weinberg Group, Inc. - Citizen Petition"
0900006480486265,Other,FDA-2003-P-0127-0001,FDA-2003-P-0127,"Acknowledgement Letter to The Weinberg Group, Inc."
0900006480486268,Other,FDA-2003-P-0127-0002,FDA-2003-P-0127,"FDA/CDER Response to The Weinberg Group Inc., February 3, 2004 - Letter"
090000648046fb07,Supporting & Related Material,FDA-2004-D-0118-0005,FDA-2004-D-0118,Guidance
090000648046fb09,Notice,FDA-2004-D-0118-0007,FDA-2004-D-0118,FDA
090000648046fb08,Supporting & Related Material,FDA-2004-D-0118-0006,FDA-2004-D-0118,Guidance
090000648046faff,Notice,FDA-2004-D-0118-0001,FDA-2004-D-0118,FDA
090000648046fb05,Supporting & Related Material,FDA-2004-D-0118-0003,FDA-2004-D-0118,Guideline
090000648046fb02,Supporting & Related Material,FDA-2004-D-0118-0002,FDA-2004-D-0118,Guideline
090000648046fb06,Supporting & Related Material,FDA-2004-D-0118-0004,FDA-2004-D-0118,Guideline
090000648044d23f,Notice,FDA-2005-N-0401-0001,FDA-2005-N-0401,FDA
090000648044d269,Notice,FDA-2005-N-0401-0002,FDA-2005-N-0401,FDA
090000648044d26b,Supporting & Related Material,FDA-2005-N-0401-0003,FDA-2005-N-0401,Supporting Statement
090000648044d270,Notice,FDA-2005-N-0401-0005,FDA-2005-N-0401,FDA
090000648044d26d,Supporting & Related Material,FDA-2005-N-0401-0004,FDA-2005-N-0401,Supporting Statement
09000064804562e3,Notice,FDA-2006-D-0229-0001,FDA-2006-D-0229,FDA
09000064804562e4,Supporting & Related Material,FDA-2006-D-0229-0002,FDA-2006-D-0229,Guidance
0900006480bbe739,Other,FDA-2010-P-0396-0003,FDA-2010-P-0396,"Cephalon, Inc - Supplement"
0900006480b21361,Other,FDA-2010-P-0396-0002,FDA-2010-P-0396,"Acknowledgement Letter to Cephalon, Inc"
0900006480bc9e86,Other,FDA-2010-P-0396-0004,FDA-2010-P-0396,"FDA/CDER to Fish & Richardson, P.C., (Cephalon , Inc.) - Petition Denial"
0900006480b21223,Other,FDA-2010-P-0396-0001,FDA-2010-P-0396,"Cephalon, Inc. - Citizen Petition"
0900006482a8cb69,Other,FDA-2017-P-5080-0001,FDA-2017-P-5080,Citizen Petition from Quagen Pharmaceuticals LLC
0900006482a8d28e,Other,FDA-2017-P-5080-0002,FDA-2017-P-5080,Acknowledgement Letter from FDA DDM to Quagen Pharmaceuticals LLC
090000648499e486,Other,FDA-2017-P-5080-0004,FDA-2017-P-5080,Withdrawal from Quagen Pharmaceuticals LLC
0900006482f31492,Other,FDA-2017-P-5080-0003,FDA-2017-P-5080,Interim Response Letter from FDA CDER to Quagen Pharmaceuticals LLC
0900006480fe6e4a,Other,FDA-2012-P-0317-0001,FDA-2012-P-0317,Abbott Laboratories (Covington & Burling LLP) -  Citizen Petition
09000064821533b9,Other,FDA-2012-P-0317-0009,FDA-2012-P-0317,AbbVie Meeting Minutes
090000648225d84a,Other,FDA-2012-P-0317-0010,FDA-2012-P-0317,Citizen Petition Denial Response from FDA CDER to Covington & Burling LLP (Abbott Laboratories)
0900006480fe7a80,Other,FDA-2012-P-0317-0002,FDA-2012-P-0317,Acknowledgement Letter to Abbott Laboratories (Covington & Burling LLP)
090000648114ac14,Other,FDA-2012-P-0317-0005,FDA-2012-P-0317,Interim Response to Abbott Laboratories (Covington & Burling LLP) - Letter
090000648446403b,Other,FDA-2020-P-1181-0001,FDA-2020-P-1181,"Petition for Stay of Action from Todd & Weld, LLP"
09000064848579c7,Other,FDA-2020-P-1181-0003,FDA-2020-P-1181,"Letter from FDA CDRH to Todd & Weld, LLP"
090000648446403c,Other,FDA-2020-P-1181-0002,FDA-2020-P-1181,"Acknowledgment Letter from FDA DMS to Todd & Weld, LLP"
090000648433d00f,Other,FDA-2019-P-3803-0003,FDA-2019-P-3803,"Interim Response Letter from FDA CDER to Hyman, Phelps & McNamara P C"
090000648498557f,Other,FDA-2019-P-3803-0004,FDA-2019-P-3803,Withdrawal from Hyman Phelps & McNamara
0900006483e34bf0,Other,FDA-2019-P-3803-0001,FDA-2019-P-3803,"Citizen Petition from Hyman, Phelps & McNamara P.C"
0900006483e34bf1,Other,FDA-2019-P-3803-0002,FDA-2019-P-3803,"Acknowledgment Letter from FDA DMS to Hyman, Phelps & McNamara P.C."
0900006484bd1c5d,Other,FDA-2020-P-2357-0004,FDA-2020-P-2357,180 day Interim Response Letter from FDA CFSAN to Keller and Heckman LLP
09000064849ce2e5,Other,FDA-2020-P-2357-0001,FDA-2020-P-2357,"Citizen Petition from Keller and Heckman LLP on behalf of Nexira, Alland & Robert and Importers Service Corporation"
09000064849ce2e6,Other,FDA-2020-P-2357-0002,FDA-2020-P-2357,"Acknowledgment Letter from FDA DMS to Keller and Heckman LLP n behalf of Nexira, Alland & Robert, and Importers Service Corporation"
09000064849ce2e9,Supporting & Related Material,FDA-2020-P-2357-0003,FDA-2020-P-2357,"Appendix I Uebelhack re Citizen Petition from Keller and Heckman LLP on behalf of Nexira, Alland & Robert and Importers Service Corporation"
0900006481cfd30a,Other,FDA-2015-P-3991-0002,FDA-2015-P-3991,Acknowledgement Letter from FDA DDM to The Take Back America Campaign
0900006481cfd30f,Supporting & Related Material,FDA-2015-P-3991-0003,FDA-2015-P-3991,End Notes re Citizen Petition from The Take Back America Campaign
0900006481dbfc7d,Other,FDA-2015-P-3991-0009,FDA-2015-P-3991,"Supplement from Fred Mayer, PPSI"
0900006481fba4dd,Other,FDA-2015-P-3991-0010,FDA-2015-P-3991,"Citizen Petition Interim Response from FDA OP to Roger Morgan, Frederick Mayer, Ron Allen, Scott Chipman"
0900006481cfbfd5,Other,FDA-2015-P-3991-0001,FDA-2015-P-3991,Citizen Petition from The Take Back America Campaign
0900006481d5cd54,Other,FDA-2015-P-3991-0005,FDA-2015-P-3991,Supplement from PPSI
0900006481d5cd5a,Supporting & Related Material,FDA-2015-P-3991-0006,FDA-2015-P-3991,Citizen Petition from Take Back America Campaign re Supplement from PPSI
0900006481d5cd5b,Supporting & Related Material,FDA-2015-P-3991-0007,FDA-2015-P-3991,Public Policy Statement from the American Society of Addiction Medicine re Supplement from PPSI
0900006481d5cd5c,Supporting & Related Material,FDA-2015-P-3991-0008,FDA-2015-P-3991,Letter from PPSI to FDA re Supplement from PPSI
0900006481cfd637,Supporting & Related Material,FDA-2015-P-3991-0004,FDA-2015-P-3991,Day Dreamers and Marinol re Citizen Petition from The Take Back America Campaign
09000064824e1346,Other,FDA-2017-P-1251-0002,FDA-2017-P-1251,Acknowledgement Letter from FDA DDM to American Feed Industry Association and National Grain and Feed Association
09000064824e1344,Other,FDA-2017-P-1251-0001,FDA-2017-P-1251,Citizen Petition from American Feed Industry Association and National Grain and Feed Association
0900006482a9f8c8,Other,FDA-2017-P-1251-0003,FDA-2017-P-1251,Tentative Response from FDA CVM to NGFA
09000064820a577c,Other,FDA-2016-P-0214-0007,FDA-2016-P-0214,Interim Response from CBER to Rosalind Advisors Inc
0900006481e1a1fa,Other,FDA-2016-P-0214-0002,FDA-2016-P-0214,"Acknowledgement Letter from FDA DDM to Rosalind Advisors, Inc."
09000064821b8643,Other,FDA-2016-P-0214-0008,FDA-2016-P-0214,Denial Response from FDA CBER to Public Citizen
0900006481e1a1f9,Other,FDA-2016-P-0214-0001,FDA-2016-P-0214,"Citizen Petition from Rosalind Advisors, Inc."
0900006484dc0101,Other,FDA-2021-P-0378-0003,FDA-2021-P-0378,Interim Response Letter from FDA CDER to Public Citizen’s Health Research Group
0900006484aa49c6,Other,FDA-2021-P-0378-0002,FDA-2021-P-0378,Acknowledgement Letter from FDA DMS to Public Citizen’s Health Research Group
0900006484aa49c4,Other,FDA-2021-P-0378-0001,FDA-2021-P-0378,Citizen Petition from Public Citizen’s Health Research Group
0900006484dc3cfa,Other,FDA-2021-P-1102-0001,FDA-2021-P-1102,Citizen Petition from Pet Schooled
0900006484dc3ee3,Other,FDA-2021-P-1102-0002,FDA-2021-P-1102,Acknowledgment Letter from FDA DMS to Pet Schooled
090000648299cde7,Other,FDA-2015-P-3391-0006,FDA-2015-P-3391,"Denial Letter from CFSAN to Ashley Franz (Patricia Syverson, Bonnett Fairbourn Friedmant & Balint, PC)"
0900006481c7c2c9,Other,FDA-2015-P-3391-0002,FDA-2015-P-3391,"Acknowledgement Letter from FDA DDM to Patricia Syverson, Bonnett Fairbourn Friedmant & Balint, PC"
0900006481c7cdc5,Supporting & Related Material,FDA-2015-P-3391-0003,FDA-2015-P-3391,"Attachment A Images of Product Label re Citizen Petition from Ashley Franz (Patricia Syverson, Bonnett Fairbourn Friedmant & Balint, PC)"
0900006481c7cdc6,Supporting & Related Material,FDA-2015-P-3391-0004,FDA-2015-P-3391,"Attachment B Order Granting Motion from the United States District Court Southern District of California re Citizen Petition from  Ashley Franz (Patricia Syverson, Bonnett Fairbourn Friedmant & Balint, PC)"
0900006481c7c167,Other,FDA-2015-P-3391-0001,FDA-2015-P-3391,"Citizen Petition from Ashley Franz (Patricia Syverson, Bonnett Fairbourn Friedmant & Balint, PC)"
0900006483b68912,Other,FDA-2019-P-1364-0005,FDA-2019-P-1364,Withdrawal from Public Citizen
0900006483b134a9,Other,FDA-2019-P-1364-0003,FDA-2019-P-1364,Acknowledgment Letter from FDA DDM to Public Citizen's Health Research Group
0900006483b13310,Other,FDA-2019-P-1364-0001,FDA-2019-P-1364,Citizen Petition from Public Citizen's Health Research Group
0900006483b13efe,Other,FDA-2019-P-1364-0002,FDA-2019-P-1364,Cover Letter Petition  from Public Citizen's Health Research Group
0900006483b13ef8,Supporting & Related Material,FDA-2019-P-1364-0004,FDA-2019-P-1364,"Attachment 1 - New Opioid Analgesic Approvals and Outpatient Utilization of Opioid Analgesics in the United States, 1997 through 2015 re:  Citizen Petition from Public Citizen’s Health Research Group"
0900006482538d3c,Supporting & Related Material,FDA-2017-P-2044-0003,FDA-2017-P-2044,"Attachment A - Understanding the Epidemic _ Drug Overdose _ CDC Injury Center-1 re Citizen Petition from Nirsum Pharmaceuticals, LLC"
0900006482538d3f,Supporting & Related Material,FDA-2017-P-2044-0006,FDA-2017-P-2044,"Attachment D Drug Approvals and Databases _ June 2015_ Additions and Deletions to the Drug Product List re Citizen Petition from Nirsum Pharmaceuticals, LLC"
090000648258019b,Other,FDA-2017-P-2044-0013,FDA-2017-P-2044,Report from Nikej Shah
0900006482c4111a,Other,FDA-2017-P-2044-0017,FDA-2017-P-2044,"Final Determination Response to Nirsum Pharmaceuticals, Inc"
0900006482c3e67f,Notice,FDA-2017-P-2044-0016,FDA-2017-P-2044,"Determination That REVEX (Nalmefene Hydrochloride Injection), 0.1 Milligram Base/Milliliter and 1.0 Milligram Base/Milliliter, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
0900006482538d56,Supporting & Related Material,FDA-2017-P-2044-0012,FDA-2017-P-2044,"Attachment J - Selincro EPAR re Citizen Petition from Nirsum Pharmaceuticals, LLC"
0900006482538d55,Supporting & Related Material,FDA-2017-P-2044-0011,FDA-2017-P-2044,"Attachment I - Essence 2  re Citizen Petition from Nirsum Pharmaceuticals, LLC"
0900006482538d3d,Supporting & Related Material,FDA-2017-P-2044-0004,FDA-2017-P-2044,"Attachment B - Revex Orange Book re Citizen Petition from Nirsum Pharmaceuticals, LLC"
0900006482538d52,Supporting & Related Material,FDA-2017-P-2044-0008,FDA-2017-P-2044,"Attachment F - Revex Label Updated April 2006 re Citizen Petition from Nirsum Pharmaceuticals, LLC"
0900006482538d54,Supporting & Related Material,FDA-2017-P-2044-0010,FDA-2017-P-2044,"Attachment H - Essence 1 re Citizen Petition from Nirsum Pharmaceuticals, LLC"
09000064825875a6,Other,FDA-2017-P-2044-0014,FDA-2017-P-2044,Report from Nikej Shah
0900006482538d3e,Supporting & Related Material,FDA-2017-P-2044-0005,FDA-2017-P-2044,"Attachment C - Drug Approvals and Databases _ June 2008_ Additions and Deletions to the Drug Product List re Citizen Petition from Nirsum Pharmaceuticals, LLC"
0900006482538d53,Supporting & Related Material,FDA-2017-P-2044-0009,FDA-2017-P-2044,"Attachment G - Essence 1 - 2 Subgroup Analysis re Citizen Petition from Nirsum Pharmaceuticals, LLC"
0900006482538d51,Supporting & Related Material,FDA-2017-P-2044-0007,FDA-2017-P-2044,"Attachment E - FDA sNDA Letter 2006 re Citizen Petition from Nirsum Pharmaceuticals, LLC"
0900006482538845,Other,FDA-2017-P-2044-0001,FDA-2017-P-2044,"Citizen Petition from Nirsum Pharmaceuticals, LLC"
0900006482538bad,Other,FDA-2017-P-2044-0002,FDA-2017-P-2044,"Acknowledgment Letter from FDA DDM to Nirsum Pharmaceuticals, LLC"
090000648253da36,Supporting & Related Material,FDA-2017-P-2128-0004,FDA-2017-P-2128,Exhibit III - Proposed Label re Citizen Petition from Jubilant Generics Limited
090000648253da34,Supporting & Related Material,FDA-2017-P-2128-0005,FDA-2017-P-2128,Exhibit I - Orange Book re Citizen Petition from Jubilant Generics Limited
090000648253da35,Supporting & Related Material,FDA-2017-P-2128-0003,FDA-2017-P-2128,Exhibit II - Fluoxetine tabs 60 mg RLD label re Citizen Petition from Jubilant Generics Limited
090000648253dcaa,Other,FDA-2017-P-2128-0002,FDA-2017-P-2128,Acknowledgment Letter from FDA DDM to Jubilant Generics Limited
090000648253da32,Other,FDA-2017-P-2128-0001,FDA-2017-P-2128,Citizen Petition from Jubilant Generics Limited
0900006482db3e96,Supporting & Related Material,FDA-2018-P-0098-0005,FDA-2018-P-0098,"Attachment 3 Labeling for Zonegran® re Citizen Petition from Lachman Consultant Services, Inc."
0900006482db3e95,Supporting & Related Material,FDA-2018-P-0098-0004,FDA-2018-P-0098,"Attachment 2 Draft Insert Labeling Proposed for Zonisamide Capsules re Citizen Petition from Lachman Consultant Services, Inc."
0900006482db3e94,Supporting & Related Material,FDA-2018-P-0098-0003,FDA-2018-P-0098,"Attachment 1 Relevant copy of the page from the current edition of the electronic Approved Drug Products with Therapeutic Equivalence Evaluations, accessed January 8, 2018 re Citizen Petition from Lachman Consultant Services, Inc."
0900006482db3e90,Other,FDA-2018-P-0098-0001,FDA-2018-P-0098,"Citizen Petition from Lachman Consultant Services, Inc."
0900006482dcef25,Other,FDA-2018-P-0098-0002,FDA-2018-P-0098,"Acknowledgment Letter from FDA DDM  to Lachman Consultant Services, Inc."
09000064810c7496,Notice,FDA-2011-N-0608-0010,FDA-2011-N-0608,"Agency Information Collection Activities; Proposals, Submissions, and Approvals: MedWatch, Food and Drug Administration Medical Products Reporting Program"
0900006480f14d60,Notice,FDA-2011-N-0608-0001,FDA-2011-N-0608,"Agency Information Collection Activities; Proposals, Submissions, and Approvals: MedWatch - Medical Products Reporting Program"
0900006480f7d55c,Notice,FDA-2011-N-0608-0009,FDA-2011-N-0608,"Agency Information Collection Activities; Proposals, Submissions, and Approvals: MedWatch; Medical Products Reporting Program"
0900006483516f51,Other,FDA-2018-P-1740-0005,FDA-2018-P-1740,Amended Citizen Petition from Provetica Animal Health LLC
090000648360175b,Other,FDA-2018-P-1740-0006,FDA-2018-P-1740,Suitability Response Letter from FDA CVM to Provetica Animal Health LLC
090000648322860d,Supporting & Related Material,FDA-2018-P-1740-0004,FDA-2018-P-1740,"Appendix 2-Proposed Product Label (Draft) - Generic Deracoxib Chewable Tablets, Provetica Animal Health LLC"
0900006483228932,Other,FDA-2018-P-1740-0002,FDA-2018-P-1740,Acknowledgment Letter from FDA DDM to Provetica Animal Health LLC
090000648322860c,Supporting & Related Material,FDA-2018-P-1740-0003,FDA-2018-P-1740,"Appendix 1- Pioneer Product Label - Deramaxx™ (deracoxib) Chewable Tablets, Elanco US Inc., NADA 141-203"
09000064832283ff,Other,FDA-2018-P-1740-0001,FDA-2018-P-1740,Citizen Petition from Provetica Animal Health LLC
090000648313c16e,Other,FDA-2015-A-5109-0003,FDA-2015-A-5109,Petition Denial Letter from FDA CFSAN
0900006481ddfb0d,Other,FDA-2015-A-5109-0001,FDA-2015-A-5109,"Advisory Opinion Request from Wallace, Jordan, Ratliff & Brandt, LLC"
0900006481ddfb0f,Other,FDA-2015-A-5109-0002,FDA-2015-A-5109,"Acknowledgement Letter from FDA DDM to Wallace, Jordan, Ratliff & Brandt, LLC"
0900006481d92cbe,Other,FDA-2015-D-4380-0002,FDA-2015-D-4380,"Best Practices for Communication Between IND Sponsors and FDA
During Drug Development Guidance for Industry and Review Staff"
0900006481d9267b,Notice,FDA-2015-D-4380-0001,FDA-2015-D-4380,"Best Practices for Communication Between Investigational New Drug
Sponsors and Food and Drug Administration During Drug Development; Draft Guidance for Industry and Review Staff; Availability"
09000064816d0a96,Other,FDA-2014-P-0534-0002,FDA-2014-P-0534,Acknowledgement Letter from FDA DDM to Neurelis Inc. (Pacific Link Consulting)
09000064816e91a7,Other,FDA-2014-P-0534-0004,FDA-2014-P-0534,Withdrawal from Pacific-Link Consulting
09000064816cfdcd,Other,FDA-2014-P-0534-0001,FDA-2014-P-0534,Citizen Petition from Neurelis Inc. (Pacific Link Consulting)
09000064816f2f0c,Other,FDA-2014-P-0534-0003,FDA-2014-P-0534,Withdrawal Letter From Pacific Link Consulting
09000064843c64cf,Other,FDA-2020-P-0983-0001,FDA-2020-P-0983,Citizen Petition from grBiosystems Inc.
09000064843c64d0,Other,FDA-2020-P-0983-0002,FDA-2020-P-0983,Acknowledgment Letter from FDA DMS to grBiosystems Inc.
090000648484500b,Other,FDA-2020-P-0983-0003,FDA-2020-P-0983,Interim Response Letter from FDA CDER to grBiosystems Inc
090000648377a1e9,Notice,FDA-2018-D-1752-0001,FDA-2018-D-1752,"Public Availability of Lists of Retail Consignees To Effectuate Certain
Human and Animal Food Recalls; Draft Guidance for Industry and Food and Drug Administration Staff; Availability"
090000648377c2d6,Other,FDA-2018-D-1752-0002,FDA-2018-D-1752,Public Availability of Lists of Retail Consignees to Effectuate Certain Human and Animal Food Recalls Guidance for Industry and FDA Staff
090000648497085c,Other,FDA-2018-D-1752-0029,FDA-2018-D-1752,"Public Availability of Lists of Retail Consignees To Effectuate Certain
Human and Animal Food Recalls; Guidance for Industry and Food and
Drug Administration Staff; Availability"
0900006484970634,Notice,FDA-2018-D-1752-0028,FDA-2018-D-1752,"Public Availability of Lists of Retail Consignees To Effectuate Certain
Human and Animal Food Recalls; Guidance for Industry and Food and
Drug Administration Staff; Availability"
090000648377d7ae,Other,FDA-2018-P-3672-0001,FDA-2018-P-3672,Suitability Petition from Zoetis Inc.
090000648377d867,Other,FDA-2018-P-3672-0002,FDA-2018-P-3672,Acknowledgment Letter from FDA DDM to Zoetis lnc.
09000064839bef4a,Other,FDA-2018-P-3672-0005,FDA-2018-P-3672,Suitability Petition Approval Letter from FDA CVM to  from Zoetis Inc.
090000648377d86b,Supporting & Related Material,FDA-2018-P-3672-0003,FDA-2018-P-3672,"Attachment 1. Pioneer Product Label - Nicarb• (nicarbazin) 25% Type A Medicated Article, NADA 009-476, Phibro Animal Health Corporation re: Suitability Petition from Zoetis Inc."
090000648377d86c,Supporting & Related Material,FDA-2018-P-3672-0004,FDA-2018-P-3672,"Attachment 2. Proposed Generic Product Label (Draft) - Generic ""Nkarbazin 25% Type A Medicated Article,""Zoetls Inc re: Suitability Petition from Zoetis Inc."
0900006482b650a9,Supporting & Related Material,FDA-2017-P-5787-0007,FDA-2017-P-5787,Reference 5 Andersson_Cloned human and rat steroid 5α-reductases (PNAS 1990) re Citizen Petition Post- Finasteride Syndrome Foundation
0900006482b658b5,Supporting & Related Material,FDA-2017-P-5787-0011,FDA-2017-P-5787,"Reference 9 Antiandrogen Drugs Definition (Free Online Medical Dictionary, Thesaurus and Encyclopedia 2013) re Citizen Petition Post- Finasteride Syndrome Foundation"
0900006482b658b6,Supporting & Related Material,FDA-2017-P-5787-0012,FDA-2017-P-5787,Reference 10 Aumuller_Localization of 5AR Isoenzymes in Human Tissue (Acta Anat 1996) re Citizen Petition Post- Finasteride Syndrome Foundation
0900006482b658d7,Supporting & Related Material,FDA-2017-P-5787-0028,FDA-2017-P-5787,Reference 26 Castelli_Regional Distribution of 5AR2 in Rat Brain (Psychoneuroendocrin 2013) re Citizen Petition Post- Finasteride Syndrome Foundation
0900006482b658d9,Supporting & Related Material,FDA-2017-P-5787-0030,FDA-2017-P-5787,Reference 28 Castro-Magana_Finasteride and Human Testicular Steroidogenesis (J Androl 1996) re Citizen Petition Post- Finasteride Syndrome Foundation
0900006482b659f2,Supporting & Related Material,FDA-2017-P-5787-0054,FDA-2017-P-5787,Reference 52 Geller_Castration-Like Effects of Finasteride on Prostate (J Cell Biochem 1992) re Citizen Petition Post- Finasteride Syndrome Foundation
0900006482b65a1e,Supporting & Related Material,FDA-2017-P-5787-0069,FDA-2017-P-5787,Reference 67 Imperato-McGinley_5AR Deficiency and Pseudohermaphrotism (Science 1974) re Citizen Petition Post- Finasteride Syndrome Foundation
0900006482b65a20,Supporting & Related Material,FDA-2017-P-5787-0071,FDA-2017-P-5787,Reference 69 Imperato-McGinley_C19 and C21 Metabolites w Finasteride and 5AR2 Deficiency (JCEM 1990) re Citizen Petition Post- Finasteride Syndrome Foundation
0900006482b65a8d,Supporting & Related Material,FDA-2017-P-5787-0093,FDA-2017-P-5787,Reference 91 Labrie_Serum Steroid Precursors and Androgen Metabolites (J Clin Endocrinol Metab 1997) re Citizen Petition Post- Finasteride Syndrome Foundation
0900006482b65ba9,Supporting & Related Material,FDA-2017-P-5787-0199,FDA-2017-P-5787,Reference 197 Whiting_Finasteride 1 mg in MPHL age 41-60 (Eur J Dermotol 2003) re Citizen Petition Post- Finasteride Syndrome Foundation
0900006482b65bac,Supporting & Related Material,FDA-2017-P-5787-0202,FDA-2017-P-5787,Reference 200 Yamana_Type 3 5AR inhibition by finasteride and dutasteride (Horm Mol Clin Invest 2010) re Citizen Petition Post- Finasteride Syndrome Foundation
0900006482b65d4e,Supporting & Related Material,FDA-2017-P-5787-0057,FDA-2017-P-5787,Reference 55 Glina_Finasteride and Infertility (Rev Hosp Clin 2004) re Citizen Petition Post- Finasteride Syndrome Foundation
0900006482b65d51,Supporting & Related Material,FDA-2017-P-5787-0060,FDA-2017-P-5787,"Reference 58 Gormley_Treating AGA with 5-Alpha Reductase Inhibitors_U.S. Patent # 5,547,957 (20-Aug-1996) re Citizen Petition Post- Finasteride Syndrome Foundation"
0900006482b65aa8,Supporting & Related Material,FDA-2017-P-5787-0098,FDA-2017-P-5787,Reference 96 Lugg_DHT and NO Penile Erection in the the Rat (Endocrin 1995) re Citizen Petition Post- Finasteride Syndrome Foundation
0900006482b65aab,Supporting & Related Material,FDA-2017-P-5787-0101,FDA-2017-P-5787,Reference 99 Mantzoros_DHT and Male Sexual Behavior (BMJ 1995) re Citizen Petition Post- Finasteride Syndrome Foundation
0900006482b65ac9,Supporting & Related Material,FDA-2017-P-5787-0111,FDA-2017-P-5787,Reference 109 MedWatch FDA Form 3500_PFSS#4 continued (26-May-2017) re Citizen Petition Post- Finasteride Syndrome Foundation
0900006482b65afa,Supporting & Related Material,FDA-2017-P-5787-0127,FDA-2017-P-5787,Reference 125 Moore_Finasteride and Uncertainty in Establishing Harm (JAMA Derm 2015) re Citizen Petition Post- Finasteride Syndrome Foundation
0900006482b65b00,Supporting & Related Material,FDA-2017-P-5787-0131,FDA-2017-P-5787,Reference 129 O'Donnell_T-Dependent Spermatogenesis in Rats and 5ARI (J Androl 1999) re Citizen Petition Post- Finasteride Syndrome Foundation
0900006482b65b03,Supporting & Related Material,FDA-2017-P-5787-0134,FDA-2017-P-5787,Reference 132 Park_Androgens and NOS mRNA in Rat Corpus Cavernosum (BJU Int 1999) re Citizen Petition Post- Finasteride Syndrome Foundation
0900006482b65b27,Supporting & Related Material,FDA-2017-P-5787-0145,FDA-2017-P-5787,Reference 143 Propecia Full Prescribing Info (31-Jan-2014) re Citizen Petition Post- Finasteride Syndrome Foundation
0900006482b65b2e,Supporting & Related Material,FDA-2017-P-5787-0152,FDA-2017-P-5787,"Reference 150 Rittmaster_Adiol-G in Liver, Skin and Prostate (JCEM 1993) re Citizen Petition Post- Finasteride Syndrome Foundation"
0900006482b65b73,Supporting & Related Material,FDA-2017-P-5787-0178,FDA-2017-P-5787,Reference 176 Suzuki_PK and Binding of Finasteride to 5AR1 and 5AR2 (Drug Metab Pharmacokin 2010)
0900006482b65b74,Supporting & Related Material,FDA-2017-P-5787-0179,FDA-2017-P-5787,Reference 177 Tay_Finasteride in Adenoca of Prostate (Ann Onc 2004) re Citizen Petition Post- Finasteride Syndrome Foundation
0900006482b65b75,Supporting & Related Material,FDA-2017-P-5787-0180,FDA-2017-P-5787,Reference 178 The Pharma Letter_FDA C'tee Raises Concerns Over Merck's Propecia (11-19-97) re Citizen Petition Post- Finasteride Syndrome Foundation
0900006482b65b76,Supporting & Related Material,FDA-2017-P-5787-0181,FDA-2017-P-5787,Reference 179 The Pharma Letter_Propecia Approved in US for MPB (1-12-98) re Citizen Petition Post- Finasteride Syndrome Foundation
09000064842c8ffc,Notice,FDA-2019-N-5646-0001,FDA-2019-N-5646,"Food and Drug Administration Rare Disease Day 2020: Supporting the Future of Rare Disease Product Development; Public Meeting; Request
for Comments"
090000648447b8be,Supporting & Related Material,FDA-2020-P-1238-0003,FDA-2020-P-1238,"Exhibits re Petition for Stay of Action from Cigar Association of America, Inc."
0900006484472a76,Other,FDA-2020-P-1238-0001,FDA-2020-P-1238,"Petition for Stay of Action from Cigar Association of America, Inc."
090000648447b8bc,Other,FDA-2020-P-1238-0002,FDA-2020-P-1238,"Acknowledgment Letter from FDA DMS to Cigar Association of America, Inc."
09000064849f2b38,Supporting & Related Material,FDA-2021-P-0074-0005,FDA-2021-P-0074,"Attachment 3 re Suitability Petition from Hyman, Phelps & McNamara PC"
09000064849f2ea5,Supporting & Related Material,FDA-2021-P-0074-0003,FDA-2021-P-0074,"Attachment 1 re Suitability Petition from Hyman, Phelps & McNamara PC"
09000064849f2ea6,Supporting & Related Material,FDA-2021-P-0074-0004,FDA-2021-P-0074,"Attachment 2 re Suitability Petition from Hyman, Phelps & McNamara PC"
09000064849f2ea4,Other,FDA-2021-P-0074-0002,FDA-2021-P-0074,"Acknowledgement Letter from FDA DMS to HYMAN, PHELPS & MCNAMARA, P.C."
09000064849f2ea3,Other,FDA-2021-P-0074-0001,FDA-2021-P-0074,"Suitability Petition from Hyman, Phelps & McNamara, P.C."
09000064838bd33f,Other,FDA-2018-P-4306-0001,FDA-2018-P-4306,Citizen Petition from Jill H. Osborne
0900006483c3e5c3,Other,FDA-2018-P-4306-0037,FDA-2018-P-4306,Interim Response from FDA CDER  re Citizen Petition
0900006484b306c8,Other,FDA-2018-P-4306-0050,FDA-2018-P-4306,Response Letter from FDA CDER to Jill H. Osborne
09000064838bdb53,Other,FDA-2018-P-4306-0002,FDA-2018-P-4306,Acknowledgment Letter from FDA DDM to Jill H. Osborne
090000648045c689,Supporting & Related Material,FDA-2006-N-0308-0003,FDA-2006-N-0308,Supporting Statement
090000648045c68f,Supporting & Related Material,FDA-2006-N-0308-0006,FDA-2006-N-0308,Supporting Statement
090000648045c682,Notice,FDA-2006-N-0308-0002,FDA-2006-N-0308,FDA
090000648045c68b,Supporting & Related Material,FDA-2006-N-0308-0004,FDA-2006-N-0308,Supporting Statement
090000648045c68d,Supporting & Related Material,FDA-2006-N-0308-0005,FDA-2006-N-0308,Supporting Statement
090000648045c667,Notice,FDA-2006-N-0308-0001,FDA-2006-N-0308,FDA
090000648045c691,Notice,FDA-2006-N-0308-0007,FDA-2006-N-0308,FDA
09000064809c8b1d,Notice,FDA-2009-N-0251-0001,FDA-2009-N-0251,"Agency Information Collection Activities; Proposals, Submissions, and Approvals"
0900006480a59071,Notice,FDA-2009-N-0251-0003,FDA-2009-N-0251,Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; User Fee Cover Sheet; Form FDA 3397
090000648080b358,Other,FDA-2009-P-0663-0002,FDA-2009-P-0663,"Acknowledgment Letter from FDA DDM to PharmaForce, Inc."
090000648080b337,Other,FDA-2009-P-0663-0001,FDA-2009-P-0663,"Citizen Petition from PharmaForce, Inc."
090000648097fcef,Other,FDA-2009-P-0663-0003,FDA-2009-P-0663,"Withdrawal Letter from PharmaForce, Inc."
0900006484a924b0,Other,FDA-2021-P-0344-0002,FDA-2021-P-0344,Acknowledgment Letter from FDA DMS to Zydus Pharmaceuticals USA Inc
0900006484a924ae,Other,FDA-2021-P-0344-0001,FDA-2021-P-0344,Suitability Petition from Zydus Pharmaceuticals USA Inc
0900006484a924d0,Supporting & Related Material,FDA-2021-P-0344-0004,FDA-2021-P-0344,Attachment 2 Approved labeling for INDOCIN indomethacin Suppositories NDA re Suitability Petition from Zydus Pharmaceuticals USA Inc
0900006484a924cf,Supporting & Related Material,FDA-2021-P-0344-0003,FDA-2021-P-0344,Attachment 1 Orange Book Pages of RLD INDOCIN indomethacin Suppositories re Suitability Petition from Zydus Pharmaceuticals USA Inc
0900006484d67902,Notice,FDA-2018-N-3037-0004,FDA-2018-N-3037,"Agency Information Collection Activities; Proposed Collection; Comment Request; Generic Clearance for Quantitative Testing for the Development of Food and Drug
Administration Communications"
09000064839cbd39,Notice,FDA-2018-N-3037-0002,FDA-2018-N-3037,"Agency Information Collection Activities; Submission for Office of
Management and Budget Review; Comment Request; Generic Clearance
for Quantitative Testing for the Development of Food and Drug
Administration Communications"
0900006483694ae5,Notice,FDA-2018-N-3037-0001,FDA-2018-N-3037,Agency Information Collection Activities; Proposed Collection; Comment Request; Generic Clearance for Quantitative Testing for the Development of FDA Communications
0900006483c131a7,Notice,FDA-2018-N-3037-0003,FDA-2018-N-3037,"Agency Information Collection Activities; Announcement of Office of
Management and Budget Approvals"
0900006484dbe791,Supporting & Related Material,FDA-2021-P-1085-0004,FDA-2021-P-1085,"Envelope RE Suitability Petition from Ray Law Firm, PLLC"
0900006484dbe7db,Supporting & Related Material,FDA-2021-P-1085-0003,FDA-2021-P-1085,"Attachment 1 RE Suitability Petition from Ray Law Firm, PLLC"
0900006484dbe7d9,Other,FDA-2021-P-1085-0002,FDA-2021-P-1085,"Acknowledgment Letter from FDA DMS to Ray Law Firm, PLLC"
0900006484dbe6c3,Other,FDA-2021-P-1085-0001,FDA-2021-P-1085,"Suitability Petition from Ray Law Firm, PLLC"
09000064843d0508,Other,FDA-2020-P-1003-0001,FDA-2020-P-1003,"Citizen Petition from John J. Coleman,  M.A., M.S., Ph.D."
09000064843d0302,Other,FDA-2020-P-1003-0002,FDA-2020-P-1003,"Acknowledgment Letter from FDA DMS to John J. Coleman,  M.A., M.S., Ph.D."
090000648471012f,Other,FDA-2020-P-1003-0003,FDA-2020-P-1003,Interim Response Letter from FDA CDRH to John J. Coleman
090000648216dfea,Supporting & Related Material,FDA-2016-P-2478-0013,FDA-2016-P-2478,"Tab 11 - Wallace P. Adams et al., Demonstrating Bioequivalence of Locally Acting Orally Inhaled Drug Products, 23 J AEROSOL MED PULM DRUG DELIV 1 (2010) re Citizen Petition from Hogan Lovells US LLP (United Therapeutics Corporation (UT)"
090000648216e28f,Supporting & Related Material,FDA-2016-P-2478-0003,FDA-2016-P-2478,"Tab 1 - ISO 27427, Anaesthetic and respiratory equipment – Nebulizing systems and components (2010) re Citizen Petition from Hogan Lovells US LLP (United Therapeutics Corporation (UT)"
090000648216e292,Supporting & Related Material,FDA-2016-P-2478-0006,FDA-2016-P-2478,"Tab 4 - AH Kendrick et al., Selecting and using nebulizer equipment, 52 Suppl 2 THORAX S92 (1997) re Citizen Petition from Hogan Lovells US LLP (United Therapeutics Corporation (UT)"
090000648216e291,Supporting & Related Material,FDA-2016-P-2478-0005,FDA-2016-P-2478,"Tab 3 - Andrew M. Wilson et al., Importance of drug-device interaction in determining systemic effects of inhaled corticosteroids, 353 LANCET 2128 (1999) re Citizen Petition from Hogan Lovells US LLP (United Therapeutics Corporation (UT)"
090000648216e294,Supporting & Related Material,FDA-2016-P-2478-0008,FDA-2016-P-2478,"Tab 6 - D. Todd Loffert et al., A comparison of commercial jet nebulizers, 106 CHEST 1788 (1994) re Citizen Petition from Hogan Lovells US LLP (United Therapeutics Corporation (UT)"
090000648216e28b,Other,FDA-2016-P-2478-0002,FDA-2016-P-2478,Acknowledgement Lette from FDA DDM to Hogan Lovells US LLP
090000648216dfe6,Supporting & Related Material,FDA-2016-P-2478-0009,FDA-2016-P-2478,"Tab 7  - JG Hardy et al., Lung deposition from four nebulizers, 87 RESPIR MED 461 (1993) re Citizen Petition from Hogan Lovells US LLP (United Therapeutics Corporation (UT)"
090000648216dfe8,Supporting & Related Material,FDA-2016-P-2478-0011,FDA-2016-P-2478,"Tab 9 -  T. Gessler et al., Ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension, 17 EUR RESPIR J 14, 16-17 (2001) re Citizen Petition from Hogan Lovells US LLP (United Therapeutics Corporation (UT)"
090000648216e1a8,Other,FDA-2016-P-2478-0001,FDA-2016-P-2478,Citizen Petition from Hogan Lovells US LLP (United Therapeutics Corporation (UT)
090000648216e290,Supporting & Related Material,FDA-2016-P-2478-0004,FDA-2016-P-2478,"Tab 2 - Food and Drug Administration, Respiratory Drug Delivery Devices – A CDRH Perspective (Nov. 2, 2010) re Citizen Petition from Hogan Lovells US LLP (United Therapeutics Corporation (UT)"
090000648216e293,Supporting & Related Material,FDA-2016-P-2478-0007,FDA-2016-P-2478,"Tab 5 - Dean Hess et al., Medication nebulizer performance: effects of diluent volume, nebulizer flow, and nebulizer brand, 110 CHEST 498 (1996) re Citizen Petition from Hogan Lovells US LLP (United Therapeutics Corporation (UT)"
090000648216dfe7,Supporting & Related Material,FDA-2016-P-2478-0010,FDA-2016-P-2478,"Tab 8 - Christopher O’Callaghan & Peter W. Barry, The science of nebulised drug delivery, 52 Suppl 2 THORAX S31, S36 (1997) re Citizen Petition from Hogan Lovells US LLP (United Therapeutics Corporation (UT)"
090000648216dfe9,Supporting & Related Material,FDA-2016-P-2478-0012,FDA-2016-P-2478,"Tab 10 - Lawrence X. Yu, Quality by Design for Orally Inhaled Drug Products, PQRI Workshop on Demonstrating Bioequivalence of Locally Acting Orally Inhaled Drug Products (Mar. 9-11, 2009) re Citizen Petition from Hogan Lovells US LLP (United Therapeutics Corporation (UT)"
090000648244de3f,Other,FDA-2016-P-2478-0014,FDA-2016-P-2478,Petition Denial Letter from FDA CDER to Hogan Lovells US LLP
090000648253fbbf,Supporting & Related Material,FDA-2017-P-2162-0006,FDA-2017-P-2162,"Tab 4 - AH Kendrick et al., Selecting and using nebulizer equipment, 52 Suppl 2 THORAX S92 (1997) re Citizen Petition from Hyman, Phelps & McNamara, P.C. (United Therapeutics Corp)"
090000648253fbc2,Supporting & Related Material,FDA-2017-P-2162-0009,FDA-2017-P-2162,"Tab 7 - JG Hardy et al., Lung deposition from four nebulizers, 87 RESPIR MED 461 (1993) re Citizen Petition from Hyman, Phelps & McNamara, P.C. (United Therapeutics Corp)"
090000648253fbc3,Supporting & Related Material,FDA-2017-P-2162-0010,FDA-2017-P-2162,"Tab 8 - Christopher O’Callaghan & Peter W. Barry, The science of nebulised drug delivery, 52 Suppl 2 THORAX S31, S36 (1997) re Citizen Petition from Hyman, Phelps & McNamara, P.C. (United Therapeutics Corp)"
090000648253fbbe,Supporting & Related Material,FDA-2017-P-2162-0005,FDA-2017-P-2162,"Tab 3 - Andrew M. Wilson et al., Importance of drug-device interaction in determining systemic effects of inhaled corticosteroids, 353 LANCET 2128 (1999) re Citizen Petition from Hyman, Phelps & McNamara, P.C. (United Therapeutics Corp)"
0900006482b02489,Other,FDA-2017-P-2162-0014,FDA-2017-P-2162,"Letter from FDA to Hyman, Phelps & McNamara"
090000648253fbab,Supporting & Related Material,FDA-2017-P-2162-0003,FDA-2017-P-2162,"Tab 1 - ISO 27427, Anaesthetic and respiratory equipment – Nebulizing systems and components (2010) re Citizen Petition from Hyman, Phelps & McNamara, P.C. (United Therapeutics Corp)"
090000648253fbc0,Supporting & Related Material,FDA-2017-P-2162-0007,FDA-2017-P-2162,"Tab 5 - Dean Hess et al., Medication nebulizer performance: effects of diluent volume, nebulizer flow, and nebulizer brand, 110 CHEST 498 (1996) re Citizen Petition from Hyman, Phelps & McNamara, P.C. (United Therapeutics Corp)"
090000648253fbc6,Supporting & Related Material,FDA-2017-P-2162-0013,FDA-2017-P-2162,"Tab 11- Wallace P. Adams et al., Demonstrating Bioequivalence of Locally Acting Orally Inhaled Drug Products, 23 J AEROSOL MED PULM DRUG DELIV 1 (2010) re Citizen Petition from Hyman, Phelps & McNamara, P.C. (United Therapeutics Corp)"
090000648253fbbd,Supporting & Related Material,FDA-2017-P-2162-0004,FDA-2017-P-2162,"Tab 2 - Food and Drug Administration, Respiratory Drug Delivery Devices – A CDRH Perspective (Nov. 2, 2010) re Citizen Petition from Hyman, Phelps & McNamara, P.C. (United Therapeutics Corp)"
090000648253fbc1,Supporting & Related Material,FDA-2017-P-2162-0008,FDA-2017-P-2162,"Tab 6 - D. Todd Loffert et al., A comparison of commercial jet nebulizers, 106 CHEST 1788 (1994) re Citizen Petition from Hyman, Phelps & McNamara, P.C. (United Therapeutics Corp)"
090000648253fbc4,Supporting & Related Material,FDA-2017-P-2162-0011,FDA-2017-P-2162,"Tab 9 - T. Gessler et al., Ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension, 17 EUR RESPIR J 14, 16-17 (2001) re Citizen Petition from Hyman, Phelps & McNamara, P.C. (United Therapeutics Corp)"
090000648253fbc5,Supporting & Related Material,FDA-2017-P-2162-0012,FDA-2017-P-2162,"Tab 10 - Lawrence X. Yu, Quality by Design for Orally Inhaled Drug Products, PQRI Workshop on Demonstrating Bioequivalence of Locally Acting Orally Inhaled Drug Products (Mar. 9-11, 2009) re Citizen Petition from Hyman, Phelps & McNamara, P.C. (United Therapeutics Corp)"
090000648253fba7,Other,FDA-2017-P-2162-0001,FDA-2017-P-2162,"Citizen Petition from Hyman, Phelps & McNamara, P.C. (United Therapeutics Corp)"
090000648253fba9,Other,FDA-2017-P-2162-0002,FDA-2017-P-2162,"Acknowledgment Letter from FDA DDM to  Hyman, Phelps & McNamara, P.C."
0900006480f54e1e,Notice,FDA-2011-N-0529-0012,FDA-2011-N-0529,Burden of FDA Food Safety Modernization Act Fee Amounts on Small Business
0900006480ed1f09,Notice,FDA-2011-N-0529-0001,FDA-2011-N-0529,Burden of Food and Drug Administration Food Safety Modernization Act Fee Amounts on Small Business
0900006481705d7c,Supporting & Related Material,FDA-2014-P-0654-0004,FDA-2014-P-0654,Reference 2 Attachment 2 Citizen Petition From Edwards Lifesciences LLC
0900006481735f75,Other,FDA-2014-P-0654-0008,FDA-2014-P-0654,Supplement from Edwards Lifesciences LLC
090000648170561f,Other,FDA-2014-P-0654-0002,FDA-2014-P-0654,Acknowledgement Letter From FDA DDM to Edwards Lifesciences LLC
0900006481705d7d,Supporting & Related Material,FDA-2014-P-0654-0005,FDA-2014-P-0654,Reference 3 Attachment 3 Citizen Petition From Edwards Lifesciences LLC
0900006481918149,Other,FDA-2014-P-0654-0009,FDA-2014-P-0654,Request for Reconsideration from Edwards Lifesciences LLC
090000648170561c,Other,FDA-2014-P-0654-0001,FDA-2014-P-0654,Citizen Petition From  Edwards Lifesciences LLC
0900006481705d7b,Supporting & Related Material,FDA-2014-P-0654-0003,FDA-2014-P-0654,Reference 1 Attachment 1 Citizen Petition From Edwards Lifesciences LLC
0900006481705d7e,Supporting & Related Material,FDA-2014-P-0654-0006,FDA-2014-P-0654,Reference 4 Attachment 4 Citizen Petition From Edwards Lifesciences LLC
0900006481a6d3b6,Supporting & Related Material,FDA-2015-P-0989-0003,FDA-2015-P-0989,Tab 1 FDA FOIA 2015_713 Citizen Petition From Organic Pastures
0900006481a6d459,Supporting & Related Material,FDA-2015-P-0989-0009,FDA-2015-P-0989,Tab 7 653 F.Supp.1229 Citizen Petition From Organic Pastures
0900006481a6d460,Supporting & Related Material,FDA-2015-P-0989-0015,FDA-2015-P-0989,Tab 13 Definitions Citizen Petition From Organic Pastures
0900006481a6d3b8,Supporting & Related Material,FDA-2015-P-0989-0005,FDA-2015-P-0989,Tab 3 CADPH FOIA Response Citizen Petition From Organic Pastures
0900006481a6d45b,Supporting & Related Material,FDA-2015-P-0989-0011,FDA-2015-P-0989,Tab 9 CDFA FOIA Request Citizen Petition From Organic Pastures
0900006481a6d3b7,Supporting & Related Material,FDA-2015-P-0989-0004,FDA-2015-P-0989,Tab 2 FDA FOIA Appeal Citizen Petition From Organic Pastures
0900006481a6d458,Supporting & Related Material,FDA-2015-P-0989-0008,FDA-2015-P-0989,Tab 6 CA FOIA Response Citizen Petition From Organic Pastures
0900006481a6d3b4,Other,FDA-2015-P-0989-0002,FDA-2015-P-0989,Acknowledgement Letter From FDA DDM to Organic Pastures Dairy Company
0900006481a6d457,Supporting & Related Material,FDA-2015-P-0989-0007,FDA-2015-P-0989,Tab 5 FDA FOIA Ack Letter Citizen Petition From Organic Pastures
0900006481a6d45d,Supporting & Related Material,FDA-2015-P-0989-0012,FDA-2015-P-0989,Tab 10 PMO Definitions Citizen Petition From Organic Pastures
0900006481a6d45e,Supporting & Related Material,FDA-2015-P-0989-0013,FDA-2015-P-0989,Tab 11 21CFR1240.61 Citizen Petition From Organic Pastures
0900006481a6d5b7,Supporting & Related Material,FDA-2015-P-0989-0016,FDA-2015-P-0989,Tab 14 FDA Food Safety Document Citizen Petition From Organic Pastures
0900006481a6d5b9,Supporting & Related Material,FDA-2015-P-0989-0018,FDA-2015-P-0989,Tab 16 CDC FOIA Request Citizen Petition From Organic Pastures
0900006481a6d3b2,Other,FDA-2015-P-0989-0001,FDA-2015-P-0989,Citizen Petition From Organic Pastures Dairy Company
0900006481a6d3b9,Supporting & Related Material,FDA-2015-P-0989-0006,FDA-2015-P-0989,Tab 4 FDA FOIA Request Citizen Petition From Organic Pastures
0900006481a6d45a,Supporting & Related Material,FDA-2015-P-0989-0010,FDA-2015-P-0989,Tab 8 CA FOIA Response Citizen Petition From Organic Pastures
0900006481a6d45f,Supporting & Related Material,FDA-2015-P-0989-0014,FDA-2015-P-0989,Tab 12 NCSL Document Citizen Petition From Organic Pastures
0900006481a6d5b8,Supporting & Related Material,FDA-2015-P-0989-0017,FDA-2015-P-0989,Tab 15 Psychrotrophs in Dairy Products Citizen Petition From Organic Pastures
090000648200404a,Notice,FDA-2016-D-1159-0001,FDA-2016-D-1159,"Food and Drug Administration Categorization of Investigational Device Exemption Devices To Assist the Centers for Medicare and Medicaid
Services With Coverage Decisions; Draft Guidance for Sponsors, Clinical
Investigators, Industry, Institutional Review Boards, and Food and Drug
Administration Staff; Availability"
0900006482ce1245,Other,FDA-2016-D-1159-0007,FDA-2016-D-1159,"FDA Categorization of Investigational Device Exemption (IDE) Devices to Assist the Centers for Medicare and Medicaid Services (CMS) with  Coverage Decisions Guidance for Sponsors, Clinical Investigators, Industry, Institutional Review Boards, and Food and Drug Administration Staff"
0900006482014c42,Other,FDA-2016-D-1159-0002,FDA-2016-D-1159,"FDA Categorization of Investigational Device Exemption (IDE) Devices to Assist the Centers for Medicare and Medicaid Services (CMS) with Coverage Decisions Draft Guidance for Sponsors, Clinical Investigators, Industry, Institutional Review Boards and Food and Drug Administration Staff"
0900006482cdbd97,Notice,FDA-2016-D-1159-0006,FDA-2016-D-1159,"Food and Drug Administration Categorization of Investigational Device Exemption Devices To Assist the Centers for Medicare and Medicaid
Services With Coverage Decisions; Guidance for Sponsors, Clinical
Investigators, Industry, Institutional Review Boards, and Food and Drug
Administration Staff; Availability"
0900006483badd00,Other,FDA-2019-P-1818-0002,FDA-2019-P-1818,Acknowledgment Letter from FDA DDM to Public Citizen Health Research Group
0900006483badd40,Supporting & Related Material,FDA-2019-P-1818-0005,FDA-2019-P-1818,Attachment 3 Rebound-associated vertebral fractures after discontinuation of denosumab—from clinic and biomechanics. re : Citizen Petition from Public Citizen Health Research Group
0900006483bad73e,Other,FDA-2019-P-1818-0001,FDA-2019-P-1818,Citizen Petition from Public Citizen Health Research Group
0900006483badd38,Supporting & Related Material,FDA-2019-P-1818-0003,FDA-2019-P-1818,Attachment 1 FDA Required REMS safety Information re: Citizen Petition from Public Citizen Health Research Group
0900006484089569,Other,FDA-2019-P-1818-0007,FDA-2019-P-1818,Interim Response from FDA CDER to Public Citizen's Health Research Group
0900006483badd3a,Supporting & Related Material,FDA-2019-P-1818-0004,FDA-2019-P-1818,Attachment 2 Duration of Treatment in Postmenopausal Osteoporosis: How Long to Treat and What are the Consequences of Cessation of Treatment? re: Citizen Petition from Public Citizen Health Research Group
09000064844c68e2,Other,FDA-2019-P-1818-0008,FDA-2019-P-1818,Agency Response Letter from FDA CDER to Public Citizen's Health Research Group
0900006482b9bff8,Other,FDA-2017-P-6027-0001,FDA-2017-P-6027,"Citizen Petition from Axinn, Veltrop & Harkrider LLP"
0900006482b9c29f,Supporting & Related Material,FDA-2017-P-6027-0004,FDA-2017-P-6027,"Attachment - 2 ANDA 071293 APPROVED LABELING - re Citizen Petition from Axinn, Veltrop & Harkrider LLP"
0900006482b9c317,Supporting & Related Material,FDA-2017-P-6027-0005,FDA-2017-P-6027,"Attachment - 3 PROPOSED DRAFT LABELING re Citizen Petition from Axinn, Veltrop & Harkrider LLP"
0900006482b9c05f,Supporting & Related Material,FDA-2017-P-6027-0003,FDA-2017-P-6027,"Attachment -1 FDA ORANGE BOOK - re Citizen Petition from Axinn, Veltrop & Harkrider LLP"
0900006482b9c664,Other,FDA-2017-P-6027-0002,FDA-2017-P-6027,"Acknowledgment Letter from FDA DDM to Axinn, Veltrop & Harkrider LLP"
0900006483bf6be0,Other,FDA-2018-D-2074-0002,FDA-2018-D-2074,"Initiation of Voluntary Recalls Under 21 CFR Part 7, Subpart C Guidance for Industry and FDA Staff DRAFT GUIDANCE"
0900006483be94d9,Proposed Rule,FDA-2018-D-2074-0001,FDA-2018-D-2074,Initiation of Voluntary Recalls Draft Guidance for Industry and Food and Drug Administration Staff; Availability
09000064848531ab,Other,FDA-2020-P-1871-0002,FDA-2020-P-1871,Acknowledgment Letter from FDA DMS to Siri & Glimstad LLP on behalf of Informed Consent Action Network
0900006484973f36,Supporting & Related Material,FDA-2020-P-1871-0018,FDA-2020-P-1871,Attachment 1 re: Citizen Petition from Siri & Glimstad LLP on behalf of Informed Consent Action Network
0900006484852c30,Other,FDA-2020-P-1871-0001,FDA-2020-P-1871,Citizen Petition from Siri & Glimstad LLP on behalf of Informed Consent Action Network
09000064849683a5,Other,FDA-2020-P-1871-0017,FDA-2020-P-1871,Withdrawal letter from Siri & Glimstad
09000064848532df,Supporting & Related Material,FDA-2020-P-1871-0003,FDA-2020-P-1871,Attachment 1 re: Citizen Petition from Siri & Glimstad LLP on behalf of Informed Consent Action Network
0900006483246793,Other,FDA-2017-P-6479-0004,FDA-2017-P-6479,Interim Response from FDA CDER to Teligent Pharma inc
0900006482c6c1aa,Other,FDA-2017-P-6479-0001,FDA-2017-P-6479,"Citizen Petition from Teligent Pharma, Inc."
0900006482c6c6d3,Supporting & Related Material,FDA-2017-P-6479-0003,FDA-2017-P-6479,"Orange Book Listing for Nicardipine Hydrochloride Injection accessed on November 13, 2017 re Citizen Petition from Teligent Pharma, Inc."
0900006482c6c507,Other,FDA-2017-P-6479-0002,FDA-2017-P-6479,Acknowledgement Letter from FDA DDM to Teligent Pharma Inc.
0900006484864037,Other,FDA-2017-P-6479-0005,FDA-2017-P-6479,"Letter from Lachman Consultants Services Inc. and Teligent Pharma, Inc. and Hyman, Phelps & McNamara, P.C."
09000064849c1209,Other,FDA-2020-P-2008-0006,FDA-2020-P-2008,Interim Response Letter from FDA CDRH to Philips Respironics
090000648487682a,Other,FDA-2020-P-2008-0002,FDA-2020-P-2008,Acknowledgment Letter from FDA DMS to Philips Respironics
0900006484876bc3,Supporting & Related Material,FDA-2020-P-2008-0003,FDA-2020-P-2008,ATTACHMENT C RE: Citizen Petition from Philips Respironics
0900006484876984,Other,FDA-2020-P-2008-0001,FDA-2020-P-2008,Citizen Petition from Philips Respironics
0900006484876bc2,Supporting & Related Material,FDA-2020-P-2008-0004,FDA-2020-P-2008,ATTACHMENT B RE: Citizen Petition from Philips Respironics
0900006484876bc1,Supporting & Related Material,FDA-2020-P-2008-0005,FDA-2020-P-2008,ATTACHMENT A RE: Citizen Petition from Philips Respironics
09000064843513ae,Supporting & Related Material,FDA-2020-P-0734-0018,FDA-2020-P-0734,Appendix 16 NRFit Single Use Epidural Catheter Feeder Example Images re Citizen Petition from GBUK Group Ltd
09000064843513a4,Supporting & Related Material,FDA-2020-P-0734-0008,FDA-2020-P-0734,Appendix 6 NRFit Single Use Blunt Drawing Up Filter Needle Example Labels re Citizen Petition from GBUK Group Ltd
09000064843513a8,Supporting & Related Material,FDA-2020-P-0734-0012,FDA-2020-P-0734,Appendix 10 NRFit Single Use Tuohy Borst Adaptor Example Labels BNS re Citizen Petition from GBUK Group Ltd
090000648435137b,Supporting & Related Material,FDA-2020-P-0734-0004,FDA-2020-P-0734,Appendix 2 NRFit Singel Use Slip Syringe Example Labels re Citizen Petition from GBUK Group Ltd
09000064843513a6,Supporting & Related Material,FDA-2020-P-0734-0010,FDA-2020-P-0734,Appendix 8 NRFit Single Use Bacterial Disc Filter Example Labels re Citizen Petition from GBUK Group Ltd
090000648435137a,Supporting & Related Material,FDA-2020-P-0734-0003,FDA-2020-P-0734,Appendix 1 NRFit Single Use Lock Syringe Example Labels re Citizen Petition from GBUK Group Ltd
09000064843513a5,Supporting & Related Material,FDA-2020-P-0734-0009,FDA-2020-P-0734,Appendix 7 NRFit Single Use Blunt Drawing Up Needle Example Labels re Citizen Petition from GBUK Group Ltd
09000064843513a7,Supporting & Related Material,FDA-2020-P-0734-0011,FDA-2020-P-0734,Appendix 9 NRFit Single Use Epidural Flat Filter Example Labels re Citizen Petition from GBUK Group Ltd
090000648435137c,Supporting & Related Material,FDA-2020-P-0734-0005,FDA-2020-P-0734,Appendix 3 NRFit Single Use Loss of Resistance Syringe Example Labels re Citizen Petition from GBUK Group Ltd
09000064843513a9,Supporting & Related Material,FDA-2020-P-0734-0013,FDA-2020-P-0734,Appendix 11 NRFit Single Use Needle Hub Cap Example Labels re Citizen Petition from GBUK Group Ltd
09000064843513ac,Supporting & Related Material,FDA-2020-P-0734-0016,FDA-2020-P-0734,Appendix 14 NRFit Single Use Lock Syringe Example Images re Citizen Petition from GBUK Group Ltd
09000064843513a3,Supporting & Related Material,FDA-2020-P-0734-0007,FDA-2020-P-0734,Appendix 5 NRFit Single Use Drawing Up Filter Straw Example Labels re Citizen Petition from GBUK Group Ltd
09000064843513aa,Supporting & Related Material,FDA-2020-P-0734-0014,FDA-2020-P-0734,Appendix 12 NRFit Single Use Syringe to Syringe Adaptor Example Labels re Citizen Petition from GBUK Group Ltd
09000064843513ad,Supporting & Related Material,FDA-2020-P-0734-0017,FDA-2020-P-0734,Appendix 15 NRFit Single Use Needle Hub Cap Example Images re Citizen Petition from GBUK Group Ltd
09000064843513af,Supporting & Related Material,FDA-2020-P-0734-0019,FDA-2020-P-0734,Appendix 17 NRFit Single Use Blunt Drawing Up Filter Needle Example Images re Citizen Petition from GBUK Group Ltd
0900006484351377,Other,FDA-2020-P-0734-0002,FDA-2020-P-0734,Acknowledgment Letter from FDA DMS to GBUK Group Ltd
0900006484787408,Other,FDA-2020-P-0734-0020,FDA-2020-P-0734,Interim Response letter from FDA CDRH to GBUK Group Ltd
090000648435137d,Supporting & Related Material,FDA-2020-P-0734-0006,FDA-2020-P-0734,Appendix 4 NRFit Single Use Syringe Cap Example Labels re Citizen Petition from GBUK Group Ltd
09000064843513ab,Supporting & Related Material,FDA-2020-P-0734-0015,FDA-2020-P-0734,Appendix 13 NRFit Singel Use Epidural Catheter Feeder Example Labels BNS re Citizen Petition from GBUK Group Ltd
0900006484351376,Other,FDA-2020-P-0734-0001,FDA-2020-P-0734,Citizen Petition from GBUK Group Ltd
0900006483741ce7,Other,FDA-2018-P-1013-0004,FDA-2018-P-1013,Interim Response from FDA CBER
0900006482fa416e,Other,FDA-2018-P-1013-0001,FDA-2018-P-1013,Citizen Petition from Akin Gump Strauss Hauer & Feld LLP on behalf of Verax Biomedical Incorporated
0900006482fa431b,Other,FDA-2018-P-1013-0002,FDA-2018-P-1013,Acknowledgment Letter from FDA DDM to Akin Gump Strauss Hauer & Feld LLP on behalf of Verax Biomedical Incorporated
0900006482fa431d,Supporting & Related Material,FDA-2018-P-1013-0003,FDA-2018-P-1013,Attachment 1 re Citizen Petition from Akin Gump Strauss Hauer & Feld LLP on behalf of Verax Biomedical Incorporated
090000648048ea18,Supporting & Related Material,FDA-2003-D-0242-0004,FDA-2003-D-0242,Guidance
090000648048ea08,Supporting & Related Material,FDA-2003-D-0242-0002,FDA-2003-D-0242,Guideline
090000648048e9da,Notice,FDA-2003-D-0242-0001,FDA-2003-D-0242,FDA
090000648048ea16,Supporting & Related Material,FDA-2003-D-0242-0003,FDA-2003-D-0242,Guideline
090000648048ea1a,Supporting & Related Material,FDA-2003-D-0242-0005,FDA-2003-D-0242,Guidance
090000648048ea1c,Notice,FDA-2003-D-0242-0006,FDA-2003-D-0242,FDA
09000064804402e8,Supporting & Related Material,FDA-2005-D-0158-0003,FDA-2005-D-0158,Guidance
09000064804402e6,Supporting & Related Material,FDA-2005-D-0158-0002,FDA-2005-D-0158,Guidance
09000064804402e9,Supporting & Related Material,FDA-2005-D-0158-0004,FDA-2005-D-0158,Guidance
09000064804402e4,Notice,FDA-2005-D-0158-0001,FDA-2005-D-0158,FDA
0900006480440ea2,Other,FDA-2005-G-0193-0002,FDA-2005-G-0193,Guidance for Industry and FDA Staff - Class II Special Controls Guidance Document: Low Energy Ultrasound Wound Cleaner
0900006480440e70,Notice,FDA-2005-G-0193-0001,FDA-2005-G-0193,Guidance for Industry and Food and Drug Administration Staff; Class II Special Controls Guidance Document: Low Energy Ultrasound Wound Cleaner; Availability
090000648067d46d,Supporting & Related Material,FDA-2007-P-0017-0006,FDA-2007-P-0017,Mutual Pharmaceutical Co . - Copyrighted Material
090000648069ea0a,Other,FDA-2007-P-0017-0007,FDA-2007-P-0017,FDA Center for Drug Evaluation and Research to William B. Schultz Zuckerman Spaeder LLP - Petition Denial
0900006480630398,Other,FDA-2007-P-0017-0002,FDA-2007-P-0017,Mutual Pharmaceutical Company - Citizen Petition
0900006480429396,Other,FDA-2007-P-0017-0001,FDA-2007-P-0017,Acknowledgement Letter to Zuckerman Spaeder LLP
0900006480630394,Supporting & Related Material,FDA-2007-P-0017-0003,FDA-2007-P-0017,Mutual Pharmaceutical Co . Tab A: Skelaxin (active ingredient metaxalone) proposed revised packaging insert
0900006480630396,Supporting & Related Material,FDA-2007-P-0017-0004,FDA-2007-P-0017,Mutual Pharmaceutical Co . - Tab B: In Vitro Assessment of Reaction Phenotyping (Enzyme Identification) for Human Cytochrome P450 Enzymes
0900006480630393,Supporting & Related Material,FDA-2007-P-0017-0005,FDA-2007-P-0017,Mutual Pharmaceutical Co . - Tab C: A list of the drugs and foods that are recognized to inhibit or induce the P450 enzymes
0900006480b51dc1,Notice,FDA-2010-N-0308-0001,FDA-2010-N-0308,Parallel Review of Medical Products
0900006480f5cb51,Notice,FDA-2010-N-0308-0044,FDA-2010-N-0308,Pilot Program for Parallel Review of Medical Products: Correction
0900006480f501bb,Notice,FDA-2010-N-0308-0043,FDA-2010-N-0308,Pilot Program for Parallel Review of Medical Products
09000064823432a7,Notice,FDA-2010-N-0308-0047,FDA-2010-N-0308,Program for Parallel Review of Medical Devices
090000648234481d,Supporting & Related Material,FDA-2010-N-0308-0048,FDA-2010-N-0308,"Reference 1 - Requests for Feedback on Medical Device Submissions:
The Pre-Submission Program and Meetings with Food and Drug Administration Staff Guidance for Industry and Food and Drug Administration Staff"
09000064814c8a96,Notice,FDA-2010-N-0308-0045,FDA-2010-N-0308,See FDA-2010-N-0308-0046
09000064814c8999,Notice,FDA-2010-N-0308-0046,FDA-2010-N-0308,Pilot Program for Parallel Review of Medical Products; Extension of the Duration of the Program
0900006480bf730f,Other,FDA-2010-P-0545-0006,FDA-2010-P-0545,"FDA/CDER to UCB, Inc. - Petition Denial"
0900006480b7198f,Supporting & Related Material,FDA-2010-P-0545-0003,FDA-2010-P-0545,"Exhibit A - Curriculum Vitae, Stanley M. Fineman, M.D. MBA - [U.C.B, Inc. - Citizen Petition]"
0900006480b71989,Other,FDA-2010-P-0545-0001,FDA-2010-P-0545,"UCB, Inc. - Citizen Petition"
0900006480b719b8,Other,FDA-2010-P-0545-0004,FDA-2010-P-0545,"Acknowledgement Letter to UCB, Inc."
0900006480b7198e,Supporting & Related Material,FDA-2010-P-0545-0002,FDA-2010-P-0545,"Appendix A - Declaration of Stanley M. Fineman, M.D. MBA - [U.C.B, Inc. - Citizen Petition]"
090000648432c195,Other,FDA-2020-P-0624-0002,FDA-2020-P-0624,"Acknowledgment Letter from FDA DMS to Reguliance, LLC on behalf of Medichem, S.A."
0900006484d60e26,Supporting & Related Material,FDA-2020-P-0624-0006,FDA-2020-P-0624,"Response to Information Request RE Citizen Petition from Reguliance, LLC on behalf of Medichem, S.A."
090000648432c19a,Supporting & Related Material,FDA-2020-P-0624-0005,FDA-2020-P-0624,"Attachment 3 - Medichem Rufinamide tablets labeling re Citizen Petition from Reguliance, LLC on behalf of Medichem, S.A."
090000648432c198,Supporting & Related Material,FDA-2020-P-0624-0003,FDA-2020-P-0624,"Attachment 1 - Banzel_Orange book re Citizen Petition from Reguliance, LLC on behalf of Medichem, S.A."
090000648432c199,Supporting & Related Material,FDA-2020-P-0624-0004,FDA-2020-P-0624,"Attachment 2  - Banzel_labeling 11_2019 re Citizen Petition from Reguliance, LLC on behalf of Medichem, S.A."
090000648432c185,Other,FDA-2020-P-0624-0001,FDA-2020-P-0624,"Citizen Petition from Reguliance, LLC on behalf of Medichem, S.A."
0900006483d80544,Supporting & Related Material,FDA-2019-P-3347-0003,FDA-2019-P-3347,"Appendix A MAUDE Database for Product Code INK: May 30, 2014-May 30, 2019 re Citizen Petition from Stryker"
0900006483d7e9e9,Other,FDA-2019-P-3347-0002,FDA-2019-P-3347,Acknowledgment Letter from FDA DDM to Stryker
0900006483f6e65a,Notice,FDA-2019-P-3347-0004,FDA-2019-P-3347,Medical Devices; Exemption From Premarket Notification: Class II; Powered Wheeled Stretcher; Request for Comments
0900006483d7e444,Other,FDA-2019-P-3347-0001,FDA-2019-P-3347,Citizen Petition from Stryker
0900006484276af7,Other,FDA-2019-P-3347-0005,FDA-2019-P-3347,Petition Response Letter from FDA CDRH to Stryker Medical
090000648429e1b6,Rule,FDA-2019-P-3347-0006,FDA-2019-P-3347,Medical Devices; Exemption From Premarket Notification; Class II Devices; Powered Wheeled Stretcher
090000648155a284,Other,FDA-2010-P-0613-0004,FDA-2010-P-0613,"Citizen Petition Denial Response from FDA CDER to Watson Pharmaceuticals, Inc."
0900006480baa535,Other,FDA-2010-P-0613-0002,FDA-2010-P-0613,"Acknowledgement Letter to Watson Laboratories, Inc."
0900006480baa531,Other,FDA-2010-P-0613-0001,FDA-2010-P-0613,"Watson Laboratories, Inc. - Citizen Petition"
0900006480baa534,Supporting & Related Material,FDA-2010-P-0613-0003,FDA-2010-P-0613,"Attachment A - ANDRODERM Labeling [Watson Laboratories, Inc. Citizen Petition]"
09000064804420b6,Other,FDA-2006-D-0031-0006,FDA-2006-D-0031,"Frequently Asked Questions About Medical Devices:  Guidance For IRBs, Clinical Investigators, and Sponsors"
09000064817ae075,Other,FDA-2006-D-0031-0008,FDA-2006-D-0031,"Draft Informed Consent Information Sheet: Guidance for Institutional
Review Boards, Clinical Investigators, and Sponsors"
09000064817ad90f,Notice,FDA-2006-D-0031-0007,FDA-2006-D-0031,"Draft Informed Consent Information Sheet: Guidance for Institutional
Review Boards, Clinical Investigators, and Sponsors; Availability"
09000064804420b4,Supporting & Related Material,FDA-2006-D-0031-0004,FDA-2006-D-0031,Waiver of IRB Requirements for Drug and Biological Products Stuides
0900006481892941,Notice,FDA-2006-D-0031-0125,FDA-2006-D-0031,"Draft Informed Consent Information Sheet: Guidance for Institutional
Review Boards, Clinical Investigators, and Sponsors; Reopening of the
Comment Period"
09000064804420b2,Supporting & Related Material,FDA-2006-D-0031-0003,FDA-2006-D-0031,FDA Institutional Review Board Inspections
090000648184359d,Other,FDA-2006-D-0031-0023,FDA-2006-D-0031,Request for Extension of the Comment Period from Biotechnology Industry Organization (BIO)
09000064804420b0,Supporting & Related Material,FDA-2006-D-0031-0002,FDA-2006-D-0031,"Information Sheet Guidance For IRBs,Clinical Investigators, and Sponsors"
09000064804420ae,Notice,FDA-2006-D-0031-0001,FDA-2006-D-0031,FDA
09000064804420b5,Other,FDA-2006-D-0031-0005,FDA-2006-D-0031,"Significant Risk and Nonsignificant Risk Medical Device Studies:  Guidance For IRBs, Clinical Investigators, and Sponsors"
09000064823bc9df,Other,FDA-2016-P-4047-0002,FDA-2016-P-4047,Acknowledgment Letter from FDA DDM to Mayne Pharma lnternational Pty Ltd
09000064825e9e63,Other,FDA-2016-P-4047-0003,FDA-2016-P-4047,Interim Response Letter from CDER to Mayne Pharma lnternational Pty Ltd
09000064823bc4c4,Other,FDA-2016-P-4047-0001,FDA-2016-P-4047,Citizen Petitions from Mayne Pharma lnternational Pty Ltd
09000064830569f6,Other,FDA-2016-P-4047-0005,FDA-2016-P-4047,Final Response Letter from CDER to Mayne Pharma lnternational Pty Ltd
0900006482324a05,Supporting & Related Material,FDA-2016-P-3465-0003,FDA-2016-P-3465,Exhibit 1 Letter from Inwood Pharmacy to Novitium Pharma LLC re Citizen Petition from Novitium Pharma LLC
0900006482324a06,Supporting & Related Material,FDA-2016-P-3465-0004,FDA-2016-P-3465,Exhibit 2 Controlled Correspondence from FDA CDER to Novitium Pharma LLC re Citizen Petition from Novitium Pharma LLC
0900006482324a01,Other,FDA-2016-P-3465-0001,FDA-2016-P-3465,Citizen Petition from Novitium Pharma LLC
0900006482538463,Other,FDA-2016-P-3465-0005,FDA-2016-P-3465,Withdrawal from Novitium Pharma LLC
0900006482324a03,Other,FDA-2016-P-3465-0002,FDA-2016-P-3465,Acknowledgement Letter from FDA DDM to Novitium Pharma LLC
09000064832d8716,Other,FDA-2018-P-1185-0006,FDA-2018-P-1185,Amended Suitability Petition from Provetica Animal Health L. L. C.
0900006483416db9,Other,FDA-2018-P-1185-0007,FDA-2018-P-1185,Petition Response Letter from FDA CVM to Provetica Animal Health LLC
09000064830270b2,Other,FDA-2018-P-1185-0001,FDA-2018-P-1185,Suitability Petition from Provetica Animal Health LLC
090000648319a6ba,Other,FDA-2018-P-1185-0005,FDA-2018-P-1185,Amended Suitability Petition from Provetica Animal Health LLC
09000064830271d0,Other,FDA-2018-P-1185-0002,FDA-2018-P-1185,Acknowledgment Letter from FDA DDM to Provetica Animal Health LLC
090000648302734d,Supporting & Related Material,FDA-2018-P-1185-0003,FDA-2018-P-1185,Appendix 1- Pioneer Product Label - Heartgard Plus re: Suitability Petition from Provetica Animal Health LLC
0900006483027653,Supporting & Related Material,FDA-2018-P-1185-0004,FDA-2018-P-1185,Appendix 2 - Proposed Product Label (Draft) Generic re: Suitability Petition from Provetica Animal Health LLC
0900006481e7c2a7,Other,FDA-2014-D-1318-0126,FDA-2014-D-1318,"Testimony from Daniel Fisher, MD, PhD"
0900006481dd91f1,Other,FDA-2014-D-1318-0002,FDA-2014-D-1318,"Electroconvulsive Therapy (ECT) Devices for Class II Intended Uses Draft Guidance for Industry, Clinicians and Food and Drug Administration Staff"
0900006481dd7b15,Notice,FDA-2014-D-1318-0001,FDA-2014-D-1318,"Electroconvulsive Therapy Devices for Class II Intended Uses: Draft Guidance for Industry, Clinicians, and FDA Staff; Availability"
09000064813af1e8,Other,FDA-2013-P-0148-0004,FDA-2013-P-0148,FDA/CDER Interim Response to Crowell & Moring LLP - Letter
090000648159d2bd,Other,FDA-2013-P-0148-0006,FDA-2013-P-0148,Citizen Petition Denial Response from FDA/CDER to Crowell & Moring LLP
09000064811ef1b7,Other,FDA-2013-P-0148-0002,FDA-2013-P-0148,Acknowledgement Letter to Crowell & Moring LLP
09000064811ed89f,Other,FDA-2013-P-0148-0001,FDA-2013-P-0148,Crowell & Moring LLP - Citizen Petition
09000064818be8c6,Other,FDA-2014-P-1611-0001,FDA-2014-P-1611,Citizen Petition from Southern Network on Adverse Reactions SONAR
09000064818bfd3d,Other,FDA-2014-P-1611-0002,FDA-2014-P-1611,Acknowledgement Letter From FDA DDM to Southern Network on Adverse Reactions (SONAR)
09000064834cd23b,Other,FDA-2014-P-1611-0005,FDA-2014-P-1611,Partial Approval and Partial Denial Response From FDA CDER to the Southern Network on Adverse Reactions Regarding Levaquin
0900006481fccb6e,Supporting & Related Material,FDA-2014-P-1611-0004,FDA-2014-P-1611,"Exhibit 1 Bennett et al, Fluoroquinolone-related neiropshychiatric and mitochondrial toxicity re Citizen Petition From SONAR"
0900006481a34041,Other,FDA-2014-P-1611-0003,FDA-2014-P-1611,Interim Response From CDER to the Southern Network on Adverse Reactions
090000648260659a,Supporting & Related Material,FDA-2017-P-3251-0021,FDA-2017-P-3251,Exhibit T to Cerdelga Due Diligence Petition Patent 1 Cerdelga re Citizen Petition from Petitioner
09000064826065a1,Supporting & Related Material,FDA-2017-P-3251-0024,FDA-2017-P-3251,Exhibit W to Cerdelga Due Diligence Petition Clinical Trial 1 re Citizen Petition from Petitioner
0900006482607045,Supporting & Related Material,FDA-2017-P-3251-0010,FDA-2017-P-3251,Exhibit I to Cerdelga Due Diligence Petition Article 2009 re Costa Rica(1) re Citizen Petition from Petitioner
0900006482606511,Supporting & Related Material,FDA-2017-P-3251-0007,FDA-2017-P-3251,Exhibit F to Cerdelga Due Diligence Petition Article WSJ 2005 re Citizen Petition from Petitioner
0900006482606515,Supporting & Related Material,FDA-2017-P-3251-0013,FDA-2017-P-3251,Exhibit L to Cerdelga Due Diligence Petition Article 1991 NYT re Citizen Petition from Petitioner
090000648260659b,Supporting & Related Material,FDA-2017-P-3251-0026,FDA-2017-P-3251,Exhibit T to Cerdelga Due Diligence Petition Patent 2 for Cerdelga re Citizen Petition from Petitioner
09000064826065a2,Supporting & Related Material,FDA-2017-P-3251-0022,FDA-2017-P-3251,Exhibit U to Cerdelga Due Diligence Petition Patent Assignment 1 re Citizen Petition from Petitioner
09000064829dff6c,Other,FDA-2017-P-3251-0031,FDA-2017-P-3251,Denial Letter from CDER to Petitioner
09000064826059ba,Supporting & Related Material,FDA-2017-P-3251-0004,FDA-2017-P-3251,Exhibit B to Cerdelga Due Diligence Petition FDA okays Genzyme pill for Gaucher disease - The Boston Globe(1) re Citizen Petition from Petitioner
0900006482606512,Supporting & Related Material,FDA-2017-P-3251-0006,FDA-2017-P-3251,"Exhibit E to Cerdelga Due Diligence Petition New Genzyme pill to treat rare Gaucher disease will cost US patients $310,250 a year re Citizen Petition from Petitioner"
0900006482606599,Supporting & Related Material,FDA-2017-P-3251-0020,FDA-2017-P-3251,Exhibit S to Cerdelga Due Diligence Petition Orange Book Patent Listings for Cerdelga re Citizen Petition from Petitioner
09000064826059bc,Supporting & Related Material,FDA-2017-P-3251-0008,FDA-2017-P-3251,"Exhibit G to Cerdelga Due Diligence Petition When a Drug Costs $300,000 - The New York Times re Citizen Petition from Petitioner"
0900006482606518,Supporting & Related Material,FDA-2017-P-3251-0016,FDA-2017-P-3251,Exhibit O to Cerdelga Due Diligence Petition U-Michigan signs royalty agreement for Gaucher disease drug _ University of Michigan re Citizen Petition from Petitioner
090000648260651a,Supporting & Related Material,FDA-2017-P-3251-0018,FDA-2017-P-3251,Exhibit Q  to Cerdelga Due Diligence Petition Article 3 re Citizen Petition from Petitioner
09000064825ffe12,Other,FDA-2017-P-3251-0001,FDA-2017-P-3251,Citizen Petition from Petitioner
0900006482601a74,Other,FDA-2017-P-3251-0002,FDA-2017-P-3251,Acknowledgment Letter from FDA DDM to Petitioner
0900006482606513,Supporting & Related Material,FDA-2017-P-3251-0009,FDA-2017-P-3251,Exhibit H to Cerdelga Due Diligence Petition Explanation of Benefits 1(1) re Citizen Petition from Petitioner
0900006482606516,Supporting & Related Material,FDA-2017-P-3251-0014,FDA-2017-P-3251,Exhibit M to Cerdelga Due Diligence Petition Approval Dates for Cerezyme re Citizen Petition from Petitioner
0900006482606517,Supporting & Related Material,FDA-2017-P-3251-0015,FDA-2017-P-3251,Exhibit N to Cerdelga Due Diligence Petition More contamination troubles for Genzyme - The Boston Globe re Citizen Petition from Petitioner
090000648260659c,Supporting & Related Material,FDA-2017-P-3251-0011,FDA-2017-P-3251,Exhibit J to Cerdelga Due Diligence Petition Orphan Drug Bounty Comes At Steep Price - Shots - Health News - NPR re Citizen Petition from Petitioner
090000648260659d,Supporting & Related Material,FDA-2017-P-3251-0027,FDA-2017-P-3251,Exhibit T to Cerdelga Due Diligence Petition Patent 3 for Cerdelga re Citizen Petition from Petitioner
090000648260659e,Supporting & Related Material,FDA-2017-P-3251-0023,FDA-2017-P-3251,Exhibit V to Cerdelga Due Diligence Petition Clinical Trials listing re Citizen Petition from Petitioner
090000648260659f,Supporting & Related Material,FDA-2017-P-3251-0025,FDA-2017-P-3251,Exhibit X to Cerdelga Due Diligence Petition Clinical Trial 2 re Citizen Petition from Petitioner
09000064826059b9,Supporting & Related Material,FDA-2017-P-3251-0003,FDA-2017-P-3251,Exhibit A Cerdelga Due Diligence Petition FDA approves U-M invented drug for Gaucher disease _ University of Michigan News(4) re Citizen Petition from Petitioner
09000064826059bb,Supporting & Related Material,FDA-2017-P-3251-0005,FDA-2017-P-3251,"Exhibit D to Cerdelga Due Diligence Petition Cerdelga, 25 years in the making _ Biotech Primer(2) re Citizen Petition from Petitioner"
09000064837c0eed,Other,FDA-2018-P-3861-0002,FDA-2018-P-3861,Acknowledgment Letter from FDA DDM to Innogenix LLC
09000064837c0f5b,Supporting & Related Material,FDA-2018-P-3861-0006,FDA-2018-P-3861,Attachment 4 Draft Package Insert Labeling for Metronidazole Tablets re Citizen Petition from Innogenix LLC
09000064837c0f59,Supporting & Related Material,FDA-2018-P-3861-0004,FDA-2018-P-3861,Attachment 2 Current Package Insert Labeling for Flagyl Tablets re Citizen Petition from Innogenix LLC
09000064837c0f5a,Supporting & Related Material,FDA-2018-P-3861-0005,FDA-2018-P-3861,Attachment 3 CDC Growth Charts re Citizen Petition from Innogenix LLC
09000064837c0f58,Supporting & Related Material,FDA-2018-P-3861-0003,FDA-2018-P-3861,Attachment 1 Approved Drug Products with Therapeutic Equivalence Evaluations re Citizen Petition from Innogenix LLC
09000064837c0eeb,Other,FDA-2018-P-3861-0001,FDA-2018-P-3861,Citizen Petition from Innogenix LLC
090000648391ceb3,Other,FDA-2018-P-4590-0002,FDA-2018-P-4590,"Acknowledgment Letter from FDA DDM to Ascend Laboratories, LLC"
0900006483cb9c2a,Other,FDA-2018-P-4590-0005,FDA-2018-P-4590,"Letter from FDA CDER to Ascend Laboratories, LLC"
090000648391ceb1,Other,FDA-2018-P-4590-0001,FDA-2018-P-4590,"Citizen Petition from Ascend Laboratories, LLC"
090000648408937d,Other,FDA-2019-P-3311-0004,FDA-2019-P-3311,"Denial Response Letter from FDA CDER to RC Outsourcing, LLC"
090000648408928b,Other,FDA-2019-P-3311-0003,FDA-2019-P-3311,Denial for Citizen Petition from FDA CDER to RC Outsourcing LLC
0900006483d75e5f,Other,FDA-2019-P-3311-0001,FDA-2019-P-3311,"Citizen Petition from RC Outsourcing, LLC."
0900006483d75f77,Other,FDA-2019-P-3311-0002,FDA-2019-P-3311,"Acknowledgment Letter from FDA DDM to RC Outsourcing, LLC"
0900006484651679,Other,FDA-2020-D-1407-0001,FDA-2020-D-1407,"Devices Used to Process Human Cells, Tissues, and Cellular and Tissue-Based Products HCT Ps Guidance for Industry and FDA Staff"
0900006481a17d83,Supporting & Related Material,FDA-2015-P-0596-0003,FDA-2015-P-0596,Attachment 1
0900006481a17d84,Supporting & Related Material,FDA-2015-P-0596-0004,FDA-2015-P-0596,Attachment 2
0900006481a17d7e,Other,FDA-2015-P-0596-0001,FDA-2015-P-0596,Citizen Petition Request from LACHMAN CONSULTANT SERVICES INC
09000064847396bc,Other,FDA-2015-P-0596-0006,FDA-2015-P-0596,"Letter from FDA CDER to Lachman Consultant Services, Inc."
0900006481a17d81,Other,FDA-2015-P-0596-0002,FDA-2015-P-0596,Acknowledgement Letter from FDA DDM to LACHMAN CONSULTANT SERVICES INC
0900006481a17d85,Supporting & Related Material,FDA-2015-P-0596-0005,FDA-2015-P-0596,Attachment 3
09000064833f76b9,Other,FDA-2018-P-2073-0003,FDA-2018-P-2073,Interim Response Letter from FDA CDRH to LMS Direct Research Foundation
09000064849d22af,Other,FDA-2018-P-2073-0005,FDA-2018-P-2073,Citizen Petition Response to LMS Direct Research Foundation
090000648331224d,Other,FDA-2018-P-2073-0001,FDA-2018-P-2073,Citizen Petition from LMS Direct Research Foundation
090000648331224e,Other,FDA-2018-P-2073-0002,FDA-2018-P-2073,Acknowledgment Letter from FDA DDM to LMS Direct Research Foundation
09000064849ec500,Supporting & Related Material,FDA-2021-P-0036-0003,FDA-2021-P-0036,"Attachment 1 re Suitability Petition from Hyman, Phelps & McNamara PC"
09000064849ec653,Supporting & Related Material,FDA-2021-P-0036-0004,FDA-2021-P-0036,"Attachment 2 re Suitability Petition from Hyman, Phelps & McNamara PC"
09000064849ebcfd,Other,FDA-2021-P-0036-0002,FDA-2021-P-0036,"Acknowledgment Letter from FDA DMS to Hyman, Phelps & McNamara, PC"
09000064849ebcfc,Other,FDA-2021-P-0036-0001,FDA-2021-P-0036,"Suitability Petition from Hyman, Phelps & McNamara, PC"
09000064849ec654,Supporting & Related Material,FDA-2021-P-0036-0005,FDA-2021-P-0036,"Attachment 3 re Suitability Petition from Hyman, Phelps & McNamara PC"
0900006484a08a92,Supporting & Related Material,FDA-2021-P-0125-0004,FDA-2021-P-0125,"Attachment 2 re Suitability Petition from Hyman, Phelps & McNamara P.C."
0900006484a08a90,Supporting & Related Material,FDA-2021-P-0125-0003,FDA-2021-P-0125,"Attachment 1 re Suitability Petition from Hyman, Phelps & McNamara P.C."
0900006484a08a93,Supporting & Related Material,FDA-2021-P-0125-0005,FDA-2021-P-0125,"Attachment 3 re Suitability Petition from Hyman, Phelps & McNamara P.C."
0900006484a08a8c,Other,FDA-2021-P-0125-0002,FDA-2021-P-0125,"Acknowledgment Letter from FDA DMS to Hyman, Phelps & McNamara P.C."
0900006484a08a8a,Other,FDA-2021-P-0125-0001,FDA-2021-P-0125,"Suitability Petition from Hyman, Phelps & McNamara P.C."
090000648375a2a9,Other,FDA-2018-P-3599-0002,FDA-2018-P-3599,Acknowledgment Letter from FDA DDM to AuroMedics Pharma LLC
0900006484bfa9b4,Other,FDA-2018-P-3599-0004,FDA-2018-P-3599,Citizen Petition Approval Letter from FDA CDER to AuroMedics Pharma LLC
0900006483759c25,Other,FDA-2018-P-3599-0001,FDA-2018-P-3599,Citizen Petition from AuroMedics Pharma LLC
0900006483b083f7,Other,FDA-2018-P-3599-0003,FDA-2018-P-3599,Letter from FDA CDER to AuroMedics Pharma LLC
0900006480483355,Notice,FDA-2003-D-0091-0001,FDA-2003-D-0091,FDA
0900006480483384,Supporting & Related Material,FDA-2003-D-0091-0002,FDA-2003-D-0091,Guidance
0900006480473724,Supporting & Related Material,FDA-2004-D-0373-0004,FDA-2004-D-0373,Background Material
0900006480473722,Supporting & Related Material,FDA-2004-D-0373-0002,FDA-2004-D-0373,Background Material
0900006480473723,Supporting & Related Material,FDA-2004-D-0373-0003,FDA-2004-D-0373,Background Material
0900006480473721,Notice,FDA-2004-D-0373-0001,FDA-2004-D-0373,FDA
09000064804504f7,Supporting & Related Material,FDA-2006-P-0149-0002,FDA-2006-P-0149,See FDA 2006-P-0149-0001
09000064804504f5,Other,FDA-2006-P-0149-0001,FDA-2006-P-0149,Acknowledgement Letter (ACK1) to Washington Legal Foundation (WLF)
09000064804504f8,Supporting & Related Material,FDA-2006-P-0149-0003,FDA-2006-P-0149,See FDA-2006-P-0149-0001
09000064804504fa,Other,FDA-2006-P-0149-0004,FDA-2006-P-0149,Washington Legal Foundation (WLF) - Citizen Petition
09000064817f26c9,Other,FDA-2006-P-0149-0010,FDA-2006-P-0149,Citizen Petition Denial Response from FDA CDRH to Washington Legal Foundation
090000648044928d,Supporting & Related Material,FDA-2005-D-0340-0004,FDA-2005-D-0340,Guidance
090000648044927b,Supporting & Related Material,FDA-2005-D-0340-0002,FDA-2005-D-0340,Guidance
0900006480449242,Notice,FDA-2005-D-0340-0001,FDA-2005-D-0340,FDA
090000648044928a,Supporting & Related Material,FDA-2005-D-0340-0003,FDA-2005-D-0340,Guidance
090000648048772c,Supporting & Related Material,FDA-2003-N-0155-0004,FDA-2003-N-0155,Supporting Statement
090000648048772f,Supporting & Related Material,FDA-2003-N-0155-0005,FDA-2003-N-0155,Supporting Statement
09000064804876f0,Notice,FDA-2003-N-0155-0001,FDA-2003-N-0155,FDA
0900006480487731,Notice,FDA-2003-N-0155-0006,FDA-2003-N-0155,FDA
0900006480487717,Notice,FDA-2003-N-0155-0002,FDA-2003-N-0155,FDA
0900006480487729,Notice,FDA-2003-N-0155-0003,FDA-2003-N-0155,FDA
09000064804736ca,Supporting & Related Material,FDA-2004-D-0368-0002,FDA-2004-D-0368,Guidance
09000064804736c9,Notice,FDA-2004-D-0368-0001,FDA-2004-D-0368,FDA
09000064804736cb,Supporting & Related Material,FDA-2004-D-0368-0003,FDA-2004-D-0368,Guidance
0900006480a86ae0,Other,FDA-2009-P-0364-0008,FDA-2009-P-0364,"FDA/CDER to Graceway Pharmaceuticals, LLC - Petition Denial"
09000064809ff00e,Supporting & Related Material,FDA-2009-P-0364-0003,FDA-2009-P-0364,"Tab A - ""Reconsideration of the Approval of ANDA 77-524; Spear Pharmaceuticals Fluorouracil Cream, USP 5%, for the Treatment of Actinic Keratosis (AK) and Superficial Basal Cell Carcinoma (sBCC),"" FDA/CDER Memorandum dated May 30, 2008 - [Graceway Pharmaceuticals, LLC - Citizen Petition] re: FDA-2009-P-0364-0001"
09000064809ff087,Supporting & Related Material,FDA-2009-P-0364-0005,FDA-2009-P-0364,"Tab P - ""Valeant Pharmaceuticals International Citizen Petition 2004P-0557: Request that FDA Refrain from Approving ANDAs for Generic Versions of Efudex Cream,"" FDA/CDER Memorandum dated December 3, 2007 - [Graceway Pharmaceuticals, LLC - Citizen Petition] re: FDA-2009-P-0364-0001"
09000064809ff0f5,Supporting & Related Material,FDA-2009-P-0364-0007,FDA-2009-P-0364,"Tab BB - ""The Development and Use of Topical Bioavailability Data: A Regulatory View,"" FDA/CDER PowerPoint Presentation - [Graceway Pharmaceuticals, LLC - Citizen Petition] re: FDA-2009-P-0364-0001"
09000064809fee1a,Other,FDA-2009-P-0364-0001,FDA-2009-P-0364,"Graceway Pharmaceuticals, LLC - Citizen Petition"
09000064809ff04b,Supporting & Related Material,FDA-2009-P-0364-0004,FDA-2009-P-0364,"Tab C - ""FDA/CDER Response to Graceway Pharmaceutical, LLC"" - [Graceway Pharmaceuticals, LLC - Citizen Petition] re: FDA-2009-P-0364-0001"
09000064809ff0fa,Other,FDA-2009-P-0364-0002,FDA-2009-P-0364,"Acknowledgement Letter to Graceway Pharmaceutical, LLP"
09000064809ff0d7,Supporting & Related Material,FDA-2009-P-0364-0006,FDA-2009-P-0364,"Tab AA - ""FDA/CDER Approval Package for 3M Pharmaceuticals - Aldara 5% Cream (Imiquimod) (Application Number NDA 20-723/S016)"" - [Graceway Pharmaceuticals, LLC - Citizen Petition] re: FDA-2009-P-0364-0001"
0900006484b08d4f,Other,FDA-2021-P-0460-0002,FDA-2021-P-0460,Acknowledgment Letter from FDA DMS to Scientific Advisory Board on behalf of Children's Health Defense
0900006484b08da5,Supporting & Related Material,FDA-2021-P-0460-0003,FDA-2021-P-0460,Appendix Vol 1 of 5 Footnotes 1 13 re Citizen Petition from Scientific Advisory Board on behalf of Children's Health Defense
0900006484b08da9,Supporting & Related Material,FDA-2021-P-0460-0007,FDA-2021-P-0460,Appendix Vol 5 of 5 Footnotes 69 73 re Citizen Petition from Scientific Advisory Board on behalf of Children's Health Defense
0900006484b08da6,Supporting & Related Material,FDA-2021-P-0460-0004,FDA-2021-P-0460,Appendix Vol 2 of 5 Footnotes 14 29 re Citizen Petition from Scientific Advisory Board on behalf of Children's Health Defense
0900006484b08da8,Supporting & Related Material,FDA-2021-P-0460-0006,FDA-2021-P-0460,Appendix Vol 4 of 5 Footnotes 48 68 re Citizen Petition from Scientific Advisory Board on behalf of Children's Health Defense
0900006484b08d4d,Other,FDA-2021-P-0460-0001,FDA-2021-P-0460,Citizen Petition from Scientific Advisory Board on behalf of Children's Health Defense
0900006484c9deb9,Other,FDA-2021-P-0460-30085,FDA-2021-P-0460,Response Letter to Citizen Petition from FDA CBER to Children’s Health Defense
0900006484b08da7,Supporting & Related Material,FDA-2021-P-0460-0005,FDA-2021-P-0460,Appendix Vol 3 of 5 Footnotes 30 47 re Citizen Petition from Scientific Advisory Board on behalf of Children's Health Defense
0900006482cfe8f2,Other,FDA-2015-P-5081-0080,FDA-2015-P-5081,Final Response Letter from FDA to Meghan O' Hara
0900006481dd9c0e,Other,FDA-2015-P-5081-0002,FDA-2015-P-5081,Acknowledgement Letter from FDA DDM to O'Hara et al.
0900006481dd9c0b,Other,FDA-2015-P-5081-0001,FDA-2015-P-5081,"Citizen Petiton from O'Hara, Vogel, Bazlen, Craig, Denning, Willson, Weir and Larock"
090000648205557f,Other,FDA-2015-P-5081-0021,FDA-2015-P-5081,Interim Response FDA-2015-P-5081
090000648499d847,Other,FDA-2020-P-2299-0001,FDA-2020-P-2299,Citizen Petition from Zydus Pharmaceuticals USA Inc
090000648499d84b,Supporting & Related Material,FDA-2020-P-2299-0003,FDA-2020-P-2299,Annexure 1 Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations re Citizen Petition from Zydus Pharmaceuticals USA Inc
0900006484a91f36,Other,FDA-2020-P-2299-0004,FDA-2020-P-2299,Withdrawal Citizen Petition from Zydus Pharmaceuticals USA Inc
090000648499d848,Other,FDA-2020-P-2299-0002,FDA-2020-P-2299,Acknowledgment Letter from FDA DMS to Zydus Pharmaceuticals USA Inc
0900006484c0b10d,Supporting & Related Material,FDA-2021-P-0786-0006,FDA-2021-P-0786,References 19 to 23 RE Citizen Petition from Coalition Advocating for Adequately Licensed Medicines (CAALM)
0900006484c0b10e,Supporting & Related Material,FDA-2021-P-0786-0007,FDA-2021-P-0786,References 24 to 32 RE Citizen Petition from Coalition Advocating for Adequately Licensed Medicines (CAALM)
0900006484c0b12d,Supporting & Related Material,FDA-2021-P-0786-0008,FDA-2021-P-0786,References 33 to 36 RE Citizen Petition from Coalition Advocating for Adequately Licensed Medicines (CAALM)
0900006484c0b12e,Supporting & Related Material,FDA-2021-P-0786-0009,FDA-2021-P-0786,References 37 to 47 RE Citizen Petition from Coalition Advocating for Adequately Licensed Medicines (CAALM)
0900006484c0acc8,Other,FDA-2021-P-0786-0002,FDA-2021-P-0786,Acknowledgment Letter from FDA DMS to Coalition Advocating for Adequately Licensed Medicines (CAALM)
0900006484c0b10a,Supporting & Related Material,FDA-2021-P-0786-0004,FDA-2021-P-0786,References 09 to 16 RE Citizen Petition from Coalition Advocating for Adequately Licensed Medicines (CAALM)
0900006484c0b10b,Supporting & Related Material,FDA-2021-P-0786-0005,FDA-2021-P-0786,References 17 to 18 RE Citizen Petition from Coalition Advocating for Adequately Licensed Medicines (CAALM)
0900006484c0acc6,Other,FDA-2021-P-0786-0001,FDA-2021-P-0786,Citizen Petition from Coalition Advocating for Adequately Licensed Medicines (CAALM)
0900006484c9e06a,Other,FDA-2021-P-0786-1557,FDA-2021-P-0786,Response Letter to Citizen Petition from FDA CBER to Coalition Advocating for Adequately Licensed Medicines (CAALM)
0900006484c0b109,Supporting & Related Material,FDA-2021-P-0786-0003,FDA-2021-P-0786,References 01 to 08 RE Citizen Petition from Coalition Advocating for Adequately Licensed Medicines (CAALM)
09000064846c9701,Supporting & Related Material,FDA-2020-P-1478-0006,FDA-2020-P-1478,Appendix IV  - RE: Citizen Petition from The Sugar Association
09000064846c9703,Supporting & Related Material,FDA-2020-P-1478-0008,FDA-2020-P-1478,Appendix VI  - RE: Citizen Petition from The Sugar Association
09000064846c9705,Supporting & Related Material,FDA-2020-P-1478-0010,FDA-2020-P-1478,Appendix VIII - RE: Citizen Petition from The Sugar Association
09000064846c96fe,Supporting & Related Material,FDA-2020-P-1478-0003,FDA-2020-P-1478,Appendix I - Glossary of Terms - RE: Citizen Petition from The Sugar Association
09000064846c9702,Supporting & Related Material,FDA-2020-P-1478-0007,FDA-2020-P-1478,Appendix V  - RE: Citizen Petition from The Sugar Association
09000064846c96ff,Supporting & Related Material,FDA-2020-P-1478-0004,FDA-2020-P-1478,Appendix II - RE: Citizen Petition from The Sugar Association
09000064846c9700,Supporting & Related Material,FDA-2020-P-1478-0005,FDA-2020-P-1478,Appendix III - RE: Citizen Petition from The Sugar Association
09000064846c9704,Supporting & Related Material,FDA-2020-P-1478-0009,FDA-2020-P-1478,Appendix VII - RE: Citizen Petition from The Sugar Association
09000064846c9717,Supporting & Related Material,FDA-2020-P-1478-0012,FDA-2020-P-1478,Appendix X - RE: Citizen Petition from The Sugar Association
09000064846c9706,Supporting & Related Material,FDA-2020-P-1478-0011,FDA-2020-P-1478,Appendix IX - RE: Citizen Petition from The Sugar Association
09000064846cae23,Other,FDA-2020-P-1478-0002,FDA-2020-P-1478,Acknowledgment Letter from FDA DMS to The Sugar Association
0900006484999969,Other,FDA-2020-P-1478-0048,FDA-2020-P-1478,Interim Response Letter from FDA CFSAN to The Sugar Association
09000064846c8470,Other,FDA-2020-P-1478-0001,FDA-2020-P-1478,Citizen Petition from The Sugar Association
0900006480afe1bb,Other,FDA-1995-N-0259-0004,FDA-1995-N-0259,National Association of Convenience Stores - Letter
0900006480ecc7f8,Supporting & Related Material,FDA-1995-N-0259-0005,FDA-1995-N-0259,"FDA/OC Regulations Policy and Management Staff, OMB Review - Memorandum re Regulations Restricting the Sale and Distribution of Cigarettes and Smokeless Tobacco to Protect Children and Adolescents (Final Rule) FDA-1995-N-0259-0002"
0900006480ac184d,Rule,FDA-1995-N-0259-0002,FDA-1995-N-0259,Regulations Restricting the Sale and Distribution of Cigarettes and Smokeless Tobacco To Protect Children and Adolescents
0900006480572ba7,Proposed Rule,FDA-1995-N-0259-0001,FDA-1995-N-0259,Regulations Restricting the Sale & Distribution of Cigarettes & Smokeless Tobacco Products to Protect Children & Adolescents
0900006480ac015e,Supporting & Related Material,FDA-1995-N-0259-0003,FDA-1995-N-0259,"Reference 1 - ""SAMHSA Results From the 2008 National Survey on Drug Use and Health"" - [ Regulations Restricting the Sale and Distribution of Cigarettes and Smokeless Tobacco to Protect Children and Adolescents; Reissuance of Final Rule]"
0900006480ae8bc6,Other,FDA-2010-D-0189-0002,FDA-2010-D-0189,Guidance for Industry and FDA Staff: Enforcement Policy Concerning Certain Regulations Restricting the Sale and Distribution of Cigarettes and Smokeless Tobacco
0900006480ae8af4,Notice,FDA-2010-D-0189-0001,FDA-2010-D-0189,Guidance for Industry and Food and Drug Administration Staff: Enforcement Policy Concerning Regulations Restricting Sale and Distribution of Cigarettes and Smokeless Tobacco
0900006480ac1897,Proposed Rule,FDA-2010-N-0136-0001,FDA-2010-N-0136,Implementation of the Family Smoking Prevention and Tobacco Control Act; Request for Comments
09000064813dc732,Rule,FDA-2010-N-0136-0037,FDA-2010-N-0136,General Enforcement Regulations
0900006480abf873,Supporting & Related Material,FDA-2010-N-0136-0010,FDA-2010-N-0136,"Reference - ""National Cancer Institute Control Monograph Series"" -  [Implementation of the Family Smoking Prevention and Tobacco Control Act; Request for Comments] re FDA-2010-N-0136-0001"
0900006480aef9ea,Proposed Rule,FDA-2010-N-0136-0013,FDA-2010-N-0136,Implementation of the Family Smoking Prevention and Tobacco Control Act; Extension of Comment Period
0900006480f17e16,Other,FDA-2010-N-0136-0035,FDA-2010-N-0136,"OMB Review, Executive Order 12866, Request for Comment on Implementation of the Family Smoking Prevention and Tobacco Control Act; ANPRM March 19, 2010"
0900006480ae3b34,Other,FDA-2010-N-0136-0011,FDA-2010-N-0136,"Lorillard Tobacco Company (Covington & Burling, LLP) - Request for Extension of Comment Due Date"
09000064823c8f0a,Supporting & Related Material,FDA-2016-P-4093-0006,FDA-2016-P-4093,Tab D -- Gender difference in antidiuretic response to desmopressin re Citizen Petition from Ferring Pharmaceuticals Inc
09000064823c8f0f,Supporting & Related Material,FDA-2016-P-4093-0011,FDA-2016-P-4093,"Tab I -- Memorandum of Meeting Minutes (September 8, 2015) (relevant excerpts) re Citizen Petition from Ferring Pharmaceuticals Inc."
09000064823c8f15,Supporting & Related Material,FDA-2016-P-4093-0014,FDA-2016-P-4093,"Tab L -- Memorandum of Meeting Minutes (June 5, 2013) (relevant excerpts) re Citizen Petition from Ferring Pharmaceuticals Inc."
09000064823c8f0b,Supporting & Related Material,FDA-2016-P-4093-0007,FDA-2016-P-4093,"Tab E -- April 22, 2010 Complete Response Letter re Citizen Petition from Ferring Pharmaceuticals Inc"
09000064823c8f10,Supporting & Related Material,FDA-2016-P-4093-0012,FDA-2016-P-4093,"Tab J -- FDA Briefing Material SER120 (October 19, 2016) re Citizen Petition from Ferring Pharmaceuticals Inc."
09000064823c8f11,Supporting & Related Material,FDA-2016-P-4093-0013,FDA-2016-P-4093,"Tab K -- FDA Briefing Material NOCDURNA (January 12, 2015) re Citizen Petition from Ferring Pharmaceuticals Inc."
09000064823c8f09,Supporting & Related Material,FDA-2016-P-4093-0005,FDA-2016-P-4093,Tab C -- Sex differences in vasopressin V2 receptor expression and vasopressin-induced antidiuresis re Citizen Petition from Ferring Pharmaceuticals Inc
09000064823c8f0d,Supporting & Related Material,FDA-2016-P-4093-0009,FDA-2016-P-4093,"Tab G -- Ferring Briefing Material NOCDURNA (January 12, 2015) (relevant excerpts) re Citizen Petition from Ferring Pharmaceuticals Inc."
09000064823c8f18,Supporting & Related Material,FDA-2016-P-4093-0017,FDA-2016-P-4093,Tab O -- Low-dose desmopressin combined with serum sodium monitoring re Citizen Petition from Ferring Pharmaceuticals Inc
09000064823c8f1a,Supporting & Related Material,FDA-2016-P-4093-0019,FDA-2016-P-4093,Tab Q -- Gender difference in efficacy and dose re Citizen Petition from Ferring Pharmaceuticals Inc
09000064823c9420,Other,FDA-2016-P-4093-0002,FDA-2016-P-4093,Acknowledgement Letter from FDA DDM to Ferring Pharmaceuticals Inc
09000064824eac35,Other,FDA-2016-P-4093-0021,FDA-2016-P-4093,Citizen Petition Denial Letter from FDA CDER to Ferring Pharmaceuticals Inc
09000064823c8f08,Supporting & Related Material,FDA-2016-P-4093-0004,FDA-2016-P-4093,Tab B -- The evaluation and treatment of nocturia re Citizen Petition from Ferring Pharmaceuticals Inc
09000064823c8f0c,Supporting & Related Material,FDA-2016-P-4093-0008,FDA-2016-P-4093,"Tab F -- January 30, 2013 Complete Response Letter re Citizen Petition from Ferring Pharmaceuticals Inc."
09000064823c8f16,Supporting & Related Material,FDA-2016-P-4093-0015,FDA-2016-P-4093,"Tab M -- Memorandum of Meeting Minutes (June 18, 2007) (relevant excerpts) re Citizen Petition from Ferring Pharmaceuticals Inc."
09000064823c8f19,Supporting & Related Material,FDA-2016-P-4093-0018,FDA-2016-P-4093,Tab P -- Desmopressin in elderly patients with nocturia re Citizen Petition from Ferring Pharmaceuticals Inc
09000064823c8f1b,Supporting & Related Material,FDA-2016-P-4093-0020,FDA-2016-P-4093,"Tab R -- Summary Minutes EMDAC (January 12, 2015) re Citizen Petition from Ferring Pharmaceuticals Inc."
09000064823c941e,Other,FDA-2016-P-4093-0001,FDA-2016-P-4093,Citizen Petition from Ferring Pharmaceuticals Inc
09000064823c9422,Supporting & Related Material,FDA-2016-P-4093-0003,FDA-2016-P-4093,Tab A -- The effect of nocturia on sleep quality and daytime function in patients with lower urinary tract symptoms a cross sectional study re Citizen Petition from Ferring Pharmaceuticals Inc
09000064823c8f0e,Supporting & Related Material,FDA-2016-P-4093-0010,FDA-2016-P-4093,"Tab H -- January 30, 2015 Complete Response Letter re Citizen Petition from Ferring Pharmaceuticals Inc."
09000064823c8f17,Supporting & Related Material,FDA-2016-P-4093-0016,FDA-2016-P-4093,Tab N -- Desmopressin Treatment in Nocturia re Citizen Petition from Ferring Pharmaceuticals Inc
0900006482b7c59d,Other,FDA-2017-P-5921-0001,FDA-2017-P-5921,Citizen Petition from Arent Fox LLP
0900006482b7c3f5,Other,FDA-2017-P-5921-0002,FDA-2017-P-5921,Acknowledgement Letter from FDA DDM to Arent Fox LLP
0900006482fa61aa,Other,FDA-2017-P-5921-0003,FDA-2017-P-5921,Citizens Petition Withdrawal from Arent Fox LLP
090000648228fbed,Other,FDA-2016-P-3112-0002,FDA-2016-P-3112,Acknowledgment Letter from FDA DDM to Mario Morais
090000648249f0c0,Other,FDA-2016-P-3112-0003,FDA-2016-P-3112,Interim Response Letter from FDA OC to Mr. Mario Morais
090000648228fbeb,Other,FDA-2016-P-3112-0001,FDA-2016-P-3112,Citizen Petition from Mario Morais
09000064824ab05a,Other,FDA-2016-P-3112-0009,FDA-2016-P-3112,Petitioner Response to FDA Petition Denial
09000064824a14a5,Other,FDA-2016-P-3112-0004,FDA-2016-P-3112,Petition Denial Letter FDA-2016-P-3112
09000064824a1b07,Supporting & Related Material,FDA-2016-P-3112-0005,FDA-2016-P-3112,Reference List for 3112
09000064824a1b08,Supporting & Related Material,FDA-2016-P-3112-0006,FDA-2016-P-3112,"Reference 1 September 15 2012 email from Buckles, D"
09000064824a1b09,Supporting & Related Material,FDA-2016-P-3112-0007,FDA-2016-P-3112,Reference 2 Biovail Corp v US Food and Drug Admin
09000064843385ac,Other,FDA-2019-P-3937-0003,FDA-2019-P-3937,"Interim Response Letter from FDA CDER to Teva Pharmaceuticals USA, Inc"
0900006483e7d3a9,Other,FDA-2019-P-3937-0001,FDA-2019-P-3937,"Citizen Petition from Teva Pharmaceuticals USA, Inc."
0900006483e7d3ab,Other,FDA-2019-P-3937-0002,FDA-2019-P-3937,"Acknowledgment Letter from FDA DMS to Teva Pharmaceuticals USA, Inc"
0900006482454fc4,Supporting & Related Material,FDA-2017-P-0137-0004,FDA-2017-P-0137,"Reference 2 Detailed IMS, Moving annual total (MAT) data re Citizen Petition from Macleods Pharmaceuticals Limited"
0900006482852346,Other,FDA-2017-P-0137-0005,FDA-2017-P-0137,Interim Response Letter to Macleods Pharmaceuticals Limited from FDA CDER
0900006482454f8d,Other,FDA-2017-P-0137-0002,FDA-2017-P-0137,Acknowledgement Letter from FDA DDM to Macleods Pharmaceuticals Limited
0900006482454f8b,Other,FDA-2017-P-0137-0001,FDA-2017-P-0137,Citizen Petition from Macleods Pharmaceuticals Limited
0900006482454fc3,Supporting & Related Material,FDA-2017-P-0137-0003,FDA-2017-P-0137,Reference 1 Current Orange Book Search Results re Citizen Petition from Macleods Pharmaceuticals Limited
0900006483646694,Other,FDA-2017-P-0137-0006,FDA-2017-P-0137,Withdrawal of Citizen Petition  from Macleods Pharmaceuticals Limited
0900006481fec4e0,Supporting & Related Material,FDA-2016-P-1319-0003,FDA-2016-P-1319,Attachment 1 NDA # 21-572 Detail Record from the current electronic edition of the Orange Book re Citizen Petition from Florek & Endres PLLC
0900006481fec369,Supporting & Related Material,FDA-2016-P-1319-0004,FDA-2016-P-1319,"Attachment 2 CUBICIN® (Daptomycin for injection), 500 mg/vial Package Insert (RLD labeling) re Citizen Petition from Florek & Endres PLLC"
0900006481fec368,Supporting & Related Material,FDA-2016-P-1319-0005,FDA-2016-P-1319,"Attachment 3 U.S. Centers for Disease Control and Prevention, National Center for Health Statistics, Body Measurements, available at http://www.cdc.gov/nchs/fastats/body-measurements.htm (last updated Nov. 2, 2012) re Citizen Petition from Florek & Endres PLLC"
0900006481fec364,Other,FDA-2016-P-1319-0001,FDA-2016-P-1319,Citizen Petition from Florek & Endres PLLC
0900006481fec366,Other,FDA-2016-P-1319-0002,FDA-2016-P-1319,Acknowledgement Letter from FDA DDM to  Florek & Endres PLLC
090000648378c7e8,Other,FDA-2018-P-3742-0002,FDA-2018-P-3742,Acknowledgment Letter from FDA DDM to Pharmacmechanics
09000064837914f8,Other,FDA-2018-P-3742-0003,FDA-2018-P-3742,Acknowledgment Letter from FDA DDM to Pharmacmechanics
090000648378c7b1,Other,FDA-2018-P-3742-0001,FDA-2018-P-3742,Citizen Petition from Pharmacmechanics
0900006483b52c55,Other,FDA-2018-P-3742-0004,FDA-2018-P-3742,Letter from FDA CDER to Pharmacomechanics
09000064811d148a,Notice,FDA-2012-D-1240-0001,FDA-2012-D-1240,Draft Guidances for Industry and Staff; Availability: Submissions for Postapproval Modifications to a Combination Product Approved UnderCertain Marketing Applications
09000064811d1b7e,Other,FDA-2012-D-1240-0002,FDA-2012-D-1240,Draft Guidances for Industry and Staff; Submissions for Postapproval Modifications to a Combination Product Approved UnderCertain Marketing Applications
0900006483b05d37,Other,FDA-2019-P-1318-0001,FDA-2019-P-1318,Citizen Petition from Lachman Consultants
0900006483b06087,Supporting & Related Material,FDA-2019-P-1318-0003,FDA-2019-P-1318,Attachment 1 Orange Book Listing for Abraxane (paclitaxel) for Injectable Suspension accessed 11/22/16 Re: Citizen Petition from Lachman Consultants.
0900006483b06089,Supporting & Related Material,FDA-2019-P-1318-0004,FDA-2019-P-1318,Attachment 2 Reference Listed Drug Prescribing Information for Abraxane (paclitaxel) for Injectable Suspension Re: Citizen Petition from Lachman Consultants
0900006483b06355,Other,FDA-2019-P-1318-0002,FDA-2019-P-1318,Acknowledgment Letter from FDA DDM to Lachman Consultants.
0900006483b0608a,Supporting & Related Material,FDA-2019-P-1318-0005,FDA-2019-P-1318,"Attachment 3 Proposed Prescribing Information for Paclitaxel for Injectable Suspension, 100 mg/vial and 200 mg/vial Re: Citizen Petition from Lachman Consultants."
09000064818c2bc8,Supporting & Related Material,FDA-2014-P-1622-0003,FDA-2014-P-1622,Exhibit 1
09000064818c28cf,Other,FDA-2014-P-1622-0002,FDA-2014-P-1622,Acknowledgement Letter from FDA DDM to Genesee Health System
0900006481cb1a7c,Other,FDA-2014-P-1622-0013,FDA-2014-P-1622,Withdrawal of Citizen Petition from GHS Genesee Health System
09000064818c2bc9,Supporting & Related Material,FDA-2014-P-1622-0004,FDA-2014-P-1622,Exhibit 2
09000064818c2bcb,Supporting & Related Material,FDA-2014-P-1622-0006,FDA-2014-P-1622,Exhibit 4
09000064818c2bcc,Supporting & Related Material,FDA-2014-P-1622-0007,FDA-2014-P-1622,Exhibit 5
09000064818c2bcd,Supporting & Related Material,FDA-2014-P-1622-0008,FDA-2014-P-1622,Exhibit 6
09000064818c2c34,Supporting & Related Material,FDA-2014-P-1622-0009,FDA-2014-P-1622,Exhibit 7
0900006481a3a47f,Other,FDA-2014-P-1622-0012,FDA-2014-P-1622,Interim Response From CDER to Genesee Health System
09000064818c2230,Other,FDA-2014-P-1622-0001,FDA-2014-P-1622,Citizen Petition from Genesee Health System
09000064818c2bca,Supporting & Related Material,FDA-2014-P-1622-0005,FDA-2014-P-1622,exhibit 3
09000064818c2c35,Supporting & Related Material,FDA-2014-P-1622-0011,FDA-2014-P-1622,Exhibit 8
09000064818c2c36,Supporting & Related Material,FDA-2014-P-1622-0010,FDA-2014-P-1622,Exhibit 9
0900006481b2f54f,Other,FDA-2015-P-2149-0001,FDA-2015-P-2149,Citizen Petition from the Natural Solutions Foundation
0900006481b3081c,Other,FDA-2015-P-2149-0002,FDA-2015-P-2149,Acknowledgement Letter from FDA DDM to the Natural Solutions Foundation
0900006481d8e76b,Other,FDA-2015-P-2149-0003,FDA-2015-P-2149,Citizen Petition Denial Response Letter from FDA CDER to National Solutions Foundation
0900006482556d05,Other,FDA-2017-P-2365-0002,FDA-2017-P-2365,Acknowledgement Letter from FDA DDM to Senators Schumer & Gillibrand
0900006482bc0e21,Other,FDA-2017-P-2365-0005,FDA-2017-P-2365,Interim Response Letter from CFSAN to Senators Schumer & Gillibrand
0900006482d3c0b3,Other,FDA-2017-P-2365-0006,FDA-2017-P-2365,Final Response Letter from FDA to The Office of Senator Charles E. Schumer
0900006482556b5f,Other,FDA-2017-P-2365-0001,FDA-2017-P-2365,Citizen Petition from Senators Schumer & Gillibrand
0900006484876bc7,Other,FDA-2020-P-2010-0001,FDA-2020-P-2010,Citizen Petition from Philips Respironics
0900006484877182,Supporting & Related Material,FDA-2020-P-2010-0003,FDA-2020-P-2010,Attachment D re: Citizen Petition from Philips Respironics
09000064849c1206,Other,FDA-2020-P-2010-0007,FDA-2020-P-2010,Interim Response Letter from FDA CDRH to Philips Respironics
0900006484877181,Supporting & Related Material,FDA-2020-P-2010-0004,FDA-2020-P-2010,Attachment C re: Citizen Petition from Philips Respironics
0900006484876e80,Other,FDA-2020-P-2010-0002,FDA-2020-P-2010,Acknowledgment Letter from FDA DMS to Philips Respironics
0900006484877180,Supporting & Related Material,FDA-2020-P-2010-0005,FDA-2020-P-2010,Attachment B re: Citizen Petition from Philips Respironics
090000648487717f,Supporting & Related Material,FDA-2020-P-2010-0006,FDA-2020-P-2010,Attachment A re: Citizen Petition from Philips Respironics
09000064844cfa2c,Supporting & Related Material,FDA-2020-P-1305-0004,FDA-2020-P-1305,Attachment 2- Emergency-Use-Authorization Jan 2017-of-Medical-Products RE: Citizen Petition from Dr. S. Albert Edwards
09000064844cfa2b,Supporting & Related Material,FDA-2020-P-1305-0003,FDA-2020-P-1305,Attachment 1 - TITLE 21--FOOD AND DRUGS CHAPTER I--FOOD AND DRUG ADMINISTRATION DEPARTMENT OF HEALTH AND HUMAN SERVICES SUBCHAPTER D--DRUGS FOR HUMAN USE-  RE: Citizen Petition from Dr. S. Albert Edwards
090000648471c56d,Other,FDA-2020-P-1305-0005,FDA-2020-P-1305,Withdrawal from S Albert Edwards
09000064844cf5c5,Other,FDA-2020-P-1305-0002,FDA-2020-P-1305,Acknowledgment Letter from FDA DMS to Dr. S. Albert Edwards
09000064844cea63,Other,FDA-2020-P-1305-0001,FDA-2020-P-1305,Citizen Petition from Dr. Albert Edwards
090000648237b7b4,Notice,FDA-2016-P-2674-0003,FDA-2016-P-2674,"Determination That CALAN SR (Verapamil Hydrochloride) Extended-
Release Oral Tablet, 180 Milligrams, Was Not Withdrawn From Sale for
Reasons of Safety or Effectiveness"
09000064821e93b4,Other,FDA-2016-P-2674-0002,FDA-2016-P-2674,"Acknowledgment Letter from FDA DDM to Heritage Pharma Labs, Inc."
09000064823884d9,Other,FDA-2016-P-2674-0004,FDA-2016-P-2674,"FDA CDER Response to Heritage Pharma Labs, Inc."
09000064821e8ef4,Other,FDA-2016-P-2674-0001,FDA-2016-P-2674,"Citizen Petition from Heritage Pharma, Inc."
0900006480472e97,Supporting & Related Material,FDA-2004-D-0306-0003,FDA-2004-D-0306,Guideline
0900006480472e94,Notice,FDA-2004-D-0306-0001,FDA-2004-D-0306,FDA
0900006480472e98,Supporting & Related Material,FDA-2004-D-0306-0004,FDA-2004-D-0306,Guideline
0900006480472e9a,Notice,FDA-2004-D-0306-0006,FDA-2004-D-0306,FDA
0900006480472e99,Supporting & Related Material,FDA-2004-D-0306-0005,FDA-2004-D-0306,Guideline
0900006480472e95,Supporting & Related Material,FDA-2004-D-0306-0002,FDA-2004-D-0306,Guideline
090000648042d706,Supporting & Related Material,FDA-2007-N-0381-0004,FDA-2007-N-0381,Jeffrey Shuren
090000648042d6f9,Notice,FDA-2007-N-0381-0001,FDA-2007-N-0381,FDA
090000648042d702,Notice,FDA-2007-N-0381-0002,FDA-2007-N-0381,FDA
090000648042d705,Notice,FDA-2007-N-0381-0003,FDA-2007-N-0381,FDA
090000648042d707,Supporting & Related Material,FDA-2007-N-0381-0005,FDA-2007-N-0381,Jeffrey Shuren
09000064844beca3,Other,FDA-2019-D-5573-0002,FDA-2019-D-5573,"Technical Considerations for Demonstrating Reliability of Emergency-Use Injectors Submitted under a BLA, NDA or ANDA: Guidance for Industry and Food and Drug Administration Staff Draft Guidance"
09000064844bee36,Notice,FDA-2019-D-5573-0001,FDA-2019-D-5573,"Technical Considerations for Demonstrating Reliability of Emergency-Use Injectors Submitted Under a Biologics License Application, New Drug Application, or Abbreviated New Drug Application; Draft Guidance for Industry and Food and Drug Administration; Availability"
09000064824f7fec,Other,FDA-2016-P-3195-0004,FDA-2016-P-3195,"Denial Letter from CDRH  to Wood, Herron & Evans, L.L.P."
09000064822a3371,Supporting & Related Material,FDA-2016-P-3195-0003,FDA-2016-P-3195,"Exhibit 1 MRIaudio Product Information re Citiizen Petition from Wood, Herron & Evans, LLP"
09000064822a1f29,Other,FDA-2016-P-3195-0001,FDA-2016-P-3195,"Citizen Petition from Wood, Herron & Evans, LLP"
09000064822a27f2,Other,FDA-2016-P-3195-0002,FDA-2016-P-3195,"Acknowledgment Letter from FDA DDM to Wood, Herron & Evans, LLP"
0900006483980af7,Notice,FDA-2018-N-4087-0001,FDA-2018-N-4087,The Food and Drug Administration’s Proposed Current Good Manufacturing Practice Policies for Outsourcing Facilities: Considerations Regarding Access to Office Stock; Public Meeting; Request for Comments
0900006480f785d0,Other,FDA-2011-P-0575-0003,FDA-2011-P-0575,"FDA/CDER  to Warner Chilcott Company, LLC - Petition Approval"
0900006480ed39eb,Other,FDA-2011-P-0575-0002,FDA-2011-P-0575,"Acknowledgement Letter to Warner Chilcott Company, LLC"
0900006480ed3940,Other,FDA-2011-P-0575-0001,FDA-2011-P-0575,"Warner Chilcott Company, LLC -  Citizen Petition"
0900006481e6f4ee,Other,FDA-2011-P-0086-0007,FDA-2011-P-0086,Supplement from Janssen
0900006480becf96,Supporting & Related Material,FDA-2011-P-0086-0003,FDA-2011-P-0086,"Exhibit 3 - ""Diagnostic & Statistical Manual of Mental Disorders"" - [Johnson & Johnson Pharmaceutical Research, LLC., (Ropes & Gray, LLP) - Citizen Petition]"
0900006481e881a5,Other,FDA-2011-P-0086-0008,FDA-2011-P-0086,Supplement from Janssen Research and Development
0900006480becc27,Other,FDA-2011-P-0086-0001,FDA-2011-P-0086,"Johnson & Johnson Pharmaceutical Research, LLC., (Ropes & Gray, LLP) - Citizen Petition"
0900006482360a28,Other,FDA-2011-P-0086-0009,FDA-2011-P-0086,"Supplement from Janssen Research & Development, LLC"
09000064814ba9d1,Other,FDA-2011-P-0086-0006,FDA-2011-P-0086,"Janssen Research & Development, LLC. - Supplement"
0900006480becc2c,Other,FDA-2011-P-0086-0002,FDA-2011-P-0086,"Acknowledgement Letter to Johnson & Johnson Pharmaceutical Research, LLC., (Ropes & Gray, LLP)"
090000648236fae8,Supporting & Related Material,FDA-2016-P-3696-0003,FDA-2016-P-3696,Attachment 1 Orange Book Drug Products Listing re Citizen Petition from ANDA Consultants
090000648236fae6,Other,FDA-2016-P-3696-0002,FDA-2016-P-3696,Acknowledgment Letter from FDA DDM to ANDA Consultants
090000648236e933,Other,FDA-2016-P-3696-0001,FDA-2016-P-3696,Citizen Petition from ANDA Consultants
090000648237c52b,Supporting & Related Material,FDA-2016-P-3696-0004,FDA-2016-P-3696,Attachment 2 Product-Specific Guidance List No Listing For Fluorometholone Ophthalmic Suspension re Citizen Petition from ANDA Consultants
09000064824a73ab,Other,FDA-2016-P-3696-0005,FDA-2016-P-3696,"Withdrawal Notification from Mark Shaw, ANDA Consultants"
0900006482c60dee,Other,FDA-2017-P-6451-0001,FDA-2017-P-6451,Suitability Petition from Locke Lord LLP
0900006482c60fc6,Supporting & Related Material,FDA-2017-P-6451-0004,FDA-2017-P-6451,Attachment2_Draft Insert Labeling for Proposed Micafungin Sodium for Injection 50-100-150(1) re: Suitability Petition from Locke Lord LLP
0900006482c60df0,Other,FDA-2017-P-6451-0002,FDA-2017-P-6451,Acknowledgment Letter from FDA DDM to Locke Lord LLP
0900006482c60df2,Supporting & Related Material,FDA-2017-P-6451-0003,FDA-2017-P-6451,Attachment1_Approved Drug Products with Therapeutic Equivalent Evaluation re: Suitability Petition from Locke Lord LLP
0900006482c60fc7,Supporting & Related Material,FDA-2017-P-6451-0005,FDA-2017-P-6451,"Attachment3_Labeling of the Approved Product, Mycamine® for Injection ) re: Suitability Petition from Locke Lord LLP"
09000064839e38a3,Other,FDA-2019-P-0114-0002,FDA-2019-P-0114,"Acknowledgment Letter from FDA DDM to Pfizer Innovative Health Global Regulatory Affairs, Hopira, Inc."
09000064839e37fa,Other,FDA-2019-P-0114-0001,FDA-2019-P-0114,"Citizen Petition from  Pfizer Innovative Health Global Regulatory Affairs, Hopira, Inc."
090000648185aeec,Supporting & Related Material,FDA-2014-P-1281-0003,FDA-2014-P-1281,Attachment A re Citizen Petition from Arnall Golden FDA-214-P-1281-0001 Gregory LLP
0900006482af4712,Other,FDA-2014-P-1281-0006,FDA-2014-P-1281,Withdrawal  email of Citizen Petition Arnall Golden Gregory LLP’s (AGG) to FDA
09000064819ae7bb,Other,FDA-2014-P-1281-0005,FDA-2014-P-1281,Interim Response Letter from FDA CDER to Arnall Golden Gregory LLP
090000648185aeed,Supporting & Related Material,FDA-2014-P-1281-0004,FDA-2014-P-1281,Attachment B re Citizen Petition from Arnall Golden FDA-2014-P-1281-0001 Gregory LLP
0900006481853477,Other,FDA-2014-P-1281-0002,FDA-2014-P-1281,Acknowledgement Letter from Arnall Golden Gregory LLP
0900006481853475,Other,FDA-2014-P-1281-0001,FDA-2014-P-1281,Citizen Petition from Arnall Golden Gregory LLP
0900006480f6d42a,Other,FDA-2011-P-0823-0002,FDA-2011-P-0823,Acknowledgement Letter to AstraZeneca Pharmaceuticals LP (Covington & Burling LLP)
0900006480f6ccb5,Other,FDA-2011-P-0823-0001,FDA-2011-P-0823,AstraZeneca Pharmaceuticals LP (Covington & Burling LLP) - Citizen Petition
090000648100ae07,Other,FDA-2011-P-0823-0003,FDA-2011-P-0823,"FDA/CDER Response to AstraZeneca Pharmaceuticals LP Dated May 11, 2012 - Petition Denial"
0900006482433da8,Notice,FDA-2016-N-4342-0001,FDA-2016-N-4342,Agency Information Collection Activities; Proposed Collection; Comment Request; Application for Participation in the Food and Drug Administration Regulatory Science Student Internship Program
0900006482fbb23b,Other,FDA-2018-P-1040-0002,FDA-2018-P-1040,Acknowledgment Letter from FDA DDM to Joshua Brooks
0900006482fbb233,Other,FDA-2018-P-1040-0001,FDA-2018-P-1040,Citizen Petition From Joshua Brooks
0900006483796020,Supporting & Related Material,FDA-2018-P-3786-0005,FDA-2018-P-3786,"Attachment 3 re Citizen Petition from Hyman, Phelps & McNamara PC"
0900006483795ff5,Supporting & Related Material,FDA-2018-P-3786-0004,FDA-2018-P-3786,"Attachment 2 re Citizen Petition from Hyman, Phelps & McNamara PC"
0900006483795ff2,Other,FDA-2018-P-3786-0002,FDA-2018-P-3786,"Acknowledgment Letter from FDA DDM to Hyman, Phelps & McNamara"
0900006483795ff4,Supporting & Related Material,FDA-2018-P-3786-0003,FDA-2018-P-3786,"Attachment 1 re Citizen Petition from Hyman, Phelps & McNamara PC"
0900006483795ff0,Other,FDA-2018-P-3786-0001,FDA-2018-P-3786,"Citizen Petition from Hyman, Phelps & McNamara PC"
0900006482bbc248,Other,FDA-2017-P-6108-0002,FDA-2017-P-6108,Acknowledgement Letter from FDA DDM to Goodwin Procter LLP
09000064831476a1,Other,FDA-2017-P-6108-0003,FDA-2017-P-6108,Petition Approval Letter from FDA CDER
0900006482bbc246,Other,FDA-2017-P-6108-0001,FDA-2017-P-6108,Citizen Petition from Goodwin Procter LLP
09000064849594b9,Supporting & Related Material,FDA-2020-P-2181-0004,FDA-2020-P-2181,"Attachment 2 - Micro-K Labeling RE Suitability Petition from Hyman, Phelps & McNamara, P.C."
09000064849594b5,Other,FDA-2020-P-2181-0002,FDA-2020-P-2181,"Acknowledgment Letter from FDA DMS to Hyman, Phelps & McNamara, P.C."
09000064849594b4,Other,FDA-2020-P-2181-0001,FDA-2020-P-2181,"Suitability Petition from Hyman, Phelps & McNamara, P.C."
09000064849594ba,Supporting & Related Material,FDA-2020-P-2181-0005,FDA-2020-P-2181,"Attachment 3 - Proposed Micro-K LS Labeling RE Suitability Petition from Hyman, Phelps & McNamara, P.C."
09000064849594b8,Supporting & Related Material,FDA-2020-P-2181-0003,FDA-2020-P-2181,"Attachment 1 - Micro-K LS -Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations RE Suitability Petition from Hyman, Phelps & McNamara, P.C."
0900006483a88ce2,Notice,FDA-2018-D-4711-0001,FDA-2018-D-4711,"Nonbinding Feedback After Certain Food and Drug Administration
Inspections of Device Establishments; Draft Guidance for Industry and Food and Drug Administration Staff; Availability"
09000064844beeed,Notice,FDA-2018-D-4711-0010,FDA-2018-D-4711,Nonbinding Feedback After Certain Food and Drug Administration Inspections of Device Establishments; Guidance for Industry and Food and Drug Administration Staff; Availability
0900006483a8889f,Other,FDA-2018-D-4711-0003,FDA-2018-D-4711,Request for Extension from Advanced Medical Technology Association (AdvaMed)
09000064844c68e5,Other,FDA-2018-D-4711-0011,FDA-2018-D-4711,Nonbinding Feedback After Certain FDA Inspections of Device Establishments Guidance for Industry and Food and Drug Administration Staff
090000648465dec0,Notice,FDA-2018-D-4711-0012,FDA-2018-D-4711,"Agency Information Collection Activities; Announcement of Office of
Management and Budget Approvals"
0900006483a8918c,Other,FDA-2018-D-4711-0002,FDA-2018-D-4711,Nonbinding Feedback After Certain FDA Inspections of Device Establishments; Draft Guidance for Industry and Food and Drug Administration Staff; Draft Guidance
09000064844418b1,Notice,FDA-2018-D-4711-0008,FDA-2018-D-4711,Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Nonbinding Feedback After Certain Food and Drug Administration Inspections of Device Establishments
090000648435b94d,Other,FDA-2019-P-3907-0003,FDA-2019-P-3907,Interim Response Letter from FDA CDER to Novitium Pharma LLC
0900006483e6f50b,Other,FDA-2019-P-3907-0001,FDA-2019-P-3907,Citizen Petition from Novitium Pharma LLC
0900006483e6f50c,Other,FDA-2019-P-3907-0002,FDA-2019-P-3907,Acknowledgment Letter from FDA DMS to Novitium Pharma LLC
0900006484a81fa9,Other,FDA-2019-P-3907-0004,FDA-2019-P-3907,Withdrawal from Novitium Pharma LLC
090000648244a4aa,Supporting & Related Material,FDA-2017-P-0052-0007,FDA-2017-P-0052,Reference 4 DSRResearch Anonymity2015 re Citizen Petition from Donor Sibling Registry
090000648361f8aa,Supporting & Related Material,FDA-2017-P-0052-0205,FDA-2017-P-0052,"Reference 1 - The Genetic Basis of Complex Traits Rare Variants or Common Gene, Common Disease re: Response letter from FDA CBER to Donor Sibling Registry"
090000648361f8a9,Supporting & Related Material,FDA-2017-P-0052-0204,FDA-2017-P-0052,List of References re: Response letter from FDA CBER to Donor Sibling Registry
090000648361f8ac,Supporting & Related Material,FDA-2017-P-0052-0206,FDA-2017-P-0052,Reference 2 - Recent Advances in the Genetics of Schizophrenia re: Response letter from FDA CBER to Donor Sibling Registry
090000648244a4ac,Supporting & Related Material,FDA-2017-P-0052-0009,FDA-2017-P-0052,Reference 4 DSRResearchDonorsParents2013 re Citizen Petition from Donor Sibling Registry
090000648244a4b0,Supporting & Related Material,FDA-2017-P-0052-0013,FDA-2017-P-0052,Reference 4 DSRResearchNon-Bio_Parent_Paper2012 re Citizen Petition from Donor Sibling Registry
090000648244a4b1,Supporting & Related Material,FDA-2017-P-0052-0014,FDA-2017-P-0052,Reference 4 DSRResearchOffspring_Paper2011 re Citizen Petition from Donor Sibling Registry
090000648244a4c1,Supporting & Related Material,FDA-2017-P-0052-0018,FDA-2017-P-0052,Reference 4 DSRResearchOocyeParents2012 re Citizen Petition from Donor Sibling Registry
090000648244de45,Other,FDA-2017-P-0052-0003,FDA-2017-P-0052,Signed Certification W. Kramer
090000648361f837,Other,FDA-2017-P-0052-0203,FDA-2017-P-0052,Response letter from FDA CBER to Donor Sibling Registry
090000648244a4a9,Supporting & Related Material,FDA-2017-P-0052-0006,FDA-2017-P-0052,Reference 4 DSR Research 1700 mothers 2013 re Citizen Petition from Donor Sibling Registry
090000648244a4ae,Supporting & Related Material,FDA-2017-P-0052-0011,FDA-2017-P-0052,Reference 4 DSRResearchEmergingModelsContact2015 re Citizen Petition from Donor Sibling Registry
090000648244a4af,Supporting & Related Material,FDA-2017-P-0052-0012,FDA-2017-P-0052,Reference 4 DSRResearchGeneticIssuesDonors2013 re Citizen Petition from Donor Sibling Registry
090000648244a4bf,Supporting & Related Material,FDA-2017-P-0052-0016,FDA-2017-P-0052,Reference 4 DSRResearchOffspringIdentity2016 re Citizen Petition from Donor Sibling Registry
090000648244a4c2,Supporting & Related Material,FDA-2017-P-0052-0019,FDA-2017-P-0052,Reference 4 DSRresearchParents_Exeriences2009 re Citizen Petition from Donor Sibling Registry
090000648244a4c8,Supporting & Related Material,FDA-2017-P-0052-0025,FDA-2017-P-0052,Reference 12 ComparativeAnalysisof sperm banks re Citizen Petition from Donor Sibling Registry
090000648244a4b2,Supporting & Related Material,FDA-2017-P-0052-0015,FDA-2017-P-0052,Reference 4 DSRResearchOffspringContactsiblings2016 re Citizen Petition from Donor Sibling Registry
090000648244a4c4,Supporting & Related Material,FDA-2017-P-0052-0021,FDA-2017-P-0052,Reference 4 DSRResearchSperm_and_Egg_Donors_Experiences2010 re Citizen Petition from Donor Sibling Registry
090000648244a4c5,Supporting & Related Material,FDA-2017-P-0052-0022,FDA-2017-P-0052,Reference 4 DSRReseearchOffspring2013 re Citizen Petition from Donor Sibling Registry
090000648244a4c6,Supporting & Related Material,FDA-2017-P-0052-0023,FDA-2017-P-0052,Reference 4 DSRRsearchEggDonorParents2012 re Citizen Petition from Donor Sibling Registry
090000648244a83f,Supporting & Related Material,FDA-2017-P-0052-0026,FDA-2017-P-0052,Reference 19 Kretchmar cystic fibrosis re Citizen Petition from Donor Sibling Registry
090000648254ad57,Supporting & Related Material,FDA-2017-P-0052-0128,FDA-2017-P-0052,Attachment 3 2015-2017 Huffington Post Contributions re: Comment from Wendy Kramer
090000648244a29e,Other,FDA-2017-P-0052-0001,FDA-2017-P-0052,Citizen Petition from Donor Sibling Registry
090000648244a2a0,Other,FDA-2017-P-0052-0002,FDA-2017-P-0052,Acknowledgement Letter from FDA DDM to Donor Sibling Registry
090000648244a2a3,Supporting & Related Material,FDA-2017-P-0052-0004,FDA-2017-P-0052,Reference 1 ASRM Recommendations re Citizen Petition from Donor Sibling Registry
0900006484a679f6,Other,FDA-2021-P-0284-0001,FDA-2021-P-0284,Citizen Petition from Donavan Melton
0900006484a67a01,Other,FDA-2021-P-0284-0002,FDA-2021-P-0284,Acknowledgment Letter from FDA DMS to Donavan Melton
0900006484c03ba1,Other,FDA-2021-P-0284-0003,FDA-2021-P-0284,Final Response to Donavan Melton from FDA CVM
0900006480b09408,Notice,FDA-2010-N-0180-0002,FDA-2010-N-0180,"Agency Information Collection Activities; Proposals, Submissions, and Approvals: Adoption of Food and Drug Administration Food Code by Local, State, and Tribal Governments"
0900006480ad7226,Notice,FDA-2010-N-0180-0001,FDA-2010-N-0180,"Agency Information Collection Activities; Proposals, Submissions, and Approvals: Adoption of FDA Food Code by Local, State, and Tribal Governments"
0900006480ba4316,Notice,FDA-2010-N-0180-0003,FDA-2010-N-0180,"Agency Information Collection Activities; Proposals, Submissions, and Approvals: Adoption of Food and Drug Administration Food Code by Local, State and Tribal Governments"
090000648435061c,Supporting & Related Material,FDA-2020-P-0725-0005,FDA-2020-P-0725,Appendix 3 ENFit ISOSAF NN Single Use Syringe Example Labels re Citizen Petition from GBUK Group Ltd
09000064843502eb,Supporting & Related Material,FDA-2020-P-0725-0003,FDA-2020-P-0725,Appendix 1 ENFit ISOSAF Single Use Syringe Example Labels re Citizen Petition from GBUK Group Ltd
09000064843502e8,Other,FDA-2020-P-0725-0002,FDA-2020-P-0725,Acknowledgment Letter from FDA DMS to GBUK Group Ltd
090000648435061b,Supporting & Related Material,FDA-2020-P-0725-0004,FDA-2020-P-0725,Appendix 2 ENFit ISOSAF Single Use Syringe LDT Example Labels re Citizen Petition from GBUK Group Ltd
090000648435061d,Supporting & Related Material,FDA-2020-P-0725-0006,FDA-2020-P-0725,Appendix 4 ENFit ISOSAF Single Use Syringe and Push Fit Cap Example Labels re Citizen Petition from GBUK Group Ltd
0900006484350620,Supporting & Related Material,FDA-2020-P-0725-0009,FDA-2020-P-0725,Appendix 7 Drawing Up Devices Example Labels re Citizen Petition from GBUK Group Ltd
09000064843502e7,Other,FDA-2020-P-0725-0001,FDA-2020-P-0725,Citizen Petition from GBUK Group Ltd
0900006484350621,Supporting & Related Material,FDA-2020-P-0725-0010,FDA-2020-P-0725,Appendix 8 Example Images re Citizen Petition from GBUK Group Ltd
09000064847873e6,Other,FDA-2020-P-0725-0011,FDA-2020-P-0725,Interim Response letter from FDA CDRH to GBUK Group Ltd
090000648435061f,Supporting & Related Material,FDA-2020-P-0725-0008,FDA-2020-P-0725,Appendix 6 Bottle Adaptors Example Labels re Citizen Petition from GBUK Group Ltd
090000648435061e,Supporting & Related Material,FDA-2020-P-0725-0007,FDA-2020-P-0725,Appendix 5 Syringe Cap Example Labels re Citizen Petition from GBUK Group Ltd
090000648294d5c6,Other,FDA-2017-P-4351-0002,FDA-2017-P-4351,Acknowledgment Letter from FDA DDM to Hogan Lovells US LLP (Relypsa Inc.)
090000648294d5cb,Supporting & Related Material,FDA-2017-P-4351-0006,FDA-2017-P-4351,Exhibit 4 - Lesko et al 2017 Veltassa DDI reprint re Citizen Petition from Hogan Lovells US LLP  ( Relypsa Inc.)
090000648294bcfc,Other,FDA-2017-P-4351-0001,FDA-2017-P-4351,Citizen Petition from Hogan Lovells US LLP  ( Relypsa Inc.)
0900006482c3c1de,Other,FDA-2017-P-4351-0008,FDA-2017-P-4351,Petition Withdrawal Letter from Relypsa Inc.
090000648294d5c8,Supporting & Related Material,FDA-2017-P-4351-0003,FDA-2017-P-4351,"Exhibit 1 - FDA Press Release for Veltassaa Oct 21, 2015 re Citizen Petition from Hogan Lovells US LLP  ( Relypsa Inc.)"
090000648294d5c9,Supporting & Related Material,FDA-2017-P-4351-0004,FDA-2017-P-4351,"Exhibit 2 - FDA Drug Safety Communication for Kayexalate Oct 22, 2015 re Citizen Petition from Hogan Lovells US LLP  ( Relypsa Inc.)"
090000648294dcb6,Supporting & Related Material,FDA-2017-P-4351-0007,FDA-2017-P-4351,"Exhibit 5 - Kayexalate Prescribing Information Jan 3, 2011 re Citizen Petition from Hogan Lovells US LLP  ( Relypsa Inc.)"
090000648294d5ca,Supporting & Related Material,FDA-2017-P-4351-0005,FDA-2017-P-4351,"Exhibit 3 - Veltassa Prescribing Information Nov 25, 2016 re Citizen Petition from Hogan Lovells US LLP  ( Relypsa Inc.)"
0900006481239e43,Other,FDA-2013-P-0337-0001,FDA-2013-P-0337,"Hyman, Phelps & McNamara, PC - Petition for Stay of Action"
090000648124f805,Other,FDA-2013-P-0337-0003,FDA-2013-P-0337,"Hyman, Phelps & McNamara, P.C. - Withdrawal of Petition for Stay of Action"
0900006481239e98,Other,FDA-2013-P-0337-0002,FDA-2013-P-0337,"Acknowledgement Letter to Hyman, Phelps & McNamara, PC"
0900006481ff6c7c,Supporting & Related Material,FDA-2016-P-1364-0003,FDA-2016-P-1364,"Attachment 1 Orange Book Listing for Abraxane (paclitaxel) for Injectable Suspension accessed 05/24/16 re Citizen Petition from Lachman Consultant Services, Inc."
0900006481ff6cc4,Other,FDA-2016-P-1364-0002,FDA-2016-P-1364,"Acknowledgement Letter from FDA DDM to Lachman Consultant Services, Inc."
0900006481ff6c7a,Other,FDA-2016-P-1364-0001,FDA-2016-P-1364,"Citizen Petition from Lachman Consultant Services, Inc."
0900006481ff6c9c,Supporting & Related Material,FDA-2016-P-1364-0004,FDA-2016-P-1364,"Attachment 2 Reference Listed Drug Prescribing Information for Abraxane (paclitaxel) for Injectable Suspension) re Citizen Petition from Lachman Consultant Services, Inc."
0900006481ff6c9d,Supporting & Related Material,FDA-2016-P-1364-0005,FDA-2016-P-1364,"Attachment 3 Proposed Prescribing Information for Paclitaxel for Injectable Suspension, 250 mg/vial re Citizen Petition from Lachman Consultant Services, Inc."
0900006482b77d4b,Other,FDA-2017-P-5909-0002,FDA-2017-P-5909,Acknowledgment Letter from FDA DDM to  Goodwin Procter LLP
0900006482c9fada,Other,FDA-2017-P-5909-0004,FDA-2017-P-5909,Petition Response Letter
0900006482c98c5d,Notice,FDA-2017-P-5909-0003,FDA-2017-P-5909,"Determination That TRINTELLIX (Vortioxetine Hydrobromide) Oral
Tablet, EQ 15 Milligram Base, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
0900006482b77278,Other,FDA-2017-P-5909-0001,FDA-2017-P-5909,Citizen Petition from Goodwin Procter LLP
090000648253d67a,Supporting & Related Material,FDA-2017-P-2129-0004,FDA-2017-P-2129,Exhibit II - Medrol Label re
090000648253dcac,Other,FDA-2017-P-2129-0002,FDA-2017-P-2129,Acknowledgment Letter from FDA DDM to Jubilant Generics Limited
090000648253d677,Other,FDA-2017-P-2129-0001,FDA-2017-P-2129,Citizen Petition from Jubilant Generics Limited
090000648253d67b,Supporting & Related Material,FDA-2017-P-2129-0005,FDA-2017-P-2129,Exhibit III - Proposed Label re
090000648253d679,Supporting & Related Material,FDA-2017-P-2129-0003,FDA-2017-P-2129,"Exhibit I - Orange Book: Approved Drug Products with Therapeutic
Equivalence Evaluations"
0900006480b8a278,Other,FDA-2010-P-0580-0003,FDA-2010-P-0580,"Acknowledgement Letter to Bracewell & Giuliani, LLP"
0900006480b8a154,Supporting & Related Material,FDA-2010-P-0580-0002,FDA-2010-P-0580,"Exhibit A - ""FDA/CDRH Response to Medtronic MiniMed, Apirl 7, 2006"" - [Bracewell & Giuliani, LLP - Citizen Petition]"
0900006480c3f4bd,Other,FDA-2010-P-0580-0004,FDA-2010-P-0580,"FDA/Center for Devices and Radiological Health - Interim Repsonse to Bracewell & Giuliani, LLP"
0900006480c3f4c7,Other,FDA-2010-P-0580-0005,FDA-2010-P-0580,"Houssiere Durant Houssiere, LLP - Letter"
09000064816b6d75,Other,FDA-2010-P-0580-0006,FDA-2010-P-0580,"Citizen Petition Response from FDA CDRH to Houssiere, Durant & Houssiere, LLP and Bracewell & Giuliani, LLP"
0900006480b8a152,Other,FDA-2010-P-0580-0001,FDA-2010-P-0580,"Bracewell & Giuliani, LLP - Citizen Petition"
0900006480fbebd5,Other,FDA-2011-D-0674-0002,FDA-2011-D-0674,"Draft Guidance for Industry FDA Records Access Authority under Section 414 and 704 of the Federal Food, Drug, & Cosmetic Act"
090000648169ddb1,Rule,FDA-2011-D-0674-0043,FDA-2011-D-0674,"Guidance for Industry: Food and Drug Administration Records Access
Authority Under the Federal Food, Drug, and Cosmetic Act; Availability"
0900006480fbeaae,Notice,FDA-2011-D-0674-0001,FDA-2011-D-0674,"Draft Guidance for Industry;Food and Drug Administration Records Access Authority under Federal Food, Drug, and Cosmetic Act; Availability"
090000648169ddb5,Other,FDA-2011-D-0674-0044,FDA-2011-D-0674,"Guidance for Industry; FDA Records Access Authority Under Sections 414 and 704 of the Federal Food, Drug, and Cosmetic Act"
0900006480efc77a,Other,FDA-2011-P-0623-0002,FDA-2011-P-0623,"Acknowledgement Letter to International Premium Cigar & Pipe Retailers Association (IPCPR), Hyman Phelps & McNamara, P.C."
0900006480ef8fa8,Other,FDA-2011-P-0623-0001,FDA-2011-P-0623,"International Premium Cigar & Pipe Retailers Association (IPCPR) Hyman, Phelps and McNamara, P.C. -  Citizen Petition"
0900006481fbaec9,Other,FDA-2011-P-0623-0006,FDA-2011-P-0623,"Citizen Petition Final Response from FDA CTP to Hyman, Phelps & McNamara, P.C."
0900006480f7bbad,Other,FDA-2011-P-0623-0003,FDA-2011-P-0623,"FDA/CTP Interim Response to International Premium Cigar & Pipe Retailers Association (IPCPR) Hyman, Phelps and McNamara, P.C. - Letter"
09000064816a49de,Other,FDA-2014-P-0407-0001,FDA-2014-P-0407,"Citizen Petition From Almatica Pharma, Inc."
09000064816b526d,Other,FDA-2014-P-0407-0003,FDA-2014-P-0407,Supplement from Almatica Pharma Inc
0900006481719aa8,Supporting & Related Material,FDA-2014-P-0407-0004,FDA-2014-P-0407,Exhibit C Naprelan Controlled Release Tablets Supplement from Almatica Pharma Inc
09000064818a7e58,Other,FDA-2014-P-0407-0007,FDA-2014-P-0407,"Interim Response from FDA/CDER to Almatica Pharma, Inc."
0900006481d73efd,Other,FDA-2014-P-0407-0008,FDA-2014-P-0407,"Citizen Petition Denial Response Letter from FDA CDER to Almatica Pharma, Inc."
09000064816a4a46,Other,FDA-2014-P-0407-0002,FDA-2014-P-0407,Acknowledgement Letter From FDA DDM to Almatica Pharm Inc
0900006481719aaa,Supporting & Related Material,FDA-2014-P-0407-0005,FDA-2014-P-0407,Exhibit E FDA Draft Guidance on Naproxen Sodium Supplement from Almatica Pharma Inc
0900006481719aac,Supporting & Related Material,FDA-2014-P-0407-0006,FDA-2014-P-0407,Exhibit K FDA Guidance Document on Bioavavailability and Bioequivalence Studies for Orally Administered Drug Products Supplement from Almatica Pharma Inc
09000064816b7603,Other,FDA-2014-P-0461-0002,FDA-2014-P-0461,Acknowledgement Letter From FDA DDM to Wiley Rein LLP
09000064816b737f,Other,FDA-2014-P-0461-0001,FDA-2014-P-0461,Citizen Petition From Wiley Rein LLP
0900006482bc2a0c,Other,FDA-2014-P-0461-0004,FDA-2014-P-0461,Withdrawal From Wiley Rein LLP
09000064816b7ab6,Other,FDA-2014-P-0462-0002,FDA-2014-P-0462,Acknowledgement Letter From FDA DDM to Wiley Rein LLP
0900006482bc25f7,Other,FDA-2014-P-0462-0005,FDA-2014-P-0462,Withdrawal From Wiley Rein LLP
09000064816b7a74,Other,FDA-2014-P-0462-0001,FDA-2014-P-0462,Citizen Petition From Wiley Rein LLP
0900006481ca27bb,Other,FDA-2014-P-0462-0004,FDA-2014-P-0462,Letter From Wiley Rein LLP
090000648170395b,Other,FDA-2014-P-0648-0002,FDA-2014-P-0648,Acknowledgement Letter From FDA DDM to Burdock Group Consultants
0900006481703960,Supporting & Related Material,FDA-2014-P-0648-0004,FDA-2014-P-0648,Reference 1 Footnotes Citizen Petition From Burdock Group Consultants
09000064817034db,Other,FDA-2014-P-0648-0001,FDA-2014-P-0648,Citizen Petition From InovoBiologic (Burdock Group Consultants)
0900006481703961,Supporting & Related Material,FDA-2014-P-0648-0005,FDA-2014-P-0648,Reference 1 References Citizen Petition From Burdock Group Consultants
090000648170395f,Supporting & Related Material,FDA-2014-P-0648-0003,FDA-2014-P-0648,Reference 1 Appendicies Citizen Petition From Burdock Group Consultants
0900006481d543f1,Other,FDA-2015-P-4307-0003,FDA-2015-P-4307,Acknowledgement Letter From FDA DDM to Guy Aliotta
0900006481d4f18e,Other,FDA-2015-P-4307-0001,FDA-2015-P-4307,Citizen Petition from Guy Aliotta
0900006481d543ed,Supporting & Related Material,FDA-2015-P-4307-0002,FDA-2015-P-4307,Multiple Signatures to Change.org Xylitol Petition re Citizen Petition from Guy Aliotta
0900006482039828,Other,FDA-2015-P-4307-0004,FDA-2015-P-4307,Interim Response Letter from FDA CFSAN to Guy Aliotta
0900006483fa1b53,Notice,FDA-2019-N-3403-0001,FDA-2019-N-3403,"The Food and Drug Administration Solicits Input on Potential Role for
Abuse-Deterrent Formulations of Central Nervous System Stimulants;
Establishment of a Public Docket; Request for Comments"
0900006484470c61,Other,FDA-2020-D-1057-0001,FDA-2020-D-1057,Notifying FDA of a Permanent Discontinuance or Interruption in Manufacturing Under Section 506C of the FD&C Act Guidance for Industry
090000648447e178,Notice,FDA-2020-D-1057-0003,FDA-2020-D-1057,"Notifying the Food and Drug Administration of a Permanent Discontinuance or Interruption in Manufacturing Under Section 506C of
the Federal Food, Drug, and Cosmetic Act; Guidance for Industry; Availability"
09000064844ae92f,Other,FDA-2020-D-1057-0006,FDA-2020-D-1057,BIO Feedback on FDA Guidance During COVID19 Pandemic
090000648447ed08,Other,FDA-2020-D-1057-0004,FDA-2020-D-1057,Notifying FDA of a Permanent Discontinuance or Interruption in Manufacturing Under Section 506C of the FD&C Act Guidance for Industry
0900006483c82a88,Supporting & Related Material,FDA-2019-P-2370-0003,FDA-2019-P-2370,Exhibit 1- Orange Book: Approved Drug Products with Therapeutic Equivalence Equations re: Citizen Petition from ALEMBIC PHARMACEUTICALS LIMITED
0900006483c829ff,Other,FDA-2019-P-2370-0002,FDA-2019-P-2370,Acknowledgment Letter from FDA DDM to ALEMBIC PHARMACEUTICALS LIMITED
0900006483c8299a,Other,FDA-2019-P-2370-0001,FDA-2019-P-2370,Citizen Petition from ALEMBIC PHARMACEUTICALS LIMITED
09000064840e96fe,Other,FDA-2019-P-2370-0004,FDA-2019-P-2370,Response Letter from FDA CDER to Alembic Pharmaceuticals Limited
09000064826addc5,Supporting & Related Material,FDA-2017-P-3581-0003,FDA-2017-P-3581,Exhibit-1 Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations re Citizen Petition from Alembic Pharmaceuticals Limited
09000064826addc3,Other,FDA-2017-P-3581-0001,FDA-2017-P-3581,Citizen Petition from Alembic Pharmaceuticals Limited
0900006482bf9705,Other,FDA-2017-P-3581-0005,FDA-2017-P-3581,Response from FDA CDER to Alembic Pharmaceuticals
0900006482bf72d4,Notice,FDA-2017-P-3581-0004,FDA-2017-P-3581,"Determination That ELAVIL (Amitriptyline Hydrochloride) Oral Tablets, 10, 25, 50, 75, 100, and 150 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
09000064826ae52f,Other,FDA-2017-P-3581-0002,FDA-2017-P-3581,Acknowledgment Letter from FDA DDM to Alembic Pharmaceuticals Limited
090000648420224f,Other,FDA-2019-P-2945-0062,FDA-2019-P-2945,FDA Interim Response
0900006483d23067,Supporting & Related Material,FDA-2019-P-2945-0014,FDA-2019-P-2945,Attachment L Examples of Advertisements for THC/CBD Products for Pets re Citizen Petition from Jesse J LeBlanc III
0900006483d2307c,Supporting & Related Material,FDA-2019-P-2945-0016,FDA-2019-P-2945,Attachment N Environmental Impact re Citizen Petition from Jesse J LeBlanc III
0900006483d23121,Supporting & Related Material,FDA-2019-P-2945-0004,FDA-2019-P-2945,Attachment B Flow Chart Comparing Adverse Effects of Nicotine (Tobacco) to THC (Marinol) re Citizen Petition from Jesse J LeBlanc III
0900006483d23060,Supporting & Related Material,FDA-2019-P-2945-0009,FDA-2019-P-2945,Attachment G Canadian Public Health Warnings pages G1 - G3 re Citizen Petition from Jesse J LeBlanc III
0900006483d23068,Supporting & Related Material,FDA-2019-P-2945-0015,FDA-2019-P-2945,Attachment M FDA Laboratory Reports on Cannabis Products (2015 and 2016) pages Ml to M7 re Citizen Petition from Jesse J LeBlanc III
0900006483d23124,Supporting & Related Material,FDA-2019-P-2945-0007,FDA-2019-P-2945,"Attachment E Cannabis Advertisement in Print: Marisol Therapeutic Gardens, Pueblo West, Colorado; etc. re Citizen Petition from Jesse J LeBlanc III"
0900006483d23061,Supporting & Related Material,FDA-2019-P-2945-0010,FDA-2019-P-2945,Attachment H Sections of State Laws Listing Health Conditions Approved to Use Medical Cannabis re Citizen Petition from Jesse J LeBlanc III
0900006483d23128,Supporting & Related Material,FDA-2019-P-2945-0008,FDA-2019-P-2945,"Attachment F ""Cannabis Abuse Disorder Risk Assessment"", by Jesse LeBlanc III (2018) and Charlotte's Web Calculations re Citizen Petition from Jesse J LeBlanc III"
0900006483d22cee,Other,FDA-2019-P-2945-0001,FDA-2019-P-2945,Citizen Petition from Jesse J LeBlanc III
0900006483d23122,Supporting & Related Material,FDA-2019-P-2945-0005,FDA-2019-P-2945,"Attachment C FDA's Consumer Updates: ""6-Tip Offs: Don't Fall for Health Fraud"" and ""Products Claiming ""Cure"" for Cancer are a Cruel Deception"" re Citizen Petition from Jesse J LeBlanc III"
0900006483d23123,Supporting & Related Material,FDA-2019-P-2945-0006,FDA-2019-P-2945,"Attachment D Listing of CBD Health Claims Taken from ""Hemp Health Revolution: The A to Z Benefits of Hemp Extract"" by Sherill Sellman, N.D. re Citizen Petition from Jesse J LeBlanc III"
0900006483d23120,Supporting & Related Material,FDA-2019-P-2945-0003,FDA-2019-P-2945,Attachment A Flow Chart Highlighting Adverse Effects from Epidiolex (CBD) and Marinol (THC) re Citizen Petition from Jesse J LeBlanc III
0900006483d23066,Supporting & Related Material,FDA-2019-P-2945-0013,FDA-2019-P-2945,Attachment K Stories of Persons Harmed by Non-FDA Approved Cannabis Drugs re Citizen Petition from Jesse J LeBlanc III
0900006483d22cf0,Other,FDA-2019-P-2945-0002,FDA-2019-P-2945,Acknowledgment Letter from FDA DDM to Jesse J LeBlanc III
0900006483d23062,Supporting & Related Material,FDA-2019-P-2945-0011,FDA-2019-P-2945,"Attachment I Advertising Along Interstate Highway 25, Pueblo, Colorado; and Colorado Highway 50 near Pueblo West, Colorado re Citizen Petition from Jesse J LeBlanc III"
0900006483d23065,Supporting & Related Material,FDA-2019-P-2945-0012,FDA-2019-P-2945,"Attachment J FDA ""Warning Letter"" to Dr. Young Lee, president Advanced
Spine and Pain LLC, March 28. 2019 pages J1 to J6 re Citizen Petition from Jesse J LeBlanc III"
0900006483d0b671,Other,FDA-2019-P-2853-0001,FDA-2019-P-2853,Citizen Petition from Fresenius Medical Care North America
09000064841ee4c1,Other,FDA-2019-P-2853-0003,FDA-2019-P-2853,Interim Response Letter from FDA to Fresenius Medical Care North America
0900006484870383,Other,FDA-2019-P-2853-0004,FDA-2019-P-2853,Final Response from FDA CDER to Fresenius Medical Care North America
0900006483d0ba13,Other,FDA-2019-P-2853-0002,FDA-2019-P-2853,Acknowledgment Letter from FDA DDM to Fresenius Medical Care North America
0900006482bea5ef,Supporting & Related Material,FDA-2017-P-6219-0003,FDA-2017-P-6219,"Attachment 1 FDA Orange Book page for Exalgo® (Hydromorphone HCl), extended-release tablets, 32mg re Citizen Petition from Axinn, Veltrop & Harkrider LLP"
0900006482bea5f0,Supporting & Related Material,FDA-2017-P-6219-0004,FDA-2017-P-6219,"Attachment 2 Copy of approved labeling for Exalgo® (Hydromorphone HCl), extended-release tablets, 32mg re Citizen Petition from Axinn, Veltrop & Harkrider LLP"
0900006482bea277,Other,FDA-2017-P-6219-0001,FDA-2017-P-6219,"Citizen Petition from Axinn, Veltrop & Harkrider LLP"
0900006482bea5ed,Other,FDA-2017-P-6219-0002,FDA-2017-P-6219,"Acknowledgement Letter from FDA DDM to Axinn, Veltrop & Harkrider LLP"
0900006484729915,Other,FDA-2017-P-6219-0006,FDA-2017-P-6219,"Withdrawal from Axinn, Veltrop & Harkrider LLP"
0900006482bea5f1,Supporting & Related Material,FDA-2017-P-6219-0005,FDA-2017-P-6219,"Attachment 3 Copy of proposed draft labeling for Hydromorphone HCl extended-release tablets, 24 mg re Citizen Petition from Axinn, Veltrop & Harkrider LLP"
0900006483ef086e,Supporting & Related Material,FDA-2019-P-4140-0005,FDA-2019-P-4140,"EXHIBIT 3 - Declaration (curriculum vitae) of Christopher G. Gharibo, M.D. re: Citizen Petition from Persion Pharmaceuticals LLC"
0900006483ef05ae,Other,FDA-2019-P-4140-0002,FDA-2019-P-4140,Acknowledgment Letter from FDA DMS to Persion Pharmaceuticals LLC
0900006483ef0d8a,Supporting & Related Material,FDA-2019-P-4140-0008,FDA-2019-P-4140,EXHIBIT 6 - NIH Public Access The Role of Opioid Prescription in Incident Opioid Abuse and Dependence Among Individuals with Chronic Non-Cancer Pain: The Role of Opioid Prescription re: Citizen Petition from Persion Pharmaceuticals LLC
0900006483ef0d8e,Supporting & Related Material,FDA-2019-P-4140-0011,FDA-2019-P-4140,EXHIBIT 9 - Highlights of Prescribing Information (Vantrela ER) re: Citizen Petition from Persion Pharmaceuticals LLC
0900006483ef0145,Other,FDA-2019-P-4140-0001,FDA-2019-P-4140,Citizen Petition from Persion Pharmaceuticals LLC
0900006483ef086d,Supporting & Related Material,FDA-2019-P-4140-0004,FDA-2019-P-4140,EXHIBIT 2 - Effects of renal impairment and hepatic impairment on the pharmacokinetics of hydrocodone after administration of a novel extended-release hydrocodone tablet formulated with OraGuardTM technology re: Citizen Petition from Persion Pharmaceuticals
0900006483ef0d88,Supporting & Related Material,FDA-2019-P-4140-0006,FDA-2019-P-4140,EXHIBIT 4 - Declaration of Craig Antell. D.O. re: Citizen Petition from Persion Pharmaceuticals LLC
0900006483ef086c,Supporting & Related Material,FDA-2019-P-4140-0003,FDA-2019-P-4140,EXHIBIT 1 Johnson (2007) Opioid Safety in Patients With Renal or Hepatic Dysfunction re: Citizen Petition from Persion Pharmaceuticals LLC
09000064842cb5fe,Other,FDA-2019-P-4140-0016,FDA-2019-P-4140,Response Letter from FDA CDER to Persion Pharmaceuticals LLC
0900006483ef0d89,Supporting & Related Material,FDA-2019-P-4140-0007,FDA-2019-P-4140,EXHIBIT 5 - Dasgupta et al (2015) Cohort Study of the Impact of High-Dose Opioid Analgesics on Overdose Mortality re: Citizen Petition from Persion Pharmaceuticals LLC
0900006483ef0d8b,Supporting & Related Material,FDA-2019-P-4140-0009,FDA-2019-P-4140,EXHIBIT 7 -  Younossi et al (2011) Changes in the Prevalence of the Most Common Causes of Chronic Liver Diseases in the United States From 1988 to 2008 re: Citizen Petition from Persion Pharmaceuticals LLC
0900006483ef0d8c,Supporting & Related Material,FDA-2019-P-4140-0010,FDA-2019-P-4140,EXHIBIT 8 - NIh Public Access Pain and Opioid Use in Chronic Liver Disease re: Citizen Petition from Persion Pharmaceuticals LLC
09000064821b9e4f,Other,FDA-2016-P-2568-0001,FDA-2016-P-2568,Citizen Petition from Fresenius Kabi USA
09000064821b9c78,Supporting & Related Material,FDA-2016-P-2568-0003,FDA-2016-P-2568,Attachment A Product Listing from the Active Section of the Orange Book re Citizen Petition from Fresenius Kabi USA
09000064821b9c7f,Other,FDA-2016-P-2568-0002,FDA-2016-P-2568,Acknowledgment Letter from FDA DDM to Fresenius Kabi USA
090000648484cec6,Other,FDA-2020-P-1864-0001,FDA-2020-P-1864,"Citizen Petition from Kambiz Tajkarimi, MD"
0900006484b14ca5,Other,FDA-2020-P-1864-0003,FDA-2020-P-1864,Interim Response Letter from FDA CDRH to Kambiz Tajkarimi
090000648484cf40,Other,FDA-2020-P-1864-0002,FDA-2020-P-1864,Acknowledgment Letter from FDA DMS to Kambiz Tajkarimi
09000064804993b2,Notice,FDA-2003-D-0375-0006,FDA-2003-D-0375,FDA
09000064804993b4,Supporting & Related Material,FDA-2003-D-0375-0007,FDA-2003-D-0375,Guidance
09000064804992f9,Notice,FDA-2003-D-0375-0001,FDA-2003-D-0375,FDA
090000648049937c,Supporting & Related Material,FDA-2003-D-0375-0002,FDA-2003-D-0375,Guidance
09000064804993b7,Notice,FDA-2003-D-0375-0008,FDA-2003-D-0375,FDA
09000064804993ab,Notice,FDA-2003-D-0375-0003,FDA-2003-D-0375,FDA
09000064804993ad,Supporting & Related Material,FDA-2003-D-0375-0004,FDA-2003-D-0375,Supporting Statement
09000064804993b0,Supporting & Related Material,FDA-2003-D-0375-0005,FDA-2003-D-0375,Supporting Statement
0900006480474585,Other,FDA-2004-P-0409-0001,FDA-2004-P-0409,"HFA-305 to Lachman Consultant Services, Inc."
0900006480474588,Other,FDA-2004-P-0409-0002,FDA-2004-P-0409,"HFA-305 to Lachman Consultant Services, Inc."
090000648047458b,Other,FDA-2004-P-0409-0003,FDA-2004-P-0409,"HFD-600 to Lachman Consultant Services, Inc`"
090000648048f41f,Supporting & Related Material,FDA-2003-N-0249-0003,FDA-2003-N-0249,SUPPORTING STATEMENT
090000648048f40e,Notice,FDA-2003-N-0249-0002,FDA-2003-N-0249,FDA
090000648048f3d4,Notice,FDA-2003-N-0249-0001,FDA-2003-N-0249,FDA
090000648048f424,Notice,FDA-2003-N-0249-0005,FDA-2003-N-0249,FDA
090000648048f422,Supporting & Related Material,FDA-2003-N-0249-0004,FDA-2003-N-0249,SUPPORTING STATEMENT
09000064805f8421,Notice,FDA-2008-N-0286-0001,FDA-2008-N-0286,Agency Information Collection Activities; Proposed Collection; Comment Request; Survey to Evaluate FDAs Food Defense Awareness Initiative ALERT
09000064809375b3,Notice,FDA-2008-N-0286-0003,FDA-2008-N-0286,"Agency Information Collection Activities; Proposals, Submissions, and Approvals"
0900006480b03323,Supporting & Related Material,FDA-2010-N-0295-0007,FDA-2010-N-0295,"Reference 3 - ""...Tobacco Use Among U.S. Racial/Ethmic Minority Groups - African Americans, America Indians and Alaska Natives, Asian Americans and Pacific Islanders, and Hispanics:A Report of the Surgeon General 1998"" - [Web-Based Public Meeting To Discuss Issues Related to the Development of an Enforcement Action Plan; Request for Data, Information, and Views]"
0900006480b0329f,Supporting & Related Material,FDA-2010-N-0295-0005,FDA-2010-N-0295,"Reference 1 - ""Centers for Disease Control and Prevention, ""Smoking-Attributable Mortality, Years of Potential Life Lost, and Productivity Losses - United States, 2000-2004,"" Morbidity and Mortality Weekly Report"" - [Web-Based Public Meeting To Discuss Issues Related to the Development of an Enforcement Action Plan; Request for Data, Information, and Views]"
0900006480b28548,Other,FDA-2010-N-0295-0016,FDA-2010-N-0295,"Overview of Section 105: Enforcement Action Plan for Advertising and Promotion Restrictions, ASimoneau, June 30, 2010 - [Web-Based Public Meeting To Discuss Issues Related to the Development of an Enforcement Action Plan; Request for Data, Information, and Views] - Presentation"
0900006480b2854e,Other,FDA-2010-N-0295-0019,FDA-2010-N-0295,"Tobacco Enforcement Program Practices & Strategies for Enforcement, NManzanilla, June 30, 2010 - [Web-Based Public Meeting To Discuss Issues Related to the Development of an Enforcement Action Plan; Request for Data, Information, and Views] - Presentation"
0900006480b2854c,Other,FDA-2010-N-0295-0018,FDA-2010-N-0295,"South Seattle: The South Park Community Experience, SHouston, June 30, 2010 - [Web-Based Public Meeting To Discuss Issues Related to the Development of an Enforcement Action Plan; Request for Data, Information, and Views] - Presentation"
0900006480b033ad,Supporting & Related Material,FDA-2010-N-0295-0009,FDA-2010-N-0295,"Reference 9 - ""Id., p. 15"" - [Web-Based Public Meeting To Discuss Issues Related to the Development of an Enforcement Action Plan; Request for Data, Information, and Views]"
0900006480b032a5,Supporting & Related Material,FDA-2010-N-0295-0006,FDA-2010-N-0295,"Reference 2 - ""National Cancer Institute, U.S. Department of Health & Human Services, The Role of the Media in Promoting and Reducing Tobacco Use""  - [Web-Based Public Meeting To Discuss Issues Related to the Development of an Enforcement Action Plan; Request for Data, Information, and Views]"
0900006480b2852e,Other,FDA-2010-N-0295-0013,FDA-2010-N-0295,"ASTHO Tobacco Issues Forum, JEngel, June 30, 2010 - [Web-Based Public Meeting To Discuss Issues Related to the Development of an Enforcement Action Plan; Request for Data, Information, and Views] - Presentation"
0900006480b2852c,Other,FDA-2010-N-0295-0012,FDA-2010-N-0295,"Background and Overview of the FDA Center for Tobacco Products, the Family Smoking Prevention and Tobacco Control Act (the Tobacco Control Act), ASimoneau, June 30, 2010 - [Web-Based Public Meeting To Discuss Issues Related to the Development of an Enforcement Action Plan; Request for Data, Information, and Views] - Presentation"
0900006480b2843e,Other,FDA-2010-N-0295-0010,FDA-2010-N-0295,"Web-Based Public Meeting on Issues Related to Development of Enforcement Plan, June 30, 2010 - [Web-Based Public Meeting To Discuss Issues Related to the Development of an Enforcement Action Plan; Request for Data, Information, and Views] - Transcript"
0900006480b03354,Supporting & Related Material,FDA-2010-N-0295-0008,FDA-2010-N-0295,"Reference 8 - ""National Cancer Institute, U.S. Department of Health & Human Services, The Role of the Media in Promoting and Reducing Tobacco Use"" - [Web-Based Public Meeting To Discuss Issues Related to the Development of an Enforcement Action Plan; Request for Data, Information, and Views]"
0900006480b2852a,Other,FDA-2010-N-0295-0011,FDA-2010-N-0295,"Marketing of Menthol and Other Cigarettes to Youth and to Minority Youth, CHusten, June 30, 2010 - [Web-Based Public Meeting To Discuss Issues Related to the Development of an Enforcement Action Plan; Request for Data, Information, and Views] - Presentation"
0900006480b2854a,Other,FDA-2010-N-0295-0017,FDA-2010-N-0295,"Promotion and Advertising of Menthol and Other Cigarettes to Youth, Including Youth in Minority Communities, ABullock, June 30, 2010 - [Web-Based Public Meeting To Discuss Issues Related to the Development of an Enforcement Action Plan; Request for Data, Information, and Views] - Presentation"
0900006480b28530,Other,FDA-2010-N-0295-0014,FDA-2010-N-0295,"Follow the Signs: Big Tobacco Retail Contriacts and Practices in Urban Markets, LWright, June 30, 2010 - [Web-Based Public Meeting To Discuss Issues Related to the Development of an Enforcement Action Plan; Request for Data, Information, and Views] - Presentation"
0900006480b28532,Other,FDA-2010-N-0295-0015,FDA-2010-N-0295,"Mapping Tobacco Marketing: Who's Targeting You?, NPope, June 30, 2010 - [Web-Based Public Meeting To Discuss Issues Related to the Development of an Enforcement Action Plan; Request for Data, Information, and Views] - Presentation"
0900006480b055e3,Notice,FDA-2010-N-0295-0001,FDA-2010-N-0295,"Web-Based Public Meeting To Discuss Issues Related to the Development of an Enforcement Action Plan; Request for Data, Information, and Views"
0900006484b7f8c5,Other,FDA-2021-P-0558-0002,FDA-2021-P-0558,Acknowledgement Letter from FDA DMS to Environmental Working Group and Women’s Voices for the Earth
0900006484b8000b,Other,FDA-2021-P-0558-0001,FDA-2021-P-0558,Citizen Petition from Environmental Working Group and Women’s Voices for the Earth
090000648228e8ae,Supporting & Related Material,FDA-2016-P-2863-0016,FDA-2016-P-2863,"Attachment 13 - Effect of high performance chicory inulin on constipation re Citizen Petition from General Mills, Inc."
090000648228e8b5,Supporting & Related Material,FDA-2016-P-2863-0017,FDA-2016-P-2863,"Attachment 14 - Selective stimulation of bifidobacteria in the human colon by oligofructose and inulin re Citizen Petition from General Mills, Inc."
090000648228e994,Supporting & Related Material,FDA-2016-P-2863-0007,FDA-2016-P-2863,"Attachment 4 - Evans 1992 The normal range and a simple diagram for recording whole gut transit time re Citizen Petition from General Mills, Inc."
090000648228eab2,Supporting & Related Material,FDA-2016-P-2863-0012,FDA-2016-P-2863,"Attachment 9 - Effect of cereal fruit and vegetable fibers on fecal weight and transit time: A comprehensive review of intervention trials re Citizen Petition from General Mills, Inc."
090000648228eabb,Supporting & Related Material,FDA-2016-P-2863-0013,FDA-2016-P-2863,"Attachment 10 - Effect of yacon on colonic transit time in healthy volunteers re Citizen Petition from General Mills, Inc."
090000648228eaed,Supporting & Related Material,FDA-2016-P-2863-0014,FDA-2016-P-2863,"Attachment 11 - Effect of nondig oligosacch on large bowel functions blood lipid concentrations and glucose absorption young healthy males re Citizen Petition from General Mills, Inc."
09000064822922fd,Supporting & Related Material,FDA-2016-P-2863-0033,FDA-2016-P-2863,"Attachment 30 - Randomized double blind cross over study investigating prebiotic effect of agave fructans in healthy human subjects re Citizen Petition from General Mills, Inc."
0900006482292d5c,Supporting & Related Material,FDA-2016-P-2863-0040,FDA-2016-P-2863,"Attachment 37 - Jerusalem artichoke and chicory inulin in bakery products affect faecal microbiota of healthy volunteers re Citizen Petition from General Mills, Inc."
0900006482296f21,Supporting & Related Material,FDA-2016-P-2863-0080,FDA-2016-P-2863,"Attachment 77 - Effect of Oligofructose-enriched Inulin on Bone Metabolismin Girls with Low Calcium Intakes re Citizen Petition from General Mills, Inc."
0900006482296f22,Supporting & Related Material,FDA-2016-P-2863-0081,FDA-2016-P-2863,"Attachment 78 - Inulin and oligofructose do not influence the absorption ofcholesterol, or the excretion of cholesterol, Ca, Mg, Zn, Fe, orbile acids but increases energy excretion in ileostomy subjects re Citizen Petition from General Mills, Inc."
09000064822958c6,Supporting & Related Material,FDA-2016-P-2863-0063,FDA-2016-P-2863,"Attachment 60 - Fructooligosaccharides exhibit more rapid fermentation than long-chaininulin in an in vitro fermentation system re Citizen Petition from General Mills, Inc."
0900006482296910,Supporting & Related Material,FDA-2016-P-2863-0068,FDA-2016-P-2863,"Attachment 65 - Microbiota benefits after inulin and partially hydrolized guar gum supplementation – a randomized clinical trial in constipated women re Citizen Petition from General Mills, Inc."
090000648229693d,Supporting & Related Material,FDA-2016-P-2863-0069,FDA-2016-P-2863,"Attachment 66 - Dietary Fiber Mixture in Pediatric Patients With Controlled Chronic Constipation re Citizen Petition from General Mills, Inc."
0900006482296945,Supporting & Related Material,FDA-2016-P-2863-0073,FDA-2016-P-2863,"Attachment 70 - Effects of thickened beverages fortified with inulin on beverage acceptance, gastrointestinal function, and bone resorption ininstitutionalized adults re Citizen Petition from General Mills, Inc."
0900006482296f1a,Supporting & Related Material,FDA-2016-P-2863-0074,FDA-2016-P-2863,"Attachment 71- Inulin as the Soluble Fiber in Liquid Enteral Nutrition re Citizen Petition from General Mills, Inc."
090000648228ec96,Supporting & Related Material,FDA-2016-P-2863-0024,FDA-2016-P-2863,"Attachment 21 - Prolonged administration of low dose inulin stimulates the growth of bifidobacteria in humans re Citizen Petition from General Mills, Inc."
090000648228f0e2,Supporting & Related Material,FDA-2016-P-2863-0029,FDA-2016-P-2863,"Attachment 26 -Effects of chicory inulin in constipated elderly people: a double-blind controlled trial re Citizen Petition from General Mills, Inc."
0900006482294ffb,Supporting & Related Material,FDA-2016-P-2863-0057,FDA-2016-P-2863,"Attachment 54 - Nondigestible oligosaccharides do not interfere with calcium and nonheme iron absorption in young healthy men re Citizen Petition from General Mills, Inc."
090000648223ffe2,Other,FDA-2016-P-2863-0001,FDA-2016-P-2863,"Citizen Petition from General Mills, Inc."
09000064822924c7,Supporting & Related Material,FDA-2016-P-2863-0037,FDA-2016-P-2863,"Attachment 34 - Prebiotic effect of fruit and vegetable shots containing Jerusalem artichokeinulin: a human intervention study re Citizen Petition from General Mills, Inc."
0900006482292ce4,Supporting & Related Material,FDA-2016-P-2863-0048,FDA-2016-P-2863,"Attachment 45 - Young Adolescents Who Respond to anInulin -Type Fructan Substantially Increase Total Absorbed Calcium and Daily Calcium Accretion to the Skeleton re Citizen Petition from General Mills, Inc."
09000064822939b2,Supporting & Related Material,FDA-2016-P-2863-0051,FDA-2016-P-2863,"Attachment 48 - Non-digestible oligosaccharides and calcium absorptionin girls with adequate calcium intakes re Citizen Petition from General Mills, Inc."
09000064822f32d2,Other,FDA-2016-P-2863-0085,FDA-2016-P-2863,Amendment  from General Mills
090000648228ea4f,Supporting & Related Material,FDA-2016-P-2863-0010,FDA-2016-P-2863,"Attachment 7 -  Comparison of dye and pellet GI transit time during controlled diet differing in protein and fiber levels re Citizen Petition from General Mills, Inc."
090000648228f035,Supporting & Related Material,FDA-2016-P-2863-0027,FDA-2016-P-2863,"Attachment 24 -Dietary fructo-oligosaccharides in healthy adults do not negatively affectfaecal cytotoxicity: a randomised, double-blind, placebo-controlledcrossover trial re Citizen Petition from General Mills, Inc."
09000064842b1c53,Other,FDA-2020-P-0284-0001,FDA-2020-P-0284,"Citizen Petition from Hyman, Phelps & McNamara, P.C."
0900006484864039,Other,FDA-2020-P-0284-0003,FDA-2020-P-0284,"Letter from FDA CDER to Lachman Consultants Services Inc. and Teligent Pharma, Inc. and Hyman, Phelps & McNamara, P.C."
09000064842b1c55,Other,FDA-2020-P-0284-0002,FDA-2020-P-0284,"Acknowledgment Letter from FDA DMS to Hyman, Phelps & McNamara, P.C."
0900006484dc28f4,Other,FDA-2021-P-1100-0001,FDA-2021-P-1100,Citizen Petition from Pet Schooled
0900006484dc2c5f,Other,FDA-2021-P-1100-0002,FDA-2021-P-1100,Acknowledgment Letter from FDA DMS to Pet Schooled
090000648491195d,Other,FDA-2019-P-5441-0005,FDA-2019-P-5441,"Letter from Hyman, Phelps & McNamara, P.C."
0900006484177e69,Other,FDA-2019-P-5441-0001,FDA-2019-P-5441,"Citizen Petition from Hyman, Phelps & McNamara, P.C."
0900006484177e6b,Other,FDA-2019-P-5441-0002,FDA-2019-P-5441,"Acknowledgment Letter from FDA DMS to Hyman, Phelps & McNamara, P.C."
0900006484a7633f,Other,FDA-2019-P-5441-0006,FDA-2019-P-5441,"Withdrawal from Hyman, Phelps & McNamara"
0900006484207392,Other,FDA-2019-P-5441-0003,FDA-2019-P-5441,"Supplemental to Citizen Petition from Hyman, Phelps & McNamara, P.C."
09000064845bebd8,Other,FDA-2019-P-5441-0004,FDA-2019-P-5441,"Interim Response from FDA to Hyman, Phelps & McNamara, P.C."
0900006483aa4cca,Supporting & Related Material,FDA-2019-P-0777-0004,FDA-2019-P-0777,Attachment B News Release from NMPF re Citizen Petition from National Milk Producers Federation
0900006483aa4ccd,Supporting & Related Material,FDA-2019-P-0777-0007,FDA-2019-P-0777,Attachment E DMI Consumer Perceptions: Dairy and Plant-based Milks Phase II re Citizen Petition from National Milk Producers Federation
0900006483aa4ccf,Supporting & Related Material,FDA-2019-P-0777-0009,FDA-2019-P-0777,Attachment G NDC Average Daily Servings of Dairy Foods by Ethnicity and Age Group (NHANES 2011-2014) re Citizen Petition from National Milk Producers Federation
0900006483aa4ccb,Supporting & Related Material,FDA-2019-P-0777-0005,FDA-2019-P-0777,Attachment C Nutrient Composition of Imitation Dairy Beverages Compared to Milk re Citizen Petition from National Milk Producers Federation
0900006483aa4fa0,Other,FDA-2019-P-0777-0002,FDA-2019-P-0777,Acknowledgment Letter from FDA DDM to National Milk Producers Federation
090000648404dac4,Other,FDA-2019-P-0777-0024,FDA-2019-P-0777,Interim Response Letter from FDA CFSAN to National Milk Producers Federation
0900006483aa4cc9,Supporting & Related Material,FDA-2019-P-0777-0003,FDA-2019-P-0777,Attachment A Section-By-Section Analysis of the Amendments to Section 101.3(e) re Citizen Petition from National Milk Producers Federation
0900006483aa4cd2,Supporting & Related Material,FDA-2019-P-0777-0012,FDA-2019-P-0777,Appendix Copyrighted Articles re Citizen Petition from National Milk Producers Federation - Part 1
0900006483aa4cda,Supporting & Related Material,FDA-2019-P-0777-0013,FDA-2019-P-0777,Appendix to WHO Guidelines on food fortification with micronutrients re Citizen Petition from National Milk Producers Federation - Part 2
0900006483aa4cce,Supporting & Related Material,FDA-2019-P-0777-0008,FDA-2019-P-0777,Attachment F NDC Contribution of Dairy Foods to Nutrient Intakes by Americans (March 2015) re Citizen Petition from National Milk Producers Federation
0900006483aa4cd0,Supporting & Related Material,FDA-2019-P-0777-0010,FDA-2019-P-0777,Attachment H NDC Average Contribution of Dairy Foods to Calorie and Nutrient Intakes (NHANES 2011-2014) re Citizen Petition from National Milk Producers Federation
0900006483aa4f9e,Other,FDA-2019-P-0777-0001,FDA-2019-P-0777,Citizen Petition from National Milk Producers Federation
0900006483aa4cd1,Supporting & Related Material,FDA-2019-P-0777-0011,FDA-2019-P-0777,Attachment I NDC NHANES 2011-2014 Dairy Foods Messaging re Citizen Petition from National Milk Producers Federation
0900006483aa4ccc,Supporting & Related Material,FDA-2019-P-0777-0006,FDA-2019-P-0777,Attachment D NDC Consumer Perceptions: Dairy Milk and Plant-based Milk Alternatives re Citizen Petition from National Milk Producers Federation
09000064822f54b0,Other,FDA-2016-P-3312-0002,FDA-2016-P-3312,"Acknowledgment Letter from FDA DDM to Gilead Sciences, Inc."
09000064824a121b,Other,FDA-2016-P-3312-0003,FDA-2016-P-3312,"Request to Withdraw Citizen Petition from Gilead Sciences, Inc to FDA CDER"
09000064822f54ae,Other,FDA-2016-P-3312-0001,FDA-2016-P-3312,"Citizen Petition from Gilead Sciences, Inc."
0900006481d843cd,Supporting & Related Material,FDA-2015-P-4564-0009,FDA-2015-P-4564,Appendix 1 Reference 23 Fish and Marine Omega-3 Polyunsatured Fatty Acid Consumption and Incidence of Type 2 Diabetes: A Systematic Review and Meta-Analysis re Citizen Petition from KIND LLC
090000648250aad3,Other,FDA-2015-P-4564-0017,FDA-2015-P-4564,Interim Response Letter from CFSAN to KIND LLC
0900006481d843ff,Supporting & Related Material,FDA-2015-P-4564-0011,FDA-2015-P-4564,Appendix 2 - Letter of Support from Sara Baer-Sinnott et al re Citizen Petition from KIND LLC
0900006481d84401,Supporting & Related Material,FDA-2015-P-4564-0012,FDA-2015-P-4564,"Appendix 2 - Letter of Support from David J.A. Jenkins, MD, PhD, DSc re Citizen Petition from KIND LLC"
0900006481d84405,Supporting & Related Material,FDA-2015-P-4564-0015,FDA-2015-P-4564,"Appendix 2 - Letter of Support from Walter C. Willett, Harvard School of Public Health, Department of Nutrition re Citizen Petition from KIND LLC"
0900006481d81c24,Other,FDA-2015-P-4564-0001,FDA-2015-P-4564,Citizen Petition from KIND LLC
0900006481d84257,Supporting & Related Material,FDA-2015-P-4564-0003,FDA-2015-P-4564,Appendix 1- Reference List re Citizen Petition from KIND LLC
0900006481d843c7,Supporting & Related Material,FDA-2015-P-4564-0007,FDA-2015-P-4564,Appendix 1 Reference 18 USDA: Changes in Eating Patterns and re Citizen Petition from KIND LLC
0900006481d84403,Supporting & Related Material,FDA-2015-P-4564-0014,FDA-2015-P-4564,"Appendix 2 - Letter of Support from Michael Roussell, Naked Nutrition, LLC re Citizen Petition from KIND LLC"
0900006482575432,Other,FDA-2015-P-4564-0018,FDA-2015-P-4564,Supplement from KIND LLC
0900006481d84561,Supporting & Related Material,FDA-2015-P-4564-0004,FDA-2015-P-4564,"Appendix 1 Reference 7 Intake of Saturated and Trans Unsaturated Fatty Acids and Risk of All Cause Mortality, Cardiovascular Disease, and Type 2 Diabetes:  Systematic Review and Meta-Analysis of Observational Studies re Citizen Petition from KIND LLC"
0900006481d81c8e,Other,FDA-2015-P-4564-0002,FDA-2015-P-4564,Acknowledgement Letter from FDA DDM to KIND LLC
0900006481d843cb,Supporting & Related Material,FDA-2015-P-4564-0008,FDA-2015-P-4564,"Appendix 1 Reference 21 Effect of a Moderate Fat Diet With and Without Avocados on Lipoprotein Particle Number, Size and Subclasses in Overweight and Obese Adults: A Randomized, Controlled Trial re Citizen Petition from KIND LLC"
0900006481d843fe,Supporting & Related Material,FDA-2015-P-4564-0010,FDA-2015-P-4564,Appendix 2 - Index of Letters of Support re Citizen Petition from KIND LLC
0900006481d84402,Supporting & Related Material,FDA-2015-P-4564-0013,FDA-2015-P-4564,"Appendix 2 - Letter of Support from Dariush Mozaffarian, Tufts University re Citizen Petition from KIND LLC"
0900006481d84334,Supporting & Related Material,FDA-2015-P-4564-0005,FDA-2015-P-4564,Appendix 1 Reference 8 2013 AHA ACC Guideline on Lifestyle Management to Reduce Cardiovascular Risk re Citizen Petition from KIND LLC
0900006481d8435f,Supporting & Related Material,FDA-2015-P-4564-0006,FDA-2015-P-4564,"Appendix 1 Reference 15 Relationships Among Food Label Use, Motivation, and Dietary Quality re Citizen Petition from KIND LLC"
0900006483f2bc44,Other,FDA-2019-P-0913-0009,FDA-2019-P-0913,Interim Response Letter from FDA CFSAN to Independent Nutrition Inc
0900006483b01cf4,Supporting & Related Material,FDA-2019-P-0913-0005,FDA-2019-P-0913,Attachment 3 re Citizen Petition from Independent Nutrition Inc
0900006483b021ca,Supporting & Related Material,FDA-2019-P-0913-0008,FDA-2019-P-0913,Attachment 6 re Citizen Petition from Independent Nutrition
0900006483b01cf5,Supporting & Related Material,FDA-2019-P-0913-0006,FDA-2019-P-0913,Attachment 4 re Citizen Petition from Independent Nutrition Inc
0900006483b01cee,Other,FDA-2019-P-0913-0001,FDA-2019-P-0913,Citizen Petition from Independent Nutrition Inc
0900006483b01cf0,Other,FDA-2019-P-0913-0002,FDA-2019-P-0913,Acknowledgment Letter from FDA DDM to Independent Nutrition Inc
0900006483b01cf3,Supporting & Related Material,FDA-2019-P-0913-0004,FDA-2019-P-0913,Attachment 2 re Citizen Petition from Independent Nutrition Inc
0900006483b01cf2,Supporting & Related Material,FDA-2019-P-0913-0003,FDA-2019-P-0913,Attachment 1 re Citizen Petition from Independent Nutrition Inc
0900006483b01cf6,Supporting & Related Material,FDA-2019-P-0913-0007,FDA-2019-P-0913,Attachment 5 re Citizen Petition from Independent Nutrition Inc
0900006483a96b7c,Other,FDA-2018-P-2408-0022,FDA-2018-P-2408,Agency Response Letter fro FDA CDER to Public Citizen
090000648343ad9c,Supporting & Related Material,FDA-2018-P-2408-0006,FDA-2018-P-2408,attachment 3-Phase II Febux_Arthritis Rheum_2005 re: Citizen Petition from Public Citizen
090000648343ada2,Supporting & Related Material,FDA-2018-P-2408-0011,FDA-2018-P-2408,attachment 9-Urate and Gout from Managed Care Data_J Clin Rheumatol_2006 re: Citizen Petition from Public Citizen
090000648343ada7,Supporting & Related Material,FDA-2018-P-2408-0016,FDA-2018-P-2408,attachment 13-Collaborative overview of randomised trials_BMJ_1994 re: Citizen Petition from Public Citizen
090000648343adab,Supporting & Related Material,FDA-2018-P-2408-0020,FDA-2018-P-2408,attachment 18-CV Safety Febuxostat vs Allopurinol_NEJM_2018-With SUPPL re: Citizen Petition from Public Citizen
090000648343ada0,Supporting & Related Material,FDA-2018-P-2408-0009,FDA-2018-P-2408,attachment 7-ACR Guidelines for Gout_Arthritis Care _ Research_2012 re: Citizen Petition from Public Citizen
090000648343ada1,Supporting & Related Material,FDA-2018-P-2408-0010,FDA-2018-P-2408,attachment 8-RCT Allopurinol Dose Escalation_Ann Rheum Dis_2009 re: Citizen Petition from Public Citizen
090000648343ad9a,Supporting & Related Material,FDA-2018-P-2408-0004,FDA-2018-P-2408,attachment 1-Trial-Febuxostat vs Allopurinol for Gout_Arthritis Res Ther_2010 re :Citizen Petition from Public Citizen
090000648343ada4,Supporting & Related Material,FDA-2018-P-2408-0013,FDA-2018-P-2408,attachment 11-2016 EULAR recommendations for management of gout_Ann Rheum Dis_2017 re: Citizen Petition from Public Citizen
090000648343ada9,Supporting & Related Material,FDA-2018-P-2408-0018,FDA-2018-P-2408,attachment 15-CV Thrombotic Events in celecoxib APTC reference_Am J Cardiol_2003 re: Citizen Petition from Public Citizen
090000648343adac,Supporting & Related Material,FDA-2018-P-2408-0021,FDA-2018-P-2408,attachment 19-CV Risk in Older Adults on Febux_Circulation_2018 re: Citizen Petition from Public Citizen
090000648343ada6,Supporting & Related Material,FDA-2018-P-2408-0015,FDA-2018-P-2408,attachment 13-Allopurinol High Dose_Arthritis _ Rheumatism_2011 re: Citizen Petition from Public Citizen
090000648343ad9d,Supporting & Related Material,FDA-2018-P-2408-0007,FDA-2018-P-2408,attachment 4-Phase II Febux_Arthritis Rheum_2005 re: Citizen Petition from Public Citizen
090000648343ada8,Supporting & Related Material,FDA-2018-P-2408-0017,FDA-2018-P-2408,attachment 14-Ch 395_ Gout and other crystal-associated arthropathies_Harrisons_2014 re: Citizen Petition from Public Citizen
0900006483439f51,Other,FDA-2018-P-2408-0002,FDA-2018-P-2408,Acknowledgement Letter fro FDA DDM to Public Citizen
090000648343ad9b,Supporting & Related Material,FDA-2018-P-2408-0005,FDA-2018-P-2408,attachment 2- Long-Term Extension Study_J Rheumatol_2009 re: Citizen Petition from Public Citizen
090000648343ad9e,Supporting & Related Material,FDA-2018-P-2408-0008,FDA-2018-P-2408,attachment 5-FACT Trial-Febuxostat vs Allopurinol for Gout_N Engl J Med_2005 re: Citizen Petition from Public Citizen
090000648343ada3,Supporting & Related Material,FDA-2018-P-2408-0012,FDA-2018-P-2408,attachment 10-APEX Trial-Effect of Fuboxostat vs Allopurinol and Placebo for Gout_Arthritis Rheum_2008 re: Citizen Petition from Public Citizen
090000648343ad9f,Supporting & Related Material,FDA-2018-P-2408-0003,FDA-2018-P-2408,attachment 6-Ch 44 Gout_Current Diagnosis _ Treatment Rheumatology_2013 re: Citizen Petition from Public Citizen
090000648343ada5,Supporting & Related Material,FDA-2018-P-2408-0014,FDA-2018-P-2408,attachment 12-FOCUS Open label Trial_Rheum_2009 re: Citizen Petition from Public Citizen
090000648343adaa,Supporting & Related Material,FDA-2018-P-2408-0019,FDA-2018-P-2408,attachment 17-Febuxostat for Gout_Cochrane Syst Rev_2012 re: Citizen Petition from Public Citizen
0900006483439cb6,Other,FDA-2018-P-2408-0001,FDA-2018-P-2408,Citizen Petition from Public Citizen
09000064810cd925,Other,FDA-2012-P-0119-0006,FDA-2012-P-0119,Interim Response to Mario Morais Letter
09000064824a25ce,Supporting & Related Material,FDA-2012-P-0119-0016,FDA-2012-P-0119,04 - Reference 2-PDUFA _ The Voice of the Patient_ A Series of Reports from FDA's Patient-Focused Drug Development Initiative
090000648109970e,Other,FDA-2012-P-0119-0005,FDA-2012-P-0119,"Mario Morais June 19, 2012 - Supplement"
090000648250c03c,Other,FDA-2012-P-0119-0021,FDA-2012-P-0119,Mario Morais Email March 15 2017
09000064824a25c2,Supporting & Related Material,FDA-2012-P-0119-0014,FDA-2012-P-0119,02 Guidance for Industry 1-Expanded Access to Investigational Drugs for Treatment Use — Questions and Answers
09000064824a25d0,Supporting & Related Material,FDA-2012-P-0119-0018,FDA-2012-P-0119,06 Reference 4-Fed Register PDUFA Patient-focused Drug Development - Request for Comments
09000064824a25d1,Supporting & Related Material,FDA-2012-P-0119-0019,FDA-2012-P-0119,07 Reference 5-Prescription Drug User Fee Act (PDUFA) _ Patient-Focused Drug Development_ Disease Area Meetings Planned for Fiscal Years 2013-2017
09000064824a25d2,Supporting & Related Material,FDA-2012-P-0119-0020,FDA-2012-P-0119,08 Reference 6-PDUFA Reauthorization Performance Goals and Procedures FY18-22
0900006481878b58,Other,FDA-2012-P-0119-0010,FDA-2012-P-0119,Redacted Appeal from Mario Morais
09000064810057e2,Other,FDA-2012-P-0119-0003,FDA-2012-P-0119,"Mario Morais March 17, 2012 - Supplement"
09000064824a25d3,Other,FDA-2012-P-0119-0011,FDA-2012-P-0119,FDA Response to joint appeal in FDA-2012-P-0119 and FDA-2013-P-0735
0900006481878b56,Other,FDA-2012-P-0119-0009,FDA-2012-P-0119,Appeal From Mario Morais
0900006480faf553,Other,FDA-2012-P-0119-0001,FDA-2012-P-0119,Mario Morais - Citizen Petition
09000064811802b7,Other,FDA-2012-P-0119-0007,FDA-2012-P-0119,"Mario Morais August 14, 2012 - Supplement"
09000064824a25c0,Supporting & Related Material,FDA-2012-P-0119-0012,FDA-2012-P-0119,Reference List for 0119
09000064824a25c1,Supporting & Related Material,FDA-2012-P-0119-0013,FDA-2012-P-0119,01 Reference  1-Safety Communications _ Chronic Cerebrospinal Venous Insufficiency Treatment in Multiple Sclerosis Patients_ FDA Safety Communication
09000064824a25cd,Supporting & Related Material,FDA-2012-P-0119-0015,FDA-2012-P-0119,03 Guidance for Industry 2-Individual Patient Expanded Access Applications_ Form FDA 3926
09000064824a25cf,Supporting & Related Material,FDA-2012-P-0119-0017,FDA-2012-P-0119,05 Reference 3-PDUFA _ Enhancing Benefit-Risk Assessment in Regulatory Decision-Making
0900006481832500,Other,FDA-2012-P-0119-0008,FDA-2012-P-0119,Redacted Partial Approval Partial Denial Response from FDA/CDRH to Mario Morais
0900006480faf55c,Other,FDA-2012-P-0119-0002,FDA-2012-P-0119,Acknowledgement Letter to Mario Morias
09000064812dfb96,Notice,FDA-2012-N-1131-0002,FDA-2012-N-1131,Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; New Animal Drug Applications and Supporting Regulations and Form FDA 356V
090000648116eb64,Notice,FDA-2012-N-1131-0001,FDA-2012-N-1131,"Agency Information Collection Activities; Proposals, Submissions, and Approvals: New Animal Drug Applications and Supporting Regulations"
09000064816b26e3,Other,FDA-2014-P-0446-0001,FDA-2014-P-0446,Citizen Petition From Starkist Company (Pisani and Roll LLP)
0900006482b95df7,Other,FDA-2014-P-0446-0003,FDA-2014-P-0446,Final Response Letter from FDA to Pisani & Roll LLP
09000064816b271a,Other,FDA-2014-P-0446-0002,FDA-2014-P-0446,Acknowledgement Letter From FDA DDM to Pisani and Roll LLP
0900006482ce5ac4,Supporting & Related Material,FDA-2017-P-6751-0006,FDA-2017-P-6751,Exhibit 4 A true and correct copy of the “Compare to dairy” chart re Citizen Petition from Capstone Law APC on behalf of Melanie Kelley
0900006482ce5ac1,Supporting & Related Material,FDA-2017-P-6751-0003,FDA-2017-P-6751,Exhibit 1 Judge O'Neill's Order re Citizen Petition from Capstone Law APC on behalf of Melanie Kelley
0900006483425d02,Other,FDA-2017-P-6751-0012,FDA-2017-P-6751,180 Day Interim Response Letter from FDA CFSAN to Capstone Law APC
0900006482ce5ac2,Supporting & Related Material,FDA-2017-P-6751-0004,FDA-2017-P-6751,Exhibit 2 Judge Carter's Order re Citizen Petition from Capstone Law APC on behalf of Melanie Kelley
0900006482ce5abf,Other,FDA-2017-P-6751-0002,FDA-2017-P-6751,Acknowledgement Letter from FDA DDM to Capstone Law APC on behalf of Melanie Kelley
0900006482ce5abd,Other,FDA-2017-P-6751-0001,FDA-2017-P-6751,Citizen Petition from Capstone Law APC on behalf of Melanie Kelley
0900006482ce5ac3,Supporting & Related Material,FDA-2017-P-6751-0005,FDA-2017-P-6751,Exhibit 3 Front label images of Silk Unsweetened Vanilla Almondmilk re Citizen Petition from Capstone Law APC on behalf of Melanie Kelley
090000648229b435,Other,FDA-2016-D-1270-0010,FDA-2016-D-1270,Request for Extension from Valerie Lis
0900006482095c65,Notice,FDA-2016-D-1270-0001,FDA-2016-D-1270,Use of Standards in the Food and Drug Administration’s Regulatory Oversight of Next Generation Sequencing-Based In Vitro Diagnostics Used for Diagnosing Germline Diseases; Draft Guidance for Stakeholders and Food and Drug Administration Staff; Availability
090000648313a560,Notice,FDA-2016-D-1270-0040,FDA-2016-D-1270,"Considerations for Design, Development, and Analytical Validation of Next Generation Sequencing-Based In Vitro Diagnostics Intended To Aid in the Diagnosis of Suspected Germline Diseases; Guidance for Stakeholders and Food and Drug Administration Staff; Availability"
09000064820ae5cd,Other,FDA-2016-D-1270-0002,FDA-2016-D-1270,Use of Standards in FDA Regulatory Oversight of Next Generation Sequencing (NGS)-Based In Vitro Diagnostics (IVDs) Used for Diagnosing Germline Diseases Draft Guidance for Stakeholders and Food and Drug Administration Staff
090000648314ed7e,Other,FDA-2016-D-1270-0041,FDA-2016-D-1270,"Considerations for Design, Development, and Analytical Validation of Next Generation Sequencing (NGS) - Based In Vitro Diagnostics (IVDs) Intended to Aid in the Diagnosis of Suspected Germline Diseases
Guidance for Stakeholders and Food and Drug Administration Staff"
0900006483582583,Other,FDA-2018-P-1283-0005,FDA-2018-P-1283,"Petition Response Letter Metaxalone Tablets, 640 mg, Withdrawal was not due to Safety and Effectiveness"
090000648305503b,Other,FDA-2018-P-1283-0002,FDA-2018-P-1283,"Acknowledgment Letter from FDA DDM to Sovereign Pharmaceuticals, LLC"
090000648305503d,Supporting & Related Material,FDA-2018-P-1283-0003,FDA-2018-P-1283,Attachment 1 Orange Book re Citizen Petition from Sovereign Pharmaceuticals LLC
0900006483567867,Notice,FDA-2018-P-1283-0004,FDA-2018-P-1283,"Determination That Metaxalone Tablets, 640 Milligrams, Were Not
Withdrawn From Sale for Reasons of Safety or Effectiveness"
0900006483055039,Other,FDA-2018-P-1283-0001,FDA-2018-P-1283,Citizen Petition from Sovereign Pharmaceuticals LLC
09000064824fc8a0,Supporting & Related Material,FDA-2017-P-1463-0003,FDA-2017-P-1463,Appendix A re Citizen Petition from Tate & Lyle Ingredients Americas LLC
09000064824fc86f,Other,FDA-2017-P-1463-0001,FDA-2017-P-1463,Citizen Petition from Tate & Lyle Ingredients Americas LLC
09000064824fc89d,Other,FDA-2017-P-1463-0002,FDA-2017-P-1463,Acknowledgement Letter from FDA DDM to Tate & Lyle Ingredients Americas LLC
0900006483548a07,Supporting & Related Material,FDA-2018-P-2862-0005,FDA-2018-P-2862,"Attachment 3 re Citizen Petition from Lupin Pharmaceuticals, Inc"
0900006483548a08,Supporting & Related Material,FDA-2018-P-2862-0006,FDA-2018-P-2862,"Attachment 4 re Citizen Petition from Lupin Pharmaceuticals, Inc"
0900006483548a06,Supporting & Related Material,FDA-2018-P-2862-0004,FDA-2018-P-2862,"Attachment 2 re Citizen Petition from Lupin Pharmaceuticals, Inc"
09000064839fb109,Other,FDA-2018-P-2862-0007,FDA-2018-P-2862,"Interim response from FDA CDER to  Lupin Pharmaceuticals, Inc"
0900006483548a01,Other,FDA-2018-P-2862-0001,FDA-2018-P-2862,"Citizen Petition from Lupin Pharmaceuticals, Inc"
0900006483548a05,Supporting & Related Material,FDA-2018-P-2862-0003,FDA-2018-P-2862,"Attachment 1 re Citizen Petition from Lupin Pharmaceuticals, Inc"
0900006483548a03,Other,FDA-2018-P-2862-0002,FDA-2018-P-2862,"Acknowledgment Letter from FDA DDM to Lupin Pharmaceuticals, Inc"
0900006483d44b9b,Other,FDA-2018-P-2862-0008,FDA-2018-P-2862,"Letter from FDA CDER to Lupin Pharmaceuticals, Inc."
09000064841fc48f,Other,FDA-2019-P-5800-0002,FDA-2019-P-5800,Acknowledgment Letter from FDA DMS to Akin Gump Strauss Hauer & Feld LLP on behalf of Verax Biomedical Incorporated
0900006484985250,Other,FDA-2019-P-5800-0004,FDA-2019-P-5800,Partial Petition Approval and Denial from FDA CBER  to Verax
09000064846aeb79,Other,FDA-2019-P-5800-0003,FDA-2019-P-5800,Interim response to Verax from FDA CBER
09000064841fc7ba,Other,FDA-2019-P-5800-0001,FDA-2019-P-5800,Citizen Petition from Akin Gump Strauss Hauer & Feld LLP on behalf of Verax Biomedical Incorporated
09000064846f0156,Other,FDA-2020-P-1562-0001,FDA-2020-P-1562,Petition for Stay of Action from Station Management Consultants Inc. d/b/a Sunoco
09000064846f0157,Other,FDA-2020-P-1562-0002,FDA-2020-P-1562,Acknowledgment Letter from FDA DMS to Station Management Consultants Inc. d/b/a Sunoco
09000064846f1f65,Other,FDA-2020-P-1562-0003,FDA-2020-P-1562,"Withdrawal Letter from Station Management Consultants, Inc. d/b/a Sunoco"
0900006481cc9210,Other,FDA-2015-P-2375-0005,FDA-2015-P-2375,Interim Response Letter from FDA CDRH to Public Citizen Health Research Group
0900006481b6d808,Other,FDA-2015-P-2375-0001,FDA-2015-P-2375,Citizen Petition from Public Citizen
0900006484a10138,Other,FDA-2015-P-2375-0006,FDA-2015-P-2375,Public Citizen Seprafilm Final Response
0900006481b6e115,Other,FDA-2015-P-2375-0004,FDA-2015-P-2375,Acknowledgement Letter from FDA DDM to Public Citizen
0900006481b6e118,Supporting & Related Material,FDA-2015-P-2375-0002,FDA-2015-P-2375,Appendix A Seprafilm Safety and Efficacy Data re Citizen Petition from Public Citizen
0900006481b6e119,Supporting & Related Material,FDA-2015-P-2375-0003,FDA-2015-P-2375,Appendix B MAUDE Death Reports Involving Seprafilm re Citizen Petition from Public Citizen
0900006484b3e93d,Other,FDA-2020-P-2301-0004,FDA-2020-P-2301,"Response Letter from FDA CDER to Alpha Cognition USA, Inc."
09000064849a1fea,Supporting & Related Material,FDA-2020-P-2301-0003,FDA-2020-P-2301,"Attachment 1 - Screenshot of the electronic Orange Book search results for Galantamine Oral Tablet RE Citizen Petition from Alpha Cognition USA, Inc"
09000064849a1fe6,Other,FDA-2020-P-2301-0001,FDA-2020-P-2301,"Citizen Petition from Alpha Cognition USA, Inc"
09000064849a1fe7,Other,FDA-2020-P-2301-0002,FDA-2020-P-2301,"Acknowledgment Letter from FDA DMS to Alpha Cognition USA, Inc"
09000064841ed868,Other,FDA-2019-P-5759-0002,FDA-2019-P-5759,Acknowledgment Letter from FDA DMS to Aavis Pharmaceuticals
09000064841ed886,Supporting & Related Material,FDA-2019-P-5759-0004,FDA-2019-P-5759,Annex-II-Prescribing information of Canada approved product re Citizen Petition from Aavis Pharmaceuticals
09000064841ed867,Other,FDA-2019-P-5759-0001,FDA-2019-P-5759,Citizen Petition from Aavis Pharmaceuticals
09000064841ed885,Supporting & Related Material,FDA-2019-P-5759-0003,FDA-2019-P-5759,Annex-I-List of the approved product re Citizen Petition from Aavis Pharmaceuticals
0900006484ac8918,Other,FDA-2019-P-5759-0007,FDA-2019-P-5759,Response to Information Request from Aavis Pharmaceuticals
09000064841ed888,Supporting & Related Material,FDA-2019-P-5759-0006,FDA-2019-P-5759,Annex-IV FDA Draft Guidance on Acetaminophen; Butalbital re Citizen Petition from Aavis Pharmaceuticals
09000064841ed887,Supporting & Related Material,FDA-2019-P-5759-0005,FDA-2019-P-5759,Annex-III-Draft prescribing information re Citizen Petition from Aavis Pharmaceuticals
0900006484c2bbfd,Supporting & Related Material,FDA-2021-P-0508-0008,FDA-2021-P-0508,Reference 6 DiNardo Fall From GRASE re Citizen Petition from Joe DiNardo and Craig A Downs
0900006484c2bc01,Supporting & Related Material,FDA-2021-P-0508-0012,FDA-2021-P-0508,Reference 10 Zhong Comparison of toxicological effects of oxybenzone avobenzone octocrylene and octinoxate sunscreen re Citizen Petition from Joe DiNardo and Craig A Downs
0900006484c2bbbf,Supporting & Related Material,FDA-2021-P-0508-0004,FDA-2021-P-0508,Reference 2 NTP Benzophenone Carcinogenicity Report re Citizen Petition from Joe DiNardo and Craig A Downs
0900006484c2bc00,Supporting & Related Material,FDA-2021-P-0508-0011,FDA-2021-P-0508,Reference 9 DiNardo Comments FDA 1978 N 0018 1508 attachment 1 re Citizen Petition from Joe DiNardo and Craig A Downs
0900006484c2c92a,Supporting & Related Material,FDA-2021-P-0508-0016,FDA-2021-P-0508,Reference 14 Zhang Assessment of multiple hormone activities of a UV-filter octocrylene in zebrafish Danio rerio re Citizen Petition from Joe DiNardo and Craig A Downs
0900006484c2c92b,Supporting & Related Material,FDA-2021-P-0508-0017,FDA-2021-P-0508,Reference 15 Molins Delgado A Potential New Threat to Wild Life Presence of UV Filters in Bird Eggs from a Preserved Area re Citizen Petition from Joe DiNardo and Craig A Downs
0900006484c2c929,Supporting & Related Material,FDA-2021-P-0508-0015,FDA-2021-P-0508,Reference 13 Picot-Groz Diurnal variations in personal care products in seawater and mussels at three Mediterranean coastal re Citizen Petition from Joe DiNardo and Craig A Downs
0900006484c2bbbe,Supporting & Related Material,FDA-2021-P-0508-0003,FDA-2021-P-0508,Reference 1 Downs Octocrylene to BP March 2021 Chemical Research in Toxicology re Citizen Petition from Joe DiNardo and Craig A Downs
0900006484c2bbc0,Supporting & Related Material,FDA-2021-P-0508-0005,FDA-2021-P-0508,Reference 3 BP Federal Register Food Additive Regulations Synthetic Flavoring Agents and Adjuvants re Citizen Petition from Joe DiNardo and Craig A Downs
0900006484c2bbc1,Supporting & Related Material,FDA-2021-P-0508-0006,FDA-2021-P-0508,Reference 4 Matta Effect of Sunscreen Application on Plasma Concentration of Sunscreen Active Ingredients A Randomized Clinical Trial re Citizen Petition from Joe DiNardo and Craig A Downs
0900006484c2bbfe,Supporting & Related Material,FDA-2021-P-0508-0009,FDA-2021-P-0508,Reference 7 Bronaugh In vivo percutaneous absorption of fragrance ingredients in rhesus monkeys and humans re Citizen Petition from Joe DiNardo
0900006484c2c6c3,Other,FDA-2021-P-0508-0002,FDA-2021-P-0508,Acknowledgement Letter from FDA DMS to Joe DiNardo and Craig A Downs
0900006484c2bbc3,Supporting & Related Material,FDA-2021-P-0508-0018,FDA-2021-P-0508,Reference 16 Alonso Toxic heritage Maternal transfer of pyrethroid insecticides and sunscreen agents in dolphins from B re Citizen Petition from Joe DiNardo and Craig A Downs
0900006484c2c928,Supporting & Related Material,FDA-2021-P-0508-0014,FDA-2021-P-0508,Reference 12 Cunha Co-occurrence of musk fragrances and UV-filters in seafood and macroalgae collected in European hots re Citizen Petition from Joe DiNardo and Craig A Downs
0900006484c2bbc4,Supporting & Related Material,FDA-2021-P-0508-0019,FDA-2021-P-0508,Reference 17 He Toxicological effects of two organic ultraviolet filters and a related commercial sunscreen product re Citizen Petition from Joe DiNardo and Craig A Downs
0900006484c2c6c1,Other,FDA-2021-P-0508-0001,FDA-2021-P-0508,Citizen Petition from Joe DiNardo and Craig A Downs
0900006484c2bbc5,Supporting & Related Material,FDA-2021-P-0508-0020,FDA-2021-P-0508,Reference 18 Stien Metabolomics Reveal That Octocrylene Accumulates in Pocillopora damicornis Tissues as Fatty Acid Con re Citizen Petition from Joe DiNardo and Craig A Downs
0900006484c2bc02,Supporting & Related Material,FDA-2021-P-0508-0013,FDA-2021-P-0508,Reference 11 Yan Reproductive toxicity and estrogen activity in Japanese medaka Oryzias latipes exposed to environm re Citizen Petition from Joe DiNardo and Craig A Downs
0900006484c2bbc2,Supporting & Related Material,FDA-2021-P-0508-0007,FDA-2021-P-0508,Reference 5 Foubert The presence of benzophenone in sunscreens and cosmetics containing the organic UV filter octocrylen re Citizen Petition from Joe DiNardo and Craig A Downs
0900006484c2bbff,Supporting & Related Material,FDA-2021-P-0508-0010,FDA-2021-P-0508,Reference 8 National Drug Code Directory FDA re Citizen Petition from Joe DiNardo and Craig A Downs
090000648042b3ba,Notice,FDA-2007-N-0272-0001,FDA-2007-N-0272,FDA
090000648042b3bd,Notice,FDA-2007-N-0272-0002,FDA-2007-N-0272,FDA
090000648047023a,Notice,FDA-2004-D-0183-0001,FDA-2004-D-0183,FDA
090000648047023f,Other,FDA-2004-D-0183-0003,FDA-2004-D-0183,"Class II Special Controls Guidance Document: Immunomagnetic Circulating Cancer Cell Selection and Enumeration System Guidance for Industry
and FDA Staff"
090000648047023e,Supporting & Related Material,FDA-2004-D-0183-0002,FDA-2004-D-0183,Guidance
0900006480470240,Supporting & Related Material,FDA-2004-D-0183-0004,FDA-2004-D-0183,Guidance
090000648044c132,Supporting & Related Material,FDA-2005-D-0384-0002,FDA-2005-D-0384,GUIDANCE
090000648044c165,Supporting & Related Material,FDA-2005-D-0384-0005,FDA-2005-D-0384,Guidance
090000648044c0f7,Notice,FDA-2005-D-0384-0001,FDA-2005-D-0384,FDA
090000648044c169,Notice,FDA-2005-D-0384-0006,FDA-2005-D-0384,FDA
090000648044c163,Notice,FDA-2005-D-0384-0004,FDA-2005-D-0384,FDA
090000648069e961,Other,FDA-2008-D-0406-0002,FDA-2008-D-0406,"Information Sheet Guidance for Sponsors, Clinical Investigators, and  IRBs - Frequently Asked Questions-Statment of Investigator (Form FDA 1572) - Draft Guidance"
090000648069e78b,Notice,FDA-2008-D-0406-0001,FDA-2008-D-0406,"Draft Information Sheet Guidance for Sponsors, Clinical Investigators, and Institutional Review Boards on Frequently Asked Questions--Statement of Investigator (Form FDA 1572); Availability"
0900006480afb847,Other,FDA-2008-D-0406-0038,FDA-2008-D-0406,"Information Sheet Guidance for Sponsors, Clinical Investigators, and IRBs; Frequently Asked Questions - Statement of Investigator (Form FDA 1572)"
0900006480afbba8,Notice,FDA-2008-D-0406-0037,FDA-2008-D-0406,"Information Sheet Guidance for Sponsors, Clinical Investigators, and IRBs: Frequently Asked QuestionsStatement of Investigator (Form FDA 1572); Availability"
0900006484b23af1,Other,FDA-2008-D-0406-0043,FDA-2008-D-0406,Information Sheet Guidance for Sponsors Clinical Investigators and IRBs Frequently Asked Questions Statement of Investigator (Form FDA 1572) (Revision 1); Draft Guidance
0900006484b23723,Notice,FDA-2008-D-0406-0042,FDA-2008-D-0406,"Frequently Asked Questions— Statement of Investigator (Form FDA 1572) (Revision 1); Draft Information 
Sheet Guidance for Sponsors, Clinical Investigators, and Institutional Review Boards; Availability"
0900006480632db6,Supporting & Related Material,FDA-2008-P-0363-0008,FDA-2008-P-0363,Tab 5 - Danish Cattle Federation - [Figures on Danish Cattle] - Citizen Petition
0900006480632dd8,Supporting & Related Material,FDA-2008-P-0363-0009,FDA-2008-P-0363,Tab 6 - Danish Veterinary and Food Administration - [The Current Status of BSE and Scrapie in Denmark{February 2006}] - Citizen Petition
09000064806329d2,Other,FDA-2008-P-0363-0010,FDA-2008-P-0363,Acknowlegement Letter to Nordic Cryobank ApS
0900006480632d4a,Supporting & Related Material,FDA-2008-P-0363-0007,FDA-2008-P-0363,Tab 3 - Access GPO - [Bovine Spongiform Encephalopathy (BSE)] - Citizen Petition
090000648083ee2c,Other,FDA-2008-P-0363-0012,FDA-2008-P-0363,FDA/CBER Interim Response to Nordic Cryobank ApS - Letter
09000064809610dd,Other,FDA-2008-P-0363-0013,FDA-2008-P-0363,FDA/CBER Interim Response to Nordic Cryobank ApS - Letter
090000648065015c,Supporting & Related Material,FDA-2008-P-0363-0003,FDA-2008-P-0363,Exhibit G - United Kingdom BSE Cases - Citizen Petition
0900006480650162,Supporting & Related Material,FDA-2008-P-0363-0004,FDA-2008-P-0363,Exhibit H - Europe (excluding UN) BSE Cases - Citizen Petition
0900006480650146,Supporting & Related Material,FDA-2008-P-0363-0002,FDA-2008-P-0363,Exhibit F - Percentage of BSE Cases by Country - Citizen Petition
090000648065016c,Supporting & Related Material,FDA-2008-P-0363-0005,FDA-2008-P-0363,Exhibit I - vCJD Occurence [vCJD Cases (onset data) - Citizen Petition
0900006480650180,Supporting & Related Material,FDA-2008-P-0363-0006,FDA-2008-P-0363,Exhibit J - BSE Comparison [BSE Cases] - Citizen Petition
0900006480b74729,Other,FDA-2008-P-0363-0014,FDA-2008-P-0363,"FDA/CBER Response to Nordic Cryobank ApS, June 17, 2010 - Petition Denial"
0900006480632971,Other,FDA-2008-P-0363-0001,FDA-2008-P-0363,Nordic Cryobank ApS - Citizen Petition
0900006480820bd0,Other,FDA-2008-P-0363-0011,FDA-2008-P-0363,Nordic Cryobank ApS to FDA/CBER - Letter
09000064817301bd,Notice,FDA-2010-D-0194-0023,FDA-2010-D-0194,"Agency Information Collection Activities; Announcement of Office of
Management and Budget Approval; Safety Assurance Case"
09000064816aadb0,Notice,FDA-2010-D-0194-0022,FDA-2010-D-0194,"Agency Information Collection Activities; Submission for Office of
Management and Budget Review; Comment Request; Draft Guidance for
Industry and FDA Staff; Total Product Life Cycle: Infusion Pump—Premarket Notification Submissions"
090000648195509a,Other,FDA-2010-D-0194-0025,FDA-2010-D-0194,Infusion Pumps Total Product Life Cycle; Guidance for Industry and FDA Administration Staff
0900006481232915,Notice,FDA-2010-D-0194-0018,FDA-2010-D-0194,"Agency Information Collection Activities; Proposals, Submissions, and Approvals: Draft Guidance for Industry and FDA Staff; Total Product Life Cycle, Infusion Pump - Premarket Notification Submissions"
0900006480b1071d,Other,FDA-2010-D-0194-0002,FDA-2010-D-0194,Guidance for Industry and FDA Staff; Total Product Life Cycle: Infusion Pump – Premarket Notification (510(k)) Submissions; Draft Guidance
0900006480b10719,Notice,FDA-2010-D-0194-0001,FDA-2010-D-0194,Draft Guidance for Industry and FDA Staff; Total Product Life Cycle: Infusion Pump – Premarket Notification (510(k)) Submissions; Availability
0900006481953fe6,Notice,FDA-2010-D-0194-0024,FDA-2010-D-0194,"Infusion Pumps Total Product Life Cycle; Guidance for Industry and Food
and Drug Administration Staff; Availability"
0900006484d6d19b,Other,FDA-2021-P-0992-0002,FDA-2021-P-0992,Acknowledgment Letter from FDA DMS to Zoetis Inc
0900006484d6c9bc,Supporting & Related Material,FDA-2021-P-0992-0004,FDA-2021-P-0992,ATTACHMENT 2 Policy Letter from DHHS  RE: Citizen Petition from Zoetis Inc
0900006484d6c9bb,Supporting & Related Material,FDA-2021-P-0992-0003,FDA-2021-P-0992,"ATTACHMENT 1 Dechra Veterinary Products, LLC RE: Citizen Petition from Zoetis Inc"
0900006484d6cbf5,Other,FDA-2021-P-0992-0001,FDA-2021-P-0992,Citizen Petition from Zoetis Inc
09000064849faabc,Notice,FDA-2021-Z-0025-0002,FDA-2021-Z-0025,Requests for Proposals for Insulin Reimportation and Personal Prescription Drug Importation
0900006484ac7a40,Notice,FDA-2021-Z-0025-0008,FDA-2021-Z-0025,Withdrawal of Notice Regarding the Food and Drug Administration Drug Review Timeline Transparency; Revocation of Statement of Policy
0900006484c0e025,Notice,FDA-2021-Z-0025-0015,FDA-2021-Z-0025,Medical Devices; Class I Surgeon’s and Patient Examination Gloves
0900006484dff4c7,Proposed Rule,FDA-2021-Z-0025-0016,FDA-2021-Z-0025,Securing Updated and Necessary Statutory Evaluations Timely; Proposal To Withdraw or Repeal
0900006484aa9678,Notice,FDA-2021-Z-0025-0003,FDA-2021-Z-0025,"Making Permanent Regulatory Flexibilities Provided During the COVID–19 Public Health Emergency by 
Exempting Certain Medical Devices From Premarket Notification Requirements; Withdrawal of Proposed Exemptions"
09000064849f7f15,Rule,FDA-2021-Z-0025-0001,FDA-2021-Z-0025,Securing Updated and Necessary Statutory Evaluations Timely
0900006484bdf3c6,Notice,FDA-2021-Z-0025-0014,FDA-2021-Z-0025,Requests for Proposals for Insulin Reimportation and Personal Prescription Drug Importation; Withdrawal
0900006484aa97fd,Notice,FDA-2021-Z-0025-0004,FDA-2021-Z-0025,Medical Devices; Class I Surgeon’s and Patient Examination Glove
09000064841b6f9d,Supporting & Related Material,FDA-2019-P-5593-0003,FDA-2019-P-5593,"Attachment 1 - Orange Book Details re Citizen Petition from Hyman, Phelps & McNamara, P.C."
09000064841b6f31,Other,FDA-2019-P-5593-0001,FDA-2019-P-5593,"Citizen Petition from Hyman, Phelps & McNamara, P.C."
09000064841b6f9f,Supporting & Related Material,FDA-2019-P-5593-0005,FDA-2019-P-5593,"Attachment 3 - Proposed Labeling re Citizen Petition from Hyman, Phelps & McNamara, P.C."
09000064841b6f32,Other,FDA-2019-P-5593-0002,FDA-2019-P-5593,"Acknowledgment Letter from FDA DMS to Hyman, Phelps & McNamara, P.C."
09000064841b6f9e,Supporting & Related Material,FDA-2019-P-5593-0004,FDA-2019-P-5593,"Attachment 2 - ULTRAM Label re Citizen Petition from Hyman, Phelps & McNamara, P.C."
090000648321b0ff,Supporting & Related Material,FDA-2018-P-1698-0006,FDA-2018-P-1698,Exhibit 4 - BPCA Priority List 2017-18 re Suitability Petition from Haynes and Boone LLP
090000648321b441,Other,FDA-2018-P-1698-0001,FDA-2018-P-1698,"Suitability Petition from Haynes and Boone, LLP"
090000648321b443,Other,FDA-2018-P-1698-0002,FDA-2018-P-1698,"Acknowledgment Letter from FDA DDM to Haynes and Boone, LLP"
0900006483222847,Supporting & Related Material,FDA-2018-P-1698-0007,FDA-2018-P-1698,Exhibit 5 - CONFIDENTIAL - Midodrine Prevalence Report excerpt 4812-9019-5812_1 re Suitability Petition from Haynes and Boone
090000648321b0fe,Supporting & Related Material,FDA-2018-P-1698-0005,FDA-2018-P-1698,Exhibit 3 - midodrine-draft-label re Suitability Petition from Haynes and Boone LLP
090000648321b446,Supporting & Related Material,FDA-2018-P-1698-0003,FDA-2018-P-1698,Exhibit 1 - Mylan Midodrine HCl Tablets OB listing re Suitability Petition from Haynes and Boone LLP
090000648321b448,Supporting & Related Material,FDA-2018-P-1698-0004,FDA-2018-P-1698,Exhibit 2 - Mylan Midodrine HCl label re Suitability Petition from Haynes and Boone LLP
0900006482a95b4e,Supporting & Related Material,FDA-2017-P-5118-0003,FDA-2017-P-5118,Attachment 1 Teriyaki Marinade Neck Tab re Citizen Petition from Tricia Thompson
0900006482a95b50,Supporting & Related Material,FDA-2017-P-5118-0005,FDA-2017-P-5118,Attachment 3 Teriyaki Sauce Front Label re Citizen Petition from Tricia Thompson
0900006482a95b4f,Supporting & Related Material,FDA-2017-P-5118-0004,FDA-2017-P-5118,Attachment 2 Teriyaki Marinade Back Label re Citizen Petition from Tricia Thompson
0900006482a95efa,Supporting & Related Material,FDA-2017-P-5118-0008,FDA-2017-P-5118,Attachment 6 Mini Rice Cakes Back Label re Citizen Petition from Tricia Thompson
0900006482a95efc,Supporting & Related Material,FDA-2017-P-5118-0010,FDA-2017-P-5118,Attachment 8 Gluten Free Watchdog Post re Citizen Petition from Tricia Thompson
0900006482a95b4c,Other,FDA-2017-P-5118-0002,FDA-2017-P-5118,Acknowledgement Letter from FDA DDM to Tricia Thompson
0900006482a95b4a,Other,FDA-2017-P-5118-0001,FDA-2017-P-5118,Citizen Petition from Tricia Thompson
0900006482d03c8c,Other,FDA-2017-P-5118-1133,FDA-2017-P-5118,Supplement from Tricia Thompson
0900006482a95efb,Supporting & Related Material,FDA-2017-P-5118-0009,FDA-2017-P-5118,Attachment 7 Power Point Slides 1 and 15 from FDA Webinar re Citizen Petition from Tricia Thompson
0900006482d86292,Other,FDA-2017-P-5118-1172,FDA-2017-P-5118,Supplement from Tricia Thompson
0900006482f398f2,Other,FDA-2017-P-5118-1369,FDA-2017-P-5118,"Interim Response Letter from FDA CFSAN to Gluten Free Watchdog, LLC"
0900006482a95b51,Supporting & Related Material,FDA-2017-P-5118-0006,FDA-2017-P-5118,Attachment 4 Teryaki Sauce Back Label re Citizen Petition from Tricia Thompson
0900006482a95ef9,Supporting & Related Material,FDA-2017-P-5118-0007,FDA-2017-P-5118,Attachment 5 Mini Rice Cakes Front Label re Citizen Petition from Tricia Thompson
09000064829c8409,Other,FDA-2017-P-4736-0002,FDA-2017-P-4736,Acknowledgement Letter from FDA DDM to American Dental Association
09000064829c819b,Other,FDA-2017-P-4736-0001,FDA-2017-P-4736,Citizen Petition from American Dental Association
0900006482e8765e,Other,FDA-2017-P-4736-0003,FDA-2017-P-4736,Interim Response from FDA CDER to the Americal Dental Association
09000064839fbdde,Other,FDA-2017-P-4736-0004,FDA-2017-P-4736,Denial of Citizen Petition from FDA CDER to American Dental Association
0900006482b9bc9c,Other,FDA-2017-P-6020-0002,FDA-2017-P-6020,"Acknowledgment Letter from DDM to Axinn, Veltrop & Harkrider LLP"
0900006482b9b6f5,Supporting & Related Material,FDA-2017-P-6020-0005,FDA-2017-P-6020,"Attachment - 3 PROPOSED DRAFT LABELING re Citizen Petition from Axinn, Veltrop & Harkrider LLP"
0900006482b9b32c,Other,FDA-2017-P-6020-0001,FDA-2017-P-6020,"Citizen Petition from Axinn, Veltrop & Harkrider LLP"
0900006482b9b32e,Supporting & Related Material,FDA-2017-P-6020-0003,FDA-2017-P-6020,"Attachment -1 FDA ORANGE BOOK (NDA 202155) re Citizen Petition from Axinn, Veltrop & Harkrider LLP"
0900006482b9b32f,Supporting & Related Material,FDA-2017-P-6020-0004,FDA-2017-P-6020,"Attachment - 2 NDA 202155 APPROVED LABELING re Citizen Petition from Axinn, Veltrop & Harkrider LLP"
0900006481849cd0,Other,FDA-2014-P-1057-0001,FDA-2014-P-1057,Citizen Petition from Pharmacists Planning Service Inc
0900006481849cd2,Other,FDA-2014-P-1057-0002,FDA-2014-P-1057,Second Acknowledgement Letter From FDA DDM to Pharmacists Planning Service Inc
0900006481a84f72,Other,FDA-2014-P-1057-0004,FDA-2014-P-1057,Petition Denial Letter from FDA CDER to Pharmacists Planning Service Inc. PPSI
0900006481849cd1,Other,FDA-2014-P-1057-0003,FDA-2014-P-1057,Acknowledgement Letter From FDA DDM to Pharmacists Planning Service Inc
0900006481b40d13,Other,FDA-2015-P-2230-0001,FDA-2015-P-2230,Citizen Petition from Hyman Phelps and McNamara PC
0900006481b40d18,Supporting & Related Material,FDA-2015-P-2230-0004,FDA-2015-P-2230,Attachment 2 Product Labeling for Nexium 24 HR re Citizen Petition from Hyman Phelps and McNamara PC
0900006481d7d82c,Other,FDA-2015-P-2230-0005,FDA-2015-P-2230,"Withdrawal from Hyman, Phelps, & McNamara, P.C."
0900006481b40d15,Other,FDA-2015-P-2230-0002,FDA-2015-P-2230,Acknowledgement Letter from FDA DDM to Hyman Phelps and McNamara PC
0900006481b40d17,Supporting & Related Material,FDA-2015-P-2230-0003,FDA-2015-P-2230,Attachment 1 Orange Book Listing re Citizen Petition from Hyman Phelps and McNamara PC
09000064816bd7f8,Other,FDA-2014-P-0496-0001,FDA-2014-P-0496,Citizen Petition from Pharmacists Planning Service Inc
09000064816bd83c,Other,FDA-2014-P-0496-0002,FDA-2014-P-0496,Acknowledgement Letter From FDA DDM to Pharmacists Planning Service Inc
09000064818ad449,Other,FDA-2014-P-0496-0004,FDA-2014-P-0496,"Citizen Petition Interim Response from FDA CDER to Pharmacists Planning Services, Inc. (PPSI)"
0900006481a805f8,Other,FDA-2014-P-0496-0005,FDA-2014-P-0496,Petition Denial Letter from FDA CDER to Pharmacists Planning Service Inc. PPSI
090000648244fdde,Other,FDA-2017-P-0115-0002,FDA-2017-P-0115,Acknowledgement Letter from FDA DDM to Jubilant Generics Limited
090000648244fde1,Supporting & Related Material,FDA-2017-P-0115-0003,FDA-2017-P-0115,Exhibit I Listing drugs@fda re Citizen Petition from Jubilant Generics Limited
090000648244fde2,Supporting & Related Material,FDA-2017-P-0115-0004,FDA-2017-P-0115,Exhibit II RLD Label re Citizen Petition from Jubilant Generics Limited
090000648244fddd,Other,FDA-2017-P-0115-0001,FDA-2017-P-0115,Citizen Petition from Jubilant Generics Limited
090000648244fbc3,Supporting & Related Material,FDA-2017-P-0115-0006,FDA-2017-P-0115,Jubilant Citizen Petition FDA receipt re Citizen Petition from Jubilant Generics Limited
090000648244fbc2,Supporting & Related Material,FDA-2017-P-0115-0005,FDA-2017-P-0115,Exhibit III Proposed Label re Citizen Petition from Jubilant Generics Limited
0900006481ba85ab,Other,FDA-2015-P-2678-0001,FDA-2015-P-2678,"Citizen Petition from Brian C. Weiner, Marlboro Gastroenterology PC"
0900006481dbab83,Other,FDA-2015-P-2678-0003,FDA-2015-P-2678,"Interim Response Letter from FDA CFSAN to Brian C. Weiner, Marlboro Gastroenterology PC"
0900006481ba85ac,Other,FDA-2015-P-2678-0002,FDA-2015-P-2678,"Acknowledgement Letter from FDA DDM to Brian C. Weiner, Marlboro Gastroenterology PC"
090000648361dc4f,Notice,FDA-2018-N-2701-0001,FDA-2018-N-2701,"Agency Information Collection Activities;  Submission for Office of Management and Budget Review; Comment Request; Food and drug Administration Food Safety, Health, and Diet Survey"
0900006483cd85bf,Other,FDA-2018-P-4851-0009,FDA-2018-P-4851,"Letter from FDA CDER to Hetero Labs Ltd. (Hetero USA, Inc.)"
0900006483cd5b28,Notice,FDA-2018-P-4851-0008,FDA-2018-P-4851,"Determination That LUPRON (Leuprolide Acetate) Injection, 1 Milligram/0.2 Milliliter, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
09000064839c023c,Supporting & Related Material,FDA-2018-P-4851-0003,FDA-2018-P-4851,Attachment 2 re: Citizen Petition from Hetero Labs Limited
09000064839c023d,Supporting & Related Material,FDA-2018-P-4851-0004,FDA-2018-P-4851,Attachment 3- Lachman_Consultant_Services_Inc_Citizen_Petition re: Citizen Petition from Hetero Labs Limited
09000064839c023e,Supporting & Related Material,FDA-2018-P-4851-0005,FDA-2018-P-4851,"Attachment 4- Response_Letter_From_CDER_ORP_to_Lachman_Consultant_Services,_Inc_ re: Citizen Petition from Hetero Labs Limited"
09000064839c023f,Supporting & Related Material,FDA-2018-P-4851-0006,FDA-2018-P-4851,Attachment 5- Lupron Review Document re: Citizen Petition from Hetero Labs Limited
09000064839c0781,Other,FDA-2018-P-4851-0007,FDA-2018-P-4851,Acknowledgment letter from FDA DDM to Hetero Labs Limited
09000064839c023b,Supporting & Related Material,FDA-2018-P-4851-0002,FDA-2018-P-4851,Attachment 1 re: Citizen Petition from Hetero Labs Limited
09000064839bfdbd,Other,FDA-2018-P-4851-0001,FDA-2018-P-4851,Citizen Petition from Hetero Labs Limited
090000648411b383,Supporting & Related Material,FDA-2019-P-5151-0052,FDA-2019-P-5151,"Tab 51 - Annual Periodic Adverse Experience Report to FDA. (April 28, 2006) (Excerpt) Re Citizen Petition from GlaxoSmithKline"
090000648411af72,Supporting & Related Material,FDA-2019-P-5151-0026,FDA-2019-P-5151,Tab 24 - NTX/89/001: GR38032F: Preliminary study for the reproduction study in rabbits by oral administration during the period of fetal organogenesis (I) (Study No. T-881001). (ZFN00077091-113) Re Citizen Petition from GlaxoSmithKline
090000648411b359,Supporting & Related Material,FDA-2019-P-5151-0003,FDA-2019-P-5151,"Tab 1 - Zofran Tablets Label ZFT 9PI, October 2016  Re Citizen Petition from GlaxoSmithKline"
090000648411b35e,Supporting & Related Material,FDA-2019-P-5151-0008,FDA-2019-P-5151,Tab 6 - American College of Obstetricians and Gynecologists (ACOG). Practice Bulletin No. 189. Nausea and Vomiting of Pregnancy. Obstet Gynecol 2018;131(1):e15-e30 Re Citizen Petition from GlaxoSmithKline
090000648411b363,Supporting & Related Material,FDA-2019-P-5151-0013,FDA-2019-P-5151,Tab 11 - Draft label with FDA comments. (November 2015) (NPCZOFR00003937) Re Citizen Petition from GlaxoSmithKline
090000648411b369,Supporting & Related Material,FDA-2019-P-5151-0019,FDA-2019-P-5151,Tab 17 - FDA Pharmacologist Review (NDA 20-781). (ZFN00002134-249) - Re Citizen Petition from GlaxoSmithKline
090000648411b36b,Supporting & Related Material,FDA-2019-P-5151-0021,FDA-2019-P-5151,Tab 19 - NTX/91/001: Reproduction Study on GR38032F (SN-307) in rats by intravenous administration during the period of organogenesis (Study No. 100424) (ZFN00077547) Re Citizen Petition from GlaxoSmithKline
090000648411b36c,Supporting & Related Material,FDA-2019-P-5151-0022,FDA-2019-P-5151,Tab 20 - NTX/90/009: Reproduction Study (Seg II) on GR38032F (SN-307) in rabbits by oral route. (Study No. 100441) (ZFN00077391) Re Citizen Petition from GlaxoSmithKline
090000648411b378,Supporting & Related Material,FDA-2019-P-5151-0042,FDA-2019-P-5151,"Tab 41 - Shimizu M, Ota T, Kato S, Kobayashi Y, Yamashita Y, Asano M, Mori K, Fujimura T. Reproduction Study (Seg II) of ondansetron hydrochloride in rats by intravenous route. Jpn Pharmacol Ther 1992;20:155-74. (Japanese version, GSK translation and plaintiffs’ translation) Re Citizen Petition from GlaxoSmithKline"
090000648411b379,Supporting & Related Material,FDA-2019-P-5151-0043,FDA-2019-P-5151,"Tab 42 - Ezaki H, Yokoyama S, Takahashi N, Takamatsu M, Tokado Y, and Takeda K. Reproduction Study (Seg. II) of ondansetron hydrochloride in rabbits by oral route.  Jpn Pharmacol Ther 1992;20:ss1187-96. (Japanese version, GSK translation and plaintiffs’ translation) Re Citizen Petition from GlaxoSmithKline"
090000648411af73,Supporting & Related Material,FDA-2019-P-5151-0027,FDA-2019-P-5151,Tab 25 - NTX/89/002: GR38032F (SN-307): Preliminary study for the reproduction study in rabbits by oral administration during the period of fetal organogenesis (II). (Study No. T-881002). (ZFN00077114-145) Re Citizen Petition from GlaxoSmithKline
090000648411b35c,Supporting & Related Material,FDA-2019-P-5151-0006,FDA-2019-P-5151,Tab 4 - 20-007 Approval Package (ZOFNDAA0095829) Re Citizen Petition from GlaxoSmithKline
090000648411b37f,Supporting & Related Material,FDA-2019-P-5151-0049,FDA-2019-P-5151,"Tab 48 - Kuryshev YA, Brown AM, Wang L, Benedict CR, Rampe D. Interactions of the 5-hydroxytryptamine 3 antagonist class of antiemetic drugs with human cardiac ion channels. J Pharmacol Experiment Ther 2000;295:614-620 Re Citizen Petition from GlaxoSmithKline"
090000648411b382,Supporting & Related Material,FDA-2019-P-5151-0051,FDA-2019-P-5151,"Tab 50 - Annual Periodic Adverse Experience Report to FDA. (April 27, 2005) (Excerpt) Re Citizen Petition from GlaxoSmithKline"
090000648411b38a,Supporting & Related Material,FDA-2019-P-5151-0059,FDA-2019-P-5151,"Tab 58 - EUROCAT Guide 1.3, European Surveillance of Congenital Anomalies, Instructions for the Registration and Surveillance of Congenital Anomalies. (2005) Re Citizen Petition from GlaxoSmithKline"
0900006484491037,Other,FDA-2019-P-5151-0074,FDA-2019-P-5151,Supplement from Jennerlaw part 1 of 2
09000064842f5b7b,Other,FDA-2019-P-5151-0063,FDA-2019-P-5151,Memo to Docket - 11-8-19 call
090000648411af75,Supporting & Related Material,FDA-2019-P-5151-0029,FDA-2019-P-5151,"Tab 27 - Danielsson, B, Wikner BN, Kallen B. Use of ondansetron in pregnancy and congenital malformations in the infant. Repro Toxicol 2014;50:134-137 Re Citizen Petition from GlaxoSmithKline"
090000648411b388,Supporting & Related Material,FDA-2019-P-5151-0057,FDA-2019-P-5151,"Tab 56 - CDC, Metropolitan Atlanta Congenital Defects Program (MACDP). CDC/BPA 6-Digit Code for Congenital Anomalies. (2018) Re Citizen Petition from GlaxoSmithKline"
090000648411b37c,Supporting & Related Material,FDA-2019-P-5151-0046,FDA-2019-P-5151,"Tab 45 - Secker RC, et al. Reproduction Study (Seg. III) of ondansetron hydrochloride in rats by oral route. Jpn Pharmacol Ther (1992); 20:221-236. (Japanese version, GSK translation and plaintiffs’ translation) Re Citizen Petition from GlaxoSmithKline"
090000648411b387,Supporting & Related Material,FDA-2019-P-5151-0056,FDA-2019-P-5151,"Tab 55 - CDC, Metropolitan Atlanta Congenital Defects Program (MACDP). Birth Defects and Genetic Diseases Branch 6-Digit Code for Reportable Congenital Anomalies (2004) Re Citizen Petition from GlaxoSmithKline"
090000648411b38b,Supporting & Related Material,FDA-2019-P-5151-0060,FDA-2019-P-5151,"Tab 59 - EUROCAT Guide 1.4, European Surveillance of Congenital Anomalies. (2013) Re Citizen Petition from GlaxoSmithKline"
090000648411af74,Supporting & Related Material,FDA-2019-P-5151-0028,FDA-2019-P-5151,"Tab 26 - Danielsson B, Webster WS, Ritchie HE. Ondansetron and teratogenicity in rats: evidence for a mechanism mediated via embryonic hERG blockade. Reprod Toxicol 2018;81:237-245 Re Citizen Petition from GlaxoSmithKline"
090000648411b360,Supporting & Related Material,FDA-2019-P-5151-0010,FDA-2019-P-5151,"Tab 8 - James P. Reichmann Citizen Petition. (January 4, 2012) Re Citizen Petition from GlaxoSmithKline"
090000648411b367,Supporting & Related Material,FDA-2019-P-5151-0017,FDA-2019-P-5151,Tab 15 - 27-531 Annual Report. (1993) (ZOFINDAC0013783) Re Citizen Petition from GlaxoSmithKline
0900006482b11e1c,Other,FDA-2016-P-2675-0006,FDA-2016-P-2675,Letter from FDA to Foley & Lardner LLP
09000064821e9d47,Supporting & Related Material,FDA-2016-P-2675-0003,FDA-2016-P-2675,"Attachment 1 Orange Book: Approved Drug Products with Therapeutic
Equivalence Evaluations re Citizen Petition from Foley & Lardner LLP"
09000064824f0113,Other,FDA-2016-P-2675-0004,FDA-2016-P-2675,Interim response from FDA CDER to Foley & Lardner LLP
0900006482b0f6c3,Notice,FDA-2016-P-2675-0005,FDA-2016-P-2675,"Determination That GYNOREST (Dydrogesterone) Oral Tablets, 5  Milligrams and 10 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
09000064821e9d45,Other,FDA-2016-P-2675-0002,FDA-2016-P-2675,Acknowledgment Letter from FDA DDM to Foley & Lardner LLP
09000064821e97c2,Other,FDA-2016-P-2675-0001,FDA-2016-P-2675,Citizen Petition from Foley & Lardner LLP
090000648430fea4,Other,FDA-2020-P-0512-0001,FDA-2020-P-0512,"Citizen Petition from Hyman, Phelps, & McNamara PC"
090000648430ff25,Other,FDA-2020-P-0512-0002,FDA-2020-P-0512,"Acknowledgment Letter from FDA DMS to Hyman, Phelps, & McNamara PC"
09000064843161fb,Supporting & Related Material,FDA-2020-P-0512-0004,FDA-2020-P-0512,"Attachment 2 - Highlights of Prescribing Information for ABRAXANE re: Citizen Petition from Hyman, Phelps, & McNamara PC"
09000064843161fa,Supporting & Related Material,FDA-2020-P-0512-0003,FDA-2020-P-0512,"Attachment 1 - Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations re: Citizen Petition from Hyman, Phelps, & McNamara PC"
09000064843161ff,Supporting & Related Material,FDA-2020-P-0512-0005,FDA-2020-P-0512,"Attachment 3 - Highlights of Prescribing Information for PACLITAXEL re: Citizen Petition from Hyman, Phelps, & McNamara PC"
0900006484316200,Supporting & Related Material,FDA-2020-P-0512-0006,FDA-2020-P-0512,"Attachment 4 - PACLITAXEL protein-bound particles for injectable suspension (albumin0bound)  - Citizen Petition from Hyman, Phelps, & McNamara PC"
0900006484b9b4be,Other,FDA-2021-P-0567-0002,FDA-2021-P-0567,Acknowledgement Letter from FDA DMS to M A Pharmaceutical Consulting Inc
0900006484b9b462,Other,FDA-2021-P-0567-0001,FDA-2021-P-0567,Suitability Petition from M A Pharmaceutical Consulting Inc
0900006484ba0eba,Supporting & Related Material,FDA-2021-P-0567-0003,FDA-2021-P-0567,Attachment 1 Approved Drug Products with Therapeutic Equivalence Evaluations re Suitability Petition from M A Pharmaceutical Consulting Inc
0900006484ba0f31,Supporting & Related Material,FDA-2021-P-0567-0004,FDA-2021-P-0567,Attachment 2 Vesicare LS Solifenacin Succinate Oral Suspension re Suitability Petition from M A Pharmaceutical Consulting Inc
0900006484ba0f32,Supporting & Related Material,FDA-2021-P-0567-0005,FDA-2021-P-0567,Attachment 3 Proposed label for Solifenacin Succinate Oral Solution re Suitability Petition from M A Pharmaceutical Consulting Inc
09000064806aef85,Other,FDA-2008-D-0434-0002,FDA-2008-D-0434,"Draft Guidance for HDE Holders, Institutional Review Boards (IRBs), Clinical Investigators, and FDA Staff - Humanitarian Device Exemption (HDE) Regulation: Questions and Answers"
0900006480aa737b,Notice,FDA-2008-D-0434-0011,FDA-2008-D-0434,"Agency Information Collection Activities; Proposals, Submissions, and Approvals: Guidance for Humanitarian Device Exemption Holders, Institutional Review Boards, Clinical Investigators, and FDA Staff, etc."
09000064806aecd9,Notice,FDA-2008-D-0434-0001,FDA-2008-D-0434,"Humanitarian Device Exemption Regulation: Draft Guidance for Exemption Holders, Institutional Review Boards, Clinical Investigators, and Food and Drug Administration Staff; Questions and Answers"
0900006480a31abf,Notice,FDA-2008-D-0434-0010,FDA-2008-D-0434,"Agency Information Collection Activities; Proposals, Submissions, and Approvals"
0900006480b15515,Notice,FDA-2008-D-0434-0012,FDA-2008-D-0434,"Guidance for Humanitarian Device Exemption Holders, et al.; Availability: Humanitarian Device Exemption Regulation; Questions and Answers"
0900006480b154b6,Other,FDA-2008-D-0434-0013,FDA-2008-D-0434,"Guidance for HDE Holders, Institutional Review Boards (IRBs), Clinical Investigators, and Food and Drug Administration Staff - Humanitarian Device Exemption (HDE) Regulation: Questions and Answers"
0900006483baeb44,Supporting & Related Material,FDA-2019-P-1783-0003,FDA-2019-P-1783,"Attachment 1 - New Opioid Analgesic Approvals and Outpatient
Utilization of Opioid Analgesics in the United States,
1997 through 2015 - Re: Citizen petition from Public Citizen"
0900006483f1122a,Other,FDA-2019-P-1783-0005,FDA-2019-P-1783,Response Letter ( Denial) from FDA CDER to Public Citizen's Health Research Group
0900006483baee9b,Other,FDA-2019-P-1783-0002,FDA-2019-P-1783,Acknowledgment Letter from FDA DDM to Public Citizen
0900006483bae3e2,Other,FDA-2019-P-1783-0001,FDA-2019-P-1783,Citizen Petition from Public Citizen
0900006480fa13a3,Other,FDA-2010-P-0644-0009,FDA-2010-P-0644,Interim Response to International Packaged Ice Association - Letter
0900006480bbad1a,Supporting & Related Material,FDA-2010-P-0644-0004,FDA-2010-P-0644,"Appendix 3 - ""NACS Daily Community Columns Foodservice"" -  [International Packaged Ice Association (IPIA) - Citizen Petition]"
0900006480bbad19,Supporting & Related Material,FDA-2010-P-0644-0003,FDA-2010-P-0644,"Appendix 2 - ""Department of Public Health and Human Serices, Chapter 110 Subchapter 8 Drinking Water and Ice"" -  [International Packaged Ice Association (IPIA) - Citizen Petition]"
0900006480bbad1c,Supporting & Related Material,FDA-2010-P-0644-0006,FDA-2010-P-0644,"Appendix 5 - ""Department of Defense Standard Practice, Sanitation Requirements for Food Establishments"" -  [International Packaged Ice Association (IPIA) - Citizen Petition]"
0900006480bbad17,Other,FDA-2010-P-0644-0001,FDA-2010-P-0644,International Packaged Ice Association (IPIA) - Citizen Petition
0900006480bbad1b,Supporting & Related Material,FDA-2010-P-0644-0005,FDA-2010-P-0644,"Appendix 4 - ""99-Manurfacture and Storage of Ice in Puerto Rico"" -  [International Packaged Ice Association (IPIA) - Citizen Petition]"
0900006480bbad1d,Supporting & Related Material,FDA-2010-P-0644-0007,FDA-2010-P-0644,"Appendix 6 - ""Amendment of Solicitation/Modification of Contact...."" -  [International Packaged Ice Association (IPIA) - Citizen Petition]"
090000648148763c,Other,FDA-2010-P-0644-0010,FDA-2010-P-0644,International Packaged Ice Association - Supplement
0900006480bbad18,Supporting & Related Material,FDA-2010-P-0644-0002,FDA-2010-P-0644,"Appendix 1 - ""State of Florida Regulations for Packaged Ice Dealers"" - [International Packaged Ice Association (IPIA) - Citizen Petition]"
0900006480bbad3d,Other,FDA-2010-P-0644-0008,FDA-2010-P-0644,Acknowledgement Letter to International Packaged Ice Association (IPIA)
09000064839baa33,Other,FDA-2018-P-4832-0001,FDA-2018-P-4832,Citizen Petition from Goodwin Procter LLP (on behalf of Amneal Pharmaceuticals LLC
09000064839bad14,Other,FDA-2018-P-4832-0002,FDA-2018-P-4832,Acknowledgment Letter from FDA DDM to Goodwin Procter LLP
0900006483d1e951,Other,FDA-2018-P-4832-0004,FDA-2018-P-4832,Interim Response Letter from FDA CDER to Goodwin Procter LLP
09000064811bb825,Other,FDA-2012-P-0747-0003,FDA-2012-P-0747,"Interim Response to Leroy Leslie Hamilton, Ph.D. - Letter"
090000648108a992,Other,FDA-2012-P-0747-0002,FDA-2012-P-0747,"Acknowledgement Letter to Leroy Leslie Hamilton, Ph.D."
090000648121ea1b,Other,FDA-2012-P-0747-0004,FDA-2012-P-0747,"FDA/CDRH to Leroy Leslie Hamilton, Ph.D. - Petition Approval"
090000648108a990,Other,FDA-2012-P-0747-0001,FDA-2012-P-0747,"Leroy Leslie Hamilton, Ph.D. - Citizen Petition"
090000648216523f,Notice,FDA-2012-N-0748-0008,FDA-2012-N-0748,"Agency Information Collection Activities; Proposals, Submissions, and Approvals"
0900006481cb3234,Notice,FDA-2012-N-0748-0007,FDA-2012-N-0748,"Agency Information Collection Activities; Proposed Collection;
Submission for Office of Management and Budget Review; Guidance for
Industry on Generic Drug User Fee Cover Sheet"
0900006481b152df,Notice,FDA-2012-N-0748-0006,FDA-2012-N-0748,"Agency Information Collection Activities; Proposed Collection;
Comment Request; Guidance for Industry on Generic Drug User Fee
Cover Sheet; Form FDA 3794"
09000064810b1b31,Notice,FDA-2012-N-0748-0001,FDA-2012-N-0748,Agency Information Collection Activities; Proposed Collection Comment Request; Generic Drug User Fee Cover Sheet; Form FDA 3794
090000648115f3c7,Notice,FDA-2012-N-0748-0005,FDA-2012-N-0748,"Agency Information Collection Activities; Proposals, Submissions, and Approvals: Generic Drug User Fee Cover Sheet"
090000648221526e,Supporting & Related Material,FDA-2016-P-2782-0004,FDA-2016-P-2782,Exhibit 2 re Request the Commissioner of FDA to require any ANDA applicant who cites Ciprodex as the RLD to establish bioequivalence by performing in vivo clinical endpoint studies
09000064824ba07b,Other,FDA-2016-P-2782-0031,FDA-2016-P-2782,Citizen Petition Partial Approval and Denial Response from FDA CDER to Novartis Pharmaceuticals Ophthalmology
09000064822150e5,Supporting & Related Material,FDA-2016-P-2782-0019,FDA-2016-P-2782,Exhibit 17 re Request the Commissioner of FDA to require any ANDA applicant who cites Ciprodex as the RLD to establish bioequivalence by performing in vivo clinical endpoint studies
09000064822150ec,Supporting & Related Material,FDA-2016-P-2782-0025,FDA-2016-P-2782,Exhibit 23 re Request the Commissioner of FDA to require any ANDA applicant who cites Ciprodex as the RLD to establish bioequivalence by performing in vivo clinical endpoint studies
09000064822151b8,Other,FDA-2016-P-2782-0001,FDA-2016-P-2782,"Citizen Petition from Alcon Pharmaceuticals, Ltd. (Novartis Pharmaceuticals Corporation)"
09000064822150e0,Supporting & Related Material,FDA-2016-P-2782-0014,FDA-2016-P-2782,Exhibit 12 re Request the Commissioner of FDA to require any ANDA applicant who cites Ciprodex as the RLD to establish bioequivalence by performing in vivo clinical endpoint studies
0900006482215270,Supporting & Related Material,FDA-2016-P-2782-0006,FDA-2016-P-2782,Exhibit 4 re Request the Commissioner of FDA to require any ANDA applicant who cites Ciprodex as the RLD to establish bioequivalence by performing in vivo clinical endpoint studies
0900006482215271,Supporting & Related Material,FDA-2016-P-2782-0007,FDA-2016-P-2782,Exhibit 5 re Request the Commissioner of FDA to require any ANDA applicant who cites Ciprodex as the RLD to establish bioequivalence by performing in vivo clinical endpoint studies
0900006482215274,Supporting & Related Material,FDA-2016-P-2782-0010,FDA-2016-P-2782,Exhibit 8 re Request the Commissioner of FDA to require any ANDA applicant who cites Ciprodex as the RLD to establish bioequivalence by performing in vivo clinical endpoint studies
09000064822150e2,Supporting & Related Material,FDA-2016-P-2782-0016,FDA-2016-P-2782,Exhibit 14 re Request the Commissioner of FDA to require any ANDA applicant who cites Ciprodex as the RLD to establish bioequivalence by performing in vivo clinical endpoint studies
09000064822150e8,Supporting & Related Material,FDA-2016-P-2782-0022,FDA-2016-P-2782,Exhibit 20 re Request the Commissioner of FDA to require any ANDA applicant who cites Ciprodex as the RLD to establish bioequivalence by performing in vivo clinical endpoint studies
0900006482215217,Supporting & Related Material,FDA-2016-P-2782-0003,FDA-2016-P-2782,Exhibit 1 re Request the Commissioner of FDA to require any ANDA applicant who cites Ciprodex as the RLD to establish bioequivalence by performing in vivo clinical endpoint studies
0900006482215272,Supporting & Related Material,FDA-2016-P-2782-0008,FDA-2016-P-2782,Exhibit 6 re Request the Commissioner of FDA to require any ANDA applicant who cites Ciprodex as the RLD to establish bioequivalence by performing in vivo clinical endpoint studies
0900006482215273,Supporting & Related Material,FDA-2016-P-2782-0009,FDA-2016-P-2782,Exhibit 7 re Request the Commissioner of FDA to require any ANDA applicant who cites Ciprodex as the RLD to establish bioequivalence by performing in vivo clinical endpoint studies
090000648221526f,Supporting & Related Material,FDA-2016-P-2782-0005,FDA-2016-P-2782,Exhibit 3 re Request the Commissioner of FDA to require any ANDA applicant who cites Ciprodex as the RLD to establish bioequivalence by performing in vivo clinical endpoint studies
0900006482215276,Supporting & Related Material,FDA-2016-P-2782-0012,FDA-2016-P-2782,Exhibit 10 re Request the Commissioner of FDA to require any ANDA applicant who cites Ciprodex as the RLD to establish bioequivalence by performing in vivo clinical endpoint studies
09000064822150e4,Supporting & Related Material,FDA-2016-P-2782-0018,FDA-2016-P-2782,Exhibit 16 re Request the Commissioner of FDA to require any ANDA applicant who cites Ciprodex as the RLD to establish bioequivalence by performing in vivo clinical endpoint studies
09000064822150e6,Supporting & Related Material,FDA-2016-P-2782-0020,FDA-2016-P-2782,Exhibit 18 re Request the Commissioner of FDA to require any ANDA applicant who cites Ciprodex as the RLD to establish bioequivalence by performing in vivo clinical endpoint studies
09000064822150eb,Supporting & Related Material,FDA-2016-P-2782-0024,FDA-2016-P-2782,Exhibit 22 re Request the Commissioner of FDA to require any ANDA applicant who cites Ciprodex as the RLD to establish bioequivalence by performing in vivo clinical endpoint studies
09000064822150ed,Supporting & Related Material,FDA-2016-P-2782-0026,FDA-2016-P-2782,Exhibit 24 re Request the Commissioner of FDA to require any ANDA applicant who cites Ciprodex as the RLD to establish bioequivalence by performing in vivo clinical endpoint studies
09000064822150f0,Supporting & Related Material,FDA-2016-P-2782-0029,FDA-2016-P-2782,Exhibit 27 re Request the Commissioner of FDA to require any ANDA applicant who cites Ciprodex as the RLD to establish bioequivalence by performing in vivo clinical endpoint studies
09000064822150f1,Supporting & Related Material,FDA-2016-P-2782-0030,FDA-2016-P-2782,Exhibit 28 re Request the Commissioner of FDA to require any ANDA applicant who cites Ciprodex as the RLD to establish bioequivalence by performing in vivo clinical endpoint studies
09000064822150e3,Supporting & Related Material,FDA-2016-P-2782-0017,FDA-2016-P-2782,Exhibit 15 re Request the Commissioner of FDA to require any ANDA applicant who cites Ciprodex as the RLD to establish bioequivalence by performing in vivo clinical endpoint studies
09000064822150e7,Supporting & Related Material,FDA-2016-P-2782-0021,FDA-2016-P-2782,Exhibit 19 re Request the Commissioner of FDA to require any ANDA applicant who cites Ciprodex as the RLD to establish bioequivalence by performing in vivo clinical endpoint studies
09000064822150ee,Supporting & Related Material,FDA-2016-P-2782-0027,FDA-2016-P-2782,Exhibit 25 re Request the Commissioner of FDA to require any ANDA applicant who cites Ciprodex as the RLD to establish bioequivalence by performing in vivo clinical endpoint studies
0900006482532adc,Supporting & Related Material,FDA-2017-P-1990-0005,FDA-2017-P-1990,"Reference 2 Improvement of Constipation by a Small Amount of Xylooligosaccharides re Citizen Petition from AIDP, Inc"
0900006482532ae0,Supporting & Related Material,FDA-2017-P-1990-0009,FDA-2017-P-1990,"Reference 6 Effect of Xylooligosaccharide Intake on Severe Constipation in Pregnant Women re Citizen Petition from AIDP, Inc"
09000064834111b3,Other,FDA-2017-P-1990-0019,FDA-2017-P-1990,FDA-2017-P-1990-AIDP - Addendum
0900006483074d38,Supporting & Related Material,FDA-2017-P-1990-0018,FDA-2017-P-1990,A supplemental submission to previous Citizen Petition FDA-2017-P-1990
0900006482532add,Supporting & Related Material,FDA-2017-P-1990-0006,FDA-2017-P-1990,"Reference 3 - Translation of Reference 2 Article - Improvement of Constipation by a Small Amount of Xylooligosaccharides re Citizen Petition from AIDP, Inc"
090000648253274b,Other,FDA-2017-P-1990-0002,FDA-2017-P-1990,"Acknowledgement Letter from FDA DDM to AIDP, Inc."
0900006482532ae3,Supporting & Related Material,FDA-2017-P-1990-0012,FDA-2017-P-1990,"Reference 9 Effects of Xylooligosaccharide in Type 2 Diabetes Mellitus re Citizen Petition from AIDP, Inc"
0900006482532ae8,Supporting & Related Material,FDA-2017-P-1990-0013,FDA-2017-P-1990,"Reference 10 Effects of Xylooligosaccharide on Fecal Bifdobacteria, Lactic Acid and Lipid Metabolism re Citizen Petition from AIDP, Inc"
0900006482532adb,Supporting & Related Material,FDA-2017-P-1990-0004,FDA-2017-P-1990,"Reference 1 Xylo-oligosaccharides alone or in synbiotic combination re Citizen Petition from AIDP, Inc"
09000064839346e9,Other,FDA-2017-P-1990-0021,FDA-2017-P-1990,Letter from FDA CFSAN to AIDP Inc.
0900006482bc3323,Other,FDA-2017-P-1990-0016,FDA-2017-P-1990,Interim Response Letter from FDA to AIDP
09000064838f1ae8,Other,FDA-2017-P-1990-0020,FDA-2017-P-1990,Letter from FDA CFSAN to AIDP Inc.
0900006482532749,Other,FDA-2017-P-1990-0001,FDA-2017-P-1990,"Citizen Petition from AIDP, Inc"
0900006482532ada,Supporting & Related Material,FDA-2017-P-1990-0003,FDA-2017-P-1990,"Reference List re Citizen Petition from AIDP, Inc"
0900006482532ade,Supporting & Related Material,FDA-2017-P-1990-0007,FDA-2017-P-1990,"Reference 4 Effect of xylooligosaccharide-sugar mixture on defecation re Citizen Petition from AIDP, Inc"
0900006482532adf,Supporting & Related Material,FDA-2017-P-1990-0008,FDA-2017-P-1990,"Reference 5 Trasnlation of Reference 4 article -Effect of xylooligosaccharide-sugar mixture on defecation re Citizen Petition from AIDP, Inc"
0900006482532ae1,Supporting & Related Material,FDA-2017-P-1990-0010,FDA-2017-P-1990,"Reference 7 Xyloogosaccharides Improved Intestinal Dysfunction re Citizen Petition from AIDP, Inc"
0900006482532ae2,Supporting & Related Material,FDA-2017-P-1990-0011,FDA-2017-P-1990,"Reference 8 Xylooligosaccharide Increases Bifidobacteria re Citizen Petition from AIDP, Inc"
0900006482532ae9,Supporting & Related Material,FDA-2017-P-1990-0014,FDA-2017-P-1990,"Reference 11 - Translation of Reference 10 article - Effects of Xylooligosaccharide on Fecal Bifdobacteria, Lactic Acid and Lipid Metabolism re Citizen Petition from AIDP, Inc"
0900006482532aea,Supporting & Related Material,FDA-2017-P-1990-0015,FDA-2017-P-1990,"Reference 12 Dietary Intake of Xylooligosaccharides improves the intestinal microbiota, fecal moisture re Citizen Petition from AIDP, Inc"
09000064830745fb,Supporting & Related Material,FDA-2017-P-1990-0017,FDA-2017-P-1990,Supplemental submission of publications  -  re Request that the FDA amend 21 CFR § 101.9 (c)(6)(i) to recognize xylooligosaccharides as a dietary fiber for the purposes of nutrition labeling.
09000064817030da,Other,FDA-2014-P-0646-0001,FDA-2014-P-0646,Citizen Petition from Kamat Pharmatech
0900006482214fbd,Supporting & Related Material,FDA-2014-P-0646-0010,FDA-2014-P-0646,Draft Proposed Trazodone Oral Solution Prescribing Information re Supplement from Kamat Pharmatech
0900006482d8388b,Other,FDA-2014-P-0646-0011,FDA-2014-P-0646,Letter from Kamat Pharmatech to FDA DDM
090000648199a04b,Supporting & Related Material,FDA-2014-P-0646-0004,FDA-2014-P-0646,Citizen Petition from Kamat Pharmatech re Letter from Kamat Pharmatech to FDA/DDM
090000648199a275,Other,FDA-2014-P-0646-0002,FDA-2014-P-0646,Letter from Kamat Pharmatech to FDA/DDM
0900006482214e28,Other,FDA-2014-P-0646-0007,FDA-2014-P-0646,Supplement from Kamat Pharmatech
09000064817030de,Other,FDA-2014-P-0646-0005,FDA-2014-P-0646,Acknowledgement Letter From FDA DDM to Kamat Pharmatech
0900006482214e2a,Supporting & Related Material,FDA-2014-P-0646-0009,FDA-2014-P-0646,Trazodone RLD Prescribing Information re Supplement from Kamat Pharmatech
0900006482214e29,Supporting & Related Material,FDA-2014-P-0646-0008,FDA-2014-P-0646,Kamat Pharmatech's Suitability Petition Revision
09000064821ddb39,Other,FDA-2014-P-0646-0006,FDA-2014-P-0646,Letter from Kamat Pharmatech to FDA
090000648199a464,Other,FDA-2014-P-0646-0003,FDA-2014-P-0646,Letter from Kamat Pharmatech to FDA/DDM
09000064817032a0,Other,FDA-2014-P-0647-0002,FDA-2014-P-0647,Acknowledgement Letter from FDA DDM to Kamat Pharmatech
09000064819ad0bf,Supporting & Related Material,FDA-2014-P-0647-0004,FDA-2014-P-0647,Citizen Petition from Kamat Pharmatech re Letter from Kamat Pharmatech to FDA/DDM
09000064819ad0bd,Other,FDA-2014-P-0647-0003,FDA-2014-P-0647,Letter from Kamat Pharmatech to FDA/DDM
090000648170329e,Other,FDA-2014-P-0647-0001,FDA-2014-P-0647,Citizen Petition From Kamat Pharmatech
0900006481922959,Other,FDA-2014-P-1882-0001,FDA-2014-P-1882,Citizen Petition From Isabella Guajardo
090000648192298a,Other,FDA-2014-P-1882-0002,FDA-2014-P-1882,Acknowledgement Letter From FDA DDM to Isabella Guajardo
090000648330e2d6,Other,FDA-2016-P-1246-0007,FDA-2016-P-1246,Response Letter from FDA CDER to the Working Group on Women's Health and Well-Being in Menopause and The North American Menopause Society
0900006481fd70cf,Supporting & Related Material,FDA-2016-P-1246-0004,FDA-2016-P-1246,Attachment 1 Why the product labeling for low-dose vaginal estrogen should be changed re Citizen Petition  from the Working Group on Women's Health and Well-Being in Menopause and The North American Menopause Society
0900006481fae7e8,Other,FDA-2016-P-1246-0002,FDA-2016-P-1246,Acknowledgement Letter from FDA DDM to the Working Group on Women's Health and Well-Being in Menopause and The North American Menopause Society
0900006481fd70ce,Supporting & Related Material,FDA-2016-P-1246-0003,FDA-2016-P-1246,Attachment 2 - 050916 NAMS Petition Signatures re Citizen Petition  from the Working Group on Women's Health and Well-Being in Menopause and The North American Menopause Society
0900006481faea92,Other,FDA-2016-P-1246-0001,FDA-2016-P-1246,Citizen Petition  from the Working Group on Women's Health and Well-Being in Menopause and The North American Menopause Society
0900006482033b07,Other,FDA-2016-P-1246-0005,FDA-2016-P-1246,Correction from The North American Menopause Society
0900006481cd0f79,Supporting & Related Material,FDA-2015-P-3778-0009,FDA-2015-P-3778,Appendix 7  Table D‐2 ANSI-AAMI-IEC 60601‐1 Third edition re Citizen Petition from Orthofix
0900006481cd11dd,Supporting & Related Material,FDA-2015-P-3778-0007,FDA-2015-P-3778,Appendix 5  Guidance for Industry “Alternative to Certain Prescription Device Labeling Requirements 1-21-2000 re Citizen Petition from Orthofix
0900006481cd11d4,Other,FDA-2015-P-3778-0002,FDA-2015-P-3778,"Acknowledgement Letter from FDA DDM to Orthofix, Inc."
0900006481f7d367,Other,FDA-2015-P-3778-0012,FDA-2015-P-3778,Interim Response to Orthofix
0900006481cd11db,Supporting & Related Material,FDA-2015-P-3778-0005,FDA-2015-P-3778,Appendix 3  FDA Public Workshop Presentation “Use of Symbols on Medical Device Labeling” re Citizen Petition from Orthofix
0900006482155681,Other,FDA-2015-P-3778-0013,FDA-2015-P-3778,Withdrawal from Orthofix Inc.
0900006481cd0f78,Supporting & Related Material,FDA-2015-P-3778-0008,FDA-2015-P-3778,Appendix 6  ASTM F2503‐13 Standard Practice for Marking Medical Devices and Other Items for Safety in the Magnetic Resonance Environment re Citizen Petition from Orthofix
0900006481f68908,Other,FDA-2015-P-3778-0011,FDA-2015-P-3778,Interim Response to Orthofix
0900006481cd0f7a,Supporting & Related Material,FDA-2015-P-3778-0010,FDA-2015-P-3778,Appendix 8  Use of Certain Symbols in Labeling” FDA Docket FDA‐2013‐N‐0125 re Citizen Petition from Orthofix
0900006481cd11dc,Supporting & Related Material,FDA-2015-P-3778-0006,FDA-2015-P-3778,Appendix 4  Guidance for Industry and FDA Staff- Use of Symbols on Labels 11-30-2004 re Citizen Petition from Orthofix
0900006481cd11d9,Supporting & Related Material,FDA-2015-P-3778-0003,FDA-2015-P-3778,"Appendix 1 Federal Register Volume 78, Number 76 at page 23508‐23513 April 19, 2013 re Citizen Petition from Orthofix"
0900006481cd11da,Supporting & Related Material,FDA-2015-P-3778-0004,FDA-2015-P-3778,Appendix 2  ISO 15223‐1:2012 re Citizen Petition from Orthofix
0900006481cd0eda,Other,FDA-2015-P-3778-0001,FDA-2015-P-3778,Citizen Petition from Orthofix
09000064823048ed,Other,FDA-2016-D-3329-0001,FDA-2016-D-3329,Guidance for FDA Staff Compliance Policy Guide Section 101.100 FDA Considerations for Recommending Charges Under 21 U.S.C. §331(a) or (d) for Causing the Introduction of Violative Products into Interstate Commerce
0900006483716433,Supporting & Related Material,FDA-2018-P-3535-0003,FDA-2018-P-3535,Appendix 1 re Petition from Norbrook Laboratories Limited
0900006483716435,Supporting & Related Material,FDA-2018-P-3535-0005,FDA-2018-P-3535,Appendix 3 re Petition from Norbrook Laboratories Limited
0900006483716758,Other,FDA-2018-P-3535-0001,FDA-2018-P-3535,Petition from Norbrook Laboratories Limited
09000064838d245a,Other,FDA-2018-P-3535-0006,FDA-2018-P-3535,Amendment to Suitability Petition FDA-2018-P-3535: Pimobendan Oral Solution
0900006483716434,Supporting & Related Material,FDA-2018-P-3535-0004,FDA-2018-P-3535,Appendix 2 re Petition from Norbrook Laboratories Limited
0900006483716431,Other,FDA-2018-P-3535-0002,FDA-2018-P-3535,Acknowledgment Letter from FDA DDM to Norbrook Laboratories Limited
09000064838d689b,Supporting & Related Material,FDA-2018-P-4340-0005,FDA-2018-P-4340,Annex III FK Package Insert (Tigecycline) re Citizen Petition from Freyr Inc.
09000064838d6d4a,Other,FDA-2018-P-4340-0002,FDA-2018-P-4340,Acknowledgment Letter from FDA DDM to Freyr Inc.
09000064838d6411,Other,FDA-2018-P-4340-0001,FDA-2018-P-4340,Citizen Petition from Freyr Inc.
09000064838d6899,Supporting & Related Material,FDA-2018-P-4340-0003,FDA-2018-P-4340,Annex I Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations re Citizen Petition from Freyr Inc.
09000064838d689a,Supporting & Related Material,FDA-2018-P-4340-0004,FDA-2018-P-4340,Annex II Reference Listed Drug Package Insert (Tygacil) re Citizen Petition from Freyr Inc.
090000648367f6d4,Supporting & Related Material,FDA-2018-P-3327-0006,FDA-2018-P-3327,"Attachment 4 re Citizen Petition from Hyman, Phelps & McNamara, PC"
090000648367f6d6,Supporting & Related Material,FDA-2018-P-3327-0008,FDA-2018-P-3327,"Attachment 6 re Citizen Petition from Hyman, Phelps & McNamara, PC"
090000648367eeb5,Other,FDA-2018-P-3327-0001,FDA-2018-P-3327,"Citizen Petition from Hyman, Phelps & McNamara, PC"
090000648367f666,Other,FDA-2018-P-3327-0002,FDA-2018-P-3327,"Acknowledgment Letter from FDA DDM to Hyman, Phelps & McNamara, P.C."
090000648367f6d2,Supporting & Related Material,FDA-2018-P-3327-0004,FDA-2018-P-3327,"Attachment 2 re Citizen Petition from Hyman, Phelps & McNamara, PC"
090000648367f6d3,Supporting & Related Material,FDA-2018-P-3327-0005,FDA-2018-P-3327,"Attachment 3 re Citizen Petition from Hyman, Phelps & McNamara, PC"
090000648367f6d1,Supporting & Related Material,FDA-2018-P-3327-0003,FDA-2018-P-3327,"Attachment 1 re Citizen Petition from Hyman, Phelps & McNamara, PC"
090000648367f6d5,Supporting & Related Material,FDA-2018-P-3327-0007,FDA-2018-P-3327,"Attachment 5 re Citizen Petition from Hyman, Phelps & McNamara, PC"
090000648367f6d7,Supporting & Related Material,FDA-2018-P-3327-0009,FDA-2018-P-3327,"Attachment 7 re Citizen Petition from Hyman, Phelps & McNamara, PC"
09000064849a8125,Other,FDA-2020-P-1506-0009,FDA-2020-P-1506,Partial Interim Response from FDA CVM to Daniel Waltz
09000064846dc535,Supporting & Related Material,FDA-2020-P-1506-0005,FDA-2020-P-1506,FOOTNOTES 19-24 re Citizen Petition from Animal Legal Defense Fund
09000064846d4bff,Other,FDA-2020-P-1506-0002,FDA-2020-P-1506,Acknowledgment Letter from Animal Legal Defense Fund
09000064846dc538,Supporting & Related Material,FDA-2020-P-1506-0008,FDA-2020-P-1506,FOOTNOTES 69-83 re Citizen Petition from Animal Legal Defense Fund
09000064846dc536,Supporting & Related Material,FDA-2020-P-1506-0006,FDA-2020-P-1506,FOOTNOTES 25-47 re Citizen Petition from Animal Legal Defense Fund
09000064846dc537,Supporting & Related Material,FDA-2020-P-1506-0007,FDA-2020-P-1506,FOOTNOTES 48-68 re Citizen Petition from Animal Legal Defense Fund
09000064846cf29e,Other,FDA-2020-P-1506-0001,FDA-2020-P-1506,Citizen Petition from Animal Legal Defense Fund
09000064846dc383,Supporting & Related Material,FDA-2020-P-1506-0004,FDA-2020-P-1506,FOOTNOTES 16-19 re Citizen Petition from Animal Legal Defense Fund
09000064846dc382,Supporting & Related Material,FDA-2020-P-1506-0003,FDA-2020-P-1506,FOOTNOTES 4-15 re Citizen Petition from Animal Legal Defense Fund
09000064839e9fd2,Other,FDA-2019-P-0175-0001,FDA-2019-P-0175,"Citizen Petition  from Fresenius Kabi USA, LLC"
09000064839e9fcf,Other,FDA-2019-P-0175-0002,FDA-2019-P-0175,"Acknowledgment Letter from FDA DDM to  Fresenius Kabi USA, LLC"
090000648229c201,Supporting & Related Material,FDA-2016-P-3162-0003,FDA-2016-P-3162,Attachment 1 Orange Book Drug Products Listing re Citizen Petition from ANDA Consultants
090000648229c1ff,Other,FDA-2016-P-3162-0002,FDA-2016-P-3162,Acknowledgement Letter from FDA DDM to ANDA Consultants
090000648249369d,Other,FDA-2016-P-3162-0004,FDA-2016-P-3162,Withdrawal from ANDA Consultants
090000648229c1fd,Other,FDA-2016-P-3162-0001,FDA-2016-P-3162,Citizen Petition from ANDA Consultants
09000064849f3df1,Supporting & Related Material,FDA-2021-P-0083-0003,FDA-2021-P-0083,"Attachment 1 re Suitability Petition from Hyman, Phelps & McNamara PC"
09000064849f3ebd,Supporting & Related Material,FDA-2021-P-0083-0005,FDA-2021-P-0083,"Attachment 3 re Suitability Petition from Hyman, Phelps & McNamara PC"
09000064849f3df2,Supporting & Related Material,FDA-2021-P-0083-0004,FDA-2021-P-0083,"Attachment 2 re Suitability Petition from Hyman, Phelps & McNamara PC"
09000064849f3ded,Other,FDA-2021-P-0083-0002,FDA-2021-P-0083,"Acknowledgment Letter from FDA DMS to Hyman, Phelps & McNamara PC"
09000064849f3dec,Other,FDA-2021-P-0083-0001,FDA-2021-P-0083,"Suitability Petition from Hyman, Phelps & McNamara PC"
090000648485ac5f,Other,FDA-2020-P-1881-0002,FDA-2020-P-1881,Acknowledgment Letter from FDA DMS to The Weinberg Group
0900006484a6b556,Other,FDA-2020-P-1881-0003,FDA-2020-P-1881,Interim Response from FDA CDER to The Weinberg Group a ProPharma Group Company
0900006484a95e90,Other,FDA-2020-P-1881-0005,FDA-2020-P-1881,Letter to The Weinberg Group from FDA CDER
090000648485a88c,Other,FDA-2020-P-1881-0001,FDA-2020-P-1881,Citizen Petition from The Weinberg Group
0900006484a93000,Notice,FDA-2020-P-1881-0004,FDA-2020-P-1881,"Determination That SERENTIL (Mesoridazine Besylate) Tablets, 10 Milligrams, 25 Milligrams, 50 Milligrams, and 100 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
0900006484a67d67,Other,FDA-2021-P-0268-0003,FDA-2021-P-0268,Supplement from Foley Hoag LLP
0900006484a5fab8,Other,FDA-2021-P-0268-0001,FDA-2021-P-0268,"Citizen Petition from Foley Hoag, LLP"
0900006484a5fabb,Other,FDA-2021-P-0268-0002,FDA-2021-P-0268,"Acknowledgment Letter from FDA DMS to Foley Hoag, LLP"
0900006484cb33aa,Other,FDA-2021-P-0268-0004,FDA-2021-P-0268,"Interim Response from FDA CDER to Foley Hoag, LLP"
090000648042b382,Notice,FDA-2007-N-0267-0002,FDA-2007-N-0267,FDA
090000648042b383,Notice,FDA-2007-N-0267-0001,FDA-2007-N-0267,FDA
09000064814413c3,Other,FDA-2004-P-0401-0004,FDA-2004-P-0401,FDA/CDER to FDA/DDM - Memorandum
09000064804744d6,Other,FDA-2004-P-0401-0002,FDA-2004-P-0401,"HFA-305 to Andrx Pharmaceuticals, Inc."
09000064804744d0,Other,FDA-2004-P-0401-0001,FDA-2004-P-0401,"HFA-305 to Andrx Pharmaceuticals, Inc."
09000064804744da,Other,FDA-2004-P-0401-0003,FDA-2004-P-0401,"HFD-005 to Foley & Lardner, LLP"
090000648048633c,Other,FDA-2005-P-0517-0618,FDA-2005-P-0517,Wyeth (Wiley Rein & Fielding LLP) - Citizen Petition
090000648048634c,Other,FDA-2005-P-0517-0228,FDA-2005-P-0517,Acknowledgement Letter to Wyeth (Wiley Rein & Fielding LLP)
0900006480499293,Other,FDA-2005-P-0517-0306,FDA-2005-P-0517,See FDA-2005-P-0517-0028
0900006480499294,Other,FDA-2005-P-0517-0028,FDA-2005-P-0517,"FDA Center for Drug Evaluation and Research to Wiley, Rein, & Felding, LLP"
09000064804862b2,Supporting & Related Material,FDA-2005-P-0517-0001,FDA-2005-P-0517,Acknowledgement Letter to Wyeth (Wiley Rein & Fielding LLP) re FDA-2005-P-0517-0228
0900006480486387,Supporting & Related Material,FDA-2005-P-0517-0646,FDA-2005-P-0517,International Academy of Compounding Pharmacists (IACP) - Comment re FDA-2005-P-0517-0629
090000648049c0bd,Other,FDA-2005-P-0517-0649,FDA-2005-P-0517,FDA Office of Regulatory Affairs to Wyeth (Wiley Rein & Fielding LLP) - Partial Petition Approval/Denial
0900006480a421e1,Notice,FDA-2009-N-0483-0001,FDA-2009-N-0483,Agency Information Collection Activities; Proposed Collection; Comment Request; Medical Device User Fee Cover Sheet; Form FDA 3601
0900006480a7f651,Notice,FDA-2009-N-0483-0002,FDA-2009-N-0483,Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Medical Device User Fee Cover Sheet-Form FDA 3601
0900006480ae71a4,Notice,FDA-2009-N-0483-0003,FDA-2009-N-0483,"Agency Information Collection Activities; Proposals, Submissions, and Approvals: Medical Device User Fee Cover Sheet (Form FDA 3601)"
0900006480558358,Notice,FDA-1995-P-0003-0001,FDA-1995-P-0003,FDA
0900006480558359,Other,FDA-1995-P-0003-0003,FDA-1995-P-0003,Indiana Medical Device Mfg Council - Citizen Petition
0900006480558364,Notice,FDA-1995-P-0003-0002,FDA-1995-P-0003,FDA
0900006481cde6a0,Supporting & Related Material,FDA-2015-P-3876-0002,FDA-2015-P-3876,Press Release - EPA Will Propose Rule to Protect Waterways by Reducing Mercury from Dental Offices re Citizen Petition from World Alliance for Mercury-Free Dentistry
0900006481cde6a3,Supporting & Related Material,FDA-2015-P-3876-0003,FDA-2015-P-3876,"Letter to the Honorable John Kerry, Secretary of State re Citizen Petition from World Alliance for Mercury-Free Dentistry"
0900006481cde6ce,Supporting & Related Material,FDA-2015-P-3876-0004,FDA-2015-P-3876,State Department Urged to Press FDA to Curb Mercury Dental Fillings re Citizen Petition from World Alliance for Mercury-Free Dentistry
0900006481cde6d0,Supporting & Related Material,FDA-2015-P-3876-0006,FDA-2015-P-3876,Minamata Convention  on Mercury (2013) re Citizen Petition from World Alliance for Mercury-Free Dentistry
0900006481cde6cf,Supporting & Related Material,FDA-2015-P-3876-0005,FDA-2015-P-3876,The Real Cost of Dental Mercury re Citizen Petition from World Alliance for Mercury-Free Dentistry
0900006481cde4c4,Other,FDA-2015-P-3876-0001,FDA-2015-P-3876,Citizen Petition from World Alliance for Mercury-Free Dentistry
0900006481cde6d2,Supporting & Related Material,FDA-2015-P-3876-0007,FDA-2015-P-3876,"Changing Patterns in the Use, Recycling, and Material Substitution of Mercury in the United States (2013) re Citizen Petition from World Alliance for Mercury-Free Dentistry"
0900006481f7825f,Other,FDA-2015-P-3876-0009,FDA-2015-P-3876,Interim Response to World Alliance for Mercury-Free Dentistry
0900006481cdeba5,Other,FDA-2015-P-3876-0008,FDA-2015-P-3876,Acknowledgement Letter from FDA DDM to World Alliance for Mercury-Free Dentistry
0900006483bdc637,Supporting & Related Material,FDA-2019-P-1911-0004,FDA-2019-P-1911,Appendix II - Akeo Paper - Japanese and English Translation re: Acknowledgment Letter from FDA DDM to Keller and Heckman LLP
0900006483bdc5c9,Other,FDA-2019-P-1911-0001,FDA-2019-P-1911,"Citizen Petition from Keller and Heckman LLP on behalf of Nexira, Ingredion and TIC Gums, Alland and Robert, Importers Service Corporation"
09000064841096fd,Other,FDA-2019-P-1911-0007,FDA-2019-P-1911,Interim Response Letter from FDA CFSAN to Keller and Heckman LLP
0900006483bdc4df,Other,FDA-2019-P-1911-0002,FDA-2019-P-1911,Acknowledgment Letter from FDA DDM to Keller and Heckman LLP
0900006484325a5e,Other,FDA-2019-P-1911-0008,FDA-2019-P-1911,Final Response Letter from FDA CFSAN to Keller and Heckman LLP
0900006483bdc636,Supporting & Related Material,FDA-2019-P-1911-0003,FDA-2019-P-1911,Appendix I - Manufacturing Process of Gum Acacia re: Acknowledgment Letter from FDA DDM to Keller and Heckman LLP
0900006483bdc638,Supporting & Related Material,FDA-2019-P-1911-0005,FDA-2019-P-1911,Appendix III - University of Minnesota Study (2019) re: Acknowledgment Letter from FDA DDM to Keller and Heckman LLP
0900006483bdc639,Supporting & Related Material,FDA-2019-P-1911-0006,FDA-2019-P-1911,Appendix IV - GI Labs Study (2019)  re: Acknowledgment Letter from FDA DDM to Keller and Heckman LLP
0900006484dbcb6f,Other,FDA-2021-P-1082-0001,FDA-2021-P-1082,Suitability Petition from HYMAN PHELPS MCNAMARA P.C.
0900006484dbd0f0,Other,FDA-2021-P-1082-0002,FDA-2021-P-1082,Acknowledgment Letter from FDA DMS to HYMAN PHELPS MCNAMARA PC
09000064846c79c1,Other,FDA-2019-P-5833-0008,FDA-2019-P-5833,"Letter from FDA CDER to Archway Apothecary, LLC"
0900006484202825,Supporting & Related Material,FDA-2019-P-5833-0005,FDA-2019-P-5833,"Attachment 3 - A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD re: Citizen Petition from Archway Apothecary, LLC"
0900006484202826,Supporting & Related Material,FDA-2019-P-5833-0006,FDA-2019-P-5833,"Attachment 4 - Archway Apothecary NAD Potency Test Results re: Citizen Petition from Archway Apothecary, LLC."
0900006484202823,Supporting & Related Material,FDA-2019-P-5833-0003,FDA-2019-P-5833,"Attachment 1- Intravenous Administration of Nicotinamide Adenine Dinucleotide Significantly Reduces Self Report Craving Ratings Associated with Opiate and Alcohol Withdrawal re: Citizen Petition from Archway Apothecary, LLC"
0900006484202827,Supporting & Related Material,FDA-2019-P-5833-0007,FDA-2019-P-5833,"Attachment 5 - Beta-Nicotinamide Adenine Dnucleotide (NAD) Method Validation Final Report re: Citizen Petition from Archway Apothecary, LLC"
0900006484202221,Other,FDA-2019-P-5833-0001,FDA-2019-P-5833,"Citizen Petition from Archway Apothecary, LLC"
090000648420281f,Other,FDA-2019-P-5833-0002,FDA-2019-P-5833,"Acknowledgment Letter from FDA DMS to Archway Apothecary, LLC"
0900006484202824,Supporting & Related Material,FDA-2019-P-5833-0004,FDA-2019-P-5833,"Attachment 2 - Therapeutic Effect of BR+NAD on Opioid and Alcohol Withdrawal: Implications for Clinical Populations RE: Citizen Petition from Archway Apothecary, LLC"
090000648294dcbd,Supporting & Related Material,FDA-2017-P-4352-0005,FDA-2017-P-4352,"Attachment 5 - CDC Guideline for Prescribing Opioids for Chronic Pain-4 re Citizen Petition from  Pharmaceutical Manufacturing Research Services, Inc."
090000648294dcbf,Supporting & Related Material,FDA-2017-P-4352-0007,FDA-2017-P-4352,Attachment 10 - Opioid Abuse in Chronic Pain _ Misconceptions and Mitigation Strategies-3
090000648294e0b5,Supporting & Related Material,FDA-2017-P-4352-0009,FDA-2017-P-4352,"Attachment 12 - CDC, Understanding the Epidemic-1 re Citizen Petition from  Pharmaceutical Manufacturing Research Services, Inc."
090000648294e0ba,Supporting & Related Material,FDA-2017-P-4352-0014,FDA-2017-P-4352,"Attachment 22- NIDA, Overdose Death Rates re Citizen Petition from  Pharmaceutical Manufacturing Research Services, Inc."
090000648294e0b6,Supporting & Related Material,FDA-2017-P-4352-0010,FDA-2017-P-4352,"Attachment 13- CDC, Opioid Overdose-1 re Citizen Petition from  Pharmaceutical Manufacturing Research Services, Inc."
090000648294e0b7,Supporting & Related Material,FDA-2017-P-4352-0011,FDA-2017-P-4352,"Attachment 14 - CDC, Opioid Data Analysis-1 re Citizen Petition from  Pharmaceutical Manufacturing Research Services, Inc."
090000648294e0b9,Supporting & Related Material,FDA-2017-P-4352-0013,FDA-2017-P-4352,"Attachment 18 - Characteristics of Initial Prescription Episodes and Likelihood of Long-Term Opioid Use Supplemental Table re Citizen Petition from  Pharmaceutical Manufacturing Research Services, Inc."
090000648294dcb7,Other,FDA-2017-P-4352-0001,FDA-2017-P-4352,"Citizen Petition from  Pharmaceutical Manufacturing Research Services, Inc."
090000648294dcbe,Supporting & Related Material,FDA-2017-P-4352-0006,FDA-2017-P-4352,"Attachment 9 - A Proactive Response to Prescription Opioid Abuse-3 re Citizen Petition from  Pharmaceutical Manufacturing Research Services, Inc."
090000648294e0b4,Supporting & Related Material,FDA-2017-P-4352-0008,FDA-2017-P-4352,"Attachment 11- The Promotion and Marketing of OxyContin Commercial Triumph, Public Health Tragedy-1 re Citizen Petition from  Pharmaceutical Manufacturing Research Services, Inc."
0900006482d155a7,Other,FDA-2017-P-4352-0017,FDA-2017-P-4352,Petition Denial from FDA CDER to E. Thompson
090000648294dcb9,Other,FDA-2017-P-4352-0002,FDA-2017-P-4352,"Acknowledgement Letter from FDA DDM to  Pharmaceutical Manufacturing Research Services, Inc."
090000648294dcbb,Supporting & Related Material,FDA-2017-P-4352-0003,FDA-2017-P-4352,"Attachment 3 - Assessment of Analgesic Treatment of Chronic Pain A Public Workshop Transcripts May 31 2013-2 re Citizen Petition from  Pharmaceutical Manufacturing Research Services, Inc."
090000648294dcbc,Supporting & Related Material,FDA-2017-P-4352-0004,FDA-2017-P-4352,"Attachment 4 - Reducing the Risks of Relief _ The CDC Opioid-Prescribing Guideline re Citizen Petition from  Pharmaceutical Manufacturing Research Services, Inc."
090000648294e0b8,Supporting & Related Material,FDA-2017-P-4352-0012,FDA-2017-P-4352,"Attachment 17- Characteristics of Initial Prescription Episodes and Likelihood of Long-Term Opioid Use-1 re Citizen Petition from  Pharmaceutical Manufacturing Research Services, Inc."
0900006481b72890,Other,FDA-2015-P-2413-0002,FDA-2015-P-2413,"Acknowledgement Letter from FDA DDM to Acura Pharmaceuticals, Inc."
0900006481b7283a,Other,FDA-2015-P-2413-0001,FDA-2015-P-2413,"Citizen Petition from Acura Pharmaceuticals, Inc."
0900006481d86833,Other,FDA-2015-P-2413-0003,FDA-2015-P-2413,"Citizen Petition Denial Response from FDA CDER to Acura Pharmaceuticals, Inc."
090000648427fd4c,Other,FDA-2020-P-0129-0002,FDA-2020-P-0129,"Acknowledgment Letter from FDA DMS to Hyman, Phelps & McNamara, P. C."
090000648427fd4b,Other,FDA-2020-P-0129-0001,FDA-2020-P-0129,"Citizen Petition from Hyman, Phelps & McNamara, P. C."
090000648494ab9b,Other,FDA-2020-P-0129-0004,FDA-2020-P-0129,"Letter from Hyman, Phelps & McNamara, PC"
09000064849583ce,Other,FDA-2020-P-0129-0005,FDA-2020-P-0129,"Withdrawal from Hyman, Phelps & McNamara P.C."
090000648472a159,Other,FDA-2020-P-0129-0003,FDA-2020-P-0129,"Letter from FDA CDER to Hyman, Phelps & McNamara, P. C."
090000648322c949,Other,FDA-2017-P-6745-0008,FDA-2017-P-6745,Supplement from Foley Hoag LLP
0900006482ce1f74,Supporting & Related Material,FDA-2017-P-6745-0004,FDA-2017-P-6745,Exhibit 2 United States Patent for Method for Production of Botulinum Toxin re Citizen Petition from Foley Hoag LLP on behalf of Medytox Inc.
0900006483a33cac,Other,FDA-2017-P-6745-0010,FDA-2017-P-6745,Response Letter from FDA CDER to Foley Hoag LLP
09000064833225c5,Other,FDA-2017-P-6745-0009,FDA-2017-P-6745,Interim Response Letter from FDA CDER to Foley Hoag LLP
0900006482ce20b6,Supporting & Related Material,FDA-2017-P-6745-0006,FDA-2017-P-6745,Exhibit 4 Notarial Certificate from E-Hyun Law Firm and Notary Office re Citizen Petition from Foley Hoag LLP on behalf of Medytox Inc.
0900006482ce20b7,Supporting & Related Material,FDA-2017-P-6745-0007,FDA-2017-P-6745,"Exhibit 5 Earnings Review Report from Korea Investment & Securitties Co., Ltd. re Citizen Petition from Foley Hoag LLP on behalf of Medytox Inc."
0900006482ce1f71,Other,FDA-2017-P-6745-0002,FDA-2017-P-6745,Acknowledgement Letter from FDA DDM to Foley Hoag LLP
0900006482ce1f73,Supporting & Related Material,FDA-2017-P-6745-0003,FDA-2017-P-6745,"Exhibit 1 Declaration of Theresa J. Smith, M.S. re Citizen Petition from Foley Hoag LLP on behalf of Medytox Inc."
0900006482ce1f75,Supporting & Related Material,FDA-2017-P-6745-0005,FDA-2017-P-6745,Exhibit 3 Transcript of text from Geotext Translations re Citizen Petition from Foley Hoag LLP on behalf of Medytox Inc.
0900006482ce1f6f,Other,FDA-2017-P-6745-0001,FDA-2017-P-6745,Citizen Petition from Foley Hoag LLP on behalf of Medytox Inc.
0900006481d7e89a,Supporting & Related Material,FDA-2015-P-4529-0006,FDA-2015-P-4529,Exhibit F Sumant Ramachandra Lessons for the United States: Biosimilar Market Development Worldwide re: Citizen Petition from UAW Retiree Medical Benefits Trust
0900006481d7e3dd,Other,FDA-2015-P-4529-0001,FDA-2015-P-4529,Citizen Petition from UAW Retiree Medical Benefits Trust
0900006481d7e456,Supporting & Related Material,FDA-2015-P-4529-0003,FDA-2015-P-4529,Exhibit A  Kevin Riley Citi on the Impact of Biosimilars and Losing $360 Billion in Revenues re: Citizen Petition from UAW Retiree Medical Benefits Trust
0900006481d7e89b,Supporting & Related Material,FDA-2015-P-4529-0007,FDA-2015-P-4529,Exhibit G Mark McCamish Effect of Naming on Competition and Innovation re: Citizen Petition from UAW Retiree Medical Benefits Trust
0900006481d7e89d,Supporting & Related Material,FDA-2015-P-4529-0009,FDA-2015-P-4529,Exhibit I Transcript from PBS Newshour What's keeping less expensive biologic drugs from the U.S. market? re: Citizen Petition from UAW Retiree Medical Benefits Trust
0900006481fe0138,Other,FDA-2015-P-4529-0011,FDA-2015-P-4529,Interim Response May 19 2016
0900006481d7e89c,Supporting & Related Material,FDA-2015-P-4529-0008,FDA-2015-P-4529,Exhibit H What you need to know about Biosimilar Medicinal Products re: Citizen Petition from UAW Retiree Medical Benefits Trust
0900006481d7e459,Supporting & Related Material,FDA-2015-P-4529-0004,FDA-2015-P-4529,Exhibit B Pfizer to Acquire Hospira re: Citizen Petition from UAW Retiree Medical Benefits Trust
0900006481d7e89f,Supporting & Related Material,FDA-2015-P-4529-0010,FDA-2015-P-4529,Exhibit K Investor Statement on Board Oversight of BIosimilar Issues re: Citizen Petition from UAW Retiree Medical Benefits Trust
09000064820aa053,Other,FDA-2015-P-4529-0012,FDA-2015-P-4529,Petition Denial Letter
0900006481d7e3e4,Other,FDA-2015-P-4529-0002,FDA-2015-P-4529,Acknowledgement Letter from FDA DDM to UAW Retiree Medical Benefits Trust
0900006481d7e45d,Supporting & Related Material,FDA-2015-P-4529-0005,FDA-2015-P-4529,Exhibit D Fernandez and Hurtado Biosimilars: Company Strategies to Capture Value from the Biologics Market re: Citizen Petition from UAW Retiree Medical Benefits Trust
09000064827ded10,Supporting & Related Material,FDA-2017-P-4027-0003,FDA-2017-P-4027,Attachment 1 Annex I - Orange book details - Prednisone Tablets 1 mg
09000064827ded0d,Other,FDA-2017-P-4027-0002,FDA-2017-P-4027,Acknowledgment Letter from FDA DDM  to Strides Pharma Inc.
09000064827de997,Other,FDA-2017-P-4027-0001,FDA-2017-P-4027,Citizen Petition from Strides Pharma Inc
0900006482ce317c,Other,FDA-2017-P-4027-0005,FDA-2017-P-4027,Relisting Notice Meticorten
0900006482cc9ac1,Notice,FDA-2017-P-4027-0004,FDA-2017-P-4027,"Determination That METICORTEN (Prednisone) Tablets, 1 Milligram and 5
Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or
Effectiveness"
09000064849a0b49,Supporting & Related Material,FDA-2020-P-2296-0011,FDA-2020-P-2296,Reference 8. - British National Formulary RE: Citizen Petition from Parenteral Technologies LLC
09000064849a0b54,Supporting & Related Material,FDA-2020-P-2296-0022,FDA-2020-P-2296,Reference 19. - Do Parents give what they Intend -OTC Meds re: Citizen Petition from Parenteral Technologies LLC
09000064849a0b4d,Supporting & Related Material,FDA-2020-P-2296-0015,FDA-2020-P-2296,Reference 12. - Temple Comments to FDA RE: Citizen Petition from Parenteral Technologies LLC
0900006484b3cd5f,Other,FDA-2020-P-2296-0025,FDA-2020-P-2296,"Interim Response Letter from FDA CDER to Parenteral Technologies, LLC"
090000648499cb09,Other,FDA-2020-P-2296-0001,FDA-2020-P-2296,Citizen Petition from Parenteral Technologies LLC
09000064849a0b4e,Supporting & Related Material,FDA-2020-P-2296-0016,FDA-2020-P-2296,Reference 13. - Temple Comparison of Dosign Regimens and Report on Three Legacy Studies
09000064849a0b51,Supporting & Related Material,FDA-2020-P-2296-0019,FDA-2020-P-2296,Reference 16. - Acute Pain Underdosing RE: Citizen Petition from Parenteral Technologies LLC
09000064849a09d1,Supporting & Related Material,FDA-2020-P-2296-0003,FDA-2020-P-2296,References_ PDF_ Citizen Petition_Parenteral Technologies re: Citizen Petition from Parenteral Technologies LLC
09000064849a0b45,Supporting & Related Material,FDA-2020-P-2296-0007,FDA-2020-P-2296,Reference 4. - Evaluation of Aspirin-Acetaminophen Combination RE: Citizen Petition from Parenteral Technologies LLC
09000064849a0b47,Supporting & Related Material,FDA-2020-P-2296-0009,FDA-2020-P-2296,Reference 6. - Windofer A. Vogel RE: Citizen Petition from Parenteral Technologies LLC
09000064849a0b4b,Supporting & Related Material,FDA-2020-P-2296-0013,FDA-2020-P-2296,Reference 10. Temple Pediatric Dosing of Acetaminophen RE: Citizen Petition from Parenteral Technologies LLC
09000064849a0b43,Supporting & Related Material,FDA-2020-P-2296-0005,FDA-2020-P-2296,Reference 2. - Clincial Comparison of Three Antipyretic Agents RE: Citizen Petition from Parenteral Technologies LLC
09000064849a0b46,Supporting & Related Material,FDA-2020-P-2296-0008,FDA-2020-P-2296,Reference 5. - Efficacy and Safety of Acetaminophen vs Ibuprofen RE: Citizen Petition from Parenteral Technologies LLC
09000064849a0b52,Supporting & Related Material,FDA-2020-P-2296-0020,FDA-2020-P-2296,Reference 17. - FDA Briefing Information for the June 29-30 2009 Joint Meeting RE: Citizen Petition from Parenteral Technologies LLC
09000064849a0b4c,Supporting & Related Material,FDA-2020-P-2296-0014,FDA-2020-P-2296,Reference 11. Boston Fever Study - Safety of Acetaminophen and Ibuprofen - Lesko RE: Citizen Petition from Parenteral Technologies LLC
09000064849a0b56,Supporting & Related Material,FDA-2020-P-2296-0024,FDA-2020-P-2296,Reference 21. - Analysis of Liquid medciation Dose Errors made by Parents and Caregivers re: Citizen Petition from Parenteral Technologies LLC
090000648499cb0c,Other,FDA-2020-P-2296-0002,FDA-2020-P-2296,"Acknowledgment Letter from FDA DMS to Parenteral Technologies, LLC"
09000064849a0b4a,Supporting & Related Material,FDA-2020-P-2296-0012,FDA-2020-P-2296,Reference 9. Clinical Pharmacokinetics in Infants and Children RE: Citizen Petition from Parenteral Technologies LLC
09000064849a09d2,Supporting & Related Material,FDA-2020-P-2296-0004,FDA-2020-P-2296,Reference 1.  - US FDA Meeting of the Nonprescrpition Drugs Advisory Committee RE: Citizen Petition from Parenteral Technologies LLC
09000064849a0b44,Supporting & Related Material,FDA-2020-P-2296-0006,FDA-2020-P-2296,Reference 3. - Comparison of the Effect of Acetaminophen and Aspirin re: Citizen Petition from Parenteral Technologies LLC
09000064849a0b4f,Supporting & Related Material,FDA-2020-P-2296-0017,FDA-2020-P-2296,Reference 14. - Liquid Medciation Errors and Dosing Tools RE: Citizen Petition from Parenteral Technologies LLC
09000064849a0b53,Supporting & Related Material,FDA-2020-P-2296-0021,FDA-2020-P-2296,Reference 18. - Unit of Measurement used a Parent Dosing Error RE: Citizen Petition from Parenteral Technologies LLC
09000064849a0b55,Supporting & Related Material,FDA-2020-P-2296-0023,FDA-2020-P-2296,Reference 20. - Evaluation of Consistency in Dosing Directions re: Citizen Petition from Parenteral Technologies LLC
09000064849a0b48,Supporting & Related Material,FDA-2020-P-2296-0010,FDA-2020-P-2296,Reference 7. - Pharmacokinetics of Acetaminophen in Children RE: Citizen Petition from Parenteral Technologies LLC
09000064849a0b50,Supporting & Related Material,FDA-2020-P-2296-0018,FDA-2020-P-2296,Reference 15. - Underdosing of Acetaminophen RE: Citizen Petition from Parenteral Technologies LLC
090000648464e010,Other,FDA-2020-P-1403-0002,FDA-2020-P-1403,"Acknowledgment Letter from FDA DMS to Hyman, Phelps & McNamara, P.C."
090000648464e00f,Other,FDA-2020-P-1403-0001,FDA-2020-P-1403,"Citizen Petition from Hyman, Phelps & McNamara, P.C."
0900006484c6ea72,Other,FDA-2020-P-1403-0005,FDA-2020-P-1403,"Citizen Petition Withdrawal Letter from Hyman, Phelps & McNamara, P.C."
0900006480bfdf83,Other,FDA-2011-P-0127-0002,FDA-2011-P-0127,"Acknowledgement Letter to Baxter Healthcare Corporation, et al (King & Spalding LLP)"
0900006480e3e5de,Other,FDA-2011-P-0127-0007,FDA-2011-P-0127,"FDA/CDER to Baxter Healthcare Corporation, et al., (King & Spalding LLP) - Petition Partial Approval and Denial"
0900006480bfdf7e,Other,FDA-2011-P-0127-0001,FDA-2011-P-0127,"Baxter Healthcare Corporation, et al., (King & Spalding LLP) - Citizen Petition"
0900006481535e8e,Other,FDA-2013-P-1641-0003,FDA-2013-P-1641,Supplement from TEVA Pharmaceutical Industries Ltd.
09000064814c4529,Other,FDA-2013-P-1641-0001,FDA-2013-P-1641,Citizen Petition from TEVA Pharmaceuticals
09000064815fccf0,Other,FDA-2013-P-1641-0004,FDA-2013-P-1641,"Presentation from TEVA Pharmacuetical  re February 25, 2014 Type C FDA Meeting on Scientific Data on Copaxone’s Complexity and Mode of Action in Consideration of Evidentiary Standards for Follow on Products"
09000064816e2a7e,Other,FDA-2013-P-1641-0009,FDA-2013-P-1641,"Citizen Petition Denial Response from FDA CDER to Teva Neuroscience, Inc."
09000064814c457d,Other,FDA-2013-P-1641-0002,FDA-2013-P-1641,Acknowledgement Letter to TEVA Pharmaceuticals
0900006481661939,Other,FDA-2013-P-1641-0005,FDA-2013-P-1641,"Memorandum of Meeting Minutes February 25, 2014"
0900006481683ff7,Other,FDA-2013-P-1641-0006,FDA-2013-P-1641,Supplement from Teva Pharmaceutical Industries Ltd.
0900006481715590,Other,FDA-2014-P-0700-0002,FDA-2014-P-0700,Acknowledgement Letter from FDA DDM to Qilu Pharma
09000064817155c7,Supporting & Related Material,FDA-2014-P-0700-0003,FDA-2014-P-0700,"Attachment 1 Approved Package Insert for RLD Citizen Petition From Qilu Pharma, Inc. (Qilu Pharmaceutical Co., Ltd.)"
09000064817155c8,Supporting & Related Material,FDA-2014-P-0700-0004,FDA-2014-P-0700,"Attachment 2 Proposed Package Insert Citizen Petition From Qilu Pharma, Inc. (Qilu Pharmaceutical Co., Ltd.)"
090000648171558b,Other,FDA-2014-P-0700-0001,FDA-2014-P-0700,"Citizen Petition From Qilu Pharma, Inc. (Qilu Pharmaceutical Co., Ltd.)"
09000064818e581c,Supporting & Related Material,FDA-2014-P-1670-0003,FDA-2014-P-1670,Attachment 1
09000064818e581d,Supporting & Related Material,FDA-2014-P-1670-0004,FDA-2014-P-1670,Attachment 2
09000064818e5748,Other,FDA-2014-P-1670-0002,FDA-2014-P-1670,Acknowledgement Letter from FDA DDM to Gordon Johnston Regulatory Consultants LLC
09000064818e562a,Other,FDA-2014-P-1670-0001,FDA-2014-P-1670,Citizen Petition from Gordon Johnston Regulatory Consultants LLC
09000064818e581f,Supporting & Related Material,FDA-2014-P-1670-0005,FDA-2014-P-1670,Attachment 3
090000648193885a,Other,FDA-2014-P-1975-0002,FDA-2014-P-1975,"Acknowledgement Letter From FDA DDM to e5 Pharma, LLC"
09000064819387d4,Other,FDA-2014-P-1975-0001,FDA-2014-P-1975,"Citizen Petition From e5 Pharma, LLC"
09000064819387dc,Supporting & Related Material,FDA-2014-P-1975-0004,FDA-2014-P-1975,Attachment 2 Proposed Amendments to Pioneer Labeling Citizen Petition From e5 Pharma LLC
09000064819c8079,Other,FDA-2014-P-1975-0005,FDA-2014-P-1975,Suitability Petition Approval Response Letter from FDA CVM to e5 Pharma LLC
09000064819387d8,Supporting & Related Material,FDA-2014-P-1975-0003,FDA-2014-P-1975,Attachment 1Pioneer Labeling Clomicalm Tablets Citizen Petition From e5 Pharma LLC
09000064817a0e48,Other,FDA-2014-P-0980-0002,FDA-2014-P-0980,Acknowledgement Letter to Lachman Consultant Services Inc
09000064817a0c97,Other,FDA-2014-P-0980-0001,FDA-2014-P-0980,Citizen Petition From Lachman Consultant Services Inc
09000064817a0e4a,Supporting & Related Material,FDA-2014-P-0980-0003,FDA-2014-P-0980,Attachment 1 Supplement Approval Letter re Citizen Petition from Lachman Consultant Services Inc
09000064819a648c,Notice,FDA-2014-P-0980-0004,FDA-2014-P-0980,"Determination That REYATAZ (Atazanavir Sulfate) Capsules, 100 Milligrams, Were Withdrawn From Sale for Reasons of Safety or Effectiveness"
0900006481bbc9af,Supporting & Related Material,FDA-2015-P-2830-0003,FDA-2015-P-2830,"Attachment 1:  NIH NINDS The Epilsepsies and Seizures Hope Through Research re Citizen Petition from Supernus Pharmaceuticals (Ropes and Gray, LLP)"
0900006481bbcbe4,Supporting & Related Material,FDA-2015-P-2830-0007,FDA-2015-P-2830,"Attachment 8: US Prescribing Information OXTELLAR XR re Citizen Petition from Supernus Pharmaceuticals (Ropes and Gray, LLP)"
0900006481bbcbe9,Supporting & Related Material,FDA-2015-P-2830-0009,FDA-2015-P-2830,"Attachment 13: Epilepsy Foundation Sudden Unexpected Death in Epilepsy (SUDEP) re Citizen Petition from Supernus Pharmaceuticals (Ropes and Gray, LLP)"
0900006481bbcc03,Supporting & Related Material,FDA-2015-P-2830-0019,FDA-2015-P-2830,"Attachment 35: FDA CDER Meeting of the Advisory Committee for Pharmaceutical Science and Clinical Pharmacology, Briefing Information,(4-13-10) re Citizen Petition from Supernus Pharmaceuticals (Ropes and Gray, LLP)"
0900006481bbcbee,Supporting & Related Material,FDA-2015-P-2830-0012,FDA-2015-P-2830,"Attachment 16:  FDA CDER NDA 202810 Summary Review re Citizen Petition from Supernus Pharmaceuticals (Ropes and Gray, LLP)"
0900006481bc1228,Other,FDA-2015-P-2830-0002,FDA-2015-P-2830,"Acknowledgment Letter from FDA DDM to Supernus Pharmaceuticals (Ropes and Gray, LLP)"
0900006481bbcbe7,Supporting & Related Material,FDA-2015-P-2830-0008,FDA-2015-P-2830,"Attachment 11: Epilepsy Foundation Seizure Emergencies re Citizen Petition from Supernus Pharmaceuticals (Ropes and Gray, LLP)"
0900006481bbcc04,Supporting & Related Material,FDA-2015-P-2830-0020,FDA-2015-P-2830,"Attachment 36: Midha, K. and McKay G. Use of Partial Area Under the Curve for BE Assessment of Products with Complex PK Profiles; a View Point re Citizen Petition from Supernus Pharmaceuticals (Ropes and Gray, LLP)"
0900006481bbcbef,Supporting & Related Material,FDA-2015-P-2830-0013,FDA-2015-P-2830,"Attachment 17:  FDA CDER NDA 202810 Medical Review re Citizen Petition from Supernus Pharmaceuticals (Ropes and Gray, LLP)"
0900006481bbcbf2,Supporting & Related Material,FDA-2015-P-2830-0014,FDA-2015-P-2830,"Attachment 20: Transcript from FDA CDER Advisory Committee for Pharmaceutical Science Meeting (July 26, 2011) re Citizen Petition from Supernus Pharmaceuticals (Ropes and Gray, LLP)"
0900006481bbc9ac,Other,FDA-2015-P-2830-0001,FDA-2015-P-2830,"Citizen Petition from Supernus Pharmaceuticals (Ropes and Gray, LLP)"
0900006481bbcc02,Supporting & Related Material,FDA-2015-P-2830-0018,FDA-2015-P-2830,"Attachment 34:  GDUFA Regulatory Science Priorities for Fiscal Year 2015 re Citizen Petition from Supernus Pharmaceuticals (Ropes and Gray, LLP)"
0900006481bbcc05,Supporting & Related Material,FDA-2015-P-2830-0021,FDA-2015-P-2830,"Attachment 37 - Yu, Approaches to Demonstrate Bioequivalence of Narrow Therapeutic Index Drug (2011) re Citizen Petition from Supernus Pharmaceuticals (Ropes and Gray, LLP)"
0900006481e01655,Other,FDA-2015-P-2830-0022,FDA-2015-P-2830,Citizen Petition Denial Response from FDA CDER to Ropes and Gray LLP
0900006481bbc9b0,Supporting & Related Material,FDA-2015-P-2830-0004,FDA-2015-P-2830,"Attachment 2:  CDC Epilepsy Fast Facts re Citizen Petition from Supernus Pharmaceuticals (Ropes and Gray, LLP)"
0900006481bbcbe1,Supporting & Related Material,FDA-2015-P-2830-0005,FDA-2015-P-2830,"Attachment 5: CDC Epilepsy FAQ re Citizen Petition from Supernus Pharmaceuticals (Ropes and Gray, LLP)"
0900006481bbcbe3,Supporting & Related Material,FDA-2015-P-2830-0006,FDA-2015-P-2830,"Attachment 7 Citizen Petition from UCB Inc re Citizen Petition from Supernus Pharmaceuticals (Ropes and Gray, LLP)"
0900006481bbcbec,Supporting & Related Material,FDA-2015-P-2830-0010,FDA-2015-P-2830,"Attachment 14: US Prescribing Information Trileptal re Citizen Petition from Supernus Pharmaceuticals (Ropes and Gray, LLP)"
0900006481bbcbed,Supporting & Related Material,FDA-2015-P-2830-0011,FDA-2015-P-2830,"Attachment 15: FDA CDER NDA 20810 Clinical Pharmacology and Biopharmaceutics Review(s) re Citizen Petition from Supernus Pharmaceuticals (Ropes and Gray, LLP)"
0900006481bbcbfd,Supporting & Related Material,FDA-2015-P-2830-0015,FDA-2015-P-2830,"Attachment 29: MHPRA, Antiepileptic Drugs: new advice on switching between different manufacturers' products for a particular drug re Citizen Petition from Supernus Pharmaceuticals (Ropes and Gray, LLP)"
0900006481bbcbfe,Supporting & Related Material,FDA-2015-P-2830-0016,FDA-2015-P-2830,"Attachment 30: Danish Health Medicines Authority, Bioequivalence and labeling of medicines with regard to generic substitution re Citizen Petition from Supernus Pharmaceuticals (Ropes and Gray, LLP)"
0900006481bbcbff,Supporting & Related Material,FDA-2015-P-2830-0017,FDA-2015-P-2830,"Attachment 31: Verbeeck, R. and Musuamba, F. The Revised 2010 EMA Guideline for the Investigation of Bioequivalence for Immediate Release Oral Formulations with Systemic Action re Citizen Petition from Supernus Pharmaceuticals (Ropes and Gray, LLP)"
0900006481a52ae4,Other,FDA-2015-P-0876-0002,FDA-2015-P-0876,Acknowledgment Letter From FDA DDM to Jill Escher
0900006481fc092e,Other,FDA-2015-P-0876-0004,FDA-2015-P-0876,Letter from Escher Fund for Autism to FDA CDER
090000648267787f,Other,FDA-2015-P-0876-0006,FDA-2015-P-0876,Letter from Escher Fund for Autism to FDA CDER
0900006481c5563a,Other,FDA-2015-P-0876-0003,FDA-2015-P-0876,Interim Response Letter from FDA CDER to Escher Fund for Autism
09000064824c03d7,Other,FDA-2015-P-0876-0005,FDA-2015-P-0876,Letter from Escher Fund for Autism to FDA CDER
0900006482f06fe3,Other,FDA-2015-P-0876-0007,FDA-2015-P-0876,Letter from Escher Fund for Autism to FDA DDM
0900006482f32af4,Other,FDA-2015-P-0876-0008,FDA-2015-P-0876,Response Letter from FDA CDER to Escher Fund for Autism
0900006481a52ae0,Other,FDA-2015-P-0876-0001,FDA-2015-P-0876,Citizen Petition from The Escher Fund For Autism
09000064843d420e,Other,FDA-2019-P-4155-0003,FDA-2019-P-4155,"Interim Response Letter from FDA CDER to Teva Pharmaceuticals USA, Inc"
0900006483f08eda,Other,FDA-2019-P-4155-0002,FDA-2019-P-4155,"Acknowledgment Letter from FDA DMS to Teva Pharmaceuticals USA, Inc."
0900006483f08ed9,Other,FDA-2019-P-4155-0001,FDA-2019-P-4155,"Citizen Petition from Teva Pharmaceuticals USA, Inc"
0900006482d84da8,Supporting & Related Material,FDA-2017-P-7033-0004,FDA-2017-P-7033,Exhibit 2 RLD Label re Citizen Petition from Jubliant Generics Limited
0900006482d84daa,Supporting & Related Material,FDA-2017-P-7033-0006,FDA-2017-P-7033,Exhibit 4 Oxetol Dosage & Drug Information re Citizen Petition from Jubliant Generics Limited
0900006482d84da4,Other,FDA-2017-P-7033-0002,FDA-2017-P-7033,Acknowledgment Letter from FDA DDM to Jubilant Generics Limited
0900006482d84d79,Other,FDA-2017-P-7033-0001,FDA-2017-P-7033,Citizen Petition from Jubliant Generics Limited
0900006482d84da7,Supporting & Related Material,FDA-2017-P-7033-0003,FDA-2017-P-7033,Exhibit 1 Orange Book Listing re Citizen Petition from Jubliant Generics Limited
0900006482d84da9,Supporting & Related Material,FDA-2017-P-7033-0005,FDA-2017-P-7033,Exhibit 3 Proposed Product Draft Label re Citizen Petition from Jubliant Generics Limited
0900006482bbbda9,Other,FDA-2017-P-2229-0014,FDA-2017-P-2229,Interim Response Letter from CFSAN to American Bakers Association
0900006482bbbd2b,Other,FDA-2017-P-2229-0013,FDA-2017-P-2229,Interim Response Letter from CFSAN to Covington & Burling LLP
09000064825483e5,Other,FDA-2017-P-2229-0002,FDA-2017-P-2229,"Acknowledgment Letter from FDA DDM to Covington & Burling, LLP and American Bakers Association"
0900006482547f12,Supporting & Related Material,FDA-2017-P-2229-0004,FDA-2017-P-2229,"Appendix B - Food Labeling: Revision of the Nutrition and Supplement Facts Labels, Docket No. FDA-2012-N-1210 re Citizen Petition from Covington & Burling, LLP and American Bakers Association"
09000064834111b7,Other,FDA-2017-P-2229-0015,FDA-2017-P-2229,FDA-2017-P-2229 - ABA Letter
0900006482547f0f,Other,FDA-2017-P-2229-0001,FDA-2017-P-2229,"Citizen Petition from  American Bakers Association (Covington & Burling, LLP)"
0900006482547f11,Supporting & Related Material,FDA-2017-P-2229-0003,FDA-2017-P-2229,"Appendix A -  THE RECORDS ACCESS PROVISION OF THE REGULATION EXCEEDS FDA’S STATUTORY AUTHORITY re Citizen Petition from Covington & Burling, LLP and American Bakers Association"
0900006483595a5f,Other,FDA-2018-P-2985-0002,FDA-2018-P-2985,Acknowledgement Letter from FDA DDM to Norbrook Inc.
09000064836e9f0d,Other,FDA-2018-P-2985-0006,FDA-2018-P-2985,Amendment to Citizen Petition from Norbrook Inc.
090000648383aa21,Other,FDA-2018-P-2985-0007,FDA-2018-P-2985,Petition Approval Letter from FDA CVM to Norbrook Inc.
09000064835943d9,Other,FDA-2018-P-2985-0001,FDA-2018-P-2985,Citizen Petition from Norbrook Inc.
09000064835993a9,Supporting & Related Material,FDA-2018-P-2985-0003,FDA-2018-P-2985,Appendix 1 Pioneer Labeling for Felimazole Coated Tablets 2.5mg and 5mg Re: Citizen Petition from Norbrook Inc.
09000064835993aa,Supporting & Related Material,FDA-2018-P-2985-0004,FDA-2018-P-2985,"Appendix 2 Label differences between the pioneer, Felimazole 2.5mg & 5mg Coated Tablets Re: Citizen Petition from Norbrook Inc."
09000064835993ab,Supporting & Related Material,FDA-2018-P-2985-0005,FDA-2018-P-2985,Appendix 3 Patent Certification Statement Re: Citizen Petition from Norbrook Inc.
09000064835d8c12,Other,FDA-2018-P-0614-0003,FDA-2018-P-0614,Interim response from FDA DDM to  GeneYork Pharmaceuticals Group LLC
0900006482eff648,Other,FDA-2018-P-0614-0001,FDA-2018-P-0614,Citizen Petition from GeneYork Pharmaceuticals Group LLC
09000064847f48c4,Other,FDA-2018-P-0614-0004,FDA-2018-P-0614,Letter from FDA CDER to GeneYork Pharmaceuticals Group LLC
0900006482eff64a,Other,FDA-2018-P-0614-0002,FDA-2018-P-0614,Acknowledgment Letter from FDA DDM to GeneYork Pharmaceuticals Group LLC
0900006481abfc50,Supporting & Related Material,FDA-2015-P-1433-0005,FDA-2015-P-1433,"Exhibit 3 Reeves et al. Scientific Standards and the Regulation of GM Insects, re: Citizen Petition from Michael Welber"
09000064821578f5,Other,FDA-2015-P-1433-0081,FDA-2015-P-1433,"Petition Denial August 5, 2016"
0900006481abf79a,Other,FDA-2015-P-1433-0002,FDA-2015-P-1433,Acknowledgement Letter from FDA DDM to Michael Welber
0900006481abfc4f,Supporting & Related Material,FDA-2015-P-1433-0004,FDA-2015-P-1433,"Exhibit 2 MillerLoaiza 2015 Expansion of Aedes Albopictus Panama, re: Citizen Petition from Michael Welber"
0900006481d1d826,Other,FDA-2015-P-1433-0069,FDA-2015-P-1433,Interim Response Letter from FDA CVM to Mr. Michael Welber
0900006481abf794,Other,FDA-2015-P-1433-0001,FDA-2015-P-1433,Citizen Petition from Michael Welber
0900006481abf79d,Supporting & Related Material,FDA-2015-P-1433-0003,FDA-2015-P-1433,"Exhibit 1 Genewatch UK Mosquitoes and Tetracycline, re: Citizen Petition from Michael Welber"
0900006482f64378,Supporting & Related Material,FDA-2018-P-0874-0007,FDA-2018-P-0874,Appendix 6 re Citizen Petition from Bonumose LLC
090000648318e5b2,Supporting & Related Material,FDA-2018-P-0874-0024,FDA-2018-P-0874,Attachment 2 - Bonumose_D-tagatose citizen petition appendix 2 part 1 re Amended Citizen Petition from Bonumose LLC
090000648318e5b3,Supporting & Related Material,FDA-2018-P-0874-0025,FDA-2018-P-0874,Attachment 3 - Bonumose_D-tagatose citizen petition appendix 2 part 2 re Amended Citizen Petition from Bonumose LLC
090000648318e5b4,Supporting & Related Material,FDA-2018-P-0874-0026,FDA-2018-P-0874,Attachment 4 - Bonumose_D-tagatose citizen petition appendix 2 part 3 re Amended Citizen Petition from Bonumose LLC
090000648318e9fe,Supporting & Related Material,FDA-2018-P-0874-0033,FDA-2018-P-0874,Attachment 11 - Bonumose_D-tagatose citizen petition appendix 2 part 10 re Amended Citizen Petition from Bonumose LLC
090000648318ea02,Supporting & Related Material,FDA-2018-P-0874-0037,FDA-2018-P-0874,Attachment 15 - Bonumose_D-tagatose citizen petition appendix 2 part 14 re Amended Citizen Petition from Bonumose LLC
090000648318ea13,Supporting & Related Material,FDA-2018-P-0874-0040,FDA-2018-P-0874,Attachment 18 - Bonumose_D-tagatose citizen petition appendix 2 part 17 re Amended Citizen Petition from Bonumose LLC
090000648318ea15,Supporting & Related Material,FDA-2018-P-0874-0042,FDA-2018-P-0874,Attachment 20 - Bonumose_D-tagatose citizen petition appendix 2 part 19 re Amended Citizen Petition from Bonumose LLC
0900006482f64379,Supporting & Related Material,FDA-2018-P-0874-0008,FDA-2018-P-0874,Appendix 7 re Citizen Petition from Bonumose LLC
0900006482f64380,Supporting & Related Material,FDA-2018-P-0874-0015,FDA-2018-P-0874,Appendix 14 re Citizen Petition from Bonumose LLC
0900006482f643b1,Supporting & Related Material,FDA-2018-P-0874-0020,FDA-2018-P-0874,Appendix 19 re Citizen Petition from Bonumose LLC
0900006482f64368,Supporting & Related Material,FDA-2018-P-0874-0005,FDA-2018-P-0874,Appendix 4 re Citizen Petition from Bonumose LLC
090000648318e0f0,Other,FDA-2018-P-0874-0023,FDA-2018-P-0874,Amended Citizen Petition from Bonumose LLC
090000648318e9fc,Supporting & Related Material,FDA-2018-P-0874-0031,FDA-2018-P-0874,Attachment 9 - Bonumose_D-tagatose citizen petition appendix 2 part 8 re Amended Citizen Petition from Bonumose LLC
090000648318e9fd,Supporting & Related Material,FDA-2018-P-0874-0032,FDA-2018-P-0874,Attachment 10 - Bonumose_D-tagatose citizen petition appendix 2 part 9 re Amended Citizen Petition from Bonumose LLC
090000648318ea01,Supporting & Related Material,FDA-2018-P-0874-0036,FDA-2018-P-0874,Attachment 14 - Bonumose_D-tagatose citizen petition appendix 2 part 13 re Amended Citizen Petition from Bonumose LLC
090000648318ea14,Supporting & Related Material,FDA-2018-P-0874-0041,FDA-2018-P-0874,Attachment 19 - Bonumose_D-tagatose citizen petition appendix 2 part 18 re Amended Citizen Petition from Bonumose LLC
0900006482f6437b,Supporting & Related Material,FDA-2018-P-0874-0010,FDA-2018-P-0874,Appendix 9 re Citizen Petition from Bonumose LLC
0900006482f6437a,Supporting & Related Material,FDA-2018-P-0874-0009,FDA-2018-P-0874,Appendix 8 re Citizen Petition from Bonumose LLC
0900006482f643ac,Supporting & Related Material,FDA-2018-P-0874-0016,FDA-2018-P-0874,Appendix 15 re Citizen Petition from Bonumose LLC
0900006482f643af,Supporting & Related Material,FDA-2018-P-0874-0018,FDA-2018-P-0874,Appendix 17 re Citizen Petition from Bonumose LLC
0900006482f64361,Other,FDA-2018-P-0874-0001,FDA-2018-P-0874,Citizen Petition from Bonumose LLC
0900006482f6437c,Supporting & Related Material,FDA-2018-P-0874-0011,FDA-2018-P-0874,Appendix 10 re Citizen Petition from Bonumose LLC
0900006482f64366,Supporting & Related Material,FDA-2018-P-0874-0003,FDA-2018-P-0874,Appendix 2 re Citizen Petition from Bonumose LLC
0900006482f6437d,Supporting & Related Material,FDA-2018-P-0874-0012,FDA-2018-P-0874,Appendix 11 re Citizen Petition from Bonumose LLC
090000648219ba07,Other,FDA-2016-P-0770-0004,FDA-2016-P-0770,Interim Response from FDA CDER
090000648219de7b,Other,FDA-2016-P-0770-0005,FDA-2016-P-0770,"Citizen Petition Interim Response Letter from FDA CDER to International Isotopes, Inc."
0900006481e96e6f,Supporting & Related Material,FDA-2016-P-0770-0002,FDA-2016-P-0770,Attachment 1 - Electronic Orange Book Listing for Xenon XE-133 Gas Inhalation re Citizen Petition from International Isotopes Inc.
0900006481e96280,Other,FDA-2016-P-0770-0001,FDA-2016-P-0770,Citizen Petition from International Isotopes Inc.
0900006481e96ea2,Other,FDA-2016-P-0770-0003,FDA-2016-P-0770,Acknowledgement Letter from FDA DDM to International Isotopes Inc.
09000064841d90b9,Other,FDA-2016-P-0770-0006,FDA-2016-P-0770,"Letter from FDA CDER to International Isotopes, Inc."
09000064804719e7,Notice,FDA-2004-D-0244-0005,FDA-2004-D-0244,FDA
09000064804719dc,Supporting & Related Material,FDA-2004-D-0244-0003,FDA-2004-D-0244,Guideline
09000064804719db,Supporting & Related Material,FDA-2004-D-0244-0002,FDA-2004-D-0244,Guideline
09000064804719e6,Supporting & Related Material,FDA-2004-D-0244-0004,FDA-2004-D-0244,Guidance
09000064804719da,Notice,FDA-2004-D-0244-0001,FDA-2004-D-0244,FDA
09000064845d84e3,Other,FDA-2020-D-1375-0001,FDA-2020-D-1375,"Guidance for Industry: Color Additive Petitions - FDA Recommendations for Submission of Chemical and Technological Data on Color Additives for Food, Drugs, Cosmetics, or Medical Devices"
0900006481c700bf,Supporting & Related Material,FDA-2011-P-0646-0023,FDA-2011-P-0646,Exhibit 22 - 23 FDA Material on Helping Consumers Reduce Sodium Intake and Sodium Reduction re: Amended Citizen Petition from the City of Philadelphia
0900006481c69313,Supporting & Related Material,FDA-2011-P-0646-0014,FDA-2011-P-0646,Exhibit 3 Vital Statistics Report Philadelphia 2012 (Natality Findings and Mortality Findings) re: Amended Citizen Petition from the City of Philadelphia
0900006481c69310,Supporting & Related Material,FDA-2011-P-0646-0011,FDA-2011-P-0646,"Exhibit 2 Department of Agriculture Nutrient Intakes from Food and Beverages: Mean Amounts Consumed per Individual, by Gender and Age 2011-2012 re: Amended Citizen Petition from the City of Philadelphia"
09000064814e26bf,Other,FDA-2011-P-0646-0004,FDA-2011-P-0646,Supplement from the City of Philadelphia Department of Public Health
0900006481c69314,Supporting & Related Material,FDA-2011-P-0646-0015,FDA-2011-P-0646,Exhibit 3 Vital Statistics Report Philadelphia 2012 (Appendix) re: Amended Citizen Petition from the City of Philadelphia
0900006481c69315,Supporting & Related Material,FDA-2011-P-0646-0016,FDA-2011-P-0646,Exhibit 3 Vital Statistics Report Philadelphia 2012 (Technical Notes) re: Amended Citizen Petition from the City of Philadelphia
0900006481cb1cc9,Other,FDA-2011-P-0646-0027,FDA-2011-P-0646,Letter from Health Promotion Council to City of Philadelphia
0900006480f12202,Other,FDA-2011-P-0646-0002,FDA-2011-P-0646,"Acknowledgement Letter to the City of Philadelphia, Department of Public Health"
0900006481c700bd,Supporting & Related Material,FDA-2011-P-0646-0021,FDA-2011-P-0646,"Exhibit 20 Food and Nutrition Board, Institute of Medicine, National Academies, Dietary Reference Intakes (DRis): Tolerable Upper Intake Levels re: Amended Citizen Petition from the City of Philadelphia"
0900006480f81bf5,Other,FDA-2011-P-0646-0003,FDA-2011-P-0646,"Interim Response to City of Philadephia, Department of Public Health - Letter"
0900006481cbdf92,Other,FDA-2011-P-0646-0028,FDA-2011-P-0646,Letter from Thomas Jefferson University College of Population Health to  City of Philadelphia
0900006481c69312,Supporting & Related Material,FDA-2011-P-0646-0013,FDA-2011-P-0646,Exhibit 3 Vital Statistics Report Philadelphia 2012 (Population Findings) re: Amended Citizen Petition from the City of Philadelphia
0900006481c69311,Supporting & Related Material,FDA-2011-P-0646-0012,FDA-2011-P-0646,Exhibit 3 Vital Statistics Report Philadelphia 2012 re: Amended Citizen Petition from the City of Philadelphia
0900006481c691d8,Other,FDA-2011-P-0646-0008,FDA-2011-P-0646,"Amended Citizen Petition from City of Philadelphia, Department of Public Health"
0900006481c69317,Supporting & Related Material,FDA-2011-P-0646-0018,FDA-2011-P-0646,"Exhibit 5 Philadelphia Department of Public Health, Hypertension and Heart Disease Comparison by Ten Largest Counties, 2011 re: Amended Citizen Petition from the City of Philadelphia"
0900006480f0e7e9,Other,FDA-2011-P-0646-0001,FDA-2011-P-0646,"City of Philadephia, Department of Public Health - Citizen Petition"
0900006481dd8a66,Other,FDA-2011-P-0646-0031,FDA-2011-P-0646,"Interim Response Letter from FDA CFSAN to Deparment of Public Health, City of Philadelphia"
0900006481c69318,Supporting & Related Material,FDA-2011-P-0646-0019,FDA-2011-P-0646,"Exhibit 6 Philadelphia Department of Public Health, Premature Cardiovascular Mortality Rate per 100,000 re: Amended Citizen Petition from the City of Philadelphia"
0900006481c700be,Supporting & Related Material,FDA-2011-P-0646-0022,FDA-2011-P-0646,"Exhibit 21 U.S. Centers for Disease Control and Prevention, Sodium Reduction in Communities
Program (SRCP), re: Amended Citizen Petition from the City of Philadelphia"
0900006481c700bc,Supporting & Related Material,FDA-2011-P-0646-0020,FDA-2011-P-0646,"Exhibit 19 American Heart Association, Government to Issue Guidelines for Lowering Sodium in Foods re: Amended Citizen Petition from the City of Philadelphia"
0900006481c6930e,Supporting & Related Material,FDA-2011-P-0646-0009,FDA-2011-P-0646,Attachment 1 List of Exhibits re: Amended Citizen Petition from the City of Philadelphia
0900006481c6930f,Supporting & Related Material,FDA-2011-P-0646-0010,FDA-2011-P-0646,"Exhibit 1 DHHS, Philadelphia City Council Hearing Transcripts, October 9, 2007 re: Amended Citizen Petition from the City of Philadelphia"
0900006481c69316,Supporting & Related Material,FDA-2011-P-0646-0017,FDA-2011-P-0646,Exhibit 4 Public Health Management Corp Southeastern PA Household Health Survey (2014-15) re: Amended Citizen Petition from the City of Philadelphia
0900006482cfec92,Other,FDA-2017-P-2659-0005,FDA-2017-P-2659,Final Response Letter from FDA to Jubilant Generics Limited
0900006482bc8171,Other,FDA-2017-P-2659-0004,FDA-2017-P-2659,Interim Response from FDA to Jubilant Generics
09000064825801e6,Supporting & Related Material,FDA-2017-P-2659-0003,FDA-2017-P-2659,"Attachment 1 Orange Book: Approved Drug Products with Therapeutic
Equivalence Evaluations re"
09000064825801e0,Other,FDA-2017-P-2659-0001,FDA-2017-P-2659,Citizen Petition from Jubilant Generics
09000064825801e2,Other,FDA-2017-P-2659-0002,FDA-2017-P-2659,Acknowledgment Letter from FDA DDM to Jubilant Generics
0900006482cfd5ec,Notice,FDA-2017-P-2659-0006,FDA-2017-P-2659,"Determination That NOROXIN (Norfloxacin) Tablets, 400 Milligrams,
Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
0900006483787532,Other,FDA-2018-P-3709-0002,FDA-2018-P-3709,Acknowledgment Letter from FDA DDM to Jennifer Nelson
090000648385a5c6,Supporting & Related Material,FDA-2018-P-3709-0005,FDA-2018-P-3709,Attachment 2- Recall Type re: Citizen Petition from Jennifer Nelson recall type 10 25 2019
090000648385a5df,Other,FDA-2018-P-3709-0004,FDA-2018-P-3709,Addendum to Citizen Petition from Jennifer Nelson
090000648378790b,Supporting & Related Material,FDA-2018-P-3709-0003,FDA-2018-P-3709,Attachment 1- Cautery dld maudeExcel re: Citizen Petition from Jennifer Nelson
0900006483b4b800,Other,FDA-2018-P-3709-0011,FDA-2018-P-3709,Interim Response Letter from FDA CDRH to Jennifer Nelson
0900006483786d77,Other,FDA-2018-P-3709-0001,FDA-2018-P-3709,Citizen Petition from Jennifer Nelson
090000648326a4cd,Other,FDA-2018-N-1794-0001,FDA-2018-N-1794,"FDA Report on the Quality, Safety, and Effectiveness of Servicing of Medical Devices In accordance with Section 710 of the Food and Drug Administration Reauthorization Act of 2017 (FDARA)"
0900006482b9c7fd,Other,FDA-2017-P-6028-0002,FDA-2017-P-6028,"Acknowledgment Letter from FDA DDM to Axinn, Veltrop & Harkrider LLP"
0900006482ba35d4,Supporting & Related Material,FDA-2017-P-6028-0007,FDA-2017-P-6028,"Attachment 2 ANDA 076186 APPROVED LABELING re Citizen Petition from Axinn, Veltrop & Harkrider LLP"
0900006482b9cdb6,Supporting & Related Material,FDA-2017-P-6028-0004,FDA-2017-P-6028,"Attachment - 2 ANDA 071293 APPROVED LABELING - re Citizen Petition from Axinn, Veltrop & Harkrider LLP"
0900006482ba2c9a,Supporting & Related Material,FDA-2017-P-6028-0006,FDA-2017-P-6028,"Attachment 1 FDA ORANGE BOOK re Citizen Petition from Axinn, Veltrop & Harkrider LLP"
0900006482b9cc47,Supporting & Related Material,FDA-2017-P-6028-0003,FDA-2017-P-6028,"Attachment -1 FDA ORANGE BOOK  - re Citizen Petition from Axinn, Veltrop & Harkrider LLP"
0900006482b9cdba,Supporting & Related Material,FDA-2017-P-6028-0005,FDA-2017-P-6028,"Attachment - 3 PROPOSED DRAFT LABELING re Citizen Petition from Axinn, Veltrop & Harkrider LLP"
0900006482ba35d5,Supporting & Related Material,FDA-2017-P-6028-0008,FDA-2017-P-6028,"Attachment 3 PROPOSED DRAFT LABELING re Citizen Petition from Axinn, Veltrop & Harkrider LLP"
0900006482b9c9b6,Other,FDA-2017-P-6028-0001,FDA-2017-P-6028,"Citizen Petition from Axinn, Veltrop & Harkrider LLP"
0900006483a171ff,Other,FDA-2019-P-0412-0001,FDA-2019-P-0412,Citizen Petition from Summit Pharmaceuticals Inc
0900006483a1750e,Supporting & Related Material,FDA-2019-P-0412-0004,FDA-2019-P-0412,Appendix 2 re Citizen Petition from Summit Pharmaceuticals Inc
0900006483a17201,Other,FDA-2019-P-0412-0002,FDA-2019-P-0412,Acknowledgment Letter from FDA DDM to Summit Pharmaceuticals Inc
0900006483a1750f,Supporting & Related Material,FDA-2019-P-0412-0005,FDA-2019-P-0412,Appendix 3 re Citizen Petition from Summit Pharmaceuticals Inc
0900006483a1750d,Supporting & Related Material,FDA-2019-P-0412-0003,FDA-2019-P-0412,Appendix 1 re Citizen Petition from Summit Pharmaceuticals Inc
09000064837c7d23,Other,FDA-2018-P-3883-0002,FDA-2018-P-3883,Acknowledgment Letter from FDA DDM to Foley & Lardner LLP
0900006483b65cc4,Other,FDA-2018-P-3883-0005,FDA-2018-P-3883,Letter from FDA CDER to Foley & Lardner LLP
09000064837c7d20,Other,FDA-2018-P-3883-0001,FDA-2018-P-3883,Citizen Petition from Foley & Lardner LLP
0900006483b631ae,Notice,FDA-2018-P-3883-0004,FDA-2018-P-3883,"Determination That CORTISPORIN (Hydrocortisone/Neomycin Sulfate/ Polymyxin B Sulfate) Otic Solution, 10 Milligrams/Milliliter Hydrocortisone, 3.5 Milligrams Base/Milliliter Neomycin Sulfate, 10,000 Units/Milliliter Polymyxin B Sulfate, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
0900006484954a7a,Other,FDA-2020-P-2004-0003,FDA-2020-P-2004,"Withdrawal from Lachman Consulting Services, Inc"
0900006484873703,Other,FDA-2020-P-2004-0002,FDA-2020-P-2004,"Acknowledgment Letter from FDA DMS to Lachman Consulting Services, Inc"
0900006484873702,Other,FDA-2020-P-2004-0001,FDA-2020-P-2004,"Citizen Petition from Lachman Consulting Services, Inc"
0900006481b6dc41,Other,FDA-2015-P-2374-0001,FDA-2015-P-2374,Citizen Petition from Hyman Phelps and McNamara PC
0900006481b6d75d,Supporting & Related Material,FDA-2015-P-2374-0004,FDA-2015-P-2374,Attachment 3 Proposed Prescribing Information for Abiraterone Acetate Tablets re Citizen Petition from Hyman Phelps and McNamara PC
090000648481b175,Other,FDA-2015-P-2374-0005,FDA-2015-P-2374,Withdrawal from Hyman Phelps and McNamara PC
0900006481b6dc44,Other,FDA-2015-P-2374-0002,FDA-2015-P-2374,Acknowledgement Letter from FDA DDM to Hyman Phelps and McNamara PC
0900006481b6d75b,Supporting & Related Material,FDA-2015-P-2374-0003,FDA-2015-P-2374,Attachment 1 Orange Book Listing for Zytiga Tablets re Citizen Petition from Hyman Phelps and McNamara PC
09000064814a61ed,Notice,FDA-2013-N-0579-0002,FDA-2013-N-0579,"Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Biological Products: Reporting of Biological Product Deviations and Human Cells, Tissues, and Cellular and Tissue-Based Product Deviations in Manufacturing; Forms FDA 3486 and 3486A"
09000064823935bf,Notice,FDA-2013-N-0579-0005,FDA-2013-N-0579,"Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Biological Products: Reporting of Biological Product Deviations and Human Cells, Tissues, and Cellular and Tissue-Based Deviations in Manufacturing"
090000648130b88c,Notice,FDA-2013-N-0579-0001,FDA-2013-N-0579,"Agency Information Collection Activities; Proposed Collection; Comment Request; Biological Products: Reporting of Biological Product Deviations and Human Cells, Tissues, and Cellular and Tissue-Based Product Deviations in Manufacturing; Forms FDA 3486 and 3486A"
0900006482018b27,Notice,FDA-2013-N-0579-0003,FDA-2013-N-0579,"Agency Information Collection Activities; Proposed Collection; Comment Request; Biological Products: Reporting of Biological Product Deviations and Human Cells, Tissues, and Cellular and Tissue-Based Deviations in Manufacturing; Forms FDA 3486 and 3486A"
090000648424ffef,Notice,FDA-2013-N-0579-0009,FDA-2013-N-0579,"Agency Information Collection Activities; Submission for Office of
Management and Budget Review; Comment Request; Biological
Products: Reporting of Biological Product Deviations and Human Cells,
Tissues, and Cellular and Tissue-Based Deviations in Manufacturing"
0900006482611b62,Notice,FDA-2013-N-0579-0006,FDA-2013-N-0579,"Agency Information Collection Activities; Announcement of Office of
Management and Budget Approvals"
090000648444cc69,Notice,FDA-2013-N-0579-0010,FDA-2013-N-0579,"Agency Information Collection Activities; Announcement of Office of
Management and Budget Approvals"
0900006483dd472a,Notice,FDA-2013-N-0579-0007,FDA-2013-N-0579,"Agency Information Collection Activities; Proposed Collection;
Comment Request; Biological Products: Reporting of Biological
Product Deviations and Human Cells, Tissues, and Cellular and TissueBased Deviations in Manufacturing"
0900006484467b1b,Other,FDA-2020-P-1205-0001,FDA-2020-P-1205,"Petition for Stay of Action from Steptoe & Johnson LLP on Behalf of Alec Bradley Cigar Distributors, Inc., et al."
0900006484467b1f,Supporting & Related Material,FDA-2020-P-1205-0003,FDA-2020-P-1205,"Exhibits Part I re Steptoe & Johnson LLP on Behalf of Alec Bradley Cigar Distributors, Inc., et al."
0900006484467c52,Other,FDA-2020-P-1205-0002,FDA-2020-P-1205,"Acknowledgment Letter from FDA  DMS to Steptoe & Johnson LLP on Behalf of Alec Bradley Cigar Distributors, Inc., et al."
0900006484467b20,Supporting & Related Material,FDA-2020-P-1205-0004,FDA-2020-P-1205,"Exhibits Part II re Steptoe & Johnson LLP on Behalf of Alec Bradley Cigar Distributors, Inc., et al."
0900006483fcf373,Supporting & Related Material,FDA-2019-P-4515-0003,FDA-2019-P-4515,Attachment 1 - Propranolol Hydrochloride Tablets re Citizen Petition from Foley & Lardner LLP
0900006483fcf371,Other,FDA-2019-P-4515-0002,FDA-2019-P-4515,Acknowledgment Letter from FDA DMS to Foley & Lardner LLP
090000648445739d,Other,FDA-2019-P-4515-0004,FDA-2019-P-4515,Interim Response from Foley & Lardner LLP to FDA CDER
0900006483fcf2d6,Other,FDA-2019-P-4515-0001,FDA-2019-P-4515,Citizen Petition from Foley & Lardner LLP
09000064848603f8,Other,FDA-2019-P-4515-0005,FDA-2019-P-4515,Letter from FDA CDER to Foley & Lardner LLP
09000064824b7709,Other,FDA-2016-P-2497-0005,FDA-2016-P-2497,Interim Response Letter from CDRH to Clinical Decision Support Coalition
09000064821826cf,Other,FDA-2016-P-2497-0001,FDA-2016-P-2497,Citizen Petition from Clinical Decision Support Coalition
09000064821826d3,Supporting & Related Material,FDA-2016-P-2497-0003,FDA-2016-P-2497,"Appendix A Case Studies Involving Software that
Guides the Use of Pharmaceuticals re Citizen Petition from Clinical Decision Support Coalition"
09000064821826d1,Other,FDA-2016-P-2497-0002,FDA-2016-P-2497,Acknowledgement Letter from FDA DDM to Clinical Decision Support Coalition
09000064821826d4,Supporting & Related Material,FDA-2016-P-2497-0004,FDA-2016-P-2497,Reference Documents Citizen Petition Reference Documents re Citizen Petition from Clinical Decision Support Coalition
0900006484057604,Notice,FDA-2018-N-3728-0004,FDA-2018-N-3728,Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Collection of Conflict of Interest Information for Participation in Food and Drug Administration Non-Employee Fellowship and Traineeship Programs
09000064849e8b26,Notice,FDA-2018-N-3728-0008,FDA-2018-N-3728,"Agency Information Collection
Activities; Proposed Collection;
Comment Request; Collection of
Information for Participation in the
Food and Drug Administration Non-
Employee Fellowship and Traineeship
Programs"
090000648444cc6e,Notice,FDA-2018-N-3728-0007,FDA-2018-N-3728,"Agency Information Collection Activities; Announcement of Office of
Management and Budget Approvals"
0900006484197fee,Notice,FDA-2018-N-3728-0005,FDA-2018-N-3728,Agency Information Collection Activities; Proposed Collection; Comment Request; Collection of Information for Participation in the Food and Drug Administration Non- Employee Fellowship and Traineeship Programs
0900006483837c42,Notice,FDA-2018-N-3728-0001,FDA-2018-N-3728,Agency Information Collection Activities; Proposed Collection; Comment Request; Collection of Conflict of Interest Information for Participation in Food and Drug Administration Non-Employee Fellowship and  Traineeship Programs
0900006484bd64dd,Other,FDA-2021-P-0674-0001,FDA-2021-P-0674,"Suitability Petition from Hyman, Phelps & McNamara, P.C."
0900006484bd6f2c,Supporting & Related Material,FDA-2021-P-0674-0003,FDA-2021-P-0674,"Attachment 1 PRESCRIPTION DRUG PRODUCT LIST (Topiramate Capsules ANDA SP)  re: Citizen Petition from Hyman, Phelps & McNamara, P.C."
0900006484bd6fb6,Supporting & Related Material,FDA-2021-P-0674-0004,FDA-2021-P-0674,"Attachment 2 (Topiramate Capsules ANDA SP) TOPAMAX- topiramate tablet, coated re: Citizen Petition Hyman, Phelps & McNamara, P.C."
0900006484bd6fbb,Supporting & Related Material,FDA-2021-P-0674-0005,FDA-2021-P-0674,"Attachment 3 HIGHLIGHTS OF PRESCRIBING INFORMATION (Topiramate Capsules ANDA SP) (1) re: Citizen Petition Hyman, Phelps & McNamara, P.C."
0900006484bd6d31,Other,FDA-2021-P-0674-0002,FDA-2021-P-0674,"Acknowledgement Letter FDA DMS to Hyman, Phelps & McNamara, P.C."
0900006480472e86,Supporting & Related Material,FDA-2004-D-0305-0003,FDA-2004-D-0305,Guidance
0900006480472e82,Supporting & Related Material,FDA-2004-D-0305-0002,FDA-2004-D-0305,Guidance
0900006480472e80,Notice,FDA-2004-D-0305-0001,FDA-2004-D-0305,FDA
090000648042a71d,Other,FDA-2007-P-0183-0004,FDA-2007-P-0183,"Purdue Pharma L.P., & Rhodes Technologies - Letter"
090000648042a71c,Other,FDA-2007-P-0183-0003,FDA-2007-P-0183,"Acknowledgement Letter to Purdue Pharma L.P., & Rhodes Technologies"
090000648043f8b5,Other,FDA-2007-P-0183-0005,FDA-2007-P-0183,"FDA Letter to Purdue Pharma L.P. & Rhodes Technologies, Inc. - Petition Denial"
090000648050c969,Other,FDA-2007-P-0183-0006,FDA-2007-P-0183,Petition for Reconsideration - Philip C. Strassburger
090000648050c9e2,Other,FDA-2007-P-0183-0007,FDA-2007-P-0183,Acknowledgement Letter - Purdue Pharma L.P.
090000648042a712,Other,FDA-2007-P-0183-0001,FDA-2007-P-0183,"Acknowledgement Letter to Purdue Pharma L.P., & Rhodes Technologies"
090000648042a71a,Other,FDA-2007-P-0183-0002,FDA-2007-P-0183,Purdue Pharma L.P. and Rhodes Technologies - Petition for Stay
090000648045d30a,Other,FDA-2006-P-0334-0005,FDA-2006-P-0334,Center for Science in the Public Interest - Citizen Petition
090000648045d301,Supporting & Related Material,FDA-2006-P-0334-0006,FDA-2006-P-0334,Center for Science in the Public Interest - Appendix II - Comparison of Nutritional Criteria for Several Food Labeling Systems
090000648045d2e9,Other,FDA-2006-P-0334-0001,FDA-2006-P-0334,FDA/DDM to Center for Science in the Public Interest
090000648045d30d,Other,FDA-2006-P-0334-0002,FDA-2006-P-0334,FDA/DDM to Center for Science in the Public Interest
090000648045d310,Other,FDA-2006-P-0334-0004,FDA-2006-P-0334,FDA/DDM to Center for Science in the Public Interest
090000648045d30c,Supporting & Related Material,FDA-2006-P-0334-0008,FDA-2006-P-0334,Center for Science in the Public Interest - Appendix I - A list of individuals that have asked that they be listed as supporters of this petition
090000648045d308,Supporting & Related Material,FDA-2006-P-0334-0007,FDA-2006-P-0334,Center for Science in the Public Interest - Appendix III - PDP Symbols Used by Private Label Programs
090000648045d30f,Other,FDA-2006-P-0334-0003,FDA-2006-P-0334,FDA/DDM to Center for Science in the Public Interest
0900006480b24efc,Other,FDA-2010-P-0377-0003,FDA-2010-P-0377,Acknowledgement Letter to the Great Lakes Environmental Law Center and the Natural Resources Defense Council
09000064810ce837,Other,FDA-2010-P-0377-0009,FDA-2010-P-0377,The Great Lakes Environmental Law Center and the Natural Resources Defense Council - Letter
0900006480b17b18,Supporting & Related Material,FDA-2010-P-0377-0002,FDA-2010-P-0377,See FDA-2010-P-0377-0003
090000648120992e,Other,FDA-2010-P-0377-0010,FDA-2010-P-0377,FDA/CDER to Great Lakes Environmental Law Center and The Natural Resources Defense Council - Petition Denial
0900006480b179bf,Other,FDA-2010-P-0377-0001,FDA-2010-P-0377,Great Lakes Environmental Law Center and The Natural Resources Defense Council - Citizen Petition
0900006480ee122d,Other,FDA-2010-P-0377-0008,FDA-2010-P-0377,Interim Response to Great Lakes Environmental Law Center and the Natural Resources Defense Council - Letter
0900006480bca90e,Other,FDA-2010-P-0377-0005,FDA-2010-P-0377,Interim Response to Great Lakes Environmental Law Center and the Natural Resources Defense Council
0900006484dbcae0,Supporting & Related Material,FDA-2021-P-1081-0003,FDA-2021-P-1081,"Attachment 1 Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations re Suitability Petition from Hyman, Phelps & McNamara, P.C."
0900006484dbcae1,Supporting & Related Material,FDA-2021-P-1081-0005,FDA-2021-P-1081,"Attachment 3 Therapeutic monitoring of vancomycin for serious
methicillin-
resistant Staphylococcus aureus infections:
A revised consensus guideline and review by the American
Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases  re Suitability Petition from Hyman, Phelps & McNamara, P.C."
0900006484dbcad1,Supporting & Related Material,FDA-2021-P-1081-0004,FDA-2021-P-1081,"Attachment 2 HIGHLIGHTS OF PRESCRIBING INFORMATION re Suitability Petition from Hyman, Phelps & McNamara, P.C."
0900006484dbcacd,Other,FDA-2021-P-1081-0001,FDA-2021-P-1081,"Suitability Petition from Hyman, Phelps & McNamara, P.C."
0900006484dbcad2,Supporting & Related Material,FDA-2021-P-1081-0006,FDA-2021-P-1081,"Attachment 4 Proposed Labeling re Suitability Petition from Hyman, Phelps & McNamara, P.C."
0900006484dbcade,Other,FDA-2021-P-1081-0002,FDA-2021-P-1081,"Acknowledgment Letter from FDA DMS to Hyman, Phelps & McNamara, P.C."
09000064831b8f38,Other,FDA-2018-P-0033-0003,FDA-2018-P-0033,"Petition Response Letter from FDA CDER to Hyman, Phelps & McNamara, P.C."
0900006482d926bc,Other,FDA-2018-P-0033-0001,FDA-2018-P-0033,"Citizen Petition from Hyman, Phelps & McNamara"
0900006482d9270c,Other,FDA-2018-P-0033-0002,FDA-2018-P-0033,"Acknowledgment Letter from FDA DDM to Hyman, Phelps & McNamara"
09000064812e2f3a,Notice,FDA-2011-D-0057-0020,FDA-2011-D-0057,Guidance for Industry and Food and Drug Administration Staff on Best Practices for Conducting and Reporting Pharmacoepidemiologic Safety Studies Using Electronic Healthcare Data; Availability
09000064812e3665,Other,FDA-2011-D-0057-0021,FDA-2011-D-0057,Guidance for Industry and FDA Staff ;  Best Practices for Conducting and Reporting Pharmacoepidemiologic Safety Studies Using Electronic Healthcare Data
0900006480bf039b,Notice,FDA-2011-D-0057-0001,FDA-2011-D-0057,Draft Guidance for Industry and Food and Drug Administration Staff; Availability: Best Practices for Conducting and Reporting Pharmacoepidemiologic Safety Studies Using Electronic Healthcare Data Sets
0900006480bf0733,Other,FDA-2011-D-0057-0002,FDA-2011-D-0057,Best Practices for Conducting and Reporting Pharmacoepidemiologic Safety Studies Using Electronic Healthcare Data Sets - Draft Guidance
0900006482956e20,Other,FDA-2017-P-4388-0002,FDA-2017-P-4388,"Acknowledgment Letter from FDA DDM to Abhai, LLC."
0900006482956e24,Supporting & Related Material,FDA-2017-P-4388-0004,FDA-2017-P-4388,"Attachment 2 Butalbital, Acetaminophen and Caffeine- butalbital, acetaminophen, and caffeine tablet Par Pharmaceutical re Suitability Petition from Abhai, LLC"
09000064829567e2,Other,FDA-2017-P-4388-0001,FDA-2017-P-4388,"Suitability Petition from Abhai, LLC"
0900006482956e22,Supporting & Related Material,FDA-2017-P-4388-0003,FDA-2017-P-4388,"Attachment 1 Orange Book; Approved Drug Products with Therapeutic Equivalence Evaluations Product Details for ANDA 040511 re Suitability Petition from Abhai, LLC"
09000064819d21bf,Supporting & Related Material,FDA-2015-P-0181-0004,FDA-2015-P-0181,"Exhibits7-17 Citizen Petition From Mylan Specialty, L.P."
0900006481af4ddb,Other,FDA-2015-P-0181-0008,FDA-2015-P-0181,Supplement from Mylan Specialty
09000064819d21c0,Supporting & Related Material,FDA-2015-P-0181-0005,FDA-2015-P-0181,"Exhibits18-22 Citizen Petition From Mylan Specialty, L.P."
0900006481b373c3,Other,FDA-2015-P-0181-0009,FDA-2015-P-0181,Citizen Petition Denial Response from FDA CDER to Mylan Speciality L.P.
0900006481ac0beb,Other,FDA-2015-P-0181-0007,FDA-2015-P-0181,"Supplement from Mylan Specialty, LP"
09000064819d21c1,Supporting & Related Material,FDA-2015-P-0181-0006,FDA-2015-P-0181,"Exhibits 23-28 Citizen Petition From Mylan Specialty, L.P."
09000064819d1d72,Supporting & Related Material,FDA-2015-P-0181-0003,FDA-2015-P-0181,"Exhibits1-6 Citizen Petition From Mylan Specialty, L.P."
09000064819d1d70,Other,FDA-2015-P-0181-0001,FDA-2015-P-0181,"Citizen Petition From Mylan Specialty, L.P."
09000064819d21c2,Other,FDA-2015-P-0181-0002,FDA-2015-P-0181,"Acknowledgement Letter From FDA DDM to Mylan Specialty, L.P."
0900006481bb2ded,Supporting & Related Material,FDA-2015-P-2482-0008,FDA-2015-P-2482,"Attachment 5 House of Representatives 105th Congress 1st Session Report 105-310 re: Comment from Alkermes, Inc."
0900006481c2b7c2,Other,FDA-2015-P-2482-0013,FDA-2015-P-2482,Supplement from Otsuka (Venable LLP)
0900006481cb1cf5,Other,FDA-2015-P-2482-0015,FDA-2015-P-2482,"Citizen Petition Denial Response from FDA/CDER to Otsuka Pharmaceutical Development and Commercialization, Inc."
0900006481bb2dee,Supporting & Related Material,FDA-2015-P-2482-0009,FDA-2015-P-2482,"Attachment 6 Clinical Review and Evaluation NDA 20-450 Cerebyx (fosphenytoin) re: Comment from Alkermes, Inc."
0900006481bb2deb,Supporting & Related Material,FDA-2015-P-2482-0007,FDA-2015-P-2482,"Attachment 3 Congressional Record House re: Comment from Alkermes, Inc."
0900006481bc610b,Other,FDA-2015-P-2482-0011,FDA-2015-P-2482,Supplement from Venable LLC
0900006481b83c26,Other,FDA-2015-P-2482-0002,FDA-2015-P-2482,"Acknowledgement Letter from FDA DDM to Otsuka Pharmaceutical Development and Commercialization, Inc."
0900006481b83c22,Other,FDA-2015-P-2482-0001,FDA-2015-P-2482,"Citizen Petition from Otsuka Pharmaceutical Development and Commercialization, Inc."
0900006481baf4b5,Supporting & Related Material,FDA-2015-P-2482-0004,FDA-2015-P-2482,Supplement from Otsuka (Venable LLP)
0900006481bb2de7,Supporting & Related Material,FDA-2015-P-2482-0005,FDA-2015-P-2482,"Attachment 1 US District Court Veloxis Pharmaceuticals vs FDA re: Comment from Alkermes, Inc."
0900006481bb2dea,Supporting & Related Material,FDA-2015-P-2482-0006,FDA-2015-P-2482,"Attachment 2 US District Court Otsuka Pharmaceutical Co LTD vs Sylvia Mathews Burwell et al re: Comment from Alkermes, Inc."
0900006481c30e91,Supporting & Related Material,FDA-2015-P-2482-0014,FDA-2015-P-2482,Supplement from Otsuka (Venable LLP)
0900006481f114c5,Other,FDA-2016-P-1104-0001,FDA-2016-P-1104,Citizen Petition from Gordon Johnston Regulatory Consultants LLC
090000648235b4c5,Other,FDA-2016-P-1104-0004,FDA-2016-P-1104,Letter from CDER FDA to Gordon Johnston Regulatory Consultants LLC
0900006481f14768,Other,FDA-2016-P-1104-0002,FDA-2016-P-1104,Acknowledgement Letter from FDA DDM to Gordon Johnston Regulatory Consultants LLC
0900006481f1169b,Supporting & Related Material,FDA-2016-P-1104-0003,FDA-2016-P-1104,Attachment A  Product Listing from the Active Section of the Orange Book - re Citizen Petition from Gordon Johnston Regulatory Consultants LLC
09000064827ba615,Other,FDA-2017-P-2164-0005,FDA-2017-P-2164,Interim Response Letter to Steptoe & Johnson LLP dtd 6-29-2017
09000064825439d7,Supporting & Related Material,FDA-2017-P-2164-0003,FDA-2017-P-2164,"Attachment 1 re Citizen Petition from Steptoe & Johnson, LLP"
09000064825435df,Other,FDA-2017-P-2164-0002,FDA-2017-P-2164,"Acknowledgment Letter from FDA DDM to Steptoe & Johnson, LLP"
09000064825400ca,Other,FDA-2017-P-2164-0001,FDA-2017-P-2164,"Citizen Petition from Steptoe & Johnson, LLP (National Association of Convenience Stores)"
090000648257f8fa,Other,FDA-2017-P-2660-0001,FDA-2017-P-2660,Citizen Petition from Jubilant Generics
0900006482c1673f,Other,FDA-2017-P-2660-0006,FDA-2017-P-2660,Final Response from FDA CDER to Jubilant Generics
090000648257fce8,Other,FDA-2017-P-2660-0002,FDA-2017-P-2660,Acknowledgment Letter from FDA DDM to Jubilant Generics
0900006482c11632,Notice,FDA-2017-P-2660-0005,FDA-2017-P-2660,"Determination That CARDENE SR (Nicardipine HCl) Extended-Release
Capsules, 30 Milligrams, 45 Milligrams, and 60 Milligrams, Were Not
Withdrawn From Sale for Reasons of Safety or Effectiveness"
0900006482bf99e5,Other,FDA-2017-P-2660-0004,FDA-2017-P-2660,Interim Response from FDA CDER to Jubilant Generics
090000648257fcea,Supporting & Related Material,FDA-2017-P-2660-0003,FDA-2017-P-2660,"Attachment 1 - Orange Book: Approved Drug Products with Therapeutic
Equivalence Evaluations re Citizen Petition from Jubilant Generics"
09000064817b2bdd,Other,FDA-2014-P-0984-0002,FDA-2014-P-0984,Acknowledgement Letter to Lachman Consultant Services Inc
09000064817b2bdb,Other,FDA-2014-P-0984-0001,FDA-2014-P-0984,Citizen Petition from Lachman Consultant Services Inc.
090000648411605a,Other,FDA-2019-P-2982-0004,FDA-2019-P-2982,Agency Response Letter from FDA CDER to Hetero Labs Limited
0900006483d2a74e,Other,FDA-2019-P-2982-0002,FDA-2019-P-2982,Acknowledgment Letter from FDA DDM to Hetero Labs Limited
0900006484113e5f,Notice,FDA-2019-P-2982-0003,FDA-2019-P-2982,"Determination That MEXITIL (Mexiletine Hydrochloride) Capsules, 150 Milligrams, 200 Milligrams, and 250 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
0900006483d2a557,Other,FDA-2019-P-2982-0001,FDA-2019-P-2982,Citizen Petition from Hetero Labs Limited
0900006482d3ce66,Other,FDA-2017-P-6922-0002,FDA-2017-P-6922,"Acknowledgment Letter from FDA DDM to Haynes and Boone, LLP"
0900006482d3ce64,Other,FDA-2017-P-6922-0001,FDA-2017-P-6922,"Citizen Petition from Haynes and Boone, LLP"
0900006482d3ced7,Supporting & Related Material,FDA-2017-P-6922-0006,FDA-2017-P-6922,"Exhibit C - Lionberger 2008 re Citizen Petition from Haynes and Boone, LLP"
0900006482d3ced5,Supporting & Related Material,FDA-2017-P-6922-0008,FDA-2017-P-6922,"Exhibit A - SSP BE guidance_July 2014 re Citizen Petition from Haynes and Boone, LLP"
090000648327dbcc,Other,FDA-2017-P-6922-0009,FDA-2017-P-6922,Petition Denial Letter from FDA CDER
0900006482d3ced8,Supporting & Related Material,FDA-2017-P-6922-0005,FDA-2017-P-6922,"Exhibit D - FDA Draft Guidance Nasal Aerosols and Nasal Sprays (2003) re Citizen Petition from Haynes and Boone, LLP"
0900006482d3ced6,Supporting & Related Material,FDA-2017-P-6922-0007,FDA-2017-P-6922,"Exhibit B - Sucralfate Oral Suspension Guidance October 2017 re Citizen Petition from Haynes and Boone, LLP"
0900006482d3ced9,Supporting & Related Material,FDA-2017-P-6922-0004,FDA-2017-P-6922,"Exhibit E - Tabibian 1989 re Citizen Petition from Haynes and Boone, LLP"
0900006482d3ceda,Supporting & Related Material,FDA-2017-P-6922-0003,FDA-2017-P-6922,"Exhibit F - Lam 1985 re Citizen Petition from Haynes and Boone, LLP"
0900006482d738a2,Other,FDA-2017-P-4249-0006,FDA-2017-P-4249,Withdrawal from GE Healthcare Inc
0900006482923ca8,Supporting & Related Material,FDA-2017-P-4249-0002,FDA-2017-P-4249,Attachment 1 Orange Book Product Listing Dotarem re Suitability Petition from GE Healthcare Inc
0900006482924167,Supporting & Related Material,FDA-2017-P-4249-0004,FDA-2017-P-4249,Attachment 2 Dotarem approved label re Suitability Petition from GE Healthcare Inc
0900006482923ca3,Other,FDA-2017-P-4249-0001,FDA-2017-P-4249,Suitability Petition from GE Healthcare Inc
0900006482923ca6,Other,FDA-2017-P-4249-0003,FDA-2017-P-4249,Acknowledgement Letter from FDA DDM to GE Healthcare Inc
0900006482924168,Supporting & Related Material,FDA-2017-P-4249-0005,FDA-2017-P-4249,Attachment 3 Draft labeling for the proposed 5mL product re Suitability Petition from GE Healthcare Inc
09000064847d20b8,Other,FDA-2020-P-1730-0002,FDA-2020-P-1730,"Acknowledgment Letter from FDA DMS to Hyman, Phelps & McNamara, PC"
09000064847d20b7,Other,FDA-2020-P-1730-0001,FDA-2020-P-1730,"Suitability Petition from Hyman, Phelps & McNamara, PC"
09000064847d2994,Supporting & Related Material,FDA-2020-P-1730-0003,FDA-2020-P-1730,"Attachment 1 re Suitability Petition from Hyman, Phelps & McNamara, PC"
09000064847d2995,Supporting & Related Material,FDA-2020-P-1730-0004,FDA-2020-P-1730,"Attachment 2 re Suitability Petition from Hyman, Phelps & McNamara, PC"
09000064847d2996,Supporting & Related Material,FDA-2020-P-1730-0005,FDA-2020-P-1730,"Attachment 3 re Suitability Petition from Hyman, Phelps & McNamara, PC"
0900006484879770,Other,FDA-2019-P-5394-0003,FDA-2019-P-5394,Interim Response Letter from FDA CFSAN to Consumer Healthcare Products Association
090000648415675b,Other,FDA-2019-P-5394-0001,FDA-2019-P-5394,Citizen Petition from Consumer Healthcare Products Association
0900006484156ac4,Other,FDA-2019-P-5394-0002,FDA-2019-P-5394,Acknowledgment Letter from FDA DMS to Consumer Healthcare Products Association
0900006484949819,Supporting & Related Material,FDA-2020-P-2144-0003,FDA-2020-P-2144,Attachment 1 EMA/274695/2017; Committee for Medicinal Products for Human Use (CHMP) Assessment Report on Extension of Marketing Authorisation: Brilique (ticagrelor) re Citizen Petition from Robert van Osdel
09000064849431a5,Other,FDA-2020-P-2144-0002,FDA-2020-P-2144,Acknowledgment Letter from FDA DMS to Robert van Osdel
090000648494981a,Supporting & Related Material,FDA-2020-P-2144-0004,FDA-2020-P-2144,"Attachment 2 Approved labeling for the RLD, Brilinta® re Citizen Petition from Robert van Osdel"
09000064849431a4,Other,FDA-2020-P-2144-0001,FDA-2020-P-2144,Citizen Petition from Robert van Osdel
090000648494981b,Supporting & Related Material,FDA-2020-P-2144-0005,FDA-2020-P-2144,"Attachment 3 Draft labeling for the proposed product, Ticagrelor Orally Disintegrating Tablet 90 mg re Citizen Petition from Robert van Osdel"
0900006484959bb5,Other,FDA-2020-P-2180-0005,FDA-2020-P-2180,CITIZEN PETITION FOR STAY OF ACTION REGARDING EFFICACY END POINTS OF THE PHASE III CLINICAL TRIALS OF COVID-19  VACCINES from Siri & Glimstad LLP on behalf of Informed Consent Action Network
0900006484973f39,Supporting & Related Material,FDA-2020-P-2180-0069,FDA-2020-P-2180,All Cited Materials - Footnotes 2 through 29 - re Citizen Petition from Siri & Glimstad LLP on behalf of Informed Consent Action Network
090000648495716c,Supporting & Related Material,FDA-2020-P-2180-0004,FDA-2020-P-2180,All Cited Materials - Footnotes 2 through 29 - re Citizen Petition from Siri & Glimstad LLP on behalf of Informed Consent Action Network
0900006484959da5,Supporting & Related Material,FDA-2020-P-2180-0007,FDA-2020-P-2180,ALL - Part 2 Footnote 21 through 33 re Citizen Petition from Siri & Glimstad LLP on behalf of Informed Consent Action Network
0900006484957166,Supporting & Related Material,FDA-2020-P-2180-0003,FDA-2020-P-2180,Cover letter from Siri & Glimstad LLP on behalf of Informed Consent Action Network
0900006484957167,Other,FDA-2020-P-2180-0001,FDA-2020-P-2180,Citizen Petition from Siri & Glimstad LLP on behalf of Informed Consent Action Network
0900006484959da0,Supporting & Related Material,FDA-2020-P-2180-0006,FDA-2020-P-2180,ALL - Part 1 Footnote 2  through 19 re Citizen Petition from Siri & Glimstad LLP on behalf of Informed Consent Action Network
0900006484957168,Other,FDA-2020-P-2180-0002,FDA-2020-P-2180,Acknowledgment Letter from FDA DMS to Siri & Glimstad LLP on behalf of Informed Consent Action Network
090000648499c70d,Other,FDA-2020-P-2180-0070,FDA-2020-P-2180,Denial Letter from FDA CBER to Siri & Glimstad LLP
0900006481a6907d,Other,FDA-2015-P-0569-0005,FDA-2015-P-0569,"Trade Complaint Referral, Actions Against Bayer Healthcare and Essure Product"
0900006481a1158e,Other,FDA-2015-P-0569-0001,FDA-2015-P-0569,"Citizen Petition From Koch Parafinczuk and Wolf, P.A."
0900006481a11864,Other,FDA-2015-P-0569-0002,FDA-2015-P-0569,"Acknowledgement Letter From FDA DDM to Koch Parafinczuk & Wolf, P.A."
0900006481a11590,Supporting & Related Material,FDA-2015-P-0569-0003,FDA-2015-P-0569,"Exhibits A to F Citizen Petition From Koch Parafinczuk and Wolf, P.A."
0900006483bec695,Other,FDA-2019-P-1980-0002,FDA-2019-P-1980,Acknowledgment Letter from FDA DDM to Novitium Pharma LLC
09000064840c0615,Other,FDA-2019-P-1980-0006,FDA-2019-P-1980,Interim Response Letter from FDA CDER to Novitium Pharma LLC
0900006483bebb13,Supporting & Related Material,FDA-2019-P-1980-0003,FDA-2019-P-1980,Attachment 1 Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations re Citizen Petition from Novitium Pharma LLC
0900006483bebb14,Supporting & Related Material,FDA-2019-P-1980-0004,FDA-2019-P-1980,Attachment 2 Regulatory Agent Appointment Letter from Gemini Lab LLC to FDA re Citizen Petition from Novitium Pharma LLC
0900006484a81f95,Other,FDA-2019-P-1980-0007,FDA-2019-P-1980,Withdrawal from Novitium Pharma LLC
0900006483bebb15,Supporting & Related Material,FDA-2019-P-1980-0005,FDA-2019-P-1980,Attachment 3 Letters from FDA CDER to Novitium Pharma LLC re Citizen Petition from Novitium Pharma LLC
0900006483beba19,Other,FDA-2019-P-1980-0001,FDA-2019-P-1980,Citizen Petition from Novitium Pharma LLC
0900006484aeb18e,Other,FDA-2021-P-0445-0002,FDA-2021-P-0445,Acknowledgment Letter from FDA DMS to Janice S. Lintz
0900006484aeb18c,Other,FDA-2021-P-0445-0001,FDA-2021-P-0445,Citizen Petition from Janice S. Lintz
09000064806fe2ad,Other,FDA-2007-A-0100-0005,FDA-2007-A-0100,"Wiley Rein, LLP - Withdrawal of Advisory Opinion Request"
0900006480429d87,Other,FDA-2007-A-0100-0003,FDA-2007-A-0100,"FDA Response to Wiley Rein, LLP - Letter"
0900006480429d85,Other,FDA-2007-A-0100-0002,FDA-2007-A-0100,"FDA Acknowledgement Letter to Wiley Rein, LLP"
0900006480429d82,Other,FDA-2007-A-0100-0001,FDA-2007-A-0100,FDA/DDM to WileyRein LLP
0900006480429d84,Other,FDA-2007-A-0100-0004,FDA-2007-A-0100,"Wiley Rein, LLP - Advisory Opinion Petition"
090000648043f49b,Supporting & Related Material,FDA-2005-D-0087-0003,FDA-2005-D-0087,Guidance
090000648043f499,Notice,FDA-2005-D-0087-0001,FDA-2005-D-0087,FDA
090000648043f49a,Supporting & Related Material,FDA-2005-D-0087-0002,FDA-2005-D-0087,Guidance
0900006484e29c47,Other,FDA-2021-P-0893-0071,FDA-2021-P-0893,Supplement from Sidley Austin LLP part 3 of 4
0900006484e28d9b,Other,FDA-2021-P-0893-0070,FDA-2021-P-0893,Supplement from Sidley Austin LLP part 2 of 4
0900006484c48b9f,Supporting & Related Material,FDA-2021-P-0893-0027,FDA-2021-P-0893,"Tab 24 - Drugs; Official Names, New Names, 34 Fed. Reg. 6043 (Apr. 3, 1969) RE Citizen Petition from SIDLEY AUSTIN LLP on behalf of  Vifor (International) Inc Switzerland"
0900006484c48cba,Supporting & Related Material,FDA-2021-P-0893-0008,FDA-2021-P-0893,"Tab 5 - Mary S. Leffell et al., Red Blood Cell Transfusions and the Risk Allosensitization in Patients Awaiting Primary Kidney Transplantation, 97 TRANSPLANTATION 525 (2014) RE Citizen Petition from SIDLEY AUSTIN LLP on behalf of  Vifor (International) Inc Switzerland"
0900006484c48cbd,Supporting & Related Material,FDA-2021-P-0893-0011,FDA-2021-P-0893,"Tab 8 - Anne Tompkins Goetsch et al., Observations on the Effect of Massive Doses of Iron Given Intravenously to Patients with Hypochromic Anemia, 1 BLOOD (Mar. 1946) RE Citizen Petition from SIDLEY AUSTIN LLP on behalf of  Vifor (International) Inc Switzerland"
0900006484c48cbf,Supporting & Related Material,FDA-2021-P-0893-0013,FDA-2021-P-0893,"Tab 10 - Elizabeth C. Theil et al., Similarity of the Structure of Ferritin and Iron Dextran (Imferon) Determined by Extended X-Ray Absorption Fine Structure Analysis, 254 THE JOURNAL OF BIOLOGICAL CHEMISTRY 8132 (1979) RE Citizen Petition from SIDLEY AUSTIN LLP on behalf of  Vifor (International) Inc Switzerland"
0900006484c48cc8,Supporting & Related Material,FDA-2021-P-0893-0022,FDA-2021-P-0893,"Tab 19 - S. Rep. No. 87-1744, at 19 (1962) RE Citizen Petition from SIDLEY AUSTIN LLP on behalf of  Vifor (International) Inc Switzerland"
0900006484c48cc9,Supporting & Related Material,FDA-2021-P-0893-0043,FDA-2021-P-0893,"Tab 40 - Jamie B. Vora, Milliman, Inc. White Paper, “Evaluation of Medical Specialty Medications: Utilization and Management Opportunities” (Apr. 8, 2014) RE Citizen Petition from SIDLEY AUSTIN LLP on behalf of  Vifor (International) Inc Switzerland"
0900006484c4b0c7,Supporting & Related Material,FDA-2021-P-0893-0061,FDA-2021-P-0893,"Tab 58 - Sree Rayavarapu et al., Comparative Risk Assessment of Formulation Changes in Generic Drug Products: A Pharmacology/Toxicology Perspective, 146 TOXICOLOGICAL SCIENCES, 2, 3 (2015) RE Citizen Petition from SIDLEY AUSTIN LLP on behalf of  Vifor (International) Inc Switzerland"
0900006484c45860,Supporting & Related Material,FDA-2021-P-0893-0005,FDA-2021-P-0893,"Tab 2 - Iain C. Macdougall et al., Iron Sucrose: A Wealth of Experience in Treating Iron Deficiency, 37 ADV THER 1960 (2020) RE Citizen Petition from SIDLEY AUSTIN LLP on behalf of  Vifor (International) Inc Switzerland"
0900006484c48ba0,Supporting & Related Material,FDA-2021-P-0893-0028,FDA-2021-P-0893,"Tab 25 - Drugs; Official Names, New Names, 34 Fed. Reg. 12178 (Jul. 23, 1969) RE Citizen Petition from SIDLEY AUSTIN LLP on behalf of  Vifor (International) Inc Switzerland"
0900006484c48cbb,Supporting & Related Material,FDA-2021-P-0893-0009,FDA-2021-P-0893,"Tab 6 - Emma L. O’Lone et al., Parenteral Versus Oral Iron Therapy for Adults and Children with Chronic Kidney Disease, Cochrane Database of Systematic Reviews 2019, Issue 2. Art. No.: CD007857 RE Citizen Petition from SIDLEY AUSTIN LLP on behalf of  Vifor (International) Inc Switzerland"
0900006484c48cbe,Supporting & Related Material,FDA-2021-P-0893-0012,FDA-2021-P-0893,"Tab 9 - Felix Funk et al., The New Generation of Intravenous Iron: Chemistry, Pharmacology, and Toxicology of Ferric Carboxymaltose, 60 ARZNEIMITTELFORSCHUNG (June 2010) RE Citizen Petition from SIDLEY AUSTIN LLP on behalf of  Vifor (International) Inc Switzerland"
0900006484c48cc1,Supporting & Related Material,FDA-2021-P-0893-0015,FDA-2021-P-0893,"Tab 12 - Peter Geisser & Susanna Burckhardt, The Pharmacokinetics and Pharmacodynamics of Iron Preparations, 3 PHARMACEUTICS 12 (2011) RE Citizen Petition from SIDLEY AUSTIN LLP on behalf of  Vifor (International) Inc Switzerland"
0900006484c49c29,Supporting & Related Material,FDA-2021-P-0893-0031,FDA-2021-P-0893,"Tab 28 - Drugs; Official Names, New Names, 36 Fed. Reg. 778 (Jan. 16, 1971) RE Citizen Petition from SIDLEY AUSTIN LLP on behalf of  Vifor (International) Inc Switzerland"
0900006484c4af6f,Supporting & Related Material,FDA-2021-P-0893-0058,FDA-2021-P-0893,"Tab 55 - Gerald J. Dal Pan et al., Postmarketing Spontaneous Pharmacovigilance Systems 178, in Brian L. Strom et al., PHARMACOEPIDEMIOLOGY (6th ed. 2020) RE Citizen Petition from SIDLEY AUSTIN LLP on behalf of  Vifor (International) Inc Switzerland"
0900006484c48cc0,Supporting & Related Material,FDA-2021-P-0893-0014,FDA-2021-P-0893,"Tab 11 - Lawrence X. Yu et al., Understanding Pharmaceutical Quality by Design, 16 AAPS JOURNAL 771 (2014) RE Citizen Petition from SIDLEY AUSTIN LLP on behalf of  Vifor (International) Inc Switzerland"
0900006484c49c2c,Supporting & Related Material,FDA-2021-P-0893-0034,FDA-2021-P-0893,"Tab 31 - USAN, Procedure for USAN Name Selection RE Citizen Petition from SIDLEY AUSTIN LLP on behalf of  Vifor (International) Inc Switzerland"
0900006484c49d75,Supporting & Related Material,FDA-2021-P-0893-0053,FDA-2021-P-0893,"Tab 50 - Virginie Korb-Savoldellia, Prevalence of Computerized Physician Order Entry Systems–Related Medication Prescription Errors: A Systematic Review, 111 INTERNATIONAL JOURNAL OF MEDICAL INFORMATICS 112 (2018) RE Citizen Petition from SIDLEY AUSTIN LLP on behalf of  Vifor (International) Inc Switzerland"
0900006484c49d80,Supporting & Related Material,FDA-2021-P-0893-0054,FDA-2021-P-0893,"Tab 51 - Ka-Chun Cheung et al., Medication Errors: The Importance of Safe Dispensing, 67 BRITISH JOURNAL OF CLINICAL PHARMACOLOGY 676 (2009) RE Citizen Petition from SIDLEY AUSTIN LLP on behalf of  Vifor (International) Inc Switzerland"
0900006484c48a9f,Other,FDA-2021-P-0893-0002,FDA-2021-P-0893,Acknowledgment Letter from FDA DMS to SIDLEY AUSTIN LLP on behalf of  Vifor (International) Inc Switzerland
0900006484e29c71,Other,FDA-2021-P-0893-0072,FDA-2021-P-0893,Supplement from Sidley Austin LLP part 4 of 4
0900006484c45861,Supporting & Related Material,FDA-2021-P-0893-0006,FDA-2021-P-0893,"Tab 3 - Angelo Karaboyas et al., Low hemoglobin at hemodialysis initiation: an international study of anemia management and mortality in the early dialysis period, 13 CLINICAL KIDNEY JOURNAL 425 (2019) RE Citizen Petition from SIDLEY AUSTIN LLP on behalf of  Vifor (International) Inc Switzerland"
0900006484c48cca,Supporting & Related Material,FDA-2021-P-0893-0044,FDA-2021-P-0893,"Tab 41 - Robert Nease et al., “Express Scripts Specialty Benefit Services: Specialty Drug Trend Report” (June 2011) RE Citizen Petition from SIDLEY AUSTIN LLP on behalf of  Vifor (International) Inc Switzerland"
0900006484c49c2e,Supporting & Related Material,FDA-2021-P-0893-0036,FDA-2021-P-0893,"Tab 33 - The United States Pharmacopeia, Twentieth Revision and The National Formulary, Fifteenth Edition at 421 (Official from Jul. 1, 1980) RE Citizen Petition from SIDLEY AUSTIN LLP on behalf of  Vifor (International) Inc Switzerland"
09000064841f726a,Supporting & Related Material,FDA-2019-P-5791-0003,FDA-2019-P-5791,"Attachment 1- Approved Drug Products with Therapeutic Equivalence Evaluation, accessed November 22, 2019 (Orange Book) re Citizen Petition from Guvam Pharma LLC"
09000064841f726b,Supporting & Related Material,FDA-2019-P-5791-0004,FDA-2019-P-5791,Attachment 2- Federal Register Notice that Azo Gantanol and Azo Gantrisin were not withdrawn from sale for reason of safety or effectiveness RE Citizen Petition from Guvam Pharma LLC
09000064841f726c,Supporting & Related Material,FDA-2019-P-5791-0005,FDA-2019-P-5791,Attachment 3- NDA 21-105 Labeling RE Citizen Petition from Guvam Pharma LLC
09000064841f7115,Other,FDA-2019-P-5791-0001,FDA-2019-P-5791,"Citizen Petition from Guvam Pharma, LLC"
09000064841f75fa,Other,FDA-2019-P-5791-0002,FDA-2019-P-5791,Acknowledgment Letter from FDA DMS to Guvam Pharma LLC
09000064841f726d,Supporting & Related Material,FDA-2019-P-5791-0006,FDA-2019-P-5791,"Attachment 4- Draft Package Insert Labeling for Phenazopyridire Hydrochloride Tablets, 50mg, 100mg and 200mg RE Citizen Petition from Guvam Pharma LLC"
09000064832daa54,Other,FDA-2017-P-6692-0040,FDA-2017-P-6692,Interim Response from FDA CDER to Drug Watch Int.
0900006482cca918,Other,FDA-2017-P-6692-0002,FDA-2017-P-6692,"Acknowledgment Letter from FDA DDM to Drug Watch International, Inc."
0900006482cca916,Other,FDA-2017-P-6692-0001,FDA-2017-P-6692,"Citizen Petition from Drug Watch International, Inc."
0900006483d9e026,Other,FDA-2017-P-6692-0102,FDA-2017-P-6692,"Letter from FDA CDER to Drug Watch International, Inc."
0900006483494a5a,Other,FDA-2017-P-6692-0042,FDA-2017-P-6692,"Petition Denial Letter from FDA CDER to Drug Watch International, Inc"
09000064835f2499,Other,FDA-2017-P-6692-0043,FDA-2017-P-6692,"Citizen Petition for Reconsideration from Drug Watch International, Inc."
090000648472225d,Other,FDA-2020-P-1626-0001,FDA-2020-P-1626,"Citizen Petition from Hyman, Phelps & McNamara, P.C."
0900006484722028,Other,FDA-2020-P-1626-0002,FDA-2020-P-1626,"Acknowledgment Letter from FDA DMS to Hyman, Phelps & McNamara, PC."
0900006484a6602b,Other,FDA-2020-P-1626-0004,FDA-2020-P-1626,"Withdrawal of citizen petition from Hyman, Phelps & McNamara, P.C."
09000064849999b3,Other,FDA-2020-P-1626-0003,FDA-2020-P-1626,"Interim Response Letter from FDA CDER to Hyman, Phelps & McNamara, PC"
090000648425e1d0,Other,FDA-2019-P-6099-0001,FDA-2019-P-6099,Citizen Petition from George M. Stone on behalf of Patients for Access to Advanced Therapy for Hemophilia
09000064846d6fcc,Other,FDA-2019-P-6099-0004,FDA-2019-P-6099,Interim Response from FDA CBER to Public Citizen
09000064848af559,Other,FDA-2019-P-6099-0005,FDA-2019-P-6099,Final Response from FDA CBER to Patients for Access to Advanced Therapy for Hemophilia (PAATH)
090000648425e1d2,Other,FDA-2019-P-6099-0002,FDA-2019-P-6099,Acknowledgment Letter from FDA DMS to George M. Stone
09000064844ad201,Other,FDA-2019-P-6099-0003,FDA-2019-P-6099,Letter from George M. Stone on behalf of Patients for Access to Advanced Therapy for Hemophilia
0900006484c48aa3,Other,FDA-2021-P-0894-0002,FDA-2021-P-0894,Acknowledgment Letter from FDA DMS to Pet Schooled
0900006484c48aa1,Other,FDA-2021-P-0894-0001,FDA-2021-P-0894,Citizen Petition from Pet Schooled
0900006481f39751,Supporting & Related Material,FDA-2016-P-1115-0004,FDA-2016-P-1115,Final Petition Index re Citizen Petition from Mostyn Law Firm
0900006481f39907,Supporting & Related Material,FDA-2016-P-1115-0015,FDA-2016-P-1115,"Exhibit 11 - BSCM06700722854 BSC ran short of Marlex in 2011, creating a fire drill inside BSC re Citizen Petition from Mostyn Law Firm"
0900006481f3990c,Supporting & Related Material,FDA-2016-P-1115-0020,FDA-2016-P-1115,"Exhibit 16 - BSCM13000000037 Marlex background, update slides re Citizen Petition from Mostyn Law Firm"
0900006481f3990f,Supporting & Related Material,FDA-2016-P-1115-0023,FDA-2016-P-1115,Exhibit 19 - BSCM13800009800 BSC hid the intended purpose of the Marlex because the information might scare away the Chinese sellers re Citizen Petition from Mostyn Law Firm
0900006481f39910,Supporting & Related Material,FDA-2016-P-1115-0024,FDA-2016-P-1115,Exhibit 20 - BSCM13800008924 Zhao detailed visits to 5 Chinese distributors of Marlex found on alibaba.com re Citizen Petition from Mostyn Law Firm
0900006481f39911,Supporting & Related Material,FDA-2016-P-1115-0025,FDA-2016-P-1115,Exhibit 21 - “There’s no end in sight for Alibaba’s counterfeit problem” published in Fortune Magazine at http://fortune.com/2015/05/18/theres-no-end-in-sight-for-alibabas-counterfeit-problem/. re Citizen Petition from Mostyn Law Firm
0900006481f39912,Supporting & Related Material,FDA-2016-P-1115-0026,FDA-2016-P-1115,Exhibit 22 - BSCM13800008343 R&D executive Ron Ciulla stressed the need for a C of C to Defendant McCaslin. Defendant McCaslin acknowledged the need and asked if all would be dead without a C of C re Citizen Petition from Mostyn Law Firm
0900006481f3991c,Supporting & Related Material,FDA-2016-P-1115-0035,FDA-2016-P-1115,Exhibit 31- Letters to doctors in response to allegations that BSC is using counterfeit resin re Citizen Petition from Mostyn Law Firm
0900006481f3991f,Supporting & Related Material,FDA-2016-P-1115-0038,FDA-2016-P-1115,Exhibit 34 - BSCM11500006055 Mechanical Testing Protocol re Citizen Petition from Mostyn Law Firm
0900006481f39922,Supporting & Related Material,FDA-2016-P-1115-0041,FDA-2016-P-1115,Exhibit 37 - BSCM07300073860 The limited and flawed testing that was done revealed differences between the single pellet of the counterfeit resin and material purchased from Channel Prime Alliance in 2005 re Citizen Petition from Mostyn Law Firm
0900006481f39752,Supporting & Related Material,FDA-2016-P-1115-0005,FDA-2016-P-1115,"Exhibit 1 - BSCM13500000937 Robert Mullally asks, ""How did all this resin end up in China if it was made in Texas?"" re Citizen Petition from Mostyn Law Firm"
0900006481f39756,Supporting & Related Material,FDA-2016-P-1115-0009,FDA-2016-P-1115,Exhibit 5 - BSCM07300068256 Cambridge Polymer Group Test Results re Citizen Petition from Mostyn Law Firm
0900006481f39905,Supporting & Related Material,FDA-2016-P-1115-0013,FDA-2016-P-1115,Exhibit 9 - BSCM04500000465 2004 Marlex HGX-030-01 MSDS re Citizen Petition from Mostyn Law Firm
0900006481f3990d,Supporting & Related Material,FDA-2016-P-1115-0021,FDA-2016-P-1115,"Exhibit 17 - BSCM11200014917 Impending Marlex shortage would cost BSC $120,000,000 in annual profits re Citizen Petition from Mostyn Law Firm"
0900006481f39916,Supporting & Related Material,FDA-2016-P-1115-0030,FDA-2016-P-1115,"Exhibit 26 - BSCM13500000465 BSC solved its dilemma by declaring that the Chinese resin was made by Dongguan Sunmei Plastic Raw Material Co., Ltd., a Chinese company, to clear Chinese customs re Citizen Petition from Mostyn Law Firm"
0900006481f3991a,Supporting & Related Material,FDA-2016-P-1115-0033,FDA-2016-P-1115,"Exhibit 29 - BSCM11500006697 The shipper of the 4,400 lbs by air was not ""over-cautious"" re Citizen Petition from Mostyn Law Firm"
0900006481f3991b,Supporting & Related Material,FDA-2016-P-1115-0034,FDA-2016-P-1115,"Exhibit 30 - BSCM11500006979 Even though BSC’s chance of being audited was low, BSC played it safe and split the resin into 4 separate shipments re Citizen Petition from Mostyn Law Firm"
0900006481f3991d,Supporting & Related Material,FDA-2016-P-1115-0036,FDA-2016-P-1115,Exhibit 32 - BSCM11500005941 Burrill Report - Equivalency Testing re Citizen Petition from Mostyn Law Firm
0900006481f38f9c,Other,FDA-2016-P-1115-0001,FDA-2016-P-1115,Citizen Petition from Mostyn Law Firm
0900006481fdcd30,Supporting & Related Material,FDA-2016-P-1115-0047,FDA-2016-P-1115,Footnote 29 BSCM07700280242
09000064824541a1,Other,FDA-2016-P-1115-0053,FDA-2016-P-1115,Supplement from Mostyn Law
0900006481fdcd2f,Supporting & Related Material,FDA-2016-P-1115-0046,FDA-2016-P-1115,82. Footnote 34 BSCM14700006847 - unsealed by 3.22.16 agreement
0900006481fdcd31,Supporting & Related Material,FDA-2016-P-1115-0048,FDA-2016-P-1115,Footnote 82 BSCM07700158425
0900006481f39755,Supporting & Related Material,FDA-2016-P-1115-0008,FDA-2016-P-1115,Exhibit 4 - 1/24/16 Order of the Honorable Judge Goodwin re Citizen Petition from Mostyn Law Firm
0900006481f39757,Supporting & Related Material,FDA-2016-P-1115-0010,FDA-2016-P-1115,Exhibit 6 - http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm204199.htm re Citizen Petition from Mostyn Law Firm
0900006481fe9554,Other,FDA-2015-P-4566-0004,FDA-2015-P-4566,Interim Response from FDA CDER
0900006481d83080,Supporting & Related Material,FDA-2015-P-4566-0002,FDA-2015-P-4566,"Attachment 1 Expert Statement of Manju T. Beier, Pharm D. re Citizen Petition from Concordia Pharmaceuticals (Buchanan Ingersoll and Rooney PC)"
0900006481d83000,Other,FDA-2015-P-4566-0003,FDA-2015-P-4566,Acknowledgement Letter from FDA DDM to Buchanan Ingersoll and Rooney PC
0900006482af6158,Other,FDA-2015-P-4566-0005,FDA-2015-P-4566,Final Response from FDA CDER to Buchanan Ingersoll & Rooney PC
0900006481d82c69,Other,FDA-2015-P-4566-0001,FDA-2015-P-4566,Citizen Petition from Concordia Pharmaceuticals (Buchanan Ingersoll and Rooney PC)
0900006482092d6d,Supporting & Related Material,FDA-2016-P-1946-0005,FDA-2016-P-1946,"Attachment 3 Effects of Various Tampering Methods on Exposure to Oxycodone in Healthy Subjects re Citizen Petition from Hyman, Phelps & McNamara, PC"
09000064824c86d6,Other,FDA-2016-P-1946-0008,FDA-2016-P-1946,"CP Denial Letter from FDA CDER to Hyman, Phelps & McNamara, P.C."
0900006482092d6c,Supporting & Related Material,FDA-2016-P-1946-0004,FDA-2016-P-1946,"Attachment 2 Relative abuse of abuse-deterrent formulations via alternative oral routes re Citizen Petition from Hyman, Phelps & McNamara, PC"
0900006482092caf,Supporting & Related Material,FDA-2016-P-1946-0003,FDA-2016-P-1946,"Attachment 1 Comparing the Effect of Tampering on the Oral Pharmacokinetic Profiles of Two Extended-Release Oxycodone Formulation with Abuse-Deterrent Properties re Citizen Petition from Hyman, Phelps & McNamara, PC"
0900006482092cad,Other,FDA-2016-P-1946-0001,FDA-2016-P-1946,"Citizen Petition from Hyman, Phelps & McNamara, PC (Collegium Pharmaceutical, Inc. )"
0900006482092e14,Other,FDA-2016-P-1946-0002,FDA-2016-P-1946,"Acknowledgement Letter from FDA DDM to Hyman, Phelps & McNamara, PC"
090000648235f3a0,Supporting & Related Material,FDA-2016-P-3620-0004,FDA-2016-P-3620,"Appendix B (Evidence to Support the Use of Fibersym® RW and FiberRite® RW Modified Wheat Starch as a Source of Dietary Fiber in the United States) re Citizen Petition from MGP Ingredients, Inc."
09000064833f0c39,Other,FDA-2016-P-3620-0014,FDA-2016-P-3620,"Memorandum for the Record, Phone call participant list June 6 2018 call."
090000648235f39f,Supporting & Related Material,FDA-2016-P-3620-0003,FDA-2016-P-3620,"Appendix A (Additional Evidence in Support of Other Physiological Effects Beneficial to Human Health) re Citizen Petition from MGP Ingredients, Inc."
0900006483ae29cc,Other,FDA-2016-P-3620-0018,FDA-2016-P-3620,"Addendum from MGP Ingredients, Inc."
090000648251565f,Other,FDA-2016-P-3620-0009,FDA-2016-P-3620,"Letter from General Mills , Inc. to FDA DDM"
09000064831c5f19,Supporting & Related Material,FDA-2016-P-3620-0012,FDA-2016-P-3620,"M. G. P. Ingredients Inc. re: Citizen Petition from MGP Ingredients, Inc."
09000064831c6238,Supporting & Related Material,FDA-2016-P-3620-0013,FDA-2016-P-3620,"Letter from South Dakota State University re: Citizen Petition from MGP Ingredients, Inc."
090000648235f425,Other,FDA-2016-P-3620-0002,FDA-2016-P-3620,"Acknowledgment Letter from FDA DDM to MGP Ingredients, Inc."
090000648257b4bf,Other,FDA-2016-P-3620-0010,FDA-2016-P-3620,"Interim Response Letter from CFSAN to MGP Ingredients, Inc."
090000648235f39d,Other,FDA-2016-P-3620-0001,FDA-2016-P-3620,"Citizen Petition from MGP Ingredients, Inc."
09000064831c5f16,Supporting & Related Material,FDA-2016-P-3620-0011,FDA-2016-P-3620,"Addendum to Citizen Petition re: Citizen Petition from MGP Ingredients, Inc."
0900006483a4e9a1,Other,FDA-2016-P-3620-0017,FDA-2016-P-3620,"Addendum from MGP Ingredients, Inc."
09000064834109eb,Other,FDA-2016-P-3620-0015,FDA-2016-P-3620,"MGP Ingredients, Inc Addendum"
090000648235f3a1,Supporting & Related Material,FDA-2016-P-3620-0005,FDA-2016-P-3620,"Appendix C (Technical Data Sheets for Fibersym® RW and FiberRite® RW) re Citizen Petition from MGP Ingredients, Inc."
0900006483b34ca7,Other,FDA-2016-P-3620-0019,FDA-2016-P-3620,"Letter from FDA CFSAN to MGP Ingredients, Inc."
09000064838bd406,Other,FDA-2016-P-3620-0016,FDA-2016-P-3620,"Addendum from MGP Ingredients, Inc."
0900006481ee0545,Other,FDA-2016-P-1088-0002,FDA-2016-P-1088,"Acknowledgement Letter from FDA DDM to ABHAI LLP c/o KVK-Tech, Inc"
0900006481edffa8,Supporting & Related Material,FDA-2016-P-1088-0004,FDA-2016-P-1088,"Attachment 2 Package Information Oxybutynin Hydrochloride 2.5 mg and 5 mg Tablets re: Citizen Petition from ABHAI LLC c/o: KVK-tech, Inc"
0900006481edffa9,Supporting & Related Material,FDA-2016-P-1088-0005,FDA-2016-P-1088,"Attachment 3 Label Information Oxybutynin Chloride Tablets re: Citizen Petition from ABHAI LLC c/o: KVK-tech, Inc"
09000064848d5ce8,Other,FDA-2016-P-1088-0007,FDA-2016-P-1088,"Amendment to Suitability Petition for Oxybutynin Chloride Tablets, USP 2.5 mg"
0900006481edffaa,Supporting & Related Material,FDA-2016-P-1088-0006,FDA-2016-P-1088,"Attachment 4 Label Information Oxybutynin Chloride Tablets, USP re Citizen Petition from ABHAI LLC c/o: KVK-tech, Inc"
0900006481edffa5,Other,FDA-2016-P-1088-0001,FDA-2016-P-1088,"Citizen Petition from ABHAI LLC c/o KVK-Tech, Inc"
0900006481edffa7,Supporting & Related Material,FDA-2016-P-1088-0003,FDA-2016-P-1088,"Attachment 1 Package Leaflet Ditropan 2.5 mg and 5 mg Tablets re: Citizen Petition from ABHAI LLC c/o: KVK-tech, Inc"
0900006484969987,Other,FDA-2016-P-1088-0008,FDA-2016-P-1088,"Agency Response Letter from FDA CDER to ABHAI LLP c/o KVK-Tech, Inc"
0900006480b13840,Other,FDA-2010-P-0359-0001,FDA-2010-P-0359,"Goodwin Procter, LLP - Citizen Petition"
0900006480bb615d,Other,FDA-2010-P-0359-0003,FDA-2010-P-0359,Goodwin Procter LLP - Letter
0900006480b13a22,Other,FDA-2010-P-0359-0002,FDA-2010-P-0359,Acknowledgement Letter to Goodwin Procter LLP
0900006483ed552e,Other,FDA-2010-P-0359-0004,FDA-2010-P-0359,Interim Response to Goodwin Procter LLP. from CDRH
0900006482a94fd6,Other,FDA-2017-P-5114-0002,FDA-2017-P-5114,Acknowledgement Letter from FDA DDM to Locke Lord LLP
0900006482a94fda,Supporting & Related Material,FDA-2017-P-5114-0004,FDA-2017-P-5114,Attachment 2 re Citizen Petition from Locke Lord LLP
0900006482a94f87,Other,FDA-2017-P-5114-0001,FDA-2017-P-5114,Citizen Petition from Locke Lord LLP
0900006482a94fdb,Supporting & Related Material,FDA-2017-P-5114-0005,FDA-2017-P-5114,Attachment 3 re Citizen Petition from Locke Lord LLP
0900006482c9fadd,Other,FDA-2017-P-5114-0007,FDA-2017-P-5114,Petition Response Letter
0900006482a94fd9,Supporting & Related Material,FDA-2017-P-5114-0003,FDA-2017-P-5114,Attachment 1 re Citizen Petition from Locke Lord LLP
0900006482c98c5b,Notice,FDA-2017-P-5114-0006,FDA-2017-P-5114,"Determination That TRINTELLIX (Vortioxetine Hydrobromide) Oral
Tablet, EQ 15 Milligram Base, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
0900006482428120,Other,FDA-2016-P-1106-0004,FDA-2016-P-1106,"Letter from FDA CDER to Gordon Johnston Regulatory Consultants, LLC"
0900006481f11632,Other,FDA-2016-P-1106-0001,FDA-2016-P-1106,Citizen Petition from Gordon Johnston Regulatory Consultants LLC
0900006481f13d7a,Other,FDA-2016-P-1106-0002,FDA-2016-P-1106,Acknowledgement Letter from FDA DDM to Gordon Johnston Regulatory Consultants LLC
0900006481f11698,Supporting & Related Material,FDA-2016-P-1106-0003,FDA-2016-P-1106,Attachment A Product Listing from the Active Section of the Orange Book -  re Citizen Petition from Gordon Johnston Regulatory Consultants LLC
090000648301d61d,Other,FDA-2018-P-1174-0002,FDA-2018-P-1174,Citizen Petition from Pharma Regulatory Consultants LLC
090000648301e145,Supporting & Related Material,FDA-2018-P-1174-0005,FDA-2018-P-1174,"Attachment 3- Approved labeling for reference- listed drug, Revatio ( Sildenafil Citrate) by Pfizer re:  Citizen Petition from Pharma Regulatory Consultants LLC"
090000648301e144,Supporting & Related Material,FDA-2018-P-1174-0004,FDA-2018-P-1174,Attachment 2- Draft insert labeling for proposed product re: Citizen Petition from Pharma Regulatory Consultants LLC
090000648301d704,Other,FDA-2018-P-1174-0001,FDA-2018-P-1174,Acknowledgment Letter from FDA DDM to Pharma Regulatory Consultants LLC
090000648301e143,Supporting & Related Material,FDA-2018-P-1174-0003,FDA-2018-P-1174,Attachment 1 Orange Book' Approved Drug Products with Therapeutic Equivalence Evaluations re: Citizen Petition from Pharma Regulatory Consultants LLC
0900006483aa8261,Supporting & Related Material,FDA-2019-P-0915-0004,FDA-2019-P-0915,"Attachment B Package Insert of Lacosamide Granules for Oral Solution re: Suitability Petition from Sunshine Lake Pharma Co., Ltd."
0900006483aa7b08,Other,FDA-2019-P-0915-0001,FDA-2019-P-0915,"Suitability Petition from Sunshine Lake Pharma Co., Ltd."
0900006483aa8260,Supporting & Related Material,FDA-2019-P-0915-0003,FDA-2019-P-0915,"Attachment A Package Insert of Reference List Drug (Vimpat ®) re Suitability Petition from Sunshine Lake Pharma Co., Ltd."
0900006483aa7f22,Other,FDA-2019-P-0915-0002,FDA-2019-P-0915,"Acknowledgment Letter from FDA DDM to Sunshine Lake Pharma Co., Ltd."
09000064811762a5,Proposed Rule,FDA-2012-N-1148-0001,FDA-2012-N-1148,Actions Related to Nicotine Replacement Therapies and Smoking-Cessation Products: Report to Congress on Innovative Products and Treatments for Tobacco Dependence; Public Hearing
090000648119460a,Supporting & Related Material,FDA-2012-N-1148-0004,FDA-2012-N-1148,Testimony Regarding NRT and Innovative Tobacco Cessation - Testimony
09000064811a3b89,Proposed Rule,FDA-2012-N-1148-0011,FDA-2012-N-1148,Food and Drug Administration Actions Related to Nicotine Replacement Therapies and Smoking-Cessation Products; Report to Congress on Innovative Products and Treatments for Tobacco Dependence; Public Hearing; Extension of Comment Period
0900006481194525,Supporting & Related Material,FDA-2012-N-1148-0005,FDA-2012-N-1148,Slides Presented at 12/17/12 Public Hearing
0900006481f114c8,Other,FDA-2016-P-1105-0001,FDA-2016-P-1105,Citizen Petition from Gordon Johnston Regulatory Consultants LLC
0900006481f13d7c,Other,FDA-2016-P-1105-0002,FDA-2016-P-1105,Acknowledgement Letter from FDA DDM to Gordon Johnston Regulatory Consultants LLC
090000648235b7c1,Other,FDA-2016-P-1105-0004,FDA-2016-P-1105,Letter from CDER FDA to Gordon Johnston Regulatory Consultants LLC
0900006481f1169a,Supporting & Related Material,FDA-2016-P-1105-0003,FDA-2016-P-1105,Attachment A Product Listing from the Active Section of the Orange Book re Citizen Petition from Gordon Johnston Regulatory Consultants LLC
09000064824f45c8,Other,FDA-2017-P-1391-0002,FDA-2017-P-1391,Acknowledgement Letter from FDA DDM to Epstein Becker & Green P.C.
09000064824f43ec,Other,FDA-2017-P-1391-0001,FDA-2017-P-1391,Citizen Petition from Epstein Becker & Green P.C.
0900006481f62e4d,Supporting & Related Material,FDA-2015-P-3794-0004,FDA-2015-P-3794,Interim Response - Savage re Citizen Petition from Lawrence R. Savage
0900006481f5d84e,Other,FDA-2015-P-3794-0003,FDA-2015-P-3794,Interim response letter to Lawrence Savage
0900006481cd14cb,Other,FDA-2015-P-3794-0001,FDA-2015-P-3794,Citizen Petition From Lawrence R. Savage
0900006481cd177d,Other,FDA-2015-P-3794-0002,FDA-2015-P-3794,Acknowledgment Letter from FDA DDM to Lawrence R. Savage
090000648493c511,Supporting & Related Material,FDA-2020-P-2136-0003,FDA-2020-P-2136,"Cover Letter RE Citizen Petition from SIRI & GLIMSTAD, LLP (on behalf of Informed Consent Action Network)"
090000648493c50e,Other,FDA-2020-P-2136-0002,FDA-2020-P-2136,"Acknowledgment Letter from FDA DMS to SIRI & GLIMSTAD, LLP (on behalf of Informed Consent Action Network)"
090000648493c512,Supporting & Related Material,FDA-2020-P-2136-0004,FDA-2020-P-2136,"Footnotes 2-3 RE Citizen Petition from SIRI & GLIMSTAD, LLP (on behalf of Informed Consent Action Network)"
090000648493c50d,Other,FDA-2020-P-2136-0001,FDA-2020-P-2136,"Citizen Petition from SIRI & GLIMSTAD, LLP (on behalf of Informed Consent Action Network)"
0900006484aabc0a,Other,FDA-2020-P-2136-0005,FDA-2020-P-2136,"Interim Response from FDA CBER to Siri & Glimstad, LLP"
0900006483988ec2,Supporting & Related Material,FDA-2018-P-4714-0007,FDA-2018-P-4714,"Exhibit 12 Copyrighted Article Isbill, K. (2018) Thoughts on Sexual Health re Citizen Petition from TherapeuticMD, Inc."
090000648398806d,Supporting & Related Material,FDA-2018-P-4714-0003,FDA-2018-P-4714,"Exhibits 1-4 Copyrighted Articles re Citizen Petition from TherapeuticsMD, Inc."
0900006483988bdd,Supporting & Related Material,FDA-2018-P-4714-0009,FDA-2018-P-4714,"Exhibit 14 Citizen Petition Partial Approval and Denial Response Letter from FDA CDER to Novo Nordisk Inc. re Citizen Petition from TherapeuticMD, Inc."
0900006483988c8b,Supporting & Related Material,FDA-2018-P-4714-0012,FDA-2018-P-4714,"Exhibit 17 Copyrighted Article Chang, Raw, Lionberger, and Yu (2012) Generic Development of Topical Dermatologic Products: Formulation Development, Process Development, and Testing of Topical Dermatologic Products re Citizen Petition from TherapeuticsMD, Inc."
0900006483988bde,Supporting & Related Material,FDA-2018-P-4714-0010,FDA-2018-P-4714,"Exhibit 15 Copyrighted Article Marques, M. (2014) Enzymes in the Dissolution Testing of Gelatin Capsules re Citizen Petition from TherpeuticMD, Inc. re Citizen Petition from TherapeuticMD, Inc."
09000064839890aa,Supporting & Related Material,FDA-2018-P-4714-0015,FDA-2018-P-4714,"Exhibit 20 Highlights of Prescribing Information Imvexxy re Citizen Petition from TherapeuticMD, Inc."
090000648398806e,Supporting & Related Material,FDA-2018-P-4714-0004,FDA-2018-P-4714,"Exhibit 5 Bransaeter and Nelson (1955) Proteolysis by Lactobacillus Casei II. Peptidase Activity re Citizen Petition from TherapeuticsMD, Inc."
090000648398806f,Supporting & Related Material,FDA-2018-P-4714-0005,FDA-2018-P-4714,"Exhibits 6-10 Copyrighted Articles re Citizen Petition from TherapeuticsMD, Inc."
0900006483988bdc,Supporting & Related Material,FDA-2018-P-4714-0008,FDA-2018-P-4714,"Exhibit 13 NDA Approval Letter from FDA CDER to TherapeuticsMD, Inc."
0900006483cffd39,Other,FDA-2018-P-4714-0016,FDA-2018-P-4714,"Letter from FDA CDER to TherapeuticsMD, Inc."
090000648398806b,Other,FDA-2018-P-4714-0001,FDA-2018-P-4714,"Citizen Petition from TherapeuticsMD, Inc."
0900006483988070,Supporting & Related Material,FDA-2018-P-4714-0006,FDA-2018-P-4714,"Exhibit 11 Pickar, Amadio, Bernick, and Mirkin (2016) Pharmacokinetic studies of solubilized estradiol given vaginally in a novel softgel capsule re Citizen Petition from TherapeuticsMD, Inc."
0900006483988c8c,Supporting & Related Material,FDA-2018-P-4714-0013,FDA-2018-P-4714,"Exhibit 18 Copyrighted Article Kingsberg et al (2017) Patient acceptability and satisfaction with a low-dose solubilized vaginal estradiol softgel capsule, TX-004HR re Citizen Petition from TherapeuticMD, Inc."
09000064839890a9,Supporting & Related Material,FDA-2018-P-4714-0014,FDA-2018-P-4714,"Exhibit 19 FDA In Vitro Bioequivalence Data for a Topical
Product: Bioequivalence Review Perspective re Citizen Petition from TherapeuticMD, Inc."
0900006483988c8a,Supporting & Related Material,FDA-2018-P-4714-0011,FDA-2018-P-4714,"Exhibit 16 Copyrighted Article Press, Nousek-Goebl, Bur, and Greene (1986) Estrogen Receptor Localization in the Female Genital Tract re Citizen Petition from TherapeuticsMD, Inc."
090000648398806c,Other,FDA-2018-P-4714-0002,FDA-2018-P-4714,"Acknowledgment Letter from FDA DDM to TherapeuticsMD, Inc."
0900006484a12399,Other,FDA-2021-P-0136-0002,FDA-2021-P-0136,Acknowledgment Letter from FDA DMS to Principal Lassman Law +Policy
0900006484a122da,Other,FDA-2021-P-0136-0001,FDA-2021-P-0136,Citizen Petition from Lassman Law+Policy
0900006484c0fc86,Other,FDA-2021-P-0136-0003,FDA-2021-P-0136,"Interim Response to Principal, Lassman Law+Policy from FDA CDER"
09000064806f11a5,Other,FDA-2007-P-0009-0006,FDA-2007-P-0009,FDA Response to the Honorable Dianne Feinstein [in support of CASA/CP1-FDA-2007-P-0009-0002] - Letter
0900006480c759f1,Other,FDA-2007-P-0009-0009,FDA-2007-P-0009,Interim Response to The National Center on Addiction and Substance Abuse at Columbia University
09000064806eeeee,Other,FDA-2007-P-0009-0005,FDA-2007-P-0009,The National Center on Addiction and Substance Abuse at Columbia University to FDA Commissioner von Eschenbach - Letter
09000064804292e5,Other,FDA-2007-P-0009-0002,FDA-2007-P-0009,The National Center on Addiction and Substance Abuse at Columbia University (CASA) - Citizen Petition
0900006480bd780f,Other,FDA-2007-P-0009-0007,FDA-2007-P-0009,"National Center on Addiction and Substance Abuse (CASA) at Columbia University to FDA/CDER, January 31, 2011  - Letter"
090000648054899d,Other,FDA-2007-P-0009-0003,FDA-2007-P-0009,Center for Drug Evaluation and Research to The National center for Addiction and Substance Abuse at Columbia University - Letter
0900006480c014b2,Other,FDA-2007-P-0009-0008,FDA-2007-P-0009,National Center on Addiction and Substance Abuse (CASA) - Supplement
0900006481334521,Other,FDA-2007-P-0009-0010,FDA-2007-P-0009,FDA/CDER Response to National Center on Addiction and Substance Abuse at Columbia University - Denial of Petition
09000064804292e0,Other,FDA-2007-P-0009-0001,FDA-2007-P-0009,Acknowledgement Letter to The National Center on Addiction and Substance Abuse at Columbia University
0900006480a52aac,Notice,FDA-2009-D-0319-0001,FDA-2009-D-0319,Guidance for Industry and Food and Drug Administration Staff; In Vitro Diagnostic 2009 H1N1 Tests for Use in the 2009 H1N1 Emergency; Availability
0900006480a5303e,Other,FDA-2009-D-0319-0002,FDA-2009-D-0319,Guidance for Industry and Food and Drug Administration Staff; In Vitro Diagnostic 2009 H1N1 Tests for Use in the 2009 H1N1 Emergency; Availability
0900006484e357a9,Supporting & Related Material,FDA-2021-P-1209-0004,FDA-2021-P-1209,"Attachment - Labeling Ketorolac  10mg rs RE Suitability Petition from Senores Pharmaceuticals, Inc."
0900006484e35b43,Supporting & Related Material,FDA-2021-P-1209-0003,FDA-2021-P-1209,"Attachment 1 - Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations RE Suitability Petition from Senores Pharmaceuticals, Inc."
0900006484e35b44,Supporting & Related Material,FDA-2021-P-1209-0005,FDA-2021-P-1209,"Attachment 3 - Draft Labeling RE Suitability Petition from Senores Pharmaceuticals, Inc."
0900006484e357ad,Supporting & Related Material,FDA-2021-P-1209-0007,FDA-2021-P-1209,"Attachment - 5 - Bio Guidance RE Suitability Petition from Senores Pharmaceuticals, Inc."
0900006484e35b20,Other,FDA-2021-P-1209-0001,FDA-2021-P-1209,"Suitability Petition from Senores Pharmaceuticals, Inc."
0900006484e357ac,Supporting & Related Material,FDA-2021-P-1209-0006,FDA-2021-P-1209,"Attachment 4 - Labeling Side by Side Comparision RE Suitability Petition from Senores Pharmaceuticals, Inc."
0900006484e357a7,Other,FDA-2021-P-1209-0002,FDA-2021-P-1209,"Acknowledgment Letter from FDA DMS to Senores Pharmaceuticals, Inc."
0900006483e81982,Supporting & Related Material,FDA-2019-P-3946-0009,FDA-2019-P-3946,Exhibit 7 - Changes in the Prevalence of the Most Common Causes of Chronic Liver Diseases in the United States From 1988 to 2008 re Citizens Petition from Persion Pharmaceuticals LLC
0900006483e8180b,Supporting & Related Material,FDA-2019-P-3946-0003,FDA-2019-P-3946,Exhibit 1 - Opioid Safety in Patients with Renal or Hepatic Dysfunction re Citizens Petition from Persion Pharmaceuticals LLC
0900006483e81070,Other,FDA-2019-P-3946-0002,FDA-2019-P-3946,Acknowledgment Letter from FDA DMS to Persion Pharmaceuticals LLC
0900006483e8197f,Supporting & Related Material,FDA-2019-P-3946-0006,FDA-2019-P-3946,"Exhibit 4 - DECLARATION OF Craig Antell, D.O. re Citizens Petition from Persion Pharmaceuticals LLC"
0900006483e8180c,Supporting & Related Material,FDA-2019-P-3946-0004,FDA-2019-P-3946,Exhibit 2 - Effects of renal impairment and hepatic impairment on the pharmacokinetics of hydrocodone after administration of a novel extended-release hydrocodone tablet formulated with OraGuardTM technology re Citizens Petition from Persion Pharmaceuticals LLC
0900006483e81983,Supporting & Related Material,FDA-2019-P-3946-0010,FDA-2019-P-3946,Exhibit 8 - Pain and Opioid Use in Chronic Liver Disease re Citizens Petition from Persion Pharmaceuticals LLC
0900006483e81984,Supporting & Related Material,FDA-2019-P-3946-0011,FDA-2019-P-3946,Exhibit 9 - HIGHLIGHTS OF PRESCRIBING INFORMATION re Citizens Petition from Persion Pharmaceuticals LLC
0900006483edb9e9,Other,FDA-2019-P-3946-0012,FDA-2019-P-3946,Withdrawal from Persion Pharmaceuticals LLC
0900006483e81981,Supporting & Related Material,FDA-2019-P-3946-0008,FDA-2019-P-3946,"Exhibit 6 - The Role of Opioid Prescription in Incident Opioid Abuse and
Dependence Among Individuals with Chronic Non-Cancer Pain:
The Role of Opioid Prescription re Citizens Petition from Persion Pharmaceuticals LLC"
0900006483e80a6b,Other,FDA-2019-P-3946-0001,FDA-2019-P-3946,Citizens Petition from Persion Pharmaceuticals LLC
0900006483e81980,Supporting & Related Material,FDA-2019-P-3946-0007,FDA-2019-P-3946,Exhibit 5 - Cohort Study of the Impact of High-Dose Opiod Analgesics on Overdose Mortality re Citizens Petition from Persion Pharmaceuticals LLC
0900006483eefbb5,Other,FDA-2019-P-3946-0013,FDA-2019-P-3946,Citizen Petition from Persion Pharmaceuticals LLC
0900006483e8180d,Supporting & Related Material,FDA-2019-P-3946-0005,FDA-2019-P-3946,"Exhibit 3 - DECLARATION OF Christopher G. Gharibo, M.D. re Citizens Petition from Persion Pharmaceuticals LLC"
090000648214dcb7,Supporting & Related Material,FDA-2016-P-2375-0003,FDA-2016-P-2375,Attachment 1 Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations re Citizen Petition from AKORN Specialty Generics
090000648214dcb5,Other,FDA-2016-P-2375-0002,FDA-2016-P-2375,Acknowledgement Letter from FDA DDM to Akorn Specialty Generics
09000064824992f8,Other,FDA-2016-P-2375-0004,FDA-2016-P-2375,Interim Response Letter from CDER to Akorn Pharmaceuticals
090000648214dcaf,Other,FDA-2016-P-2375-0001,FDA-2016-P-2375,Citizen Petition from AKORN Specialty Generics
09000064839ac1b4,Other,FDA-2016-P-2375-0005,FDA-2016-P-2375,"Letter from FDA CDER to Akorn Pharmaceuticals, Mylan Pharmaceuticals, Inc., Gland Pharma Limited, Foley & Lardner LLP"
09000064824c39f7,Other,FDA-2017-P-1002-0002,FDA-2017-P-1002,"Acknowledgment Letter from FDA DDM to Inrange Systems, Inc."
0900006482bc4d77,Other,FDA-2017-P-1002-0003,FDA-2017-P-1002,"Denial Response from FDA CDRH to INRange Systems, Inc"
09000064824c39f5,Other,FDA-2017-P-1002-0001,FDA-2017-P-1002,"Citizen Petition from Inrange Systems, Inc."
090000648324fef3,Other,FDA-2018-P-1808-0001,FDA-2018-P-1808,"Citizen Petition from Lachman Consultant Services, Inc"
090000648324fef8,Supporting & Related Material,FDA-2018-P-1808-0003,FDA-2018-P-1808,"Attachment 1 Orange Book re Citizen Petition from Lachman Consultant Services, Inc"
090000648324fef5,Other,FDA-2018-P-1808-0002,FDA-2018-P-1808,"Acknowledgment Letter from FDA DDM to Lachman Consultant Services, Inc"
090000648324fef9,Supporting & Related Material,FDA-2018-P-1808-0004,FDA-2018-P-1808,"Attachment 2 Proposed Labeling re Citizen Petition from Lachman Consultant Services, Inc"
090000648324ff54,Supporting & Related Material,FDA-2018-P-1808-0005,FDA-2018-P-1808,"Attachment 3 Approved Labeling for Reference Listed Drug re Citizen Petition from Lachman Consultant Services, Inc"
0900006482b87979,Other,FDA-2017-P-5967-0002,FDA-2017-P-5967,Acknowledgement Letter from FDA DDM to Apotex Inc.
0900006482c9fa7e,Other,FDA-2017-P-5967-0005,FDA-2017-P-5967,Final Petition Response
0900006482c98464,Notice,FDA-2017-P-5967-0004,FDA-2017-P-5967,"Determination That TRINTELLIX (Vortioxetine Hydrobromide) Oral
Tablet, EQ 15 Milligram Base, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
0900006482b87977,Other,FDA-2017-P-5967-0001,FDA-2017-P-5967,Citizen Petition from Apotex Inc.
0900006482b8797d,Supporting & Related Material,FDA-2017-P-5967-0003,FDA-2017-P-5967,Attachment 1 - Orange Book: Approved Drug Products with Therapeutic Equivalence  Evaluations re Citizen Petition from Apotex Inc.
090000648248674c,Other,FDA-2017-P-0398-0001,FDA-2017-P-0398,Citizen Petition from Florek & Endres PLLC
0900006482486750,Supporting & Related Material,FDA-2017-P-0398-0003,FDA-2017-P-0398,Attachment 1 NDA # 21-217 Detail Record from the current electronic edition of the Orange Book re Citizen Petition from Florek & Endres PLLC
0900006482486752,Supporting & Related Material,FDA-2017-P-0398-0004,FDA-2017-P-0398,"Attachment 2 EXALGO® (Hydromorphone HCl), extended-release tablets, for oral use Package Insert (RLD labeling) re Citizen Petition from Florek & Endres PLLC"
0900006482c0602e,Other,FDA-2017-P-0398-0005,FDA-2017-P-0398,Withdrawal from Florek & Endres PLLC
090000648248674e,Other,FDA-2017-P-0398-0002,FDA-2017-P-0398,Acknowledgement Letter from FDA DDM to Florek & Endress PLLC
090000648190535c,Notice,FDA-2014-N-1009-0002,FDA-2014-N-1009,"Agency Information Collection Activities; Submission for Office of
Management and Budget Review; Comment Request; Information
Request Regarding pH of Smokeless Tobacco Products"
09000064817d76c9,Notice,FDA-2014-N-1009-0001,FDA-2014-N-1009,"Agency Information Collection Activities; Proposed Collection;
Comment Request; Information Request Regarding pH of Smokeless
Tobacco Products"
09000064811607d1,Other,FDA-2012-P-1107-0002,FDA-2012-P-1107,Acknowledgement Letter to FzioMed Inc. (Hogan Lovells US LLP)
090000648167003e,Other,FDA-2012-P-1107-0028,FDA-2012-P-1107,"Letter from FzioMed , Inc, (Nogan Lovells US LLP) to FDA CDRH"
0900006481718955,Other,FDA-2012-P-1107-0038,FDA-2012-P-1107,Letter from FDA CDRH to FDA OC
090000648171893c,Other,FDA-2012-P-1107-0037,FDA-2012-P-1107,Letter from FDA CDRH to FDA OC
0900006481717052,Other,FDA-2012-P-1107-0035,FDA-2012-P-1107,Letter from FDA CDRH to FDA DDM and FDA OC
0900006481a54871,Other,FDA-2012-P-1107-0040,FDA-2012-P-1107,"Letter From OC to FzioMed, Inc. (Hunton and Williams, LLP) Closing the Docket"
0900006481735188,Notice,FDA-2012-P-1107-0039,FDA-2012-P-1107,"OXIPLEX/SP Gel; FzioMed, Incorporated’s Petition for Review of
the Food and Drug Administration’s Denial of Premarket Approval; Notice
of Meeting Cancellation"
090000648146356b,Other,FDA-2012-P-1107-0022,FDA-2012-P-1107,FDA/OC Response to FzioMed Inc. (Hogan Lovells US LLP) - Petition Approval
09000064816700b4,Other,FDA-2012-P-1107-0029,FDA-2012-P-1107,"Memorandum from FDA CDRH to Division of Dockets Management and Administrative Team for the Office of the Commissioner Dated March 14, 2014"
09000064819a8a56,Other,FDA-2012-P-1107-0041,FDA-2012-P-1107,Withdrawal from Hunton & Williams
09000064817168f7,Other,FDA-2012-P-1107-0034,FDA-2012-P-1107,Letter from FDA CDRH to FDA DDM and FDA OC
09000064815a2dce,Other,FDA-2012-P-1107-0024,FDA-2012-P-1107,Letter from FDA CDRH to Hogan Lovell US LLP and CDRH
09000064816f9561,Notice,FDA-2012-P-1107-0033,FDA-2012-P-1107,"Oxiplex®/SP Gel; FzioMed, Incorporated’s Petition for Review of
the Food and Drug Administration’s Denial of Premarket Approval; Notice
of Meeting"
09000064816e9fee,Other,FDA-2012-P-1107-0032,FDA-2012-P-1107,Letter from FDA/OC to Hogan Lovells US LLP and CDRH
0900006481718745,Other,FDA-2012-P-1107-0036,FDA-2012-P-1107,Letter from FDA CDRH to FDA OC
09000064816d9ef2,Other,FDA-2012-P-1107-0031,FDA-2012-P-1107,Letter from FDA/OC to Hogan Lovells US LLP and CDRH
0900006481535e8b,Other,FDA-2012-P-1107-0023,FDA-2012-P-1107,Memorandum from FDA CDRH to DDM
090000648162f9f1,Other,FDA-2012-P-1107-0026,FDA-2012-P-1107,"Letter from FzioMed, Inc. (Hogan Lovells US LLP)"
0900006481160690,Other,FDA-2012-P-1107-0001,FDA-2012-P-1107,FzioMed Inc. (Hogan Lovells US LLP) - Citizen Petition
09000064816b29e7,Other,FDA-2012-P-1107-0030,FDA-2012-P-1107,CDRH Executive Summary for the 515(g)(2) Panel to Review the Denial of P070023
0900006481674ae0,Other,FDA-2012-P-1107-0025,FDA-2012-P-1107,Letter from FDA CDER to Hogan Lovells US LLP and FDA CDRH
0900006481869ed8,Supporting & Related Material,FDA-2014-P-1044-0003,FDA-2014-P-1044,Attachment II Current Drug Shortage Bulletin: Mercaptopurine Tablets re Citizen Petition from Zydus Pharmaceuticals Inc FDA-2014-P-1044-0001
090000648198fde8,Other,FDA-2014-P-1044-0007,FDA-2014-P-1044,"Withdrawal from Zydus Pharmaceuticals (USA), Inc."
0900006481869ed9,Supporting & Related Material,FDA-2014-P-1044-0004,FDA-2014-P-1044,Attachment III  Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations re Citizen Petition from Zydus Pharmaceuticals Inc FDA-2014-P-1044-0001
0900006481869b15,Supporting & Related Material,FDA-2014-P-1044-0005,FDA-2014-P-1044,Shipping Label re Citizen Petition from Zydus Pharmaceuticals Inc
0900006481869e84,Supporting & Related Material,FDA-2014-P-1044-0002,FDA-2014-P-1044,Attachment I Cited Correspondence re Citizen Petition from Zydus Pharmaceuticals Inc FDA-2014-P-1044-0001
0900006481869e82,Other,FDA-2014-P-1044-0006,FDA-2014-P-1044,Acknowledgement Letter From FDA DDM to Zydus Pharmaceuticals Inc
0900006481869e80,Other,FDA-2014-P-1044-0001,FDA-2014-P-1044,Citizen Petition from Zydus Pharmaceuticals Inc
0900006481223059,Other,FDA-2013-D-0168-0002,FDA-2013-D-0168,Draft Guidance for Industry and Staff; Recommendations for Labeling Medical Products to Inform Users the Product or Product Container Is Not Made With Natural Rubber Latex
0900006481223626,Notice,FDA-2013-D-0168-0001,FDA-2013-D-0168,Draft Guidance for Industry and Staff; Availability: Recommendations for Labeling Medical Products to Inform Users the Product or Product Container Is Not Made With Natural Rubber Latex
0900006481954f4b,Other,FDA-2013-D-0168-0010,FDA-2013-D-0168,"Recommendations for Labeling Medical Products To Inform Users That
the Product or Product Container Is Not Made With Natural Rubber Latex;
Guidance for Industry and Food and Drug Administration Staff."
0900006481953f62,Notice,FDA-2013-D-0168-0009,FDA-2013-D-0168,"Recommendations for Labeling Medical Products To Inform Users That
the Product or Product Container Is Not Made With Natural Rubber Latex;
Guidance for Industry and Food and Drug Administration Staff; Availability."
0900006482922b8d,Supporting & Related Material,FDA-2017-P-4233-0004,FDA-2017-P-4233,Attachment 2 - Draft insert labeling for proposed product re Citizen Petition from Lachman Consultant Services Inc
0900006482922b8e,Supporting & Related Material,FDA-2017-P-4233-0005,FDA-2017-P-4233,"Attachment 3 - Approved labeling for reference-listed drug, Vimpat (lacosamide) Tablets re Citizien Petition from Lachman Consultant Services Inc"
0900006482922b8c,Supporting & Related Material,FDA-2017-P-4233-0003,FDA-2017-P-4233,"Attachment 1 -  Approved Drug Products with Therapeutic Equivalence Evaluations, Electronic Orange Book listing, accessed 7/12/17 re Citizen Petition Lachman Consultant Services Inc"
0900006482922570,Other,FDA-2017-P-4233-0001,FDA-2017-P-4233,"Citizen Petition from Lachman Consultant Services, Inc."
0900006482922578,Other,FDA-2017-P-4233-0002,FDA-2017-P-4233,Acknowledgement Letter from DDM to Lachman Consultant Services Inc
090000648178e162,Supporting & Related Material,FDA-2014-P-0933-0005,FDA-2014-P-0933,Exhibit 3 Colloid CP Citizen Petition From Teva Neuroscience Inc.
090000648178e163,Supporting & Related Material,FDA-2014-P-0933-0006,FDA-2014-P-0933,Exhibit 4 FDA Response to 6th Copax Petition Citizen Petition From Teva Neuroscience Inc.
090000648178e166,Supporting & Related Material,FDA-2014-P-0933-0009,FDA-2014-P-0933,Exhibit 7 2008 Petition Citizen Petition From Teva Neuroscience Inc.
090000648178d253,Supporting & Related Material,FDA-2014-P-0933-0003,FDA-2014-P-0933,Exhibit 1 FDA June 9 Letter Citizen Petition From Teva Neuroscience Inc.
090000648178e167,Supporting & Related Material,FDA-2014-P-0933-0010,FDA-2014-P-0933,Exhibit 8 2009 Petition Citizen Petition From Teva Neuroscience Inc.
090000648178e169,Supporting & Related Material,FDA-2014-P-0933-0012,FDA-2014-P-0933,Exhibit 10 2012 Petition Citizen Petition From Teva Neuroscience Inc.
090000648178e16b,Supporting & Related Material,FDA-2014-P-0933-0014,FDA-2014-P-0933,Exhibit 12 Bakshi Paper Citizen Petition From Teva Neuroscience Inc.
090000648178d254,Supporting & Related Material,FDA-2014-P-0933-0004,FDA-2014-P-0933,Exhibit 2 6thCopax Petition Citizen Petition From Teva Neuroscience Inc.
090000648178e164,Supporting & Related Material,FDA-2014-P-0933-0007,FDA-2014-P-0933,Exhibit 5 Towfic Article Citizen Petition From Teva Neuroscience Inc.
0900006481949949,Other,FDA-2014-P-0933-0021,FDA-2014-P-0933,"Denial Petition Response Letter from FDA CDER to Teva Neuroscience, Inc.,Teva Pharmaceuticals"
090000648178e165,Supporting & Related Material,FDA-2014-P-0933-0008,FDA-2014-P-0933,Exhibit 6 Teva Slides from Type C Meeting Citizen Petition From Teva Neuroscience Inc.
090000648178e168,Supporting & Related Material,FDA-2014-P-0933-0011,FDA-2014-P-0933,Exhibit 9 2010 Petition Citizen Petition From Teva Neuroscience Inc.
090000648180d4f8,Other,FDA-2014-P-0933-0018,FDA-2014-P-0933,"Supplement from Teva Neuroscience, Inc."
090000648178d251,Other,FDA-2014-P-0933-0002,FDA-2014-P-0933,Acknowledgement Letter From FDA DDM to Teva Neuroscience Inc
090000648178d24f,Other,FDA-2014-P-0933-0001,FDA-2014-P-0933,Citizen Petition From Teva Neuroscience
09000064817b5bbf,Other,FDA-2014-P-0933-0016,FDA-2014-P-0933,"Supplement from Teva Neuroscience, Inc."
090000648178e16a,Supporting & Related Material,FDA-2014-P-0933-0013,FDA-2014-P-0933,Exhibit 11 Leber Letter Citizen Petition From Teva Neuroscience Inc.
090000648343b713,Other,FDA-2018-P-1949-0045,FDA-2018-P-1949,"Petition Response Letter from FDA CDER to Avadel Specialty Pharmaceuticals, LLC"
090000648327fa49,Other,FDA-2018-P-1949-0001,FDA-2018-P-1949,"Citizen Petition from Avadel Specialty Pharmaceuticals, LLC"
090000648327fa4b,Other,FDA-2018-P-1949-0002,FDA-2018-P-1949,"Acknowledgment Letter from FDA DDM to Avadel Specialty Pharmaceuticals, LLC"
090000648327fa70,Supporting & Related Material,FDA-2018-P-1949-0009,FDA-2018-P-1949,"Fn 8_Stanley 2005 Eur Urol Supp_Importance of Sleep re Citizen Petition from Avadel Specialty Pharmaceuticals, LLC"
090000648327facf,Supporting & Related Material,FDA-2018-P-1949-0040,FDA-2018-P-1949,"Fn 47_20150112-EMDAC-T1-Transcript re Citizen Petition from Avadel Specialty Pharmaceuticals, LLC"
090000648327face,Supporting & Related Material,FDA-2018-P-1949-0039,FDA-2018-P-1949,"Fn 46_Ad Comm Minutes 1_12_15 re Citizen Petition from Avadel Specialty Pharmaceuticals, LLC"
090000648327fac6,Supporting & Related Material,FDA-2018-P-1949-0034,FDA-2018-P-1949,"Fn 38_NCT01262456 ClinicalTrials_gov re Citizen Petition from Avadel Specialty Pharmaceuticals, LLC"
090000648327fa89,Supporting & Related Material,FDA-2018-P-1949-0021,FDA-2018-P-1949,"Fn 22_Cohn 2017_Expert Rev Clin Pharmacol re Citizen Petition from Avadel Specialty Pharmaceuticals, LLC"
090000648327fa72,Supporting & Related Material,FDA-2018-P-1949-0011,FDA-2018-P-1949,"Fn 10_Stewart 1992 J Am Ger Soc_Nocturia Risk of Falls in Elderly re Citizen Petition from Avadel Specialty Pharmaceuticals, LLC"
090000648327faa4,Supporting & Related Material,FDA-2018-P-1949-0023,FDA-2018-P-1949,"Fn 24_Ad Comm Transcript 1_12_15 re Citizen Petition from Avadel Specialty Pharmaceuticals, LLC"
090000648327facb,Supporting & Related Material,FDA-2018-P-1949-0036,FDA-2018-P-1949,"Fn 42_Guidance for Industry_PRO Measures 2009 re Citizen Petition from Avadel Specialty Pharmaceuticals, LLC"
090000648327fad0,Supporting & Related Material,FDA-2018-P-1949-0041,FDA-2018-P-1949,"Fn 48_Nocdurna 2015 Complete Response Letter_Redacted re Citizen Petition from Avadel Specialty Pharmaceuticals, LLC"
090000648327fad1,Supporting & Related Material,FDA-2018-P-1949-0042,FDA-2018-P-1949,"Fn 49_Furness 2011 Cochrane Oral Health Group re Citizen Petition from Avadel Specialty Pharmaceuticals, LLC"
090000648327faca,Supporting & Related Material,FDA-2018-P-1949-0035,FDA-2018-P-1949,"Fn 41_Chapple et al_2006 Eur Urol re Citizen Petition from Avadel Specialty Pharmaceuticals, LLC"
090000648327facc,Supporting & Related Material,FDA-2018-P-1949-0037,FDA-2018-P-1949,"Fn 43_Abrams 2018 Neurourology Urodynamics re Citizen Petition from Avadel Specialty Pharmaceuticals, LLC"
090000648327fa4d,Supporting & Related Material,FDA-2018-P-1949-0003,FDA-2018-P-1949,"Fn 2_Bosch 2010 prevalence and cause of nocturia re Citizen Petition from Avadel Specialty Pharmaceuticals, LLC"
090000648327fa4e,Supporting & Related Material,FDA-2018-P-1949-0004,FDA-2018-P-1949,"Fn 3_Markland 2011 J Urol_NHANES prevalence of nocturia voids per night re Citizen Petition from Avadel Specialty Pharmaceuticals, LLC"
090000648327fa4f,Supporting & Related Material,FDA-2018-P-1949-0005,FDA-2018-P-1949,"Fn 4_Wein 2002 BJUI re Citizen Petition from Avadel Specialty Pharmaceuticals, LLC"
090000648327fa74,Supporting & Related Material,FDA-2018-P-1949-0013,FDA-2018-P-1949,"Fn 12_Kobelt 2003 BJU Intl_Vitality Utility Productivity in Nocturia re Citizen Petition from Avadel Specialty Pharmaceuticals, LLC"
090000648327fa75,Supporting & Related Material,FDA-2018-P-1949-0014,FDA-2018-P-1949,"Fn 13_Tikkinen 2010 Eur Urol_Nocturia frequency bother and QOL Finland re Citizen Petition from Avadel Specialty Pharmaceuticals, LLC"
090000648327fa84,Supporting & Related Material,FDA-2018-P-1949-0018,FDA-2018-P-1949,"Fn 19_Fjellestad 1993 Clinical Endocrinol re Citizen Petition from Avadel Specialty Pharmaceuticals, LLC"
090000648327fac2,Supporting & Related Material,FDA-2018-P-1949-0030,FDA-2018-P-1949,"Fn 34_Jin 2008 Indian J Urol_Practical mgmt of nocturia re Citizen Petition from Avadel Specialty Pharmaceuticals, LLC"
090000648327facd,Supporting & Related Material,FDA-2018-P-1949-0038,FDA-2018-P-1949,"Fn 44_Bennett 2018 Neurourology Urodynamics re Citizen Petition from Avadel Specialty Pharmaceuticals, LLC"
090000648327fad2,Supporting & Related Material,FDA-2018-P-1949-0043,FDA-2018-P-1949,"Fn 50_Nocdurna sublingual wafers_Product Information re Citizen Petition from Avadel Specialty Pharmaceuticals, LLC"
090000648327fa6f,Supporting & Related Material,FDA-2018-P-1949-0008,FDA-2018-P-1949,"Fn 7_Weiss 2009 J Urol_Prev of NP in nocturia re Citizen Petition from Avadel Specialty Pharmaceuticals, LLC"
0900006481b6dc3f,Other,FDA-2015-P-2373-0002,FDA-2015-P-2373,"Acknowledgement Letter from FDA DDM to David K. Cundiff, MD"
090000648490b114,Other,FDA-2015-P-2373-0008,FDA-2015-P-2373,Response Letter from FDA CDER to Dr. David K. Cundiff
0900006481dd5a42,Other,FDA-2015-P-2373-0006,FDA-2015-P-2373,Interim Response Letter from FDA CDER to Dr. David K. Cundiff
0900006481b6d5ee,Other,FDA-2015-P-2373-0001,FDA-2015-P-2373,"Citizen Petition from David K. Cundiff, MD"
090000648457a555,Other,FDA-2019-P-4424-0004,FDA-2019-P-4424,Response letter from FDA  CDER to Hibrow Healthcare  LLC
0900006483fac2b1,Other,FDA-2019-P-4424-0001,FDA-2019-P-4424,Citizen Petition from Hibrow Healthcare LLC
0900006483fac2b2,Other,FDA-2019-P-4424-0002,FDA-2019-P-4424,Acknowledgment Letter from FDA DMS to Hibrow Healthcare LLC
09000064844bf0e2,Other,FDA-2019-P-4424-0003,FDA-2019-P-4424,Interim Response Letter from FDA CDER to Hibrow Healthcare LLC
0900006482d843bf,Other,FDA-2017-P-7032-0001,FDA-2017-P-7032,Citizen Petition from Jubilant Generics Limited
0900006482d84aba,Supporting & Related Material,FDA-2017-P-7032-0005,FDA-2017-P-7032,Exhibit 3 Draft Labeling for proposed product re Citizen Petition from Jubilant Generics Limited
0900006482d84ab7,Supporting & Related Material,FDA-2017-P-7032-0003,FDA-2017-P-7032,Exhibit 1 Electronic Orange Book re Citizen Petition from Jubilant Generics Limited
0900006482d843c1,Other,FDA-2017-P-7032-0002,FDA-2017-P-7032,Acknowledgment Letter from FDA DDM to Jubilant Generics Limited
0900006482d84ab8,Supporting & Related Material,FDA-2017-P-7032-0004,FDA-2017-P-7032,Exhibit 2 RLD Labeling re Citizen Petition from Jubilant Generics Limited
0900006484c4a80a,Other,FDA-2017-P-7032-0006,FDA-2017-P-7032,Petition Approval Letter from FDA CDER to Jubilant Generics Limited
09000064841edadf,Supporting & Related Material,FDA-2019-P-5760-0005,FDA-2019-P-5760,Attachment 3 Reference Listed Drug Prescribing Information for Levetiracetam in Sodium Chloride Injection re: Citizen Petition from Sun Pharmaceutical Industries Limited
09000064841edad8,Other,FDA-2019-P-5760-0002,FDA-2019-P-5760,Acknowledgment Letter from FDA DMS to Sun Pharmaceutical Industries Limited
09000064841edade,Supporting & Related Material,FDA-2019-P-5760-0004,FDA-2019-P-5760,"Attachment 2 Proposed Prescribing Information for Levetiracetam in Sodium Chloride Injection 2.5 mg/mL, 5 mg/mL, 10 mg/mL and 15 mg/mL re: Citizen Petition from Sun Pharmaceutical Industries Limited"
0900006484bd644b,Other,FDA-2019-P-5760-0006,FDA-2019-P-5760,Amendment from Sun Pharmaceutical Industries Limited
09000064841ed95d,Other,FDA-2019-P-5760-0001,FDA-2019-P-5760,Citizen Petition from Sun Pharmaceutical Industries Limited
09000064841edadd,Supporting & Related Material,FDA-2019-P-5760-0003,FDA-2019-P-5760,Attachment 1 Approved Drug products with Therapeutic Equivalence Evaluation re: Citizen Petition from Sun Pharmaceutical Industries Limited
09000064844c6c80,Other,FDA-2019-P-1351-1251,FDA-2019-P-1351,Letter from Law Office of Alan Dumoff
0900006483b0f6dc,Other,FDA-2019-P-1351-0002,FDA-2019-P-1351,"Acknowledgment Letter from FDA DDM to Law Office of Alan Dumoff on behalf of American Association of Naturopathic Physicians, et al"
0900006483b0d4e2,Other,FDA-2019-P-1351-0001,FDA-2019-P-1351,"Citizen Petition from Law Office of Alan Dumoff on behalf of American Association of Naturopathic Physicians, et al"
0900006483f87413,Other,FDA-2019-P-1351-0351,FDA-2019-P-1351,Interim Response Letter from FDA CDER to Law Office of Alan Dumoff on behalf of American Association of Naturopathic Physicians
09000064804619af,Notice,FDA-2006-N-0425-0002,FDA-2006-N-0425,FDA
0900006480461999,Notice,FDA-2006-N-0425-0001,FDA-2006-N-0425,FDA
0900006480463622,Notice,FDA-2006-N-0491-0001,FDA-2006-N-0491,FDA
090000648046364e,Notice,FDA-2006-N-0491-0002,FDA-2006-N-0491,FDA
0900006480a007e0,Notice,FDA-2009-N-0353-0001,FDA-2009-N-0353,Cooperative Agreement Between the Food and Drug Administration and the Dauphin Island Sea Lab
09000064837dd937,Other,FDA-2018-P-3896-0002,FDA-2018-P-3896,Acknowledgment Letter from FDA DDM Chul-Hi Park Ph.D.
09000064837de290,Supporting & Related Material,FDA-2018-P-3896-0003,FDA-2018-P-3896,Attachment 1 Pedestrian Physics of Staple Line Leaks re: Citizen Petition from Chul-Hi Park Ph.D.
090000648495db00,Other,FDA-2018-P-3896-0005,FDA-2018-P-3896,Interim Response from FDA CDRH to Chul-Hi Park
09000064837dad33,Other,FDA-2018-P-3896-0001,FDA-2018-P-3896,Citizen Petition from Chul-Hi Park Ph.D.
0900006484dc39fa,Other,FDA-2018-P-3896-0006,FDA-2018-P-3896,Petition Response from FDA CDRH to Chul-Hi Park
0900006484dc9b20,Other,FDA-2021-P-1124-0002,FDA-2021-P-1124,Acknowledgment Letter from FDA DMS to Pet Schooled
0900006484dc9a35,Other,FDA-2021-P-1124-0001,FDA-2021-P-1124,Citizen Petition from Pet Schooled
0900006481f11635,Other,FDA-2016-P-1107-0001,FDA-2016-P-1107,Citizen Petition from Gordon Johnston Regulatory Consultants LLC
0900006481f11697,Supporting & Related Material,FDA-2016-P-1107-0003,FDA-2016-P-1107,Attachment A Product Listing from the Active Section of the Orange Book -  re Citizen Petition from Gordon Johnston Regulatory Consultants LLC
090000648235b994,Other,FDA-2016-P-1107-0004,FDA-2016-P-1107,Letter from CDER FDA to Gordon Johnston Regulatory Consultants LLC
0900006481f13d78,Other,FDA-2016-P-1107-0002,FDA-2016-P-1107,Acknowledgement Letter from FDA DDM to Gordon Johnston Regulatory Consultants LLC
0900006480be0f3b,Notice,FDA-2011-N-0049-0001,FDA-2011-N-0049,"Agency Information Collection Activities; Proposals, Submissions, and Approvals: Presubmission Conferences, New Animal Drug Applications and Supporting Regulations, etc."
0900006480c25e9a,Notice,FDA-2011-N-0049-0002,FDA-2011-N-0049,"Agency Information Collection Activities; Submission for Office  of Management  and Budget Review; Comment Request; Presubmission Conferences, New Animal Drug Applications and Supporting Regulations, and Food and Drug Administation Form 356V"
0900006482953f1d,Supporting & Related Material,FDA-2017-P-4372-0001,FDA-2017-P-4372,"Attachment 1- Biosmetics Eye Care re Citizen Petition from AEGIS Regulatory, Inc."
0900006482e19815,Other,FDA-2017-P-4372-0004,FDA-2017-P-4372,Petition Denial Letter from FDA CFSAN to AEGIS
090000648295386b,Other,FDA-2017-P-4372-0002,FDA-2017-P-4372,"Citizen Petition from AEGIS Regulatory, Inc."
0900006482953e5f,Other,FDA-2017-P-4372-0003,FDA-2017-P-4372,"Acknowledgment Letter from FDA DDM to AEGIS Regulatory, Inc."
0900006482bfe2c4,Other,FDA-2017-P-6248-0001,FDA-2017-P-6248,"Citizen Petiton from Lachman Consultant Services, Inc"
0900006482bfe3b2,Supporting & Related Material,FDA-2017-P-6248-0004,FDA-2017-P-6248,"Attachment 2 Draft insert labeling for proposed product re Citizen Petiton from Lachman Consultant Services, Inc"
0900006482bfe3b1,Supporting & Related Material,FDA-2017-P-6248-0003,FDA-2017-P-6248,"Attachment 1 Approved Drug Products with Therapeutic Equivalence Evaluations re Citizen Petiton from Lachman Consultant Services, Inc"
0900006482bfe3af,Other,FDA-2017-P-6248-0002,FDA-2017-P-6248,"Acknowledgement Letter from FDA DDM to Lachman Consultant Services, Inc"
0900006482bfe3b3,Supporting & Related Material,FDA-2017-P-6248-0005,FDA-2017-P-6248,"Attachment 3 Approved labeling for reference-listed drug, Topamax (Topiramate) Tablets re Citizen Petiton from Lachman Consultant Services, Inc"
090000648172a4bb,Other,FDA-2014-P-0752-0002,FDA-2014-P-0752,"Citizen Petition From Pharmacist's Planning Service, Inc."
0900006481a805fa,Other,FDA-2014-P-0752-0003,FDA-2014-P-0752,Petition Denial Letter from FDA CDER to Pharmacists Planning Service Inc. PPSI
090000648172a4c1,Other,FDA-2014-P-0752-0001,FDA-2014-P-0752,"Acknowledgement Letter From FDA DDM to Pharmacists Planning Service, Inc."
0900006482344c9e,Supporting & Related Material,FDA-2014-P-1282-0007,FDA-2014-P-1282,ATTACHMENT 3 FDA-Approved Labeling for RLD (2016) re Suitability Petition Amendment from Morgan Lewis & Bockius LLP
0900006482344e28,Supporting & Related Material,FDA-2014-P-1282-0008,FDA-2014-P-1282,ATTACHMENT 4 Draft Labeling for Proposed ANDA Product (2016} re Suitability Petition Amendment from Morgan Lewis & Bockius LLP
0900006482344c07,Other,FDA-2014-P-1282-0005,FDA-2014-P-1282,Suitability Petition AMENDMENT from Morgan Lewis & Bockius LLP
0900006481864b3c,Supporting & Related Material,FDA-2014-P-1282-0004,FDA-2014-P-1282,Attachment 1 FDA Approved Labeling for Reference Listed Drug
0900006481864b3b,Supporting & Related Material,FDA-2014-P-1282-0003,FDA-2014-P-1282,Attachment 2 Draft labeling for Proposed ANDA Drug
0900006481857034,Other,FDA-2014-P-1282-0001,FDA-2014-P-1282,Citizen Petition from Morgan Lewis & Bockius LLP
0900006482344c99,Supporting & Related Material,FDA-2014-P-1282-0006,FDA-2014-P-1282,ATTACHMENT 2 Draft Labeling for Proposed ANDA Product (2014) re Suitability Petition Amendment from Morgan Lewis & Bockius LLP
0900006481857036,Other,FDA-2014-P-1282-0002,FDA-2014-P-1282,Acknowledgement Letter from FDA DDM to Morgan Lewis & Bockius LLP
09000064821e0d87,Notice,FDA-2016-P-1037-0004,FDA-2016-P-1037,"Determination That PREVACID IV (Lansoprazole) Intravenous Injection,
30 Milligrams/Vial, Was Not Withdrawn From Sale for Reasons of Safety or
Effectiveness"
0900006481ed7162,Other,FDA-2016-P-1037-0001,FDA-2016-P-1037,"Citizen Petition from Rose Zhao, Emprise Pharma"
0900006481ed7508,Other,FDA-2016-P-1037-0003,FDA-2016-P-1037,Acknowledgement Letter from FDA DDM to Rose Zhao
0900006481ed7d94,Supporting & Related Material,FDA-2016-P-1037-0002,FDA-2016-P-1037,"Attachment 1 - Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations for Prevacid IV re Citizen Petition from Rose Zhao, Emprise Pharma"
0900006481856a09,Supporting & Related Material,FDA-2014-P-1038-0004,FDA-2014-P-1038,"Attachment B Amphetamine Sulfate Description  Each tablet for oral administration contains 5 mg or 10 mg of amphetamine sulfate re Citizen Petition From Lachman Consultant Services Inc., FDA-2014-P-1038-0001"
0900006481856a08,Supporting & Related Material,FDA-2014-P-1038-0003,FDA-2014-P-1038,"Attachment A Orange Book Approved Drug Products with Therapeutic Equivalence Evaluations re Citizen Petition From Lachman Consultant Services Inc., FDA-2014-P-1038-0001"
090000648185693a,Other,FDA-2014-P-1038-0002,FDA-2014-P-1038,Acknowledgement Letter From FDA DDM to Lachman Consultant Services Inc
0900006481855c94,Other,FDA-2014-P-1038-0001,FDA-2014-P-1038,Citizen Petition From Lachman Consultant Services Inc
0900006481856a0a,Supporting & Related Material,FDA-2014-P-1038-0005,FDA-2014-P-1038,"Attachment C Amphetamine Sulfate Description  Each tablet for oral administration contains 2.5 mg  5 mg 10 mg 15 mg 20 mg or 30 mg of amphetamine sulfate re Citizen Petition From Lachman Consultant Services Inc., FDA-2014-P-1038-0001"
090000648424b53f,Other,FDA-2019-P-3082-0004,FDA-2019-P-3082,"Interim Response Letter from FDA CDER to Andarix Pharmaceuticals, Inc"
0900006483d42e3e,Other,FDA-2019-P-3082-0001,FDA-2019-P-3082,"Citizen Petition from Andarix Pharmaceuticals, Inc."
0900006483d42b69,Other,FDA-2019-P-3082-0002,FDA-2019-P-3082,"Acknowledgment Letter from FDA DDM to Andarix Pharmaceuticals, Inc."
0900006483d44de6,Supporting & Related Material,FDA-2019-P-3082-0003,FDA-2019-P-3082,"Appendix 1- Electronic Orange Book Listing of NEO Tect Kit re Citizen Petition from Andarix Pharmaceuticals, Inc."
09000064843d8726,Notice,FDA-2019-P-3082-0005,FDA-2019-P-3082,Determination That NEO TECT KIT (Kit for the Preparation of Technetium TC–99m Depreotide Injection) Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
09000064823da94a,Other,FDA-2016-P-4164-0002,FDA-2016-P-4164,"Acknowledgment Letter from FDA DDM to Lachman Consultant Services, Inc."
09000064823daa90,Supporting & Related Material,FDA-2016-P-4164-0005,FDA-2016-P-4164,ATTACHMENT 3 - CARBINOXAMINE MALEATE- carbinoxamine maleate tablet re Citizen Petition from Lachman Consultant Services Inc
09000064823daa8e,Supporting & Related Material,FDA-2016-P-4164-0003,FDA-2016-P-4164,ATTACHMENT 1 - Orange Book Approved Drug Products with Therapeutic Equivalence re Citizen Petition from Lachman Consultant Services Inc
09000064823daa8f,Supporting & Related Material,FDA-2016-P-4164-0004,FDA-2016-P-4164,ATTACHMENT 2 - CARBINOXAMINE MALEATE - carbinoxamine maleate orally disintegrating tablet re Citizen Petition from Lachman Consultant Services Inc
0900006484841d57,Other,FDA-2016-P-4164-0006,FDA-2016-P-4164,Response for Information Request from Lachman Consultant Services
09000064823da316,Other,FDA-2016-P-4164-0001,FDA-2016-P-4164,Citizen Petition from Lachman Consultant Services Inc
0900006481750c88,Supporting & Related Material,FDA-2014-P-0813-0004,FDA-2014-P-0813,"Attachment 2 Labeling for Listed Drug, Sandoz, Citizen Petition From Lachman Consultant Services Inc."
0900006481750c89,Supporting & Related Material,FDA-2014-P-0813-0005,FDA-2014-P-0813,"Attachment 3 Labeling for Drug, Eagle Pharm, Citizen Petition From Lachman Consultant Services Inc."
090000648484f8c1,Other,FDA-2014-P-0813-0007,FDA-2014-P-0813,"Withdrawal from Lachman Consultant Services, Inc."
0900006481750c8a,Supporting & Related Material,FDA-2014-P-0813-0006,FDA-2014-P-0813,"Attachment 4 Draft Insert Labeling, Citizen Petition From Lachman Consultant Services Inc."
0900006481750b20,Other,FDA-2014-P-0813-0001,FDA-2014-P-0813,"Citizen Petition From Lachman Consultant Services, Inc."
0900006481750c85,Other,FDA-2014-P-0813-0002,FDA-2014-P-0813,"Acknowledgement Letter From FDA DDM to Lachman Consultant Services, Inc."
0900006481750c87,Supporting & Related Material,FDA-2014-P-0813-0003,FDA-2014-P-0813,Attachment 1 Orange Book Excerpt Citizen Petition From Lachman Consultant Services Inc.
0900006482a9619d,Other,FDA-2017-P-5124-0001,FDA-2017-P-5124,"Citizen Petition from Hyman, Phelps & McNamara, PC"
0900006482ef71e5,Other,FDA-2017-P-5124-0004,FDA-2017-P-5124,"Final Response Letter from FDA to Hyman, Phelps & McNamara, PC"
090000648300e7c9,Rule,FDA-2017-P-5124-0005,FDA-2017-P-5124,Medical Devices: Exemption from Premarket Notification; Class II Devices; Over-the-Counter Denture Repair Kit
0900006482c9142c,Notice,FDA-2017-P-5124-0003,FDA-2017-P-5124,Medical Devices; Exemption From Premarket Notification: Over-the-Counter Denture Repair Kits
0900006482a961a1,Other,FDA-2017-P-5124-0002,FDA-2017-P-5124,"Acknowledgement Letter from FDA DDM to Hyman, Phelps & McNamara, PC"
090000648297f09f,Other,FDA-2017-P-4500-0001,FDA-2017-P-4500,Citizen Petition from Kent Heckenlively
0900006484486259,Other,FDA-2017-P-4500-1795,FDA-2017-P-4500,Interim Response Heckenlively CP FINAL
090000648297f601,Supporting & Related Material,FDA-2017-P-4500-0003,FDA-2017-P-4500,Exhibit A VACCINATION MORATORIUM REGULATION re Citizen Petition from Kent Heckenlively
090000648297f0cb,Other,FDA-2017-P-4500-0002,FDA-2017-P-4500,Acknowledgement Letter from FDA DDM to Kent Heckenlively
0900006484b39782,Supporting & Related Material,FDA-2021-P-0513-0003,FDA-2021-P-0513,"Attachment 1 - COLESTID Prescription Drug List re Suitability Petition from Hyman, Phelps & McNamara P.C."
0900006484b39785,Supporting & Related Material,FDA-2021-P-0513-0004,FDA-2021-P-0513,"Attachment 2 - COLESTID PI FLAVORED COLESTID- colestipol hydrochloride granule, for suspension Pharmacia and Upjohn Company LLC re Suitability Petition from Hyman, Phelps & McNamara P.C."
0900006484b39786,Supporting & Related Material,FDA-2021-P-0513-0005,FDA-2021-P-0513,"Attachment 3 - Colestipol hydrochloride PI Colestipol hydrochloride granules for oral suspension re Suitability Petition from Hyman, Phelps & McNamara P.C."
0900006484b38fcd,Other,FDA-2021-P-0513-0002,FDA-2021-P-0513,"Acknowledgment Letter from FDA DMS to Hyman, Phelps & McNamara P.C."
0900006484b38fcb,Other,FDA-2021-P-0513-0001,FDA-2021-P-0513,"Suitability Petition from Hyman, Phelps & McNamara P.C."
0900006484b4186d,Other,FDA-2020-P-2247-0020,FDA-2020-P-2247,Interim Response Letter from FDA CDER to Boehringer Ingelheim USA Corporation
0900006484ab8e22,Supporting & Related Material,FDA-2020-P-2247-0018,FDA-2020-P-2247,Summary of 3-17-21 Meeting with Boehringer Ingelheim
0900006484981e75,Supporting & Related Material,FDA-2020-P-2247-0006,FDA-2020-P-2247,"Exhibit 9 re: Boehringer Ingelheim USA Corporation on behalf of Boehringer Ingelheim Pharmaceuticals, Inc"
0900006484981e4c,Supporting & Related Material,FDA-2020-P-2247-0013,FDA-2020-P-2247,"Exhibit 2 re: Boehringer Ingelheim USA Corporation on behalf of Boehringer Ingelheim Pharmaceuticals, Inc"
0900006484981e77,Supporting & Related Material,FDA-2020-P-2247-0004,FDA-2020-P-2247,"Exhibit 11 re: Boehringer Ingelheim USA Corporation on behalf of Boehringer Ingelheim Pharmaceuticals, Inc"
0900006484981e76,Supporting & Related Material,FDA-2020-P-2247-0005,FDA-2020-P-2247,"Exhibit 10 re: Boehringer Ingelheim USA Corporation on behalf of Boehringer Ingelheim Pharmaceuticals, Inc"
0900006484981e4d,Supporting & Related Material,FDA-2020-P-2247-0012,FDA-2020-P-2247,"Exhibit 3 re: Boehringer Ingelheim USA Corporation on behalf of Boehringer Ingelheim Pharmaceuticals, Inc"
0900006484981e74,Supporting & Related Material,FDA-2020-P-2247-0007,FDA-2020-P-2247,"Exhibit 8 re: Boehringer Ingelheim USA Corporation on behalf of Boehringer Ingelheim Pharmaceuticals, Inc"
0900006484981e4f,Supporting & Related Material,FDA-2020-P-2247-0010,FDA-2020-P-2247,"Exhibit 5 re: Boehringer Ingelheim USA Corporation on behalf of Boehringer Ingelheim Pharmaceuticals, Inc"
0900006484981e78,Supporting & Related Material,FDA-2020-P-2247-0003,FDA-2020-P-2247,"Exhibit 12 re: Boehringer Ingelheim USA Corporation on behalf of Boehringer Ingelheim Pharmaceuticals, Inc"
0900006484981e49,Other,FDA-2020-P-2247-0002,FDA-2020-P-2247,"Acknowledgment Letter from FDA DMS to Boehringer Ingelheim USA Corporation on behalf of Boehringer Ingelheim Pharmaceuticals, Inc"
0900006484982237,Other,FDA-2020-P-2247-0001,FDA-2020-P-2247,"Citizen Petition from Boehringer Ingelheim USA Corporation on behalf of Boehringer Ingelheim Pharmaceuticals, Inc"
0900006484ab8e23,Supporting & Related Material,FDA-2020-P-2247-0019,FDA-2020-P-2247,Boehringer Ingelheim FDA Meeting Slides
0900006484981e4b,Supporting & Related Material,FDA-2020-P-2247-0014,FDA-2020-P-2247,"Exhibit 1 re: Boehringer Ingelheim USA Corporation on behalf of Boehringer Ingelheim Pharmaceuticals, Inc"
0900006484981e4e,Supporting & Related Material,FDA-2020-P-2247-0011,FDA-2020-P-2247,"Exhibit 4 re: Boehringer Ingelheim USA Corporation on behalf of Boehringer Ingelheim Pharmaceuticals, Inc"
0900006484981e50,Supporting & Related Material,FDA-2020-P-2247-0009,FDA-2020-P-2247,"Exhibit 6 re: Boehringer Ingelheim USA Corporation on behalf of Boehringer Ingelheim Pharmaceuticals, Inc"
0900006484981e51,Supporting & Related Material,FDA-2020-P-2247-0008,FDA-2020-P-2247,"Exhibit 7 re: Boehringer Ingelheim USA Corporation on behalf of Boehringer Ingelheim Pharmaceuticals, Inc"
0900006484cb2a60,Other,FDA-2021-P-0953-0001,FDA-2021-P-0953,Citizen Petition from Lisa Harper
0900006484cb2a37,Other,FDA-2021-P-0953-0002,FDA-2021-P-0953,Acknowledgment Letter from FDA DMS to Lisa Harper
090000648045729b,Notice,FDA-2006-N-0245-0004,FDA-2006-N-0245,FDA
0900006480457292,Supporting & Related Material,FDA-2006-N-0245-0002,FDA-2006-N-0245,Supporting Statement
090000648045729a,Supporting & Related Material,FDA-2006-N-0245-0003,FDA-2006-N-0245,Supporting Statement
0900006480457276,Notice,FDA-2006-N-0245-0001,FDA-2006-N-0245,FDA
0900006480a5f1d0,Other,FDA-2009-D-0563-0002,FDA-2009-D-0563,"Draft Guidance for Industry and Food and Drug Administration Staff; Preliminary Timetable for the Review of Applications for Modified Risk Tobacco Products Under the Federal Food, Drug, and Cosmetic Act; Guidance"
0900006480a5f56b,Notice,FDA-2009-D-0563-0001,FDA-2009-D-0563,"Draft Guidance for Industry and Food and Drug Administration Staff; Preliminary Timetable for the Review of Applications for Modified Risk Tobacco Products Under the Federal Food, Drug, and Cosmetic Act; Availability"
0900006484a73c42,Other,FDA-2021-P-0311-0002,FDA-2021-P-0311,Acknowledgment Letter from FDA DMS to Loeb & Loeb LLP
0900006484a73c40,Other,FDA-2021-P-0311-0001,FDA-2021-P-0311,Citizen Petition from Loeb & Loeb LLP
0900006484d7c830,Other,FDA-2021-P-0311-0003,FDA-2021-P-0311,Interim Response from FDA CDER to James N. Czaban and Eve Costopoulos
0900006482a32e19,Other,FDA-2017-P-4939-0002,FDA-2017-P-4939,Acknowledgement Letter from FDA DDM to Chul-Hi Park
09000064833efb10,Other,FDA-2017-P-4939-0005,FDA-2017-P-4939,Interim Response Letter to Dr. Chul-Hi Park
0900006483338191,Other,FDA-2017-P-4939-0004,FDA-2017-P-4939,Interim response letter from FDA-CDRH to Dr. Chul-Hi Park
0900006484dc39d8,Other,FDA-2017-P-4939-0006,FDA-2017-P-4939,Petition Response from FDA CDRH to Chul-Hi Park
0900006482a32dc7,Other,FDA-2017-P-4939-0001,FDA-2017-P-4939,Citizen Petition from Chul-Hi Park
0900006484e42d22,Supporting & Related Material,FDA-2021-P-1215-0003,FDA-2021-P-1215,Attachment 1 - Federal register RE: Citizen Petition from Alembic Pharmaceutical Limited
0900006484e42c90,Other,FDA-2021-P-1215-0002,FDA-2021-P-1215,Acknowledgment Letter from FDA DMS to Alembic Pharmaceutical Limited
0900006484e42d23,Supporting & Related Material,FDA-2021-P-1215-0004,FDA-2021-P-1215,Attachment 2 - Electronic orange book RE: Citizen Petition from Alembic Pharmaceutical Limited
0900006484e42036,Other,FDA-2021-P-1215-0001,FDA-2021-P-1215,Citizen Petition from Alembic Pharmaceutical Limited
09000064822f358e,Supporting & Related Material,FDA-2016-P-3311-0003,FDA-2016-P-3311,Attachment A Evidence to Support the Use of Polydextrose as a Source of Dietary Fiber in the United States: Evidence Summarizing its Physiological Effects and Caloric Content re Citizen Petition from Tate & Lyle Ingredients Americas LLC  and DuPont Nutrition & Health
09000064822f358f,Supporting & Related Material,FDA-2016-P-3311-0004,FDA-2016-P-3311,"Attachment B - Part 1 Gastrointestinal effects and energy value of polydextrose in healthy non obese men 1, 2 re Citizen Petition from Tate & Lyle Ingredients Americas LLC  and DuPont Nutrition & Health"
09000064822f3592,Supporting & Related Material,FDA-2016-P-3311-0007,FDA-2016-P-3311,Attachment B - Part 4 Impact of Dietary Polydextrose Fiber on the Human Gut Metabolome re Citizen Petition from Tate & Lyle Ingredients Americas LLC  and DuPont Nutrition & Health
09000064822f358c,Other,FDA-2016-P-3311-0001,FDA-2016-P-3311,Citizen Petition from Tate & Lyle Ingredients Americas LLC  and DuPont Nutrition & Health
09000064822f3594,Supporting & Related Material,FDA-2016-P-3311-0009,FDA-2016-P-3311,Attachment B - Part 6  Polydextrose: its impact on short-term food intake and subjective feelings of satiety in males-a randomized controlled cross-over study re Citizen Petition from Tate & Lyle Ingredients Americas LLC  and DuPont Nutrition & Health
0900006482534b14,Other,FDA-2016-P-3311-0012,FDA-2016-P-3311,Tate & Lyle Ingredients Americas LLC and DuPont Nutrition & Health
09000064822f3593,Supporting & Related Material,FDA-2016-P-3311-0008,FDA-2016-P-3311,"Attachment B - Part 5 Comparative Laxation of Psyllium with and without
Senna in an Ambulatory Constipated Population re Citizen Petition from Tate & Lyle Ingredients Americas LLC  and DuPont Nutrition & Health"
09000064822f43d7,Other,FDA-2016-P-3311-0002,FDA-2016-P-3311,Acknowledgment Letter from FDA DDM to Tate & Lyle Ingredients Americas LLC  and DuPont Nutrition & Health
09000064822f3590,Supporting & Related Material,FDA-2016-P-3311-0005,FDA-2016-P-3311,"Attachment B - Part 2 Effect of High Cholesterol Diet and Polydextrose Supplementation on the Microflora, Bacterial Enzyme Activity, Putrefactive Products, Volatile Faty Acid re Citizen Petition from Tate & Lyle Ingredients Americas LLC  and DuPont Nutrition & Health"
09000064822f3591,Supporting & Related Material,FDA-2016-P-3311-0006,FDA-2016-P-3311,Attachment B - Part 3 Effects of polydextrose on different levels of energy intake.  A systematic review and meta-analysis re Citizen Petition from Tate & Lyle Ingredients Americas LLC  and DuPont Nutrition & Health
0900006483410f0c,Other,FDA-2016-P-3311-0013,FDA-2016-P-3311,FDA-2016-P-3311 TateLyle DuPont Nutrition Granting Response
0900006484e03fba,Other,FDA-2021-P-1183-0002,FDA-2021-P-1183,Acknowledgment Letter from FDA DMS to Pet Schooled
0900006484e03f8a,Other,FDA-2021-P-1183-0001,FDA-2021-P-1183,Citizen Petition from Pet Schooled
09000064849ae940,Notice,FDA-2010-N-0161-0012,FDA-2010-N-0161,Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Export of Food and Drug Administration-Regulated Products: Export Certificates
0900006482cae34e,Notice,FDA-2010-N-0161-0007,FDA-2010-N-0161,"Agency Information Collection Activities; Proposed Collection; 
Comment Request; Export of Food and Drug Administration-Regulated 
Products: Export Certificates"
090000648192e746,Notice,FDA-2010-N-0161-0003,FDA-2010-N-0161,"Agency Information Collection Activities; Proposed Collection;
Comment Request; Export of Food and Drug Administration Regulated
Products: Export Certificates"
09000064849f0cfc,Notice,FDA-2010-N-0161-0013,FDA-2010-N-0161,Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Export of Food and Drug Administration-Regulated Products: Export Certificates
0900006484b1b457,Notice,FDA-2010-N-0161-0015,FDA-2010-N-0161,Agency Information Collection Activities; Announcement of Office of Management and Budget Approvals
0900006480acd1ce,Notice,FDA-2010-N-0161-0001,FDA-2010-N-0161,"Agency Information Collection Activities; Proposals, Submissions, and Approvals: Export of Food and Drug Administration Regulated Products; Export Certificates"
0900006480b67bc8,Notice,FDA-2010-N-0161-0002,FDA-2010-N-0161,"Agency Information Collection Activities; Proposals, Submissions, and Approvals: Export of Food and Drug Administration Regulated Products; Export Certificates"
0900006482f453d7,Notice,FDA-2010-N-0161-0010,FDA-2010-N-0161,"Agency Information Collection Activities; Submission for Office of
Management and Budget Review; Comment Request; Export of Food and Drug Administration-Regulated Products: Export Certificates"
09000064819f7e45,Notice,FDA-2010-N-0161-0004,FDA-2010-N-0161,"Agency Information Collection Activities; Submission for Office of
Management and Budget Review; Comment Request; Export of Food and Drug Administration Regulated Products: Export Certificates"
090000648337b832,Notice,FDA-2010-N-0161-0011,FDA-2010-N-0161,"Agency Information Collection Activities; Announcement of Office of
Management and Budget Approvals"
0900006481a02519,Notice,FDA-2010-N-0161-0005,FDA-2010-N-0161,"Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Export of Food and Drug Administration Regulated Products: Export Certificates;
Correction"
0900006481b5dc5e,Notice,FDA-2010-N-0161-0006,FDA-2010-N-0161,"Agency Information Collection Activities; Announcement of Office of
Management and Budget Approval; Export Certificates for Food and Drug Administration Regulated Products"
09000064824e152e,Supporting & Related Material,FDA-2017-P-1230-0003,FDA-2017-P-1230,Attachment 1 Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations re Citizen Petition from Regcon Solutions
09000064824e152b,Other,FDA-2017-P-1230-0001,FDA-2017-P-1230,Citizen Petition from Regcon Solutions
09000064824e152d,Other,FDA-2017-P-1230-0002,FDA-2017-P-1230,Acknowledgement Letter from FDA DDM to Regcon Solutions
0900006482d441c1,Other,FDA-2017-P-1230-0006,FDA-2017-P-1230,Final Response from FDA CDER to RegCon Solutions
0900006482a8da9b,Other,FDA-2017-P-1230-0004,FDA-2017-P-1230,Interim Response from FDA CDER to RegCon Solutions
09000064839ac197,Other,FDA-2016-P-1285-0008,FDA-2016-P-1285,"Letter from FDA CDER to Akorn Pharmaceuticals, Mylan Pharmaceuticals, Inc., Gland Pharma Limited, Foley & Lardner LLP"
0900006481fd8973,Supporting & Related Material,FDA-2016-P-1285-0003,FDA-2016-P-1285,"Attachment 1 Approved Drug Products with Therapeutic Equivalence Evaluation (Electronic Orange Book) accessed May 11, 2016 re Citizen Petition from Mylan Pharmaceuticals Inc"
0900006481fda244,Other,FDA-2016-P-1285-0002,FDA-2016-P-1285,Acknowledgement Letter from FDA DDM to Mylan Pharmaceuticals Inc
0900006481fd8971,Other,FDA-2016-P-1285-0001,FDA-2016-P-1285,Citizen Petition from Mylan Pharmaceuticals Inc
0900006481fd8975,Supporting & Related Material,FDA-2016-P-1285-0005,FDA-2016-P-1285,"Attachment 3 Labeling of the approved product, Furosemide Injection-10 mg/mL by Fresenius Kabi re Citizen Petition from Mylan Pharmaceuticals Inc"
0900006481fd8974,Supporting & Related Material,FDA-2016-P-1285-0004,FDA-2016-P-1285,"Attachment 2 Draft Insert Labeling Proposed for Furosemide Injection, USP-10 mg/mL re Citizen Petition from Mylan Pharmaceuticals Inc"
0900006481fd8976,Supporting & Related Material,FDA-2016-P-1285-0006,FDA-2016-P-1285,"Attachment 4 Labeling of the approved product, Furosemide Injection-10 mg/mL by Hospira re Citizen Petition from Mylan Pharmaceuticals Inc"
0900006482f3ad3a,Other,FDA-2016-P-1285-0007,FDA-2016-P-1285,Interim Response Letter from FDA CDER to Mylan Pharmaceuticals Inc
0900006480f4c517,Notice,FDA-2011-N-0708-0001,FDA-2011-N-0708,"Agency Information Collection Activities; Proposed Collection; Comment Request; FDA Form 3728, Animal Generic Drug User Fee Act Cover Sheet"
090000648109da1c,Notice,FDA-2011-N-0708-0002,FDA-2011-N-0708,"Agency Information Collection Activities; Proposals, Submissions, and Approvals: Animal Generic Drug User Fee Act Cover Sheet"
0900006480f65e5a,Other,FDA-2011-P-0355-0020,FDA-2011-P-0355,"Mela Sciences, Inc. - Withdrawal of Citizen Petition"
0900006480c7a537,Supporting & Related Material,FDA-2011-P-0355-0017,FDA-2011-P-0355,"Attachment 20 - ""Electronic Correspondence Between EOSciences and FDA/CDRH, re P090012- MelaFind, November 23, 2009"" - [MELA™ Sciences, Inc. - Citizen Petition]  - [MELA™ Sciences, Inc. - Citizen Petition]"
0900006480c79fd1,Supporting & Related Material,FDA-2011-P-0355-0007,FDA-2011-P-0355,"Attachment 9 - ""FDA/CDRH Letter to Electro-Optical Sciences, Inc., October 4, 2006 re MelaFind"" - [MELA™ Sciences, Inc. - Citizen Petition]"
0900006480c7a10e,Supporting & Related Material,FDA-2011-P-0355-0010,FDA-2011-P-0355,"Attachment 12 - ""FDA PMA P090012 Executive Summary, November 18, 2010"" - [MELA™ Sciences, Inc. - Citizen Petition]"
0900006480c7a534,Supporting & Related Material,FDA-2011-P-0355-0014,FDA-2011-P-0355,"Attachment 17 - ""Electronic Correspondence Between EOSciences and FDA/CDRH, re P090012 Corrected Filing Letter, August 24, 2009"" - [MELA™ Sciences, Inc. - Citizen Petition]"
0900006480c79fcc,Supporting & Related Material,FDA-2011-P-0355-0003,FDA-2011-P-0355,"Attachment 4 - ""105TH Congress, House of Representatives (Report 105-307) re Medical Device Regulatory Modernization Act of 1997"" - [MELA™ Sciences, Inc.  - Citizen Petition]"
0900006480c79fcf,Supporting & Related Material,FDA-2011-P-0355-0006,FDA-2011-P-0355,"Attachment 7 - ""Electronic Correspondence Between EOSciences and FDA/CDRH, re Revised Protocol 20061, January 4, 2006"" - [MELA™ Sciences, Inc. - Citizen Petition]"
0900006480c7a111,Supporting & Related Material,FDA-2011-P-0355-0011,FDA-2011-P-0355,"Attachment 13 - ""FDA Advisory Committee, General and Plastic Surgery Devices Panel, November 18, 2010"" - [MELA™ Sciences, Inc. - Citizen Petition]"
0900006480c7a112,Supporting & Related Material,FDA-2011-P-0355-0012,FDA-2011-P-0355,"Attachment 14 - ""FDA Presentation, P090012 MelaFind® MELA Sciences, Inc., November 18. 2010"" - [MELA™ Sciences, Inc. - Citizen Petition]"
0900006480f65bee,Other,FDA-2011-P-0355-0021,FDA-2011-P-0355,"FDA/CDRH to Mela Science, Inc. - Response Letter"
0900006480c7a539,Other,FDA-2011-P-0355-0019,FDA-2011-P-0355,"Acknowledgement Letter to MELA Sciences, Inc."
0900006480c79fce,Supporting & Related Material,FDA-2011-P-0355-0005,FDA-2011-P-0355,"Attachment 6 - Electro-Optical Sciences, Inc.™ Protocol 20061: Evaluation of Pigmented Skin Lesions with MelaFind® System - [MELA™ Sciences, Inc. - Citizen Petition]"
0900006480c79fd2,Supporting & Related Material,FDA-2011-P-0355-0008,FDA-2011-P-0355,"Attachment 10 - ""FDA/CDRH Letter to Electro-Optical Sciences, Inc., March 10, 2010, re MelaFind"" - [MELA™ Sciences, Inc. - Citizen Petition]"
0900006480c79fcb,Supporting & Related Material,FDA-2011-P-0355-0002,FDA-2011-P-0355,"Attachment 3 - ""FDA/CDRH Division of General, Restorative and Neurological Devices  Letter to Electro-Optical Sciences, Inc., October 29, 2004"" - [MELA™ Sciences, Inc. - Citizen Petition]"
0900006480c79fcd,Supporting & Related Material,FDA-2011-P-0355-0004,FDA-2011-P-0355,"Attachment 5 - Melafinf® Panel Meeting November 24, 2010 - [MELA™ Sciences, Inc. - Citizen Petition]"
0900006480c7a10d,Supporting & Related Material,FDA-2011-P-0355-0009,FDA-2011-P-0355,"Attachment 11 - ""Electro-Optical Sciences, Inc., (Goodwin Procter) Letter to FDA/CDRH, April 15, 2010 re P090012 MelaFind...."" - [MELA™ Sciences, Inc. - Citizen Petition]"
0900006480c7a535,Supporting & Related Material,FDA-2011-P-0355-0015,FDA-2011-P-0355,"Attachment 18 - ""Electronic Correspondence Between EOSciences and FDA/CDRH, re P090012 90-Day Letter, October 13, 2009"" - [MELA™ Sciences, Inc. - Citizen Petition]"
0900006480c7a536,Supporting & Related Material,FDA-2011-P-0355-0016,FDA-2011-P-0355,"Attachment 19 - ""FDA/CDRH Letters to Electro-Optical Sciences, Inc., August 18, 2009 and July 29, 2009"" - [MELA™ Sciences, Inc. - Citizen Petition]"
0900006480c7a538,Supporting & Related Material,FDA-2011-P-0355-0018,FDA-2011-P-0355,"Attachment 21 - ""FDA Panel Meeting, November, 18, 2010, re FDA Alters the Definition of Safety & Effectiveness"" - [MELA™ Sciences, Inc. - Citizen Petition]"
0900006480c75c18,Other,FDA-2011-P-0355-0001,FDA-2011-P-0355,"MELA Sciences, Inc. - Citizen Petition"
0900006480c7a116,Supporting & Related Material,FDA-2011-P-0355-0013,FDA-2011-P-0355,"Attachment 16 - ""Original Premarket Approval Application PMA# P090012 MelaFind®, Non-Invasive Imaging Device for the Early Detection of Melanoma, Electro-Optical Sciences, Inc."" - [MELA™ Sciences, Inc. - Citizen Petition]"
09000064819090bd,Other,FDA-2014-P-1771-0001,FDA-2014-P-1771,Citizen Petition From Amgen Sidley Austin LLP
0900006481a68396,Other,FDA-2014-P-1771-0004,FDA-2014-P-1771,Citizen Petition Denial Response
09000064819090c0,Other,FDA-2014-P-1771-0002,FDA-2014-P-1771,Acknowledgement Letter From FDA DDM to Sidley Austin LLP
0900006481a84f74,Other,FDA-2014-P-1569-0003,FDA-2014-P-1569,Petition Denial Letter from CDER to Pharmacists Planning Service Inc.
09000064818b90ee,Other,FDA-2014-P-1569-0001,FDA-2014-P-1569,Acknowledgment Letter from FDA DDM to Pharmacists Planning Service Inc
09000064818b6fc0,Other,FDA-2014-P-1569-0002,FDA-2014-P-1569,Citizen Petition from Pharmacists Planning Service Inc
090000648261034e,Notice,FDA-2013-N-0578-0006,FDA-2013-N-0578,"Agency Information Collection Activities; Announcement of Office of
Management and Budget Approvals"
0900006483f9b1fd,Notice,FDA-2013-N-0578-0007,FDA-2013-N-0578,"Agency Information Collection Activities; Proposed Collection; Comment Request; General Licensing Provisions: Biologics License Application, Changes to an Approved Application, Labeling, Revocation and Suspension, Postmarketing Studies Status Reports, and Form FDA 356h"
090000648444cc70,Notice,FDA-2013-N-0578-0009,FDA-2013-N-0578,"Agency Information Collection Activities; Announcement of Office of
Management and Budget Approvals"
090000648146a14d,Notice,FDA-2013-N-0578-0002,FDA-2013-N-0578,"Review; Comment Request; General Licensing Provisions: Biologics License Application, Changes to an Approved Application, Labeling, Revocation and Suspension, Postmarketing Studies Status Reports, and Forms FDA 356h and 2567"
090000648151cd35,Notice,FDA-2013-N-0578-0003,FDA-2013-N-0578,"Agency Information Collection Activities; Announcement of Office of
Management and Budget Approval; General Licensing Provisions:
Biologics License Application, Changes to an Approved Application,
Labeling, Revocation and Suspension, Postmarketing Studies Status Reports, and Forms FDA 356h and 2567"
090000648131aea8,Notice,FDA-2013-N-0578-0001,FDA-2013-N-0578,"Agency Information Collection Activities; Proposals, Submissions, and Approvals: General Licensing Provisions - Biologics License Application, etc."
09000064842b64fa,Notice,FDA-2013-N-0578-0008,FDA-2013-N-0578,"Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; General Licensing Provisions: Biologics License Application, Changes to an Approved Application, Labeling, Revocation and Suspension, Postmarketing Studies Status Reports, and Form FDA 356h"
090000648235ae12,Notice,FDA-2013-N-0578-0005,FDA-2013-N-0578,"Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; General Licensing 
Provisions: Biologics License Application, Changes to an Approved 
Application, Labeling, Revocation and Suspension, and Postmarketing 
Studies Status Reports"
090000648209bee6,Notice,FDA-2013-N-0578-0004,FDA-2013-N-0578,"Agency Information Collection Activities; Proposed Collection; Comment Request; General Licensing Provisions: Biologics License Application, Changes to an Approved Application, Labeling, Revocation and Suspension, Postmarketing Studies Status Reports, and Form FDA 356h"
0900006484253497,Supporting & Related Material,FDA-2019-P-3192-0042,FDA-2019-P-3192,"Exhibit 11 re Petition for Reconsideration from US WorldMeds, LLC"
09000064842534a6,Supporting & Related Material,FDA-2019-P-3192-0044,FDA-2019-P-3192,"Exhibit 13 re Petition for Reconsideration from US WorldMeds, LLC"
09000064842534a9,Supporting & Related Material,FDA-2019-P-3192-0047,FDA-2019-P-3192,"Exhibit 16 re Petition for Reconsideration from US WorldMeds, LLC"
09000064842534ae,Supporting & Related Material,FDA-2019-P-3192-0052,FDA-2019-P-3192,"Exhibit 21 re Petition for Reconsideration from US WorldMeds, LLC"
0900006484253493,Supporting & Related Material,FDA-2019-P-3192-0038,FDA-2019-P-3192,"Exhibit 7 re Petition for Reconsideration from US WorldMeds, LLC"
0900006483d570cb,Supporting & Related Material,FDA-2019-P-3192-0009,FDA-2019-P-3192,Exhibit 7- APOKYN Apomorphine Hydrochloride Injection re Citizen Petition from US WorldMeds
0900006483d5794c,Supporting & Related Material,FDA-2019-P-3192-0013,FDA-2019-P-3192,Exhibit 11- Patients’ and caregivers’ experiences of the impact of Parkinson’s disease on health status re Citizen Petition from US WorldMeds
0900006483d577cb,Supporting & Related Material,FDA-2019-P-3192-0026,FDA-2019-P-3192,Exhibit 24- Injection Safety re Citizen Petition from US WorldMeds
0900006484251530,Supporting & Related Material,FDA-2019-P-3192-0032,FDA-2019-P-3192,"Exhibit 1 re Petition for Reconsideration from US WorldMeds, LLC"
0900006484253492,Supporting & Related Material,FDA-2019-P-3192-0037,FDA-2019-P-3192,"Exhibit 6 re Petition for Reconsideration from US WorldMeds, LLC"
09000064842534ad,Supporting & Related Material,FDA-2019-P-3192-0051,FDA-2019-P-3192,"Exhibit 20 re Petition for Reconsideration from US WorldMeds, LLC"
09000064842534a5,Supporting & Related Material,FDA-2019-P-3192-0043,FDA-2019-P-3192,"Exhibit 12 re Petition for Reconsideration from US WorldMeds, LLC"
0900006483d57254,Supporting & Related Material,FDA-2019-P-3192-0007,FDA-2019-P-3192,Exhibit 5- Parkinson's Disease and Movement Disorders: Moving Forward re Citizen Petition from US WorldMeds
0900006483d57697,Supporting & Related Material,FDA-2019-P-3192-0021,FDA-2019-P-3192,Exhibit 19- Center for Drug Evaluation and Research: Summary Review re Citizen Petition from US WorldMeds
0900006483d577ca,Supporting & Related Material,FDA-2019-P-3192-0025,FDA-2019-P-3192,Exhibit 23- Sharing Insulin Pens: Are You Putting Patients at Risk re Citizen Petition from US WorldMeds
0900006483d57979,Supporting & Related Material,FDA-2019-P-3192-0018,FDA-2019-P-3192,Exhibit 16- Starting APOKYN re Citizen Petition from US WorldMeds
0900006483d57222,Supporting & Related Material,FDA-2019-P-3192-0006,FDA-2019-P-3192,"Exhibit 4- Past, Present, and Future of Parkinson's Disease: A Special Essay on the 200th Anniversary of the Shaking Palsy re Citizen Petition from US WorldMeds"
0900006483d57220,Supporting & Related Material,FDA-2019-P-3192-0004,FDA-2019-P-3192,Exhibit 2- Cognitive Decline in Parkinson Disease re Citizen Petition from US WorldMeds
0900006483d577cc,Supporting & Related Material,FDA-2019-P-3192-0027,FDA-2019-P-3192,"Exhibit 25- FDA in Brief: To advance efficient development and review of combination products, the FDA outlines principles to promote a more predictable premarket review pathway re Citizen Petition from US WorldMeds"
090000648425348f,Supporting & Related Material,FDA-2019-P-3192-0034,FDA-2019-P-3192,"Exhibit 3 re Petition for Reconsideration from US WorldMeds, LLC"
09000064842534a7,Supporting & Related Material,FDA-2019-P-3192-0045,FDA-2019-P-3192,"Exhibit 14 re Petition for Reconsideration from US WorldMeds, LLC"
0900006483d570cc,Supporting & Related Material,FDA-2019-P-3192-0010,FDA-2019-P-3192,Exhibit 8- The Voice of the Patient re Citizen Petition from US WorldMeds
0900006483d57696,Supporting & Related Material,FDA-2019-P-3192-0020,FDA-2019-P-3192,Exhibit 18- Center for Drug Evaluation and Research: Other Action Letters re Citizen Petition from US WorldMeds
0900006483d57699,Supporting & Related Material,FDA-2019-P-3192-0023,FDA-2019-P-3192,Exhibit 21- Complete Response re Citizen Petition from US WorldMeds
0900006483d5794f,Supporting & Related Material,FDA-2019-P-3192-0016,FDA-2019-P-3192,Exhibit 14- About APOKYN re Citizen Petition from US WorldMeds
09000064821e830f,Supporting & Related Material,FDA-2016-P-2672-0015,FDA-2016-P-2672,"Exhibit 12 Letter from Charles M. Lizza to Hon. Esther Salas, U.S.D.J., ECF No. 312, Jazz Pharm., Inc. v. Amneal Pharm. LLC et al., No. 2:13-cv-391 (filed Aug. 12, 2016) re Citizen Petition from Jazz Pharmaceuticals Inc."
09000064821e8304,Supporting & Related Material,FDA-2016-P-2672-0008,FDA-2016-P-2672,"Exhibit 5 Decision Instituting (in Part) Inter Partes Review, Paper No. 10, Ranbaxy Inc. v. Jazz Pharm., Inc., IPR2016-00024 (P.T.A.B. Apr. 12, 2016) re Citizen Petition from Jazz Pharmaceuticals Inc."
09000064821e823c,Other,FDA-2016-P-2672-0001,FDA-2016-P-2672,Citizen Petition from Jazz Pharmaceuticals Inc.
09000064821e8310,Supporting & Related Material,FDA-2016-P-2672-0016,FDA-2016-P-2672,"Exhibit 13 Expert Report of Leslie Z. Benet, Ph.D. re Citizen Petition from Jazz Pharmaceuticals Inc."
090000648247f348,Other,FDA-2016-P-2672-0019,FDA-2016-P-2672,"Petition Approval Letter from FDA CDER to Jazz Pharmaceuticals, Inc."
09000064821e8948,Other,FDA-2016-P-2672-0002,FDA-2016-P-2672,"Acknowledgment Letter from FDA DDM to Jazz Pharmaceuticals, Inc."
09000064821e8241,Supporting & Related Material,FDA-2016-P-2672-0003,FDA-2016-P-2672,Index of Exhibits re Citizen Petition from Jazz Pharmaceuticals Inc.
09000064821e8302,Supporting & Related Material,FDA-2016-P-2672-0006,FDA-2016-P-2672,"Exhibit 3  Petition for Inter Partes Review of U.S. Patent No. 8,772,306, Paper No. 1, Ranbaxy Inc. v. Jazz Pharm., Inc., IPR2016-00024 (P.T.A.B. Apr. 12, 2016) re Citizen Petition from Jazz Pharmaceuticals Inc."
09000064821e8308,Supporting & Related Material,FDA-2016-P-2672-0012,FDA-2016-P-2672,"Exhibit 9 Decl. of Bradford C. Frese in Supp. of Mot. for J. on the Pleadings as to U.S. Patent No. 8,772,306 Under Rule 12(c), ECF No. 244-1, Jazz Pharm., Inc. v. Amneal Pharm. LLC et al., No. 2:13-cv-391 (filed Mar. 23, 2016) re Citizen Petition from Jazz Pharmaceuticals Inc."
09000064821e830e,Supporting & Related Material,FDA-2016-P-2672-0014,FDA-2016-P-2672,"Exhibit 11 Def. Par’s Reply to Jazz’s Opp’n to the Mot. for J. on the Pleadings as to U.S. Patent No. 8,772, 306 Under Rule 12(c) (Redacted), ECF No. 309, Jazz Pharm., Inc., v. Amneal Pharm. LLC et al., No. 2:13-cv-391 (filed July 25, 2016) re Citizen Petition from Jazz Pharmaceuticals Inc."
09000064821e8303,Supporting & Related Material,FDA-2016-P-2672-0007,FDA-2016-P-2672,"Exhibit 4 Eller M et al., Evaluation of drug–drug interactions of sodium oxybate with divalproex: Results from a pharmacokinetic / pharmacodynamic study. Sleep Medicine. 2013 December; 14:e302-e303 re Citizen Petition from Jazz Pharmaceuticals Inc."
09000064821e8306,Supporting & Related Material,FDA-2016-P-2672-0010,FDA-2016-P-2672,"Exhibit 7 Letter from Michelle Bonomi-Huvala, Par Pharm., Inc. to Jazz Pharm., Inc., Notice of Paragraph IV Certification, Enclosure (Aug. 5, 2014) re Citizen Petition from Jazz Pharmaceuticals Inc."
09000064821e830d,Supporting & Related Material,FDA-2016-P-2672-0013,FDA-2016-P-2672,"Exhibit 10 Jazz’s Mem. of Law in Opp’n to Par’s Mot. for J. on the Pleadings as to U.S. Patent No. 8,772,306 Under Rule 12(c) (Redacted), ECF No. 308, Jazz Pharm., Inc., v. Amneal Pharm. LLC et al., No. 2:13-cv-391 (filed July 21, 2016) re Citizen Petition from Jazz Pharmaceuticals Inc."
09000064821e8300,Supporting & Related Material,FDA-2016-P-2672-0004,FDA-2016-P-2672,"Exhibit 1 Petition for Inter Partes Review of U.S. Patent No. 8,772,306, Paper No. 3, Par Pharm., Inc. v. Jazz Pharm., Inc., IPR2016-00002 (P.T.A.B. Apr. 12, 2016) re Citizen Petition from Jazz Pharmaceuticals Inc."
09000064821e8301,Supporting & Related Material,FDA-2016-P-2672-0005,FDA-2016-P-2672,"Exhibit 2 Petition for Inter Partes Review of U.S. Patent No. 8,772,306, 16, Paper No. 1, Amneal Pharm. LLC v. Jazz Pharm., Inc., IPR2016-00546 (P.T.A.B. filed Feb. 2, re Citizen Petition from Jazz Pharmaceuticals Inc.
2016)"
09000064821e8305,Supporting & Related Material,FDA-2016-P-2672-0009,FDA-2016-P-2672,"Exhibit 6 Decision Denying Inter Partes Review, Paper No. 11, Amneal Pharmaceuticals LLC . v. Jazz Pharm., Inc., IPR2016-00546 (P.T.A.B. July 28, 2016) re Citizen Petition from Jazz Pharmaceuticals Inc."
09000064821e8307,Supporting & Related Material,FDA-2016-P-2672-0011,FDA-2016-P-2672,"Exhibit 8 Letter from Michelle Bonomi-Huvala, Par Pharm., Inc. to Jazz Pharm., Inc., Notice of Paragraph IV Certification, Enclosure (Sept. 1, 2015) re Citizen Petition from Jazz Pharmaceuticals Inc."
0900006483f5881d,Supporting & Related Material,FDA-2019-P-4281-0006,FDA-2019-P-4281,Valisure Citizen Petition Attachment D - ACC Resolution - Chemical Variability in Pharmaceutical Products
0900006483f58b41,Other,FDA-2019-P-4281-0002,FDA-2019-P-4281,"Acknowledgment Letter from FDA DMS to Valisure, LLC"
0900006483f5881a,Supporting & Related Material,FDA-2019-P-4281-0003,FDA-2019-P-4281,Valisure Citizen Petition Attachment A - Chemist Affidavit - Wolfgang Hinz
090000648445107c,Other,FDA-2019-P-4281-0007,FDA-2019-P-4281,"Interim Response Letter from FDA CDER to Valisure, LLC"
0900006483f58b40,Other,FDA-2019-P-4281-0001,FDA-2019-P-4281,"Citizen Petition from Valisure, LLC"
090000648448039a,Other,FDA-2019-P-4281-0008,FDA-2019-P-4281,"Decision from FDA CDER to Valisure, LLC"
0900006483f5881b,Supporting & Related Material,FDA-2019-P-4281-0004,FDA-2019-P-4281,Valisure Citizen Petition Attachment B - GC-MS Ranitidine Data Report
0900006483f5881c,Supporting & Related Material,FDA-2019-P-4281-0005,FDA-2019-P-4281,Valisure Citizen Petition Attachment C - Dr. Ernstoff Statement
090000648304e7d2,Other,FDA-2018-P-1263-0001,FDA-2018-P-1263,Citizen Petition from Kratz & Barry LLP on behalf of Rubicon Research Private Limited
09000064841bf49b,Other,FDA-2018-P-1263-0006,FDA-2018-P-1263,Letter from FDA CDER to Kratz & Barry LLP and Yiling Pharmaceutical Ltd.
0900006483310837,Other,FDA-2018-P-1263-0004,FDA-2018-P-1263,Supplement from Rubicon Research Private Limited
090000648304e7d6,Supporting & Related Material,FDA-2018-P-1263-0003,FDA-2018-P-1263,Attachment 1 Declaration of Rubicon re Citizen Petition from Kratz & Barry LLP on behalf of Rubicon Research Private Limited
0900006483726844,Other,FDA-2018-P-1263-0005,FDA-2018-P-1263,Interim Response Letter from FDA CDER to Kratz & Barry LLP
090000648304e7d4,Other,FDA-2018-P-1263-0002,FDA-2018-P-1263,Acknowledgment Letter from FDA DDM to Kratz & Barry LLP
090000648047353d,Notice,FDA-2004-D-0353-0001,FDA-2004-D-0353,FDA
0900006480473541,Supporting & Related Material,FDA-2004-D-0353-0002,FDA-2004-D-0353,Guidance
0900006480492902,Supporting & Related Material,FDA-2008-D-0205-0002,FDA-2008-D-0205,"Content and Review of Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications (INDs); - Guidance"
09000064843108d9,Supporting & Related Material,FDA-2008-D-0205-0056,FDA-2008-D-0205,"Reference 21 Q2B Validation of Analytical Procedures Methodology re Chemistry, Manufacturing, and Control Information for Human Gene Therapy Investigational New Drug Applications; Guidance for Industry; Availability"
090000648431083d,Supporting & Related Material,FDA-2008-D-0205-0037,FDA-2008-D-0205,"Reference 2 National Academies Report on Human Genome Editing re Chemistry, Manufacturing, and Control Information for Human Gene Therapy Investigational New Drug Applications; Guidance for Industry; Availability"
0900006484310843,Supporting & Related Material,FDA-2008-D-0205-0043,FDA-2008-D-0205,"Reference 8 Q11 Development and Manufacture of Drug Substances re Chemistry, Manufacturing, and Control Information for Human Gene Therapy Investigational New Drug Applications; Guidance for Industry; Availability"
090000648430fed3,Other,FDA-2008-D-0205-0034,FDA-2008-D-0205,"Chemistry, Manufacturing, and Control Information for Human Gene Therapy Investigational New Drug Applications; Guidance for Industry; Availability"
090000648430fedb,Supporting & Related Material,FDA-2008-D-0205-0036,FDA-2008-D-0205,"Reference 1 M4Q- The CTD - Quality re Chemistry, Manufacturing, and Control Information for Human Gene Therapy Investigational New Drug Applications; Guidance for Industry; Availability"
09000064843108da,Supporting & Related Material,FDA-2008-D-0205-0057,FDA-2008-D-0205,"Reference 22 Quality of Biotechnological Products Stability Testing of Biotechnological Biological Products re Chemistry, Manufacturing, and Control Information for Human Gene Therapy Investigational New Drug Applications; Guidance for Industry; Availability"
09000064843108dc,Supporting & Related Material,FDA-2008-D-0205-0059,FDA-2008-D-0205,"Reference 24 Q1E Evaluation of Stability Data re Chemistry, Manufacturing, and Control Information for Human Gene Therapy Investigational New Drug Applications; Guidance for Industry; Availability"
090000648431087c,Supporting & Related Material,FDA-2008-D-0205-0050,FDA-2008-D-0205,"Reference 15 Federal Register Notice International Conference on Harmonisation Guidance on Quality of Biotechnological Biological Products re Chemistry, Manufacturing, and Control Information for Human Gene Therapy Investigational New Drug Applications; Guidance for Industry; Availability"
0900006484310880,Supporting & Related Material,FDA-2008-D-0205-0053,FDA-2008-D-0205,"Reference 18 Potency Tests for Cellular and Gene Therapy Products re Chemistry, Manufacturing, and Control Information for Human Gene Therapy Investigational New Drug Applications; Guidance for Industry; Availability"
0900006484310844,Supporting & Related Material,FDA-2008-D-0205-0044,FDA-2008-D-0205,"Reference 9 Recommendations for Microbial Vectors used for Gene Therapy re Chemistry, Manufacturing, and Control Information for Human Gene Therapy Investigational New Drug Applications; Guidance for Industry; Availability"
090000648431087e,Supporting & Related Material,FDA-2008-D-0205-0051,FDA-2008-D-0205,"Reference 16 Reid Y et al Authentication of Human Cell Lines by STR DNA Profiling Analysis re Chemistry, Manufacturing, and Control Information for Human Gene Therapy Investigational New Drug Applications; Guidance for Industry; Availability"
0900006484310879,Supporting & Related Material,FDA-2008-D-0205-0047,FDA-2008-D-0205,"Reference 12 Characterization and Qualification of Cell Substrates and Other Biological Materials re Chemistry, Manufacturing, and Control Information for Human Gene Therapy Investigational New Drug Applications; Guidance for Industry; Availability"
09000064843108dd,Supporting & Related Material,FDA-2008-D-0205-0060,FDA-2008-D-0205,"Reference 25 Container Closure Systems for Packaging Human Drugs and Biologics re Chemistry, Manufacturing, and Control Information for Human Gene Therapy Investigational New Drug Applications; Guidance for Industry; Availability"
090000648430feda,Supporting & Related Material,FDA-2008-D-0205-0035,FDA-2008-D-0205,"Reference list CMC re Chemistry, Manufacturing, and Control Information for Human Gene Therapy Investigational New Drug Applications; Guidance for Industry; Availability"
090000648431083e,Supporting & Related Material,FDA-2008-D-0205-0038,FDA-2008-D-0205,"Reference 3 Using the eCTD Specifications Guidance re Chemistry, Manufacturing, and Control Information for Human Gene Therapy Investigational New Drug Applications; Guidance for Industry; Availability"
0900006484310881,Supporting & Related Material,FDA-2008-D-0205-0054,FDA-2008-D-0205,"Reference 19 Points to Consider in the Characterization of Cell Lines Used to Produce Biologicals re Chemistry, Manufacturing, and Control Information for Human Gene Therapy Investigational New Drug Applications; Guidance for Industry; Availability"
090000648431087a,Supporting & Related Material,FDA-2008-D-0205-0048,FDA-2008-D-0205,"Reference 13 Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use re Chemistry, Manufacturing, and Control Information for Human Gene Therapy Investigational New Drug Applications; Guidance for Industry; Availability"
090000648431087f,Supporting & Related Material,FDA-2008-D-0205-0052,FDA-2008-D-0205,"Reference 17 Process Validation General Principles and Practices re Chemistry, Manufacturing, and Control Information for Human Gene Therapy Investigational New Drug Applications; Guidance for Industry; Availability"
090000648048d039,Supporting & Related Material,FDA-2008-D-0205-0003,FDA-2008-D-0205,"Content and Review of Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy Investigational New Drug Application (INDs) - Reference List"
09000064835c5dd5,Other,FDA-2008-D-0205-0007,FDA-2008-D-0205,Request for Extension from Biotechnology Innovation Organization (BIO)
09000064843108df,Supporting & Related Material,FDA-2008-D-0205-0062,FDA-2008-D-0205,"Reference 27 Quality Systems Approach to Pharmaceutical CGMP Regulations re Chemistry, Manufacturing, and Control Information for Human Gene Therapy Investigational New Drug Applications; Guidance for Industry; Availability"
09000064836b3161,Notice,FDA-2008-D-0205-0008,FDA-2008-D-0205,"Draft Guidances Relating to the Development of Human Gene Therapy
Products; Availability; Extension of Comment Period"
09000064804a3293,Notice,FDA-2008-D-0205-0001,FDA-2008-D-0205,"Guidance for Food and Drug Administration Reviewers and Sponsors: Content and Review of Chemistry, Manufacturing, and Control Information for Human Gene Therapy Investigational New Drug Applications; Availability"
09000064834d74a3,Notice,FDA-2008-D-0205-0004,FDA-2008-D-0205,"Chemistry, Manufacturing, and Control Information for Human Gene Therapy Investigational New Drug Applications; Draft Guidance for Industry; Availability"
090000648043ed63,Other,FDA-2005-P-0053-0001,FDA-2005-P-0053,HFA-305 to Buc & Beardsley
090000648043ed73,Other,FDA-2005-P-0053-0002,FDA-2005-P-0053,HFA-305 to Buc & Beardsley
090000648043ed7c,Other,FDA-2005-P-0053-0003,FDA-2005-P-0053,HFD-001 to Ranbaxy Laboratories Limited
090000648484a57f,Supporting & Related Material,FDA-2020-P-1857-0004,FDA-2020-P-1857,Footnotes 16-44 re: Citizen Petition from SIRI & GLIMSTAD LLP
090000648484a019,Other,FDA-2020-P-1857-0001,FDA-2020-P-1857,Citizen Petition from SIRI & GLIMSTAD LLP
090000648484a01e,Other,FDA-2020-P-1857-0002,FDA-2020-P-1857,Acknowledgment Letter from FDA DMS to SIRI & GLIMSTAD LLP
0900006484a607af,Other,FDA-2020-P-1857-0936,FDA-2020-P-1857,"Interim Response Letter Siri & Glimstad, LLP"
090000648484a020,Supporting & Related Material,FDA-2020-P-1857-0003,FDA-2020-P-1857,Footnotes 4-14 re: Citizen Petition from SIRI & GLIMSTAD LLP
0900006482f64adb,Supporting & Related Material,FDA-2018-P-0877-0003,FDA-2018-P-0877,Appendix re Citizen Petition from The Food Lawyers
090000648341122f,Other,FDA-2018-P-0877-0005,FDA-2018-P-0877,FDA-2018-P-0877 - The Food Lawyers Interim Response
0900006482f64ad9,Other,FDA-2018-P-0877-0002,FDA-2018-P-0877,Acknowledgment Letter from FDA DDM to The Food Lawyers
09000064838d09c9,Other,FDA-2018-P-0877-0006,FDA-2018-P-0877,Supplement to Citizen Petition Requesting 21 CFR 101.9(c)(6)(i) Listing of Dietary Fibers be Amended to include Konjac Flour
09000064832649a6,Other,FDA-2018-P-0877-0004,FDA-2018-P-0877,Memo of correspondence with The Food Lawyers on Konjac Flour Citizen Petition
0900006484286704,Other,FDA-2018-P-0877-0010,FDA-2018-P-0877,Petition Response Letter from FDA CFSAN to The Food Lawyers
0900006482f64ad7,Other,FDA-2018-P-0877-0001,FDA-2018-P-0877,Citizen Petition from The Food Lawyers
09000064838d1132,Supporting & Related Material,FDA-2018-P-0877-0007,FDA-2018-P-0877,Appendix of scientific papers cited  in supplement to citizen petition requesting CFR 101.9 (c)(6)(i) listing of dietary fibers be amended to include Konjac Flour
0900006483d8c118,Other,FDA-2018-P-0877-0009,FDA-2018-P-0877,Supplement from The Food Lawyers
0900006482ae2824,Other,FDA-2016-P-1108-0005,FDA-2016-P-1108,"Response letter from FDA to Gordon Johnston Regulatory Consultants, LLC"
0900006481f11695,Supporting & Related Material,FDA-2016-P-1108-0003,FDA-2016-P-1108,Attachment A Product Listing from the Active Section of the Orange Book- re Citizen Petition from Gordon Johnston Regulatory Consultants LLC
0900006481f13d76,Other,FDA-2016-P-1108-0002,FDA-2016-P-1108,Acknowledgement Letter from FDA DDM to Gordon Johnston Regulatory Consultants LLC
0900006481f11637,Other,FDA-2016-P-1108-0001,FDA-2016-P-1108,Citizen Petition from Gordon Johnston Regulatory Consultants LLC
0900006482428124,Other,FDA-2016-P-1108-0004,FDA-2016-P-1108,"Letter from FDA CDER to Gordon Johnston Regulatory Consultants, LLC"
0900006481f93b87,Supporting & Related Material,FDA-2016-P-1213-0004,FDA-2016-P-1213,"Attachment 2 Draft labeling for the proposed product, Goody's Migraine re Citizen Petition from Medtech Products Inc."
0900006481f93b88,Supporting & Related Material,FDA-2016-P-1213-0005,FDA-2016-P-1213,Attachment 3 Request for Waiver from requirement to submit a pediatric assessment re Citizen Petition from Medtech Products Inc.
0900006481f93b89,Other,FDA-2016-P-1213-0002,FDA-2016-P-1213,Acknowledgement Letter from FDA DDM to Medtech Products Inc.
0900006481f93b86,Supporting & Related Material,FDA-2016-P-1213-0003,FDA-2016-P-1213,"Attachment 1 Approved labeling for the RLD, Excedrin (migraine) re Citizen Petition from Medtech Products Inc."
0900006481f93b7a,Other,FDA-2016-P-1213-0001,FDA-2016-P-1213,Citizen Petition from Medtech Products Inc.
0900006482ef0acd,Other,FDA-2016-P-1213-0006,FDA-2016-P-1213,Notice of Withdrawal Letter from FDA to A Prestige Brands Company
09000064820488d1,Other,FDA-2016-P-1676-0002,FDA-2016-P-1676,"Acknowledgement Letter from FDA DDM to JR Rapoza Associates, Inc."
0900006482504d6b,Other,FDA-2016-P-1676-0006,FDA-2016-P-1676,"Final Response Letter to JR Rapoza Associates, Inc."
0900006482401959,Other,FDA-2016-P-1676-0005,FDA-2016-P-1676,"Interim Response Letter to JR Rapoza Associates, Inc."
09000064820488d3,Supporting & Related Material,FDA-2016-P-1676-0003,FDA-2016-P-1676,"Attachment 1 Orange Book Listing re Citizen Petition from JR Rapoza Associates, Inc."
09000064820488d4,Supporting & Related Material,FDA-2016-P-1676-0004,FDA-2016-P-1676,"Attachment 2 Approved Drug Labeling RLD re Citizen Petition from JR Rapoza Associates, Inc."
0900006482048712,Other,FDA-2016-P-1676-0001,FDA-2016-P-1676,"Citizen Petition from JR Rapoza Associates, Inc."
090000648250c66d,Notice,FDA-2016-P-1676-0007,FDA-2016-P-1676,"Determination that CYANOCOBALAMIN INJECTION, 1 Milligram per Milliliter in a 10 Milliliter Vial, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
0900006481971e3c,Other,FDA-2014-P-2188-0001,FDA-2014-P-2188,Citizen Petition from Acura Pharmaceuticals Inc
09000064819728e0,Supporting & Related Material,FDA-2014-P-2188-0011,FDA-2014-P-2188,Exibit I
09000064819728e2,Supporting & Related Material,FDA-2014-P-2188-0013,FDA-2014-P-2188,Exibit K
09000064819728e6,Supporting & Related Material,FDA-2014-P-2188-0017,FDA-2014-P-2188,Exibit O
09000064819728e8,Supporting & Related Material,FDA-2014-P-2188-0019,FDA-2014-P-2188,Exibit Q
09000064819728ec,Supporting & Related Material,FDA-2014-P-2188-0023,FDA-2014-P-2188,Exibit U
0900006481a8c0a8,Other,FDA-2014-P-2188-0024,FDA-2014-P-2188,"Supplement from Acura Pharmaceuticals, Inc."
09000064819728dd,Supporting & Related Material,FDA-2014-P-2188-0008,FDA-2014-P-2188,Exibit F
0900006481972ae1,Supporting & Related Material,FDA-2014-P-2188-0007,FDA-2014-P-2188,Exibit E
09000064819728de,Supporting & Related Material,FDA-2014-P-2188-0009,FDA-2014-P-2188,Exibit G
09000064819728e4,Supporting & Related Material,FDA-2014-P-2188-0015,FDA-2014-P-2188,Exibit M
09000064819728e5,Supporting & Related Material,FDA-2014-P-2188-0016,FDA-2014-P-2188,Exibit N
09000064819728e9,Supporting & Related Material,FDA-2014-P-2188-0020,FDA-2014-P-2188,Exibit R
0900006481972add,Supporting & Related Material,FDA-2014-P-2188-0003,FDA-2014-P-2188,Exibit A
0900006481972ae0,Supporting & Related Material,FDA-2014-P-2188-0006,FDA-2014-P-2188,Exibit D
09000064819728ea,Supporting & Related Material,FDA-2014-P-2188-0021,FDA-2014-P-2188,Exibit S
090000648197285a,Other,FDA-2014-P-2188-0002,FDA-2014-P-2188,Acknowledgement Letter from FDA DDM to Wiley Rein LLP
09000064819728df,Supporting & Related Material,FDA-2014-P-2188-0010,FDA-2014-P-2188,Exibit H
09000064819728e1,Supporting & Related Material,FDA-2014-P-2188-0012,FDA-2014-P-2188,Exibit J
09000064819728e3,Supporting & Related Material,FDA-2014-P-2188-0014,FDA-2014-P-2188,Exibit L
09000064819728eb,Supporting & Related Material,FDA-2014-P-2188-0022,FDA-2014-P-2188,Exibit T
0900006481972ade,Supporting & Related Material,FDA-2014-P-2188-0004,FDA-2014-P-2188,Exibit B
0900006481972adf,Supporting & Related Material,FDA-2014-P-2188-0005,FDA-2014-P-2188,Exibit C
0900006481ad6916,Other,FDA-2014-P-2188-0025,FDA-2014-P-2188,Citizen Petition Denial Response Letter from FDA CDER to Wiley Rein LLP
09000064819728e7,Supporting & Related Material,FDA-2014-P-2188-0018,FDA-2014-P-2188,Exibit P
09000064820aa04f,Other,FDA-2015-P-2000-0012,FDA-2015-P-2000,Petition Denial Letter
0900006481d7fbde,Other,FDA-2015-P-2000-0010,FDA-2015-P-2000,"Interim Response Letter from FDA CDER to AbbVie, Inc."
0900006481b16af1,Supporting & Related Material,FDA-2015-P-2000-0003,FDA-2015-P-2000,"Attachment A Labeling Information re Citizen Petition from AbbVie, Inc"
0900006481b16aef,Other,FDA-2015-P-2000-0002,FDA-2015-P-2000,"Acknowledgement Letter from FDA DDM to AbbVie, Inc."
0900006481b16aed,Other,FDA-2015-P-2000-0001,FDA-2015-P-2000,"Citizen Petition from AbbVie, Inc"
0900006481c01af0,Other,FDA-2015-P-2000-0007,FDA-2015-P-2000,"Supplement from AbbVie, Inc."
0900006482c98c5f,Notice,FDA-2017-P-5910-0003,FDA-2017-P-5910,"Determination That TRINTELLIX (Vortioxetine Hydrobromide) Oral
Tablet, EQ 15 Milligram Base, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
0900006482b7736c,Other,FDA-2017-P-5910-0001,FDA-2017-P-5910,Citizen Petition from Cipla Limited
0900006482b77c53,Other,FDA-2017-P-5910-0002,FDA-2017-P-5910,Acknowledgement Letter from FDA DDM to Cipla Limited
0900006482c9fa8e,Other,FDA-2017-P-5910-0004,FDA-2017-P-5910,Petition Response Letter
090000648391d2c7,Other,FDA-2018-D-4587-0001,FDA-2018-D-4587,External Guidance Document Submission from International Pharmaceutical Excipients Council of the Americas (IPEC-Americas)
090000648391d963,Other,FDA-2018-D-4587-0002,FDA-2018-D-4587,Acknowledgment Letter from FDA DDM to  International Pharmaceutical Excipients Council of the Americas (IPEC-Americas)
0900006482dcf7b1,Supporting & Related Material,FDA-2018-P-0130-0003,FDA-2018-P-0130,"Attachment 1 Relevant copy of the page from the current edition of the electronic Approved Drug Products with Therapeutic Equivalence Evaluations, accessed January 8, 20 18 re Citizen Petition from Lachman Consultant Services, Inc."
0900006482dcf7b3,Supporting & Related Material,FDA-2018-P-0130-0005,FDA-2018-P-0130,"Attachment 3 Labeling for Zonegran® Capsules re Citizen Petition from Lachman Consultant Services, Inc."
0900006482dcf7af,Other,FDA-2018-P-0130-0001,FDA-2018-P-0130,"Citizen Petition from Lachman Consultant Services, Inc."
0900006482dcf7b2,Supporting & Related Material,FDA-2018-P-0130-0004,FDA-2018-P-0130,"Attachment 2 Draft Insert Labeling Proposed for Zonisamide Tablets re Citizen Petition from Lachman Consultant Services, Inc."
0900006482dcf7b4,Other,FDA-2018-P-0130-0002,FDA-2018-P-0130,"Acknowledgment Letter from FDA DDM  to Lachman Consultant Services, Inc."
090000648404c00c,Other,FDA-2019-P-4670-0001,FDA-2019-P-4670,Citizen Petition from Lonza Inc.
09000064847dfe00,Supporting & Related Material,FDA-2019-P-4670-0006,FDA-2019-P-4670,"STUDY REPORT  - An Acute, Randomized, Double-blind, Controlled, Crossover Study to Investigate the Effect of an Arabinogalactan Product
on Glucose and Insulin Response in Adults, Study Report
BIO-1904"
090000648480da0b,Other,FDA-2019-P-4670-0007,FDA-2019-P-4670,Report from Lonza
0900006484485d36,Other,FDA-2019-P-4670-0005,FDA-2019-P-4670,Interim Response Letter from FDA CFSAN to Lonza Inc
090000648404c03b,Supporting & Related Material,FDA-2019-P-4670-0004,FDA-2019-P-4670,Appendix B Full-Length Copies of All Relevant References re Citizen Petition from Lonza Inc
090000648404c00d,Other,FDA-2019-P-4670-0002,FDA-2019-P-4670,Acknowledgment Letter from FDA DMS to Lonza Inc.
090000648404c010,Supporting & Related Material,FDA-2019-P-4670-0003,FDA-2019-P-4670,Appendix A Qualitative Results from 3 Human Studies on the Effects of Arabinogalactan on Immune Function re Citizen Petition from Lonza Inc.
090000648304398f,Other,FDA-2018-P-1238-0002,FDA-2018-P-1238,"Acknowledgment Letter from FDA DDM  to Lachman Consultant Services, Inc."
0900006483043b70,Supporting & Related Material,FDA-2018-P-1238-0005,FDA-2018-P-1238,"Attachment 3 Proposed Labeling for Succinylcholine Chloride re: Citizen Petition from Lachman Consultant Services, Inc."
09000064830439dd,Supporting & Related Material,FDA-2018-P-1238-0003,FDA-2018-P-1238,"Attachment 1 Approved Drug Products with Therapeutic Equivalence Evaluations re: Citizen Petition from Lachman Consultant Services, Inc."
0900006483043b6f,Supporting & Related Material,FDA-2018-P-1238-0004,FDA-2018-P-1238,"Attachment 2 RLD Labeling QUELICIN- re: Citizen Petition from Lachman Consultant Services, Inc."
0900006483043849,Other,FDA-2018-P-1238-0001,FDA-2018-P-1238,Citizen Petition from Lachman Consultant Services Inc.
0900006484487134,Other,FDA-2020-P-1248-0002,FDA-2020-P-1248,Acknowledgment Letter from FDA DMS to Mark Miles
0900006484486e1a,Other,FDA-2020-P-1248-0001,FDA-2020-P-1248,Citizen Petition from Mark Miles
0900006484874b79,Other,FDA-2020-P-1248-0003,FDA-2020-P-1248,Interim Response Letter from FDA CDER to Mark Miles
090000648480bba7,Other,FDA-2020-P-1052-0004,FDA-2020-P-1052,Tentative Response from FDA CTP to National Tobacco Reform Initiative (NTRI)
0900006484409d03,Other,FDA-2020-P-1052-0001,FDA-2020-P-1052,Citizen Petition from National Tobacco Reform Initiative (NTRI)
090000648440bac4,Other,FDA-2020-P-1052-0002,FDA-2020-P-1052,Acknowledgment Letter from FDA DMS to National Tobacco Reform Initiative (NTRI)
0900006483b78606,Supporting & Related Material,FDA-2019-P-1679-0020,FDA-2019-P-1679,"Exhibit 17 reCitizen Petition from Goodwin Procter,  LLP on behalf of Braeburn, Inc."
0900006483b784b3,Supporting & Related Material,FDA-2019-P-1679-0011,FDA-2019-P-1679,"Exhibit 9 re Citizen Petition from Goodwin Procter,  LLP on behalf of Braeburn, Inc."
0900006483b733b0,Supporting & Related Material,FDA-2019-P-1679-0003,FDA-2019-P-1679,"Exhibit 1 re Citizen Petition from Goodwin Procter,  LLP on behalf of Braeburn, Inc."
0900006483b733ae,Other,FDA-2019-P-1679-0002,FDA-2019-P-1679,"Acknowledgment Letter from FDA DDM to Goodwin Procter, LLP on behalf of Braeburn, Inc"
0900006483cc0d04,Other,FDA-2019-P-1679-0052,FDA-2019-P-1679,"Change of Address Letter from Braeburn, Inc."
0900006484067157,Other,FDA-2019-P-1679-0077,FDA-2019-P-1679,Interim Response from FDA Office of Orphan Products to Lassman Law + Policy
0900006484087d08,Other,FDA-2019-P-1679-0078,FDA-2019-P-1679,"Supplement from Braeburn, Inc."
0900006483e9a813,Other,FDA-2019-P-1679-0074,FDA-2019-P-1679,"Supplement from Braeburn, Inc."
0900006483b733b1,Supporting & Related Material,FDA-2019-P-1679-0004,FDA-2019-P-1679,"Exhibit 2 re Citizen Petition from Goodwin Procter,  LLP on behalf of Braeburn, Inc."
0900006483b73893,Supporting & Related Material,FDA-2019-P-1679-0005,FDA-2019-P-1679,"Exhibit 3 re Citizen Petition from Goodwin Procter,  LLP on behalf of Braeburn, Inc."
0900006483b784b0,Supporting & Related Material,FDA-2019-P-1679-0008,FDA-2019-P-1679,"Exhibit 6 re Citizen Petition from Goodwin Procter,  LLP on behalf of Braeburn, Inc."
0900006483b78601,Supporting & Related Material,FDA-2019-P-1679-0014,FDA-2019-P-1679,"Exhibit 12 reCitizen Petition from Goodwin Procter,  LLP on behalf of Braeburn, Inc."
0900006483b78604,Supporting & Related Material,FDA-2019-P-1679-0018,FDA-2019-P-1679,"Exhibit 15 re Citizen Petition from Goodwin Procter,  LLP on behalf of Braeburn, Inc."
0900006483b78607,Supporting & Related Material,FDA-2019-P-1679-0021,FDA-2019-P-1679,"Exhibit 18 reCitizen Petition from Goodwin Procter,  LLP on behalf of Braeburn, Inc."
0900006483b73894,Supporting & Related Material,FDA-2019-P-1679-0006,FDA-2019-P-1679,"Exhibit 4 re Citizen Petition from Goodwin Procter,  LLP on behalf of Braeburn, Inc."
0900006483b73895,Supporting & Related Material,FDA-2019-P-1679-0007,FDA-2019-P-1679,"Exhibit 5 re Citizen Petition from Goodwin Procter,  LLP on behalf of Braeburn, Inc."
0900006483b78600,Supporting & Related Material,FDA-2019-P-1679-0013,FDA-2019-P-1679,"Exhibit 11 re Citizen Petition from Goodwin Procter,  LLP on behalf of Braeburn, Inc."
0900006483b78605,Supporting & Related Material,FDA-2019-P-1679-0019,FDA-2019-P-1679,"Exhibit 16 re Citizen Petition from Goodwin Procter,  LLP on behalf of Braeburn, Inc."
0900006483b72aef,Other,FDA-2019-P-1679-0001,FDA-2019-P-1679,"Citizen Petition from Goodwin Procter,  LLP on behalf of Braeburn, Inc."
0900006483e56804,Other,FDA-2019-P-1679-0073,FDA-2019-P-1679,"Supplement from Braeburn, Inc."
0900006483b784b1,Supporting & Related Material,FDA-2019-P-1679-0009,FDA-2019-P-1679,"Exhibit 7 re Citizen Petition from Goodwin Procter,  LLP on behalf of Braeburn, Inc."
0900006483b784b2,Supporting & Related Material,FDA-2019-P-1679-0010,FDA-2019-P-1679,"Exhibit 8 re Citizen Petition from Goodwin Procter,  LLP on behalf of Braeburn, Inc."
0900006483b78602,Supporting & Related Material,FDA-2019-P-1679-0016,FDA-2019-P-1679,"Exhibit 13 reCitizen Petition from Goodwin Procter,  LLP on behalf of Braeburn, Inc."
0900006483b784b4,Supporting & Related Material,FDA-2019-P-1679-0012,FDA-2019-P-1679,"Exhibit 10 re Citizen Petition from Goodwin Procter,  LLP on behalf of Braeburn, Inc."
0900006483b78603,Supporting & Related Material,FDA-2019-P-1679-0017,FDA-2019-P-1679,"Exhibit 14 re Citizen Petition from Goodwin Procter,  LLP on behalf of Braeburn, Inc."
090000648364f8be,Notice,FDA-2005-N-0101-0002,FDA-2005-N-0101,Agency Information Collection Activities; Proposed Collection; Comment Request; Prescription Drug User Fee Cover Sheet; Form FDA 3397
0900006483a49c2f,Notice,FDA-2005-N-0101-0003,FDA-2005-N-0101,Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Prescription Drug User Fee Cover Sheet; Form FDA 3397
090000648043f8a4,Notice,FDA-2005-N-0101-0001,FDA-2005-N-0101,FDA
0900006483c131a9,Notice,FDA-2005-N-0101-0004,FDA-2005-N-0101,"Agency Information Collection Activities; Announcement of Office of
Management and Budget Approvals"
090000648044b048,Other,FDA-2005-P-0367-0003,FDA-2005-P-0367,Interim Response Letter from FDA CDER to Foley & Lardner LLP
090000648044b043,Other,FDA-2005-P-0367-0008,FDA-2005-P-0367,Reply Letter from Foley & Lardner LLP to FDA DDM
09000064807b06cd,Other,FDA-2005-P-0367-0005,FDA-2005-P-0367,Citizen Petition Partial Approval and Denial Response Letter from FDA CDER to Foley & Lardner LLP
090000648044b03c,Other,FDA-2005-P-0367-0002,FDA-2005-P-0367,Acknowledgment Letter from FDA DDM to Foley & Lardner LLP
090000648044aff5,Other,FDA-2005-P-0367-0001,FDA-2005-P-0367,Acknowledgment Letter from FDA DDM to Foley & Lardner LLP
090000648044b02c,Other,FDA-2005-P-0367-0004,FDA-2005-P-0367,Citizen Petition from Foley & Lardner LLP
090000648456acb9,Supporting & Related Material,FDA-2020-P-1344-0004,FDA-2020-P-1344,"Attachment 2 Federal Register Notice for Docket No. FDA–2013–P–0241, Aug 5, 2013 [78 Fed. Reg. 47321] re Citizen Petition from Lachman Consultant Services, Inc."
090000648456aa34,Other,FDA-2020-P-1344-0001,FDA-2020-P-1344,"Citizen Petition from Lachman Consultant Services, Inc."
090000648456acba,Supporting & Related Material,FDA-2020-P-1344-0005,FDA-2020-P-1344,"Attachment 3 Federal Register Notice for Docket No. 01P–0333, Mar 1, 2004 [69 Fed. Reg. 9630] re Citizen Petition from Lachman Consultant Services, Inc."
090000648456aa37,Other,FDA-2020-P-1344-0002,FDA-2020-P-1344,"Acknowledgment Letter from FDA DMS to Lachman Consultant Services, Inc."
090000648456aa39,Supporting & Related Material,FDA-2020-P-1344-0003,FDA-2020-P-1344,"Attachment 1 Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations listing for Cytoxan, NDA 012142, accessed 05/05/2020  re Citizen Petition from Lachman Consultant Services, Inc."
0900006484258f6c,Other,FDA-2019-P-6049-0001,FDA-2019-P-6049,"Citizen Petition from US WorldMeds, LLC"
0900006484251fea,Supporting & Related Material,FDA-2019-P-6049-0018,FDA-2019-P-6049,"Exhibit 16 re Citizen Petition from US WorldMeds, LLC"
0900006484251ffe,Supporting & Related Material,FDA-2019-P-6049-0020,FDA-2019-P-6049,"Exhibit 18 re Citizen Petition from US WorldMeds, LLC"
0900006484252000,Supporting & Related Material,FDA-2019-P-6049-0022,FDA-2019-P-6049,"Exhibit 20 re Citizen Petition from US WorldMeds, LLC"
0900006484251cf4,Supporting & Related Material,FDA-2019-P-6049-0004,FDA-2019-P-6049,"Exhibit 2 re Citizen Petition from US WorldMeds, LLC"
0900006484251fe2,Supporting & Related Material,FDA-2019-P-6049-0010,FDA-2019-P-6049,"Exhibit 8 re Citizen Petition from US WorldMeds, LLC"
0900006484251fe5,Supporting & Related Material,FDA-2019-P-6049-0013,FDA-2019-P-6049,"Exhibit 11 re Citizen Petition from US WorldMeds, LLC"
0900006484252001,Supporting & Related Material,FDA-2019-P-6049-0023,FDA-2019-P-6049,"Exhibit 21 re Citizen Petition from US WorldMeds, LLC"
0900006484252005,Supporting & Related Material,FDA-2019-P-6049-0027,FDA-2019-P-6049,"Exhibit 25 re Citizen Petition from US WorldMeds, LLC"
0900006484251fe6,Supporting & Related Material,FDA-2019-P-6049-0014,FDA-2019-P-6049,"Exhibit 12 re Citizen Petition from US WorldMeds, LLC"
0900006484252002,Supporting & Related Material,FDA-2019-P-6049-0024,FDA-2019-P-6049,"Exhibit 22 re Citizen Petition from US WorldMeds, LLC"
0900006484252006,Supporting & Related Material,FDA-2019-P-6049-0028,FDA-2019-P-6049,"Exhibit 26 re Citizen Petition from US WorldMeds, LLC"
0900006484251cf8,Supporting & Related Material,FDA-2019-P-6049-0008,FDA-2019-P-6049,"Exhibit 6 re Citizen Petition from US WorldMeds, LLC"
0900006484252003,Supporting & Related Material,FDA-2019-P-6049-0025,FDA-2019-P-6049,"Exhibit 23 re Citizen Petition from US WorldMeds, LLC"
0900006484258f70,Other,FDA-2019-P-6049-0002,FDA-2019-P-6049,"Acknowledgment Letter from FDA DMS to US WorldMeds, LLC"
0900006484251cf5,Supporting & Related Material,FDA-2019-P-6049-0005,FDA-2019-P-6049,"Exhibit 3 re Citizen Petition from US WorldMeds, LLC"
0900006484251fe7,Supporting & Related Material,FDA-2019-P-6049-0015,FDA-2019-P-6049,"Exhibit 13 re Citizen Petition from US WorldMeds, LLC"
0900006484251ffd,Supporting & Related Material,FDA-2019-P-6049-0019,FDA-2019-P-6049,"Exhibit 17 re Citizen Petition from US WorldMeds, LLC"
0900006484251fff,Supporting & Related Material,FDA-2019-P-6049-0021,FDA-2019-P-6049,"Exhibit 19 re Citizen Petition from US WorldMeds, LLC"
0900006484251cf3,Supporting & Related Material,FDA-2019-P-6049-0003,FDA-2019-P-6049,"Exhibit 1 re Citizen Petition from US WorldMeds, LLC"
0900006484251fe8,Supporting & Related Material,FDA-2019-P-6049-0016,FDA-2019-P-6049,"Exhibit 14 re Citizen Petition from US WorldMeds, LLC"
0900006484252004,Supporting & Related Material,FDA-2019-P-6049-0026,FDA-2019-P-6049,"Exhibit 24 re Citizen Petition from US WorldMeds, LLC"
0900006484664570,Other,FDA-2019-P-6049-0030,FDA-2019-P-6049,"Response Letter from FDA CDER to US WorldMeds, LLC"
0900006484251cf7,Supporting & Related Material,FDA-2019-P-6049-0007,FDA-2019-P-6049,"Exhibit 5 re Citizen Petition from US WorldMeds, LLC"
0900006484251fe1,Supporting & Related Material,FDA-2019-P-6049-0009,FDA-2019-P-6049,"Exhibit 7 re Citizen Petition from US WorldMeds, LLC"
0900006482e2ffb0,Other,FDA-2013-S-0610-0003,FDA-2013-S-0610,Electronic Method for Specific Electronic Submissions to FDA's Dockets Management Staff
09000064814cb005,Supporting & Related Material,FDA-2013-S-0610-0001,FDA-2013-S-0610,Specific Electronic Submissions
09000064814caa73,Supporting & Related Material,FDA-2013-S-0610-0002,FDA-2013-S-0610,Instructions from the Division of Dockets Management on How to Submit Electronic Citizen Petitions re Citizen Petition Submission; Technical Amendment
0900006483fe24a3,Other,FDA-2019-P-1560-0003,FDA-2019-P-1560,"Interim Response Letter from FDA CDER to Hyman, Phelps & McNamara, P.C."
0900006483b593fe,Other,FDA-2019-P-1560-0002,FDA-2019-P-1560,"Acknowledgment Letter from FDA DDM to Hyman, Phelps & McNamara on behalf of Xellia Pharmaceuticals ApS and Xellia Pharmaceuticals USA, LLC"
0900006483b58e2c,Other,FDA-2019-P-1560-0001,FDA-2019-P-1560,"Citizen Petition from Hyman, Phelps & McNamara on behalf of Xellia Pharmaceuticals ApS and Xellia Pharmaceuticals USA, LLC."
090000648195ee4c,Other,FDA-2014-D-1891-0002,FDA-2014-D-1891,Draft Guidance for Industry on How to Obtain a Letter from FDA Stating that Bioequivalence Study Protocols Contain Safety Protections Comparable to Applicable REMS for RLD
090000648195e613,Notice,FDA-2014-D-1891-0001,FDA-2014-D-1891,"How To Obtain a Letter From the Food and Drug Administration Stating That Bioequivalence Study Protocols Contain Safety Protections
Comparable to Applicable Risk Evaluation and Mitigation Strategies
for Reference Listed Drugs; Draft Guidance for Industry; Availability"
0900006482331232,Other,FDA-2016-P-3482-0001,FDA-2016-P-3482,Citizen Petition from Zydus Pharmaceuticals (USA) Inc
0900006482330fb0,Supporting & Related Material,FDA-2016-P-3482-0004,FDA-2016-P-3482,"Annex II Copy of Drugs@FDA listing of subject formulation, LYNPARZA (Oiaparib capsules, for oral use, 50 mg). re Citizen Petition from Zydus Pharmaceuticals (USA) Inc"
0900006482330fb1,Supporting & Related Material,FDA-2016-P-3482-0005,FDA-2016-P-3482,"Annex III  Copy of current approved FDA labeling for L YNPARZA (Olaparib capsules, for oral use, 50 mg dated 12/2014) re Citizen Petition from Zydus Pharmaceuticals (USA) Inc"
0900006482331234,Other,FDA-2016-P-3482-0002,FDA-2016-P-3482,Acknowledgement Letter from FDA DDM to Zydus Pharmaceuticals (USA) Inc
0900006482330faf,Supporting & Related Material,FDA-2016-P-3482-0003,FDA-2016-P-3482,"Annex I Copy of Orange Book current through October 2016, listing the subject formulation, L YNPARZA (Olaparib capsules, for oral use, 50 mg). re Citizen Petition from Zydus Pharmaceuticals (USA) Inc"
09000064824d84a2,Other,FDA-2016-P-3482-0006,FDA-2016-P-3482,Citizen Petition Withdrawal Letter from Zydus Pharmaceuticals Inc. to FDA CDER
0900006483410571,Other,FDA-2016-P-4275-0057,FDA-2016-P-4275,Letter from FDA CFSAN to BioNeutra North America Inc - Denial Response
09000064825652e9,Other,FDA-2016-P-4275-0054,FDA-2016-P-4275,Letter from BioNeutra North America Inc. to FDA DDM
09000064823ee087,Supporting & Related Material,FDA-2016-P-4275-0045,FDA-2016-P-4275,"Appendix C - Tamura et al 2016 Prevalence and Self-recognition of Chronic
Constipation: Results of an Internet Survey re Citizen Petition from BioNeutra North America Inc"
09000064823ee0a4,Supporting & Related Material,FDA-2016-P-4275-0053,FDA-2016-P-4275,"Appendix C - Yen et al 2011 Long-term supplementation of isomalto-oligosaccharides improved colonic microflora profile, bowel function, and blood cholesterol levels in constipated elderly peopledA placebo-controlled, diet-controlled trial re Citizen Petition from BioNeutra North America Inc"
09000064823ee136,Supporting & Related Material,FDA-2016-P-4275-0010,FDA-2016-P-4275,"Appendix C - Cummings et al 1992 Fecal Weight, Colon Cancer Risk, and Dietary Intake of Nonstarch Polysaccharides (Dietary Fiber) re Citizen Petition from BioNeutra North America Inc"
09000064823ee137,Supporting & Related Material,FDA-2016-P-4275-0011,FDA-2016-P-4275,Appendix C - Cummings et al 2004 PASSCLAIM1 – Gut health and immunity re Citizen Petition from BioNeutra North America Inc
09000064823ee139,Supporting & Related Material,FDA-2016-P-4275-0013,FDA-2016-P-4275,Appendix C - Dhingra et al 2012 Dietary fibre in foods: a review re Citizen Petition from BioNeutra North America Inc
09000064823ee155,Supporting & Related Material,FDA-2016-P-4275-0016,FDA-2016-P-4275,"Appendix C - Everhart et al 1989 A Longitudinal Survey of Self-Reported
Bowel Habits in the United States re Citizen Petition from BioNeutra North America Inc"
09000064823ee164,Supporting & Related Material,FDA-2016-P-4275-0034,FDA-2016-P-4275,Appendix C - McGill et al 2015 Ten-Year Trends in Fiber and Whole Grain Intakes and Food Sources for the United States Population: National Health and Nutrition Examination Survey 2001–2010 re Citizen Petition from BioNeutra North America Inc
09000064823edcd8,Supporting & Related Material,FDA-2016-P-4275-0003,FDA-2016-P-4275,Appendix A - Key Research Aspects of Four Human Studies on IMO and Bowel Function re Citizen Petition from BioNeutra North America Inc
09000064823ee07d,Supporting & Related Material,FDA-2016-P-4275-0028,FDA-2016-P-4275,Appendix C - Kaneko et al 1994 Effects of Isomaltooligosaccharides with Different Degrees of Polymerization on Human Fecal Bifidobacteria re Citizen Petition from BioNeutra North America Inc
09000064823ee07f,Supporting & Related Material,FDA-2016-P-4275-0030,FDA-2016-P-4275,Appendix C - Kohmoto et al 1991 Dose-response Test of  Isomaltooligosaccharides for Increasing Fecal Bifidobacteria re Citizen Petition from BioNeutra North America Inc
09000064823ee08e,Supporting & Related Material,FDA-2016-P-4275-0051,FDA-2016-P-4275,Appendix C - U S FDA 2016d re Citizen Petition from BioNeutra North America Inc
0900006482a19e26,Other,FDA-2016-P-4275-0056,FDA-2016-P-4275,Letter from BioNeutra North America Inc to FDA CFSAN
09000064823ee133,Supporting & Related Material,FDA-2016-P-4275-0007,FDA-2016-P-4275,"Appendix C - Chang et al 2012 Prevalence of functional gastrointestinal disorders in Taiwan: questionnaire-based survey for adults based on
the Rome III criteria re Citizen Petition from BioNeutra North America Inc"
09000064823ee134,Supporting & Related Material,FDA-2016-P-4275-0008,FDA-2016-P-4275,Appendix C - Chen et al 2001 Effects of Isomalto-Oligosaccharides on Bowel Functions and Indicators of Nutritional Status in Constipated Elderly Men re Citizen Petition from BioNeutra North America Inc
09000064823ee158,Supporting & Related Material,FDA-2016-P-4275-0019,FDA-2016-P-4275,Appendix C - Harari et al 1996 Bowel Habit in Relation to Age and Gender re Citizen Petition from BioNeutra North America Inc
09000064823ee165,Supporting & Related Material,FDA-2016-P-4275-0035,FDA-2016-P-4275,Appendix C - Nishino et al 1981 Oligosaccharides in Soy Sauce re Citizen Petition from BioNeutra North America Inc
09000064823ee167,Supporting & Related Material,FDA-2016-P-4275-0037,FDA-2016-P-4275,"Appendix C - Pare et al 2001 An Epidemiological Survey of Constipation in
Canada: Definitions, Rates, Demographics, and Predictors of Health Care Seeking re Citizen Petition from BioNeutra North America Inc"
09000064823ee168,Supporting & Related Material,FDA-2016-P-4275-0038,FDA-2016-P-4275,"Appendix C - Rome Foundation 2006 Rome III Diagnostic Criteria for
Functional Gastrointestinal Disorders re Citizen Petition from BioNeutra North America Inc"
090000648275cf5e,Other,FDA-2016-P-4275-0055,FDA-2016-P-4275,CFSAN Interim Response Letter  to BioNeutra North America Inc.
09000064823ee135,Supporting & Related Material,FDA-2016-P-4275-0009,FDA-2016-P-4275,Appendix C - Connell et al 1965 Variation of Bowel Habit in Two Population Samples re Citizen Petition from BioNeutra North America Inc
09000064823ee156,Supporting & Related Material,FDA-2016-P-4275-0017,FDA-2016-P-4275,Appendix C - Fukuda et al 2007 Pattern of dietary fiber intake among the Japanese general population re Citizen Petition from BioNeutra North America Inc
09000064823ee15b,Supporting & Related Material,FDA-2016-P-4275-0020,FDA-2016-P-4275,Appendix C - Health Canada 2013 List of Dietary Fibres Reviewed and Accepted by Health Canada’s Food Directorate re Citizen Petition from BioNeutra North America Inc
09000064823ee15d,Supporting & Related Material,FDA-2016-P-4275-0022,FDA-2016-P-4275,Appendix C - Higgins & Johanson 2004 Epidemiology of Constipation in North America: A Systematic Review re Citizen Petition from BioNeutra North America Inc
090000648320d894,Other,FDA-2018-P-1678-0001,FDA-2018-P-1678,"Citizen Petition from  Mapi USA, Inc"
090000648320e044,Other,FDA-2018-P-1678-0002,FDA-2018-P-1678,"Acknowledgment Letter from FDA DDM to  Mapi USA, Inc"
090000648320d896,Supporting & Related Material,FDA-2018-P-1678-0003,FDA-2018-P-1678,"Appendix 1 - Proposed Labeling for Midazolam Injection USP (20 pages) re Citizen Petition from  Mapi USA, Inc"
090000648320d897,Supporting & Related Material,FDA-2018-P-1678-0004,FDA-2018-P-1678,"Appendix 2 - Approved Labeling for Midazolam Injection by Hospira - Reference Standard (41 pages) re Citizen Petition from  Mapi USA, Inc"
090000648320d898,Supporting & Related Material,FDA-2018-P-1678-0005,FDA-2018-P-1678,"Appendix 3- Side-by-side comparison table and justifications of proposed and approved labeling for Midazolam Injection (47 pages) re Citizen Petition from  Mapi USA, Inc"
09000064827a27ad,Other,FDA-2016-P-4591-0003,FDA-2016-P-4591,"Petition denial letter from FDA CDER to   Hyman, Phelps & McNamara PC"
090000648243bb33,Other,FDA-2016-P-4591-0001,FDA-2016-P-4591,"Citizen Petition from Hyman, Phelps & McNamara, PC"
090000648243c1c4,Other,FDA-2016-P-4591-0002,FDA-2016-P-4591,"Acknowledgement Letter from FDA DDM to Hyman, Phelps & McNamara, P.C."
0900006481715199,Other,FDA-2014-P-0699-0002,FDA-2014-P-0699,Acknowledgement Letter From FDA DDM to Jason Williams
0900006481715143,Other,FDA-2014-P-0699-0001,FDA-2014-P-0699,Citizen Petition From Jason Williams
09000064818cd987,Other,FDA-2014-P-0699-0008,FDA-2014-P-0699,Citizen Petition Denial Response Letter from FDA/CDER to Jason Williams
0900006481f73c79,Other,FDA-2014-P-0511-0004,FDA-2014-P-0511,Gablofen/Baclofen Petition Close out Memorandum from CDER Director
09000064816bf01d,Other,FDA-2014-P-0511-0001,FDA-2014-P-0511,Citizen Petition From Agila Specialties Inc.
09000064818a7e56,Other,FDA-2014-P-0511-0003,FDA-2014-P-0511,Interim Response from FDA/CDER to Agila Specialties Inc.
09000064816bf020,Other,FDA-2014-P-0511-0002,FDA-2014-P-0511,Acknowledgement Letter From FDA DDM to Agila Specialties Inc.
09000064818be29c,Supporting & Related Material,FDA-2014-P-1603-0004,FDA-2014-P-1603,Attachment II
09000064818be199,Other,FDA-2014-P-1603-0001,FDA-2014-P-1603,Citizen Petition from Zydus Pharmaceuticals USA Inc
09000064818be23f,Other,FDA-2014-P-1603-0002,FDA-2014-P-1603,Aknowledgment Letter from FDA DDM to Zydus Pharmaceuticals USA Inc
09000064818be29d,Supporting & Related Material,FDA-2014-P-1603-0005,FDA-2014-P-1603,Attachment III
09000064818be29b,Supporting & Related Material,FDA-2014-P-1603-0003,FDA-2014-P-1603,Attachment I
090000648239a670,Other,FDA-2014-P-0445-0004,FDA-2014-P-0445,Denial letter from CDRH to Robert Lytle
0900006481723a91,Other,FDA-2014-P-0445-0003,FDA-2014-P-0445,Citizen Petition Interim Response from FDA CDRH to Robert L Lytle
09000064816b1e95,Other,FDA-2014-P-0445-0002,FDA-2014-P-0445,Acknowledgement Letter From FDA DDM to Robert L Lytle
09000064816b1e64,Other,FDA-2014-P-0445-0001,FDA-2014-P-0445,Citizen Petition From Robert L. Lytle
09000064816c10fa,Other,FDA-2014-P-0513-0001,FDA-2014-P-0513,Citizen Petition From University of TX MD Anderson Cancer Center
09000064816c1541,Other,FDA-2014-P-0513-0002,FDA-2014-P-0513,Acknowledgement Letter from FDA DDM to the University of TX MD Anderson Cancer Center
0900006481b65298,Other,FDA-2014-P-0513-0003,FDA-2014-P-0513,Citizen Petition Approval Response Letter from FDA CDER to the University of Texas MD Anderson Cancer Center
0900006481d83adb,Other,FDA-2015-P-4582-0001,FDA-2015-P-4582,Citizen Petition from Margaret Moustafa
0900006481d83c16,Supporting & Related Material,FDA-2015-P-4582-0007,FDA-2015-P-4582,Attachment 6 CoraLynn B. Trewet Interstitial Lung Disease Pulmonary Fibrosis re: Citizen Petition from Margaret Moustafa
0900006481d83e08,Supporting & Related Material,FDA-2015-P-4582-0004,FDA-2015-P-4582,Attachment 2 CoraLynn B. Trewet Drug Induced Pulmonary Diseases re: Citizen Petition from Margaret Moustafa
0900006481d83e0b,Supporting & Related Material,FDA-2015-P-4582-0006,FDA-2015-P-4582,Attachment 5 Kevin R. Flaherty Nonspecific Interstitial Pneumonia re: Citizen Petition from Margaret Moustafa
0900006481d83e06,Supporting & Related Material,FDA-2015-P-4582-0003,FDA-2015-P-4582,Attachment 1 References re: Citizen Petition from Margaret Moustafa
0900006481d83e03,Other,FDA-2015-P-4582-0002,FDA-2015-P-4582,Acknowledgement Letter from FDA DDM to Margaret Moustafa
0900006481fdcca4,Other,FDA-2015-P-4582-0008,FDA-2015-P-4582,Interim Response May 18 2016
0900006481d83e0a,Supporting & Related Material,FDA-2015-P-4582-0005,FDA-2015-P-4582,Attachment 4 Collard and King Classification of Diffuse Lung Disease re: Citizen Petition from Margaret Moustafa
09000064843288d9,Other,FDA-2018-P-3281-0013,FDA-2018-P-3281,Final Response Letter from FDA CDER to Pfizer Essential Health
0900006483a8808c,Other,FDA-2018-P-3281-0010,FDA-2018-P-3281,Letter from FDA CDER to Pfizer Essential Health
090000648365d019,Other,FDA-2018-P-3281-0001,FDA-2018-P-3281,Citizen Petition from Pfizer Inc
090000648365d3a3,Other,FDA-2018-P-3281-0002,FDA-2018-P-3281,Acknowledgment Letter from FDA DDM to Pfizer Inc.
0900006483adbbbc,Supporting & Related Material,FDA-2019-P-1198-0006,FDA-2019-P-1198,Appendix 2 Letter of Support re Citizen Petition from KIND LLC
0900006483adbd18,Other,FDA-2019-P-1198-0002,FDA-2019-P-1198,"Acknowledgment Letter from FDA DDM to KIND, LLC"
0900006483adbbb9,Supporting & Related Material,FDA-2019-P-1198-0003,FDA-2019-P-1198,"Appendix 1 Reference 1 Copyrighted Article Lles, et al (2018) Nutrient Content Claims How They Impact Perceived Healthfulness of Fortified Snack Foods and the Moderating Effects of Nutrition Facts Labels re Citizen Petition from KIND, LLC"
090000648449edb8,Other,FDA-2019-P-1198-0009,FDA-2019-P-1198,Interim Response Letter from FDA CFSAN to KIND LLC
0900006483adb871,Other,FDA-2019-P-1198-0001,FDA-2019-P-1198,Citizen Petition from KIND LLC
0900006483adbbba,Supporting & Related Material,FDA-2019-P-1198-0004,FDA-2019-P-1198,Appendix 1 Reference 2 Copyrighted Article Kalergis and MacDonald (2009)  Discretionary Food Fortification: Implications of Consumer Attitudes re Citizen Petition from KIND LLC (1)
0900006483adbbbb,Supporting & Related Material,FDA-2019-P-1198-0005,FDA-2019-P-1198,Appendix 1 Reference 3 Manuscript Katz et al The Public Health Case for Modernizing the Definition of Protein Quality re Citizen Petition from KIND LLC
0900006482590eef,Supporting & Related Material,FDA-2017-P-2803-0014,FDA-2017-P-2803,Exhibit K - Pharmacokinetics and Pharmacodynamics of Pegfilgrastim - Yang re Citizen Petition from Apotex
0900006482590d94,Other,FDA-2017-P-2803-0003,FDA-2017-P-2803,"Acknowledgment Letter from FDA DDM to Apotex, Inc."
0900006482b8cebe,Other,FDA-2017-P-2803-0018,FDA-2017-P-2803,"Petition Response Letter from FDA CDER to Apotex, Inc."
0900006482590eeb,Supporting & Related Material,FDA-2017-P-2803-0010,FDA-2017-P-2803,Exhibit G - Optimizing Adjuvant Chemotherapy in Early-Stage Breast Cancer - Perez re Citizen Petition from Apotex
0900006482592092,Other,FDA-2017-P-2803-0016,FDA-2017-P-2803,"Citizen Petition from Apotex, Inc."
0900006482590eed,Supporting & Related Material,FDA-2017-P-2803-0012,FDA-2017-P-2803,Exhibit I - Granulocyte-colony stimulating factor administration - Tigue re Citizen Petition from Apotex
090000648259116d,Supporting & Related Material,FDA-2017-P-2803-0004,FDA-2017-P-2803,Exhibit A - Confirmation of Biosimilarity - Desai re Citizen Petition from Apotex
0900006482590ee8,Supporting & Related Material,FDA-2017-P-2803-0007,FDA-2017-P-2803,Exhibit D - Predicting Individual Risk of Neutropenic Complications - Lyman II re Citizen Petition from Apotex
0900006482590ee9,Supporting & Related Material,FDA-2017-P-2803-0008,FDA-2017-P-2803,Exhibit E - Risk Models for Predicting Chemotherapy-Induced Neutropenia - Lyman I re Citizen Petition from Apotex
0900006482590eee,Supporting & Related Material,FDA-2017-P-2803-0013,FDA-2017-P-2803,Exhibit J - First and Subsequent Cycle Use of Pegfilgrastim - Vogel re Citizen Petition from Apotex
090000648259116c,Supporting & Related Material,FDA-2017-P-2803-0001,FDA-2017-P-2803,"Declaration of Dr.  Scadden re Citizen Petition from Apotex, Inc."
0900006482590eec,Supporting & Related Material,FDA-2017-P-2803-0011,FDA-2017-P-2803,Exhibit H - Pharmacokinetic Pharmacodynamic Modeling - Roskos re Citizen Petition from Apotex
0900006482590ef0,Supporting & Related Material,FDA-2017-P-2803-0015,FDA-2017-P-2803,Exhibit L - Neutrophil dynamics in response to chemotherapy and G-CSF - Zhuge re Citizen Petition from Apotex
0900006482590eea,Supporting & Related Material,FDA-2017-P-2803-0009,FDA-2017-P-2803,Exhibit F - Neutropenia in cancer patients - Mayor re Citizen Petition from Apotex
090000648259116e,Supporting & Related Material,FDA-2017-P-2803-0005,FDA-2017-P-2803,Exhibit B - Chemotherapy for breast cancer - Hassan re Citizen Petition from Apotex
090000648259116f,Supporting & Related Material,FDA-2017-P-2803-0006,FDA-2017-P-2803,Exhibit C - PEGylation of therapeutic proteins - Jevsevar re Citizen Petition from Apotex
090000648258f9a5,Other,FDA-2017-P-2803-0002,FDA-2017-P-2803,"Citizen Petition from Apotex, Inc."
0900006482c9fae2,Other,FDA-2017-P-4195-0004,FDA-2017-P-4195,Petition Response Letter
0900006482c98c5a,Notice,FDA-2017-P-4195-0003,FDA-2017-P-4195,"Determination That TRINTELLIX (Vortioxetine Hydrobromide) Oral
Tablet, EQ 15 Milligram Base, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
0900006482921ba5,Other,FDA-2017-P-4195-0001,FDA-2017-P-4195,"Citizen Petition from  INC Research, LLC"
0900006482922b91,Other,FDA-2017-P-4195-0002,FDA-2017-P-4195,"Acknowledgment Letter from FDA DDM to  INC Research, LLC"
0900006483306d3f,Supporting & Related Material,FDA-2018-P-2050-0003,FDA-2018-P-2050,"References re Citizen Petition from SS Formulations, LLC."
0900006483307315,Other,FDA-2018-P-2050-0002,FDA-2018-P-2050,"Acknowledgment Letter from FDA DDM to SS Formulations, LLC."
0900006483306996,Other,FDA-2018-P-2050-0001,FDA-2018-P-2050,"Citizen Petition from SS Formulations, LLC."
09000064838e6dff,Other,FDA-2018-P-2050-0004,FDA-2018-P-2050,"Letter from FDA CDER to SS Formulations, LLC"
09000064824ffb80,Other,FDA-2017-P-1495-0001,FDA-2017-P-1495,Citizen Petition from Sandoz Inc
09000064825ac89f,Other,FDA-2017-P-1495-0003,FDA-2017-P-1495,Withdrawal of CP from Sandoz Inc
09000064824ffb82,Other,FDA-2017-P-1495-0002,FDA-2017-P-1495,Acknowledgement Letter from FDA DDM to Sandoz Inc
090000648046ecc0,Notice,FDA-2004-N-0066-0001,FDA-2004-N-0066,FDA
090000648046ecc4,Notice,FDA-2004-N-0066-0002,FDA-2004-N-0066,FDA
09000064804737f9,Notice,FDA-2004-N-0378-0002,FDA-2004-N-0378,FDA
09000064804737f7,Notice,FDA-2004-N-0378-0001,FDA-2004-N-0378,FDA
09000064804737fc,Notice,FDA-2004-N-0378-0005,FDA-2004-N-0378,FDA
09000064804737fa,Supporting & Related Material,FDA-2004-N-0378-0003,FDA-2004-N-0378,Supporting Statement
09000064804737fb,Supporting & Related Material,FDA-2004-N-0378-0004,FDA-2004-N-0378,Supporting Statement
0900006480429ca2,Notice,FDA-2007-N-0088-0001,FDA-2007-N-0088,FDA
09000064804420cd,Supporting & Related Material,FDA-2006-D-0032-0002,FDA-2006-D-0032,Draft Guidance
09000064804420c8,Notice,FDA-2006-D-0032-0001,FDA-2006-D-0032,FDA
09000064804420d6,Notice,FDA-2006-D-0032-0005,FDA-2006-D-0032,FDA
09000064804420d7,Other,FDA-2006-D-0032-0006,FDA-2006-D-0032,"Guidance for Clinical Investigators, Institutional Review Boards and Sponsors; Process for Handling Referrals to FDA Under 21 CFR 50.54;  Additional Safeguards for Children in Clinical Investigations"
09000064804420d8,Supporting & Related Material,FDA-2006-D-0032-0007,FDA-2006-D-0032,Guidance
09000064804420ce,Supporting & Related Material,FDA-2006-D-0032-0003,FDA-2006-D-0032,Draft Guidance
09000064804420cf,Supporting & Related Material,FDA-2006-D-0032-0004,FDA-2006-D-0032,Draft Guidance
0900006480a71ffd,Other,FDA-2009-P-0602-0002,FDA-2009-P-0602,"Acknowledgement Letter to Kaiser Permanente Health Plan, Inc"
0900006480a71ffa,Other,FDA-2009-P-0602-0001,FDA-2009-P-0602,"Kaiser Permanente Health Plan, Inc. - Citizen Petition"
0900006480b08e1b,Other,FDA-2009-P-0602-0004,FDA-2009-P-0602,"Interim Response to Kaiser Foundation Health Plan, Inc."
0900006483d61ee6,Other,FDA-2009-P-0602-0005,FDA-2009-P-0602,Memorandum of Meeting from  FDA/CDER
0900006484dda744,Other,FDA-2021-P-1142-0001,FDA-2021-P-1142,"Citizen Petition from BioDelivery Sciences International, Inc."
0900006484dda746,Other,FDA-2021-P-1142-0002,FDA-2021-P-1142,"Acknowledgment Letter from FDM DMS to BioDelivery Sciences International, Inc."
0900006481fc4730,Other,FDA-2015-P-4946-0004,FDA-2015-P-4946,Withdrawal from Zydus Pharmaceuticals (USA) Inc.
0900006481dbed80,Supporting & Related Material,FDA-2015-P-4946-0002,FDA-2015-P-4946,Annexure I Orange Book Approved Drug Products with Therapeutic Equivalence Evaluations re Citizen Petition from Zydus Pharmaceuticals (USA) Inc.
0900006481dbed03,Other,FDA-2015-P-4946-0003,FDA-2015-P-4946,Acknowledgement Letter from FDA DDM to Zydus Pharmaceuticals (USA) Inc.
0900006481dbe8fb,Other,FDA-2015-P-4946-0001,FDA-2015-P-4946,Citizen Petition from Zydus Pharmaceuticals (USA) Inc.
09000064820066a6,Other,FDA-2015-P-3739-0003,FDA-2015-P-3739,Interim Response Letter from FDA CFSAN to Bryan Kutz
0900006481ccc985,Other,FDA-2015-P-3739-0002,FDA-2015-P-3739,Acknowledgement Letter from FDA DDM to Bryan Kutz
0900006481ccc4c0,Other,FDA-2015-P-3739-0001,FDA-2015-P-3739,Citizen Petition from Bryan Kutz
090000648299c6b9,Supporting & Related Material,FDA-2017-P-4670-0005,FDA-2017-P-4670,Attachment 3 - EMEND Merck Website Product Listing re Citizen Petition from Baxter Healthcare Corporation
0900006482e77ed5,Other,FDA-2017-P-4670-0008,FDA-2017-P-4670,Interim Response from FDA to Baxter Healthcare Corporation
090000648299c6b8,Supporting & Related Material,FDA-2017-P-4670-0004,FDA-2017-P-4670,Attachment 2 - EMEND DailyMed Labels re Citizen Petition from Baxter Healthcare Corporation
090000648299b0cb,Other,FDA-2017-P-4670-0001,FDA-2017-P-4670,Citizen Petition from Baxter Healthcare Corporation
090000648299c597,Other,FDA-2017-P-4670-0002,FDA-2017-P-4670,Acknowledgment Letter from FDA DDM to Baxter Healthcare Corporation
090000648299c6ba,Supporting & Related Material,FDA-2017-P-4670-0006,FDA-2017-P-4670,Attachment 4 - EMEND DrugsatFDA Label Approved 31 May 2017 NDA 022023s015 re Citizen Petition from Baxter Healthcare Corporation
090000648299c6bb,Supporting & Related Material,FDA-2017-P-4670-0007,FDA-2017-P-4670,Attachment 5 - Fresenius Kabi DrugsatFDA Label Approved 09 June 2016 Original ANDA 206197 re Citizen Petition from Baxter Healthcare Corporation
09000064837b55db,Other,FDA-2017-P-4670-0009,FDA-2017-P-4670,Petition Approval Letter from FDA CDER to Baxter Healthcare Corp
090000648299c6b7,Supporting & Related Material,FDA-2017-P-4670-0003,FDA-2017-P-4670,Attachment 1 - EMEND (Fosaprepitant Dimeglumine) Orange Book Listing re Citizen Petition from Baxter Healthcare Corporation
0900006484021236,Supporting & Related Material,FDA-2019-P-4645-0004,FDA-2019-P-4645,"Attachment 2 - Vesicare approved labeling re Citizen Petition from Reguliance LLC on behalf of  INTAS Pharmaceuticals, Ltd."
0900006484021245,Supporting & Related Material,FDA-2019-P-4645-0007,FDA-2019-P-4645,"Attachment 5 - OGD Product-specific guidance re Citizen Petition from Reguliance LLC on behalf of  INTAS Pharmaceuticals, Ltd."
0900006484021243,Supporting & Related Material,FDA-2019-P-4645-0005,FDA-2019-P-4645,"Attachment 3 - Proposed labeling for Solifenacin INTAS ODT re Citizen Petition from Reguliance LLC on behalf of  INTAS Pharmaceuticals, Ltd."
0900006484021247,Supporting & Related Material,FDA-2019-P-4645-0009,FDA-2019-P-4645,"Attachment 7 - Comparative in-vitro dissolution studies re Citizen Petition from Reguliance LLC on behalf of  INTAS Pharmaceuticals, Ltd."
090000648402119b,Other,FDA-2019-P-4645-0001,FDA-2019-P-4645,"Citizen Petition from Reguliance LLC on behalf of  INTAS Pharmaceuticals, Ltd."
0900006484021235,Supporting & Related Material,FDA-2019-P-4645-0003,FDA-2019-P-4645,"Attachment 1 - Copy of Orange Book pages for Vesicare re Citizen Petition from Reguliance LLC on behalf of  INTAS Pharmaceuticals, Ltd."
0900006484021248,Supporting & Related Material,FDA-2019-P-4645-0010,FDA-2019-P-4645,"Attachment 8 - PREA Automatic Full Waiver_list 8-14-2019 re Citizen Petition from Reguliance LLC on behalf of  INTAS Pharmaceuticals, Ltd."
0900006484021246,Supporting & Related Material,FDA-2019-P-4645-0008,FDA-2019-P-4645,"Attachment 6 - OGD recommended dissolution method re Citizen Petition from Reguliance LLC on behalf of  INTAS Pharmaceuticals, Ltd."
090000648402142d,Other,FDA-2019-P-4645-0002,FDA-2019-P-4645,Acknowledgment Letter from FDA DMS to Reguliance LLC on behalf of INTAS Pharmaceuticals Ltd.
0900006484021244,Supporting & Related Material,FDA-2019-P-4645-0006,FDA-2019-P-4645,"Attachment 4 - Side-by-side comparison of Vesicare and Solifenacin labeling re Citizen Petition from Reguliance LLC on behalf of  INTAS Pharmaceuticals, Ltd."
0900006481fbb1aa,Other,FDA-2016-P-1250-0002,FDA-2016-P-1250,Acknowledgement Letter from FDA DDM to PTS Consulting
09000064827ab0e0,Other,FDA-2016-P-1250-0007,FDA-2016-P-1250,Letter from PTS Consulting  requesting to  withdraw CP
0900006481fbb1a8,Other,FDA-2016-P-1250-0001,FDA-2016-P-1250,Citizen Petition from PTS Consulting
0900006481fbb1ac,Supporting & Related Material,FDA-2016-P-1250-0003,FDA-2016-P-1250,"Attachment 1 - Chlorpromazine Hydrochloride Tables, 100 mg, ANDA No. 080439, Sandoz (Discontinued) 36th Edition"
0900006481fbb1ad,Supporting & Related Material,FDA-2016-P-1250-0004,FDA-2016-P-1250,"Attachment 2 - USL Pharma's ANDA No 084114 for Chlorpromazine Hydrochloride Tables, 100 mg 36th Edition"
0900006482369b08,Other,FDA-2016-P-1250-0005,FDA-2016-P-1250,Interim response from CDER to PTS Consulting LLC
0900006481f93b76,Supporting & Related Material,FDA-2016-P-1212-0003,FDA-2016-P-1212,"Attachment 1 Approved labeling for the RLD, Excedrin (migraine) re Citizen Petition from Medtech Products Inc."
0900006481f93b77,Supporting & Related Material,FDA-2016-P-1212-0004,FDA-2016-P-1212,"Attachment 2 Draft labeling for the proposed product, Goody's Migraine re Citizen Petition from Medtech Products Inc."
0900006481f93b78,Supporting & Related Material,FDA-2016-P-1212-0005,FDA-2016-P-1212,Attachment 3 Request for Waiver from requirement to submit a pediatric assessment re Citizen Petition from Medtech Products Inc.
0900006481f93b8b,Other,FDA-2016-P-1212-0002,FDA-2016-P-1212,Acknowledgement Letter from FDA DDM to Medtech Products Inc.
0900006481f93b74,Other,FDA-2016-P-1212-0001,FDA-2016-P-1212,Citizen Petition from Medtech Products Inc.
0900006482eee5b0,Other,FDA-2016-P-1212-0006,FDA-2016-P-1212,Notice of Withdrawal Letter from FDA to A Prestige Brands Company
09000064825de6db,Other,FDA-2016-P-4141-0003,FDA-2016-P-4141,"Interim Response Letter from CDER to Hyman, Phelps & McNamara, P.C."
0900006483aea054,Other,FDA-2016-P-4141-0004,FDA-2016-P-4141,"Response Letter from CDER to Hyman, Phelps & McNamara, P.C."
09000064823cd319,Other,FDA-2016-P-4141-0002,FDA-2016-P-4141,"Acknowledgment Letter from FDA DDM to Hyman Phelps & McNamara,  P.C."
09000064823ccc67,Other,FDA-2016-P-4141-0001,FDA-2016-P-4141,"Citizen Petition from Hyman Phelps & McNamara, P.C. (Upsher-Smith Laboratories, Inc.)"
0900006483b6b1ef,Other,FDA-2019-P-1643-0002,FDA-2019-P-1643,Acknowledgment Letter from FDA DDM to Public Citizen's Health Research Group
0900006483b70296,Other,FDA-2019-P-1643-0003,FDA-2019-P-1643,Supplement from Public Citizen
0900006483b7f0b4,Other,FDA-2019-P-1643-0004,FDA-2019-P-1643,Withdrawal from Public Citizen
0900006483b6ad28,Other,FDA-2019-P-1643-0001,FDA-2019-P-1643,Citizen Petition from Public Citizen's Health Research Group
09000064818e4a34,Other,FDA-2014-P-1660-0001,FDA-2014-P-1660,Citizen Petition from Teva Pharmaceutical Industries Ltd Teva Respiratory LLC
09000064818e4cfb,Other,FDA-2014-P-1660-0002,FDA-2014-P-1660,Acknowledgement Letter From FDA DDM to Teva Pharmaceuticals
0900006481af1be0,Other,FDA-2014-P-1660-0003,FDA-2014-P-1660,"FDA CDER to Teva Respiratory, LLC  Citizen Petition Partial Approval and Partial Denial"
0900006481966d70,Other,FDA-2014-P-2142-0001,FDA-2014-P-2142,Citizen Petition from ZYDUS Pharmaceuticals
0900006481966868,Other,FDA-2014-P-2142-0002,FDA-2014-P-2142,Acknowledgement Letter From FDA DDM to Zydus Pharmaceuticals
0900006481cbd45f,Other,FDA-2014-P-2142-0003,FDA-2014-P-2142,"Withdrawal of Citizen Petition from Zydus Pharmaceuticals, Inc"
09000064812632f3,Notice,FDA-2013-D-0362-0001,FDA-2013-D-0362,Draft Guidance for Industry and Food and Drug Administration Staff; Glass Syringes for Delivering Drug and Biological Products: Technical Information To Supplement Standardization Standard 11040–4; Availability
0900006481264a85,Other,FDA-2013-D-0362-0002,FDA-2013-D-0362,Draft Guidance for Industry and Food and Drug Administration Staff; Glass Syringes for Delivering Drug and Biological Products: Technical Information To Supplement Standardization Standard 11040–4
09000064824d4c1a,Other,FDA-2017-P-1108-0002,FDA-2017-P-1108,Acknowledgement Letter from FDA DDM to Orbicular Pharmaceutical Technologies
09000064824d4c18,Other,FDA-2017-P-1108-0001,FDA-2017-P-1108,Citizen Petition from Orbicular Pharmaceutical Technologies
0900006482b486e3,Other,FDA-2017-P-1108-0005,FDA-2017-P-1108,"Response Letter from FDA to Orbicular Pharmaceutical Technologies, Pvt. Ltd"
0900006482a8d92f,Other,FDA-2017-P-1108-0003,FDA-2017-P-1108,Interim Response Letter re Citizen Petition from Orbicular Pharmaceutical Technologies
0900006482b3b694,Notice,FDA-2017-P-1108-0004,FDA-2017-P-1108,"Determination That TIMOPTIC (Timolol Maleate Ophthalmic Solution), 0.25 Percent and 0.5 Percent, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
0900006484420d31,Other,FDA-2020-P-1065-0002,FDA-2020-P-1065,Acknowledgment Letter from FDA DMS to B. Braun Medical Inc.
090000648483c700,Other,FDA-2020-P-1065-0004,FDA-2020-P-1065,Letter from FDA CDER to B. Braun Medical Inc.
0900006484420d30,Other,FDA-2020-P-1065-0001,FDA-2020-P-1065,Citizen Petition from B. Braun Medical Inc.
0900006484420b29,Supporting & Related Material,FDA-2020-P-1065-0003,FDA-2020-P-1065,Appendix 1: List of B. Braun Drug Products for which TE Code Designation is Requested RE Citizen Petition from B. Braun Medical Inc.
0900006484704ef7,Other,FDA-2020-P-0678-0005,FDA-2020-P-0678,"Petition Response Letter from FDA CDER to Fresenius Kabi USA, LLC"
090000648433c777,Other,FDA-2020-P-0678-0001,FDA-2020-P-0678,"Citizen Petition from Fresenius Kabi USA, LLC."
09000064847042cd,Notice,FDA-2020-P-0678-0004,FDA-2020-P-0678,"Determination That DEXTROSE IN PLASTIC CONTAINER (Dextrose)  Injectable, 30 Grams/100 Milliliters, 40 Grams/100 Milliliters, 60 Grams/100 Milliliters, and 70 Grams/100 Milliliters, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
090000648433c77b,Supporting & Related Material,FDA-2020-P-0678-0003,FDA-2020-P-0678,"Attachment A - Current Orange Book Listing of Dextrose 70% re Citizen Petition from Fresenius Kabi USA, LLC."
090000648433c778,Other,FDA-2020-P-0678-0002,FDA-2020-P-0678,"Acknowledgment Letter from FDA DMS to Fresenius Kabi USA, LLC."
0900006484a46ffd,Supporting & Related Material,FDA-2021-P-0211-0004,FDA-2021-P-0211,Attachment 2- NDA 018897 RLD Labeling re: Suitability Petition from Fresenius Kabi USA LLC
0900006484a46e21,Other,FDA-2021-P-0211-0001,FDA-2021-P-0211,Suitability Petition from Fresenius Kabi USA LLC
0900006484a46fe2,Supporting & Related Material,FDA-2021-P-0211-0003,FDA-2021-P-0211,Attachment 1- Orange Book Listing of Sodium Chloride re: Suitability Petition from Fresenius Kabi USA LLC
0900006484a46fda,Other,FDA-2021-P-0211-0002,FDA-2021-P-0211,Acknowledgment Letter from FDA DMS to Fresenius Kabi USA LLC
0900006484a47000,Supporting & Related Material,FDA-2021-P-0211-0005,FDA-2021-P-0211,Attachment 3- Fresenius Kabi Proposed Labeling Sodium Chloride PBP PI re: Suitability Petition from Fresenius Kabi USA LLC
09000064822360ee,Supporting & Related Material,FDA-2016-P-2737-0006,FDA-2016-P-2737,Attachment 3- Appendix Tabs 19-20-2 re Citizen Petition from Natural Resources Defense Council
09000064822367c1,Supporting & Related Material,FDA-2016-P-2737-0048,FDA-2016-P-2737,Attachment 45 - Appendix Tabs 99-102 re Citizen Petition from Natural Resources Defense Council
09000064822367c4,Supporting & Related Material,FDA-2016-P-2737-0051,FDA-2016-P-2737,Attachment 48 - Appendix Tab 103-3 re Citizen Petition from Natural Resources Defense Council
09000064822367c5,Supporting & Related Material,FDA-2016-P-2737-0052,FDA-2016-P-2737,Attachment 49 - Appendix Tab 103-4 re Citizen Petition from Natural Resources Defense Council
090000648223679e,Supporting & Related Material,FDA-2016-P-2737-0013,FDA-2016-P-2737,Attachment 10 - Appendix Tabs 76-77 re Citizen Petition from Natural Resources Defense Council
090000648223679f,Supporting & Related Material,FDA-2016-P-2737-0014,FDA-2016-P-2737,Attachment 11 - Appendix Tab 78-1 re Citizen Petition from Natural Resources Defense Council
09000064822367a0,Supporting & Related Material,FDA-2016-P-2737-0015,FDA-2016-P-2737,Attachment 12 - Appendix Tab 78-2-3 re Citizen Petition from Natural Resources Defense Council
09000064822367a3,Supporting & Related Material,FDA-2016-P-2737-0018,FDA-2016-P-2737,Attachment 15 - Appendix Tab 79-2 re Citizen Petition from Natural Resources Defense Council
09000064822367ab,Supporting & Related Material,FDA-2016-P-2737-0026,FDA-2016-P-2737,Attachment 23 - Appendix Tab 79-10-1 re Citizen Petition from Natural Resources Defense Council
09000064822367b0,Supporting & Related Material,FDA-2016-P-2737-0031,FDA-2016-P-2737,Attachment 28 - Appendix Tab 79-15-1 re Citizen Petition from Natural Resources Defense Council
09000064822367bc,Supporting & Related Material,FDA-2016-P-2737-0043,FDA-2016-P-2737,Attachment 40 - Appendix Tab 79-27 re Citizen Petition from Natural Resources Defense Council
09000064822367c0,Supporting & Related Material,FDA-2016-P-2737-0047,FDA-2016-P-2737,Attachment 44 - Appendix Tabs 80-98 re Citizen Petition from Natural Resources Defense Council
090000648223679b,Supporting & Related Material,FDA-2016-P-2737-0010,FDA-2016-P-2737,Attachment 7- Appendix Tabs 39-56 re Citizen Petition from Natural Resources Defense Council
09000064822367a4,Supporting & Related Material,FDA-2016-P-2737-0019,FDA-2016-P-2737,Attachment 16 - Appendix Tab 79-3 re Citizen Petition from Natural Resources Defense Council
09000064822367a6,Supporting & Related Material,FDA-2016-P-2737-0021,FDA-2016-P-2737,Attachment 18 - Appendix Tab 79-5 re Citizen Petition from Natural Resources Defense Council
09000064822367af,Supporting & Related Material,FDA-2016-P-2737-0030,FDA-2016-P-2737,Attachment 27 - Appendix Tab 79-14-1 re Citizen Petition from Natural Resources Defense Council
09000064822367b4,Supporting & Related Material,FDA-2016-P-2737-0035,FDA-2016-P-2737,Attachment 32 - Appendix Tab 79-19 re Citizen Petition from Natural Resources Defense Council
09000064822360ed,Supporting & Related Material,FDA-2016-P-2737-0005,FDA-2016-P-2737,Attachment 2 - Appendix Tabs 1-18 re Citizen Petition from Natural Resources Defense Council
09000064822367c2,Supporting & Related Material,FDA-2016-P-2737-0049,FDA-2016-P-2737,Attachment 46 - Appendix Tab 103-1 re Citizen Petition from Natural Resources Defense Council
09000064822367c8,Supporting & Related Material,FDA-2016-P-2737-0055,FDA-2016-P-2737,Attachment 52 - Appendix Tabs 104-108 re Citizen Petition from Natural Resources Defense Council
09000064846c0f80,Supporting & Related Material,FDA-2016-P-2737-0142,FDA-2016-P-2737,Attachment 7 Supplement Tabs S22-S25 re Supplement to Citizen Petition from Natural Resources Defense Council
0900006482500c0c,Other,FDA-2016-P-2737-0125,FDA-2016-P-2737,Interim Response Letter from CVM to Natural Resources Defense Council
0900006484a57697,Other,FDA-2016-P-2737-0144,FDA-2016-P-2737,Final Response Letter to Natural Resources Defense Council from FDA CVM
09000064822360ef,Supporting & Related Material,FDA-2016-P-2737-0007,FDA-2016-P-2737,Attachment 4- Appendix Tabs 21-25 re Citizen Petition from Natural Resources Defense Council
09000064822367c6,Supporting & Related Material,FDA-2016-P-2737-0053,FDA-2016-P-2737,Attachment 50 - Appendix Tab 103-5 re Citizen Petition from Natural Resources Defense Council
09000064849ec65b,Supporting & Related Material,FDA-2021-P-0037-0005,FDA-2021-P-0037,"Attahcment 3 re Suitability Petition from Hyman, Phelps & McNamara PC"
09000064849ec656,Other,FDA-2021-P-0037-0002,FDA-2021-P-0037,"Acknowledgment Letter from FDA DMS to Hyman, Phelps & McNamara PC"
09000064849ec65a,Supporting & Related Material,FDA-2021-P-0037-0004,FDA-2021-P-0037,"Attahcment 2 re Suitability Petition from Hyman, Phelps & McNamara PC"
09000064849ec655,Other,FDA-2021-P-0037-0001,FDA-2021-P-0037,"Suitability Petition from Hyman, Phelps & McNamara PC"
09000064849ec659,Supporting & Related Material,FDA-2021-P-0037-0003,FDA-2021-P-0037,"Attahcment 1 re Suitability Petition from Hyman, Phelps & McNamara PC"
09000064849ffd52,Other,FDA-2021-P-0037-0006,FDA-2021-P-0037,"Withdrawal from Hyman, Phelps & McNamara PC"
09000064849deda5,Other,FDA-2021-P-0027-0002,FDA-2021-P-0027,Acknowledgment Letter from FDA DMS to Pet Schooled
0900006484bd2355,Other,FDA-2021-P-0027-0007,FDA-2021-P-0027,Response Letter from FDA CVM to Pet Schooled
09000064849deda4,Other,FDA-2021-P-0027-0001,FDA-2021-P-0027,Citizen Petition from Pet Schooled
090000648048f1e0,Supporting & Related Material,FDA-2008-D-0206-0003,FDA-2008-D-0206,"Content and Review of Chemistry, Manufacturing, and Control (CMC) Information for Human Somatic Cell Therapy Investigational New Drug Applications (INDs) - Reference List"
0900006480493652,Other,FDA-2008-D-0206-0002,FDA-2008-D-0206,"Content and Review of Chemistry, Manufacturing, and Control (CMC) Information for Human Somatic Cell Therapy Investigational New Drug Applications (INDs):  Guidance for FDA Reviewers and Sponsors"
09000064804a3276,Notice,FDA-2008-D-0206-0001,FDA-2008-D-0206,"Guidance for Food and Drug Administration Reviewers and Sponsors: Content and Review of Chemistry, Manufacturing, and Control Information for Human Somatic Cell Therapy Investigational New Drug Applications; Availability"
09000064804440b1,Notice,FDA-2005-N-0240-0001,FDA-2005-N-0240,FDA
09000064804440ae,Notice,FDA-2005-N-0240-0002,FDA-2005-N-0240,FDA
090000648045c57a,Notice,FDA-2006-N-0306-0001,FDA-2006-N-0306,FDA
090000648045c593,Notice,FDA-2006-N-0306-0002,FDA-2006-N-0306,FDA
0900006480bd6958,Other,FDA-2010-D-0281-0015,FDA-2010-D-0281,"Guidance for Industry and Food and Drug Administration Staff; “‘Harmful and Potentially Harmful Constituents’ in Tobacco Products as Used in Section 904(e) of the Federal Food, Drug, and Cosmetic Act”"
0900006480c2de49,Notice,FDA-2010-D-0281-0017,FDA-2010-D-0281,Pediatric Advisory Committee; Notice of Meeting
0900006480b4da5e,Other,FDA-2010-D-0281-0013,FDA-2010-D-0281,Altria Client Services - Supplement
0900006480bd6814,Notice,FDA-2010-D-0281-0014,FDA-2010-D-0281,"Guidance for Industry and Food and Drug Administration Staff; Availability: Harmful and Potentially Harmful Constituents in Tobacco Products, etc."
09000064821bd935,Other,FDA-2010-D-0281-0018,FDA-2010-D-0281,"Guidance for Industry for “Harmful and Potentially Harmful Constituents” in Tobacco Products as Used in Section 904(e) of the Federal Food, Drug, and Cosmetic Act (Revised)*"
0900006480aff64a,Other,FDA-2010-D-0281-0002,FDA-2010-D-0281,"Guidance for Industry and FDA Staff: ""Harmful and Potenially Harmful Constituents"" in Tobacco Products as Used in Secion 904(e) of the Federal Food, Drug, and Cosmetic Act"
0900006480aff991,Notice,FDA-2010-D-0281-0001,FDA-2010-D-0281,"Draft Guidance for Industry and Food and Drug Administration Staff: ""Harmful and Potentially Harmful Constituents in Tobacco Products as Used in Section 904(e) of the Federal Food, Drug, and Cosmetic Act"""
0900006483805a0c,Other,FDA-2018-P-3951-0001,FDA-2018-P-3951,Citizen Petition from Chul-Hi Park
0900006483c50bdf,Other,FDA-2018-P-3951-0004,FDA-2018-P-3951,Interim Response Letter from FDA CDRH
0900006483805a0e,Other,FDA-2018-P-3951-0002,FDA-2018-P-3951,Acknowledgment Letter from FDA DDM to Chul-Hi Park
0900006484dc39fc,Other,FDA-2018-P-3951-0005,FDA-2018-P-3951,Petition Response from FDA CDRH to Chul-Hi Park
0900006484bc2b57,Notice,FDA-2021-P-0424-0003,FDA-2021-P-0424,"Medical Devices; Exemption From Premarket Notification: Powered Patient Transport, All Other Powered Patient Transport"
0900006484dcec1d,Other,FDA-2021-P-0424-0006,FDA-2021-P-0424,Petition Response Letter from FDA CDRH to Stryker Medical
0900006484ac839b,Other,FDA-2021-P-0424-0002,FDA-2021-P-0424,Acknowledgment Letter from FDA DMS to Stryker Medical
0900006484c0a28b,Notice,FDA-2021-P-0424-0005,FDA-2021-P-0424,"Medical Devices; Exemption From Premarket Notification: Powered 
Patient Transport, All Other Powered Patient Transport; Extension of 
Comment Period"
0900006484ac8399,Other,FDA-2021-P-0424-0001,FDA-2021-P-0424,Citizen Petition from Stryker Medical
09000064816058f4,Notice,FDA-2014-N-0237-0001,FDA-2014-N-0237,"Report to Congress; Report on the Food and Drug Administration’s Policy
To Be Proposed Regarding Premarket Notification Requirements for
Modifications to Legally Marketed Devices; Notice to Public of Web Site
Location of Report to Congress"
0900006481172df3,Other,FDA-2012-P-0906-0003,FDA-2012-P-0906,"FDA/CDER Response to Lachman Consultant Services, Inc. - Petition Approval"
09000064810e205a,Other,FDA-2012-P-0906-0001,FDA-2012-P-0906,"Lachman Consultant Services, Inc. - Citizen Petition"
09000064810e20f0,Other,FDA-2012-P-0906-0002,FDA-2012-P-0906,"Acknowledgement Letter to Lachman Consultant Sevices, Inc."
0900006481cb1458,Other,FDA-2014-P-2301-0004,FDA-2014-P-2301,Citizen Petition Denial Response from FDA CDER to Probiomed SA de CV
0900006481996c83,Other,FDA-2014-P-2301-0002,FDA-2014-P-2301,"Acknowledgement Letter From FDA DDM to Probiomed S.A. de C.V., Mexico"
0900006481991a9e,Other,FDA-2014-P-2301-0001,FDA-2014-P-2301,Citizen Petition From Probiomed S.A. de C.V. Mexico
0900006481b43220,Other,FDA-2014-P-2301-0003,FDA-2014-P-2301,Interim Response Letter from FDA CDER to Probiomed SA de CV
0900006481911791,Supporting & Related Material,FDA-2014-P-1802-0003,FDA-2014-P-1802,Appendix 1
0900006481911793,Supporting & Related Material,FDA-2014-P-1802-0004,FDA-2014-P-1802,Appendix 2
09000064819c7fb9,Other,FDA-2014-P-1802-0005,FDA-2014-P-1802,Suitability Petition Approval Response Letter from FDA CVM to e5 Pharma LLC
0900006481911711,Other,FDA-2014-P-1802-0002,FDA-2014-P-1802,Acknowledgement Letter from FDA DDM to e5 Pharma LLC
090000648191174c,Other,FDA-2014-P-1802-0001,FDA-2014-P-1802,"Citizen Petition from e5 Pharma, LLC"
090000648190d3f9,Other,FDA-2014-P-1773-0001,FDA-2014-P-1773,"Citizen Petition From Pharmacists Planning Service, Inc."
0900006482d5085d,Other,FDA-2014-P-1773-0005,FDA-2014-P-1773,"Citizen Petition Denial Response Letter from FDA CDER to Pharmacists Planning Service, Inc."
0900006481cb8490,Other,FDA-2014-P-1773-0004,FDA-2014-P-1773,"Citizen Petition Partial Denial Response Letter from FDA CFSAN to Pharmacists Planning Service, Inc."
0900006481a30b65,Other,FDA-2014-P-1773-0003,FDA-2014-P-1773,Interim Response from CDER to PPSI
090000648190d3fb,Other,FDA-2014-P-1773-0002,FDA-2014-P-1773,Acknowledgement Letter From FDA DDM to Pharmacits Planning Sercive Inc. (PPSI)
0900006481866f2c,Other,FDA-2014-P-1343-0002,FDA-2014-P-1343,"Acknowledgement Letter from DDM to American Society of Interventional Pain Physicians (ASIPP) (Pain Management Center of Paducah Clinical Professor, Anesthesiology and Perioperative Medicine University of Louisville, Kentucky and Millennium Pain Center)"
090000648185f014,Other,FDA-2014-P-1343-0001,FDA-2014-P-1343,"Citizen Petition from American Society of Interventional Pain Physicians (ASIPP) (Pain Management Center of Paducah Clinical Professor, Anesthesiology and Perioperative Medicine University of Louisville, Kentucky and Millennium Pain Center)"
0900006481a2b41f,Other,FDA-2014-P-1343-0003,FDA-2014-P-1343,Interim Response to Petition
0900006481cb1533,Other,FDA-2014-P-1343-0005,FDA-2014-P-1343,Citizen Petition Partial Approval and Denial Response from FDA CDER to American Society of Interventional Pain Physicians
0900006481edc448,Other,FDA-2015-P-2807-0005,FDA-2015-P-2807,"Citizen Petition Approval Response from FDA CDER to Lachman Consultant Services, Inc."
0900006481bb6c82,Other,FDA-2015-P-2807-0002,FDA-2015-P-2807,Acknowledgment Letter from FDA DDM to  Lachman Consulting Services Inc.
0900006481bb629a,Supporting & Related Material,FDA-2015-P-2807-0003,FDA-2015-P-2807,Attachment 1 Orange Book Listing re: Citizen Petition from Lachman Consultant Services Inc.
0900006481bb9d44,Other,FDA-2015-P-2807-0001,FDA-2015-P-2807,Citizen Petition from Lachman Consultant Services Inc
0900006481e3752b,Other,FDA-2015-P-2807-0004,FDA-2015-P-2807,"Interim Response Letter from FDA CDER to Lachman Consultant Services, Inc."
0900006481a02a92,Supporting & Related Material,FDA-2015-P-0464-0007,FDA-2015-P-0464,Attach 2
0900006481a02a96,Supporting & Related Material,FDA-2015-P-0464-0011,FDA-2015-P-0464,Attach 6
0900006481a01fee,Supporting & Related Material,FDA-2015-P-0464-0003,FDA-2015-P-0464,Attach 1A - 1G
0900006481a01ff0,Supporting & Related Material,FDA-2015-P-0464-0005,FDA-2015-P-0464,Attach 1N
0900006481a02a93,Supporting & Related Material,FDA-2015-P-0464-0008,FDA-2015-P-0464,Attach 3
0900006481a02e9e,Supporting & Related Material,FDA-2015-P-0464-0019,FDA-2015-P-0464,Attach 14
0900006481a02a9a,Supporting & Related Material,FDA-2015-P-0464-0015,FDA-2015-P-0464,Attach 10
0900006481a02e9b,Supporting & Related Material,FDA-2015-P-0464-0016,FDA-2015-P-0464,Attach 11
0900006481a02e9f,Supporting & Related Material,FDA-2015-P-0464-0020,FDA-2015-P-0464,Attach 15
0900006481e4c741,Other,FDA-2015-P-0464-0022,FDA-2015-P-0464,Interim Response Letter from FDA CDER to Colgate-Palmolive Company
0900006481a01fef,Supporting & Related Material,FDA-2015-P-0464-0004,FDA-2015-P-0464,Attach 1H - 1M
0900006481a02a91,Supporting & Related Material,FDA-2015-P-0464-0006,FDA-2015-P-0464,Attach 1O - 1U
0900006481a02a98,Supporting & Related Material,FDA-2015-P-0464-0013,FDA-2015-P-0464,Attach 8
0900006481a02a99,Supporting & Related Material,FDA-2015-P-0464-0014,FDA-2015-P-0464,Attach 9 pdf
0900006481a02e9d,Supporting & Related Material,FDA-2015-P-0464-0018,FDA-2015-P-0464,Attach 13
0900006481a02a94,Supporting & Related Material,FDA-2015-P-0464-0009,FDA-2015-P-0464,Attach 4
0900006481a02a95,Supporting & Related Material,FDA-2015-P-0464-0010,FDA-2015-P-0464,Attach 5
0900006481a02a97,Supporting & Related Material,FDA-2015-P-0464-0012,FDA-2015-P-0464,Attach 7
0900006481a02e9c,Supporting & Related Material,FDA-2015-P-0464-0017,FDA-2015-P-0464,Attach 12 pdf
0900006481a01fec,Other,FDA-2015-P-0464-0002,FDA-2015-P-0464,Acknowledgement Letter from FDA DDM to Colgate Palmolive Company
0900006481a01fea,Other,FDA-2015-P-0464-0001,FDA-2015-P-0464,Citizen Petition from Colgate Palmolive Company
0900006482d92336,Other,FDA-2018-P-0034-0002,FDA-2018-P-0034,"Acknowledgment Letter from FDA DDM to Hyman, Phelps & McNamara"
0900006482d92334,Other,FDA-2018-P-0034-0001,FDA-2018-P-0034,"Citizen Petition from Hyman, Phelps & McNamara"
090000648367eeb3,Other,FDA-2018-P-0034-0005,FDA-2018-P-0034,Agency Response Letter from FDA CDER to Strides Pharma Inc.
090000648346d33a,Other,FDA-2018-P-0034-0004,FDA-2018-P-0034,"Interim Response Letter from FDA CDER to Hyman, Phelps & McNamara"
090000648390d53a,Other,FDA-2017-P-6245-0009,FDA-2017-P-6245,Interim response letter from FDA CFSAN to ViGuard Health Inc.
0900006482bfdf10,Other,FDA-2017-P-6245-0002,FDA-2017-P-6245,Acknowledgement Letter from FDA DDM to ViGuard Health Inc.
0900006482bfdaa4,Other,FDA-2017-P-6245-0001,FDA-2017-P-6245,Citizen Petition from ViGuard Health Inc.
0900006483aebade,Other,FDA-2017-P-6245-0010,FDA-2017-P-6245,Withdrawal from ViGuard Health Inc.
0900006482616f51,Other,FDA-2017-P-3329-0001,FDA-2017-P-3329,"Citizen Petition from Hyman, Phelps, & McNamara, P.C."
0900006482c93384,Other,FDA-2017-P-3329-0003,FDA-2017-P-3329,"Interim Response from FDA to Hyman, Phelps & McNamara, P.C."
0900006482619ed2,Other,FDA-2017-P-3329-0002,FDA-2017-P-3329,"Acknowledgement Letter from FDA DDM to Hyman, Phelps & McNamara, P.C."
0900006483ae9eca,Other,FDA-2017-P-3329-0004,FDA-2017-P-3329,"Response from FDA CDER to Hyman, Phelps & McNamara, P.C."
0900006483ec1c13,Other,FDA-2018-N-4002-0005,FDA-2018-N-4002,"International Council for Harmonization (ICH) E2B (R3) Standards - Transcript Wednesday, July 17, 2019"
09000064838df0b4,Notice,FDA-2018-N-4002-0001,FDA-2018-N-4002,"Electronic Submission of Adverse Event Reports to the Food and Drug
Administration Adverse Event Reporting System Using International
Council for Harmonisation E2B(R3) Standards; Public Meetings; Request
for Comments"
0900006483c4e958,Other,FDA-2018-N-4002-0003,FDA-2018-N-4002,Meeting Transcript - Electronic Submission of Adverse Event Reports to FDA Adverse Event Reporting System (FAERS) using International Council for Harmonisation (ICH) E2B (R3) Standards
0900006483ade980,Notice,FDA-2018-N-4002-0002,FDA-2018-N-4002,"Electronic Submission of Adverse Event Reports to the Food and Drug
Administration Adverse Event Reporting System Using International
Council for Harmonisation E2B(R3) Standards; Public Meetings; Request
for Comments"
09000064847c5ca0,Other,FDA-2018-N-4002-0006,FDA-2018-N-4002,International Council for Harmonization (ICH) E2B(R3) Standards - Transcript 02/19/2020
0900006482b81bc8,Other,FDA-2017-P-5946-0001,FDA-2017-P-5946,Citizen Petition from Goodwin Procter LLP
0900006482fd697a,Other,FDA-2017-P-5946-0004,FDA-2017-P-5946,Response Letter from FDA to Goodwin Procter LLP
0900006482b81bca,Other,FDA-2017-P-5946-0002,FDA-2017-P-5946,Acknowledgement Letter from FDA DDM to Goodwin Procter LLP
0900006482fcf267,Notice,FDA-2017-P-5946-0003,FDA-2017-P-5946,"Determination That DORYX MPC (Doxycycline Hyclate), Delayed-Release Tablets, 60 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
09000064846bb3db,Supporting & Related Material,FDA-2020-P-1443-0005,FDA-2020-P-1443,Tab 2 Re: Citizen Petition from Elanco Animal Health
09000064846bb418,Supporting & Related Material,FDA-2020-P-1443-0022,FDA-2020-P-1443,Tab 13 Re: Citizen Petition from Elanco Animal Health
09000064846bb41a,Supporting & Related Material,FDA-2020-P-1443-0020,FDA-2020-P-1443,Tab 15 Re: Citizen Petition from Elanco Animal Health
09000064846bba14,Supporting & Related Material,FDA-2020-P-1443-0018,FDA-2020-P-1443,Tab 17 Re: Citizen Petition from Elanco Animal Health
09000064846bba1e,Supporting & Related Material,FDA-2020-P-1443-0008,FDA-2020-P-1443,Tab 27 Re: Citizen Petition from Elanco Animal Health
09000064846bba16,Supporting & Related Material,FDA-2020-P-1443-0016,FDA-2020-P-1443,Tab 19 Re: Citizen Petition from Elanco Animal Health
09000064846bba1a,Supporting & Related Material,FDA-2020-P-1443-0012,FDA-2020-P-1443,Tab 23 Re: Citizen Petition from Elanco Animal Health
09000064846bb3e0,Supporting & Related Material,FDA-2020-P-1443-0028,FDA-2020-P-1443,Tab 7 Re: Citizen Petition from Elanco Animal Health
09000064846bba19,Supporting & Related Material,FDA-2020-P-1443-0013,FDA-2020-P-1443,Tab 22 Re: Citizen Petition from Elanco Animal Health
09000064846bb3da,Supporting & Related Material,FDA-2020-P-1443-0004,FDA-2020-P-1443,Tab 1 Re: Citizen Petition from Elanco Animal Health
09000064846bb3de,Supporting & Related Material,FDA-2020-P-1443-0030,FDA-2020-P-1443,Tab 5 Re: Citizen Petition from Elanco Animal Health
09000064846bb412,Supporting & Related Material,FDA-2020-P-1443-0027,FDA-2020-P-1443,Tab 8 Re: Citizen Petition from Elanco Animal Health
09000064846bba1b,Supporting & Related Material,FDA-2020-P-1443-0011,FDA-2020-P-1443,Tab 24 Re: Citizen Petition from Elanco Animal Health
09000064846bb3d9,Supporting & Related Material,FDA-2020-P-1443-0003,FDA-2020-P-1443,Appendix 1 Re: Citizen Petition from Elanco Animal Health
09000064846bb3dd,Supporting & Related Material,FDA-2020-P-1443-0007,FDA-2020-P-1443,Tab 4 Re: Citizen Petition from Elanco Animal Health
09000064846bb413,Supporting & Related Material,FDA-2020-P-1443-0026,FDA-2020-P-1443,Tab 9 Re: Citizen Petition from Elanco Animal Health
09000064846bba1c,Supporting & Related Material,FDA-2020-P-1443-0010,FDA-2020-P-1443,Tab 25 Re: Citizen Petition from Elanco Animal Health
09000064846bb41b,Supporting & Related Material,FDA-2020-P-1443-0019,FDA-2020-P-1443,Tab 16 Re: Citizen Petition from Elanco Animal Health
09000064846bb419,Supporting & Related Material,FDA-2020-P-1443-0021,FDA-2020-P-1443,Tab 14 Re: Citizen Petition from Elanco Animal Health
09000064846bb3dc,Supporting & Related Material,FDA-2020-P-1443-0006,FDA-2020-P-1443,Tab 3 Re: Citizen Petition from Elanco Animal Health
09000064846bb414,Supporting & Related Material,FDA-2020-P-1443-0025,FDA-2020-P-1443,Tab 10 Re: Citizen Petition from Elanco Animal Health
09000064846bb417,Supporting & Related Material,FDA-2020-P-1443-0023,FDA-2020-P-1443,Tab 12 Re: Citizen Petition from Elanco Animal Health
09000064846bba15,Supporting & Related Material,FDA-2020-P-1443-0017,FDA-2020-P-1443,Tab 18 Re: Citizen Petition from Elanco Animal Health
09000064846bba18,Supporting & Related Material,FDA-2020-P-1443-0014,FDA-2020-P-1443,Tab 21 Re: Citizen Petition from Elanco Animal Health
09000064846bba1d,Supporting & Related Material,FDA-2020-P-1443-0009,FDA-2020-P-1443,Tab 26 Re: Citizen Petition from Elanco Animal Health
0900006481495921,Notice,FDA-2011-D-0305-0058,FDA-2011-D-0305,Distribution of In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only: Guidance for Industry and Food and Drug Administration Staff; Availability
0900006480fb95ae,Other,FDA-2011-D-0305-0057,FDA-2011-D-0305,"Hyman, Phelps & McNamara, P.C. - Supplement Comment re FDA-2011-D-0305-0050"
0900006480e38c85,Notice,FDA-2011-D-0305-0001,FDA-2011-D-0305,Draft Guidance for Industry and FDA Staff: Commercially Distributed In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only: Frequently Asked Questions; Availability
0900006480e3906e,Other,FDA-2011-D-0305-0002,FDA-2011-D-0305,Commercially Distributed In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only: Frequently Asked Questions - Draft Guidance
09000064821487f4,Other,FDA-2016-P-2344-0001,FDA-2016-P-2344,Citizen Petition from ANDA Consultants
09000064821487f7,Other,FDA-2016-P-2344-0002,FDA-2016-P-2344,Acknowledgement Letter from FDA DDM to ANDA Consultants
0900006480457401,Notice,FDA-2006-N-0249-0002,FDA-2006-N-0249,FDA
090000648045741e,Notice,FDA-2006-N-0249-0001,FDA-2006-N-0249,FDA
0900006480441ad1,Other,FDA-2006-P-0021-0002,FDA-2006-P-0021,See FDA-2006-P-0021-0001
0900006480441a75,Other,FDA-2006-P-0021-0001,FDA-2006-P-0021,Acknowledgement Letter to Kerr Corporation
0900006480441a87,Other,FDA-2006-P-0021-0004,FDA-2006-P-0021,Kerr Corporation - Citizen Petition
0900006480441ad2,Other,FDA-2006-P-0021-0003,FDA-2006-P-0021,FDA/CDRH to Kerr Corporation - Letter
0900006480b15f5a,Notice,FDA-2010-N-0101-0002,FDA-2010-N-0101,"Agency Information Collection Activities; Proposals, Submissions, and Approvals: Human Cells, Tissues, and Cellular and Tissue-Based Products"
0900006480abaf76,Notice,FDA-2010-N-0101-0001,FDA-2010-N-0101,"Agency Information Collection Activities; Proposals, Submissions, and Approvals: Human Cells, Tissues, and Cellular and Tissue-BasedProducts, etc."
0900006480abe656,Other,FDA-2010-P-0150-0003,FDA-2010-P-0150,Acknowledgement Letter to the United States Pharmacopeial Convention (USP)
0900006480abe658,Supporting & Related Material,FDA-2010-P-0150-0002,FDA-2010-P-0150,"Appendix A - ""Food Chemicals Codex Standards Incorported by Reference in FDA GRAS Regulations"" - [United States Pharmacopeial Convention (USP) - Citizen Petition]"
0900006484721cc0,Other,FDA-2010-P-0150-0005,FDA-2010-P-0150,CP Withdrawal letter from United States Pharmacopeial  (USP)
0900006480b5c4cd,Other,FDA-2010-P-0150-0004,FDA-2010-P-0150,Interim Response  to United States Pharmacopeial Convention
0900006480abe653,Other,FDA-2010-P-0150-0001,FDA-2010-P-0150,United States Pharmacopeial Convention (USP) - Citizen Petition
09000064849d0890,Other,FDA-2020-P-2360-0001,FDA-2020-P-2360,Citizen Petition from Pet Schooled The Educated Community
09000064849d20b5,Other,FDA-2020-P-2360-0002,FDA-2020-P-2360,Acknowledgment Letter from FDA DMS to Pet Schooled
0900006484bcd0fc,Other,FDA-2020-P-2360-0068,FDA-2020-P-2360,Response Letter from FDA CVM to Pet Schooled
0900006484776f50,Supporting & Related Material,FDA-2020-P-1674-0003,FDA-2020-P-1674,ATTACHMENT- Detailed Position Paper to Support the Addition of Sickle Cell Disease to the Current List of Neglected Tropical Diseases on the Priority Review Voucher List Section 524 of the Food Drug and Cosmetic Act re: Citizen Petition from Putting Rare Diseases Patients First!
09000064849ed8a4,Other,FDA-2020-P-1674-0017,FDA-2020-P-1674,Interim Response Letter from FDA CDER to Putting Rare Diseases Patients First!
0900006484d8e855,Other,FDA-2020-P-1674-0022,FDA-2020-P-1674,Response Letter from FDA CDER to Putting Rare Diseases Patients First!®
0900006484776f4d,Other,FDA-2020-P-1674-0002,FDA-2020-P-1674,Acknowledgment Letter from FDA DMS to Putting Rare Diseases Patients First!
090000648476e4bf,Other,FDA-2020-P-1674-0001,FDA-2020-P-1674,Citizen Petition from Putting Rare Diseases Patients First!
09000064844ad265,Other,FDA-2020-P-1297-0002,FDA-2020-P-1297,Acknowledgment Letter from FDA DMS to Joe DiNardo
09000064844ad264,Other,FDA-2020-P-1297-0001,FDA-2020-P-1297,Citizen Petition from Joe DiNardo
09000064848fd5cf,Other,FDA-2020-P-1297-0003,FDA-2020-P-1297,Letter from FDA CDER to Joe DiNardo
0900006484da7aa1,Other,FDA-2020-P-1297-0004,FDA-2020-P-1297,Response Letter from FDA CDER to Joe DiNardo
0900006484de4fc1,Other,FDA-2021-P-1147-0001,FDA-2021-P-1147,Citizen Petition from Andrej Tokmakov
0900006484e66663,Other,FDA-2021-P-1147-0020,FDA-2021-P-1147,Supplement  Information for Citizen Petition from Andrej Tokmakov page 2
0900006484de4b9e,Other,FDA-2021-P-1147-0002,FDA-2021-P-1147,Acknowledgment Letter from FDA DMS to Andrej Tokmakov
0900006484e66665,Other,FDA-2021-P-1147-0019,FDA-2021-P-1147,Supplement  Information for Citizen Petition from Andrej Tokmakov page 1
0900006484de5165,Supporting & Related Material,FDA-2021-P-1147-0003,FDA-2021-P-1147,Attachment 1 re: Citizen Petition from Andrej Tokmakov
0900006484229cdd,Other,FDA-2019-P-5970-0001,FDA-2019-P-5970,Citizen Petition from IQVIA RDS Inc
090000648422a0c6,Other,FDA-2019-P-5970-0002,FDA-2019-P-5970,Acknowledgment Letter from FDA DMS to IQVIA RDS Inc
090000648422a0ca,Supporting & Related Material,FDA-2019-P-5970-0004,FDA-2019-P-5970,Attachment 2 Information of Current and Resolved Drug Shortages and Discontinuations Reported to FDA re Citizen Petition from IQVIA RDS Inc
090000648422a0c9,Supporting & Related Material,FDA-2019-P-5970-0003,FDA-2019-P-5970,Attachment 1 Electronic Orange Book search results re Citizen Petition from IQVIA RDS Inc
090000648430d93c,Other,FDA-2019-P-5970-0005,FDA-2019-P-5970,Response Letter from FDA CDER to IQVIA RDS In
0900006482d84d72,Supporting & Related Material,FDA-2017-P-7034-0003,FDA-2017-P-7034,Exhibit 1 Orange Book Listing re Citizen Petition from Jubilant Generics Limited
0900006482d84d74,Supporting & Related Material,FDA-2017-P-7034-0005,FDA-2017-P-7034,Exhibit 3 Proposed Product Draft Label re Citizen Petition from Jubilant Generics Limited
0900006482d84d2a,Other,FDA-2017-P-7034-0001,FDA-2017-P-7034,Citizen Petition from Jubilant Generics Limited
0900006482d84d75,Supporting & Related Material,FDA-2017-P-7034-0006,FDA-2017-P-7034,Exhibit 4 Valtrex Tablets 250 mg re Citizen Petition from Jubilant Generics Limited
0900006482d84d73,Supporting & Related Material,FDA-2017-P-7034-0004,FDA-2017-P-7034,Exhibit 2 RLD Label re Citizen Petition from Jubilant Generics Limited
0900006482d84d2c,Other,FDA-2017-P-7034-0002,FDA-2017-P-7034,Acknowledgment Letter from FDA DDM to Jubilant Generics Limited
09000064810e98aa,Other,FDA-2012-D-0585-0002,FDA-2012-D-0585,Draft Guidances for Industry: Necessity of Use of Food Categories in Food Facility Registrations and Updates to Food Categories
090000648114e449,Notice,FDA-2012-D-0585-0016,FDA-2012-D-0585,Guidance for Industry: Necessity of Use of Food Product Categories in Food Facility Registrations and Updates to Food Product Categories; Availability
09000064810dabde,Notice,FDA-2012-D-0585-0001,FDA-2012-D-0585,Draft Guidances for Industry: Necessity of Use of Food Categories in Food Facility Registrations and Updates to Food Categories
090000648114df62,Other,FDA-2012-D-0585-0017,FDA-2012-D-0585,Guidance for Industry: Necessity of Use of Food Product Categories in Food Facility Registrations and Updates to Food Product Categories
0900006483d998b9,Supporting & Related Material,FDA-2019-P-3423-0003,FDA-2019-P-3423,Attachment 1 - FDA Electronic Orange Book printout for Baclofen products Labeling for Ivax/Teva Baclofen Tablets re Suitability Petition from Oxford Pharmaceuticals LLC
0900006483d99458,Other,FDA-2019-P-3423-0002,FDA-2019-P-3423,Acknowledgment Letter from FDA DDM to Oxford Pharmaceuticals LLC
0900006483d9927a,Other,FDA-2019-P-3423-0001,FDA-2019-P-3423,"Suitability Petition from Oxford Pharmaceuticals, LLC"
09000064816e13dc,Other,FDA-2014-P-0585-0001,FDA-2014-P-0585,Citizen Petition from A. Haggag (Capstone Law)
09000064819e06e6,Other,FDA-2014-P-0585-0003,FDA-2014-P-0585,Interim Response Letter from FDA CFSAN to Capstone Law APC
09000064816e140d,Other,FDA-2014-P-0585-0002,FDA-2014-P-0585,Acknowledgement letter from FDA DDM to Capstone Law APC
0900006481cafbcb,Other,FDA-2014-P-0585-0004,FDA-2014-P-0585,Citizen Petition Denial Response from FDA CFSAN to Captsone Law APC
0900006480f414a1,Other,FDA-2011-P-0709-0001,FDA-2011-P-0709,Jennifer Kuzdzal - Citizen Petition
0900006480f414a5,Other,FDA-2011-P-0709-0002,FDA-2011-P-0709,Acknowledgement Letter to Jennifer Kuzdzal
0900006481e12d7d,Other,FDA-2015-P-1752-0006,FDA-2015-P-1752,Withdrawal Letter from Actavis Elizabeth LLC
0900006481db7dc3,Other,FDA-2015-P-1752-0005,FDA-2015-P-1752,Withdrawal from Wiley Rein LLP
0900006481ae5958,Other,FDA-2015-P-1752-0001,FDA-2015-P-1752,Citizen Petition from Wiley Rein LLP
0900006481ae595f,Other,FDA-2015-P-1752-0002,FDA-2015-P-1752,Acknowledgement Letter from FDA DDM to Wiley Rein LLP
0900006481d2aa32,Other,FDA-2015-P-1752-0003,FDA-2015-P-1752,Interim Response Letter from FDA CDER to Wiley Rein LLP
0900006483a3a530,Other,FDA-2019-P-0537-0001,FDA-2019-P-0537,Citizen Petition from Kulkarni Law Firm
0900006483a3a9f6,Other,FDA-2019-P-0537-0002,FDA-2019-P-0537,Acknowledgment Letter from FDA DDM to Kulkarni Law Firm
0900006483dd93de,Other,FDA-2019-P-0537-0003,FDA-2019-P-0537,Letter from FDA CDER to The Kulkarni Law Firm
0900006484387cb5,Other,FDA-2019-P-0537-0004,FDA-2019-P-0537,Response Letter from FDA CDER to Kulkarni Law Firm
0900006482f1de55,Other,FDA-2018-P-0674-0002,FDA-2018-P-0674,Acknowledgment Letter from FDA DDM to Medtech Products Inc
0900006482f1de57,Supporting & Related Material,FDA-2018-P-0674-0003,FDA-2018-P-0674,"Attachment 1 Approved labeling for the RLD, Excedrin® (Migraine) re Citizen Petition from Medtech Products Inc"
0900006482f1bab2,Other,FDA-2018-P-0674-0001,FDA-2018-P-0674,Citizen Petition from Medtech Products Inc
0900006482f1de59,Supporting & Related Material,FDA-2018-P-0674-0005,FDA-2018-P-0674,Attachment 3 Request for Waiver from requirement to submit a pediatric assessment re Citizen Petition from Medtech Products Inc
0900006482f1de58,Supporting & Related Material,FDA-2018-P-0674-0004,FDA-2018-P-0674,"Attachment 2 Draft labeling for the proposed product, Goody's® Migraine re Citizen Petition from Medtech Products Inc"
0900006484731920,Supporting & Related Material,FDA-2020-P-1641-0003,FDA-2020-P-1641,Exhibit 1 Copy of Current FDA-approved label for Epidiolex re Citizen Petition from John J Coleman
0900006484731921,Supporting & Related Material,FDA-2020-P-1641-0004,FDA-2020-P-1641,Exhibit 2 Copy of June 25 2018 press release by FDA announcing approval of Epidiolex re Citizen Petition from John J Coleman
09000064847cede0,Other,FDA-2020-P-1641-0006,FDA-2020-P-1641,Response letter from FDA CDER to John J. Coleman
0900006484731922,Supporting & Related Material,FDA-2020-P-1641-0005,FDA-2020-P-1641,Exhibit 3 DEA Final Order placing all FDA-approved CBD drugs in Schedule V re Citizen Petition from John J Coleman
090000648473191d,Other,FDA-2020-P-1641-0002,FDA-2020-P-1641,Acknowledgment Letter from FDA DMS to John J Coleman
090000648473191c,Other,FDA-2020-P-1641-0001,FDA-2020-P-1641,Citizen Petition from John J Coleman
0900006481856fce,Supporting & Related Material,FDA-2014-P-1293-0004,FDA-2014-P-1293,"Attachment B Primakoff, et al., Fully Effective Contraception in Male and Female Guinea Pigs Immunized With the Sperm Protein PH-20 re Citizen Petition from Hyman Phelps & McNamara PC FDA-2014-P-1293-0001"
0900006481856d9b,Other,FDA-2014-P-1293-0001,FDA-2014-P-1293,Citizen Petition From Hyman Phelps & McNamara PC
0900006481967f47,Other,FDA-2014-P-1293-0009,FDA-2014-P-1293,Withdrawal of Citizen Petition
0900006481856d9f,Supporting & Related Material,FDA-2014-P-1293-0003,FDA-2014-P-1293,"Attachment A Wassermann, et al., Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulins for Primary Immunodeficiency re Citizen Petition from Hyman Phelps & McNamara PC FDA-2014-P-1293-0001"
0900006481856fd0,Supporting & Related Material,FDA-2014-P-1293-0006,FDA-2014-P-1293,"Attachment D Hunnicutt, et al., Sperm Surface Protein PH-20 Is Bifunctional: One Activity Is a Hyaluronidase and a Second, Distinct Activity Is Required in Secondary Sperm-Zona Binding re Citizen Petition from Hyman Phelps & McNamara PC FDA-2014-P-1293-0001"
0900006481856fd1,Supporting & Related Material,FDA-2014-P-1293-0007,FDA-2014-P-1293,"Attachment E Cherr, et. al., The dual Functions of GPI-Anchored PH-20: Hyaluronidase and Intracellular Signalingre Citizen Petition from Hyman Phelps & McNamara PC FDA-2014-P-1293-0001"
0900006481856fcf,Supporting & Related Material,FDA-2014-P-1293-0005,FDA-2014-P-1293,"Attachment C Coska, et al., Purification and Microsequencing of Hyaluronidase Isozymes From Human Urine re Citizen Petition from Hyman Phelps & McNamara PC FDA-2014-P-1293-0001"
0900006481856fd2,Supporting & Related Material,FDA-2014-P-1293-0008,FDA-2014-P-1293,"Attachment F Hegg, et al., Immunogenicity of Trastuzumab Intravenous and Subcutaneous Formulations in the Phase III HannaH Study re Citizen Petition from Hyman Phelps & McNamara PC FDA-2014-P-1293-0001"
0900006481856d9d,Other,FDA-2014-P-1293-0002,FDA-2014-P-1293,Acknowledgement Letter From FDA DDM to Hyman Phelps & McNamara PC
09000064816b5dd5,Notice,FDA-2014-N-0386-0001,FDA-2014-N-0386,"Agency Information Collection Activities; Proposed Collection;
Comment Request; Orphan Drugs Products: Common European
Medicines Agency/Food and Drug Administration Application Form for
Orphan Medicinal Product Designation"
09000064848b4f92,Notice,FDA-2014-N-0386-0003,FDA-2014-N-0386,"Agency Information Collection Activities; Proposed Collection;
Comment Request; Orphan Drugs"
0900006484a7eb64,Notice,FDA-2014-N-0386-0007,FDA-2014-N-0386,Agency Information Collection Activities; Announcement of Office of Management and Budget Approvals
09000064818af03d,Notice,FDA-2014-N-0386-0002,FDA-2014-N-0386,"Agency Information Collection Activities; Submission for Office of
Management and Budget Review; Comment Request; Orphan Drugs;
Common European Medicines Agency/ Food and Drug Administration
Application Form for Orphan Medicinal Product Designation"
09000064849c0f39,Notice,FDA-2014-N-0386-0005,FDA-2014-N-0386,Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Orphan Drugs
09000064805336f0,Other,FDA-2007-P-0345-0004,FDA-2007-P-0345,FDA/CDER Interim Response to HellerEhrman LLP - Letter
090000648042b940,Other,FDA-2007-P-0345-0001,FDA-2007-P-0345,Acknowledgement Letter to HellerEhrman LLP
09000064807d7e26,Other,FDA-2007-P-0345-0005,FDA-2007-P-0345,FDA/CDER to Cooley Godward Kronish LLP - Responce to Ctitizen Petition
090000648042b941,Supporting & Related Material,FDA-2007-P-0345-0002,FDA-2007-P-0345,See: FDA-2007-P-0345-0001
090000648042b942,Other,FDA-2007-P-0345-0003,FDA-2007-P-0345,HellerEhrman LLP - Citizen Petition
090000648044027e,Supporting & Related Material,FDA-2005-D-0156-0002,FDA-2005-D-0156,Guidance
0900006480440287,Supporting & Related Material,FDA-2005-D-0156-0004,FDA-2005-D-0156,Guidance
0900006480440268,Notice,FDA-2005-D-0156-0001,FDA-2005-D-0156,FDA
0900006480440288,Notice,FDA-2005-D-0156-0005,FDA-2005-D-0156,FDA
0900006484b612e1,Supporting & Related Material,FDA-2021-P-0545-0003,FDA-2021-P-0545,Children Health Defense Brief re Citizen Petition from Theo Allen
0900006484d697b9,Other,FDA-2021-P-0545-0004,FDA-2021-P-0545,Withdrawal of Citizen Petition from Theo Allen
0900006484b611b9,Other,FDA-2021-P-0545-0001,FDA-2021-P-0545,Citizen Petition from Theo Allen
0900006484b612de,Other,FDA-2021-P-0545-0002,FDA-2021-P-0545,Acknowledgment Letter from FDA DMS to Theo Allen
09000064841e21d0,Other,FDA-2019-P-5691-0002,FDA-2019-P-5691,Acknowledgment Letter from FDA DMS to FOLEY & Lardner LLP
09000064841e015f,Other,FDA-2019-P-5691-0001,FDA-2019-P-5691,"Suitability Petition from Foley & Lardner, LLP"
09000064841e0162,Supporting & Related Material,FDA-2019-P-5691-0004,FDA-2019-P-5691,"Attachment 2 - label re: Suitability Petition from Foley & Lardner, LLP"
0900006484e389b0,Other,FDA-2019-P-5691-0006,FDA-2019-P-5691,"Amendment from Foley & Lardner, LLP"
09000064841e0161,Supporting & Related Material,FDA-2019-P-5691-0003,FDA-2019-P-5691,"Attachment 1 - Orange Book_ Approved Drug Products with Therapeutic Equivalenc re: Suitability Petition from Foley & Lardner, LLP"
09000064841e0163,Supporting & Related Material,FDA-2019-P-5691-0005,FDA-2019-P-5691,"Attachment 3 - Microsoft Word - Proposed labeling.doc re: Suitability Petition from Foley & Lardner, LLP"
090000648480d9e0,Other,FDA-2020-P-1771-0002,FDA-2020-P-1771,"Acknowledgment Letter from FDA DMS to Windels Marx Lane & Mittendorf, LLP"
090000648480d038,Other,FDA-2020-P-1771-0001,FDA-2020-P-1771,"Citizen Petition from Windels Marx Lane & Mittendorf, LLP"
09000064849662ee,Other,FDA-2020-P-1771-0003,FDA-2020-P-1771,Withdrawal from Windels Marx Lane Mittendorf LLP
090000648423a331,Other,FDA-2019-P-5997-0001,FDA-2019-P-5997,"Citizen Petition for Center for Biological Diversity, Center for Environmental Health, Farmworkers Association of Florida, Johns Hopkins Center for a Livable Future, Migrant Clinicians Network, and U.S. Public Interest Research Group"
090000648423c51f,Other,FDA-2019-P-5997-0002,FDA-2019-P-5997,"Acknowledgment Letter from FDA DMS to Center for Biological Diversity, Center for Environmental Health, Farmworkers Association of Florida, Johns Hopkins Center for a Livable Future, Migrant Clinicians Network, and U.S. Public Interest Research Group"
0900006482dcf653,Supporting & Related Material,FDA-2018-P-0131-0003,FDA-2018-P-0131,"Attachment 1 Relevant copy of the page from the current edition of the electronic Approved Drug Products with Therapeutic Equi valence Evaluations, accessed January 8, 20 18 re Citizen Petition from Lachman Consultant Services, Inc."
0900006482dcf651,Other,FDA-2018-P-0131-0001,FDA-2018-P-0131,"Citizen Petition from Lachman Consultant Services, Inc."
0900006482dcf655,Supporting & Related Material,FDA-2018-P-0131-0005,FDA-2018-P-0131,"Attachment 3 Labeling for Zonegran® Capsules re Citizen Petition from Lachman Consultant Services, Inc."
0900006482dcf654,Supporting & Related Material,FDA-2018-P-0131-0004,FDA-2018-P-0131,"Attachment 2 Draft [nsert Labeling Proposed for Zonisamide Orally Disintegrating Tablets re Citizen Petition from Lachman Consultant Services, Inc."
0900006482dcf656,Other,FDA-2018-P-0131-0002,FDA-2018-P-0131,"Acknowledgment Letter from FDA DDM  to Lachman Consultant Services, Inc."
090000648184cac3,Other,FDA-2014-P-1269-0002,FDA-2014-P-1269,Acknowledgement Letter From FDA DDM to Pfizer Inc
0900006481c7999c,Other,FDA-2014-P-1269-0003,FDA-2014-P-1269,Citizen Petition Partial Approval and Denial Response Letter from FDA CDER to Pfizer Inc.
090000648182bd41,Other,FDA-2014-P-1269-0001,FDA-2014-P-1269,"Citizen Petition from Pfizer, Inc."
0900006482ac8344,Other,FDA-2017-P-5205-0001,FDA-2017-P-5205,"Citizen Petition from Xiromed, LLC on behalf of LifePharma FZE"
0900006482f39a76,Other,FDA-2017-P-5205-0003,FDA-2017-P-5205,"Interim Response Letter from FDA CDER to Xiromed, LLC"
0900006482ac8346,Other,FDA-2017-P-5205-0002,FDA-2017-P-5205,"Acknowledgement Letter from FDA DDM to Xiromed, LLC on behalf of LifePharma FZE"
090000648383fec7,Other,FDA-2017-P-5205-0004,FDA-2017-P-5205,Letter re Citizen Petition from FDA CDER-ORP to Xiromed LLC
090000648379dc86,Other,FDA-2017-P-6214-0004,FDA-2017-P-6214,Interim Response Letter from FDA CDER to Esophageal Cancer Action Network Inc.
0900006482be548e,Other,FDA-2017-P-6214-0001,FDA-2017-P-6214,Citizen Petition from Yabao Pharmaceutical Co. Ltd BJ
09000064831927dc,Other,FDA-2017-P-6214-0003,FDA-2017-P-6214,Interim Response Letter from FDA CDER to Yabao Pharmaceutical Co. Ltd BJ
0900006482be5a74,Other,FDA-2017-P-6214-0002,FDA-2017-P-6214,Acknowledgment Letter from FDA DDM to Yabao Pharmaceutical Co. Ltd BJ
090000648259471d,Other,FDA-2017-P-2869-0001,FDA-2017-P-2869,"Citizen Petition from Lachman Consultant Services, Inc."
0900006482594723,Supporting & Related Material,FDA-2017-P-2869-0005,FDA-2017-P-2869,Attachment 3 Approved Labeling for RLD Robinul Forte Tablets by Casper re Citizen Petition from Lachman Consultants Services Inc
0900006482594721,Supporting & Related Material,FDA-2017-P-2869-0003,FDA-2017-P-2869,Attachment 1 Approved Drug Products with Therapeutic Equivalence Evaluations re Citizen Petition from Lachman Consultants Services Inc
0900006482594722,Supporting & Related Material,FDA-2017-P-2869-0004,FDA-2017-P-2869,Attachment 2 Draft Insert Labeling for Proposed Product re Citizen Petition from Lachman Consultants Services Inc
090000648259471f,Other,FDA-2017-P-2869-0002,FDA-2017-P-2869,"Acknowledgement Letter from FDA DDM to Lachman Consultant Services, Inc."
09000064836cb8a9,Other,FDA-2018-P-3426-0001,FDA-2018-P-3426,"Citizen Petition from Pharmax Group, Inc"
0900006483ae88ec,Other,FDA-2018-P-3426-0004,FDA-2018-P-3426,"Response Letter from FDA CDER to Pharmax Group, Inc"
09000064836cb8ab,Other,FDA-2018-P-3426-0002,FDA-2018-P-3426,"Acknowledgment Letter from FDA DDM to Pharmax Group, Inc"
09000064836cb8ad,Supporting & Related Material,FDA-2018-P-3426-0003,FDA-2018-P-3426,"Attachment 1 Orange Book Cyproheptadine Approvals Sept 6 2018 re Citizen Petition from Pharmax Group, Inc"
0900006484a91e53,Supporting & Related Material,FDA-2021-P-0342-0004,FDA-2021-P-0342,Attachment 2 - NIOSH List 2016 RE Suitability Petition from Cardinal Health Regulatory Sciences
0900006484a91e54,Supporting & Related Material,FDA-2021-P-0342-0005,FDA-2021-P-0342,Attachment 3 - USP 800 FAQs RE Suitability Petition from Cardinal Health Regulatory Sciences
0900006484a91e4e,Other,FDA-2021-P-0342-0001,FDA-2021-P-0342,Suitability Petition from Cardinal Health Regulatory Sciences
0900006484a91eca,Supporting & Related Material,FDA-2021-P-0342-0009,FDA-2021-P-0342,Attachment 7 - Draft Label for the Proposed Product RE Suitability Petition from Cardinal Health Regulatory Sciences
0900006484a91e52,Supporting & Related Material,FDA-2021-P-0342-0003,FDA-2021-P-0342,Attachment 1 - Orange Book_ Approved Drug Products with Therapeutic Equivalence Evaluations RE Suitability Petition from Cardinal Health Regulatory Sciences
0900006484a91e55,Supporting & Related Material,FDA-2021-P-0342-0006,FDA-2021-P-0342,Attachment 4 - Letter from FDA about Model Labeling for RLD (VFEND) RE Suitability Petition from Cardinal Health Regulatory Sciences
0900006484a91ec8,Supporting & Related Material,FDA-2021-P-0342-0007,FDA-2021-P-0342,Attachment 5 - RLD (VFEND) Model Label Carved Exclusivity Information RE Suitability Petition from Cardinal Health Regulatory Sciences
0900006484a91ec9,Supporting & Related Material,FDA-2021-P-0342-0008,FDA-2021-P-0342,"Attachment 6 - RLD (VFEND) Label from drugs@fda (version January, 2021) RE Suitability Petition from Cardinal Health Regulatory Sciences"
0900006484a91e50,Other,FDA-2021-P-0342-0002,FDA-2021-P-0342,Acknowledgement Letter from FDA DMS to Cardinal Health Regulatory Sciences
09000064848f9147,Other,FDA-2020-P-2066-0001,FDA-2020-P-2066,Citizens Petition from The America's Frontline Doctors
09000064848fa2ec,Other,FDA-2020-P-2066-0002,FDA-2020-P-2066,Acknowledgment Letter from FDA DMS to America’s Frontline Doctors
0900006484aa05e9,Other,FDA-2020-P-2066-0003,FDA-2020-P-2066,Interim Response from FDA CDER to America's Frontline Doctors c/o Free Speech Foundation
0900006480473152,Other,FDA-2004-P-0334-0001,FDA-2004-P-0334,HFA-305 to Environmental Working Group
0900006480473156,Other,FDA-2004-P-0334-0002,FDA-2004-P-0334,FDA/CDER Response to Environmental Working Group - Letter
0900006480473157,Other,FDA-2004-P-0334-0003,FDA-2004-P-0334,FDA/CDER Response to Environmental Working Group - Letter
090000648039ad45,Notice,FDA-2008-N-0027-0001,FDA-2008-N-0027,"Agency Information Collection Activities; Proposed Collection; Comment Request; Medical Device User Fee Amendments of 2007; Foreign Small Business Qualification Certification, FDA Form 3602A"
09000064804a3bbd,Notice,FDA-2008-N-0027-0005,FDA-2008-N-0027,"Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Medical Device User Fee Amendments of 2007; Foreign Small Business Qualification Certification, Form FDA 3602A"
09000064804a3235,Notice,FDA-2008-N-0027-0004,FDA-2008-N-0027,"Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Medical Device User Fee Amendments of 2007; Foreign Small Business Qualification Certification, Form FDA 3602A"
0900006480949ec2,Other,FDA-2008-P-0444-0003,FDA-2008-P-0444,Codonics to FDA - Letter
09000064806b21bc,Other,FDA-2008-P-0444-0002,FDA-2008-P-0444,"Acknowledgement Letter to Codonics, Inc."
09000064806b2183,Other,FDA-2008-P-0444-0001,FDA-2008-P-0444,Codonics Inc. - Citizen Petition
0900006480c3dd31,Other,FDA-2008-P-0444-0005,FDA-2008-P-0444,FDA/CDRH to Codonics Inc. - Petition Denial
09000064809ed100,Other,FDA-2008-P-0444-0004,FDA-2008-P-0444,"FDA/CDRH Interim Response to Codonics, Inc. - Letter"
090000648092e62c,Other,FDA-2008-P-0529-0007,FDA-2008-P-0529,FDA/CDER Response to Teva Pharmaceutical Industries Ltd. - Petition Denial
090000648072c7f6,Other,FDA-2008-P-0529-0001,FDA-2008-P-0529,"Teva Pharmaceutical Industries Ltd., Teva Neuroscience Inc. - Citizen Petition"
090000648072c83c,Other,FDA-2008-P-0529-0002,FDA-2008-P-0529,"Acknowledgement Letter to Teva Pharmaceutical Industries Ltd., Teva Neuroscience Inc. (TEVA)"
09000064808db1c7,Other,FDA-2008-P-0529-0004,FDA-2008-P-0529,Ira S. Krull [re FDA-2008-P-0529-0003.1] - Letter
0900006484d7d3b0,Other,FDA-2021-P-0308-0003,FDA-2021-P-0308,"Interim Response from FDA CDER to Hyman, Phelps& McNamara, P.C."
0900006484a71d08,Other,FDA-2021-P-0308-0002,FDA-2021-P-0308,"Acknowledgment Letter from FDA DMS to Hyman, Phelps and McNamara, P.C. (on behalf of Exela Pharma Sciences, LLC)"
0900006484a71d03,Other,FDA-2021-P-0308-0001,FDA-2021-P-0308,"Citizen Petition from Hyman, Phelps and McNamara, P.C. (on behalf of Exela Pharma Sciences, LLC)"
090000648314f976,Other,FDA-2018-P-1532-0002,FDA-2018-P-1532,Acknowledgment Letter from FDA DDM to King & Spalding LLP
090000648314f978,Supporting & Related Material,FDA-2018-P-1532-0003,FDA-2018-P-1532,Attachment 1 Approved Drug Products with Therapeutic Equivalence Evaluations (Electronic Orange Book) for Akovaz re Petition from King & Spalding LLP
0900006484d99c0f,Other,FDA-2018-P-1532-0007,FDA-2018-P-1532,Petition Denial Letter from FDA CDER to King & Spalding LLP
090000648314f979,Supporting & Related Material,FDA-2018-P-1532-0004,FDA-2018-P-1532,Attachment 2 Reference Listed Drug Prescribing Information for Akovaz re Petition from King & Spalding LLP
090000648314f97a,Supporting & Related Material,FDA-2018-P-1532-0005,FDA-2018-P-1532,"Attachment 3 Draft Labeling for Proposed Ephedrine Sulfate Injection, USP 50 mg/10 mL re Petition from King & Spalding LLP"
090000648314f7a6,Other,FDA-2018-P-1532-0001,FDA-2018-P-1532,Petition from King & Spalding LLP
0900006483f959bb,Supporting & Related Material,FDA-2019-P-4362-0003,FDA-2019-P-4362,"Attachment 1 39th Edition 2019 Approved Drug Product List [Discontinued Drug Product List] re Citizen Petition from Hyman, Phelps & McNamara, P.C."
0900006483f957be,Other,FDA-2019-P-4362-0001,FDA-2019-P-4362,"Citizen Petition from Hyman, Phelps & McNamara, P.C."
0900006484e24e42,Other,FDA-2019-P-4362-0008,FDA-2019-P-4362,"Citizen Petition Approval letter from FDA CDER to Hyman, Phelps & McNamara, P.C."
09000064844833a0,Other,FDA-2019-P-4362-0007,FDA-2019-P-4362,"Letter from Hyman, Phelps & McNamara"
0900006483f959bd,Supporting & Related Material,FDA-2019-P-4362-0005,FDA-2019-P-4362,"Attachment 3 Cefazolin for Injection, USP re Citizen Petition from Hyman, Phelps & McNamara, P.C."
0900006483f959bc,Supporting & Related Material,FDA-2019-P-4362-0004,FDA-2019-P-4362,"Attachment 2 Prescribing Information ANCEF® Cefazolin for injection re Citizen Petition from Hyman, Phelps & McNamara, P.C."
0900006483f959be,Supporting & Related Material,FDA-2019-P-4362-0006,FDA-2019-P-4362,"Attachment 4 Heuer, et al (2017) Journal Title re Citizen Petition from Hyman, Phelps & McNamara, P.C."
0900006483f957bf,Other,FDA-2019-P-4362-0002,FDA-2019-P-4362,"Acknowledgment Letter from FDA DMS to Hyman, Phelps & Mcnamara, P.C."
0900006482092d72,Supporting & Related Material,FDA-2016-P-1952-0003,FDA-2016-P-1952,"Attachment A Product Listing from the Discontinued Section of Orange Book  re Citizen Petition from Fresenius Kabi USA, LLC"
090000648209366e,Supporting & Related Material,FDA-2016-P-1952-0004,FDA-2016-P-1952,Attachment B Currently approved ANDAs in the Orange Book re Fresenius Kabi Citizen Petition
09000064821c4a03,Other,FDA-2016-P-1952-0005,FDA-2016-P-1952,Response letter from FDA CDER to Fresenius Kabi USA LLC
090000648209366c,Other,FDA-2016-P-1952-0002,FDA-2016-P-1952,Acknowledgement Letter from FDA DDM to Fresenius Kabi USA LLC
0900006482092d70,Other,FDA-2016-P-1952-0001,FDA-2016-P-1952,"Citizen Petition from Fresenius Kabi USA, LLC"
09000064832547ab,Other,FDA-2017-P-6211-0012,FDA-2017-P-6211,Interim Response Ltr for FDA-2017-P-6211 to Hugh C Welsh of DSM dtd 4-19-18
0900006482be57ab,Other,FDA-2017-P-6211-0002,FDA-2017-P-6211,Acknowledgement Letter from FDA DDM to DSM Nutritional Products LLC
0900006482be53bc,Other,FDA-2017-P-6211-0001,FDA-2017-P-6211,Citizen Petition from DSM Nutritional Products LLC
0900006481a3aee6,Other,FDA-2015-P-0762-0002,FDA-2015-P-0762,Acknowledgement Letter From FDA DDM to Pharmacists Planning Service Inc.
0900006481a3ade2,Other,FDA-2015-P-0762-0001,FDA-2015-P-0762,Citizen Petition From Pharmacists Planning Service Inc.
0900006481ca0a6e,Other,FDA-2015-P-0762-0003,FDA-2015-P-0762,"Interim Response from FDA CFSAN to Pharmacists Planning Services, Inc"
09000064820290df,Supporting & Related Material,FDA-2016-P-1547-0004,FDA-2016-P-1547,"Attachment 2 Orange Book: Approved Drug Products with
Therapeutic Equivalence Evaluations re Citizens Petition from Baxter Healthcare Corporation"
090000648202e5c8,Other,FDA-2016-P-1547-0002,FDA-2016-P-1547,Acknowledgement Letter from FDA DDM to Baxter Healthcare Corporation
09000064823debf3,Other,FDA-2016-P-1547-0005,FDA-2016-P-1547,Approval letter from CDER FDA to Baxter Healthcare Corporation
09000064820290dc,Other,FDA-2016-P-1547-0001,FDA-2016-P-1547,Citizens Petition from Baxter Healthcare Corporation
09000064820290de,Supporting & Related Material,FDA-2016-P-1547-0003,FDA-2016-P-1547,Attachment 1 Current and Resolved Drug Shortages and Discontinuations Reported to FDA re Citizens Petition from Baxter Healthcare Corporation
090000648196be12,Other,FDA-2014-P-2168-0001,FDA-2014-P-2168,Citizen Petition from Lachman Consultant Services  Inc
090000648196c14f,Supporting & Related Material,FDA-2014-P-2168-0003,FDA-2014-P-2168,Attach 1
090000648196c150,Supporting & Related Material,FDA-2014-P-2168-0004,FDA-2014-P-2168,Attach 2
090000648196c151,Supporting & Related Material,FDA-2014-P-2168-0005,FDA-2014-P-2168,Attach 3
090000648196c149,Other,FDA-2014-P-2168-0002,FDA-2014-P-2168,Acknowledgement Letter from FDA DDM to Lachman Consultant Services Inc
0900006482ef26e3,Other,FDA-2017-P-0176-0003,FDA-2017-P-0176,Interim Response from FDA to American Herbal Products Association
090000648245cdca,Other,FDA-2017-P-0176-0002,FDA-2017-P-0176,Acknowledgement Letter from FDA DDM to American Herbal Products Association
090000648245cdc8,Other,FDA-2017-P-0176-0001,FDA-2017-P-0176,Citizen Petition from American Herbal Products Association
0900006481abf3a4,Supporting & Related Material,FDA-2015-P-1431-0023,FDA-2015-P-1431,"Tab Q NCCN Clinical Practice Guidelines in Oncology Non-Hodgkins Lymphoma Version 2 2015 (March 3 2015) (excerpts), re Citizen Petition From Teva Pharmaceuticals (Cephalon, Inc.)"
0900006481abf361,Supporting & Related Material,FDA-2015-P-1431-0004,FDA-2015-P-1431,"Tab B Approval Letter, NDA 022249 (March 20, 2008), re Citizen Petition From Teva Pharmaceuticals (Cephalon, Inc.)"
0900006481abf393,Supporting & Related Material,FDA-2015-P-1431-0011,FDA-2015-P-1431,"Tab I Package Insert, NDA 50708 (April 27, 2006), re Citizen Petition From Teva Pharmaceuticals (Cephalon, Inc.)"
0900006481abf39e,Supporting & Related Material,FDA-2015-P-1431-0022,FDA-2015-P-1431,"Tab U FDA Petition Response regarding Xyzal (levocetirizine hydrochloride), Docket No FDA-2010-P-0545 (Feb 24, 2011), re Citizen Petition From Teva Pharmaceuticals (Cephalon, Inc.)"
0900006481abf35e,Other,FDA-2015-P-1431-0002,FDA-2015-P-1431,"Acknowledgement Letter from FDA DDM to Teva Pharmaceuticals (Cephalon, Inc.)"
0900006481abea41,Other,FDA-2015-P-1431-0001,FDA-2015-P-1431,"Citizen Petition from Teva Pharmaceuticals (Cephalon, Inc)"
0900006481abf392,Supporting & Related Material,FDA-2015-P-1431-0010,FDA-2015-P-1431,"Tab H ANDA 065461, Approval Summary 1, Labeling_Review Branch (March 5, 2009), re Citizen Petition From Teva Pharmaceuticals (Cephalon, Inc.)"
0900006481abf396,Supporting & Related Material,FDA-2015-P-1431-0014,FDA-2015-P-1431,"Tab L Package Insert, ANDA 200882, re Citizen Petition From Teva Pharmaceuticals (Cephalon, Inc.)"
0900006481abf363,Supporting & Related Material,FDA-2015-P-1431-0006,FDA-2015-P-1431,"Tab D NDA 022249, Package Insert (March 15, 2015), re Citizen Petition From Teva Pharmaceuticals (Cephalon, Inc.)"
0900006481abf397,Supporting & Related Material,FDA-2015-P-1431-0015,FDA-2015-P-1431,"Tab M Pub L No 97-414, 96 Stat 2049 (1983), re Citizen Petition From Teva Pharmaceuticals (Cephalon, Inc.)"
0900006481abf39c,Supporting & Related Material,FDA-2015-P-1431-0020,FDA-2015-P-1431,"Tab S FDA Petition Response regarding Rapamune (sirolimus), Docket No 2003P-0518 (Sept 20, 2004), re Citizen Petition From Teva Pharmaceuticals (Cephalon, Inc.)"
0900006481abf362,Supporting & Related Material,FDA-2015-P-1431-0005,FDA-2015-P-1431,"Tab C Approval Letter, NDA 022303 (Oct 31, 2008), re Citizen Petition From Teva Pharmaceuticals (Cephalon, Inc.)"
0900006481abf39a,Supporting & Related Material,FDA-2015-P-1431-0018,FDA-2015-P-1431,"Tab P BLA 103705, Prescribing Information (Rituxan PI) (August 12, 2014), re Citizen Petition From Teva Pharmaceuticals (Cephalon, Inc.)"
0900006481abf391,Supporting & Related Material,FDA-2015-P-1431-0009,FDA-2015-P-1431,"Tab G Approval Letter, NDA 50708 (March 29, 2006), re Citizen Petition From Teva Pharmaceuticals (Cephalon, Inc.)"
0900006481abf395,Supporting & Related Material,FDA-2015-P-1431-0013,FDA-2015-P-1431,"Tab K Package Insert, NDA 021689 (December 19, 2014), re Citizen Petition From Teva Pharmaceuticals (Cephalon, Inc.)"
0900006481abf39d,Supporting & Related Material,FDA-2015-P-1431-0021,FDA-2015-P-1431,"Tab T FDA Petition Response regarding Lyrica (pregabalin), Docket No FDA-2010-P-0087 (August 3, 2010), re Citizen Petition From Teva Pharmaceuticals (Cephalon, Inc.)"
0900006481abf360,Supporting & Related Material,FDA-2015-P-1431-0003,FDA-2015-P-1431,"Tab A Clinical Review NDA 022249 (February 26, 2008), re Citizen Petition From Teva Pharmaceuticals (Cephalon, Inc.)"
0900006481abf394,Supporting & Related Material,FDA-2015-P-1431-0012,FDA-2015-P-1431,"Tab J Package Insert, ANDA 065461 (August 10, 2009), re Citizen Petition From Teva Pharmaceuticals (Cephalon, Inc.)"
0900006481abf398,Supporting & Related Material,FDA-2015-P-1431-0016,FDA-2015-P-1431,"Tab N HR Report No 97-840, 97th Congress 2nd Session (Sept 17, 1982), re Citizen Petition From Teva Pharmaceuticals (Cephalon, Inc.)"
0900006481abf399,Supporting & Related Material,FDA-2015-P-1431-0017,FDA-2015-P-1431,"Tab O FDA Petition Response regarding Colcrys (colchicine), Docket No 2012-P-1018 (Feb 15, 2013), re Citizen Petition From Teva Pharmaceuticals (Cephalon, Inc.)"
0900006481abf364,Supporting & Related Material,FDA-2015-P-1431-0007,FDA-2015-P-1431,"Tab E Package Insert, NDA 22303 (October 31, 2008), re Citizen Petition From Teva Pharmaceuticals (Cephalon, Inc.)"
0900006481abf39b,Supporting & Related Material,FDA-2015-P-1431-0019,FDA-2015-P-1431,"Tab R NDA 022249 Clinical Review at 62, re Citizen Petition From Teva Pharmaceuticals (Cephalon, Inc.)"
0900006481abf365,Supporting & Related Material,FDA-2015-P-1431-0008,FDA-2015-P-1431,"Tab F Clinical Review, NDA 022303 (July 30, 2008), re Citizen Petition From Teva Pharmaceuticals (Cephalon, Inc.)"
0900006481c94876,Other,FDA-2015-P-1431-0025,FDA-2015-P-1431,FDA Final Response Denial Letter
09000064819f6aa4,Supporting & Related Material,FDA-2015-P-0389-0006,FDA-2015-P-0389,Annex 4
09000064819f583a,Other,FDA-2015-P-0389-0001,FDA-2015-P-0389,Citizen Petition Request from Orbicular Pharmaceutical Technologies Pvt Ltd
09000064819f6aa3,Supporting & Related Material,FDA-2015-P-0389-0005,FDA-2015-P-0389,Annex 3
09000064819f68b6,Other,FDA-2015-P-0389-0002,FDA-2015-P-0389,Acknowledgement Letter from FDA DDM to Orbicular Pharmaceutical Technologies Pvt Ltd
0900006481aed573,Other,FDA-2015-P-0389-0007,FDA-2015-P-0389,Withdrawal from Orbicular Pharmaceutical Technologies Pvt Ltd
09000064819f68bb,Supporting & Related Material,FDA-2015-P-0389-0004,FDA-2015-P-0389,Annex 2
09000064819f68ba,Supporting & Related Material,FDA-2015-P-0389-0003,FDA-2015-P-0389,Annex 1
0900006481fda552,Supporting & Related Material,FDA-2016-P-1286-0004,FDA-2016-P-1286,"Attachment 1 Orange Book Listing for Glycopyrrolate Injection accessed 05/12/2016 re Citizen Petition from Lachman Consultant Services, Inc."
0900006481fda556,Other,FDA-2016-P-1286-0002,FDA-2016-P-1286,"Acknowledgement Letter from FDA DDM to  Lachman Consultant Services, Inc."
0900006481fda24b,Supporting & Related Material,FDA-2016-P-1286-0005,FDA-2016-P-1286,"Attachment 2 Reference Listed Drug Prescribing Information for Glycopyrrolate Injection, 0.2 mg/mL 0.4 mg/2 mL, 1 mg/5 mL, and 4 mg/20 mL re Citizen Petition from Lachman Consultant Services, Inc."
0900006481fda24a,Supporting & Related Material,FDA-2016-P-1286-0003,FDA-2016-P-1286,"Attachment 3 Proposed Prescribing Information for Glycopyrrolate Injection 0.1 mg/0.5 mL pre-filled syringe (single-dose) re Citizen Petition from Lachman Consultant Services, Inc."
0900006481fda248,Other,FDA-2016-P-1286-0001,FDA-2016-P-1286,"Citizen Petition from Lachman Consultant Services, Inc."
090000648487169c,Other,FDA-2016-P-1286-0006,FDA-2016-P-1286,Response from Lachman Consultant Services
0900006484214556,Supporting & Related Material,FDA-2019-P-5922-0003,FDA-2019-P-5922,"Exhibit 1- Introduction, Conclusions, and Historical BackgroundRelative to E-Cigarettes re: Citizen Petition for Respira Technologies, Inc."
090000648421455b,Supporting & Related Material,FDA-2019-P-5922-0008,FDA-2019-P-5922,"Exhibit 6- E-Cigarette Use Among Youth and Young Adults: A Report of the Surgeon General RE: Citizen Petition for Respira Technologies, Inc."
0900006484214580,Supporting & Related Material,FDA-2019-P-5922-0010,FDA-2019-P-5922,"Exhibit 8- The Public Health Rationale for Recommended Restrictions on New Tobacco Product Labeling, Advertising, Marketing, and Promotion RE: Citizen Petition for Respira Technologies, Inc."
0900006484214559,Supporting & Related Material,FDA-2019-P-5922-0006,FDA-2019-P-5922,"Exhibit 4- Pathology of Vaping-Associated Lung Injury RE: Citizen Petition for Respira Technologies, Inc."
090000648421455c,Supporting & Related Material,FDA-2019-P-5922-0009,FDA-2019-P-5922,"Exhibit 7- Letter to Norman E. ""Ned"" Sharpless, M.D. from U.S. Senators RE: Citizen Petition for Respira Technologies, Inc."
0900006484214581,Supporting & Related Material,FDA-2019-P-5922-0011,FDA-2019-P-5922,"Exhibit 9- Safer Technologies Program for Medical Devices Draft Guidance for Industry and Food and Drug Administration Staff Draft Guidance RE: Citizen Petition for Respira Technologies, Inc."
09000064845617e2,Other,FDA-2019-P-5922-0013,FDA-2019-P-5922,"Interim Response Letter from FDA CTP to Respira Technologies, Inc."
09000064842141f9,Other,FDA-2019-P-5922-0001,FDA-2019-P-5922,"Citizen Petition from Respira Technologies, Inc."
0900006484213cca,Other,FDA-2019-P-5922-0002,FDA-2019-P-5922,"Acknowledgment Letter from FDA DDM to Respira Technologies, Inc"
0900006484214557,Supporting & Related Material,FDA-2019-P-5922-0004,FDA-2019-P-5922,"Exhibit 2- Health Effects of E‑Cigarette Use Among U.S. Youth and Young Adults RE: Citizen Petition for Respira Technologies, Inc."
0900006484214558,Supporting & Related Material,FDA-2019-P-5922-0005,FDA-2019-P-5922,"Exhibit 3- Understanding the Health Impact and Dangers of Smoke and ""Vapor"" re Citizen Petition for Respira Technologies, Inc."
090000648421455a,Supporting & Related Material,FDA-2019-P-5922-0007,FDA-2019-P-5922,"Exhibit 5- Survey RE: Citizen Petition for Respira Technologies, Inc."
090000648302afa8,Other,FDA-2018-P-1195-0001,FDA-2018-P-1195,"Citizen Petition from Hyman, Phelps & McNamara, PC"
090000648361f194,Supporting & Related Material,FDA-2018-P-1195-0005,FDA-2018-P-1195,"Attachment 1 - Citizen Petition Supplement  from Hyman, Phelps & McNamara, PC"
0900006483d058f1,Other,FDA-2018-P-1195-0009,FDA-2018-P-1195,Petition for Reconsideration and Stay Regarding from Arnall Golden Gregory LLP
0900006483d05457,Supporting & Related Material,FDA-2018-P-1195-0010,FDA-2018-P-1195,Attachment to Petition for Reconsideration and Stay from Arnall Golden Gregory LLP
09000064836efbfc,Other,FDA-2018-P-1195-0007,FDA-2018-P-1195,"Interim Response from FDA CDER to Hyman, Phelps & McNamara, PC"
0900006483d86907,Other,FDA-2018-P-1195-0012,FDA-2018-P-1195,"Letter from FDA CDER to Arnall Golden Gregory, LLP"
090000648302afde,Other,FDA-2018-P-1195-0002,FDA-2018-P-1195,"Acknowledgment Letter from FDA DDM to Hyman, Phelps & McNamara"
0900006483daa962,Other,FDA-2018-P-1195-0015,FDA-2018-P-1195,Acknowledgment Letter from FDA DDM to Arnall Golden Gregory LLP
090000648361f179,Other,FDA-2018-P-1195-0004,FDA-2018-P-1195,"Citizen Petition Supplement  from Hyman, Phelps & McNamara, PC"
0900006483c47797,Other,FDA-2018-P-1195-0008,FDA-2018-P-1195,"Letter from FDA CDER to Hyman, Phelps & McNamara, P.C."
09000064836efad1,Other,FDA-2018-P-1195-0006,FDA-2018-P-1195,Interim Response Letter from FDA CDER to Kurt Karst
09000064846afe3e,Other,FDA-2018-P-1195-0016,FDA-2018-P-1195,"Petition Response Letter from FDA CDER to Arnall Golden Gregory, LLC"
0900006483d0f6e0,Other,FDA-2018-P-1195-0011,FDA-2018-P-1195,Acknowledgment Letter from FDA DDM to Arnall Golden Gregory LLP
0900006484a1bfeb,Other,FDA-2015-P-4770-0004,FDA-2015-P-4770,"Response Letter from FDA CDER to Epic Pharma, LLC"
0900006481d9ef2a,Supporting & Related Material,FDA-2015-P-4770-0003,FDA-2015-P-4770,"Attachment 2 Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations re Citizen Petition from Epic Pharma, LLC"
0900006481d9eeb8,Other,FDA-2015-P-4770-0001,FDA-2015-P-4770,"Acknowledgement Letter from FDA DDM to Epic Pharma, LLC"
0900006481d9eebc,Supporting & Related Material,FDA-2015-P-4770-0002,FDA-2015-P-4770,"Attachment 1 Package Insert and Proposed Package Insert re Citizen Petition from Epic Pharma, LLC"
0900006484c21113,Other,FDA-2021-P-0852-0002,FDA-2021-P-0852,"Acknowledgement Letter from FDA DMS to Lachman Consultant Services, Inc."
0900006484c21111,Other,FDA-2021-P-0852-0001,FDA-2021-P-0852,"Citizen Petition from Lachman Consultant Services, Inc."
090000648099d851,Other,FDA-2009-P-0227-0003,FDA-2009-P-0227,Acknowledgement Letter to The National Center on Addiction and Substance Abuse at Columbia University
090000648099d850,Other,FDA-2009-P-0227-0001,FDA-2009-P-0227,The National Center on Addiction and Substance Abuse at Columbia University - Citizen Petition
0900006480a5bcdc,Other,FDA-2009-P-0227-0005,FDA-2009-P-0227,The National Center on Addiction and Substance Abuse at Columbia University - Letter
0900006480a56766,Other,FDA-2009-P-0227-0004,FDA-2009-P-0227,FDA/CDER Interim Response to The National Center on Addiction - Letter
090000648099d852,Supporting & Related Material,FDA-2009-P-0227-0002,FDA-2009-P-0227,Appendix A: Under The Counter: The Diversion and Abuse of Controlled Prescription Drugs in the U.S. (2002) - [The National Center on Addiction and Substance Abuse at Columbia University - Citizen Petition]
090000648133451e,Other,FDA-2009-P-0227-0006,FDA-2009-P-0227,FDA/CDER Response to National Center on Addiction and Substance Abuse at Columbia University - Denial of Petition
0900006480a3ba57,Notice,FDA-2009-D-0470-0001,FDA-2009-D-0470,"Draft Guidance for Industry and FDA Staff; the Scope of the Prohibition Against Marketing a Tobacco Product in Combination With Another Article or Product Regulated Under the Federal Food, Drug, and Cosmetic Act; Availability"
0900006480a3bb34,Other,FDA-2009-D-0470-0002,FDA-2009-D-0470,"Draft Guidance for Industry and FDA Staff; The Scope of the Prohibition Against Marketing a Tobacco Product in Combination With Another Article or Product Regulated Under the Federal Food, Drug, and Cosmetic Act"
0900006484a6b5dc,Supporting & Related Material,FDA-2021-P-0293-0003,FDA-2021-P-0293,"Exhibits 1-5 RE Citizen Petition from TherapeuticsMD, Inc."
0900006484a6b5dd,Supporting & Related Material,FDA-2021-P-0293-0004,FDA-2021-P-0293,"Exhibits 6-10 RE Citizen Petition from TherapeuticsMD, Inc."
0900006484d628dd,Other,FDA-2021-P-0293-0005,FDA-2021-P-0293,"Interim Response from FDA CDER to TherapeuticsMD, Inc."
0900006484a6b5d8,Other,FDA-2021-P-0293-0002,FDA-2021-P-0293,"Acknowledgment Letter from FDA DMS to Citizen Petition from TherapeuticsMD, Inc."
0900006484a6b3dd,Other,FDA-2021-P-0293-0001,FDA-2021-P-0293,"Citizen Petition from Therapeutics MD, Inc."
0900006483a003b1,Other,FDA-2018-P-2901-0003,FDA-2018-P-2901,Interim response from FDA CDER to Yiling Pharmaceutical Ltd
090000648355d3c5,Other,FDA-2018-P-2901-0002,FDA-2018-P-2901,Acknowledgement Letter from FDA DDM to Yiling Pharmaceutical Ltd
09000064841bf4cd,Other,FDA-2018-P-2901-0004,FDA-2018-P-2901,Letter from FDA CDER to Kratz & Barry LLP and Yiling Pharmaceutical Ltd.
090000648355d2e5,Other,FDA-2018-P-2901-0001,FDA-2018-P-2901,Citizen Petition from Yiling Pharmaceutical Ltd
0900006483b5993f,Supporting & Related Material,FDA-2019-P-1566-0004,FDA-2019-P-1566,"Appendix 2 Draft Label of the Proposed Generic Soft Chewable Tablet re Citizen Petition from Noble Pharma, LLC"
0900006483dabd89,Other,FDA-2019-P-1566-0006,FDA-2019-P-1566,"Amendment from Noble Pharma, LLC"
0900006483d43df2,Other,FDA-2019-P-1566-0005,FDA-2019-P-1566,"Letter from FDA CVM to Nobel Pharma, LLC"
0900006483b593de,Other,FDA-2019-P-1566-0001,FDA-2019-P-1566,"Citizen Petition from Noble Pharma, LLC"
0900006483b595b8,Other,FDA-2019-P-1566-0002,FDA-2019-P-1566,"Acknowledgment Letter from FDA DDM to Noble Pharma, LLC"
0900006483b5993e,Supporting & Related Material,FDA-2019-P-1566-0003,FDA-2019-P-1566,"Appendix 1 Pioneer Label re Citizen Petition from Noble Pharma, LLC"
0900006483e035df,Other,FDA-2019-P-1566-0007,FDA-2019-P-1566,Request to Withdraw Amendment
0900006482c50db7,Other,FDA-2017-P-3405-0003,FDA-2017-P-3405,Interim response  from FDA CDRH  to  Michael Boggi
0900006483598350,Other,FDA-2017-P-3405-0004,FDA-2017-P-3405,Letter from FDA CDRH to  Michael Boggi
090000648266f8dd,Other,FDA-2017-P-3405-0002,FDA-2017-P-3405,Acknowledgement Letter from FDA DDM to Michael Boggi
090000648266f8db,Other,FDA-2017-P-3405-0001,FDA-2017-P-3405,Citizen Petition from Michael Boggi
0900006481fbb1a4,Other,FDA-2016-P-1249-0001,FDA-2016-P-1249,"Citizen Petition from Hyman, Phelps & McNamara, P. C."
0900006481fbb1a6,Other,FDA-2016-P-1249-0002,FDA-2016-P-1249,"Hyman, Phelps & McNamara, P. C. from FDA DDM to  Hyman, Phelps & McNamara, P. C."
090000648228718c,Other,FDA-2016-P-1249-0004,FDA-2016-P-1249,"Citizen Petition Denial Response from FDA CDER to Haner & Kuo, PLLC"
090000648220c71f,Supporting & Related Material,FDA-2016-P-2736-0022,FDA-2016-P-2736,"Appendix C - 2 - Copies of References Cited in Citizen Petition on Human Intervention Studies Regarding Effect of ITF on Calcium Absorption re Citizen Petition from Hyman, Phelps & McNamara, P.C. (Beneo, Cosucra Groupe Warcoing S.A., and Sensus B.V.)"
090000648220c774,Supporting & Related Material,FDA-2016-P-2736-0056,FDA-2016-P-2736,"Appendix G - 4 - Copies of Misc References Cited in Citizen Petition other than Copies Included in Appendices B-E re Citizen Petition from Hyman, Phelps & McNamara, P.C. (Beneo, Cosucra Groupe Warcoing S.A., and Sensus B.V.)"
090000648220c797,Supporting & Related Material,FDA-2016-P-2736-0070,FDA-2016-P-2736,"Appendix G - 18 - Copies of Misc References Cited in Citizen Petition other than Copies Included in Appendices B-E re Citizen Petition from Hyman, Phelps & McNamara, P.C. (Beneo, Cosucra Groupe Warcoing S.A., and Sensus B.V.)"
090000648220c920,Supporting & Related Material,FDA-2016-P-2736-0032,FDA-2016-P-2736,"Appendix D - 3 - Copies of References Cited in Citizen Petition on Human Intervention Studies Regarding Effect of ITF on Blood Cholesterol Levels re Citizen Petition from Hyman, Phelps & McNamara, P.C. (Beneo, Cosucra Groupe Warcoing S.A., and Sensus B.V.)"
090000648220c921,Supporting & Related Material,FDA-2016-P-2736-0033,FDA-2016-P-2736,"Appendix D - 4 - Copies of References Cited in Citizen Petition on Human Intervention Studies Regarding Effect of ITF on Blood Cholesterol Levels reCitizen Petition from Hyman, Phelps & McNamara, P.C. (Beneo, Cosucra Groupe Warcoing S.A., and Sensus B.V.)"
090000648220c922,Supporting & Related Material,FDA-2016-P-2736-0034,FDA-2016-P-2736,"Appendix D - 5 - Copies of References Cited in Citizen Petition on Human Intervention Studies Regarding Effect of ITF on Blood Cholesterol Levels re Citizen Petition from Hyman, Phelps & McNamara, P.C. (Beneo, Cosucra Groupe Warcoing S.A., and Sensus B.V.)"
090000648220c924,Supporting & Related Material,FDA-2016-P-2736-0036,FDA-2016-P-2736,"Appendix D - 7 - Copies of References Cited in Citizen Petition on Human Intervention Studies Regarding Effect of ITF on Blood Cholesterol Levels re Citizen Petition from Hyman, Phelps & McNamara, P.C. (Beneo, Cosucra Groupe Warcoing S.A., and Sensus B.V.)"
090000648220c930,Supporting & Related Material,FDA-2016-P-2736-0039,FDA-2016-P-2736,"Appendix D - 10 - Copies of References Cited in Citizen Petition on Human Intervention Studies Regarding Effect of ITF on Blood Cholesterol Levels re Citizen Petition from Hyman, Phelps & McNamara, P.C. (Beneo, Cosucra Groupe Warcoing S.A., and Sensus B.V.)"
090000648220c932,Supporting & Related Material,FDA-2016-P-2736-0041,FDA-2016-P-2736,"Appendix D - 12 - Copies of References Cited in Citizen Petition on Human Intervention Studies Regarding Effect of ITF on Blood Cholesterol Levels re Citizen Petition from Hyman, Phelps & McNamara, P.C. (Beneo, Cosucra Groupe Warcoing S.A., and Sensus B.V.)"
090000648220c0f6,Supporting & Related Material,FDA-2016-P-2736-0015,FDA-2016-P-2736,"Appendix B - 12 - Copies of References Cited in Citizen Petition on Human Intervention Studies Regarding Effect of the ITF on Bowel Function re Citizen Petition from Hyman, Phelps & McNamara, P.C. (Beneo, Cosucra Groupe Warcoing S.A., and Sensus B.V.)"
090000648220c60a,Supporting & Related Material,FDA-2016-P-2736-0007,FDA-2016-P-2736,"Appendix B - 4 - Copies of References Cited in Citizen Petition on Human Intervention Studies Regarding Effect of the ITF on Bowel Function re Citizen Petition from Hyman, Phelps & McNamara, P.C. (Beneo, Cosucra Groupe Warcoing S.A., and Sensus B.V.)"
090000648220c71c,Supporting & Related Material,FDA-2016-P-2736-0019,FDA-2016-P-2736,"Appendix B - 16 - Copies of References Cited in Citizen Petition on Human Intervention Studies Regarding Effect of the ITF on Bowel Function re Citizen Petition from Hyman, Phelps & McNamara, P.C. (Beneo, Cosucra Groupe Warcoing S.A., and Sensus B.V.)"
090000648220c71e,Supporting & Related Material,FDA-2016-P-2736-0021,FDA-2016-P-2736,"Appendix C - 1 - Copies of References Cited in Citizen Petition on Human Intervention Studies Regarding Effect of ITF on Calcium Absorption re Citizen Petition from Hyman, Phelps & McNamara, P.C. (Beneo, Cosucra Groupe Warcoing S.A., and Sensus B.V.)"
090000648220c971,Supporting & Related Material,FDA-2016-P-2736-0063,FDA-2016-P-2736,"Appendix G - 11 - Copies of Misc References Cited in Citizen Petition other than Copies Included in Appendices B-E re Citizen Petition from Hyman, Phelps & McNamara, P.C. (Beneo, Cosucra Groupe Warcoing S.A., and Sensus B.V.)"
090000648220c773,Supporting & Related Material,FDA-2016-P-2736-0055,FDA-2016-P-2736,"Appendix G - 3 - Copies of Misc References Cited in Citizen Petition other than Copies Included in Appendices B-E re Citizen Petition from Hyman, Phelps & McNamara, P.C. (Beneo, Cosucra Groupe Warcoing S.A., and Sensus B.V.)"
090000648220c91e,Supporting & Related Material,FDA-2016-P-2736-0030,FDA-2016-P-2736,"Appendix D - 1 - Copies of References Cited in Citizen Petition on Human Intervention Studies Regarding Effect of ITF on Blood Cholesterol Levels re Citizen Petition from Hyman, Phelps & McNamara, P.C. (Beneo, Cosucra Groupe Warcoing S.A., and Sensus B.V.)"
090000648220c923,Supporting & Related Material,FDA-2016-P-2736-0035,FDA-2016-P-2736,"Appendix D - 6 - Copies of References Cited in Citizen Petition on Human Intervention Studies Regarding Effect of ITF on Blood Cholesterol Levels re Citizen Petition from Hyman, Phelps & McNamara, P.C. (Beneo, Cosucra Groupe Warcoing S.A., and Sensus B.V.)"
090000648220c935,Supporting & Related Material,FDA-2016-P-2736-0044,FDA-2016-P-2736,"Appendix D - 15 - Copies of References Cited in Citizen Petition on Human Intervention Studies Regarding Effect of ITF on Blood Cholesterol Levels re Citizen Petition from Hyman, Phelps & McNamara, P.C. (Beneo, Cosucra Groupe Warcoing S.A., and Sensus B.V.)"
090000648220c936,Supporting & Related Material,FDA-2016-P-2736-0045,FDA-2016-P-2736,"Appendix D - 16 - Copies of References Cited in Citizen Petition on Human Intervention Studies Regarding Effect of ITF on Blood Cholesterol Levels re Citizen Petition from Hyman, Phelps & McNamara, P.C. (Beneo, Cosucra Groupe Warcoing S.A., and Sensus B.V.)"
090000648220c96e,Supporting & Related Material,FDA-2016-P-2736-0060,FDA-2016-P-2736,"Appendix G - 8 - Copies of Misc References Cited in Citizen Petition other than Copies Included in Appendices B-E re Citizen Petition from Hyman, Phelps & McNamara, P.C. (Beneo, Cosucra Groupe Warcoing S.A., and Sensus B.V.)"
090000648220c76d,Supporting & Related Material,FDA-2016-P-2736-0049,FDA-2016-P-2736,"Appendix E - 3 - Copies of References Cited in Citizen Petition on Human Intervention Studies Regarding Effect of ITF on Postprandial Glycemic Response re Citizen Petition from Hyman, Phelps & McNamara, P.C. (Beneo, Cosucra Groupe Warcoing S.A., and Sensus B.V.)"
090000648220c76f,Supporting & Related Material,FDA-2016-P-2736-0051,FDA-2016-P-2736,"Appendix E - 5 - Copies of References Cited in Citizen Petition on Human Intervention Studies Regarding Effect of ITF on Postprandial Glycemic Response re Citizen Petition from Hyman, Phelps & McNamara, P.C. (Beneo, Cosucra Groupe Warcoing S.A., and Sensus B.V.)"
090000648220c770,Supporting & Related Material,FDA-2016-P-2736-0052,FDA-2016-P-2736,"Appendix F - References cited in Citizen Petition not included in Appendix A re Citizen Petition from Hyman, Phelps & McNamara, P.C. (Beneo, Cosucra Groupe Warcoing S.A., and Sensus B.V.)"
090000648220c602,Other,FDA-2016-P-2736-0001,FDA-2016-P-2736,"Citizen Petition from Hyman, Phelps & McNamara, P.C. (Beneo, Cosucra Groupe Warcoing S.A., and Sensus B.V.)"
090000648220c608,Supporting & Related Material,FDA-2016-P-2736-0005,FDA-2016-P-2736,"Appendix B - 2 - Copies of References Cited in Citizen Petition on Human Intervention Studies Regarding Effect of the ITF on Bowel Function re Citizen Petition from Hyman, Phelps & McNamara, P.C. (Beneo, Cosucra Groupe Warcoing S.A., and Sensus B.V.)"
0900006482e28106,Other,FDA-2018-P-0258-0002,FDA-2018-P-0258,Acknowledgment Letter from FDA DDM to Gilman Cheese Corporation
0900006483a6444d,Other,FDA-2018-P-0258-0009,FDA-2018-P-0258,Letter from FDA CFSAN to GILMAN CHEESE CORPORATION
0900006482e28103,Other,FDA-2018-P-0258-0001,FDA-2018-P-0258,Citizen Petition from Gilman Cheese Corporation
090000648196be15,Other,FDA-2014-P-2169-0001,FDA-2014-P-2169,Citizen Petition Request from Lachman Consultant Services Inc
090000648196bf3d,Supporting & Related Material,FDA-2014-P-2169-0004,FDA-2014-P-2169,Attach 2
090000648196bf3c,Supporting & Related Material,FDA-2014-P-2169-0003,FDA-2014-P-2169,Attach 1
090000648196bf3e,Supporting & Related Material,FDA-2014-P-2169-0005,FDA-2014-P-2169,Attach 3
090000648196c152,Other,FDA-2014-P-2169-0002,FDA-2014-P-2169,Aknowledgement Letter from FDA DDM to Lachman Consultant Services Inc
09000064817772e3,Other,FDA-2014-P-0916-0001,FDA-2014-P-0916,Citizen Petition From Hope Pharmaceuticals
090000648191375d,Other,FDA-2014-P-0916-0006,FDA-2014-P-0916,Citizen Petition Denial Letter to Craig Sherman MD of Hope Pharmaceuticals
09000064818721ea,Other,FDA-2014-P-0916-0004,FDA-2014-P-0916,Supplement from Hope Pharmaceuticals
09000064817b2bd9,Supporting & Related Material,FDA-2014-P-0916-0003,FDA-2014-P-0916,Withdrawal Letter From Hope Pharmaceuticals re FDA-2014-P-0771-0003
09000064818cdafa,Other,FDA-2014-P-0916-0005,FDA-2014-P-0916,Revised Supplement from Hope Pharmaceuticals
09000064817772ea,Other,FDA-2014-P-0916-0002,FDA-2014-P-0916,Acknowledgment Letter From FDA DDM to Hope Pharmaceuticals
0900006481e04099,Other,FDA-2016-P-0135-0002,FDA-2016-P-0135,"Acknowledgement Letter from FDA DDM to Hyman, Phelps & McNamara, P.C."
0900006482277e57,Other,FDA-2016-P-0135-0004,FDA-2016-P-0135,"Letter from Hyman, Phelps & McNamara, P.C. to FDA  withdrawing Petition"
090000648209b04f,Other,FDA-2016-P-0135-0003,FDA-2016-P-0135,Interim Response from FDA CDER
090000648227611b,Other,FDA-2016-P-0135-0005,FDA-2016-P-0135,"Withdrawal from Hyman, Phelps & McNamara, P.C."
0900006481e03f6d,Other,FDA-2016-P-0135-0001,FDA-2016-P-0135,"Citizen Petition from Hyman, Phelps & McNamara, P.C. - Per Petitioner, withdrawal of Petition"
0900006483959707,Other,FDA-2018-P-4656-0001,FDA-2018-P-4656,Citizen Petition from Animal Legal Defense Fund
09000064839598ed,Other,FDA-2018-P-4656-0002,FDA-2018-P-4656,Acknowledgment Letter from FDA DDM to Animal Legal Defense Fund
0900006483ca61d2,Other,FDA-2018-P-4656-0006,FDA-2018-P-4656,Letter from FDA CVM to Animal Legal Defense Fund
0900006483da9110,Other,FDA-2018-P-3640-0008,FDA-2018-P-3640,180 Day Interim Response Letter from FDA CFSAN to Information Technology and Innovation Foundation
090000648377119a,Other,FDA-2018-P-3640-0001,FDA-2018-P-3640,Citizen Petition from Information Technology and Innovation Foundation
090000648377119d,Other,FDA-2018-P-3640-0002,FDA-2018-P-3640,Acknowledgment Letter from FDA DDM to Information Technology and Innovation Foundation
090000648404db24,Other,FDA-2018-P-3640-0009,FDA-2018-P-3640,Interim Response Letter from FDA CFSAN to Information Tech and Innovation Foundation
0900006481b93482,Other,FDA-2015-P-2481-0002,FDA-2015-P-2481,Acknowledgement Letter from FDA CDRH to SweetSpot Diabetes Care
090000648413267c,Other,FDA-2015-P-2481-0004,FDA-2015-P-2481,Petition Withdrawal Letter from Dexcom to FDA
0900006482f01034,Other,FDA-2015-P-2481-0003,FDA-2015-P-2481,"Contact Person Transfer Letter for SweetSpot Diabetes Care, Inc."
0900006481b9347d,Other,FDA-2015-P-2481-0001,FDA-2015-P-2481,Reclassification Petition from SweetSpot Diabetes Care
0900006484066a16,Other,FDA-2017-P-2626-0007,FDA-2017-P-2626,Response letter from FDA  CFSAN Emord and Associates on behalf of Real Food Consumer Coalition
090000648257b69d,Other,FDA-2017-P-2626-0002,FDA-2017-P-2626,"Acknowledgement Letter from FDA DDM to Emord & Associates, P. C."
090000648257b58e,Other,FDA-2017-P-2626-0001,FDA-2017-P-2626,"Citizen Petition from Emord & Associates, P. C."
0900006482bd8106,Other,FDA-2017-P-2626-0003,FDA-2017-P-2626,"Interim Response Letter from FDA CFSAN to Emord & Associates, P. C."
090000648495d4b4,Supporting & Related Material,FDA-2020-P-2187-0003,FDA-2020-P-2187,"ATTACHMENT 1 - Copy of the relevant excerpt from the current electronic Edition of the Approved Drug Products with Therapeutic Equivalence Evaluations RE Suitability Petition from Lachman Consulting Services, Inc."
090000648495d4b0,Other,FDA-2020-P-2187-0001,FDA-2020-P-2187,"Suitability Petition from Lachman Consulting Services, Inc."
09000064849a2dbc,Other,FDA-2020-P-2187-0006,FDA-2020-P-2187,Withdrawal from Lachman Consultant Services
090000648495d4b6,Supporting & Related Material,FDA-2020-P-2187-0005,FDA-2020-P-2187,"ATTACHMENT 3: Draft Package Insert Proposed for Vancomycin Hydrochloride for Oral Solution incorporating the proposed additional strength of EQ 125 mg (base)/5 mL RE Suitability Petition from Lachman Consulting Services, Inc."
090000648495d4b5,Supporting & Related Material,FDA-2020-P-2187-0004,FDA-2020-P-2187,"ATTACHMENT 2 - Current labeling for Vancomycin Hydrochloride, For Solution, Oral EQ 250 mg (base)/5 mL by ANI Pharmaceuticals Inc., approved under ANDAA061667, Product Number 002, Source: DailyMed) RE Suitability Petition from Lachman Consulting Services, Inc."
090000648495d4b1,Other,FDA-2020-P-2187-0002,FDA-2020-P-2187,"Acknowledgment Letter from FDA DMS to Lachman Consulting Services, Inc."
09000064823167af,Supporting & Related Material,FDA-2016-P-3426-0004,FDA-2016-P-3426,Exhibit 2 Controlled Correspondence from FDA CDER to Novitium Pharma LLC re Citizen Petition from Novitium Pharma LLC
0900006482316a92,Other,FDA-2016-P-3426-0001,FDA-2016-P-3426,Citizen Petition from Novitium Pharma LLC
0900006482316a96,Supporting & Related Material,FDA-2016-P-3426-0003,FDA-2016-P-3426,Exhibit 1 Letter from Inwood Pharmacy to Novitium Pharma LLC re Citizen Petition from Novitium Pharma LLC
090000648251122f,Other,FDA-2016-P-3426-0005,FDA-2016-P-3426,Petition Response Letter from FDA CDER to Novitium Pharma LLC
0900006482316a94,Other,FDA-2016-P-3426-0002,FDA-2016-P-3426,Acknowledgement Letter from FDA DDM to Novitium Pharma LLC
0900006481f93b72,Supporting & Related Material,FDA-2016-P-1211-0004,FDA-2016-P-1211,"Attachment 2 Draft labeling for the proposed product, Goody's Migraine re Citizen Petition from Medtech Products Inc."
0900006481f93dec,Other,FDA-2016-P-1211-0001,FDA-2016-P-1211,Citizen Petition from Medtech Products Inc.
0900006481f93df0,Supporting & Related Material,FDA-2016-P-1211-0003,FDA-2016-P-1211,"Attachment 1 Approved labeling for the RLD, Excedrin (migraine) re Citizen Petition from Medtech Products Inc."
0900006482eee082,Other,FDA-2016-P-1211-0006,FDA-2016-P-1211,Notice of Withdrawal Letter from FDA to A Prestige Brands Company
0900006481f93b8d,Other,FDA-2016-P-1211-0002,FDA-2016-P-1211,Acknowledgement Letter from FDA DDM to Medtech Products Inc.
0900006481f93b73,Supporting & Related Material,FDA-2016-P-1211-0005,FDA-2016-P-1211,Attachment 3 Request for Waiver from requirement to submit a pediatric assessment re Citizen Petition from Medtech Products Inc.
09000064846d4d46,Supporting & Related Material,FDA-2020-P-1511-0006,FDA-2020-P-1511,Attachment 2 Nymalize (nimodipine) oral solution re Citizens Petition from Annora Pharma Private Limited
09000064846d4c08,Supporting & Related Material,FDA-2020-P-1511-0007,FDA-2020-P-1511,Attachment 1 Orange Book Nimodipine Oral Solution re Citizens Petition from Annora Pharma Private Limited
0900006484a3add5,Other,FDA-2020-P-1511-0011,FDA-2020-P-1511,Final Response Letter from FDA CDER to Annora Pharma Private Limited
09000064846d4c04,Other,FDA-2020-P-1511-0002,FDA-2020-P-1511,Citizens Petition from Annora Pharma Private Limited
09000064846d4cb7,Supporting & Related Material,FDA-2020-P-1511-0004,FDA-2020-P-1511,Attachment 4 Package Inser for 3 mg per mL re Citizens Petition from Annora Pharma Private Limited
0900006484a39793,Notice,FDA-2020-P-1511-0010,FDA-2020-P-1511,"Determination That NYMALIZE (nimodipine), Oral Solution, 3 Milligrams/Milliliter, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
09000064846d4cb8,Supporting & Related Material,FDA-2020-P-1511-0003,FDA-2020-P-1511,Attachment 5 Package insert for 6 mg per mL (new concentration) re Citizens Petition from Annora Pharma Private Limited
090000648497e03c,Other,FDA-2020-P-1511-0009,FDA-2020-P-1511,Interim Response Letter from FDA CDER to Annora Pharma Private Limited
09000064846d4c05,Other,FDA-2020-P-1511-0001,FDA-2020-P-1511,Acknowledgment Letter from FDA DMS to Annora Pharma Private Limited
09000064846d4cb6,Supporting & Related Material,FDA-2020-P-1511-0005,FDA-2020-P-1511,Attachment 3 Notice of Formulation Change by Arbor Pharmaceuticals LLC re Citizens Petition from Annora Pharma Private Limited
09000064804758a1,Other,FDA-2004-P-0465-0002,FDA-2004-P-0465,HFA-305 to London and Mead
09000064804758c2,Other,FDA-2004-P-0465-0003,FDA-2004-P-0465,HFD-1 to London & Mead
0900006480475877,Other,FDA-2004-P-0465-0001,FDA-2004-P-0465,HFA-305 to London and Mead
090000648408ff27,Other,FDA-2003-P-0291-0004,FDA-2003-P-0291,Response Letter from FDA CFSAN to Center for Science in the Public Interest
0900006480492bd9,Other,FDA-2003-P-0291-0001,FDA-2003-P-0291,FDA/DDM to CSPI
0900006480492c43,Other,FDA-2003-P-0291-0003,FDA-2003-P-0291,Center for Science in the Public Interest (CSPI)
0900006480492c4c,Other,FDA-2003-P-0291-0002,FDA-2003-P-0291,FDA/CFSAN to Center for Science in the Public Interest
0900006480495f70,Other,FDA-2003-P-0334-0002,FDA-2003-P-0334,"HFA-305 to Cape Cod, Inc."
0900006480f5524b,Other,FDA-2003-P-0334-0004,FDA-2003-P-0334,"Associates of Cape Cod (ACC), Inc. - Withdrawal"
0900006480495f26,Other,FDA-2003-P-0334-0001,FDA-2003-P-0334,"HFA-305 to Cape Cod, Inc."
0900006480495f95,Other,FDA-2003-P-0334-0003,FDA-2003-P-0334,"HFM-1 to Hyman, Phelps &amp; McNamara, PC"
0900006481fdb470,Supporting & Related Material,FDA-2016-P-1287-0003,FDA-2016-P-1287,"Attachment 1  Orange Book for Amphotericin B Liposome for Injection, accessed 05/12/16 re Citizen Petition from Lachman Consultant Services, Inc."
0900006484877df5,Other,FDA-2016-P-1287-0006,FDA-2016-P-1287,Letter from Lachman Consultant Services
0900006481fdb4a2,Other,FDA-2016-P-1287-0001,FDA-2016-P-1287,"Citizen Petition from Lachman Consultant Services, Inc."
0900006484d628d7,Other,FDA-2016-P-1287-0007,FDA-2016-P-1287,"Approval Letter from FDA CDER to Lachman Consultant Services, Inc."
0900006481fdb46f,Supporting & Related Material,FDA-2016-P-1287-0004,FDA-2016-P-1287,"Attachment 2 Reference Listed Drug Prescribing Informaiton for AmBisome (Amphotericin B Liposome) for Injection, 50 mg/vial by Astellas Pharmaceuticals re Citizen Petition from Lachman Consultant Services, Inc."
0900006481fdb4a4,Other,FDA-2016-P-1287-0002,FDA-2016-P-1287,"Acknowledgement Letter from FDA DDM to  Lachman Consultant Services, Inc."
0900006481fdb46e,Supporting & Related Material,FDA-2016-P-1287-0005,FDA-2016-P-1287,"Attachment 3 Proposed Prescribing Information for Amphotericin B Liposome for Injection 250 mg/vial re Citizen Petition from Lachman Consultant Services, Inc."
090000648420dd1d,Other,FDA-2019-P-5887-0002,FDA-2019-P-5887,Acknowledgment Letter from FDA DMS to Upfield US Inc.
090000648420dd20,Supporting & Related Material,FDA-2019-P-5887-0003,FDA-2019-P-5887,Appendix A re Citizen Petition from Upfield US Inc. Citizen Petition from Upfield US Inc.
090000648420d4cb,Other,FDA-2019-P-5887-0001,FDA-2019-P-5887,Citizen Petition from Upfield US Inc.
0900006481e44e52,Notice,FDA-2013-N-0662-0003,FDA-2013-N-0662,"Agency Information Collection Activities: Proposed Collection; Comment Request; Applications for Food and Drug Administration Approval to Market a New Drug: Patent Submission and Listing Requirements and Application of 30-Month Stays on Approval of Abbreviated New Drug
Applications Certifying That a Patent Claiming a Drug Is Valid or Will Not Be Infringed"
0900006482408286,Notice,FDA-2013-N-0662-0006,FDA-2013-N-0662,"Agency Information Collection Activities; Announcement of Office of
Management and Budget Approvals"
090000648425db89,Notice,FDA-2013-N-0662-0009,FDA-2013-N-0662,"Agency Information Collection Activities; Announcement of Office of
Management and Budget Approvals"
0900006481427764,Notice,FDA-2013-N-0662-0002,FDA-2013-N-0662,Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Applications for Food and Drug Administration Approval to Market a New Drug: Patent Submission and Listing Requirements
0900006483ca08dc,Notice,FDA-2013-N-0662-0007,FDA-2013-N-0662,"Agency Information Collection Activities; Proposed Collection; Comment Request; Applications for Food and Drug Administration
Approval To Market a New Drug: Patent Submission and Listing Requirements"
0900006483eed742,Notice,FDA-2013-N-0662-0008,FDA-2013-N-0662,"Agency Information Collection Activities; Submission for Office of
Management and Budget Review; Comment Request; Applications for
Food and Drug Administration Approval To Market a New Drug— Patent Submission and Listing Requirements"
090000648217555a,Notice,FDA-2013-N-0662-0005,FDA-2013-N-0662,"Agency Information Collection Activities; Submission for Office of
Management and Budget Review; Comment Request; Applications for
Food and Drug Administration Approval To Market a New Drug: Patent Submission and Listing Requirements and Application of 30-Month Stays on Approval of Abbreviated New Drug Applications Certifying That a Patent Claiming a Drug Is Valid or Will Not Be Infringed"
09000064813282d7,Notice,FDA-2013-N-0662-0001,FDA-2013-N-0662,Agency Information Collection Activities: Proposed Collection; Comment Request; Applications for Food and Drug Administration Approval to Market a New Drug:  Patent Submission and Listing Requirements
0900006484c0254a,Other,FDA-2021-P-0767-0001,FDA-2021-P-0767,Citizen Petition from Buchanan Ingersoll and Rooney PC on behalf of Covis Pharma GmbH
0900006484c0257f,Other,FDA-2021-P-0767-0002,FDA-2021-P-0767,Acknowledgment Letter from FDA DMS to Buchanan Ingersoll and Rooney PC on behalf of Covis Pharma GmbH
09000064843181b1,Other,FDA-2018-P-1751-0005,FDA-2018-P-1751,Response Letter from FDA  CDER RegCon Solutions LLC
09000064838750e4,Other,FDA-2018-P-1751-0004,FDA-2018-P-1751,"Interim Response Letter from FDA CDER to RegCon Solutions, LLC."
090000648322c314,Other,FDA-2018-P-1751-0002,FDA-2018-P-1751,"Acknowledgment Letter from FDA DDM to RegCon Solutions, LLC."
090000648322c07b,Supporting & Related Material,FDA-2018-P-1751-0003,FDA-2018-P-1751,Attachment 1- Orange Book_ Approved Drug Products with Therapeutic Equivalence Evaluations
090000648322c079,Other,FDA-2018-P-1751-0001,FDA-2018-P-1751,"Citizen Petition from RegCon Solutions, LLC."
0900006481e96f7a,Other,FDA-2016-P-0769-0001,FDA-2016-P-0769,"Citizen Petition from Empire State Consumer Project, Inc."
0900006481e971a1,Other,FDA-2016-P-0769-0002,FDA-2016-P-0769,"Acknowledgement Letter from FDA DDM to Empire State Consumer Project, Inc."
090000648219de79,Other,FDA-2016-P-0769-0003,FDA-2016-P-0769,"Interim Response Letter from FDA CDER to Empire State Consumer Project, Inc."
0900006482c2ae3a,Other,FDA-2016-P-0769-0007,FDA-2016-P-0769,Final Response Letter from FDA to Empire State Consumer Project Inc
0900006482afbc27,Supporting & Related Material,FDA-2017-P-5370-0005,FDA-2017-P-5370,Footnote 4-relative abuse liability of prescription opiods compared to heroin in morphhine-maintained heroin abusers re Citizen Petition from Dennis Ryll
0900006482afbc29,Supporting & Related Material,FDA-2017-P-5370-0007,FDA-2017-P-5370,Footnote 6-Buprenorphine Induces Ceiling Respiratory Depression but not in Analgesia-British Journal of Anesthesia re Citizen Petition from Dennis Ryll
0900006482afbc2a,Supporting & Related Material,FDA-2017-P-5370-0008,FDA-2017-P-5370,Footnote 7-Buprenorphine Infrequently Found in Fatal Overdoses in New York City-Drug Alcohol Dep re Citizen Petition from Dennis Ryll
0900006482afbc2b,Supporting & Related Material,FDA-2017-P-5370-0009,FDA-2017-P-5370,Footnote 8-Characteristics of Initial Prescription Episodes and liklihood of Long Term Opiod Use- United Staes 2006-2015-Morbidity Mortality Weekly re Citizen Petition from Dennis Ryll
0900006482afbf55,Other,FDA-2017-P-5370-0001,FDA-2017-P-5370,Citizen Petition from Dennis Ryll
09000064839006c2,Other,FDA-2017-P-5370-0013,FDA-2017-P-5370,Withdrawal from Dennis Ryll
0900006482afbc26,Supporting & Related Material,FDA-2017-P-5370-0004,FDA-2017-P-5370,Footnote 3-Twelve reasons for considering buprenorphine as a frontline analgesic re Citizen Petition from Dennis Ryll
0900006482afbf58,Other,FDA-2017-P-5370-0002,FDA-2017-P-5370,Acknowledgement Letter from FDA DDM to Dennis L Ryll
0900006482afbc25,Supporting & Related Material,FDA-2017-P-5370-0003,FDA-2017-P-5370,Footnote 2-opioid pharmacology and pharmacogenetics draft re Citizen Petition from Dennis Ryll
0900006482afbc2c,Supporting & Related Material,FDA-2017-P-5370-0010,FDA-2017-P-5370,Footnote 9-Buprenorphine an Attractive Opiod with Underutilized Potential in Treatment of Chronic Pain-Journal of Pain Research re Citizen Petition from Dennis Ryll
09000064839080d5,Other,FDA-2017-P-5370-0012,FDA-2017-P-5370,Withdrawal Letter from Dennis Ryll
0900006482f6584f,Other,FDA-2017-P-5370-0011,FDA-2017-P-5370,Interim Response from FDA to Dennis Ryll
0900006482afbc28,Supporting & Related Material,FDA-2017-P-5370-0006,FDA-2017-P-5370,Footnote 5-A Double Blind within Subject Comparison of Spontaneous Opiod Witthdrawl from Buprenorphine versus Heroin-opioid pharmacology and pharma re Citizen Petition from Dennis Ryll
090000648249399c,Supporting & Related Material,FDA-2017-P-0494-0005,FDA-2017-P-0494,Annex 3 re Citizen Petition From Navinta LLC
090000648249399a,Supporting & Related Material,FDA-2017-P-0494-0003,FDA-2017-P-0494,Annex 1 re Citizen Petition From Navinta LLC
0900006482493996,Other,FDA-2017-P-0494-0002,FDA-2017-P-0494,Acknowledgment Letter  from FDA DDM to Navinta LLC
090000648249399b,Supporting & Related Material,FDA-2017-P-0494-0004,FDA-2017-P-0494,Annex 2 re Citizen Petition From Navinta LLC
090000648249360e,Other,FDA-2017-P-0494-0001,FDA-2017-P-0494,Citizen Petition From Navinta LLC
0900006481a34e9d,Other,FDA-2014-P-1353-0003,FDA-2014-P-1353,Denial Response from FDA CFSAN to the International Formula Council
090000648186a230,Other,FDA-2014-P-1353-0002,FDA-2014-P-1353,Acknowledgement Letter from FDA/DDM to International Formula Council (IFC)
090000648185fc82,Other,FDA-2014-P-1353-0001,FDA-2014-P-1353,Citizen Petition from International Formula Council (IFC)
0900006481919aa3,Other,FDA-2014-P-1844-0001,FDA-2014-P-1844,Citizen Petition Request from Lachman Consultant Services Inc
0900006481919aa9,Supporting & Related Material,FDA-2014-P-1844-0003,FDA-2014-P-1844,Attachment 1
0900006482499761,Other,FDA-2014-P-1844-0005,FDA-2014-P-1844,Request to Withdraw Petition
0900006481919aaa,Other,FDA-2014-P-1844-0002,FDA-2014-P-1844,Acknowledgement Letter from FDA DDM to Terri Nataline Lachman Consultant Services  Inc
0900006481adc7f4,Other,FDA-2014-P-1844-0004,FDA-2014-P-1844,"Interim Response Letter from FDA CDER to Lachman Consultant Services, Inc."
0900006481d85d6a,Other,FDA-2015-P-4601-0001,FDA-2015-P-4601,Citizen Petition from Frier Levitt
0900006481d85d6e,Other,FDA-2015-P-4601-0002,FDA-2015-P-4601,Acknowledgement Letter from FDA DDM to Frier Levitt
090000648389da87,Other,FDA-2015-P-4601-0005,FDA-2015-P-4601,Letter from FDA CDER to John E. Morrone
0900006481d85d70,Supporting & Related Material,FDA-2015-P-4601-0003,FDA-2015-P-4601,Exhibit A Support Letter from Dr. Patricia Stafford re: Citizen Petition from Frier Levitt
090000648204b84c,Other,FDA-2015-P-4601-0004,FDA-2015-P-4601,Interim Response re: FDA-2015-P-4601
09000064819b0218,Supporting & Related Material,FDA-2015-P-0095-0007,FDA-2015-P-0095,"Attachment 1 Citizen Petition From DuVal and Associates (Leonhard Lang, GmbH)"
09000064819b01f2,Other,FDA-2015-P-0095-0008,FDA-2015-P-0095,"Citizen Petition From DuVal and Associates (Leonhard Lang, GmbH)"
09000064819b021d,Supporting & Related Material,FDA-2015-P-0095-0002,FDA-2015-P-0095,"Attachment 6 Citizen Petition From DuVal and Associates (Leonhard Lang, GmbH)"
09000064819b021a,Supporting & Related Material,FDA-2015-P-0095-0005,FDA-2015-P-0095,"Attachment 3 Citizen Petition From DuVal and Associates (Leonhard Lang, GmbH)"
09000064819b021b,Supporting & Related Material,FDA-2015-P-0095-0004,FDA-2015-P-0095,"Attachment 4 Citizen Petition From DuVal and Associates (Leonhard Lang, GmbH)"
09000064819b021c,Supporting & Related Material,FDA-2015-P-0095-0003,FDA-2015-P-0095,"Attachment 5 Citizen Petition From DuVal and Associates (Leonhard Lang, GmbH)"
09000064819b0219,Supporting & Related Material,FDA-2015-P-0095-0006,FDA-2015-P-0095,"Attachment 2 Citizen Petition From DuVal and Associates (Leonhard Lang, GmbH)"
09000064819b021e,Other,FDA-2015-P-0095-0001,FDA-2015-P-0095,"Acknowledgement Letter From FDA DDM to DuVal and Associates, P.A."
0900006481948c11,Supporting & Related Material,FDA-2014-P-2058-0003,FDA-2014-P-2058,"Attachment 1 FDA Orange Book Listing Citizen Petition From Lachman Consultant Services, Inc."
0900006481948c13,Supporting & Related Material,FDA-2014-P-2058-0005,FDA-2014-P-2058,"Attachment 3 Proposed Labeling Citizen Petition From Lachman Consultant Services, Inc."
0900006481948c14,Other,FDA-2014-P-2058-0002,FDA-2014-P-2058,"Acknowledgement Letter From FDA DDM to Lachman Consultant Services, Inc."
0900006481948c0f,Other,FDA-2014-P-2058-0001,FDA-2014-P-2058,"Citizen Petition From Lachman Consultant Services, Inc."
0900006481948c12,Supporting & Related Material,FDA-2014-P-2058-0004,FDA-2014-P-2058,"Attachment 2 Product Labeling Citizen Petition From Lachman Consultant Services, Inc."
0900006482a8df20,Other,FDA-2017-P-5082-0002,FDA-2017-P-5082,"Acknowledgment Letter from FDA DDM to ChromaDex, Inc."
0900006482f35b2f,Other,FDA-2017-P-5082-0014,FDA-2017-P-5082,"Interim Response Letter from FDA CFSAN to ChromaDex, Inc."
0900006482a8c848,Supporting & Related Material,FDA-2017-P-5082-0003,FDA-2017-P-5082,"Exhibit 1 Elysium Basis Summary Report re Citizen Petition from  ChromaDex, Inc."
0900006482a8c846,Other,FDA-2017-P-5082-0001,FDA-2017-P-5082,"Citizen Petition from  ChromaDex, Inc."
0900006482e15079,Other,FDA-2017-P-5082-0011,FDA-2017-P-5082,"Supplement from Sheldon Bradshaw, King & Spalding LLP"
0900006482be5372,Other,FDA-2017-P-6208-0002,FDA-2017-P-6208,Acknowledgment Letter from FDA DDM to INC Research/inVentiv Health/inVentiv Health
0900006482be5374,Supporting & Related Material,FDA-2017-P-6208-0003,FDA-2017-P-6208,Exhibit 1 Orange Book Listing - Citizen Petition from INC Research/inVentiv Health/inVentiv Health
0900006483146f8c,Other,FDA-2017-P-6208-0004,FDA-2017-P-6208,Interim Response Letter
0900006482be5371,Other,FDA-2017-P-6208-0001,FDA-2017-P-6208,Citizen Petition from INC Research/inVentiv Health/inVentiv Health
0900006484b02546,Other,FDA-2017-P-6208-0005,FDA-2017-P-6208,Withdrawal of Citizen petition for INC Research/inVentiv Health
0900006484b5d305,Other,FDA-2017-P-6208-0006,FDA-2017-P-6208,"Withdrawal from Kinapse, a Syneos Health Company"
0900006480494960,Supporting & Related Material,FDA-2003-D-0309-0002,FDA-2003-D-0309,Guidance
0900006480494923,Notice,FDA-2003-D-0309-0001,FDA-2003-D-0309,FDA
0900006480532c5f,Notice,FDA-2008-D-0229-0001,FDA-2008-D-0229,Guidance for Industry on the Food and Drug Administration Recommendations for Sampling and Testing Yellow Corn and Dry-Milled Yellow Corn Shipments Intended for Human Food Use for Cry9C Protein Residues; Withdrawal of Guidance
0900006480532c37,Notice,FDA-2008-D-0229-0002,FDA-2008-D-0229,EPA White Paper Regarding StarLink[reg]Corn Dietary Exposure and Risk; Availability
0900006480a8e976,Notice,FDA-2010-N-0057-0001,FDA-2010-N-0057,"Agency Information Collection Activities; Proposals, Submissions, and Approvals"
0900006480aef92c,Notice,FDA-2010-N-0057-0002,FDA-2010-N-0057,"Agency Information Collection Activities; Proposals, Submissions, and Approvals: How to Submit Information in Electronic Format to Center for Veterinary Medicine Using FDA Electronic Submission Gateway"
090000648421d9dc,Supporting & Related Material,FDA-2019-P-5943-0006,FDA-2019-P-5943,"Attachment 3 - Draft PI_Redacted re Citizen Petition from Hyman, Phelps & McNamara, P.C."
090000648421d968,Other,FDA-2019-P-5943-0001,FDA-2019-P-5943,"Citizen Petition from Hyman, Phelps & McNamara, P.C."
090000648421d9d9,Supporting & Related Material,FDA-2019-P-5943-0003,FDA-2019-P-5943,"Attachment 1 - Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations re Citizen Petition from Hyman, Phelps & McNamara, P.C."
090000648421d96a,Other,FDA-2019-P-5943-0002,FDA-2019-P-5943,"Acknowledgment Letter from FDA DMS to Hyman, Phelps & McNamara, P.C."
090000648421d9da,Supporting & Related Material,FDA-2019-P-5943-0004,FDA-2019-P-5943,"Attachment 2 - VibraTabs labeling re Citizen Petition from Hyman, Phelps & McNamara, P.C."
090000648421d9db,Supporting & Related Material,FDA-2019-P-5943-0005,FDA-2019-P-5943,"Attachment 3 - Draft PI re Citizen Petition from Hyman, Phelps & McNamara, P.C."
0900006484251331,Supporting & Related Material,FDA-2019-P-6047-0005,FDA-2019-P-6047,"Attachment 3 Fresenius Kabi Proposed Package Insert re Suitability Petition from Fresenius Kabi USA, LLC"
09000064842516ea,Other,FDA-2019-P-6047-0001,FDA-2019-P-6047,"Suitability Petition from Fresenius Kabi USA, LLC"
090000648425132f,Supporting & Related Material,FDA-2019-P-6047-0003,FDA-2019-P-6047,"Attachment 1 Orange Book Listing of Sterile Water for Irrigation re Citizen Petition from Fresenius Kabi USA, LLC"
09000064842516eb,Other,FDA-2019-P-6047-0002,FDA-2019-P-6047,"Acknowledgment Letter from FDA DMS to Fresenius Kabi USA, LLC"
0900006484251330,Supporting & Related Material,FDA-2019-P-6047-0004,FDA-2019-P-6047,"Attachment 2 Reference Listed Drug Labeling Sterile Water for Irrigation USP re Suitability Petition from Fresenius Kabi USA, LLC"
09000064823bccfd,Other,FDA-2016-P-1955-0009,FDA-2016-P-1955,Petition Denial Letter from FDA CDER to Mallinckrodt Pharmaceuticals
0900006482186110,Other,FDA-2016-P-1955-0006,FDA-2016-P-1955,Supplement from Mallinckrodt Pharmaceuticals
0900006482093671,Other,FDA-2016-P-1955-0002,FDA-2016-P-1955,Acknowledgement Letter from FDA DDM to Mallinckrodt Pharmaceuticals
0900006482092dc9,Supporting & Related Material,FDA-2016-P-1955-0003,FDA-2016-P-1955,"Exhibit A - Transcript of Proceedings, Anesthesiology and Respiratory Therapy Devices Panel of the Medical Devices Advisory Committee (Nov. 22, 1996) re Citizen Petition from Mallinckrodt Pharmaceuticals"
0900006482092dca,Supporting & Related Material,FDA-2016-P-1955-0004,FDA-2016-P-1955,"Exhibit B  Lavoie, A. et al., Life-threatening effects of discontinuing inhaled nitric oxide in severe respiratory failure. Am. J. Respir. Crit. Care Med. 1996:153;1985-87 re Citizen Petition from Mallinckrodt Pharmaceuticals"
0900006482092dcb,Supporting & Related Material,FDA-2016-P-1955-0005,FDA-2016-P-1955,"Exhibit C - Import Alert # 89-04, Detention Without Physical Examination of Devices from Firms that Have not met Device Quality System Requirements (March 16, 2016) (Excerpt) re Citizen Petition from Mallinckrodt Pharmaceuticals"
0900006482092dc8,Other,FDA-2016-P-1955-0001,FDA-2016-P-1955,Citizen Petition from Mallinckrodt Pharmaceuticals
0900006483a34134,Other,FDA-2018-P-3401-0010,FDA-2018-P-3401,"Agency Response Letter from FDA CDER to Novo Nordisk, Inc."
0900006483a33c49,Other,FDA-2018-P-3401-0009,FDA-2018-P-3401,"Agency Response Letter from FDA CDER to Novo Nordisk, Inc."
09000064836bcb86,Supporting & Related Material,FDA-2018-P-3401-0006,FDA-2018-P-3401,NovoNordisk_CitizenPetition_05September2018_References_Part_4_of_6 RE: Citizen Petition from Novo Nordisk Inc
09000064836bcba8,Supporting & Related Material,FDA-2018-P-3401-0007,FDA-2018-P-3401,NovoNordisk_CitizenPetition_05September2018_References_Part_5_of_6-1RE: Citizen Petition from Novo Nordisk Inc
09000064836bcba9,Supporting & Related Material,FDA-2018-P-3401-0008,FDA-2018-P-3401,NovoNordisk_CitizenPetition_05September2018_References_Part_6_of_6 RE: Citizen Petition from Novo Nordisk Inc
09000064836bca45,Other,FDA-2018-P-3401-0001,FDA-2018-P-3401,Citizen Petition from Novo Nordisk Inc.
09000064836bce6d,Other,FDA-2018-P-3401-0002,FDA-2018-P-3401,"Acknowledgment Letter from FDA DDM to Novo Nordisk, Inc."
09000064836bcb84,Supporting & Related Material,FDA-2018-P-3401-0004,FDA-2018-P-3401,NovoNordisk_CitizenPetition_05September2018_References_Part_2_of_6-1 RE: Citizen Petition from Novo Nordisk Inc
09000064836bcb85,Supporting & Related Material,FDA-2018-P-3401-0005,FDA-2018-P-3401,NovoNordisk_CitizenPetition_05September2018_References_Part_3_of_6-1RE: Citizen Petition from Novo Nordisk Inc
09000064836bcb83,Supporting & Related Material,FDA-2018-P-3401-0003,FDA-2018-P-3401,NovoNordisk_CitizenPetition_05September2018_References_Part_1_of_6 RE: Citizen Petition from Novo Nordisk Inc
09000064839ec6fa,Other,FDA-2018-P-2749-0003,FDA-2018-P-2749,Interim response from FDA CDER to Anne A. Shirinian-Orlando
090000648351271d,Other,FDA-2018-P-2749-0001,FDA-2018-P-2749,Citizen Petition from Anne A. Shirinian-Orlando
0900006483cea079,Other,FDA-2018-P-2749-0004,FDA-2018-P-2749,Letter from FDA CDER to Anne A. Shirinian-Orlando
090000648351271f,Other,FDA-2018-P-2749-0002,FDA-2018-P-2749,Acknowledgment Letter from FDA DDM to Anne A. Shirinian-Orlando
09000064818422e5,Notice,FDA-2014-P-0549-0003,FDA-2014-P-0549,"Determination That SULAR (Nisoldipine) Extended-Release
Tablets, 10 Milligrams, 20 Milligrams, 25.5 Milligrams, 30 Milligrams, and 40 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or
Effectiveness"
0900006481844a21,Other,FDA-2014-P-0549-0004,FDA-2014-P-0549,Response Letter From FDA CDER to Emcure Pharmaceuticals Inc.
09000064816d4cab,Other,FDA-2014-P-0549-0001,FDA-2014-P-0549,"Citizen Petition From Emcure Pharmaceuticals USA, Inc"
09000064816d575b,Other,FDA-2014-P-0549-0002,FDA-2014-P-0549,Acknowledgement Letter From FDA DDM to Emcure Pharmaceuticals Inc.
09000064816e8840,Other,FDA-2014-P-0603-0002,FDA-2014-P-0603,Acknowledgement Letter From FDA DDM to Pacific Link Consulting
09000064816e883c,Other,FDA-2014-P-0603-0001,FDA-2014-P-0603,Citizen Petition from Pacific Link Consulting
09000064818a85a2,Other,FDA-2014-P-0603-0003,FDA-2014-P-0603,Citizen Petition Denial Response from FDA CDER to Pacific Link Consulting
09000064817202ba,Supporting & Related Material,FDA-2011-P-0610-0009,FDA-2011-P-0610,Attachments A through E Perrigo v. FDA Supplement from AbbVie Inc. Hogan Lovells US LLP
090000648119c7f7,Supporting & Related Material,FDA-2011-P-0610-0004,FDA-2011-P-0610,"Hogan Lovells LLP (behalf of AbbVie, Inc.) - Citizen Petition Supplement"
090000648171fc35,Other,FDA-2011-P-0610-0008,FDA-2011-P-0610,Supplement from AbbVie Inc. Hogan Lovells US LLP
09000064817da617,Other,FDA-2011-P-0610-0010,FDA-2011-P-0610,Petition Approval/Denial from FDA/CDER
0900006480ee6771,Other,FDA-2011-P-0610-0002,FDA-2011-P-0610,"Acknowledgement Letter to Abbott Laboratories (Mayer Brown, LLP)"
09000064814bb904,Other,FDA-2011-P-0610-0005,FDA-2011-P-0610,AbbVie Inc. (Hogan Lovells) - Supplement
0900006480fea041,Other,FDA-2011-P-0610-0003,FDA-2011-P-0610,"FDA/CDER Letter to Mayer Brown LLP, dated February 16, 2012"
0900006480ee676f,Other,FDA-2011-P-0610-0001,FDA-2011-P-0610,"Abbott Laboratories (Mayer Brown, LLP) - Citizen Petition"
0900006482957054,Other,FDA-2017-P-4389-0002,FDA-2017-P-4389,"Acknowledgement Letter from FDA DDM to Wildway, LLC"
0900006482e311db,Other,FDA-2017-P-4389-0003,FDA-2017-P-4389,Interim Response Letter
0900006482957052,Other,FDA-2017-P-4389-0001,FDA-2017-P-4389,"Citizen Petition from Wildway , LLC"
090000648199e0c8,Other,FDA-2015-P-0014-0001,FDA-2015-P-0014,"Citizen Petition From Edward Boshnick, O.D."
090000648199e0ca,Other,FDA-2015-P-0014-0002,FDA-2015-P-0014,"Acknowledgement Letter from FDA DDM to Edward Boshnick, O.D."
0900006481d1b5c8,Other,FDA-2015-P-4131-0003,FDA-2015-P-4131,Acknowledgement Letter from FDA DDM to the University of Florida
0900006481d1b5c0,Other,FDA-2015-P-4131-0001,FDA-2015-P-4131,Citizen Petition from the University of Florida
0900006481fa80f3,Other,FDA-2015-P-4131-0004,FDA-2015-P-4131,Interim Response FDA-2015-P-4131
0900006481d1b6e6,Supporting & Related Material,FDA-2015-P-4131-0002,FDA-2015-P-4131,Reference List re Citizen Petition from University of Florida
0900006482548ae0,Supporting & Related Material,FDA-2017-P-2233-0028,FDA-2017-P-2233,"Attachment 26 -  Lynch, Managing phase down of amalgam part i educational and training issues re Citizen Petition from Consumers for Dental Choice"
09000064825488b3,Supporting & Related Material,FDA-2017-P-2233-0018,FDA-2017-P-2233,"Attachment 16 -  European Commission, Final Report, Review of the Community Strategy Concerning Mercury re Citizen Petition from Consumers for Dental Choice"
09000064825488ba,Supporting & Related Material,FDA-2017-P-2233-0025,FDA-2017-P-2233,"Attachment 23 -  Jones, 30-year follow-up of residual effects on NZ school dental nurses (2007) re Citizen Petition from Consumers for Dental Choice"
09000064825488c6,Supporting & Related Material,FDA-2017-P-2233-0043,FDA-2017-P-2233,"Attachment 41 -  UNEP, Lessons from Countries Phasing Down Dental Amalgam Use re Citizen Petition from Consumers for Dental Choice"
0900006482548869,Supporting & Related Material,FDA-2017-P-2233-0005,FDA-2017-P-2233,"Attachment 3 - Changing Patterns in the Use, Recycling, and Material Substitution of Mercury in the United States re Citizen Petition from Consumers for Dental Choice"
09000064825488b6,Supporting & Related Material,FDA-2017-P-2233-0021,FDA-2017-P-2233,"Attachment 19 -  Haj-Ali, Survey of general dentists regarding posterior restorations, selection criteria, and associated clinical problems re Citizen Petition from Consumers for Dental Choice"
09000064825488b8,Supporting & Related Material,FDA-2017-P-2233-0023,FDA-2017-P-2233,"Attachment 21 -  Hendriks, Cost Benefit Analysis of Direct Posterior Restorations (1985) re Citizen Petition from Consumers for Dental Choice"
09000064825488c0,Supporting & Related Material,FDA-2017-P-2233-0037,FDA-2017-P-2233,"Attachment 35 -  Riley, Components of patient satisfaction with dental restorative visit (2012) re Citizen Petition from Consumers for Dental Choice"
09000064825488c5,Supporting & Related Material,FDA-2017-P-2233-0042,FDA-2017-P-2233,Attachment 40 -  The Real Cost of Dental Mercury re Citizen Petition from Consumers for Dental Choice
0900006482548ae1,Supporting & Related Material,FDA-2017-P-2233-0029,FDA-2017-P-2233,"Attachment 27 -  Lynch, Minimally-invasive management of dental caries in dental schools re Citizen Petition from Consumers for Dental Choice"
0900006482548ae2,Supporting & Related Material,FDA-2017-P-2233-0030,FDA-2017-P-2233,"Attachment 28 -  Mandari, Six-year success rates of occlusal amalgam and glass-ionomer restorations placed using minial intervention approaches (20 re Citizen Petition from Consumers for Dental Choice"
090000648254b121,Supporting & Related Material,FDA-2017-P-2233-0050,FDA-2017-P-2233,"Attachment 48 - Swedish Chemicals Agency, Mercury Phase-out, a study of the experience of Swedish companies re Citizen Petition from Consumer for Dental Choice"
0900006482548ad2,Supporting & Related Material,FDA-2017-P-2233-0006,FDA-2017-P-2233,"Attachment 4 -  da Mata, Cost-effectiveness of ART restorations in elderly adults re Citizen Petition from Consumers for Dental Choice"
0900006482548ad9,Supporting & Related Material,FDA-2017-P-2233-0013,FDA-2017-P-2233,Attachment 11 -  Environmental costs of mercury pollution re Citizen Petition from Consumers for Dental Choice
0900006482548adb,Supporting & Related Material,FDA-2017-P-2233-0015,FDA-2017-P-2233,Attachment 13 -  EPA Will Propose Rule to Protect Waterways by Reducing Mercury from Dental Offices re Citizen Petition from Consumers for Dental Choice
0900006482548ade,Supporting & Related Material,FDA-2017-P-2233-0026,FDA-2017-P-2233,"Attachment 24 -  Lei Yin, Associations of blood mercury, inorganic mercury, methyl mercury etc_ (2016) re Citizen Petition from Consumers for Dental Choice"
0900006482548adf,Supporting & Related Material,FDA-2017-P-2233-0027,FDA-2017-P-2233,Attachment 25 -  Letter to Secretary John Kerry (21 September 2015) re Citizen Petition from Consumers for Dental Choice
0900006482548ae3,Supporting & Related Material,FDA-2017-P-2233-0031,FDA-2017-P-2233,"Attachment 29 -  Mickenautsch, Comparative cost of ART and conventional treatment within a dental school clinic (2009) re Citizen Petition from Consumers for Dental Choice"
0900006482548af1,Supporting & Related Material,FDA-2017-P-2233-0048,FDA-2017-P-2233,"Attachment 46 -  Zanata, Ten-year survival of ART restorations in permanent posterior teeth (2011) re Citizen Petition from Consumers for Dental Choice"
09000064825488c4,Supporting & Related Material,FDA-2017-P-2233-0041,FDA-2017-P-2233,"Attachment 39 -  Swedish Chemicals Agency, Dental amalgam, prohibition to use dental amalgam re Citizen Petition from Consumers for Dental Choice"
0900006482548ad6,Supporting & Related Material,FDA-2017-P-2233-0010,FDA-2017-P-2233,"Attachment 8 -  Dentsply, Annual Report per SEC Form 10-K (31 Dec_ 2014) re Citizen Petition from Consumers for Dental Choice"
0900006482548ad8,Supporting & Related Material,FDA-2017-P-2233-0012,FDA-2017-P-2233,"Attachment 10 -  Duplinsky _ Cicchetti, Health status of dentists exposed to mercury from amalgam tooth resotrations (2012) re Citizen Petition from Consumers for Dental Choice"
0900006482548ada,Supporting & Related Material,FDA-2017-P-2233-0014,FDA-2017-P-2233,Attachment 12 -  EPA Health Services Industry Detailed Study -- Dental Amalgam (2008) re Citizen Petition from Consumers for Dental Choice
0900006482548ae7,Supporting & Related Material,FDA-2017-P-2233-0035,FDA-2017-P-2233,"Attachment 33 -  Opdam, Longevity of repaired restorations (copy) re Citizen Petition from Consumers for Dental Choice"
090000648254b122,Supporting & Related Material,FDA-2017-P-2233-0051,FDA-2017-P-2233,Attachment 49 - Minamata Convention (2013) re Citizen Petition from Consumers for Dental Choice
0900006484973ddc,Other,FDA-2020-P-1878-0004,FDA-2020-P-1878,Withdrawal from Foley & Lardner LLP
0900006484864d65,Other,FDA-2020-P-1878-0001,FDA-2020-P-1878,"Citizen Petition from Foley & Lardner, LLP"
0900006484864d66,Other,FDA-2020-P-1878-0002,FDA-2020-P-1878,Acknowledgment Letter from FDA DMS to Foley & Lardner LLP
0900006484864d69,Supporting & Related Material,FDA-2020-P-1878-0003,FDA-2020-P-1878,"Attachment A re Citizens Petition from Foley & Lardner, LLP"
0900006483269f66,Other,FDA-2018-P-1892-0002,FDA-2018-P-1892,"Acknowledgment Letter from FDA DDM to Aurobindo Pharma USA, Inc"
090000648423c423,Other,FDA-2018-P-1892-0004,FDA-2018-P-1892,"Petition Response Letter from FDA CDER to Aurobindo Pharma USA, Inc"
0900006483269f61,Other,FDA-2018-P-1892-0001,FDA-2018-P-1892,"Citizen Petiton from Aurobindo Pharma USA, Inc"
0900006483a0d2f4,Other,FDA-2018-P-1892-0003,FDA-2018-P-1892,"Interim response  from FDA CDER to  Aurobindo Pharma USA, Inc"
0900006484aeb26a,Other,FDA-2020-P-2060-0003,FDA-2020-P-2060,Interim Response from FDA CDRH to Penn Avenue Law & Policy
09000064848ecb69,Other,FDA-2020-P-2060-0001,FDA-2020-P-2060,Citizen Petition from Penn Avenue Law & Policy
09000064848ed38f,Other,FDA-2020-P-2060-0002,FDA-2020-P-2060,Acknowledgment Letter from FDA DMS to Penn Avenue Law & Policy
0900006480487234,Notice,FDA-2003-D-0151-0001,FDA-2003-D-0151,FDA
090000648043f2ff,Notice,FDA-2005-D-0071-0001,FDA-2005-D-0071,FDA
090000648043f301,Supporting & Related Material,FDA-2005-D-0071-0003,FDA-2005-D-0071,Guideline
090000648043f300,Supporting & Related Material,FDA-2005-D-0071-0002,FDA-2005-D-0071,Guideline
090000648149dd68,Other,FDA-2008-P-0486-0004,FDA-2008-P-0486,FDA/CDER Memorandum to File Withdrawal of Citizens Petition
09000064808ea89b,Other,FDA-2008-P-0486-0003,FDA-2008-P-0486,FDA/CDER Interim Response to Norman Lefkovitz - Letter
09000064806f0fcb,Other,FDA-2008-P-0486-0002,FDA-2008-P-0486,"Acknowledgement Letter to Norman W. Lefkovitz, M.D."
09000064806f0f80,Other,FDA-2008-P-0486-0001,FDA-2008-P-0486,"Norman W. Lefkovitz, M.D. - Citizen Petition"
0900006480ae71e4,Notice,FDA-2009-N-0486-0003,FDA-2009-N-0486,"Agency Information Collection Activities; Proposals, Submissions, and Approvals: Fiscal Year 2010 Medical Device User Fee Small Business Qualification and Certification"
0900006480a49ad9,Notice,FDA-2009-N-0486-0001,FDA-2009-N-0486,"Agency Information Collection Activities; Proposals, Submissions, and Approvals"
0900006480a7f62f,Notice,FDA-2009-N-0486-0002,FDA-2009-N-0486,"Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Guidance for Industry, FDA, and Foreign Governments: Fiscal Year 2010 Medical Device User Fee Small Business Qualification and Certification"
0900006483abc6f2,Other,FDA-2018-P-3413-0003,FDA-2018-P-3413,Letter from FDA CDER to Pharmaceutical R & D and QA Consulting Services
0900006484dc3c57,Other,FDA-2018-P-3413-0004,FDA-2018-P-3413,Withdrawal letter from Pharmaceutical R & D and QA Consulting Services to FDA CDER
09000064836cacf8,Other,FDA-2018-P-3413-0001,FDA-2018-P-3413,Citizen Petition from Pharmaceutical R&D and QA Consulting Services on behalf of Centaur Pharmaceuticals Private Limited
09000064836cacfa,Other,FDA-2018-P-3413-0002,FDA-2018-P-3413,Acknowledgment Letter from FDA DDM to Pharmaceutical R&D and QA Consulting Services on behalf of Centaur Pharmaceuticals Private Limited
0900006484aa000d,Other,FDA-2021-P-0358-0001,FDA-2021-P-0358,Citizen Petition from Nexus Pharmaceuticals Inc.
0900006484aa0182,Other,FDA-2021-P-0358-0002,FDA-2021-P-0358,Acknowledgment Letter from FDA DMS to Nexus Pharmaceuticals Inc.
0900006484dba3bc,Other,FDA-2021-P-0358-0005,FDA-2021-P-0358,"Interim Response Letter from FDA CDER to Nexus Pharmaceuticals, Inc."
09000064825310b3,Other,FDA-2016-P-3082-0014,FDA-2016-P-3082,Interim Response Letter from FDA CDER to  Ropes & Gray LLP (Pfizer Inc.)
090000648228e03d,Other,FDA-2016-P-3082-0002,FDA-2016-P-3082,Acknowledgment Letter from FDA DDM to  Ropes & Gray LLP (Pfizer Inc.)
0900006482535a32,Supporting & Related Material,FDA-2016-P-3082-0017,FDA-2016-P-3082,Exhibit 2 to Supplement to CP from Ropes & Gray LLP (Pfizer Inc.) to FDA CDER
0900006482535a37,Supporting & Related Material,FDA-2016-P-3082-0022,FDA-2016-P-3082,Exhibit 7 to Supplement to CP from Ropes & Gray LLP (Pfizer Inc.) to FDA CDER
090000648228e78c,Supporting & Related Material,FDA-2016-P-3082-0004,FDA-2016-P-3082,Exhibit 2 Citizen Petition re Citizen Petition from Ropes & Gray LLP (Pfizer Inc.)
090000648228e78d,Supporting & Related Material,FDA-2016-P-3082-0005,FDA-2016-P-3082,Exhibit 3 CITIZEN PETITION re Citizen Petition from Ropes & Gray LLP (Pfizer Inc.)
0900006482286d0e,Other,FDA-2016-P-3082-0001,FDA-2016-P-3082,Citizen Petition from Ropes & Gray LLP (Pfizer Inc.)
09000064826b9ca8,Other,FDA-2016-P-3082-0026,FDA-2016-P-3082,Petition Approval from FDA CDER  to Ropes & Gray LLp
090000648228e78b,Supporting & Related Material,FDA-2016-P-3082-0003,FDA-2016-P-3082,Exhibit 1 CITIZEN PETITION re Citizen Petition from Ropes & Gray LLP (Pfizer Inc.)
0900006482531b64,Other,FDA-2016-P-3082-0025,FDA-2016-P-3082,Supplement from Pfizer Inc. (Ropes & Gray LLP)
090000648228e9fd,Supporting & Related Material,FDA-2016-P-3082-0009,FDA-2016-P-3082,"Exhibit 7 COMPLAINT FOR DECLARATORY, INJUNCTIVE, AND OTHER RELIEF re Citizen Petition from Ropes & Gray LLP (Pfizer Inc.)"
090000648228e9fe,Supporting & Related Material,FDA-2016-P-3082-0010,FDA-2016-P-3082,Exhibit 8 MEMORANDUM OPINION re Citizen Petition from Ropes & Gray LLP (Pfizer Inc.)
090000648228e9ff,Supporting & Related Material,FDA-2016-P-3082-0011,FDA-2016-P-3082,Exhibit 9 combined response to two petitions re Citizen Petition from Ropes & Gray LLP (Pfizer Inc.)
090000648228ea01,Supporting & Related Material,FDA-2016-P-3082-0013,FDA-2016-P-3082,"Exhibit 11 MEMORANDUM OF POINTS AND AUTHORITIES IN SUPPORT OF
PLAINTIFF’S MOTION FOR RECONSIDERATION re Citizen Petition from Ropes & Gray LLP (Pfizer Inc.)"
0900006482535b47,Other,FDA-2016-P-3082-0015,FDA-2016-P-3082,Supplement to CP from Ropes & Gray LLP (Pfizer Inc.) to FDA CDER
090000648228e9fa,Supporting & Related Material,FDA-2016-P-3082-0006,FDA-2016-P-3082,Exhibit 4 combined response  to three citizen petitions re Citizen Petition from Ropes & Gray LLP (Pfizer Inc.)
090000648228e9fc,Supporting & Related Material,FDA-2016-P-3082-0008,FDA-2016-P-3082,Exhibit 6 response to the citizen petition re Citizen Petition from Ropes & Gray LLP (Pfizer Inc.)
090000648228e9fb,Supporting & Related Material,FDA-2016-P-3082-0007,FDA-2016-P-3082,Exhibit 5 CITIZEN PETITION re Citizen Petition from Ropes & Gray LLP (Pfizer Inc.)
090000648228ea00,Supporting & Related Material,FDA-2016-P-3082-0012,FDA-2016-P-3082,Exhibit 10 MEMORANDUM OPINION re Citizen Petition from Ropes & Gray LLP (Pfizer Inc.)
0900006482535a33,Supporting & Related Material,FDA-2016-P-3082-0018,FDA-2016-P-3082,Exhibit 3 to Supplement to CP from Ropes & Gray LLP (Pfizer Inc.) to FDA CDER
090000648253590a,Supporting & Related Material,FDA-2016-P-3082-0016,FDA-2016-P-3082,Exhibit 1 to Supplement to CP from Ropes & Gray LLP (Pfizer Inc.) to FDA CDER
0900006482535a36,Supporting & Related Material,FDA-2016-P-3082-0021,FDA-2016-P-3082,Exhibit 6 to Supplement to CP from Ropes & Gray LLP (Pfizer Inc.) to FDA CDER
0900006482535a38,Supporting & Related Material,FDA-2016-P-3082-0023,FDA-2016-P-3082,Exhibit 8 to Supplement to CP from Ropes & Gray LLP (Pfizer Inc.) to FDA CDER
0900006482535a34,Supporting & Related Material,FDA-2016-P-3082-0019,FDA-2016-P-3082,Exhibit 4 to Supplement to CP from Ropes & Gray LLP (Pfizer Inc.) to FDA CDER
0900006482535a35,Supporting & Related Material,FDA-2016-P-3082-0020,FDA-2016-P-3082,Exhibit 5 to Supplement to CP from Ropes & Gray LLP (Pfizer Inc.) to FDA CDER
09000064836b2051,Supporting & Related Material,FDA-2017-P-6029-0027,FDA-2017-P-6029,NovoNordisk_CitizenPetition_05September2018_References_Part_3_of_6-1RE: Citizen Petition from Novo Nordisk Inc
09000064836b2052,Supporting & Related Material,FDA-2017-P-6029-0028,FDA-2017-P-6029,NovoNordisk_CitizenPetition_05September2018_References_Part_4_of_6 RE: Citizen Petition from Novo Nordisk Inc
0900006482b9d399,Supporting & Related Material,FDA-2017-P-6029-0003,FDA-2017-P-6029,References List re Citizen Petition from Novo Nordisk Inc
0900006482b9d39a,Supporting & Related Material,FDA-2017-P-6029-0004,FDA-2017-P-6029,Reference 1 Challenges in Industrial Prodcution re Citizen Petition from Novo Nordisk Inc
0900006482b9d39d,Supporting & Related Material,FDA-2017-P-6029-0007,FDA-2017-P-6029,Reference 4 Strategies for the Assessment of Protein Aggregates re Citizen Petition from Novo Nordisk Inc
0900006482b9d3aa,Supporting & Related Material,FDA-2017-P-6029-0013,FDA-2017-P-6029,Reference 10 Stability of Protein Pharmaceuticals Manning 2010 re Citizen Petition from Novo Nordisk Inc
0900006482b9d3ad,Supporting & Related Material,FDA-2017-P-6029-0016,FDA-2017-P-6029,Reference 13 Observations regarding the immunogenicity Sauna 2012 re Citizen Petition from Novo Nordisk Inc
09000064836b204f,Supporting & Related Material,FDA-2017-P-6029-0025,FDA-2017-P-6029,NovoNordisk_CitizenPetition_05September2018_References_Part_1_of_6 RE: Citizen Petition from Novo Nordisk Inc
09000064836b2053,Supporting & Related Material,FDA-2017-P-6029-0029,FDA-2017-P-6029,NovoNordisk_CitizenPetition_05September2018_References_Part_5_of_6-1 RE: Citizen Petition from Novo Nordisk Inc
09000064836b2054,Supporting & Related Material,FDA-2017-P-6029-0030,FDA-2017-P-6029,NovoNordisk_CitizenPetition_05September2018_References_Part_6_of_6 RE: Citizen Petition from Novo Nordisk Inc
0900006482b9d39e,Supporting & Related Material,FDA-2017-P-6029-0008,FDA-2017-P-6029,Reference 5 European Medicines Agency 2009 re Citizen Petition from Novo Nordisk Inc
0900006482d9e58c,Other,FDA-2017-P-6029-0022,FDA-2017-P-6029,"Response Letter from FDA CDER to Novo Nordisk, Inc"
09000064836b1f49,Other,FDA-2017-P-6029-0024,FDA-2017-P-6029,Acknowledgment  Letter from FDA DDM to Novo Nordisk Inc
0900006482b9d3a7,Supporting & Related Material,FDA-2017-P-6029-0010,FDA-2017-P-6029,Reference 7 FDA_Regulatory Considerations for Peptide Drug Products PPT re Citizen Petition from Novo Nordisk Inc
0900006482b9d39b,Supporting & Related Material,FDA-2017-P-6029-0005,FDA-2017-P-6029,Reference 2 Protein Aggregation and Bioprocessing Cromwell 2005 re Citizen Petition from Novo Nordisk Inc
0900006482b9d39c,Supporting & Related Material,FDA-2017-P-6029-0006,FDA-2017-P-6029,Reference 3 Pharmacokinetics re Citizen Petition from Novo Nordisk Inc
0900006482b9d3ac,Supporting & Related Material,FDA-2017-P-6029-0015,FDA-2017-P-6029,Reference 12 Quantitative predictions Nielsen 2008 re Citizen Petition from Novo Nordisk Inc
0900006482b9d3b0,Supporting & Related Material,FDA-2017-P-6029-0019,FDA-2017-P-6029,Reference 16 The Molecular Basis Steensgaard 2008 re Citizen Petition from Novo Nordisk Inc
0900006482b9d6e2,Supporting & Related Material,FDA-2017-P-6029-0021,FDA-2017-P-6029,Reference 18 The opposite effects of Cu Zhou 2012 re Citizen Petition from Novo Nordisk Inc
09000064836b2050,Supporting & Related Material,FDA-2017-P-6029-0026,FDA-2017-P-6029,NovoNordisk_CitizenPetition_05September2018_References_Part_2_of_6-1RE: Citizen Petition from Novo Nordisk Inc
09000064836b19b7,Other,FDA-2017-P-6029-0023,FDA-2017-P-6029,Citizen Petition from Novo Nordisk Inc.
0900006482b9d39f,Supporting & Related Material,FDA-2017-P-6029-0009,FDA-2017-P-6029,Reference 6 FDA_ Salmon Calcitonin CP Response re Citizen Petition from Novo Nordisk Inc
0900006482b9d3a8,Supporting & Related Material,FDA-2017-P-6029-0011,FDA-2017-P-6029,Reference 8 Characterization of seed nuclei Hoppe 2008 re Citizen Petition from Novo Nordisk Inc
0900006482b9d3af,Supporting & Related Material,FDA-2017-P-6029-0018,FDA-2017-P-6029,Reference 15 Statement by Janet Woodcock 2007 re Citizen Petition from Novo Nordisk Inc
0900006482b9d6e1,Supporting & Related Material,FDA-2017-P-6029-0020,FDA-2017-P-6029,Reference 17 The FDAs assessment Woodcock 2007 re Citizen Petition from Novo Nordisk Inc
0900006483c1c9ef,Other,FDA-2019-P-2070-0001,FDA-2019-P-2070,"Citizen Petition from TechReg Services, Inc."
0900006483c1cae2,Other,FDA-2019-P-2070-0002,FDA-2019-P-2070,"Acknowledgment Letter from FDA DDM to TechReg Services, Inc."
09000064819c8794,Other,FDA-2014-P-1694-0004,FDA-2014-P-1694,Suitability Petition Denial Response Letter from FDA CVM to Parnell Corporate Services US Inc
09000064818f8811,Other,FDA-2014-P-1694-0001,FDA-2014-P-1694,Suitability Citizen Petition from Parnell Corporate Services US Inc
09000064818f8db0,Other,FDA-2014-P-1694-0002,FDA-2014-P-1694,Acknowledgement Letter form FDA DDM  to Parnell Corporate Services US Inc
09000064818f8db2,Supporting & Related Material,FDA-2014-P-1694-0003,FDA-2014-P-1694,Appendix 1
0900006481a4e50a,Other,FDA-2015-P-0840-0002,FDA-2015-P-0840,Acknowledgment Letter from FDA DDM to Dr. Richard Sherman
0900006481a4e50e,Supporting & Related Material,FDA-2015-P-0840-0005,FDA-2015-P-0840,"Attachment 3  Table of Phosphate Content of Selected Prescription Medications, Citizen Petition From Dr. Richard Sherman"
0900006481a4e50c,Supporting & Related Material,FDA-2015-P-0840-0003,FDA-2015-P-0840,"Attachement 1 KI Dearth of data, Citizen Petition From Dr. Richard Sherman"
0900006481a4e50d,Supporting & Related Material,FDA-2015-P-0840-0004,FDA-2015-P-0840,"Attachment 2 Phosphorus Content in Prescrip Medications New Considerations, Citizen Petition From Dr. Richard Sherman"
0900006481a4e508,Other,FDA-2015-P-0840-0001,FDA-2015-P-0840,Citizen Petition From Dr. Richard Sherman
0900006481c6d887,Other,FDA-2015-P-0840-0023,FDA-2015-P-0840,Interim Response Letter from FDA CDER to Dr. Richard Sherman
0900006483618f6b,Other,FDA-2015-P-1201-0014,FDA-2015-P-1201,Report from Tate & Lyle
0900006481aa26d0,Other,FDA-2015-P-1201-0001,FDA-2015-P-1201,Citizen Petition from Tate & Lyle
0900006481aa22eb,Supporting & Related Material,FDA-2015-P-1201-0003,FDA-2015-P-1201,"Appendix A - Metabolism Study, Metabolism StudySnopsis Report re Citizen Petition from Tate & Lyle"
0900006481aa239c,Supporting & Related Material,FDA-2015-P-1201-0005,FDA-2015-P-1201,"Appendix C - Consumer and Health Professional Research, Qualitative Consumer Group Researh, Health Professional Quantitative Study, Consumer Quantitative Label Test re Citizen Petition from Tate & Lyle"
0900006481aa239b,Supporting & Related Material,FDA-2015-P-1201-0004,FDA-2015-P-1201,"Appendix B - Glycemic Studies, Glycemic Response Allulose Study1, Glycemic Response Allulose Study 2 re Citizen Petition from Tate & Lyle"
0900006481aa22e8,Other,FDA-2015-P-1201-0002,FDA-2015-P-1201,Acknowledgement Letter From FDA DDM to Tate & Lyle
09000064836473ce,Other,FDA-2015-P-1201-0015,FDA-2015-P-1201,Supplement from Matsutani Chemical Industry Co. Ltd.
0900006481e997d7,Other,FDA-2015-P-1201-0011,FDA-2015-P-1201,Interim Response Letter from FDA CFSAN to Tate & Lyle
0900006481aa239d,Supporting & Related Material,FDA-2015-P-1201-0006,FDA-2015-P-1201,"Appendix D - Previously Granted Labeling Exemptions, 61 Fed Red 3126 (Olestra), 61 Fed Red 42754 (Orange Roughty) re Citizen Petition from Tate & Lyle"
0900006481a85a5a,Supporting & Related Material,FDA-2015-P-1050-0007,FDA-2015-P-1050,"Exhibit 5 2010 Copax Petition, Citizen Petition From Teva Pharmaceuticals"
0900006481a85e3f,Supporting & Related Material,FDA-2015-P-1050-0011,FDA-2015-P-1050,"Exhibit 7 2013 Copax Colloid Citizen Petition, Citizen Petition From Teva Pharmaceuticals"
0900006481aa98bf,Other,FDA-2015-P-1050-0012,FDA-2015-P-1050,Citizen Petition Denial Letter From CDER to Teva Pharmaceuticals
0900006481a85a54,Other,FDA-2015-P-1050-0002,FDA-2015-P-1050,Acknowledgement Letter from FDA DDM to Teva Pharmaceuticals
0900006481a85a5b,Supporting & Related Material,FDA-2015-P-1050-0010,FDA-2015-P-1050,"Exhibit 6 2012 Copax Petition, Citizen Petition From Teva Pharmaceuticals"
0900006481a85a59,Supporting & Related Material,FDA-2015-P-1050-0006,FDA-2015-P-1050,"Exhibit 4 2009 Copax Petition, Citizen Petition From Teva Pharmaceuticals"
0900006481a85e40,Supporting & Related Material,FDA-2015-P-1050-0008,FDA-2015-P-1050,"Exhibit 8 2013 Copax Petition, Citizen Petition From Teva Pharmaceuticals"
0900006481a85e41,Supporting & Related Material,FDA-2015-P-1050-0009,FDA-2015-P-1050,"Exhibit 9 2014 Copax Petition, Citizen Petition From Teva Pharmaceuticals"
0900006481a85a58,Supporting & Related Material,FDA-2015-P-1050-0005,FDA-2015-P-1050,"Exhibit 3 2008 Petition, Citizen Petition From Teva Pharmaceuticals"
0900006481a859af,Other,FDA-2015-P-1050-0001,FDA-2015-P-1050,Citizen Petition From Teva Pharmaceuticals
0900006481a85a56,Supporting & Related Material,FDA-2015-P-1050-0003,FDA-2015-P-1050,Exhibit 1 FDA June 9 Letter Citizen Petition From Teva Pharmaceuticals
0900006481a85a57,Supporting & Related Material,FDA-2015-P-1050-0004,FDA-2015-P-1050,"Exhibit 2 FDA Response to 2014 Copax Petition, Citizen Petition From Teva Pharmaceuticals"
0900006481b3f4ed,Supporting & Related Material,FDA-2015-P-2141-0003,FDA-2015-P-2141,Controlled Correspondence 188990 re Citizen Petition From Heritage Pharma Labs Inc.
0900006481d8b2a1,Other,FDA-2015-P-2141-0004,FDA-2015-P-2141,"Interim Response Letter from FDA CDER to Heritage Pharma Labs, Inc."
0900006481b2ba22,Other,FDA-2015-P-2141-0001,FDA-2015-P-2141,Citizen Petition from Heritage Pharma Labs Inc
0900006481b2c5a2,Other,FDA-2015-P-2141-0002,FDA-2015-P-2141,Acknowledgement Letter from FDA DDM to Heritage Pharma Labs Inc
0900006481ecbef3,Other,FDA-2015-P-4945-0003,FDA-2015-P-4945,Interim Response Letter from FDA CDRH to Mr. Ryszard Rokicki
0900006481dbe6dc,Other,FDA-2015-P-4945-0001,FDA-2015-P-4945,Citizen Petition from Ryszard Rokicki
0900006481dbe6dd,Other,FDA-2015-P-4945-0002,FDA-2015-P-4945,Acknowledgement Letter from FDA DDM to Ryszard Rokicki
090000648327a722,Other,FDA-2015-P-4945-0008,FDA-2015-P-4945,Letter from FDA CDRH to Mr. Ryszard Rokicki
09000064819de45f,Supporting & Related Material,FDA-2015-P-0233-0007,FDA-2015-P-0233,Attachment 5 Skin Lightening and Beauty in Four Asian Cultures Citizen Petition From the Madison Company
09000064819de461,Supporting & Related Material,FDA-2015-P-0233-0009,FDA-2015-P-0233,Attachment 7 WSJ Women Embrace the No Makeup Look Citizen Petition From the Madison Company
0900006481b818b6,Other,FDA-2015-P-0233-0010,FDA-2015-P-0233,Interim Response Letter from FDA CDER to the Madison Company
09000064819de459,Other,FDA-2015-P-0233-0001,FDA-2015-P-0233,Citizen Petition From the Madison Company
09000064819de45d,Supporting & Related Material,FDA-2015-P-0233-0005,FDA-2015-P-0233,Attachment 3 Galderma Receives FDA Approval of Mirvaso Citizen Petition From the Madison Company
09000064819de45b,Supporting & Related Material,FDA-2015-P-0233-0003,FDA-2015-P-0233,Attachment 1 Achieving an Even Skin Tone Citizen Petition From The Madison Company
09000064819de460,Supporting & Related Material,FDA-2015-P-0233-0008,FDA-2015-P-0233,Attachment 6 Top Five Beauty Trends in 2014 Euromonitor Citizen Petition From the Madison Company
09000064819de45e,Supporting & Related Material,FDA-2015-P-0233-0006,FDA-2015-P-0233,"Attachment 4 Grammer K, Fink B, Matts P Visible skin color distribution Citizen Petition From the Madison Company"
09000064819de45c,Supporting & Related Material,FDA-2015-P-0233-0004,FDA-2015-P-0233,Attachment 2 Final Tone 2 by P&G Citizen Petition From The Madison Company
09000064819ded84,Other,FDA-2015-P-0233-0002,FDA-2015-P-0233,Acknowledgement Letter From FDA DDM to the Madison Company
0900006483908721,Other,FDA-2018-P-4549-0001,FDA-2018-P-4549,"Citizen Petition from Unichem Pharmaceuticals (USA), Inc."
09000064845072cd,Other,FDA-2018-P-4549-0009,FDA-2018-P-4549,"Response Letter from FDA CDER to Unichem Pharmaceuticals, Inc"
0900006483cc25c8,Other,FDA-2018-P-4549-0007,FDA-2018-P-4549,Interim Response Letter for FDA-2018-P-4549
0900006483908a4e,Supporting & Related Material,FDA-2018-P-4549-0006,FDA-2018-P-4549,"Exhibit 4 - IMS data from January 2018 through September 2018 for Terbinafine Tablets, 250 mg re: Citizen Petition from Unichem Pharmaceuticals (USA), Inc."
0900006483908a4c,Supporting & Related Material,FDA-2018-P-4549-0004,FDA-2018-P-4549,"Exhibit-2  - Current and Resolved Drug Shortages and Discontinuations Reported to FDA: Reference for Discontinuation ofLamisil Tablets, 250 mgre: Citizen Petition from Unichem Pharmaceuticals (USA), Inc."
0900006483908a0e,Supporting & Related Material,FDA-2018-P-4549-0003,FDA-2018-P-4549,"Exhibit-1 - Screenshot of the electric Orange Book search results for Lamisi!® Tablets (RLD/RS)  re: Citizen Petition from Unichem Pharmaceuticals (USA), Inc."
090000648390e01b,Other,FDA-2018-P-4549-0002,FDA-2018-P-4549,"Acknowledgment Letter from FDA DDM to Unichem Pharmaceuticals (USA), Inc."
0900006483908a4d,Supporting & Related Material,FDA-2018-P-4549-0005,FDA-2018-P-4549,"Exhibit-3 - Screenshot of the electronic Orange Book search results for Terbinafine Tablets, 250 mg (Aurobindo's ANDA) re: Citizen Petition from Unichem Pharmaceuticals (USA), Inc."
09000064824df0f2,Other,FDA-2017-P-1226-0002,FDA-2017-P-1226,"Acknowledgement Letter from FDA DDM to INRange Systems, Inc"
09000064824df0f0,Other,FDA-2017-P-1226-0001,FDA-2017-P-1226,"Citizen Petition from INRange Systems, Inc"
0900006482bc4d7a,Other,FDA-2017-P-1226-0004,FDA-2017-P-1226,Denial Response from FDA CDRH to INRange Systems Inc
09000064824df0f4,Supporting & Related Material,FDA-2017-P-1226-0003,FDA-2017-P-1226,"Exhibit A Live Product Information re Citizen Petition from INRange Systems, Inc"
0900006483269d4e,Other,FDA-2018-P-1891-0002,FDA-2018-P-1891,"Acknowledgment Letter from FDA DDM to PuraCap Pharmaceutical, LLC"
09000064832698fd,Other,FDA-2018-P-1891-0001,FDA-2018-P-1891,"Citizen Petition from PuraCap Pharmaceutical, LLC on behalf of Epic Pharma, LLC"
0900006483269d50,Supporting & Related Material,FDA-2018-P-1891-0003,FDA-2018-P-1891,"Attachment 1 Orange Book re Citizen Petition from PuraCap Pharmaceutical, LLC on behalf of Epic Pharma, LLC"
0900006481ca49ca,Other,FDA-2015-P-3410-0002,FDA-2015-P-3410,Acknowledgement Letter from FDA DDM to David Cundiff
0900006481edaf6a,Other,FDA-2015-P-3410-0003,FDA-2015-P-3410,Interim Response from FDA CDER to David K. Cundiff
0900006481c9e5fb,Other,FDA-2015-P-3410-0001,FDA-2015-P-3410,Citizen Petition from David K Cundiff
090000648490b118,Other,FDA-2015-P-3410-0004,FDA-2015-P-3410,Response Letter from FDA CDER to Dr. David K. Cundiff
09000064844b98b3,Other,FDA-2012-P-0153-0004,FDA-2012-P-0153,Citizen Petition Denial Response Letter from FDA CDRH to Intertek
0900006480fb6e80,Other,FDA-2012-P-0153-0002,FDA-2012-P-0153,Acknowledgement Letter to Intertek
0900006480fb6333,Other,FDA-2012-P-0153-0001,FDA-2012-P-0153,Intertek - Citizen Petition
090000648136f1dc,Other,FDA-2012-P-0153-0003,FDA-2012-P-0153,FDA CDRH Letter to lntertek Third Party Program - Interim Response
090000648494c340,Other,FDA-2020-P-2166-0002,FDA-2020-P-2166,"Acknowledgment Letter from FDA DMS to Emprise Pharma, LLC on behalf of New Time Pharmaceutical Co Ltd"
090000648494d236,Supporting & Related Material,FDA-2020-P-2166-0005,FDA-2020-P-2166,"Reference 3 Pharmacokinetic Properties of a New Controlled-Release Formulation of Carvedilol re Suitability Petition from Emprise Pharma LLC, on behalf of New Time Pharmaceutical Co, Ltd"
090000648494d237,Supporting & Related Material,FDA-2020-P-2166-0006,FDA-2020-P-2166,"Reference 4 US Patent 8101209B2 re Suitability Petition from Emprise Pharma LLC, on behalf of New Time Pharmaceutical Co, Ltd"
090000648494c33f,Other,FDA-2020-P-2166-0001,FDA-2020-P-2166,"Suitability Petition from Emprise Pharma LLC, on behalf of New Time Pharmaceutical Co, Ltd"
090000648494d234,Supporting & Related Material,FDA-2020-P-2166-0003,FDA-2020-P-2166,"Reference 1 Package insert for Coreg re Suitability Petition from Emprise Pharma LLC, on behalf of New Time Pharmaceutical Co, Ltd"
090000648494d238,Supporting & Related Material,FDA-2020-P-2166-0007,FDA-2020-P-2166,"Reference 5 US Patent 8883207B2 re Suitability Petition from Emprise Pharma LLC, on behalf of New Time Pharmaceutical Co, Ltd"
090000648494d235,Supporting & Related Material,FDA-2020-P-2166-0004,FDA-2020-P-2166,"Reference 2 Package insert for Coreg CR re Suitability Petition from Emprise Pharma LLC, on behalf of New Time Pharmaceutical Co, Ltd"
09000064846e1016,Other,FDA-2020-P-1540-0002,FDA-2020-P-1540,Acknowledgment Letter from FDA DMS to Alliance for Natural Health USA
0900006484a692c0,Other,FDA-2020-P-1540-0003,FDA-2020-P-1540,Interim Response to Alliance For Natural Health USA from FDA CDER
09000064846e0606,Other,FDA-2020-P-1540-0001,FDA-2020-P-1540,Citizen Petition from Alliance For Natural Health USA
0900006484a69721,Other,FDA-2020-P-1540-0004,FDA-2020-P-1540,Supplement from Alliance for Natural Health USA
0900006484979278,Other,FDA-2020-P-2236-0002,FDA-2020-P-2236,Acknowledgment Letter from FDA DMS to Covington & Burling LLP on behalf of Pharmaceutical Research and Manufacturers of America
0900006484b2edd0,Other,FDA-2020-P-2236-0003,FDA-2020-P-2236,Response Letter from FDA CDER to Covington & Burling LLP
0900006484979277,Other,FDA-2020-P-2236-0001,FDA-2020-P-2236,"Citizen Petition from Covington & Burling, LLP on behalf of Pharmaceutical Research and Manufacturers of America"
0900006484552b1d,Supporting & Related Material,FDA-2020-P-1334-0026,FDA-2020-P-1334,"Exhibit 8 re Citizen Petition from Therapeutics MD, Inc."
0900006484552b2f,Supporting & Related Material,FDA-2020-P-1334-0013,FDA-2020-P-1334,"Exhibit 21 re Citizen Petition from Therapeutics MD, Inc."
0900006484552a16,Other,FDA-2020-P-1334-0002,FDA-2020-P-1334,"Acknowledgment Letter from FDA DMS to Therapeutics MD, Inc."
0900006484552b2c,Supporting & Related Material,FDA-2020-P-1334-0015,FDA-2020-P-1334,"Exhibit 19 re Citizen Petition from Therapeutics MD, Inc."
09000064845532d9,Supporting & Related Material,FDA-2020-P-1334-0032,FDA-2020-P-1334,"Exhibit 2 re Citizen Petition from Therapeutics MD, Inc."
0900006484552b1f,Supporting & Related Material,FDA-2020-P-1334-0024,FDA-2020-P-1334,"Exhibit 10 re Citizen Petition from Therapeutics MD, Inc."
0900006484552b23,Supporting & Related Material,FDA-2020-P-1334-0020,FDA-2020-P-1334,"Exhibit 14 re Citizen Petition from Therapeutics MD, Inc."
09000064845533ca,Supporting & Related Material,FDA-2020-P-1334-0027,FDA-2020-P-1334,"Exhibit 7 re Citizen Petition from Therapeutics MD, Inc."
0900006484552b22,Supporting & Related Material,FDA-2020-P-1334-0021,FDA-2020-P-1334,"Exhibit 13 re Citizen Petition from Therapeutics MD, Inc."
0900006484552b30,Supporting & Related Material,FDA-2020-P-1334-0012,FDA-2020-P-1334,"Exhibit 22 re Citizen Petition from Therapeutics MD, Inc."
090000648492ed1d,Other,FDA-2020-P-1334-0034,FDA-2020-P-1334,"Interim Response from FDA CDER to TherapeuticsMD, Inc."
09000064845514d5,Other,FDA-2020-P-1334-0001,FDA-2020-P-1334,"Citizen Petition from Therapeutics MD, Inc."
0900006484552b26,Supporting & Related Material,FDA-2020-P-1334-0017,FDA-2020-P-1334,"Exhibit 17 re Citizen Petition from Therapeutics MD, Inc."
0900006484553609,Supporting & Related Material,FDA-2020-P-1334-0004,FDA-2020-P-1334,"Exhibit 30 re Citizen Petition from Therapeutics MD, Inc."
0900006484552b21,Supporting & Related Material,FDA-2020-P-1334-0022,FDA-2020-P-1334,"Exhibit 12 re Citizen Petition from Therapeutics MD, Inc."
0900006484552b32,Supporting & Related Material,FDA-2020-P-1334-0010,FDA-2020-P-1334,"Exhibit 24 re Citizen Petition from Therapeutics MD, Inc."
09000064845532da,Supporting & Related Material,FDA-2020-P-1334-0031,FDA-2020-P-1334,"Exhibit 3 re Citizen Petition from Therapeutics MD, Inc."
0900006484552b31,Supporting & Related Material,FDA-2020-P-1334-0011,FDA-2020-P-1334,"Exhibit 23 re Citizen Petition from Therapeutics MD, Inc."
09000064845533c9,Supporting & Related Material,FDA-2020-P-1334-0028,FDA-2020-P-1334,"Exhibit 6 re Citizen Petition from Therapeutics MD, Inc."
0900006484552b2d,Supporting & Related Material,FDA-2020-P-1334-0014,FDA-2020-P-1334,"Exhibit 20 re Citizen Petition from Therapeutics MD, Inc."
09000064845532db,Supporting & Related Material,FDA-2020-P-1334-0030,FDA-2020-P-1334,"Exhibit 4 re Citizen Petition from Therapeutics MD, Inc."
0900006484552b20,Supporting & Related Material,FDA-2020-P-1334-0023,FDA-2020-P-1334,"Exhibit 11 re Citizen Petition from Therapeutics MD, Inc."
0900006484553606,Supporting & Related Material,FDA-2020-P-1334-0007,FDA-2020-P-1334,"Exhibit 27 re Citizen Petition from Therapeutics MD, Inc."
090000648455360a,Supporting & Related Material,FDA-2020-P-1334-0003,FDA-2020-P-1334,"Exhibit 31 re Citizen Petition from Therapeutics MD, Inc."
0900006484552b2b,Supporting & Related Material,FDA-2020-P-1334-0016,FDA-2020-P-1334,"Exhibit 18 re Citizen Petition from Therapeutics MD, Inc."
0900006484b3987c,Other,FDA-2021-P-0514-0002,FDA-2021-P-0514,"Acknowledgment Letter from FDA DMS to Hyman, Phelps & McNamara, P.C."
0900006484b394c9,Supporting & Related Material,FDA-2021-P-0514-0005,FDA-2021-P-0514,"Attachment 3 Naloxone Nasal Spray PI re Suitability Petition from Hyman, Phelps & McNamara P.C."
0900006484b39cf8,Supporting & Related Material,FDA-2021-P-0514-0004,FDA-2021-P-0514,"Attachment 2 - NARCAN PI re Suitability Petition from Hyman, Phelps & McNamara P.C."
0900006484b39879,Other,FDA-2021-P-0514-0001,FDA-2021-P-0514,"Suitability Petition from Hyman, Phelps & McNamara, P.C."
0900006484b39cf7,Supporting & Related Material,FDA-2021-P-0514-0003,FDA-2021-P-0514,"Attachment 1 - Narcan re Suitability Petition from Hyman, Phelps & McNamara P.C."
090000648046e86f,Supporting & Related Material,FDA-2004-D-0046-0003,FDA-2004-D-0046,Guideline
090000648046e86c,Notice,FDA-2004-D-0046-0001,FDA-2004-D-0046,FDA
090000648046e86e,Supporting & Related Material,FDA-2004-D-0046-0002,FDA-2004-D-0046,Guideline
090000648046e870,Supporting & Related Material,FDA-2004-D-0046-0004,FDA-2004-D-0046,Guideline
09000064809cc394,Notice,FDA-2008-N-0572-0003,FDA-2008-N-0572,"Agency Information Collection Activities; Proposals, Submissions, and Approvals"
090000648078cbb7,Notice,FDA-2008-N-0572-0001,FDA-2008-N-0572,Agency Emergency Processing Under Office of Management and Budget Review; Implementation of the Animal Generic Drug User Fee Act of 2008; User Fee Cover Sheet Form FDA 3728
0900006480905028,Notice,FDA-2008-N-0572-0002,FDA-2008-N-0572,"Agency Information Collection Activities; Proposals, Submissions, and Approvals"
0900006480a4f381,Notice,FDA-2009-N-0360-0002,FDA-2009-N-0360,"Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Food and Drug Administration Public Health Notification Readership Survey (Formerly Known as ""Safety Alert/Public Health Advisory Readership Survey"")"
0900006480a10ad9,Notice,FDA-2009-N-0360-0001,FDA-2009-N-0360,"Agency Information Collection Activities; Proposals, Submissions, and Approvals"
09000064815562f6,Notice,FDA-2009-N-0360-0004,FDA-2009-N-0360,Agency Information Collection Activities; Proposed Collection; Comment Request; Food and Drug Administration Safety Communication Readership Survey
09000064817ed6b9,Notice,FDA-2009-N-0360-0006,FDA-2009-N-0360,"Agency Information Collection Activities; Announcement of Office of
Management and Budget Approval; FDA Safety Communication
Readership Survey"
09000064843f99ec,Notice,FDA-2009-N-0360-0010,FDA-2009-N-0360,Agency Information Collection Activities; Proposed Collection; Comment Request; Food and Drug Administration Safety Communication Readership Survey
09000064844aba16,Notice,FDA-2009-N-0360-0011,FDA-2009-N-0360,"Agency Information Collection Activities; Proposed Collection;
Comment Request; Food and Drug Administration Safety Communication Readership Survey; Withdrawal of Notice"
0900006482c4b29a,Notice,FDA-2009-N-0360-0009,FDA-2009-N-0360,"Agency Information Collection Activities; Announcement of Office of
Management and Budget Approvals"
09000064816ff439,Notice,FDA-2009-N-0360-0005,FDA-2009-N-0360,"Agency Information Collection Activities; Submission for Office of
Management and Budget Review; Comment Request; Food and Drug
Administration Safety Communication Readership Survey"
09000064825087c3,Notice,FDA-2009-N-0360-0007,FDA-2009-N-0360,Agency Information Collection Activities; Proposed Collection; Comment Request; Food and Drug Administration Safety Communication Readership Survey
09000064827dddb3,Notice,FDA-2009-N-0360-0008,FDA-2009-N-0360,"Agency Information Collection Activities; Submission for Office of
Management and Budget Review; Comment Request; Food and Drug
Administration Safety Communication Readership Survey"
0900006480bb7067,Notice,FDA-2009-N-0360-0003,FDA-2009-N-0360,"Agency Information Collection Activities; Proposals, Submissions, and Approvals: Public Health Notification Readership Survey"
0900006480f89b62,Other,FDA-2010-P-0360-0007,FDA-2010-P-0360,"Hyman, Phelps & McNamara, P.C. - Amendment"
0900006480b13bcc,Supporting & Related Material,FDA-2010-P-0360-0003,FDA-2010-P-0360,"Attachment 2 - ""Novartis Gleevec™(Imatinib Mesylate) Capsules"" - [Hyman, Phelps & McNamara, P.C. - Citizen Petition]"
0900006480b13bcb,Supporting & Related Material,FDA-2010-P-0360-0002,FDA-2010-P-0360,"Attachment 1 - ""Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations"" - [Hyman, Phelps & McNamara, P.C. - Citizen Petition]"
0900006480b13c49,Other,FDA-2010-P-0360-0006,FDA-2010-P-0360,"Acknowledgement Letter Hyman Phelps & McNamara, P.C"
0900006480b13c3a,Supporting & Related Material,FDA-2010-P-0360-0004,FDA-2010-P-0360,"Attachment 3 - ""Highlights of Prescribing Information, Gleevec"" - [Hyman, Phelps & McNamara, P.C. - Citizen Petition]"
090000648152aa68,Other,FDA-2010-P-0360-0009,FDA-2010-P-0360,"Citizen Petition Approval Response from FDA CDER to Hyman, Phelps & McNamara, P.C."
0900006480b13bca,Other,FDA-2010-P-0360-0001,FDA-2010-P-0360,"Hyman, Phelps & McNamara, P.C. - Citizen Petition"
09000064810bca90,Other,FDA-2010-P-0360-0008,FDA-2010-P-0360,"Hyman, Phelps & McNamara, P.C. - Amendment"
0900006480b13c48,Supporting & Related Material,FDA-2010-P-0360-0005,FDA-2010-P-0360,"Attachment 4 - ""Highlights of Prescribing Information - [Hyman, Phelps & McNamara, P.C. - Citizen Petition]"
0900006480b1b535,Supporting & Related Material,FDA-2010-P-0383-0002,FDA-2010-P-0383,"Exhibit A - ""Fentanyl FDA Contact Report Regarding (Product): Fentanyl Citrate Tablets (Fentora®0 - April 7, 2008"" - [Cephalon, Inc., (Fish & Richardson P.C) - Citizen Petition]"
0900006480b1b5e6,Supporting & Related Material,FDA-2010-P-0383-0009,FDA-2010-P-0383,"Exhibit 4 - ""Watson Laboratories, Inc., Process Flow Diagram of Manufacturing Process..."" - [Cephalon, Inc., (Fish & Richardson P.C) - Citizen Petition]"
0900006480b1b617,Supporting & Related Material,FDA-2010-P-0383-0011,FDA-2010-P-0383,"Exhibit 10 - ""Volume C - In the United States District Court in and for the District of Delaware"" - [Cephalon, Inc., (Fish & Richardson P.C) - Citizen Petition]"
0900006480b1b61e,Other,FDA-2010-P-0383-0013,FDA-2010-P-0383,"Acknowledgement Letter to Cephalon, Inc., (Fish & Richardson P.C)"
0900006480b1b619,Other,FDA-2010-P-0383-0014,FDA-2010-P-0383,"Fish & Richardson, P.C., to the Division of Dockets Management, re: Replacement Signature Page for Declaration Appending Citizen Petition Filing for Fish & Richardson P.C. on Behalf of Cephalon Inc."" - [Cephalon, Inc., (Fish & Richardson P.C) - Citizen Petition] - Letter"
0900006480b1b5e5,Supporting & Related Material,FDA-2010-P-0383-0008,FDA-2010-P-0383,"Exhibit 3 - ""Volume B - In the United States District Court in and for the District of Delaware, Civil Action - [Cephalon, Inc., (Fish & Richardson P.C) - Citizen Petition]"
0900006480bc9e85,Other,FDA-2010-P-0383-0017,FDA-2010-P-0383,"FDA/CDER to Fish & Richardson, P.C.  (Cephalon, Inc.) - Petition Denial"
0900006480b1b61a,Other,FDA-2010-P-0383-0015,FDA-2010-P-0383,"Fish & Richardson, P.C., to the Division of Dockets Management, re: Redacted Expert's Declaration to Append Citizen Petition Filing for Fish & Richardson P.C. on Behalf of Cephalon Inc."" - [Cephalon, Inc., (Fish & Richardson P.C) - Citizen Petition] - Letter"
0900006480b1b5e1,Supporting & Related Material,FDA-2010-P-0383-0004,FDA-2010-P-0383,"Exhibit C - ""Volume C - In the United States District Court in and for the District of Delaware, Civil Action""  - [Cephalon, Inc., (Fish & Richardson P.C) - Citizen Petition]"
0900006480b1b5e3,Supporting & Related Material,FDA-2010-P-0383-0006,FDA-2010-P-0383,"Exhibit 1 - ""Pharmaceutical Development; Fentanyl Citrate Buccal Tablets, ANDA 079075""(Redacted) - [Cephalon, Inc., (Fish & Richardson P.C) - Citizen Petition]"
0900006480b1b5e7,Supporting & Related Material,FDA-2010-P-0383-0010,FDA-2010-P-0383,"Exhibit 5 - ""Fentanyl FDA Contact Report - 4/7/08"" - [Cephalon, Inc., (Fish & Richardson P.C) - Citizen Petition]"
0900006480b1b534,Other,FDA-2010-P-0383-0001,FDA-2010-P-0383,"Cephalon, Inc., (Fish & Richardson P.C) - Citizen Petition"
0900006480b67802,Other,FDA-2010-P-0383-0016,FDA-2010-P-0383,"Cephalon, Inc. (Fish & Richardson, P.C.) - Supplement"
0900006480b1b5e0,Supporting & Related Material,FDA-2010-P-0383-0003,FDA-2010-P-0383,"Exhibit B - ""Volume A - In the United States District Court in and for the District of Delaware, Civil Action""  - [Cephalon, Inc., (Fish & Richardson P.C) - Citizen Petition]"
0900006480b1b5e2,Supporting & Related Material,FDA-2010-P-0383-0005,FDA-2010-P-0383,"Delaration of Lon J. Mathias, REDACTED - [Cephalon, Inc., (Fish & Richardson P.C) - Citizen Petition]"
0900006480b1b5e4,Supporting & Related Material,FDA-2010-P-0383-0007,FDA-2010-P-0383,"Exhibit 2 -  ""Description of Manufacturing Process and Process Controls; Fentanyl Citrate Buccal Tablets"" - [Cephalon, Inc., (Fish & Richardson P.C) - Citizen Petition]"
0900006480b1b618,Supporting & Related Material,FDA-2010-P-0383-0012,FDA-2010-P-0383,"Exhibit 11 - ""Figure 546A-13, 2, 6, 8, and 10, Fentanyl Citrate, Sodium Starch Glycolate, Mannitol, Potassium Bicarbonate, Magnesium Stearate..."" - [Cephalon, Inc., (Fish & Richardson P.C) - Citizen Petition]"
0900006483d53ee8,Other,FDA-2019-P-0538-0026,FDA-2019-P-0538,Letter from FDA CDER to K&L Gates LLP
0900006483a3c01e,Supporting & Related Material,FDA-2019-P-0538-0010,FDA-2019-P-0538,"Exhibit 008 - HR REP 98-857(II) (excerpt) Re: Citizen Petition from  K&L Gates LLP on behalf of Genus Lifesciences, Inc."
0900006483a3b783,Supporting & Related Material,FDA-2019-P-0538-0006,FDA-2019-P-0538,"Exhibit 005 - 130 Cong Rec 23,764-774Re: Citizen Petition from  K&L Gates LLP on behalf of Genus Lifesciences, Inc."
0900006483a3b888,Supporting & Related Material,FDA-2019-P-0538-0013,FDA-2019-P-0538,"Exhibit 011 - Lannett Earnings Call Transcript - Q1 2019 Re: Citizen Petition from  K&L Gates LLP on behalf of Genus Lifesciences, Inc."
0900006483a3b77f,Supporting & Related Material,FDA-2019-P-0538-0002,FDA-2019-P-0538,"Exhibit 001 - Lannett PR Newswire Re: Citizen Petition from  K&L Gates LLP on behalf of Genus Lifesciences, Inc."
0900006483a3aff6,Other,FDA-2019-P-0538-0001,FDA-2019-P-0538,"Citizen Petition from  K&L Gates LLP on behalf of Genus Lifesciences, Inc."
0900006483a3b886,Supporting & Related Material,FDA-2019-P-0538-0011,FDA-2019-P-0538,"Exhibit 009 - 130 Cong Rec 24,970-979 Re: Citizen Petition from  K&L Gates LLP on behalf of Genus Lifesciences, Inc."
0900006483a3b784,Supporting & Related Material,FDA-2019-P-0538-0008,FDA-2019-P-0538,"Exhibit 006 - 130 Cong Rec_ 15,846-853 Re: Citizen Petition from  K&L Gates LLP on behalf of Genus Lifesciences, Inc."
0900006483a3ba2b,Supporting & Related Material,FDA-2019-P-0538-0020,FDA-2019-P-0538,"Exhibit 017 - FDA Response to ISTA Citizen Petition Re: Citizen Petition from  K&L Gates LLP on behalf of Genus Lifesciences, Inc."
0900006483a3b889,Supporting & Related Material,FDA-2019-P-0538-0015,FDA-2019-P-0538,"Exhibit 012 - FDA Guidance for Refuse to File  Re: Citizen Petition from  K&L Gates LLP on behalf of Genus Lifesciences, Inc."
0900006483a3ba2c,Supporting & Related Material,FDA-2019-P-0538-0021,FDA-2019-P-0538,"Exhibit 018 - 54 Fed_ Reg_ 28,872 (July 10, 1989) Re: Citizen Petition from  K&L Gates LLP on behalf of Genus Lifesciences, Inc."
0900006483a3b167,Other,FDA-2019-P-0538-0023,FDA-2019-P-0538,"Acknowledgment Letter from FDA DDM to K& L Gates LLP on behalf of Genus Lifesciences, Inc."
0900006483a3b780,Supporting & Related Material,FDA-2019-P-0538-0003,FDA-2019-P-0538,"Exhibit 002 - LANNETT CO INC Re: Citizen Petition from  K&L Gates LLP on behalf of Genus Lifesciences, Inc."
0900006483a3ba2d,Supporting & Related Material,FDA-2019-P-0538-0022,FDA-2019-P-0538,"Exhibit 019 - 57 Fed_ Reg_ 17,950 (Apr_ 28, 1992) Re: Citizen Petition from  K&L Gates LLP on behalf of Genus Lifesciences, Inc."
0900006483a3b887,Supporting & Related Material,FDA-2019-P-0538-0012,FDA-2019-P-0538,"Exhibit 010 - 59 Fed_ Reg_ 50,338 (Oct_ 3, 1994) Re: Citizen Petition from  K&L Gates LLP on behalf of Genus Lifesciences, Inc."
0900006483a3b911,Supporting & Related Material,FDA-2019-P-0538-0017,FDA-2019-P-0538,"Exhibit 014 - 62 Fed_ Reg_ 43,535 (Aug_ 14, 1997)Re: Citizen Petition from  K&L Gates LLP on behalf of Genus Lifesciences, Inc."
0900006483a3ba2a,Supporting & Related Material,FDA-2019-P-0538-0019,FDA-2019-P-0538,"Exhibit 016 - ISTA Pharmaceuticals Citizen Petition Re: Citizen Petition from  K&L Gates LLP on behalf of Genus Lifesciences, Inc."
0900006483a3b781,Supporting & Related Material,FDA-2019-P-0538-0004,FDA-2019-P-0538,"Exhibit 003 - 129 Cong Rec 19,807-808, 19,844-845 Re: Citizen Petition from  K&L Gates LLP on behalf of Genus Lifesciences, Inc."
0900006483a3b912,Supporting & Related Material,FDA-2019-P-0538-0018,FDA-2019-P-0538,"Exhibit 015 - 66 Fed_ Reg_ 36,794 (July 13, 2001) Re: Citizen Petition from  K&L Gates LLP on behalf of Genus Lifesciences, Inc."
0900006483a3b782,Supporting & Related Material,FDA-2019-P-0538-0005,FDA-2019-P-0538,"Exhibit 004 - 130 Cong Rec 24,416-439, 458-465 Re: Citizen Petition from  K&L Gates LLP on behalf of Genus Lifesciences, Inc."
0900006483a3b88a,Supporting & Related Material,FDA-2019-P-0538-0016,FDA-2019-P-0538,"Exhibit 013 - PDUFA Performance Goals 2013-2017 Re: Citizen Petition from  K&L Gates LLP on behalf of Genus Lifesciences, Inc."
0900006483a3c01d,Supporting & Related Material,FDA-2019-P-0538-0009,FDA-2019-P-0538,"Exhibit 007 - H_R_ 3605 (1984) Re: Citizen Petition from  K&L Gates LLP on behalf of Genus Lifesciences, Inc."
0900006480f0f02a,Notice,FDA-2011-N-0556-0003,FDA-2011-N-0556,"Center for Devices and Radiological Health 510(k) Clearance Process; Recommendations Proposed in Institute of Medicine Report: ""Medical Devices and the Public's Health, The FDA 510(k) Clearance Process at 35 Years,"" Public Meeting; Correction"
0900006480ed1e22,Notice,FDA-2011-N-0556-0001,FDA-2011-N-0556,"Institute of Medicine Report; Availability: Medical Devices and the Public's Health, The FDA 510(k) Clearance Process at 35 Years"
0900006480edf586,Notice,FDA-2011-N-0556-0002,FDA-2011-N-0556,"Center for Devices and Radiological Health 510(k) Clearance Process; Recommendations Proposed in Institute of Medicine Report: ‘‘Medical Devices and the Public’s Health, The FDA 510(k) Clearance Process at 35 Years;’’ Public Meeting"
0900006481a3ade1,Supporting & Related Material,FDA-2015-P-0758-0006,FDA-2015-P-0758,"Annexure 4 Copy of FDA Federal Register Notice., Citizen Petition From Orbicular Pharmaceutical Technologies"
0900006481a3adde,Supporting & Related Material,FDA-2015-P-0758-0003,FDA-2015-P-0758,"Annexure 1 Copy of Orange Book current through September 2013, listing the subject formulation as RLD., Citizen Petition From Orbicular Pharmaceutical Technologies"
0900006481a3addc,Other,FDA-2015-P-0758-0002,FDA-2015-P-0758,Acknowledgement Letter From FDA DDM to Orbicular Pharmaceutical Technologies Pvt Ltd
0900006481a3addf,Supporting & Related Material,FDA-2015-P-0758-0004,FDA-2015-P-0758,"Annexure 2 Copy of Orange Book current through October 03,2014 & drugs@FDA listing of discontinued RLD formulation, LUMIGAN® 0.03%., Citizen Petition From Orbicular Pharmaceutical Technologies"
0900006481a3ade0,Supporting & Related Material,FDA-2015-P-0758-0005,FDA-2015-P-0758,"Annexure 3 Copy of Orange Book current through March 10, 2015 & drugs@FDA listing of Lupin's Bimatoprost., Citizen Petition From Orbicular Pharmaceutical Technologies"
0900006481aed575,Other,FDA-2015-P-0758-0007,FDA-2015-P-0758,Withdrawal from Orbicular Pharmaceutical Technologies Pvt Ltd
0900006481a3adda,Other,FDA-2015-P-0758-0001,FDA-2015-P-0758,Citizen Petition From Orbicular Pharmaceutical Technologies Pvt Ltd
0900006481d1d822,Other,FDA-2015-P-2120-0011,FDA-2015-P-2120,"Citizen Petition Denial Response from FDA CDER to Klienfeld, Kaplan and Becker, LLP (Purdue Pharma L.P.)"
0900006481b2a436,Supporting & Related Material,FDA-2015-P-2120-0004,FDA-2015-P-2120,"Exhibit 2 Physicians Desk Reference, 53rd Ed. 1999, Label for OxyContin (“OxyContin 1999 Label”) re Citizen Petition from Kleinfeld Kaplan & Becker, LLP (KKB)"
0900006481b2a914,Supporting & Related Material,FDA-2015-P-2120-0009,FDA-2015-P-2120,"Exhibit 9 Comments of Purdue Phama L.P. Docket No. FDA-2011-N-0830. June 8, 2015 re Citizen Petition from Kleinfeld Kaplan & Becker, LLP (KKB)"
0900006481b29e8b,Other,FDA-2015-P-2120-0002,FDA-2015-P-2120,"Acknowledgement Letter from FDA DDM to Kleinfeld Kaplan & Becker, LLP (KKB)"
0900006481b2a913,Supporting & Related Material,FDA-2015-P-2120-0008,FDA-2015-P-2120,"Exhibit 8 Physicians Desk Reference, 53rd Ed. 1999, Label for Roxicodone IR 5 mg (“Roxicodone IR 5mg 199 Label”) re Citizen Petition from Kleinfeld Kaplan & Becker, LLP (KKB)"
0900006481b2a435,Supporting & Related Material,FDA-2015-P-2120-0003,FDA-2015-P-2120,"Exhibit 1 Physicians Desk Reference, 53rd Ed. 1999, Label for Percodan (“Percodan 1999 label”) re Citizen Petition from Kleinfeld Kaplan & Becker, LLP (KKB)"
0900006481b2a438,Supporting & Related Material,FDA-2015-P-2120-0005,FDA-2015-P-2120,"Exhibit 4 Medical Officer Review, Integrated Summary of Efficacy, Oxycodone Controlled Release, NDA 20553, Curtis Wrights, M.D. and Medical Officer Review, OxyContin Study 0402B-Cancer Pain, Curtis Wright, M.D. re Citizen Petition from Kleinfeld Kaplan & Becker, LLP (KKB)"
0900006481b2a43a,Supporting & Related Material,FDA-2015-P-2120-0007,FDA-2015-P-2120,"Exhibit 6 NDA Review, NDA 20-553, E.D. Bashaw, PharmD, with Excerpts from Appendix to Review re Citizen Petition from Kleinfeld Kaplan & Becker, LLP (KKB)"
0900006481b29ce9,Other,FDA-2015-P-2120-0001,FDA-2015-P-2120,"Citizen Petition from Kleinfeld Kaplan & Becker, LLP (KKB)"
0900006481b2a439,Supporting & Related Material,FDA-2015-P-2120-0006,FDA-2015-P-2120,"Exhibit 5 Exclusivity Summary, NDA 20553 re Citizen Petition from Kleinfeld Kaplan & Becker, LLP (KKB)"
0900006481bc51d2,Other,FDA-2015-P-2854-0001,FDA-2015-P-2854,Citizen Petition from Olsson Frank Weeda Terman Matz PC
0900006481c1ba07,Supporting & Related Material,FDA-2015-P-2854-0004,FDA-2015-P-2854,Attachment 2: David Wright Affidavit Redacted re Citizen Petition from Olsson Frank Weeda Terman Matz PC
0900006481bc5dd7,Other,FDA-2015-P-2854-0002,FDA-2015-P-2854,Acknowledgment Letter from FDA DDM to Olsson Frank Weeda Terman Matz PC
0900006481c1b4ce,Supporting & Related Material,FDA-2015-P-2854-0003,FDA-2015-P-2854,Attachment 1: Andrew Lewis Affidavit Redacted  re Citizen Petition from Olsson Frank Weeda Terman Matz PC
0900006481e33dfe,Other,FDA-2015-P-2854-0006,FDA-2015-P-2854,Supplement from Provensis (Olsson Frank Weeda Terman Matz PC)
0900006483b2a104,Other,FDA-2019-D-1372-0004,FDA-2019-D-1372,Elemental Impurities in Human Drug Products Questions and Answers Proposed DRAFT Guidance for Industry
0900006483b1bb56,Other,FDA-2019-D-1372-0003,FDA-2019-D-1372,Acknowledgment Letter from FDA DDM to International Pharmaceutical Excipients Council of the Americas (IPEC -America)
0900006483b18d60,Other,FDA-2019-D-1372-0001,FDA-2019-D-1372,External Guidance Document Submission from International Pharmaceutical Excipients Council of the Americas (IPEC -America)
09000064842512ce,Supporting & Related Material,FDA-2019-P-6044-0004,FDA-2019-P-6044,"Exhibit 1 Safety of Epinephrine in Higher Doses re Citizen Petition from Latham & Watkins LLP on behalf of Par Sterile Products, LLC"
09000064844d3255,Other,FDA-2019-P-6044-0006,FDA-2019-P-6044,Agency Response Letter from FDA CDER to Latham and Watkins LLP
09000064842512a2,Other,FDA-2019-P-6044-0002,FDA-2019-P-6044,Acknowledgment Letter from FDA DMS to Latham & Watkins LLP
0900006484252119,Other,FDA-2019-P-6044-0003,FDA-2019-P-6044,Acknowledgment Letter from FDA DMS to Latham and Watkins LLP
090000648425101c,Other,FDA-2019-P-6044-0001,FDA-2019-P-6044,"Citizen Petition from Latham & Watkins LLP on behalf of Par Sterile Products, LLC"
0900006484425d0c,Supporting & Related Material,FDA-2020-P-1072-0003,FDA-2020-P-1072,"Attachment 1 - Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations re Citizen Petition from Yiling Pharmaceutical, LTD"
0900006484721985,Notice,FDA-2020-P-1072-0004,FDA-2020-P-1072,"Determination That ZOVIRAX (Acyclovir) Oral Capsules, 200 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
0900006484721deb,Other,FDA-2020-P-1072-0005,FDA-2020-P-1072,Response Letter from FDA CDER to Yiling Pharmaceutical LTD
0900006484425d09,Other,FDA-2020-P-1072-0002,FDA-2020-P-1072,"Acknowledgment Letter from FDA DMS to Yiling Pharmaceutical, LTD"
0900006484425d08,Other,FDA-2020-P-1072-0001,FDA-2020-P-1072,"Citizen Petition from Yiling Pharmaceutical, LTD"
0900006484dc43ec,Other,FDA-2021-P-1108-0001,FDA-2021-P-1108,"Citizen Petition from Xiromed, LLC (Xiromed) on behalf of Xiromed Pharma España S.L."
0900006484dc43ff,Other,FDA-2021-P-1108-0002,FDA-2021-P-1108,"Acknowledgment Letter from FDA DMS to  Xiromed, LLC (Xiromed) on behalf of Xiromed Pharma España S.L."
0900006484dfb330,Other,FDA-2021-P-1108-0003,FDA-2021-P-1108,Withdrawal from Xiromed LLC
0900006484e085be,Other,FDA-2021-P-1188-0002,FDA-2021-P-1188,Acknowledgment Letter from FDA DMS to Arent Fox LLP
0900006484e08fd5,Other,FDA-2021-P-1188-0001,FDA-2021-P-1188,Citizen Petition from Arent Fox LLP
0900006484e11243,Supporting & Related Material,FDA-2021-P-1188-0003,FDA-2021-P-1188,Attachment 1 re: Citizen Petition from Arent Fox LLP
0900006481ad2ba7,Other,FDA-2015-P-1590-0003,FDA-2015-P-1590,"Acknowledgement Letter from FDA DDM to Qilu Pharmaceutical Co., Ltd."
0900006481ad2b15,Other,FDA-2015-P-1590-0001,FDA-2015-P-1590,"Suitability Petition from Qilu Pharmaceutical Co., Ltd."
0900006481ad2d86,Supporting & Related Material,FDA-2015-P-1590-0002,FDA-2015-P-1590,"Attachment 2 Proposed Package Labeling for Carfilzomib re Suitability Petition from Qilu Pharmaceutical Co., Ltd."
09000064817221c0,Other,FDA-2014-P-0737-0001,FDA-2014-P-0737,Citizen Petition from Pfizer Inc (Ropes and Gray LLP)
09000064818b8f68,Other,FDA-2014-P-0737-0003,FDA-2014-P-0737,Citizen Petition Denial Response from FDA CDER to Ropes & Gray LLP
0900006481723631,Other,FDA-2014-P-0737-0002,FDA-2014-P-0737,Acknowledgement Letter from FDA DDM to Pfizer (Ropes and Gray LLP)
0900006481983f9a,Other,FDA-2014-P-2243-0001,FDA-2014-P-2243,Citizen Petition Request from Apotex Inc
0900006481b1e90b,Other,FDA-2014-P-2243-0004,FDA-2014-P-2243,Citizen Petition Approval Response from FDA CDER to Apotex Corp.
0900006481985adf,Other,FDA-2014-P-2243-0002,FDA-2014-P-2243,Acknowledgement Letter from FDA DDM to Apotex Inc
0900006481985bcc,Supporting & Related Material,FDA-2014-P-2243-0003,FDA-2014-P-2243,Attachment
0900006481ae5712,Supporting & Related Material,FDA-2015-P-1757-0002,FDA-2015-P-1757,"Appendix A, 21 CFR Part 111 CGMP Regulations Governing Dietary Supplements re Citizen Petition from the Organic and Natural Health Association"
0900006481ae598b,Other,FDA-2015-P-1757-0001,FDA-2015-P-1757,Citizen Petition from the Organic and Natural Health Association
0900006481ae598e,Other,FDA-2015-P-1757-0003,FDA-2015-P-1757,Acknowledgement Letter from FDA DDM to the Organic and Natural Health Association
0900006484115e4d,Other,FDA-2019-P-4832-0008,FDA-2019-P-4832,"Withdrawal Letter from Arent Fox LLP on behalf of Aquestive Therapeutics, Inc."
09000064840a813c,Other,FDA-2019-P-4832-0001,FDA-2019-P-4832,"Citizen Petition from Arent Fox LLP on behalf of Aquestive Therapeutics, Inc"
09000064840a8228,Supporting & Related Material,FDA-2019-P-4832-0007,FDA-2019-P-4832,"Exhibit 5- Nasal drug delivery: new developments and strategies re: Citizen Petition from Arent Fox LLP on behalf of Aquestive Therapeutics, Inc"
09000064840a8226,Supporting & Related Material,FDA-2019-P-4832-0005,FDA-2019-P-4832,"Exhibit 3- Pharmacokinetic Study of Valtoco™ (NRL-1; diazepam nasal spray) in Patients With Epilepsy Under Ictal and Inter-ictal Conditions – Interim Report re: Citizen Petition from Arent Fox LLP on behalf of Aquestive Therapeutics, Inc."
09000064840a8224,Supporting & Related Material,FDA-2019-P-4832-0003,FDA-2019-P-4832,"Exhibit 1- A pilot study assessing the bioavailability and pharmacokinetics of diazepam after intranasal and intravenous administration in healthy volunteers re: Citizen Petition from Arent Fox LLP on behalf of Aquestive Therapeutics, Inc"
09000064840a8225,Supporting & Related Material,FDA-2019-P-4832-0004,FDA-2019-P-4832,"Exhibit 2- Bioavailability and Safety of Valtoco™ (diazepam intranasal solution) Compared to Oral and Rectal Diazepam re: Citizen Petition from Arent Fox LLP on behalf of Aquestive Therapeutics, Inc"
09000064840a8227,Supporting & Related Material,FDA-2019-P-4832-0006,FDA-2019-P-4832,"Exhibit 4- Buccal midazolam for pediatric convulsive seizures: efficacy, safety, and patient acceptability re: Citizen Petition from Arent Fox LLP on behalf of Aquestive Therapeutics, Inc"
09000064840a82be,Other,FDA-2019-P-4832-0002,FDA-2019-P-4832,"Acknowledgement Letter from FDA DMS to Arent Fox LLP on behalf of Aquestive Therapeutics, Inc"
0900006482b12601,Other,FDA-2017-P-5477-0002,FDA-2017-P-5477,"Acknowledgement Letter from FDA DDM to Hyman, Phelps & McNamara, PC"
0900006482b125ff,Other,FDA-2017-P-5477-0001,FDA-2017-P-5477,"Citizen Petition from Hyman, Phelps & McNamara on behalf of United Therapeutics Corporation"
0900006482b1264c,Supporting & Related Material,FDA-2017-P-5477-0003,FDA-2017-P-5477,"Tab 1 - ISO 27427, Anaesthetic and respiratory equipment - Nebulizing systems and components (2010) re Citizen Petition from Hyman, Phelps & McNamara on behalf of United Therapeutics Corporation"
0900006482b12665,Supporting & Related Material,FDA-2017-P-5477-0013,FDA-2017-P-5477,"Tab 11 - Wallace P_ Adams et al_, Demonstrating Bioequivalence of Locally Acting Orally INhaled Drug Products, 23 J AEROSOL MED PU re Citizen Petition from Hyman, Phelps & McNamara on behalf of United Therapeutics Corporation"
0900006482b1264e,Supporting & Related Material,FDA-2017-P-5477-0005,FDA-2017-P-5477,"Tab 3 - Andrew M_ Wilson et al_, Importance of drug-device interaction in determining systemic effects of inhaled corticosteroids re Citizen Petition from Hyman, Phelps & McNamara on behalf of United Therapeutics Corporation"
0900006482b12663,Supporting & Related Material,FDA-2017-P-5477-0011,FDA-2017-P-5477,"Tab 9 - T_ Gessler et al_, Ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension, 17 EUR RESPIR J 14, 16 re Citizen Petition from Hyman, Phelps & McNamara on behalf of United Therapeutics Corporation"
0900006482b1264d,Supporting & Related Material,FDA-2017-P-5477-0004,FDA-2017-P-5477,"Tab 2 - Food and Drug Administration Respiratory Drug Delivery Devices  A CDRH Perspective (Nov. 2 2010) re Citizen Petition from Hyman, Phelps & McNamara on behalf of United Therapeutics Corporation"
0900006482b1264f,Supporting & Related Material,FDA-2017-P-5477-0006,FDA-2017-P-5477,"Tab 4 - AH Kendrick et al_, Selecting and using nebuCitizen Petition from Hyman, Phelps & McNamara on behalf of United Therapeutics Corporation Citizen Petition from Hyman,"
0900006482b12660,Supporting & Related Material,FDA-2017-P-5477-0008,FDA-2017-P-5477,"Tab 6 - D_ Todd Loffert et al_, A comparison of commercial jet nebulizers, 106 CHEST 1788 (1994) re Citizen Petition from Hyman, Phelps & McNamara on behalf of United Therapeutics Corporation"
0900006482ec4def,Other,FDA-2017-P-5477-0014,FDA-2017-P-5477,Petition Denial Letter from FDA CDER to Hyman Phelps McNamara
0900006482b12650,Supporting & Related Material,FDA-2017-P-5477-0007,FDA-2017-P-5477,"Tab 5 - Dean Hess et al_, Medication nebulizer performance effects of diluent volume, nebulizer flow, and nebulizer brand, 110 CHE re Citizen Petition from Hyman, Phelps & McNamara on behalf of United Therapeutics Corporation"
0900006482b12661,Supporting & Related Material,FDA-2017-P-5477-0009,FDA-2017-P-5477,"Tab 7 - JG Hardy et al_, Lung deposition from four nebulizers, 87 RESPIR MED 461 (1993) re Citizen Petition from Hyman, Phelps & McNamara on behalf of United Therapeutics Corporation"
0900006482b12662,Supporting & Related Material,FDA-2017-P-5477-0010,FDA-2017-P-5477,"Tab 8 - Christopher OCallaghan  Peter W. Barry The science of nebulised drug delivery 52 Suppl 2 THORAX S31 S36 (1997) re Citizen Petition from Hyman, Phelps & McNamara on behalf of United Therapeutics Corporation"
0900006482b12664,Supporting & Related Material,FDA-2017-P-5477-0012,FDA-2017-P-5477,"Tab 10 - Lawrence X_ Yu, Quality by Design for Orally Inhaled Drug Products, PQRI Workshop on Demonstrating Bioequivalence of Loca re Citizen Petition from Hyman, Phelps & McNamara on behalf of United Therapeutics Corporation"
090000648342cfb3,Supporting & Related Material,FDA-2018-P-2361-0003,FDA-2018-P-2361,Attachment1-Orange Book - Triamcinolone acetonide 0.1% re:  Citizen Petition from BF Innovation Inc. (on behalf of Bright Future Pharmaceutical Laboratories Limited)
090000648342cfb4,Supporting & Related Material,FDA-2018-P-2361-0004,FDA-2018-P-2361,Attachment 2-FDA Drug Shortages - Triamcinolone Mylan re: Citizen Petition from BF Innovation Inc. (on behalf of Bright Future Pharmaceutical Laboratories Limited)
090000648342c62f,Other,FDA-2018-P-2361-0001,FDA-2018-P-2361,Citizen Petition from BF Innovation Inc. (on behalf of Bright Future Pharmaceutical Laboratories Limited)
09000064849763d8,Other,FDA-2018-P-2361-0006,FDA-2018-P-2361,Withdrawal from Bright Future Pharmaceutical Laboratories Ltd
090000648342cf99,Other,FDA-2018-P-2361-0002,FDA-2018-P-2361,Acknowledgment Letter from FDA DDM to BF Innovation Inc. (on behalf of Bright Future Pharmaceutical Laboratories Limited)
09000064839949a5,Other,FDA-2018-P-2361-0005,FDA-2018-P-2361,Interim Response Letter from FDA CDER to BF Innovation Inc.
0900006484b33398,Notice,FDA-2020-P-2048-0005,FDA-2020-P-2048,"Determination That MANGANESE SULFATE, Injectable, Equivalent 0.1 Milligram Manganese/Milliliter, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
0900006484b3435f,Other,FDA-2020-P-2048-0006,FDA-2020-P-2048,"Response Letter from FDA CDER to Fresenius Kabi USA, LLC"
0900006484a9a681,Other,FDA-2020-P-2048-0004,FDA-2020-P-2048,"Interim Response Letter from FDA CDER to Fresenius Kabi USA, LLC"
09000064848d294b,Other,FDA-2020-P-2048-0002,FDA-2020-P-2048,"Acknowledgement Letter from FDA DMS to Fresenius Kabi USA, LLC"
09000064848d294a,Other,FDA-2020-P-2048-0001,FDA-2020-P-2048,"Citizen Petition from Fresenius Kabi USA, LLC"
09000064848d2798,Supporting & Related Material,FDA-2020-P-2048-0003,FDA-2020-P-2048,"Attachment A – Current Orange Book Listing of Manganese Sulfate RE Citizen Petition from Fresenius Kabi USA, LLC"
090000648484545b,Other,FDA-2020-P-1073-0004,FDA-2020-P-1073,"Interim Response Letter from FDA CDER to David Behar, M.D."
0900006484426ab6,Other,FDA-2020-P-1073-0002,FDA-2020-P-1073,"Acknowledgment Letter from FDA DMS to David Behar, M.D."
090000648442667d,Other,FDA-2020-P-1073-0001,FDA-2020-P-1073,"Citizen Petition from David Behar, M.D."
0900006484426b81,Supporting & Related Material,FDA-2020-P-1073-0003,FDA-2020-P-1073,"Cover Letter re: Citizen Petition from David Behar, M.D."
0900006484c195e4,Other,FDA-2020-P-1073-0005,FDA-2020-P-1073,"Final Response to David Behar, M.D. from FDA CDER"
0900006480487161,Supporting & Related Material,FDA-2003-D-0150-0002,FDA-2003-D-0150,Draft Guidance
090000648048711a,Notice,FDA-2003-D-0150-0001,FDA-2003-D-0150,FDA
0900006480445c6a,Notice,FDA-2005-N-0290-0004,FDA-2005-N-0290,FDA
0900006480445c1c,Notice,FDA-2005-N-0290-0001,FDA-2005-N-0290,FDA
0900006480445c64,Notice,FDA-2005-N-0290-0002,FDA-2005-N-0290,FDA
0900006480445c68,Supporting & Related Material,FDA-2005-N-0290-0003,FDA-2005-N-0290,Supporting Statement
0900006480552947,Other,FDA-2008-P-0291-0002,FDA-2008-P-0291,Acknowledgement Letter to PRN Publishing
09000064805528d8,Other,FDA-2008-P-0291-0001,FDA-2008-P-0291,PRN Publishing - Citizen Petition
0900006480f92c11,Other,FDA-2008-P-0291-0004,FDA-2008-P-0291,FDA/CDER to PRN Publishing - Petition Denial
090000648079832c,Other,FDA-2008-P-0291-0003,FDA-2008-P-0291,FDA/CDER Interim Response to PRN Publishing - Letter
0900006480a4222b,Notice,FDA-2009-N-0488-0001,FDA-2009-N-0488,"Agency Information Collection Activities; Proposed Collection; Comment Request; Records and Reports Concerning Experience With Approved New Animal Drugs; Adverse Event Reports on Forms FDA 1932, 1932a, and 2301"
0900006480a7f553,Notice,FDA-2009-N-0488-0002,FDA-2009-N-0488,"Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Records and Reports Concerning Experience With Approved New Animal Drugs; Adverse Event Reports on Forms FDA 1932, 1932a, and 2301"
0900006482bc4873,Supporting & Related Material,FDA-2017-P-6136-0003,FDA-2017-P-6136,Enclosure re Citizen Petition from Foley & Lardner LLP
0900006482bc486f,Other,FDA-2017-P-6136-0001,FDA-2017-P-6136,Citizen Petition from Foley & Lardner LLP
0900006482bc4871,Other,FDA-2017-P-6136-0002,FDA-2017-P-6136,Acknowledgement Letter from FDA DDM to Foley & Lardner LLP
09000064830e6d93,Other,FDA-2017-P-6136-0004,FDA-2017-P-6136,Interim response from FDA CDER to Foley & Lardner LLP
0900006483df6768,Other,FDA-2017-P-6136-0005,FDA-2017-P-6136,Denial Letter from FDA  CDER to Foley & Lardner LLP
0900006483f9c1af,Supporting & Related Material,FDA-2019-P-4386-0003,FDA-2019-P-4386,"References for Citizen Petition for Fresenius Kabi USA, LLC."
0900006483f9bcb3,Other,FDA-2019-P-4386-0002,FDA-2019-P-4386,"Acknowledgment Letter from FDA DMS to Fresenius Kabi USA, LLC"
0900006483f9bebf,Other,FDA-2019-P-4386-0001,FDA-2019-P-4386,"Citizen Petition from Fresenius Kabi USA, LLC"
0900006482098346,Other,FDA-2016-P-1963-0002,FDA-2016-P-1963,Acknowledgment Letter from FDA to Schafer Veterinary Consultants LLC
090000648209b051,Supporting & Related Material,FDA-2016-P-1963-0003,FDA-2016-P-1963,Attachment 1 Pioneer Product Labeling
090000648209770d,Other,FDA-2016-P-1963-0001,FDA-2016-P-1963,Citizen Petition from SmartVet Holdings Inc
0900006480bfd118,Supporting & Related Material,FDA-2011-P-0120-0007,FDA-2011-P-0120,"Index for Appendix C: References 118 - 150, Volume 4 of 5 - [Pronova BioPharma Norge AS (Pronova) - Citizen Petition]"
0900006480bfc88d,Supporting & Related Material,FDA-2011-P-0120-0005,FDA-2011-P-0120,"Index for Appendix B: References 97 - 117, Volume 3 of 5 - [Pronova BioPharma Norge AS (Pronova) - Citizen Petition]"
0900006480bfafd8,Supporting & Related Material,FDA-2011-P-0120-0002,FDA-2011-P-0120,"Appendix D - Index of References 1 - 190, Appendix  A-C - [Pronova BioPharma Norge AS (Pronova) - Citizen Petition]"
0900006480bfafdc,Supporting & Related Material,FDA-2011-P-0120-0003,FDA-2011-P-0120,"Index for Appendix A: References 1 - 50, Volume 1 of 5 - [Pronova BioPharma Norge AS (Pronova) - Citizen Petition]"
0900006480cdc62d,Other,FDA-2011-P-0120-0010,FDA-2011-P-0120,FDA/CDER to Pronova BioPharma Norge AS - Petition Approval
0900006480bfd003,Supporting & Related Material,FDA-2011-P-0120-0008,FDA-2011-P-0120,"Index for Appendix C: References 151 - 190, Volume 5 of 5 - [Pronova BioPharma Norge AS (Pronova) - Citizen Petition]"
0900006480bfc88e,Supporting & Related Material,FDA-2011-P-0120-0006,FDA-2011-P-0120,"Reference 97 - ATSDR Report, ""Toxicological Profiles for Polychlorinated Biphenyls (Update)"" (Appendix B: References 97 - 117, Volume 3 of 5) - [Pronova BioPharma Norge AS (Pronova) - Citizen Petition]"
0900006480bfafd4,Other,FDA-2011-P-0120-0001,FDA-2011-P-0120,Pronova BioPharma Norge AS (Pronova) - Citizen Petiton
0900006480bfd493,Other,FDA-2011-P-0120-0009,FDA-2011-P-0120,Acknowledgement Letter to Pronova BioPharma Norge AS
0900006480bfbb92,Supporting & Related Material,FDA-2011-P-0120-0004,FDA-2011-P-0120,"Index for Appendix A: References 51 - 96, Volume 2 of 5 - [Pronova BioPharma Norge AS (Pronova) - Citizen Petition]"
0900006482923084,Other,FDA-2017-P-4245-0002,FDA-2017-P-4245,Acknowledgement Letter from DDM to EAS Consulting Group LLC
090000648376f6b5,Other,FDA-2017-P-4245-0004,FDA-2017-P-4245,Withdrawal from EAS Consulting Group (Jubilant Generics)
09000064829237db,Other,FDA-2017-P-4245-0001,FDA-2017-P-4245,Citizen Petition from EAS Consulting Group (Jubilant Generics)
0900006482e11a33,Other,FDA-2017-P-4245-0003,FDA-2017-P-4245,Interim Response from FDA to Jubilant Generics
09000064824a1497,Supporting & Related Material,FDA-2017-P-0508-0027,FDA-2017-P-0508,The World Oral Health Report 2003a
09000064824a14a4,Supporting & Related Material,FDA-2017-P-0508-0029,FDA-2017-P-0508,"Added Sugar Intake and Cardiovascular Diseases Mortality
Among US Adults"
09000064824a147f,Supporting & Related Material,FDA-2017-P-0508-0016,FDA-2017-P-0508,Obesity and Sugar-sweetened Beverages in African-American Preschool Children: A Longitudinal Study
09000064824a1491,Supporting & Related Material,FDA-2017-P-0508-0021,FDA-2017-P-0508,A Longitudinal Analysis of Sugar-Sweetened Beverage Intake in Infancy and Obesity at 6 Years
09000064824a1495,Supporting & Related Material,FDA-2017-P-0508-0025,FDA-2017-P-0508,Innate and learned preferences for sweet taste during childhood.
09000064824a14a3,Supporting & Related Material,FDA-2017-P-0508-0028,FDA-2017-P-0508,Sugars intake for adults and children
09000064824a1461,Supporting & Related Material,FDA-2017-P-0508-0003,FDA-2017-P-0508,The Relationship of Sugar to Population-Level Diabetes Prevalence: An Econometric Analysis of Repeated Cross-Sectional Data
09000064824a146a,Supporting & Related Material,FDA-2017-P-0508-0009,FDA-2017-P-0508,FOOD SHOPPING BEHAVIORS AND SOCIOECONOMIC STATUS INFLUENCE OBESITY RATES IN SEATTLE AND IN PARIS
09000064824a1478,Supporting & Related Material,FDA-2017-P-0508-0010,FDA-2017-P-0508,Call to Halve Target for Added Sugar
09000064824a1480,Supporting & Related Material,FDA-2017-P-0508-0017,FDA-2017-P-0508,Public Health: The Toxic Truth about Sugar
090000648297758b,Other,FDA-2017-P-0508-0040,FDA-2017-P-0508,"Interim Response Letter from CFSAN to Union of Concerned Scientists, Center for Science and Democracy"
09000064824c01f8,Supporting & Related Material,FDA-2017-P-0508-0031,FDA-2017-P-0508,"Pure, White and Deadly by John Yudkin"
09000064824a148e,Supporting & Related Material,FDA-2017-P-0508-0019,FDA-2017-P-0508,Review of WIC Food Packages: Improving Balance and Choice: Final Report
09000064824a1496,Supporting & Related Material,FDA-2017-P-0508-0026,FDA-2017-P-0508,Added Sugars and Cardiovascular Disease Risk in Children
0900006482495847,Other,FDA-2017-P-0508-0001,FDA-2017-P-0508,"Citizen Petition from the Union of Concerned Scientists, Center for Science and Democracy"
09000064824a1490,Supporting & Related Material,FDA-2017-P-0508-0020,FDA-2017-P-0508,Sugar on Trial: What You Really Need to Know
09000064824a1494,Supporting & Related Material,FDA-2017-P-0508-0024,FDA-2017-P-0508,Dietary sugars and body weight: systematic review and meta-analyses of randomised controlled trials and cohort studies
09000064824a1463,Supporting & Related Material,FDA-2017-P-0508-0005,FDA-2017-P-0508,The Children’s Food & Beverage Advertising Initiative In Action
09000064824a1479,Supporting & Related Material,FDA-2017-P-0508-0011,FDA-2017-P-0508,Evaluating the Nutrition Quality and Marketing of Children’s Cereals
09000064824a1465,Supporting & Related Material,FDA-2017-P-0508-0007,FDA-2017-P-0508,Sugar-Sweetened Beverages and Weight Gain in 2- to 5-Year-Old Children
09000064824a1467,Supporting & Related Material,FDA-2017-P-0508-0008,FDA-2017-P-0508,Dietary Guidelines Advisory Committee 2015
09000064824a147b,Supporting & Related Material,FDA-2017-P-0508-0013,FDA-2017-P-0508,"Obesity in the Early Childhood Years: State of the Science and
Implementation of Promising Solutions: Workshop in Brief"
09000064824958ae,Other,FDA-2017-P-0508-0002,FDA-2017-P-0508,"Acknowledgment Letter from FDA DDM to the Union of Concerned Scientists, Center for Science and Democracy"
09000064824a1462,Supporting & Related Material,FDA-2017-P-0508-0004,FDA-2017-P-0508,"Consumption of high-fructose corn syrup in beverages may play a
role in the epidemic of obesity"
09000064824a1464,Supporting & Related Material,FDA-2017-P-0508-0006,FDA-2017-P-0508,The Biasing Health Halos of Fast-Food Restaurant Health Claims: Lower Calorie Estimates and Higher Side-Dish Consumption Intentions
0900006481d85ca2,Other,FDA-2015-P-4600-0002,FDA-2015-P-4600,Acknowledgement Letter from FDA DDM to Bayer HealthCare Pharmaceuticals
0900006482212543,Other,FDA-2015-P-4600-0003,FDA-2015-P-4600,Interim Response Letter from CDER to Bayer HealthCare LLC
0900006481d85d0b,Other,FDA-2015-P-4600-0001,FDA-2015-P-4600,Citizen Petition from Bayer HealthCare LLC
090000648198e714,Supporting & Related Material,FDA-2014-P-2276-0002,FDA-2014-P-2276,"Exhibit 1 Citizen Petition From Alan Laboratories, Inc."
090000648198e71c,Other,FDA-2014-P-2276-0005,FDA-2014-P-2276,"Acknowledgement Letter From FDA DDM to Alan Laboratories, Inc."
090000648198e718,Supporting & Related Material,FDA-2014-P-2276-0004,FDA-2014-P-2276,"Exhibit 3 Citizen Petition From Alan Laboratories, Inc."
0900006481b469c2,Other,FDA-2014-P-2276-0006,FDA-2014-P-2276,"Interim Response Letter from FDA CDER to Alan Laboratories, Inc."
090000648198e716,Supporting & Related Material,FDA-2014-P-2276-0003,FDA-2014-P-2276,"Exhibit 2 Citizen Petition From Alan Laboratories, Inc."
090000648220c555,Other,FDA-2014-P-2276-0007,FDA-2014-P-2276,"Letter from FDA CDER to Alan Laboratories, Inc."
090000648198e5e9,Other,FDA-2014-P-2276-0001,FDA-2014-P-2276,"Citizen Petition From Alan Laboratories, Inc."
0900006482c3b454,Other,FDA-2017-P-6357-0001,FDA-2017-P-6357,Citizen Petition from Diana Wierzchos
0900006482c3be24,Other,FDA-2017-P-6357-0002,FDA-2017-P-6357,Acknowledgment Letter from FDA DDM to  Diana Wierzchos
0900006482c3b456,Supporting & Related Material,FDA-2017-P-6357-0003,FDA-2017-P-6357,Attachment -1 Factory Farms Destroy Communities re  Citizen Petition from Diana Wierzchos
0900006481cfe1f4,Other,FDA-2015-P-1669-0005,FDA-2015-P-1669,Interim Response from FDA CDER to RegCon Solutions
0900006481adb4be,Other,FDA-2015-P-1669-0004,FDA-2015-P-1669,Acknowledgement Letter from FDA DDM to RegCon Solutions
0900006481adba2a,Supporting & Related Material,FDA-2015-P-1669-0003,FDA-2015-P-1669,Attachment B Shipping Label re Citizen Petition from RegCon Solutions
0900006481adba29,Supporting & Related Material,FDA-2015-P-1669-0002,FDA-2015-P-1669,Attachment A Orange Book Approved Drug Products with Therapeutic Equivalent Evaluation for Acamprosate re Citizen Petition from RegCon Solutions
0900006481adb33e,Other,FDA-2015-P-1669-0001,FDA-2015-P-1669,Citizen Petition from RegCon Solutions
0900006481fbcd9b,Other,FDA-2015-P-1669-0006,FDA-2015-P-1669,Citizen Petition Petition Approval Letter 04/12/2016
0900006482a34fd3,Other,FDA-2017-P-1077-0003,FDA-2017-P-1077,Interim Response Letter from CDER to Recordati Rare Diseases Inc
09000064824cb691,Other,FDA-2017-P-1077-0001,FDA-2017-P-1077,Citizen-Petition from Recordati Rare Diseases INC
09000064824cb694,Other,FDA-2017-P-1077-0002,FDA-2017-P-1077,Acknowledgement Letter from FDA DDM to Recordati Rare Diseases INC.
0900006483264f8e,Supporting & Related Material,FDA-2018-P-1877-0003,FDA-2018-P-1877,Attachment 1: Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations re: Citizen Petition from Laurus Labs
0900006483264ded,Other,FDA-2018-P-1877-0001,FDA-2018-P-1877,Citizen Petition from Laurus Labs
0900006483264f19,Other,FDA-2018-P-1877-0002,FDA-2018-P-1877,Acknowledgment Letter from FDA DDM to Laurus Labs
0900006483a3b7df,Other,FDA-2018-P-1877-0007,FDA-2018-P-1877,Letter from FDA CDER to Laurus Labs Limited
09000064838cf223,Other,FDA-2018-P-1877-0005,FDA-2018-P-1877,Letter from FDA CDER to Laurus Labs Limited re Citizen Petition
0900006483a38ba0,Notice,FDA-2018-P-1877-0006,FDA-2018-P-1877,"Determination That ESBRIET (Pirfenidone) Film Coated Tablets, 534 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
0900006483265416,Supporting & Related Material,FDA-2018-P-1877-0004,FDA-2018-P-1877,RLD ESBRIET® package insert updated in Drugs@FDA re: Citizen Petition from Laurus Labs
090000648484b473,Supporting & Related Material,FDA-2020-P-1859-0004,FDA-2020-P-1859,"Attachment 2- Hectorol (doxercalciferol) Injection, package insert re Citizen Petition from GLAND PHARMA LIMITED"
090000648484b472,Supporting & Related Material,FDA-2020-P-1859-0003,FDA-2020-P-1859,Attachment 1-  Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations re Citizen Petition from GLAND PHARMA LIMITED
090000648484b474,Supporting & Related Material,FDA-2020-P-1859-0005,FDA-2020-P-1859,Attachment III  - Draft labeling Carton container Label and Package Insert for the proposed drug product re Citizen Petition from GLAND PHARMA LIMITED
090000648484b470,Other,FDA-2020-P-1859-0002,FDA-2020-P-1859,Acknowledgment Letter from FDA DMS to GLAND PHARMA LIMITED
090000648484ab9f,Other,FDA-2020-P-1859-0001,FDA-2020-P-1859,Suitability Petition from GLAND PHARMA LIMITED
0900006484a939be,Supporting & Related Material,FDA-2021-P-0345-0004,FDA-2021-P-0345,"Attachment 2 - Highlights of Prescribing Information for Ascor RE Suitability Petition from BPI Labs, LLC"
0900006484a9399b,Supporting & Related Material,FDA-2021-P-0345-0003,FDA-2021-P-0345,"Attachment 1 - Orange Book Approved Drug Products with Therapeutic Equivalence Evaluations RE Suitability Petition from BPI Labs, LLC"
0900006484a939bf,Supporting & Related Material,FDA-2021-P-0345-0005,FDA-2021-P-0345,"Attachment 3 - Highlights of Prescribing Information for Ascorbic acid injection RE Suitability Petition from BPI Labs, LLC"
0900006484a93997,Other,FDA-2021-P-0345-0001,FDA-2021-P-0345,"Suitability Petition from BPI Labs, LLC"
0900006484a93999,Other,FDA-2021-P-0345-0002,FDA-2021-P-0345,"Acknowledgment Letter from FDA DMS to BPI Labs, LLC"
090000648494737a,Other,FDA-2020-P-2146-0001,FDA-2020-P-2146,"Citizen Petition from BF Innovation, Inc."
0900006484a9a60e,Other,FDA-2020-P-2146-0003,FDA-2020-P-2146,"Response Letter from FDA CDER to BF Innovation, Inc."
090000648494747d,Other,FDA-2020-P-2146-0002,FDA-2020-P-2146,"Acknowledgment Letter from FDA DMS to  BF Innovation, Inc."
0900006484abcac3,Other,FDA-2020-P-0421-0008,FDA-2020-P-0421,Response Letter from FDA CDER to Cooley's Anemia Foundation
09000064842eeb19,Other,FDA-2020-P-0421-0001,FDA-2020-P-0421,Citizen Petition from Cooley's Anemia Foundation (CAF)
09000064842eeb1b,Other,FDA-2020-P-0421-0002,FDA-2020-P-0421,Acknowledgment Letter to Cooley’s Anemia Foundation
09000064847961cf,Other,FDA-2020-P-0421-0007,FDA-2020-P-0421,Interim response letter from FDA CDER to Cooley's Anemia Foundation
090000648427e588,Supporting & Related Material,FDA-2020-P-0102-0003,FDA-2020-P-0102,Appendix 1 IVQIA Data re Citizen Petition from The Ritedose Corporation
090000648427dc95,Other,FDA-2020-P-0102-0002,FDA-2020-P-0102,Acknowledgment Letter from FDA DMS to The Ritedose Corporation
09000064847488ab,Other,FDA-2020-P-0102-0004,FDA-2020-P-0102,Interim response from FDA CDER to Linda Valentine
090000648427a1d2,Other,FDA-2020-P-0102-0001,FDA-2020-P-0102,Citizen Petition from The Ritedose Corporation
0900006484b95c6d,Other,FDA-2020-P-0102-0005,FDA-2020-P-0102,Withdrawal from The Ritedose Corporation
0900006484a65ebb,Other,FDA-2021-P-0278-0001,FDA-2021-P-0278,Citizen Petition from B. Braun Medical Inc.
0900006484a65ee2,Other,FDA-2021-P-0278-0002,FDA-2021-P-0278,Acknowledgment Letter from FDA DMS to B. Braun Medical Inc.
0900006484ca880c,Other,FDA-2021-P-0278-0003,FDA-2021-P-0278,Interim Response Letter from FDA CDER to B. Braun Medical Inc.
09000064804816ea,Notice,FDA-2003-D-0038-0003,FDA-2003-D-0038,FDA
09000064804816dc,Notice,FDA-2003-D-0038-0001,FDA-2003-D-0038,FDA
09000064804816e9,Supporting & Related Material,FDA-2003-D-0038-0002,FDA-2003-D-0038,Guidance
0900006480b22d91,Other,FDA-2006-P-0088-0005,FDA-2006-P-0088,Michael Patterson - Citizen Petition
0900006480b22dbd,Other,FDA-2006-P-0088-0006,FDA-2006-P-0088,See FDA-2006-P-0088-0005
09000064804449ba,Supporting & Related Material,FDA-2006-P-0088-0002,FDA-2006-P-0088,See FDA-2006-P-0088-0001
09000064804449bb,Other,FDA-2006-P-0088-0003,FDA-2006-P-0088,FDA/CDRH Interim Response to Michael Patterson - Letter
09000064804449bc,Other,FDA-2006-P-0088-0004,FDA-2006-P-0088,"FDA/CDRH Response to Michael Patterson, Ph.D. - Petition Denial"
09000064804449b7,Other,FDA-2006-P-0088-0001,FDA-2006-P-0088,Acknowledgement Letter to Michael Patterson
0900006480475f71,Other,FDA-2004-P-0479-0002,FDA-2004-P-0479,HFA-305 to AAC Consulting Group
0900006480475f76,Other,FDA-2004-P-0479-0003,FDA-2004-P-0479,HFD-600 to AAC Consulting Group
0900006480475f32,Other,FDA-2004-P-0479-0001,FDA-2004-P-0479,HFA-305 to AAC Consulting Group
09000064809edb49,Other,FDA-2009-P-0320-0002,FDA-2009-P-0320,Acknowledgement Letter to Pharma Medica
09000064809edb48,Other,FDA-2009-P-0320-0001,FDA-2009-P-0320,Pharma Medica - Citizen Petition
0900006480a4679c,Other,FDA-2009-D-0490-0002,FDA-2009-D-0490,"Guidance for Industry and FDA Staff - Investigatinal New Drug Applications (INDs) for Minimally Manipulated, Unrelated Allogenic Placental/Umbilical Cord Blood Intended for Hematopoietic Reconstitutino for Specified Indications - Draft Guidance"
0900006480ed3837,Notice,FDA-2009-D-0490-0010,FDA-2009-D-0490,"Guidance for Industry and Food and Drug Administration Staff; Availability: Investigational New Drug Applications for Minimally Manipulated, Unrelated Allogeneic Placental-Umbilical Cord Blood, etc."
090000648132872c,Other,FDA-2009-D-0490-0013,FDA-2009-D-0490,"Draft Guidance for Industry and FDA Staff:  Investigational New Drug Applications for Minimally Manipulated, Unrelated Allogeneic Placental/Umbilical Cord Blood Intended for Hematopoietic and Immunologic Reconstitution in Patients with Disorders Affecting the Hematopoietic System"
09000064815fb385,Notice,FDA-2009-D-0490-0016,FDA-2009-D-0490,"Guidance for Industry and Food and Drug Administration Staff:
Investigational New Drug Applications for Minimally Manipulated, Unrelated Allogeneic Placental/Umbilical Cord Blood Intended for Hematopoietic and Immunologic Reconstitution in Patients With Disorders Affecting the Hematopoietic System; Availability"
0900006481328036,Notice,FDA-2009-D-0490-0012,FDA-2009-D-0490,"Draft Guidance for Industry and FDA Staff:  Investigational New Drug Applications for Minimally Manipulated, Unrelated Allogeneic Placental/Umbilical Cord Blood Intended for Hematopoietic and Immunologic Reconstitution in Patients with Disorders Affecting the Hematopoietic System; Availability"
0900006480a45940,Notice,FDA-2009-D-0490-0001,FDA-2009-D-0490,"Draft Guidance for Industry and Food and Drug Administration Staff: Investigational New Drug Applications for Minimally Manipulated, Unrelated Allogeneic Placental/Umbilical Cord Blood Intended for Hematopoietic Reconstitution for Specified Indications; Availability"
09000064815fc38c,Other,FDA-2009-D-0490-0017,FDA-2009-D-0490,"Guidance for Industry and FDA Staff: Investigational New Drug Applications for Minimally Manipulated, Unrelated Allogeneic Placental/Umbilical Cord Blood Intended for Hematopoietic and Immunologic Reconstitution in Patients With Disorders Affecting the Hematopoietic System"
0900006480ed2f10,Other,FDA-2009-D-0490-0011,FDA-2009-D-0490,"Guidance for Industry and Food and Drug Administration Staff; Investigational New Drug Applications (INDs) for Minimally Manipulated, Unrelated Allogeneic Placental-Umbilical Cord Blood Intended for Hermatopoietic Reconstitution for Specified Indications"
0900006484a71cfb,Other,FDA-2021-P-0307-0001,FDA-2021-P-0307,"Citizen Petition from Covington and Burling LLP on behalf of the Pharmaceutical Research and Manufacturers of America, Ballard Spahr LLP, on behalf of the Partnership for Safe Medicines, and Sidley Austin LLP, on behalf of the Council for Affordable Health Coverage"
0900006484d686d0,Other,FDA-2021-P-0307-0003,FDA-2021-P-0307,"Interim Response Letter from FDA CDER to Covington & Burling LLP, Ballard Spahr LLP, Sidley Austin LLP"
0900006484a71d36,Other,FDA-2021-P-0307-0002,FDA-2021-P-0307,Acknowledgment Letter from FDA DMS to Covington and Burling LLP
0900006484a85a10,Other,FDA-2020-P-2033-0005,FDA-2020-P-2033,Interim Response Letter from FDA DMS to Kentucky Drug Quality Study
09000064848adbdd,Other,FDA-2020-P-2033-0002,FDA-2020-P-2033,Acknowledgment Letter from FDA DMS to Kentucky Drug Quality Study
09000064848ada3f,Other,FDA-2020-P-2033-0001,FDA-2020-P-2033,Citizen Petition from University of Kentucky Drug Quality Study
0900006482cb6c2b,Other,FDA-2017-P-6631-0001,FDA-2017-P-6631,"Citizen Petition from Amin Talati Upadhye LLP (Natural Algae Astaxanthin Association (""NAXA""))"
0900006482cb6c2d,Supporting & Related Material,FDA-2017-P-6631-0004,FDA-2017-P-6631,"Exhibit B - About Zanthosyn re Citizen Petition from Amin Talati Upadhye LLP (Natural Algae Astaxanthin Association (""NAXA""))"
0900006482cb6c2e,Supporting & Related Material,FDA-2017-P-6631-0005,FDA-2017-P-6631,"Exhibit C- 75-Day Premarket Notification of New Dietary Tngrcdients re Citizen Petition from Amin Talati Upadhye LLP (Natural Algae Astaxanthin Association (""NAXA""))"
0900006482cb77b1,Other,FDA-2017-P-6631-0002,FDA-2017-P-6631,"Acknowledgement Letter from FDA DDM to Amin Talati Upadhye LLP (Natural Algae Astaxanthin Association (""NAXA""))"
0900006482cb6c2f,Supporting & Related Material,FDA-2017-P-6631-0006,FDA-2017-P-6631,"Exhibit D ZanthoSyn (30 ct) re Citizen Petition from Amin Talati Upadhye LLP (Natural Algae Astaxanthin Association (""NAXA""))"
0900006482cb6c30,Supporting & Related Material,FDA-2017-P-6631-0003,FDA-2017-P-6631,"Exhit A Frequently Asked Questions - ZanthoSyn re Citizen Petition from Amin Talati Upadhye LLP (Natural Algae Astaxanthin Association (""NAXA""))"
09000064825a11c2,Supporting & Related Material,FDA-2017-P-2967-0003,FDA-2017-P-2967,Attachment 1 Approved Drug Products with Therapeutic Equivalence Evaluations re Citizen Petition from Lachman Consultant Services Inc
09000064825a11c3,Supporting & Related Material,FDA-2017-P-2967-0004,FDA-2017-P-2967,Attachment 2 Draft Insert Labeling for Proposed Product re Citizen Petition from Lachman Consultant Services Inc
09000064825a11c0,Other,FDA-2017-P-2967-0002,FDA-2017-P-2967,"Acknowledgement Letter from FDA DDM to Lachman Consultant Services, Inc"
09000064825a11c4,Supporting & Related Material,FDA-2017-P-2967-0005,FDA-2017-P-2967,Attachment 3 Approved Labeling for Reference Listed Drug Lipitor Tablets by Pfizer re Citizen Petition from Lachman Consultant Services Inc
09000064825a11be,Other,FDA-2017-P-2967-0001,FDA-2017-P-2967,Citizen Petition from Lachman Consultant Services Inc
090000648129c5e2,Notice,FDA-2012-N-0324-0003,FDA-2012-N-0324,"Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; Guidance for Industry, FDA Staff, and Foreign Governments: Fiscal Year 2012 Medical Device User Fee Small Business Qualification and Certification"
0900006480ff345d,Notice,FDA-2012-N-0324-0001,FDA-2012-N-0324,"Agency Information Collection Activities; Proposals, Submissions, and Approvals; Guidance for Industry, Fiscal Year 2012 Medical Device User Fee Small Business Qualification and Certification"
09000064811e0a07,Notice,FDA-2012-N-0324-0002,FDA-2012-N-0324,"Agency Information Collection Activities; Proposals, Submissions, and Approvals: Guidance for Industry, FDA Staff, and Foreign Governments; FY 2012 Medical Device User Fee Small Business Qualification and Certification"
0900006482506bdf,Other,FDA-2017-P-1573-0003,FDA-2017-P-1573,Acknowledgment Letter from FDA DDM to Hospira Inc
0900006482506e32,Other,FDA-2017-P-1573-0001,FDA-2017-P-1573,Citizen Petition from Hospira Inc
0900006482506ebe,Other,FDA-2017-P-1573-0002,FDA-2017-P-1573,"Prior approval supplemental letter from CDER to Par Sterile Products, LLC"
09000064829e047f,Other,FDA-2017-P-1573-0004,FDA-2017-P-1573,"Citizen Petition Response Letter from FDA CDER to Latham & Watkins, LLP"
0900006482b9372b,Notice,FDA-2017-P-2530-0003,FDA-2017-P-2530,"Determination that SPECTAZOLE (Econazole Nitrate) Topical Cream, 1%, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
09000064825680ec,Other,FDA-2017-P-2530-0002,FDA-2017-P-2530,"Acknowledgement Letter from FDA DDM to Lachman Consultant Services, Inc."
09000064825680e9,Other,FDA-2017-P-2530-0001,FDA-2017-P-2530,Citizen Petition from Lachman Consultants Services Inc
0900006482b95f04,Other,FDA-2017-P-2530-0004,FDA-2017-P-2530,"Final Response Letter from FDA to Lachman Consultant Services, Inc."
090000648437e0f8,Supporting & Related Material,FDA-2018-P-4143-0022,FDA-2018-P-4143,4 GSJ 2018-single center trial
090000648437e0fd,Supporting & Related Material,FDA-2018-P-4143-0027,FDA-2018-P-4143,9 Becker spine 2018
090000648437e20e,Supporting & Related Material,FDA-2018-P-4143-0034,FDA-2018-P-4143,16 UT 2019
090000648437e0f9,Supporting & Related Material,FDA-2018-P-4143-0023,FDA-2018-P-4143,5 GSJ 2019- late infections literature synthesis
090000648437e0fc,Supporting & Related Material,FDA-2018-P-4143-0026,FDA-2018-P-4143,8 Submitted to SRS _ NASS 2020 for review
090000648437e210,Supporting & Related Material,FDA-2018-P-4143-0036,FDA-2018-P-4143,Supplement material for Docket FDA
090000648437e0f7,Supporting & Related Material,FDA-2018-P-4143-0021,FDA-2018-P-4143,3 GSJ 2018- proof of error in reprocessing
090000648437e209,Supporting & Related Material,FDA-2018-P-4143-0030,FDA-2018-P-4143,12 OTW 2020
090000648437e20c,Supporting & Related Material,FDA-2018-P-4143-0033,FDA-2018-P-4143,15 SNI 2019
090000648437dfa8,Supporting & Related Material,FDA-2018-P-4143-0019,FDA-2018-P-4143,1 CSS 2018- Economic benefits-2
090000648437e20f,Supporting & Related Material,FDA-2018-P-4143-0035,FDA-2018-P-4143,17 OTW 2018
090000648437e0fb,Supporting & Related Material,FDA-2018-P-4143-0025,FDA-2018-P-4143,7 SRS 2019- multicenter trial
090000648437e0fa,Supporting & Related Material,FDA-2018-P-4143-0024,FDA-2018-P-4143,6 JSSR 2018- multicenter trial summary
090000648437e0fe,Supporting & Related Material,FDA-2018-P-4143-0028,FDA-2018-P-4143,10 Becker spine 2019
090000648437e20a,Supporting & Related Material,FDA-2018-P-4143-0031,FDA-2018-P-4143,13 SNI 2018
090000648437e500,Supporting & Related Material,FDA-2018-P-4143-0029,FDA-2018-P-4143,11 BoneZone 2019
0900006483b79469,Other,FDA-2018-P-4143-0012,FDA-2018-P-4143,Letter from FDA CDRH to University of Toledo
0900006483874e50,Supporting & Related Material,FDA-2018-P-4143-0003,FDA-2018-P-4143,Attachment 1 Orthopedics This Week re Citizen Petiton from University of Toledo
0900006483874e22,Other,FDA-2018-P-4143-0002,FDA-2018-P-4143,Acknowledgment Letter from FDA DDM to University of Toledo
090000648437dfa9,Supporting & Related Material,FDA-2018-P-4143-0020,FDA-2018-P-4143,2 GSJ 2018- past literature synthesis
0900006483874e1f,Other,FDA-2018-P-4143-0001,FDA-2018-P-4143,Citizen Petition from University of Toledo
090000648437e20b,Supporting & Related Material,FDA-2018-P-4143-0032,FDA-2018-P-4143,14 SpineUniverse 2019
0900006483b57291,Notice,FDA-2018-P-2754-0005,FDA-2018-P-2754,"Determination That ONFI (Clobazam) Tablets, 5 Milligrams, Was Not
Withdrawn From Sale for Reasons of Safety or Effectiveness"
09000064839ec94b,Other,FDA-2018-P-2754-0004,FDA-2018-P-2754,Interim response from FDA CDER to Ascend Laboratories LLC
090000648351b060,Other,FDA-2018-P-2754-0002,FDA-2018-P-2754,Acknowledgment Letter from FDA DDM to  Ascend Laboratories LLC
0900006483b58f33,Other,FDA-2018-P-2754-0006,FDA-2018-P-2754,Letter from FDA CDER to Ascend Laboratories
090000648351b114,Supporting & Related Material,FDA-2018-P-2754-0003,FDA-2018-P-2754,Attachment A- Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations re: Citizen Petition from Ascend Laboratories LLC
0900006483519329,Other,FDA-2018-P-2754-0001,FDA-2018-P-2754,Citizen Petition from Ascend Laboratories LLC
0900006483301e65,Supporting & Related Material,FDA-2018-P-1719-0005,FDA-2018-P-1719,Attachment 2 - Agency Letter along with Federal Register Notice - Redacted
09000064832211e0,Supporting & Related Material,FDA-2018-P-1719-0003,FDA-2018-P-1719,"Attachment 1 - Excerpt from the Electronic version of the Orange Book re Citizen petition from Sciarra Laboratories, Inc"
09000064832211de,Other,FDA-2018-P-1719-0002,FDA-2018-P-1719,"Acknowledgment Letter from FDA DDM to Sciarra Laboratories, Inc"
09000064832211e1,Supporting & Related Material,FDA-2018-P-1719-0004,FDA-2018-P-1719,"Attachment 2 - Agency Letter along with Federal Register Notice re Citizen petition from Sciarra Laboratories, Inc"
0900006483220cca,Other,FDA-2018-P-1719-0001,FDA-2018-P-1719,"Citizen petition from Sciarra Laboratories, Inc"
0900006483864771,Other,FDA-2018-P-1719-0006,FDA-2018-P-1719,"Letter from FDA CDER to Sciarra Laboratories, Inc."
0900006484986bc4,Other,FDA-2018-P-1719-0007,FDA-2018-P-1719,"Withdrawal from Sciarra Laboratories, Inc"
090000648495a47c,Other,FDA-2020-P-1390-0003,FDA-2020-P-1390,180 Day Interim Response Letter to Varun Varad from FDA CFSAN
0900006484606f8f,Other,FDA-2020-P-1390-0002,FDA-2020-P-1390,Acknowledgment Letter from FDA DMS to Varun Verada
0900006484605e85,Other,FDA-2020-P-1390-0001,FDA-2020-P-1390,Citizen Petition from Varun Varada
090000648470ba7e,Supporting & Related Material,FDA-2020-P-1617-0003,FDA-2020-P-1617,Attachment 1 - Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations re Citizen Petition from E4 Consulting
090000648470b6e8,Other,FDA-2020-P-1617-0001,FDA-2020-P-1617,Citizen Petition from E4 Consulting
090000648470b6e9,Other,FDA-2020-P-1617-0002,FDA-2020-P-1617,Acknowledgment Letter from FDA DMS to E4 Consulting
09000064849a99fd,Other,FDA-2020-P-1617-0004,FDA-2020-P-1617,Interim Response letter from FDA CDER to E4 Consulting
0900006483b69c46,Other,FDA-2019-P-1636-0002,FDA-2019-P-1636,"Acknowledgment Letter from FDA DDM to Nexsen Pruet, LLC"
0900006483b69f14,Supporting & Related Material,FDA-2019-P-1636-0003,FDA-2019-P-1636,"Annexure I: Copy of Orange Book current through March 2019, listing the subject formulation NeostigmineMethylsulfate Injection, Solution 3 mg/3 mL (1 mg/1mL) NDA 203629. RE: Citizen Petition from Nexsen Pruet, LLC"
0900006483b69fea,Supporting & Related Material,FDA-2019-P-1636-0004,FDA-2019-P-1636,"Annexure II: Copy of Drugs@FDA listing subject formulation Neostigmine Methylsulfate Injection, Solution3 mg/3 mL (1 mg/1mL) NDA 203629. RE: Citizen Petition from Nexsen Pruet, LLC"
09000064848654bb,Other,FDA-2019-P-1636-0007,FDA-2019-P-1636,"Letter from FDA CDER to Nexsen Pruet, LLC"
0900006483fe2646,Other,FDA-2019-P-1636-0006,FDA-2019-P-1636,"Interim Response Letter from FDA CDER to Nexsen Pruet, LLC"
0900006483b6a24b,Supporting & Related Material,FDA-2019-P-1636-0005,FDA-2019-P-1636,"Annuxure III: Copy of current approved FDA labeling for Neostigmine Methylsulfate Injection, Solution 3mg/3 mL (1 mg/1mL) NDA 203629 dated November 20, 2018. RE: Citizen Petition from Nexsen Pruet, LLC"
0900006483b69dbf,Other,FDA-2019-P-1636-0001,FDA-2019-P-1636,"Citizen Petition from Nexsen Pruet, LLC"
090000648046a8cf,Other,FDA-2004-P-0020-0002,FDA-2004-P-0020,"HFA-305 to FERDIC, Incorporated"
090000648046a8cc,Other,FDA-2004-P-0020-0001,FDA-2004-P-0020,"HFA-305 to FERDIC, Incorporated"
090000648043ee1b,Other,FDA-2005-P-0057-0002,FDA-2005-P-0057,"HFA-305 to Hyman, Phelps & McNamara, P.C"
090000648043ee1c,Other,FDA-2005-P-0057-0003,FDA-2005-P-0057,"HFA-305 to Hyman, Phelps & McNamara, P.C"
090000648302a986,Other,FDA-2005-P-0057-0004,FDA-2005-P-0057,Withdraw memo FDA-2005-P-0057
090000648043ee10,Other,FDA-2005-P-0057-0001,FDA-2005-P-0057,"HFA-305 to Hyman, Phelps & McNamara, P.C"
0900006480830776,Supporting & Related Material,FDA-2009-P-0023-0011,FDA-2009-P-0023,"Tab 17 - FDA/CDRH ""Siemens Sonocur Basic-P010039,"" January 19, 2002"
0900006480830b74,Supporting & Related Material,FDA-2009-P-0023-0015,FDA-2009-P-0023,"Tab 30 - ""Physical Medicine Devices, 21CFR890.5975, April 1, 2008"" - [Electro Medical Systems Corporation - Citizen Petition]"
0900006480830b8b,Supporting & Related Material,FDA-2009-P-0023-0017,FDA-2009-P-0023,"Tab 32 - ""FDA/CDRH Premarket Notification 510(k), November 1, 2008"" - [Electro Medical Systems Corporation - Citizen Petition]"
0900006480830b6b,Supporting & Related Material,FDA-2009-P-0023-0014,FDA-2009-P-0023,"Tab 29 - ""Physical Medicine Devices, 21CFR890.5660, April 1, 2008"" - [Electro Medical Systems Corporation - Citizen Petition]"
09000064808305fe,Supporting & Related Material,FDA-2009-P-0023-0003,FDA-2009-P-0023,"Tab 5 - ""Guidance for Industry & for FDA Reviewers ""Guidance for the Content of Premarket Notifications (510(k)s) for Extracorporeal Shock Wave Lithotripters Indicated for The Fragmentation of Kidney & Ureteral Calculi,"" August 9, 2000 - [Electro Medical Systems Corporation - Citizen Petition]"
090000648083063b,Supporting & Related Material,FDA-2009-P-0023-0007,FDA-2009-P-0023,"Tab 13 - FD&C Act Chapter V, Sections 513-523  ""Drugs & Devices"""
0900006480830642,Supporting & Related Material,FDA-2009-P-0023-0008,FDA-2009-P-0023,"Tab 14 - CDRH Consumer Information ""New Device Approval: EMS Swiss Dolorclast-P050004,"" May 7, 2007"
090000648083075e,Supporting & Related Material,FDA-2009-P-0023-0010,FDA-2009-P-0023,"Tab 16-  FDA/CDRH ""Dornier Epos Ultra-P-000048,"" January 15, 2002"
090000648083080d,Supporting & Related Material,FDA-2009-P-0023-0012,FDA-2009-P-0023,"Tab 18 - ""FDA/CDRH Orthospec Extracorporeal Shock Wave Therapy Device-P040026, April 1, 2005"" - [Electro Medical Systems Corporation - Citizen Petition]"
09000064808208b2,Other,FDA-2009-P-0023-0001,FDA-2009-P-0023,Electro Medical Systems Corporation - Citizen Petition
0900006480820975,Other,FDA-2009-P-0023-0002,FDA-2009-P-0023,Acknowledgement Letter  to Electro Medical Systems Corporation
0900006480830624,Supporting & Related Material,FDA-2009-P-0023-0004,FDA-2009-P-0023,"Tab 10 - ""Guidance for the Content of Premarket Notifications ( ) for Extracorporeal Shock Wave..."" - [Electro Medical Systems Corporation - Citizen Petition]"
0900006480830632,Supporting & Related Material,FDA-2009-P-0023-0005,FDA-2009-P-0023,"Tab 11 - 21CFR 876.4480 - ""Gastroenterology-Urology Devices,"" April 1, 2008 - [Electro Medical Systems Corporation - Citizen Petition]"
0900006480830646,Supporting & Related Material,FDA-2009-P-0023-0009,FDA-2009-P-0023,"Tab 15 - FDA/CDRH ""Ossatron-P990086"" dated October 12, 2000"
0900006480830b82,Supporting & Related Material,FDA-2009-P-0023-0016,FDA-2009-P-0023,"Tab 31- ""Food and Drug Administration, HHS - 21CFR890.9, 1175"" - [Electro Medical Systems Corporation - Citizen Petition]"
0900006480830c19,Supporting & Related Material,FDA-2009-P-0023-0018,FDA-2009-P-0023,"Tab 48 - ""FDA/CDRH Guidance Document for the Preparation of Premarket Notification [510(k)] Applications for Therapeutic Massagers & Vibrators, July 26, 1995"" - [Electro Medical Systems Corporation - Citizen Petition]"
0900006480830c1e,Supporting & Related Material,FDA-2009-P-0023-0019,FDA-2009-P-0023,"Tabs 49 & 50 - ""FDA/CDRH 510(k) Premarket Notification Database"" - [Electro Medical Systems Corporation - Citizen Petition]"
0900006480830c27,Supporting & Related Material,FDA-2009-P-0023-0020,FDA-2009-P-0023,"Tab 51 - Letter to FDA/CDRH from Electro Medical Systems, Inc., dated January 2, 2008 - [Electro Medical Systems Corporation - Citizen Petition]"
0900006480830636,Supporting & Related Material,FDA-2009-P-0023-0006,FDA-2009-P-0023,"Tab 12 - 21CFR 876.5990 - ""Gastroenterology-Urology Devices,"" April 1, 2008"
0900006480830adc,Supporting & Related Material,FDA-2009-P-0023-0013,FDA-2009-P-0023,"Tab 19 - FDA/CDRH Orbasone Pain Relief System-P040039, August 10, 2005"" - [Electro Medical Systems Corporation - Citizen Petition]"
0900006482af779f,Other,FDA-2017-P-0970-0006,FDA-2017-P-0970,Interim response letter from FDA CFSAN to RiceBran Technologies
09000064834111b0,Other,FDA-2017-P-0970-0007,FDA-2017-P-0970,FDA-2017-P-0970-RiceBran Granting Response
09000064824c10f9,Supporting & Related Material,FDA-2017-P-0970-0003,FDA-2017-P-0970,Appendix A Proprietary Laboratory Reports re Citizen Petition from RiceBran Technologies
09000064824c1502,Supporting & Related Material,FDA-2017-P-0970-0004,FDA-2017-P-0970,Appendix B Studies Reviewed on the Effect of Rice Bran Fiber re Citizen Petition from RiceBran Technologies-2
09000064824c1503,Supporting & Related Material,FDA-2017-P-0970-0005,FDA-2017-P-0970,Appendix C Studies Reviewed on the Effect of Rice Bran Fiber re Citizen Petition from RiceBran Technologies-3
09000064824c10f5,Other,FDA-2017-P-0970-0001,FDA-2017-P-0970,Citizen Petition from RiceBran Technologies
09000064824c10f7,Other,FDA-2017-P-0970-0002,FDA-2017-P-0970,Acknowledgement Letter from FDA DDM to RiceBran Technologies
090000648379db93,Other,FDA-2017-P-2733-0006,FDA-2017-P-2733,Response Letter from FDA CDER to Esophageal Cancer Action Network Inc.
0900006482588d4e,Other,FDA-2017-P-2733-0001,FDA-2017-P-2733,Citizen Petition from Esophageal Cancer Action Network Inc.
0900006482588b7d,Other,FDA-2017-P-2733-0002,FDA-2017-P-2733,Acknowledgment Letter from FDA DDM to Esophageal Cancer Action Network Inc.
0900006482c0d2f4,Other,FDA-2017-P-2733-0004,FDA-2017-P-2733,Interim Response Letter from FDA CDER to Esophageal Cancer Action Network Inc.
090000648294ff0c,Supporting & Related Material,FDA-2017-P-4360-0009,FDA-2017-P-4360,Exhibit B Life-threatening effects of discontinuing inhaled nitric oxide in sever respiratory failure re Citizen Petition from Mallinckrodt Pharmaceuticals
090000648294ff0d,Supporting & Related Material,FDA-2017-P-4360-0008,FDA-2017-P-4360,Exhibit C Detention Without Physical Examination of Devices from Firms that Hae not met DQSR re Citizen Petition from Mallinckrodt Pharmaceuticals
090000648294ff3e,Supporting & Related Material,FDA-2017-P-4360-0004,FDA-2017-P-4360,"Exhibit G Praxair Distribution, Inc vs Mallinckrodt Hospital Products IP re Citizen Petition from Mallinckrodt Pharmaceuticals"
090000648294ff0b,Supporting & Related Material,FDA-2017-P-4360-0010,FDA-2017-P-4360,"Exhibit A Transcript of Proceedings, Anesthesiology and Respiratory Therapy Device Panel re Citizen Petition from Mallinckrodt Pharmaceuticals"
090000648294ff0e,Supporting & Related Material,FDA-2017-P-4360-0007,FDA-2017-P-4360,"Exhibit D Praxair Distribution, Inc v INO Therapeutics, LLC re Citizen Petition from Mallinckrodt Pharmaceuticals"
0900006482d155a8,Other,FDA-2017-P-4360-0014,FDA-2017-P-4360,Petition Denial Letter from FDA CDER to Mallinckrodt Pharmaceuticals
090000648294ff3a,Supporting & Related Material,FDA-2017-P-4360-0006,FDA-2017-P-4360,"Exhibit E Praxair Distribution, Inc v INO Therapeutics, LLC d b a Ikaria, Inc re Citizen Petition from Mallinckrodt Pharmaceuticals"
090000648294ff07,Other,FDA-2017-P-4360-0001,FDA-2017-P-4360,Citizen Petition from Mallinckrodt Pharmaceuticals
090000648294ff09,Other,FDA-2017-P-4360-0002,FDA-2017-P-4360,Acknowledgement Letter from FDA DDM to Mallinckrodt Pharmaceuticals
090000648294ff3f,Supporting & Related Material,FDA-2017-P-4360-0003,FDA-2017-P-4360,"Exhibit H Tissue Debate Raises Fairness, Transparency Questions for Combo re Citizen Petition from Mallinckrodt Pharmaceuticals"
0900006482b5c9fc,Other,FDA-2017-P-4360-0012,FDA-2017-P-4360,Supplement from Mallinckrodt Pharmaceuticals
090000648294ff3d,Supporting & Related Material,FDA-2017-P-4360-0005,FDA-2017-P-4360,"Exhibit F Declaration of Robert T. Stone, PhD re Citizen Petition from Mallinckrodt Pharmaceuticals"
0900006482e29c03,Other,FDA-2018-P-0266-0002,FDA-2018-P-0266,Acknowledgment Letter from FDA DDM to Arent Fox LLP
0900006483507295,Other,FDA-2018-P-0266-0003,FDA-2018-P-0266,Response Letter from FDA CDER to Arent Fox LLP
0900006482e29ba1,Other,FDA-2018-P-0266-0001,FDA-2018-P-0266,Citizen Petition from Arent Fox LLP
0900006481e13fd4,Other,FDA-2016-P-0187-0002,FDA-2016-P-0187,Acknowledgement Letter from FDA DDM to Hogan Lovells US LLP
0900006481e14158,Other,FDA-2016-P-0187-0001,FDA-2016-P-0187,Citizen Petition from United Therapeutics Corporation (Hogan Lovells US LLP)
0900006481e13fd7,Supporting & Related Material,FDA-2016-P-0187-0003,FDA-2016-P-0187,Index of Exhibits re Citizen Petition from United Therapeutics Corporation (Hogan Lovells US LLP)
0900006481e141a5,Supporting & Related Material,FDA-2016-P-0187-0006,FDA-2016-P-0187,Tab 3 Importance of Drug-Device Interaction in Determining Systemic Effects of Inhaled Corticosteroids re Citizen Petition from United Therapeutics Corporation (Hogan Lovells US LLP)
0900006481e14726,Supporting & Related Material,FDA-2016-P-0187-0010,FDA-2016-P-0187,Tab 7 Lung Deposition from Four Nebulizers re Citizen Petition from United Therapeutics Corporation (Hogan Lovells US LLP)
0900006481e1477a,Supporting & Related Material,FDA-2016-P-0187-0014,FDA-2016-P-0187,Tab 11 Demonstrating Bioequivalence of Locally Acting Orally Inhaled Drug Products re Citizen Petition from United Therapeutics Corporation (Hogan Lovells US LLP)
0900006481e1419f,Supporting & Related Material,FDA-2016-P-0187-0004,FDA-2016-P-0187,Tab 1 Anaesthetic and Respiratory Equipment - Nebulizing Systems and Components re Citizen Petition from United Therapeutics Corporation (Hogan Lovells US LLP)
0900006481e14725,Supporting & Related Material,FDA-2016-P-0187-0009,FDA-2016-P-0187,Tab 6 A Comparison of Commercial Jet Nebulizers re Citizen Petition from United Therapeutics Corporation (Hogan Lovells US LLP)
0900006481e14729,Supporting & Related Material,FDA-2016-P-0187-0013,FDA-2016-P-0187,Tab 10 Quality by Design for Orally Inhaled Drug Products re Citizen Petition from United Therapeutics Corporation (Hogan Lovells US LLP)
0900006481e14724,Supporting & Related Material,FDA-2016-P-0187-0008,FDA-2016-P-0187,"Tab 5 Medication Nebulizer Performance Effects of Diluent Volume, Nebulizer Flow, and Nebulizer Brand re Citizen Petition from United Therapeutics Corporation (Hogan Lovells US LLP)"
0900006481e141a4,Supporting & Related Material,FDA-2016-P-0187-0005,FDA-2016-P-0187,Tab 2 FDA Respiratory Drug Delivery Devices - A CDRH Perspective re Citizen Petition from United Therapeutics Corporation (Hogan Lovells US LLP)
090000648203811d,Other,FDA-2016-P-0187-0015,FDA-2016-P-0187,Petition Denial Response June 13 2016
0900006481e14727,Supporting & Related Material,FDA-2016-P-0187-0011,FDA-2016-P-0187,Tab 8 The Science of Nebulised Drug Delivery re Citizen Petition from United Therapeutics Corporation (Hogan Lovells US LLP)
0900006481e14728,Supporting & Related Material,FDA-2016-P-0187-0012,FDA-2016-P-0187,Tab 9 Ultrasonic Versus Jet Nebulization of Iloprost in Severe Pulmonary Hypertension re Citizen Petition from United Therapeutics Corporation (Hogan Lovells US LLP)
0900006481e141a6,Supporting & Related Material,FDA-2016-P-0187-0007,FDA-2016-P-0187,Tab 4 Selecting and Using Nebuliser Equipment re Citizen Petition from United Therapeutics Corporation (Hogan Lovells US LLP)
090000648185d613,Other,FDA-2014-P-0328-0003,FDA-2014-P-0328,"Interim Response from FDA/CDER to Hyman, Phelps & McNamara , P.C."
090000648167201e,Other,FDA-2014-P-0328-0002,FDA-2014-P-0328,"Acknowledgement Letter From FDA/DDM to Hyman, Phelps & McNamara, P.C."
090000648192b5ae,Other,FDA-2014-P-0328-0004,FDA-2014-P-0328,Citizens Petition Approval Letter to Robert Dormer and Gordon Johnston
0900006481671ff0,Other,FDA-2014-P-0328-0001,FDA-2014-P-0328,"Citizen Petition From Hyman, Phelps & McNamara , P.C."
0900006481c3519a,Other,FDA-2015-P-3085-0002,FDA-2015-P-3085,"Acknowledgement Letter from FDA DDM to Mid-Atlantic BioTherapeutics, Inc. [Virtual Regulatory Solutions]"
0900006481c348cd,Other,FDA-2015-P-3085-0001,FDA-2015-P-3085,"Citizen Petition From Mid-Atlantic BioTherapeutics, Inc. [Virtual Regulatory Solutions]"
0900006481cb7611,Other,FDA-2015-P-3085-0003,FDA-2015-P-3085,"Withdrawal of Citizen Petition from Mid-Atlantic BioTherapeutics, Inc."
0900006481d3ab83,Other,FDA-2015-P-4237-0002,FDA-2015-P-4237,Acknowledgement Letter from FDA DDM to Gland Pharma Limited
0900006481d4230d,Supporting & Related Material,FDA-2015-P-4237-0003,FDA-2015-P-4237,Attachment 1 Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (MESNEX) re Citizen Petition from Gland Pharma Limited
0900006481d42310,Supporting & Related Material,FDA-2015-P-4237-0004,FDA-2015-P-4237,Attachment 2 Approved Labeling (Package Insert) for MESNEX (Mesna) Injection re: Citizen Petition from Gland Pharma Limited
0900006481d42311,Supporting & Related Material,FDA-2015-P-4237-0005,FDA-2015-P-4237,"Attachment 3 The Draft Labeling (Package Insert) for the Proposed Mesna Injection, 20 mg/ mL (1 g/50 mL), Infusion Bag re: Citizen Petition from Gland Pharma Limited"
0900006481d3aaf7,Other,FDA-2015-P-4237-0001,FDA-2015-P-4237,Citizen Petition from Gland Pharma Limited
090000648378ae9d,Supporting & Related Material,FDA-2018-P-3730-0004,FDA-2018-P-3730,Attachment 2 Drugs @ FDA re: Citizen Petition from Aizant Drug Research Solutions Pvt. Ltd
090000648378abc4,Other,FDA-2018-P-3730-0002,FDA-2018-P-3730,Acknowledgment Letter from FDA DDM to Aizant Drug Research Solutions Pvt. Ltd.
0900006483a3947c,Notice,FDA-2018-P-3730-0006,FDA-2018-P-3730,"Determination That ESBRIET (Pirfenidone) Film Coated Tablets, 534 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
09000064837888d4,Other,FDA-2018-P-3730-0001,FDA-2018-P-3730,Citizen Petition from Aizant Drug Research Solutions Pvt. Ltd
0900006483a3b3c9,Other,FDA-2018-P-3730-0005,FDA-2018-P-3730,Letter from FDA CDER to Aziant Drug Research Solutions Pvt. Ltd.
090000648378ae9c,Supporting & Related Material,FDA-2018-P-3730-0003,FDA-2018-P-3730,Attachment 1 Orange Book  re: Citizen Petition from Aizant Drug Research Solutions Pvt. Ltd
090000648425d320,Notice,FDA-2019-P-3877-0003,FDA-2019-P-3877,"Determination That GLUCOPHAGE (Metformin Hydrochloride) Oral Tablets, 500 Milligrams, 850 Milligrams, and 1 Gram, and GLUCOPHAGE XR (Metformin Hydrochloride) Oral Extended-Release Tablets, 500 Milligrams and 750 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
0900006483e6b6a3,Other,FDA-2019-P-3877-0002,FDA-2019-P-3877,Acknowledgment Letter from FDA DMS to Harman Finochem Limited
0900006483e5c0a8,Other,FDA-2019-P-3877-0001,FDA-2019-P-3877,Citizen Petition from Harman Finochem Limited
090000648425fa9c,Other,FDA-2019-P-3877-0004,FDA-2019-P-3877,Response Letter to Harman Finochem Limited Updated from FDA CDER
090000648487a7a5,Other,FDA-2020-P-2013-0002,FDA-2020-P-2013,"Acknowledgment Letter from FDA DMS to Lachman Consulting Services, Inc."
090000648496deaf,Other,FDA-2020-P-2013-0003,FDA-2020-P-2013,Withdrawal from Lachman Consultant Services
090000648487a79f,Other,FDA-2020-P-2013-0001,FDA-2020-P-2013,"Citizen Petition from Lachman Consulting Services, Inc."
09000064826a5c0c,Supporting & Related Material,FDA-2017-P-3486-0006,FDA-2017-P-3486,"List of References  re Citizen Petition from BioMedEcon, LLC"
090000648269b7d2,Other,FDA-2017-P-3486-0002,FDA-2017-P-3486,"Acknowledgment Letter from FDA DDM to BioMedEcon, LLC"
09000064826a5c0f,Supporting & Related Material,FDA-2017-P-3486-0003,FDA-2017-P-3486,"Appendix  A: Product Inserts pramipexole, ropinirole, rotigotine re Citizen Petition from BioMedEcon, LLC"
090000648269b721,Other,FDA-2017-P-3486-0001,FDA-2017-P-3486,"Citizen Petition from BioMedEcon, LLC"
09000064826a53d1,Supporting & Related Material,FDA-2017-P-3486-0005,FDA-2017-P-3486,"Appendix C: PRESENTATIONS. ISPOR 2016,  AMCP 2016
SLEEP 2017 (Poster AND Oral Presentation) re Citizen Petition from BioMedEcon, LLC"
09000064840e4eea,Other,FDA-2017-P-3486-0016,FDA-2017-P-3486,Letter from CDER to Public Citizen
0900006482cb22ea,Other,FDA-2017-P-3486-0013,FDA-2017-P-3486,"Interim Response to BioMedEcon, LLC from FDA CDER"
09000064826a5c10,Supporting & Related Material,FDA-2017-P-3486-0004,FDA-2017-P-3486,"Appendix  B: SYSTEMATIC LITERATURE REVIEW. SEE ATTACHED EXCEL FILE re Citizen Petition from BioMedEcon, LLC"
090000648243b8fc,Supporting & Related Material,FDA-2016-P-4587-0006,FDA-2016-P-4587,"Exhibit D Praxair Distribution, Inc. v. INO Therapeutics, LLC,
IPR2015-00884 (Patent 8,291,904 B2); IPR2015-00888 (Patent
8,776,794 B2); IPR2015-00889 (Patent 8,573,209 B2); IPR2015-00891
(Patent 8,573,210 B2); IPR2015-00893 (Patent 8,776795 B2),
Transcript of Proceedings May 16, 2016 re Citizen Petition from Mallinckrodt Pharmaceuticals"
090000648243b92e,Supporting & Related Material,FDA-2016-P-4587-0009,FDA-2016-P-4587,"Exhibit G Praxair Distribution, Inc. vs. Mallinckrodt Hospital Products IP Ltd, IPR 2015-00893 (Patent: 8,776,795 B2), Petitioner’s Reply to Patent Owners Response, Feb. 24, 2016 re Citizen Petition from Mallinckrodt Pharmaceuticals"
090000648243b8f5,Other,FDA-2016-P-4587-0001,FDA-2016-P-4587,Citizen Petition from Mallinckrodt Pharmaceuticals
090000648243b8f7,Other,FDA-2016-P-4587-0002,FDA-2016-P-4587,Acknowledgement Letter from FDA DDM to Mallinckrodt Pharmaceuticals
090000648256de63,Other,FDA-2016-P-4587-0012,FDA-2016-P-4587,Supplement from Mallinckrodt Pharmaceuticals
090000648243b8fd,Supporting & Related Material,FDA-2016-P-4587-0007,FDA-2016-P-4587,"Exhibit E Praxair Distribution, Inc. v. INO Therapeutics, LLC d/b/a Ikaria, Inc., Petition for Inter Partes Review of U.S. Patent No. 8,776,795, March 16, 2015 re Citizen Petition from Mallinckrodt Pharmaceuticals"
090000648243b92f,Supporting & Related Material,FDA-2016-P-4587-0010,FDA-2016-P-4587,"Exhibit H Tissue Debate Raises Fairness, Transparency Questions for Combo
Products, The Gray Sheet (4/29/2002) re Citizen Petition from Mallinckrodt Pharmaceuticals"
090000648243b8fa,Supporting & Related Material,FDA-2016-P-4587-0004,FDA-2016-P-4587,Exhibit B Life-threatening effects of discontinuing inhaled nitric oxide in severe respiratory failure. Am. J. Respir. Crit. Care Med. 1996:153;1985-87 re Citizen Petition from Mallinckrodt Pharmaceuticals
090000648243b8fb,Supporting & Related Material,FDA-2016-P-4587-0005,FDA-2016-P-4587,"Exhibit C Import Alert # 89-04, Detention Without Physical Examination of Devices from Firms that Have not met Device Quality System
Requirements (March 16, 2016) (Excerpt) re Citizen Petition from Mallinckrodt Pharmaceuticals"
090000648243b92d,Supporting & Related Material,FDA-2016-P-4587-0008,FDA-2016-P-4587,"Exhibit F Declaration of Robert T. Stone, Ph.D., IPR (unassigned, Patent: 8,291,904), March 13, 2015 re Citizen Petition from Mallinckrodt Pharmaceuticals"
090000648243b8f9,Supporting & Related Material,FDA-2016-P-4587-0003,FDA-2016-P-4587,"Exhibit A Transcript of Proceedings, Anesthesiology and Respiratory Therapy Devices Panel of the Medical Devices Advisory Committee
(Nov. 22, 1996) re Citizen Petition from Mallinckrodt Pharmaceuticals"
090000648263f08a,Other,FDA-2016-P-4587-0013,FDA-2016-P-4587,FDA-2016-P-4587 Petition Denial Letter
0900006482040779,Other,FDA-2016-P-1650-0002,FDA-2016-P-1650,"Acknowledgement Letter from FDA DDM to Lannett Company, Inc."
0900006482040777,Other,FDA-2016-P-1650-0001,FDA-2016-P-1650,"Citizen Petition from Lannett Company, Inc."
0900006484a69419,Other,FDA-2016-P-1650-0006,FDA-2016-P-1650,"Withdrawal from Lannett Company, Inc."
090000648204077b,Supporting & Related Material,FDA-2016-P-1650-0003,FDA-2016-P-1650,"Attachment 1 PDUFA Exemption Information re Citizen Petition from Lannett Company, Inc."
090000648240cfb7,Other,FDA-2016-P-1650-0004,FDA-2016-P-1650,Interim Response Letter
0900006483aa8b52,Other,FDA-2016-P-1650-0005,FDA-2016-P-1650,Meeting on User Fee Issue for Approved Product
09000064846fee8a,Supporting & Related Material,FDA-2020-P-1601-0006,FDA-2020-P-1601,Appendix 3 RE: Citizen Petition from Informed Consent Action Network
09000064846feec5,Supporting & Related Material,FDA-2020-P-1601-0010,FDA-2020-P-1601,Appendix 7 RE: Citizen Petition from Informed Consent Action Network
09000064846feed4,Supporting & Related Material,FDA-2020-P-1601-0020,FDA-2020-P-1601,Appendix 17 RE: Citizen Petition from Informed Consent Action Network
09000064846fee84,Other,FDA-2020-P-1601-0002,FDA-2020-P-1601,Acknowledgment Letter from FDA DMS to  Siri & Glimstad LLP on behalf of  Informed Consent Action Network
090000648470223d,Supporting & Related Material,FDA-2020-P-1601-0025,FDA-2020-P-1601,COVER LETTER RE: Petition for Administrative Stay of Action from SIRI & GLIMSTAD LLP on behalf of Informed Consent Action Network
09000064846fee86,Supporting & Related Material,FDA-2020-P-1601-0003,FDA-2020-P-1601,COVER LETTER - APPENDIX TO CITIZEN PETITION RE: Citizen Petition from Informed Consent Action Network
09000064846fee89,Supporting & Related Material,FDA-2020-P-1601-0005,FDA-2020-P-1601,Appendix 2 RE: Citizen Petition from Informed Consent Action Network
09000064846fee8c,Supporting & Related Material,FDA-2020-P-1601-0008,FDA-2020-P-1601,Appendix 5 RE: Citizen Petition from Informed Consent Action Network
09000064846feec9,Supporting & Related Material,FDA-2020-P-1601-0014,FDA-2020-P-1601,Appendix 11 RE: Citizen Petition from Informed Consent Action Network
09000064846feecc,Supporting & Related Material,FDA-2020-P-1601-0017,FDA-2020-P-1601,Appendix 14 RE: Citizen Petition from Informed Consent Action Network
09000064849301c6,Supporting & Related Material,FDA-2020-P-1601-0043,FDA-2020-P-1601,Appendix 1 RE: Petition for Administrative Stay of Action from Informed Consent Action Network
090000648493135b,Supporting & Related Material,FDA-2020-P-1601-0057,FDA-2020-P-1601,Appendix 6 RE: Petition for Administrative Stay of Action from Informed Consent Action Network
09000064846fed23,Other,FDA-2020-P-1601-0001,FDA-2020-P-1601,Citizen Petition from Siri & Glimstad LLP on behalf of  Informed Consent Action Network
09000064846fee88,Supporting & Related Material,FDA-2020-P-1601-0004,FDA-2020-P-1601,Appendix 1 RE: Citizen Petition from Informed Consent Action Network
09000064846feed3,Supporting & Related Material,FDA-2020-P-1601-0019,FDA-2020-P-1601,Appendix 16 RE: Citizen Petition from Informed Consent Action Network
09000064846feeca,Supporting & Related Material,FDA-2020-P-1601-0015,FDA-2020-P-1601,Appendix 12 RE: Citizen Petition from Informed Consent Action Network
09000064846feed5,Supporting & Related Material,FDA-2020-P-1601-0021,FDA-2020-P-1601,Appendix 18 RE: Citizen Petition from Informed Consent Action Network
090000648470223e,Supporting & Related Material,FDA-2020-P-1601-0026,FDA-2020-P-1601,Attachment 1- Petition for Administrative Action to require placebo control group in clinical trials of Covid-19 Vaccines re: Petition for Administrative Stay of Action from SIRI & GLIMSTAD LLP on behalf of Informed Consent Action Network
09000064849312e8,Supporting & Related Material,FDA-2020-P-1601-0050,FDA-2020-P-1601,Appendix 13 RE: Petition for Administrative Stay of Action from Informed Consent Action Network
09000064849312e9,Supporting & Related Material,FDA-2020-P-1601-0051,FDA-2020-P-1601,Appendix 12 RE: Petition for Administrative Stay of Action from Informed Consent Action Network
0900006484931357,Supporting & Related Material,FDA-2020-P-1601-0056,FDA-2020-P-1601,Appendix 7 RE: Petition for Administrative Stay of Action from Informed Consent Action Network
09000064849301c7,Supporting & Related Material,FDA-2020-P-1601-0044,FDA-2020-P-1601,Appendix 2 RE: Petition for Administrative Stay of Action from Informed Consent Action Network
090000648499c70b,Other,FDA-2020-P-1601-0069,FDA-2020-P-1601,Denial Letter from FDA CBER to Siri & Glimstad LLP
0900006484701f91,Other,FDA-2020-P-1601-0024,FDA-2020-P-1601,Acknowledgment Letter from FDA DMS to Informed Consent Action Network
09000064849301c5,Supporting & Related Material,FDA-2020-P-1601-0042,FDA-2020-P-1601,Attachment 1- Petition for Administrative Action to require placebo control group in clinical trials of Covid-19 Vaccines re: Petition for Administrative Stay of Action from SIRI & GLIMSTAD LLP on behalf of Informed Consent Action Network
090000648042add9,Notice,FDA-2007-N-0218-0001,FDA-2007-N-0218,FDA
090000648042addd,Notice,FDA-2007-N-0218-0003,FDA-2007-N-0218,FDA
090000648042addc,Notice,FDA-2007-N-0218-0002,FDA-2007-N-0218,FDA
090000648042ade0,Supporting & Related Material,FDA-2007-N-0218-0006,FDA-2007-N-0218,Supporting Statement
090000648042addf,Supporting & Related Material,FDA-2007-N-0218-0005,FDA-2007-N-0218,Supporting Statement
090000648042adde,Notice,FDA-2007-N-0218-0004,FDA-2007-N-0218,FDA
0900006482cf30e7,Other,FDA-2017-P-6777-0002,FDA-2017-P-6777,"Acknowledgement Letter from FDA DDM to Hyman, Phelps & McNamara PC"
09000064833225be,Other,FDA-2017-P-6777-0003,FDA-2017-P-6777,"Interim Response Letter from FDA CDER to Hyman, Phelps & McNamara PC"
0900006484dad41d,Other,FDA-2017-P-6777-0004,FDA-2017-P-6777,"Withdrawal from Hyman, Phelps & McNamara, P.C."
0900006482cf2fdd,Other,FDA-2017-P-6777-0001,FDA-2017-P-6777,"Citizen Petition from Hyman, Phelps & McNamara, P.C. (on behalf of Xellia Pharmaceutical )"
09000064844833a6,Other,FDA-2019-P-4363-0007,FDA-2019-P-4363,"Letter from Hyman, Phelps & McNamara"
0900006483f958e2,Supporting & Related Material,FDA-2019-P-4363-0004,FDA-2019-P-4363,"Attachment 2 re Citizen Petition from Hyman, Phelps & McNamara, P. C."
0900006483f958e3,Supporting & Related Material,FDA-2019-P-4363-0005,FDA-2019-P-4363,"Attachment 3 re Citizen Petition from Hyman, Phelps & McNamara, P. C."
0900006483f958e1,Supporting & Related Material,FDA-2019-P-4363-0003,FDA-2019-P-4363,"Attachment 1 re Citizen Petition from Hyman, Phelps & McNamara, P. C."
0900006483f958de,Other,FDA-2019-P-4363-0002,FDA-2019-P-4363,Acknowledgment Letter from FDA DMS to Hyman Phelps & McNamara PC
0900006483f958dd,Other,FDA-2019-P-4363-0001,FDA-2019-P-4363,"Citizen Petition from Hyman, Phelps & McNamara, P. C."
0900006483f958e4,Supporting & Related Material,FDA-2019-P-4363-0006,FDA-2019-P-4363,"Attachment 4 re Citizen Petition from Hyman, Phelps & McNamara, P. C."
0900006484e23f62,Other,FDA-2019-P-4363-0008,FDA-2019-P-4363,"Citizen Petition Approval letter from FDA CDER to Hyman, Phelps & McNamara, P.C."
09000064839ecc86,Other,FDA-2019-P-0198-0001,FDA-2019-P-0198,"Citizen Petition from Lachman Consultant Services, Inc."
09000064839ecf67,Supporting & Related Material,FDA-2019-P-0198-0003,FDA-2019-P-0198,"Attachment-1-orange-book re Citizen Petition from Lachman Consultant Services, Inc."
0900006484165346,Other,FDA-2019-P-0198-0006,FDA-2019-P-0198,"Response Letter from FDA to Lachman Consultant Services, Inc"
0900006483d6ddeb,Other,FDA-2019-P-0198-0005,FDA-2019-P-0198,"Letter from FDA CDER to Lachman Consultant Services, Inc."
09000064839ecf68,Supporting & Related Material,FDA-2019-P-0198-0004,FDA-2019-P-0198,"Attachment-2-smz-tmp-os-ims-data re Citizen Petition from Lachman Consultant Services, Inc."
09000064839ecc87,Other,FDA-2019-P-0198-0002,FDA-2019-P-0198,"Acknowledgment Letter from FDA DDM to Lachman Consultant Services, Inc."
0900006480f735ce,Notice,FDA-2011-N-0841-0001,FDA-2011-N-0841,"Agency Information Collection Activities; Proposals, Submissions, and Approvals: Food Safety Modernization Act; Economic Hardship Fee Reduction Guidance"
090000648348dcc4,Other,FDA-2018-P-0097-0003,FDA-2018-P-0097,Interim Response from FDA CDER
0900006482db4257,Other,FDA-2018-P-0097-0002,FDA-2018-P-0097,"Acknowledgement Letter from FDA DDM to Hyman, Phelps & McNamara PC"
0900006482db339a,Other,FDA-2018-P-0097-0001,FDA-2018-P-0097,"Citizen Petition from Hyman, Phelps & McNamara"
0900006483988972,Other,FDA-2018-P-0097-0004,FDA-2018-P-0097,"Withdrawal  of Petition from Hyman, Phelps & McNamara PC"
0900006482e29cc6,Other,FDA-2018-P-0268-0002,FDA-2018-P-0268,Acknowledgment Letter from FDA DDM to Arent Fox LLP
09000064835078e8,Other,FDA-2018-P-0268-0003,FDA-2018-P-0268,Response Letter from FDA CDER to Arent Fox LLP
0900006482e29cc4,Other,FDA-2018-P-0268-0001,FDA-2018-P-0268,Citizen Petition from Arent Fox LLP
0900006482e29ccb,Other,FDA-2018-P-0269-0002,FDA-2018-P-0269,Acknowledgment Letter from FDA DDM to Arent Fox LLP
0900006482e29cc8,Other,FDA-2018-P-0269-0001,FDA-2018-P-0269,Citizen Petition from Arent Fox LLP
09000064835078ea,Other,FDA-2018-P-0269-0003,FDA-2018-P-0269,Response Letter from FDA CDER to Arent Fox LLP
0900006482eee360,Other,FDA-2018-P-0564-0002,FDA-2018-P-0564,"Acknowledgment Letter from FDA DDM to Panera, LLC"
09000064836cfaaa,Other,FDA-2018-P-0564-0006,FDA-2018-P-0564,"Interim Response Letter from FDA CFSAN to Panera, LLC"
0900006482eee149,Other,FDA-2018-P-0564-0001,FDA-2018-P-0564,Citizen Petition from Panera LLC
0900006482b4ddea,Supporting & Related Material,FDA-2017-P-5799-0003,FDA-2017-P-5799,Attachment 1 re Citizen Petition from Granules Pharmaceuticals Inc
090000648300c1ec,Other,FDA-2017-P-5799-0004,FDA-2017-P-5799,Interim Response Letter From FDA CDER to Granules Pharmaceuticals
0900006482b4dde8,Other,FDA-2017-P-5799-0002,FDA-2017-P-5799,Acknowledgement Letter from FDA DDM to Granules Pharmaceuticals Inc
09000064837fefbc,Other,FDA-2017-P-5799-0005,FDA-2017-P-5799,Response Letter From FDA CDER to Granules Pharmaceuticals
0900006482b4ddd9,Other,FDA-2017-P-5799-0001,FDA-2017-P-5799,Citizen Petition from Granules Pharmaceuticals Inc
0900006481843c80,Other,FDA-2014-P-0637-0005,FDA-2014-P-0637,Response Letter From FDA CDER to Lachman Consultant Services Inc.
09000064816fd343,Other,FDA-2014-P-0637-0001,FDA-2014-P-0637,"Citizen Petition From Lachman Consultant Services, Inc."
09000064816fd349,Supporting & Related Material,FDA-2014-P-0637-0002,FDA-2014-P-0637,Attachment 1 Orange Book Listing Citizen Petition from Lachman Consultant Services Inc
09000064816fd347,Other,FDA-2014-P-0637-0003,FDA-2014-P-0637,Acknowledgement Letter From FDA DDM to Lachman Consultant Services Inc.
090000648183b41a,Notice,FDA-2014-P-0637-0004,FDA-2014-P-0637,"Determination That FUSILEV (Levoleucovorin Calcium), Injection, 175 Milligrams/17.5 Milliliters and 250 Milligrams/25 Milliliters, Were Not
Withdrawn From Sale for Reasons of Safety or Effectiveness"
090000648172d9a8,Other,FDA-2014-P-0771-0001,FDA-2014-P-0771,Citizen Petition From Hope Pharmaceuticals
09000064817b2740,Other,FDA-2014-P-0771-0004,FDA-2014-P-0771,Withdrawal Letter From Hope Pharmaceuticals
09000064817559ac,Other,FDA-2014-P-0771-0003,FDA-2014-P-0771,Withdrawal Letter from Hope Pharmaceuticals
090000648172d9aa,Other,FDA-2014-P-0771-0002,FDA-2014-P-0771,Acknowledgement Letter From FDA DDM to Hope Pharmaceuticals
0900006480fd2112,Other,FDA-2011-P-0662-0003,FDA-2011-P-0662,FDA/CDER to Covington & Burling LLP (AstraZeneca Pharmaceuticals LP) - Petition Denial
0900006480f17198,Other,FDA-2011-P-0662-0001,FDA-2011-P-0662,Covington & Burling LLP (AstraZeneca Pharmaceuticals LP)  - Citizen Petition
0900006480f1719d,Other,FDA-2011-P-0662-0002,FDA-2011-P-0662,Acknowledgement Letter to Covington & Burling LLP (AstraZeneca Pharmaceuticals LP)
0900006481872fa9,Other,FDA-2014-P-1383-0001,FDA-2014-P-1383,Citizens Petition from Lachman Consultant Services Inc
0900006481872fab,Supporting & Related Material,FDA-2014-P-1383-0003,FDA-2014-P-1383,Attachment I Orange Book Approved Drug Products with Therapeutic Equivalence Evaluations
0900006481873288,Other,FDA-2014-P-1383-0002,FDA-2014-P-1383,Acknowledgement Letter From FDA DDM to Lachman Consultant Services Inc
0900006481873281,Supporting & Related Material,FDA-2014-P-1383-0004,FDA-2014-P-1383,Attachment II Highlights of Prescribing Information
0900006481873282,Supporting & Related Material,FDA-2014-P-1383-0005,FDA-2014-P-1383,Attachment III Highlights of Prescribing Information
0900006481873283,Supporting & Related Material,FDA-2014-P-1383-0006,FDA-2014-P-1383,Attachment IV Highlights of Prescribing Information
0900006481b4919a,Other,FDA-2015-P-2247-0002,FDA-2015-P-2247,Cover Letter re Citizen Petition from Tricia Spencer
0900006481b49196,Other,FDA-2015-P-2247-0003,FDA-2015-P-2247,Acknowledgement Letter from FDA DDM to Tricia Spencer
0900006481dba365,Other,FDA-2015-P-2247-0006,FDA-2015-P-2247,Interim Response Letter from FDA CFSAN to Tricia Spencer
0900006481b48dbd,Other,FDA-2015-P-2247-0001,FDA-2015-P-2247,Citizen Petition from Tricia Spencer
09000064838047c6,Other,FDA-2018-P-3949-0002,FDA-2018-P-3949,"ACKNOWLEDGMENT LETTER  from FDA DDM to LACHMAN CONSULTANT SERVICES, INC."
09000064838049e9,Supporting & Related Material,FDA-2018-P-3949-0003,FDA-2018-P-3949,"Attachment 1 Orange Book re: Citizens Petition from Lachman Consultant Services, Inc."
09000064838049ea,Supporting & Related Material,FDA-2018-P-3949-0004,FDA-2018-P-3949,"Attachment 2 HIGHLIGHTS OF PRESCRIBING INFORMATION re: Citizens Petition from Lachman Consultant Services, Inc."
0900006483bb9439,Notice,FDA-2018-P-3949-0006,FDA-2018-P-3949,"Determination That TRISENOX (Arsenic Trioxide) Injection, 1 Milligram/Milliliter, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
0900006483bba430,Other,FDA-2018-P-3949-0007,FDA-2018-P-3949,"Letter from FDA CDER to Lachman Consultant Services, Inc."
0900006483804597,Other,FDA-2018-P-3949-0001,FDA-2018-P-3949,"Citizens Petition from Lachman Consultant Services, Inc."
0900006483804b1e,Supporting & Related Material,FDA-2018-P-3949-0005,FDA-2018-P-3949,"Attachment 3 HIGHLIGHTS OF PRESCRIBING INFORMATION re: Citizen Petition from Lachman Consultant Services, Inc."
090000648420cba2,Other,FDA-2019-P-3424-0003,FDA-2019-P-3424,"Response Letter from FDA CDER to Medical Research Collaborative, LLC"
0900006483d99361,Other,FDA-2019-P-3424-0002,FDA-2019-P-3424,"Acknowledgment Letter from FDA DDM to Medical Research Collaborative, LLC"
0900006483d992c3,Other,FDA-2019-P-3424-0001,FDA-2019-P-3424,"Citizen Petition from Medical Research Collaborative, LLC"
0900006482c7bb0e,Supporting & Related Material,FDA-2017-P-6513-0010,FDA-2017-P-6513,Reference-File 2 Severe intestinal malabsorption associated with re Citizen Petition from Public Citizen
0900006482c7bb12,Supporting & Related Material,FDA-2017-P-6513-0006,FDA-2017-P-6513,Reference-File 6 Olmesartan Associated Sprue-Like Enteropathy and re Citizen Petition from Public Citizen
0900006482e8e423,Other,FDA-2017-P-6513-0012,FDA-2017-P-6513,Supplement from Public Citizen
090000648406ab20,Other,FDA-2017-P-6513-0016,FDA-2017-P-6513,Citizen Petition Denial Letter from FDA CDER to Public Citizen
0900006482c7c927,Other,FDA-2017-P-6513-0002,FDA-2017-P-6513,Acknowledgment Letter from FDA DDM to  Public Citizen
0900006482c7bb10,Supporting & Related Material,FDA-2017-P-6513-0008,FDA-2017-P-6513,Reference-File 4 Chronic Diarrhea and Weight Loss re Citizen Petition from Public Citizen
0900006482c7bb14,Supporting & Related Material,FDA-2017-P-6513-0004,FDA-2017-P-6513,Reference-File 8 Antihypertensive Efficacy of Olmesartan Medoxomil and Candesartan Cilexetil Assessed by 24-Hour Ambulatory Blood Pressure Monitoring in Patients with Essential Hypertension re Citizen Petition from Public Citizen
0900006482c7bb0f,Supporting & Related Material,FDA-2017-P-6513-0009,FDA-2017-P-6513,Reference-File 3 Letters to the Editor re Citizen Petition from Public Citizen
0900006482c7bb13,Supporting & Related Material,FDA-2017-P-6513-0005,FDA-2017-P-6513,Reference-File 7 “Triple Phase” Budesonide Capsules for re Citizen Petition from Public Citizen
090000648326326a,Other,FDA-2017-P-6513-0015,FDA-2017-P-6513,Interim Response from FDA CDER to Public Citizen
0900006482c7bb0d,Supporting & Related Material,FDA-2017-P-6513-0011,FDA-2017-P-6513,Reference-File 1 - The Comparative Efficacy and Safety of the Angiotensin Receptor re Citizen Petition from Public Citizen
0900006482c7bb11,Supporting & Related Material,FDA-2017-P-6513-0007,FDA-2017-P-6513,Reference-File 5 A Case of Severe Sprue-Like Enteropathy Associated With re Citizen Petition from Public Citizen
0900006482c7bd5e,Supporting & Related Material,FDA-2017-P-6513-0003,FDA-2017-P-6513,Reference-File 9 Comparison of Efficacy and Safety of Azilsartan and Olmesartan re Citizen Petition from Public Citizen
0900006482c7bb0b,Other,FDA-2017-P-6513-0001,FDA-2017-P-6513,Citizen Petition from Public Citizen
09000064830e75f6,Other,FDA-2017-P-6411-0010,FDA-2017-P-6411,"Petition Response Letter from FDA CDER to Insys Therapeutics, Inc."
0900006482c59270,Other,FDA-2017-P-6411-0002,FDA-2017-P-6411,"Acknowledgment Letter from Insys Therapeutics, Inc."
0900006482c5926d,Other,FDA-2017-P-6411-0001,FDA-2017-P-6411,"Citizen Petition from Insys Therapeutics, Inc."
09000064824b7391,Other,FDA-2017-P-0866-0002,FDA-2017-P-0866,Acknowledgment Letter from FDA DDM to Hyman Phelps & McNamara
0900006483238d48,Other,FDA-2017-P-0866-0004,FDA-2017-P-0866,"Response Letter from CDER to Hyman, Phelps & McNamara P.C."
09000064829d6aee,Other,FDA-2017-P-0866-0003,FDA-2017-P-0866,"Interim Response Letter from CDER to Hyman, Phelps & McNamara P.C."
09000064824b70a4,Other,FDA-2017-P-0866-0001,FDA-2017-P-0866,Citizen Petition from Hyman Phelps & McNamara
09000064826c79eb,Supporting & Related Material,FDA-2017-P-3675-0003,FDA-2017-P-3675,"Attachment  1- Orange Book Listing for Nalbuphine Hydrochloride Injection accessed on June 9, 2017"
09000064826c6c8f,Other,FDA-2017-P-3675-0001,FDA-2017-P-3675,"Citizen Petition from  Teligent Pharma, Inc."
09000064831471ab,Other,FDA-2017-P-3675-0005,FDA-2017-P-3675,Petition Denial Letter from FDA CDER to Teligent Pharma
09000064826c7565,Other,FDA-2017-P-3675-0002,FDA-2017-P-3675,Acknowledgement Letter from FDA DDM to Teligent Pharma Inc.
0900006482cc68f9,Other,FDA-2017-P-3675-0004,FDA-2017-P-3675,Interim Response Letter from FDA CDER to Teligent Pharma Inc.
090000648378e4dc,Supporting & Related Material,FDA-2018-P-3746-0003,FDA-2018-P-3746,Attachment 1 Orange Book Search Results re Citizen Petition from BF Innovation Inc on behalf of Bright Future Pharmaceutical Laboratories Limited
090000648378e81b,Other,FDA-2018-P-3746-0001,FDA-2018-P-3746,Citizen Petition from BF Innovation Inc on behalf of Bright Future Pharmaceutical Laboratories Limited
090000648378e81f,Other,FDA-2018-P-3746-0002,FDA-2018-P-3746,Acknowledgment Letter from FDA DDM to BF Innovation Inc on behalf of Bright Future Pharmaceutical Laboratories Limited
090000648378e4dd,Supporting & Related Material,FDA-2018-P-3746-0004,FDA-2018-P-3746,Attachment 2 FDA Correspondence Control re Citizen Petition from BF Innovation Inc on behalf of Bright Future Pharmaceutical Laboratories Limited
090000648383fec5,Other,FDA-2018-P-3746-0005,FDA-2018-P-3746,Letter re Citizen Petition from FDA CDER to BF Innovation Inc.
09000064844253ea,Supporting & Related Material,FDA-2020-P-1071-0003,FDA-2020-P-1071,"Attachment 1 FDA Orange Book page for OFIRMEV re Suitability Petition from Hyman, Phelps & McNamara, PC"
09000064844263de,Supporting & Related Material,FDA-2020-P-1071-0005,FDA-2020-P-1071,"Attachment 3 Proposed Prescribing Information for Acetaminophen Injection re Suitability Petition from Hyman, Phelps & McNamara, PC"
09000064844263dd,Supporting & Related Material,FDA-2020-P-1071-0004,FDA-2020-P-1071,"Attachment 2 Prescribing Information for OFIRMEV re Suitability Petition from Hyman, Phelps & McNamara, PC"
09000064844253e7,Other,FDA-2020-P-1071-0002,FDA-2020-P-1071,"Acknowledgment Letter from FDA DMS to Hyman, Phelps & McNamara, PC"
09000064844253e6,Other,FDA-2020-P-1071-0001,FDA-2020-P-1071,"Suitability Petition from Hyman, Phelps & McNamara, PC"
0900006483d97936,Other,FDA-2019-P-3156-0004,FDA-2019-P-3156,"Withdrawal from Medical Research Collaborative, LLC"
0900006483d51857,Other,FDA-2019-P-3156-0001,FDA-2019-P-3156,"Citizen Petition from Medical Research Collaborative, LLC"
0900006483d525cb,Other,FDA-2019-P-3156-0002,FDA-2019-P-3156,"Acknowledgment Letter from FDA DDM to Medical Research Collaborative, LLC"
0900006483fcecd6,Other,FDA-2019-P-4507-0001,FDA-2019-P-4507,Citizen Petition from Foley & Lardner LLP
09000064840e92fa,Other,FDA-2019-P-4507-0003,FDA-2019-P-4507,Withdrawal from Foley & Lardner LLP
0900006483fcf10d,Other,FDA-2019-P-4507-0002,FDA-2019-P-4507,Acknowledgment Letter from FDA DMS to Foley & Lardner LLP
0900006481ba8cfa,Other,FDA-2013-P-0608-0005,FDA-2013-P-0608,Supplement from Janssen
09000064821eb780,Other,FDA-2013-P-0608-0007,FDA-2013-P-0608,"Supplement from Janssen Research and Development, LLC"
09000064816afeba,Other,FDA-2013-P-0608-0004,FDA-2013-P-0608,"Supplement from Janssen Research & Development, LLC"
0900006484be923e,Other,FDA-2013-P-0608-0008,FDA-2013-P-0608,"Agency Response Letter from FDA CDER to Janssen Research and Development, L.L.C. (Ropes & Gray, LLP)"
0900006481e96981,Other,FDA-2013-P-0608-0006,FDA-2013-P-0608,"Supplement from Janssen Research and Development, LLC"
090000648147ae77,Other,FDA-2013-P-0608-0003,FDA-2013-P-0608,"FDA/CDER Interim Response to Ropes & Gray, LLP - Letter"
09000064812e43a1,Other,FDA-2013-P-0608-0002,FDA-2013-P-0608,"Acknowledgement Letter to Janssen Research and Development, L.L.C. (Ropes & Gray, LLP)"
09000064812e3ad5,Other,FDA-2013-P-0608-0001,FDA-2013-P-0608,"Janssen Research and Development, L.L.C. (Ropes & Gray, LLP) - Citizen Petition"
090000648042d8a5,Other,FDA-2007-P-0401-0001,FDA-2007-P-0401,FDA/DDM to Public Citizen Health Research Group
090000648042d8b8,Other,FDA-2007-P-0401-0002,FDA-2007-P-0401,Public Citizen Health Research Group - Citizen Petition
0900006480b1cb58,Other,FDA-2007-P-0401-0004,FDA-2007-P-0401,See FDA-2007-P-0401-0005
0900006480b1cb93,Other,FDA-2007-P-0401-0005,FDA-2007-P-0401,FDA/CDER to  Public Citizen's  Health Research Group- Petition Denial
090000648042d8bc,Other,FDA-2007-P-0401-0003,FDA-2007-P-0401,FDA/CDER Interim Response to Public Citizen's Health Research Group - Letter
0900006480470253,Supporting & Related Material,FDA-2004-D-0184-0007,FDA-2004-D-0184,Guidance
0900006480470250,Supporting & Related Material,FDA-2004-D-0184-0004,FDA-2004-D-0184,Supporting Statement
090000648047024f,Notice,FDA-2004-D-0184-0003,FDA-2004-D-0184,FDA
090000648047024b,Notice,FDA-2004-D-0184-0001,FDA-2004-D-0184,FDA
0900006480470251,Supporting & Related Material,FDA-2004-D-0184-0005,FDA-2004-D-0184,Supporting Statement
0900006480470252,Notice,FDA-2004-D-0184-0006,FDA-2004-D-0184,FDA
0900006480470254,Notice,FDA-2004-D-0184-0008,FDA-2004-D-0184,FDA
090000648047024c,Supporting & Related Material,FDA-2004-D-0184-0002,FDA-2004-D-0184,Guideline
0900006484d94422,Other,FDA-2021-P-1019-0002,FDA-2021-P-1019,"Acknowledgment Letter from FDA DMS to Emery Pharma on behalf of Najafi Pharma, Inc."
0900006484d9445a,Supporting & Related Material,FDA-2021-P-1019-0004,FDA-2021-P-1019,"Appendix B Independent Testimonial from Ilkcan Cokgor, MD, Neurologist. re Citizen Petition from Emery Pharma on behalf of Najafi Pharma, Inc."
0900006484d9441e,Other,FDA-2021-P-1019-0001,FDA-2021-P-1019,"Citizen Petition from Emery Pharma on behalf of Najafi Pharma, Inc."
0900006484d94457,Supporting & Related Material,FDA-2021-P-1019-0003,FDA-2021-P-1019,"Appendix A  Recommended Dietary Allowances (RDAs) for Vitamin B6 re Citizen Petition from Emery Pharma on behalf of Najafi Pharma, Inc."
0900006484e374e3,Supporting & Related Material,FDA-2021-P-1211-0003,FDA-2021-P-1211,Exhibit A re: Citizen Petition from Axinn on behalf of Par Sterile Products LLC
0900006484e374e4,Supporting & Related Material,FDA-2021-P-1211-0004,FDA-2021-P-1211,Exhibit B re: Citizen Petition from Axinn on behalf of Par Sterile Products LLC
0900006484e374e5,Supporting & Related Material,FDA-2021-P-1211-0005,FDA-2021-P-1211,Exhibit C re: Citizen Petition from Axinn on behalf of Par Sterile Products LLC
0900006484e3817e,Other,FDA-2021-P-1211-0001,FDA-2021-P-1211,Citizen Petition from Axinn on behalf of Par Sterile Products LLC
0900006484e374e6,Supporting & Related Material,FDA-2021-P-1211-0006,FDA-2021-P-1211,Exhibit D re: Citizen Petition from Axinn on behalf of Par Sterile Products LLC
0900006484e368f5,Other,FDA-2021-P-1211-0002,FDA-2021-P-1211,Acknowledgment Letter from FDA DMS to Axinn on behalf of Par Sterile Products LLC
0900006483e73ca4,Notice,FDA-2019-P-0466-0004,FDA-2019-P-0466,"Determination That Dextrose, 20 Grams/100 Milliliters, and Dextrose, 50
Grams/100 Milliliters, in Plastic Containers, Were Not Withdrawn From
Sale for Reasons of Safety or Effectiveness"
0900006483a28e12,Other,FDA-2019-P-0466-0002,FDA-2019-P-0466,"Acknowledgment Letter from FDA DDM to Fresenius Kabi USA, LLC"
0900006483a28e10,Other,FDA-2019-P-0466-0001,FDA-2019-P-0466,"Citizen Petition from Fresenius Kabi USA, LLC"
0900006483ebeecb,Other,FDA-2019-P-0466-0005,FDA-2019-P-0466,"Letter from FDA CDER to Fresenius Kabi USA, LLC"
0900006483db8d61,Other,FDA-2019-P-0466-0003,FDA-2019-P-0466,"Letter from FDA CDER to Fresenius Kabi USA, LLC"
0900006483c5ebb0,Other,FDA-2019-P-2290-0001,FDA-2019-P-2290,Citizen Petition from Alembic Pharmaceuticals Limited
0900006483c74f56,Other,FDA-2019-P-2290-0003,FDA-2019-P-2290,Acknowledgment Letter from FDA DDM to ALEMBIC PHARMACEUTICALS LIMITED
0900006483e2d0b1,Notice,FDA-2019-P-2290-0004,FDA-2019-P-2290,"Determination That LEVITRA (Vardenafil Hydrochloride) Tablets, 2.5
Milligrams Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
0900006483e3599b,Other,FDA-2019-P-2290-0005,FDA-2019-P-2290,Letter from FDA CDER to Alembic Pharmaceuticals Limited
0900006483c5f049,Supporting & Related Material,FDA-2019-P-2290-0002,FDA-2019-P-2290,"Exhibit-1- Orange Book: Approved Drug Products with
Therapeutic Equivalence Evaluations re: Citizen Petition from Syneos Health, LLC."
0900006482d58b5b,Other,FDA-2017-P-6967-0001,FDA-2017-P-6967,Citizen Petition from Bergstrom Nutrition
0900006482d58b5f,Other,FDA-2017-P-6967-0002,FDA-2017-P-6967,Acknowledgment Letter from FDA DDM to Bergstrom Nutrition
0900006482d58b61,Supporting & Related Material,FDA-2017-P-6967-0003,FDA-2017-P-6967,Appendix for Citizen Petition from Bergstrom Nutrition
09000064838a6958,Other,FDA-2017-P-3950-0004,FDA-2017-P-3950,Withdrawal from Piramal
0900006482d35e60,Other,FDA-2017-P-3950-0003,FDA-2017-P-3950,Interim Response from FDA to Amin Talati Upadhye LLP
09000064827976ff,Other,FDA-2017-P-3950-0002,FDA-2017-P-3950,Acknowledgment Letter Citizen Petition from  Amin Talati Upadhye LLP
0900006482797669,Other,FDA-2017-P-3950-0001,FDA-2017-P-3950,Citizen Petition from  Amin Talati Upadhye LLP (Fera Pharmaceuticals LLC)
090000648240195d,Other,FDA-2016-P-1363-0006,FDA-2016-P-1363,"Letter to Gordon Johnston Regulatory Consultants, LLC"
09000064823f9857,Notice,FDA-2016-P-1363-0005,FDA-2016-P-1363,"Determination That SODIUM CHLORIDE 23.4% IN PLASTIC CONTAINER 
(Sodium Chloride), Injectable, 234 Milligrams/Milliliter, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
09000064823a3c4c,Other,FDA-2016-P-1363-0004,FDA-2016-P-1363,"Interim Response Letter from CDER to Gordon Johnston Regulatory Consultants, LLC"
0900006481ff6f89,Other,FDA-2016-P-1363-0001,FDA-2016-P-1363,"Citizen Petition from Gordon Johnston Regulatory Consultants, LLC"
0900006481ff7191,Supporting & Related Material,FDA-2016-P-1363-0003,FDA-2016-P-1363,"Attachment 1 Product Listing from the Discontinued Section of Orange Book re Gordon Johnston Regulatory Consultants, LLC"
0900006481ff6f8b,Other,FDA-2016-P-1363-0002,FDA-2016-P-1363,"Acknowledgement Letter from FDA DDM to Gordon Johnston Regulatory Consultants, LLC"
090000648260d637,Other,FDA-2016-P-4274-0004,FDA-2016-P-4274,"Citizen Petition Response Letter from FDA CDER to Teligent, Inc."
09000064823eeac1,Other,FDA-2016-P-4274-0001,FDA-2016-P-4274,"Citizen Petition from Teligent, Inc."
09000064823eeb0c,Supporting & Related Material,FDA-2016-P-4274-0003,FDA-2016-P-4274,Attachment 1 - Orange Book  Listing for Mupirocin Ointment 2% re
09000064823eeb0a,Other,FDA-2016-P-4274-0002,FDA-2016-P-4274,"Acknowledgment Letter from FDA DDM to Teligent, Inc."
0900006481e841ad,Other,FDA-2016-P-0689-0001,FDA-2016-P-0689,"Citizen Petition from Leana Wen, M.D., M.Sc., Commissioner of Health, Baltimore City Department of Health, et al."
0900006481e84884,Other,FDA-2016-P-0689-0002,FDA-2016-P-0689,"Acknowledgement Letter from FDA DDM to the Commissioner of Health, Baltimore City Department of Health"
09000064821b8b47,Other,FDA-2016-P-0689-0003,FDA-2016-P-0689,"Response letter from FDA CDER to the Commissioner of Health, Baltimore City Department of Health"
0900006480e50859,Other,FDA-2011-P-0458-0002,FDA-2011-P-0458,Acknowledgement Letter to Personal Care Products Council
09000064824a69ef,Other,FDA-2011-P-0458-0005,FDA-2011-P-0458,Scanned Letter to Ms. Westine Personal Care Products Council no ccs
0900006480e43d1b,Other,FDA-2011-P-0458-0001,FDA-2011-P-0458,Personal Care Products Council - Citizen Peition
0900006480f7bda4,Other,FDA-2011-P-0458-0003,FDA-2011-P-0458,Interim Response to Personal Care Products Council  - Letter
0900006481acf2eb,Supporting & Related Material,FDA-2015-P-1553-0006,FDA-2015-P-1553,"Attachment 5 Teva Pharmaceutical Industries, Ltd. (Teva Respiratory, L.L.C.) - Citizen Petition; Citizen Petition from 3M Drug Delivery Systems"
0900006481acf30f,Supporting & Related Material,FDA-2015-P-1553-0013,FDA-2015-P-1553,Attachment 12 Correspondence from Dr. Eli Meltzer; Citizen Petition from 3M Drug Delivery Systems
0900006481c79ec3,Other,FDA-2015-P-1553-0015,FDA-2015-P-1553,Citizen Petition Denial Response Letter from FDA CDER to 3M Health Care Business
0900006481acf2e8,Supporting & Related Material,FDA-2015-P-1553-0004,FDA-2015-P-1553,Attachment 2 Combination Products; Citizen Petition from 3M Drug Delivery Systems
0900006481acf0ae,Other,FDA-2015-P-1553-0001,FDA-2015-P-1553,Citizen Petition from 3M Drug Delivery Systems
0900006481acf2ea,Supporting & Related Material,FDA-2015-P-1553-0005,FDA-2015-P-1553,Attachment 4 Asthma Attack Action Plan; Citizen Petition from 3M Drug Delivery Systems
0900006481acf2ed,Supporting & Related Material,FDA-2015-P-1553-0008,FDA-2015-P-1553,"Attachment 7 D.K. Raynor, P. Knapp, Do patients see, read and retain the new mandatory medicines information leaflets; Citizen Petition from 3M Drug Delivery Systems"
0900006481acf30d,Supporting & Related Material,FDA-2015-P-1553-0011,FDA-2015-P-1553,Attachment 10 Label and Labeling Review; Citizen Petition from 3M Drug Delivery Systems
0900006481acf2ec,Supporting & Related Material,FDA-2015-P-1553-0007,FDA-2015-P-1553,Attachment 6 Citizen Petition Partial Approval and Denial Response from FDA CDER to TEVA Pharmaceuticals; Citizen Petition from 3M Drug Delivery Systems
0900006481acf30e,Supporting & Related Material,FDA-2015-P-1553-0012,FDA-2015-P-1553,"Attachment 11 A Patients Guide to Aerosol Drug Delivery, American Association for Respiratory Care; Citizen Petition from 3M Drug Delivery Systems"
0900006481acf0af,Other,FDA-2015-P-1553-0002,FDA-2015-P-1553,Acknowledgement Letter from FDA DDM to 3M Drug Delivery Systems
0900006481acf2e7,Supporting & Related Material,FDA-2015-P-1553-0003,FDA-2015-P-1553,Attachment 1 Guidance for Industry Metered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI) Drug Products; Citizen Petition from 3M Drug Delivery System
0900006481acf2ee,Supporting & Related Material,FDA-2015-P-1553-0009,FDA-2015-P-1553,"Attachment 8 S. Vinker, V. Eliyahu, J. Yaphe, The effect of drug information leaflets on patient behavior; Citizen Petition from 3M Drug Delivery Systems"
0900006481acf2ef,Supporting & Related Material,FDA-2015-P-1553-0010,FDA-2015-P-1553,Attachment 9 FDA's Draft Guidance for Industry and Food and Drug Administration Staff- Applying Human Factors and Usability Engineering to Optimize Medical Device Design; Citizen Petition from 3M Drug Delivery Systems
09000064829fbead,Other,FDA-2017-P-4852-0002,FDA-2017-P-4852,Acknowledgment Letter from FDA DDM to EAS Consulting Group ( Jubilant Generics Ltd.)
0900006482f38a5a,Notice,FDA-2017-P-4852-0003,FDA-2017-P-4852,"Determination That LOTENSIN HCT (Benazepril Hydrochloride;
Hydrochlorothiazide) Oral Tablets, 5 Milligrams and 6.25 Milligrams, Were
Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
09000064829fbea9,Other,FDA-2017-P-4852-0001,FDA-2017-P-4852,Citizen Petition from  EAS Consulting Group ( Jubilant Generics Ltd.)
0900006482f5269c,Other,FDA-2017-P-4852-0004,FDA-2017-P-4852,"Letter from FDA CDER to Pharmaceutical & Device Consulting Services
EAS Consulting Group, LLC"
09000064824b6ea0,Other,FDA-2017-P-0863-0002,FDA-2017-P-0863,"Acknowledgment Letter from FDA DDM to  Fresenius Kabi USA, LLC"
09000064824b7155,Other,FDA-2017-P-0863-0001,FDA-2017-P-0863,"Citizen Petition from Fresenius Kabi USA, LLC"
09000064835f388e,Other,FDA-2017-P-0863-0004,FDA-2017-P-0863,REQUEST FOR WITHDRAWAL SP for PBP
09000064824b7157,Supporting & Related Material,FDA-2017-P-0863-0003,FDA-2017-P-0863,Attachment 1 Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations
0900006481a290b5,Other,FDA-2015-P-0051-0004,FDA-2015-P-0051,Inrange Trade Complaint Response Letter Final
09000064819a777c,Other,FDA-2015-P-0051-0001,FDA-2015-P-0051,Citizen Petition Request from Inrange Systems Inc
09000064819aaa1a,Other,FDA-2015-P-0051-0002,FDA-2015-P-0051,Acknowledgement Letter from FDA DDM to Inrange Systems Inc
09000064819aaa1e,Supporting & Related Material,FDA-2015-P-0051-0003,FDA-2015-P-0051,Exhibit A
090000648375b94d,Supporting & Related Material,FDA-2018-P-3616-0003,FDA-2018-P-3616,CHLOROQUINE PHOSPHATE 250MG TAB 06-2018- IMS Data re Citizen Petition from Suven Life Sciences Limited
090000648375b5b9,Other,FDA-2018-P-3616-0001,FDA-2018-P-3616,Citizen Petition from Suven Life Sciences Limited
090000648375b951,Supporting & Related Material,FDA-2018-P-3616-0007,FDA-2018-P-3616,Non-Availablity from Pharmacy re Citizen Petition from Suven Life Sciences Limited
090000648438e94c,Other,FDA-2018-P-3616-0011,FDA-2018-P-3616,Response Letter from FDA CDER to Suven Life Sciences Limited
090000648375b949,Other,FDA-2018-P-3616-0002,FDA-2018-P-3616,Acknowledgment Letter from FDA DDM to Suven Life Sciences Limited
0900006483b01dc5,Other,FDA-2018-P-3616-0010,FDA-2018-P-3616,Letter from FDA CDER to Suven Life Sciences Limited
090000648377501e,Other,FDA-2018-P-3616-0009,FDA-2018-P-3616,Acknowledgment Letter from FDA DDM to Suven Life Sciences Limited
090000648375b94f,Supporting & Related Material,FDA-2018-P-3616-0005,FDA-2018-P-3616,Environmental-Assesement re Citizen Petition from Suven Life Sciences Limited
090000648375b950,Supporting & Related Material,FDA-2018-P-3616-0006,FDA-2018-P-3616,National Drug Code Directory-chloroquine phosphate 250mg-15-09-2018 re Citizen Petition from Suven Life Sciences Limited
090000648375b94e,Supporting & Related Material,FDA-2018-P-3616-0004,FDA-2018-P-3616,DailyMed - RISING CHLOROQUINE PHOSPHATE 250MG - chloroquine phosphate tablet re Citizen Petition from Suven Life Sciences Limited
090000648375b968,Supporting & Related Material,FDA-2018-P-3616-0008,FDA-2018-P-3616,Orange Book_ Approved Drug Products with Therapeutic Equivalence Evaluations-250mg-natco re Citizen Petition from Suven Life Sciences Limited
09000064826c7646,Other,FDA-2017-P-3684-0001,FDA-2017-P-3684,"Citizen Petition from Goodwin Procter LLP (Boehringer Ingelheim USA Corporation (""BIUSA""))"
0900006482b4b3e1,Other,FDA-2017-P-3684-0004,FDA-2017-P-3684,Final Response Letter from FDA to Goodwin Procter LLP
09000064826c860b,Supporting & Related Material,FDA-2017-P-3684-0003,FDA-2017-P-3684,"Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease 2017 Report re Citizen Petition from Goodwin Procter LLP"
09000064826c8609,Other,FDA-2017-P-3684-0002,FDA-2017-P-3684,"Acknowledgment Letter from FDA DDM to Goodwin Procter LLP (Boehringer Ingelheim USA Corporation (""BIUSA""))"
0900006484817292,Other,FDA-2020-P-1792-0002,FDA-2020-P-1792,Acknowledgment Letter from FDA DMS to Macleods Pharmaceuticals Limited
0900006484817291,Other,FDA-2020-P-1792-0001,FDA-2020-P-1792,Citizen Petition from Macleods Pharmaceuticals Limited
090000648481763e,Supporting & Related Material,FDA-2020-P-1792-0003,FDA-2020-P-1792,Attachments from Citizen Petition from Macleods Pharmaceuticals Limited
090000648496ac0f,Other,FDA-2020-P-1792-0004,FDA-2020-P-1792,Withdrawal from Macleods Pharmaceuticals Limited
09000064846fb322,Supporting & Related Material,FDA-2020-P-1597-0022,FDA-2020-P-1597,Appendix 4 RE: Petition for Administrative Stay of Action from Informed Consent Action Network
09000064846fb342,Supporting & Related Material,FDA-2020-P-1597-0019,FDA-2020-P-1597,Appendix 7 RE: Petition for Administrative Stay of Action from Informed Consent Action Network
09000064846fb343,Supporting & Related Material,FDA-2020-P-1597-0018,FDA-2020-P-1597,Appendix 8 RE: Petition for Administrative Stay of Action from Informed Consent Action Network
09000064846fb346,Supporting & Related Material,FDA-2020-P-1597-0015,FDA-2020-P-1597,Appendix 11 RE: Petition for Administrative Stay of Action from Informed Consent Action Network
09000064846fb829,Supporting & Related Material,FDA-2020-P-1597-0012,FDA-2020-P-1597,Appendix 14 RE: Petition for Administrative Stay of Action from Informed Consent Action Network
09000064846fb321,Supporting & Related Material,FDA-2020-P-1597-0023,FDA-2020-P-1597,Appendix 3 RE: Petition for Administrative Stay of Action from Informed Consent Action Network
09000064846fb323,Supporting & Related Material,FDA-2020-P-1597-0021,FDA-2020-P-1597,Appendix 5 RE: Petition for Administrative Stay of Action from Informed Consent Action Network
09000064846fb326,Supporting & Related Material,FDA-2020-P-1597-0020,FDA-2020-P-1597,Appendix 6 RE: Petition for Administrative Stay of Action from Informed Consent Action Network
09000064846fb82e,Supporting & Related Material,FDA-2020-P-1597-0007,FDA-2020-P-1597,Appendix 19 RE: Petition for Administrative Stay of Action from Informed Consent Action Network
09000064846fb345,Supporting & Related Material,FDA-2020-P-1597-0016,FDA-2020-P-1597,Appendix 10 RE: Petition for Administrative Stay of Action from Informed Consent Action Network
09000064846fb82a,Supporting & Related Material,FDA-2020-P-1597-0011,FDA-2020-P-1597,Appendix 15 RE: Petition for Administrative Stay of Action from Informed Consent Action Network
09000064846fb344,Supporting & Related Material,FDA-2020-P-1597-0017,FDA-2020-P-1597,Appendix  RE: Petition for Administrative Stay of Action from Informed Consent Action Network
09000064846fb82d,Supporting & Related Material,FDA-2020-P-1597-0008,FDA-2020-P-1597,Appendix 18 RE: Petition for Administrative Stay of Action from Informed Consent Action Network
09000064846fb31f,Supporting & Related Material,FDA-2020-P-1597-0005,FDA-2020-P-1597,Appendix 1 RE: Petition for Administrative Stay of Action from Informed Consent Action Network
09000064846fb82b,Supporting & Related Material,FDA-2020-P-1597-0010,FDA-2020-P-1597,Appendix 16 RE: Petition for Administrative Stay of Action from Informed Consent Action Network
09000064846faf80,Supporting & Related Material,FDA-2020-P-1597-0003,FDA-2020-P-1597,COVER LETTER RE: Petition for Administrative Stay of Action from SIRI & GLIMSTAD LLP on behalf of Informed Consent Action Network
09000064846fb320,Supporting & Related Material,FDA-2020-P-1597-0006,FDA-2020-P-1597,Appendix 2 RE: Petition for Administrative Stay of Action from Informed Consent Action Network
09000064846fb347,Supporting & Related Material,FDA-2020-P-1597-0014,FDA-2020-P-1597,Appendix 12 RE: Petition for Administrative Stay of Action from Informed Consent Action Network
09000064846fb348,Supporting & Related Material,FDA-2020-P-1597-0013,FDA-2020-P-1597,Appendix 13 RE: Petition for Administrative Stay of Action from Informed Consent Action Network
09000064846fb82c,Supporting & Related Material,FDA-2020-P-1597-0009,FDA-2020-P-1597,Appendix 17 RE: Petition for Administrative Stay of Action from Informed Consent Action Network
09000064846fb0f2,Supporting & Related Material,FDA-2020-P-1597-0004,FDA-2020-P-1597,Attachment 1- Petition for Administrative Action to require placebo control group in clinical trials of Covid-19 Vaccines re: Petition for Administrative Stay of Action from SIRI & GLIMSTAD LLP on behalf of Informed Consent Action Network
09000064846faf7e,Other,FDA-2020-P-1597-0002,FDA-2020-P-1597,Acknowledgment Letter from FDA DMS to Informed Consent Action Network
09000064846fab05,Other,FDA-2020-P-1597-0001,FDA-2020-P-1597,Petition for Administrative Stay of Action from Informed Consent Action Network
0900006484dfa7d2,Other,FDA-2021-P-1174-0002,FDA-2021-P-1174,Acknowledgment Letter from FDA DMS to Felix Pharmaceuticals Pvt Ltd
0900006484dfa7f6,Other,FDA-2021-P-1174-0001,FDA-2021-P-1174,Suitability Petition from Felix Pharmaceuticals Pvt Ltd
0900006484dfa6de,Supporting & Related Material,FDA-2021-P-1174-0003,FDA-2021-P-1174,Attachment 1 re Suitability Petition from Felix Pharmaceuticals Pvt Ltd
0900006484dfa6df,Supporting & Related Material,FDA-2021-P-1174-0004,FDA-2021-P-1174,Attachment 2 re Suitability Petition from Felix Pharmaceuticals Pvt Ltd
090000648207fcb3,Other,FDA-2016-P-1875-0002,FDA-2016-P-1875,Acknowledgement Letter from FDA DDM to Pacific-Link Consulting (Adapt Pharma)
090000648207fcb0,Other,FDA-2016-P-1875-0001,FDA-2016-P-1875,Citizen Petition from Pacific-Link Consulting (Adapt Pharma)
090000648213651b,Other,FDA-2016-P-1875-0003,FDA-2016-P-1875,Adapt Pharma Withdrawal 13Jul2016
09000064829509ec,Other,FDA-2016-P-3753-0007,FDA-2016-P-3753,Petition Response Letter from FDA CDER to MacLeods Pharmaceuticals Limited
09000064823840c0,Supporting & Related Material,FDA-2016-P-3753-0004,FDA-2016-P-3753,Attachment 2 Horizon Pharma plc Announces Acquisition of U.S. Rights to PENNSAID® 2% From Nuvo Research Inc. re Citizen Petition from Macleods Pharmaceuticals Limited
09000064823840bd,Other,FDA-2016-P-3753-0001,FDA-2016-P-3753,Citizen Petition from MacLeods Pharmaceuticals Limited
09000064823840c1,Supporting & Related Material,FDA-2016-P-3753-0005,FDA-2016-P-3753,Attachment 3 Growth Dynamics Audit from September 2012 to September 2016 re Citizen Petition from Macleods Pharmaceuticals Limited
0900006482595541,Other,FDA-2016-P-3753-0006,FDA-2016-P-3753,Interim Response Letter from FDA CDER to MacLeods Pharmaceuticals Limited
09000064823840bf,Supporting & Related Material,FDA-2016-P-3753-0003,FDA-2016-P-3753,Attachment 1 Approved Drug Products with Therapeutic Equivalence Evaluations re Citizen Petition from Macleods Pharmaceuticals Limited
09000064823856b2,Other,FDA-2016-P-3753-0002,FDA-2016-P-3753,Acknowledgment Letter from FDA DDM to MacLeods Pharmaceuticals Limited
0900006481a8aa21,Supporting & Related Material,FDA-2015-P-1090-0004,FDA-2015-P-1090,"Attachment B, Product Labeling for Cortifoam re Citizen Petition from Baker Hostetler, LLP"
0900006481a8a325,Other,FDA-2015-P-1090-0001,FDA-2015-P-1090,"Citizen Petition from Baker Hostetler, LLP"
0900006481c9f521,Other,FDA-2015-P-1090-0005,FDA-2015-P-1090,Interim Response Letter from FDA CDER to Baker Hostetler LLP
0900006481a8a327,Other,FDA-2015-P-1090-0002,FDA-2015-P-1090,"Acknowledgement Letter from FDA DDM to Baker Hostetler, LLP"
0900006481a8a329,Supporting & Related Material,FDA-2015-P-1090-0003,FDA-2015-P-1090,"Attachment A Background Materials re Citizen Petition from Baker Hostetler, LLP"
09000064824b9d45,Other,FDA-2017-P-0899-0001,FDA-2017-P-0899,"Citizen Petition from  Hyman, Phelps & McNamara, P.C."
09000064824b9d47,Other,FDA-2017-P-0899-0002,FDA-2017-P-0899,"Acknowledgment Letter from FDA DDM to Hyman, Phelps & McNamara,
 P. C."
090000648425184b,Supporting & Related Material,FDA-2019-P-6048-0003,FDA-2019-P-6048,"Attachment 1 Orange Book Listing of Sodium Chloride 0.9% Irrigation USP re Suitability Petition from Fresenius Kabi USA, LLC"
090000648425184d,Supporting & Related Material,FDA-2019-P-6048-0005,FDA-2019-P-6048,"Attachment 3 Fresenius Kabi Proposed Package Insert for Sodium Chloride 0.9% Irrigation USP re Suitability Petition from Fresenius Kabi USA, LLC"
090000648425197e,Other,FDA-2019-P-6048-0002,FDA-2019-P-6048,"Acknowledgment Letter from FDA DMS to Fresenius Kabi USA, LLC"
090000648425197d,Other,FDA-2019-P-6048-0001,FDA-2019-P-6048,"Suitability Petition from Fresenius Kabi USA, LLC"
090000648425184c,Supporting & Related Material,FDA-2019-P-6048-0004,FDA-2019-P-6048,"Attachment 2 Reference Listed Drug Labeling Sodium Chloride 0.9% Irrigation USP re Suitability Petition from Fresenius Kabi USA, LLC"
09000064844721dd,Other,FDA-2020-P-1166-0005,FDA-2020-P-1166,Agency Response  Letter from FDA CDRH to Eckert Seamans Cherin & Mellott LLC
0900006484461b47,Other,FDA-2020-P-1166-0002,FDA-2020-P-1166,Acknowledgment Letter from FDA DMS to Eckert Seamans Cherin & Mellott LLC
0900006484461b46,Supporting & Related Material,FDA-2020-P-1166-0004,FDA-2020-P-1166,"Petition for Stay of Action Cover Letter from Eckert Seamans Cherin & Mellott, LLC re: PETITION FOR STAY OF ACTION  from Eckert Seamans Cherin & Mellott, LLC"
0900006484461b49,Supporting & Related Material,FDA-2020-P-1166-0003,FDA-2020-P-1166,"EXHIBIT LIST re: PETITION FOR STAY OF ACTION  from Eckert Seamans Cherin & Mellott, LLC"
0900006484461b44,Other,FDA-2020-P-1166-0001,FDA-2020-P-1166,"PETITION FOR STAY OF ACTION  from Eckert Seamans Cherin & Mellott, LLC"
0900006483ebee56,Other,FDA-2019-P-4003-0002,FDA-2019-P-4003,Acknowledgment Letter from FDA DMS to Lisa Myslinski
0900006483ebee54,Other,FDA-2019-P-4003-0001,FDA-2019-P-4003,Citizen Petition from Lisa Myslinski
09000064843bc552,Other,FDA-2019-P-4003-0003,FDA-2019-P-4003,Letter from FDA CDER to Lisa Myslinski
09000064829e1136,Other,FDA-2017-P-4791-0002,FDA-2017-P-4791,"Acknowledgement Letter from DDM to Hyman, Phelps, & McNamara, P.C. (Exela Pharma Sciences )"
0900006484a6c81c,Other,FDA-2017-P-4791-0005,FDA-2017-P-4791,"Withdrawal from Hyman, Phelps, & McNamara, P.C. (Exela Pharma Sciences)"
09000064829e0d34,Other,FDA-2017-P-4791-0001,FDA-2017-P-4791,"Citizen Petition from Hyman, Phelps, & McNamara, P.C. (Exela Pharma Sciences )"
0900006482e9d32a,Other,FDA-2017-P-4791-0004,FDA-2017-P-4791,"Interim Response Letter from CDER to Hyman, Phelps, & McNamara, P.C."
09000064836ce115,Supporting & Related Material,FDA-2018-P-3422-0004,FDA-2018-P-3422,"Attachment 2 Regulatory Agent Appointment Letter for the NDA #013718, OXANDRIN®( oxandrolone) Tablets, USP 2.5 mg and IO mg. RE: Citizen Petition from Novitium Pharma LLC"
09000064836cd6a5,Other,FDA-2018-P-3422-0002,FDA-2018-P-3422,Acknowledgment Letter from FDA DDM to Novitum Pharma LLC
0900006483abc92d,Other,FDA-2018-P-3422-0005,FDA-2018-P-3422,Letter from FDA CDER to NOVITIUM PHARMA LLC
0900006484a81ee7,Other,FDA-2018-P-3422-0006,FDA-2018-P-3422,Withdrawal from Novitium Pharma LLC
09000064836cb83c,Other,FDA-2018-P-3422-0001,FDA-2018-P-3422,Citizen Petition from Novitium Pharma LLC.
09000064836cd83a,Supporting & Related Material,FDA-2018-P-3422-0003,FDA-2018-P-3422,Attachment 1- Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations  RE; Citizen Petition from Novitium Pharma LLC
0900006484932182,Other,FDA-2020-P-2130-0002,FDA-2020-P-2130,"Acknowledgment Letter from FDA DMS to Fresenius Kabi USA, LLC"
09000064849327de,Supporting & Related Material,FDA-2020-P-2130-0003,FDA-2020-P-2130,"Attachment A: Product listing from the current (26 October 2020) Orange Book for Bortezomib for Injection RE Citizen Petition from Fresenius Kabi USA, LLC"
0900006484b7c3cf,Other,FDA-2020-P-2130-0006,FDA-2020-P-2130,"Withdrawal Request  from Fresenius Kabi USA, LLC"
0900006484932181,Other,FDA-2020-P-2130-0001,FDA-2020-P-2130,"Citizen Petition from Fresenius Kabi USA, LLC"
090000648046ff88,Other,FDA-2004-P-0151-0007,FDA-2004-P-0151,McNeil Consumer & Specialty Pharmaceuticals - Supplement Petition
090000648046ff68,Other,FDA-2004-P-0151-0003,FDA-2004-P-0151,FDA CDER Interim Response to McNeil Consumer & Specialty Pharmaceuticals - Letter
09000064810a5045,Other,FDA-2004-P-0151-0011,FDA-2004-P-0151,"Johnson & Johnson Pharmaceutical Research & Development, LLC - Petition Partial Approval and Denial"
090000648046ff50,Other,FDA-2004-P-0151-0002,FDA-2004-P-0151,Acknowledgement Letter to McNeil Consumer & Specialty Pharmaceuticals
09000064807cd1af,Other,FDA-2004-P-0151-0009,FDA-2004-P-0151,McNeil Pediatrics - Amendment Petition
090000648046ff48,Other,FDA-2004-P-0151-0004,FDA-2004-P-0151,McNeil Consumer & Specialty Pharmaceuticals - Citizen Petition
09000064807cef24,Supporting & Related Material,FDA-2004-P-0151-0005,FDA-2004-P-0151,Reference List (Volume 2) - McNeil Consumer & Specialty Pharmaceuticals - Citizen Petition]
090000648046ff44,Other,FDA-2004-P-0151-0001,FDA-2004-P-0151,Acknowledgement Letter to McNeil Consumer & Specialty Pharmaceuticals
09000064807cef33,Supporting & Related Material,FDA-2004-P-0151-0006,FDA-2004-P-0151,"References - ""21 CFR 320.1, 21 CFR 320.24, and 21 CFR 320.26"" - [McNeil Consumer & Specialty Pharmaceuticals - Citizen Petition]"
090000648046ff69,Supporting & Related Material,FDA-2004-P-0151-0008,FDA-2004-P-0151,Reference Documents (Volume 1) - McNeil Consumer & Specialty Pharmaceuticals - Supplement Petition]
0900006480af00c6,Other,FDA-2004-P-0151-0010,FDA-2004-P-0151,McNeil Consumer & Specialty Pharmaceuticals - Supplement
090000648039acfd,Notice,FDA-2008-N-0025-0001,FDA-2008-N-0025,Agency Information Collection Activities; Proposed Collection; Comment Request; Orphan Drugs; Common European Medicines Agency/Food and Drug Administration Application Form for Orphan Medicinal Product Designation (Form FDA 3671)
090000648314f332,Supporting & Related Material,FDA-2018-P-1531-0006,FDA-2018-P-1531,"Attachment 4 Ephedrine Sulfate Injection, USP re Petition from King & Spalding LLP"
090000648314f316,Other,FDA-2018-P-1531-0002,FDA-2018-P-1531,Acknowledgment Letter from FDA DDM to King & Spalding LLP
090000648314f31d,Supporting & Related Material,FDA-2018-P-1531-0003,FDA-2018-P-1531,Attachment 1 Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations re Petition from King & Spalding LLP
090000648314f31f,Supporting & Related Material,FDA-2018-P-1531-0004,FDA-2018-P-1531,Attachment 2 Atropine and Ephedrine: A Significant Waste in the Operating Theatre re Petition from King & Spalding LLP
090000648314f331,Supporting & Related Material,FDA-2018-P-1531-0005,FDA-2018-P-1531,Attachment 3 AKOVAZ - Ephedrine Sulfate Injection re Petition from King & Spalding LLP
090000648314f2ba,Other,FDA-2018-P-1531-0001,FDA-2018-P-1531,Petition from King & Spalding LLP
0900006484e501e3,Other,FDA-2018-P-1531-0008,FDA-2018-P-1531,Denial Letter from CDER to King & Spalding LLP
09000064823c9414,Other,FDA-2016-P-4095-0002,FDA-2016-P-4095,"Acknowledgment Letter from FDA DDM to Mapi USA, Inc."
0900006483a5ea57,Other,FDA-2016-P-4095-0004,FDA-2016-P-4095,"Amendment to Citizen Petition from Mapi USA, Inc.  (Medunik Canada Ltd.)"
09000064823c6ed2,Supporting & Related Material,FDA-2016-P-4095-0003,FDA-2016-P-4095,"Appendices 1 - HIGHLIGHTS OF PRESCRIBING INFORMATION  re Citizen Petition from Mapi USA, Inc.  (Medunik Canada Ltd.)"
09000064823c6e05,Other,FDA-2016-P-4095-0001,FDA-2016-P-4095,"Citizen Petition from Mapi USA, Inc.  (Medunik Canada Ltd.)"
0900006482400770,Supporting & Related Material,FDA-2016-P-4341-0003,FDA-2016-P-4341,"Exhitbit 1 Physiologically Based Pharmacokinetic Modeling for Substitutability Analysis of Venlafaxine Hydrochloride Extended-Release
Formulations Using Different Release Mechanisms: Osmotic Pump
Versus Openable Matrix re Citizen Petition from Osmotica Pharmaceutical US LLC"
0900006482400773,Supporting & Related Material,FDA-2016-P-4341-0006,FDA-2016-P-4341,"Exhitbit 4 In Vivo Bioequivalence and In Vitro Similarity Factor (f2)
for Dissolution Profile Comparisons of Extended Release Formulations: How and When Do They Match? re Citizen Petition from Osmotica Pharmaceutical US LLC"
0900006482400771,Supporting & Related Material,FDA-2016-P-4341-0004,FDA-2016-P-4341,Exhitbit 2 Brand-Generic Substitutability Analysis of Venlafaxine Hydrochloride Extended-Release Tablets Based on Openable Matrix and Osmotic Pump Using PBPK Modeling and Simulation re Citizen Petition from Osmotica Pharmaceutical US LLC
0900006482400772,Supporting & Related Material,FDA-2016-P-4341-0005,FDA-2016-P-4341,Exhitbit 3 Innovative approaches for demonstration of bioequivalence: the US FDA perspective re Citizen Petition from Osmotica Pharmaceutical US LLC
0900006482526d6f,Other,FDA-2016-P-4341-0007,FDA-2016-P-4341,Citizen Petition Denial Letter from FDA CDER to Osmotica Pharmaceutical Corp.
090000648240076c,Other,FDA-2016-P-4341-0001,FDA-2016-P-4341,Citizen Petition from Osmotica Pharmaceutical US LLC
090000648240076e,Other,FDA-2016-P-4341-0002,FDA-2016-P-4341,Acknowledgement Letter from FDA DDM to Osmotica Pharmaceutical US LLC
09000064820aa5a9,Other,FDA-2016-P-2072-0001,FDA-2016-P-2072,Citizen Petition from Pacific-Link Consulting (Adapt Pharma)
09000064823f568a,Other,FDA-2016-P-2072-0005,FDA-2016-P-2072,Partial petition approval and denial letter from CDER FDA to Pacific-Link Consulting
09000064820aa76d,Other,FDA-2016-P-2072-0002,FDA-2016-P-2072,Acknowledgement Letter from FDA DDM to Pacific Link Consulting (Adapt Pharma)
090000648131aee8,Notice,FDA-2013-N-0653-0001,FDA-2013-N-0653,"Agency InAgency Information Collection Activities; Proposed Collection; Comment Request; Orphan Drugs; Common European Medicines Agency/Food and Drug Administration Application Form for Orphan Medicinal Product Designation (Form FDA 3671)formation Collection Activities; Proposals, Submissions, and Approvals: Orphan Drugs, etc."
09000064825921af,Other,FDA-2015-P-2820-0073,FDA-2015-P-2820,Declaration of Michael Vokhgelt
0900006481ecf142,Supporting & Related Material,FDA-2015-P-2820-0059,FDA-2015-P-2820,Exhibit 1 Advancing Regulatory Science at FDA August 2011 re: Amendment from Center for Responsible Science
0900006481ecf1a0,Supporting & Related Material,FDA-2015-P-2820-0067,FDA-2015-P-2820,"Exhibit 14 Attarwala, H. TGN1412; From Discovery to Disaster re: Amendment from Center for Responsible Science"
0900006481ecf1a7,Supporting & Related Material,FDA-2015-P-2820-0070,FDA-2015-P-2820,"Exhibit 21 Lougheed, K. Hepatitis C drug trial halted after patient death August 24, 2012 re: Amendment from Center for Responsible Science"
09000064828d1db1,Other,FDA-2015-P-2820-0074,FDA-2015-P-2820,Amendment (third)  from Center for Responsible Science (CRS)
0900006481eceacd,Other,FDA-2015-P-2820-0058,FDA-2015-P-2820,Amendment from Center for Responsible Science (CRS)
0900006482b8c81c,Other,FDA-2015-P-2820-0075,FDA-2015-P-2820,Amendment (Fourth)  from Center for Responsible Science (CRS)
0900006481bbb056,Supporting & Related Material,FDA-2015-P-2820-0005,FDA-2015-P-2820,Exhibit B Regulation Updates re Citizen Petition from the Center for Responsible Science
0900006481bbadf8,Other,FDA-2015-P-2820-0001,FDA-2015-P-2820,Citizen Petition from Alston and Bird (the Center for Responsible Science)
0900006481eb5c8b,Supporting & Related Material,FDA-2015-P-2820-0056,FDA-2015-P-2820,"Status Inquiry re Requests that the FDA modify existing regulations in Title 21 of the Code of Federal Regulations (CFR) that govern requirements for investigational new drug (IND) applications, investigational device exemptions (IDE), and new drug applications (NDAs)."
0900006481ecf199,Supporting & Related Material,FDA-2015-P-2820-0061,FDA-2015-P-2820,Exhibit 7 Online News Articles from Different Organizations re: Amendment from Center for Responsible Science
0900006481ecf19f,Supporting & Related Material,FDA-2015-P-2820-0066,FDA-2015-P-2820,"Exhibit 13 Brennan EMA Will Assess ANSM Review of Botched Clinical Trial in France, January 19, 2016 re: Amendment from Center for Responsible Science"
090000648256fe13,Other,FDA-2015-P-2820-0072,FDA-2015-P-2820,Amendment from Center for Responsible Science (CRS)
0900006481bbb052,Other,FDA-2015-P-2820-0003,FDA-2015-P-2820,Acknowledgement Letter from FDA DDM to Alston and Bird LLP
0900006481ed3d8d,Supporting & Related Material,FDA-2015-P-2820-0071,FDA-2015-P-2820,"Exhibit 22 O'Riordan, M. After Patient's Death, Study Shows HCV Drug Cardiotoxic in 14 of 34 Treated Patients Source: www.medscape.com/viewarticle/832251_print September 24, 2014 re: Amendment from Center for Responsible Science"
0900006481ecf143,Supporting & Related Material,FDA-2015-P-2820-0060,FDA-2015-P-2820,"Exhibit 2 Baker et al How Regulatory Updates Allowing for
More Modern Test Methods, Pragmatic Validation of Preclinical Test Methods, and FDA Guidances Will Lead to Advancement of More Predictive Preclinical Testing Tools, Efficiency, and Safer and More Effective Drugs FDLI Food and Drug Policy Forum re: Amendment from Center for Responsible Science"
0900006481ecf19d,Supporting & Related Material,FDA-2015-P-2820-0064,FDA-2015-P-2820,"Exhibit 11 The Pharmaletter, ANSM continues investigations into Bial clinical trial death, March 10, 2016 re: Amendment from Center for Responsible Science"
0900006481ecf19e,Supporting & Related Material,FDA-2015-P-2820-0065,FDA-2015-P-2820,"Exhibit 12 Minutes of the Temporary Specialist Scientific Committee (TSSC) meeting on ""FAAH (Fatty Add Amide Hydrolase) Inhibitors"" of 15 February 2016. re: Amendment from Center for Responsible Science"
09000064839bfff8,Other,FDA-2015-P-2820-0077,FDA-2015-P-2820,Interim Response Letter from FDA  to  Alston and Bird (the Center for Responsible Science)
0900006481ecf19a,Supporting & Related Material,FDA-2015-P-2820-0062,FDA-2015-P-2820,"Exhibit 8 Business Insider, Feb 5, 2016 Authorities are rapping up their investigation of a deadly drug trial that left one dead and several others in hospital re: Amendment from Center for Responsible Science"
0900006481ecf19b,Supporting & Related Material,FDA-2015-P-2820-0063,FDA-2015-P-2820,"Exhibit 9 The Guardian Man who died in French drug trial had 'unprecedented' reaction, say experts. March 2016 re: Amendment from Center for Responsible Science"
0900006481ecf1a2,Supporting & Related Material,FDA-2015-P-2820-0068,FDA-2015-P-2820,"Exhibit 16 Scientific Bloggging Science 2.0 Blood Test Predicts Cytokine Storm Drug Reaction In Humans March 9, 2015 re: Amendment from Center for Responsible Science"
0900006481bbadfb,Other,FDA-2015-P-2820-0002,FDA-2015-P-2820,Letter from Alston and Bird LLP to FDA DDM
09000064830072a5,Other,FDA-2015-P-2820-0076,FDA-2015-P-2820,Amendment (fifth) from Center for Responsible Science (CRS)
0900006481bbb055,Supporting & Related Material,FDA-2015-P-2820-0004,FDA-2015-P-2820,Exhibit A List of Petitioners re Citizen Petition from the Center for Responsible Science
09000064831476a4,Other,FDA-2018-P-0829-0003,FDA-2018-P-0829,Petition Approval Letter from FDA CDER
0900006482f53b7d,Other,FDA-2018-P-0829-0002,FDA-2018-P-0829,Acknowledgment Letter from FDA DDM to Prinston Pharmaceutical Inc.
0900006482f53b75,Other,FDA-2018-P-0829-0001,FDA-2018-P-0829,Citizen Petition from Prinston Pharmaceutical Inc.
090000648432d9ba,Other,FDA-2019-P-3809-0003,FDA-2019-P-3809,"Final Response Letter from FDA CDER to Lachman Consultant Services, Inc"
0900006483e3c3d8,Other,FDA-2019-P-3809-0002,FDA-2019-P-3809,"Acknowledgment Letter from FDA DMS to Lachman Consultant Services, Inc."
0900006483e3c3d7,Other,FDA-2019-P-3809-0001,FDA-2019-P-3809,"Citizen Petition from Lachman Consultant Services, Inc."
090000648364bf49,Supporting & Related Material,FDA-2018-P-3266-0003,FDA-2018-P-3266,"Exhibit A - Citizen Petition in Docket FDA-2018-P-1014 re Citizen Petition from Haynes and Boone, LLP"
090000648364bf2f,Other,FDA-2018-P-3266-0002,FDA-2018-P-3266,"Acknowledgment Letter from FDA DDM to Haynes and Boone, LLP"
090000648364bf7b,Supporting & Related Material,FDA-2018-P-3266-0005,FDA-2018-P-3266,"Exhibit C - Confidential Excerpts from ANDA No. 210370 re Citizen Petition from Haynes and Boone, LLP"
090000648364bc7e,Supporting & Related Material,FDA-2018-P-3266-0004,FDA-2018-P-3266,"Exhibit B - FDA Response to Citizen Petition in Docket FDA-2018-P-1014 re Citizen Petition from Haynes and Boone, LLP"
0900006484197add,Other,FDA-2018-P-3266-0007,FDA-2018-P-3266,"Final Response Letter from FDA to Haynes and Boone, LLP"
090000648364be1c,Other,FDA-2018-P-3266-0001,FDA-2018-P-3266,"Citizen Petition from Haynes and Boone, LLP"
0900006483a96b7a,Other,FDA-2018-P-3266-0006,FDA-2018-P-3266,"Interim Response Letter from FDA CDER to Haynes and Boone, LLP"
0900006482c25ff0,Other,FDA-2017-P-6307-0001,FDA-2017-P-6307,Citizen Petition from Aurolife Pharma LLC.
0900006482c260fc,Other,FDA-2017-P-6307-0002,FDA-2017-P-6307,Acknowledgment Letter from FDA DDM to Aurolife Pharma LLC
09000064830fe02b,Other,FDA-2017-P-6307-0004,FDA-2017-P-6307,Interim Response Letter from FDA CDER to Aurolife Pharma LLC
0900006483ae1176,Other,FDA-2017-P-6307-0007,FDA-2017-P-6307,Response Letter from FDA CDER to Aurolife Pharma LLC
09000064844276d9,Other,FDA-2020-P-1074-0001,FDA-2020-P-1074,Citizen Petition from Akorn Animal Health Inc.
09000064844276db,Other,FDA-2020-P-1074-0002,FDA-2020-P-1074,Acknowledgment Letter from FDA DMS to Akorn Animal Health Inc.
0900006484426f2c,Supporting & Related Material,FDA-2020-P-1074-0004,FDA-2020-P-1074,ATTACHMENT 2 - RLNAD Labeling RE: Citizen Petition from Akorn Animal Health Inc.
0900006484426f2d,Supporting & Related Material,FDA-2020-P-1074-0006,FDA-2020-P-1074,ATTACHMENT 3 - Proposed Generic Labeling RE: Citizen Petition from Akorn Animal Health Inc.
09000064846cbaa2,Other,FDA-2020-P-1074-0008,FDA-2020-P-1074,Petition Approval Letter from FDA CVM to Akorn Animal Health Inc
09000064845b9d39,Other,FDA-2020-P-1074-0007,FDA-2020-P-1074,Amendment to Citizen Petition from Akorn Animal Health Inc.
0900006484426f2b,Supporting & Related Material,FDA-2020-P-1074-0003,FDA-2020-P-1074,ATTACHMENT 1 -FDA Green Book Listing RE: Citizen Petition from Akorn Animal Health Inc.
0900006484426f2e,Supporting & Related Material,FDA-2020-P-1074-0005,FDA-2020-P-1074,ATTACHMENT 4 -Labeling for Vetropolycin HC Ointment RE: Citizen Petition from Akorn Animal Health Inc.
0900006480447a04,Other,FDA-2005-P-0313-0003,FDA-2005-P-0313,HFD-005 to Frommer Lawrence and Haug LLP
0900006480447a06,Other,FDA-2005-P-0313-0004,FDA-2005-P-0313,FDA/CDER to Charles J. Raubicheck
09000064804479e3,Other,FDA-2005-P-0313-0001,FDA-2005-P-0313,HFA-305 to Frommer Lawrence and Haug LLP
0900006480447a03,Other,FDA-2005-P-0313-0002,FDA-2005-P-0313,HFA-305 to Frommer Lawrence and Haug LLP
090000648174c569,Other,FDA-2014-P-0802-0001,FDA-2014-P-0802,Citizen Petition From Moon T. Kwon
0900006481e04e2d,Other,FDA-2014-P-0802-0004,FDA-2014-P-0802,Second Interim Response from FDA CDRH to Moon T. Kwon
090000648174c7a8,Other,FDA-2014-P-0802-0002,FDA-2014-P-0802,Acknowledgement Letter From FDA DDM to Moon T. Kwon
0900006484df9006,Other,FDA-2014-P-0802-0005,FDA-2014-P-0802,Final Response from FDA CDRH to Moon T Kwon
09000064817df053,Other,FDA-2014-P-0802-0003,FDA-2014-P-0802,Citizen Petition Interim Response from FDA CDRH to Moon T. Kwon  (Redacted)
0900006482cbd3d6,Other,FDA-2017-P-6663-0002,FDA-2017-P-6663,Acknowledgement Letter from FDA DDM to Dr. Edwards
0900006482cbd421,Supporting & Related Material,FDA-2017-P-6663-0009,FDA-2017-P-6663,Exh 04 Ireland FDA ltr to Durbin Jul 2010 re Citizen Petition from Dr. Edwards
0900006482cbd41f,Supporting & Related Material,FDA-2017-P-6663-0007,FDA-2017-P-6663,Exh 04 Chicago Trib May 2011 page 12 re Citizen Petition from Dr. Edwards
0900006482cbd428,Supporting & Related Material,FDA-2017-P-6663-0010,FDA-2017-P-6663,Exh 05 Edwards Lifesciences Letter JTF April 2013 re Citizen Petition from Dr. Edwards
0900006482cbd3d4,Other,FDA-2017-P-6663-0001,FDA-2017-P-6663,Citizen Petition from Dr. Edwards
0900006482cbd41c,Supporting & Related Material,FDA-2017-P-6663-0004,FDA-2017-P-6663,Exh 01 Edwa Lifesci ltr Jan 31 2009 re Citizen Petition from Dr. Edwards
0900006482cbd41d,Supporting & Related Material,FDA-2017-P-6663-0005,FDA-2017-P-6663,Exh 02 Edwa Lifesci fax Apr 16 2009 re Citizen Petition from Dr. Edwards
0900006482cbd420,Supporting & Related Material,FDA-2017-P-6663-0008,FDA-2017-P-6663,Exh 04 Chicago Trib May 2011 page 13 re Citizen Petition from Dr. Edwards
0900006482cbd41e,Supporting & Related Material,FDA-2017-P-6663-0006,FDA-2017-P-6663,Exh 04 Chicago Trib May 22 2011 Heart rings get a pass pg1 re Citizen Petition from Dr. Edwards
0900006483237b1a,Other,FDA-2017-P-6663-0012,FDA-2017-P-6663,Interim response from FDA CDRH to Dr. S. Albert Edwards
0900006482cbd41b,Supporting & Related Material,FDA-2017-P-6663-0003,FDA-2017-P-6663,Citizen Petition Supplement from Dr. Edwards
0900006482cbd429,Supporting & Related Material,FDA-2017-P-6663-0011,FDA-2017-P-6663,Exh 06 Rajamannan IG ltr July 28 2017 re Citizen Petition from Dr. Edwards
09000064846af6f5,Other,FDA-2017-P-6663-0014,FDA-2017-P-6663,Letter of Denial from FDA CDRH to Dr.  Albert Edwards
09000064819f3d77,Other,FDA-2014-P-1930-0004,FDA-2014-P-1930,Apotex Inc withdrawal letter 02/03/2015
090000648192eded,Supporting & Related Material,FDA-2014-P-1930-0003,FDA-2014-P-1930,Attachment 1 Approval Letter for Acticlate Citizen Petition From Apotex Inc.
090000648192edeb,Other,FDA-2014-P-1930-0002,FDA-2014-P-1930,Acknowledgement Letter From FDA DDM to Apotex Inc.
090000648192ede9,Other,FDA-2014-P-1930-0001,FDA-2014-P-1930,Citizen Petition From Apotex Inc.
0900006484157048,Other,FDA-2019-P-2590-0003,FDA-2019-P-2590,"Interim Response Letter from FDA to Fresenius Kabi USA, LLC"
0900006483cd42ee,Other,FDA-2019-P-2590-0001,FDA-2019-P-2590,"Citizen Petition from Fresenius Kabi USA, LLC"
0900006483cd42f2,Other,FDA-2019-P-2590-0002,FDA-2019-P-2590,"Acknowledgment Letter from FDA DDM to Fresenius Kabi USA, LLC"
09000064824b6dd7,Other,FDA-2017-P-0864-0001,FDA-2017-P-0864,Citizen Petition from Hyman Phelps & McNamara PC
09000064829cca17,Other,FDA-2017-P-0864-0003,FDA-2017-P-0864,"Interim Response Letter from CDER to Hyman, Phelps & McNamara P.C."
09000064824b6e72,Other,FDA-2017-P-0864-0002,FDA-2017-P-0864,Acknowledgment Letter from FDA DDM to Hyman Phelps & McNamara PC
090000648485dd4b,Other,FDA-2017-P-0864-0004,FDA-2017-P-0864,"Letter from FDA CDER to Hyman, Phelps & McNamara P.C."
09000064849144ec,Supporting & Related Material,FDA-2020-P-1769-0007,FDA-2020-P-1769,Combined - Part 1 re Amended Citizen Petition from SIRI & GLIMSTAD LLP on behalf of Informed Consent Action Network
0900006484913c5e,Other,FDA-2020-P-1769-0006,FDA-2020-P-1769,Amended Citizen Petition from SIRI & GLIMSTAD LLP on behalf of Informed Consent Action Network
090000648480bd8d,Other,FDA-2020-P-1769-0002,FDA-2020-P-1769,Acknowledgment Letter from FDA DMS to SIRI & GLIMSTAD LLP on behalf of Informed Consent Action Network
09000064849144ed,Supporting & Related Material,FDA-2020-P-1769-0008,FDA-2020-P-1769,Combined - Part 2 re Amended Citizen Petition from SIRI & GLIMSTAD LLP on behalf of Informed Consent Action Network
0900006484811b6d,Supporting & Related Material,FDA-2020-P-1769-0005,FDA-2020-P-1769,Footnotes 2 - 33 re: Administrative Stay of Action from SIRI & GLIMSTAD LLP on behalf of Informed Consent Action Network
09000064849d6b35,Other,FDA-2020-P-1769-0011,FDA-2020-P-1769,Response letter to Siri & Glimstad LLP from FDA CBER
090000648480bd8c,Other,FDA-2020-P-1769-0001,FDA-2020-P-1769,Citizen Petition from SIRI & GLIMSTAD LLP on behalf of Informed Consent Action Network
0900006484811b69,Other,FDA-2020-P-1769-0004,FDA-2020-P-1769,Administrative Stay of Action from SIRI & GLIMSTAD LLP on behalf of Informed Consent Action Network
090000648480bd90,Supporting & Related Material,FDA-2020-P-1769-0003,FDA-2020-P-1769,Footnotes 2 - 30 re Citizen Petition from SIRI & GLIMSTAD LLP on behalf of Informed Consent Action Network
0900006484ca6f1b,Other,FDA-2021-P-0939-0001,FDA-2021-P-0939,"Citizen Petition from Hyman, Phelps & McNamara, P.C."
0900006484ca728d,Other,FDA-2021-P-0939-0002,FDA-2021-P-0939,"Acknowledgment Letter from FDA DMS to Hyman, Phelps & McNamara, P.C."
0900006480a58fc5,Notice,FDA-2009-N-0545-0001,FDA-2009-N-0545,"Agency Information Collection Activities; Proposed Collection; Comment Request; Biological Products: Reporting of Biological Product Deviations and Human Cells, Tissues, and Cellular and Tissue-Based Product Deviations in Manufacturing; Form FDA 3486 and Addendum 3486A"
0900006480aed928,Notice,FDA-2009-N-0545-0002,FDA-2009-N-0545,"Agency Information Collection Activities; Proposals, Submissions, and Approvals"
0900006483d538fa,Other,FDA-2019-P-0076-0006,FDA-2019-P-0076,"Letter from FDA CDER to Unichem Pharmaceuticals (USA), Inc."
09000064839da85d,Other,FDA-2019-P-0076-0001,FDA-2019-P-0076,"Citizen Petition from Unichem Pharmaceuticals (USA), Inc."
0900006483ec15e0,Other,FDA-2019-P-0076-0008,FDA-2019-P-0076,Response Letter from FDA CDER to Unichem Pharmaceuticals USA Inc
0900006483e8c363,Notice,FDA-2019-P-0076-0007,FDA-2019-P-0076,"Determination That ZONEGRAN (Zonisamide) Capsules, 50 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
09000064839db14c,Other,FDA-2019-P-0076-0002,FDA-2019-P-0076,"Acknowledgement Letter  from FDA DDM to Unichem Pharmaceuticals (USA), Inc."
09000064839db14e,Supporting & Related Material,FDA-2019-P-0076-0004,FDA-2019-P-0076,"Attachment 2_Package Insert_11-2006 re: Citizen Petition from Unichem Pharmaceuticals (USA), Inc."
09000064839db14d,Supporting & Related Material,FDA-2019-P-0076-0003,FDA-2019-P-0076,"Attachement 1_Current_Orange Book re: Citizen Petition from Unichem Pharmaceuticals (USA), Inc."
09000064839db14f,Supporting & Related Material,FDA-2019-P-0076-0005,FDA-2019-P-0076,"Attachment 3_Package Insert_04-2009 re: Citizen Petition from Unichem Pharmaceuticals (USA), Inc."
0900006481e66aca,Other,FDA-2015-P-3009-0010,FDA-2015-P-3009,Interim Response Letter from FDA CFSAN to Physicians Committee for Responsible Medicine
0900006481c23d2c,Other,FDA-2015-P-3009-0001,FDA-2015-P-3009,Citizen Petition from the Physicians Committee for Responsible Medicine
0900006481c2406b,Supporting & Related Material,FDA-2015-P-3009-0003,FDA-2015-P-3009,Attachment 1 Effect of Animal and Industrial Trans Fatty Acids re Citizen Petition from the Physicians Committee for Responsible Medicine
0900006481c24069,Other,FDA-2015-P-3009-0002,FDA-2015-P-3009,Acknowledgement Letter from FDA DDM to the Physicians Committee for Responsible Medicine
0900006481ea6dda,Other,FDA-2015-P-3009-0011,FDA-2015-P-3009,Petition Denial Letter from FDA CFSAN to Physicians Committee for Responsible Medicine
0900006481c26ea1,Other,FDA-2015-P-3020-0001,FDA-2015-P-3020,Citizen Petition from Women's Voices for the Earth
0900006481c26ea3,Other,FDA-2015-P-3020-0002,FDA-2015-P-3020,Acknowledgement Letter from FDA DDM to Women's Voices for the Earth
09000064833f0385,Other,FDA-2015-P-3020-0009,FDA-2015-P-3020,Petition Denial Letter from FDA CFSAN to WVE
09000064833743c5,Other,FDA-2018-P-1351-0006,FDA-2018-P-1351,"Agency Response Letter from FDA CVM to Schafer Veterinary Consultants, LLC"
090000648308705e,Other,FDA-2018-P-1351-0002,FDA-2018-P-1351,"Acknowledgment Letter from FDA DDM to Douglass Oeller Consulting, Inc."
0900006483087064,Supporting & Related Material,FDA-2018-P-1351-0004,FDA-2018-P-1351,"Appendix 3 - A marked up copy of the package insert showing Felix's proposed changes re Citizen Petition from Douglass Oeller Consulting, Inc. (Felix Pharmaceuticals Pvt. Ltd.)"
090000648333525e,Other,FDA-2018-P-1351-0005,FDA-2018-P-1351,"Change of US Agent,  James H. Schafer, D.V.M (Schafer Veterinary Consultants, LLC) - 06-04-2018"
0900006483087063,Supporting & Related Material,FDA-2018-P-1351-0003,FDA-2018-P-1351,"Appendix 2 - A copy of the Zoetis package insert for this product re Citizen Petition from Douglass Oeller Consulting, Inc. (Felix Pharmaceuticals Pvt. Ltd.)"
090000648308676d,Other,FDA-2018-P-1351-0001,FDA-2018-P-1351,"Citizen Petition from Douglass Oeller Consulting, Inc. (Felix Pharmaceuticals Pvt. Ltd.)"
09000064847a9a96,Other,FDA-2020-P-1701-0002,FDA-2020-P-1701,Acknowledgment Letter from Harman Finochem Limited
09000064847a9a94,Other,FDA-2020-P-1701-0001,FDA-2020-P-1701,Citizen Petition from Harman Finochem Limited
09000064847a9dc1,Supporting & Related Material,FDA-2020-P-1701-0003,FDA-2020-P-1701,"Attachment 1 - Amneal Pharmaceuticals LLC Issues Voluntary Nationwide
Recall of Metformin Hydrochloride Extended Release Tablets, USP, 500 mg and 750 mg, Due to Detection of NNitrosodimethylamine (NDMA) Impurity re Citizen Petition from Harman Finochem Limited"
09000064847a9dc2,Supporting & Related Material,FDA-2020-P-1701-0004,FDA-2020-P-1701,Attachment 2 - Email Correspondence  re Citizen Petition from Harman Finochem Limited
090000648496ff13,Other,FDA-2020-P-1701-0005,FDA-2020-P-1701,Withdrawal from Harman Finochem Limited
09000064834cb6f2,Other,FDA-2018-P-2658-0001,FDA-2018-P-2658,"Citizen Petiton from Hyman, Phelps & McNamara, PC"
09000064839f4c58,Other,FDA-2018-P-2658-0003,FDA-2018-P-2658,"Interim response from FDA CDER to  Hyman, Phelps & McNamara"
09000064834cb6f4,Other,FDA-2018-P-2658-0002,FDA-2018-P-2658,"Acknowledgment Letter from FDA DDM to Hyman, Phelps & McNamara"
0900006484177fb3,Other,FDA-2018-P-2658-0004,FDA-2018-P-2658,"Response Letter from FDA to Hyman, Phelps, and McNamara"
090000648042d777,Notice,FDA-2007-N-0385-0002,FDA-2007-N-0385,FDA
090000648042d77e,Supporting & Related Material,FDA-2007-N-0385-0005,FDA-2007-N-0385,Supporting Statement
090000648042d77b,Supporting & Related Material,FDA-2007-N-0385-0004,FDA-2007-N-0385,Supporting Statement
090000648042d773,Notice,FDA-2007-N-0385-0001,FDA-2007-N-0385,FDA
090000648042d77f,Notice,FDA-2007-N-0385-0006,FDA-2007-N-0385,FDA
090000648042d779,Supporting & Related Material,FDA-2007-N-0385-0003,FDA-2007-N-0385,Supporting Statement
090000648042d780,Notice,FDA-2007-N-0385-0007,FDA-2007-N-0385,FDA
0900006480aef98d,Notice,FDA-2010-N-0229-0001,FDA-2010-N-0229,"Agency Information Collection Activities; Proposals, Submissions, and Approvals: Pilot Program"
0900006481eddccb,Other,FDA-2015-P-1899-0006,FDA-2015-P-1899,"Citizen Petition Approval Response from FDA CDER to Lachman Consultant Services, Inc."
0900006481b090d7,Supporting & Related Material,FDA-2015-P-1899-0002,FDA-2015-P-1899,Attachment Orange Book Listing for Fluoxetine Hydrochloride re Citizen Petition from Lachman Consultant Services Inc
0900006481b09106,Other,FDA-2015-P-1899-0001,FDA-2015-P-1899,Citizen Petition from Lachman Consultant Services Inc
0900006481b091c7,Other,FDA-2015-P-1899-0003,FDA-2015-P-1899,Acknowledgement Letter from FDA DDM to Lachman Consultant Services Inc
0900006481d6d850,Other,FDA-2015-P-1899-0004,FDA-2015-P-1899,"Interim Response Letter from FDA CDER to Lachman Consultant Services, Inc."
0900006482e4a743,Notice,FDA-2017-N-6879-0001,FDA-2017-N-6879,"Electronic Study Data Submission; Data Standards; Timetable for Updates to the Food and Drug Administration Data Standards Catalog for Study Data Submitted Electronically Under the Federal Food, Drug, and Cosmetic Act"
0900006483236d94,Supporting & Related Material,FDA-2018-P-1760-0004,FDA-2018-P-1760,"Attachment 1- References Part 2 of 2 re Citizen Petition from Serenity Pharmaceuticals, LLC."
090000648323716a,Other,FDA-2018-P-1760-0002,FDA-2018-P-1760,"Acknowledgment Letter from FDA DDM to Serenity Pharmaceuticals, LLC"
090000648343b70f,Other,FDA-2018-P-1760-0005,FDA-2018-P-1760,"Petition Response Letter from FDA CDER to Serenity Pharmaceuticals, LLC"
0900006483236ad2,Supporting & Related Material,FDA-2018-P-1760-0003,FDA-2018-P-1760,"Attachment 1- References Part 1 of 2 re Citizen Petition from Serenity Pharmaceuticals, LLC."
0900006483236ad0,Other,FDA-2018-P-1760-0001,FDA-2018-P-1760,"Citizen Petition from Serenity Pharmaceuticals, LLC."
0900006483254733,Other,FDA-2017-P-6750-0008,FDA-2017-P-6750,Petition Denial Letter From FDA CDER to Mylan N.V
0900006482ce61fd,Supporting & Related Material,FDA-2017-P-6750-0006,FDA-2017-P-6750,Exhibit D - Sandell - Inhalation Batch Variability Dec_ 2017-1 re Citizen Petition from Mylan Inc.
0900006482ce61fb,Supporting & Related Material,FDA-2017-P-6750-0004,FDA-2017-P-6750,Exhibit B - Getz Carroll Oriel Presentation CHEST-1 re Citizen Petition from Mylan Inc.
0900006482cebd3b,Other,FDA-2017-P-6750-0002,FDA-2017-P-6750,Acknowledgment Letter from FDA DDM to  Mylan Inc.
0900006482ce61fa,Supporting & Related Material,FDA-2017-P-6750-0003,FDA-2017-P-6750,Exhibit A - Getz Carroll Oriel Abstract-2 re Citizen Petition from Mylan Inc.
0900006482ce61fe,Supporting & Related Material,FDA-2017-P-6750-0007,FDA-2017-P-6750,Exhibit E - Haidar - Highly Variable-1 re Citizen Petition from Mylan Inc.
0900006482ce53e4,Other,FDA-2017-P-6750-0001,FDA-2017-P-6750,Citizen Petition from Mylan Inc.
0900006482ce61fc,Supporting & Related Material,FDA-2017-P-6750-0005,FDA-2017-P-6750,Exhibit C - USP Monograph FP-SX-1 re Citizen Petition from Mylan Inc.
0900006482e4d138,Supporting & Related Material,FDA-2018-P-0327-0003,FDA-2018-P-0327,"Reference 1- Orange Book Approved Drug Products with Therapeutic Equivalence Evaluations re: Citizen Petition Fresenius KabiUSA, LLC"
09000064833d715a,Notice,FDA-2018-P-0327-0004,FDA-2018-P-0327,"Determination That MUTAMYCIN (Mitomycin) Injectable, 5 Milligrams/ Vial and 20 Milligrams/Vial, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
0900006482e4cd72,Other,FDA-2018-P-0327-0001,FDA-2018-P-0327,"Citizen Petition Fresenius KabiUSA, LLC"
0900006482e4d0f7,Other,FDA-2018-P-0327-0002,FDA-2018-P-0327,"Acknowledgment Letter from FDA DDM to Fresenius KabiUSA, LLC"
09000064833dc83b,Other,FDA-2018-P-0327-0005,FDA-2018-P-0327,"Letter from FDA CDER to Fresenius Kabi USA, LLC"
090000648362d72c,Other,FDA-2018-P-2344-0005,FDA-2018-P-2344,Amendments to Suitability Petition from Noble Pharma LLC
0900006483425da1,Other,FDA-2018-P-2344-0001,FDA-2018-P-2344,Suitability Petition from Noble Pharma LLC
09000064834258e6,Supporting & Related Material,FDA-2018-P-2344-0003,FDA-2018-P-2344,Appendix 1 - Pioneer Label re Suitability Petition from Noble Pharma LLC
09000064834258e7,Supporting & Related Material,FDA-2018-P-2344-0004,FDA-2018-P-2344,Appendix 2 - Draft Label of the proposed generic soft chewable tablet re Suitability Petition from Noble Pharma LLC
09000064836bbf1b,Other,FDA-2018-P-2344-0006,FDA-2018-P-2344,"Petition Approval Letter from FDA CVM to Noble Pharma, LLC"
0900006483425da4,Other,FDA-2018-P-2344-0002,FDA-2018-P-2344,Acknowledgment Letter from FDA DDM to Noble Pharma LLC
0900006483147805,Other,FDA-2018-P-1516-0001,FDA-2018-P-1516,Citizen Petition from Encube Ethicals Private Limited
090000648327f7c6,Other,FDA-2018-P-1516-0003,FDA-2018-P-1516,Letter from FDA CDER to Encube Ethicals Private Limited
0900006483147808,Other,FDA-2018-P-1516-0002,FDA-2018-P-1516,Acknowledgment Letter from FDA DDM to Encube Ethicals Private Limited
0900006481975327,Other,FDA-2014-P-2193-0001,FDA-2014-P-2193,Citizen Petition From Acorda Therapeutics
090000648197652f,Supporting & Related Material,FDA-2014-P-2193-0008,FDA-2014-P-2193,Exhibit_F_-_EMA_Guideline Citizen Petition From Acorda Therapeutics
090000648197652c,Supporting & Related Material,FDA-2014-P-2193-0005,FDA-2014-P-2193,Exhibit_C_-_Acorda_Mar__4_2014_Letter Citizen Petition From Acorda Therapeutics
0900006481976530,Supporting & Related Material,FDA-2014-P-2193-0009,FDA-2014-P-2193,Exhibit_G_-_Health_Canada_Guidance Citizen Petition From Acorda Therapeutics
0900006481976533,Supporting & Related Material,FDA-2014-P-2193-0012,FDA-2014-P-2193,Exhibit_J_-_Lionberger_et_al_Citizen Petition From Acorda Therapeutics
090000648197652a,Supporting & Related Material,FDA-2014-P-2193-0003,FDA-2014-P-2193,Exhibit_A_-_Ampyra_Prescribing_Information Citizen Petition From Acorda Therapeutics
090000648197652b,Supporting & Related Material,FDA-2014-P-2193-0004,FDA-2014-P-2193,Exhibit_B_-_Ampyra_Medication_Guide Citizen Petition From Acorda Therapeutics
0900006481ae1019,Other,FDA-2014-P-2193-0014,FDA-2014-P-2193,"Citizen Petition Denial Response Letter from FDA CDER to Acorda Therapeutics, Inc."
090000648197652d,Supporting & Related Material,FDA-2014-P-2193-0006,FDA-2014-P-2193,Exhibit_D_-_Acorda_Feb__4_2011_Letter Citizen Petition From Acorda Therapeutics
0900006481976532,Supporting & Related Material,FDA-2014-P-2193-0011,FDA-2014-P-2193,Exhibit_I_-_Zhang_et_al_Citizen Petition From Acorda Therapeutics
090000648197652e,Supporting & Related Material,FDA-2014-P-2193-0007,FDA-2014-P-2193,Exhibit_E_-_Kelley_and_Rodriguez Citizen Petition From Acorda Therapeutics
09000064819769c1,Supporting & Related Material,FDA-2014-P-2193-0013,FDA-2014-P-2193,Exhibit_K_-_Vollmer_et_al_Citizen Petition From Acorda Therapeutics
09000064819769c2,Other,FDA-2014-P-2193-0002,FDA-2014-P-2193,"Acknowledgement Letter From FDA DDM to Acorda Therapeutics, Inc."
0900006481976531,Supporting & Related Material,FDA-2014-P-2193-0010,FDA-2014-P-2193,Exhibit_H_-_Jara_et_al_Citizen Petition From Acorda Therapeutics
09000064818b67f0,Other,FDA-2014-P-1562-0001,FDA-2014-P-1562,Citizen Petition from the Institute for Safe Medication Practices
0900006482427e7d,Other,FDA-2014-P-1562-0004,FDA-2014-P-1562,Petition Denial Letter from FDA CDER to the Institute for Safe Medication Practices et al
090000648191b1fd,Other,FDA-2014-P-1562-0002,FDA-2014-P-1562,Acknowledgement Letter From FDA DDM to the Institute for Safe Medication Practices
0900006481a90bbf,Other,FDA-2014-P-1562-0003,FDA-2014-P-1562,Interim Response from FDA CDER to the Institute for Safe Medication Practices
0900006483050e1c,Other,FDA-2017-P-5845-0003,FDA-2017-P-5845,"Interim Response  Letter from FDA CDER to B&H Consulting Services, Inc."
0900006482b65afb,Other,FDA-2017-P-5845-0002,FDA-2017-P-5845,"Acknowledgment  Letter from FDA DDM to B&H Consulting Services, Inc."
0900006483b6a0d1,Other,FDA-2017-P-5845-0004,FDA-2017-P-5845,"Letter from FDA CDER to B&H Consulting Services, Inc."
0900006482b65674,Other,FDA-2017-P-5845-0001,FDA-2017-P-5845,"Citizen Petition from B&H Consulting Services, Inc."
0900006481363bbf,Notice,FDA-2013-N-0731-0001,FDA-2013-N-0731,"Agency Information Collection Activities; Proposals, Submissions, and Approvals: Human Cells, Tissues, and Cellular and Tissue-Based Products, Establishment Registration and Listing; Form FDA 3356; Eligibility Determination for Donors and Current Good Tissue Practice"
09000064841e74ee,Notice,FDA-2013-N-0731-0009,FDA-2013-N-0731,"Agency Information Collection Activities; Proposed Collection; Comment Request; Human Cells, Tissues, and Cellular and Tissue-Based Products: Establishment Registration and Listing; Eligibility Determination for Donors; and Current Good Tissue Practice"
09000064844848a1,Notice,FDA-2013-N-0731-0010,FDA-2013-N-0731,"Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Human Cells, Tissues, and Cellular and Tissue-Based Products: Establishment Registration and Listing; Eligibility Determination for Donors; and Current Good Tissue Practice"
090000648482cc90,Notice,FDA-2013-N-0731-0011,FDA-2013-N-0731,"Agency Information Collection Activities; Announcement of Office of
Management and Budget Approvals"
0900006481681949,Notice,FDA-2013-N-0731-0003,FDA-2013-N-0731,"Agency Information Collection Activities; Announcement of Office of
Management and Budget Approval; Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products"
090000648151cf3e,Notice,FDA-2013-N-0731-0002,FDA-2013-N-0731,"Agency Information Collection Activities; Submission for Office of
Management and Budget Review; Comment Request; Human Cells,
Tissues, and Cellular and Tissue-Based Products: Establishment
Registration and Listing; Form FDA 3356; Eligibility Determination for
Donors; and Current Good Tissue Practice"
09000064821db835,Notice,FDA-2013-N-0731-0004,FDA-2013-N-0731,"Agency Information Collection Activities; Proposed Collection; Comment Request; Human Cells, Tissues, and Cellular and Tissue-Based Products: Establishment Registration and Listing; Eligibility Determination for Donors; and Current Good Tissue Practice"
0900006482aa02d4,Notice,FDA-2013-N-0731-0008,FDA-2013-N-0731,"Agency Information Collection Activities; Announcement of Office of
Management and Budget Approvals"
0900006482533781,Notice,FDA-2013-N-0731-0007,FDA-2013-N-0731,"Agency Information Collection Activities; Submission for Office of
Management and Budget Review; Comment Request; Human Cells,
Tissues, and Cellular and Tissue-Based Products: Establishment  Registration and Listing; Eligibility Determination for Donors; and Current Good Tissue Practice"
09000064849b0718,Other,FDA-2020-P-2318-0001,FDA-2020-P-2318,"Suitability Citizen Petition from Lachman Consulting Services, Inc."
09000064849b1603,Other,FDA-2020-P-2318-0002,FDA-2020-P-2318,"Acknowledgement Letter from FDA DMS to Lachman Consulting Services, Inc."
09000064849aefda,Notice,FDA-2020-P-1650-0003,FDA-2020-P-1650,"Determination That DOBUTREX (Dobutamine Hydrochloride), Equivalent 12.5 Milligram Base/Milliliter, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
090000648473bc28,Other,FDA-2020-P-1650-0002,FDA-2020-P-1650,Acknowledgment Letter from FDA DMS to Cardinal Health Regulatory Sciences
09000064849b0d44,Other,FDA-2020-P-1650-0004,FDA-2020-P-1650,Final Response to Citizen Petition from FDA CDER to Cardinal Health Regulatory Sciences
090000648473bb1d,Other,FDA-2020-P-1650-0001,FDA-2020-P-1650,Citizen Petition from Cardinal Health Regulatory Sciences
0900006483259a5b,Other,FDA-2018-P-1853-0001,FDA-2018-P-1853,"Citizen Petition from Aurobindo Pharma USA, Inc."
0900006483d42e39,Other,FDA-2018-P-1853-0004,FDA-2018-P-1853,"Letter from FDA CDER to AUROBINDO PHARMA USA, INC."
090000648388348f,Other,FDA-2018-P-1853-0003,FDA-2018-P-1853,Interim Response Letter from FDA CDER to Aurobindo Pharma USA Inc.
0900006483259a62,Other,FDA-2018-P-1853-0002,FDA-2018-P-1853,"Acknowledgment Letter from FDA DDM to Aurobindo Pharma USA, Inc."
09000064846ec003,Other,FDA-2020-P-0978-0009,FDA-2020-P-0978,"Response Letter from FDA CDER to Valisure, LLC"
09000064843d1af7,Other,FDA-2020-P-0978-0002,FDA-2020-P-0978,"Acknowledgment Letter from FDA DMS to Valisure, LLC"
09000064843d1afe,Supporting & Related Material,FDA-2020-P-0978-0004,FDA-2020-P-0978,"ATTACHMENT B - AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES re: Citizen Petition from Valisure, LLC"
09000064843d1afa,Supporting & Related Material,FDA-2020-P-0978-0003,FDA-2020-P-0978,"ATTACHMENT A - Valisure LC-HRMS Method for Determination of NDMA in Metformin re: Citizen Petition from Valisure, LLC"
09000064843d191b,Other,FDA-2020-P-0978-0001,FDA-2020-P-0978,"Citizen Petition from Valisure, LLC"
09000064846bbcd1,Other,FDA-2020-P-0978-0007,FDA-2020-P-0978,"Partial Response Letter from FDA CDER to Valisure, LLC"
0900006481e3b05a,Other,FDA-2016-P-0378-0001,FDA-2016-P-0378,"Citizen Petition from The Weinberg Group, Inc."
0900006481e3b788,Other,FDA-2016-P-0378-0002,FDA-2016-P-0378,"Acknowledgement Letter from FDA DDM to The Weinberg Group, Inc."
0900006482008d15,Notice,FDA-2016-P-0378-0003,FDA-2016-P-0378,"Determination That TRIVARIS (Triamcinolone Acetonide) Injectable
Suspension, 80 Milligrams/Milliliters, Was Not Withdrawn From Sale for
Reasons of Safety or Effectiveness"
090000648200e27f,Other,FDA-2016-P-0378-0004,FDA-2016-P-0378,Final Response Letter June 2 2016
090000648480bbd6,Supporting & Related Material,FDA-2020-P-1770-0003,FDA-2020-P-1770,Footnotes 3 - 32 re Citizen Petition from SIRI & GLIMSTAD LLP on behalf of Informed Consent Action Network
0900006484973e73,Supporting & Related Material,FDA-2020-P-1770-0036,FDA-2020-P-1770,Footnotes 3 - 32 re Citizen Petition from SIRI & GLIMSTAD LLP on behalf of Informed Consent Action Network
090000648491383d,Supporting & Related Material,FDA-2020-P-1770-0015,FDA-2020-P-1770,"Footnotes 21 -34 RE Amendment to Citizen Petition from SIRI & GLIMSTAD LLP,  A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, Immunogenicty, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals"
090000648491383c,Supporting & Related Material,FDA-2020-P-1770-0014,FDA-2020-P-1770,"Footnotes 1 - 20 RE Amendment to Citizen Petition from SIRI & GLIMSTAD LLP, A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, Immunogenicty, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals"
090000648499c488,Other,FDA-2020-P-1770-0037,FDA-2020-P-1770,Denial Response Letter from FDA CBER to Siri & Glimstad LLP
090000648480bbd2,Other,FDA-2020-P-1770-0001,FDA-2020-P-1770,Citizen Petition from SIRI & GLIMSTAD LLP on behalf of Informed Consent Action Network
0900006484812022,Supporting & Related Material,FDA-2020-P-1770-0005,FDA-2020-P-1770,Footnotes 3 - 35 re Administrative Stay of Action from SIRI & GLIMSTAD LLP on behalf of Informed Consent Action Network
0900006484913839,Other,FDA-2020-P-1770-0013,FDA-2020-P-1770,Amendment to Citizen Petition from SIRI & GLIMSTAD LLP
0900006484812020,Other,FDA-2020-P-1770-0004,FDA-2020-P-1770,Administrative Stay of Action from SIRI & GLIMSTAD LLP on behalf of Informed Consent Action Network
090000648480bbd3,Other,FDA-2020-P-1770-0002,FDA-2020-P-1770,Acknowledgment Letter from FDA DMS to SIRI & GLIMSTAD LLP on behalf of Informed Consent Action Network
0900006484a5c804,Notice,FDA-2020-N-1411-0003,FDA-2020-N-1411,"Agency Information Collection Activities; Submission for Office of
Management and Budget Review; Comment Request; Generic Clearance for Data To Support Cross-Center Collaboration for Social Behavioral Sciences Associated With Disease Prevention, Treatment, and the Safety, Efficacy, and Usage of Food and Drug Administration Regulated Products"
090000648472b508,Notice,FDA-2020-N-1411-0001,FDA-2020-N-1411,"Agency Information Collection Activities; Proposed Collection; Comment Request; Generic Clearance for Data to Support Cross-Center Collaboration for Social Behavioral Sciences Associated With Disease Prevention, Treatment, and the Safety, Efficacy, and Usage of Food and Drug Administration Regulated Products"
09000064848571b6,Other,FDA-2020-P-1875-0001,FDA-2020-P-1875,Citizen Petition from Grain Processing Corporation
0900006484b14aa8,Other,FDA-2020-P-1875-0004,FDA-2020-P-1875,180 Day Interim Response Letter from FDA CFSAN to Grain Processing Corporation
0900006484c2828b,Supporting & Related Material,FDA-2020-P-1875-0005,FDA-2020-P-1875,Support Letter re Citizen Petition from Grain Processing Corporation
09000064848571b7,Other,FDA-2020-P-1875-0002,FDA-2020-P-1875,Acknowledgment Letter from FDA DMS to Grain Processing Corporation
09000064848572dd,Supporting & Related Material,FDA-2020-P-1875-0003,FDA-2020-P-1875,Attachment A re Citizen Petition from Grain Processing Corporation
0900006484a6b553,Other,FDA-2021-P-0292-0002,FDA-2021-P-0292,Acknowledgment Letter from FDA DMS to Arnall Golden Gregory LLP
0900006484c9e30c,Other,FDA-2021-P-0292-0004,FDA-2021-P-0292,Response Letter from FDA CDER to Arnall Golden Gregory LLP
0900006484a6b533,Other,FDA-2021-P-0292-0001,FDA-2021-P-0292,Citizen Petition from Arnall Golden Gregory LLP
0900006484c9bd6e,Notice,FDA-2021-P-0292-0003,FDA-2021-P-0292,"Determination That ORTHO-CEPT (Desogestrel-Ethinyl Estradiol) 21- and 28-Day Oral Tablets, 0.15 Milligram/ 0.03 Milligram, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
0900006480557f71,Other,FDA-2008-P-0295-0001,FDA-2008-P-0295,"Par Pharmaceuticals and Kali Laboratories, Inc. - Citizen Petition"
0900006480557fbe,Other,FDA-2008-P-0295-0002,FDA-2008-P-0295,"Acknowledgement Letter to Arent Fox, LLP"
090000648079c3c3,Other,FDA-2008-P-0295-0003,FDA-2008-P-0295,"Par Pharmaceuticals and Kali Laboratories, Inc. - Citizen Petition Withdrawal"
0900006482b137a4,Other,FDA-2017-D-5478-0001,FDA-2017-D-5478,MRCT Draft FDA Guidance Return of Aggregate Results
0900006482b138a8,Other,FDA-2017-D-5478-0002,FDA-2017-D-5478,MRCT Center Cover Letter to FDA Sept 6 2017
0900006481bc7482,Supporting & Related Material,FDA-2015-P-2867-0005,FDA-2015-P-2867,"Attachment 3 Prescribing Information Capecitabine re: Citizen Petition from Lachman Consultant Services, Inc."
0900006484a99850,Other,FDA-2015-P-2867-0006,FDA-2015-P-2867,"Withdrawal from Lachman Consultant Services, Inc."
0900006481bc7867,Supporting & Related Material,FDA-2015-P-2867-0003,FDA-2015-P-2867,"Attachment 1 Excerpt from Orange Book Capecitabine re: Citizen Petition from Lachman Consultant Services, Inc."
0900006481bc7868,Supporting & Related Material,FDA-2015-P-2867-0004,FDA-2015-P-2867,"Attachment 2  Prescribing Information Xeloda re: Citizen Petition from Lachman Consultant Services, Inc."
0900006481bc651d,Other,FDA-2015-P-2867-0002,FDA-2015-P-2867,"Acknowledgment Letter from FDA DDM to Lachman Consultant Services, Inc."
0900006481bc5fa4,Other,FDA-2015-P-2867-0001,FDA-2015-P-2867,Citizen Petition from Lachman Consultant Services Inc
0900006480481f6a,Other,FDA-2003-P-0072-0016,FDA-2003-P-0072,Acknowledgement Letter to International Dairy Foods Association
0900006480482076,Other,FDA-2003-P-0072-0007,FDA-2003-P-0072,FDA Regulations Policy & Management Staff to the Division of Dockets Management - Memorandum
0900006480481ee0,Notice,FDA-2003-P-0072-0001,FDA-2003-P-0072,"Frozen Desserts; Petition to Revoke Standards for Goat’s Milk Ice Cream and Mellorine and to Amend Standards for Ice Cream and Frozen Custard, Sherbet, and Water Ices; Petition to Amend Standards for Parmesan and Reggiano Cheese"
09000064805f8543,Other,FDA-2003-P-0072-0017,FDA-2003-P-0072,International Dairy Foods Association - Withdrawal of Citizen Petition
0900006480481f67,Other,FDA-2003-P-0072-0015,FDA-2003-P-0072,International Dairy Foods Association - Citizen Petition
09000064826c7c96,Supporting & Related Material,FDA-2017-P-3672-0005,FDA-2017-P-3672,"Tab 3 - Actavis Notice Letter (redacted)-1 re Citizen Petition from Millennium Pharmaceuticals, Inc"
09000064826c7c9b,Supporting & Related Material,FDA-2017-P-3672-0010,FDA-2017-P-3672,"Tab 8 - National Cancer Institute, Surveillance, Epidemiology, and End Results Stat Program, Cancer Stat Facts Myeloma-1 re Citizen Petition from Millennium Pharmaceuticals, Inc"
09000064826c7ca4,Supporting & Related Material,FDA-2017-P-3672-0019,FDA-2017-P-3672,"Tab 17 - Reece et al_-1 re Citizen Petition from Millennium Pharmaceuticals, Inc"
09000064826c82ff,Other,FDA-2017-P-3672-0002,FDA-2017-P-3672,"Acknowledgment Letter from FDA DDM to Millennium Pharmaceuticals, Inc"
0900006482c53ae8,Other,FDA-2017-P-3672-0022,FDA-2017-P-3672,"Response Letter from FDA to Millennium Pharmaceuticals, Inc."
09000064826c7c97,Supporting & Related Material,FDA-2017-P-3672-0006,FDA-2017-P-3672,"Tab 4 - EPA RED FACTS Boric Acid, EPA-738-F-93-006 (Sept_ 1993)-1 re Citizen Petition from Millennium Pharmaceuticals, Inc"
09000064826c7c9d,Supporting & Related Material,FDA-2017-P-3672-0012,FDA-2017-P-3672,"Tab 10 - Fryar et al_-1 re Citizen Petition from Millennium Pharmaceuticals, Inc"
09000064826c7ca2,Supporting & Related Material,FDA-2017-P-3672-0017,FDA-2017-P-3672,"Tab 15 - Report of the Food Quality Protection Act (FQPA) Tolerance Reassessment Eligibility Decision (TRED) for Boric Acid-Sodium-1 re Citizen Petition from Millennium Pharmaceuticals, Inc"
09000064826c7ca5,Supporting & Related Material,FDA-2017-P-3672-0020,FDA-2017-P-3672,"Tab 18 - Lu et al_-1 re Citizen Petition from Millennium Pharmaceuticals, Inc"
09000064826c77fb,Other,FDA-2017-P-3672-0001,FDA-2017-P-3672,"Citizen Petition from Millennium Pharmaceuticals, Inc."
09000064826c7c9a,Supporting & Related Material,FDA-2017-P-3672-0009,FDA-2017-P-3672,"Tab 7 - U_S_ EPA Integrated Risk Information System, Boron and Compounds_ CASRN 7440-42-8 (Aug_ 5, 2004)-1 re Citizen Petition from Millennium Pharmaceuticals, Inc"
09000064826c7c9e,Supporting & Related Material,FDA-2017-P-3672-0013,FDA-2017-P-3672,"Tab 11 - Mosteller-1 re Citizen Petition from Millennium Pharmaceuticals, Inc"
09000064826c7ca3,Supporting & Related Material,FDA-2017-P-3672-0018,FDA-2017-P-3672,"Tab 16 - Moreau et al_-1 re Citizen Petition from Millennium Pharmaceuticals, Inc"
09000064826c77fd,Supporting & Related Material,FDA-2017-P-3672-0003,FDA-2017-P-3672,"Tab 1 - InnoPharma Notice Letter (redacted) re Citizen Petition from Millennium Pharmaceuticals, Inc"
09000064826c7c99,Supporting & Related Material,FDA-2017-P-3672-0008,FDA-2017-P-3672,"Tab 6 - Fresenius Notice Letter (redacted)-1 re Citizen Petition from Millennium Pharmaceuticals, Inc"
09000064826c7c9f,Supporting & Related Material,FDA-2017-P-3672-0014,FDA-2017-P-3672,"Tab 12 - Dinca et al_-1 re Citizen Petition from Millennium Pharmaceuticals, Inc"
09000064826c7c95,Supporting & Related Material,FDA-2017-P-3672-0004,FDA-2017-P-3672,"Tab 2 - DRL Notice Letter (redacted)-1 re Citizen Petition from Millennium Pharmaceuticals, Inc"
09000064826c7ca0,Supporting & Related Material,FDA-2017-P-3672-0015,FDA-2017-P-3672,"Tab 13 - WHO, _Boron in drinking-water,_ WHOHSEWSH09_012 (2009)-1 re Citizen Petition from Millennium Pharmaceuticals, Inc"
09000064826c7ca1,Supporting & Related Material,FDA-2017-P-3672-0016,FDA-2017-P-3672,"Tab 14 - Hasegawa et al_-1 re Citizen Petition from Millennium Pharmaceuticals, Inc"
09000064826c7c98,Supporting & Related Material,FDA-2017-P-3672-0007,FDA-2017-P-3672,"Tab 5 - US Patent No_ 8,962,572-1 re Citizen Petition from Millennium Pharmaceuticals, Inc"
09000064826c7c9c,Supporting & Related Material,FDA-2017-P-3672-0011,FDA-2017-P-3672,"Tab 9 - National Cancer Institute, Surveillance, Epidemiology, and End Results Stat Program, Cancer Stat Facts, Non-Hodgkin Lympho-1 re Citizen Petition from Millennium Pharmaceuticals, Inc"
0900006482ef0ec6,Other,FDA-2016-P-3968-0136,FDA-2016-P-3968,Interim Response from FDA to International Probiotics Association
09000064823a3248,Other,FDA-2016-P-3968-0001,FDA-2016-P-3968,Citizen Petition from International Probiotics Association
09000064823a3502,Other,FDA-2016-P-3968-0002,FDA-2016-P-3968,Acknowledgment Letter from FDA DDM to International Probiotics Association
09000064836b152e,Other,FDA-2016-P-3968-0137,FDA-2016-P-3968,Citizen Petition Response to the International Probiotics Association (IPA) Re Probiotic Labeling
0900006482146b68,Other,FDA-2016-P-2337-0002,FDA-2016-P-2337,"Acknowledgement Letter from FDA DDM to LACHMAN CONSULTANT SERVICES, INC."
0900006482146b66,Other,FDA-2016-P-2337-0001,FDA-2016-P-2337,"Citizen Petition from LACHMAN CONSULTANT SERVICES, INC."
0900006482147992,Supporting & Related Material,FDA-2016-P-2337-0003,FDA-2016-P-2337,"Attachment 1 Approved Drug Products with Therapeutic Equivalence Evaluations, Electronic Orange Book accessed July 13, 2016 re Citizen Petition from LACHMAN CONSULTANT SERVICES, INC."
0900006482147993,Supporting & Related Material,FDA-2016-P-2337-0004,FDA-2016-P-2337,"Attachment 2 Approved Labeling for the RLD re Citizen Petition from LACHMAN CONSULTANT SERVICES, INC."
0900006482147994,Supporting & Related Material,FDA-2016-P-2337-0005,FDA-2016-P-2337,"Attachment 3 Proposed Prescribing Information for Leucovorin Calcium Injection re Citizen Petition from LACHMAN CONSULTANT SERVICES, INC."
0900006483a98e89,Other,FDA-2018-P-4642-0005,FDA-2018-P-4642,Agency Response Letter from FDA CVM to Provetica Animal Health LLC
0900006483950c75,Supporting & Related Material,FDA-2018-P-4642-0004,FDA-2018-P-4642,Appendix 2 Proposed Generic Product Label Insert re Citizen Petition from Provetica Animal Health LLC
0900006483950c76,Other,FDA-2018-P-4642-0002,FDA-2018-P-4642,Acknowledgment Letter from FDA DDM to Provetica Animal Health LLC
0900006483950747,Other,FDA-2018-P-4642-0001,FDA-2018-P-4642,Citizen Petition from Provetica Animal Health LLC
0900006483950c74,Supporting & Related Material,FDA-2018-P-4642-0003,FDA-2018-P-4642,Appendix 1 Reference Product Label Insert re Citizen Petition from Provetica Animal Health LLC
0900006481a0b7ac,Supporting & Related Material,FDA-2015-P-0543-0004,FDA-2015-P-0543,Annex 2 Citizen Petition From Gland Pharma Ltd.
0900006481a0b7b0,Supporting & Related Material,FDA-2015-P-0543-0008,FDA-2015-P-0543,Annex 6 Citizen Petition From Gland Pharma Ltd.
0900006481a0c174,Supporting & Related Material,FDA-2015-P-0543-0009,FDA-2015-P-0543,Annex 7 Citizen Petition From Gland Pharma Ltd.
0900006481a0b7ad,Supporting & Related Material,FDA-2015-P-0543-0005,FDA-2015-P-0543,Annex 3 Citizen Petition From Gland Pharma Ltd.
0900006481a0c176,Other,FDA-2015-P-0543-0002,FDA-2015-P-0543,Acknowledgement Letter From FDA DDM to Gland Pharma Ltd.
0900006481a0b7af,Supporting & Related Material,FDA-2015-P-0543-0007,FDA-2015-P-0543,Annex 5 Citizen Petition From Gland Pharma Ltd.
0900006481a0c175,Supporting & Related Material,FDA-2015-P-0543-0010,FDA-2015-P-0543,Annex 8 Citizen Petition From Gland Pharma Ltd.
0900006481a0b7ab,Supporting & Related Material,FDA-2015-P-0543-0003,FDA-2015-P-0543,Annex 1 Citizen Petition From Gland Pharma Ltd.
09000064825e27c0,Other,FDA-2015-P-0543-0012,FDA-2015-P-0543,Final Response Letter from FDA CDER to Gland Pharma Ltd.
0900006481a0b7ae,Supporting & Related Material,FDA-2015-P-0543-0006,FDA-2015-P-0543,Annex 4 Citizen Petition From Gland Pharma Ltd.
0900006481a0b7a9,Other,FDA-2015-P-0543-0001,FDA-2015-P-0543,Citizen Petition From Gland Pharma Ltd.
0900006481c2b603,Other,FDA-2015-P-0543-0011,FDA-2015-P-0543,Interim Response Letter from FDA CDER to Gland Pharma Ltd.
0900006483cd4296,Supporting & Related Material,FDA-2019-P-1800-0010,FDA-2019-P-1800,Boditech Reclassification Petition Appendix II - Submission of a 'Reclassification Petition' under Section 513(f)(3) of the FD&C Act to request the FDA Commissioner for reclassification of medical devices associated with FDA Device Product Code NCD from Class III to Class II
0900006483ba59e6,Supporting & Related Material,FDA-2019-P-1800-0003,FDA-2019-P-1800,"Attachment 1 Copyrighted Article Lewinsohn, et al (2016) Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children re Citizen Petition from Boditech Med Inc."
0900006483ba59e8,Supporting & Related Material,FDA-2019-P-1800-0005,FDA-2019-P-1800,Attachment 3 FDA Guideline for Industry Class II Special Controls Guideline: Nucleic Acid-Based In Vitro Diagnostic Devices for the Detection of Mycobacterium tuberculosis Complex in Respiratory Specimens re Citizen Petition from Boditech Med Inc.
0900006483cd3a27,Other,FDA-2019-P-1800-0007,FDA-2019-P-1800,Submission of a 'Reclassification Petition' under Section 513(f)(3) of the FD&C Act to request the FDA Commissioner for reclassification of medical devices associated with FDA Device Product Code NCD from Class III to Class II
0900006483cd3a2d,Supporting & Related Material,FDA-2019-P-1800-0008,FDA-2019-P-1800,Table of Contents - Re: Submission of a 'Reclassification Petition' under Section 513(f)(3) of the FD&C Act to request the FDA Commissioner for reclassification of medical devices associated with FDA Device Product Code NCD from Class III to Class II
0900006483ba59e9,Other,FDA-2019-P-1800-0002,FDA-2019-P-1800,Acknowledgment Letter from FDA DDM to Boditech Med Inc.
0900006483ba5eba,Other,FDA-2019-P-1800-0001,FDA-2019-P-1800,Citizen Petition from Boditech Med Inc.
0900006483bbb176,Other,FDA-2019-P-1800-0006,FDA-2019-P-1800,Denial Response from FDA CDRH to Boditech Med Inc.
0900006483cd6f71,Other,FDA-2019-P-1800-0012,FDA-2019-P-1800,Reclassification Petition Acknowledgment Letter from FDA CDRH to Boditech Med Inc
0900006483ba59e7,Supporting & Related Material,FDA-2019-P-1800-0004,FDA-2019-P-1800,Attachment 2 WHO Latent tuberculosis infection; Updated and consolidated guidelines for programmatic management re Citizen Petition from Boditech Med Inc.
0900006483cd42cc,Supporting & Related Material,FDA-2019-P-1800-0011,FDA-2019-P-1800,Boditech Reclassification Petition Appendix III - Submission of a 'Reclassification Petition' under Section 513(f)(3) of the FD&C Act to request the FDA Commissioner for reclassification of medical devices associated with FDA Device Product Code NCD from Class III to Class II
0900006483cd41f0,Supporting & Related Material,FDA-2019-P-1800-0009,FDA-2019-P-1800,Boditech Reclassification Petition Appendix I - Re: Submission of a 'Reclassification Petition' under Section 513(f)(3) of the FD&C Act to request the FDA Commissioner for reclassification of medical devices associated with FDA Device Product Code NCD from Class III to Class II
09000064848603fa,Other,FDA-2018-P-3382-0005,FDA-2018-P-3382,"Letter from FDA CDER to Fresenius Kabi USA, LLC"
09000064836bc3ea,Supporting & Related Material,FDA-2018-P-3382-0003,FDA-2018-P-3382,"Attachment A – Current Orange Book Listing of 0.45% Sodium Chloride RE: Citizen Petition from Citizen Petition from Fresenius Kabi USA, LLC"
09000064836bb9e7,Other,FDA-2018-P-3382-0001,FDA-2018-P-3382,"Citizen Petition from Fresenius Kabi USA, LLC"
0900006483ad2c88,Other,FDA-2018-P-3382-0004,FDA-2018-P-3382,"Letter from FDA CDER to Fresenius Kabi USA, LLC"
09000064836bc1a0,Other,FDA-2018-P-3382-0002,FDA-2018-P-3382,"Acknowledgment Letter from FDA DDM to Fresenius Kabi USA, LLC"
0900006483436c8c,Other,FDA-2018-P-2407-0001,FDA-2018-P-2407,"Citizen Petition from Ray Law Firm, PLLC"
0900006483436c8e,Other,FDA-2018-P-2407-0002,FDA-2018-P-2407,"Acknowledgment Letter from FDA DDM to Ray Law Firm, PLLC"
090000648380da64,Other,FDA-2018-P-2407-0003,FDA-2018-P-2407,Amendment to FDA-2018-P-2407 10-19-2018_Redacted
09000064846d9cbc,Other,FDA-2020-P-1523-0001,FDA-2020-P-1523,Citizens Petition from WineAmerica and Wine Institute
090000648499d38b,Other,FDA-2020-P-1523-0003,FDA-2020-P-1523,Response Letter from FDA CFSAN to Wine America
09000064846d9cbd,Other,FDA-2020-P-1523-0002,FDA-2020-P-1523,Acknowledgment Letter from FDA DMS to WineAmerica and Wine Institute
09000064830875eb,Supporting & Related Material,FDA-2018-P-1352-0003,FDA-2018-P-1352,"Appendix 2 - A copy of the Zoetis package insert for this product re Citizen Petition from Douglass Oeller Consulting, Inc. (Felix Pharmaceuticals Pvt. Ltd.)"
09000064833743c7,Other,FDA-2018-P-1352-0006,FDA-2018-P-1352,"Agency Response Letter from FDA CVM to Schafer Veterinary Consultants, LLC"
0900006483087441,Other,FDA-2018-P-1352-0001,FDA-2018-P-1352,"Citizen Petition from Douglass Oeller Consulting, Inc. (Felix Pharmaceuticals Pvt. Ltd.)"
0900006483335707,Other,FDA-2018-P-1352-0005,FDA-2018-P-1352,"Change of US Agent, James H. Schafer, D.V.M (Schafer Veterinary Consultants, LLC) - 06-04-2018"
0900006483087444,Other,FDA-2018-P-1352-0002,FDA-2018-P-1352,"Acknowledgment Letter from FDA DDM to Douglass Oeller Consulting, Inc."
09000064830875ec,Supporting & Related Material,FDA-2018-P-1352-0004,FDA-2018-P-1352,"Appendix 3 - A marked up copy of the package insert showing Felix's proposed changes re Citizen Petition from Douglass Oeller Consulting, Inc. (Felix Pharmaceuticals Pvt. Ltd.)"
09000064849fdf8a,Other,FDA-2019-P-4962-0004,FDA-2019-P-4962,"Correspondence from Fresenius Kabi USA, LLC to CDER"
0900006484a7ec53,Other,FDA-2019-P-4962-0005,FDA-2019-P-4962,"Interim Response Letter from FDA CDER to Fresenius Kabi USA, LLC"
09000064840f1fca,Other,FDA-2019-P-4962-0001,FDA-2019-P-4962,"Citizen Petition for Fresenius Kabi USA, LLC"
09000064840f205f,Other,FDA-2019-P-4962-0002,FDA-2019-P-4962,"Acknowledgment Letter from FDA DMS to Fresenius Kabi USA, LLC"
09000064844bed49,Other,FDA-2019-P-4962-0003,FDA-2019-P-4962,"Interim Response Letter from FDA CDER to Fresenius Kabi USA, LLC"
0900006484980495,Supporting & Related Material,FDA-2020-P-2244-0007,FDA-2020-P-2244,"Attachment 4 re: Citizen Petition from Camargo Pharmaceutical Services, LLC on behalf of Center Laboratories, Inc."
090000648497fe46,Supporting & Related Material,FDA-2020-P-2244-0003,FDA-2020-P-2244,"Attachment 1- Center Labs Citizen Petition Authorization Letter re: Citizen Petition from Camargo Pharmaceutical Services, LLC on behalf of Center Laboratories, Inc."
0900006484b1a72f,Notice,FDA-2020-P-2244-0009,FDA-2020-P-2244,"Determination That ISOPTIN (Verapamil Hydrochloride) Tablets 40 Milligrams, 80 Milligrams, and 120 Milligrams, and CALAN (Verapamil Hydrochloride) Tablets, 40 Milligrams, 80 Milligrams, 120 Milligrams, and 160 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
0900006484b1d0b8,Other,FDA-2020-P-2244-0010,FDA-2020-P-2244,Response Letter from FDA CDER to Camargo Pharmaceutical Services LLC
090000648497fe3f,Other,FDA-2020-P-2244-0001,FDA-2020-P-2244,"Citizen Petition from Camargo Pharmaceutical Services, LLC on behalf of Center Laboratories, Inc."
0900006484980494,Supporting & Related Material,FDA-2020-P-2244-0006,FDA-2020-P-2244,"Attachment 3 re: Citizen Petition from Camargo Pharmaceutical Services, LLC on behalf of Center Laboratories, Inc."
0900006484980493,Supporting & Related Material,FDA-2020-P-2244-0005,FDA-2020-P-2244,"Attachment 2 re: Citizen Petition from Camargo Pharmaceutical Services, LLC on behalf of Center Laboratories, Inc."
0900006484980492,Supporting & Related Material,FDA-2020-P-2244-0004,FDA-2020-P-2244,"Attachment 1 re: Citizen Petition from Camargo Pharmaceutical Services, LLC on behalf of Center Laboratories, Inc."
090000648497fe44,Other,FDA-2020-P-2244-0002,FDA-2020-P-2244,"Acknowledgment Letter from FDA DMS to Camargo Pharmaceutical Services, LLC. on behalf of Center Laboratories, Inc."
090000648498080c,Supporting & Related Material,FDA-2020-P-2244-0008,FDA-2020-P-2244,"Attachment 5 re: Citizen Petition from Camargo Pharmaceutical Services, LLC on behalf of Center Laboratories, Inc."
0900006484b1d00b,Supporting & Related Material,FDA-2020-P-2244-0011,FDA-2020-P-2244,IsoptinCalanFRnotice5.19.21
0900006480a5b482,Notice,FDA-2009-N-0556-0001,FDA-2009-N-0556,Agency Information Collection Activities; Proposed Collection; Comment Request; Records and Reports Concerning Experience WithApproved New Animal Drugs
0900006481ad34d2,Other,FDA-2015-P-1595-0001,FDA-2015-P-1595,"Citizen Petition from Cubist Pharmaceuticals, Inc"
0900006481cf0fd5,Other,FDA-2015-P-1595-0004,FDA-2015-P-1595,"Interim Response Letter from FDA CDER to Cubist Pharmaceutical, Inc."
0900006481ad34d6,Supporting & Related Material,FDA-2015-P-1595-0002,FDA-2015-P-1595,"Exhibit 1 Declaration of Dr. Herbert L. DuPont re Citizen Petition from Cubist Pharmaceuticals, Inc"
0900006482195b31,Other,FDA-2015-P-1595-0005,FDA-2015-P-1595,"Final Response Letter from FDA CDER to Cubist Pharmaceutical, Inc."
0900006481ad34d4,Other,FDA-2015-P-1595-0003,FDA-2015-P-1595,"Acknowledgement Letter from FDA DDM to Cubist Pharmaceuticals, Inc"
0900006482295b64,Supporting & Related Material,FDA-2016-P-0159-0008,FDA-2016-P-0159,Reference 1 - Guidance - Procedures for Class II Device Exemptions from Premarket Notification 1998
0900006481e0efaf,Other,FDA-2016-P-0159-0001,FDA-2016-P-0159,Citizen Petition from Biorex Labs LLC
0900006481e10188,Other,FDA-2016-P-0159-0002,FDA-2016-P-0159,Acknowledgement Letter from FDA DDM to Biorex Labs LLC
0900006481edc6ef,Notice,FDA-2016-P-0159-0003,FDA-2016-P-0159,"Medical Devices; Exemption From Premarket Notification: Method,
Metallic Reduction, Glucose (Urinary, Non-Quantitative) Test System in a
Reagent Tablet Format"
0900006481fa8786,Notice,FDA-2016-P-0159-0005,FDA-2016-P-0159,"Medical Devices; Exemption From Premarket Notification: Method, 
Metallic Reduction, Glucose (Urinary, Non-Quantitative) Test System in 
a Reagent Tablet Format"
09000064822912df,Rule,FDA-2016-P-0159-0007,FDA-2016-P-0159,"Medical Devices; Exemption From Premarket Notification; Method,
Metallic Reduction, Glucose (Urinary, Nonquantitative) Test System in a
Reagent Tablet Format"
09000064820a44c0,Other,FDA-2016-P-0159-0006,FDA-2016-P-0159,Denial letter from the FDA CDRH to Biorex Labs LLC
0900006481edd298,Supporting & Related Material,FDA-2016-P-0159-0004,FDA-2016-P-0159,"Procedures for Class II Device Exemptions from Premarket Notification, Guidance for Industry and CDRH Staff re Medical Devices; Exemption From Premarket Notification: Method, Metallic Reduction, Glucose (Urinary, Non-Quantitative) Test System in a Reagent Tablet Format"
0900006481856fd5,Supporting & Related Material,FDA-2014-P-1102-0002,FDA-2014-P-1102,Attachment 1 Orange Book Approved Drug Products with Therapeutic Equivalence Evaluations
0900006481857032,Other,FDA-2014-P-1102-0003,FDA-2014-P-1102,Acknowledgment Letter From FDA DDM to Lachman Consultant Services Inc
0900006481856fd3,Other,FDA-2014-P-1102-0001,FDA-2014-P-1102,Citizen Petition From Lachman Consultant Services Inc
09000064819b10b1,Other,FDA-2014-P-1102-0004,FDA-2014-P-1102,Response Letter from FDA CDER to Lachman Consultant Services
0900006481857030,Other,FDA-2014-P-1101-0002,FDA-2014-P-1101,Acknowledgement Letter From FDA DDM to Lachman Consultant Services Inc
0900006481856fd7,Other,FDA-2014-P-1101-0001,FDA-2014-P-1101,Citizen Petition From Lachman Consultant Services Inc
09000064819b10af,Other,FDA-2014-P-1101-0004,FDA-2014-P-1101,Response Letter from FDA CDER to Lachman Consultant Services
090000648185702f,Supporting & Related Material,FDA-2014-P-1101-0003,FDA-2014-P-1101,Attachment 1 Orange Book Approved Drug Products with Therapeitoc Equivalence Evaluations
0900006481bb0757,Other,FDA-2015-P-2736-0001,FDA-2015-P-2736,"Suitability Petition from Comodo Health, Inc."
0900006481bb075b,Supporting & Related Material,FDA-2015-P-2736-0003,FDA-2015-P-2736,Attachment I Package Insert for Sandoz's Argatroban re: Suitability Petition from Comodo Health Inc.
0900006481bb0759,Other,FDA-2015-P-2736-0002,FDA-2015-P-2736,Acknowledgement Letter from FDA DDM to Comodo Health Inc.
0900006482fa9a2a,Supporting & Related Material,FDA-2018-P-1019-0004,FDA-2018-P-1019,"Attachment 2- NDA 17-558/S-053 Robinul Injection (Glycopyrrolate Injection, USP) re: Citizen Petition from Lachman Consultant Services Inc."
0900006482fa9a2b,Supporting & Related Material,FDA-2018-P-1019-0005,FDA-2018-P-1019,"Attachment 3- NEOSTIGMINE METHYLSULFATE - neos tigmine methylsulfate injection, solution Fres enius Kabi USA, LLC re: Citizen Petition from Lachman Consultant Services Inc."
0900006482fa9a25,Other,FDA-2018-P-1019-0002,FDA-2018-P-1019,"Acknowledgment Letter from FDA DDM to LACHMAN CONSULTANT SERVICES, INC"
0900006482fa9a29,Supporting & Related Material,FDA-2018-P-1019-0003,FDA-2018-P-1019,Attachment 1- Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations re: Citizen Petition from Lachman Consultant Services Inc.
0900006482fa9a2c,Supporting & Related Material,FDA-2018-P-1019-0006,FDA-2018-P-1019,"Attachment 4- GLYCOPYRROLATE - glycopyrrolate injection, solution re: Citizen Petition from Lachman Consultant Services Inc."
0900006482fa8ff7,Other,FDA-2018-P-1019-0001,FDA-2018-P-1019,Citizen Petition from Lachman Consultant Services Inc.
0900006482317098,Other,FDA-2016-P-3427-0002,FDA-2016-P-3427,"Acknowledgement Letter from FDA DDM to Douglass Oeller Consulting, Inc. (Felix Pharmaceuticals Pvt. Ltd)"
0900006482466d24,Other,FDA-2016-P-3427-0006,FDA-2016-P-3427,"Petition Approval Letter from FDA CVM to Douglass Oeller Consulting, Inc."
090000648231709a,Supporting & Related Material,FDA-2016-P-3427-0003,FDA-2016-P-3427,"Attachment 1 Deramaxx re Suitability Petition from Douglass Oeller Consulting, Inc (Felix Pharmaceuticals Pvt. Ltd)"
090000648235effc,Other,FDA-2016-P-3427-0005,FDA-2016-P-3427,"Amendment  from Douglass Oeller Consulting, Inc ."
090000648231709b,Supporting & Related Material,FDA-2016-P-3427-0004,FDA-2016-P-3427,"Attachment 2 Chewable Tablets re Suitability Petition from Douglass Oeller Consulting, Inc (Felix Pharmaceuticals Pvt. Ltd)"
0900006482317094,Other,FDA-2016-P-3427-0001,FDA-2016-P-3427,"Suitability Petition from  Douglass Oeller Consulting, Inc. (Felix Pharmaceuticals Pvt. Ltd)"
09000064841295d3,Other,FDA-2019-P-5268-0002,FDA-2019-P-5268,Acknowledgment Letter from FDA DMS to Public Citizen’s Health Research Group
0900006484554b34,Other,FDA-2019-P-5268-0015,FDA-2019-P-5268,"Interim Response Letter from FDA CDER to Public Citizen’s Health Research Group and Delaram J. Taghipour, M.D."
09000064841295d2,Other,FDA-2019-P-5268-0001,FDA-2019-P-5268,Citizen Petition from Public Citizen's Health Research Group
090000648412960b,Supporting & Related Material,FDA-2019-P-5268-0012,FDA-2019-P-5268,"Reference 45, by Shah et al Re Citizen Petition from Public Citizen’s Health Research Group"
090000648412960d,Supporting & Related Material,FDA-2019-P-5268-0014,FDA-2019-P-5268,Reference 51 by Scholl et al Re Citizen Petition from Public Citizen’s Health Research Group
0900006484129605,Supporting & Related Material,FDA-2019-P-5268-0006,FDA-2019-P-5268,"Reference 12-13, by Gillen et al  Re Citizen Petition from Public Citizen’s Health Research Group"
0900006484129606,Supporting & Related Material,FDA-2019-P-5268-0007,FDA-2019-P-5268,"Reference 16 and 20-21, by VanSchaik Re Citizen Petition from Public Citizen’s Health Research Group"
0900006484129607,Supporting & Related Material,FDA-2019-P-5268-0008,FDA-2019-P-5268,"Reference 31, by Skipper et al Re Citizen Petition from Public Citizen’s Health Research Group"
0900006484129608,Supporting & Related Material,FDA-2019-P-5268-0009,FDA-2019-P-5268,"Reference 34 and 36-37, By Harrison et al Re Citizen Petition from Public Citizen’s Health Research Group"
090000648412960c,Supporting & Related Material,FDA-2019-P-5268-0013,FDA-2019-P-5268,"Reference 46-49, by Thiels et al Re Citizen Petition from Public Citizen’s Health Research Group"
09000064846b96c3,Other,FDA-2019-P-5268-0016,FDA-2019-P-5268,Supplement from Public Citizen
090000648412afed,Supporting & Related Material,FDA-2019-P-5268-0003,FDA-2019-P-5268,Appendix Boxed Warning for Oxycontin re Citizen Petition from Public Citizen’s Health Research Group
09000064841299f9,Supporting & Related Material,FDA-2019-P-5268-0004,FDA-2019-P-5268,"Reference 7-9 and 14-15, By Grond et al Re Citizen Petition from Public Citizen’s Health Research Group"
0900006484129609,Supporting & Related Material,FDA-2019-P-5268-0010,FDA-2019-P-5268,"Reference 43, by Jeong et al Re Citizen Petition from Public Citizen’s Health Research Group"
090000648412960a,Supporting & Related Material,FDA-2019-P-5268-0011,FDA-2019-P-5268,"Reference 44, by Zeng et al Re Citizen Petition from Public Citizen’s Health Research Group"
09000064841299fa,Supporting & Related Material,FDA-2019-P-5268-0005,FDA-2019-P-5268,"Reference 11, by Raffa et al Re Citizen Petition from Public Citizen’s Health Research Group"
0900006484a60974,Other,FDA-2020-P-1919-0003,FDA-2020-P-1919,"Withdrawal from Acella Pharmaceuticals, LLC"
0900006484861b36,Other,FDA-2020-P-1919-0001,FDA-2020-P-1919,"Citizen Petition from Acella Pharmaceuticals, LLC"
09000064848620de,Other,FDA-2020-P-1919-0002,FDA-2020-P-1919,"Acknowledgment Letter from FDA DMS to Acella Pharmaceuticals, LLC"
0900006484a3a72d,Other,FDA-2021-P-0193-0001,FDA-2021-P-0193,"Citizen Petition from Benjamin Ogilvie, et.al."
0900006484a3a730,Other,FDA-2021-P-0193-0002,FDA-2021-P-0193,Acknowledgment Letter from FDA DMS to Benjamin Ogilvie
0900006484c28b5e,Other,FDA-2021-P-0193-0009,FDA-2021-P-0193,Response Letter from FDA CDER to Benjamin Ogilvie
0900006484a3a74c,Supporting & Related Material,FDA-2021-P-0193-0003,FDA-2021-P-0193,Appendix A re Citizen Petition from Benjamin Ogilvie
0900006484a60d12,Other,FDA-2021-P-0271-0002,FDA-2021-P-0271,Acknowledgment Letter from FDA DMS to Hyman Phelps McNamara PC
0900006484a60d10,Other,FDA-2021-P-0271-0001,FDA-2021-P-0271,Citizen Petition from Hyman Phelps McNamara PC
0900006484c2c8f0,Other,FDA-2021-P-0271-0004,FDA-2021-P-0271,"Response Letter from FDA CDER to Hyman, Phelps& McNamara, P.C."
0900006484c2aa83,Notice,FDA-2021-P-0271-0003,FDA-2021-P-0271,"Determination That VOTRIENT (Pazopanib Hydrochloride) Tablets, 400 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
0900006484a13124,Supporting & Related Material,FDA-2021-P-0096-0028,FDA-2021-P-0096,Affidavit of Stein RE Citizen Petition from BakerHostetler LLP (on behalf of Salix Pharmaceuticals Inc)
0900006484a12b1e,Supporting & Related Material,FDA-2021-P-0096-0005,FDA-2021-P-0096,Tab 4 - Jasmohan S. Bajaj et al. - Colonic Mucosal Microbiome Differs from Stool Microbiome in Cirrhosis and Hepatic Encephalopathy and is Linked to Cognition and Inflammation RE Citizen Petition from BakerHostetler LLP (on behalf of Salix Pharmaceuticals Inc)
0900006484a12b23,Supporting & Related Material,FDA-2021-P-0096-0007,FDA-2021-P-0096,Tab 8 - Patrizia Brigidi et al. - Effects of Rifaximin Administration on the Intestinal Microbiota in Patients with Ulcerative Colitis RE Citizen Petition from BakerHostetler LLP (on behalf of Salix Pharmaceuticals Inc)
0900006484a12b60,Supporting & Related Material,FDA-2021-P-0096-0010,FDA-2021-P-0096,Tab 12 - E. Fritz et al. - Effects of Lactulose and Polyethylene Glycol on Colonic Transit RE Citizen Petition from BakerHostetler LLP (on behalf of Salix Pharmaceuticals Inc)
0900006484a12b64,Supporting & Related Material,FDA-2021-P-0096-0014,FDA-2021-P-0096,Tab 16 - Dae Joong Kang et al. - Rifaximin Exerts Beneficial Effects Independent of its Ability to Alter Microbiota Composition RE Citizen Petition from BakerHostetler LLP (on behalf of Salix Pharmaceuticals Inc)
0900006484a12b1c,Supporting & Related Material,FDA-2021-P-0096-0004,FDA-2021-P-0096,Tab 3 - Jasmohan S. Bajaj - Review Article: Potential Mechanisms of Action of Rifaximin in the Management of Hepatic Encephalopathy and Other Complications of Cirrhosis RE Citizen Petition from BakerHostetler LLP (on behalf of Salix Pharmaceuticals Inc)
0900006484a12bb0,Supporting & Related Material,FDA-2021-P-0096-0020,FDA-2021-P-0096,Tab 23 - Salix Pharm. Inc - Xifaxan Prescribing Information RE Citizen Petition from BakerHostetler LLP (on behalf of Salix Pharmaceuticals Inc)
09000064849fca5f,Other,FDA-2021-P-0096-0001,FDA-2021-P-0096,Citizen Petition from BakerHostetler LLP (on behalf of Salix Pharmaceuticals Inc)
0900006484a12b1a,Supporting & Related Material,FDA-2021-P-0096-0003,FDA-2021-P-0096,Index of Reference Documents RE Citizen Petition from BakerHostetler LLP (on behalf of Salix Pharmaceuticals Inc)
0900006484a12b63,Supporting & Related Material,FDA-2021-P-0096-0013,FDA-2021-P-0096,Tab 15 - Jamie S. Huang et al. - Use of Rifamycin Drugs and Development of Infection by Rifamycin-Resistant Strains of Clostridium difficile RE Citizen Petition from BakerHostetler LLP (on behalf of Salix Pharmaceuticals Inc)
0900006484a12bac,Supporting & Related Material,FDA-2021-P-0096-0016,FDA-2021-P-0096,"Tab 18 - David G. Levitt & Michael D. Levitt - A Model of Blood-Ammonia Homeostasis Based on a Quantitative Analysis of Nitrogen Metabolism in the Multiple Organs Involved in the Production, Catabolism,
and Excretion of Ammonia in Humans RE Citizen Petition from BakerHostetler LLP (on behalf of Salix Pharmaceuticals Inc)"
0900006484a12bb1,Supporting & Related Material,FDA-2021-P-0096-0021,FDA-2021-P-0096,Tab 36 - G. C. Viscomi et al. - Crystal Forms of Rifaximin and Their Effect on Pharmaceutical Properties RE Citizen Petition from BakerHostetler LLP (on behalf of Salix Pharmaceuticals Inc)
0900006484a12b67,Supporting & Related Material,FDA-2021-P-0096-0015,FDA-2021-P-0096,"Tab 17 - Vishesh Kothary et al. - Rifaximin Resistance in Escherichia coli Associated with Inflammatory Bowel Disease Correlates with Prior Rifaximin Use, Mutations in rpoB, and Activity of PheArg-β-Naphthylamide-Inhibitable Efflux Pumps RE Citizen Petition from BakerHostetler LLP (on behalf of Salix Pharmaceuticals Inc)"
0900006484a12bae,Supporting & Related Material,FDA-2021-P-0096-0018,FDA-2021-P-0096,Tab 21 - Deanna M. Mudie et al. - Quantification of Gastrointestinal Liquid Volumes and Distribution Following a 240 mL Dose of Water in the Fasted State RE Citizen Petition from BakerHostetler LLP (on behalf of Salix Pharmaceuticals Inc)
0900006484a14316,Supporting & Related Material,FDA-2021-P-0096-0022,FDA-2021-P-0096,Tab 37 - World Health Organization -2019 Antibacterial Agents in Clinical Development: An Analysis of the Antibacterial Clinical Development Pipeline RE Citizen Petition from BakerHostetler LLP (on behalf of Salix Pharmaceuticals Inc)
0900006484a12bb3,Supporting & Related Material,FDA-2021-P-0096-0024,FDA-2021-P-0096,"Tab 39 - Alex Yu et al. - Bioequivalence History, in FDA Bioequivalence Standards RE Citizen Petition from BakerHostetler LLP (on behalf of Salix Pharmaceuticals Inc)"
0900006484a13122,Supporting & Related Material,FDA-2021-P-0096-0026,FDA-2021-P-0096,Affidavit of Ciolkowski RE Citizen Petition from BakerHostetler LLP (on behalf of Salix Pharmaceuticals Inc)
0900006484a12b62,Supporting & Related Material,FDA-2021-P-0096-0012,FDA-2021-P-0096,Tab 14 - Ankur Gupta et al. - Role of Small Intestinal Bacterial Overgrowth and Delayed Gastrointestinal Transit Time in Cirrhotic Patients with Minimal Hepatic Encephalopathy RE Citizen Petition from BakerHostetler LLP (on behalf of Salix Pharmaceuticals Inc)
09000064849fcb2e,Other,FDA-2021-P-0096-0002,FDA-2021-P-0096,Acknowledgment Letter from FDA DMS to BakerHostetler LLP (on behalf of Salix Pharmaceuticals Inc)
0900006484a12bad,Supporting & Related Material,FDA-2021-P-0096-0017,FDA-2021-P-0096,Tab 19 - Xiaochao Ma et al. - Rifaximin is a Gut-Specific Human Pregnane X Receptor Activator RE Citizen Petition from BakerHostetler LLP (on behalf of Salix Pharmaceuticals Inc)
0900006484a13121,Supporting & Related Material,FDA-2021-P-0096-0025,FDA-2021-P-0096,Affidavit of Chasan-Taber RE Citizen Petition from BakerHostetler LLP (on behalf of Salix Pharmaceuticals Inc)
0900006484a13123,Supporting & Related Material,FDA-2021-P-0096-0027,FDA-2021-P-0096,Affidavit of Johnson RE Citizen Petition from BakerHostetler LLP (on behalf of Salix Pharmaceuticals Inc)
0900006484a12b5e,Supporting & Related Material,FDA-2021-P-0096-0008,FDA-2021-P-0096,Tab 9 - Elizabeth A. Campbell et al. - Structural Mechanism for Rifampicin Inhibition of Bacterial RNA  Polymerase RE Citizen Petition from BakerHostetler LLP (on behalf of Salix Pharmaceuticals Inc)
0900006484a12b22,Supporting & Related Material,FDA-2021-P-0096-0006,FDA-2021-P-0096,"Tab 7 - Corrado Blandizzi et al. - Impact of Crystal Polymorphism on the Systemic Bioavailability of Rifaximin, an Antibiotic Acting Locally in the Gastrointestinal Tract, in Healthy Volunteers RE Citizen Petition from BakerHostetler LLP (on behalf of Salix Pharmaceuticals Inc)"
0900006484a12b61,Supporting & Related Material,FDA-2021-P-0096-0011,FDA-2021-P-0096,Tab 13 - Tawanda Gumbo et al. - Concentration-Dependent Mycobacterium tuberculosis Killing and Prevention of Resistance by Rifampin RE Citizen Petition from BakerHostetler LLP (on behalf of Salix Pharmaceuticals Inc)
09000064822f5966,Other,FDA-2016-P-3313-0001,FDA-2016-P-3313,"Citizen Petition from Kleinfeld, Kaplan and Becker, LLP (Purdue Pharma L.P.)"
09000064824db694,Other,FDA-2016-P-3313-0003,FDA-2016-P-3313,"Supplement from Purdue Pharma L.P. (Kleinfeld, Kaplan, & Becker LLP)"
090000648250047b,Other,FDA-2016-P-3313-0004,FDA-2016-P-3313,"CP Response from FDA CDER to Kleinfeld, Kaplan and Becker, LLP"
09000064822f5968,Other,FDA-2016-P-3313-0002,FDA-2016-P-3313,"Acknowledgment Letter from FDA DDM to  Kleinfeld, Kaplan and Becker, LLP"
09000064831330bd,Other,FDA-2018-P-1492-0002,FDA-2018-P-1492,"Acknowledgment Letter from FDA DDM to Lachman Consultant Services, Inc"
09000064831330ba,Other,FDA-2018-P-1492-0001,FDA-2018-P-1492,"Citizen Petition from Lachman Consultant Services, Inc"
090000648313314f,Supporting & Related Material,FDA-2018-P-1492-0003,FDA-2018-P-1492,"Attachment Orange Book Acetaminophen and Oxycodone re Citizen Petition from Lachman Consultant Services, Inc"
090000648390d0c6,Other,FDA-2018-P-1492-0005,FDA-2018-P-1492,Withdrawal of Citizen Petition FDA-2018-P-1492
0900006482b26a4d,Other,FDA-2017-P-5592-0001,FDA-2017-P-5592,Citizens Petition from International Isotopes Inc
0900006483258ccc,Notice,FDA-2017-P-5592-0006,FDA-2017-P-5592,"Determination That SODIUM IODIDE I 123 (Sodium Iodide I-123), Oral
Solution, 2 Millicuries/Milliliter, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
0900006482fd5bf1,Other,FDA-2017-P-5592-0005,FDA-2017-P-5592,Interim Response from FDA to International Isotopes Inc
0900006482b26c26,Supporting & Related Material,FDA-2017-P-5592-0004,FDA-2017-P-5592,Appendix 2 Prescribing Information for Sodium Iodide Capsules re Citizens Petition from International Isotopes Inc
090000648326f29a,Other,FDA-2017-P-5592-0007,FDA-2017-P-5592,Final Response - Sodium Iodide
0900006482b26c25,Supporting & Related Material,FDA-2017-P-5592-0003,FDA-2017-P-5592,Appendix 1 Current Orange Book Listing for Sodium Iodide I-123 re Citizens Petition from International Isotopes Inc
0900006482b26c23,Other,FDA-2017-P-5592-0002,FDA-2017-P-5592,Acknowledgement Letter from FDA DDM to International Isotopes Inc
0900006481c63399,Supporting & Related Material,FDA-2015-P-3299-0003,FDA-2015-P-3299,Attachment 1 Prescription and Over the Counter Drug Product List Orange Book 33rd Edition re Citizen Petition from Clinipace Worldwide
0900006481e8be0b,Other,FDA-2015-P-3299-0005,FDA-2015-P-3299,Interim Response Letter from FDA CDER to Clinipace Worldwide
0900006481f8f701,Other,FDA-2015-P-3299-0007,FDA-2015-P-3299,Final Agency Response: Re-listing Letter - 4-26-16 81 FR 24107
0900006481f890ee,Notice,FDA-2015-P-3299-0006,FDA-2015-P-3299,"Determination That THALITONE (Chlorthalidone USP) Tablets, 15
Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or
Effectiveness"
0900006481c6339a,Supporting & Related Material,FDA-2015-P-3299-0004,FDA-2015-P-3299,Attachment 2  Prescription and Over the Counter Drug Product List Orange Book 35th Edition re Citizen Petition from Clinipace Worldwide
0900006481c63396,Other,FDA-2015-P-3299-0002,FDA-2015-P-3299,Acknowledgement Letter from FDA DDM to Clinipace Worldwide
0900006481c63395,Other,FDA-2015-P-3299-0001,FDA-2015-P-3299,Citizen Petition from Clinipace Worldwide
0900006481ae2723,Other,FDA-2015-P-1722-0001,FDA-2015-P-1722,Citizen Petition from Hogan Lovells US LLP (Helsinn)
0900006481ae2d08,Supporting & Related Material,FDA-2015-P-1722-0008,FDA-2015-P-1722,Tab 9 Helsinn Exela NDA Medical Review re: Citizen Petition from Hogan Lovells
0900006481ae27a3,Supporting & Related Material,FDA-2015-P-1722-0004,FDA-2015-P-1722,Tab 3 Helsinn Exela Denial Letter re: Citizen Petition from Hogan Lovells
0900006481cc0653,Other,FDA-2015-P-1722-0014,FDA-2015-P-1722,Citizen Petition Denial Response from FDA CDER to Hogan Lovells US LLP
0900006481ae2725,Other,FDA-2015-P-1722-0002,FDA-2015-P-1722,Acknowledgement Letter from FDA DDM to Hogan Lovells US LLP
0900006481ae2d07,Supporting & Related Material,FDA-2015-P-1722-0007,FDA-2015-P-1722,Tab 8 Helsinn Exela NDA Clinical Review re: Citizen Petition from Hogan Lovells
0900006481ae27a5,Supporting & Related Material,FDA-2015-P-1722-0005,FDA-2015-P-1722,Tab 5 Helsinn Exela Letter from OGD re: Citizen Petition from Hogan Lovells
0900006481ae2d09,Supporting & Related Material,FDA-2015-P-1722-0009,FDA-2015-P-1722,Tab 10 Helsinn Exela NDA Summary Review re: Citizen Petition from Hogan Lovells
0900006481ae2d0a,Supporting & Related Material,FDA-2015-P-1722-0010,FDA-2015-P-1722,Tab 11 Helsinn Exela Petition Denial re: Citizen Petition from Hogan Lovells
0900006481ae27a6,Supporting & Related Material,FDA-2015-P-1722-0006,FDA-2015-P-1722,Tab 6 Helsinn Exela Label Evaluation re: Citizen Petition from Hogan Lovells
0900006481ae27a2,Supporting & Related Material,FDA-2015-P-1722-0003,FDA-2015-P-1722,Tab 2 Helsinn Exela Label Information re: Citizen Petition from Hogan Lovells
0900006481ae2d0b,Supporting & Related Material,FDA-2015-P-1722-0011,FDA-2015-P-1722,Tab 12 Helsinn Exela Petition Denial re: Citizen Petition from Hogan Lovells
0900006481ae2d0c,Supporting & Related Material,FDA-2015-P-1722-0012,FDA-2015-P-1722,Tab 13 Helsinn Exela Journal Letter re: Citizen Petition from Hogan Lovells
0900006481ae28cc,Supporting & Related Material,FDA-2015-P-1722-0013,FDA-2015-P-1722,Tab 25 Helsinn Exela Redacted ANDA Rejection re: Citizen Petition from Hogan Lovells
090000648498004d,Supporting & Related Material,FDA-2020-P-2245-0003,FDA-2020-P-2245,"Attachment 1- Center Labs Citizen Petition Authorization Letter RE: Citizen Petition from Camargo Pharmaceutical Services, LLC on behalf of Center Laboratories, Inc."
0900006484980812,Supporting & Related Material,FDA-2020-P-2245-0007,FDA-2020-P-2245,"Attachment 4 re:  Citizen Petition from Camargo Pharmaceutical Services, LLC on behalf of Center Laboratories, Inc."
090000648498080f,Supporting & Related Material,FDA-2020-P-2245-0004,FDA-2020-P-2245,"Attachment 1 re:  Citizen Petition from Camargo Pharmaceutical Services, LLC on behalf of Center Laboratories, Inc."
0900006484b1e36b,Other,FDA-2020-P-2245-0011,FDA-2020-P-2245,"Letter from FDA CDER to Camargo Pharmaceutical Services, LLC"
0900006484980811,Supporting & Related Material,FDA-2020-P-2245-0006,FDA-2020-P-2245,"Attachment 3 re:  Citizen Petition from Camargo Pharmaceutical Services, LLC on behalf of Center Laboratories, Inc."
090000648497fe47,Other,FDA-2020-P-2245-0001,FDA-2020-P-2245,"Citizen Petition from Camargo Pharmaceutical Services, LLC on behalf of Center Laboratories, Inc."
090000648498004b,Other,FDA-2020-P-2245-0002,FDA-2020-P-2245,"Acknowledgment Letter from FDA DMS to Camargo Pharmaceutical Services, LLC on behalf of Center Laboratories, Inc."
0900006484980813,Supporting & Related Material,FDA-2020-P-2245-0008,FDA-2020-P-2245,"Attachment 5 re:  Citizen Petition from Camargo Pharmaceutical Services, LLC on behalf of Center Laboratories, Inc."
0900006484980810,Supporting & Related Material,FDA-2020-P-2245-0005,FDA-2020-P-2245,"Attachment 2 re:  Citizen Petition from Camargo Pharmaceutical Services, LLC on behalf of Center Laboratories, Inc."
0900006484b1b367,Notice,FDA-2020-P-2245-0010,FDA-2020-P-2245,"Determination That ISOPTIN (Verapamil Hydrochloride) Tablets 40 Milligrams, 80 Milligrams, and 120 Milligrams, and CALAN (Verapamil Hydrochloride) Tablets, 40 Milligrams, 80 Milligrams, 120 Milligrams, and 160 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
0900006484b1dbbe,Supporting & Related Material,FDA-2021-P-0477-0005,FDA-2021-P-0477,"Attachment  3 - NARCAN label - 1986  RE Citizen Petition from BPI Labs, LLC"
0900006484b1d0d1,Supporting & Related Material,FDA-2021-P-0477-0007,FDA-2021-P-0477,"Attachment 5 - NARCAN Label-2004  RE Citizen Petition from BPI Labs, LLC"
0900006484b1d00c,Other,FDA-2021-P-0477-0001,FDA-2021-P-0477,"Citizen Petition from BPI Labs, LLC"
0900006484b1dbbc,Supporting & Related Material,FDA-2021-P-0477-0003,FDA-2021-P-0477,"Attachment 1 - Orange Book Approved Drug Productswith Therapeutic EquivalenceEvaluations RE Citizen Petition from BPI Labs, LLC"
0900006484b1dbbd,Supporting & Related Material,FDA-2021-P-0477-0004,FDA-2021-P-0477,"Attachment 2 - Orange Book Approved Drug Products with Therapeutic Equivalence  RE Citizen Petition from BPI Labs, LLC"
0900006484b1d0c5,Other,FDA-2021-P-0477-0002,FDA-2021-P-0477,"Acknowledgment Letter from FDA DMS to BPI Labs, LLC"
0900006484b1d0d0,Supporting & Related Material,FDA-2021-P-0477-0006,FDA-2021-P-0477,"Attachment  4 -SBoA_IMS ANDA-072076  RE Citizen Petition from BPI Labs, LLC"
090000648045c70b,Supporting & Related Material,FDA-2006-N-0309-0005,FDA-2006-N-0309,Jeffrey Shuren
090000648045c70e,Supporting & Related Material,FDA-2006-N-0309-0006,FDA-2006-N-0309,Jeffrey Shuren
090000648045c708,Notice,FDA-2006-N-0309-0004,FDA-2006-N-0309,FDA
090000648045c706,Notice,FDA-2006-N-0309-0003,FDA-2006-N-0309,FDA
090000648045c6ff,Notice,FDA-2006-N-0309-0002,FDA-2006-N-0309,FDA
090000648045c6e8,Notice,FDA-2006-N-0309-0001,FDA-2006-N-0309,FDA
0900006480afeaaa,Notice,FDA-2010-N-0019-0002,FDA-2010-N-0019,"Agency Information Collection Activities; Proposals, Submissions, and Approvals: General Licensing Provisions; Biologics License Application, Changes to an Approved Application, etc."
0900006480a83d3f,Notice,FDA-2010-N-0019-0001,FDA-2010-N-0019,"Agency Information Collection Activities; Proposed Collection; Comment Request; General Licensing Provisions: Biologics License Application, Changes toan Approved Application, Labeling, Revocation and Suspension, Postmarketing Studies Status Reports, and Forms FDA 356h and 2567"
090000648257fe31,Supporting & Related Material,FDA-2017-P-2661-0003,FDA-2017-P-2661,ATTACHMENT 1 - Orange Book Approved Drug Products with Therapeutic Equivalence Evaluations re Request that the FDA to declare that Empagliflozlin Capsules 10 mg and 25 mg are suitable for submission as an ANDA and the reference product on which the contents of this petition are based is Jardiance (Empagliflozlin Tablets 10 mg and 25 mg
090000648257fe35,Supporting & Related Material,FDA-2017-P-2661-0006,FDA-2017-P-2661,ATTACHMENT 4 - NDA APPROVAL re Request that the FDA to declare that Empagliflozlin Capsules 10 mg and 25 mg are suitable for submission as an ANDA and the reference product on which the contents of this petition are based is Jardiance (Empagliflozlin Tablets 10 mg and 25 mg
09000064825801e7,Other,FDA-2017-P-2661-0002,FDA-2017-P-2661,Acknowledgment Letter from FDA DDM to Foley & Lardner LLP
090000648257fceb,Other,FDA-2017-P-2661-0001,FDA-2017-P-2661,Citizen Petition from Foley & Lardner LLP
090000648257fe34,Supporting & Related Material,FDA-2017-P-2661-0005,FDA-2017-P-2661,"ATTACHMENT 3 - JARDIANCE' (empagliflozin) tablets, for oral use re Request that the FDA to declare that Empagliflozlin Capsules 10 mg and 25 mg are suitable for submission as an ANDA and the reference product on which the contents of this petition are based is Jardiance (Empagliflozlin Tablets 10 mg and 25 mg"
0900006484db4d7e,Other,FDA-2017-P-2661-0007,FDA-2017-P-2661,Withdrawal of Citizen Petition from Foley & Lardner LLP
090000648257fe33,Supporting & Related Material,FDA-2017-P-2661-0004,FDA-2017-P-2661,ATTACHMENT 2 - Empagliflozlin Capsules 10 mg and 25 mg re Request that the FDA to declare that Empagliflozlin Capsules 10 mg and 25 mg are suitable for submission as an ANDA and the reference product on which the contents of this petition are based is Jardiance (Empagliflozlin Tablets 10 mg and 25 mg
0900006484aa34cd,Other,FDA-2021-P-0375-0001,FDA-2021-P-0375,Citizen Petition from Celerity Pharmaceuticals LLC
0900006484dbe91e,Other,FDA-2021-P-0375-0005,FDA-2021-P-0375,"Interim Response Letter from FDA CDER to Celerity Pharmaceuticals, LLC"
0900006484aa3e35,Other,FDA-2021-P-0375-0002,FDA-2021-P-0375,Acknowledgement Letter from FDA DMS to Celerity Pharmaceuticals LLC from FDA DMS
0900006484aa3e4e,Supporting & Related Material,FDA-2021-P-0375-0003,FDA-2021-P-0375,Attachment 2 re: Citizen Petition from Celerity Pharmaceuticals LLC.
0900006484aa3e5e,Supporting & Related Material,FDA-2021-P-0375-0004,FDA-2021-P-0375,Attachment 1- Orange Book RE: Citizen Petition from Celerity Pharmaceuticals LLC.
09000064847cc220,Other,FDA-2020-P-1725-0002,FDA-2020-P-1725,Acknowledgment Letter from FDA DMS to Knowledge Ecology International
0900006484a0f7c8,Other,FDA-2020-P-1725-0004,FDA-2020-P-1725,Interim Response Letter from FDA CDER to Knowledge Ecology International
09000064847cc21f,Other,FDA-2020-P-1725-0001,FDA-2020-P-1725,Citizen Petition from Knowledge Ecology International
090000648266979e,Other,FDA-2016-P-4186-0003,FDA-2016-P-4186,"Interim Response from FDA CDER to Lachman Consultant Services, Inc."
09000064823dabba,Other,FDA-2016-P-4186-0001,FDA-2016-P-4186,"Citizen Petition from Lachman Consultant Services, Inc."
09000064823dabbc,Other,FDA-2016-P-4186-0002,FDA-2016-P-4186,"Acknowledgment Letter from FDA DDM to Lachman Consultant Services, Inc."
0900006483f21297,Notice,FDA-2016-P-4186-0005,FDA-2016-P-4186,"Determination That CALCIMAR (calcitonin salmon) Injection, 200 International Units Per Milliliter, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
0900006483f22afa,Other,FDA-2016-P-4186-0004,FDA-2016-P-4186,"Response Letter from FDA CDER to Lachman Consultant Services, Inc"
0900006483a06ca4,Other,FDA-2019-P-0372-0001,FDA-2019-P-0372,"Citizen Petition from Hyman Phelps & McNamara, P.C."
0900006483a07625,Other,FDA-2019-P-0372-0002,FDA-2019-P-0372,"Acknowledgment Letter from FDA DDM to  Hyman Phelps & McNamara, P.C."
0900006483d96d32,Other,FDA-2019-P-0372-0004,FDA-2019-P-0372,"Letter from FDA CDER to Hyman Phelps & McNamara, P.C."
0900006483d94332,Notice,FDA-2019-P-0372-0003,FDA-2019-P-0372,"Determination That MIOCHOL (Acetylcholine Chloride Intraocular Solution), 20 Milligrams/Vial, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
09000064823debed,Other,FDA-2011-P-0022-0014,FDA-2011-P-0022,Interim Response Letter from CDRH to Waxler Regulatory Consultancy LLC
0900006480fdb94f,Other,FDA-2011-P-0022-0006,FDA-2011-P-0022,Waxler Regulatory Consultancy LLC - Letter
090000648185aee8,Other,FDA-2011-P-0022-0009,FDA-2011-P-0022,"Petition for Reconsideration from Waxler Consultancy, LLC"
0900006480ebc8f4,Other,FDA-2011-P-0022-0004,FDA-2011-P-0022,FDA Interim Response to Waxler Regulatory Consultancy LLC
0900006480bc6a44,Other,FDA-2011-P-0022-0001,FDA-2011-P-0022,Waxler Regulatory Consultancy LLC - Citizen Petition
0900006481afb0ad,Supporting & Related Material,FDA-2011-P-0022-0012,FDA-2011-P-0022,Exhibit 1 Citizen Petition from Waxler Regulatory Consultancy LLC re Comment from Paula Cofer
09000064823578aa,Other,FDA-2011-P-0022-0013,FDA-2011-P-0022,Reconsideration Denial letter from the FDA to Waxler Regulatory Consultancy LLC
0900006480fa41b3,Other,FDA-2011-P-0022-0005,FDA-2011-P-0022,Waxler Regulatory Consultancy LLC - Letter
09000064819df331,Other,FDA-2011-P-0022-0011,FDA-2011-P-0022,Reconsideration Petition Interim Response
09000064810dcfcf,Supporting & Related Material,FDA-2011-P-0022-0007,FDA-2011-P-0022,"Waxler Regulatory Consultancy LLC to the Division of Dockets Management August 14, 2012 - Background Material"
090000648185aee9,Other,FDA-2011-P-0022-0010,FDA-2011-P-0022,"Acknowledgement Letter from FDA/DDM to Waxler Consultancy, LLC"
0900006480bc6f16,Other,FDA-2011-P-0022-0002,FDA-2011-P-0022,Acknowledgement Letter to Waxler Regulatory Consultancy LLC
09000064818270ec,Other,FDA-2011-P-0022-0008,FDA-2011-P-0022,Citizen Petition Denial Response from FDA CDRH to Waxler Regulatory Consultancy LLC
090000648192667a,Supporting & Related Material,FDA-2014-P-1896-0003,FDA-2014-P-1896,Attachment 1 Citizen Petition From TecReg Services Inc
0900006481926d58,Supporting & Related Material,FDA-2014-P-1896-0004,FDA-2014-P-1896,Attachment 2 Citizen Petition From TechReg Services Inc
0900006481ab6699,Other,FDA-2014-P-1896-0006,FDA-2014-P-1896,"Letter from FDA CDER to TechReg Services, Inc."
0900006481926d59,Other,FDA-2014-P-1896-0002,FDA-2014-P-1896,Acknowledgement Letter From FDA DDM to TechReg Services
0900006481926678,Other,FDA-2014-P-1896-0001,FDA-2014-P-1896,Citizen Petition From TechReg Services Inc
0900006481ab34b2,Notice,FDA-2014-P-1896-0005,FDA-2014-P-1896,Determination That OXYTOCIN in 5% Dextrose Injection Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
0900006481a08f37,Supporting & Related Material,FDA-2015-P-0516-0004,FDA-2015-P-0516,Attach B
0900006481a1a53f,Other,FDA-2015-P-0516-0006,FDA-2015-P-0516,Withdrawal Request Letter from Lachman Consultants Services Inc
0900006481a08a3f,Other,FDA-2015-P-0516-0001,FDA-2015-P-0516,Citizen Pettion  Request from Lachman Consultant Services Inc
0900006481a08f38,Supporting & Related Material,FDA-2015-P-0516-0005,FDA-2015-P-0516,Attach C
0900006481a08f36,Supporting & Related Material,FDA-2015-P-0516-0003,FDA-2015-P-0516,Attach A
0900006481a08f39,Other,FDA-2015-P-0516-0002,FDA-2015-P-0516,Acknowledgement Letter from FDA DDM to LACHMAN CONSULTANT SERVICES INC
0900006483aa5347,Supporting & Related Material,FDA-2019-P-0916-0003,FDA-2019-P-0916,"Apendix 2 -Bayer Healthcare LLC package insert re: Suitability Petition from Schafer Veterinary Consultants, LLC  on behalf of Felix Pharmaceuticals Pvt. Ltd"
0900006483aa52f1,Other,FDA-2019-P-0916-0002,FDA-2019-P-0916,"Acknowledgment Letter from FDA DDM to  Schafer Veterinary Consultants, LLC  on behalf of Felix Pharmaceuticals Pvt. Ltd"
0900006483aa52ea,Other,FDA-2019-P-0916-0001,FDA-2019-P-0916,"Suitability Petition from Schafer Veterinary Consultants, LLC  on behalf of Felix Pharmaceuticals Pvt. Ltd"
09000064841ad5b3,Other,FDA-2019-P-0916-0005,FDA-2019-P-0916,Response Letter from FDA to Felix Pharmaceuticals Pvt Ltd
0900006483aa5349,Supporting & Related Material,FDA-2019-P-0916-0004,FDA-2019-P-0916,"Appendix 3 -Annotated Copy of the Package Insert showing Flex's proposed changes re: Suitability Petition from Schafer Veterinary Consultants, LLC  on behalf of Felix Pharmaceuticals Pvt. Ltd"
0900006482912323,Supporting & Related Material,FDA-2017-P-4174-0003,FDA-2017-P-4174,"Attachment A Transcript of Proceedings, Anesthesiology and Respiratory Therapy Devices Panel re Citizen Petition from Mallinckrodt Pharmaceuticals"
090000648291269a,Supporting & Related Material,FDA-2017-P-4174-0010,FDA-2017-P-4174,"Attachment H Tissue Debate Raises Fairness, Transparency Questions for Combo Products re Citizen Petition from Mallinckrodt Pharmaceuticals"
090000648294233d,Other,FDA-2017-P-4174-0011,FDA-2017-P-4174,Withdrawal from Mallinckrodt Pharmaceuticals
0900006482912325,Supporting & Related Material,FDA-2017-P-4174-0005,FDA-2017-P-4174,Attachment C Detention Without Physical Examination of Devices from Firms that Have not met Device Quality System Requirements re Citizen Petition from Mallinckrodt Pharmaceuticals
0900006482912326,Supporting & Related Material,FDA-2017-P-4174-0006,FDA-2017-P-4174,"Attachment D Praxair Distribution, Inc v INO Therapeutics, LLC Transcript of Proceedings re Citizen Petition from Mallinckrodt Pharmaceuticals"
0900006482912327,Supporting & Related Material,FDA-2017-P-4174-0007,FDA-2017-P-4174,"Attachment E Praxair Distribution, Inc v INO Therapeutics, LLC dba Ikaria, Inc Petition for Inter Partes Review re Citizen Petition from Mallinckrodt Pharmaceuticals"
0900006482912324,Supporting & Related Material,FDA-2017-P-4174-0004,FDA-2017-P-4174,Attachment B Life-threatening effects of discontinuing inhaled nitric oxide in severe respiratory failure re Citizen Petition from Mallinckrodt Pharmaceuticals
090000648291231f,Other,FDA-2017-P-4174-0001,FDA-2017-P-4174,Citizen Petition from Mallinckrodt Pharmaceuticals
0900006482912321,Other,FDA-2017-P-4174-0002,FDA-2017-P-4174,Acknowledgement Letter from FDA DDM to Mallinckrodt Pharmaceuticals
0900006482912698,Supporting & Related Material,FDA-2017-P-4174-0008,FDA-2017-P-4174,"Attachment F Declaration of Robert T Stone, PhD IPR re Citizen Petition from Mallinckrodt Pharmaceuticals"
0900006482912699,Supporting & Related Material,FDA-2017-P-4174-0009,FDA-2017-P-4174,"Attachment G Praxair Distribution, Inc vs Mallinckrodt Hospital Products IP Ltd re Citizen Petition from Mallinckrodt Pharmaceuticals"
09000064849a4940,Other,FDA-2020-P-2304-0002,FDA-2020-P-2304,"Acknowledgement Letter from FDA DMS to Fresenius Kabi USA, LLC"
09000064849a493f,Other,FDA-2020-P-2304-0001,FDA-2020-P-2304,"Citizens Petition from Fresenius Kabi USA, LLC"
0900006484ab6882,Notice,FDA-2020-P-2304-0004,FDA-2020-P-2304,"Determination That Sodium Chloride 14.6% Solution for Injection, 50  Milliequivalent/20 Milliliters, in Plastic Containers, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
0900006484ab769c,Other,FDA-2020-P-2304-0005,FDA-2020-P-2304,"Determination from FDA CDER to Fresenius Kabi USA, LLC"
09000064849a4711,Supporting & Related Material,FDA-2020-P-2304-0003,FDA-2020-P-2304,"Attachment A – Orange Book Listing of Sodium Chloride 14.6% - NDA 018897 RE Citizens Petition from Fresenius Kabi USA, LLC"
0900006484b7be1c,Supporting & Related Material,FDA-2021-P-0530-0012,FDA-2021-P-0530,Exhibit 10 re Citizen Petition from OptiNose US Inc
0900006484b7be4b,Supporting & Related Material,FDA-2021-P-0530-0023,FDA-2021-P-0530,Exhibit 21 re Citizen Petition from OptiNose US Inc
0900006484b7be74,Supporting & Related Material,FDA-2021-P-0530-0031,FDA-2021-P-0530,Exhibit 29 re Citizen Petition from OptiNose US Inc
0900006484b7be86,Supporting & Related Material,FDA-2021-P-0530-0036,FDA-2021-P-0530,Exhibit 34 re Citizen Petition from OptiNose US Inc
0900006484b7beb6,Supporting & Related Material,FDA-2021-P-0530-0052,FDA-2021-P-0530,Exhibit 50 re Citizen Petition from OptiNose US Inc
0900006484b7becd,Supporting & Related Material,FDA-2021-P-0530-0064,FDA-2021-P-0530,Exhibit 62 re Citizen Petition from OptiNose US Inc
0900006484b7bed3,Supporting & Related Material,FDA-2021-P-0530-0070,FDA-2021-P-0530,Exhibit 66 re Citizen Petition from OptiNose US Inc
0900006484b7beee,Supporting & Related Material,FDA-2021-P-0530-0076,FDA-2021-P-0530,Exhibit 72 re Citizen Petition from OptiNose US Inc
0900006484b7bf0b,Supporting & Related Material,FDA-2021-P-0530-0082,FDA-2021-P-0530,Exhibit 78 re Citizen Petition from OptiNose US Inc
0900006484b7bf0d,Supporting & Related Material,FDA-2021-P-0530-0084,FDA-2021-P-0530,Exhibit 80 re Citizen Petition from OptiNose US Inc
0900006484b7be17,Supporting & Related Material,FDA-2021-P-0530-0007,FDA-2021-P-0530,Exhibit 5 re Citizen Petition from OptiNose US Inc
0900006484b7be1a,Supporting & Related Material,FDA-2021-P-0530-0010,FDA-2021-P-0530,Exhibit 8 re Citizen Petition from OptiNose US Inc
0900006484b7be1d,Supporting & Related Material,FDA-2021-P-0530-0013,FDA-2021-P-0530,Exhibit 11 re Citizen Petition from OptiNose US Inc
0900006484b7be70,Supporting & Related Material,FDA-2021-P-0530-0027,FDA-2021-P-0530,Exhibit 25 re Citizen Petition from OptiNose US Inc
0900006484b7be88,Supporting & Related Material,FDA-2021-P-0530-0038,FDA-2021-P-0530,Exhibit 36 re Citizen Petition from OptiNose US Inc
0900006484b7be8e,Supporting & Related Material,FDA-2021-P-0530-0044,FDA-2021-P-0530,Exhibit 42 re Citizen Petition from OptiNose US Inc
0900006484b7beb9,Supporting & Related Material,FDA-2021-P-0530-0055,FDA-2021-P-0530,Exhibit 53 re Citizen Petition from OptiNose US Inc
0900006484b7bebc,Supporting & Related Material,FDA-2021-P-0530-0058,FDA-2021-P-0530,Exhibit 56 re Citizen Petition from OptiNose US Inc
0900006484b7beca,Supporting & Related Material,FDA-2021-P-0530-0061,FDA-2021-P-0530,Exhibit 59 re Citizen Petition from OptiNose US Inc
0900006484b7beea,Supporting & Related Material,FDA-2021-P-0530-0072,FDA-2021-P-0530,Exhibit 68 re Citizen Petition from OptiNose US Inc
0900006484b7beed,Supporting & Related Material,FDA-2021-P-0530-0075,FDA-2021-P-0530,Exhibit 71 re Citizen Petition from OptiNose US Inc
0900006484b7be19,Supporting & Related Material,FDA-2021-P-0530-0009,FDA-2021-P-0530,Exhibit 7 re Citizen Petition from OptiNose US Inc
0900006484b7be4a,Supporting & Related Material,FDA-2021-P-0530-0022,FDA-2021-P-0530,Exhibit 20 re Citizen Petition from OptiNose US Inc
0900006484b7be75,Supporting & Related Material,FDA-2021-P-0530-0032,FDA-2021-P-0530,Exhibit 30 re Citizen Petition from OptiNose US Inc
0900006484b7be87,Supporting & Related Material,FDA-2021-P-0530-0037,FDA-2021-P-0530,Exhibit 35 re Citizen Petition from OptiNose US Inc
0900006484a667b9,Other,FDA-2021-P-0280-0001,FDA-2021-P-0280,Citizen Petition from Harry Duty
0900006484a66fbc,Other,FDA-2021-P-0280-0002,FDA-2021-P-0280,Acknowledgment Letter from FDA DMS to Harry Duty
0900006484c03b5d,Other,FDA-2021-P-0280-0003,FDA-2021-P-0280,Final Response to Harry Duty from FDA CVM
09000064821a5641,Supporting & Related Material,FDA-2016-P-2559-0006,FDA-2016-P-2559,"Exhibit 4 Kulkarni and Melkundi (2012) Subdural Hematoma: An Adverse Event of Electroconvulsive Therapy – Case Report and Literature Review. Case Reports in re Citizen Petition from Emord and Associates, P.C.
Psychiatry"
09000064821a5644,Supporting & Related Material,FDA-2016-P-2559-0009,FDA-2016-P-2559,"Exhibit 5 part 3 MECTA Submission to FDA re Citizen Petition from Emord and Associates, P.C."
09000064821a5647,Supporting & Related Material,FDA-2016-P-2559-0012,FDA-2016-P-2559,"Exhibit 8 Akkerman- Statement of Decision on Submitted Issues, January 5, 2005 re Citizen Petition from Emord and Associates, P.C."
09000064839e7a8e,Other,FDA-2016-P-2559-0029,FDA-2016-P-2559,"Letter from FDA CDRH Emord and Associates, P.C."
0900006483a185a8,Other,FDA-2016-P-2559-0030,FDA-2016-P-2559,Meeting Regarding Citizen Petition FDA Minutes 31 July 2017-FDA
09000064821a5645,Supporting & Related Material,FDA-2016-P-2559-0010,FDA-2016-P-2559,"Exhibit 6 Manufacturer Somatics, Inc.’s 2010 Submission to the FDA re Citizen Petition from Emord and Associates, P.C."
09000064821a564b,Supporting & Related Material,FDA-2016-P-2559-0014,FDA-2016-P-2559,"Exhibit 10 Kenneth Castleman, Electroshock Therapy and Brain Damage re Citizen Petition from Emord and Associates, P.C."
09000064821a564c,Supporting & Related Material,FDA-2016-P-2559-0015,FDA-2016-P-2559,"Exhibit 11 “OPTIMIZED AND FULL spECTrum© DOSING PARAMETERS” re Citizen Petition from Emord and Associates, P.C."
09000064821a5656,Supporting & Related Material,FDA-2016-P-2559-0025,FDA-2016-P-2559,"Exhibit 21 Public Comment to the FDA regarding the ECT Proposed Ruling on ECT, from Dr. Moira Dolan re Citizen Petition from Emord and Associates, P.C."
09000064821a51c5,Other,FDA-2016-P-2559-0001,FDA-2016-P-2559,"Citizen Petition from Emord and Associates, P.C."
09000064824afebf,Other,FDA-2016-P-2559-0026,FDA-2016-P-2559,"Interim Response Letter from CDRH to Emord and Associates, P.C."
09000064821a563f,Supporting & Related Material,FDA-2016-P-2559-0004,FDA-2016-P-2559,"Exhibit 2 Dr. Moira Dolan, Feb. 28, 2012 – RE - ECT MACHINE SAFETY PROBLEMS -FDA Executive Summary re Citizen Petition from Emord and Associates, P.C."
09000064821a5640,Supporting & Related Material,FDA-2016-P-2559-0005,FDA-2016-P-2559,"Exhibit 3 Complaint of Misconduct, Center for Medical Devices and Radiological Health, Food and Drug Administration, February 8, 2012 re Citizen Petition from Emord and Associates, P.C."
09000064821a5643,Supporting & Related Material,FDA-2016-P-2559-0008,FDA-2016-P-2559,"Exhibit 5 part 2 MECTA Submission to FDA re Citizen Petition from Emord and Associates, P.C."
09000064821a564d,Supporting & Related Material,FDA-2016-P-2559-0016,FDA-2016-P-2559,"Exhibit 12 Akkerman v. MECTA Corp., No. 01-10362, U.S.D.C., CD Cal. Complaint re Citizen Petition from Emord and Associates, P.C."
09000064821a564f,Supporting & Related Material,FDA-2016-P-2559-0018,FDA-2016-P-2559,"Exhibit 14 Imogene Rohovit v, MECTA Corp re Citizen Petition from Emord and Associates, P.C."
0900006483a185aa,Other,FDA-2016-P-2559-0031,FDA-2016-P-2559,"Second Supplement from Law Office of Kendrick L. Moxon, P.C."
09000064821a563e,Supporting & Related Material,FDA-2016-P-2559-0003,FDA-2016-P-2559,"Exhibit1 FDA Executive Summary, Prepared for the January 27-28, 2011 meeting of the Neurological Devices Panel, Meeting to Discuss the Classification of Electroconvulsive Therapy Devices (ECT). Page 66 re Citizen Petition from Emord and Associates, P.C."
09000064821a5642,Supporting & Related Material,FDA-2016-P-2559-0007,FDA-2016-P-2559,"Exhibit 5 MECTA Submission to FDA re Citizen Petition from Emord and Associates, P.C."
09000064821a5646,Supporting & Related Material,FDA-2016-P-2559-0011,FDA-2016-P-2559,"Exhibit 7 Sackeim Deposition, p. 64-68. re Citizen Petition from Emord and Associates, P.C."
09000064821a5653,Supporting & Related Material,FDA-2016-P-2559-0022,FDA-2016-P-2559,"Exhibit 18 Public Comment to the FDA from the CCHR re Citizen Petition from Emord and Associates, P.C."
09000064821a5655,Supporting & Related Material,FDA-2016-P-2559-0024,FDA-2016-P-2559,"Exhibit 20 Response to Manufacturers submissions from Kendrick Moxon re Citizen Petition from Emord and Associates, P.C."
0900006482f957e2,Other,FDA-2016-P-2559-0028,FDA-2016-P-2559,"Supplement from Law Office of Kendrick L. Moxon, P.C."
09000064821a5650,Supporting & Related Material,FDA-2016-P-2559-0019,FDA-2016-P-2559,"Exhibit 15 Heirs of Jesus Torres v. MECTA Corp re Citizen Petition from Emord and Associates, P.C."
09000064821a5651,Supporting & Related Material,FDA-2016-P-2559-0020,FDA-2016-P-2559,"Exhibit 16 Freedom of Information Act Communications FDA re MDRs of ECT re Citizen Petition from Emord and Associates, P.C."
0900006481fb2c18,Other,FDA-2016-P-0621-0028,FDA-2016-P-0621,Withdrawal from Hogan Lovells US LLP
0900006481e7b5a7,Supporting & Related Material,FDA-2016-P-0621-0005,FDA-2016-P-0621,"Tab 3 - Letter from FDA to Olsson, Frank and Weeda, P.C. re: Citizen Petition from Hogan Lovells US LLP (Helsinn Healthcare SA)"
0900006481e7b5a8,Supporting & Related Material,FDA-2016-P-0621-0006,FDA-2016-P-0621,Tab 4 - Preventing Medication Errors re: Citizen Petition from Hogan Lovells US LLP (Helsinn Healthcare SA)
0900006481e7b674,Supporting & Related Material,FDA-2016-P-0621-0008,FDA-2016-P-0621,Tab 6 - Label and Labeling Review of Docetaxel Injection re: Citizen Petition from Hogan Lovells US LLP (Helsinn Healthcare SA)
0900006481e7b67a,Supporting & Related Material,FDA-2016-P-0621-0014,FDA-2016-P-0621,"Tab 12 - Letter from FDA to Lipomed, Inc. re: Citizen Petition from Hogan Lovells US LLP (Helsinn Healthcare SA)"
0900006481e7b683,Supporting & Related Material,FDA-2016-P-0621-0023,FDA-2016-P-0621,"Tab 21 - Venous Thromboembolism: Mechanisms, Treatment, and Public Awareness New Insights Into Cancer-Associated Thrombosis re: Citizen Petition from Hogan Lovells US LLP (Helsinn Healthcare SA)"
0900006481e7b676,Supporting & Related Material,FDA-2016-P-0621-0010,FDA-2016-P-0621,"Tab 8 - Center for Drug Evaluation and Research Clinical Review of Original NDA 202,091 re: Citizen Petition from Hogan Lovells US LLP (Helsinn Healthcare SA)"
0900006481e7b680,Supporting & Related Material,FDA-2016-P-0621-0020,FDA-2016-P-0621,Tab 18 - Factors Determining Peripheral Vein Tolerance to Amino Acid Infusions re: Citizen Petition from Hogan Lovells US LLP (Helsinn Healthcare SA)
0900006481e787b9,Other,FDA-2016-P-0621-0001,FDA-2016-P-0621,Citizen Petition from Hogan Lovells US LLP (Helsinn Healthcare SA)
0900006481e7b5a5,Supporting & Related Material,FDA-2016-P-0621-0003,FDA-2016-P-0621,Tab 1 - Palonosetron Hydrochloride Injection (Aloxi® ) - NDA 21-372 re: Citizen Petition from Hogan Lovells US LLP (Helsinn Healthcare SA)
0900006481e7b678,Supporting & Related Material,FDA-2016-P-0621-0012,FDA-2016-P-0621,Tab 10 - Center for Drug Evaluation and Research Cross-Discipline Team Leader Review NDA 202091 re: Citizen Petition from Hogan Lovells US LLP (Helsinn Healthcare SA)
0900006481e7b67c,Supporting & Related Material,FDA-2016-P-0621-0016,FDA-2016-P-0621,"Tab 14 - Effect of Mannitol on the Pharmacokinetics of Amikacin in
Wistar Rats re: Citizen Petition from Hogan Lovells US LLP (Helsinn Healthcare SA)"
0900006481e7b687,Supporting & Related Material,FDA-2016-P-0621-0027,FDA-2016-P-0621,Tab 25 - Letter from FDA re: Citizen Petition from Hogan Lovells US LLP (Helsinn Healthcare SA)
0900006481e7b673,Supporting & Related Material,FDA-2016-P-0621-0007,FDA-2016-P-0621,Tab 5 - Letter from FDA to Venable L.L.P. re: Citizen Petition from Hogan Lovells US LLP (Helsinn Healthcare SA)
0900006481e7b675,Supporting & Related Material,FDA-2016-P-0621-0009,FDA-2016-P-0621,Tab 7 - Side Effects Of Drugs Annual: Classification of Immunological Reactions re: Citizen Petition from Hogan Lovells US LLP (Helsinn Healthcare SA)
0900006481e7b67d,Supporting & Related Material,FDA-2016-P-0621-0017,FDA-2016-P-0621,Tab 15 - A Review of pH and Osmolarity re: Citizen Petition from Hogan Lovells US LLP (Helsinn Healthcare SA)
0900006481e7b682,Supporting & Related Material,FDA-2016-P-0621-0022,FDA-2016-P-0621,Tab 20 - Venous Thromboembolism and Cancer: Risks and Outcomes re: Citizen Petition from Hogan Lovells US LLP (Helsinn Healthcare SA)
0900006481e7b684,Supporting & Related Material,FDA-2016-P-0621-0024,FDA-2016-P-0621,"Tab 22 - Evidence for Acute Vascular Toxicity of Cisplatin-based
Chemotherapy in Patients with Germ Cell Tumor re: Citizen Petition from Hogan Lovells US LLP (Helsinn Healthcare SA)"
0900006481e7b5a3,Other,FDA-2016-P-0621-0002,FDA-2016-P-0621,Acknowledgement from FDA DDM to Hogan Lovells US LLP
0900006481e7b5a6,Supporting & Related Material,FDA-2016-P-0621-0004,FDA-2016-P-0621,Tab 2 - Prescribing Information for ALOXI re: Citizen Petition from Hogan Lovells US LLP (Helsinn Healthcare SA)
0900006481e7b677,Supporting & Related Material,FDA-2016-P-0621-0011,FDA-2016-P-0621,Tab 9 - Center for Drug Evaluation and Research Cross Discipline Team Leader Review re: Citizen Petition from Hogan Lovells US LLP (Helsinn Healthcare SA)
0900006481e7b679,Supporting & Related Material,FDA-2016-P-0621-0013,FDA-2016-P-0621,Tab 11 - Letter from FDA to Taro Pharmaceuticals U.S.A. re: Citizen Petition from Hogan Lovells US LLP (Helsinn Healthcare SA)
0900006481e7b67b,Supporting & Related Material,FDA-2016-P-0621-0015,FDA-2016-P-0621,Tab 13 - PostScript - Letters re: Citizen Petition from Hogan Lovells US LLP (Helsinn Healthcare SA)
0900006481e7b67e,Supporting & Related Material,FDA-2016-P-0621-0018,FDA-2016-P-0621,Tab 16 - Pain on I.V. Injection of Some Anaesthetic Agents is Evoked by the Unphysiological Osmolality or pH of Their Formulations re: Citizen Petition from Hogan Lovells US LLP (Helsinn Healthcare SA)
0900006481e7b67f,Supporting & Related Material,FDA-2016-P-0621-0019,FDA-2016-P-0621,Tab 17 - The Epidemiology of Peripheral Vein Infusion Thrombophlebitis: A Critical Review re: Citizen Petition from Hogan Lovells US LLP (Helsinn Healthcare SA)
09000064824041d9,Other,FDA-2016-P-1725-0003,FDA-2016-P-1725,"Interim Response from FDA CDER to Lachman Consultant Services, Inc."
09000064824ee6b1,Notice,FDA-2016-P-1725-0004,FDA-2016-P-1725,"Determination That FLONASE (Fluticasone Propionate) Nasal Spray,
0.05 Milligram, Was Not Withdrawn From Sale for Reasons of Safety or
Effectiveness"
0900006482054a1b,Other,FDA-2016-P-1725-0002,FDA-2016-P-1725,"Acknowledgement Letter from FDA DDM to Lachman Consultant Services, Inc."
090000648205449a,Other,FDA-2016-P-1725-0001,FDA-2016-P-1725,"Citizen Petition from Lachman Consultant Services, Inc."
09000064824f0110,Other,FDA-2016-P-1725-0005,FDA-2016-P-1725,"Letter from FDA CDER to Lachman Consultant Services, Inc."
0900006482281260,Supporting & Related Material,FDA-2016-P-3052-0003,FDA-2016-P-3052,"Appendix A, Virtus Pharmaceuticals, LLC Drug Product Recalls re Citizen Petition from Foley & Lardner LLP (Lehigh Valley Technologies, Inc.)"
0900006482281262,Supporting & Related Material,FDA-2016-P-3052-0005,FDA-2016-P-3052,"Appendix C, Products Submitted with a Name of Virtrate re Citizen Petition from Foley & Lardner LLP (Lehigh Valley Technologies, Inc.)"
0900006482281265,Supporting & Related Material,FDA-2016-P-3052-0008,FDA-2016-P-3052,"Appendix F, Products Submitted with a Marketing Category of Medical Food re Citizen Petition from Foley & Lardner LLP (Lehigh Valley Technologies, Inc.)"
0900006482280e74,Other,FDA-2016-P-3052-0001,FDA-2016-P-3052,"Citizen Petition from Foley & Lardner LLP (Lehigh Valley Technologies, Inc.)"
090000648228125e,Other,FDA-2016-P-3052-0002,FDA-2016-P-3052,Acknowledgement Letter from FDA DDM to Foley & Lardner LLP
0900006482281261,Supporting & Related Material,FDA-2016-P-3052-0004,FDA-2016-P-3052,"Appendix B, Virtus Products Submitted with a Marketing Category of Unnapproved Drug Other re Citizen Petition from Foley & Lardner LLP  
(Lehigh Valley Technologies, Inc.)"
0900006482281264,Supporting & Related Material,FDA-2016-P-3052-0007,FDA-2016-P-3052,"Appendix E, Products Submitted with a Marketing Category of Dietary Supplement re Citizen Petition from Foley & Lardner LLP (Lehigh Valley Technologies, Inc.)"
0900006482281263,Supporting & Related Material,FDA-2016-P-3052-0006,FDA-2016-P-3052,"Appendix D, List of Mischaracterized Imports re Citizen Petition from Foley & Lardner LLP (Lehigh Valley Technologies, Inc.)"
09000064823ecfcc,Other,FDA-2016-P-1667-0005,FDA-2016-P-1667,Interim Response Letter from CDER to Zydus Pharmaceutical (USA) Inc
0900006482047855,Supporting & Related Material,FDA-2016-P-1667-0003,FDA-2016-P-1667,"Attachment 1 - Electronic Orange Book identifying active approved drug products Meclizine Hydrochloride Tablets, 12.5 mg and 25 mg, accessed May 10, 2016 re Citizen Petition from Zydus Pharmaceutical (USA) Inc"
0900006482047856,Supporting & Related Material,FDA-2016-P-1667-0004,FDA-2016-P-1667,Attachment 2 Letter of non-availability re Citizen Petition from Zydus Pharmaceutical (USA) Inc re Citizen Petition from Zydus Pharmaceutical (USA) Inc
0900006482047853,Other,FDA-2016-P-1667-0001,FDA-2016-P-1667,Citizen Petition from Zydus Pharmaceutical (USA) Inc
09000064820485ae,Other,FDA-2016-P-1667-0002,FDA-2016-P-1667,Acknowledgement Letter from FDA DDM to Zydus Pharmaceutical (USA) Inc
09000064839fbddc,Other,FDA-2016-P-1667-0006,FDA-2016-P-1667,Response Letter from FDA CDER
09000064824f2629,Supporting & Related Material,FDA-2017-P-1359-0013,FDA-2017-P-1359,"Attachment 11 -Labeling for Percodan and Oxycontin re Citizen Petition from Pharmaceutical  Manufacturing Research Services, Inc."
09000064824f262b,Supporting & Related Material,FDA-2017-P-1359-0015,FDA-2017-P-1359,"Attachment 13- PURDUE FREDERICK MS CONTIN SUSTAINED RELEASE MORPHINE SULFATE MARKETING WITHOUT FDA APPROVAL IS JUSTIFIED BY AGENCY re Citizen Petition from Pharmaceutical  Manufacturing Research Services, Inc."
09000064824f262c,Supporting & Related Material,FDA-2017-P-1359-0016,FDA-2017-P-1359,"Attachment 14 - Warning Letter to Purdue Pharma May 11, 2000 re Citizen Petition from Pharmaceutical  Manufacturing Research Services, Inc."
09000064824f26fa,Supporting & Related Material,FDA-2017-P-1359-0022,FDA-2017-P-1359,"Attachment 20 -CDC, Understanding the Epidemic re Citizen Petition from Pharmaceutical  Manufacturing Research Services, Inc."
09000064824f2623,Supporting & Related Material,FDA-2017-P-1359-0007,FDA-2017-P-1359,"Attachment 5 -US Code 355 2012 re Citizen Petition from Pharmaceutical  Manufacturing Research Services, Inc."
09000064824f2624,Supporting & Related Material,FDA-2017-P-1359-0008,FDA-2017-P-1359,"Attachment 6 -Physician's Desk Reference 1999 label for Oxycontin re Citizen Petition from Pharmaceutical  Manufacturing Research Services, Inc."
09000064824f0b34,Other,FDA-2017-P-1359-0002,FDA-2017-P-1359,"Acknowledgment Letter from FDA DDM to Pharmaceutical  Manufacturing Research Services, Inc."
09000064824f2621,Supporting & Related Material,FDA-2017-P-1359-0005,FDA-2017-P-1359,"Attachment 3 -Food and Drug Administration, CDER_ Oxycontin NDA 20553, S022 Administrative Document Regulatory Division Directors Reviewf re Citizen Petition from Pharmaceutical  Manufacturing Research Services, Inc."
09000064824f2622,Supporting & Related Material,FDA-2017-P-1359-0006,FDA-2017-P-1359,"Attachment 4 -Food and Drug Administration, Guidance for Industry Analgesic Indications Developing Drug and Biological Products re Citizen Petition from Pharmaceutical  Manufacturing Research Services, Inc."
09000064824f2626,Supporting & Related Material,FDA-2017-P-1359-0010,FDA-2017-P-1359,"Attachment 8 - CDC Guideline for Prescribing Opioids for Chronic Pain re Citizen Petition from Pharmaceutical  Manufacturing Research Services, Inc."
09000064824f26f9,Supporting & Related Material,FDA-2017-P-1359-0021,FDA-2017-P-1359,"Attachment 19 -Opioid Abuse in Chronic Pain  Misconceptions and Mitigation Strategies re Citizen Petition from Pharmaceutical  Manufacturing Research Services, Inc."
09000064824f26fb,Supporting & Related Material,FDA-2017-P-1359-0023,FDA-2017-P-1359,"Attachment 21 -NIDA, Overdose Death Rates re Citizen Petition from Pharmaceutical  Manufacturing Research Services, Inc."
09000064824f2620,Supporting & Related Material,FDA-2017-P-1359-0004,FDA-2017-P-1359,"Attachment 2 -Timeline of Selected FDA Activities and Significant Events Addressing Opioid Misuse and Abuse re Citizen Petition from Pharmaceutical  Manufacturing Research Services, Inc."
09000064824f2627,Supporting & Related Material,FDA-2017-P-1359-0011,FDA-2017-P-1359,"Attachment 9 -Highlights of Prescribing Information Oxycontin, December 2016 re Citizen Petition from Pharmaceutical  Manufacturing Research Services, Inc."
09000064824f26fc,Supporting & Related Material,FDA-2017-P-1359-0024,FDA-2017-P-1359,"Attachment 22 -CDC, Opioid Data Analysis re Citizen Petition from Pharmaceutical  Manufacturing Research Services, Inc."
09000064824eff10,Other,FDA-2017-P-1359-0001,FDA-2017-P-1359,"Citizen Petition from Pharmaceutical  Manufacturing Research Services, Inc."
0900006482afdc1c,Other,FDA-2017-P-1359-0026,FDA-2017-P-1359,"Interim Response Letter from FDA CDER to Pharmaceutical Research Services, Inc."
09000064824f261f,Supporting & Related Material,FDA-2017-P-1359-0003,FDA-2017-P-1359,"Attachment 1 -Administrative Document Regulatory Project Manager Review re Citizen Petition from Pharmaceutical  Manufacturing Research Services, Inc."
09000064824f2625,Supporting & Related Material,FDA-2017-P-1359-0009,FDA-2017-P-1359,"Attachment 7 -Reducing the Risks of Relief The CDC Opioid-Prescribing Guideline re Citizen Petition from Pharmaceutical  Manufacturing Research Services, Inc."
09000064824f2628,Supporting & Related Material,FDA-2017-P-1359-0012,FDA-2017-P-1359,"Attachment 10- Highlights of Prescribing Information Roxicodone, December 2016 re Citizen Petition from Pharmaceutical  Manufacturing Research Services, Inc."
09000064824f262a,Supporting & Related Material,FDA-2017-P-1359-0014,FDA-2017-P-1359,"Attachment 12 -Oxycontin NDA 022272 Approval Letter re Citizen Petition from Pharmaceutical  Manufacturing Research Services, Inc."
09000064824f2691,Supporting & Related Material,FDA-2017-P-1359-0018,FDA-2017-P-1359,"Attachment 16 - Announces Safety Labeling Changes and Postmarket Study Requirements for Extended-Release and Long-Acting Opioid Analgesics re Citizen Petition from Pharmaceutical  Manufacturing Research Services, Inc."
09000064824f2692,Supporting & Related Material,FDA-2017-P-1359-0019,FDA-2017-P-1359,"Attachment 17 - History of OxyContin Labeling and Risk Management Program, Anesthetic and Life Support Drugs and Drug Safety and Risk Management re Citizen Petition from Pharmaceutical  Manufacturing Research Services, Inc."
09000064824f2693,Supporting & Related Material,FDA-2017-P-1359-0020,FDA-2017-P-1359,"Attachment 18 - Division Director Review OxyContin Tablets, Reformulated FDA Reference ID 3258740 re Citizen Petition from Pharmaceutical  Manufacturing Research Services, Inc."
09000064824f262d,Supporting & Related Material,FDA-2017-P-1359-0017,FDA-2017-P-1359,"Attachment 15 -Highlights of Prescribing Information OxyContin, April 2013 re Citizen Petition from Pharmaceutical  Manufacturing Research Services, Inc."
0900006480f57521,Other,FDA-2011-P-0767-0001,FDA-2011-P-0767,"Somaxon Pharmaceuticals, Inc. - Citizen Petition"
0900006480f58202,Other,FDA-2011-P-0767-0002,FDA-2011-P-0767,"Acknowledgement Letter to Somaxon Pharmaceuticals, Inc., Brian T. Dorsey"
0900006480ff249b,Other,FDA-2011-P-0767-0003,FDA-2011-P-0767,"FDA/CDER to Somaxon Pharmaceuticals, Inc. - Petition Part Approved and Denied"
09000064823699d9,Other,FDA-2016-P-1247-0003,FDA-2016-P-1247,"Interim response from CDER to KVK-Tech, Inc"
0900006481faf6f1,Other,FDA-2016-P-1247-0001,FDA-2016-P-1247,"Citizen Petition from ABHAI, LLC"
0900006481faf6f3,Other,FDA-2016-P-1247-0002,FDA-2016-P-1247,"Acknowledgement Letter from FDA DDM to Abhai, LLC"
0900006482c9331d,Other,FDA-2016-P-1247-0004,FDA-2016-P-1247,Withdrawal of Citizen Petition from KVK-Tech Inc
0900006483aabaa6,Other,FDA-2019-P-0941-0001,FDA-2019-P-0941,"Suitability Petition from Schafer Veterinary Consultants, LLC  on behalf of Felix Pharmaceuticals Pvt. Ltd"
0900006483aabba5,Supporting & Related Material,FDA-2019-P-0941-0003,FDA-2019-P-0941,"Appendix 2- Bayer Healthcare LLC package insert for this product Re: Suitability Petition from Schafer Veterinary Consultants, LLC  on behalf of Felix Pharmaceuticals Pvt. Ltd"
0900006483c857ca,Other,FDA-2019-P-0941-0005,FDA-2019-P-0941,"Letter from FDA CVM to Schafer Veterinary Consultants, LLC"
0900006483aabba7,Supporting & Related Material,FDA-2019-P-0941-0004,FDA-2019-P-0941,"Appendix 3- Annotated copy of the package insert showing Felix's proposed changes Re:  Suitability Petition from Schafer Veterinary Consultants, LLC  on behalf of Felix Pharmaceuticals Pvt. Ltd"
0900006483aabaa9,Other,FDA-2019-P-0941-0002,FDA-2019-P-0941,"Acknowledgment Letter from FDA DDM to Schafer Veterinary Consultants, LLC  on behalf of Felix Pharmaceuticals Pvt. Ltd"
0900006484481b51,Other,FDA-2020-P-0042-0003,FDA-2020-P-0042,Response Letter from FDA CDER to Emery Pharma
0900006484269106,Other,FDA-2020-P-0042-0002,FDA-2020-P-0042,Acknowledgment Letter from FDA DMS to Emery Pharma on behalf of Najafi Pharma Inc
0900006484268ecb,Other,FDA-2020-P-0042-0001,FDA-2020-P-0042,Citizen Petition from Emery Pharm on behalf of Najafi Pharma
0900006484160f71,Supporting & Related Material,FDA-2019-P-5403-0004,FDA-2019-P-5403,Attachment 2 - IMS Data re Citizen Petition from Husch Blackwell LLP
09000064849f1809,Other,FDA-2019-P-5403-0008,FDA-2019-P-5403,Request to withdraw Citizen petition from Seth Mailhot
0900006484160f70,Supporting & Related Material,FDA-2019-P-5403-0003,FDA-2019-P-5403,Attachment 1 - Orange Book Information (Swab Dosage Form) re Citizen Petition from Husch Blackwell LLP
0900006484161669,Supporting & Related Material,FDA-2019-P-5403-0006,FDA-2019-P-5403,Attachment 4 - Draft FDA Guidance Clindamycin_Phosphate_SOLUTION re Citizen Petition from Husch Blackwell LLP
0900006484161668,Supporting & Related Material,FDA-2019-P-5403-0005,FDA-2019-P-5403,Attachment 3 - Draft FDA Guidance Clindamycin_Phosphate_SWAB re Citizen Petition from Husch Blackwell LLP
090000648456a1f0,Other,FDA-2019-P-5403-0007,FDA-2019-P-5403,Interim Response from FDA CDER to Husch Blackwell LLP
0900006484160f6b,Other,FDA-2019-P-5403-0001,FDA-2019-P-5403,"Citizen Petition from Husch Blackwell, LLP"
0900006484160f6d,Other,FDA-2019-P-5403-0002,FDA-2019-P-5403,"Acknowledgment Letter from FDA DMS to Husch Blackwell, LLP"
0900006484b236aa,Notice,FDA-2021-P-0226-0003,FDA-2021-P-0226,"Determination That AVACLYR  (Acyclovir Ophthalmic Ointment), 3  Percent, Was Not Withdrawn From  Sale for Reasons of Safety or Effectiveness"
0900006484b2e7c0,Other,FDA-2021-P-0226-0004,FDA-2021-P-0226,Response Letter from FDA CDER to Cumulus Pharmaceutical LLC
0900006484a49f7a,Other,FDA-2021-P-0226-0002,FDA-2021-P-0226,Acknowledgment Letter from FDA DMS to Cumulus Pharmaceutical LLC
0900006484a49ee9,Other,FDA-2021-P-0226-0001,FDA-2021-P-0226,Citizen Petition from Cumulus Pharmaceutical LLC
090000648475750c,Other,FDA-2019-P-3022-0007,FDA-2019-P-3022,Amendment from Foley & Lardner LLP
0900006483d3e5bf,Supporting & Related Material,FDA-2019-P-3022-0004,FDA-2019-P-3022,Attachment - 2- Highlights of Prescribing Information re Citizen Petition from Foley & Lardner LLP
0900006483d3e5c1,Supporting & Related Material,FDA-2019-P-3022-0006,FDA-2019-P-3022,Attachment 4- Acknowledgment Receipt of Submission Letter re Citizen Petition from Foley & Lardner LLP
0900006483d3a2f8,Other,FDA-2019-P-3022-0002,FDA-2019-P-3022,Acknowledgment Letter from FDA DDM to Foley & Lardner LLP
0900006483d3a760,Other,FDA-2019-P-3022-0001,FDA-2019-P-3022,Citizen Petition from Foley & Lardner LLP
0900006483d3e5c0,Supporting & Related Material,FDA-2019-P-3022-0005,FDA-2019-P-3022,Attachment - 3- Highlights of Prescribing Information re Citizen Petition from Foley & Lardner LLP
0900006484c95b07,Other,FDA-2019-P-3022-0008,FDA-2019-P-3022,Approval Letter from FDA CDER to Foley & Lardner LLP
0900006483d3e5be,Supporting & Related Material,FDA-2019-P-3022-0003,FDA-2019-P-3022,Attachment - 1- Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations re Citizen Petition from Foley & Lardner LLP
0900006480b67dbb,Other,FDA-2010-P-0531-0002,FDA-2010-P-0531,"Acknowledgement Letter to Peptimmune, Inc."
0900006480b67d48,Other,FDA-2010-P-0531-0001,FDA-2010-P-0531,"Peptimmune, Inc. - Citizen Petition"
0900006480c13274,Other,FDA-2010-P-0531-0005,FDA-2010-P-0531,"FDA/CDER to Peptimmune, Inc. - Petition Denial"
090000648236be9c,Supporting & Related Material,FDA-2016-P-3674-0007,FDA-2016-P-3674,Attachment 5 Determination of methyl mercury in dental-unit wastewater re Citizen Petition from Consumers for Dental Choice
090000648236be9d,Supporting & Related Material,FDA-2016-P-3674-0008,FDA-2016-P-3674,Attachment 6 Environmental costs of mercury pollution re Citizen Petition from Consumers for Dental Choice
090000648236bea1,Supporting & Related Material,FDA-2016-P-3674-0012,FDA-2016-P-3674,"Attachment 10 Health Canada, The Safety of Dental Amalgam re Citizen Petition from Consumers for Dental Choice"
090000648236bea4,Supporting & Related Material,FDA-2016-P-3674-0015,FDA-2016-P-3674,"Attachment 13 National Health _ Medical Research Council, Dental Amalgam _ Filling You In re Citizen Petition from Consumers for Dental Choice"
090000648236beab,Supporting & Related Material,FDA-2016-P-3674-0017,FDA-2016-P-3674,"Attachment 15 Swedish Chemicals Agency, Mercury Phase-out, a study of the experience of Swedish companies re Citizen Petition from Consumers for Dental Choice"
090000648236beae,Supporting & Related Material,FDA-2016-P-3674-0020,FDA-2016-P-3674,"Attachment 18 United Kingdom Department of Health, Letter to Dentists re Citizen Petition from Consumers for Dental Choice"
090000648236beaf,Supporting & Related Material,FDA-2016-P-3674-0021,FDA-2016-P-3674,"Attachment 19 WHO, Future use of materials for dental restoration re Citizen Petition from Consumers for Dental Choice"
090000648236bbcb,Other,FDA-2016-P-3674-0001,FDA-2016-P-3674,Citizen Petition from Consumers for Dental Choice
090000648236bbd0,Supporting & Related Material,FDA-2016-P-3674-0004,FDA-2016-P-3674,"Attachment 2 Changing Patterns in the Use, Recycling, and Material Substitution of Mercury in the United States (2013) re Citizen Petition from Consumers for Dental Choice"
090000648236be9e,Supporting & Related Material,FDA-2016-P-3674-0009,FDA-2016-P-3674,Attachment 7 EPA Will Propose Rule to Protect Waterways by Reducing Mercury from Dental Offices re Citizen Petition from Consumers for Dental Choice
090000648258185f,Other,FDA-2016-P-3674-0023,FDA-2016-P-3674,Interim Response Letter from CDRH to Consumers for Dental Choice
090000648236be9f,Supporting & Related Material,FDA-2016-P-3674-0010,FDA-2016-P-3674,"Attachment 8 European Commission SCENIHR, Final opinion on the safety of dental amalgam and alternative dental restoration materials for patien re Citizen Petition from Consumers for Dental Choice"
090000648236bea0,Supporting & Related Material,FDA-2016-P-3674-0011,FDA-2016-P-3674,"Attachment 9 European Commission, Final Report, Review of the Community Strategy Concerning Mercury re Citizen Petition from Consumers for Dental Choice"
090000648236bea2,Supporting & Related Material,FDA-2016-P-3674-0013,FDA-2016-P-3674,"Attachment 11 Hickel, Longevity of occlusally-stressed restorations in posterior primary teeth re Citizen Petition from Consumers for Dental Choice"
090000648236bea5,Supporting & Related Material,FDA-2016-P-3674-0016,FDA-2016-P-3674,"Attachment 14 Swedish Chemicals Agency, Dental amalgam, prohibition to use dental amalgam re Citizen Petition from Consumers for Dental Choice"
090000648236bead,Supporting & Related Material,FDA-2016-P-3674-0019,FDA-2016-P-3674,"Attachment 17 UNEP, Lessons from Countries Phasing Down Dental Amalgam Use re Citizen Petition from Consumers for Dental Choice"
090000648236bbcf,Supporting & Related Material,FDA-2016-P-3674-0003,FDA-2016-P-3674,"Attachment 1 Bio Intelligence Service, Study on the potential for reducing mercury pollution from dental amalgam re Citizen Petition from Consumers for Dental Choice"
090000648236bbd3,Supporting & Related Material,FDA-2016-P-3674-0006,FDA-2016-P-3674,"Attachment 4 Dentsply, Annual Report per SEC Form 10-K (31 Dec_ 2014) re Citizen Petition from Consumers for Dental Choice"
090000648236beac,Supporting & Related Material,FDA-2016-P-3674-0018,FDA-2016-P-3674,Attachment 16 The Real Cost of Dental Mercury re Citizen Petition from Consumers for Dental Choice
090000648236bbcd,Other,FDA-2016-P-3674-0002,FDA-2016-P-3674,Acknowledgement Letter from FDA DDM to Consumers for Dental Choice
090000648236bbd2,Supporting & Related Material,FDA-2016-P-3674-0005,FDA-2016-P-3674,"Attachment 3 Danish Ministry of the Environment, Fact sheet mercury - re Citizen Petition from Consumers for Dental Choice"
090000648236bea3,Supporting & Related Material,FDA-2016-P-3674-0014,FDA-2016-P-3674,Attachment 12 Minamata Convention (2013) re Citizen Petition from Consumers for Dental Choice
0900006481a0c5b4,Supporting & Related Material,FDA-2015-P-0547-0005,FDA-2015-P-0547,"Attachment 3 Citizen Petition From Gland Pharma, Inc."
0900006481a0c17c,Supporting & Related Material,FDA-2015-P-0547-0003,FDA-2015-P-0547,"Attachment 1 Citizen Petition From Gland Pharma, Inc."
0900006481a0c5b5,Other,FDA-2015-P-0547-0002,FDA-2015-P-0547,"Acknowledgement Letter From FDA DDM to Gland Pharma, Ltd."
0900006481a0c17a,Other,FDA-2015-P-0547-0001,FDA-2015-P-0547,"Citizen Petition From Gland Pharma, Inc."
0900006481a0c17d,Supporting & Related Material,FDA-2015-P-0547-0004,FDA-2015-P-0547,"Attachment 2 Citizen Petition From Gland Pharma, Inc."
0900006481a10dee,Other,FDA-2015-P-0547-0006,FDA-2015-P-0547,"Corrected Copy of Acknowledgement Letter From FDA DDM to Gland Pharma, Ltd."
09000064824b6a18,Other,FDA-2017-P-0840-0002,FDA-2017-P-0840,Acknowledgment Letter from FDA DDM to The Weinberg Group
0900006482c0224d,Notice,FDA-2017-P-0840-0004,FDA-2017-P-0840,"Determination That OVRETTE (Norgestrel) Tablet, 0.075 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
0900006482c05edd,Other,FDA-2017-P-0840-0005,FDA-2017-P-0840,Final Response Letter from CDER to The Weinberg Group Inc
09000064824b5a95,Other,FDA-2017-P-0840-0001,FDA-2017-P-0840,Citizen Petition from The Weinberg Group
090000648298fd1a,Other,FDA-2017-P-0840-0003,FDA-2017-P-0840,Interim Response Letter from CDER to The Weinberg Group Inc
0900006481e8af59,Other,FDA-2015-P-3319-0004,FDA-2015-P-3319,Citizen Petition Response Letter from FDA CDER to Winifred M. Begley
0900006481e25259,Notice,FDA-2015-P-3319-0003,FDA-2015-P-3319,"Determination That MEVACOR (Lovastatin) Tablets, 20 Milligrams and
40 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or
Effectiveness"
0900006481c66a69,Other,FDA-2015-P-3319-0001,FDA-2015-P-3319,Citizen Petition from Winifred Begley
0900006481c66a6a,Other,FDA-2015-P-3319-0002,FDA-2015-P-3319,Acknowledgement Letter from FDA DDM to Winifred Begley
0900006481c03e22,Other,FDA-2015-P-2962-0001,FDA-2015-P-2962,Citizen Petition From Regcon Solutions LLC
0900006481c03e28,Other,FDA-2015-P-2962-0002,FDA-2015-P-2962,Acknowledgment Letter from FDA DDM to Regcon Solutions LLC
0900006482566e73,Other,FDA-2015-P-2962-0004,FDA-2015-P-2962,Citizen Petition Withdrawal Request from Regcon Solutions
0900006481c04065,Supporting & Related Material,FDA-2015-P-2962-0003,FDA-2015-P-2962,Attachment 1 Excerpts from the Orange Book Re Citizen Petition from Regcon Solutions LLC
0900006483c2e34a,Supporting & Related Material,FDA-2019-P-2142-0003,FDA-2019-P-2142,Appendix A- Energy Value Studies ID 1-3  Attachment A Scientific Evidence to Support the Labeling of the Dietary Fiber Component in Fibersol Resistant Maltodextrin as 1.4 Calories per Gram re Citizen Petition from Archer Daniels Midland Company
0900006483c2e34b,Supporting & Related Material,FDA-2019-P-2142-0004,FDA-2019-P-2142,Attachment A-Scientific Evidence to Support the Dietary Fiber Component in Fibersol Resistant Maltodextrin as Having an Energy Value of 0.7 Calories per Gram for Labeling Purposes re: Citizen Petition from Archer Daniels Midland Company
0900006483c2dcfe,Other,FDA-2019-P-2142-0001,FDA-2019-P-2142,Acknowledgment Letter from FDA DDM to Archer Daniels Midland Company
0900006484145cec,Other,FDA-2019-P-2142-0006,FDA-2019-P-2142,Interim Response Letter from FDA to Archer Daniels Midland Company
0900006483c2dc0c,Other,FDA-2019-P-2142-0002,FDA-2019-P-2142,Citizen Petition from Archer Daniels Midland Company
09000064842f7e5e,Other,FDA-2020-P-0438-0002,FDA-2020-P-0438,"Acknowledgment Letter from FDA DMS to Hyman, Phelps & McNamara, P.C."
0900006484837376,Notice,FDA-2020-P-0438-0004,FDA-2020-P-0438,"Determination That MICRO-K LS (Potassium Chloride) Extended- Release Liquid Suspension, 20 Milliequivalents/Packet, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
09000064847ad098,Other,FDA-2020-P-0438-0003,FDA-2020-P-0438,"Interim Response letter form FDA CDER to Hyman, Phelps & McNamara, P.C."
0900006484839106,Other,FDA-2020-P-0438-0005,FDA-2020-P-0438,"Letter from FDA CDER to Hyman, Phelps & McNamara, P.C."
09000064842f7e5d,Other,FDA-2020-P-0438-0001,FDA-2020-P-0438,"Citizen Petition from Hyman, Phelps & McNamara, P.C."
0900006480b719f5,Other,FDA-2010-P-0546-0001,FDA-2010-P-0546,Beckloff Associates - Citizen Petition
0900006480b719f7,Supporting & Related Material,FDA-2010-P-0546-0002,FDA-2010-P-0546,Orange Book - [Beckloff Associates - Citizen Petition]
0900006480b72176,Other,FDA-2010-P-0546-0003,FDA-2010-P-0546,Acknowledgement Letter to Beckloff Associates
0900006480b7d721,Other,FDA-2010-P-0546-0004,FDA-2010-P-0546,"Azur Pharma International III, Ltd., (Beckloff Associates) - Withdrawal"
0900006484dab787,Other,FDA-2021-P-1042-0001,FDA-2021-P-1042,Citizen Petition from Pet Schooled
0900006484dac400,Other,FDA-2021-P-1042-0002,FDA-2021-P-1042,Acknowledgment Letter from FDA DMS to PetSchooled
090000648327dc09,Other,FDA-2018-P-1310-0044,FDA-2018-P-1310,Petition Denial Letter from FDA CDER
0900006483078e28,Supporting & Related Material,FDA-2018-P-1310-0036,FDA-2018-P-1310,Exhibit 34 Confidential Material re Citizen Petition from Vertice Pharma Management Corp
0900006483063cc8,Supporting & Related Material,FDA-2018-P-1310-0005,FDA-2018-P-1310,Exhibit 3 - Cholestyramine Guidance re Citizen Petition from Vertice Pharma Management Corp
0900006483063ce4,Supporting & Related Material,FDA-2018-P-1310-0014,FDA-2018-P-1310,Exhibit 12 - Velphoro NDA 205109 Summary Review re Citizen Petition from Vertice Pharma Management Corp
0900006483063cca,Supporting & Related Material,FDA-2018-P-1310-0007,FDA-2018-P-1310,Exhibit 5 - Colesevelam HCl Tablets Guidance re Citizen Petition from Vertice Pharma Management Corp
0900006483063cc4,Other,FDA-2018-P-1310-0002,FDA-2018-P-1310,Acknowledgment Letter from FDA DDM to Vertice Pharma Management Corp
0900006483079f3d,Supporting & Related Material,FDA-2018-P-1310-0043,FDA-2018-P-1310,Exhibit 41 Confidential Material re Citizen Petition from Vertice Pharma Management Corp
0900006483065b3d,Supporting & Related Material,FDA-2018-P-1310-0031,FDA-2018-P-1310,Exhibit 29 - Graham_Dig Dis Sci_1984 re Citizen Petition from Vertice Pharma Management Corp
0900006483065b35,Supporting & Related Material,FDA-2018-P-1310-0029,FDA-2018-P-1310,Exhibit 27 - Nakazawa_Digestive diseases and sciences_1981 re Citizen Petition from Vertice Pharma Management Corp
0900006483065b41,Supporting & Related Material,FDA-2018-P-1310-0035,FDA-2018-P-1310,Exhibit 33 - Nagashima_J Clin Gastroenterol_1981_p103 re Citizen Petition from Vertice Pharma Management Corp
090000648306465d,Supporting & Related Material,FDA-2018-P-1310-0020,FDA-2018-P-1310,Exhibit 18 - Alhamami_Archives Pharm Res_2007 re Citizen Petition from Vertice Pharma Management Corp
0900006483065b3f,Supporting & Related Material,FDA-2018-P-1310-0033,FDA-2018-P-1310,Exhibit 31 - Caspary_Duodenal Ulcer Gastric Ulcer - Sucralfate A New Therapeutic Concept_1981 re Citizen Petition from Vertice Pharma Management Corp
090000648306465e,Supporting & Related Material,FDA-2018-P-1310-0021,FDA-2018-P-1310,Exhibit 19 - Chen_AAPS Journal_2013 re Citizen Petition from Vertice Pharma Management Corp
0900006483065b34,Supporting & Related Material,FDA-2018-P-1310-0028,FDA-2018-P-1310,Exhibit 26 - Simethicone_Handbook of Pharmaceutical Excipients_2009 re Citizen Petition from Vertice Pharma Management Corp
0900006483063ce0,Supporting & Related Material,FDA-2018-P-1310-0010,FDA-2018-P-1310,Exhibit 8 - Omega-3-Acid Ethyl Esters Guidance re Citizen Petition from Vertice Pharma Management Corp
0900006483063cc6,Supporting & Related Material,FDA-2018-P-1310-0003,FDA-2018-P-1310,Exhibit 1 - Sucralfate Oral Suspension Guidance October 2017 re Citizen Petition from Vertice Pharma Management Corp
0900006483065b1d,Supporting & Related Material,FDA-2018-P-1310-0022,FDA-2018-P-1310,Exhibit 20 - Lubiprostone Guidance re Citizen Petition from Vertice Pharma Management Corp
0900006483065b23,Supporting & Related Material,FDA-2018-P-1310-0024,FDA-2018-P-1310,Exhibit 22 - SCOGS Opinion No 25 - Cellulose and Certain Cellulose Derivatives_1973 re Citizen Petition from Vertice Pharma Management Corp
0900006483063ba2,Other,FDA-2018-P-1310-0001,FDA-2018-P-1310,Citizen Petition from Vertice Pharma Management Corp
0900006483063cc9,Supporting & Related Material,FDA-2018-P-1310-0006,FDA-2018-P-1310,Exhibit 4 - Colesevelam HCl Powder Guidance re Citizen Petition from Vertice Pharma Management Corp
0900006483065b20,Supporting & Related Material,FDA-2018-P-1310-0023,FDA-2018-P-1310,Exhibit 21 - Amitiza PI re Citizen Petition from Vertice Pharma Management Corp
0900006483065b31,Supporting & Related Material,FDA-2018-P-1310-0027,FDA-2018-P-1310,Exhibit 25 - SCOGS Opinion No 61 - Silicon Dioxides_1979 re Citizen Petition from Vertice Pharma Management Corp
0900006483065b36,Supporting & Related Material,FDA-2018-P-1310-0030,FDA-2018-P-1310,Exhibit 28 - Nagashima_J Clin Gastroenterol_1981_p117 re Citizen Petition from Vertice Pharma Management Corp
0900006483063ccb,Supporting & Related Material,FDA-2018-P-1310-0008,FDA-2018-P-1310,Exhibit 6 - Lanthanum Carbonate Powder Guidance re Citizen Petition from Vertice Pharma Management Corp
0900006483078fec,Supporting & Related Material,FDA-2018-P-1310-0041,FDA-2018-P-1310,Exhibit 39 Confidential Material re Citizen Petition from Vertice Pharma Management Corp
09000064829401e5,Supporting & Related Material,FDA-2013-P-1374-0044,FDA-2013-P-1374,International and National Expert Group Evaluations: Biological/Health Effects of Radiofrequency Fields re Issue a Federal Regulation to Augment FDA Citizen's Petition For Public Hearings to Establish Standards on Cellphone Radiation Adverse Health Effects That Might be Caused by Specific Absorption Rates (SAR) and Radio Frequency Radiation (RFR)/Electromagnetic Frequency (EMF)
09000064814ae187,Other,FDA-2013-P-1374-0003,FDA-2013-P-1374,"Supplement from Pharmacists Planning Service, Inc."
0900006481e406cb,Other,FDA-2013-P-1374-0029,FDA-2013-P-1374,"Supplement from Fred Mayer, PPSI"
0900006481ee8cc3,Other,FDA-2013-P-1374-0030,FDA-2013-P-1374,"Supplement from Fred Mayer, PPSI"
0900006481d9b4de,Other,FDA-2013-P-1374-0024,FDA-2013-P-1374,"Supplement from Fred Mayer, PPSI"
0900006481d8eaa0,Other,FDA-2013-P-1374-0018,FDA-2013-P-1374,"Supplement from Frederick Mayer, PPSI"
09000064821a09f3,Other,FDA-2013-P-1374-0034,FDA-2013-P-1374,"Supplement from Frederick Mayer, PPSI"
0900006481cdd2b5,Other,FDA-2013-P-1374-0014,FDA-2013-P-1374,Supplement from PPSI
090000648220c9ff,Other,FDA-2013-P-1374-0035,FDA-2013-P-1374,"Supplement from Frederick Mayer, PPSI"
0900006481d9b4dd,Other,FDA-2013-P-1374-0023,FDA-2013-P-1374,"Supplement from Fred Mayer, PPSI"
0900006481d9b4e0,Other,FDA-2013-P-1374-0026,FDA-2013-P-1374,"Supplement from Fred Mayer, PPSI"
0900006481d9b536,Other,FDA-2013-P-1374-0027,FDA-2013-P-1374,"Supplement from Fred Mayer, PPSI"
0900006481d392e5,Other,FDA-2013-P-1374-0016,FDA-2013-P-1374,"Supplement from Frederick Mayer, Pharmacists Planning Services, Inc."
090000648252bfb5,Other,FDA-2013-P-1374-0037,FDA-2013-P-1374,"Supplement from Fred Mayer, PPSI"
0900006481d8eaa1,Other,FDA-2013-P-1374-0019,FDA-2013-P-1374,"Supplement from Frederick Mayer, PPSI"
0900006481d8eaa2,Other,FDA-2013-P-1374-0020,FDA-2013-P-1374,"Supplement from Frederick Mayer, PPSI"
0900006481d8eaa3,Other,FDA-2013-P-1374-0021,FDA-2013-P-1374,"Supplement from Frederick Mayer, PPSI"
0900006482605222,Other,FDA-2013-P-1374-0038,FDA-2013-P-1374,"Supplement from Fred Mayer, PPSI"
0900006482016341,Other,FDA-2013-P-1374-0031,FDA-2013-P-1374,"Supplement from Fred Mayer, PPSI"
0900006481d9b4dc,Other,FDA-2013-P-1374-0022,FDA-2013-P-1374,"Supplement from Fred Mayer, PPSI"
0900006481e406c9,Other,FDA-2013-P-1374-0028,FDA-2013-P-1374,"Supplement from Frederick Mayer, PPSI"
0900006482016469,Other,FDA-2013-P-1374-0032,FDA-2013-P-1374,"Supplement from Fred Mayer, PPSI"
090000648293f1c3,Other,FDA-2013-P-1374-0040,FDA-2013-P-1374,"Letter (Denial) from CDRH to Pharmacists Planning Service, Inc."
0900006482212645,Other,FDA-2013-P-1374-0036,FDA-2013-P-1374,"Supplement from Frederick Mayer, PPSI"
09000064829401e2,Supporting & Related Material,FDA-2013-P-1374-0043,FDA-2013-P-1374,SCENIHR Opinion on Potential health effects of exposure to electromagnetic fields (EMF) 2015 scenihr_o_041 re Issue a Federal Regulation to Augment FDA Citizen's Petition For Public Hearings to Establish Standards on Cellphone Radiation Adverse Health Effects That Might be Caused by Specific Absorption Rates (SAR) and Radio Frequency Radiation (RFR)/Electromagnetic Frequency (EMF)
0900006482d8388f,Other,FDA-2017-P-7031-0002,FDA-2017-P-7031,"Acknowledgment Letter from FDA DDM to JRRapoza Associates, Inc"
0900006482d8388d,Other,FDA-2017-P-7031-0001,FDA-2017-P-7031,"Citizen Petition from JRRapoza Associates, Inc"
0900006482d84574,Supporting & Related Material,FDA-2017-P-7031-0004,FDA-2017-P-7031,"Attachment 2 Approved Drug Labeling RLD re Citizen Petition from JRRapoza Associates, Inc"
0900006482d83891,Supporting & Related Material,FDA-2017-P-7031-0003,FDA-2017-P-7031,"Attachment 1 Orange Book Listing re Citizen Petition from JRRapoza Associates, Inc"
0900006482b0e6f2,Other,FDA-2017-P-5435-0001,FDA-2017-P-5435,"Citizen Petition from Hyman, Phelps & McNamara PC"
0900006482d72ce0,Other,FDA-2017-P-5435-0003,FDA-2017-P-5435,"Withdrawal from Hyman, Phelps & McNamara PC"
0900006482b0e6f6,Other,FDA-2017-P-5435-0002,FDA-2017-P-5435,"Acknowledgement Letter from FDA DDM to Hyman, Phelps & McNamara PC"
090000648483c8de,Other,FDA-2020-P-1844-0002,FDA-2020-P-1844,"Acknowledgment Letter from FDA DMS to HYMAN, PHELPS & MCNAMARA, P.C."
090000648483c6fe,Other,FDA-2020-P-1844-0001,FDA-2020-P-1844,"Citizen Petition from HYMAN, PHELPS & MCNAMARA, P.C."
09000064844858d9,Other,FDA-2020-P-1246-0002,FDA-2020-P-1246,"Acknowledgment Letter from FDA DMS to Fresenius Kabi USA, LLC"
09000064844857d4,Other,FDA-2020-P-1246-0001,FDA-2020-P-1246,"Citizen Petition from Fresenius KabiUSA, LLC"
0900006484891190,Other,FDA-2020-P-1246-0003,FDA-2020-P-1246,"Interim Response letter from FDA CDER to Fresenius Kabi USA, LLC"
090000648404a46f,Other,FDA-2019-P-4669-0001,FDA-2019-P-4669,Citizen Petition from RdR Solutions on behalf of  Fiber Research International
0900006484485a98,Other,FDA-2019-P-4669-0003,FDA-2019-P-4669,Interim Response Letter from FDA CFSAN to RdR Solutions
090000648404c3ca,Other,FDA-2019-P-4669-0002,FDA-2019-P-4669,Acknowledgement Letter from FDA DMS to RdR Solutions on behalf of  Fiber Research International
0900006484729f7e,Other,FDA-2019-P-4669-0004,FDA-2019-P-4669,Final response from FDA CFSAN to Dr. Catherine Adams Hutt
0900006484020da2,Other,FDA-2019-P-4643-0002,FDA-2019-P-4643,Acknowledgment Letter from FDA DMS to Physicians Committee for Responsible Medicine
0900006484020da1,Other,FDA-2019-P-4643-0001,FDA-2019-P-4643,Citizen Petition from Physicians Committee for Responsible Medicine
0900006484020e64,Supporting & Related Material,FDA-2019-P-4643-0011,FDA-2019-P-4643,"Reference 8 Ronco et al (2002) Dairy foods and risk of breast cancer: a case–control study in Montevideo, Uruguay re Citizen Petition from Physicians Committee for Responsible Medicine"
0900006484ad9c4b,Other,FDA-2019-P-4643-0014,FDA-2019-P-4643,Final response from FDA CFSAN to Physicians Committee for Responsible Medicine
0900006484020e62,Supporting & Related Material,FDA-2019-P-4643-0009,FDA-2019-P-4643,Reference 6 (2002) Endogenous Sex Hormones and Breast Cancer in Postmenopausal Women: Reanalysis of Nine Prospective Studies re Citizen Petition from Physicians Committee for Responsible Medicine
0900006484020e5e,Supporting & Related Material,FDA-2019-P-4643-0005,FDA-2019-P-4643,Reference 2 U.S. Cancer Statistics Working Group re Citizen Petition from Physicians Committee for Responsible Medicine
0900006484020e61,Supporting & Related Material,FDA-2019-P-4643-0008,FDA-2019-P-4643,"Reference 5 Brinkman et al (2010) Consumption of animal products, their nutrient components and postmenopausal circulating steroid hormone concentrations re Citizen Petition from Physicians Committee for Responsible Medicine"
0900006484021147,Supporting & Related Material,FDA-2019-P-4643-0004,FDA-2019-P-4643,"Reference 1 CDC, Breast Cancer Statistics (May 28, 2019) re Citizen Petition from Physicians Committee for Responsible Medicine"
0900006484020e5f,Supporting & Related Material,FDA-2019-P-4643-0006,FDA-2019-P-4643,"Reference 3 Blumen et (2016) Comparison of Treatment Costs for Breast Cancer, by Tumor Stage and Type of Service re Citizen Petition from  Physicians Committee for Responsible Medicine"
0900006484020e60,Supporting & Related Material,FDA-2019-P-4643-0007,FDA-2019-P-4643,Reference 4 McCann et al (2017) Usual Consumption of Specific Dairy Foods Is Associated with Breast Cancer in the Roswell Park Cancer Institute Data Bank and BioRepository re Citizen Petition from Physicians Committee for Responsible Medicine
0900006484020e63,Supporting & Related Material,FDA-2019-P-4643-0010,FDA-2019-P-4643,"Reference 7 Kroenke, et al (2013) High- and Low-Fat Dairy Intake, Recurrence, and Mortality After Breast Cancer Diagnosis re Citizen Petition from Physicians Committee for Responsible Medicine"
0900006484020e65,Supporting & Related Material,FDA-2019-P-4643-0012,FDA-2019-P-4643,"Reference 9 Prentice et al (2019) Low-Fat Dietary Pattern among Postmenopausal Women Influences Long-Term Cancer, Cardiovascular Disease, and Diabetes Outcomes re Citizen Petition from Physicians Committee for Responsible Medicine"
0900006484020e66,Supporting & Related Material,FDA-2019-P-4643-0013,FDA-2019-P-4643,Reference 10 World Cancer Research Fund/American Institute for Cancer Research re Citizen Petition from Physicians Committee for Responsible Medicine
0900006484021146,Supporting & Related Material,FDA-2019-P-4643-0003,FDA-2019-P-4643,Reference List re Citizen Petition from Physicians Committee for Responsible Medicine
09000064847ab048,Other,FDA-2020-P-0893-0010,FDA-2020-P-0893,Interim Response letter from FDA CDRH to Kelly Roman
09000064843953d0,Supporting & Related Material,FDA-2020-P-0893-0004,FDA-2020-P-0893,"Appendix B re: Citizen Petition from Fisher Wallace Laboratories, Inc."
09000064843953d4,Supporting & Related Material,FDA-2020-P-0893-0008,FDA-2020-P-0893,"Appendix F re: Citizen Petition from Fisher Wallace Laboratories, Inc."
09000064843953d1,Supporting & Related Material,FDA-2020-P-0893-0005,FDA-2020-P-0893,"Appendix C re: Citizen Petition from Fisher Wallace Laboratories, Inc."
09000064843953d3,Supporting & Related Material,FDA-2020-P-0893-0007,FDA-2020-P-0893,"Appendix E re: Citizen Petition from Fisher Wallace Laboratories, Inc."
090000648439530b,Other,FDA-2020-P-0893-0001,FDA-2020-P-0893,"Citizen Petition from Fisher Wallace Laboratories, Inc."
09000064843953c9,Other,FDA-2020-P-0893-0002,FDA-2020-P-0893,"Acknowledgment Letter from FDA DMS to Fisher Wallace Laboratories, Inc."
09000064843956f0,Supporting & Related Material,FDA-2020-P-0893-0009,FDA-2020-P-0893,"Appendix G re: Citizen Petition from Fisher Wallace Laboratories, Inc."
09000064843953d2,Supporting & Related Material,FDA-2020-P-0893-0006,FDA-2020-P-0893,"Appendix D re: Citizen Petition from Fisher Wallace Laboratories, Inc."
0900006484d38132,Other,FDA-2020-P-0893-0011,FDA-2020-P-0893,"Final Response to Citizen Petition from FDA CDRH to Fisher Wallace Laboratories, Inc."
09000064843953cf,Supporting & Related Material,FDA-2020-P-0893-0003,FDA-2020-P-0893,"Appendix A re: Citizen Petition from Fisher Wallace Laboratories, Inc."
09000064833498ab,Other,FDA-2018-P-2175-0001,FDA-2018-P-2175,"Citizen Petition from Pharmalucence, Inc."
0900006483349c70,Other,FDA-2018-P-2175-0002,FDA-2018-P-2175,"Acknowledgment Letter from FDA DDM  to Pharmalucence, Inc."
0900006484dbeb40,Other,FDA-2018-P-2175-0003,FDA-2018-P-2175,"Withdrawal from Sun Pharmaceutical Industries, Inc."
09000064821ded4c,Supporting & Related Material,FDA-2016-P-2654-0007,FDA-2016-P-2654,"Attachment 5 Weiden PJ et al. 2016. A randomized trial of iloperidone for prevention of relapse in schizophrenia: the REPRIEVE study. CNS Drugs 30:735-747 re Citizen Petition from Vanda Pharmaceuticals, Inc."
09000064821ded49,Supporting & Related Material,FDA-2016-P-2654-0004,FDA-2016-P-2654,"Attachment 2 Buchanan RW et al. 2010. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophrenia Bulletin re Citizen Petition from Vanda Pharmaceuticals, Inc."
09000064821ded4b,Supporting & Related Material,FDA-2016-P-2654-0006,FDA-2016-P-2654,"Attachment 4 Emsley Ret al. 2016. How long should antipsychotic treatment be continued after a single episode of schizophrenia? Current Opinion Psychiatry. 29(3):224-229 re Citizen Petition from Vanda Pharmaceuticals, Inc."
09000064821ded46,Other,FDA-2016-P-2654-0001,FDA-2016-P-2654,"Citizen Petition from Vanda Pharmaceuticals, Inc."
09000064821ded4d,Other,FDA-2016-P-2654-0002,FDA-2016-P-2654,"Acknowledgment Letter from FDA DDM to Vanda Pharmaceuticals, Inc."
09000064821ded4a,Supporting & Related Material,FDA-2016-P-2654-0005,FDA-2016-P-2654,"Attachment 3 Emsley Ret al. 2013. The nature of relapse in schizophrenia. BMC Psychiatry. 13:50 re Citizen Petition from Vanda Pharmaceuticals, Inc."
09000064821ded48,Supporting & Related Material,FDA-2016-P-2654-0003,FDA-2016-P-2654,"Attachment 1 Am. Psychiatric Ass'n, Diagnostic and Statistical Manual of Mental Disorders § 295.90 (Schizophrenia) Csth ed. 2013) (DSM -5). re Citizen Petition from Vanda Pharmaceuticals, Inc."
09000064823d0afe,Other,FDA-2016-P-2654-0008,FDA-2016-P-2654,Petition Denial Letter
0900006483416b7b,Other,FDA-2018-P-1349-0007,FDA-2018-P-1349,"Petition Response Letter from FDA CVM to Douglass Oeller Consulting, Inc."
0900006483085e0c,Supporting & Related Material,FDA-2018-P-1349-0003,FDA-2018-P-1349,"Appendix 2 - A copy of the Boehringer lngelheim Vetmedica Inc package insert for this product re Citizen Petition from Douglass Oeller Consulting, Inc. (Felix Pharmaceuticals Pvt. Ltd.)"
09000064831ee6f8,Other,FDA-2018-P-1349-0005,FDA-2018-P-1349,Amendments to Suitability Petition: Revised Dosage Form of Pimobendan Tablets.
0900006483086608,Other,FDA-2018-P-1349-0002,FDA-2018-P-1349,"Acknowledgment Letter from FDA DDM to Douglass Oeller Consulting, Inc."
090000648333525a,Other,FDA-2018-P-1349-0006,FDA-2018-P-1349,"Change of US Agent, James H. Schafer, D.V.M (Schafer Veterinary Consultants, LLC) - 06-04-2018"
0900006483085e0a,Other,FDA-2018-P-1349-0001,FDA-2018-P-1349,"Citizen Petition from Douglass Oeller Consulting, Inc. (Felix Pharmaceuticals Pvt. Ltd.)"
0900006483085e0d,Supporting & Related Material,FDA-2018-P-1349-0004,FDA-2018-P-1349,"Appendix 3 - A marked up copy of the package insert showing Felix's proposed changes re Citizen Petition from Douglass Oeller Consulting, Inc. (Felix Pharmaceuticals Pvt. Ltd.)"
090000648135f7b3,Other,FDA-2013-P-0058-0004,FDA-2013-P-0058,FDA/CDER Interim Response to Hogan Lovells US LLP - Letter
09000064818b90f0,Other,FDA-2013-P-0058-0009,FDA-2013-P-0058,Citizen Petition Denial Response from FDA CDER to Hogan Lovells US LLP and Buchanan Ingersoll and Rooney PC
090000648167c394,Other,FDA-2013-P-0058-0007,FDA-2013-P-0058,Citizen Petition From Gilead Sciences Inc (Hogan Lovells US LLP)
09000064811b5197,Other,FDA-2013-P-0058-0002,FDA-2013-P-0058,"Acknowledgement Letter to Gilead Sciences, Inc. (Hogan Lovells US LLP)"
09000064811b40e1,Other,FDA-2013-P-0058-0001,FDA-2013-P-0058,"Gilead Sciences, Inc. (Hogan Lovells US LLP) - Citizen Petition"
090000648159d136,Other,FDA-2013-P-0058-0006,FDA-2013-P-0058,Citizen Petition Denial Response from FDA CDER to HoganLovells US LLP
090000648167c396,Other,FDA-2013-P-0058-0008,FDA-2013-P-0058,Acknowledgement Letter From FDA/DDM to Gilead Sciences Inc. (Hogan Lovells US LLP)
09000064818a0320,Other,FDA-2014-P-1483-0002,FDA-2014-P-1483,Acknowledgement Letter from FDA DDM to Sean Mahoney Upsher-Smith Laboratories Inc
0900006481a31894,Other,FDA-2014-P-1483-0003,FDA-2014-P-1483,"Withdrawal of Petition from Upsher-Smith Laboratories, Inc."
090000648189e41d,Other,FDA-2014-P-1483-0001,FDA-2014-P-1483,Citizen Petition from Sean Mahoney Upsher-Smith Laboratories Inc
09000064824c880a,Other,FDA-2017-P-1039-0001,FDA-2017-P-1039,Citizen Petition from Beck & Thomas
090000648292435c,Other,FDA-2017-P-1039-0003,FDA-2017-P-1039,"Citizen Petition Decision Letter from FDA CDER to Beck & Thomas, P.C."
09000064824c8b4d,Other,FDA-2017-P-1039-0002,FDA-2017-P-1039,"Acknowledgement Letter from FDA DDM to Beck & Thomas, P.C."
0900006483c6bb16,Other,FDA-2018-P-2040-0006,FDA-2018-P-2040,Withdrawal from Jerry Reed
0900006483303366,Supporting & Related Material,FDA-2018-P-2040-0004,FDA-2018-P-2040,"Exhibit 2-Proposed Package Insert for Atropine Sulfate Injection, 1.0 mg/mL (1 mL Single Dose Vial) and 0.4 mg/mL (1 mL Single Dose Vial) re: Citizen Petition from Jerry Taylor Reed"
0900006483303367,Supporting & Related Material,FDA-2018-P-2040-0005,FDA-2018-P-2040,Exhibit-3 Side by Side Comparison for the Approved RLD Package Insert and the Proposed Package Insert re: Citizen Petition from Jerry Taylor Reed
0900006483303365,Supporting & Related Material,FDA-2018-P-2040-0003,FDA-2018-P-2040,Exhibit 1- Package Insert for Fresenius Kabi USA’s Atropine Sulfate Injection 8 mg/20 mL (0.4 mg/mL) submitted under NDA 209260 (approved January 2018) re: Citizen Petition from Jerry Taylor Reed
090000648330326b,Other,FDA-2018-P-2040-0002,FDA-2018-P-2040,Acknowledgment Letter from FDA DDM to Jerry Taylor Reed
09000064833031b6,Other,FDA-2018-P-2040-0001,FDA-2018-P-2040,Citizen Petition from Jerry Taylor Reed
0900006484651ca7,Supporting & Related Material,FDA-2020-P-1405-0013,FDA-2020-P-1405,Attachment 11 -Piehler et al - Comparison of LAL and rFC Assays re: Citizen petition for bioMerieux
0900006484651caa,Supporting & Related Material,FDA-2020-P-1405-0016,FDA-2020-P-1405,"Attachment 14 - Article, improving the LAL paradigm re: Citizen petition for bioMerieux"
0900006484651ca8,Supporting & Related Material,FDA-2020-P-1405-0014,FDA-2020-P-1405,Attachment 12 -Revive and Restore Letter to USP re: Citizen petition for bioMerieux
0900006484651993,Supporting & Related Material,FDA-2020-P-1405-0003,FDA-2020-P-1405,Attachment 1- Biomedical Bleeding Process re: Citizen petition for bioMerieux
0900006484651ca1,Supporting & Related Material,FDA-2020-P-1405-0007,FDA-2020-P-1405,Attachment 5 -Horseshoe Crab Recovery Coalition - Letter to ASMFC re: Citizen petition for bioMerieux
0900006484651994,Supporting & Related Material,FDA-2020-P-1405-0004,FDA-2020-P-1405,"Attachment 2 - Bruce Loverock, Pharmacoepial Forum - Citation and Abstract re: Citizen petition for bioMerieux"
0900006484651996,Supporting & Related Material,FDA-2020-P-1405-0006,FDA-2020-P-1405,Attachment 4 -FDA Guidance for Industry - Pyrogen and Endotoxin Testing re: Citizen petition for bioMerieux
090000648491849d,Other,FDA-2020-P-1405-0031,FDA-2020-P-1405,Interim Response letter from FDA CDER to bioMerieux
0900006484651ca9,Supporting & Related Material,FDA-2020-P-1405-0015,FDA-2020-P-1405,Attachment 13 -RSPCA Letter to USP - Bacterial Endotoxin Assay re: Citizen petition for bioMerieux
0900006484651ca3,Supporting & Related Material,FDA-2020-P-1405-0009,FDA-2020-P-1405,Attachment 7 -Kikuchi Study re: Citizen petition for bioMerieux
0900006484651995,Supporting & Related Material,FDA-2020-P-1405-0005,FDA-2020-P-1405,Attachment 3 -Congressional Letter to USP - Horseshoe Crab re: Citizen petition for bioMerieux
0900006484651ca4,Supporting & Related Material,FDA-2020-P-1405-0010,FDA-2020-P-1405,Attachment 8 -Krisfalus-Gannon et al - Role of HSC in Biomedical Insdustry re: Citizen petition for bioMerieux
0900006484651ca6,Supporting & Related Material,FDA-2020-P-1405-0012,FDA-2020-P-1405,"Attachment 10 -Marius, et al -Comparison of LAL and rFC vaccine endotoxin testing re: Citizen petition for bioMerieux"
0900006484a6e3e0,Other,FDA-2020-P-1405-0035,FDA-2020-P-1405,Amendment from bioMerieux
0900006484651ca2,Supporting & Related Material,FDA-2020-P-1405-0008,FDA-2020-P-1405,Attachment 6 -IUCN Letter to USP - HSC Specialist Group re: Citizen petition for bioMerieux
0900006484651ca5,Supporting & Related Material,FDA-2020-P-1405-0011,FDA-2020-P-1405,Attachment 9 -Maloney et al - PLOS Saving the HSC re: Citizen petition for bioMerieux
0900006484651991,Other,FDA-2020-P-1405-0002,FDA-2020-P-1405,Acknowledgement Letter from DMS to bioMerieux
090000648464fb62,Other,FDA-2020-P-1405-0001,FDA-2020-P-1405,Citizen Petition from bioMerieux
0900006481b92b4c,Supporting & Related Material,FDA-2014-P-0159-0009,FDA-2014-P-0159,Appendix 1 re: Citizen Petition from Mead Killion
0900006481a92e84,Other,FDA-2014-P-0159-0005,FDA-2014-P-0159,Interim Response Letter from FDA CDRH to Etymotic Research Inc
0900006481a92e85,Other,FDA-2014-P-0159-0006,FDA-2014-P-0159,Response Letter from Etymotic Research Inc
0900006481b92b4d,Supporting & Related Material,FDA-2014-P-0159-0010,FDA-2014-P-0159,Appendix 2 re: Citizen Petition from Mead Killion
090000648153648f,Other,FDA-2014-P-0159-0002,FDA-2014-P-0159,Acknowledgement Letter From FDA DDM to Mead Killion
0900006481536337,Other,FDA-2014-P-0159-0001,FDA-2014-P-0159,Citizen Petition from Mead Killion
0900006481e04b4c,Other,FDA-2014-P-0159-0012,FDA-2014-P-0159,"Second Interim Response from FDA CDRH to Etymotic Research, Inc."
0900006481b92b4e,Supporting & Related Material,FDA-2014-P-0159-0011,FDA-2014-P-0159,Letter from FDA CDER to Mead C. Killion Dated 08/20/2014 re: Citizen Petition from Mead Killion
090000648154ba85,Other,FDA-2014-P-0159-0003,FDA-2014-P-0159,Amendment From Mead Killion to FDA-2014-P-0159
0900006484df8ba0,Other,FDA-2014-P-0159-0014,FDA-2014-P-0159,Final Response from FDA CDRH to Etymotic Research Inc
0900006481e40ee5,Other,FDA-2016-P-0383-0002,FDA-2016-P-0383,Acknowledgement Letter from FDA DDM to Fish & Richardson P.C.
0900006481e40cae,Other,FDA-2016-P-0383-0001,FDA-2016-P-0383,Citizen Petition from Fish & Richardson P. C. (Depomed Inc.)
0900006481f99d39,Other,FDA-2016-P-0383-0004,FDA-2016-P-0383,Petition Denial Letter Final Response
09000064838aea6d,Other,FDA-2018-P-1008-0006,FDA-2018-P-1008,"Withdrawal from VPCI, Inc."
0900006482f9a81a,Other,FDA-2018-P-1008-0001,FDA-2018-P-1008,"Suitability Petition from VPCI, Inc."
0900006482f9afa5,Supporting & Related Material,FDA-2018-P-1008-0004,FDA-2018-P-1008,"Attachment 2- Comparative Labeling RLD vs Proposed Drug Product re: Citizens Petition from VPCI, Inc."
0900006482f9aa42,Other,FDA-2018-P-1008-0002,FDA-2018-P-1008,"Acknowledgment Letter from FDA DDM to VPCI, Inc."
0900006482f9afa4,Supporting & Related Material,FDA-2018-P-1008-0003,FDA-2018-P-1008,"Attachment1-VAZCULEP- phenylephrine hydrochloride injection
Avadel Legacy Pharmaceuticals , LLC re: Citizens Petition from VPCI, Inc."
0900006481dd4261,Supporting & Related Material,FDA-2015-P-5022-0005,FDA-2015-P-5022,Exhibit D Summary of Product Characteristics re Citizen Petition from Pharmaceutical Research and Manufacturers of America and Biotechnology Industry Organization
09000064820aa5a7,Other,FDA-2015-P-5022-0008,FDA-2015-P-5022,Petition Denial Letter
090000648204f957,Other,FDA-2015-P-5022-0007,FDA-2015-P-5022,Interim Response from FDA CDER to PRMA
0900006481dd3aae,Other,FDA-2015-P-5022-0002,FDA-2015-P-5022,Acknowledgement Letter from FDA DDM to Pharmaceutical Research and Manufacturers of America and Biotechnology Industry Organization
0900006481dd3ae9,Supporting & Related Material,FDA-2015-P-5022-0003,FDA-2015-P-5022,"Exhibit A FDA Office of Legislation Response Letter to the Honorable Lamar Alexander, Chairman of the Senate Committee on HELP re Citizen Petition from The Pharmaceutical Research and Manufacturers of America (“PhRMA”) and the Biotechnology Industry Organization (“BIO”)"
0900006481dd425a,Supporting & Related Material,FDA-2015-P-5022-0004,FDA-2015-P-5022,Exhibit B Industry Standard Research's ASBM Labeling Survey re Citizen Petition from Pharmaceutical Research and Manufacturers of America and  Biotechnology Industry Organization
0900006481dd38b8,Other,FDA-2015-P-5022-0001,FDA-2015-P-5022,Citizen Petition from Pharmaceutical Research and Manufacturers of America and Biotechnology Industry Organization
09000064839df95b,Other,FDA-2018-P-2720-0003,FDA-2018-P-2720,"Interim response from FDA CDER to Hyman, Phelps & McNamara, P. C."
09000064834e706d,Other,FDA-2018-P-2720-0001,FDA-2018-P-2720,"Citizen Petition from Hyman, Phelps & McNamara, P.C."
0900006483bf31c9,Other,FDA-2018-P-2720-0004,FDA-2018-P-2720,"Letter from FDA CDER to Hyman, Phelps & McNamara, P.C."
09000064834e706f,Other,FDA-2018-P-2720-0002,FDA-2018-P-2720,"Acknowledgment Letter from FDA DDM to Hyman, Phelps & McNamara, P.C."
09000064823171d6,Supporting & Related Material,FDA-2016-P-3428-0004,FDA-2016-P-3428,"Attachment 2 TBD Chewable Tablets re Suitability Petition from Douglass Oeller Consulting, Inc (Felix Pharmaceuticals Pvt. Ltd)"
09000064823171d5,Supporting & Related Material,FDA-2016-P-3428-0003,FDA-2016-P-3428,"Attachment 1 Simplicef re Suitability Petition from Douglass Oeller Consulting, Inc (Felix Pharmaceuticals Pvt. Ltd)"
09000064823171d3,Other,FDA-2016-P-3428-0002,FDA-2016-P-3428,"Acknowledgement Letter from FDA DDM to Douglass Oeller Consulting, Inc. (Felix Pharmaceuticals Pvt. Ltd)"
09000064823171d1,Other,FDA-2016-P-3428-0001,FDA-2016-P-3428,"Suitability Petition from Douglass Oeller Consulting, Inc (Felix Pharmaceuticals Pvt. Ltd)"
09000064823c7644,Other,FDA-2016-P-3428-0005,FDA-2016-P-3428,"Amendment to Suitability Petition from Douglass Oeller Consulting, Inc. (Felix Pharmaceuticals)"
0900006482458c08,Other,FDA-2016-P-3428-0006,FDA-2016-P-3428,Letter from CVM to Douglass Oeller Consulting Inc
0900006484116414,Other,FDA-2019-P-1525-0005,FDA-2019-P-1525,Interim Response Letter from FDA CDER to Baxter Healthcare Corporation
0900006483b4bb9a,Other,FDA-2019-P-1525-0002,FDA-2019-P-1525,Acknowledgment Letter from FDA DDM to Baxter Healthcare Corporation
0900006483b4bb99,Supporting & Related Material,FDA-2019-P-1525-0004,FDA-2019-P-1525,Attachment 2 Controlled Correspondence (Nicardipine Hydrochloride NDA019734) Letter from FDA OGD CDER to Baxter Healthcare Corporation re Citizen Petition from Baxter Healthcare Corporation
090000648486403b,Other,FDA-2019-P-1525-0008,FDA-2019-P-1525,Letter from FDA CDER to Baxter Healthcare Corporation
09000064842dfbff,Other,FDA-2019-P-1525-0007,FDA-2019-P-1525,Final Response Letter from FDA CDER to Baxter Healthcare Corporation
09000064842de590,Notice,FDA-2019-P-1525-0006,FDA-2019-P-1525,"Determination That CARDENE (Nicardipine Hydrochloride) Injection, 25 Milligrams/10 Milliliters, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
0900006483b4bb96,Supporting & Related Material,FDA-2019-P-1525-0003,FDA-2019-P-1525,Attachment 1 Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations re Citizen Petition from Baxter Healthcare Corporation
0900006483b4be37,Other,FDA-2019-P-1525-0001,FDA-2019-P-1525,Citizen Petition from Baxter Healthcare Corporation
090000648491b5e0,Other,FDA-2020-P-2102-0001,FDA-2020-P-2102,"Suitability Petition from Aurora Pharmaceutical, Inc."
090000648491c185,Supporting & Related Material,FDA-2020-P-2102-0004,FDA-2020-P-2102,"Attachment 1. Equioxx (firocoxib) Oral Paste, labeling by Merial, rev 02-2015"
09000064849f4430,Other,FDA-2020-P-2102-0005,FDA-2020-P-2102,"Approval Letter from FDA DMS to Aurora Pharmaceutical, Inc."
090000648491c184,Supporting & Related Material,FDA-2020-P-2102-0003,FDA-2020-P-2102,"Cover Letter RE Suitability Petition from Aurora Pharmaceutical, Inc."
090000648491b5e1,Other,FDA-2020-P-2102-0002,FDA-2020-P-2102,"Acknowledgment Letter from FDA DMS to Aurora Pharmaceutical, Inc."
0900006483fc60e0,Supporting & Related Material,FDA-2019-P-4481-0004,FDA-2019-P-4481,Attachment 2 National Drug Code Directory re Citizen Petition from Macleods Pharmaceuticals Limited
0900006483fc5b55,Other,FDA-2019-P-4481-0001,FDA-2019-P-4481,Citizen Petition from Macleods Pharmaceuticals Limited
0900006483fc60e2,Supporting & Related Material,FDA-2019-P-4481-0006,FDA-2019-P-4481,Attachment 4 IMS Data re Citizen Petition from Macleods Pharmaceuticals Limited
0900006483fc60e1,Supporting & Related Material,FDA-2019-P-4481-0005,FDA-2019-P-4481,Attachment 3 FDA Approved Drug Products re Citizen Petition from Macleods Pharmaceuticals Limited
0900006483fc5ba9,Other,FDA-2019-P-4481-0002,FDA-2019-P-4481,Acknowledgment Letter from FDA DMS to Macleods Pharmaceuticals Limited
0900006483fc5be1,Supporting & Related Material,FDA-2019-P-4481-0003,FDA-2019-P-4481,Attachment 1 Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations re Citizen Petition from Macleods Pharmaceuticals Limited
090000648496c9e1,Other,FDA-2019-P-4481-0008,FDA-2019-P-4481,Withdrawal from Macleods Pharmaceuticals Limited
090000648450d333,Other,FDA-2019-P-4481-0007,FDA-2019-P-4481,Interim Response Letter from FDA CDER to Macleods Pharmaceuticals Limited
0900006484a6052f,Notice,FDA-2020-N-2354-0001,FDA-2020-N-2354,"Data Standards; Requirement Begins for the Clinical Data Interchange Standards Consortium Version 1.1 of
the Standard for Exchange of Nonclinical Data Developmental and Reproductive Toxicology Implementation Guide and Version 1.6 of the Study Data Tabulation Model; Clarification to Food and Drug Administration Data Standards"
0900006484a87f91,Other,FDA-2021-P-0340-0001,FDA-2021-P-0340,Suitability Petition from Drug Device Consulting LLC
0900006484a8836e,Supporting & Related Material,FDA-2021-P-0340-0005,FDA-2021-P-0340,Attachment 3 RLD Label for Naproxen Suspension 25mg/mL re Suitability Petition from Drug Device Consulting LLC
0900006484a8836a,Supporting & Related Material,FDA-2021-P-0340-0004,FDA-2021-P-0340,Attachment 2 Draft Label for Naproxen Suspension 50mg/mL re Suitability Petition from Drug Device Consulting LLC
0900006484a88992,Other,FDA-2021-P-0340-0002,FDA-2021-P-0340,Acknowledgment Letter from FDA DMS to Drug Device Consulting LLC
0900006484a88368,Supporting & Related Material,FDA-2021-P-0340-0003,FDA-2021-P-0340,Attachment 1 Orange Book RLD Listing re Suitability Petition from Drug Device Consulting LLC
0900006481a37edd,Supporting & Related Material,FDA-2015-P-0732-0030,FDA-2015-P-0732,"[TAB 27] Khan et al., Activation of NFkB is a novel mechanism of
pro-survival activity of glucocorticoids in breast cancer cells. Cancer Letters, 2013; 337:90–95. Citizen Petition From Celgene (Arnold and Porter)"
0900006481a37f36,Supporting & Related Material,FDA-2015-P-0732-0034,FDA-2015-P-0732,"[TAB 31] Li et al., Pharmacology of Paclitaxel Sensitive to its Delivery Vehicles Drives Distinct Clinical Outcome of Paclitaxel Formulations.
Molecular Pharmaceutics, (accepted for publication); Web Publication Date Feb, 25, 2015. DOI: 10.1021/acs.molpharmaceut.5b00026. Citizen Petition From Celgene (Arnold and Porter)"
0900006481a37fc9,Supporting & Related Material,FDA-2015-P-0732-0047,FDA-2015-P-0732,"[TAB 44] Paal et al., High affinity binding of paclitaxel to human serum
albumin. Eur J Biochem. 2001;268:2187-91. Citizen Petition From Celgene (Arnold and Porter)"
0900006481a37fcc,Supporting & Related Material,FDA-2015-P-0732-0050,FDA-2015-P-0732,"[TAB 47] Quillet et al., Anisotropic colloids through non-trivial buckling. Eur. Phys. J. E 2008 27, 13–20. Citizen Petition From Celgene (Arnold and Porter)"
0900006481a37d6f,Supporting & Related Material,FDA-2015-P-0732-0022,FDA-2015-P-0732,"[TAB 19] Green et al., Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol, 2006; 8:1263-8., Citizen Petition From Celgene (Arnold and Porter)"
0900006481a38bd0,Supporting & Related Material,FDA-2015-P-0732-0094,FDA-2015-P-0732,"[TAB 90] Nanotechnology - FDAs Approach to Regulation of Nanotechnology Products., Citizen Petition From Celgene (Arnold and Porter)"
0900006481a3856c,Supporting & Related Material,FDA-2015-P-0732-0063,FDA-2015-P-0732,"[TAB 59] Sui et al., Glucocorticoids interfere with therapeutic efficacy
of paclitaxel against human breast and ovarian xenograft tumors. Int. J. Cancer, 2006; 119, 712–717. Citizen Petition From Celgene (Arnold and Porter)"
0900006481a373bc,Supporting & Related Material,FDA-2015-P-0732-0008,FDA-2015-P-0732,"[TAB 5] Chen et al. Albumin-bound nanoparticle (nab) paclitaxel exhibits enhanced paclitaxel tissue distribution and tumor penetration. Manuscript submitted, 2015., Citizen Petition From Celgene (Arnold and Porter)"
0900006481a375e7,Supporting & Related Material,FDA-2015-P-0732-0012,FDA-2015-P-0732,"[TAB 9] Cortes, and Saura C. Nanoparticle albumin-bound (nab™)-paclitaxel: improving efficacy and tolerability by targeted drug delivery in metastatic breast cancer. EJC Supplements, 2010; 8:1-10., Citizen Petition From Celgene (Arnold and Porter)"
0900006481a37700,Supporting & Related Material,FDA-2015-P-0732-0014,FDA-2015-P-0732,"[TAB 11] Frei, E. Albumin binding ligands and albumin conjugate uptake by cancer cells. Diabetology & Metabolic Syndrome, 2011; 3:11. Citizen Petition From Celgene (Arnold and Porter)"
0900006481a379d4,Supporting & Related Material,FDA-2015-P-0732-0015,FDA-2015-P-0732,"[TAB 12] Frese et al. nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. Cancer. Discov, 2012; 2:260-9. Citizen Petition From Celgene (Arnold and Porter)"
0900006481a38b38,Supporting & Related Material,FDA-2015-P-0732-0090,FDA-2015-P-0732,"[TAB 86] TAXOTERE Prescribing Information (Rev. Nov. 2014, Sanofi-Aventis U.S. LLC)., Citizen Petition From Celgene (Arnold and Porter)"
0900006481c3fad8,Other,FDA-2015-P-0732-0110,FDA-2015-P-0732,Interim Response Letter from FDA CDER to Arnold and Porter LLP
0900006481a37f34,Supporting & Related Material,FDA-2015-P-0732-0032,FDA-2015-P-0732,"[TAB 29] Langer et al., Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer. J Thorac
Oncol, 2008; 6:623-30. Citizen Petition From Celgene (Arnold and Porter)"
0900006481a37f35,Supporting & Related Material,FDA-2015-P-0732-0033,FDA-2015-P-0732,"[TAB 30] Lee et al., Multicenter Phase II trial of Genexol-PM (Cynviloq), a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res Treat, 2008 Mar; 108:241-50. Citizen Petition From Celgene (Arnold and Porter)"
0900006481a37f6f,Supporting & Related Material,FDA-2015-P-0732-0041,FDA-2015-P-0732,"[TAB 38] Makriyannis et al., Albumin enhances the diffusion of lipophilic drugs into the membrane bilayer. Life Sci, 2005;77:1605-11. Citizen Petition From Celgene (Arnold and Porter)"
0900006481a37f71,Supporting & Related Material,FDA-2015-P-0732-0043,FDA-2015-P-0732,"[TAB 40] Merisko-Liversidge, et al. Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs. Pharm Res, 1996;13:272-278. Citizen Petition From Celgene (Arnold and Porter)"
0900006481a37d6c,Supporting & Related Material,FDA-2015-P-0732-0019,FDA-2015-P-0732,"[TAB 16] Galli, Experimental determination of the diffusion boundary layer width of micron and submicron particles. International Journal of Pharmaceutics, 2006; 313:114-22., Citizen Petition From Celgene (Arnold and Porter)"
0900006481a37d71,Supporting & Related Material,FDA-2015-P-0732-0024,FDA-2015-P-0732,"[TAB 21] Herr_Debatin, et al. Glucocorticoid Cotreatment Induces Apoptosis Resistance toward Cancer Therapy in Carcinomas. Cancer Research, 2003; 63: 3112-3120., Citizen Petition From Celgene (Arnold and Porter)"
0900006481a38568,Supporting & Related Material,FDA-2015-P-0732-0061,FDA-2015-P-0732,"[TAB 57] Sparreboom et al., Preclinical pharmacokinetics
of paclitaxel and docetaxel. Anticancer Drugs, 1998; 9:1-17. Citizen Petition From Celgene (Arnold and Porter)"
0900006481a3856e,Supporting & Related Material,FDA-2015-P-0732-0065,FDA-2015-P-0732,"[TAB 61] Ten Tije, et al., Pharmacological Effects of Formulation Vehicles Implications for Cancer Chemotherapy, Clin Pharmacokinet 2003;42 (7): 665-685; Citizen Petition From Celgene (Arnold and Porter)"
0900006481a38570,Supporting & Related Material,FDA-2015-P-0732-0067,FDA-2015-P-0732,[TAB 63] Trynda-Lemiesz L. Paclitaxel-HSA interaction. Binding sites on HSA molecule. Bioorg Med Chem. 2004;12:3269-75. Citizen Petition From Celgene (Arnold and Porter)
0900006481a386d8,Supporting & Related Material,FDA-2015-P-0732-0077,FDA-2015-P-0732,"[TAB 73] CDER, “Guidance Agenda: New & Revised Guidances CDER is Planning to Publish During Calendar Year 2015” (January 6, 2015). Citizen Petition From Celgene (Arnold and Porter)"
0900006481a386dc,Supporting & Related Material,FDA-2015-P-0732-0078,FDA-2015-P-0732,"[TAB 74] Draft version of FDA notes (Feb. 5, 2001) Citizen Petition From Celgene (Arnold and Porter)"
0900006481a386dd,Supporting & Related Material,FDA-2015-P-0732-0079,FDA-2015-P-0732,"[TAB 75] Food and Drug Administration, Pharmacology/Toxicology Review and Evaluation of ABRAXANE (NDA Number 21,660) (2004). Citizen Petition From Celgene (Arnold and Porter)"
0900006484c8d400,Supporting & Related Material,FDA-2021-P-0923-0003,FDA-2021-P-0923,Attachment - I current orange book status re Citizen Petition from Gland Pharma Limited
0900006484c8d3fe,Other,FDA-2021-P-0923-0001,FDA-2021-P-0923,Citizen Petition from Gland Pharma Limited
0900006484c8cb24,Other,FDA-2021-P-0923-0002,FDA-2021-P-0923,Acknowledgment Letter from FDA DMS to Gland Pharma Limited
0900006484cca749,Other,FDA-2021-P-0959-0002,FDA-2021-P-0959,"Acknowledgment Letter from FDA DMS to Hyman, Phelps, & McNamara P.C."
0900006484cca747,Other,FDA-2021-P-0959-0001,FDA-2021-P-0959,"Citizen Petition from Hyman, Phelps, & McNamara P.C."
09000064807e9ba8,Other,FDA-2008-P-0365-0003,FDA-2008-P-0365,FDA to ISTA Pharmaceuticals - Petition Denied
090000648063c1b1,Other,FDA-2008-P-0365-0001,FDA-2008-P-0365,ISTA Pharmaceuticals - Citizen Petition
090000648063c20f,Other,FDA-2008-P-0365-0002,FDA-2008-P-0365,Acknowledgement Letter to ISTA Pharmaceuticals
0900006484dfa83b,Other,FDA-2021-P-1173-0002,FDA-2021-P-1173,Acknowledgment Letter from FDA DMS to Felix Pharmaceuticals Pvt Ltd
0900006484dfa777,Other,FDA-2021-P-1173-0001,FDA-2021-P-1173,Suitability Petition from Felix Pharmaceuticals Pvt. Ltd.
0900006484e72a6a,Other,FDA-2021-P-1173-0005,FDA-2021-P-1173,Letter from FDA CVM to Felix Pharmaceuticals Pvt. Ltd.
0900006484dfa6e0,Supporting & Related Material,FDA-2021-P-1173-0004,FDA-2021-P-1173,Attachment 2 Pimobendan Oral Suspension re: Suitability Petition from Felix Pharmaceuticals Pvt. Ltd.
0900006484dfa6e1,Supporting & Related Material,FDA-2021-P-1173-0003,FDA-2021-P-1173,Attachment 1 Vetmedin® (pimobendan) Chewable Tablets re: Suitability Petition from Felix Pharmaceuticals Pvt. Ltd.
0900006482324dc6,Supporting & Related Material,FDA-2016-P-3463-0003,FDA-2016-P-3463,"Attachment 1 FDA Orange Book page for Eliquis® (apixaban) tablets, 2.5 mg and 5 mg re Suitability Petition from Axinn, Veltrop & Harkrider LLP"
0900006482324df0,Supporting & Related Material,FDA-2016-P-3463-0005,FDA-2016-P-3463,"Attachment 3 Proposed Prescribing Information for Apixaban Tablets re Suitability Petition from Axinn, Veltrop & Harkrider LLP"
0900006482324dc7,Supporting & Related Material,FDA-2016-P-3463-0004,FDA-2016-P-3463,"Attachment 2 Copy of approved labeling for Eliquis® (apixaban) tablets (NDA 202155, Bristol Myers Squibb) re Suitability Petition from Axinn, Veltrop & Harkrider LLP"
090000648234a2c0,Other,FDA-2016-P-3463-0006,FDA-2016-P-3463,"Attachment 3,  SUPPLEMENT TO ANDA - Proposed Prescribing Information for Apixaban Tablets re Suitability Petition from Axinn, Veltrop & Harkrider LLP"
0900006482b95205,Other,FDA-2016-P-3463-0007,FDA-2016-P-3463,"Withdrawal from Axinn, Veltrop & Harkrider LLP"
0900006482324da3,Other,FDA-2016-P-3463-0001,FDA-2016-P-3463,"Acknowledgement Letter from FDA DDM to Axinn, Veltrop & Harkrider LLP"
0900006482324d22,Other,FDA-2016-P-3463-0002,FDA-2016-P-3463,"Suitability Petition from Axinn, Veltrop & Harkrider LLP"
09000064823459c1,Supporting & Related Material,FDA-2016-P-3418-0068,FDA-2016-P-3418,"Attachment 65 Impact of Model for End-Stage Liver Disease (MELD) Scoring System on Pathological Findings at and after Liver Transplantation, 12 LIVER TRANSPLANTATION 958 (2006) re Citizen Petition from Baker & Hostetler, LLP"
09000064823459c5,Supporting & Related Material,FDA-2016-P-3418-0072,FDA-2016-P-3418,"Attachment 69 Guidance for Industry - Non-inferiority Clinical Trials (20 I 0) (draft guidance) re Citizen Petition from Baker & Hostetler, LLP"
09000064823167b4,Supporting & Related Material,FDA-2016-P-3418-0004,FDA-2016-P-3418,"Attachment 1 Xifaxan Prescribing Information re Citizen Petition from Baker & Hostetler, LLP"
09000064823167b5,Supporting & Related Material,FDA-2016-P-3418-0005,FDA-2016-P-3418,"Attachment 2 Waiver ofln Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System: Guidance for Industry (May 20 15) re Citizen Petition from Baker & Hostetler, LLP"
0900006482317139,Supporting & Related Material,FDA-2016-P-3418-0017,FDA-2016-P-3418,"Attachment 14 Guidance for Industry, Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs- General Considerations 21 (2014) (draft guidance) re Citizen Petition from Baker & Hostetler, LLP"
090000648234b80d,Supporting & Related Material,FDA-2016-P-3418-0083,FDA-2016-P-3418,"Attachment 6 A Randomized, Double-Blind, Placebo-Controlled Trial of Rifaximin To Prevent Travelers' Diarrhea re Citizen Petition from Baker & Hostetler, LLP"
090000648234b819,Supporting & Related Material,FDA-2016-P-3418-0095,FDA-2016-P-3418,"Attachment 18 Rifaximin-induced alteration of virulence of diarrhoea-producing Escherichia coli and Shigella sonnei re Citizen Petition from Baker & Hostetler, LLP"
090000648234b822,Supporting & Related Material,FDA-2016-P-3418-0104,FDA-2016-P-3418,"Attachment 27 Meta-analysis: antibiotic therapy for small intestinal bacterial overgrowth re Citizen Petition from Baker & Hostetler, LLP"
090000648234b823,Supporting & Related Material,FDA-2016-P-3418-0105,FDA-2016-P-3418,"Attachment 28 Review article: the antimicrobial effects of rifaximin on the gut microbiota re Citizen Petition from Baker & Hostetler, LLP"
090000648234b824,Supporting & Related Material,FDA-2016-P-3418-0106,FDA-2016-P-3418,"Attachment 29 Drug Absorption in Gastrointestinal Disease
and Surgery Clinical Pharmacokinetic and Therapeutic Implications re Citizen Petition from Baker & Hostetler, LLP"
0900006482345743,Supporting & Related Material,FDA-2016-P-3418-0031,FDA-2016-P-3418,"Attachment 28 Physiological Pharmaceutics: Barriers to Drug Absorption (2d ed. 2001) re Citizen Petition from Baker & Hostetler, LLP"
0900006482345755,Supporting & Related Material,FDA-2016-P-3418-0049,FDA-2016-P-3418,"Attachment 46 Concentration-Dependent Mycobacterium tuberculosis Killing and Prevention of Resistance by Rifampin, 51( 11) ANTIMICROBIAL AGENTS AND CHEMOTHER. 3781 (2007) re Citizen Petition from Baker & Hostetler, LLP"
0900006482345757,Supporting & Related Material,FDA-2016-P-3418-0051,FDA-2016-P-3418,"Attachment 48 Rifaximin: An Antibiotic with Important Biologic Effects, 15(1) MINI-REVIEWS IN MEDICINAL CHEMISTRY 1. 4 (2015) re Citizen Petition from Baker & Hostetler, LLP"
0900006482345758,Supporting & Related Material,FDA-2016-P-3418-0052,FDA-2016-P-3418,"Attachment 49 Antimicrobial Resistance Information for Health Professionals and Consumers re Citizen Petition from Baker & Hostetler, LLP"
090000648234575b,Supporting & Related Material,FDA-2016-P-3418-0055,FDA-2016-P-3418,"Attachment 52 Colonic Mucosal Microbiome Differs from Stool Microbiome in Cirrhosis and Hepatic Encephalopathy and Is Linked to Cognition and Inflammation, 303 AM. J. PHYSIOL. GASTROINTEST. LIVER PHYSIOL. G675 (2012) re Citizen Petition from Baker & Hostetler, LLP"
090000648234575d,Supporting & Related Material,FDA-2016-P-3418-0057,FDA-2016-P-3418,"Attachment 54 Rifaximin-Induced Alteration of Virulence ofDiarrhoea-Producing Escherichia coli and Shigella sonnei, 35(3) INT. J. ANTIMICROB. AGENTS 278 (2010) re Citizen Petition from Baker & Hostetler, LLP"
090000648234bb85,Supporting & Related Material,FDA-2016-P-3418-0079,FDA-2016-P-3418,"Attachment 2 PREVENTION AND TREATMENT OF TRAVELER'S DIARRHEA re Citizen Petition from Baker & Hostetler, LLP"
090000648234bc9e,Supporting & Related Material,FDA-2016-P-3418-0113,FDA-2016-P-3418,"Attachment 36 Rifaximin Is Safe and Well Tolerated for long-term Maintenance of Remission From Overt Hepatic Encephalopathy re Citizen Petition from Baker & Hostetler, LLP"
090000648234bca2,Supporting & Related Material,FDA-2016-P-3418-0117,FDA-2016-P-3418,"Attachment 40 Relevant role of efflux pumps in high levels of rifaximin resistance in Escherichia coli clinical isolates re Citizen Petition from Baker & Hostetler, LLP"
090000648234a29c,Supporting & Related Material,FDA-2016-P-3418-0075,FDA-2016-P-3418,"JOHNSON AFFIDAVIT re Citizen Petition from Baker & Hostetler, LLP"
0900006482344a39,Other,FDA-2016-P-3418-0002,FDA-2016-P-3418,Acknowledgment Letter from FDA DDM to Baker & Hostetler LLP
09000064823459c4,Supporting & Related Material,FDA-2016-P-3418-0071,FDA-2016-P-3418,"Attachment 68 Guidance for Industry, Bioavailablity and Bioequivalence Studies for Orally administered Drug Products- General Considerations (2003) re Citizen Petition from Baker & Hostetler, LLP"
0900006482317132,Supporting & Related Material,FDA-2016-P-3418-0010,FDA-2016-P-3418,"Attachment 7 Approved Drug Products with Therapeutic Equivalence Evaluations vii-viii (36th ed. 2016) re Citizen Petition from Baker & Hostetler, LLP"
0900006482317134,Supporting & Related Material,FDA-2016-P-3418-0012,FDA-2016-P-3418,"Attachment 9 Abbreviated New Drug Application Regulations, 57 Fed. Reg. at 17,950 (Apr. 28, 1992) re Citizen Petition from Baker & Hostetler, LLP"
0900006482317135,Supporting & Related Material,FDA-2016-P-3418-0013,FDA-2016-P-3418,"Attachment 10 Letter from Janet Woodcock, M.D. to A. Peter Frank, Docket No. 92P-0487, 12 (June 17, 1997) re Citizen Petition from Baker & Hostetler, LLP"
090000648325863b,Supporting & Related Material,FDA-2018-P-1846-0057,FDA-2018-P-1846,Reference 53 Eibye - Persistent genital arousal disorder confluent patient history (Case Rep Psychiatry 2014) re Citizen Petition from Data Based Medicine Americas Ltd
090000648325832b,Supporting & Related Material,FDA-2018-P-1846-0028,FDA-2018-P-1846,Reference 24 Akasheh - Comparison of the effect of sertraline with behavioral therapy (Urology 2014) re Citizen Petition from Data Based Medicine Americas Ltd
090000648325832f,Supporting & Related Material,FDA-2018-P-1846-0032,FDA-2018-P-1846,Reference 28 Lareb - SSRIs and persistent sexual dysfunction (2012) re Citizen Petition from Data Based Medicine Americas Ltd
0900006483258333,Supporting & Related Material,FDA-2018-P-1846-0036,FDA-2018-P-1846,Reference 32 Hogan - 120 cases of enduring sexual dysfunction (Int J Risk Saf Med 2014) re Citizen Petition from Data Based Medicine Americas Ltd
09000064832585fc,Supporting & Related Material,FDA-2018-P-1846-0006,FDA-2018-P-1846,Reference 2 Yilmaz - The effects of fluoxetine on several neurophysiological variables (J Urol 1999) re Citizen Petition from Data Based Medicine Americas Ltd
0900006483258606,Supporting & Related Material,FDA-2018-P-1846-0008,FDA-2018-P-1846,Reference 4 Measom - Penile anaesthesia and fluoxetine (Am J Psychiatry 1992) re Citizen Petition from Data Based Medicine Americas Ltd
0900006483258609,Supporting & Related Material,FDA-2018-P-1846-0011,FDA-2018-P-1846,Reference 7 Diesenhammer - Penile anesthesia associated with sertraline use (J Clin Psychiatry 1999) re Citizen Petition from Data Based Medicine Americas Ltd
090000648325862b,Supporting & Related Material,FDA-2018-P-1846-0044,FDA-2018-P-1846,Reference 40 Raap - Sustained desensitization of 5-HT1A receptors (J Pharmacol Exp Ther 1999) re Citizen Petition from Data Based Medicine Americas Ltd
090000648325862d,Supporting & Related Material,FDA-2018-P-1846-0046,FDA-2018-P-1846,Reference 42 de Jong - Effects of chronic treatment with fluvoxamine and paroxetine (Eur Neuropsychopharmacol 2006) re Citizen Petition from Data Based Medicine Americas Ltd
0900006483258634,Supporting & Related Material,FDA-2018-P-1846-0050,FDA-2018-P-1846,Reference 46 Leiblum - Persistent sexual arousal syndrome a newly discovered pattern (J Sex Marital Ther 2001) re Citizen Petition from Data Based Medicine Americas Ltd
09000064832585f5,Other,FDA-2018-P-1846-0001,FDA-2018-P-1846,Citizen Petition from Data Based Medicine Americas Ltd
0900006483258329,Supporting & Related Material,FDA-2018-P-1846-0027,FDA-2018-P-1846,Reference 23 Koyuncu - Escitalopram for premature ejaculation has negative effect on semen (Int J Impot Res 2011) re Citizen Petition from Data Based Medicine Americas Ltd
090000648325860a,Supporting & Related Material,FDA-2018-P-1846-0012,FDA-2018-P-1846,Reference 8 Michael - Fluoxetine-induced anaesthesia of vagina and nipples (Br J Psychiatry 2000) re Citizen Petition from Data Based Medicine Americas Ltd
090000648325860d,Supporting & Related Material,FDA-2018-P-1846-0015,FDA-2018-P-1846,Reference 11 Csoka - Persistent sexual side effects after SSRI discontinuation (Psychother Psychosom 2006) re Citizen Petition from Data Based Medicine Americas Ltd
090000648325860e,Supporting & Related Material,FDA-2018-P-1846-0016,FDA-2018-P-1846,Reference 12 Bahrick - Post SSRI sexual dysfunction (ASAP Tablet 2006) re Citizen Petition from Data Based Medicine Americas Ltd
090000648325860f,Supporting & Related Material,FDA-2018-P-1846-0017,FDA-2018-P-1846,Reference 13 Montejo - Sexual dysfunction with antidepressive agents (Actas Esp Psiquiatr 1999) re Citizen Petition from Data Based Medicine Americas Ltd
0900006483258632,Supporting & Related Material,FDA-2018-P-1846-0048,FDA-2018-P-1846,Reference 44 Gouvêa - Maternal exposure to the antidepressant fluoxetine (Pharmacol Biochem Behav 2008) re Citizen Petition from Data Based Medicine Americas Ltd
090000648325863e,Supporting & Related Material,FDA-2018-P-1846-0058,FDA-2018-P-1846,Reference 54 de MagalhÆes - Persistent genital arousal disorder following SSRI cessation (J Clin Psychopharmacol 2015) re Citizen Petition from Data Based Medicine Americas Ltd
0900006483258635,Supporting & Related Material,FDA-2018-P-1846-0051,FDA-2018-P-1846,Reference 47 Freed - Persistent sexual arousal syndrome (J Sex Med 2005) re Citizen Petition from Data Based Medicine Americas Ltd
0900006483258326,Supporting & Related Material,FDA-2018-P-1846-0024,FDA-2018-P-1846,Reference 20 Tanrikut - Adverse effect of paroxetine on sperm (Fertil Steril 2010) re Citizen Petition Healy
0900006483258334,Supporting & Related Material,FDA-2018-P-1846-0037,FDA-2018-P-1846,Reference 33 Waldinger - Penile anesthesia in PSSD responds to low-power laser irradiation (Eur J Pharmacol 2015) re Citizen Petition from Data Based Medicine Americas Ltd
09000064832585fd,Supporting & Related Material,FDA-2018-P-1846-0007,FDA-2018-P-1846,Reference 3 Neill - Penile anesthesia associated with fluoxetine use (Am J Psychiatry 1991) re Citizen Petition from Data Based Medicine Americas Ltd
0900006483258608,Supporting & Related Material,FDA-2018-P-1846-0010,FDA-2018-P-1846,Reference 6 Ellison - Fluoxetine-induced genital anesthesia relieved by Ginkgo biloba extract (J Clin Psychiatry 1998) re Citizen Petition from Data Based Medicine Americas Ltd
090000648325860c,Supporting & Related Material,FDA-2018-P-1846-0014,FDA-2018-P-1846,Reference 10 Bolton - Genital anaesthesia persisting six years after sertraline (J Sex Marital Ther 2006) re Citizen Petition from Data Based Medicine Americas Ltd
0900006483258625,Supporting & Related Material,FDA-2018-P-1846-0038,FDA-2018-P-1846,Reference 34 Ben-Sheetrit - Post-SSRI sexual dysfunction clinical characterization (J Clin Psychopharmacol 2015) re Citizen Petition from Data Based Medicine Americas Ltd
09000064819edd4a,Supporting & Related Material,FDA-2015-P-0335-0003,FDA-2015-P-0335,Attach 1
09000064819edcb7,Other,FDA-2015-P-0335-0002,FDA-2015-P-0335,Acknowledgement Letter from FDA DDM to Chrai Associates Inc.
09000064819edd4b,Supporting & Related Material,FDA-2015-P-0335-0004,FDA-2015-P-0335,Attach 2
09000064819e6fa5,Other,FDA-2015-P-0335-0001,FDA-2015-P-0335,"Citizen Petition From Chrai Associates, Inc."
09000064819edd4c,Supporting & Related Material,FDA-2015-P-0335-0005,FDA-2015-P-0335,Attach 3
090000648314b203,Other,FDA-2015-P-3364-0005,FDA-2015-P-3364,Citizen Petition Response from FDA CDRH  to Dr. Leroy L. Hamilton
0900006481c6dcf6,Other,FDA-2015-P-3364-0002,FDA-2015-P-3364,Acknowledgement Letter from FDA DDM to Dr. Leroy Hamilton
0900006482071606,Other,FDA-2015-P-3364-0003,FDA-2015-P-3364,Interim Response Letter from CDRH to Leory Hamilton
0900006483148f5b,Other,FDA-2015-P-3364-0004,FDA-2015-P-3364,Citizen Petition Denial  Response from FDA CDRH to  Leroy L Hamilton PhD
0900006481c6dcf4,Other,FDA-2015-P-3364-0001,FDA-2015-P-3364,Citizen Petition from Dr. Leroy Hamilton
0900006482f1a4aa,Supporting & Related Material,FDA-2018-P-0670-0004,FDA-2018-P-0670,"Attachment B AKORN, Inc 505(b)(2) approval letter re Citizen Petition from Lachman Consultant Services, Inc"
0900006482f1a4ab,Supporting & Related Material,FDA-2018-P-0670-0005,FDA-2018-P-0670,"Attachment C Paragon Bioteck, Inc 505(b)(2) approval letter Citizen Petition from Lachman Consultant Services, Inc"
0900006483103c15,Other,FDA-2018-P-0670-0006,FDA-2018-P-0670,"Supplement from Paragon Bioteck, Inc. (Sidley Austin LLP)"
0900006483aa8e4b,Other,FDA-2018-P-0670-0009,FDA-2018-P-0670,Meeting on User Fee Issue for Approved Product
0900006482f1a616,Other,FDA-2018-P-0670-0001,FDA-2018-P-0670,"Citizen Petition from Lachman Consultant Services, Inc"
09000064832c50a7,Other,FDA-2018-P-0670-0007,FDA-2018-P-0670,"Supplement to Citizen Petition from Paragon Bioteck, Inc."
090000648352e537,Other,FDA-2018-P-0670-0008,FDA-2018-P-0670,Interim Response Letter FDA-2018-P-0670
0900006482f1a4a9,Supporting & Related Material,FDA-2018-P-0670-0003,FDA-2018-P-0670,"Attachment A Orange Book Listing for Paragon and AKORN re Citizen Petition from Lachman Consultant Services, Inc"
0900006482f1a618,Other,FDA-2018-P-0670-0002,FDA-2018-P-0670,"Acknowledgment Letter from FDA DDM to Lachman Consultant Services, Inc"
0900006483da707d,Other,FDA-2018-P-0670-0010,FDA-2018-P-0670,Withdrawal from Sean Griffin
09000064827c17fa,Supporting & Related Material,FDA-2017-P-3989-0003,FDA-2017-P-3989,"Attachment 1 Orange Book NDA 204447 re Citizen Petition from Lachman Consultant Services, Inc"
0900006482c98c59,Notice,FDA-2017-P-3989-0006,FDA-2017-P-3989,"Determination That TRINTELLIX (Vortioxetine Hydrobromide) Oral
Tablet, EQ 15 Milligram Base, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
0900006482c9fae3,Other,FDA-2017-P-3989-0007,FDA-2017-P-3989,Petition Response Letter
09000064827bb43f,Other,FDA-2017-P-3989-0002,FDA-2017-P-3989,"Acknowledgement Letter from FDA DDM to Lachman Consultant Services, Inc"
09000064827bb6dd,Other,FDA-2017-P-3989-0001,FDA-2017-P-3989,"Citizen Petition from Lachman Consultant Services, Inc"
09000064827c17fc,Supporting & Related Material,FDA-2017-P-3989-0005,FDA-2017-P-3989,"Attachment 3 PPI 3-2017 NDA204447 re Citizen Petition from Lachman Consultant Services, Inc"
09000064827c17fb,Supporting & Related Material,FDA-2017-P-3989-0004,FDA-2017-P-3989,"Attachment 2 PPI 9-2016 NDA204447 re Citizen Petition from Lachman Consultant Services, Inc"
0900006482563db1,Other,FDA-2017-P-2496-0002,FDA-2017-P-2496,"Acknowledgement Letter from FDA DDM to KVK-Tech, Inc. (Abhai, LLC)"
0900006482b0f6c8,Notice,FDA-2017-P-2496-0004,FDA-2017-P-2496,"Determination That RITALIN LA (Methylphenidate Hydrochloride)
Extended-Release Capsules, 60 Milligrams, Were Not Withdrawn From
Sale for Reasons of Safety or Effectiveness"
0900006482563daf,Other,FDA-2017-P-2496-0001,FDA-2017-P-2496,"Citizen Petition from KVK-Tech, Inc. (Abhai, LLC)"
0900006482b11446,Other,FDA-2017-P-2496-0005,FDA-2017-P-2496,Letter from FDA to KVK-Tech Inc
0900006482563f65,Supporting & Related Material,FDA-2017-P-2496-0003,FDA-2017-P-2496,"Attachment 1 Orange Book Approved Drug Products with Therapeutic Equivalence Evaluations re Citizen Petition from KVK-Tech Inc (Abhai, LLC)"
0900006483d5d8ea,Other,FDA-2019-P-3232-0001,FDA-2019-P-3232,Citizen Petition from Lachman Consultants
09000064842394d5,Other,FDA-2019-P-3232-0004,FDA-2019-P-3232,Interim Response Letter from FDA CDER to Lachman Consultants
0900006483d5de28,Supporting & Related Material,FDA-2019-P-3232-0003,FDA-2019-P-3232,Attachment A- Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations re Citizen Petition from Lachman Consultants
0900006483d5d8f0,Other,FDA-2019-P-3232-0002,FDA-2019-P-3232,Acknowledgment Letter from FDA DDM to Lachman Consultants
0900006484aa50c7,Supporting & Related Material,FDA-2021-P-0339-0003,FDA-2021-P-0339,Attachment-I Orange Book Approved Drug Products with Therapeutic Equivalence Evaluations re Citizen Petition from Gland Pharma Limited
0900006484a88294,Other,FDA-2021-P-0339-0001,FDA-2021-P-0339,Citizen Petition from Gland Pharma Limited
0900006484ae18cd,Other,FDA-2021-P-0339-0004,FDA-2021-P-0339,Withdrawal from Gland Pharma Limited
0900006484a88297,Other,FDA-2021-P-0339-0002,FDA-2021-P-0339,Acknowledgment Letter from FDA DMS to Gland Pharma Limited
0900006481edb5ec,Supporting & Related Material,FDA-2016-P-1073-0014,FDA-2016-P-1073,"Attachment 11- Minh-Nguyet Tran et al., Alcohol dehydrogenase and catalase content in perinatal infant and adult livers: Potential influence on neonatal alcohol metabolism, 169 Toxicology Letters 245 (2007) re Citizen Petition from PAR Pharmaceutical"
0900006481edb367,Supporting & Related Material,FDA-2016-P-1073-0007,FDA-2016-P-1073,"Attachment 4 - Committee for Human Medicinal Products, Questions and Answers on Ethanol in the context of the revision of the guideline on 'Excipients in the label and package leaflet of medicinal products for human use', Eur. Med. Agency (20 14) re Citizen Petition from PAR Pharmaceutical"
0900006481edb36a,Supporting & Related Material,FDA-2016-P-1073-0011,FDA-2016-P-1073,Attachment 8 - FAMHP Position on Ethanol Content in Medicinal Products Used in Children (including herbal medicinal products and homeopathic medicinal re Citizen Petition from PAR Pharmaceutical
0900006481eea3b1,Supporting & Related Material,FDA-2016-P-1073-0009,FDA-2016-P-1073,"Attachment 6 Committee on Herbal Medicinal Products, Reflection Paper on Ethanol Content in Herbal Medicinal Products and Traditional Herbal Medicinal Products Used in Children, Eur. Med. Agency (20 1 0) re Citizen Petition from PAR Pharmaceutical"
0900006481edb5ef,Supporting & Related Material,FDA-2016-P-1073-0017,FDA-2016-P-1073,"Attachment 14 - Raymond C. Rowe et al., Handbook of Pharmaceutical Excipients, (ih ed. 2012) re Citizen Petition from PAR Pharmaceutical"
0900006481edb5f0,Supporting & Related Material,FDA-2016-P-1073-0018,FDA-2016-P-1073,"Attachment 15- Sofya Pugach & Isaac Z. Pugach, Overdose in Infant Caused by Over-theCounter Cough Medicine, 102 S. Med. J. 440, (2009) re Citizen Petition from PAR Pharmaceutical"
0900006482287007,Other,FDA-2016-P-1073-0020,FDA-2016-P-1073,Citizen Petition Interim Response from FDA CDER to PAR Pharmaceutical
0900006481edb366,Supporting & Related Material,FDA-2016-P-1073-0006,FDA-2016-P-1073,"Attachment 3 - Chen-Chang Yang et al., Hypoglycemia Following Ethanol Ingestion in Children: Report of a Case, 94 J Formos Med. Ass'n 267 (1995) re Citizen Petition from PAR Pharmaceutical"
0900006481edb5ee,Supporting & Related Material,FDA-2016-P-1073-0016,FDA-2016-P-1073,"Attachment 13- P.H. Pikkarainen & N.C.R. Raiha, Development of Alcohol Dehydrogenase Activity in the Human Liver, 1 Pediatric Res. 165 (1967) re Citizen Petition from PAR Pharmaceutical"
0900006481edb369,Supporting & Related Material,FDA-2016-P-1073-0010,FDA-2016-P-1073,"Attachment 7 - Elizabeth Marek & Walter K. Kraft, Ethanol Pharmacokinetics in Neonates and Infants re Citizen Petition from PAR Pharmaceutical"
0900006481edb72e,Other,FDA-2016-P-1073-0002,FDA-2016-P-1073,Acknowledgement Letter from FDA DDM to PAR Pharmaceutical
0900006481edb36b,Supporting & Related Material,FDA-2016-P-1073-0012,FDA-2016-P-1073,"Attachment 9 - Francis Avery Ragan, Jr. et al., Ethanol Ingestion in Children, 242 JAMA 2787 (1979) re Citizen Petition from PAR Pharmaceutical"
0900006481edb5eb,Supporting & Related Material,FDA-2016-P-1073-0013,FDA-2016-P-1073,"Attachment 10 - Gian Vincenzo Zuccotti & Valentina Fabiano, Safety issues with ethanol as an excipient in drugs intended for pediatric use, Expert Opinion Drug Safety, 499, (2011) re Citizen Petition from PAR Pharmaceutical"
0900006481edb5ed,Supporting & Related Material,FDA-2016-P-1073-0015,FDA-2016-P-1073,"Attachment 12 - Nanna Christiansen, Ethanol exposure through medicines commonly used in paediatrics, 100 Arch Dis Child Educ Pract Ed 101 (20 15) re Citizen Petition from PAR Pharmaceutical"
0900006483e7068d,Other,FDA-2016-P-1073-0021,FDA-2016-P-1073,Withdrawal from PAR Pharmaceutical
0900006481edb363,Supporting & Related Material,FDA-2016-P-1073-0003,FDA-2016-P-1073,Appendix re Citizen Petition from PAR Pharmaceutical
0900006481edb364,Supporting & Related Material,FDA-2016-P-1073-0004,FDA-2016-P-1073,"Attachment 1 - A Fiocchi et al., Ethanol in Medicines and Other Products Intended for Children: Commentary on a Medical Paradox, 3 Nutrition Res. 373 (1999) re Citizen Petition from PAR Pharmaceutical"
0900006481edb368,Supporting & Related Material,FDA-2016-P-1073-0008,FDA-2016-P-1073,"Attachment 5 - Committee on Drugs, Ethanol in Liquid Preparations Intendedfor Children, 73 Official J. Am. Acad. Pediatrics 405 (1984) re Citizen Petition from PAR Pharmaceutical"
0900006481edb365,Supporting & Related Material,FDA-2016-P-1073-0005,FDA-2016-P-1073,"Attachment 2 - A. Whittaker et al., Toxic Additives in Medication for Preterm Infants, 94 Arch Dis Child Fetal Neonatal Ed F236 (2009) re Citizen Petition from PAR Pharmaceutical"
0900006481edb5f1,Supporting & Related Material,FDA-2016-P-1073-0019,FDA-2016-P-1073,"Attachment 16  - The Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals (Maryadele J. O'Neil ed., 15th ed. 2013) re Citizen Petition from PAR Pharmaceutical"
0900006481edb579,Other,FDA-2016-P-1073-0001,FDA-2016-P-1073,Citizen Petition from PAR Pharmaceutical
09000064836530da,Other,FDA-2018-P-1361-0004,FDA-2018-P-1361,Agency Response Letter from FDA CDER to Ajanta Pharma USA Inc.
090000648308a188,Other,FDA-2018-P-1361-0001,FDA-2018-P-1361,Acknowledgment Letter from FDA DDM to  Ajanta Pharma USA inc.
0900006483642a96,Notice,FDA-2018-P-1361-0003,FDA-2018-P-1361,"Determination That DITROPAN XL (Oxybutynin Chloride) Extended
Release Tablets, 15 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
0900006483088b00,Other,FDA-2018-P-1361-0002,FDA-2018-P-1361,Citizen Petition from Ajanta Pharma USA Inc.
0900006484864035,Other,FDA-2017-P-6291-0004,FDA-2017-P-6291,"Letter from FDA CDER to Lachman Consultants Services Inc. and Teligent Pharma, Inc. and Hyman, Phelps & McNamara, P.C."
09000064831eb224,Other,FDA-2017-P-6291-0003,FDA-2017-P-6291,Interim Response Letter from FDA CDER to Lachman Consultants
0900006482c155e5,Other,FDA-2017-P-6291-0002,FDA-2017-P-6291,Acknowledgement Letter from FDA DDM to Lachman Consultants Services Inc
0900006482c14cf8,Other,FDA-2017-P-6291-0001,FDA-2017-P-6291,"CITIZEN PETITION FROM  LACHMAN CONSULTANT SERVICES, INC"
0900006483d300fd,Other,FDA-2019-P-2998-0001,FDA-2019-P-2998,Citizen Petition from SONAR
0900006484829981,Other,FDA-2019-P-2998-0104,FDA-2019-P-2998,Final Response Letter from FDA CDER to Southern Network on Adverse Reactions (SONAR)
0900006483d30594,Other,FDA-2019-P-2998-0002,FDA-2019-P-2998,Acknowledgment Letter from FDA DDM to SONAR
0900006483d30596,Supporting & Related Material,FDA-2019-P-2998-0003,FDA-2019-P-2998,Attachment 1 Highlights of Prescribing Information for Levaquin re Citizen Petition from SONAR
0900006483d30597,Supporting & Related Material,FDA-2019-P-2998-0004,FDA-2019-P-2998,Attachment 2 Floxed Map Summary re Citizen Petition from SONAR
0900006483d30598,Supporting & Related Material,FDA-2019-P-2998-0005,FDA-2019-P-2998,"Attachment 3 FDA's Safety Announcement (July 10, 2008) re Citizen Petition from SONAR"
090000648421fb6c,Other,FDA-2019-P-2998-0006,FDA-2019-P-2998,Interim Response Letter from FDA CDER to SONAR
0900006484285349,Other,FDA-2020-P-0152-0002,FDA-2020-P-0152,"Acknowledgment Letter from FDA DMS to Hyman, Phelps & McNamara, P.C. on behalf of Coalition to Preserve Access to PGx Information"
09000064846dc096,Other,FDA-2020-P-0152-0006,FDA-2020-P-0152,"Petition Interim Response from CDRH to Hyman, Phelps & McNamara, P.C."
0900006484285295,Other,FDA-2020-P-0152-0001,FDA-2020-P-0152,"Citizen Petition from Hyman, Phelps & McNamara, P.C. on behalf of Coalition to Preserve Access to PGx Information"
0900006480afb800,Other,FDA-2009-P-0105-0003,FDA-2009-P-0105,"Interim Response to Williams Kherkher Hart Boundas, LLP"
09000064808b7516,Other,FDA-2009-P-0105-0001,FDA-2009-P-0105,"Williams Kherkher Hart Boundas, LLP - Citizen Petition"
09000064808b8ec0,Other,FDA-2009-P-0105-0002,FDA-2009-P-0105,"Acknowledgement Letter to Williams Kherkher Hart Boundas, LLP"
0900006483d3a493,Supporting & Related Material,FDA-2019-P-3024-0004,FDA-2019-P-3024,Attachment 2- Highlights of Prescribing Information re Citizen Petition from Foley & Lardner LLP
0900006483d3a917,Other,FDA-2019-P-3024-0001,FDA-2019-P-3024,Citizen Petition from Foley & Lardner LLP
0900006483d3ab88,Supporting & Related Material,FDA-2019-P-3024-0005,FDA-2019-P-3024,Attachment 3- Highlights of Prescribing Information re Citizen Petition from Foley & Lardner LLP
0900006483d3a91e,Other,FDA-2019-P-3024-0002,FDA-2019-P-3024,Acknowledgment Letter from FDA DDM to Foley & Lardner LLP
0900006484d456a5,Other,FDA-2019-P-3024-0007,FDA-2019-P-3024,Withdrawal from Foley and Lardner LLP
0900006483d3ab8a,Supporting & Related Material,FDA-2019-P-3024-0006,FDA-2019-P-3024,Attachment 4- Acknowledgment Receipt of Submission Letter re Citizen Petition from Foley & Lardner LLP
0900006483d3a492,Supporting & Related Material,FDA-2019-P-3024-0003,FDA-2019-P-3024,Attachment 1- Approved Drug Products with Therapeutic Equivalence Evaluations re Citizen Petition from Foley & Lardner LLP
09000064821ead1f,Supporting & Related Material,FDA-2016-P-2676-0003,FDA-2016-P-2676,"Attachment 1 New England Natural Bakers Inc. Issues Voluntary Allergy
Alert on Undeclared Milk, Wheat and Tree Nuts (Pecans) in Coconut Cranberry Granola re Citizen Petition from Joshua Schroeder"
09000064821ea4f2,Other,FDA-2016-P-2676-0001,FDA-2016-P-2676,Citizen Petition from Joshua Schroeder
090000648397814f,Other,FDA-2016-P-2676-0005,FDA-2016-P-2676,Letter from FDA CFSAN to Joshua Schroeder
09000064824e4907,Other,FDA-2016-P-2676-0004,FDA-2016-P-2676,Interim Response Letter from CFSAN to Joshua Schroeder
09000064821ead1c,Other,FDA-2016-P-2676-0002,FDA-2016-P-2676,Acknowledgment Letter from FDA DDM to Joshua Schroeder
09000064820944d6,Other,FDA-2016-P-1962-0001,FDA-2016-P-1962,"Citizen Petition from Hyman, Phelps & McNamara, PC (Allergan plc)"
09000064820944dc,Other,FDA-2016-P-1962-0002,FDA-2016-P-1962,"Acknowledgement Letter from FDA DDM to Hyman, Phelps & McNamara, PC"
09000064835019a1,Other,FDA-2016-P-1962-0005,FDA-2016-P-1962,FDA-2016-P-1962 Response to Comments
0900006482431e45,Other,FDA-2016-P-1962-0003,FDA-2016-P-1962,"Interim Response Letter from FDA CDER to Hyman, Phelps & McNamara, PC"
09000064839d2016,Other,FDA-2016-P-1962-0006,FDA-2016-P-1962,"Letter from FDA CDER to Hyman, Phelps, and McNamara, P.C."
09000064839ac1b9,Other,FDA-2018-P-1720-0005,FDA-2018-P-1720,"Letter from FDA CDER to Akorn Pharmaceuticals, Mylan Pharmaceuticals, Inc., Gland Pharma Limited, Foley & Lardner LLP"
0900006483221221,Supporting & Related Material,FDA-2018-P-1720-0003,FDA-2018-P-1720,Annexure - I Orange Book_ Approved Drug Products with Therapeutic Equivalence Evaluations re Citizen Petition from Gland Pharma Limited
090000648322121f,Other,FDA-2018-P-1720-0002,FDA-2018-P-1720,Acknowledgment Letter from FDA DDM to Gland Pharma Limited
090000648322121d,Other,FDA-2018-P-1720-0001,FDA-2018-P-1720,Citizen Petition from Gland Pharma Limited
09000064838e0bac,Other,FDA-2018-P-1720-0004,FDA-2018-P-1720,Letter from FDA CDER to Gland Pharma Limited
0900006482b0c581,Notice,FDA-2017-P-1459-0003,FDA-2017-P-1459,"Determination That ENJUVIA (Estrogens, Conjugated Synthetic B) Tablets, 0.625 Milligrams and 1.25 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
0900006482b119f9,Other,FDA-2017-P-1459-0005,FDA-2017-P-1459,Letter from FDA to Foley & Lardner LLP
09000064824fc1b7,Other,FDA-2017-P-1459-0001,FDA-2017-P-1459,Citizen Petition from Foley & Lardner LLP
09000064824fc1b9,Other,FDA-2017-P-1459-0002,FDA-2017-P-1459,Acknowledgement Letter from FDA DDM to Foley & Lardner LLP
0900006482b0f909,Other,FDA-2017-P-1459-0004,FDA-2017-P-1459,Letter from FDA to Foley & Lardner LLP
0900006481d09345,Supporting & Related Material,FDA-2015-P-3621-0003,FDA-2015-P-3621,Product Labeling for Vancoled re Citizen Petition from Hospira
0900006481d09346,Supporting & Related Material,FDA-2015-P-3621-0004,FDA-2015-P-3621,Proposed Labeling for Vancomycin Hydrochloride re Citizen Petition from Hospira
0900006481d09344,Supporting & Related Material,FDA-2015-P-3621-0002,FDA-2015-P-3621,"September 16, 2015 Response Letter from FDA CDER to Hospira, Inc. re Citizen Petition from Hospira"
0900006481cb88a7,Other,FDA-2015-P-3621-0005,FDA-2015-P-3621,Acknowledgement Letter from FDA DDM to Hospira
0900006481dbf833,Other,FDA-2015-P-3621-0006,FDA-2015-P-3621,Response Letter from FDA CDER to Hospira
0900006481cb87f5,Other,FDA-2015-P-3621-0001,FDA-2015-P-3621,Citizen Petition from Hospira
090000648310e459,Other,FDA-2018-P-1469-0001,FDA-2018-P-1469,Citizen Petition from Epstein Becker & Green P.C. ( on behalf of Innovative Health Solutions Inc)
090000648310e8b7,Supporting & Related Material,FDA-2018-P-1469-0003,FDA-2018-P-1469,"Attachment A - Percutaneous Electrical Nerve Field Stimulation Modulates Central Pain Pathways and Attenuates Post- Inflammatory Visceral and Somatic Hyperalgesia in rats Re Citizen Petition from Epstein Becker & Green, P.C."
090000648310ece5,Supporting & Related Material,FDA-2018-P-1469-0004,FDA-2018-P-1469,"Attachment B- The American Journal of Drug and Alcohol Abuse re Citizens Petition from Epstein Becker & Green, P.C."
090000648310ecee,Supporting & Related Material,FDA-2018-P-1469-0005,FDA-2018-P-1469,"Attachment C- Neurostimulation from abdominal pain- related functional gastrointestinal disorders in adolescents: a randomized, double-blind, shame controlled trial re Citizen Petition from Epstein Becker & Green, P.C"
090000648310e45d,Other,FDA-2018-P-1469-0002,FDA-2018-P-1469,"Acknowledgment Letter from FDA DDM to Epstein Becker & Green, P.C."
090000648383d1bd,Other,FDA-2018-P-1469-0006,FDA-2018-P-1469,"Nerve Stimulators, Citizen Petition, Interim Response Letter Issued"
090000648430f6cf,Supporting & Related Material,FDA-2020-P-0511-0005,FDA-2020-P-0511,"Attachment 3 US Securities and Exchange Commission Form 20-F (Medicure, Inc.) re Citizen Petition from Novitium Pharma LLC"
090000648430f6cd,Supporting & Related Material,FDA-2020-P-0511-0003,FDA-2020-P-0511,"Attachment 1 Orange Book: Approved Drug Products with Therapeutic
Equivalence Evaluations re Citizen Petition from Novitium Pharma LLC"
090000648430f589,Other,FDA-2020-P-0511-0001,FDA-2020-P-0511,Citizen Petition from Novitium Pharma LLC
0900006484873043,Supporting & Related Material,FDA-2020-P-0511-0008,FDA-2020-P-0511,Relisting Notice_PREXXARTAN (Valsartan) Oral Solution
0900006484872fe4,Other,FDA-2020-P-0511-0007,FDA-2020-P-0511,Response letter from FDA CDER to Novitium Pharma LLC
090000648430f58a,Other,FDA-2020-P-0511-0002,FDA-2020-P-0511,Acknowledgment Letter from FDA DMS to Novitium Pharma LLC
09000064847c5866,Other,FDA-2020-P-0511-0006,FDA-2020-P-0511,Interim Response letter from FDA CDER to Novitium Pharma LLC
090000648430f6ce,Supporting & Related Material,FDA-2020-P-0511-0004,FDA-2020-P-0511,Attachment 2 FDA Email from RA Office re Citizen Petition from Novitium Pharma LLC
09000064848fdf52,Other,FDA-2020-P-2077-0001,FDA-2020-P-2077,Suitability Petition from The Weinberg Group LLC
09000064848fd8a4,Supporting & Related Material,FDA-2020-P-2077-0003,FDA-2020-P-2077,"Attachment 1 Approved Drug Products with Therapeutic Equivalence Evaluations, Electronic Orange Book accessed on August 13, 2020.
re: Suitability Petition from The Weinberg Group LLC"
09000064848fd8a6,Supporting & Related Material,FDA-2020-P-2077-0005,FDA-2020-P-2077,"Attachment 3 Proposed Prescribing Information for Vasopressin Injection USP, 50 units/2.5 mL (2.5 mL/vial in a single dose vial) and 100 units/5 mL (5 mL/vial in a single dose vial). :re: Suitability Petition from The Weinberg Group LLC"
09000064848fd8a5,Supporting & Related Material,FDA-2020-P-2077-0004,FDA-2020-P-2077,"Attachment 2  Labeling for the RLD, Vasostrict® (Vasopressin Injection USP), 20 Units/mL (single-dose vial), NDA # 204485, approved on April 15, 2020. re: Suitability Petition from The Weinberg Group LLC,"
09000064848fd833,Other,FDA-2020-P-2077-0002,FDA-2020-P-2077,Acknowledgment Letter from FDA DMS to The Weinberg Group LLC
09000064846ff4f8,Other,FDA-2020-P-1605-0002,FDA-2020-P-1605,"Acknowledgment Letter from FDA DMS to Novitium Pharma, LLC"
09000064848f2132,Other,FDA-2020-P-1605-0003,FDA-2020-P-1605,"Withdrawal from Novitium Pharma, LLC"
09000064846ff4f7,Other,FDA-2020-P-1605-0001,FDA-2020-P-1605,"Citizen Petition from Novitium Pharma, LLC"
0900006484c0ac69,Other,FDA-2021-P-0784-0001,FDA-2021-P-0784,Suitability Citizen Petition from Lachman Consultant Services Inc.
0900006484c0acbf,Other,FDA-2021-P-0784-0002,FDA-2021-P-0784,Acknowledgement Letter from FDA DMS to Lachman Consultant Services Inc
090000648046fe91,Other,FDA-2004-P-0146-0002,FDA-2004-P-0146,HFA-305 to Heller Ehrman Attorneys
090000648046fe86,Other,FDA-2004-P-0146-0001,FDA-2004-P-0146,HFA-305 to Heller Ehrman Attorneys
090000648046fe96,Other,FDA-2004-P-0146-0003,FDA-2004-P-0146,HF-22 to White & McAuliffe LLP
0900006482bc19f9,Other,FDA-2017-P-6116-0001,FDA-2017-P-6116,Citizen Petition from King & Spalding LLP
0900006482bc1abb,Supporting & Related Material,FDA-2017-P-6116-0004,FDA-2017-P-6116,Attachment 2- Reference Listed Drug Prescribing Information for Bloxiverz- re Citizen Petition from King & Spalding LLP
0900006482bc1b4e,Supporting & Related Material,FDA-2017-P-6116-0005,FDA-2017-P-6116,Attachment 3 -Draft  labeling  for proposed  Neostigmine  Methylsulfate  Injection - re Citizen Petition from King & Spalding LLP
0900006482bc1ab6,Supporting & Related Material,FDA-2017-P-6116-0003,FDA-2017-P-6116,"Attachment 1- Approved  Drug Products with Therapeutic Equivalence  Evaluations  (Electronic Orange Book) for Bloxiverz, accessed 09/28/2017- re Citizen Petition from King & Spalding LLP"
0900006482bc1780,Other,FDA-2017-P-6116-0002,FDA-2017-P-6116,Acknowledgment Letter from FDA DDM to King & Spalding LLP
0900006483b52832,Supporting & Related Material,FDA-2019-P-1534-0008,FDA-2019-P-1534,Other Sources Group 3 Women's Health Analysis of Severe Adverse Events Related to the Use of Mifepristone as an Abortifacient Re:  American Association of Pro-Life Obstetricians and Gynecologists and American College of Pediatricians
0900006483b52834,Supporting & Related Material,FDA-2019-P-1534-0012,FDA-2019-P-1534,Other Sources Group 5 Court Records In the District Court in and for Oklahoma County State of Oklahoma Re: American Association of Pro-Life Obstetricians and Gynecologists and American College of Pediatricians
0900006483b54fc1,Supporting & Related Material,FDA-2019-P-1534-0005,FDA-2019-P-1534,FDA Documents Mifepristone U.S. Post-Marketing Adverse Events Summary through 12/31/2017 Re: American Association of Pro-Life Obstetricians and Gynecologists and American College of Pediatricians
0900006483b52833,Supporting & Related Material,FDA-2019-P-1534-0009,FDA-2019-P-1534,"Other Sources Group 4 DANIEL GROSSMAN, MD Research Protocol
ALTERNATIVE PROVISION OF MEDICATION ABORTION VIA PHARMACY DISPENSING Re:  American Association of Pro-Life Obstetricians and Gynecologists and American College of Pediatricians"
0900006483b52837,Supporting & Related Material,FDA-2019-P-1534-0013,FDA-2019-P-1534,Other Sources Group 7 Which Abortion Patients Have Had a Prior Abortion? Findings from the 2014 U.S. Abortion Patient Survey Re:  American Association of Pro-Life Obstetricians and Gynecologists and American College of Pediatricians
0900006483b52836,Supporting & Related Material,FDA-2019-P-1534-0010,FDA-2019-P-1534,Other Sources Group 6 Proposed Rule ARC 0891C to Amend IAC 653- Chapter 13 to Establish Standards of Practice for Physicians who Prescribe or Administer Abortion-inducing Drugs Re: American Association of Pro-Life Obstetricians and Gynecologists and American College of Pediatricians
0900006483b54819,Supporting & Related Material,FDA-2019-P-1534-0004,FDA-2019-P-1534,"Other Government Documents FOOD AND DRUG ADMINISTRATION
Information on Mifeprex Labeling Changes and Ongoing Monitoring
Efforts Re: American Association of Pro-Life Obstetricians and Gynecologists and American College of Pediatricians"
0900006483b5282f,Supporting & Related Material,FDA-2019-P-1534-0011,FDA-2019-P-1534,Exhibit B Attached References and Sources Re: American Association of Pro-Life Obstetricians and Gynecologists and American College of Pediatricians
0900006483b522b6,Other,FDA-2019-P-1534-0001,FDA-2019-P-1534,Citizen Petition from American Association of Pro-Life Obstetricians and Gynecologists and American College of Pediatricians
0900006483b52830,Supporting & Related Material,FDA-2019-P-1534-0006,FDA-2019-P-1534,Other Sources Group 1 The American College of Obstetricians and Gynecologists WOMEN’S HEALTH CARE PHYSICIANS PRACTICE BULLETIN CLINICAL MANAGEMENT GUIDELINES FOR OBSTETRICIAN–GYNECOLOGISTS Re: American Association of Pro-Life Obstetricians and Gynecologists and American College of Pediatricians
0900006483b5277b,Other,FDA-2019-P-1534-0002,FDA-2019-P-1534,Acknowledgment Letter from FDA DDM to American Association of Pro-Life Obstetricians and Gynecologists and American College of Pediatricians
0900006483fcee17,Other,FDA-2019-P-1534-0014,FDA-2019-P-1534,Interim Response Letter from FDA CDER to American Association of Pro-Life Obstetricians and Gynecologists and American College of Pediatricians
0900006483b5282e,Supporting & Related Material,FDA-2019-P-1534-0003,FDA-2019-P-1534,Exhibit A Current and Requested Language (from Mifeprex Label and Risk Evaluation and Mitigation Strategy) Re: American Association of Pro-Life Obstetricians and Gynecologists and American College of Pediatricians
0900006483b52831,Supporting & Related Material,FDA-2019-P-1534-0007,FDA-2019-P-1534,Other Sources Group 2 FamilyPlanning: Review Mifepristone With Buccal Misoprostol for Medical Abortion Re: American Association of Pro-Life Obstetricians and Gynecologists and American College of Pediatricians
09000064829da752,Supporting & Related Material,FDA-2017-P-4745-0011,FDA-2017-P-4745,Tab 9 - Molecular Pharmaceutics 2014 re Citizen Petition from Allergan
09000064829da757,Supporting & Related Material,FDA-2017-P-4745-0016,FDA-2017-P-4745,Tab 14 - Zheng Nan_2017 re Citizen Petition from Allergan
0900006482d91ad2,Other,FDA-2017-P-4745-0026,FDA-2017-P-4745,"Petition Denial Letter from FDA CDER to Allergan, Inc"
09000064829da74f,Supporting & Related Material,FDA-2017-P-4745-0008,FDA-2017-P-4745,Tab 6 - Choi_Clinical Pharmacokinetic and In Vitro Studies_2016 (2) re Citizen Petition from Allergan
09000064829da755,Supporting & Related Material,FDA-2017-P-4745-0014,FDA-2017-P-4745,Tab 12 - Department of Health and Human Services HHSF223201610105C To Physical Pharmaceutica LLC $281 re Citizen Petition from Allergan
09000064829da756,Supporting & Related Material,FDA-2017-P-4745-0015,FDA-2017-P-4745,Tab 13 - June 2017 Notice of Intent to Award a Contract Modification to Physical Pharmaceutica re Citizen Petition from Allergan
09000064829cb066,Other,FDA-2017-P-4745-0002,FDA-2017-P-4745,Acknowledgment Letter from FDA DDM to  Allergan
0900006482bc933d,Other,FDA-2017-P-4745-0023,FDA-2017-P-4745,Supplement from Allergan
09000064829da74e,Supporting & Related Material,FDA-2017-P-4745-0007,FDA-2017-P-4745,Tab 5 - Ophthalmology Management_ Nov 2016 re Citizen Petition from Allergan
09000064829da754,Supporting & Related Material,FDA-2017-P-4745-0013,FDA-2017-P-4745,Tab 11 - Wu et al FDA Abstract re Globule Size AND Petrochenko et al FDA Abstract re Globule Size Distribution re Citizen Petition from Allergan
09000064829da75b,Supporting & Related Material,FDA-2017-P-4745-0019,FDA-2017-P-4745,Tab 17 - Gottlieb To Be More Forceful Inside Health Policy re Citizen Petition from Allergan
09000064829da486,Supporting & Related Material,FDA-2017-P-4745-0004,FDA-2017-P-4745,Tab 2 - Gottlieb Forbes July 7  2014 re Citizen Petition from Allergan
09000064829da487,Supporting & Related Material,FDA-2017-P-4745-0005,FDA-2017-P-4745,Tab 3 - Hussaarts_et_al-2017-Annals_of_the_New_York_Academy_of_Sciences re Citizen Petition from Allergan
09000064829da750,Supporting & Related Material,FDA-2017-P-4745-0009,FDA-2017-P-4745,Tab 7 - Absar and Choi Scientific Considerations for Generic Cyclosporine Ophthalmic Emulsion In Vitro BE Studies re Citizen Petition from Allergan
09000064829da753,Supporting & Related Material,FDA-2017-P-4745-0012,FDA-2017-P-4745,Tab 10 - Absar and Choi Scientific Considerations for Generic Cyclosporine Ophthalmic Emulsion In Vitro BE Studies re Citizen Petition from Allergan
09000064829da759,Supporting & Related Material,FDA-2017-P-4745-0017,FDA-2017-P-4745,Tab 15 - House EC Committee ltr to GAO re Citizen Petition from Allergan
09000064829c8eef,Other,FDA-2017-P-4745-0001,FDA-2017-P-4745,Citizen Petition from Allergan
09000064829da488,Supporting & Related Material,FDA-2017-P-4745-0006,FDA-2017-P-4745,Tab 4 - Gore. Ocular Emulsion Gabi Review Article - 2017 (7) (2) re Citizen Petition from Allergan
09000064829da75c,Supporting & Related Material,FDA-2017-P-4745-0020,FDA-2017-P-4745,Tab 18 - Gottlieb tackles speculators FDA transparency  Endpoints News re Citizen Petition from Allergan re Citizen Petition from Allergan
0900006482a8d323,Other,FDA-2017-P-4745-0022,FDA-2017-P-4745,Acknowledgement Letter from FDA DDM to Allergan
09000064829da485,Supporting & Related Material,FDA-2017-P-4745-0003,FDA-2017-P-4745,Tab 1 - WA Chambers Ophthalmic Generkcs - Are They Really the Same re Citizen Petition from Allergan
09000064829da751,Supporting & Related Material,FDA-2017-P-4745-0010,FDA-2017-P-4745,Tab 8 - Lionberger Scientific Agenda Update Oct 26 2016 re Citizen Petition from Allergan
09000064829da75a,Supporting & Related Material,FDA-2017-P-4745-0018,FDA-2017-P-4745,Tab 16 - Allergan Comment to FDA regarding October 2016 Draft Guidance on Cyclosporine (with attachments) re Citizen Petition from Allergan
0900006482f96bf0,Other,FDA-2018-P-0998-0001,FDA-2018-P-0998,Citizen Petition from Hyman Phelps & McNamara P.C.
0900006482f9e8fa,Other,FDA-2018-P-0998-0002,FDA-2018-P-0998,Acknowledgment Letter from FDA DDM to Hyman Phelps & McNamara P.C.
09000064835fd123,Other,FDA-2018-P-0998-0004,FDA-2018-P-0998,"Letter from FDA CDER to Hyman, Phelps & McNamara, P.C."
09000064835f8c45,Notice,FDA-2018-P-0998-0003,FDA-2018-P-0998,"Determination That PROLIXIN (Fluphenazine Hydrochloride) Tablets,
1 Milligram, 2.5 Milligrams, 5 Milligrams, and 10 Milligrams, Was Not
Withdrawn From Sale for Reasons of Safety or Effectiveness"
0900006481a750b1,Supporting & Related Material,FDA-2015-P-1003-0003,FDA-2015-P-1003,Attachment B FR Determination of Safety and Effectiveness Citizen Petition From Lachman Consultant Services Inc.
0900006481a750b2,Supporting & Related Material,FDA-2015-P-1003-0004,FDA-2015-P-1003,Attachment C Current Labeling Citizen Petition From Lachman Consultant Services Inc.
0900006481a750b3,Supporting & Related Material,FDA-2015-P-1003-0005,FDA-2015-P-1003,Attachment D Proposed Labeling Citizen Petition from Lachman Consultant Services Inc.
0900006481a7358e,Other,FDA-2015-P-1003-0001,FDA-2015-P-1003,Citizen Petition From Lachman Consultant Services Inc.
0900006481a74fb6,Supporting & Related Material,FDA-2015-P-1003-0002,FDA-2015-P-1003,Attachment A Orange Book Listing Citizen Petition From Lachman Consultant Services Inc.
0900006481a74fb0,Other,FDA-2015-P-1003-0006,FDA-2015-P-1003,Acknowledgement Letter From FDA DDM to Lachman Consultant Services Inc.
09000064820ab5f9,Supporting & Related Material,FDA-2014-P-0935-0010,FDA-2014-P-0935,Supplement from The Juice Products Association (JPA)
090000648178e480,Supporting & Related Material,FDA-2014-P-0935-0007,FDA-2014-P-0935,Exhibit 5 Juice Products Association Thailand Coconut Water Brix Citizen Petition From the Juice Products Association
090000648178e39a,Supporting & Related Material,FDA-2014-P-0935-0003,FDA-2014-P-0935,Exhibit 1 Juice Products Association Philippines Coconut Water Brix Data Nov 2011 to July 2012 Citizen Petition From the Juice Products Association
09000064819e09c4,Other,FDA-2014-P-0935-0009,FDA-2014-P-0935,Interim Response from FDA CFSAN to Juice Products Association
090000648178e47b,Supporting & Related Material,FDA-2014-P-0935-0005,FDA-2014-P-0935,Exhibit 3 Juice Products Association Philippines Coconut Water Brix Data January 2013 October 2013 Citizen Petition From the Juice Products Association
090000648178e398,Other,FDA-2014-P-0935-0002,FDA-2014-P-0935,Acknowledgment Letter From FDA DDM to The Juice Products Association
09000064820cb3b0,Supporting & Related Material,FDA-2014-P-0935-0011,FDA-2014-P-0935,Exhibit A Processor A (Indonesia) re: Supplement from The Juice Products Association (JPA)
090000648178e482,Supporting & Related Material,FDA-2014-P-0935-0008,FDA-2014-P-0935,Exhibit 6 Juice Products Association Thailand Coconut Water Brix Data 2 Citizen Petition From the Juice Products Association
09000064820cb3b2,Supporting & Related Material,FDA-2014-P-0935-0013,FDA-2014-P-0935,Exhibit C Processor C (Philippines) re: Supplement from The Juice Products Association (JPA)
09000064820cb3b3,Supporting & Related Material,FDA-2014-P-0935-0014,FDA-2014-P-0935,Exhibit D Processor D (Philippines) re: Supplement from The Juice Products Association (JPA)
09000064820cb3b1,Supporting & Related Material,FDA-2014-P-0935-0012,FDA-2014-P-0935,Exhibit B Processor B (Indonesia) re: Supplement from The Juice Products Association (JPA)
090000648178e199,Other,FDA-2014-P-0935-0001,FDA-2014-P-0935,Citizen Petition From The Juice Products Association
090000648178e47e,Supporting & Related Material,FDA-2014-P-0935-0006,FDA-2014-P-0935,Exhibit 4 Juice Products Association Philippines Coconut Water Data September 2012 February2013 Citizen Petition From the Juice Products Association
090000648178e479,Supporting & Related Material,FDA-2014-P-0935-0004,FDA-2014-P-0935,Exhibit 2 Juice Products Association Brix Data Indonesia 2009 2012 Citizen Petition From the Juice Products Association
090000648365e6c1,Supporting & Related Material,FDA-2018-P-3284-0004,FDA-2018-P-3284,"Tab 2 re: Citizen Petition from Keryx Biopharmaceuticals, Inc."
090000648365e6c5,Supporting & Related Material,FDA-2018-P-3284-0008,FDA-2018-P-3284,"Tab 6 re: Citizen Petition from Keryx Biopharmaceuticals, Inc."
090000648365e7d5,Supporting & Related Material,FDA-2018-P-3284-0020,FDA-2018-P-3284,"Tab 16 re: Citizen Petition from Keryx Biopharmaceuticals, Inc."
090000648365e7cd,Supporting & Related Material,FDA-2018-P-3284-0011,FDA-2018-P-3284,"Tab 9 re: Citizen Petition from Keryx Biopharmaceuticals, Inc."
0900006483a9181b,Other,FDA-2018-P-3284-0023,FDA-2018-P-3284,Petition for Reconsideration from Hogan Lovells US LLP
0900006483a30be5,Other,FDA-2018-P-3284-0022,FDA-2018-P-3284,"Response Letter from FDA CDER to  Keryx Biopharmaceuticals, Inc."
090000648365e6c0,Supporting & Related Material,FDA-2018-P-3284-0003,FDA-2018-P-3284,"Tab 1 re: Citizen Petition from Keryx Biopharmaceuticals, Inc."
090000648365e6c2,Supporting & Related Material,FDA-2018-P-3284-0005,FDA-2018-P-3284,"Tab 3 re: Citizen Petition from Keryx Biopharmaceuticals, Inc."
090000648365e7d2,Supporting & Related Material,FDA-2018-P-3284-0017,FDA-2018-P-3284,"Tab 14 re: Citizen Petition from Keryx Biopharmaceuticals, Inc."
090000648365e7d3,Supporting & Related Material,FDA-2018-P-3284-0019,FDA-2018-P-3284,"Tab 15 re: Citizen Petition from Keryx Biopharmaceuticals, Inc."
090000648365e6c3,Supporting & Related Material,FDA-2018-P-3284-0006,FDA-2018-P-3284,"Tab 4 re: Citizen Petition from Keryx Biopharmaceuticals, Inc."
090000648365f3b3,Other,FDA-2018-P-3284-0002,FDA-2018-P-3284,"Acknowledgment Letter from FDA DDM to  Keryx Biopharmaceuticals, Inc."
090000648365e7ce,Supporting & Related Material,FDA-2018-P-3284-0012,FDA-2018-P-3284,"Tab 10 re: Citizen Petition from Keryx Biopharmaceuticals, Inc."
090000648365e7d0,Supporting & Related Material,FDA-2018-P-3284-0014,FDA-2018-P-3284,"Tab 12 re: Citizen Petition from Keryx Biopharmaceuticals, Inc."
090000648365e7d1,Supporting & Related Material,FDA-2018-P-3284-0015,FDA-2018-P-3284,"Tab 13 re: Citizen Petition from Keryx Biopharmaceuticals, Inc."
090000648365e6c4,Supporting & Related Material,FDA-2018-P-3284-0007,FDA-2018-P-3284,"Tab 5 re: Citizen Petition from Keryx Biopharmaceuticals, Inc."
090000648365e6c6,Supporting & Related Material,FDA-2018-P-3284-0009,FDA-2018-P-3284,"Tab 7 re: Citizen Petition from Keryx Biopharmaceuticals, Inc."
090000648365e7cc,Supporting & Related Material,FDA-2018-P-3284-0010,FDA-2018-P-3284,"Tab 8 re: Citizen Petition from Keryx Biopharmaceuticals, Inc."
090000648365e7cf,Supporting & Related Material,FDA-2018-P-3284-0013,FDA-2018-P-3284,"Tab 11 re: Citizen Petition from Keryx Biopharmaceuticals, Inc."
0900006483a9181d,Other,FDA-2018-P-3284-0024,FDA-2018-P-3284,Acknowledgment Letter from FDA DDM to Hogan Lovells US LLP
090000648365dffc,Other,FDA-2018-P-3284-0001,FDA-2018-P-3284,"Citizen Petition from Keryx Biopharmaceuticals, Inc."
0900006484861475,Other,FDA-2020-P-1914-0001,FDA-2020-P-1914,"Citizen Petition from Aurolife Pharma, LLC. - Redacted Copy"
0900006484958dc8,Other,FDA-2020-P-1914-0003,FDA-2020-P-1914,"Withdrawal from Aurolife Pharma, LLC"
09000064848619fa,Other,FDA-2020-P-1914-0002,FDA-2020-P-1914,Acknowledgment Letter from FDA DMS to Aurolife Pharma LLC
0900006484785bf0,Other,FDA-2020-P-1678-0001,FDA-2020-P-1678,Citizen Petition from Cardinal Health Regulatory Sciences
0900006484785bf1,Other,FDA-2020-P-1678-0002,FDA-2020-P-1678,Acknowledgment Letter from FDA DMS to Cardinal Health Regulatory Sciences
0900006484a6c5bf,Notice,FDA-2020-P-1678-0005,FDA-2020-P-1678,"Determination That NIPRIDE RTU (Sodium Nitroprusside), 10 Milligrams/ 50 Milliliters (0.2 Milligrams/Milliliters), Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
0900006484a70b44,Other,FDA-2020-P-1678-0006,FDA-2020-P-1678,Letter to Cardinal Health Regulatory Sciences from FDA CDER
09000064849fa896,Other,FDA-2020-P-1678-0004,FDA-2020-P-1678,Interim Response Letter from FDA to Cardinal Health Regulatory Sciences
09000064847872d5,Supporting & Related Material,FDA-2020-P-1678-0003,FDA-2020-P-1678,Attachment A - Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations re Citizen Petition from Cardinal Health Regulatory Sciences
0900006484dfa326,Other,FDA-2021-P-1175-0002,FDA-2021-P-1175,Acknowledgment Letter from FDA DMS to Felix Pharmaceuticals Pvt. Ltd.
0900006484dfa853,Other,FDA-2021-P-1175-0001,FDA-2021-P-1175,Suitability Petition from Felix Pharmaceuticals Pvt. Ltd.
0900006484dfa871,Supporting & Related Material,FDA-2021-P-1175-0003,FDA-2021-P-1175,Attachment 1 - RLNAD Package Insert RE Suitability Petition from Felix Pharmaceuticals Pvt. Ltd.
0900006484dfa86a,Supporting & Related Material,FDA-2021-P-1175-0004,FDA-2021-P-1175,Attachment 2 - Draft proposed package insert RE Suitability Petition from Felix Pharmaceuticals Pvt. Ltd.
0900006484d69889,Other,FDA-2021-P-0984-0004,FDA-2021-P-0984,Citizen Petition from Theo Allen
0900006484d6988c,Other,FDA-2021-P-0984-0005,FDA-2021-P-0984,Acknowledgment Letter from FDA DMS to Theo Allen
0900006484e051c3,Other,FDA-2021-P-0984-0011,FDA-2021-P-0984,Response Letter from FDA CBER to Theo Allen
090000648242dda5,Other,FDA-2016-P-1874-0005,FDA-2016-P-1874,Interim Response Letter from CDER to Public Citizen's Health Research Group
090000648207fc83,Other,FDA-2016-P-1874-0002,FDA-2016-P-1874,Acknowledgement Letter from FDA DDM to Public Citizen Health Research Group
090000648207f7f5,Other,FDA-2016-P-1874-0001,FDA-2016-P-1874,Citizen Petition from Public Citizen Health Research Group
090000648207fc86,Supporting & Related Material,FDA-2016-P-1874-0004,FDA-2016-P-1874,Appendix B - RCTs in Parkinson’s disease reporting impulse-control problems and compulsive behaviors for dopamine agonists* re Citizen Petition from Public Citizen Health Research Group
090000648207fc85,Supporting & Related Material,FDA-2016-P-1874-0003,FDA-2016-P-1874,Appendix A - Current dopamine agonist and partial dopamine agonist drugs available in the US and their labeling regarding impulse-control problems/compulsive behaviors re Citizen Petition from Public Citizen Health Research Group
09000064824e7a97,Other,FDA-2016-P-1874-0006,FDA-2016-P-1874,Supplement from Public Citizen
09000064838688b1,Other,FDA-2018-P-1734-0003,FDA-2018-P-1734,"Letter from FDA CDER to Foley & Lardner, LLP"
090000648398f4af,Other,FDA-2018-P-1734-0005,FDA-2018-P-1734,"Letter from FDA CDER to Foley & Lardner, LLP"
090000648322793c,Other,FDA-2018-P-1734-0002,FDA-2018-P-1734,Acknowledgment Letter from FDA DDM to Foley & Lardner LLP
090000648322752c,Other,FDA-2018-P-1734-0001,FDA-2018-P-1734,Citizen Petition from Foley & Lardner LLP
090000648398ec98,Notice,FDA-2018-P-1734-0004,FDA-2018-P-1734,"Determination That IC–GREEN (Indocyanine Green for Injection), 10
Milligrams/Vial, 40 Milligrams/Vial, and 50 Milligrams/Vial Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
0900006482a8db3c,Other,FDA-2017-P-5090-0001,FDA-2017-P-5090,Citizen Petition from Macleods Pharmaceuticals Limited
0900006482e9e843,Other,FDA-2017-P-5090-0003,FDA-2017-P-5090,Interim Response Letter from CDER to Macleods Pharmaceuticals
0900006483ae17ba,Other,FDA-2017-P-5090-0004,FDA-2017-P-5090,Response Letter from CDER to Macleods Pharmaceuticals
0900006482a8e48a,Other,FDA-2017-P-5090-0002,FDA-2017-P-5090,Acknowledgment Letter from FDA DDM to Macleods Pharmaceuticals Limited
0900006483d5b235,Notice,FDA-2019-P-0692-0003,FDA-2019-P-0692,"Determination That THAM Solution (Tromethamine) Injectable, 3.6 Grams/ 100 Milliliters, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
0900006483a67d42,Other,FDA-2019-P-0692-0001,FDA-2019-P-0692,Citizen Petition from Arent Fox LLP
0900006483a67f23,Other,FDA-2019-P-0692-0002,FDA-2019-P-0692,Acknowledgment Letter from FDA DDM to Arent Fox LLP
0900006483d5d73d,Other,FDA-2019-P-0692-0004,FDA-2019-P-0692,Letter from FDA CDER to Arent Fox LLP
09000064838e2208,Other,FDA-2018-P-3211-0004,FDA-2018-P-3211,Denial letter for suitability petition  from FDA CVM to Aurora Pharmaceutical LLC
090000648363301e,Other,FDA-2018-P-3211-0002,FDA-2018-P-3211,Acknowledgment Letter from FDA DDM to Aurora Pharmaceutical LLC
0900006483633543,Supporting & Related Material,FDA-2018-P-3211-0003,FDA-2018-P-3211,"Attachment, Equioxx Paste Label-1 re: Citizen Petition from Aurora Pharmaceutical LLC."
090000648363287a,Other,FDA-2018-P-3211-0001,FDA-2018-P-3211,Citizen Petition from Aurora Pharmaceutical LLC.
090000648045fca2,Notice,FDA-2006-N-0366-0001,FDA-2006-N-0366,FDA
090000648045fca7,Notice,FDA-2006-N-0366-0002,FDA-2006-N-0366,FDA
0900006484dc5d38,Supporting & Related Material,FDA-2021-P-1115-0012,FDA-2021-P-1115,Exhibit J re Citizen Petition from Professional Compounding Centers of America
0900006484dc5d3b,Supporting & Related Material,FDA-2021-P-1115-0015,FDA-2021-P-1115,Exhibit M re Citizen Petition from Professional Compounding Centers of America
0900006484dc5d3f,Supporting & Related Material,FDA-2021-P-1115-0019,FDA-2021-P-1115,Exhibit Q re Citizen Petition from Professional Compounding Centers of America
0900006484dc5a61,Supporting & Related Material,FDA-2021-P-1115-0007,FDA-2021-P-1115,Exhibit E re Citizen Petition from Professional Compounding Centers of America
0900006484dc5a63,Supporting & Related Material,FDA-2021-P-1115-0009,FDA-2021-P-1115,Exhibit G re Citizen Petition from Professional Compounding Centers of America
0900006484dc5d39,Supporting & Related Material,FDA-2021-P-1115-0013,FDA-2021-P-1115,Exhibit K re Citizen Petition from Professional Compounding Centers of America
0900006484dc5d4c,Supporting & Related Material,FDA-2021-P-1115-0021,FDA-2021-P-1115,Exhibit S re Citizen Petition from Professional Compounding Centers of America
0900006484dc5a62,Supporting & Related Material,FDA-2021-P-1115-0008,FDA-2021-P-1115,Exhibit F re Citizen Petition from Professional Compounding Centers of America
0900006484dc5a5d,Supporting & Related Material,FDA-2021-P-1115-0003,FDA-2021-P-1115,Exhibit A re Citizen Petition from Professional Compounding Centers of America
0900006484dc5d4d,Supporting & Related Material,FDA-2021-P-1115-0022,FDA-2021-P-1115,Exhibit T re Citizen Petition from Professional Compounding Centers of America
0900006484dc5d36,Supporting & Related Material,FDA-2021-P-1115-0010,FDA-2021-P-1115,Exhibit H re Citizen Petition from Professional Compounding Centers of America
0900006484dc5d3c,Supporting & Related Material,FDA-2021-P-1115-0016,FDA-2021-P-1115,Exhibit N re Citizen Petition from Professional Compounding Centers of America
0900006484dc5a5e,Supporting & Related Material,FDA-2021-P-1115-0004,FDA-2021-P-1115,Exhibit B re Citizen Petition from Professional Compounding Centers of America
0900006484dc5d37,Supporting & Related Material,FDA-2021-P-1115-0011,FDA-2021-P-1115,Exhibit I re Citizen Petition from Professional Compounding Centers of America
0900006484dc5d3a,Supporting & Related Material,FDA-2021-P-1115-0014,FDA-2021-P-1115,Exhibit L re Citizen Petition from Professional Compounding Centers of America
0900006484dc5d3d,Supporting & Related Material,FDA-2021-P-1115-0017,FDA-2021-P-1115,Exhibit O re Citizen Petition from Professional Compounding Centers of America
0900006484dc5d25,Other,FDA-2021-P-1115-0002,FDA-2021-P-1115,Acknowledgment Letter from FDA DMS to Professional Compounding Centers of America
0900006484dc5d23,Other,FDA-2021-P-1115-0001,FDA-2021-P-1115,Citizen Petition from Professional Compounding Centers of America
0900006484dc5d3e,Supporting & Related Material,FDA-2021-P-1115-0018,FDA-2021-P-1115,Exhibit P re Citizen Petition from Professional Compounding Centers of America
0900006484dc5a5f,Supporting & Related Material,FDA-2021-P-1115-0005,FDA-2021-P-1115,Exhibit C re Citizen Petition from Professional Compounding Centers of America
0900006484dc5a60,Supporting & Related Material,FDA-2021-P-1115-0006,FDA-2021-P-1115,Exhibit D re Citizen Petition from Professional Compounding Centers of America
0900006484dc5d4b,Supporting & Related Material,FDA-2021-P-1115-0020,FDA-2021-P-1115,Exhibit R re Citizen Petition from Professional Compounding Centers of America
0900006484dcb098,Supporting & Related Material,FDA-2021-P-1127-0002,FDA-2021-P-1127,Exhibit A RE: Citizen Petition from Professional Compounding Centers of America
0900006484dcbb4e,Supporting & Related Material,FDA-2021-P-1127-0012,FDA-2021-P-1127,Exhibit K RE: Citizen Petition from Professional Compounding Centers of America
0900006484dcb9d8,Other,FDA-2021-P-1127-0001,FDA-2021-P-1127,Citizen Petition from Professional Compounding Centers of America
0900006484dcb7a5,Other,FDA-2021-P-1127-0013,FDA-2021-P-1127,Acknowledgment Letter from FDA DMS to Professional Compounding Centers of America
0900006484dcb099,Supporting & Related Material,FDA-2021-P-1127-0003,FDA-2021-P-1127,Exhibit B RE: Citizen Petition from Professional Compounding Centers of America
0900006484dcbb4a,Supporting & Related Material,FDA-2021-P-1127-0008,FDA-2021-P-1127,Exhibit G RE: Citizen Petition from Professional Compounding Centers of America
0900006484dcbb48,Supporting & Related Material,FDA-2021-P-1127-0006,FDA-2021-P-1127,Exhibit E RE: Citizen Petition from Professional Compounding Centers of America
0900006484dcbb49,Supporting & Related Material,FDA-2021-P-1127-0007,FDA-2021-P-1127,Exhibit F RE: Citizen Petition from Professional Compounding Centers of America
0900006484dcbb4b,Supporting & Related Material,FDA-2021-P-1127-0009,FDA-2021-P-1127,Exhibit H RE: Citizen Petition from Professional Compounding Centers of America
0900006484dcbb47,Supporting & Related Material,FDA-2021-P-1127-0005,FDA-2021-P-1127,Exhibit D RE: Citizen Petition from Professional Compounding Centers of America
0900006484dcbb4c,Supporting & Related Material,FDA-2021-P-1127-0010,FDA-2021-P-1127,Exhibit I RE: Citizen Petition from Professional Compounding Centers of America
0900006484dcbb46,Supporting & Related Material,FDA-2021-P-1127-0004,FDA-2021-P-1127,Exhibit C RE: Citizen Petition from Professional Compounding Centers of America
0900006484dcbb4d,Supporting & Related Material,FDA-2021-P-1127-0011,FDA-2021-P-1127,Exhibit J RE: Citizen Petition from Professional Compounding Centers of America
09000064824fba4a,Other,FDA-2016-P-2713-0003,FDA-2016-P-2713,Letter from Strides Pharma Inc.  requesting to withdraw Citizen Petition
0900006482205561,Other,FDA-2016-P-2713-0001,FDA-2016-P-2713,"Citizen Petition from Strides Pharma, Inc."
0900006482205564,Other,FDA-2016-P-2713-0002,FDA-2016-P-2713,"Acknowledgement Letter from FDA DDM to Strides Pharma, Inc."
090000648377c5e8,Other,FDA-2018-P-3666-0001,FDA-2018-P-3666,"Citizen Petition from Fresenius Kabi USA, LLC"
090000648377c91a,Other,FDA-2018-P-3666-0002,FDA-2018-P-3666,"Acknowledgment Letter from FDA DDM to Fresenius Kabi USA, LLC"
0900006483b134d8,Other,FDA-2018-P-3666-0003,FDA-2018-P-3666,"Letter from FDA CDER to Fresenius Kabi USA, LLC"
0900006481b08a16,Other,FDA-2015-P-1898-0001,FDA-2015-P-1898,"Citizen Petition from Hyman, Phelps & McNamara, P.C."
0900006481b09a13,Other,FDA-2015-P-1898-0002,FDA-2015-P-1898,"Acknowledgement Letter from FDA DDM to Hyman, Phelps & McNamara, P.C."
0900006481dd3cba,Notice,FDA-2015-P-1898-0003,FDA-2015-P-1898,"Determination That KYTRIL Granisetron Hydrochloride) Tablets, Equivalent 1 Milligram and 2 Milligram Base, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
0900006481ddee16,Other,FDA-2015-P-1898-0004,FDA-2015-P-1898,"Letter from FDA CDER to Hyman, Phelps & McNamara PC"
0900006482b8b9d6,Supporting & Related Material,FDA-2017-P-5978-0004,FDA-2017-P-5978,Attachment 2 DailyMed Label: Nicardipine Hydrochloride- nicardipine hydrochloride injection
0900006483051b56,Other,FDA-2017-P-5978-0005,FDA-2017-P-5978,Interim Response Letter from FDA CDER to JR Rapoza Associates Inc.
090000648497e0e1,Other,FDA-2017-P-5978-0006,FDA-2017-P-5978,"Withdrawal from JR Rapoza Associates, Inc."
0900006482b8b5de,Other,FDA-2017-P-5978-0001,FDA-2017-P-5978,"Citizen Petition from JR Rapoza Associates, Inc."
0900006482b8b6ec,Other,FDA-2017-P-5978-0002,FDA-2017-P-5978,Acknowledgement Letter from FDA DDM to JR Rapoza Associates Inc.
0900006482b8b744,Supporting & Related Material,FDA-2017-P-5978-0003,FDA-2017-P-5978,Attachment 1 Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations
0900006483cdd64d,Other,FDA-2018-P-4664-0003,FDA-2018-P-4664,"Letter from FDA CDER to Fresenius Kabi USA, LLC"
0900006483973e3d,Other,FDA-2018-P-4664-0001,FDA-2018-P-4664,"Citizen Petition from Fresenius Kabi USA, LLC"
0900006483975950,Other,FDA-2018-P-4664-0002,FDA-2018-P-4664,"Acknowledgment Letter from FDA DDM to Fresenius Kabi USA, LLC"
090000648362b5ee,Notice,FDA-2018-N-2970-0001,FDA-2018-N-2970,Agency Information Collection Activities; Proposed Collection; Comment Request; Surveys and Interviews With Investigational New Drug Sponsors To Assess Current Communication Practices With Food and Drug Administration Review Staff Under the Sixth Authorization of the Prescription Drug User Fee Act
09000064838ce9cc,Notice,FDA-2018-N-2970-0002,FDA-2018-N-2970,Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Surveys and Interviews With Investigational New Drug Sponsors To Assess Current Communication Practices With Food and Drug Administration Review Staff Under the Sixth Authorization of the Prescription Drug User Fee Act
0900006483bad4cc,Notice,FDA-2018-N-2970-0003,FDA-2018-N-2970,"Agency Information Collection Activities; Announcement of Office of
Management and Budget Approvals"
090000648478c14a,Supporting & Related Material,FDA-2020-P-1689-0007,FDA-2020-P-1689,Exhibit 5  re Citizen Petition from Lassman Law + Policy
09000064849fd09b,Other,FDA-2020-P-1689-0012,FDA-2020-P-1689,Interim Response from FDA CBER to Lassman Law + Policy
090000648478c143,Other,FDA-2020-P-1689-0002,FDA-2020-P-1689,Acknowledgment Letter from FDA DMS to Lassman Law + Policy
090000648478bf63,Supporting & Related Material,FDA-2020-P-1689-0010,FDA-2020-P-1689,Exhibit 8  re Citizen Petition from Lassman Law + Policy
090000648478c142,Other,FDA-2020-P-1689-0001,FDA-2020-P-1689,Citizen Petition from Lassman Law + Policy
090000648478bf61,Supporting & Related Material,FDA-2020-P-1689-0008,FDA-2020-P-1689,Exhibit 6  re Citizen Petition from Lassman Law + Policy
090000648478bf62,Supporting & Related Material,FDA-2020-P-1689-0009,FDA-2020-P-1689,Exhibit 7  re Citizen Petition from Lassman Law + Policy
090000648478bf64,Supporting & Related Material,FDA-2020-P-1689-0011,FDA-2020-P-1689,Exhibit 9  re Citizen Petition from Lassman Law + Policy
090000648478c147,Supporting & Related Material,FDA-2020-P-1689-0004,FDA-2020-P-1689,Exhibit 2  re Citizen Petition from Lassman Law + Policy
090000648478c149,Supporting & Related Material,FDA-2020-P-1689-0006,FDA-2020-P-1689,Exhibit 4  re Citizen Petition from Lassman Law + Policy
090000648478c146,Supporting & Related Material,FDA-2020-P-1689-0003,FDA-2020-P-1689,Exhibit 1 re Citizen Petition from Lassman Law + Policy
090000648478c148,Supporting & Related Material,FDA-2020-P-1689-0005,FDA-2020-P-1689,Exhibit 3  re Citizen Petition from Lassman Law + Policy
0900006484a70c41,Other,FDA-2020-P-1991-0003,FDA-2020-P-1991,"Interim Response Letter from FDA CDER to Hyman, Phelps & McNamara, P.C."
090000648486b878,Other,FDA-2020-P-1991-0002,FDA-2020-P-1991,"Acknowledgment Letter from FDA DMS to Hyman, Phelps & McNamara, P.C."
090000648486b876,Other,FDA-2020-P-1991-0001,FDA-2020-P-1991,"Citizen Petition from HYMAN, PHELPS & MCNAMARA, P.C."
090000648480b45f,Supporting & Related Material,FDA-2020-P-1768-0003,FDA-2020-P-1768,Footnotes 2 - 17 re Citizen Petition from SIRI & GLIMSTAD LLP on behalf of Informed Consent Action Network
0900006484811ac5,Supporting & Related Material,FDA-2020-P-1768-0008,FDA-2020-P-1768,Footnotes 18-30 re: Administrative Stay of Action from SIRI & GLIMSTAD LLP on behalf of Informed Consent Action Network
0900006484811ac6,Supporting & Related Material,FDA-2020-P-1768-0007,FDA-2020-P-1768,Footnotes 31-48 re: Administrative Stay of Action from SIRI & GLIMSTAD LLP on behalf of Informed Consent Action Network
090000648480b30a,Other,FDA-2020-P-1768-0001,FDA-2020-P-1768,Citizen Petition from SIRI & GLIMSTAD LLP on behalf of Informed Consent Action Network
090000648480b461,Supporting & Related Material,FDA-2020-P-1768-0005,FDA-2020-P-1768,Footnotes 31 - 41 re Citizen Petition from SIRI & GLIMSTAD LLP on behalf of Informed Consent Action Network
0900006484973a31,Supporting & Related Material,FDA-2020-P-1768-0044,FDA-2020-P-1768,Footnotes 2 - 17 re Citizen Petition from SIRI & GLIMSTAD LLP on behalf of Informed Consent Action Network
090000648480b460,Supporting & Related Material,FDA-2020-P-1768-0004,FDA-2020-P-1768,Footnotes 18 - 30 re Citizen Petition from SIRI & GLIMSTAD LLP on behalf of Informed Consent Action Network
0900006484811ac4,Supporting & Related Material,FDA-2020-P-1768-0009,FDA-2020-P-1768,Footnotes 2-17 re: Administrative Stay of Action from SIRI & GLIMSTAD LLP on behalf of Informed Consent Action Network
0900006484811e83,Other,FDA-2020-P-1768-0006,FDA-2020-P-1768,Administrative Stay of Action from SIRI & GLIMSTAD LLP on behalf of Informed Consent Action Network
0900006484aa3a7d,Other,FDA-2020-P-1768-0048,FDA-2020-P-1768,"Interim Response Letter from FDA CBER to Siri & Glimstad, LLP"
0900006484913841,Other,FDA-2020-P-1768-0010,FDA-2020-P-1768,Amended Citizen Petition SIRI & GLIMSTAD LLP on behalf of Informed Consent Action Network
0900006484973e6c,Supporting & Related Material,FDA-2020-P-1768-0046,FDA-2020-P-1768,Footnotes 31-48 re: Administrative Stay of Action from SIRI & GLIMSTAD LLP on behalf of Informed Consent Action Network
0900006484973dfa,Supporting & Related Material,FDA-2020-P-1768-0045,FDA-2020-P-1768,Footnotes 18 - 30 re Citizen Petition from SIRI & GLIMSTAD LLP on behalf of Informed Consent Action Network
090000648480b45c,Other,FDA-2020-P-1768-0002,FDA-2020-P-1768,Acknowledgment Letter from FDA DMS to SIRI & GLIMSTAD LLP on behalf of Informed Consent Action Network
090000648487321d,Other,FDA-2020-P-2003-0002,FDA-2020-P-2003,Acknowledgment Letter from FDA DMS to Environmental Defense Fund
0900006484873aba,Supporting & Related Material,FDA-2020-P-2003-0004,FDA-2020-P-2003,Appendix C Review of GRAS Notifications re: Citizen Petition from Environmental Defense Fund
09000064848736fe,Supporting & Related Material,FDA-2020-P-2003-0007,FDA-2020-P-2003,"Attachment 1- The Healthfulness of the US Packaged Food and
Beverage Supply: A Cross-Sectional Study re: Citizen Petition from Environmental Defense Fund"
0900006484a6b478,Other,FDA-2020-P-2003-0455,FDA-2020-P-2003,180 Day Interim Response Letter from FDA CFSAN to Environmental Defense Fund
0900006484873ab9,Supporting & Related Material,FDA-2020-P-2003-0005,FDA-2020-P-2003,"Appendix B Review of FDA’s Regulations, Forms, and Associated Instructions for Industry Regarding Petitions and Notifications re: Citizen Petition from Environmental Defense Fund"
090000648487321b,Other,FDA-2020-P-2003-0001,FDA-2020-P-2003,Citizen Petition from Environmental Defense Fund
0900006484873ab8,Supporting & Related Material,FDA-2020-P-2003-0006,FDA-2020-P-2003,Appendix A Specific Changes Requested to FDA’s Regulations re: Citizen Petition from Environmental Defense Fund
0900006484873abb,Supporting & Related Material,FDA-2020-P-2003-0003,FDA-2020-P-2003,Appendix D Review of FDA Guidance to Industry re: Citizen Petition from Environmental Defense Fund
0900006484c4a80f,Other,FDA-2021-P-0895-0002,FDA-2021-P-0895,Acknowledgment Letter from Eagle Pharmaceuticals
0900006484c4a80d,Other,FDA-2021-P-0895-0001,FDA-2021-P-0895,Citizen Petition from Eagle Pharmaceuticals
0900006481991a9b,Other,FDA-2014-P-0919-0004,FDA-2014-P-0919,Interim Response from CDRH to Daniel Schumaier
0900006484df8c43,Other,FDA-2014-P-0919-0006,FDA-2014-P-0919,Final Response from FDA CDRH to Daniel Schumaier
090000648177d0e9,Supporting & Related Material,FDA-2014-P-0919-0003,FDA-2014-P-0919,Supporting  And Related Materials Citizen Petition from Daniel Schumaier PhD
090000648177d0e7,Other,FDA-2014-P-0919-0002,FDA-2014-P-0919,Acknowledgement Letter From FDA DDM to Daniel Schumaier
0900006481e5b351,Other,FDA-2014-P-0919-0005,FDA-2014-P-0919,"Interim Response Letter from FDA CDRH to Daniel Schumaier, PhD."
0900006481779c07,Other,FDA-2014-P-0919-0001,FDA-2014-P-0919,"Citizen Petition From Daniel Schumaier, Ph.D."
0900006484acdca5,Other,FDA-2021-P-0433-0001,FDA-2021-P-0433,"Citizen Petition from Siri & Glimstad, LLP"
0900006484dfc8cf,Other,FDA-2021-P-0433-0042,FDA-2021-P-0433,"Interim Response Letter from FDA CBER to Siri & Glimstad, LLP"
0900006484acdca8,Other,FDA-2021-P-0433-0002,FDA-2021-P-0433,"Acknowledgment Letter from FDA DMS to Siri & Glimstad, LLP"
0900006482afdc20,Other,FDA-2016-P-2738-0004,FDA-2016-P-2738,Petition Response Letter from FDA CDER to Metabolic Therapy Inc.
090000648220d2a1,Other,FDA-2016-P-2738-0001,FDA-2016-P-2738,Citizen Petition from Metabolic Therapy Inc.
0900006482504d65,Other,FDA-2016-P-2738-0003,FDA-2016-P-2738,Interim Response Letter from FDA CDER to Metabolic Therapy Inc.
090000648220d6e7,Other,FDA-2016-P-2738-0002,FDA-2016-P-2738,Acknowledgement Letter from FDA DDM to Metabolic Therapy Inc.
0900006481a2e9ee,Other,FDA-2014-P-0628-0004,FDA-2014-P-0628,Intetim Response Letter From CFSAN to Shauce Co.
09000064816f8d6b,Other,FDA-2014-P-0628-0002,FDA-2014-P-0628,Acknowledgement Letter From FDA DDM to Shauce Co
09000064816f8d6d,Supporting & Related Material,FDA-2014-P-0628-0003,FDA-2014-P-0628,Reference 1 Analysis Report from Shauce Co RE: Citizen Petition From Shauce Company
09000064816f8d69,Other,FDA-2014-P-0628-0001,FDA-2014-P-0628,Citizen Petition From Shauce Company
09000064824ae716,Other,FDA-2017-P-0757-0002,FDA-2017-P-0757,Acknowledgment Letter from FDA DDM  to Beck & Thomas
09000064824ae714,Other,FDA-2017-P-0757-0001,FDA-2017-P-0757,Citizen Petition from Beck & Thomas
09000064824ba38a,Other,FDA-2017-P-0757-0003,FDA-2017-P-0757,Withdrawal from Vertice Pharma (Beck & Thomas)
0900006484d62771,Supporting & Related Material,FDA-2021-P-0985-0004,FDA-2021-P-0985,Attachment 2 RE: Citizen Petition from President Island Green Living Association  Personal Care Products Toxicologist
0900006484d624d3,Supporting & Related Material,FDA-2021-P-0985-0005,FDA-2021-P-0985,"Attachment 3 Benzophenone Accumulates over Time from the Degradation of
Octocrylene in Commercial Sunscreen Products RE: Citizen Petition from President Island Green Living Association  Personal Care Products Toxicologist"
0900006484d624d4,Supporting & Related Material,FDA-2021-P-0985-0003,FDA-2021-P-0985,Attachment 1 Sunscreen Drug Products for Over-the-Counter Human Use RE: Citizen Petition from President Island Green Living Association  Personal Care Products Toxicologist
0900006484d624e4,Other,FDA-2021-P-0985-0001,FDA-2021-P-0985,Citizen Petition from President Island Green Living Association  Personal Care Products Toxicologist
0900006484d624d8,Supporting & Related Material,FDA-2021-P-0985-0009,FDA-2021-P-0985,Attachment 7 Reproductive toxicity and estrogen activity in Japanese medaka (Oryzias latipes) exposed to environmentally relevant concentrations of octocrylene RE: Citizen Petition from President Island Green Living Association  Personal Care Products Toxicologist
0900006484d624d9,Supporting & Related Material,FDA-2021-P-0985-0015,FDA-2021-P-0985,"Attachment 13 Unveiling complex responses at the molecular level: Transcriptional alterations by mixtures of bisphenol A, octocrylene, and 2'-ethylhexyl 4-(dimethylamino)benzoate on Chironomus ripariusRE: Citizen Petition from President Island Green Living Association  Personal Care Products Toxicologist"
0900006484d6276f,Supporting & Related Material,FDA-2021-P-0985-0011,FDA-2021-P-0985,Attachment 9 A unique approach to monitor stress in coral exposed to emerging pollutants RE: Citizen Petition from President Island Green Living Association  Personal Care Products Toxicologist
0900006484d62776,Supporting & Related Material,FDA-2021-P-0985-0013,FDA-2021-P-0985,"Attachment 11 Multiresidue Analysis of Organic UV Filters and UV
Stabilizers in Fish of Common Consumption RE: Citizen Petition from President Island Green Living Association  Personal Care Products Toxicologist"
0900006484d624d2,Supporting & Related Material,FDA-2021-P-0985-0008,FDA-2021-P-0985,"Attachment 6 Effect of 10 UV filters on the brine shrimp Artemia 
3 salina and the marine microalga Tetraselmis sp RE: Citizen Petition from President Island Green Living Association  Personal Care Products Toxicologist"
0900006484d624d7,Supporting & Related Material,FDA-2021-P-0985-0012,FDA-2021-P-0985,"Attachment 10 Metabolomics reveal that octocrylene accumulates in
Pocillopora damicornis tissues as fatty acid conjugates and triggers coral cell mitochondrial dysfunction RE: Citizen Petition from President Island Green Living Association  Personal Care Products Toxicologist"
0900006484d62778,Supporting & Related Material,FDA-2021-P-0985-0014,FDA-2021-P-0985,"Attachment 12 Emerging contaminants in aquatic environments and coastal waters affected by urban wastewater discharge in Thailand: An ecological 
risk perspective RE: Citizen Petition from President Island Green Living Association  Personal Care Products Toxicologist"
0900006484d62770,Supporting & Related Material,FDA-2021-P-0985-0006,FDA-2021-P-0985,Attachment 4 Discontinuation of Uvinul N 539T (Octocrylene)  RE: Citizen Petition from President Island Green Living Association  Personal Care Products Toxicologist
0900006484d624e6,Other,FDA-2021-P-0985-0002,FDA-2021-P-0985,Acknowledgment Letter from FDA DMS to President Island Green Living Association and Personal Care Products Toxicologist
0900006484d624d6,Supporting & Related Material,FDA-2021-P-0985-0016,FDA-2021-P-0985,Attachment 14 Biomarker-based assessment of sublethal toxicity of organic UV filters (ensulizole and octocrylene) in a sentinel marine bivalve Mytilus edulis RE: Citizen Petition from President Island Green Living Association  Personal Care Products Toxicologist
0900006484d62772,Supporting & Related Material,FDA-2021-P-0985-0018,FDA-2021-P-0985,Attachment 16 Skincare Chemicals and Coral Reefs RE: Citizen Petition from President Island Green Living Association  Personal Care Products Toxicologist
0900006484d62775,Supporting & Related Material,FDA-2021-P-0985-0017,FDA-2021-P-0985,"Attachment 15 Oxybenzone contamination from sunscreen pollution and its ecological threat to Hanauma Bay, Oahu, Hawaii, U.S.A. RE: Citizen Petition from President Island Green Living Association  Personal Care Products Toxicologist"
0900006484d62777,Supporting & Related Material,FDA-2021-P-0985-0010,FDA-2021-P-0985,Attachment 8 A burning issue: The effect of organic ultraviolet filter exposure on the behaviour and physiology of Daphnia magna RE: Citizen Petition from President Island Green Living Association  Personal Care Products Toxicologist
0900006484d624d5,Supporting & Related Material,FDA-2021-P-0985-0007,FDA-2021-P-0985,Attachment 5 Science of the Total Environment RE: Citizen Petition from President Island Green Living Association  Personal Care Products Toxicologist
0900006483ccc7eb,Other,FDA-2019-P-2559-0002,FDA-2019-P-2559,Acknowledgment Letter from FDA DDM to Ajanta Pharma USA Inc
0900006483dc2022,Notice,FDA-2019-P-2559-0003,FDA-2019-P-2559,"Determination That FORTAMET (Metformin Hydrochloride) Extended-
Release Tablets, 500 Milligrams and 1 Gram, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
0900006483ccc6ae,Other,FDA-2019-P-2559-0001,FDA-2019-P-2559,Citizen Petition from Ajanta Pharma USA Inc
0900006483dc63b2,Other,FDA-2019-P-2559-0004,FDA-2019-P-2559,Letter from FDA CDER to Ajanta Pharma USA Inc
090000648420e91b,Other,FDA-2019-P-1607-0003,FDA-2019-P-1607,"Response Letter from FDA to Aurobindo Pharma USA, Inc"
0900006483b636eb,Other,FDA-2019-P-1607-0002,FDA-2019-P-1607,"Acknowledgment Letter from FDA DDM to Aurobindo Pharma USA, Inc."
0900006483b634e7,Other,FDA-2019-P-1607-0001,FDA-2019-P-1607,"Citizen Petition from Aurobindo Pharma USA, Inc."
0900006484a0ffd1,Supporting & Related Material,FDA-2021-P-0086-0003,FDA-2021-P-0086,"Comment from Neeraj Agrawal, Schafer Veterinary Consultants, LLC"
09000064849f8abf,Other,FDA-2021-P-0086-0002,FDA-2021-P-0086,Acknowledgement Letter from FDA DMS to  Felix Pharmaceuticals Pvt. Ltd
09000064849f8d0e,Other,FDA-2021-P-0086-0001,FDA-2021-P-0086,Suitability Citizen Petition from Felix Pharmaceuticals Pvt. Ltd
0900006484aa060d,Other,FDA-2021-P-0086-0004,FDA-2021-P-0086,"Approval of Suitability Petition from FDA CVM to Schafer Veterinary Consultants, LLC"
09000064847b4531,Supporting & Related Material,FDA-2020-P-1718-0008,FDA-2020-P-1718,"Attachment F Examples of Beverages Labeled as Nutrition Drinks, Nutritional Drinks, Nutrition Shakes re: Citizen Petition from Public Health Advocacy Institute, Inc. on behalf  of 1,000 Days, et al."
09000064847b3ef4,Other,FDA-2020-P-1718-0002,FDA-2020-P-1718,"Acknowledgment Letter from FDA DMS to Public Health Advocacy Institute, Inc. on behalf  of 1,000 Days, et al."
0900006484a15d09,Other,FDA-2020-P-1718-0013,FDA-2020-P-1718,"Response Letter to Citizen Petition from FDA CFSAN to Public Health Advocacy Institute, Inc. on behalf  of 1,000 Days, et al."
09000064847b452c,Supporting & Related Material,FDA-2020-P-1718-0003,FDA-2020-P-1718,"Attachment A Transition Formula & Toddler Milk Products for Sale in November 2019 re: Citizen Petition from Public Health Advocacy Institute, Inc. on behalf  of 1,000 Days, et al."
09000064847b452e,Supporting & Related Material,FDA-2020-P-1718-0005,FDA-2020-P-1718,"Attachment C Side by Side Comparison of Nutrient Content of Infant Formula vs Transition Formula re:  Citizen Petition from Public Health Advocacy Institute, Inc. on behalf  of 1,000 Days, et al."
09000064847b4530,Supporting & Related Material,FDA-2020-P-1718-0007,FDA-2020-P-1718,"Attachment E Marketing Claims & Comparisons to Plain Milk & Whole Foods re: Citizen Petition from Public Health Advocacy Institute, Inc. on behalf  of 1,000 Days, et al."
09000064847b4532,Supporting & Related Material,FDA-2020-P-1718-0009,FDA-2020-P-1718,"Attachment G Incorrect Use of the Term Toddler to Encompass Infants Less Than 12 Months Old re: Citizen Petition from Public Health Advocacy Institute, Inc. on behalf  of 1,000 Days, et al."
09000064847b3ef3,Other,FDA-2020-P-1718-0001,FDA-2020-P-1718,"Citizen Petition from Public Health Advocacy Institute, Inc. on behalf  of 1,000 Days, et al."
09000064847b452d,Supporting & Related Material,FDA-2020-P-1718-0004,FDA-2020-P-1718,"Attachment B Price Comparison of Cow's Milk, Transition Formula & Toddler Milk re: Citizen Petition from Public Health Advocacy Institute, Inc. on behalf  of 1,000 Days, et al."
09000064847b452f,Supporting & Related Material,FDA-2020-P-1718-0006,FDA-2020-P-1718,"Attachment D Nutritional Composition of Toddler Milk vs Plain Milk re: Citizen Petition from Public Health Advocacy Institute, Inc. on behalf  of 1,000 Days, et al."
09000064832405ee,Other,FDA-2018-P-1780-0001,FDA-2018-P-1780,"Citizen Petition from Pacira Pharmaceuticals, Inc"
0900006483240a11,Other,FDA-2018-P-1780-0002,FDA-2018-P-1780,"Acknowledgment Letter from FDA DDM to Pacira Pharmaceuticals, Inc"
0900006483883493,Other,FDA-2018-P-1780-0004,FDA-2018-P-1780,"Interim Response Letter from FDA CDER to Pacira Pharmaceuticals, Inc."
0900006484af90f3,Other,FDA-2018-P-1780-0005,FDA-2018-P-1780,"Response Letter from FDA CDER to Pacira Pharmaceuticals, Inc."
0900006483ad2f44,Supporting & Related Material,FDA-2019-P-1130-0003,FDA-2019-P-1130,Exhibit A Vaccination Suspension Regulation Proposed Regulations Terms re Citizen Petition from Kent Heckenlively et al
0900006483acf5b4,Other,FDA-2019-P-1130-0002,FDA-2019-P-1130,Acknowledgment Letter from FDA DDM to Kent Heckenlively
0900006483acf526,Other,FDA-2019-P-1130-0001,FDA-2019-P-1130,Citizen Petition from Kent Heckenlively et al
0900006481e373bd,Other,FDA-2015-P-3053-0004,FDA-2015-P-3053,Citizen Petition Response Letter from FDA CDER to Florek & Endres PLLC
0900006481c2eaf6,Other,FDA-2015-P-3053-0002,FDA-2015-P-3053,Acknowledgement Letter from FDA DDM to Florek & Endres PLLC
0900006481c2ed67,Other,FDA-2015-P-3053-0001,FDA-2015-P-3053,Citizen Petition from Florek & Endres PLLC
0900006481e2f692,Notice,FDA-2015-P-3053-0003,FDA-2015-P-3053,"Determination That IZBA (Travoprost Ophthalmic Solution), 0.003 Percent, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
0900006481c8c746,Supporting & Related Material,FDA-2015-P-3400-0002,FDA-2015-P-3400,Prescription and Over-the Counter Drug Product List from the Orange Book
0900006481c8c744,Other,FDA-2015-P-3400-0001,FDA-2015-P-3400,"Citizen Petition from Lupin Pharmaceuticals, Inc."
09000064839fbdda,Other,FDA-2015-P-3400-0005,FDA-2015-P-3400,Response Letter from FDA CDER
0900006481ecc157,Other,FDA-2015-P-3400-0004,FDA-2015-P-3400,"Interim Response Letter from FDA CDER to Lupin Pharmaceuticals, Inc."
0900006481c8c815,Other,FDA-2015-P-3400-0003,FDA-2015-P-3400,"Acknowledgement Letter from FDA DDM to Lupin Pharmaceuticals, Inc."
0900006481cb82c2,Other,FDA-2015-P-3485-0002,FDA-2015-P-3485,Acknowledgement Letter from FDA DDM to National Chicken Council
0900006481cb85da,Other,FDA-2015-P-3485-0001,FDA-2015-P-3485,"Citizen Petition from the National Chicken Council, et al."
0900006484326d04,Other,FDA-2020-P-0598-0001,FDA-2020-P-0598,"Citizen Petition from Lachman Consulting Services, Inc."
0900006484326dfb,Supporting & Related Material,FDA-2020-P-0598-0004,FDA-2020-P-0598,Attachment 2- IMS Data-Prochlorperazine RE: Citizen Petition from Lachman Consultants
0900006484326dfa,Supporting & Related Material,FDA-2020-P-0598-0003,FDA-2020-P-0598,Attachment 1- Orange Book_ Approved Drug Products with Therapeutic Equivalence Evaluations RE: Citizen Petition from Lachman Consultants
0900006484326d87,Other,FDA-2020-P-0598-0002,FDA-2020-P-0598,"Acknowledgment Letter from FDA DMS to Lachman Consulting Services, Inc"
0900006484455313,Other,FDA-2020-P-0598-0005,FDA-2020-P-0598,"Citizen Petition Withdrawal Request from Lachman Consulting Services, Inc. to FDA CDER"
09000064849b07a7,Other,FDA-2020-P-2317-0001,FDA-2020-P-2317,Citizen Petition from Baxter Healthcare Corporation
0900006484b5ca79,Other,FDA-2020-P-2317-0004,FDA-2020-P-2317,Response Letter from FDA CDER to Baxter Healthcare Corporation
09000064849b07aa,Other,FDA-2020-P-2317-0002,FDA-2020-P-2317,Acknowledgment Letter from FDA DMS to Baxter Healthcare Corporation
0900006484b59180,Notice,FDA-2020-P-2317-0003,FDA-2020-P-2317,"Determination That QUELICIN PRESERVATIVE FREE (Succinylcholine Chloride) Injection, 20 Milligrams/Milliliter, 50 Milligrams/Milliliter, and 100 Milligrams/Milliliter, Was Not Withdrawn From Sale for
Reasons of Safety or Effectiveness"
0900006484b81467,Other,FDA-2021-P-0559-0002,FDA-2021-P-0559,Acknowledgment Letter from FDA DMS to Catalyst Pharmaceuticals
0900006484be5a07,Other,FDA-2021-P-0559-0003,FDA-2021-P-0559,Withdrawal of Citizens Petition from Catalyst Pharmaceuticals
0900006484b80a58,Other,FDA-2021-P-0559-0001,FDA-2021-P-0559,Citizen Petition from Catalyst Pharmaceuticals
0900006480450f0d,Other,FDA-2005-A-0476-0001,FDA-2005-A-0476,Acknowledgement Letter to GlaxoSmithKline
09000064846c2558,Other,FDA-2005-A-0476-0006,FDA-2005-A-0476,"Response Letter from FDA CDER to GlaxoSmithKline, Wilmer Cutler Pickering Hale and Dorr LLP,  Ropes & Gray LLP,  Novo Nordisk Inc. and Finnegan, Henderson, Farabow, Garrett & Dunner, LLP"
09000064808d46b5,Other,FDA-2005-A-0476-0004,FDA-2005-A-0476,GlaxoSmithKline (Advisory Opinion Petition) - Supplement
0900006480450f15,Other,FDA-2005-A-0476-0002,FDA-2005-A-0476,FDA/CDER Interim Response to GlaxoSmithKline - Letter
0900006480450f0f,Other,FDA-2005-A-0476-0003,FDA-2005-A-0476,GlaxoSmithKline - Advisory Opinion Petition
0900006480c7a5b4,Other,FDA-2005-A-0476-0005,FDA-2005-A-0476,See FDA-2005-A-0476-0003
0900006484ad47c6,Other,FDA-2021-P-0437-0001,FDA-2021-P-0437,"Citizen Petition from Siri & Glimstad, LLP (on behalf of Informed Consent Action Network)"
0900006484ad47c8,Other,FDA-2021-P-0437-0002,FDA-2021-P-0437,"Acknowledgment Letter from FDA DMS to Siri & Glimstad, LLP (on behalf of Informed Consent Action Network)"
0900006484ad47ca,Supporting & Related Material,FDA-2021-P-0437-0003,FDA-2021-P-0437,"Exhibit A -  The measurement and full statistical analysis including Bayesian methods of the aluminium content of infant vaccines RE Citizen Petition from Siri & Glimstad, LLP (on behalf of Informed Consent Action Network)"
0900006484dfc8fa,Other,FDA-2021-P-0437-0007,FDA-2021-P-0437,"Interim Response Letter from FDA CBER to Siri & Glimstad, LLP"
0900006484a5ecdc,Supporting & Related Material,FDA-2021-P-0267-0005,FDA-2021-P-0267,Reference 2 - Ischemia-Triggered Glutamate Excitotoxicity From the Perspective of Glial Cells RE Citizen Petition from Adrienne Samuels
0900006484a5ece0,Supporting & Related Material,FDA-2021-P-0267-0006,FDA-2021-P-0267,Reference 3  - Statistics: An Intuitive Approach and Reference 4 -  Statistical Analysis in Psychology and Education RE Citizen Petition from Adrienne Samuels
0900006484a5ece5,Supporting & Related Material,FDA-2021-P-0267-0010,FDA-2021-P-0267,"Reference 8, 9, 10 - Brain damage in infant mice following oral intake of glutamate, aspartate or cysteine, Reference 9 - Brain damage in mice from voluntary ingestion of glutamate and aspartate and Reference 10  -Brain-damaging potential of protein hydrolysates RE Citizen Petition from Adrienne Samuels"
0900006484a5ecf2,Supporting & Related Material,FDA-2021-P-0267-0016,FDA-2021-P-0267,"Reference 16 - Brain lesions, obesity, and other disturbances in mice treated with monosodium glutamate RE Citizen Petition from Adrienne Samuels"
0900006484a5ecda,Supporting & Related Material,FDA-2021-P-0267-0003,FDA-2021-P-0267,Cover Letter RE Citizen Petition from Adrienne Samuels
0900006484a5ece1,Supporting & Related Material,FDA-2021-P-0267-0007,FDA-2021-P-0267,Reference 5 - The Alleged Safety of Monosodium Glutamate (MSG) Excerpted from MSG: A Review of the Literature and Critique of Industry Sponsored Research. RE Citizen Petition from Adrienne Samuels
0900006484a5ecf5,Supporting & Related Material,FDA-2021-P-0267-0018,FDA-2021-P-0267,Reference 18 - History of glutamate production RE Citizen Petition from Adrienne Samuels
0900006484a5ecee,Supporting & Related Material,FDA-2021-P-0267-0014,FDA-2021-P-0267,Reference 14 - Memorandum: Summary of Adverse Reactions Attributed to Aspartame RE Citizen Petition from Adrienne Samuels
0900006484a5ecfc,Supporting & Related Material,FDA-2021-P-0267-0021,FDA-2021-P-0267,"Reference 21 - Global Food Flavor Enhancer Market Report, History and Forecast. 2014-2025,
Breakdown Data by Manufacturers, Key Regions, Types and Application RE Citizen Petition from Adrienne Samuels"
0900006484a5ecd3,Other,FDA-2021-P-0267-0002,FDA-2021-P-0267,Acknowledgement Letter from FDA DMS to Adrienne Samuels
0900006484a5ecdb,Supporting & Related Material,FDA-2021-P-0267-0004,FDA-2021-P-0267,"Reference 1 - Excitotoxicity in the pathogenesis of neurological and psychiatric disorders: Therapeutic
implications RE Citizen Petition from Adrienne Samuels"
0900006484a5ece4,Supporting & Related Material,FDA-2021-P-0267-0009,FDA-2021-P-0267,Reference 7 - Designed for Deception: The fail-safe way to ensure that their studies would conclude MSG is harmless RE Citizen Petition from Adrienne Samuels
0900006484a5ece6,Supporting & Related Material,FDA-2021-P-0267-0011,FDA-2021-P-0267,"Reference 11 - Data from the 1960s and 1970s demonstrate that monosodium glutamate causes  hypothalamic damage, endocrine disruption, and behavior disorders when given to immature animals after
either subcutaneous or oral doses. RE Citizen Petition from Adrienne Samuels"
0900006484a5ece8,Supporting & Related Material,FDA-2021-P-0267-0013,FDA-2021-P-0267,Reference 13  -  Memorandum: Summary of Adverse Reactions Attributed to MSG RE Citizen Petition from Adrienne Samuels
0900006484a5ecf4,Supporting & Related Material,FDA-2021-P-0267-0017,FDA-2021-P-0267,Reference 17 - Discovery and History of Amino Acid Fermentation RE Citizen Petition from Adrienne Samuels
0900006484a5ecbe,Other,FDA-2021-P-0267-0001,FDA-2021-P-0267,Citizen Petition from Adrienne Samuels
0900006484a5ecef,Supporting & Related Material,FDA-2021-P-0267-0015,FDA-2021-P-0267,Reference 15 - Designed for Deception: The fail-safe way to ensure that their studies would conclude MSG is harmless RE Citizen Petition from Adrienne Samuels
0900006484a5ece2,Supporting & Related Material,FDA-2021-P-0267-0008,FDA-2021-P-0267,Reference 6 - THE TOXICITY/SAFETY OF PROCESSED FREE GLUTAMIC ACID (MSG): A STUDY IN SUPPRESSION OF INFORMATION RE Citizen Petition from Adrienne Samuels
0900006484a5ece7,Supporting & Related Material,FDA-2021-P-0267-0012,FDA-2021-P-0267,Reference 12 - Letter from International Glutamate Technical Committee RE Citizen Petition from Adrienne Samuels
0900006484a5ecfa,Supporting & Related Material,FDA-2021-P-0267-0019,FDA-2021-P-0267,"Reference 19 - Global Monosodium Glutamate Market Poised to Surge from USD 4,500.0 Million in 2014
to USD 5,850.0 Million by 2020 – MarketResearchStore.Com  RE Citizen Petition from Adrienne Samuels"
0900006484a5ecfb,Supporting & Related Material,FDA-2021-P-0267-0020,FDA-2021-P-0267,Reference 20 - Global Flavor Enhancers Market: Report Highlights RE Citizen Petition from Adrienne Samuels
0900006482978c64,Other,FDA-2017-P-3064-0025,FDA-2017-P-3064,"Letter from FDA CDER to  Pharmaceutical Manufacturing Research Services, Inc."
09000064825bb998,Supporting & Related Material,FDA-2017-P-3064-0015,FDA-2017-P-3064,"Attachment 13 Inspirion Presentation re Citizen Petition from Pharmaceutical Manufacturing Research Services, Inc."
09000064825bb994,Supporting & Related Material,FDA-2017-P-3064-0011,FDA-2017-P-3064,"Attachment 9  Generic AD Opioid Draft Guidance re Citizen Petition from Pharmaceutical Manufacturing Research Services, Inc."
09000064825bb993,Supporting & Related Material,FDA-2017-P-3064-0010,FDA-2017-P-3064,"Attachment 8 Highlights of Prescribing Information RoxyBond, April 2017 re Citizen Petition from Pharmaceutical Manufacturing Research Services, Inc."
09000064825bb997,Supporting & Related Material,FDA-2017-P-3064-0014,FDA-2017-P-3064,"Attachment 12 IR REMS - FDA re Citizen Petition from Pharmaceutical Manufacturing Research Services, Inc."
0900006482c2afac,Other,FDA-2017-P-3064-0030,FDA-2017-P-3064,"Petition Response Letter from FDA CDER to  Pharmaceutical Manufacturing Research Services, Inc."
09000064825bb0a4,Supporting & Related Material,FDA-2017-P-3064-0005,FDA-2017-P-3064,"Attachment 3 CDC Guideline for Prescribing Opioids for Chronic Pain re Citizen Petition from Pharmaceutical Manufacturing Research Services, Inc."
09000064825bb995,Supporting & Related Material,FDA-2017-P-3064-0012,FDA-2017-P-3064,"Attachment 10 FDA Briefing Information (Addendum) re Citizen Petition from Pharmaceutical Manufacturing Research Services, Inc."
09000064825bb992,Supporting & Related Material,FDA-2017-P-3064-0009,FDA-2017-P-3064,"Attachment 7 AD Opioid Evaluation and Labeling Guidance re Citizen Petition from Pharmaceutical Manufacturing Research Services, Inc."
09000064825bb996,Supporting & Related Material,FDA-2017-P-3064-0013,FDA-2017-P-3064,"Attachment 11 Inspirion Briefing Information re Citizen Petition from Pharmaceutical Manufacturing Research Services, Inc."
09000064825bb999,Supporting & Related Material,FDA-2017-P-3064-0016,FDA-2017-P-3064,"Attachment 14 Pokrovnichka History of OxyContin Labeling and Risk Management Program re Citizen Petition from Pharmaceutical Manufacturing Research Services, Inc."
09000064825bb99b,Supporting & Related Material,FDA-2017-P-3064-0018,FDA-2017-P-3064,"Attachment 16 FDA Briefing Information re Citizen Petition from Pharmaceutical Manufacturing Research Services, Inc."
09000064825bb0a5,Supporting & Related Material,FDA-2017-P-3064-0006,FDA-2017-P-3064,"Attachment 4 Inspirion Delivery Sciences Receives FDA Approval for RoxyBond (oxycodone hydrochloride) tablets-2 re Citizen Petition from Pharmaceutical Manufacturing Research Services, Inc."
09000064825bb99c,Other,FDA-2017-P-3064-0002,FDA-2017-P-3064,"Acknowledgment Letter from FDA DDM to  Pharmaceutical Manufacturing Research Services, Inc."
09000064825bb0a0,Other,FDA-2017-P-3064-0001,FDA-2017-P-3064,"Citizen Petition from Pharmaceutical Manufacturing Research Services, Inc."
09000064825c6db3,Supporting & Related Material,FDA-2017-P-3064-0019,FDA-2017-P-3064,"Attachment 17  Citizen Petition FDA-2017-P-1359 (2) re Citizen Petition from Pharmaceutical Manufacturing Research Services, Inc."
09000064825c6db4,Supporting & Related Material,FDA-2017-P-3064-0020,FDA-2017-P-3064,Attachment 18  Citizen Petition FDA-2016-P-0645 - REDACTED
09000064825bb0a2,Supporting & Related Material,FDA-2017-P-3064-0003,FDA-2017-P-3064,"Attachment 1  CDER Interim Response Letter re Citizen Petition from Pharmaceutical Manufacturing Research Services, Inc."
09000064825bb991,Supporting & Related Material,FDA-2017-P-3064-0008,FDA-2017-P-3064,"Attachment 6 A Proactive Response to Prescription Opioid Abuse re Citizen Petition from Pharmaceutical Manufacturing Research Services, Inc."
09000064825bb99a,Supporting & Related Material,FDA-2017-P-3064-0017,FDA-2017-P-3064,"Attachment 15 Letter from Janet Woodcock, Docket 1992-P-0494 re Citizen Petition from Pharmaceutical Manufacturing Research Services, Inc."
09000064825bb990,Supporting & Related Material,FDA-2017-P-3064-0007,FDA-2017-P-3064,"Attachment 5 Letter from Edwin R_ Thompson-2  re Citizen Petition from Pharmaceutical Manufacturing Research Services, Inc."
09000064825bb0a3,Supporting & Related Material,FDA-2017-P-3064-0004,FDA-2017-P-3064,"Attachment 2 Washington Post April 5-2 re Citizen Petition from Pharmaceutical Manufacturing Research Services, Inc."
090000648259a6fd,Other,FDA-2017-P-1221-0005,FDA-2017-P-1221,Suitability Petition Amendment from Aurora Pharmaceutical LLC
09000064824de81c,Supporting & Related Material,FDA-2017-P-1221-0003,FDA-2017-P-1221,"Attachment 1 Equioxx® Oral Paste, labeling by Merial, rev 06-2015 re Suitability Petition from Aurora Pharmaceutical LLC"
09000064824de81a,Other,FDA-2017-P-1221-0002,FDA-2017-P-1221,Acknowledgement Letter from FDA DDM to Aurora Pharmaceutical LLC
09000064824de471,Other,FDA-2017-P-1221-0001,FDA-2017-P-1221,Suitability Petition from Aurora Pharmaceutical LLC
09000064825832b2,Other,FDA-2017-P-1221-0004,FDA-2017-P-1221,Amendment from Aurora Pharmaceutical LLC
09000064825f62a9,Other,FDA-2017-P-1221-0006,FDA-2017-P-1221,"Letter from CVM to Aurora Pharmaceutical, LLC"
09000064841245ca,Supporting & Related Material,FDA-2019-P-5237-0003,FDA-2019-P-5237,"Attachment 1 Orange Book: Approved Drug Products with
Therapeutic Equivalence Evaluations- Redacted re Citizen Petition from Aurobindo Pharma USA, Inc"
090000648484b516,Other,FDA-2019-P-5237-0005,FDA-2019-P-5237,Letter from FDA CDER to Aurobindo Pharma Limited
0900006484124585,Other,FDA-2019-P-5237-0001,FDA-2019-P-5237,"Citizen Petition from Aurobindo Pharma USA, Inc"
0900006484124dba,Other,FDA-2019-P-5237-0002,FDA-2019-P-5237,"Acknowledgment Letter from DMS to Aurobindo Pharma USA, Inc"
09000064844d307f,Other,FDA-2019-P-5237-0004,FDA-2019-P-5237,Interim Response Letter from FDA CDER to US Agent for Aurobindo Pharma Limited
09000064849999b7,Other,FDA-2020-P-1575-0004,FDA-2020-P-1575,Interim response letter from FDA CDER to  Francis E. O'Donnell
09000064846f40a6,Supporting & Related Material,FDA-2020-P-1575-0003,FDA-2020-P-1575,Attachment 1 - HHS Guide for Clinicians on the Appropriate Dosage Reduction or Discontinuation of Long-Term Opioid Analgesics RE: Citizen Petition from Francis E. O'Donnell
09000064846f42ff,Other,FDA-2020-P-1575-0001,FDA-2020-P-1575,Citizen Petition from Francis E. O'Donnell
09000064846f40a3,Other,FDA-2020-P-1575-0002,FDA-2020-P-1575,Acknowledgment Letter from FDA DMS to Francis E. O'Donnell
0900006484a71c7d,Other,FDA-2021-P-0306-0002,FDA-2021-P-0306,Acknowledgment Letter from FDA DMS to Encube Ethicals Private Limited
0900006484affd66,Notice,FDA-2021-P-0306-0004,FDA-2021-P-0306,"Determination That OVIDE (Malathion) Lotion, 0.5%, Was Not Withdrawn From Sale for Reasons of Safety or
Effectiveness"
0900006484a74cb7,Supporting & Related Material,FDA-2021-P-0306-0003,FDA-2021-P-0306,Attachment re Citizen Petition from Encube Ethicals Private Limited
0900006484a71c7a,Other,FDA-2021-P-0306-0001,FDA-2021-P-0306,Citizen Petition from Encube Ethicals Private Limited
0900006484b077a3,Other,FDA-2021-P-0306-0005,FDA-2021-P-0306,Response Letter from FDA CDER to Encube Ethicals Private Limited
0900006484be6030,Other,FDA-2021-P-0705-0002,FDA-2021-P-0705,Acknowledgment Letter from FDA DMS to Catalyst Pharmaceuticals
0900006484be5a09,Other,FDA-2021-P-0705-0001,FDA-2021-P-0705,Citizen Petition from Catalyst Pharmaceuticals
09000064809f11ad,Other,FDA-2009-P-0325-0001,FDA-2009-P-0325,Reckitt Benckiser Pharmaceuticals Inc. - Citizen Petition
0900006480a0f90f,Supporting & Related Material,FDA-2009-P-0325-0005,FDA-2009-P-0325,"Exhibit 1 - Guidance for Industry--ANDAs: Impurities in Drug Substances - [Reckitt Benckiser Pharmaceuticals, Inc. - Supplement Citizen Petition] re FDA-2009-P-0325-0004"
09000064809f1bbd,Supporting & Related Material,FDA-2009-P-0325-0002,FDA-2009-P-0325,"Exhibit 1 - Labeling - [Reckitt Benckiser, Pharmaceuticals Inc. - Citizen Petition]"
0900006480a3edce,Other,FDA-2009-P-0325-0006,FDA-2009-P-0325,"FDA to Reckitt Benckiser Pharmaceuticals, Inc. - Petition Partial Approval and Denial"
0900006480a0f90d,Other,FDA-2009-P-0325-0004,FDA-2009-P-0325,"Reckitt Benckiser Pharmaceuticals, Inc. - Supplement Citizen Petition"
09000064809f11ae,Other,FDA-2009-P-0325-0003,FDA-2009-P-0325,Acknowledgement Letter to Reckitt Benckiser Pharmaceuticals Inc.
0900006484de516c,Other,FDA-2021-P-0413-0003,FDA-2021-P-0413,Interim Response from FDA CDER to Radius Health Inc
0900006484ab849f,Other,FDA-2021-P-0413-0001,FDA-2021-P-0413,"Citizen Petition from Radius Health, Inc."
0900006484ab854a,Other,FDA-2021-P-0413-0002,FDA-2021-P-0413,Acknowledgment Letter to Radius Health Inc from FDA DMS
0900006484de575e,Other,FDA-2021-P-1148-0001,FDA-2021-P-1148,Citizen Petition from Marlene Keeling
0900006484de5760,Other,FDA-2021-P-1148-0002,FDA-2021-P-1148,Acknowledgment Letter from FDA DMS to Marlene Keeling
0900006483d7a3ce,Other,FDA-2018-P-3102-0069,FDA-2018-P-3102,Letter from FDA CDRH to Richard M. Fleming
090000648393b4c2,Other,FDA-2018-P-3102-0068,FDA-2018-P-3102,Supplement from Richard Fleming
09000064835f38e4,Supporting & Related Material,FDA-2018-P-3102-0005,FDA-2018-P-3102,Gamma Gazette March 2011- Issue 1re: Citizen Petition from Richard M Fleming
09000064835f38e6,Supporting & Related Material,FDA-2018-P-3102-0007,FDA-2018-P-3102,Use of Parabolic Model in Tomographic Diagnosis of Infarction and Stenosis. re: Citizen Petition from Richard M Fleming
09000064835f3c35,Supporting & Related Material,FDA-2018-P-3102-0016,FDA-2018-P-3102,"Both Percent Diameter Stenosis (%DS) and Coronary Flow Reserve (CFR)
can be Derived Directly from Myocardial Perfusion Imaging (MPI) using
FMTVDM©℗ and Measurement of Isotope Redistribution re: Citizen Petition from Richard M Fleming"
09000064835f3c4d,Supporting & Related Material,FDA-2018-P-3102-0036,FDA-2018-P-3102,"Myoview and Sestamibi redistribution, stress once- image twice protocol improves detection of ischemia in addition to improving patient throughput and reducing patient radiation  re: Citizen Petition from Richard M Fleming"
09000064835f3c56,Supporting & Related Material,FDA-2018-P-3102-0042,FDA-2018-P-3102,Training physicians and healthcare providers to accurately  re: Citizen Petition from Richard M Fleming
09000064835f38e5,Supporting & Related Material,FDA-2018-P-3102-0006,FDA-2018-P-3102,The evolution of Nuclear Cardiology takes us back to the beginning to develop today’s “New standard of care” for Cardiac Imaging: How Quantifying Regional Radioactive counts at five and 60 minute post-stress unmasks hidden Ischemia re: Citizen Petition from Richard M Fleming
09000064835f3c36,Supporting & Related Material,FDA-2018-P-3102-0017,FDA-2018-P-3102,"FMTVDM©℗ Stress-First/Stress-Only Imaging is here! But First We Need
to Clarify the Use of What (1) Stress, (2) Rest, (3) Redistribution and (4)
Quantification, Really Mean re: Citizen Petition from Richard M Fleming"
09000064835f3c3a,Supporting & Related Material,FDA-2018-P-3102-0021,FDA-2018-P-3102,"Breast cancer genes, breast cancer and FMTVDMBEST
©℗ imaging re: Citizen Petition from Richard M Fleming"
09000064835f3c4a,Supporting & Related Material,FDA-2018-P-3102-0033,FDA-2018-P-3102,"FMTVDM©℗*** Nuclear Imaging Artificial (AI) Intelligence But First We Need to Clarify the Use Of (1) Stress, (2) Rest, (3) Redistribution And (4) Quantification re: Citizen Petition from Richard M Fleming"
09000064835f3c37,Supporting & Related Material,FDA-2018-P-3102-0018,FDA-2018-P-3102,United State Senate Charles E Grassley re: Citizen Petition from Richard M Fleming
09000064835f3c39,Supporting & Related Material,FDA-2018-P-3102-0020,FDA-2018-P-3102,"Breast Enhanced Scintigraphy Testing Distinguishes Between Normal, Inflammatory Breast Changes, and Breast Cancer: A Prospective
Analysis and Comparison With Mammographyre: Citizen Petition from Richard M Fleming"
09000064835f3c45,Supporting & Related Material,FDA-2018-P-3102-0030,FDA-2018-P-3102,Integrative Cancer Therapies re: Citizen Petition from Richard M Fleming
09000064835f3c4b,Supporting & Related Material,FDA-2018-P-3102-0034,FDA-2018-P-3102,Are There Differences in Breast Tissue as a Result of Hormone Replacement Therapy? Can BEST Imaging Distinguish These Differences? re: Citizen Petition from Richard M Fleming
09000064836cbc0d,Supporting & Related Material,FDA-2018-P-3102-0045,FDA-2018-P-3102,Fludeoxyglucose F 18 PET Radiopharmacuticals  Lantheus
09000064835f37ab,Other,FDA-2018-P-3102-0002,FDA-2018-P-3102,Acknowledgment Letter from FDA DDM to Richard M Fleming
09000064835f3c33,Supporting & Related Material,FDA-2018-P-3102-0014,FDA-2018-P-3102,"The Development of FMTVDM-BEST IMAGING©℗: The Answer for Breast
Cancer. Breast Enhanced Scintigraphy Test (BEST©℗): Quantifying the
Detection of Breast Cancer and its Treatment. re: Citizen Petition from Richard M Fleming"
09000064835f3c3e,Supporting & Related Material,FDA-2018-P-3102-0024,FDA-2018-P-3102,FMTVDM©℗ – Evolution of Nuclear Cardiology & Nuclear Medicine. re: Citizen Petition from Richard M Fleming
09000064835f3c4f,Supporting & Related Material,FDA-2018-P-3102-0038,FDA-2018-P-3102,Expert Endorsement re: Citizen Petition from Richard M Fleming
09000064835f3c44,Supporting & Related Material,FDA-2018-P-3102-0029,FDA-2018-P-3102,"THE EVOLUTION OF NUCLEAR CARDIOLOGY TAKES US BACK TO THE
BEGINNING TO DEVELOP TODAY’S “NEW STANDARD OF CARE” FOR CARDIAC IMAGING: HOW QUANTIFYING REGIONAL RADIOACTIVE COUNTS AT FIVE AND 60 MINUTES POST-STRESS UNMASKS
HIDDEN ISCHEMIA re: Citizen Petition from Richard M Fleming"
09000064835f3c46,Supporting & Related Material,FDA-2018-P-3102-0031,FDA-2018-P-3102,"RIA-FHRWW© analysis of the redistribution properties of Tc-99m isotope agents,sestamibi and myoview, enhances the detection of ischemic heart disease re: Citizen Petition from Richard M Fleming"
09000064835f3c58,Supporting & Related Material,FDA-2018-P-3102-0043,FDA-2018-P-3102,CURRICULUM VITAE  Richard Maximus Fleming re: Citizen Petition from Richard M Fleming
09000064835f3c31,Supporting & Related Material,FDA-2018-P-3102-0012,FDA-2018-P-3102,Renewed Application of an Old Method Improves Detection of Coronary lschemia: A Higher Standard of Carere: Citizen Petition from Richard M Fleming
09000064835f3c41,Supporting & Related Material,FDA-2018-P-3102-0026,FDA-2018-P-3102,"FMTVDM-TFM©℗: True quantification requires standardization of the tool
being used to measure, with a known, unchanging standard to produce accurate, consistent and reproducible quantified measurements re: Citizen Petition from Richard M Fleming"
0900006483318f95,Other,FDA-2017-P-6805-0003,FDA-2017-P-6805,Interim Response Letter from FDA CDER to Bracco Diagnostics Inc.
0900006482cf8411,Other,FDA-2017-P-6805-0002,FDA-2017-P-6805,Acknowledgment Letter from FDA DDM to Bracco Diagnostics Inc.
0900006482cf8273,Other,FDA-2017-P-6805-0001,FDA-2017-P-6805,Citizen Petition from Bracco Diagnostics Inc
09000064821487f2,Supporting & Related Material,FDA-2016-P-2342-0004,FDA-2016-P-2342,"Orange Book Printout of RLD re Citizen Petition from Sovereign Pharmaceuticals, LLC"
09000064821484ce,Other,FDA-2016-P-2342-0002,FDA-2016-P-2342,"Acknowledgement Letter from FDA DDM to Sovereign Pharmaceuticals, LLC"
09000064821484cc,Other,FDA-2016-P-2342-0001,FDA-2016-P-2342,"Citizen Petition from Sovereign Pharmaceuticals, LLC"
09000064821484d0,Supporting & Related Material,FDA-2016-P-2342-0003,FDA-2016-P-2342,"Draft Guidance on Metaxalone re Citizen Petition from Sovereign Pharmaceuticals, LLC"
09000064821487f3,Supporting & Related Material,FDA-2016-P-2342-0005,FDA-2016-P-2342,"Orange Book Printout of Proposed Strengths re Citizen Petition from Sovereign Pharmaceuticals, LLC"
0900006483857e2f,Other,FDA-2016-P-2342-0006,FDA-2016-P-2342,"Withdrawal Letter from Sovereign Pharmaceuticals LLC, (Xspire Pharma, LLC)"
0900006482c2addd,Supporting & Related Material,FDA-2017-P-6316-0003,FDA-2017-P-6316,"Exhibit A -USP Monographs for Methylene Blue and Methylene Blue Injection re Citizen Petition from Kleinfeld Kaplan & Becker, LLP (Provepharm SAS)"
09000064831e964d,Other,FDA-2017-P-6316-0009,FDA-2017-P-6316,"Interim Response from FDA CDER to Provepharm, SAS"
0900006482c2adde,Supporting & Related Material,FDA-2017-P-6316-0004,FDA-2017-P-6316,"Exhibit B - Petzer, A., et al., Azure B, a metabolite of methylene blue, is a high-potency, reversible inhibitor of monoamine oxidase, Toxicol re Citizen Petition from Kleinfeld Kaplan & Becker, LLP (Provepharm SAS)"
0900006482c2ade2,Supporting & Related Material,FDA-2017-P-6316-0008,FDA-2017-P-6316,"Exhibit F - Akom Package Insert (April 2017) re Citizen Petition from Kleinfeld Kaplan & Becker, LLP (Provepharm SAS)"
0900006482c2addf,Supporting & Related Material,FDA-2017-P-6316-0005,FDA-2017-P-6316,"Exhibit C- Delport, A. et al., Azure B and a synthetic structural analogue of methylene blue, ethylthioninium chloride, present with antidepressant-like properties re Citizen Petition from Kleinfeld Kaplan & Becker, LLP (Provepharm SAS)"
0900006482c2ade0,Supporting & Related Material,FDA-2017-P-6316-0006,FDA-2017-P-6316,"Exhibit D - Jacobson-Kram, D and McGovern, T, Toxicological overview of impurities in pharmaceutical products, Advan Drug Deliv Rev, 59 (2007) 38-42 re Citizen Petition from Kleinfeld Kaplan & Becker, LLP (Provepharm SAS)"
0900006482c2ade1,Supporting & Related Material,FDA-2017-P-6316-0007,FDA-2017-P-6316,"Exhibit E - Akom Product page for Methylene Blue Injection, USP re Citizen Petition from Kleinfeld Kaplan & Becker, LLP (Provepharm SAS)"
0900006482c29e92,Other,FDA-2017-P-6316-0001,FDA-2017-P-6316,"Citizen Petition from Kleinfeld Kaplan & Becker, LLP (Provepharm SAS)"
0900006482c2a39e,Other,FDA-2017-P-6316-0002,FDA-2017-P-6316,"Acknowledgement Letter from FDA DDM to Kleinfeld Kaplan & Becker, LLP (Provepharm SAS)"
0900006481fdb7ff,Supporting & Related Material,FDA-2016-P-1288-0018,FDA-2016-P-1288,Exhibits-192-205 re Citizen Petition from Fluoride Action Network
0900006481fdb7fd,Supporting & Related Material,FDA-2016-P-1288-0016,FDA-2016-P-1288,Exhibits-154-173 re Citizen Petition from Fluoride Action Network
0900006481fdbb3f,Supporting & Related Material,FDA-2016-P-1288-0005,FDA-2016-P-1288,Exhibit_013 re Citizen Petition from Fluoride Action Network
0900006481fdbb39,Other,FDA-2016-P-1288-0002,FDA-2016-P-1288,Acknowledgement Letter from FDA DDM to Fluoride Action Network
09000064823c8f8c,Other,FDA-2016-P-1288-0020,FDA-2016-P-1288,Petition Denial Letter from FDA DDM to Fluoride Action Network
0900006481fdb7dc,Supporting & Related Material,FDA-2016-P-1288-0007,FDA-2016-P-1288,Exhibits_027 re Citizen Petition from Fluoride Action Network
0900006481fdb7e1,Supporting & Related Material,FDA-2016-P-1288-0012,FDA-2016-P-1288,Exhibits_084-95 re Citizen Petition from Fluoride Action Network
0900006481fdb7e2,Supporting & Related Material,FDA-2016-P-1288-0013,FDA-2016-P-1288,Exhibits-096-109 re Citizen Petition from Fluoride Action Network
0900006481fdbb3c,Supporting & Related Material,FDA-2016-P-1288-0003,FDA-2016-P-1288,Exhibits 001-07 re Citizen Petition from Fluoride Action Network
0900006481fdb7df,Supporting & Related Material,FDA-2016-P-1288-0010,FDA-2016-P-1288,Exhibits_061-72 re Citizen Petition from Fluoride Action Network
0900006481fdb7e3,Supporting & Related Material,FDA-2016-P-1288-0014,FDA-2016-P-1288,Exhibits-110-128 re Citizen Petition from Fluoride Action Network
0900006481fdb7db,Supporting & Related Material,FDA-2016-P-1288-0006,FDA-2016-P-1288,Exhibits_014-26 re Citizen Petition from Fluoride Action Network
0900006481fdb7fe,Supporting & Related Material,FDA-2016-P-1288-0017,FDA-2016-P-1288,Exhibits-174-191 re Citizen Petition from Fluoride Action Network
0900006481fdba91,Other,FDA-2016-P-1288-0001,FDA-2016-P-1288,Citizen Petition from Fluoride Action Network
0900006481fdbb3d,Supporting & Related Material,FDA-2016-P-1288-0004,FDA-2016-P-1288,Exhibits_008-12 re Citizen Petition from Fluoride Action Network
0900006481fdb7dd,Supporting & Related Material,FDA-2016-P-1288-0008,FDA-2016-P-1288,Exhibits_028-47 re Citizen Petition from Fluoride Action Network
0900006481fdb7de,Supporting & Related Material,FDA-2016-P-1288-0009,FDA-2016-P-1288,Exhibits_048-60 re Citizen Petition from Fluoride Action Network
0900006481fdb7e0,Supporting & Related Material,FDA-2016-P-1288-0011,FDA-2016-P-1288,Exhibits_073-83 re Citizen Petition from Fluoride Action Network
0900006481fdb7e4,Supporting & Related Material,FDA-2016-P-1288-0015,FDA-2016-P-1288,Exhibits-129-153 re Citizen Petition from Fluoride Action Network
0900006481fdb801,Supporting & Related Material,FDA-2016-P-1288-0019,FDA-2016-P-1288,Exhibits-206-209 re Citizen Petition from Fluoride Action Network
0900006481a8e609,Other,FDA-2015-P-1103-0001,FDA-2015-P-1103,"Citizen Petition from Hyman, Phelps & McNamara, P.C."
0900006481d1cb54,Other,FDA-2015-P-1103-0004,FDA-2015-P-1103,"Withdrawal Letter from Hyman, Phelps, & McNamara, P.C."
0900006481a8e792,Other,FDA-2015-P-1103-0002,FDA-2015-P-1103,"Acknowledgement Letter from FDA DDM to Hyman, Phelps & McNamara, P.C."
0900006481c9f525,Other,FDA-2015-P-1103-0003,FDA-2015-P-1103,"Interim Response Letter from FDA CDER to Hyman, Phelps & McNamara, P.C."
090000648252e93c,Other,FDA-2016-P-2377-0010,FDA-2016-P-2377,Interim Response Letter from CFSAN to Archer Daniels Midland Company
090000648214f74d,Supporting & Related Material,FDA-2016-P-2377-0003,FDA-2016-P-2377,Appendix A Scientific Evidence re Citizen Petition from Archer Daniels Midland Company
090000648214f751,Supporting & Related Material,FDA-2016-P-2377-0007,FDA-2016-P-2377,Appendix D re Citizen Petition from Archer Daniels Midland Company
090000648214f753,Supporting & Related Material,FDA-2016-P-2377-0009,FDA-2016-P-2377,Appendix F re Citizen Petition from Archer Daniels Midland Company
090000648214f497,Other,FDA-2016-P-2377-0001,FDA-2016-P-2377,Citizen Petition from Archer Daniels Midland Company
090000648214f74f,Supporting & Related Material,FDA-2016-P-2377-0005,FDA-2016-P-2377,Appendix B re Citizen Petition from Archer Daniels Midland Company
090000648214f499,Other,FDA-2016-P-2377-0002,FDA-2016-P-2377,Acknowledgement Letter from FDA DDM to Archer Daniels Midland Company
090000648214f750,Supporting & Related Material,FDA-2016-P-2377-0006,FDA-2016-P-2377,Appendix C re Citizen Petition from Archer Daniels Midland Company
090000648214f752,Supporting & Related Material,FDA-2016-P-2377-0008,FDA-2016-P-2377,Appendix E re Citizen Petition from Archer Daniels Midland Company
090000648214f74e,Supporting & Related Material,FDA-2016-P-2377-0004,FDA-2016-P-2377,Appendix A re Citizen Petition from Archer Daniels Midland Company
090000648341077b,Other,FDA-2016-P-2377-0011,FDA-2016-P-2377,FDA-2016-P-2377 - Archer Daniels Midland - Granting Response
09000064807b0083,Notice,FDA-2008-N-0571-0001,FDA-2008-N-0571,"Agency Information Collection Activities; Proposed Collection; Comment Request; Guidance for Industry and Food and Drug Administration Staff; Compliance With the Medical Device User Fee and Modernization Act of 2002, as Amended: Prominent and Conspicous Mark of Manufacturers on Single-Use Devices (formerly ""Reprocessed Single-Use Device Labeling"")"
09000064808525d0,Notice,FDA-2008-N-0571-0004,FDA-2008-N-0571,"Agency Information Collection Activities; Proposals, Submissions, and Approvals"
09000064846d4cb9,Supporting & Related Material,FDA-2020-P-1510-0015,FDA-2020-P-1510,Appendix #1 “Operation Plan for Adding Drugs to HPUS” RE: Citizen's Petition from AMERICANS FOR HOMEOPATHY CHOICE FOUNDATION
09000064846d4cdb,Supporting & Related Material,FDA-2020-P-1510-0005,FDA-2020-P-1510,"Appendix #11 69 Fed. Reg. 227, 68834 (Nov. 26, 2004) RE: Citizen's Petition from AMERICANS FOR HOMEOPATHY CHOICE FOUNDATION"
09000064846d4cdd,Supporting & Related Material,FDA-2020-P-1510-0003,FDA-2020-P-1510,"Appendix #13 “The Safety of Homeopathy,”Americans for Homeopathy Choice, and Ronald W. Dushkin, MD and Ronald D. Whitmont, MD RE: Citizen's Petition from AMERICANS FOR HOMEOPATHY CHOICE FOUNDATION"
09000064846d4cbc,Supporting & Related Material,FDA-2020-P-1510-0012,FDA-2020-P-1510,"Appendix #4  “Supplements to the Homeopathic Pharmacopeia
of the United States” RE: Citizen's Petition from AMERICANS FOR HOMEOPATHY CHOICE FOUNDATION"
09000064846d4cbb,Supporting & Related Material,FDA-2020-P-1510-0013,FDA-2020-P-1510,Appendix #3 A Proposal by Americans for Homeopathy Choice for the Application of a Risk-Based Policy to Homeopathic Drugs & Drug Products Labeled as Homeopathic RE: Citizen's Petition from AMERICANS FOR HOMEOPATHY CHOICE FOUNDATION
09000064846d4cd8,Supporting & Related Material,FDA-2020-P-1510-0008,FDA-2020-P-1510,"Appendix #8 “Homeopathic Monographs Added to the Homeopathic
Pharmacopoeia Since 2000” RE: Citizen's Petition from AMERICANS FOR HOMEOPATHY CHOICE FOUNDATION"
09000064846d4c02,Other,FDA-2020-P-1510-0001,FDA-2020-P-1510,Acknowledgment Letter from FDA DMS to Americans for Homeopathy Choice Foundation
09000064849e86af,Other,FDA-2020-P-1510-22552,FDA-2020-P-1510,Interim response from FDA CDER to Americans for Homeopathy Choice Foundation
09000064846d4cd7,Supporting & Related Material,FDA-2020-P-1510-0009,FDA-2020-P-1510,"Appendix #7 48 Fed. Reg. 64, 14004 (April 1, 1983) RE: Citizen's Petition from AMERICANS FOR HOMEOPATHY CHOICE FOUNDATION"
09000064846d4cd9,Supporting & Related Material,FDA-2020-P-1510-0007,FDA-2020-P-1510,"Appendix #9 “Over-the-Counter Drug Review,” 21 CFR part 330.1 RE: Citizen's Petition from AMERICANS FOR HOMEOPATHY CHOICE FOUNDATION"
09000064846d4cda,Supporting & Related Material,FDA-2020-P-1510-0006,FDA-2020-P-1510,"Appendix #10 “Over-the-Counter Drug Review,” 21 CFR part 330.1 RE: Citizen's Petition from AMERICANS FOR HOMEOPATHY CHOICE FOUNDATION"
09000064846d4cbd,Supporting & Related Material,FDA-2020-P-1510-0011,FDA-2020-P-1510,Appendix #5 Limitations of FAERS Data RE: Citizen's Petition from AMERICANS FOR HOMEOPATHY CHOICE FOUNDATION
09000064846d4cdc,Supporting & Related Material,FDA-2020-P-1510-0004,FDA-2020-P-1510,"Appendix #12 “FDA’s Statements of General Policy or Interpretation”
found in 37 Fed. Reg. 156, 16174 (Aug 11, 1972) RE: Citizen's Petition from AMERICANS FOR HOMEOPATHY CHOICE FOUNDATION"
09000064846d4cba,Supporting & Related Material,FDA-2020-P-1510-0014,FDA-2020-P-1510,Appendix #2 80 Fed. Reg. 16327 “Homeopathic Product Regulation: Evaluating the Food and Drug Administration’s Regulatory Framework After a Quarter-Century: Public Hearing” RE: Citizen's Petition from AMERICANS FOR HOMEOPATHY CHOICE FOUNDATION
09000064846d4cbe,Supporting & Related Material,FDA-2020-P-1510-0010,FDA-2020-P-1510,"Appendix #6 “Epidemic Infectious Diseases, Public Health and Homeopathy,” by Andre Saine, ND RE: Citizen's Petition from AMERICANS FOR HOMEOPATHY CHOICE FOUNDATION"
09000064846d1276,Other,FDA-2020-P-1510-0002,FDA-2020-P-1510,Citizen's Petition from AMERICANS FOR HOMEOPATHY CHOICE FOUNDATION
0900006482c0b6ba,Supporting & Related Material,FDA-2017-P-6274-0005,FDA-2017-P-6274,Attachment 3-USP Official Monograph (Teriparatide) re Citizen Petition from Amneal Pharmaceuticals
0900006482c0b4f9,Supporting & Related Material,FDA-2017-P-6274-0003,FDA-2017-P-6274,Attachment 1-Reference Listed Drug Prescribing Information for Forteo re Citizen Petition from Amneal Pharmaceuticals
0900006482c0b6bb,Supporting & Related Material,FDA-2017-P-6274-0006,FDA-2017-P-6274,Attachment 4-FDA Draft Guidance for Industry ANDAs for Certain Highly Purified Synthetic Peptide Drug re Citizen Petition from Amneal Pharmaceuticals
0900006482c0b6b9,Supporting & Related Material,FDA-2017-P-6274-0004,FDA-2017-P-6274,Attachment 2-Chemistry review on potential impurities in synthetic Teriparatide re Citizen Petition from Amneal Pharmaceuticals
0900006482c0b478,Other,FDA-2017-P-6274-0001,FDA-2017-P-6274,Citizen Petition from Amneal Pharmaceuticals
0900006482c0b4f7,Other,FDA-2017-P-6274-0002,FDA-2017-P-6274,Acknowledgement Letter from FDA DDM to Amneal Pharmaceuticals
0900006482d9e58e,Other,FDA-2017-P-6274-0007,FDA-2017-P-6274,Response Letter from FDA CDER to Amneal Pharmaceuticals
0900006482486094,Other,FDA-2016-P-2469-0006,FDA-2016-P-2469,"Determination letter from CDER to Hyman, Phelps & McNamara, P.C."
090000648216266d,Supporting & Related Material,FDA-2016-P-2469-0003,FDA-2016-P-2469,"Attachment 1 Applicant Name Changes re Citizen Petition from Hyman, Phelps & McNamara, P. C."
09000064821620a2,Other,FDA-2016-P-2469-0001,FDA-2016-P-2469,"Citizen Petition from Hyman, Phelps & McNamara, P. C."
090000648248055b,Notice,FDA-2016-P-2469-0005,FDA-2016-P-2469,"Determination That SYMMETREL (Amantadine Hydrochloride), Syrup, 50
Milligrams/5 Milliliters, Was Not Withdrawn From Sale for Reasons of
Safety or Effectiveness"
0900006482369b24,Other,FDA-2016-P-2469-0004,FDA-2016-P-2469,"Correction from Hyman, Phelps & McNamara, P.C."
09000064821620a4,Other,FDA-2016-P-2469-0002,FDA-2016-P-2469,"Acknowledgement Letter from FDA DDM to Hyman, Phelps & McNamara, P.  C."
0900006481b67e4a,Other,FDA-2015-P-2344-0001,FDA-2015-P-2344,Citizen Petition from Lachman Consultant Services Inc
0900006481b67f51,Supporting & Related Material,FDA-2015-P-2344-0005,FDA-2015-P-2344,Attachment 2 RLD Labeling for Oxycodone and Acetaminophen Tablets re Citizen Petition from Lachman Consultant Services Inc
0900006481b67ed2,Other,FDA-2015-P-2344-0004,FDA-2015-P-2344,Acknowledgement Letter from FDA DDM to Lachman Consultant Services Inc
0900006481b67f50,Supporting & Related Material,FDA-2015-P-2344-0002,FDA-2015-P-2344,Attachment 1 Electronic Orange Book Listing re Citizen Petition from Lachman Consultant Services Inc
0900006481b67f52,Supporting & Related Material,FDA-2015-P-2344-0003,FDA-2015-P-2344,Attachment 3 Proposed Labeling for Oxycodone and Acetaminophen Tablets re Citizen Petition from Lachman Consultant Services Inc
0900006483780eaa,Other,FDA-2018-P-3691-0002,FDA-2018-P-3691,"Acknowledgment Letter from FDA DDM to Avanthi, LLC."
0900006483780af6,Other,FDA-2018-P-3691-0001,FDA-2018-P-3691,"Citizen Petition from Avanthi, LLC."
0900006483b572c6,Notice,FDA-2018-P-3691-0004,FDA-2018-P-3691,"TRIMETON ALLERGY 12 HOUR (Chlorpheniramine Maleate) Extended
Release Tablets, 8 Milligrams and 12 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
0900006483b59139,Other,FDA-2018-P-3691-0005,FDA-2018-P-3691,"Letter from FDA CDER to KVK-TECH, INC."
0900006483781108,Supporting & Related Material,FDA-2018-P-3691-0003,FDA-2018-P-3691,"Attachment 1-Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations re: Citizen Petition from Avanthi, LLC."
09000064824e67df,Other,FDA-2017-P-1297-0002,FDA-2017-P-1297,Acknowledgement Letter from FDA DDM to Regcon Solutions
09000064824e67dd,Other,FDA-2017-P-1297-0001,FDA-2017-P-1297,Citizen Petition from Regcon Solutions
09000064824e6824,Supporting & Related Material,FDA-2017-P-1297-0005,FDA-2017-P-1297,Exhibit III SINCALIDE FOR INJECTION PROPOSED PACKAGE INSERT re Citizen Petition from Regcon Solutions
0900006482b4ff19,Other,FDA-2017-P-1297-0006,FDA-2017-P-1297,Interim Response Letter from FDA CDER to Regcon Solutions
09000064824e6823,Supporting & Related Material,FDA-2017-P-1297-0004,FDA-2017-P-1297,Exhibit II KINEVAC FOR INJECTION CURRENT PACKAGE INSERT re Citizen Petiton from Regcon Solutions
09000064824e6822,Supporting & Related Material,FDA-2017-P-1297-0003,FDA-2017-P-1297,Exhibit I KINEVAC FOR INJECTION OLD FORMULA PACKAGE INSERT re Citizen Petition from Regcon Solutions
0900006482cbde3a,Other,FDA-2017-P-1297-0007,FDA-2017-P-1297,Response in Opposition to Citizen Petition FDA-2017-P-1297
0900006484954922,Other,FDA-2020-P-1427-0003,FDA-2020-P-1427,"Withdrawal from Aurobindo Pharma USA, Inc"
09000064846b3a4f,Other,FDA-2020-P-1427-0001,FDA-2020-P-1427,"Citizen Petition from Aurobindo Pharma USA, Inc."
09000064846b3f17,Other,FDA-2020-P-1427-0002,FDA-2020-P-1427,"Acknowledgment Letter from FDA DMS to Aurobindo Pharma USA, Inc"
0900006484ca7033,Other,FDA-2021-P-0940-0002,FDA-2021-P-0940,"Acknowledgment Letter from FDA DMS to Hyman, Phelps, & McNamara, P.C."
0900006484ca7031,Other,FDA-2021-P-0940-0001,FDA-2021-P-0940,"Citizen Petition from Hyman, Phelps, & McNamara, P.C."
0900006480447f9b,Other,FDA-2005-P-0321-0003,FDA-2005-P-0321,National Institute of Oilseed Products - Citizen Petition
0900006480930b9d,Other,FDA-2005-P-0321-0004,FDA-2005-P-0321,FDA to National Institute of Oilseed Products - Petition Denial
0900006480447f51,Other,FDA-2005-P-0321-0001,FDA-2005-P-0321,HFA-305 to National Institute of Oilseed Products
0900006480447f9e,Other,FDA-2005-P-0321-0002,FDA-2005-P-0321,HFA-305 to National Institute of Oilseed Products
0900006484bdaef6,Other,FDA-2021-P-0680-0001,FDA-2021-P-0680,Citizen Petition from Joe DiNardo and Craig A Downs
0900006484da7a9c,Other,FDA-2021-P-0680-0020,FDA-2021-P-0680,Response Letter from FDA CDER to Joe DiNardo and Craig A Downs
0900006484bd8f44,Supporting & Related Material,FDA-2021-P-0680-0004,FDA-2021-P-0680,Reference 2 NTP Benzophenone Carcinogenicity Report re Citizen Petition from Joe DiNardo and Craig A Downs
0900006484bd8f4a,Supporting & Related Material,FDA-2021-P-0680-0010,FDA-2021-P-0680,Reference 8 National Drug Code Directory FDA re Citizen Petition from Joe DiNardo and Craig A Downs
0900006484bdb58f,Supporting & Related Material,FDA-2021-P-0680-0017,FDA-2021-P-0680,Reference 15 Molins Delgado A Potential New Threat to Wild Life Presence of UV Filters in Bird Eggs from a Preserved Area re Citizen Petition from Joe DiNardo and Craig A Downs
0900006484bdb58c,Supporting & Related Material,FDA-2021-P-0680-0014,FDA-2021-P-0680,Reference 12 Cunha Co-occurrence of musk fragrances and UV-filters in seafood and macroalgae collected in European hots re Citizen Petition from Joe DiNardo and Craig A Downs
0900006484bd8f43,Supporting & Related Material,FDA-2021-P-0680-0003,FDA-2021-P-0680,Reference 1 Downs Octocrylene to BP March 2021 Chemical Research in Toxicology re Citizen Petition from Joe DiNardo and Craig A Downs
0900006484bdb24f,Supporting & Related Material,FDA-2021-P-0680-0018,FDA-2021-P-0680,Reference 16 Alonso Toxic heritage Maternal transfer of pyrethroid insecticides and sunscreen agents in dolphins from B re Citizen Petition from Joe DiNardo and Craig A Downs
0900006484bdb58e,Supporting & Related Material,FDA-2021-P-0680-0016,FDA-2021-P-0680,Reference 14 Zhang Assessment of multiple hormone activities of a UV-filter octocrylene in zebrafish Danio rerio re Citizen Petition from Joe DiNardo and Craig A Downs
0900006484bdb58a,Supporting & Related Material,FDA-2021-P-0680-0012,FDA-2021-P-0680,Reference 10 Zhong Comparison of toxicological effects of oxybenzone avobenzone octocrylene and octinoxate sunscreen re Citizen Petition from Joe DiNardo and Craig A Downs
0900006484bd8f45,Supporting & Related Material,FDA-2021-P-0680-0005,FDA-2021-P-0680,Reference 3 BP Federal Register Food Additive Regulations Synthetic Flavoring Agents and Adjuvants re Citizen Petition from Joe DiNardo and Craig A Downs
0900006484bd8f46,Supporting & Related Material,FDA-2021-P-0680-0006,FDA-2021-P-0680,Reference 4 Matta Effect of Sunscreen Application on Plasma Concentration of Sunscreen Active Ingredients A Randomized Clinical Trial re Citizen Petition from Joe DiNardo and Craig A Downs
0900006484bd8f49,Supporting & Related Material,FDA-2021-P-0680-0009,FDA-2021-P-0680,Reference 7 Bronaugh In vivo percutaneous absorption of fragrance ingredients in rhesus monkeys and humans re Citizen Petition from Joe DiNardo and Craig A Downs
0900006484bdaefa,Other,FDA-2021-P-0680-0002,FDA-2021-P-0680,Acknowledgement Letter from FDA DMS to Joe DiNardo and Craig A Downs
0900006484bdb589,Supporting & Related Material,FDA-2021-P-0680-0011,FDA-2021-P-0680,Reference 9 DiNardo Comments FDA-1978-N-0018-1508_attachment_1 re Citizen Petition from Joe DiNardo and Craig A Downs
0900006484bdb58b,Supporting & Related Material,FDA-2021-P-0680-0013,FDA-2021-P-0680,Reference 11 Yan Reproductive toxicity and estrogen activity in Japanese medaka Oryzias latipes exposed to environm re Citizen Petition from Joe DiNardo and Craig A Downs
0900006484bdb58d,Supporting & Related Material,FDA-2021-P-0680-0015,FDA-2021-P-0680,Reference 13 Picot-Groz Diurnal variations in personal care products in seawater and mussels at three Mediterranean coastal re Citizen Petition from Joe DiNardo and Craig A Downs
0900006484bd8f48,Supporting & Related Material,FDA-2021-P-0680-0008,FDA-2021-P-0680,Reference 6 DiNardo Fall From GRASE re Citizen Petition from Joe DiNardo and Craig A Downs
0900006484bd8f47,Supporting & Related Material,FDA-2021-P-0680-0007,FDA-2021-P-0680,Reference 5 Foubert The presence of benzophenone in sunscreens and cosmetics containing the organic UV filter octocrylen re Citizen Petition from Joe DiNardo and Craig A Downs
0900006484bdb3b7,Supporting & Related Material,FDA-2021-P-0680-0019,FDA-2021-P-0680,Reference 17 He Toxicological effects of two organic ultraviolet filters and a related commercial sunscreen product re Citizen Petition from Joe DiNardo and Craig A Downs
090000648263a992,Supporting & Related Material,FDA-2017-P-3352-0003,FDA-2017-P-3352,"Exhibit A BPI Labs epinephrine package insert free of sulfites re Citizen Petition from Belcher Pharmaceuticals, LLC"
090000648263a994,Supporting & Related Material,FDA-2017-P-3352-0005,FDA-2017-P-3352,"Exhibit C EpiPen package insert re Citizen Petition from Belcher Pharmaceuticals, LLC"
090000648263a993,Supporting & Related Material,FDA-2017-P-3352-0004,FDA-2017-P-3352,"Exhibit B Adrenalin package insert re Citizen Petition from Belcher Pharmaceuticals, LLC"
090000648263a65b,Other,FDA-2017-P-3352-0002,FDA-2017-P-3352,"Acknowledgement Letter from FDA DDM to Belcher Pharmaceuticals, LLC"
090000648263a658,Other,FDA-2017-P-3352-0001,FDA-2017-P-3352,"Citizen Petition from Belcher Pharmaceuticals, LLC"
0900006481d8e0c2,Supporting & Related Material,FDA-2015-P-4664-0005,FDA-2015-P-4664,Exhibit 3 CDC Salmonella Risk Graph re: Citizen Petition from Richard Fife
0900006481d8e0c5,Supporting & Related Material,FDA-2015-P-4664-0007,FDA-2015-P-4664,Exhibit 5 FDA Consumer Health Information Pet Turtles Cute but Contaminated with Salmonella re: Citizen Petition from Richard Fife
0900006481d8db14,Other,FDA-2015-P-4664-0001,FDA-2015-P-4664,Citizen Petition from Richard Fife
0900006481d8dbf6,Other,FDA-2015-P-4664-0002,FDA-2015-P-4664,Acknowledgement Letter from FDA DDM to Richard Fife
0900006483ad280f,Other,FDA-2015-P-4664-0039,FDA-2015-P-4664,Letter from FDA CVM to Richard Fife
0900006483ad2c45,Other,FDA-2015-P-4664-0040,FDA-2015-P-4664,"Letter from FDA CVM to Independent Turtle Farmers of Louisiana, Inc."
0900006481d8e0c4,Supporting & Related Material,FDA-2015-P-4664-0006,FDA-2015-P-4664,"Exhibit 4 Survey Demographics for ""How Much Would You pay For a Turtle for a Child under 5-Years Old October 17, 2015"" (SurveyMonkey©) re: Citizen Petition from Richard Fife"
0900006481fdf4c9,Other,FDA-2015-P-4664-0031,FDA-2015-P-4664,Interim Response 05_19_2016
0900006483cddea3,Other,FDA-2015-P-4664-0041,FDA-2015-P-4664,Citizen Petition Response_Redacted
0900006481d8dbfb,Supporting & Related Material,FDA-2015-P-4664-0003,FDA-2015-P-4664,Exhibit 1 Code of Federal Regulation Title 21 Part 1240 Control of Communicable Diseases re: Citizen Petition from Richard Fife
0900006481d8dbfc,Supporting & Related Material,FDA-2015-P-4664-0004,FDA-2015-P-4664,Exhibit 2 Turtles Tortoises and Terrapins bred in captivity by TTPG Members (Turtle and Tortoise Preservation Group) re: Citizen Petition from Richard Fife
090000648046f534,Other,FDA-2004-P-0100-0001,FDA-2004-P-0100,HFA-305 to City of Arlington Texas
090000648046f53b,Other,FDA-2004-P-0100-0006,FDA-2004-P-0100,City of Arlington Texas
090000648046f53d,Other,FDA-2004-P-0100-0007,FDA-2004-P-0100,HFZ-001 to City of Arlington Texas
090000648046f538,Other,FDA-2004-P-0100-0004,FDA-2004-P-0100,HFA-305 to City of Arlington Texas
090000648046f53a,Other,FDA-2004-P-0100-0005,FDA-2004-P-0100,City of Arlington Texas
090000648234581c,Other,FDA-2016-P-3510-0001,FDA-2016-P-3510,"Citizen Petition from Aleon Pharma International, Inc. (Zhuhai Kinhoo Pharmaceutical Co., Ltd)"
0900006482345dc1,Supporting & Related Material,FDA-2016-P-3510-0003,FDA-2016-P-3510,"Attachment 1 Approved Drug Products with Therapeutic Equivalence Evaluations re Citizen Petition from Aleon Pharma International, Inc."
0900006482345dc3,Supporting & Related Material,FDA-2016-P-3510-0005,FDA-2016-P-3510,"Attachment 3 FDA Approved Labeling for the Reference-listed drug Cefadroxil Tablet re Citizen Petition from Aleon Pharma International, Inc."
0900006482345dc5,Supporting & Related Material,FDA-2016-P-3510-0007,FDA-2016-P-3510,"Attachment 5 Suitability Petition Approval Letter for Metformin HCI Chewable Tablet, SP 2011p-0558 re Citizen Petition from Aleon Pharma International, Inc."
0900006482345dc4,Supporting & Related Material,FDA-2016-P-3510-0006,FDA-2016-P-3510,"Attachment 4 ANDA Approval Letter for Cefixime Chewable Tablet, ANDA 065380 re Citizen Petition from Aleon Pharma International, Inc."
0900006482345dc2,Supporting & Related Material,FDA-2016-P-3510-0004,FDA-2016-P-3510,"Attachment 2 Draft Labeling Proposed for Cefadroxil Chewable Tablets re Citizen Petition from Aleon Pharma International, Inc."
090000648234581e,Other,FDA-2016-P-3510-0002,FDA-2016-P-3510,"Acknowledgement Letter from FDA DDM to Aleon Pharma International, Inc."
090000648312e72b,Supporting & Related Material,FDA-2018-P-1484-0003,FDA-2018-P-1484,Attachment 1- Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations re Citizen Petition from Macleods Pharmaceuticals Limited
090000648312ea95,Supporting & Related Material,FDA-2018-P-1484-0006,FDA-2018-P-1484,"Attachment 4- Detailed IMS, Moving annual total (MAT) data re Citizen Petition from Macleods Pharmaceuticals Limited"
090000648312e1f2,Other,FDA-2018-P-1484-0002,FDA-2018-P-1484,Acknowledgment Letter from FDA DDM Macleods Pharmaceuticals Limited
09000064837a008c,Other,FDA-2018-P-1484-0007,FDA-2018-P-1484,Interim Response from FDA CDER  to Macleods Pharmaceuticals Limited
090000648312e4ea,Supporting & Related Material,FDA-2018-P-1484-0004,FDA-2018-P-1484,Attachment 2- National Drug Code Directory re Citizen Petition from Macleods Pharmaceuticals Limited
090000648312e8e7,Supporting & Related Material,FDA-2018-P-1484-0005,FDA-2018-P-1484,Attachment 3- Drugs@FDA: FDA Approved Drug Products re Citizen Petition from Macleods Pharmaceuticals Limited
0900006483e6057d,Other,FDA-2018-P-1484-0008,FDA-2018-P-1484,Response Letter  from CDER to Macleods Pharmaceuticals Limited
090000648312dac7,Other,FDA-2018-P-1484-0001,FDA-2018-P-1484,Citizen Petition from Macleods Pharmaceuticals Limited
0900006483f20725,Other,FDA-2018-P-1484-0009,FDA-2018-P-1484,Updated Response Letter from CDER to Macleods Pharmaceuticals Limited
090000648301dde7,Other,FDA-2018-P-1173-0002,FDA-2018-P-1173,Acknowledgment Letter from FDA DDM to Alliance for Natural Health USA
090000648301d303,Other,FDA-2018-P-1173-0001,FDA-2018-P-1173,Citizen Petition from the Alliance for Natural Health USA
09000064836dc86f,Other,FDA-2018-P-1173-0034,FDA-2018-P-1173,Interim Response Letter from FDA CDER to Alliance for Natural Health USA
0900006483cc4d3d,Supporting & Related Material,FDA-2019-P-2537-0003,FDA-2019-P-2537,Attachment 1 Hancock and Parks (2000) What is the True Solubility Advantage for Amorphous Pharmaceuticals? re: Citizen Petition from Allergan Holdings Unlimited Company
0900006483cc3a54,Other,FDA-2019-P-2537-0001,FDA-2019-P-2537,Citizen Petition from Allergan Holdings Unlimited Company
0900006483cc4d37,Other,FDA-2019-P-2537-0002,FDA-2019-P-2537,Acknowledgment Letter from FDA DDM to Allergan Holding Company
0900006483cc4d3e,Supporting & Related Material,FDA-2019-P-2537-0004,FDA-2019-P-2537,Attachment 2 Murdande et al (2010) Solubility Advantage of Amorphous Pharmaceuticals: II. Application of Quantitative Thermodynamic Relationships for Prediction of Solubility Enhancement in Structurally Diverse Insoluble Pharmaceuticals re: Citizen Petition from Allergan Holdings Unlimited Company
09000064841780fb,Other,FDA-2019-P-2537-0005,FDA-2019-P-2537,Interim Response from FDA to Allergan Holdings Unlimited Company
0900006482d7f298,Other,FDA-2017-P-4039-0003,FDA-2017-P-4039,Interim Response Letter from FDA CDER to Center for Lawful Access and Abuse Deterrence
09000064827deb78,Other,FDA-2017-P-4039-0001,FDA-2017-P-4039,Citizen Petition from Center for Lawful Access and Abuse Deterrance
09000064827dee8e,Other,FDA-2017-P-4039-0002,FDA-2017-P-4039,Acknowledgment Letter from FDA DDM to Center for Lawful Access and Abuse Deterrence
0900006484803520,Other,FDA-2020-P-1766-0001,FDA-2020-P-1766,Suitability Petition from The Weinberg Group LLC
0900006484809eb3,Supporting & Related Material,FDA-2020-P-1766-0003,FDA-2020-P-1766,"Attachment 1 Approved Drug Products with Therapeutic Equivalence Evaluations, Electronic Orange Book accessed on August 13, 2020  re: Suitability Petition from The Weinberg Group LLC"
0900006484803522,Other,FDA-2020-P-1766-0002,FDA-2020-P-1766,Acknowledgment Letter from FDA DMS to The Weinberg Group LLC
0900006484809eb7,Supporting & Related Material,FDA-2020-P-1766-0005,FDA-2020-P-1766,"Attachment 3 Proposed Prescribing Information for Vasopressin Injection USP, 50 units/2.5 mL (2.5 mL/vial in a single dose vial) and 100 units/5 mL (5 mL/vial in a single dose vial)  re: Suitability Petition from The Weinberg Group LLC"
09000064848f5319,Other,FDA-2020-P-1766-0006,FDA-2020-P-1766,Withdrawal from The Weinberg Group
0900006484809eb6,Supporting & Related Material,FDA-2020-P-1766-0004,FDA-2020-P-1766,"Attachment 2 Labeling for the RLD, Vasostrict® (Vasopressin Injection USP), 20 Units/mL (single-dose vial), NDA # 204485, approved on April 15, 2020  re: Suitability Petition from The Weinberg Group LLC"
09000064820723de,Supporting & Related Material,FDA-2016-P-1825-0003,FDA-2016-P-1825,"Attachment 1 - FDA Approved Drug Products  Drug Details re Citizen Petition from Lachman Consultant Services, Inc."
090000648240d84d,Other,FDA-2016-P-1825-0005,FDA-2016-P-1825,"Interim Response Letter from FDA CDER to Lachman Consultant Services, Inc."
0900006482cfe709,Other,FDA-2016-P-1825-0006,FDA-2016-P-1825,"Final Response Letter from FDA to Lachman Consultant Services, Inc"
09000064820720fd,Other,FDA-2016-P-1825-0001,FDA-2016-P-1825,"Citizen Petition from Lachman Consultant Services, Inc."
09000064820723df,Supporting & Related Material,FDA-2016-P-1825-0004,FDA-2016-P-1825,"Attachment 2 Drugs@FDA Label and Approval History re Citizen Petition from Lachman Consultant Services, Inc."
09000064820723d6,Other,FDA-2016-P-1825-0002,FDA-2016-P-1825,"Acknowledgement Letter from FDA DDM to Lachman Consultant Services, Inc."
0900006484ba0408,Other,FDA-2021-P-0576-0002,FDA-2021-P-0576,Acknowledgment Letter to Husch Blackwell from FDA DMS
0900006484c164a4,Other,FDA-2021-P-0576-0003,FDA-2021-P-0576,Withdrawal from Husch Blackwell LLP
0900006484ba018b,Other,FDA-2021-P-0576-0001,FDA-2021-P-0576,Citizen Petition from Husch Blackwell LLP on behalf of Brenntag Great Lakes LLC
0900006484df3e6d,Other,FDA-2021-P-1154-0001,FDA-2021-P-1154,Citizen Petition from Lachman Consultant Services Inc.
0900006484df3e6f,Other,FDA-2021-P-1154-0002,FDA-2021-P-1154,Acknowledgment Letter from FDA DMS to Lachman Consultant Services Inc
09000064824defa1,Other,FDA-2017-P-1225-0002,FDA-2017-P-1225,Acknowledgement Letter from FDA DDM to Aurora Pharmaceutical LLC 2
09000064824defa3,Supporting & Related Material,FDA-2017-P-1225-0003,FDA-2017-P-1225,"Attachment 1 GastroGard® Oral Paste, labeling by Merial, rev 05-2014 re Suitability Petition from Aurora Pharmaceutical LLC 2"
09000064824def9f,Other,FDA-2017-P-1225-0001,FDA-2017-P-1225,Suitability Petition from Aurora Pharmaceutical LLC 2
09000064825eab0f,Other,FDA-2017-P-1225-0004,FDA-2017-P-1225,Letter from FDA to Aurora Pharmaceuticals LLC
0900006483263f59,Supporting & Related Material,FDA-2018-P-1869-0006,FDA-2018-P-1869,"Detailed IMS, Moving annual total (MAT) data indicating Approved Generic product Dicyclomine Hydrochloride Capsules USP, 10 mg (ANDA # 085082), of Watson Laboratories Inc., as the leading player in the U.S market. re: Citizen Petition from Aurobindo Pharma USA Inc"
0900006483263e22,Supporting & Related Material,FDA-2018-P-1869-0005,FDA-2018-P-1869,Drugs @ FDA Search Results re: Citizen Petition from Aurobindo Pharma Usa Inc.
090000648388348d,Other,FDA-2018-P-1869-0008,FDA-2018-P-1869,Interim Response Letter from FDA CDER to Aurobindo Pharma USA Inc.
090000648326378f,Other,FDA-2018-P-1869-0002,FDA-2018-P-1869,Acknowledgment Letter from FDA DDM to Aurobindo Pharma USA Inc.
0900006483263e1b,Supporting & Related Material,FDA-2018-P-1869-0003,FDA-2018-P-1869,Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations re: Citizen Petition from Aurobindo Pharma Usa Inc.
0900006483263fde,Supporting & Related Material,FDA-2018-P-1869-0007,FDA-2018-P-1869,Non availability of samples statement from pharmacy re: Citizen Petition from Aurobindo Pharma USA Inc.
090000648423ca33,Other,FDA-2018-P-1869-0009,FDA-2018-P-1869,Petition Response Letter from FDA CDER to Aurobindo Pharma USA Inc
0900006483263e20,Supporting & Related Material,FDA-2018-P-1869-0004,FDA-2018-P-1869,National Drug Code Directory Search Results re: Citizen Petition from Aurobindo Pharma Usa Inc.
090000648326326c,Other,FDA-2018-P-1869-0001,FDA-2018-P-1869,Citizen Petition from Aurobindo Pharma USA Inc
09000064841160e8,Other,FDA-2019-P-5121-0002,FDA-2019-P-5121,"Acknowledgment Letter from FDA DMS to Arent Fox LLP on behalf of Aquestive Therapeutics, Inc"
09000064841e35f0,Other,FDA-2019-P-5121-0009,FDA-2019-P-5121,"Supplement from Aquestive Therapeutics, Inc. (Arent Fox)"
09000064841160f0,Supporting & Related Material,FDA-2019-P-5121-0003,FDA-2019-P-5121,"Exhibit 1- A pilot study assessing the bioavailability and pharmacokinetics of diazepam after intranasal and intravenous administration in healthy volunteers re: Citizen Petition and Petition for Stay of Action from Arent Fox LLP on behalf of Aquestive Therapeutics, Inc."
090000648411628a,Supporting & Related Material,FDA-2019-P-5121-0007,FDA-2019-P-5121,"Exhibit 5- Nasal drug delivery: new developments and strategies re: Citizen Petition and Petition for Stay of Action from Arent Fox LLP on behalf of Aquestive Therapeutics, Inc."
0900006484291b6a,Other,FDA-2019-P-5121-0011,FDA-2019-P-5121,Petition Response Letter from FDA CDER to Arent Fox LLP
0900006484116288,Supporting & Related Material,FDA-2019-P-5121-0005,FDA-2019-P-5121,"Exhibit 3- Pharmacokinetic Study of Valtoco™ (NRL-1; diazepam nasal spray) in Patients With Epilepsy Under Ictal and Inter-ictal Conditions – Interim Report re: Citizen Petition and Petition for Stay of Action from Arent Fox LLP on behalf of Aquestive Therapeutics, Inc."
0900006484116241,Other,FDA-2019-P-5121-0001,FDA-2019-P-5121,"Citizen Petition and Petition for Stay of Action from Arent Fox LLP on behalf of Aquestive Therapeutics, Inc."
0900006484116287,Supporting & Related Material,FDA-2019-P-5121-0004,FDA-2019-P-5121,"Exhibit 2- Bioavailability and Safety of Valtoco™ (diazepam intranasal solution) Compared to Oral and Rectal Diazepam re: Citizen Petition and Petition for Stay of Action from Arent Fox LLP on behalf of Aquestive Therapeutics, Inc."
0900006484116289,Supporting & Related Material,FDA-2019-P-5121-0006,FDA-2019-P-5121,"Exhibit 4- Buccal midazolam for pediatric convulsive seizures: efficacy, safety, and patient acceptability re: Citizen Petition and Petition for Stay of Action from Arent Fox LLP on behalf of Aquestive Therapeutics, Inc."
0900006484e58069,Supporting & Related Material,FDA-2021-P-1227-0003,FDA-2021-P-1227,Petition Footnote 24 Referenece by Klein et al RE Citizen Petition from Public Citizen’s Health Research Group
0900006484e57f56,Other,FDA-2021-P-1227-0001,FDA-2021-P-1227,Citizen Petition from Public Citizen’s Health Research Group
0900006484e59a07,Other,FDA-2021-P-1227-0002,FDA-2021-P-1227,Acknowledgment Letter from FDA DMS to Public Citizen’s Health Research Group
090000648243b754,Supporting & Related Material,FDA-2016-P-4584-0006,FDA-2016-P-4584,Carilion-Prandin Label Aug 2016 re Citizen Petition from Public Citizens Health Research Group
090000648243b755,Supporting & Related Material,FDA-2016-P-4584-0007,FDA-2016-P-4584,Clopidogrel - 2016-09 re Citizen Petition from Public Citizens Health Research Group
090000648243b756,Supporting & Related Material,FDA-2016-P-4584-0008,FDA-2016-P-4584,Health Canada Warning Repaglinide Jul 2015 re Citizen Petition from Public Citizens Health Research Group
09000064829cacf7,Other,FDA-2016-P-4584-0012,FDA-2016-P-4584,Response letter from FDA CDER to Public Citizen's Health Research Group
090000648243b3c5,Supporting & Related Material,FDA-2016-P-4584-0004,FDA-2016-P-4584,Canadian drug label - clopidogrel 2016-06 re Citizen Petition from Public Citizens Health Research Group
090000648243b759,Supporting & Related Material,FDA-2016-P-4584-0011,FDA-2016-P-4584,"Glucuronidation Converts Clopidogrel to a Strong Time-Dependent Inhibitor of CYP2C8: A Phase II Metabolite as a Perpetrator of Drug–Drug
Interactions re Citizen Petition from Public Citizens Health Research Group"
090000648243b3c0,Other,FDA-2016-P-4584-0001,FDA-2016-P-4584,Citizen Petition from Public Citizens Health Research Group
090000648243b757,Supporting & Related Material,FDA-2016-P-4584-0009,FDA-2016-P-4584,Clarification of the Mechanism of Clopidogrel-Mediated Drug-Drug Interaction in a Clinical Cassette Small-dose Study and Its Prediction re Citizen Petition from Public Citizens Health Research Group
090000648243b3c2,Other,FDA-2016-P-4584-0002,FDA-2016-P-4584,Acknowledgement Letter from FDA DDM to Public Citizens Health Research Group
090000648243b758,Supporting & Related Material,FDA-2016-P-4584-0010,FDA-2016-P-4584,Repaglinide - 2016-08 re Citizen Petition from Public Citizens Health Research Group
090000648243b3c4,Supporting & Related Material,FDA-2016-P-4584-0003,FDA-2016-P-4584,BMS-Plavix Label Sept 2016 re Citizen Petition from Public Citizens Health Research Group
090000648243b753,Supporting & Related Material,FDA-2016-P-4584-0005,FDA-2016-P-4584,Canadian drug label - repaglinide 2016-04 re Citizen Petition from Public Citizens Health Research Group
0900006482560340,Other,FDA-2017-P-2460-0002,FDA-2017-P-2460,Acknowledgement Letter from FDA DDM to AuroMedics Pharma LLC (Aurobindo Pharma Limited)
09000064829ffcbc,Other,FDA-2017-P-2460-0003,FDA-2017-P-2460,Withdrawal from AuroMedics Pharma LLC
090000648256033e,Other,FDA-2017-P-2460-0001,FDA-2017-P-2460,Citizen Petition from AuroMedics Pharma LLC (Aurobindo Pharma Limited)
090000648186e47f,Other,FDA-2014-P-1354-0003,FDA-2014-P-1354,"Correction re Acknowledgement Letter from FDA/DDM to Otsuka Pharmaceutical Company Ltd., (Otsuka Pharmaceutical Development & Commercialization, Inc.)"
09000064819f20d1,Other,FDA-2014-P-1354-0004,FDA-2014-P-1354,Petition Denial
0900006481869eda,Other,FDA-2014-P-1354-0001,FDA-2014-P-1354,"Citizen Petition from Otsuka Pharmaceutical Company Ltd., (Otsuka Pharmaceutical Development & Commercialization, Inc.)"
0900006481869edc,Other,FDA-2014-P-1354-0002,FDA-2014-P-1354,"Acknowledgement Letter from FDA/DDM to Otsuka Pharmaceutical Company Ltd., (Otsuka Pharmaceutical Development & Commercialization, Inc.)"
09000064818e6f1a,Supporting & Related Material,FDA-2014-P-1656-0003,FDA-2014-P-1656,Addendum Part 1
09000064818e6f1b,Supporting & Related Material,FDA-2014-P-1656-0004,FDA-2014-P-1656,Addendum Part 2
09000064818e6f1c,Supporting & Related Material,FDA-2014-P-1656-0005,FDA-2014-P-1656,Addendum Part 3
09000064818e6f1d,Supporting & Related Material,FDA-2014-P-1656-0006,FDA-2014-P-1656,Addendum Part 4
09000064818e6f20,Other,FDA-2014-P-1656-0002,FDA-2014-P-1656,Acknowledgement Letter from FDA DDM to Alaska Seafood Marketing Institute and the Golden King Crab Coalition
0900006482c8383f,Other,FDA-2014-P-1656-0007,FDA-2014-P-1656,Final Response Letter from FDA to  Alaska Seafood Marketing Institute (Golden King Crab)
09000064818b70d9,Other,FDA-2014-P-1656-0001,FDA-2014-P-1656,Citizen Petition from Alaska Seafood Marketing Institute and the Golden King Crab Coalition
0900006482a400af,Other,FDA-2017-P-1096-0003,FDA-2017-P-1096,"Interim Response Letter from CDER to Hyman, Phelps & McNamara, P.C."
09000064824d149a,Other,FDA-2017-P-1096-0001,FDA-2017-P-1096,"Citizen Petition from Hyman, Phelps & McNamara, P.C."
09000064824d1c5a,Other,FDA-2017-P-1096-0002,FDA-2017-P-1096,"Acknowledgment Letter from FDA DDM to Hyman, Phelps & McNamara, P.C."
09000064839fbde0,Other,FDA-2017-P-1096-0004,FDA-2017-P-1096,"Response Letter from FDA CDER to Hyman, Phelps & McNamara, P.C."
0900006482d43ea2,Other,FDA-2017-P-6851-0002,FDA-2017-P-6851,Acknowledgment Letter from DDM to Shire Development LLC
0900006482d44124,Supporting & Related Material,FDA-2017-P-6851-0006,FDA-2017-P-6851,Exhibit D- Combination Pharmacotherapy for Adult ADHD RE Citizen Petition from Shire Development LLC
0900006482d44123,Supporting & Related Material,FDA-2017-P-6851-0005,FDA-2017-P-6851,Exhibit C- A Review of Pharmacological Management of Attention- Deficit/ Hyperactivity Disorder RE Citizen Petition from Shire Development LLC
0900006482d44122,Supporting & Related Material,FDA-2017-P-6851-0004,FDA-2017-P-6851,Exhibit B- Atomoxetine versus methylpjemidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized double-blind comparison trail RE Citizen Petition from Shire Development LLC
0900006482d44126,Supporting & Related Material,FDA-2017-P-6851-0008,FDA-2017-P-6851,Exhibit F- Attention-Deficit/  Hyperactivity Disorder: Medication Treatment-dosing and Duration of Action RE Citizen Petition from Shire Development LLC
0900006482d43e73,Other,FDA-2017-P-6851-0001,FDA-2017-P-6851,Citizen Petition from Shire Development LLC
0900006482d44121,Supporting & Related Material,FDA-2017-P-6851-0003,FDA-2017-P-6851,Exhibit A- Atomoxetine: a selective noradrenaline reuptake inhibitor for the treatment of attention-deficit/ hyperactivity disorder RE Citizen Petition from Shire Development LLC
0900006482d44125,Supporting & Related Material,FDA-2017-P-6851-0007,FDA-2017-P-6851,Exhibit E- Clinical Presentations of Adult Patients with ADHD RE Citizen Petition from Shire Development LLC
090000648327a81c,Other,FDA-2017-P-6851-0009,FDA-2017-P-6851,Letter from FDA CDER to Sascha Haverfield
090000648279743e,Other,FDA-2017-P-1278-0003,FDA-2017-P-1278,Petition Approval FDA-2017-P-1278
09000064824e522a,Other,FDA-2017-P-1278-0002,FDA-2017-P-1278,"Acknowledgment Letter from FDA DDM to Gilead Sciences, Inc."
09000064824e51a2,Other,FDA-2017-P-1278-0001,FDA-2017-P-1278,"Citizen Petition from Gilead Sciences, Inc."
09000064838fa641,Other,FDA-2018-P-4490-0001,FDA-2018-P-4490,"Citizen Petition from Hyman, Phelps & McNamara, P. C."
09000064838fa7ad,Other,FDA-2018-P-4490-0002,FDA-2018-P-4490,"Acknowledgment Letter from FDA DDM to Hyman, Phelps & McNamara PC ."
0900006483b4904e,Other,FDA-2018-P-4490-0006,FDA-2018-P-4490,"Citizen Petition Denial Response Letter from FDA CDER to Hyman, Phelps & McNamara"
0900006484100c47,Supporting & Related Material,FDA-2019-P-5008-0003,FDA-2019-P-5008,Exhibit 1 re Citizen Petition from Foley Hoag LLP on behalf of Vifor Fresenius Medical Care Renal Pharma France
0900006484100c49,Supporting & Related Material,FDA-2019-P-5008-0005,FDA-2019-P-5008,Exhibit 3 re Citizen Petition from Foley Hoag LLP on behalf of Vifor Fresenius Medical Care Renal Pharma France
090000648410120e,Supporting & Related Material,FDA-2019-P-5008-0026,FDA-2019-P-5008,Exhibit 25 re Citizen Petition from Foley Hoag LLP on behalf of Vifor Fresenius Medical Care Renal Pharma France
09000064841011fb,Supporting & Related Material,FDA-2019-P-5008-0008,FDA-2019-P-5008,Exhibit 6 re Citizen Petition from Foley Hoag LLP on behalf of Vifor Fresenius Medical Care Renal Pharma France
0900006484101209,Supporting & Related Material,FDA-2019-P-5008-0022,FDA-2019-P-5008,Exhibit 20 re Citizen Petition from Foley Hoag LLP on behalf of Vifor Fresenius Medical Care Renal Pharma France
090000648410120c,Supporting & Related Material,FDA-2019-P-5008-0024,FDA-2019-P-5008,Exhibit 23 re Citizen Petition from Foley Hoag LLP on behalf of Vifor Fresenius Medical Care Renal Pharma France
090000648410120d,Supporting & Related Material,FDA-2019-P-5008-0025,FDA-2019-P-5008,Exhibit 24 re Citizen Petition from Foley Hoag LLP on behalf of Vifor Fresenius Medical Care Renal Pharma France
0900006484100c42,Other,FDA-2019-P-5008-0001,FDA-2019-P-5008,Citizen Petition from Foley Hoag LLP on behalf of Vifor Fresenius Medical Care Renal Pharma France
09000064841011fa,Supporting & Related Material,FDA-2019-P-5008-0007,FDA-2019-P-5008,Exhibit 5 re Citizen Petition from Foley Hoag LLP on behalf of Vifor Fresenius Medical Care Renal Pharma France
0900006484101204,Supporting & Related Material,FDA-2019-P-5008-0017,FDA-2019-P-5008,Exhibit 15 re Citizen Petition from Foley Hoag LLP on behalf of Vifor Fresenius Medical Care Renal Pharma France
09000064841014c6,Supporting & Related Material,FDA-2019-P-5008-0030,FDA-2019-P-5008,Exhibit 29 re Citizen Petition from Foley Hoag LLP on behalf of Vifor Fresenius Medical Care Renal Pharma France
09000064841011fc,Supporting & Related Material,FDA-2019-P-5008-0009,FDA-2019-P-5008,Exhibit 7 re Citizen Petition from Foley Hoag LLP on behalf of Vifor Fresenius Medical Care Renal Pharma France
09000064841011fe,Supporting & Related Material,FDA-2019-P-5008-0011,FDA-2019-P-5008,Exhibit 9 re Citizen Petition from Foley Hoag LLP on behalf of Vifor Fresenius Medical Care Renal Pharma France
0900006484101201,Supporting & Related Material,FDA-2019-P-5008-0014,FDA-2019-P-5008,Exhibit 12 re Citizen Petition from Foley Hoag LLP on behalf of Vifor Fresenius Medical Care Renal Pharma France
0900006484101203,Supporting & Related Material,FDA-2019-P-5008-0016,FDA-2019-P-5008,Exhibit 14 re Citizen Petition from Foley Hoag LLP on behalf of Vifor Fresenius Medical Care Renal Pharma France
0900006484101205,Supporting & Related Material,FDA-2019-P-5008-0018,FDA-2019-P-5008,Exhibit 16 re Citizen Petition from Foley Hoag LLP on behalf of Vifor Fresenius Medical Care Renal Pharma France
0900006484101208,Supporting & Related Material,FDA-2019-P-5008-0021,FDA-2019-P-5008,Exhibit 19 re Citizen Petition from Foley Hoag LLP on behalf of Vifor Fresenius Medical Care Renal Pharma France
090000648410120a,Supporting & Related Material,FDA-2019-P-5008-0023,FDA-2019-P-5008,Exhibit 21 re Citizen Petition from Foley Hoag LLP on behalf of Vifor Fresenius Medical Care Renal Pharma France
09000064841011ff,Supporting & Related Material,FDA-2019-P-5008-0012,FDA-2019-P-5008,Exhibit 10 re Citizen's Petition from Foley Hoag LLP on behalf of Vifor Fresenius Medical Care Renal Pharma France
0900006484101207,Supporting & Related Material,FDA-2019-P-5008-0020,FDA-2019-P-5008,Exhibit 18 re Citizen Petition from Foley Hoag LLP on behalf of Vifor Fresenius Medical Care Renal Pharma France
0900006484100c48,Supporting & Related Material,FDA-2019-P-5008-0004,FDA-2019-P-5008,Exhibit 2 re Citizen Petition from Foley Hoag LLP on behalf of Vifor Fresenius Medical Care Renal Pharma France
09000064841011f9,Supporting & Related Material,FDA-2019-P-5008-0006,FDA-2019-P-5008,Exhibit 4 re Citizen Petition from Foley Hoag LLP on behalf of Vifor Fresenius Medical Care Renal Pharma France
0900006484101202,Supporting & Related Material,FDA-2019-P-5008-0015,FDA-2019-P-5008,Exhibit 13 re Citizen Petition from Foley Hoag LLP on behalf of Vifor Fresenius Medical Care Renal Pharma France
0900006484101206,Supporting & Related Material,FDA-2019-P-5008-0019,FDA-2019-P-5008,Exhibit 17 re Citizen Petition from Foley Hoag LLP on behalf of Vifor Fresenius Medical Care Renal Pharma France
0900006484100c46,Other,FDA-2019-P-5008-0002,FDA-2019-P-5008,Acknowledgment Letter from FDA DMS to Foley Hoag LLP
0900006482e54e90,Supporting & Related Material,FDA-2018-P-0345-0003,FDA-2018-P-0345,Attachment-1 Current Orange Book Search Results re: Citizen Petition from Macleods Pharmaceuticals Limited
090000648495b9db,Other,FDA-2018-P-0345-0008,FDA-2018-P-0345,Withdrawal from Macleods Pharmaceuticals Limited
09000064834da41e,Other,FDA-2018-P-0345-0006,FDA-2018-P-0345,Interim Response Letter from FDA CDER to Macleods Pharmaceuticals Limited
0900006482e54fb1,Supporting & Related Material,FDA-2018-P-0345-0005,FDA-2018-P-0345,"Attachment-3 Detailed IMS, Moving annual total (MAT) data indicating Approved Generic product ANDA #A201679 Nitrofurantoin Oral Suspension 25mg/5mL, of AMNEAL PHARMS as the market leadrer re: Citizen Petition from Macleods Pharmaceuticals Limited"
0900006482e54e91,Supporting & Related Material,FDA-2018-P-0345-0004,FDA-2018-P-0345,Attachment-2 Drugs@FDA: FDA Approved Drug Products Search Results re: Citizen Petition from Macleods Pharmaceuticals Limited
0900006482e54ba2,Other,FDA-2018-P-0345-0001,FDA-2018-P-0345,Citizen Petition from Macleods Pharmaceuticals Limited
090000648495cd87,Other,FDA-2018-P-0345-0007,FDA-2018-P-0345,Withdrawal of Citizen Petition
0900006484964eea,Other,FDA-2018-P-0345-0009,FDA-2018-P-0345,Withdrawal of Citizen Petition Macleods Pharmaceuticals Limited
0900006482e54892,Other,FDA-2018-P-0345-0002,FDA-2018-P-0345,Acknowledgment Letter from FDA DDM to Macleods Pharmaceuticals Limited
090000648207688c,Supporting & Related Material,FDA-2016-P-1826-0004,FDA-2016-P-1826,"Exhibit A to Citizen Petition filed by NuTek Food Science, LLC June 27, 2016 re Citizen Petition from NuTek Food Science LLC"
09000064820720cc,Other,FDA-2016-P-1826-0001,FDA-2016-P-1826,Citizen Petition from NuTek Food Science LLC
0900006482076894,Supporting & Related Material,FDA-2016-P-1826-0006,FDA-2016-P-1826,"Reference 21 - Sodium, Chloride, and Potassium re Citizen Petition from NuTek Food Science LLC"
09000064820769a0,Supporting & Related Material,FDA-2016-P-1826-0008,FDA-2016-P-1826,"References 38 through 44 - The effect of salt reduction on sensory quality and microbial growth in hotdog sausages, bacon, ham and salami re Citizen Petition from NuTek Food Science LLC"
0900006483d8cca3,Other,FDA-2016-P-1826-0049,FDA-2016-P-1826,"Citizen Petition Withdrawal Letter from NuTek Food Science, LLC to FDA CFSAN"
0900006482076893,Supporting & Related Material,FDA-2016-P-1826-0005,FDA-2016-P-1826,References 1 through 20 - Sodium Reduction re Citizen Petition from NuTek Food Science LLC
0900006482076895,Supporting & Related Material,FDA-2016-P-1826-0007,FDA-2016-P-1826,References 22 through 37 - Potassium Chloride re Citizen Petition from NuTek Food Science LLC
09000064820769a2,Supporting & Related Material,FDA-2016-P-1826-0010,FDA-2016-P-1826,References 53 through 62 - Effect of increased potassium intake on cardiovascular risk factors and disease: systematic review and meta-analyses re Citizen Petition from NuTek Food Science LLC
09000064820769a3,Supporting & Related Material,FDA-2016-P-1826-0011,FDA-2016-P-1826,References 63 through 70 - Micronutrient re Citizen Petition from NuTek Food Science LLC
09000064820720ce,Other,FDA-2016-P-1826-0002,FDA-2016-P-1826,"Acknowledgement Letter from FDA DDM to NuTek Food Science, LLC"
09000064820720d0,Supporting & Related Material,FDA-2016-P-1826-0003,FDA-2016-P-1826,Attachment 1 - References Links re Citizen Petition from NuTek Food Science LLC
09000064820769a1,Supporting & Related Material,FDA-2016-P-1826-0009,FDA-2016-P-1826,References 45 through 52 - Childhood Blood Pressure Trends and Risk Factors for High Blood Pressures re Citizen Petition from NuTek Food Science LLC
0900006484891f24,Other,FDA-2020-P-2017-0001,FDA-2020-P-2017,Citizen Petition from Alston & Bird LLP
0900006484891f26,Other,FDA-2020-P-2017-0002,FDA-2020-P-2017,Acknowledgment Letter from FDA DMS to Alston & Bird LLP
090000648496d1cb,Other,FDA-2020-P-2017-0003,FDA-2020-P-2017,Citizen Petition Withdrawal  for Alston & Bird LLP
0900006483db82a2,Supporting & Related Material,FDA-2019-P-3545-0003,FDA-2019-P-3545,Exhibit A- Pharmacokinetic comparison of two carbamazepine slow-release formulations re: Citizen Petition from Axinn on behalf of  Zydus Pharmaceuticals (USA) Inc.
0900006483db82a0,Other,FDA-2019-P-3545-0002,FDA-2019-P-3545,Acknowledgment Letter from FDA DDM to Axinn on behalf of  Zydus Pharmaceuticals (USA) Inc.
0900006483db82a3,Supporting & Related Material,FDA-2019-P-3545-0004,FDA-2019-P-3545,"Exhibit B-  Therapeutic Drug Monitoring of Antiepileptic
Drugs by Use of Saliva re: Citizen Petition from Axinn on behalf of  Zydus Pharmaceuticals (USA) Inc."
0900006483db82a4,Supporting & Related Material,FDA-2019-P-3545-0005,FDA-2019-P-3545,Exhibit C- DRAFT GUIDANCE ON CARBAMAZEPINE re: Citizen Petition from Axinn on behalf of  Zydus Pharmaceuticals (USA) Inc.
0900006483db7d1f,Other,FDA-2019-P-3545-0001,FDA-2019-P-3545,Citizen Petition from Axinn on behalf of  Zydus Pharmaceuticals (USA) Inc.
0900006484239993,Other,FDA-2019-P-3545-0008,FDA-2019-P-3545,"Response Letter from FDA CDER to Axinn, Veltrop & Harkrider LLP"
0900006483db82a5,Supporting & Related Material,FDA-2019-P-3545-0006,FDA-2019-P-3545,Exhibit D- Switching from Brand-Name to Generic Psychotropic Medications: A Literature Review re: Citizen Petition from Axinn on behalf of  Zydus Pharmaceuticals (USA) Inc.
0900006484b7ac2d,Supporting & Related Material,FDA-2021-P-0550-0037,FDA-2021-P-0550,"Reference 48 Sam Raney, U.S. Food & Drug Admin., Strategies to Improve Patient 
Access to High Quality Topical Products, Am. Ass’n of Pharm. Scientists Workshop on Dermatological Drug Products: Developmental & Regulatory Considerations at 36 (Nov. 12, 2017). re: Citizen Petition from Baker Hostetler on behalf of Bausch Health Companies, Inc_ REDACTED"
0900006484b7fce0,Supporting & Related Material,FDA-2021-P-0550-0040,FDA-2021-P-0550,"Affidavit of Lorin K. Johnson, Ph.D. re: Citizen Petition from Baker Hostetler on behalf of Bausch Health Companies, Inc_ REDACTED"
0900006484b6700b,Supporting & Related Material,FDA-2021-P-0550-0004,FDA-2021-P-0550,"Reference 1 Alex Yu et al., Bioequivalence History, in FDA Bioequivalence 
Standards 3–4 (Lawrence X. Yu & Bing V. Li eds., 2014) [hereinafter Yu et al.] re: Citizen Petition from Baker Hostetler on behalf of Bausch Health Companies, Inc_ REDACTED"
0900006484b6d27a,Supporting & Related Material,FDA-2021-P-0550-0015,FDA-2021-P-0550,"Reference 12 Emil A. Tanghetti et al., Optimized Formulation for Topical 
Application Of A Fixed Combination Halobetasol/Tazarotene Lotion 
Using Polymeric Emulsion Technology, 4 J. Dermatological 
Treatment 1, 6 (2019) [hereinafter Tanghetti 2019]. re: Citizen Petition from Baker Hostetler on behalf of Bausch Health Companies, Inc_ REDACTED"
0900006484b6d2a1,Supporting & Related Material,FDA-2021-P-0550-0017,FDA-2021-P-0550,"Reference 17 David M. Pariser et al., Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: 
Maintenance of Therapeutic Effect After Cessation of Therapy, 17 J. 
Drugs in Dermatology 723, 724 (2018) re: Citizen Petition from Baker Hostetler on behalf of Bausch Health Companies, Inc_ REDACTED"
0900006484b6d2a7,Supporting & Related Material,FDA-2021-P-0550-0018,FDA-2021-P-0550,"Reference 18 Emil A. Tanghetti et al., Tazarotene Revisited: Safety and Efficacy in 
Plaque Psoriasis and Its Emerging Role in Treatment Strategy, 17 J. Drugs in Dermatology 1280, 1283 (2018). re: Citizen Petition from Baker Hostetler on behalf of Bausch Health Companies, Inc_ REDACTED"
0900006484b728c7,Supporting & Related Material,FDA-2021-P-0550-0021,FDA-2021-P-0550,"Reference 21 Benedetta Brazzini & Nicola Pimpinelli, New & Established Topical 
Corticosteroids in Dermatology: Clinical Pharmacology & 
Therapeutic Use, 3 Am. J. Clinical Dermatology 47, 48 (2002) re:"
0900006484b728c9,Supporting & Related Material,FDA-2021-P-0550-0023,FDA-2021-P-0550,"Reference 23 Malcom W. Greaves, Anti-inflammatory action of corticosteroids, 52 Postgraduate Med. J. 631, 632 (1976). re: Citizen Petition from Baker Hostetler on behalf of Bausch Health Companies, Inc_ REDACTED"
0900006484b728cc,Supporting & Related Material,FDA-2021-P-0550-0026,FDA-2021-P-0550,"Reference 26 Ralph Ruhl et al., Role of Vitamin A Elimination or Supplementation 
Diets During Postnatal Development on the Allergic Sensitisation in 
Mice, 51 Molecular Nutrition Food Res. 1173 (2007). re: Citizen Petition from Baker Hostetler on behalf of Bausch Health Companies, Inc_ REDACTED"
0900006484b7ac28,Supporting & Related Material,FDA-2021-P-0550-0032,FDA-2021-P-0550,"Reference 32 Hilde Hermansen Steineger et al., Retinoid X Receptor (RXRα) Gene 
Expression is Regulated by Fatty Acids & Dexamethasone in Hepatic 
Cells, 79 Biochimie 107 (1997). re: Citizen Petition from Baker Hostetler on behalf of Bausch Health Companies, Inc_ REDACTED"
0900006484b6ccf7,Supporting & Related Material,FDA-2021-P-0550-0013,FDA-2021-P-0550,"Reference 10 Leon H. Kircik et al., Assessing the Synergistic Effect of a Fixed 
Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% 
Lotion in Moderate-to-Severe Plaque Psoriasis, 18 J. Drugs in 
Dermatology 279, 280 (2019) [hereinafter Kircik et al.]. re: Citizen Petition from Baker Hostetler on behalf of Bausch Health Companies, Inc_ REDACTED"
0900006484b6d26b,Supporting & Related Material,FDA-2021-P-0550-0014,FDA-2021-P-0550,"Reference 11 Mark G. Lebwohl et al., Long-Term Safety and Efficacy of a Fixed 
Combination Halobetasol Propionate 0.01%/Tazarotene 0.045% 
Lotion in Moderate-to-Severe Plaque Psoriasis: Phase 3 Open-Label 
Study, 35 J. European Academy of Dermatology & Venerology, 
1152, 1157 (2021)[hereinafter Lebwohl 2021] re: Citizen Petition from Baker Hostetler on behalf of Bausch Health Companies, Inc_ REDAC"
0900006484b6d2ae,Supporting & Related Material,FDA-2021-P-0550-0019,FDA-2021-P-0550,"Reference 19 Ronald M. Evans & David J. Mangelsdorf, Nuclear Receptors, RXR, 
& the Big Bang, 157 Cell 255, 257(2014). re: Citizen Petition from Baker Hostetler on behalf of Bausch Health Companies, Inc_ REDACTED"
0900006484b6d2b3,Supporting & Related Material,FDA-2021-P-0550-0020,FDA-2021-P-0550,"Reference 20 Peter J. Barnes, Anti-inflammatory Actions of Glucocorticoids: 
Molecular Mechanisms, 94 Clinical Sci. 557 (1998). re: Citizen Petition from Baker Hostetler on behalf of Bausch Health Companies, Inc_ REDACTED"
0900006484b7309e,Supporting & Related Material,FDA-2021-P-0550-0028,FDA-2021-P-0550,"Reference 28 Thomas C. Roos et al., Retinoid Metabolism in the Skin, 50 
Pharmacological Rev. 315, 316 (1998). re: Citizen Petition from Baker Hostetler on behalf of Bausch Health Companies, Inc_ REDACTED"
0900006484b74ef1,Supporting & Related Material,FDA-2021-P-0550-0030,FDA-2021-P-0550,"Reference 30 Peter M. Elias et al., Retinoid Effects on Epidermal Structure, 
Differentiation, & Permeability. 44 Laboratory Investigation 531 (1981). re: Citizen Petition from Baker Hostetler on behalf of Bausch Health Companies, Inc_ REDACTED"
0900006484b7ac2a,Supporting & Related Material,FDA-2021-P-0550-0034,FDA-2021-P-0550,"Reference 34 Sachiko Yamaguchi et al., Glucocorticoids Increase Retinoid-X 
Receptor Alpha (Rxrα) Expression & Enhance Thyroid Hormone Action in Primary Cultured Rat Hepatocytes, 22 J. Molecular Endocrinology 81 (1992) re: Citizen Petition from Baker Hostetler on behalf of Bausch Health Companies, Inc_ REDACTED"
0900006484b66f07,Other,FDA-2021-P-0550-0002,FDA-2021-P-0550,"Acknowledgement  Letter from FDM DMS to Baker  Hostetler LLP on behalf of Bausch Health Companies, Inc. _redacted"
0900006484b6ccf0,Supporting & Related Material,FDA-2021-P-0550-0005,FDA-2021-P-0550,"Reference 2 Sam Raney, U.S. Food & Drug Admin., A Generic Perspective on the 
Use of In Vitro Assessment Methods, (July 30, 2019), at slide 6. re: Citizen Petition from Baker Hostetler on behalf of Bausch Health Companies, Inc_ REDACTED"
0900006484b6ccf2,Supporting & Related Material,FDA-2021-P-0550-0007,FDA-2021-P-0550,"Reference 4 Katrin I. Tiffner et al., A Comprehensive Approach to Qualify and 
Validate the Essential Parameters of an In Vitro Release Test (IVRT) 
Method for Acyclovir Cream, 5%, 535 Int’l J. of Pharm. 217, 217 
(2018). re: Citizen Petition from Baker Hostetler on behalf of Bausch Health Companies, Inc_ REDACTED"
0900006484b728cb,Supporting & Related Material,FDA-2021-P-0550-0025,FDA-2021-P-0550,"Reference 25 Ralph Ruhl, Effects of Dietary Retinoids & Carotenoids on Immune 
Development, 66 Proc. Nutrition Soc’y 458 (2007). re: Citizen Petition from Baker Hostetler on behalf of Bausch Health Companies, Inc_ REDACTED"
0900006484b74ef2,Supporting & Related Material,FDA-2021-P-0550-0031,FDA-2021-P-0550,"Reference 31 Janine Gericke et al., Regulation of Retinoid-Mediated Signaling 
Involved in Skin Homeostasis by RAR and RXR Agonists/Antagonists in Mouse Skin, 8 Plos One e62643, 6–7 (2013). re: Citizen Petition from Baker Hostetler on behalf of Bausch Health Companies, Inc_ REDACTED"
0900006484b88f96,Supporting & Related Material,FDA-2021-P-0550-0010,FDA-2021-P-0550,"Reference 7 - Linda Stein Gold MD, Rapid Onset of Action in Patients With Moderateto-Severe Plaque Psoriasis With Halobetasol
0.01%/Tazarotene 0.045% Fixed Combination"
0900006484b6ccf5,Supporting & Related Material,FDA-2021-P-0550-0011,FDA-2021-P-0550,"Reference 8 Vidhatha Reddy et al., Impact of Halobetasol Propionate and 
Tazarotene Lotion 0.01%/0.045% in the Management of Plaque 
Psoriasis in Adults, 13 Clinical, Cosm. & Investigational Dermatology 
391 (2020) [hereinafter Reddy 2020]. re: Citizen Petition from Baker Hostetler on behalf of Bausch Health Companies, Inc"
0900006484b6d293,Supporting & Related Material,FDA-2021-P-0550-0016,FDA-2021-P-0550,"Reference 16 Jeffrey L. Sugarman et al., Safety and Efficacy of a Fixed 
Combination Halobetasol and Tazarotene Lotion in the Treatment of 
Moderate-to-Severe Plaque Psoriasis: A Pooled Analysis of Two 
Phase 3 Studies, 17 J. Drugs in Dermatology 855, 860 (2018). re: Citizen Petition from Baker Hostetler on behalf of Bausch Health Companies, Inc_ REDACTED"
0900006484c64124,Other,FDA-2021-P-0910-0002,FDA-2021-P-0910,"Acknowledgment Letter from FDA DMS to Shilpa Pharma, Inc."
0900006484c63c2a,Supporting & Related Material,FDA-2021-P-0910-0003,FDA-2021-P-0910,"Attachment 1 - Approved Drug Products with Therapeutic Equivalence Evaluation (Electronic Orange Book) accessed August 12, 2021 RE Suitability petition from Shilpa Pharma, Inc."
0900006484c63c2c,Supporting & Related Material,FDA-2021-P-0910-0005,FDA-2021-P-0910,"Attachment 3 - Labeling of the approved product, Azacitidine for Injection -100 mg/vial by Celgene Corporation RE Suitability petition from Shilpa Pharma, Inc."
0900006484c63e6a,Other,FDA-2021-P-0910-0001,FDA-2021-P-0910,"Suitability petition  from Shilpa Pharma, Inc."
0900006484c63c2b,Supporting & Related Material,FDA-2021-P-0910-0004,FDA-2021-P-0910,"Attachment 2 - Draft Insert Labeling for Proposed Azacitidine for Injection -50 mg/vial & 150mg/vial RE Suitability petition  from Shilpa Pharma, Inc."
09000064843455cf,Supporting & Related Material,FDA-2020-P-0698-0010,FDA-2020-P-0698,Reference 9 re Citizen Petition from Physicians Committee for Responsible Medicine
09000064843455cb,Supporting & Related Material,FDA-2020-P-0698-0006,FDA-2020-P-0698,Reference 5 re Citizen Petition from Physicians Committee for Responsible Medicine
09000064843455ce,Supporting & Related Material,FDA-2020-P-0698-0009,FDA-2020-P-0698,Reference 8 re Citizen Petition from Physicians Committee for Responsible Medicine
090000648434559e,Supporting & Related Material,FDA-2020-P-0698-0003,FDA-2020-P-0698,Reference 2 re Citizen Petition from Physicians Committee for Responsible Medicine
09000064843455ca,Supporting & Related Material,FDA-2020-P-0698-0005,FDA-2020-P-0698,Reference 4 re Citizen Petition from Physicians Committee for Responsible Medicine
09000064843455cd,Supporting & Related Material,FDA-2020-P-0698-0008,FDA-2020-P-0698,Reference 7 re Citizen Petition from Physicians Committee for Responsible Medicine
09000064843455d0,Supporting & Related Material,FDA-2020-P-0698-0011,FDA-2020-P-0698,Reference 10 re Citizen Petition from Physicians Committee for Responsible Medicine
090000648434559a,Other,FDA-2020-P-0698-0012,FDA-2020-P-0698,Acknowledgment Letter from FDA DMS to Physicians Committee for Responsible Medicine
0900006484345599,Other,FDA-2020-P-0698-0001,FDA-2020-P-0698,Citizen Petition from Physicians Committee for Responsible Medicine
090000648434559d,Supporting & Related Material,FDA-2020-P-0698-0002,FDA-2020-P-0698,Reference 1 re Citizen Petition from Physicians Committee for Responsible Medicine
090000648434559f,Supporting & Related Material,FDA-2020-P-0698-0004,FDA-2020-P-0698,Reference 3 re Citizen Petition from Physicians Committee for Responsible Medicine
09000064843455cc,Supporting & Related Material,FDA-2020-P-0698-0007,FDA-2020-P-0698,Reference 6 re Citizen Petition from Physicians Committee for Responsible Medicine
0900006482af6154,Other,FDA-2013-P-1377-0004,FDA-2013-P-1377,Final Response from FDA CDER to Buchanan Ingersoll & Rooney PC
0900006481482fe5,Other,FDA-2013-P-1377-0002,FDA-2013-P-1377,Acknowledgement Letter to Covis Pharma Sarl (Buchanan Ingersoll & Rooney PC)
0900006481482fd0,Other,FDA-2013-P-1377-0001,FDA-2013-P-1377,Covis Pharma Sarl (Buchanan Ingersoll & Rooney PC) - Citizen Petition
0900006481674a4c,Other,FDA-2013-P-1377-0003,FDA-2013-P-1377,Interim Response from FDA CDER to Buchanan Ingersoll & Rooney PC
0900006483d5acb3,Notice,FDA-2019-P-1366-0003,FDA-2019-P-1366,"Determination That CLAFORAN (Cefotaxime Sodium) for Injection, 500
Milligrams/Vial, 1 Gram/Vial, 2 Grams/Vial and 10 Grams/Vial, Was Not
Withdrawn From Sale for Reasons of Safety or Effectiveness"
0900006483b17fc9,Other,FDA-2019-P-1366-0002,FDA-2019-P-1366,Acknowledgment Letter from FDA DDM to  Cardinal Health Regulatory Sciences
0900006483b17dc6,Other,FDA-2019-P-1366-0001,FDA-2019-P-1366,Citizen Petition from Cardinal Health Regulatory Sciences
0900006483d5bbc5,Other,FDA-2019-P-1366-0004,FDA-2019-P-1366,Letter from CDER to Cardinal Health Regulatory Sciences
0900006484811ba8,Other,FDA-2020-P-1775-0002,FDA-2020-P-1775,Acknowledgment Letter from FDA DMS to Novitium Pharma LLC
0900006484811ba7,Other,FDA-2020-P-1775-0001,FDA-2020-P-1775,Citizen Petition from Novitium Pharma LLC
0900006484828897,Other,FDA-2020-P-1775-0003,FDA-2020-P-1775,Citizen Petition Withdrawal from Novitium Pharma LLC
09000064843bcfbc,Other,FDA-2020-P-0963-0002,FDA-2020-P-0963,"Acknowledgment Letter from FDA DMS to Aurora Pharmaceutical, Inc."
09000064843bdcca,Other,FDA-2020-P-0963-0001,FDA-2020-P-0963,Suitability Citizen Petition for Aurora Pharmaceutical Inc.
0900006484606b56,Other,FDA-2020-P-0963-0005,FDA-2020-P-0963,"Suitability Petition Letter from FDA CVM to Aurora Pharmaceutical, Inc."
09000064844706f2,Other,FDA-2020-P-0963-0004,FDA-2020-P-0963,Amendment to Suitability Citizen Petition from Aurora Pharmaceutical Inc.
09000064843bcfe0,Supporting & Related Material,FDA-2020-P-0963-0003,FDA-2020-P-0963,Attachment 1-Deramaxx Chewable Tablets re: Suitability Citizen Petition for Aurora Pharmaceutical Inc.
090000648082975b,Supporting & Related Material,FDA-2008-D-0224-0029,FDA-2008-D-0224,"Certifications To Accompany Drug, Biological Product, and Device Applications/ Submissions: Compliance with Section 402(j) of The Public Health Service Act, 42 U.S.C. § 282(j), Added By Title VIII of The Food and Drug Administration Amendments Act of 2007 - Final Guidance for Sponsors, Industry, Researchers, Investigators and FDA Staff"
0900006480511b12,Notice,FDA-2008-D-0224-0001,FDA-2008-D-0224,"Draft Guidance for Sponsors, Industry, Researchers, Investigators, and Food and Drug Administration Staff: Certifications to Accompany Drug, Biological Product, and Device Applications/ Submissions: Compliance With Section 402(j) of the Public Health Service Act, Added by Title VIII of the Food and Drug Administration Amendments Act of 2007"
090000648082941b,Notice,FDA-2008-D-0224-0026,FDA-2008-D-0224,"Final Guidance for Sponsors, Industry, Researchers, Investigators, and Food and Drug Administration Staff: Certifications to Accompany Drug, Biological Product, and Device Applications/Submissions; Compliance with Section 402(j) of The Public Health Service Act, 42 U.S.C. § 282(j), Added By Title VIII of The Food and Drug Administration Amendments Act of 2007"
0900006480511e08,Other,FDA-2008-D-0224-0005,FDA-2008-D-0224,"Draft Guidance for Sponsors, Industry, Researchers, Investigators, and Food and Drug Administration Staff: Certifications to Accompany Drug, Biological Product, and Device Applications/ Submissions: Compliance With Section 402(j) of the Public Health Service Act, Added by Title VIII of the Food and Drug Administration Amendments Act of 2007 - Guidance Document"
09000064803af984,Other,FDA-2008-P-0052-0004,FDA-2008-P-0052,URL Mutual - Supplement
090000648069ea46,Other,FDA-2008-P-0052-0005,FDA-2008-P-0052,"FDA Center for Drug Evaluation and Research Response to Mutual Pharmaceuticals, Inc. - Petition Denial"
09000064803a1bbc,Other,FDA-2008-P-0052-0002,FDA-2008-P-0052,Acknowledgement Letter to Mutual Pharmaceutical United Research
09000064803a6300,Supporting & Related Material,FDA-2008-P-0052-0003,FDA-2008-P-0052,Attachment-A-Report-vol1.pdf
09000064803a1a4a,Other,FDA-2008-P-0052-0001,FDA-2008-P-0052,URL Mutual - Citizen Petition
090000648436b864,Other,FDA-2020-P-0813-0002,FDA-2020-P-0813,Acknowledgment Letter from FDA DMS to Citizen Petition from Unichem Pharmaceuticals (USA) Inc.
09000064847043b8,Notice,FDA-2020-P-0813-0004,FDA-2020-P-0813,"Determination That TENEX (Guanfacine Hydrochloride) Tablets, 1
Milligram, 2 Milligrams, and 3 Milligrams, Was Not Withdrawn From
Sale for Reasons of Safety or Effectiveness"
090000648436b831,Supporting & Related Material,FDA-2020-P-0813-0003,FDA-2020-P-0813,"Exhibit-1 Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations re: Citizen Petition from Unichem Pharmaceuticals (USA), Inc."
0900006484705266,Other,FDA-2020-P-0813-0005,FDA-2020-P-0813,Agency Response Letter from FDA CDER to Unichem Pharmaceuticals USA Inc
090000648436ad7d,Other,FDA-2020-P-0813-0001,FDA-2020-P-0813,Citizen Petition from Unichem Pharmaceuticals (USA) Inc.
09000064823bcb33,Other,FDA-2016-P-1873-0007,FDA-2016-P-1873,Letter from CDER to North American Specialty Medicines
090000648207f7f1,Supporting & Related Material,FDA-2016-P-1873-0003,FDA-2016-P-1873,Tab A - Difficult to swallow: patient preferences for alternative valproate pharmaceutical formulations re Citizen Petition from Teva Pharmaceuticals
090000648207f7f2,Supporting & Related Material,FDA-2016-P-1873-0004,FDA-2016-P-1873,Tab B -  Pill Properties that Cause Dysphagia and Treatment Failure re Citizen Petition from Teva Pharmaceuticals
090000648207f7f4,Supporting & Related Material,FDA-2016-P-1873-0006,FDA-2016-P-1873,Tab D - Analysis of Bead Sizes for MR Capsules Labeled for Sprinkle re Citizen Petition from Teva Pharmaceuticals
090000648207f7ed,Other,FDA-2016-P-1873-0001,FDA-2016-P-1873,Citizen Petition from Teva Pharmaceuticals
090000648207f7ef,Other,FDA-2016-P-1873-0002,FDA-2016-P-1873,Acknowledgement Letter from FDA DDM to  Teva Pharmaceuticals
090000648207f7f3,Supporting & Related Material,FDA-2016-P-1873-0005,FDA-2016-P-1873,"Tab C - Difficulties swallowing solid oral dosage forms in a general practice population: prevalence, causes, and relationship to dosage forms re Citizen Petition from Teva Pharmaceuticals"
090000648247f1a0,Other,FDA-2017-P-0290-0001,FDA-2017-P-0290,Citizen Petition from Malaysian Rubber Export Promotion Council
0900006482797171,Other,FDA-2017-P-0290-0003,FDA-2017-P-0290,Letter from CDRH to Malaysian Rubber Export Promotion Council-USA
090000648247f21e,Other,FDA-2017-P-0290-0002,FDA-2017-P-0290,Acknowledgement Letter from FDA DDM to Malaysian Rubber Export Promotion Council
0900006481ec5841,Other,FDA-2015-P-1924-0007,FDA-2015-P-1924,Citizen Petition Denial Response Letter from FDA CDRH to Hunton & Williams LLP
0900006481b0d74d,Supporting & Related Material,FDA-2015-P-1924-0003,FDA-2015-P-1924,Attachment B  Zeltiq Investor Day Presentation re Citizen Petition from Hunton and Williams LLP
0900006481b0d650,Other,FDA-2015-P-1924-0001,FDA-2015-P-1924,Citizen Petition from Hunton and Williams LLP
0900006481b0d74c,Supporting & Related Material,FDA-2015-P-1924-0002,FDA-2015-P-1924,Attachment A 510k Premarket Notifications for Zeltiq System re Citizen Petition from Hunton and Williams LLP
0900006481b0d651,Other,FDA-2015-P-1924-0005,FDA-2015-P-1924,Acknowledgement Letter from FDA DDM to Hunton and Williams LLP
0900006481b0d74e,Supporting & Related Material,FDA-2015-P-1924-0004,FDA-2015-P-1924,Attachment C Zeltiq Aesthetics Press Release re Citizen Petition from Hunton and Williams LLP
0900006481cc8f5e,Other,FDA-2015-P-1924-0006,FDA-2015-P-1924,"Interim Response Letter from FDA CDRH to Hunton & William, LLP"
090000648243b95d,Other,FDA-2014-P-1685-0004,FDA-2014-P-1685,Petition Denial Letter
09000064818ea61e,Other,FDA-2014-P-1685-0001,FDA-2014-P-1685,Citizen Petition from Larry R. Pilot
0900006481a4a207,Other,FDA-2014-P-1685-0003,FDA-2014-P-1685,Interim Response from CDER to Larry R. Pilot
09000064818eb7d2,Other,FDA-2014-P-1685-0002,FDA-2014-P-1685,Acknowledgement Letter from FDA DDM to Larry R Pilot
0900006484dc9591,Supporting & Related Material,FDA-2021-P-1123-0003,FDA-2021-P-1123,Attachment 1 RE: Citizen Petition from Melinta Therapeutics LLC
0900006484dc98ca,Supporting & Related Material,FDA-2021-P-1123-0007,FDA-2021-P-1123,Attachment 5 RE: Citizen Petition from Melinta Therapeutics LLC
0900006484dc98cc,Supporting & Related Material,FDA-2021-P-1123-0009,FDA-2021-P-1123,Attachment 7 RE: Citizen Petition from Melinta Therapeutics LLC
0900006484dc9a33,Other,FDA-2021-P-1123-0001,FDA-2021-P-1123,Citizen Petition from Melinta Therapeutics LLC
0900006484dc9592,Supporting & Related Material,FDA-2021-P-1123-0004,FDA-2021-P-1123,Attachment 2 RE: Citizen Petition from Melinta Therapeutics LLC
0900006484dc9594,Supporting & Related Material,FDA-2021-P-1123-0006,FDA-2021-P-1123,Attachment 4 RE: Citizen Petition from Melinta Therapeutics LLC
0900006484dc9593,Supporting & Related Material,FDA-2021-P-1123-0005,FDA-2021-P-1123,Attachment 3 RE: Citizen Petition from Melinta Therapeutics LLC
0900006484dc98cd,Supporting & Related Material,FDA-2021-P-1123-0010,FDA-2021-P-1123,Attachment 8 RE: Citizen Petition from Melinta Therapeutics LLC
0900006484dc9be8,Other,FDA-2021-P-1123-0002,FDA-2021-P-1123,Acknowledgment Letter from FDM DMS to Melinta Therapeutics LLC
0900006484dc98cb,Supporting & Related Material,FDA-2021-P-1123-0008,FDA-2021-P-1123,Attachment 6 RE: Citizen Petition from Melinta Therapeutics LLC
0900006484b488df,Supporting & Related Material,FDA-2021-P-0523-0003,FDA-2021-P-0523,Attachment A re: Citizen Petition from The Council for Responsible Nutrition
0900006484b488dd,Other,FDA-2021-P-0523-0002,FDA-2021-P-0523,Acknowledgment Letter from FDA DMS to  The Council for Responsible Nutrition (CRN)
0900006484b488db,Other,FDA-2021-P-0523-0001,FDA-2021-P-0523,Citizen Petition from The Council for Responsible Nutrition (CRN)
0900006482b2fa3c,Other,FDA-2017-P-1460-0004,FDA-2017-P-1460,Withdrawal Letter from Covington & Burling LLP
0900006482afd785,Other,FDA-2017-P-1460-0003,FDA-2017-P-1460,Interim Response Letter from FDA CDER to Covington & Burling LLP
09000064824fc50d,Other,FDA-2017-P-1460-0001,FDA-2017-P-1460,Citizen Petition from Covington & Burling LLP
09000064824fc2ff,Other,FDA-2017-P-1460-0002,FDA-2017-P-1460,Acknowledgement Letter from FDA DDM to Covington & Burling LLP
0900006483aace20,Other,FDA-2018-P-3933-0003,FDA-2018-P-3933,"Response Letter from FDA CDER to Fresenius Kabi USA, LLC"
09000064837fe806,Other,FDA-2018-P-3933-0001,FDA-2018-P-3933,Citizen Petition from Fresenius Kabi USA LLC
09000064837fe808,Other,FDA-2018-P-3933-0002,FDA-2018-P-3933,"Acknowledgment Letter from FDA DDM to Fresenius Kabi USA, LLC"
0900006481c385a4,Other,FDA-2015-P-3107-0001,FDA-2015-P-3107,Citizen Petition from Ferrosan Medical Devices (DuVal & Associates)
0900006481e2890e,Other,FDA-2015-P-3107-0003,FDA-2015-P-3107,"Interim Response Letter from FDA CDRH to DuVal & Associates, P.A."
0900006481c385a7,Other,FDA-2015-P-3107-0002,FDA-2015-P-3107,Acknowledgement Letter from FDA DDM to Ferrosan Medical Devices (DuVal & Associates)
0900006481690d32,Other,FDA-2014-P-0367-0002,FDA-2014-P-0367,Acknowledgement Letter From FDA/DDM to Hyman Phelps and McNamara P.C.
0900006481690458,Other,FDA-2014-P-0367-0001,FDA-2014-P-0367,Citizen Petition From Hyman Phelps and McNamara PC
0900006481875af2,Other,FDA-2014-P-0367-0003,FDA-2014-P-0367,Interim Response Letter from FDA/CDER to Hyman Phelps and McNamara P.C.
0900006483cea04e,Other,FDA-2014-P-0367-0004,FDA-2014-P-0367,"Letter from FDA CDER to Hyman,  Phelps & McNamara, P.C."
09000064840fa6de,Other,FDA-2019-P-2088-0003,FDA-2019-P-2088,Interim Response Letter from FDA CDER to Summit Health Pharmacy Inc
0900006483c1f06b,Other,FDA-2019-P-2088-0002,FDA-2019-P-2088,Acknowledgment  Letter from FDA DDM to Summit Health Pharmacy Inc.
0900006483c1ef73,Other,FDA-2019-P-2088-0001,FDA-2019-P-2088,Citizen Petition from Summit Health Pharmacy Inc.
0900006484a456f1,Notice,FDA-2020-P-1549-0008,FDA-2020-P-1549,"Determination That NYMALIZE (nimodipine), Oral Solution, 3 Milligrams/Milliliter, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
0900006484a3b67c,Other,FDA-2020-P-1549-0007,FDA-2020-P-1549,"Final Response Letter from FDA CDER to Windels Marx Lane & Mittendorf, LLP"
09000064846e3f02,Other,FDA-2020-P-1549-0001,FDA-2020-P-1549,"Citizen Petition from Windels Marx Lane & Mittendorf, LLP"
09000064846e46ad,Supporting & Related Material,FDA-2020-P-1549-0003,FDA-2020-P-1549,"Exhibit-1 Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations re: Citizen Petition from Windels Marx Lane & Mittendorf, LLP."
09000064846e46ab,Other,FDA-2020-P-1549-0002,FDA-2020-P-1549,"Acknowledgment Letter from FDA DMS to Windels Marx Lane& Mittendorf, LLP"
090000648497e03e,Other,FDA-2020-P-1549-0006,FDA-2020-P-1549,"Interim Response Letter from FDA CDER to Windels Marx Lane & Mittendorf, LLP"
0900006484a6ddbf,Supporting & Related Material,FDA-2021-P-0299-0003,FDA-2021-P-0299,"Attachment 1 - Current (March 16, 2021) Orange Book Listing of EFUDEX (Fluorouracil) Topical Solutions, 5%; NDA N016831 held by BAUSCH HEALTH AMERICAS INC. RE Citizen Petition from Encube Ethicals Private Limited"
0900006484a6ddbb,Other,FDA-2021-P-0299-0002,FDA-2021-P-0299,Acknowledgment Letter from FDA DMS to Encube Ethicals Private Limited
0900006484a6ddb9,Other,FDA-2021-P-0299-0001,FDA-2021-P-0299,Citizen Petition from Encube Ethicals Private Limited
0900006484c1495b,Notice,FDA-2021-P-0299-0004,FDA-2021-P-0299,"Determination That EFUDEX (Fluorouracil) Topical Solution, 5 Percent, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
0900006484c178df,Other,FDA-2021-P-0299-0005,FDA-2021-P-0299,Response Letter to Encube Ethicals Private Limited from FDA CDER
0900006484dc5605,Other,FDA-2021-P-1111-0001,FDA-2021-P-1111,Citizen Petition from Lachman Consultant Services Inc
0900006484dc562e,Other,FDA-2021-P-1111-0002,FDA-2021-P-1111,Acknowledgment Letter from FDA DMS to Lachman Consultant Services Inc.
09000064841936fe,Other,FDA-2019-P-5535-0001,FDA-2019-P-5535,Citizen Petition from Foley & Lardner LLP
0900006484193700,Other,FDA-2019-P-5535-0002,FDA-2019-P-5535,Acknowledgment Letter from FDA DDM to Foley & Lardner LLP
0900006484193799,Supporting & Related Material,FDA-2019-P-5535-0004,FDA-2019-P-5535,"Attachment 2 Approved Labeling for the RLD, PROTONIX re Citizen Petition from Foley & Lardner LLP"
090000648419379a,Supporting & Related Material,FDA-2019-P-5535-0005,FDA-2019-P-5535,Attachment 3 Proposed Labeling re Citizen Petition from Foley & Lardner LLP
0900006484193798,Supporting & Related Material,FDA-2019-P-5535-0003,FDA-2019-P-5535,Attachment 1 Approved Drug Products with Therapeutic Equivalence Evaluations Orange Book Excerpt re Citizen Petition from Foley & Lardner LLP
0900006482682b80,Other,FDA-2017-P-3468-0002,FDA-2017-P-3468,"Acknowledgment Letter from FDA DDM to Teligent Pharma, Inc."
090000648323bfcd,Other,FDA-2017-P-3468-0005,FDA-2017-P-3468,"Petition Denial Letter from FDA CDER to Teligent Pharma, Inc"
09000064826811b3,Other,FDA-2017-P-3468-0001,FDA-2017-P-3468,"Citizen Petition from Teligent Pharma, Inc."
0900006482682b82,Supporting & Related Material,FDA-2017-P-3468-0003,FDA-2017-P-3468,"Attachment 1 Orange Book Listing for Ketoconazole Cream 2% accessed on June 1, 2017"
0900006482cb0fe2,Other,FDA-2017-P-3468-0004,FDA-2017-P-3468,"Interim Response from FDA to Teligent Pharma, Inc"
0900006483b63136,Notice,FDA-2018-P-3412-0006,FDA-2018-P-3412,"Determination That QVAR 40 and QVAR 80 (Beclomethasone Dipropionate HFA) Inhalation Aerosol, 40 Micrograms and 80 Micrograms, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
09000064836c9ef7,Other,FDA-2018-P-3412-0001,FDA-2018-P-3412,Citizen Petition from Aurolife Pharma LLC
0900006483abc997,Other,FDA-2018-P-3412-0005,FDA-2018-P-3412,Letter from FDA CDER to Aurolife Pharma LLC
09000064836cb06b,Supporting & Related Material,FDA-2018-P-3412-0003,FDA-2018-P-3412,"Attachment 2- Orange Book: Approved Drug Products with
Therapeutic Equivalence Evaluations RE: Citizen Petition from Aurolife Pharma LLC"
0900006483b65731,Other,FDA-2018-P-3412-0007,FDA-2018-P-3412,Letter from FDA CDER to Aurolife Pharma LLC
09000064836cb066,Other,FDA-2018-P-3412-0002,FDA-2018-P-3412,Acknowledgment Letter from FDA DDM to Aurolife Pharma LLC
09000064836cacf3,Supporting & Related Material,FDA-2018-P-3412-0004,FDA-2018-P-3412,Attachment 1- FDA Drug Shortages RE: Citizen Petition from Aurolife Pharma LLC
090000648294136c,Supporting & Related Material,FDA-2017-P-4334-0008,FDA-2017-P-4334,Tab33 Shire Development Inc - Warning Letter re Citizen Petition from Sidley Austin LLP (Vifor Fresenius Medical Care Renal Pharma Ltd)
090000648294136b,Supporting & Related Material,FDA-2017-P-4334-0007,FDA-2017-P-4334,Tab 34 Watson Pharmaceuticals Inc - Warning Letter re Citizen Petition from Sidley Austin LLP (Vifor Fresenius Medical Care Renal Pharma Ltd)
090000648294136d,Supporting & Related Material,FDA-2017-P-4334-0009,FDA-2017-P-4334,Tab 32 Nobel Laboratories LLC - Warning Letter re Citizen Petition from Sidley Austin LLP (Vifor Fresenius Medical Care Renal Pharma Ltd)
090000648294149e,Supporting & Related Material,FDA-2017-P-4334-0022,FDA-2017-P-4334,Tab19 Fibroblast growth factor 23 is elevated before parathyroid hormone re Citizen Petition from Sidley Austin LLP (Vifor Fresenius Medical Care Renal Pharma Ltd)
09000064829414a9,Supporting & Related Material,FDA-2017-P-4334-0023,FDA-2017-P-4334,Tab 18 Fibroblast Growth Factor-23 Mitigates Hyperphosphatemia re Citizen Petition from Sidley Austin LLP (Vifor Fresenius Medical Care Renal Pharma Ltd)
09000064829414aa,Supporting & Related Material,FDA-2017-P-4334-0024,FDA-2017-P-4334,Tab 17 Hyperphosphatemia in Renal Failure re Citizen Petition from Sidley Austin LLP (Vifor Fresenius Medical Care Renal Pharma Ltd)
09000064829414c3,Supporting & Related Material,FDA-2017-P-4334-0037,FDA-2017-P-4334,Tab 4 Time-Dependent Associations between Iron and Mortality in Hemodialysis Patients re Citizen Petition from Sidley Austin LLP (Vifor Fresenius Medical Care Renal Pharma Ltd)
0900006482940ca5,Other,FDA-2017-P-4334-0002,FDA-2017-P-4334,Acknowledgement Letter from FDA DDM to Sidley Austin LLP (Vifor Fresenius Medical Care Renal Pharma Ltd)
0900006482a31f32,Supporting & Related Material,FDA-2017-P-4334-0041,FDA-2017-P-4334,Withdrawal Letter from FDA-2017-P-4023 to justify use of June 30th Submission Date
090000648294149c,Supporting & Related Material,FDA-2017-P-4334-0020,FDA-2017-P-4334,Tab 21 Bloomberg Transcript Jefferies Global Health Care Conference re Citizen Petition from Sidley Austin LLP (Vifor Fresenius Medical Care Renal Pharma Ltd)
09000064829414bf,Supporting & Related Material,FDA-2017-P-4334-0033,FDA-2017-P-4334,Tab 8 Gastrointestinal Blood Loss in Patients with Chronic Renal Failure re Citizen Petition from Sidley Austin LLP (Vifor Fresenius Medical Care Renal Pharma Ltd)
0900006482941368,Supporting & Related Material,FDA-2017-P-4334-0004,FDA-2017-P-4334,Tab 37 Auryxia Pharmacodynamics re Citizen Petition from Sidley Austin LLP (Vifor Fresenius Medical Care Renal Pharma Ltd)
090000648294136a,Supporting & Related Material,FDA-2017-P-4334-0006,FDA-2017-P-4334,Tab 35 Schein Pharmaceutical Inc Letter re Citizen Petition from Sidley Austin LLP (Vifor Fresenius Medical Care Renal Pharma Ltd)
090000648294136f,Supporting & Related Material,FDA-2017-P-4334-0011,FDA-2017-P-4334,Tab 30 Velphoro Highlights of Prescribing Information re Citizen Petition from Sidley Austin LLP (Vifor Fresenius Medical Care Renal Pharma Ltd)
0900006482c53bb0,Other,FDA-2017-P-4334-0042,FDA-2017-P-4334,Response Letter from FDA to Sidley Austin LLP
0900006482941498,Supporting & Related Material,FDA-2017-P-4334-0016,FDA-2017-P-4334,Tab 25 Ferric Citrate Reduces Intravenous Iron and Erythropoiesis re Citizen Petition from Sidley Austin LLP (Vifor Fresenius Medical Care Renal Pharma Ltd)
09000064829414ae,Supporting & Related Material,FDA-2017-P-4334-0028,FDA-2017-P-4334,Tab 13 Effects of Phosphate Binders in Moderate CKD re Citizen Petition from Sidley Austin LLP (Vifor Fresenius Medical Care Renal Pharma Ltd)
09000064829414b1,Supporting & Related Material,FDA-2017-P-4334-0031,FDA-2017-P-4334,Tab 10 A Proton Pump Inhibitor a Day Keeps the Iron Away re Citizen Petition from Sidley Austin LLP (Vifor Fresenius Medical Care Renal Pharma Ltd)
09000064829414c4,Supporting & Related Material,FDA-2017-P-4334-0038,FDA-2017-P-4334,Tab 3 KDIGO 2017 Clinical Practice Guideline Update re Citizen Petition from Sidley Austin LLP (Vifor Fresenius Medical Care Renal Pharma Ltd)
0900006482941620,Supporting & Related Material,FDA-2017-P-4334-0003,FDA-2017-P-4334,"Tab 1 Press Release Investor Relations Keryx Biopharmaceuticals, Inc re Citizen Petition from Sidley Austin LLP (Vifor Fresenius Medical Care Renal Pharma Ltd)"
090000648294136e,Supporting & Related Material,FDA-2017-P-4334-0010,FDA-2017-P-4334,Tab 31 Bayer HealthCare LLC - Warning Letter re Citizen Petition from Sidley Austin LLP (Vifor Fresenius Medical Care Renal Pharma Ltd)
0900006482941495,Supporting & Related Material,FDA-2017-P-4334-0013,FDA-2017-P-4334,Tab 28 Highlights of Prescribing Information re Citizen Petition from Sidley Austin LLP (Vifor Fresenius Medical Care Renal Pharma Ltd)
090000648294149b,Supporting & Related Material,FDA-2017-P-4334-0019,FDA-2017-P-4334,Tab 22 Ferric Citrate Hydrate for the Treatment of Hyperphosphatemia re Citizen Petition from Sidley Austin LLP (Vifor Fresenius Medical Care Renal Pharma Ltd)
090000648294149d,Supporting & Related Material,FDA-2017-P-4334-0021,FDA-2017-P-4334,Tab 20 Bloomberg Transcript Cowen and Company Global Health Care Conference re Citizen Petition from Sidley Austin LLP (Vifor Fresenius Medical Care Renal Pharma Ltd)
09000064829414ab,Supporting & Related Material,FDA-2017-P-4334-0025,FDA-2017-P-4334,Tab 16 Bloomberg Transcript Management Discussion Section re Citizen Petition from Sidley Austin LLP (Vifor Fresenius Medical Care Renal Pharma Ltd)
09000064827c5301,Supporting & Related Material,FDA-2017-P-4023-0004,FDA-2017-P-4023,Attachment 2 Effects of Ferric Citrate in Patients with Nondialysis-Dependent CKD re Citizen Petition from Sidley Austin LLP (Vifor Fresenius Medical Care Renal Pharma Ltd)
09000064827c54d6,Supporting & Related Material,FDA-2017-P-4023-0039,FDA-2017-P-4023,Attachment 37 Auryxia Pharmacodynamics re Citizen Petition from Sidley Austin LLP (Vifor Fresenius Medical Care Renal Pharma Ltd)
09000064827c552f,Supporting & Related Material,FDA-2017-P-4023-0012,FDA-2017-P-4023,Attachment 10 A Proton Pump Inhibitor a Day Keeps the Iron Away re Citizen Petition from Sidley Austin LLP (Vifor Fresenius Medical Care Renal Pharma Ltd)
09000064827c5532,Supporting & Related Material,FDA-2017-P-4023-0015,FDA-2017-P-4023,Attachment 13 Effects of Phosphate Binders in Moderate CKD re Citizen Petition from Sidley Austin LLP (Vifor Fresenius Medical Care Renal Pharma Ltd)
09000064827c5533,Supporting & Related Material,FDA-2017-P-4023-0016,FDA-2017-P-4023,Attachment 14 Highlights of Prescribing Information re Citizen Petition from Sidley Austin LLP (Vifor Fresenius Medical Care Renal Pharma Ltd)
09000064827c5549,Supporting & Related Material,FDA-2017-P-4023-0029,FDA-2017-P-4023,Attachment 27 Ferric Citrate (Auryxia) for the Treatment of Hyperphosphatemia re Citizen Petition from Sidley Austin LLP (Vifor Fresenius Medical Care Renal Pharma Ltd)
09000064827c554c,Supporting & Related Material,FDA-2017-P-4023-0032,FDA-2017-P-4023,Attachment 30 Velphoro Highlights of Prescribing Information re Citizen Petition from Sidley Austin LLP (Vifor Fresenius Medical Care Renal Pharma Ltd)
09000064827c554f,Supporting & Related Material,FDA-2017-P-4023-0035,FDA-2017-P-4023,Attachment 33 Shire Development Inc - Warning Letter re Citizen Petition from Sidley Austin LLP (Vifor Fresenius Medical Care Renal Pharma Ltd)
09000064827c5550,Supporting & Related Material,FDA-2017-P-4023-0036,FDA-2017-P-4023,Attachment 34 Watson Pharmaceuticals Inc - Warning Letter re Citizen Petition from Sidley Austin LLP (Vifor Fresenius Medical Care Renal Pharma Ltd)
09000064827c5551,Supporting & Related Material,FDA-2017-P-4023-0037,FDA-2017-P-4023,Attachment 35 Schein Pharmaceutical Inc Letter re Citizen Petition from Sidley Austin LLP (Vifor Fresenius Medical Care Renal Pharma Ltd)
09000064827c552b,Supporting & Related Material,FDA-2017-P-4023-0008,FDA-2017-P-4023,Attachment 6 NKF-K DOQI Clinical Practice Guidelines for Anemia re Citizen Petition from Sidley Austin LLP (Vifor Fresenius Medical Care Renal Pharma Ltd)
09000064827c552c,Supporting & Related Material,FDA-2017-P-4023-0009,FDA-2017-P-4023,Attachment 7 The prevalence of anemia in patients with chronic kidney disease re Citizen Petition from Sidley Austin LLP (Vifor Fresenius Medical Care Renal Pharma Ltd)
09000064827c5539,Supporting & Related Material,FDA-2017-P-4023-0021,FDA-2017-P-4023,Attachment 19 Fibroblast growth factor 23 is elevated before parathyroid hormone re Citizen Petition from Sidley Austin LLP (Vifor Fresenius Medical Care Renal Pharma Ltd)
09000064827c553c,Supporting & Related Material,FDA-2017-P-4023-0024,FDA-2017-P-4023,Attachment 22 Ferric Citrate Hydrate for the Treatment of Hyperphosphatemia re Citizen Petition from Sidley Austin LLP (Vifor Fresenius Medical Care Renal Pharma Ltd)
09000064827c553e,Supporting & Related Material,FDA-2017-P-4023-0026,FDA-2017-P-4023,Attachment 24 A randomized controlled trial comparing intravenous ferric re Citizen Petition from Sidley Austin LLP (Vifor Fresenius Medical Care Renal Pharma Ltd)
09000064827c5548,Supporting & Related Material,FDA-2017-P-4023-0028,FDA-2017-P-4023,Attachment 26 Ferric Citrate Controls Phosphorus and Delivers Iron in Patients on Dialysis re Citizen Petition from Sidley Austin LLP (Vifor Fresenius Medical Care Renal Pharma Ltd)
09000064827c5304,Supporting & Related Material,FDA-2017-P-4023-0007,FDA-2017-P-4023,Attachment 5 National Kidney Foundation Practice Guidelines for Chronic Kidney Disease re Citizen Petition from Sidley Austin LLP (Vifor Fresenius Medical Care Renal Pharma Ltd)
09000064827c552e,Supporting & Related Material,FDA-2017-P-4023-0011,FDA-2017-P-4023,Attachment 9 Iron management in chronic kidney disease re Citizen Petition from Sidley Austin LLP (Vifor Fresenius Medical Care Renal Pharma Ltd)
09000064827c5530,Supporting & Related Material,FDA-2017-P-4023-0013,FDA-2017-P-4023,Attachment 11 Hepcidin - A Potential Novel Biomarker for Iron Status in Chronic Kidney Disease re Citizen Petition from Sidley Austin LLP (Vifor Fresenius Medical Care Renal Pharma Ltd)
09000064827c553d,Supporting & Related Material,FDA-2017-P-4023-0025,FDA-2017-P-4023,Attachment 23 FIND-CKD a randomized trial of intravenous terric carboxymaltose re Citizen Petition from Sidley Austin LLP (Vifor Fresenius Medical Care Renal Pharma Ltd)
09000064827c5537,Supporting & Related Material,FDA-2017-P-4023-0019,FDA-2017-P-4023,Attachment 17 Hyperphosphatemia in Renal Failure re Citizen Petition from Sidley Austin LLP (Vifor Fresenius Medical Care Renal Pharma Ltd)
09000064827c5538,Supporting & Related Material,FDA-2017-P-4023-0020,FDA-2017-P-4023,Attachment 18 Fibroblast Growth Factor-23 Mitigates Hyperphosphatemia re Citizen Petition from Sidley Austin LLP (Vifor Fresenius Medical Care Renal Pharma Ltd)
09000064827c553f,Supporting & Related Material,FDA-2017-P-4023-0027,FDA-2017-P-4023,Attachment 25 Ferric Citrate Reduces Intravenous Iron and Erythropoiesis re Citizen Petition from Sidley Austin LLP (Vifor Fresenius Medical Care Renal Pharma Ltd)
09000064827c5300,Supporting & Related Material,FDA-2017-P-4023-0003,FDA-2017-P-4023,"Attachment 1 Press Release Investor Relations Keryx Biopharmaceuticals, Inc re Citizen Petition from Sidley Austin LLP (Vifor Fresenius Medical Care Renal Pharma Ltd)"
09000064827c52fc,Other,FDA-2017-P-4023-0001,FDA-2017-P-4023,Citizen Petition from Sidley Austin LLP (Vifor Fresenius Medical Care Renal Pharma Ltd)
0900006482fd5bec,Supporting & Related Material,FDA-2018-P-1068-0016,FDA-2018-P-1068,"Attachment14_N - SUPAC 1997 Guidance - re Citizen Petition from Spear Pharmaceuticals, Inc"
0900006482fd5d32,Supporting & Related Material,FDA-2018-P-1068-0004,FDA-2018-P-1068,"Attachment2_B - Fluorouracil Draft Guidance - re Citizen Petition from Spear Pharmaceuticals, Inc"
0900006482fd5d95,Supporting & Related Material,FDA-2018-P-1068-0006,FDA-2018-P-1068,"Attachment4_D - Vale et al_ - re Citizen Petition from Spear Pharmaceuticals, Inc"
0900006482fd5bed,Supporting & Related Material,FDA-2018-P-1068-0017,FDA-2018-P-1068,"Attachment15_O - USP 1724 SS Performance Tests - re Citizen Petition from Spear Pharmaceuticals, Inc"
0900006482fd5d2e,Other,FDA-2018-P-1068-0002,FDA-2018-P-1068,"Acknowledgment Letter from FDA DDM to Spear Pharmaceuticals, Inc"
0900006482fd5bea,Supporting & Related Material,FDA-2018-P-1068-0014,FDA-2018-P-1068,"Attachment12_L - Luke FDA powerpoint - re Citizen Petition from Spear Pharmaceuticals, Inc"
0900006482fd5d31,Supporting & Related Material,FDA-2018-P-1068-0003,FDA-2018-P-1068,"Attachment1_A - Raney powerpoint - re Citizen Petition from Spear Pharmaceuticals, Inc"
0900006482fd5beb,Supporting & Related Material,FDA-2018-P-1068-0015,FDA-2018-P-1068,"Attachment13_M - Stinchcombe FDA powerpoint - re Citizen Petition from Spear Pharmaceuticals, Inc"
0900006482fd5d9a,Supporting & Related Material,FDA-2018-P-1068-0010,FDA-2018-P-1068,"Attachment8_H - Zovirax label - re Citizen Petition from Spear Pharmaceuticals, Inc"
0900006482fd5d9c,Supporting & Related Material,FDA-2018-P-1068-0012,FDA-2018-P-1068,"Attachment10_J - Soolantra label - re Citizen Petition from Spear Pharmaceuticals, Inc"
0900006482fd5d96,Supporting & Related Material,FDA-2018-P-1068-0007,FDA-2018-P-1068,"Attachment5_E - Yanofsky et al_ - re Citizen Petition from Spear Pharmaceuticals, Inc"
0900006482fd5d9b,Supporting & Related Material,FDA-2018-P-1068-0011,FDA-2018-P-1068,"Attachment9_I - Aczone label - re Citizen Petition from Spear Pharmaceuticals, Inc"
09000064830f93c2,Other,FDA-2018-P-1068-0019,FDA-2018-P-1068,"Docket No_ FDA-2018-P-1068 - Request for Withdrawal of Citizen Petition - April 9, 2018-1"
0900006482fd5bee,Supporting & Related Material,FDA-2018-P-1068-0018,FDA-2018-P-1068,"Attachment16_P - IMS Data - re Citizen Petition from Spear Pharmaceuticals, Inc"
0900006482fd5d94,Supporting & Related Material,FDA-2018-P-1068-0005,FDA-2018-P-1068,"Attachment3_C - FINAL Welgus Decl_ with exhibits - re Citizen Petition from Spear Pharmaceuticals, Inc"
0900006482fd5d98,Supporting & Related Material,FDA-2018-P-1068-0008,FDA-2018-P-1068,"Attachment6_F - Sigma 5-fluorouracil - re Citizen Petition from Spear Pharmaceuticals, Inc"
0900006482fd5d99,Supporting & Related Material,FDA-2018-P-1068-0009,FDA-2018-P-1068,"Attachment7_G - MSDS Fluorouracil - re Citizen Petition from Spear Pharmaceuticals, Inc"
0900006482fd5d9d,Supporting & Related Material,FDA-2018-P-1068-0013,FDA-2018-P-1068,"Attachment11_K - Acyclovir draft guidance - re Citizen Petition from Spear Pharmaceuticals, Inc"
0900006482fd5d2b,Other,FDA-2018-P-1068-0001,FDA-2018-P-1068,"Citizen Petition from Spear Pharmaceuticals, Inc"
09000064825bbb05,Other,FDA-2017-P-3065-0002,FDA-2017-P-3065,Acknowledgment Letter from FDA DDM to NJOY et. al.
0900006482c3bfcf,Other,FDA-2017-P-3065-3519,FDA-2017-P-3065,Petition Decision Letter from FDA CTP to NJOY LLC
09000064825bb911,Other,FDA-2017-P-3065-0001,FDA-2017-P-3065,Citizen Petition from NJOY et. al.
09000064840c5bea,Other,FDA-2019-P-4879-0001,FDA-2019-P-4879,"Citizen Petition from  Lachman Consultant Services, Inc."
09000064840c6f6a,Supporting & Related Material,FDA-2019-P-4879-0003,FDA-2019-P-4879,"Attachment 1 -  Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations re: Citizen Petition from  Lachman Consultant Services, Inc."
09000064846bce49,Other,FDA-2019-P-4879-0004,FDA-2019-P-4879,"Interim Response from FDA CDER to Lachman Consultant Services, Inc"
09000064840c6f6b,Other,FDA-2019-P-4879-0002,FDA-2019-P-4879,"Acknowledgment Letter from DMS to Lachman Consultant Services, Inc."
090000648498aa77,Other,FDA-2019-P-4879-0005,FDA-2019-P-4879,"Withdrawal from Lachman Consultant Services, Inc."
090000648463247a,Other,FDA-2020-P-1393-0002,FDA-2020-P-1393,Acknowledgment Letter from FDA DMS to Nexus Pharmaceuticals Inc
0900006484632eb3,Other,FDA-2020-P-1393-0001,FDA-2020-P-1393,Suitability Petition from Nexus Pharmaceuticals Inc
09000064847457b1,Other,FDA-2020-P-1653-0002,FDA-2020-P-1653,"Acknowledgment Letter from FDA DMS to Aurobindo Pharma USA, Inc."
09000064847457ae,Other,FDA-2020-P-1653-0001,FDA-2020-P-1653,"Citizen Petition from Aurobindo Pharma USA, Inc."
0900006484954485,Other,FDA-2020-P-1653-0004,FDA-2020-P-1653,"Withdrawal of Aurobindo Pharma USA, Inc."
09000064823c8f32,Other,FDA-2016-P-4094-0001,FDA-2016-P-4094,Citizen Petition from Adapt Pharma Operations Lts
090000648256e980,Other,FDA-2016-P-4094-0003,FDA-2016-P-4094,Response Letter from FDA CDER to Adapt Pharma Operations Ltd
09000064823c8f34,Other,FDA-2016-P-4094-0002,FDA-2016-P-4094,Acknowledgment Letter from FDA DDM to Adapt Pharma Operations Ltd
0900006484a20d06,Other,FDA-2021-P-0168-0001,FDA-2021-P-0168,Citizen Petition from The Center for Science in the Public Interest (CSPI)
0900006484c005e5,Other,FDA-2021-P-0168-0146,FDA-2021-P-0168,180 Day Interim Response Letter from FDA CFSAN to Center for Science in the Public Interest
0900006484a20d08,Other,FDA-2021-P-0168-0002,FDA-2021-P-0168,Acknowledgement Letter from FDA DMS to The Center for Science in the Public Interest (CSPI)
0900006481e81d4b,Other,FDA-2016-P-0644-0002,FDA-2016-P-0644,"Acknowledgement Letter from FDA DDM to Gordon Johnston Regulatory Consultants, LLC"
0900006481e81de2,Supporting & Related Material,FDA-2016-P-0644-0003,FDA-2016-P-0644,"Attachment 1 - FDA Electronic Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations for Olmesartan Medoxomil  Tablets 20 mg, 40 mg, and 5 mg re Citizen Petition from Gordon Johnston Regulatory Consultants, LLC"
0900006481e81de3,Supporting & Related Material,FDA-2016-P-0644-0004,FDA-2016-P-0644,"Attachment 2 - BENICAR (olmesartan medoxomi) Tablets 5 mg, 20 mg and 40 mg approved labeling (RLD Labeling) re Citizen Petition from Gordon Johnston Regulatory Consultants, LLC"
0900006481e8074d,Other,FDA-2016-P-0644-0001,FDA-2016-P-0644,"Citizen Petition from Gordon Johnston Regulatory Consultants, LLC"
0900006481e81de4,Supporting & Related Material,FDA-2016-P-0644-0005,FDA-2016-P-0644,"Attachment 3 -  Draft Labeling for Olmesartan Medoxomil Tablets 5 mg, 20 mg and 40 mg re Citizen Petition from Gordon Johnston Regulatory Consultants, LLC"
09000064836530dc,Other,FDA-2018-P-1335-0004,FDA-2018-P-1335,"Agency Response Letter from FDA CDER to Hyman, Phelps & McNamara, P.C."
090000648307529b,Other,FDA-2018-P-1335-0001,FDA-2018-P-1335,"Citizen Petition form Hyman, Phelps & McNamara, P.C."
0900006483643974,Notice,FDA-2018-P-1335-0003,FDA-2018-P-1335,"Determination That DITROPAN XL (Oxybutynin Chloride) Extended
Release Tablets, 15 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
0900006483075a6d,Other,FDA-2018-P-1335-0002,FDA-2018-P-1335,"Acknowledgment Letter from FDA DDM to Hyman, Phelps & McNamara, P.C."
0900006482cf9607,Other,FDA-2017-P-6809-0002,FDA-2017-P-6809,Acknowledgement Letter from DDM to Freyr Inc.
0900006483341cd9,Other,FDA-2017-P-6809-0003,FDA-2017-P-6809,Interim Response Letter from FDA CDER to Freyr Inc
090000648485a4a9,Other,FDA-2017-P-6809-0004,FDA-2017-P-6809,Final Response Letter from FDA CDER to Freyr Inc.
0900006482cf9084,Other,FDA-2017-P-6809-0001,FDA-2017-P-6809,Citizen Petition from Freyr Inc.
09000064838d697a,Supporting & Related Material,FDA-2018-P-4338-0004,FDA-2018-P-4338,Attachment 2-OxyContin Reference Meeting Minutes Re: Citizen Petition from PMRS
09000064838d69b1,Supporting & Related Material,FDA-2018-P-4338-0006,FDA-2018-P-4338,Attachment 3-PMRS Response to FDA Notice Re: Citizen Petition from PMRS
09000064838d69b2,Supporting & Related Material,FDA-2018-P-4338-0007,FDA-2018-P-4338,Attachment 4-Roxicodone Label Re: Citizen Petition from PMRS
09000064838d69ba,Supporting & Related Material,FDA-2018-P-4338-0011,FDA-2018-P-4338,"Attachment 8-CDC, Community Outbreak of HIV Infection Linked to Injection Drug Use of Oxymorphone - Indiana, 2015(1) Re: Citizen Petition from PMRS"
09000064838d69b3,Supporting & Related Material,FDA-2018-P-4338-0008,FDA-2018-P-4338,Attachment 5-Percodan Label Re: Citizen Petition from PMRS
09000064838d5dca,Other,FDA-2018-P-4338-0001,FDA-2018-P-4338,Citizen Petition from PMRS
09000064838d6979,Supporting & Related Material,FDA-2018-P-4338-0003,FDA-2018-P-4338,Attachment 1-Approval Letter of NDA 20-553/S-022 from FDA CDER ODE to Purdue Pharma L.P.  Re: Citizen Petition from PMRS
09000064838d69b5,Supporting & Related Material,FDA-2018-P-4338-0010,FDA-2018-P-4338,"Attachment 7--CDC, Thrombotic Thrombocytopenic Purpura (TTP)-Like Illness Associated with Intravenous Opana ER Abuse - Tennessee, 2012(2) Re: Citizen Petition from PMRS"
09000064838d69d4,Supporting & Related Material,FDA-2018-P-4338-0013,FDA-2018-P-4338,Attachment 10- Correct Title Data Summary Report of a Cutting Force Method for Multiple Formulations of CII Narcotic Drug Products Re: Citizen Petition from PMRS
09000064838d69d6,Supporting & Related Material,FDA-2018-P-4338-0015,FDA-2018-P-4338,"Attachment 12-CDC, Opioid Data Analysis Re: Citizen Petition from PMRS"
09000064838d69d8,Supporting & Related Material,FDA-2018-P-4338-0017,FDA-2018-P-4338,"Attachment 14-CDC Division of Vital Statistics, Mortality DataRe: Citizen Petition from PMRS"
09000064838d69d9,Supporting & Related Material,FDA-2018-P-4338-0018,FDA-2018-P-4338,"Attachment 15-NIDA, Overdose Death Rates Re: Citizen Petition from PMRS"
09000064838d69b4,Supporting & Related Material,FDA-2018-P-4338-0009,FDA-2018-P-4338,Attachment 6-Highlights of Prescribing Information (Oxycontin) Re: Citizen Petition from PMRS
0900006483b8bb72,Other,FDA-2018-P-4338-0025,FDA-2018-P-4338,Agency Response Letter from FDA CDER to PMRS
09000064838d69d5,Supporting & Related Material,FDA-2018-P-4338-0014,FDA-2018-P-4338,"Attachment 11-CDC, Understanding the Epidemic Re: Citizen Petition from PMRS"
09000064838d69d3,Supporting & Related Material,FDA-2018-P-4338-0012,FDA-2018-P-4338,Attachment 9-DEA quota history Re: Citizen Petition from PMRS
09000064838d69d7,Supporting & Related Material,FDA-2018-P-4338-0016,FDA-2018-P-4338,"Attachment 13-CDC, Morbidity and Mortality Weekly Report Re: Citizen Petition from PMRS"
09000064838d6568,Other,FDA-2018-P-4338-0002,FDA-2018-P-4338,Acknowledgment Letter from FDA DDM to PMRS
0900006482f31437,Other,FDA-2017-P-5081-0004,FDA-2017-P-5081,"Interim Response Letter from FDA CDER to Pfizer, Inc."
09000064846fb8b4,Other,FDA-2017-P-5081-0005,FDA-2017-P-5081,"Response from FDA CDER to Pfizer Essential Health - Pfizer, Inc."
0900006482a8c845,Supporting & Related Material,FDA-2017-P-5081-0003,FDA-2017-P-5081,"Appendix 1 SUMMARY FOR REPORT (REPORT NO.: 20466F) OF STUDY T91IE13 TITLED AS PHARMACOKINETICS OF ESTRADIOL AFTER APPLICATION OF AN ESTRADIOL RELEASING VAGINAL RING. KABI PHARMACIA, 1992 re Citizen Petition from Pfizer, Inc."
0900006482a8ceb7,Other,FDA-2017-P-5081-0002,FDA-2017-P-5081,"Acknowledgment Letter from FDA DDM to Pfizer, Inc."
0900006482a8cb26,Other,FDA-2017-P-5081-0001,FDA-2017-P-5081,"Citizen Petition from Pfizer, Inc."
0900006483c293cc,Other,FDA-2019-P-2122-0002,FDA-2019-P-2122,Acknowledgment Letter from FDA DDM to Handcrafted Soap & Cosmetic Guild
0900006483c29ac3,Other,FDA-2019-P-2122-0001,FDA-2019-P-2122,Citizen Petition from Handcrafted Soap & Cosmetic Guild
09000064849e7909,Supporting & Related Material,FDA-2021-P-0032-0011,FDA-2021-P-0032,Citation 41 - The Role of Nicotine in the Effects of Maternal Smoking during Pregnancy on Lung Development and Childhood Respiratory Disease
09000064849e790d,Supporting & Related Material,FDA-2021-P-0032-0015,FDA-2021-P-0032,Citation 45  Adverse effects of perinatal nicotine exposure on reproductive outcomes
09000064849e790b,Supporting & Related Material,FDA-2021-P-0032-0013,FDA-2021-P-0032,"Citation 43 - Relationship Between Birth Weight, Maternal Smoking During Pregnancy, and Childhood and Adolescent Lung Function"
09000064849e7915,Supporting & Related Material,FDA-2021-P-0032-0020,FDA-2021-P-0032,"Citation 50 - Low Birthweight, Preterm Births and Intrauterine Growth Retardation in Relation to Maternall Smoking"
09000064849e7918,Supporting & Related Material,FDA-2021-P-0032-0023,FDA-2021-P-0032,Citation 53 -  The Influence of Gestational Age and Smoking Habits on the Risk of Subsequent Preterm Deliveries
09000064849e7911,Supporting & Related Material,FDA-2021-P-0032-0019,FDA-2021-P-0032,Citation 49 - Low Birth Weight of Children is Positively Associated with Mother's Prenatal Tobacco SMoke Exposure  in Shanghi
09000064849e72ff,Supporting & Related Material,FDA-2021-P-0032-0003,FDA-2021-P-0032,Citation 33 - Maternal  Smoking Before and During Pregnancy and the Risk of Sudden Unexpected tInfant Death
0900006484acb496,Other,FDA-2021-P-0032-0025,FDA-2021-P-0032,Final Response from FDA CTP to Angela Bryan
09000064849e7219,Other,FDA-2021-P-0032-0001,FDA-2021-P-0032,Citizen's Petition from Angela Bryan
09000064849e7302,Supporting & Related Material,FDA-2021-P-0032-0006,FDA-2021-P-0032,Citation 36 - The Alteration of Neonatal Raphe Neurons by Prenatal-Perinatal Nicotine
09000064849e7917,Supporting & Related Material,FDA-2021-P-0032-0022,FDA-2021-P-0032,Citation 52 - Previous Preterm and Small for Gestational Age Births and the Subsequent Risk of Stillbith
09000064849e790c,Supporting & Related Material,FDA-2021-P-0032-0014,FDA-2021-P-0032,Citation 44 - Maternal Smoking and the Risk of Still Birth Systematic Review and Meta Analysis
09000064849e7916,Supporting & Related Material,FDA-2021-P-0032-0021,FDA-2021-P-0032,Citation 51 - Maternal Smoking and Causes of Very Preterm Birth
09000064849e7301,Supporting & Related Material,FDA-2021-P-0032-0005,FDA-2021-P-0032,Citation 35 - The amount of brainstem gliosis in sudden infant death dyndrome victims correlates with maternal cigarette smoking during pregnancy
09000064849e7919,Supporting & Related Material,FDA-2021-P-0032-0024,FDA-2021-P-0032,Citation 54 - Estimates of Healthcare Spending for Preterm and Low-birthweight Infants in a Commercially Insured Population 2008-2016
09000064849e7908,Supporting & Related Material,FDA-2021-P-0032-0010,FDA-2021-P-0032,Citation 40 - In utero Exposures to Electronic- Cigarette Aerosols Impair the Wnt Signaling During Mouse Lung Development
09000064849e7910,Supporting & Related Material,FDA-2021-P-0032-0018,FDA-2021-P-0032,"Citation 48 - Parental Smoking During Pregnancy and its Association with Low Birthweigh, Small for Gestational Age, and Pre-Term Birth"
09000064849e7474,Other,FDA-2021-P-0032-0002,FDA-2021-P-0032,Acknowledgment Letter from FDA DMS to Angela Bryan
09000064849e7300,Supporting & Related Material,FDA-2021-P-0032-0004,FDA-2021-P-0032,Citation 34 - The Role of Maternal Smoking in Sudden Fetal and Infant Death Pathogenesis
09000064849e7305,Supporting & Related Material,FDA-2021-P-0032-0009,FDA-2021-P-0032,Citation 39 - Pulmonary Effects of Maternal Smoking on the Fetus and Child
09000064849e7303,Supporting & Related Material,FDA-2021-P-0032-0007,FDA-2021-P-0032,Citation 37 - Respiratory Dysfunction Induced By Prenatal Nicotine Exposure
09000064849e7304,Supporting & Related Material,FDA-2021-P-0032-0008,FDA-2021-P-0032,Citation 38 - Impact of  Tobacco Smoke and Nicotine Exposure on Lung Development
09000064849e790a,Supporting & Related Material,FDA-2021-P-0032-0012,FDA-2021-P-0032,Citation 42 - The Toxicity of E-Cigarettes and Children's Respiratory Health
09000064849e790e,Supporting & Related Material,FDA-2021-P-0032-0016,FDA-2021-P-0032,Citation 46 - Maternal Active Smoking During Pregnancy and Low Birth Weight in the Americas A Systematic Review and Meta-analysis
09000064849e790f,Supporting & Related Material,FDA-2021-P-0032-0017,FDA-2021-P-0032,Citation 47- Exposure to tobacco smoke and low birth weight from epidemiology to metabolomics
09000064809beeff,Other,FDA-2009-P-0253-0001,FDA-2009-P-0253,Scott A. Tolchin - Citizen Petition
09000064809bef02,Other,FDA-2009-P-0253-0002,FDA-2009-P-0253,Acknowledgement Letter to Scott A. Tolchin
0900006480af1697,Other,FDA-2009-P-0253-0004,FDA-2009-P-0253,FDA/OC Reponse Letter to Scott A. Tolchin  - Petition Denial
0900006481c38916,Other,FDA-2015-P-3108-0001,FDA-2015-P-3108,Citizen Petition from Ferrosan Medical Devices (DuVal & Associates)
0900006484dae700,Other,FDA-2015-P-3108-0003,FDA-2015-P-3108,Petition Response to Ferrosan Medical Devices (DuVal & Associates) from CDRH
0900006481c386c5,Other,FDA-2015-P-3108-0002,FDA-2015-P-3108,Acknowledgement Letter from FDA DDM to Ferrosan Medical Devices (DuVal & Associates)
0900006484dc2ae3,Other,FDA-2021-P-1097-0001,FDA-2021-P-1097,Citizen Petition from Ajanta Pharma USA Inc
0900006484dc2793,Other,FDA-2021-P-1097-0002,FDA-2021-P-1097,Acknowledgment Letter from FDA DMS to Ajanta Pharma USA Inc
09000064820a6c62,Supporting & Related Material,FDA-2016-P-2030-0007,FDA-2016-P-2030,Appendix I - pages 53 - 79 - Regulations and Scientific Papers re Citizen Petition from The Food Lawyers
09000064820a96c1,Other,FDA-2016-P-2030-0002,FDA-2016-P-2030,Acknowledgement Letter from FDA DDM to The Food Lawyers
09000064820a6c63,Supporting & Related Material,FDA-2016-P-2030-0008,FDA-2016-P-2030,Appendix II -- GRAS Notices and FDA Response Letters to GRAS Notifications re Citizen Petition from The Food Lawyers
09000064820a6db2,Supporting & Related Material,FDA-2016-P-2030-0005,FDA-2016-P-2030,Appendix I - pages 1 - 23 - Regulations and Scientific Papers re Citizen Petition from The Food Lawyers
09000064820a6c61,Supporting & Related Material,FDA-2016-P-2030-0006,FDA-2016-P-2030,Appendix I - pages 24 - 52 - Regulations and Scientific Papers re Citizen Petition from The Food Lawyers
09000064820a6db1,Supporting & Related Material,FDA-2016-P-2030-0004,FDA-2016-P-2030,Exhibit B Composite Analysis of Kendall (2014) and Lee (1998) Studies Plasma Glucose over time following treatment re Citizen Petition from The Food Lawyers
0900006482534cf4,Other,FDA-2016-P-2030-0011,FDA-2016-P-2030,Interim Response Letter from CFSAN to The Food Lawyers
09000064820a6dab,Other,FDA-2016-P-2030-0001,FDA-2016-P-2030,Citizen Petition from The Food Lawyers
09000064820a6db0,Supporting & Related Material,FDA-2016-P-2030-0003,FDA-2016-P-2030,Exhibit A Existing Regulation 5 and Proposed Amendment Which Is §G re Citizen Petition from The Food Lawyers
0900006482344817,Other,FDA-2016-P-3509-0001,FDA-2016-P-3509,Citizen Petition from Metabolic Therapy Inc
0900006482556e83,Other,FDA-2016-P-3509-0003,FDA-2016-P-3509,Petition Denial Response from CDER
0900006482344819,Other,FDA-2016-P-3509-0002,FDA-2016-P-3509,Acknowledgement Letter from FDA DDM to Metabolic Therapy Inc
09000064819fc702,Other,FDA-2015-D-0268-0002,FDA-2015-D-0268,"Individual Patient Expanded Access Applications: Form FDA 3926; Draft
Guidance for Industry"
0900006481ebbfe3,Notice,FDA-2015-D-0268-0011,FDA-2015-D-0268,"Agency Information Collection Activities; Submission for Office of
Management and Budget Review; Comment Request; Guidance for
Industry on Individual Patient Expanded Access Applications: Form
FDA 3926"
09000064819fca41,Rule,FDA-2015-D-0268-0001,FDA-2015-D-0268,"Individual Patient Expanded Access Applications: Form FDA 3926; Draft
Guidance for Industry; Availability"
090000648200e1ee,Other,FDA-2015-D-0268-0013,FDA-2015-D-0268,Guidance for Industry on Individual Patient Expanded Access Applications - Form FDA 3926
090000648200d4f8,Notice,FDA-2015-D-0268-0012,FDA-2015-D-0268,"Individual Patient Expanded Access Applications: Form FDA 3926; 
Guidance for Industry; Availability"
0900006480bc6e60,Other,FDA-2010-P-0549-0004,FDA-2010-P-0549,Lupin Limited - Reply Comment
0900006480e324c2,Other,FDA-2010-P-0549-0006,FDA-2010-P-0549,"FDA/CDER to Rakoczy Molino Mazzochi Siwik, LLP - Petition Denial"
0900006480c2efd6,Other,FDA-2010-P-0549-0005,FDA-2010-P-0549,"Interim Response to Rakoczy Molino Mazzochi Siwik, LLP"
0900006480b7378f,Other,FDA-2010-P-0549-0002,FDA-2010-P-0549,Acknowledgement Letter to Lupin Limited
0900006480b7323f,Other,FDA-2010-P-0549-0001,FDA-2010-P-0549,"Lupin Limited (Rakoczy Molino Mazzochi Siwik, LLP) - Citizen Petition"
0900006481dd73da,Supporting & Related Material,FDA-2015-P-5108-0016,FDA-2015-P-5108,"Exhibit 3 Published Reports of Kaplan et al (1998), Heiskanen and Kalso (1997) and Bruera et al (1998) re Citizen Petition from Purdue Pharma L.P. (Kleinfeld, Kaplan and Becker, LLP)"
0900006481fe4be3,Other,FDA-2015-P-5108-0012,FDA-2015-P-5108,Final Agency Decision Petition Denial
0900006481dd7785,Supporting & Related Material,FDA-2015-P-5108-0015,FDA-2015-P-5108,"Exhibit 7 Kirvela, et al., The Pharmacokinetics of Oxycodone in Uremic Patients Undergoing Renal Transplantation re Citizen Petition from   Purdue Pharma L.P. (Kleinfeld, Kaplan and Becker, LLP)"
0900006481dd778a,Supporting & Related Material,FDA-2015-P-5108-0014,FDA-2015-P-5108,"Exhibit 8 Physicians Desk Reference, 53rd Ed. 1999 Label for Roxicodone IR 5 mg re Citizen Petition from Purdue Pharma L.P. (Kleinfeld, Kaplan and Becker, LLP)"
0900006481dd91ac,Supporting & Related Material,FDA-2015-P-5108-0013,FDA-2015-P-5108,"Exhibit 10 Gandelman, K et al. Single and Multiple Dose Study to Evaluate Pharmacokinetics Safety and Tolerability in Healthy Volunteers re Citizen Petition from Purdue Pharma L.P. (Kleinfeld, Kaplan and Becker, LLP)"
0900006481ddf501,Other,FDA-2015-P-5108-0002,FDA-2015-P-5108,"Acknowledgement Letter from FDA DDM to Kleinfeld, Kaplan and Becker, LLP"
0900006481dd91ad,Supporting & Related Material,FDA-2015-P-5108-0009,FDA-2015-P-5108,"Exhibit 11 Benziger, Cheng, Miotto,  and Grandy  Comparative Pharmacokinetics of Controlled Release Oxycodone (OxyContin) in special populations re Citizen Petition from Purdue Pharma L.P. (Kleinfeld, Kaplan and Becker, LLP)"
0900006481dd73d9,Supporting & Related Material,FDA-2015-P-5108-0004,FDA-2015-P-5108,"Exhibit 2 Physicians Desk Reference, 53rd Ed. 1999 Label for OxyContin re Citizen Petition from Purdue Pharma L.P. (Kleinfeld, Kaplan and Becker, LLP)"
0900006481dd73db,Supporting & Related Material,FDA-2015-P-5108-0005,FDA-2015-P-5108,"Exhibit 4 Medical Officer Review, Integrated Summary of Efficacy, Oxycodone Controlled Release, NDA 20553 and Medical officer Review, OxyContin Study 0402B-Cancer Pain re Citizen Petition from Purdue Pharma L.P. (Kleinfeld, Kaplan and Becker, LLP)"
0900006481dd73d8,Supporting & Related Material,FDA-2015-P-5108-0003,FDA-2015-P-5108,"Exhibit 1 Physicians Desk Reference, 53rd Ed. 1999 Label for Percodan re Citizen Petition from Purdue Pharma L.P. (Kleinfeld, Kaplan and Becker, LLP)"
0900006481dd91ae,Supporting & Related Material,FDA-2015-P-5108-0010,FDA-2015-P-5108,"Exhibit 12 Kaiko, Grandy, Hou, and Benziger Controlled Release Oxycodone Pharmacokinetics Pharmacodynamics in Hepatic Cirrhosis (Abstract) re Citizen Petition from Purdue Pharma L.P. (Kleinfeld, Kaplan and Becker, LLP)"
0900006481dd7b86,Supporting & Related Material,FDA-2015-P-5108-0006,FDA-2015-P-5108,"Exhibit 5 Exclusivity Summary, NDA 20553 re Citizen Petition from Purdue Pharma L.P. (Kleinfeld, Kaplan and Becker, LLP)"
0900006481e9eae4,Other,FDA-2015-P-5108-0017,FDA-2015-P-5108,Supplement from Purdue Pharma L.P.
0900006481dd5e86,Other,FDA-2015-P-5108-0001,FDA-2015-P-5108,"Citizen Petition from Purdue Pharma L.P. (Kleinfeld, Kaplan and Becker, LLP)"
0900006481dd7783,Supporting & Related Material,FDA-2015-P-5108-0007,FDA-2015-P-5108,"Exhibit 6 NDA Review, NDA 20-553 E.D. Bashaw, PharmD, with Excerpts from Appendix to Review
re Citizen Petition from Purdue Pharma L.P. (Kleinfeld, Kaplan and Becker, LLP)"
0900006481dd91ab,Supporting & Related Material,FDA-2015-P-5108-0008,FDA-2015-P-5108,"Exhibit 9 Comments from Purdue Pharma L.P. Docket No. FDA-2011-N-0830 (June 8, 2015) re  Citizen Petition from Purdue Pharma L.P. (Kleinfeld, Kaplan and Becker, LLP)"
0900006482bcf325,Other,FDA-2017-P-2245-0005,FDA-2017-P-2245,Petition Withdrawal Letter from Fresenius Kabi USA LLC
0900006482549a75,Other,FDA-2017-P-2245-0001,FDA-2017-P-2245,"Citizen Petiton from Fresenius Kabi USA, LLC"
090000648254a0b8,Other,FDA-2017-P-2245-0002,FDA-2017-P-2245,"Acknowledgment Letter from FDA DDM to Fresenius Kabi USA, LLC"
0900006482b9b496,Other,FDA-2017-P-2245-0004,FDA-2017-P-2245,"Interim Response Letter from CDER to Fresenius Kabi USA, LLC"
090000648254a0bc,Supporting & Related Material,FDA-2017-P-2245-0003,FDA-2017-P-2245,"Attachment A -  Current Orange Book Listing of Lactated Ringer's and Dextrose 5% re for Citizen Petition from Fresenius Kabi USA, LLC"
090000648355d155,Supporting & Related Material,FDA-2018-P-2851-0011,FDA-2018-P-2851,012-020553_S022_OXYCONTIN_AP
090000648355d157,Supporting & Related Material,FDA-2018-P-2851-0013,FDA-2018-P-2851,028-Percodan Label (007337s049lbl)
090000648355d158,Supporting & Related Material,FDA-2018-P-2851-0014,FDA-2018-P-2851,028-PMRS Motion for Summary Judgment
0900006483547d42,Other,FDA-2018-P-2851-0001,FDA-2018-P-2851,"Citizen Petition from Pharmaceutical Manufacturing Research Services, Inc"
09000064835485d6,Supporting & Related Material,FDA-2018-P-2851-0004,FDA-2018-P-2851,Combined Attachments 2 of 6
09000064835482dc,Supporting & Related Material,FDA-2018-P-2851-0006,FDA-2018-P-2851,Combined Attachments 4 of 6
09000064835482e0,Supporting & Related Material,FDA-2018-P-2851-0008,FDA-2018-P-2851,Combined Attachments 6 of 6
09000064835482dd,Supporting & Related Material,FDA-2018-P-2851-0007,FDA-2018-P-2851,Combined Attachments 5 of 6
090000648355d156,Supporting & Related Material,FDA-2018-P-2851-0012,FDA-2018-P-2851,025-PMRS_Response_to_FDA_Notice
090000648355d15a,Supporting & Related Material,FDA-2018-P-2851-0016,FDA-2018-P-2851,036-Roxicodone Label [12-2016] (021011s006lbl)
090000648355d15c,Supporting & Related Material,FDA-2018-P-2851-0018,FDA-2018-P-2851,084-022272Orig1s014lbl
090000648355d166,Supporting & Related Material,FDA-2018-P-2851-0021,FDA-2018-P-2851,"113-CDC, Thrombotic Thrombocytopenic Purpura (TTP)-Like Illness Associated with Intravenous Opana ER Abuse - Tennessee, 2012"
090000648355d168,Supporting & Related Material,FDA-2018-P-2851-0023,FDA-2018-P-2851,118-DEA quota history
090000648355d16a,Supporting & Related Material,FDA-2018-P-2851-0025,FDA-2018-P-2851,"130-CDC, Opioid Data Analysis"
0900006483547d44,Other,FDA-2018-P-2851-0002,FDA-2018-P-2851,"Acknowledgment Letter from FDA DDM to Pharmaceutical Manufacturing Research Services, Inc"
090000648355ae1e,Supporting & Related Material,FDA-2018-P-2851-0009,FDA-2018-P-2851,008-OxyContin_Reference_-_020553_Original_Approval_Pkg-OxyContin_-_highlighted
090000648355d15b,Supporting & Related Material,FDA-2018-P-2851-0017,FDA-2018-P-2851,"060-Oxycontin Antitrust Litigation, Purdue v. Teva"
090000648355d15d,Supporting & Related Material,FDA-2018-P-2851-0019,FDA-2018-P-2851,092-OxyContin Package Insert (020553s060lbl)
090000648355d169,Supporting & Related Material,FDA-2018-P-2851-0024,FDA-2018-P-2851,"128-CDC, Understanding the Epidemic"
090000648355d154,Supporting & Related Material,FDA-2018-P-2851-0010,FDA-2018-P-2851,011-OxyContin_Reference_-_Meeting_Minutes_2001-06-14_-_labeling_and_development_plan_for_reformulation_-_by_FDA
090000648355d165,Supporting & Related Material,FDA-2018-P-2851-0020,FDA-2018-P-2851,093-AS0363600 DSR CII Drug Product Cutting Force Method
090000648355d16c,Supporting & Related Material,FDA-2018-P-2851-0027,FDA-2018-P-2851,"138-NIDA, Overdose Death Rates"
090000648355d159,Supporting & Related Material,FDA-2018-P-2851-0015,FDA-2018-P-2851,029-Roxicodone Label [2009 approval] (021011s003lbl)
090000648355d167,Supporting & Related Material,FDA-2018-P-2851-0022,FDA-2018-P-2851,"117-CDC, Community Outbreak of HIV Infection Linked to Injection Drug Use of Oxymorphone - Indiana, 2015"
090000648355d16b,Supporting & Related Material,FDA-2018-P-2851-0026,FDA-2018-P-2851,"133-CDC, mm6610a1"
09000064841adddf,Supporting & Related Material,FDA-2019-P-5571-0005,FDA-2019-P-5571,"Attachment 3 - Structure, Properties, and Function of aCopper(I)-Copper(II) Complex of D-Penicillamine:Pentathalli um( I) μ8-Chloro-dodeca(D-penicillaminato )octacuprate(I )hexacu prate( II) n-Hydrate re: Citizen Petition from Sheppard, Mullin, Richter & Hampton LLP on behalf of Apicore Pharmaceutical Private Ltd"
09000064841adddd,Supporting & Related Material,FDA-2019-P-5571-0003,FDA-2019-P-5571,"Attachment 1 - Clinical Pharmacokinetics re Citizen Petition from Sheppard, Mullin, Richter & Hampton LLP on behalf of Apicore Pharmaceutical Private Ltd"
09000064841addde,Supporting & Related Material,FDA-2019-P-5571-0004,FDA-2019-P-5571,"Attachment 2 - Identification of factors limiting the accuratemeasurement of plasma D-penicillamine in rheumatoidarthritis patients re: Citizen Petition from Sheppard, Mullin, Richter & Hampton LLP on behalf of Apicore Pharmaceutical Private Ltd"
09000064841bfbc9,Other,FDA-2019-P-5571-0001,FDA-2019-P-5571,"Citizen Petition from Sheppard, Mullin, Richter & Hampton LLP on behalf of Apicore Pharmaceutical Private Ltd"
09000064843795be,Other,FDA-2019-P-5571-0007,FDA-2019-P-5571,"Withdrawal from Sheppard, Mullin, Richter & Hampton LLP on behalf of Apicore Pharmaceutical Private Ltd"
09000064841adde0,Supporting & Related Material,FDA-2019-P-5571-0006,FDA-2019-P-5571,"Attachment 4 - CAPSULESCUPRIMINE® (PENICILLAMINE) re: Citizen Petition from Sheppard, Mullin, Richter & Hampton LLP on behalf of Apicore Pharmaceutical Private Ltd"
09000064841bfc63,Other,FDA-2019-P-5571-0002,FDA-2019-P-5571,"Acknowledgment Letter from FDA DDM to Apicore Pharmaceutical Private, Ltd."
0900006482bec070,Other,FDA-2017-P-2563-0042,FDA-2017-P-2563,Interim Response from FDA to The Tatia Oden French Memorial Foundation
0900006482bfbe89,Other,FDA-2017-P-2563-0053,FDA-2017-P-2563,Supplement from Tatia Oden French Memorial Foundation
090000648257a171,Other,FDA-2017-P-2563-0002,FDA-2017-P-2563,Acknowledgment Letter from FDA DDM to The Tatia Oden French Memorial Foundation
09000064825739b9,Other,FDA-2017-P-2563-0001,FDA-2017-P-2563,Citizen Petition from The Tatia Oden French Memorial Foundation
09000064832f580b,Other,FDA-2017-P-2563-0056,FDA-2017-P-2563,Supplement from The Tatia Oden French Memorial Foundation
09000064839ac3c5,Other,FDA-2017-P-2563-0057,FDA-2017-P-2563,Letter from FDA CDER to The Tatia Oden French Memorial Foundation
0900006482358264,Other,FDA-2016-P-3578-0001,FDA-2016-P-3578,Citizen Petition from Association for TruthinPetFood.com (ATPF)
0900006483d86d1d,Other,FDA-2016-P-3578-0007,FDA-2016-P-3578,Petition for Reconsideration from Association for Truth in Pet Food (ATPF)
090000648432d939,Other,FDA-2016-P-3578-0838,FDA-2016-P-3578,Final Response Letter from FDA CVM to Association for Truth in Pet Food
0900006483d8737d,Other,FDA-2016-P-3578-0008,FDA-2016-P-3578,Acknowledgment Letter from FDA DDM to Association for Truth in Pet Food
0900006482358266,Other,FDA-2016-P-3578-0002,FDA-2016-P-3578,Acknowledgment Letter from FDA DDM to Association for TruthinPetFood.com (ATPF)
09000064826801eb,Other,FDA-2016-P-3578-0003,FDA-2016-P-3578,Interim Response Letter from CVM to TruthinPetFood.com
0900006483c1f6fa,Other,FDA-2016-P-3578-0006,FDA-2016-P-3578,Final Response - Letter from FDA CVM to AssociationforTruthinPetFood.com
09000064828ca926,Other,FDA-2016-P-3578-0004,FDA-2016-P-3578,Addendum to Citizen Petition FDA-2016-P-3578  from the Association for Truth in Pet Food (ATPF)
090000648410a39e,Supporting & Related Material,FDA-2019-P-5048-0003,FDA-2019-P-5048,"Attachment A- Percutaneous Electrical Nerve Field Stimulation Modulates Central Pain Pathways and Attenuates Post-Inflammatory Visceral and Somatic Hyperalgesia In Rats re Citizen Petition from Epstein, Becker and Green on behalf of  Innovative Health Solutions, Inc."
0900006484502dce,Other,FDA-2019-P-5048-0005,FDA-2019-P-5048,"Interim Response Letter from FDA CDRH to Epstein Becker & Green, PC"
090000648410a39f,Supporting & Related Material,FDA-2019-P-5048-0004,FDA-2019-P-5048,"Attachment B- Neonatal nociceptive somatic stimulation differentially
modifies the activity of spinal neurons in rats and results in altered somatic and visceral sensation re Citizen Petition from Epstein, Becker and Green on behalf of  Innovative Health Solutions, Inc."
090000648410a260,Other,FDA-2019-P-5048-0001,FDA-2019-P-5048,"Citizen Petition from Epstein, Becker and Green P.C. on behalf of  Innovative Health Solutions, Inc."
090000648410a39a,Other,FDA-2019-P-5048-0002,FDA-2019-P-5048,"Acknowledgment Letter from FDA DMS to Epstein Becker & Green, P.C. on behalf of Innovative Health Solutions, Inc."
090000648327dd93,Other,FDA-2017-P-6923-0003,FDA-2017-P-6923,Petition Denial Letter from FDA CDER to Zydus Noveltech Inc.
0900006482d3cf5e,Other,FDA-2017-P-6923-0001,FDA-2017-P-6923,CONFIDENTIAL Citizen Petition from Zydus Noveltech Inc
09000064832bf2bd,Other,FDA-2017-P-6923-0004,FDA-2017-P-6923,Exelon - Acknoledgement letter - Corrected
0900006482d3cf60,Other,FDA-2017-P-6923-0002,FDA-2017-P-6923,Acknowledgment Letter from FDA DDM to Zydus Noveltech Inc.
0900006483009a0f,Other,FDA-2018-P-1110-0002,FDA-2018-P-1110,Acknowledgment Letter from FDA DDM to Haynes and Boone LLP
0900006483009264,Other,FDA-2018-P-1110-0001,FDA-2018-P-1110,Citizen Petition from Haynes and Boone LLP
090000648458605a,Other,FDA-2020-P-1356-0002,FDA-2020-P-1356,"Acknowledgment Letter from FDA DMS to Qilu Pharmaceutical Co., LTD."
0900006484958604,Other,FDA-2020-P-1356-0003,FDA-2020-P-1356,"Withdrawal from Qilu Pharma, INC."
0900006484586059,Other,FDA-2020-P-1356-0001,FDA-2020-P-1356,"Citizen petition  from Qilu Pharmaceutical Co., Ltd"
090000648227fb10,Other,FDA-2016-P-3015-0001,FDA-2016-P-3015,"Citizen Petition from Douglass Oeller Consulting, Inc. (Felix Pharmaceuticals Pvt. Ltd.)"
090000648227fbb5,Supporting & Related Material,FDA-2016-P-3015-0003,FDA-2016-P-3015,"Attachment 1 Baytril® ( enrofloxacin) Taste Tabs® Antibacterial Tablets for Dogs and Cats re Citizen Petition from Douglass Oeller Consulting, Inc. (Felix Pharmaceuticals Pvt. Ltd.)"
090000648227fbb6,Supporting & Related Material,FDA-2016-P-3015-0004,FDA-2016-P-3015,"Attachment 2 Felix Pharmaceuticals Pvt. Ltd; TBD (enrofloxacin)
Soft Chew Tabs® Antibacterial Tablets for Dogs and Cats re Citizen Petition from Douglass Oeller Consulting, Inc. (Felix Pharmaceuticals Pvt. Ltd.)"
0900006482481e47,Other,FDA-2016-P-3015-0005,FDA-2016-P-3015,Letter from CVM to Douglass Oeller Consulting Inc
090000648227fbb3,Other,FDA-2016-P-3015-0002,FDA-2016-P-3015,"Acknowledgment Letter from FDA DDM to Douglass Oeller Consulting, Inc."
0900006482575a28,Other,FDA-2016-P-3598-0004,FDA-2016-P-3598,Interim Response from FDA to Axinn Veltrop & Harkrider LLP
0900006482b26502,Other,FDA-2016-P-3598-0005,FDA-2016-P-3598,"Final Response Letter from FDA to Axinn, Veltrop & Harkrider LLP"
090000648235b5fd,Supporting & Related Material,FDA-2016-P-3598-0003,FDA-2016-P-3598,Attachment 1 - FDA Orange Book page for Melphalan Hydrochloride
090000648235b5fb,Other,FDA-2016-P-3598-0002,FDA-2016-P-3598,"Acknowledgment Letter from FDA DDM to Axinn, Veltrop & Harkrider LLP"
090000648235b5f9,Other,FDA-2016-P-3598-0001,FDA-2016-P-3598,"Citizen Petition from Axinn, Veltrop & Harkrider LLP"
090000648239e99d,Other,FDA-2016-P-3912-0001,FDA-2016-P-3912,Citizen Petition from Adapt Pharma Operations Ltd.
090000648239ea16,Other,FDA-2016-P-3912-0002,FDA-2016-P-3912,Acknowledgment Letter from FDA DDM to Adapt Pharma Operations Ltd
09000064823be092,Other,FDA-2016-P-3912-0003,FDA-2016-P-3912,Withdrawal from Pacific-Link Consulting
0900006481fdd5d1,Supporting & Related Material,FDA-2016-P-1303-0003,FDA-2016-P-1303,Attachment 1 Determination of methyl mercury in dental-unit wastewater re Citizen Petition from Consumers for Dental Choice
0900006481fdd5d2,Supporting & Related Material,FDA-2016-P-1303-0004,FDA-2016-P-1303,Attachment 2 EPA Will Propose Rule to Protect Waterways by Reducing Mercury from Dental Offices re Citizen Petition from Consumers for Dental Choice
0900006481fdd5d7,Supporting & Related Material,FDA-2016-P-1303-0009,FDA-2016-P-1303,Attachment 7 Zogby poll (2006) re Citizen Petition from Consumers for Dental Choice
0900006481fdd5d6,Supporting & Related Material,FDA-2016-P-1303-0008,FDA-2016-P-1303,Attachment 6 The Real Cost of Dental Mercury re Citizen Petition from Consumers for Dental Choice
0900006481fdd5dd,Supporting & Related Material,FDA-2016-P-1303-0013,FDA-2016-P-1303,"Attachment 11 Climate and Pollution Agency, Review of Norwegian experiences with the phase-out of dental amalgam use re Citizen Petition from Consumers for Dental Choice"
0900006481fdd201,Other,FDA-2016-P-1303-0002,FDA-2016-P-1303,Acknowledgement Letter from FDA DDM to  Consumers for Dental Choice
0900006481fdd5d3,Supporting & Related Material,FDA-2016-P-1303-0005,FDA-2016-P-1303,Attachment 3 Environmental costs of mercury pollution re Citizen Petition from Consumers for Dental Choice
0900006481fdd5d5,Supporting & Related Material,FDA-2016-P-1303-0007,FDA-2016-P-1303,Attachment 5 Minamata Convention (2013) re Citizen Petition from Consumers for Dental Choice
0900006481fdd5dc,Supporting & Related Material,FDA-2016-P-1303-0012,FDA-2016-P-1303,"Attachment 10 Swedish Chemicals Agency, Mercury Phase-Out, A Study of the Experiences of Swedish Companies re Citizen Petition from Consumers for Dental Choice"
0900006481fdd5d8,Supporting & Related Material,FDA-2016-P-1303-0010,FDA-2016-P-1303,"Attachment 8 UNEP, Lessons from Countries Phasing Down Dental Amalgam Use re Citizen Petition from Consumers for Dental Choice"
0900006481fdd5d9,Supporting & Related Material,FDA-2016-P-1303-0011,FDA-2016-P-1303,Attachment 9 Request for Information of Mercury in Products and Processes re Citizen Petition from Consumers for Dental Choice
0900006481fdd5de,Supporting & Related Material,FDA-2016-P-1303-0014,FDA-2016-P-1303,Attachment 12  Measurably Misleading re Citizen Petition from Consumers for Dental Choice
0900006482795570,Other,FDA-2016-P-1303-0015,FDA-2016-P-1303,Interim Response Letter from CDRH to Consumers for Dental Choice
0900006481fdd1ff,Other,FDA-2016-P-1303-0001,FDA-2016-P-1303,Citizen Petition from Consumers for Dental Choice
0900006481fdd5d4,Supporting & Related Material,FDA-2016-P-1303-0006,FDA-2016-P-1303,"Attachment 4 Changing Patterns in the Use, Recycling, and Material Substitution of Mercury in the United States (2013) re Citizen Petition from Consumers for Dental Choice"
09000064824fc6fd,Other,FDA-2017-P-1461-0001,FDA-2017-P-1461,Citizen Petition from FOLEY & LARDNER LLP
09000064824fcce5,Other,FDA-2017-P-1461-0002,FDA-2017-P-1461,Acknowledgment Letter from FDA DDM to Foley & Lardner LLP
0900006482af77a1,Other,FDA-2017-P-1461-0004,FDA-2017-P-1461,Response Letter from FDA CDER to Foley & Lardner LLP
0900006482af3dfb,Notice,FDA-2017-P-1461-0003,FDA-2017-P-1461,"Determination That CENESTIN (Estrogens, Conjugated Synthetic A)  Tablets, 0.3 Milligrams, 0.45 Milligrams, 0.625 Milligrams, 0.9 Milligrams, and 1.25 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
090000648185aeee,Other,FDA-2014-P-1302-0001,FDA-2014-P-1302,Citizen Petition from Duchesnay
090000648185af92,Other,FDA-2014-P-1302-0004,FDA-2014-P-1302,"Acknowledgement Letter from FDA/DDM to Duchesnay, FDA-2014-P-1302-0001"
09000064818877eb,Other,FDA-2014-P-1302-0005,FDA-2014-P-1302,Withdrawal Letter from Duchesnay
090000648185af8e,Supporting & Related Material,FDA-2014-P-1302-0003,FDA-2014-P-1302,"Attachment 2 Koren, et al., Sex Differences in the Pharmacokinetics and Bioequivalence of the Delayed-Release Combination of Doxylamine Succinate-Pyridoxine Hydrochloride Implications for Pharmacotherapy The Journal of Clinical Pharmacology in Pregnancy re Citizen Petition from Duchesnay, FDA-2014-P-1302-0001"
090000648185aeef,Supporting & Related Material,FDA-2014-P-1302-0002,FDA-2014-P-1302,"Attachment 1 re Citizen Petition from Duchesnay, FDA-2014-P-1302-0001"
090000648417de3b,Other,FDA-2019-P-5463-0001,FDA-2019-P-5463,"Citizen Petition from Sheppard, Mullin, Richter & Hampton LLP on behalf of Apicore Pharmaceutical Private, Ltd."
090000648417db52,Supporting & Related Material,FDA-2019-P-5463-0006,FDA-2019-P-5463,"Attachment 4 - Label Prescribing Information (RLD Cuprimine NDA) re Citizen Petition from Sheppard, Mullin, Richter & Hampton LLP on behalf of Apicore Pharmaceutical Private, Ltd."
090000648417db4f,Supporting & Related Material,FDA-2019-P-5463-0003,FDA-2019-P-5463,"Attachment 1 - Netter Clinical Pharmacokinetics (1987) re Citizen Petition from Sheppard, Mullin, Richter & Hampton LLP on behalf of Apicore Pharmaceutical Private, Ltd."
090000648417db50,Supporting & Related Material,FDA-2019-P-5463-0004,FDA-2019-P-5463,"Attachment 2 - Webb et al Ann Clin Biochem (1988) (1) re Citizen Petition from Sheppard, Mullin, Richter & Hampton LLP on behalf of Apicore Pharmaceutical Private, Ltd."
090000648417db51,Supporting & Related Material,FDA-2019-P-5463-0005,FDA-2019-P-5463,"Attachment 3 - Birker Journal American Chem Soc (1977) re Citizen Petition from Sheppard, Mullin, Richter & Hampton LLP on behalf of Apicore Pharmaceutical Private, Ltd."
090000648417db4b,Other,FDA-2019-P-5463-0002,FDA-2019-P-5463,"Acknowledgment Letter from FDA DMS to Sheppard, Mullin, Richter & Hampton LLP on behalf of Apicore Pharmaceutical Private, Ltd."
09000064841b150c,Other,FDA-2019-P-5463-0007,FDA-2019-P-5463,"Withdrawal from Sheppard, Mullin, Richter & Hampton LLP"
0900006484e0530a,Other,FDA-2021-P-1184-0002,FDA-2021-P-1184,Acknowledgment Letter from FDA DMS to Lachman Consultant Services Inc
0900006484e05d7c,Other,FDA-2021-P-1184-0001,FDA-2021-P-1184,Citizen Petition from Lachman Consultant Services Inc
0900006482fa58fc,Supporting & Related Material,FDA-2018-P-1014-0007,FDA-2018-P-1014,Exhibit E - Zhang_PLOS One_2014 re Citizen Petition from Haynes and Boone LLP
0900006482fa58f8,Supporting & Related Material,FDA-2018-P-1014-0003,FDA-2018-P-1014,Exhibit A - Mycophenolate Mofetil Oral Suspension Draft Guidance October 2017 re Citizen Petition from Haynes and Boone LLP
0900006482fa58f9,Supporting & Related Material,FDA-2018-P-1014-0004,FDA-2018-P-1014,Exhibit B - Cellcept PI re Citizen Petition from Haynes and Boone LLP
0900006482fa5940,Supporting & Related Material,FDA-2018-P-1014-0012,FDA-2018-P-1014,Exhibit J - ProAmatine Prescribing Information re Citizen Petition from Haynes and Boone LLP
0900006482fa58fe,Supporting & Related Material,FDA-2018-P-1014-0009,FDA-2018-P-1014,Exhibit G - Borrows_American Journal of Transplantation_2006 re Citizen Petition from Haynes and Boone LLP
0900006482fa58ff,Supporting & Related Material,FDA-2018-P-1014-0010,FDA-2018-P-1014,Exhibit H - Midodrine HCl Draft Guidance re Citizen Petition from Haynes and Boone LLP
0900006482fa5941,Supporting & Related Material,FDA-2018-P-1014-0013,FDA-2018-P-1014,Exhibit K - Temodar Prescribing Information re Citizen Petition from Haynes and Boone LLP
09000064835c6e89,Other,FDA-2018-P-1014-0014,FDA-2018-P-1014,"Petition Response Letter from FDA CDER to Haynes and Boone, LLP"
0900006482fa58fa,Supporting & Related Material,FDA-2018-P-1014-0005,FDA-2018-P-1014,Exhibit C - Partani_J Sep Sci_2015 re Citizen Petition from Haynes and Boone LLP
0900006482fa58fd,Supporting & Related Material,FDA-2018-P-1014-0008,FDA-2018-P-1014,Exhibit F - Levesque_CLINICAL PHARMACOLOGY THERAPEUTICS_2007 re Citizen Petition from Haynes and Boone LLP
0900006482fa58fb,Supporting & Related Material,FDA-2018-P-1014-0006,FDA-2018-P-1014,Exhibit D - Fujiyama_Drug Metabolism and Disposition_2010 re Citizen Petition from Haynes and Boone LLP
0900006482fa5900,Supporting & Related Material,FDA-2018-P-1014-0011,FDA-2018-P-1014,Exhibit I - Temozolomide Draft Guidance re Citizen Petition from Haynes and Boone LLP
0900006482fa53de,Other,FDA-2018-P-1014-0002,FDA-2018-P-1014,"Acknowledgment Letter from FDA DDM to Haynes and Boone, LLP"
0900006482fa53dc,Other,FDA-2018-P-1014-0001,FDA-2018-P-1014,Citizen Petition from Haynes and Boone LLP
09000064823ccd8a,Other,FDA-2015-P-4935-0006,FDA-2015-P-4935,Interim Response Letter from FDA CDER to AbbVie Inc
0900006481dbe473,Other,FDA-2015-P-4935-0001,FDA-2015-P-4935,Citizen Petition from AbbVie Inc.
0900006481dbe47b,Other,FDA-2015-P-4935-0002,FDA-2015-P-4935,Acknowledgement Letter from FDA DDM to AbbVie Inc
09000064821533bd,Other,FDA-2015-P-4935-0005,FDA-2015-P-4935,AbbVie Meeting Minutes
090000648247ef15,Other,FDA-2015-P-4935-0007,FDA-2015-P-4935,"Citizen Petition Denial Letter from FDA CDER to AbbVie, Inc."
090000648448bd08,Other,FDA-2019-P-4683-0007,FDA-2019-P-4683,Interim Response Letter from FDA CDER to Public Citizen
09000064848de0e2,Other,FDA-2019-P-4683-0008,FDA-2019-P-4683,Response Letter from FDA  to Public Citizen's Health Research Group
090000648405c4d0,Supporting & Related Material,FDA-2019-P-4683-0004,FDA-2019-P-4683,Reference 12 Prevention of Recurrent Preterm Delivery by 17 Alpha Hydroxyprogesterone Caproate re: Citizen Petition from Public Citizen
090000648405c460,Other,FDA-2019-P-4683-0001,FDA-2019-P-4683,Citizen Petition from Public Citizen
090000648405c4d1,Supporting & Related Material,FDA-2019-P-4683-0003,FDA-2019-P-4683,Reference 2 Progestin Therapy to prevent preterm birth: History and Effectiveness of current strategies and development of novel approaches re: Citizen Petition from Public Citizen
090000648405c719,Other,FDA-2019-P-4683-0002,FDA-2019-P-4683,Acknowledgment Letter from FDA DMS to Public Citizen
090000648450ec2f,Supporting & Related Material,FDA-2020-P-1312-0003,FDA-2020-P-1312,"Attachment A - Current Lonsurf Labeling -  RE: Citizen Petition from Foley & Lardner LLP on behalf of Taiho Oncology, Inc."
090000648450d7e8,Other,FDA-2020-P-1312-0002,FDA-2020-P-1312,"Acknowledgment Letter from FDA DMS to Foley & Lardner LLP on behalf of Taiho Oncology, Inc."
0900006484866c1e,Other,FDA-2020-P-1312-0005,FDA-2020-P-1312,Letter from CDER to Foley & Lardner LLP
090000648450cb13,Other,FDA-2020-P-1312-0001,FDA-2020-P-1312,"Citizen Petition from Foley & Lardner LLP on behalf of Taiho Oncology, Inc."
090000648447bd27,Other,FDA-2020-P-1239-0002,FDA-2020-P-1239,"Acknowledgment Letter from FDA DMS to Wiley Rein, LLP"
090000648447ed29,Other,FDA-2020-P-1239-0003,FDA-2020-P-1239,"Letter from Wiley Rein, LLP"
090000648460dd1b,Other,FDA-2020-P-1239-0005,FDA-2020-P-1239,Withdrawal from Wiley Rein LLP
090000648447bd26,Other,FDA-2020-P-1239-0001,FDA-2020-P-1239,"Petition for Stay of Action from Wiley Rein, LLP"
090000648449143f,Other,FDA-2020-P-1239-0004,FDA-2020-P-1239,Supplement from Wiley Rein LLP
09000064823e5a6f,Supporting & Related Material,FDA-2016-P-4233-0006,FDA-2016-P-4233,Attachments 4 - 2016 05 15 - KFSU00038 Nutrition and Mineral Analyses - Finished Product Q240-2 re Citizen Petition from KFSU Ltd
09000064823e5a69,Other,FDA-2016-P-4233-0002,FDA-2016-P-4233,Citizen Petition from KFSU Ltd
09000064823e5a6d,Supporting & Related Material,FDA-2016-P-4233-0005,FDA-2016-P-4233,Attachment 3 - 2015 12 15 - KFSU00036 Nutrition and Mineral Analyses-2 re Citizen Petition from KFSU Ltd
090000648275d092,Other,FDA-2016-P-4233-0008,FDA-2016-P-4233,CFSAN Interim Response Letter to KFSU Ltd Sugarcane Flour
09000064823e5a6b,Supporting & Related Material,FDA-2016-P-4233-0003,FDA-2016-P-4233,Attachment 1 KFSU Process Flowchart 2 (1) (002)-1 re Citizen Petition from KFSU Ltd
09000064823e5a6c,Supporting & Related Material,FDA-2016-P-4233-0004,FDA-2016-P-4233,Attachment 2 - An Analysis of the Lignocellulosic Diversity of Sugarcane-2 re Citizen Petition from KFSU Ltd
09000064823e7b86,Other,FDA-2016-P-4233-0001,FDA-2016-P-4233,Acknowledgment Letter from FDA DDM to KFSU Ltd
0900006483410f0e,Other,FDA-2016-P-4233-0009,FDA-2016-P-4233,FDA-2016-P-4233 - KFSU Granting Response Letter
09000064823e5a6e,Supporting & Related Material,FDA-2016-P-4233-0007,FDA-2016-P-4233,Attachment 5 - 2016 03 23 - KFSU00037 Nutrition Analyses Report-2 re Citizen Petition from KFSU Ltd
0900006484661843,Supporting & Related Material,FDA-2020-P-1416-0026,FDA-2020-P-1416,"TAB 14 re Citizen Petition from Sidley Austin, LLP. (on behalf of Cell2in, Inc.)"
0900006484661851,Supporting & Related Material,FDA-2020-P-1416-0020,FDA-2020-P-1416,"TAB 20 re Citizen Petition from Sidley Austin, LLP. (on behalf of Cell2in, Inc.)"
0900006484661857,Supporting & Related Material,FDA-2020-P-1416-0014,FDA-2020-P-1416,"TAB 26 re Citizen Petition from Sidley Austin, LLP. (on behalf of Cell2in, Inc.)"
090000648465f7fe,Other,FDA-2020-P-1416-0002,FDA-2020-P-1416,"Acknowledgment Letter from FDA DMS to Sidley Austin, LLP. on behalf of Cell2in, Inc."
0900006484661804,Supporting & Related Material,FDA-2020-P-1416-0033,FDA-2020-P-1416,"TAB 7 re Citizen Petition from Sidley Austin, LLP. (on behalf of Cell2in, Inc.)"
0900006484661862,Supporting & Related Material,FDA-2020-P-1416-0009,FDA-2020-P-1416,"TAB 31 re Citizen Petition from Sidley Austin, LLP. (on behalf of Cell2in, Inc.)"
0900006484661803,Supporting & Related Material,FDA-2020-P-1416-0034,FDA-2020-P-1416,"TAB 6 re Citizen Petition from Sidley Austin, LLP. (on behalf of Cell2in, Inc.)"
0900006484661805,Supporting & Related Material,FDA-2020-P-1416-0032,FDA-2020-P-1416,"TAB 8 re Citizen Petition from Sidley Austin, LLP. (on behalf of Cell2in, Inc.)"
090000648466183f,Supporting & Related Material,FDA-2020-P-1416-0030,FDA-2020-P-1416,"TAB 10 re Citizen Petition from Sidley Austin, LLP. (on behalf of Cell2in, Inc.)"
0900006484661861,Supporting & Related Material,FDA-2020-P-1416-0010,FDA-2020-P-1416,"TAB 30 re Citizen Petition from Sidley Austin, LLP. (on behalf of Cell2in, Inc.)"
0900006484661867,Supporting & Related Material,FDA-2020-P-1416-0004,FDA-2020-P-1416,"TAB 36 re Citizen Petition from Sidley Austin, LLP. (on behalf of Cell2in, Inc.)"
0900006484661855,Supporting & Related Material,FDA-2020-P-1416-0016,FDA-2020-P-1416,"TAB 24 re Citizen Petition from Sidley Austin, LLP. (on behalf of Cell2in, Inc.)"
090000648465f7fd,Other,FDA-2020-P-1416-0001,FDA-2020-P-1416,"Citizen Petition from Sidley Austin, LLP.  on behalf of Cell2in, Inc."
0900006484661864,Supporting & Related Material,FDA-2020-P-1416-0007,FDA-2020-P-1416,"TAB 33 re Citizen Petition from Sidley Austin, LLP. (on behalf of Cell2in, Inc.)"
0900006484661845,Supporting & Related Material,FDA-2020-P-1416-0024,FDA-2020-P-1416,"TAB 16 re Citizen Petition from Sidley Austin, LLP. (on behalf of Cell2in, Inc.)"
0900006484661840,Supporting & Related Material,FDA-2020-P-1416-0029,FDA-2020-P-1416,"TAB 11 re Citizen Petition from Sidley Austin, LLP. (on behalf of Cell2in, Inc.)"
0900006484661842,Supporting & Related Material,FDA-2020-P-1416-0027,FDA-2020-P-1416,"TAB 13 re Citizen Petition from Sidley Austin, LLP. (on behalf of Cell2in, Inc.)"
0900006484661868,Supporting & Related Material,FDA-2020-P-1416-0003,FDA-2020-P-1416,"TAB 37 re Citizen Petition from Sidley Austin, LLP. (on behalf of Cell2in, Inc.)"
090000648495a084,Other,FDA-2020-P-1416-0040,FDA-2020-P-1416,Interim Response from CBER to Peter Choi
0900006484661863,Supporting & Related Material,FDA-2020-P-1416-0008,FDA-2020-P-1416,"TAB 32 re Citizen Petition from Sidley Austin, LLP. (on behalf of Cell2in, Inc.)"
0900006484661847,Supporting & Related Material,FDA-2020-P-1416-0022,FDA-2020-P-1416,"TAB 18 re Citizen Petition from Sidley Austin, LLP. (on behalf of Cell2in, Inc.)"
0900006484661806,Supporting & Related Material,FDA-2020-P-1416-0031,FDA-2020-P-1416,"TAB 9 re Citizen Petition from Sidley Austin, LLP. (on behalf of Cell2in, Inc.)"
0900006484661846,Supporting & Related Material,FDA-2020-P-1416-0023,FDA-2020-P-1416,"TAB 17 re Citizen Petition from Sidley Austin, LLP. (on behalf of Cell2in, Inc.)"
0900006484661858,Supporting & Related Material,FDA-2020-P-1416-0013,FDA-2020-P-1416,"TAB 27 re Citizen Petition from Sidley Austin, LLP. (on behalf of Cell2in, Inc.)"
0900006484661859,Supporting & Related Material,FDA-2020-P-1416-0012,FDA-2020-P-1416,"TAB 28  re Citizen Petition from Sidley Austin, LLP. (on behalf of Cell2in, Inc.)"
0900006484ca1d32,Other,FDA-2021-P-0938-0002,FDA-2021-P-0938,Acknowledgment Letter from FDA DMS to Daniel Fabricant
0900006484ca210b,Other,FDA-2021-P-0938-0001,FDA-2021-P-0938,Citizen Petition from Daniel Fabricant
0900006484ca1d35,Supporting & Related Material,FDA-2021-P-0938-0003,FDA-2021-P-0938,Envelope RE Citizen Petition from Daniel Fabricant
090000648362dbab,Other,FDA-2017-P-5947-0005,FDA-2017-P-5947,Request to Withdraw CP
0900006482b81fea,Supporting & Related Material,FDA-2017-P-5947-0003,FDA-2017-P-5947,Attachment A Orange Book Approved Drug Products re Citizen Petition from Teligent Pharma Inc
09000064830409ac,Other,FDA-2017-P-5947-0004,FDA-2017-P-5947,Interim Response Letter from FDA CDER to Teligent Pharma Inc
0900006482b81fd8,Other,FDA-2017-P-5947-0001,FDA-2017-P-5947,Citizen Petition from Teligent Pharma Inc
0900006482b81fe8,Other,FDA-2017-P-5947-0002,FDA-2017-P-5947,Acknowledgement Letter from FDA DDM to Teligent Pharma Inc
090000648174307e,Supporting & Related Material,FDA-2014-P-0794-0003,FDA-2014-P-0794,Reference 1 Label Information Felimazole Citizen Petition From e5 Pharma LLC
090000648180436e,Other,FDA-2014-P-0794-0004,FDA-2014-P-0794,"Amendment from e5 Pharma, LLC"
0900006481741daa,Other,FDA-2014-P-0794-0001,FDA-2014-P-0794,Citizen Petition From E5 Pharma LLC
0900006481858d9b,Other,FDA-2014-P-0794-0005,FDA-2014-P-0794,"Citizen Petition Approval Letter from FDA/CVM to e5 Pharma, LLC"
0900006481742931,Other,FDA-2014-P-0794-0002,FDA-2014-P-0794,Acknowledgement Letter From FDA DDM to E5 Pharma LLC
0900006483a88092,Other,FDA-2018-P-3597-0005,FDA-2018-P-3597,Letter from FDA CDER to ARENT FOX LLP
09000064837590db,Supporting & Related Material,FDA-2018-P-3597-0003,FDA-2018-P-3597,Attachment 1- Growth Dynamics Audit from June 2014 to June 2018. RE: Citizen Petition from Arent Fox
0900006483758ed8,Other,FDA-2018-P-3597-0001,FDA-2018-P-3597,Citizen Petition from Arent Fox LLP
0900006483a6c9f4,Notice,FDA-2018-P-3597-0004,FDA-2018-P-3597,"Determination That LOTRIMIN (Clotrimazole) Topical Solution, 1%, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
09000064837590d9,Other,FDA-2018-P-3597-0002,FDA-2018-P-3597,Acknowledgment Letter from FDA DDM to Arent Fox LLP
0900006484328604,Other,FDA-2020-P-0599-0002,FDA-2020-P-0599,"Acknowledgment Letter from FDA DMS to Foley & Lardner, LLP  on behalf of Romark Laboratories, L.C."
0900006484328603,Other,FDA-2020-P-0599-0001,FDA-2020-P-0599,"Citizen Petition from Foley & Lardner, LLP. on behalf of Romark Laboratories, L.C."
0900006484979ca6,Other,FDA-2020-P-0599-0004,FDA-2020-P-0599,"Response letter from FDA CDER to Romark Laboratories, L.C."
09000064847b02ed,Other,FDA-2020-P-0599-0003,FDA-2020-P-0599,"Interim Response letter from FDA CDER to Romark Laboratories, L.C."
0900006483bc55a6,Supporting & Related Material,FDA-2019-P-1893-0004,FDA-2019-P-1893,Tab 2 Feng et al (2012) LCZ696: a dual-acting sodium supramolecular complex re Citizen Petition from Novartis Pharmaceuticals Corporation
090000648408ed91,Other,FDA-2019-P-1893-0008,FDA-2019-P-1893,Interim Response Letter from FDA CDER to Novartis Pharmaceuticals Corporation
0900006483bc55a7,Supporting & Related Material,FDA-2019-P-1893-0005,FDA-2019-P-1893,"Tab 3 Gu et al (2010) Pharmacokinetics and Pharmacodynamics of LCZ696, a Novel Dual-Acting Angiotensin Receptor-Neprilysin Inhibitor (ARNi) re Citizen Petition from Novartis Pharmaceuticals Corporation"
0900006483bc55a8,Supporting & Related Material,FDA-2019-P-1893-0006,FDA-2019-P-1893,Tab 4 Kobalava et al (2016) Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/Valsartan (LCZ696) in Patients with Heart Failure and Reduced Ejection Fraction re Citizen Petition from Novartis Pharmaceuticals Corporation
0900006483bc55aa,Other,FDA-2019-P-1893-0002,FDA-2019-P-1893,Acknowledgment Letter from FDA DDM to Novartis Pharmaceuticals Corporation
0900006483bc55a1,Other,FDA-2019-P-1893-0001,FDA-2019-P-1893,Citizen Petition from Novartis Pharmaceuticals Corporation
0900006483bc55a9,Supporting & Related Material,FDA-2019-P-1893-0007,FDA-2019-P-1893,"Tab 5 Ayalasomayajula et al (2015) Assessment of Drug Interaction Potential between LCZ696, an Angiotensin Receptor Neprilysin Inhibitor, and Digoxin or Warfarin re Citizen Petition from Novartis Pharmaceuticals Corporation"
0900006483bc55a5,Supporting & Related Material,FDA-2019-P-1893-0003,FDA-2019-P-1893,Tab 1 McMurray et al (2014) Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure re: Citizen Petition from Novartis Pharmaceuticals Corporation
0900006481a39c2c,Supporting & Related Material,FDA-2014-P-1065-0009,FDA-2014-P-1065,Letter from FDA CDER to Zydus Pharmaceuticals
0900006481a39e02,Other,FDA-2014-P-1065-0008,FDA-2014-P-1065,Letter from Zydus Pharmaceuticals to FDA
0900006481869b16,Supporting & Related Material,FDA-2014-P-1065-0006,FDA-2014-P-1065,Shipping Label re Citizen Petition from Zydus Pharmaceuticals Inc FDA-2014-P-1065-0001
09000064817ee192,Supporting & Related Material,FDA-2014-P-1065-0002,FDA-2014-P-1065,Attachment 2 Orange Book re Citizen Petition From Zydus Pharmaceuticals Inc FDA-2014-P-1065-0001
09000064817ee193,Supporting & Related Material,FDA-2014-P-1065-0003,FDA-2014-P-1065,Attachment 3 Another Response re Citizen Petition From Zydus Pharmaceuticals Inc FDA-2014-P-1065-0001
0900006481999f0d,Other,FDA-2014-P-1065-0007,FDA-2014-P-1065,Citizen Petition Approval Response Letter from FDA CDER to Zydus Pharmaceuticals Inc
09000064817ed366,Other,FDA-2014-P-1065-0001,FDA-2014-P-1065,Citizen Petition from Zydus Pharmaceuticals Inc
09000064817ed47d,Other,FDA-2014-P-1065-0004,FDA-2014-P-1065,Acknowledgement Letter From FDA DDM to Zydus Oharmaceuticals
09000064817ee18f,Supporting & Related Material,FDA-2014-P-1065-0005,FDA-2014-P-1065,Attachment 1 Prescribing Information Prasco Label re Citizen Petition From Zydus Pharmaceuticals Inc FDA-2014-P-1065-0001
09000064825303d7,Other,FDA-2015-P-1977-0243,FDA-2015-P-1977,Supplement from Gerald Steel
0900006482974124,Other,FDA-2015-P-1977-0244,FDA-2015-P-1977,Testimony from Julie Simms (Gerald Steel)
0900006481b15811,Other,FDA-2015-P-1977-0001,FDA-2015-P-1977,Citizen Petition from Gerald Steel
0900006481b1617a,Supporting & Related Material,FDA-2015-P-1977-0009,FDA-2015-P-1977,Attachment 7 NSF Fact Sheet re Citizen Petition from Gerald Steel
0900006481b1617d,Supporting & Related Material,FDA-2015-P-1977-0012,FDA-2015-P-1977,Attachment 10 Letter from EPA to Gerald Steel re Citizen Petition from Gerald Steel
0900006481b1617c,Supporting & Related Material,FDA-2015-P-1977-0011,FDA-2015-P-1977,Attachment 9 Sodium Flouride Analysis re Citizen Petition from Gerald Steel
090000648395ab47,Other,FDA-2015-P-1977-0249,FDA-2015-P-1977,Acknowledgment Letter from FDA DDM to Gerald Steel
0900006481b16179,Supporting & Related Material,FDA-2015-P-1977-0008,FDA-2015-P-1977,Attachment 6 Letter from Gerald Steel to FDA Product Jurisdiction Officer re Citizen Petition from Gerald Steel
0900006481b161ad,Supporting & Related Material,FDA-2015-P-1977-0014,FDA-2015-P-1977,Attachment 12 Letter from Gerald Steel to FDA Office of Combination Products re Citizen Petition from Gerald Steel
0900006481b16177,Supporting & Related Material,FDA-2015-P-1977-0006,FDA-2015-P-1977,Attachment 4 Letter from FDA CDER to Gerald Steeel re Citizen Petition from Gerald Steel
0900006481b161b0,Supporting & Related Material,FDA-2015-P-1977-0017,FDA-2015-P-1977,Attachment 15 Flouride and ADHD re Citizen Petition from Gerald Steel
09000064842f5b78,Other,FDA-2015-P-1977-0254,FDA-2015-P-1977,Response Letter from FDA CDER to Gerald Steel
09000064838cfd42,Other,FDA-2015-P-1977-0247,FDA-2015-P-1977,Letter from FDA CDRH to Gerald Steel re Citizen Petition
0900006481d6db9e,Other,FDA-2015-P-1977-0235,FDA-2015-P-1977,Interim Response Letter from FDA CDER to Gerald Steel
0900006481b16178,Supporting & Related Material,FDA-2015-P-1977-0007,FDA-2015-P-1977,Attachment 5 Letter from FDA CDER to Ms. McElheney re Citizen Petition from Gerald Steel
0900006481b161ac,Supporting & Related Material,FDA-2015-P-1977-0013,FDA-2015-P-1977,Attachment 11 Letter from Gerald Steel to FDA Product Jurisdiction Officer re Citizen Petition From Gerald Steel
0900006481b16174,Supporting & Related Material,FDA-2015-P-1977-0003,FDA-2015-P-1977,Attachment 1 NSF Fact Sheet re Citizen Petition From Gerald Steel
0900006481b15f03,Other,FDA-2015-P-1977-0002,FDA-2015-P-1977,Acknowledgement Letter from FDA DDM to Gerald Steel
09000064839eacd1,Other,FDA-2015-P-1977-0253,FDA-2015-P-1977,Supplement from Gerald Steel
0900006481b161ae,Supporting & Related Material,FDA-2015-P-1977-0015,FDA-2015-P-1977,Attachment 13 FDA Email Correspondence re Citizen Petition from Gerald Steel
0900006481b16175,Supporting & Related Material,FDA-2015-P-1977-0004,FDA-2015-P-1977,Attachment 2 Letter from Gerald Steel to FDA re Citizen Petition from Gerald Steel
0900006481b16176,Supporting & Related Material,FDA-2015-P-1977-0005,FDA-2015-P-1977,Attachment 3 Letter from FDA CDER to Dr. Kailin and Gerald Steel re Citizen Petition From Gerald Steel
0900006481b161af,Supporting & Related Material,FDA-2015-P-1977-0016,FDA-2015-P-1977,Attachment 14 Letter from Office of Combination Products to Gerald Steel re Citizen Petition from Gerald Steel
0900006481b1617b,Supporting & Related Material,FDA-2015-P-1977-0010,FDA-2015-P-1977,Attachment 8 Federal Register Notice 44 FR 42775 re Citizen Petition from Gerald Steel
0900006483946e31,Other,FDA-2015-P-1977-0248,FDA-2015-P-1977,Citizen Petition for Reconsideration from Gerald Steel
090000648487976e,Other,FDA-2020-P-1251-0003,FDA-2020-P-1251,Interim Response Letter from FDA CFSAN to Varun Varada
090000648448ac4e,Other,FDA-2020-P-1251-0002,FDA-2020-P-1251,Acknowledgment Letter from FDA DMS to Varun Verada
090000648448ac11,Other,FDA-2020-P-1251-0001,FDA-2020-P-1251,Citizen Petition from Varun Verada
09000064818cdb48,Other,FDA-2014-P-1570-0002,FDA-2014-P-1570,Acknowlegement Letter from DDM to Natural Solutions Foundation
09000064818ba6d8,Other,FDA-2014-P-1570-0001,FDA-2014-P-1570,Citizen Petition From the Natural Solutions Foundation
09000064806b1ca2,Other,FDA-2008-P-0441-0001,FDA-2008-P-0441,Warner Chilcott - Citizen Petiton
09000064806b1cf6,Other,FDA-2008-P-0441-0002,FDA-2008-P-0441,Acknowledgement Letter to Warner Chilcott
09000064807b6d08,Other,FDA-2008-P-0441-0003,FDA-2008-P-0441,Warner Chilcott - Withdrawal of Citizen Petition
0900006484ace3fa,Other,FDA-2021-P-0434-0002,FDA-2021-P-0434,Acknowledgment Letter from FDA DMS to Braintree
0900006484dfd494,Other,FDA-2021-P-0434-0003,FDA-2021-P-0434,Interim Response from FDA CDER to Braintree
0900006484ace3f8,Other,FDA-2021-P-0434-0001,FDA-2021-P-0434,Citizen Petition from Braintree
0900006484d4356f,Other,FDA-2021-P-0967-0002,FDA-2021-P-0967,Acknowledgment Letter from FDA DMS to Labaton Sucharow
0900006484d4356d,Other,FDA-2021-P-0967-0001,FDA-2021-P-0967,Citizen Petition from Labaton Sucharow
0900006484d6783c,Other,FDA-2021-P-0967-0005,FDA-2021-P-0967,Supplement from Labaton Sucharow
0900006484d4250d,Supporting & Related Material,FDA-2021-P-0967-0004,FDA-2021-P-0967,Attachment 2 re Citizen Petition from Labaton Sucharow
0900006484d4250c,Supporting & Related Material,FDA-2021-P-0967-0003,FDA-2021-P-0967,Attachment 1 re Citizen Petition from Labaton Sucharow
09000064839b9484,Other,FDA-2018-P-4812-0002,FDA-2018-P-4812,Acknowledgment Letter from FDA DDM to Arent Fox LLP
0900006483d04c4e,Other,FDA-2018-P-4812-0004,FDA-2018-P-4812,Letter from FDA CDER to Arent Fox LLP
09000064839b8ccc,Other,FDA-2018-P-4812-0001,FDA-2018-P-4812,Citizen Petition from Arent Fox LLP
0900006483d012e6,Notice,FDA-2018-P-4812-0003,FDA-2018-P-4812,"Determination That NIZORAL (Ketoconazole) Topical Cream, 2%, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
0900006483a17398,Supporting & Related Material,FDA-2019-P-0417-0004,FDA-2019-P-0417,Attachment 2 re Citizen Petition from Scilex Pharmaceuticals Inc
0900006483a185a6,Supporting & Related Material,FDA-2019-P-0417-0008,FDA-2019-P-0417,Attachment 6 re Citizen Petition from Scilex Pharmaceuticals Inc
0900006483a17395,Other,FDA-2019-P-0417-0002,FDA-2019-P-0417,"Acknowledgment Letter from FDA DDM to Scilex Pharmaceuticals, Inc"
0900006483a17397,Supporting & Related Material,FDA-2019-P-0417-0003,FDA-2019-P-0417,Attachment 1 re Citizen Petition from Scilex Pharmaceuticals Inc
0900006483a28073,Supporting & Related Material,FDA-2019-P-0417-0009,FDA-2019-P-0417,Attachment 7 re Citizen Petition from Scilex Pharmaceuticals Inc
0900006483a17393,Other,FDA-2019-P-0417-0001,FDA-2019-P-0417,Citizen Petition from Scilex Pharmaceuticals Inc
0900006483d5391a,Other,FDA-2019-P-0417-0010,FDA-2019-P-0417,"Letter from FDA CDER to Scilex Pharmaceuticals, Inc."
0900006483a1739b,Supporting & Related Material,FDA-2019-P-0417-0007,FDA-2019-P-0417,Attachment 5 re Citizen Petition from Scilex Pharmaceuticals Inc
0900006483a17399,Supporting & Related Material,FDA-2019-P-0417-0005,FDA-2019-P-0417,Attachment 3 re Citizen Petition from Scilex Pharmaceuticals Inc
0900006483a1739a,Supporting & Related Material,FDA-2019-P-0417-0006,FDA-2019-P-0417,Attachment 4 re Citizen Petition from Scilex Pharmaceuticals Inc
0900006483e7a714,Other,FDA-2019-P-3934-0002,FDA-2019-P-3934,Acknowledgment Letter from FDA DMS to AuroMedics Pharma LLC on behalf of Aurobindo Pharma Ltd
0900006483e7a713,Other,FDA-2019-P-3934-0001,FDA-2019-P-3934,Suitability Petition from AuroMedics Pharma LLC on behalf of Aurobindo Pharma Ltd
0900006483adcb4e,Other,FDA-2018-P-0664-0004,FDA-2018-P-0664,Withdrawal from Prinston Pharmaceutical Inc.
09000064835e8504,Other,FDA-2018-P-0664-0003,FDA-2018-P-0664,Interim response from FDA CDER to Prinston Pharmaceutical Inc.
0900006482f176e9,Other,FDA-2018-P-0664-0002,FDA-2018-P-0664,Acknowledgment Letter from FDA DDM to  Prinston Pharmaceutical Inc.
0900006482f17096,Other,FDA-2018-P-0664-0001,FDA-2018-P-0664,Citizen Petition from Prinston Pharmaceutical Inc.
0900006483cd12a3,Supporting & Related Material,FDA-2019-P-2582-0002,FDA-2019-P-2582,"Attachment 1- Orange Book: Approved Drug Products with Therapeutic Equivalance Evaluations re: Suitability Petition from PharmaCore Biotech Co., Ltd."
0900006483cd108f,Other,FDA-2019-P-2582-0001,FDA-2019-P-2582,"Suitability Petition from PharmaCore Biotech Co., Ltd."
0900006483cd12fd,Supporting & Related Material,FDA-2019-P-2582-0003,FDA-2019-P-2582,"Attachment 2- Approved Package Insert for ALIMTA re:Suitability Petition from PharmaCore Biotech Co., Ltd."
0900006483cd12fe,Supporting & Related Material,FDA-2019-P-2582-0004,FDA-2019-P-2582,"Attachment 3- DRAFT Package Insert for Proposed Drug Product re: Suitability Petition from PharmaCore Biotech Co., Ltd."
0900006483cd13bf,Other,FDA-2019-P-2582-0005,FDA-2019-P-2582,"Acknowledgment Letter from FDA DDM to PharmaCore Biotech Co., Ltd."
09000064841cb14a,Other,FDA-2019-P-2687-0003,FDA-2019-P-2687,Letter from FDA/CDER to AuroMedics Pharma LLC
0900006483ce6cc8,Other,FDA-2019-P-2687-0002,FDA-2019-P-2687,Acknowledgment Letter from FDA DDM to AuroMedics Pharma LLC
0900006483ce6290,Other,FDA-2019-P-2687-0001,FDA-2019-P-2687,Citizen Petition from AuroMedics Pharma LLC
090000648353bd99,Supporting & Related Material,FDA-2018-P-2838-0004,FDA-2018-P-2838,"Attachment 2  Trends in Alternative Medicine Use in the United State, 1990-1997 re: Citizen Petition from Public Citizen’s Health Research Group"
090000648353bd9c,Supporting & Related Material,FDA-2018-P-2838-0007,FDA-2018-P-2838,Attachment 5 Electrophysiological Effects of Cesium and  Tetraethylammonium in Canine Cardiac Purkinje Fibers1 ANNE re: Citizen Petition from Public Citizen’s Health Research Group
090000648353dbbd,Supporting & Related Material,FDA-2018-P-2838-0008,FDA-2018-P-2838,Attachment 6 Case Reports of Adverse Events Linked to Cesium Use re: Citizen Petition from Public Citizen’s Health Research Group
090000648353b410,Other,FDA-2018-P-2838-0002,FDA-2018-P-2838,Acknowledgment Letter from FDA DDM to Public Citizen’s Health Research Group
090000648353b40c,Other,FDA-2018-P-2838-0001,FDA-2018-P-2838,Citizen Petition from Public Citizen's Health Research Group
0900006483a441be,Other,FDA-2018-P-2838-0010,FDA-2018-P-2838,Letter from FDA CFSAN to Public Citizen's Health Research Group
090000648432e340,Other,FDA-2018-P-2838-0011,FDA-2018-P-2838,Final Response Letter from FDA CFSAN to Public Citizen's Health Research Group
090000648353bd9a,Supporting & Related Material,FDA-2018-P-2838-0005,FDA-2018-P-2838,"Attachment 3 Blood and Tissue Concentration of Cesium after Exposure
to Cesium Chloride re: Citizen Petition from Public Citizen’s Health Research Group"
090000648353bd98,Supporting & Related Material,FDA-2018-P-2838-0003,FDA-2018-P-2838,Attachment 1  The  High pH Therapy for Cancer Tests on Mice and Humans re: Citizen Petition from Public Citizen’s Health Research Group
090000648353bd9b,Supporting & Related Material,FDA-2018-P-2838-0006,FDA-2018-P-2838,Attachment 4 Central depressant action of cesium in mice re: Citizen Petition from Public Citizen’s Health Research Group
09000064834cba49,Supporting & Related Material,FDA-2018-P-2659-0012,FDA-2018-P-2659,"Tab 10 - Lawrence X Yu, Quality by Design for Orally Inhaled Drug Products, re Citizen Petiton from Hyman, Phelps & McNamara, PC on behalf of United Therapeutics Corporation"
09000064834cbdec,Supporting & Related Material,FDA-2018-P-2659-0004,FDA-2018-P-2659,"Tab 2 - Food and Drug Administration Respiratory Drug Delivery Devices A CDRH Perspective (Nov_ 2 2010) re Citizen Petiton from Hyman, Phelps & McNamara, PC on behalf of United Therapeutics Corporation"
09000064834cb9c5,Other,FDA-2018-P-2659-0001,FDA-2018-P-2659,"Citizen Petiton from Hyman, Phelps & McNamara, PC on behalf of United Therapeutics Corporation"
09000064834cbdf3,Supporting & Related Material,FDA-2018-P-2659-0011,FDA-2018-P-2659,"Tab 9 - T_ Gessler et al Ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension, re Citizen Petiton from Hyman, Phelps & McNamara, PC on behalf of United Therapeutics Corporation"
09000064834cbded,Supporting & Related Material,FDA-2018-P-2659-0005,FDA-2018-P-2659,"Tab 3 - Andrew M_ Wilson et al Importance of drug-device interaction in determining systemic re Citizen Petiton from Hyman, Phelps & McNamara, PC on behalf of United Therapeutics Corporation"
09000064834cbdee,Supporting & Related Material,FDA-2018-P-2659-0006,FDA-2018-P-2659,"Tab 4 - AH Kendrick et al_, Selecting and using nebulizer equipment re Citizen Petiton from Hyman, Phelps & McNamara, PC on behalf of United Therapeutics Corporation"
09000064834cba4a,Supporting & Related Material,FDA-2018-P-2659-0013,FDA-2018-P-2659,"Tab 11 - Wallace P_ Adams et al Demonstrating Bioequivalence of Locally Acting Orally Inhaled Drug Products re Citizen Petiton from Hyman, Phelps & McNamara, PC on behalf of United Therapeutics Corporation"
09000064834cbdef,Supporting & Related Material,FDA-2018-P-2659-0007,FDA-2018-P-2659,"Tab 5 - Dean Hess et al Medication nebulizer performance effects of diluent volume, re Citizen Petiton from Hyman, Phelps & McNamara, PC on behalf of United Therapeutics Corporation"
09000064834cbdf1,Supporting & Related Material,FDA-2018-P-2659-0009,FDA-2018-P-2659,"Tab 7 - JG Hardy et al_, Lung deposition from four nebulizers, 87 RESPIR MED 461 (1993) re Citizen Petiton from Hyman, Phelps & McNamara, PC on behalf of United Therapeutics Corporation"
09000064834cbdf2,Supporting & Related Material,FDA-2018-P-2659-0010,FDA-2018-P-2659,"Tab 8 - Christopher OCallaghan Peter W_ Barry The science of nebulised drug delivery 52 Suppl 2 THORAX S31 S36 (1997) re Citizen Petiton from Hyman, Phelps & McNamara, PC on behalf of United Therapeutics Corporation"
090000648362bf8d,Other,FDA-2018-P-2659-0014,FDA-2018-P-2659,"Withdrawal from Hyman, Phelps & McNamara, P.C."
09000064834cbdf0,Supporting & Related Material,FDA-2018-P-2659-0008,FDA-2018-P-2659,"Tab 6 - D_ Todd Loffert et al_, A comparison of commercial jet nebulizers, 106 CHEST 1788 (1994) re Citizen Petiton from Hyman, Phelps & McNamara, PC on behalf of United Therapeutics Corporation"
09000064834cb9c7,Other,FDA-2018-P-2659-0002,FDA-2018-P-2659,"Acknowledgment Letter from FDA DDM to Hyman, Phelps & McNamara on behalf of United Therapeutics Corporation"
09000064834cbdeb,Supporting & Related Material,FDA-2018-P-2659-0003,FDA-2018-P-2659,"Tab 1 - ISO 27427, Anaesthetic and respiratory equipment _ Nebulizing systems and components (2010) re Citizen Petiton from Hyman, Phelps & McNamara, PC on behalf of United Therapeutics Corporation"
090000648209e86b,Supporting & Related Material,FDA-2016-P-1991-0003,FDA-2016-P-1991,"Attachment - 1 - Rimadyl re Citizen Petition from Douglass Oeller Consulting, Inc. (Felix Pharmaceuticals Pvt. Ltd)"
090000648209e86c,Other,FDA-2016-P-1991-0002,FDA-2016-P-1991,"Acknowledgement Letter from FDA DDM to Douglass Oeller Consulting, Inc."
0900006482267607,Other,FDA-2016-P-1991-0004,FDA-2016-P-1991,"Suitability Petition Approval Letter from FDA CVM to Douglass Oeller Consulting, Inc."
090000648209e639,Other,FDA-2016-P-1991-0001,FDA-2016-P-1991,"Citizen Petition from Douglass Oeller Consulting, Inc. (Felix Pharmaceuticals Pvt. Ltd)"
0900006484481f91,Other,FDA-2020-P-1243-0002,FDA-2020-P-1243,Acknowledgment Letter from FDA DMS to Varun Varada
0900006484481f06,Other,FDA-2020-P-1243-0001,FDA-2020-P-1243,Citizen Petition from Varun Varada
090000648487976a,Other,FDA-2020-P-1243-0003,FDA-2020-P-1243,Interim Response Letter from FDA CFSAN to Varun Varada
090000648447b77b,Other,FDA-2020-P-1237-0001,FDA-2020-P-1237,"Citizen Petition from Wiley Rein, LLP"
090000648460dd06,Other,FDA-2020-P-1237-0006,FDA-2020-P-1237,Withdrawal from Wiley Rein LLP
090000648447b840,Supporting & Related Material,FDA-2020-P-1237-0003,FDA-2020-P-1237,"Exhibit A - VoltarenRx Labeling re Citizen Petition from Wiley Rein, LLP."
090000648447b842,Supporting & Related Material,FDA-2020-P-1237-0005,FDA-2020-P-1237,"Exhibit B - OTC Label - 2 of 2 re Citizen Petition from Wiley Rein, LLP."
090000648447b841,Supporting & Related Material,FDA-2020-P-1237-0004,FDA-2020-P-1237,"Exhibit B - OTC Label - 1 of 2 re Citizen Petition from Wiley Rein, LLP."
090000648447b77d,Other,FDA-2020-P-1237-0002,FDA-2020-P-1237,"Acknowledgment Letter from FDA DMS to Wiley Rein, LLP"
09000064847281dd,Supporting & Related Material,FDA-2020-P-1633-0003,FDA-2020-P-1633,"Exhibit A - Clinical trials for treatment and prevention of C_ difficile disease re Citizen Petition from Foley Hoag, LLP (on behalf of the Microbiome Therapeutics Innovation Group)"
09000064849d0105,Other,FDA-2020-P-1633-0005,FDA-2020-P-1633,"Interim Response Letter from FDA CBER to Foley Hoag, LLP (on behalf of the Microbiome Therapeutics Innovation Group)"
09000064847281d9,Other,FDA-2020-P-1633-0001,FDA-2020-P-1633,"Citizen Petition from Foley Hoag, LLP (on behalf of the Microbiome Therapeutics Innovation Group)"
09000064847281da,Other,FDA-2020-P-1633-0002,FDA-2020-P-1633,"Acknowledgment Letter from FDA DMS to Foley Hoag, LLP (on behalf of the Microbiome Therapeutics Innovation Group)"
0900006483ec02a1,Supporting & Related Material,FDA-2019-P-4006-0003,FDA-2019-P-4006,Attachment A Scientific Evidence Review re Citizen Petition from Tate & Lyle Ingredients Americas LLC
0900006483ec02a3,Supporting & Related Material,FDA-2019-P-4006-0005,FDA-2019-P-4006,Attachment C Human studies that evaluated energy value re Citizen Petition from Tate & Lyle Ingredients Americas LLC
09000064847e355e,Other,FDA-2019-P-4006-0008,FDA-2019-P-4006,Addendum from Tate & Lyle Ingredients Americas LLC
09000064843f2046,Other,FDA-2019-P-4006-0007,FDA-2019-P-4006,Interim Response Letter from FDA CFSAN to Tate & Lyle Ingredients Americas LLC
0900006483ec029c,Other,FDA-2019-P-4006-0002,FDA-2019-P-4006,Acknowledgment Letter from FDA DMS to Tate & Lyle Ingredients Americas LLC
0900006483ec029b,Other,FDA-2019-P-4006-0001,FDA-2019-P-4006,Citizen Petition from Tate & Lyle Ingredients Americas LLC
0900006483ec02a2,Supporting & Related Material,FDA-2019-P-4006-0004,FDA-2019-P-4006,Attachment B_ RESTRICTED Summary of Breath Hydrogen Study re Citizen Petition from Tate & Lyle Ingredients Americas LLC
090000648448c514,Supporting & Related Material,FDA-2020-P-1252-0003,FDA-2020-P-1252,"Attachment 1 re Suitability Petition from Foley & Lardner, LLP"
090000648448c507,Other,FDA-2020-P-1252-0001,FDA-2020-P-1252,"Suitability Petition from Foley & Lardner, LLP"
090000648448c517,Supporting & Related Material,FDA-2020-P-1252-0006,FDA-2020-P-1252,"Attachment 4 re Suitability Petition from Foley & Lardner, LLP"
090000648448c508,Other,FDA-2020-P-1252-0002,FDA-2020-P-1252,"Acknowledgment Letter from FDA DMS to Foley & Lardner, LLP"
090000648448c516,Supporting & Related Material,FDA-2020-P-1252-0005,FDA-2020-P-1252,"Attachment 3 re Suitability Petition from Foley & Lardner, LLP"
090000648448c515,Supporting & Related Material,FDA-2020-P-1252-0004,FDA-2020-P-1252,"Attachment 2 re Suitability Petition from Foley & Lardner, LLP"
0900006484d46020,Other,FDA-2020-P-1252-0007,FDA-2020-P-1252,Withdrawal from Foley & Lardner LLP
0900006482cc4e17,Other,FDA-2017-P-6689-0002,FDA-2017-P-6689,Acknowledgement Letter from FDA DDM to Novitium Pharma LLC
09000064832cd162,Other,FDA-2017-P-6689-0004,FDA-2017-P-6689,Interim response from FDA CDER to Muthusamy Shanmugam
0900006483d0545f,Other,FDA-2017-P-6689-0007,FDA-2017-P-6689,Petition for Reconsideration and Stay from Arnall Golden Gregory LLP
09000064846afe42,Other,FDA-2017-P-6689-0015,FDA-2017-P-6689,"Petition Response Letter from FDA CDER to Arnall Golden Gregory, LLC"
0900006483da6d32,Other,FDA-2017-P-6689-0011,FDA-2017-P-6689,Acknowledgment Letter from FDA DDM to Arnall Golden Gregory LLP_signed_revised
0900006483d85cd8,Other,FDA-2017-P-6689-0010,FDA-2017-P-6689,"Letter from FDA CDER to Arnall Golden Gregory, LLP"
0900006483d054af,Supporting & Related Material,FDA-2017-P-6689-0008,FDA-2017-P-6689,Attachment to Petition for Reconsideration and Stay from Arnall Golden Gregory LLP
0900006483d0f6e8,Other,FDA-2017-P-6689-0009,FDA-2017-P-6689,Acknowledgment Letter from FDA DDM to Arnall Golden Gregory LLP
0900006482cc4cf4,Other,FDA-2017-P-6689-0001,FDA-2017-P-6689,Citizen Petition from Novitium Pharma LLC
0900006483c47d35,Other,FDA-2017-P-6689-0006,FDA-2017-P-6689,"Letter from FDA CDER to Novitium Pharma, LLC"
09000064846afe3c,Other,FDA-2017-P-6689-0013,FDA-2017-P-6689,"Petition Response Letter from FDA CDER to Arnall Golden Gregory, LLC"
0900006482cc4e19,Supporting & Related Material,FDA-2017-P-6689-0003,FDA-2017-P-6689,Exhibit 1 Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations re Citizen Petition from Novitium Pharma LLC
0900006483da8b88,Other,FDA-2017-P-6689-0012,FDA-2017-P-6689,Acknowledgment Letter from FDA DDM to Arnall Golden Gregory LLP
09000064846afe40,Other,FDA-2017-P-6689-0014,FDA-2017-P-6689,"Petition Response Letter from FDA CDER to Arnall Golden Gregory, LLC"
0900006480c08d6e,Notice,FDA-2011-N-0109-0001,FDA-2011-N-0109,"Certification Requirements for Caseins, Caseinates, and Mixtures Thereof Exported from Ireland to the U.S."
09000064813c6749,Other,FDA-2013-P-0247-0004,FDA-2013-P-0247,"Novartis Pharmaceuticals Corporation (Kleinfeld, Kaplan and Becker, LLP) - Petition for Reconsideration"
09000064813c5898,Other,FDA-2013-P-0247-0005,FDA-2013-P-0247,"Acknowledgement Letter to Novartis Pharmaceuticals Corporation (Kleinfeld, Kaplan and Becker, LLP)"
0900006481213d56,Other,FDA-2013-P-0247-0002,FDA-2013-P-0247,Acknowledgement Letter to Novartis Pharmaceuticals Corporation
09000064814ae31c,Other,FDA-2013-P-0247-0006,FDA-2013-P-0247,"FDA/CDER Denial Response Letter to Novartis Pharmaceuticals Corporation (Kleinfeld, Kaplan and Becker, LLP)"
0900006481212835,Other,FDA-2013-P-0247-0001,FDA-2013-P-0247,Novartis Pharmaceuticals Corporation - Citizen Petition
09000064813c0b7d,Other,FDA-2013-P-0247-0003,FDA-2013-P-0247,FDA/CDER to Novartis Pharmaceuticals Corporation - Denial of Petition
0900006481d5e0b2,Notice,FDA-2015-P-3404-0004,FDA-2015-P-3404,"Determination That LIPTRUZET (Ezetimibe and Atorvastatin) Tablets,
10 Milligrams/10 Milligrams, 10 Milligrams/20 Milligrams, 10
Milligrams/40 Milligrams, and 10 Milligrams/80 Milligrams, Were Not
Withdrawn From Sale for Reasons of Safety or Effectiveness"
0900006481c8f3b4,Other,FDA-2015-P-3404-0003,FDA-2015-P-3404,"Acknowledgement Letter from FDA DDM to Lupin Pharmaceuticals, Inc."
0900006481d61232,Other,FDA-2015-P-3404-0005,FDA-2015-P-3404,"Letter from FDA CDER to Lupin Pharmaceuticals, Inc."
0900006481c8f3b3,Supporting & Related Material,FDA-2015-P-3404-0002,FDA-2015-P-3404,"Attachment 1 Prescription and Over the Counter Drug Product List from the Orange Book re Citizen Petition from Lupin Pharmaceuticals, Inc."
0900006481c8f3b1,Other,FDA-2015-P-3404-0001,FDA-2015-P-3404,"Citizen Petition from Lupin Pharmaceuticals, Inc."
0900006481c42b25,Other,FDA-2015-P-0720-0006,FDA-2015-P-0720,"Citizen Petition Approval Response from FDA CDER to Zydus Pharmaceutical, Inc."
0900006481a30c00,Supporting & Related Material,FDA-2015-P-0720-0004,FDA-2015-P-0720,Attach II Citizen Petition from ZYDUS Pharmaceuticals Inc
0900006481a30bfd,Other,FDA-2015-P-0720-0002,FDA-2015-P-0720,Acknowledgement Letter from FDA DDM to ZYDUS Pharmaceuticals Inc
0900006481a30947,Other,FDA-2015-P-0720-0001,FDA-2015-P-0720,Citizen Petition request from ZYDUS Pharmaceuticals Inc
0900006481a30bff,Supporting & Related Material,FDA-2015-P-0720-0003,FDA-2015-P-0720,Attach I Citizen Petition from ZYDUS Pharmaceuticals Inc
0900006481a30c01,Supporting & Related Material,FDA-2015-P-0720-0005,FDA-2015-P-0720,Attach III Citizen Petition from ZYDUS Pharmaceuticals Inc
090000648331eb4a,Supporting & Related Material,FDA-2018-P-2104-0003,FDA-2018-P-2104,"Attachment 1- Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations re Citizen Petition from Nostrum Pharmaceuticals, LLC."
090000648331f12b,Other,FDA-2018-P-2104-0002,FDA-2018-P-2104,"Acknowledgment Letter from FDA DDM to Nostrum Pharmaceuticals, LLC."
09000064842ec9e9,Other,FDA-2018-P-2104-0005,FDA-2018-P-2104,"Citizen Petition-Withdrawal from Nostrum Pharmaceuticals, LLC"
090000648331eb44,Other,FDA-2018-P-2104-0001,FDA-2018-P-2104,"Citizen Petition from Nostrum Pharmaceuticals, LLC."
09000064838ff37d,Other,FDA-2018-P-2104-0004,FDA-2018-P-2104,"Letter from FDA CDER to Nostrum Pharmaceuticals, LLC"
09000064849627c2,Supporting & Related Material,FDA-2020-P-1421-0053,FDA-2020-P-1421,Tab 40 re Citizen Petition for reconsideration from Encore Dermatology Inc
09000064846ad348,Supporting & Related Material,FDA-2020-P-1421-0004,FDA-2020-P-1421,"Tab 2 re Citizen Petition from Encore Dermatology, Inc."
09000064846ad356,Supporting & Related Material,FDA-2020-P-1421-0008,FDA-2020-P-1421,"Tab 6 re Citizen Petition from Encore Dermatology, Inc."
09000064846acf2d,Supporting & Related Material,FDA-2020-P-1421-0025,FDA-2020-P-1421,"Tab 22 re Citizen Petition from Encore Dermatology, Inc."
09000064846ad357,Supporting & Related Material,FDA-2020-P-1421-0009,FDA-2020-P-1421,"Tab 7 re Citizen Petition from Encore Dermatology, Inc."
09000064846acf38,Supporting & Related Material,FDA-2020-P-1421-0035,FDA-2020-P-1421,"Tab 32 re Citizen Petition from Encore Dermatology, Inc"
09000064846acf3b,Supporting & Related Material,FDA-2020-P-1421-0038,FDA-2020-P-1421,"Tab 35 re Citizen Petition from Encore Dermatology, Inc."
09000064846acf37,Supporting & Related Material,FDA-2020-P-1421-0034,FDA-2020-P-1421,"Tab 31 re Citizen Petition from Encore Dermatology, Inc."
09000064846acf3a,Supporting & Related Material,FDA-2020-P-1421-0037,FDA-2020-P-1421,"Tab 34 re Citizen Petition from Encore Dermatology, Inc."
09000064846ad342,Other,FDA-2020-P-1421-0002,FDA-2020-P-1421,"Acknowledgment Letter from FDA DMS to Encore Dermatology, Inc."
09000064846acf2c,Supporting & Related Material,FDA-2020-P-1421-0024,FDA-2020-P-1421,"Tab 21 re Citizen Petition from Encore Dermatology, Inc."
09000064846acf33,Supporting & Related Material,FDA-2020-P-1421-0030,FDA-2020-P-1421,"Tab 27 re Citizen Petition from Encore Dermatology, Inc."
09000064846ad349,Supporting & Related Material,FDA-2020-P-1421-0005,FDA-2020-P-1421,"Tab 3 re Citizen Petition from Encore Dermatology, Inc."
09000064846ad355,Supporting & Related Material,FDA-2020-P-1421-0007,FDA-2020-P-1421,"Tab 5 re Citizen Petition from Encore Dermatology, Inc."
09000064846ad358,Supporting & Related Material,FDA-2020-P-1421-0010,FDA-2020-P-1421,"Tab 8 re Citizen Petition from Encore Dermatology, Inc."
09000064846aceff,Supporting & Related Material,FDA-2020-P-1421-0016,FDA-2020-P-1421,"Tab 14 - CONFIDENTIAL UNREDACTED  - re Citizen Petition from Encore Dermatology, Inc."
09000064846acf29,Supporting & Related Material,FDA-2020-P-1421-0021,FDA-2020-P-1421,"Tab 18 re Citizen Petition from Encore Dermatology, Inc."
09000064846ad347,Supporting & Related Material,FDA-2020-P-1421-0003,FDA-2020-P-1421,"Tab 1 re Citizen Petition from Encore Dermatology, Inc."
09000064846ad34a,Supporting & Related Material,FDA-2020-P-1421-0006,FDA-2020-P-1421,"Tab 4 re Citizen Petition from Encore Dermatology, Inc."
09000064846acf39,Supporting & Related Material,FDA-2020-P-1421-0036,FDA-2020-P-1421,"Tab 33 re Citizen Petition from Encore Dermatology, Inc."
09000064846ad359,Supporting & Related Material,FDA-2020-P-1421-0011,FDA-2020-P-1421,"Tab 9 re Citizen Petition from Encore Dermatology, Inc."
09000064846acf00,Supporting & Related Material,FDA-2020-P-1421-0017,FDA-2020-P-1421,"Tab 14 REDACTED re Citizen Petition from Encore Dermatology, Inc."
09000064846acf26,Supporting & Related Material,FDA-2020-P-1421-0019,FDA-2020-P-1421,"Tab 16 re Citizen Petition from Encore Dermatology, Inc."
09000064846ad35d,Supporting & Related Material,FDA-2020-P-1421-0015,FDA-2020-P-1421,"Tab 13 re Citizen Petition from Encore Dermatology, Inc."
090000648491869e,Other,FDA-2020-P-1421-0041,FDA-2020-P-1421,"Final decision from FDA CDER to Encore Dermatology, Inc."
0900006483a93d9a,Supporting & Related Material,FDA-2019-P-0837-0014,FDA-2019-P-0837,"Exhibit 12 FDA Late-Cycle Meeting Minutes 8-1-2013 re: Citizen Petition from Takeda Pharmaceuticals U.S.A., Inc. and H. Lundbeck A/S"
0900006483a93d94,Supporting & Related Material,FDA-2019-P-0837-0008,FDA-2019-P-0837,"Exhibit 6 APA, Practice Guidelines re: Citizen Petition from Takeda Pharmaceuticals U.S.A., Inc. and H. Lundbeck A/S"
0900006483a92f23,Supporting & Related Material,FDA-2019-P-0837-0005,FDA-2019-P-0837,"Exhibit 3 FDA Supplement Approval Letter 5-2-2016 re: Citizen Petition from Takeda Pharmaceuticals U.S.A., Inc. and H. Lundbeck A/S"
0900006483a93d95,Supporting & Related Material,FDA-2019-P-0837-0009,FDA-2019-P-0837,"Exhibit 7 FDA Mem_ of Meeting Minutes 2-5-2008 re: Citizen Petition from Takeda Pharmaceuticals U.S.A., Inc. and H. Lundbeck A/S"
0900006483a93da1,Supporting & Related Material,FDA-2019-P-0837-0021,FDA-2019-P-0837,"Exhibit 19 Ogle and Akkerman Guidance for the discontinuation or switching of antidepressant therapies in adults re: Citizen Petition from Takeda Pharmaceuticals U.S.A., Inc. and H. Lundbeck A/S"
0900006483a93d9b,Supporting & Related Material,FDA-2019-P-0837-0015,FDA-2019-P-0837,"Exhibit 13 TRINTELLIX Clinical Review re: Citizen Petition from Takeda Pharmaceuticals U.S.A., Inc. and H. Lundbeck A/S"
0900006483a93d96,Supporting & Related Material,FDA-2019-P-0837-0010,FDA-2019-P-0837,"Exhibit 8 Khin re: Citizen Petition from Takeda Pharmaceuticals U.S.A., Inc. and H. Lundbeck A/S"
0900006483a92ce8,Supporting & Related Material,FDA-2019-P-0837-0003,FDA-2019-P-0837,"Exhibit 1 FDA Approval Letter Trintellix re: Citizen Petition from Takeda Pharmaceuticals U.S.A., Inc. and H. Lundbeck A/S"
0900006483a93d93,Supporting & Related Material,FDA-2019-P-0837-0007,FDA-2019-P-0837,"Exhibit 5 DSM-5 re: Citizen Petition from Takeda Pharmaceuticals U.S.A., Inc. and H. Lundbeck A/S"
0900006483a93d9c,Supporting & Related Material,FDA-2019-P-0837-0016,FDA-2019-P-0837,"Exhibit 14 CYMBALTA PI (Dec_ 2017) re: Citizen Petition from Takeda Pharmaceuticals U.S.A., Inc. and H. Lundbeck A/S"
0900006483a93da2,Other,FDA-2019-P-0837-0002,FDA-2019-P-0837,"Acknowledgment Letter from FDA DDM to Takeda Pharmaceuticals U.S.A., Inc. and H. Lundbeck A/S"
0900006483a94ad6,Supporting & Related Material,FDA-2019-P-0837-0023,FDA-2019-P-0837,"Exhibit 21 Letter from FDA to Sidley Austin re Colcrys re: Citizen Petition from Takeda Pharmaceuticals U.S.A., Inc. and H. Lundbeck A/S"
0900006483a93d9e,Supporting & Related Material,FDA-2019-P-0837-0018,FDA-2019-P-0837,"Exhibit 16 Clayton re: Citizen Petition from Takeda Pharmaceuticals U.S.A., Inc. and H. Lundbeck A/S"
0900006483a93da0,Supporting & Related Material,FDA-2019-P-0837-0020,FDA-2019-P-0837,"Exhibit 18 Keks austprescr-39-076 re: Citizen Petition from Takeda Pharmaceuticals U.S.A., Inc. and H. Lundbeck A/S"
0900006483d9cf7f,Other,FDA-2019-P-0837-0026,FDA-2019-P-0837,"Letter from FDA CDER to Takeda Pharmaceuticals U.S.A., Inc."
0900006483a93d9f,Supporting & Related Material,FDA-2019-P-0837-0019,FDA-2019-P-0837,"Exhibit 17 Bostwick Mayo Clin Proc 85 538_550 2010 re: Citizen Petition from Takeda Pharmaceuticals U.S.A., Inc. and H. Lundbeck A/S"
0900006483a93d9d,Supporting & Related Material,FDA-2019-P-0837-0017,FDA-2019-P-0837,"Exhibit 15 Hu compressed re: Citizen Petition from Takeda Pharmaceuticals U.S.A., Inc. and H. Lundbeck A/S"
0900006483a93d98,Supporting & Related Material,FDA-2019-P-0837-0012,FDA-2019-P-0837,"Exhibit 10 Orange Book re: Citizen Petition from Takeda Pharmaceuticals U.S.A., Inc. and H. Lundbeck A/S"
0900006483a93d99,Supporting & Related Material,FDA-2019-P-0837-0013,FDA-2019-P-0837,"Exhibit 11 Cassano Ann Clin Psychiatry 16 15-25 2004 re: Citizen Petition from Takeda Pharmaceuticals U.S.A., Inc. and H. Lundbeck A/S"
0900006483a92ce9,Supporting & Related Material,FDA-2019-P-0837-0004,FDA-2019-P-0837,"Exhibit 2 FDA Approves Brand Name Change for Brintellix re: Citizen Petition from Takeda Pharmaceuticals U.S.A., Inc. and H. Lundbeck A/S"
0900006483a92f24,Supporting & Related Material,FDA-2019-P-0837-0006,FDA-2019-P-0837,"Exhibit 4 Label October 2018 re: Citizen Petition from Takeda Pharmaceuticals U.S.A., Inc. and H. Lundbeck A/S"
0900006483a94ad7,Supporting & Related Material,FDA-2019-P-0837-0024,FDA-2019-P-0837,"Exhibit 22 Letter from Woodcock to Gulino re: Citizen Petition from Takeda Pharmaceuticals U.S.A., Inc. and H. Lundbeck A/S"
0900006483a93d97,Supporting & Related Material,FDA-2019-P-0837-0011,FDA-2019-P-0837,"Exhibit 9 TRINTELLIX PI (Sept_ 2013) re: Citizen Petition from Takeda Pharmaceuticals U.S.A., Inc. and H. Lundbeck A/S"
0900006483a94ad5,Supporting & Related Material,FDA-2019-P-0837-0022,FDA-2019-P-0837,"Exhibit 20 Letter from FDA to M Labson re Rapamune re: Citizen Petition from Takeda Pharmaceuticals U.S.A., Inc. and H. Lundbeck A/S"
0900006483a92c0b,Other,FDA-2019-P-0837-0001,FDA-2019-P-0837,"Citizen Petition from Takeda Pharmaceuticals U.S.A., Inc. and H. Lundbeck A/S"
0900006484704e2a,Supporting & Related Material,FDA-2020-P-1611-0008,FDA-2020-P-1611,Footnote 34_Danne et al re Citizen Petition from Public Citizen’s Health Research Group
0900006484704e30,Supporting & Related Material,FDA-2020-P-1611-0014,FDA-2020-P-1611,Footnote 43_Hampp et al re Citizen Petition from Public Citizen’s Health Research Group
0900006484704e31,Supporting & Related Material,FDA-2020-P-1611-0015,FDA-2020-P-1611,Footnote 44_Hampp et al-Supplement re Citizen Petition from Public Citizen’s Health Research Group
0900006484704dcf,Supporting & Related Material,FDA-2020-P-1611-0004,FDA-2020-P-1611,Footnote 28_Dandona et al re Citizen Petition from Public Citizen’s Health Research Group
0900006484704e2c,Supporting & Related Material,FDA-2020-P-1611-0010,FDA-2020-P-1611,Footnote 37_Lu et al re Citizen Petition from Public Citizen’s Health Research Group
0900006484704dce,Supporting & Related Material,FDA-2020-P-1611-0003,FDA-2020-P-1611,Footnote 27_Henry et al re Citizen Petition from Public Citizen’s Health Research Group
0900006484704e2e,Supporting & Related Material,FDA-2020-P-1611-0012,FDA-2020-P-1611,Footnote 39_Baker et al re Citizen Petition from Public Citizen’s Health Research Group
0900006484704dd0,Supporting & Related Material,FDA-2020-P-1611-0005,FDA-2020-P-1611,Footnote 29_Mathieu et al re Citizen Petition from Public Citizen’s Health Research Group
0900006484704e28,Supporting & Related Material,FDA-2020-P-1611-0006,FDA-2020-P-1611,Footnote 31_Rosenstock et al re Citizen Petition from Public Citizen’s Health Research Group
0900006484704e2d,Supporting & Related Material,FDA-2020-P-1611-0011,FDA-2020-P-1611,Footnote 38_Bode et al re Citizen Petition from Public Citizen’s Health Research Group
0900006484704dcb,Other,FDA-2020-P-1611-0002,FDA-2020-P-1611,Acknowledgment Letter from FDA DMS to Public Citizen’s Health Research Group
0900006484704e2f,Supporting & Related Material,FDA-2020-P-1611-0013,FDA-2020-P-1611,Footnote 40_Taylor et al re Citizen Petition from Public Citizen’s Health Research Group
0900006484704e29,Supporting & Related Material,FDA-2020-P-1611-0007,FDA-2020-P-1611,Footnote 33_Buse et al re Citizen Petition from Public Citizen’s Health Research Group
0900006484704dca,Other,FDA-2020-P-1611-0001,FDA-2020-P-1611,Citizen Petition from Public Citizen's Health Research Group
0900006484704e2b,Supporting & Related Material,FDA-2020-P-1611-0009,FDA-2020-P-1611,Footnote 35_Garg et al re Citizen Petition from Public Citizen’s Health Research Group
09000064849a99ff,Other,FDA-2020-P-1611-0016,FDA-2020-P-1611,Interim Response letter from FDA CDER to Public Citizen's Health Research Group
0900006481e825fd,Other,FDA-2016-P-0645-0002,FDA-2016-P-0645,"Acknowledgement Letter from FDA DDM to Pharmaceutical Manufacturing Research Services, Inc."
0900006481eb5c91,Supporting & Related Material,FDA-2016-P-0645-0008,FDA-2016-P-0645,46. FDA-2012-P-0895-0015 FR re Request FDA uniformly apply its standards for permitting a drug to be labeled as abuse deterrent y (a) requiring pre-marketing scientific proof of manipulation and extraction studies for abuse deterrent formulation in both small and large volume extraction
09000064839bc185,Other,FDA-2016-P-0645-0014,FDA-2016-P-0645,"CDER Response Letter to Pharmaceutical Manufacturing Research Services, Inc."
0900006481eb5ebc,Supporting & Related Material,FDA-2016-P-0645-0011,FDA-2016-P-0645,62. Oxycontin Package Insert re Request FDA uniformly apply its standards for permitting a drug to be labeled as abuse deterrent y (a) requiring pre-marketing scientific proof of manipulation and extraction studies for abuse deterrent formulation in both small and large volume extraction
0900006481e82090,Other,FDA-2016-P-0645-0001,FDA-2016-P-0645,"Citizen Petition from Pharmaceutical Manufacturing Research Services, Inc."
0900006481eb5c8c,Supporting & Related Material,FDA-2016-P-0645-0003,FDA-2016-P-0645,1. A Proactive Response to Prescription Opioid Abuse re Request FDA uniformly apply its standards for permitting a drug to be labeled as abuse deterrent y (a) requiring pre-marketing scientific proof of manipulation and extraction studies for abuse deterrent formulation in both small and large volume extraction
0900006481eb5c8f,Supporting & Related Material,FDA-2016-P-0645-0006,FDA-2016-P-0645,23. Chemistry Review NDA 022272s000 re Request FDA uniformly apply its standards for permitting a drug to be labeled as abuse deterrent y (a) requiring pre-marketing scientific proof of manipulation and extraction studies for abuse deterrent formulation in both small and large volume extraction
090000648219d362,Other,FDA-2016-P-0645-0013,FDA-2016-P-0645,Amendment  from Pharmaceutical Manufacturing Research Services Inc. (PMRS)
0900006481eb5eba,Supporting & Related Material,FDA-2016-P-0645-0009,FDA-2016-P-0645,"51. Oxycontin Antitrust Litigation, Purdue v. Teva re Request FDA uniformly apply its standards for permitting a drug to be labeled as abuse deterrent y (a) requiring pre-marketing scientific proof of manipulation and extraction studies for abuse deterrent formulation in both small and large volume extraction"
0900006481eb5ebb,Supporting & Related Material,FDA-2016-P-0645-0010,FDA-2016-P-0645,56. FDA-2012-P-0895-0014 re Request FDA uniformly apply its standards for permitting a drug to be labeled as abuse deterrent y (a) requiring pre-marketing scientific proof of manipulation and extraction studies for abuse deterrent formulation in both small and large volume extraction
09000064821858db,Other,FDA-2016-P-0645-0012,FDA-2016-P-0645,"CDER Interim Response Letter to Pharmaceutical Manufacturing Research Services, Inc."
0900006481eb5c8d,Supporting & Related Material,FDA-2016-P-0645-0004,FDA-2016-P-0645,5. Abuse-Deterrent Opioids Evaluation and Labeling Guidance for Industry re Request FDA uniformly apply its standards for permitting a drug to be labeled as abuse deterrent y (a) requiring pre-marketing scientific proof of manipulation and extraction studies for abuse deterrent formulation in both small and large volume extraction
0900006481eb5c8e,Supporting & Related Material,FDA-2016-P-0645-0005,FDA-2016-P-0645,22. Judge Fines OxyContin Maker and 3 Executives re Request FDA uniformly apply its standards for permitting a drug to be labeled as abuse deterrent y (a) requiring pre-marketing scientific proof of manipulation and extraction studies for abuse deterrent formulation in both small and large volume extraction
0900006481eb5c90,Supporting & Related Material,FDA-2016-P-0645-0007,FDA-2016-P-0645,27. FDA-2011-P-0473-0011 FR re Request FDA uniformly apply its standards for permitting a drug to be labeled as abuse deterrent y (a) requiring pre-marketing scientific proof of manipulation and extraction studies for abuse deterrent formulation in both small and large volume extraction
09000064839c163c,Other,FDA-2016-P-0645-0015,FDA-2016-P-0645,"CDER Response Letter to Pharmaceutical Manufacturing Research Services, Inc."
0900006484967260,Supporting & Related Material,FDA-2020-P-2212-0017,FDA-2020-P-2212,Tab 11 re Citizen Petition from Encore Dermatology Inc
09000064849672b9,Supporting & Related Material,FDA-2020-P-2212-0031,FDA-2020-P-2212,Tab 45 re Citizen Petition from Encore Dermatology Inc
09000064849675ec,Supporting & Related Material,FDA-2020-P-2212-0027,FDA-2020-P-2212,Tab 1 re Citizen Petition from Encore Dermatology Inc
0900006484967670,Supporting & Related Material,FDA-2020-P-2212-0041,FDA-2020-P-2212,Tab 35 re Citizen Petition from Encore Dermatology Inc
0900006484967644,Supporting & Related Material,FDA-2020-P-2212-0004,FDA-2020-P-2212,Tab 24 re Citizen Petition from Encore Dermatology Inc
090000648496766b,Supporting & Related Material,FDA-2020-P-2212-0046,FDA-2020-P-2212,Tab 30 re Citizen Petition from Encore Dermatology Inc
09000064849675ee,Supporting & Related Material,FDA-2020-P-2212-0025,FDA-2020-P-2212,Tab 3 re Citizen Petition from Encore Dermatology Inc
0900006484967668,Supporting & Related Material,FDA-2020-P-2212-0049,FDA-2020-P-2212,Tab 27 re Citizen Petition from Encore Dermatology Inc
090000648496766d,Supporting & Related Material,FDA-2020-P-2212-0044,FDA-2020-P-2212,Tab 32 re Citizen Petition from Encore Dermatology Inc
09000064849672b6,Supporting & Related Material,FDA-2020-P-2212-0034,FDA-2020-P-2212,Tab 42 re Citizen Petition from Encore Dermatology Inc
090000648496719a,Other,FDA-2020-P-2212-0002,FDA-2020-P-2212,"Acknowledgment Letter from FDA DMS to Encore Dermatology, Inc."
0900006484967264,Supporting & Related Material,FDA-2020-P-2212-0014,FDA-2020-P-2212,Tab 14 re Citizen Petition from Encore Dermatology Inc
0900006484967197,Other,FDA-2020-P-2212-0001,FDA-2020-P-2212,Citizen Petition from Encore Dermatology Inc
0900006484967267,Supporting & Related Material,FDA-2020-P-2212-0011,FDA-2020-P-2212,Tab 17 re Citizen Petition from Encore Dermatology Inc
09000064849672b4,Supporting & Related Material,FDA-2020-P-2212-0036,FDA-2020-P-2212,Tab 40 re Citizen Petition from Encore Dermatology Inc
0900006484967667,Supporting & Related Material,FDA-2020-P-2212-0050,FDA-2020-P-2212,Tab 26 re Citizen Petition from Encore Dermatology Inc
090000648496725f,Supporting & Related Material,FDA-2020-P-2212-0018,FDA-2020-P-2212,Tab 10 re Citizen Petition from Encore Dermatology Inc
0900006484967268,Supporting & Related Material,FDA-2020-P-2212-0010,FDA-2020-P-2212,Tab 18 re Citizen Petition from Encore Dermatology Inc
09000064849672b1,Supporting & Related Material,FDA-2020-P-2212-0039,FDA-2020-P-2212,Tab 37 re Citizen Petition from Encore Dermatology Inc
09000064849672b3,Supporting & Related Material,FDA-2020-P-2212-0037,FDA-2020-P-2212,"Tab 39 FY2018 GDUFA Science and Research Report Topical Dermatological Drug Products re Citizen Petition from Encore Dermatology, Inc."
09000064849675f0,Supporting & Related Material,FDA-2020-P-2212-0023,FDA-2020-P-2212,Tab 5 re Citizen Petition from Encore Dermatology Inc
09000064849675f1,Supporting & Related Material,FDA-2020-P-2212-0022,FDA-2020-P-2212,Tab 6 re Citizen Petition from Encore Dermatology Inc
09000064849675f3,Supporting & Related Material,FDA-2020-P-2212-0020,FDA-2020-P-2212,"Tab 8 LABE re Citizen Petition from Encore Dermatology, Inc."
0900006484af212e,Other,FDA-2020-P-2212-0051,FDA-2020-P-2212,"Interim response from FDA CDER to Encore Dermatology, Inc."
09000064849672b0,Supporting & Related Material,FDA-2020-P-2212-0040,FDA-2020-P-2212,Tab 36 re Citizen Petition from Encore Dermatology Inc
0900006484e57e59,Other,FDA-2021-P-0930-0161,FDA-2021-P-0930,Third Supplement from Labaton Sucharow to Citizens Petition Associated with Cassava Sciences Inc
0900006484c9d396,Other,FDA-2021-P-0930-0001,FDA-2021-P-0930,Citizen Petition from Labaton Sucharow
0900006484c9d303,Supporting & Related Material,FDA-2021-P-0930-0004,FDA-2021-P-0930,"Attachment 2  Statement of Concern Regarding the Accuracy and Integrity of Clinical and Preclinical Data Supporting the Ongoing Clinical Evaluation of 
Compound PTI-125, Also Known As Simufilam re Citizen Petition from Labaton Sucharow"
0900006484c9d302,Supporting & Related Material,FDA-2021-P-0930-0003,FDA-2021-P-0930,Attachment 1 Cassava Science VS Whistleblower Submission re Citizen Petition from Labaton Sucharow
0900006484c9d398,Other,FDA-2021-P-0930-0002,FDA-2021-P-0930,Acknowledgment Letter from FDA DMS to Labaton Sucharow
0900006484d67805,Other,FDA-2021-P-0930-0113,FDA-2021-P-0930,Supplement from Labaton Sucharow
0900006484cb4d42,Other,FDA-2021-P-0930-0023,FDA-2021-P-0930,Supplement from Labaton Sucharow
0900006482548469,Other,FDA-2017-P-2231-0001,FDA-2017-P-2231,"Citizen Petition from Qilu Pharma, Inc. as the US Agent of Qilu Pharmaceutical Co., Ltd"
090000648254846f,Other,FDA-2017-P-2231-0002,FDA-2017-P-2231,Acknowledgment Letter from FDA DDM to Qilu Pharma Inc
090000648267e055,Other,FDA-2017-P-2231-0003,FDA-2017-P-2231,"Withdrawal from Qilu Pharma, Inc."
0900006481a9e6d0,Other,FDA-2015-P-1187-0002,FDA-2015-P-1187,Acknowledgement Letter from FDA DDM to U.S. Right To Know
0900006481a9e5de,Other,FDA-2015-P-1187-0001,FDA-2015-P-1187,Citizen Petition from U.S. Right To Know (US RTK)
0900006482c7bf05,Other,FDA-2015-P-1187-0004,FDA-2015-P-1187,Final Response Letter from FDA to U.S. Right to Know
0900006481cafbca,Other,FDA-2015-P-1187-0003,FDA-2015-P-1187,Interim Response from FDA CFSAN to U.S. Right to Know
09000064842f7be1,Other,FDA-2020-P-0436-0002,FDA-2020-P-0436,"Acknowledgment Letter to   Foley and Lardner LLP on behalf of Romark Laboratories, L.C."
09000064842f7a1b,Other,FDA-2020-P-0436-0001,FDA-2020-P-0436,"Citizen Petition from Foley and Lardner LLP on behalf of Romark Laboratories, L.C."
0900006484307af4,Other,FDA-2020-P-0436-0003,FDA-2020-P-0436,Withdrawal from Foley & Lardner LLP
0900006484450c78,Other,FDA-2019-P-4523-0005,FDA-2019-P-4523,"Citizen Petition Response Letter from FDA CDER to Fresenius Kabi USA, LLC"
0900006483fddeca,Other,FDA-2019-P-4523-0002,FDA-2019-P-4523,"Acknowledgment Letter from FDA DMS to Fresenius Kabi USA, LLC"
090000648444c03e,Notice,FDA-2019-P-4523-0004,FDA-2019-P-4523,"Determination That Potassium Chloride in 5% Dextrose and 0.225%
Sodium Chloride Injection, 5 Milliequivalents, 10 Milliequivalents, 15
Milliequivalents, 20 Milliequivalents, 30 Milliequivalents, and 40
Milliequivalents, in Plastic Containers, Were Not Withdrawn From Sale for
Reasons of Safety or Effectiveness"
0900006483fddecb,Supporting & Related Material,FDA-2019-P-4523-0003,FDA-2019-P-4523,"Attachment A Orange Book Listing of Potassium Chloride in Dextrose 5% and Sodium Chloride 0.225% - NDA 018365 (September 26, 2019) re Citizen Petition from Fresenius Kabi USA, LLC"
0900006483fddec9,Other,FDA-2019-P-4523-0001,FDA-2019-P-4523,"Citizen Petition from Fresenius Kabi USA, LLC"
0900006484470c5f,Supporting & Related Material,FDA-2020-P-1220-0004,FDA-2020-P-1220,Attachment 2 FDA e-mail confirmation-removal from Class III re Petition for Reconsideration from C Laser Inc
0900006484470c5e,Supporting & Related Material,FDA-2020-P-1220-0003,FDA-2020-P-1220,Attachment 1 Reference Figures and Tables Referred to in the petition re Petition for Reconsideration from C Laser Inc
0900006484470c11,Other,FDA-2020-P-1220-0001,FDA-2020-P-1220,Petition for Reconsideration from C Laser Inc
0900006484798280,Other,FDA-2020-P-1220-0006,FDA-2020-P-1220,Denial letter for Petition for Reconsideration from FDA CDRH to C Laser Inc.
0900006484470c60,Supporting & Related Material,FDA-2020-P-1220-0005,FDA-2020-P-1220,Attachment 3 Updated Supporting Document List With Video Links re Petition for Reconsideration from C Laser Inc
0900006484470c12,Other,FDA-2020-P-1220-0002,FDA-2020-P-1220,Acknowledgment Letter from FDA DMS to C Laser Inc
0900006484b4c4ce,Notice,FDA-2021-P-0163-0003,FDA-2021-P-0163,"Determination That SANDOSTATIN (Octreotide Acetate) Injection, Equal to 0.2 Milligrams Base/Milliliter and Equal to 1 Milligrams Base/Milliliter, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
0900006484a1e626,Other,FDA-2021-P-0163-0002,FDA-2021-P-0163,Acknowledgment Letter from FDA DMS to Caplin Steriles Limited
0900006484b56dee,Other,FDA-2021-P-0163-0004,FDA-2021-P-0163,Response Letter from FDA CDER to Caplin Steriles Limited
0900006484a1e624,Other,FDA-2021-P-0163-0001,FDA-2021-P-0163,Citizen Petition from Caplin Steriles Limited
0900006484a1e56b,Other,FDA-2021-P-0162-0001,FDA-2021-P-0162,Citizen Petition from Nexsen Pruet LLC
0900006484a1e622,Other,FDA-2021-P-0162-0002,FDA-2021-P-0162,Acknowledgment Letter from FDA DMS to Nexsen Pruet LLC
0900006484b236e6,Notice,FDA-2021-P-0162-0003,FDA-2021-P-0162,"Determination That NORMODYNE (Labetalol Hydrochloride) Injection, 5 Milligrams per Milliliter, Was Not 
Withdrawn From Sale for Reasons of Safety or Effectiveness"
0900006484b2e963,Other,FDA-2021-P-0162-0004,FDA-2021-P-0162,"Response Letter from FDA CDER to Nexsen Pruet, LLC"
0900006484c3dec0,Supporting & Related Material,FDA-2021-P-0885-0004,FDA-2021-P-0885,Envelope RE Citizen Petition from Zydus Pharmaceuticals (USA) Inc.
0900006484c3dadd,Other,FDA-2021-P-0885-0002,FDA-2021-P-0885,Acknowledgment Letter from FDA DMS to Zydus Pharmaceuticals (USA) Inc.
0900006484c3debd,Other,FDA-2021-P-0885-0001,FDA-2021-P-0885,Citizen Petition from Zydus Pharmaceuticals (USA) Inc.
0900006484c3debf,Supporting & Related Material,FDA-2021-P-0885-0003,FDA-2021-P-0885,"Attachment 1 - Current (August 03, 2021) Orange Book Listing of PEPCID® (famotidine) Tablets, 20 mg and 40 mg, NDA # N019462, Held by VALEANT PHARMACEUTICALS NORTH AMERICA LLC RE Citizen Petition from Zydus Pharmaceuticals (USA) Inc."
09000064804960bb,Other,FDA-2003-P-0335-0004,FDA-2003-P-0335,HFD-240 to Fulcrum Inc.
09000064804960b5,Other,FDA-2003-P-0335-0003,FDA-2003-P-0335,HFD-001 to James O. Maloy
090000648049605e,Other,FDA-2003-P-0335-0001,FDA-2003-P-0335,HFA-305 to Fulcrum Inc.
09000064804960ad,Other,FDA-2003-P-0335-0002,FDA-2003-P-0335,"HFD-005 to Fulcrum, Inc."
0900006482e414d9,Other,FDA-2017-P-5954-0004,FDA-2017-P-5954,"Supplement from Elite Laboratories, Inc."
09000064837b5410,Other,FDA-2017-P-5954-0006,FDA-2017-P-5954,Petition Denial Letter from FDA CDER to Elite Laboratories Inc
0900006482b82e71,Other,FDA-2017-P-5954-0001,FDA-2017-P-5954,Citizen Petition from Elite Laboratories Inc
0900006482b82e73,Other,FDA-2017-P-5954-0002,FDA-2017-P-5954,Acknowledgement Letter from FDA DDM to Elite Laboratories Inc
0900006482b82e76,Supporting & Related Material,FDA-2017-P-5954-0003,FDA-2017-P-5954,Attachment A Orange book - Dantrium re Citizen Petition from Elite Laboratories Inc
0900006483050b38,Other,FDA-2017-P-5954-0005,FDA-2017-P-5954,"Interim Response  Letter from FDA CDER to Elite Laboratories, Inc."
09000064824f8019,Supporting & Related Material,FDA-2017-P-1392-0004,FDA-2017-P-1392,"Attachment 2 - October 3, 2016 Citizen Petition re Citizen Petition from Latham & Watkins, LLP"
09000064824fa142,Other,FDA-2017-P-1392-0002,FDA-2017-P-1392,"Acknowledgment Letter from FDA DDM to Latham & Watkins, LLP"
09000064824f801a,Supporting & Related Material,FDA-2017-P-1392-0005,FDA-2017-P-1392,"Attachment 3 - FDA Denial Letter re Citizen Petition from Latham & Watkins, LLP"
09000064829e047b,Other,FDA-2017-P-1392-0006,FDA-2017-P-1392,"Citizen Petition Response Letter from FDA CDER to Latham & Watkins, LLP"
09000064824f8018,Supporting & Related Material,FDA-2017-P-1392-0003,FDA-2017-P-1392,"Attachment 1 - August 1 2016 Citizen Petition re Citizen Petition from Latham & Watkins, LLP"
09000064824f8016,Other,FDA-2017-P-1392-0001,FDA-2017-P-1392,"Citizen Petition from Latham & Watkins, LLP (Par Sterile Products, LLC)"
0900006482f88128,Supporting & Related Material,FDA-2018-P-0964-0003,FDA-2018-P-0964,"Attachment A – Current Orange Book Listing of Plasma-Lyte M and Dextrose 5% re :Citizen Petition from Fresenius Kabi USA, LLC"
090000648365b9d5,Other,FDA-2018-P-0964-0005,FDA-2018-P-0964,"Agency Response Letter from FDA CDER to Fresenius Kabi USA, LLC"
0900006482f87988,Other,FDA-2018-P-0964-0001,FDA-2018-P-0964,"Citizen Petition from Fresenius Kabi USA, LLC"
090000648364fa80,Notice,FDA-2018-P-0964-0004,FDA-2018-P-0964,"Determination That PLASMA–LYTE M AND DEXTROSE 5% and PLASMA
LYTE 148 AND DEXTROSE 5% Were Not Withdrawn From Sale for Reasons
of Safety or Effectiveness"
0900006482f8798c,Other,FDA-2018-P-0964-0002,FDA-2018-P-0964,"Acknowledgment Letter from FDA DDM to Fresenius Kabi USA, LLC"
09000064835198b0,Supporting & Related Material,FDA-2018-P-2755-0006,FDA-2018-P-2755,"Attachment IV - NON AVAILABILITY LETTER-METADATE re Citizen Petition from Ascend Laboratories, LLC"
09000064839f4c56,Other,FDA-2018-P-2755-0007,FDA-2018-P-2755,"Interim response from FDA CDER to Ascend Laboratories, LLC"
0900006483519ae6,Supporting & Related Material,FDA-2018-P-2755-0003,FDA-2018-P-2755,"Attachment I - Orange Book Search re Citizen Petition from Ascend Laboratories, LLC"
0900006483519ae2,Other,FDA-2018-P-2755-0002,FDA-2018-P-2755,"Acknowledgment Letter from FDA DDM to Ascend Laboratories, LLC"
0900006483519ae0,Other,FDA-2018-P-2755-0001,FDA-2018-P-2755,"Citizen Petition from Ascend Laboratories, LLC"
0900006483519ae8,Supporting & Related Material,FDA-2018-P-2755-0005,FDA-2018-P-2755,"Attachment III - Trade customer Notification Letter from UCB re Citizen Petition from Ascend Laboratories, LLC"
0900006484177fba,Other,FDA-2018-P-2755-0008,FDA-2018-P-2755,"Response Letter from FDA to Hyman, Phelps, and McNamara"
0900006483519ae7,Supporting & Related Material,FDA-2018-P-2755-0004,FDA-2018-P-2755,"Attachment II - Approval Letter re Citizen Petition from Ascend Laboratories, LLC"
0900006481ae2bde,Other,FDA-2015-P-1721-0002,FDA-2015-P-1721,Acknowledgement Letter from FDA DDM to Hogan Lovells US LLP
0900006481ae2be1,Supporting & Related Material,FDA-2015-P-1721-0004,FDA-2015-P-1721,Tab 2 Helsinn Cipla Redacted Cipla Application re: Citizen Petition from Hogan Lovells US LLP
0900006481ae2be6,Supporting & Related Material,FDA-2015-P-1721-0005,FDA-2015-P-1721,Tab 7 Helsinn Cipla Redacted ANDA Rejection re: Citizen Petition from Hogan Lovells US LLP
0900006481ae26ca,Supporting & Related Material,FDA-2015-P-1721-0006,FDA-2015-P-1721,Tab 14 Helsinn Cipla Letter from OGD re: itizen Petition from Hogan Lovells US LLP
0900006481ae2be0,Supporting & Related Material,FDA-2015-P-1721-0003,FDA-2015-P-1721,Tab 1 Helsinn Cipla Label Information re: Citizen Petition from Hogan Lovells US LLP
0900006481ae2b15,Other,FDA-2015-P-1721-0001,FDA-2015-P-1721,Citizen Petition from Hogan Lovells US LLP (Helsinn)
0900006481cc0613,Other,FDA-2015-P-1721-0007,FDA-2015-P-1721,Citizen Petition Denial Response from FDA CDER to Hogan Lovells US LLP
0900006482476cb7,Other,FDA-2016-P-2955-0032,FDA-2016-P-2955,Supplement from Nicholas Isel
0900006483a315e1,Other,FDA-2016-P-2955-0116,FDA-2016-P-2955,Supplement from Nicholas Isel
0900006483a31315,Other,FDA-2016-P-2955-0115,FDA-2016-P-2955,Supplement from Nicholas Isel
0900006482527f70,Other,FDA-2016-P-2955-0078,FDA-2016-P-2955,Supplement from Nicholas Isel
0900006483a31571,Other,FDA-2016-P-2955-0113,FDA-2016-P-2955,Supplement from Nicholas Isel
09000064847a3b51,Other,FDA-2016-P-2955-0339,FDA-2016-P-2955,"Denial letter on petition and petition for reconsideration from FDA OC to Michelle J. Rozovics, Esq."
0900006482272d4d,Other,FDA-2016-P-2955-0001,FDA-2016-P-2955,Citizen Petition from Nicholas Isel
09000064843c7d83,Other,FDA-2016-P-2955-0330,FDA-2016-P-2955,Signed Petitioner Response
09000064824787f9,Other,FDA-2016-P-2955-0034,FDA-2016-P-2955,Supplement from Nicholas Isel
09000064836e2d88,Other,FDA-2016-P-2955-0085,FDA-2016-P-2955,Petition to Reconsider from Rozovics Law Firm LLC on behalf of Nicholas Isel
09000064824f1ff2,Other,FDA-2016-P-2955-0053,FDA-2016-P-2955,Interim Response from CBER to Nicholas Isel
09000064836e7eda,Other,FDA-2016-P-2955-0087,FDA-2016-P-2955,Petition to Reconsider from Rozovics Law Firm LLC on behalf of Nicholas Isel_Redacted
09000064836e7f5c,Other,FDA-2016-P-2955-0088,FDA-2016-P-2955,Response from FDA CBER to Nicholas Isel_Redacted
090000648361e6e0,Supporting & Related Material,FDA-2016-P-2955-0081,FDA-2016-P-2955,List of References re: Response  from FDA CBER to Nicholas Isel
0900006483604ef2,Other,FDA-2016-P-2955-0080,FDA-2016-P-2955,Response  from FDA CBER to Nicholas Isel
090000648361eb07,Supporting & Related Material,FDA-2016-P-2955-0083,FDA-2016-P-2955,Reference 2 - Recent Advances in the Genetics of Schizophrenia re: Response  from FDA CBER to Nicholas Isel
0900006483aa7142,Other,FDA-2016-P-2955-0136,FDA-2016-P-2955,Interim Response Letter from FDA CBER to Rozovics Law Firm LLC
0900006483aa2f2d,Other,FDA-2016-P-2955-0134,FDA-2016-P-2955,"Letter from FDA CBER to ROZOVICS LAW FIRM, LLC"
0900006482529c68,Other,FDA-2016-P-2955-0338,FDA-2016-P-2955,Supplement from Nicholas Isel
0900006483a31607,Other,FDA-2016-P-2955-0117,FDA-2016-P-2955,Supplement from Nicholas Isel
0900006482476ff0,Other,FDA-2016-P-2955-0031,FDA-2016-P-2955,Comment from Nicholas Isel
0900006483a315b3,Other,FDA-2016-P-2955-0114,FDA-2016-P-2955,Supplement from Nicholas Isel
0900006482272bdb,Other,FDA-2016-P-2955-0002,FDA-2016-P-2955,Acknowledgment Letter from FDA DDM to Nicholas Isel
090000648361eb08,Supporting & Related Material,FDA-2016-P-2955-0084,FDA-2016-P-2955,Reference 3 - Sequencing-Based Diagnostics for Pediatric Genetic Diseases Progress and Potential re: Response  from FDA CBER to Nicholas Isel
090000648361eb06,Supporting & Related Material,FDA-2016-P-2955-0082,FDA-2016-P-2955,"Reference 1 - The Genetic Basis of Complex Traits Rare Variants or Common Gene, Common Disease re:   Response  from FDA CBER to Nicholas Isel"
0900006482287d93,Supporting & Related Material,FDA-2016-P-3089-0006,FDA-2016-P-3089,"Attachment 4 ANDA Approval Letter for Cefixime chewable tablet, ANDA 065380 re Citizen Petition from Aleon Pharma International, Inc"
0900006482287d91,Supporting & Related Material,FDA-2016-P-3089-0004,FDA-2016-P-3089,"Attachment 2 Draft Labeling Proposed for Cefixime Tablets for oral suspension re Citizen Petition from Aleon Pharma International, Inc"
0900006482287d92,Supporting & Related Material,FDA-2016-P-3089-0005,FDA-2016-P-3089,"Attachment 3 FDA Approved Labeling for the reference-listed drug Suprax re Citizen Petition from Aleon Pharma International, Inc"
0900006482287d94,Supporting & Related Material,FDA-2016-P-3089-0007,FDA-2016-P-3089,"Attachment 5 Suitability Petition Approval Letter for Amoxicillin and Clavulanate Potassium tablet re Citizen Petition from Aleon Pharma International, Inc"
0900006482287844,Supporting & Related Material,FDA-2016-P-3089-0003,FDA-2016-P-3089,"Attachment 1 Approved Drug Products with Therapeutic Equivalence re Citizen Petition from Aleon Pharma International, Inc"
0900006482287842,Other,FDA-2016-P-3089-0002,FDA-2016-P-3089,"Acknowledgement Letter from FDA DDM to Aleon Pharma International, Inc"
0900006482287840,Other,FDA-2016-P-3089-0001,FDA-2016-P-3089,"Citizen Petition from Aleon Pharma International, Inc"
0900006484936fcb,Other,FDA-2020-P-2133-0002,FDA-2020-P-2133,Acknowledgment Letter from FDA DMS to Fresenius Kabi USA LLC
0900006484936ab5,Other,FDA-2020-P-2133-0001,FDA-2020-P-2133,"Citizen Petition from Fresenius Kabi USA, LLC"
0900006484ab4d28,Other,FDA-2020-P-2133-0003,FDA-2020-P-2133,Interim Response Letter from FDA CDER to Fresenius Kabi USA LLC
0900006484b14c70,Other,FDA-2020-P-2133-0004,FDA-2020-P-2133,Response Letter from FDA CDER to Fresenius Kabi USA LLC
0900006484aa3abe,Other,FDA-2021-P-0376-0002,FDA-2021-P-0376,Acknowledgement Letter from FDA DMS to Braintree SEBELA PHARMACEUTICALS
0900006484acb787,Other,FDA-2021-P-0376-0003,FDA-2021-P-0376,Withdrawal from Braintree
0900006484aa3a45,Other,FDA-2021-P-0376-0001,FDA-2021-P-0376,Citizen Petition from Braintree SEBELA PHARMACEUTICALS
0900006481f72251,Supporting & Related Material,FDA-2016-P-1163-0024,FDA-2016-P-1163,"Exhibit 21 Apr. 3, 2013 General Advice Letter re Citizen Petition from Foley Hoag LLP (Vifor Fresenius Medical Care Renal Pharma France)"
0900006481f72254,Supporting & Related Material,FDA-2016-P-1163-0026,FDA-2016-P-1163,"Exhibit 23 Aug. 11 , 2014 Meeting Request re Citizen Petition from Foley Hoag LLP (Vifor Fresenius Medical Care Renal Pharma France)"
0900006481f72259,Supporting & Related Material,FDA-2016-P-1163-0031,FDA-2016-P-1163,Exhibit 28 E-Mail Correspondence re Citizen Petition from Foley Hoag LLP (Vifor Fresenius Medical Care Renal Pharma France)
0900006481f72565,Supporting & Related Material,FDA-2016-P-1163-0033,FDA-2016-P-1163,"Exhibit 30 Center for Drug Evaluation and Research, Application No. 21-135, Chemical Reviews re Citizen Petition from Foley Hoag LLP (Vifor Fresenius Medical Care Renal Pharma France)"
0900006481f72568,Supporting & Related Material,FDA-2016-P-1163-0036,FDA-2016-P-1163,Exhibit 33 FDA Draft Guidance on Sodium Fenic Gluconate Complex (June 2013)  re Citizen Petition from Foley Hoag LLP (Vifor Fresenius Medical Care Renal Pharma France)
0900006481f7256e,Supporting & Related Material,FDA-2016-P-1163-0041,FDA-2016-P-1163,Exhibit 38 D VanWyck et al. Labile iron in parenteral iron formulations: a quantitative and comparative study. Nephrol Dial Transplant. 2004;19:561-556 re Citizen Petition from Foley Hoag LLP (Vifor Fresenius Medical Care Renal Pharma France)
0900006481f72571,Supporting & Related Material,FDA-2016-P-1163-0044,FDA-2016-P-1163,"Exhibit 41 HH Popper. Etiology, pathogenesis and differential diagnosis of lung grnulomatosis. An update. Patologia. 1999; 32(3):395-39 re Citizen Petition from Foley Hoag LLP (Vifor Fresenius Medical Care Renal Pharma France)"
0900006481f74b5e,Supporting & Related Material,FDA-2016-P-1163-0058,FDA-2016-P-1163,"Exhibit 10 BG Danielson. Structure, Chemistty, and Pharmacokinetics of Intravenous Iron Agents. J Am Soc Nephrol. 2004;15:S93-S98 re Citizen Petition from Foley Hoag LLP (Vifor Fresenius Medical Care Renal Pharma France)"
0900006481f74b66,Supporting & Related Material,FDA-2016-P-1163-0065,FDA-2016-P-1163,"Exhibit 18 Feb. 13 , 2013 General Advice Letter re Citizen Petition from Foley Hoag LLP (Vifor Fresenius Medical Care Renal Pharma France)"
0900006481f74b68,Supporting & Related Material,FDA-2016-P-1163-0067,FDA-2016-P-1163,"Exhibit 20 Mar. 11 , 2013 Response to FDA's General Advice re Citizen Petition from Foley Hoag LLP (Vifor Fresenius Medical Care Renal Pharma France)"
0900006481f74b69,Supporting & Related Material,FDA-2016-P-1163-0068,FDA-2016-P-1163,"Exhibit 21 Apr. 3, 2013 General Advice Letter re Citizen Petition from Foley Hoag LLP (Vifor Fresenius Medical Care Renal Pharma France)"
0900006481f74b7b,Supporting & Related Material,FDA-2016-P-1163-0083,FDA-2016-P-1163,Exhibit 34 European Medicines Agency. Reflection paper on non-clinical studies for generic nanoparticle iron medicinal product applications. 2011 re Citizen Petition from Foley Hoag LLP (Vifor Fresenius Medical Care Renal Pharma France)
0900006481f74b7c,Supporting & Related Material,FDA-2016-P-1163-0084,FDA-2016-P-1163,Exhibit 35 N Desai. Challenges in development ofNanoparticle-Based Therapeutics. AAPS J. 20 12; 14(2):282-295 re Citizen Petition from Foley Hoag LLP (Vifor Fresenius Medical Care Renal Pharma France)
0900006481f74b7f,Supporting & Related Material,FDA-2016-P-1163-0087,FDA-2016-P-1163,Exhibit 38 D VanWyck et al. Labile iron in parenteral iron formulations: a quantitative and comparative study. Nephrol Dial Transplant. 2004;19:561-556 re Citizen Petition from Foley Hoag LLP (Vifor Fresenius Medical Care Renal Pharma France)
0900006481f74b86,Supporting & Related Material,FDA-2016-P-1163-0094,FDA-2016-P-1163,"Exhibit 45 Amarin v. Apotex, 14-cv-02550 (D.N.J.), Dkt. No. 100-3 re Citizen Petition from Foley Hoag LLP (Vifor Fresenius Medical Care Renal Pharma France)"
0900006481f74b55,Supporting & Related Material,FDA-2016-P-1163-0056,FDA-2016-P-1163,Exhibit 7 Ferrlecit Label re Citizen Petition from Foley Hoag LLP (Vifor Fresenius Medical Care Renal Pharma France) re Citizen Petition from Foley Hoag LLP (Vifor Fresenius Medical Care Renal Pharma France)
0900006481f74b60,Supporting & Related Material,FDA-2016-P-1163-0059,FDA-2016-P-1163,Exhibit 12 JE Tobbli eta!. Comparison of Oxidative Stress and Inflammation Induced by Different Intravenous Iron Sucrose Similar Preparations in a Rat Model. Inflammation & Allergy - Drug Targets. 2012;11 :66-78 re Citizen Petition from Foley Hoag LLP (Vifor Fresenius Medical Care Renal Pharma France)
0900006481f74b64,Supporting & Related Material,FDA-2016-P-1163-0063,FDA-2016-P-1163,"Exhibit 16 S Muhlebach, B Fluhma1m. Iron Carbohydrate Complexes: Characteristics and Regulatory Challenges. In: DJA Crommelin, JSB de Vlieger, editors. Non-Biological Complex Drugs. Switzerland: Springer International Publishing; 2015 re Citizen Petition from Foley Hoag LLP (Vifor Fresenius Medical Care Renal Pharma France)"
0900006481f74b6d,Supporting & Related Material,FDA-2016-P-1163-0074,FDA-2016-P-1163,"Exhibit 25 Sept. 24, 2014 Background/Briefing Materials re Citizen Petition from Foley Hoag LLP (Vifor Fresenius Medical Care Renal Pharma France)"
0900006481f74b6f,Supporting & Related Material,FDA-2016-P-1163-0076,FDA-2016-P-1163,"Exhibit 27 Apr. 30, 2015 Letter re Citizen Petition from Foley Hoag LLP (Vifor Fresenius Medical Care Renal Pharma France)"
0900006481f74b70,Supporting & Related Material,FDA-2016-P-1163-0077,FDA-2016-P-1163,Exhibit 28 E-Mail Correspondence re Citizen Petition from Foley Hoag LLP (Vifor Fresenius Medical Care Renal Pharma France)
0900006481f74b71,Supporting & Related Material,FDA-2016-P-1163-0078,FDA-2016-P-1163,"Exhibit 29 Feb.15, 2016Letter re Citizen Petition from Foley Hoag LLP (Vifor Fresenius Medical Care Renal Pharma France)"
0900006481f74b87,Supporting & Related Material,FDA-2016-P-1163-0095,FDA-2016-P-1163,Exhibit 46 European Medicines Agency. Velphoro Assessment Report. 2014 re Citizen Petition from Foley Hoag LLP (Vifor Fresenius Medical Care Renal Pharma France)
0900006481f72253,Supporting & Related Material,FDA-2016-P-1163-0025,FDA-2016-P-1163,"Exhibit 22 Dec. 5, 2013 Exclusivity Summary re Citizen Petition from Foley Hoag LLP (Vifor Fresenius Medical Care Renal Pharma France)"
0900006481f72569,Supporting & Related Material,FDA-2016-P-1163-0037,FDA-2016-P-1163,Exhibit 34 European Medicines Agency. Reflection paper on non-clinical studies for generic nanoparticle iron medicinal product applications. 2011 re Citizen Petition from Foley Hoag LLP (Vifor Fresenius Medical Care Renal Pharma France)
0900006483bfd8a2,Supporting & Related Material,FDA-2019-P-2038-0005,FDA-2019-P-2038,Exhibits 21-31 re: Citizen Petition from American Dental Association
0900006483bfd9b6,Other,FDA-2019-P-2038-0001,FDA-2019-P-2038,Citizen Petition from American Dental Association
0900006483cd8ded,Other,FDA-2019-P-2038-0063,FDA-2019-P-2038,Petition Denial Letter from FDA CDRH to American Dental Association
0900006483c1320a,Supporting & Related Material,FDA-2019-P-2038-0006,FDA-2019-P-2038,Exhibit 2: re: Citizen Petition from American Dental Association
0900006483c1320b,Supporting & Related Material,FDA-2019-P-2038-0007,FDA-2019-P-2038,Exhibit 13-14 re: Citizen Petition from American Dental Association
0900006483bfd8a1,Supporting & Related Material,FDA-2019-P-2038-0004,FDA-2019-P-2038,Exhibits 11-12 and 15-20 re: Citizen Petition from American Dental Association
0900006483bfe1ad,Other,FDA-2019-P-2038-0002,FDA-2019-P-2038,Acknowledgment Letter from FDA DDM to American Dental Association
0900006483bfd8a0,Supporting & Related Material,FDA-2019-P-2038-0003,FDA-2019-P-2038,Exhibits 1 and 3-10 re: Citizen Petition from American Dental Association
090000648229807d,Supporting & Related Material,FDA-2016-P-2860-0003,FDA-2016-P-2860,E-mail from Maha Tahiri
090000648252f12a,Other,FDA-2016-P-2860-0005,FDA-2016-P-2860,"Interim Response Letter from CFSAN to General Mills, Inc."
090000648223ffe0,Other,FDA-2016-P-2860-0001,FDA-2016-P-2860,"Citizen Petition from General Mills, Inc."
0900006483410813,Other,FDA-2016-P-2860-0006,FDA-2016-P-2860,FDA-2016P-2860  and FDA-2016-2863 General Mills - Denying Part and Granting Part Response
0900006482246f1e,Other,FDA-2016-P-2860-0002,FDA-2016-P-2860,"Acknowledgment Letter from FDA DDM General Mills, Inc."
09000064822f8e01,Other,FDA-2016-P-3356-0001,FDA-2016-P-3356,Citizen Petition from Sandoz Inc
090000648230490a,Supporting & Related Material,FDA-2016-P-3356-0017,FDA-2016-P-3356,"Attachment O Covance, Inc., Analytical Methods for Bioanalysis (2015) re Citizen Petition from Sandoz Inc"
0900006482304495,Supporting & Related Material,FDA-2016-P-3356-0004,FDA-2016-P-3356,"Attachment B Robert Lionberger, Interpreting Pharmacokinetics for Inhalation Bioequivalence, Presentation at the International Pharmaceutical Aerosol Consortium on Regulatory Science / University of Florida Orlando Inhalation Conference (Mar. 19, 2014) re Citizen Petition from Sandoz Inc"
09000064822f93b5,Supporting & Related Material,FDA-2016-P-3356-0003,FDA-2016-P-3356,"Attachment A  Günther Hochhaus, et al., Generics for Oral Inhaled Drugs: Knowledge Gaps for Streamlining Bioequivalence Approval, Presentation at the FDA Generic Drug User Fee Amendments of 2012 Regulatory Science Initiatives Part 15 Public Hearing (June 21, 2013) re Citizen Petition from Sandoz Inc"
0900006482304497,Supporting & Related Material,FDA-2016-P-3356-0006,FDA-2016-P-3356,"Attachment D Donald J. Schuirmann, A Comparison of the Two One-Sided Tests Procedure and the Power Approach for Assessing the Equivalence of Average Bioavailability, 15 J. Pharmacokinetics & Biopharmaceutics 657 (1987) re Citizen Petition from Sandoz Inc"
0900006482304499,Supporting & Related Material,FDA-2016-P-3356-0008,FDA-2016-P-3356,"Attachment F FDA, Background for Advisory Committee for Pharmaceutical Science: Concept and Criteria of BioINequivalence (Oct. 20, 2004) re Citizen Petition from Sandoz Inc"
09000064822f921d,Other,FDA-2016-P-3356-0002,FDA-2016-P-3356,Acknowledgement Letter from FDA DDM to Sandoz Inc
0900006482304908,Supporting & Related Material,FDA-2016-P-3356-0015,FDA-2016-P-3356,"Attachment M GSK, Comments Submitted to Docket No. FDA-2007-D-0369 (Nov. 12, 2013) re Citizen Petition from Sandoz Inc"
0900006482304498,Supporting & Related Material,FDA-2016-P-3356-0007,FDA-2016-P-3356,"Attachment E Günther Hochhaus, et al., Meeting Report: Pharmacokinetics of Orally Inhaled Drug Products, 17 Am. Ass’n of Pharmaceutical Scientists J. 769, 773 (2015) re Citizen Petition from Sandoz Inc"
090000648250047e,Other,FDA-2016-P-3356-0018,FDA-2016-P-3356,CP Response from FDA CDER to Sandoz Inc.
090000648230449b,Supporting & Related Material,FDA-2016-P-3356-0010,FDA-2016-P-3356,"Attachment H H. Möllmann, et al., Pharmacokinetic and Pharmacodynamic Evaluation of Fluticasone Propionate After Inhaled Administration, 53 European J. Clinical Pharmacology 459 (1998) re Citizen Petition from Sandoz Inc"
0900006482304909,Supporting & Related Material,FDA-2016-P-3356-0016,FDA-2016-P-3356,"Attachment N Rashmi Mehta, et al., Comparison of the Pharmacokinetics of Salmeterol and Fluticasone Propionate 50/100 ug Delivered in Combination as a Dry Powder Via a Capsule-Based Inhaler and a Multi-Dose Inhaler, 35 Clinical Drug Investigation 319 (2015) re Citizen Petition from Sandoz Inc"
090000648230449d,Supporting & Related Material,FDA-2016-P-3356-0012,FDA-2016-P-3356,"Attachment J Lars Thorsson, et al., Pharmacokinetics and Systemic Activity of Fluticasone Via Diskus® and pMDI, and of Budesonide via Thurbuhaler®, 52 British J. Clinical Pharmacology 529 (2001) re Citizen Petition from Sandoz Inc"
0900006482304906,Supporting & Related Material,FDA-2016-P-3356-0013,FDA-2016-P-3356,"Attachment K Charles Brindley, et al., Absorption Kintetics After Inhalation of Fluticasone Propionate via the Diskahler®, Diskus®, and Metered-Dose Inhaler in Healthy Volunteers, 39 Supp. 1 Clinical Pharmacokinetics 1 (2000) re Citizen Petition from Sandoz Inc"
0900006482304907,Supporting & Related Material,FDA-2016-P-3356-0014,FDA-2016-P-3356,"Attachment L S. Kirby, et al., Salmeterol and Fluticasone Propionate Given as a Combination: Lack of Systemic Pharmacodynamic and Pharmacokinetic Interactions, 56 European J. Clinical Pharmacology 781 (2001) re Citizen Petition from Sandoz Inc"
090000648230449c,Supporting & Related Material,FDA-2016-P-3356-0011,FDA-2016-P-3356,"Attachment I R. Kunka, et al., Dose Proportionality of Fluticasone Propionate from Hydrofluoroalkane Pressurized Petered Dose Inhalers (pMDIs) and Comparability with Chlorofluorocarbon pMDIs, 94 Supp. B Respiratory Medicine S-10 (2000) re Citizen Petition from Sandoz Inc"
0900006482304496,Supporting & Related Material,FDA-2016-P-3356-0005,FDA-2016-P-3356,Attachment C Advair Diskus Prescribing Information & Medication Guide (Rev. Apr. 2016) re Citizen Petition from Sandoz Inc
090000648230449a,Supporting & Related Material,FDA-2016-P-3356-0009,FDA-2016-P-3356,"Attachment G Elise Burmeister Getz, et al., Batch-to-Batch Pharmacokinetic Variability Confounds Current Bioequivalence Regulations: A Dry Powder Inhaler Randomized Clinical Trial, Clinical Pharmacology & Therapeutics (Advance Online Publication 2016) re Citizen Petition from Sandoz Inc"
0900006482ceaec6,Other,FDA-2017-P-6758-0002,FDA-2017-P-6758,Acknowledgement Letter from FDA DDM to Public Citizen’s Health Research Group
0900006483533f90,Other,FDA-2017-P-6758-0004,FDA-2017-P-6758,Partial Approval and Partial Denial of Petition for FDA-2017-P-6758
0900006482ceaec3,Other,FDA-2017-P-6758-0001,FDA-2017-P-6758,Citizen Petition from Public Citizen's Health Research Group
0900006483337165,Other,FDA-2017-P-6758-0003,FDA-2017-P-6758,Interim Response from FDA CDER to Public Citizen
090000648373b44d,Other,FDA-2018-P-1099-0005,FDA-2018-P-1099,Withdrawal Letter from Lachman Consultants Services Inc.
09000064830066ee,Supporting & Related Material,FDA-2018-P-1099-0003,FDA-2018-P-1099,Attachment 1~ PRODUCT LISTING FROM THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS
090000648300660c,Other,FDA-2018-P-1099-0002,FDA-2018-P-1099,"Acknowledgment Letter from FDA DDM to LACHMAN CONSULTANT SERVICES, INC."
090000648374217e,Other,FDA-2018-P-1099-0006,FDA-2018-P-1099,"Correction from Lachman Consultants Services, Inc."
09000064836c36ce,Other,FDA-2018-P-1099-0004,FDA-2018-P-1099,"Letter from FDA CDER to Lachman Consultant Services, Inc."
0900006483006605,Other,FDA-2018-P-1099-0001,FDA-2018-P-1099,"Citizen Petition from Lachman Consultant Services, Inc."
09000064836b33ba,Other,FDA-2018-P-1453-0019,FDA-2018-P-1453,"Response from FDA CDER to Spear Pharmaceuticals, Inc."
09000064830fd2ec,Supporting & Related Material,FDA-2018-P-1453-0008,FDA-2018-P-1453,"Attachment6_F - Sigma 5-fluorouracil re Citizen Petition from Spear Pharmaceuticals, Inc"
09000064830fd30d,Supporting & Related Material,FDA-2018-P-1453-0018,FDA-2018-P-1453,"Attachment16_P - IMS Data re Citizen Petition from Spear Pharmaceuticals, Inc"
09000064830fd1fa,Other,FDA-2018-P-1453-0002,FDA-2018-P-1453,"Acknowledgment Letter from FDA DDM to Spear Pharmaceuticals, Inc"
09000064830fd2ea,Supporting & Related Material,FDA-2018-P-1453-0006,FDA-2018-P-1453,"Attachment4_D - Vale et al re Citizen Petition from Spear Pharmaceuticals, Inc"
09000064830fd2ee,Supporting & Related Material,FDA-2018-P-1453-0010,FDA-2018-P-1453,"Attachment8_H - Zovirax label re Citizen Petition from Spear Pharmaceuticals, Inc"
09000064830fd2e8,Supporting & Related Material,FDA-2018-P-1453-0004,FDA-2018-P-1453,"Attachment2_B - Fluorouracil Draft Guidance re Citizen Petition from Spear Pharmaceuticals, Inc"
09000064830fd2e9,Supporting & Related Material,FDA-2018-P-1453-0005,FDA-2018-P-1453,"Attachment3_C - FINAL Welgus Decl_ with exhibits re Citizen Petition from Spear Pharmaceuticals, Inc"
09000064830fd1f8,Other,FDA-2018-P-1453-0001,FDA-2018-P-1453,"Citizen Petition from Spear Pharmaceuticals, Inc"
09000064830fd2e7,Supporting & Related Material,FDA-2018-P-1453-0003,FDA-2018-P-1453,"Attachment1_A - Raney powerpoint re Citizen Petition from Spear Pharmaceuticals, Inc"
09000064830fd30a,Supporting & Related Material,FDA-2018-P-1453-0015,FDA-2018-P-1453,"Attachment13_M - Stinchcombe FDA powerpoint re Citizen Petition from Spear Pharmaceuticals, Inc"
09000064830fd2eb,Supporting & Related Material,FDA-2018-P-1453-0007,FDA-2018-P-1453,"Attachment5_E - Yanofsky et al re Citizen Petition from Spear Pharmaceuticals, Inc"
09000064830fd2ef,Supporting & Related Material,FDA-2018-P-1453-0011,FDA-2018-P-1453,"Attachment9_I - Aczone label re Citizen Petition from Spear Pharmaceuticals, Inc"
09000064830fd30b,Supporting & Related Material,FDA-2018-P-1453-0016,FDA-2018-P-1453,"Attachment14_N - SUPAC 1997 Guidance re Citizen Petition from Spear Pharmaceuticals, Inc"
09000064830fd2ed,Supporting & Related Material,FDA-2018-P-1453-0009,FDA-2018-P-1453,"Attachment7_G - MSDS Fluorouracil re Citizen Petition from Spear Pharmaceuticals, Inc"
09000064830fd309,Supporting & Related Material,FDA-2018-P-1453-0014,FDA-2018-P-1453,"Attachment12_L - Luke FDA powerpoint re Citizen Petition from Spear Pharmaceuticals, Inc"
09000064830fd2f0,Supporting & Related Material,FDA-2018-P-1453-0012,FDA-2018-P-1453,"Attachment10_J - Soolantra label re Citizen Petition from Spear Pharmaceuticals, Inc"
09000064830fd30c,Supporting & Related Material,FDA-2018-P-1453-0017,FDA-2018-P-1453,"Attachment15_O - USP 1724 SS Performance Tests re Citizen Petition from Spear Pharmaceuticals, Inc"
09000064830fd308,Supporting & Related Material,FDA-2018-P-1453-0013,FDA-2018-P-1453,"Attachment11_K - Acyclovir draft guidance re Citizen Petition from Spear Pharmaceuticals, Inc"
09000064825c7b8a,Supporting & Related Material,FDA-2017-P-3092-0006,FDA-2017-P-3092,Exhibits 16-25-1 re Citizen Petition from AstraZeneca Pharmaceuticals LP
0900006482bc15d8,Other,FDA-2017-P-3092-0010,FDA-2017-P-3092,Response Letter from FDA to AstraZeneca Global Medicines Development
09000064825c7725,Supporting & Related Material,FDA-2017-P-3092-0004,FDA-2017-P-3092,Exhibits 3-9 re Citizen Petition from AstraZeneca Pharmaceuticals LP
09000064825c7726,Supporting & Related Material,FDA-2017-P-3092-0005,FDA-2017-P-3092,Exhibits 10-15-1 re Citizen Petition from AstraZeneca Pharmaceuticals LP
09000064825c7b8b,Supporting & Related Material,FDA-2017-P-3092-0007,FDA-2017-P-3092,Exhibit 26-1 re Citizen Petition from AstraZeneca Pharmaceuticals LP
09000064825ca158,Other,FDA-2017-P-3092-0002,FDA-2017-P-3092,Acknowledgment Letter from FDA DDM to AstraZeneca Pharmaceuticals LP
09000064825c7722,Other,FDA-2017-P-3092-0001,FDA-2017-P-3092,Citizen Petition from AstraZeneca Pharmaceuticals LP
09000064825c7b8c,Supporting & Related Material,FDA-2017-P-3092-0008,FDA-2017-P-3092,Exhibits 27-29-1 re Citizen Petition from AstraZeneca Pharmaceuticals LP
09000064825c7b8d,Supporting & Related Material,FDA-2017-P-3092-0009,FDA-2017-P-3092,Exhibit 30 re Citizen Petition from AstraZeneca Pharmaceuticals LP
09000064825c7724,Supporting & Related Material,FDA-2017-P-3092-0003,FDA-2017-P-3092,Exhibits 1-2 re Citizen Petition from AstraZeneca Pharmaceuticals LP
0900006483ebf790,Other,FDA-2019-P-4002-0002,FDA-2019-P-4002,Acknowledgment Letter from FDA DMS to Otsuka Pharmaceutical Development & Commercialization Inc.
09000064842b0baf,Other,FDA-2019-P-4002-0003,FDA-2019-P-4002,"Letter from FDA CDER to  Otsuka Pharmaceutical Development & Commercialization, Inc."
0900006483ebe4b5,Other,FDA-2019-P-4002-0001,FDA-2019-P-4002,"Citizen Petition from Otsuka Pharmaceutical Development & Commercialization, Inc."
09000064820a6d7f,Supporting & Related Material,FDA-2016-P-2029-0004,FDA-2016-P-2029,"Attachment 2 The Dispensatory of The United States of America - The 20th Edition re Citizen Petition from Buchanan Ingersoll & Rooney PC (Virtus Pharmaceuticals OpCo, LLC)"
09000064820a6bf7,Supporting & Related Material,FDA-2016-P-2029-0011,FDA-2016-P-2029,"Attachment 9 Pharma Research Software Solutions re Citizen Petition from Buchanan Ingersoll & Rooney PC (Virtus Pharmaceuticals OpCo, LLC)"
09000064820a6c01,Supporting & Related Material,FDA-2016-P-2029-0016,FDA-2016-P-2029,"Attachment 16 Order Business Documents re Citizen Petition from Buchanan Ingersoll & Rooney PC (Virtus Pharmaceuticals OpCo, LLC)"
09000064820a6bfa,Supporting & Related Material,FDA-2016-P-2029-0019,FDA-2016-P-2029,"Attachment 12 re Citizen Petition from Buchanan Ingersoll & Rooney PC (Virtus Pharmaceuticals OpCo, LLC)"
09000064820a6d7c,Other,FDA-2016-P-2029-0001,FDA-2016-P-2029,"Citizen Petition from Buchanan Ingersoll & Rooney PC  (Virtus Pharmaceuticals OpCo, LLC)"
09000064820a96bf,Other,FDA-2016-P-2029-0002,FDA-2016-P-2029,"Acknowledgement Letter from FDA DDM to Buchanan Ingersoll & Rooney PC  (Virtus Pharmaceuticals OpCo, LLC)"
09000064820a6bf8,Supporting & Related Material,FDA-2016-P-2029-0012,FDA-2016-P-2029,"Attachment 10 Pharma Research Software Solutions, LLC re Citizen Petition from Buchanan Ingersoll & Rooney PC (Virtus Pharmaceuticals OpCo, LLC)"
09000064820a6d7e,Supporting & Related Material,FDA-2016-P-2029-0003,FDA-2016-P-2029,"Attachment 1 Current Concepts Hypokalemia re Citizen Petition from Buchanan Ingersoll & Rooney PC (Virtus Pharmaceuticals OpCo, LLC)"
09000064820a6bf5,Supporting & Related Material,FDA-2016-P-2029-0009,FDA-2016-P-2029,"Attachment 7 Pharma Research Software Solutions re Citizen Petition from Buchanan Ingersoll & Rooney PC (Virtus Pharmaceuticals OpCo, LLC)"
09000064820a6d80,Supporting & Related Material,FDA-2016-P-2029-0005,FDA-2016-P-2029,"Attachment 3 The Dispensatory of The United States of America - the 23rd Edition re Citizen Petition from Buchanan Ingersoll & Rooney PC (Virtus Pharmaceuticals OpCo, LLC)"
09000064820a6d81,Supporting & Related Material,FDA-2016-P-2029-0006,FDA-2016-P-2029,"Attachment 4 Physicians' Desk Reference to Pharmaceutical Specialties and Biologicals in Five Sections re Citizen Petition from Buchanan Ingersoll & Rooney PC (Virtus Pharmaceuticals OpCo, LLC)"
09000064823887c8,Other,FDA-2016-P-2029-0027,FDA-2016-P-2029,Petition Denial Letter
09000064820a6c04,Supporting & Related Material,FDA-2016-P-2029-0022,FDA-2016-P-2029,"Attachment 19 re Citizen Petition from Buchanan Ingersoll & Rooney PC (Virtus Pharmaceuticals OpCo, LLC)"
09000064820a6c00,Supporting & Related Material,FDA-2016-P-2029-0015,FDA-2016-P-2029,"Attachment 15 Identify and Dev Innovative Oral Delivery Technolo re  Citizen Petition from Buchanan Ingersoll & Rooney PC (Virtus Pharmaceuticals OpCo, LLC)"
09000064820a6c02,Supporting & Related Material,FDA-2016-P-2029-0017,FDA-2016-P-2029,"Attachment 17 Formulation Development re  Citizen Petition from Buchanan Ingersoll & Rooney PC (Virtus Pharmaceuticals OpCo, LLC)"
09000064820a6c03,Supporting & Related Material,FDA-2016-P-2029-0021,FDA-2016-P-2029,"Attachment 18 re Citizen Petition from Buchanan Ingersoll & Rooney PC (Virtus Pharmaceuticals OpCo, LLC)"
09000064820a6c05,Supporting & Related Material,FDA-2016-P-2029-0018,FDA-2016-P-2029,"Attachment 20 United States Securities and Exchange Commission Form 10-Q re Citizen Petition from Buchanan Ingersoll & Rooney PC (Virtus Pharmaceuticals OpCo, LLC)"
09000064820a6bfc,Supporting & Related Material,FDA-2016-P-2029-0014,FDA-2016-P-2029,"Attachment 14 United States District Court for the District of New Jersey Complaint and Demand for Jury Trial re Citizen Petition from Buchanan Ingersoll & Rooney PC (Virtus Pharmaceuticals OpCo, LLC)"
09000064820a6bfb,Supporting & Related Material,FDA-2016-P-2029-0020,FDA-2016-P-2029,"Attachment 13 re Citizen Petition from Buchanan Ingersoll & Rooney PC (Virtus Pharmaceuticals OpCo, LLC)"
09000064820a6bf3,Supporting & Related Material,FDA-2016-P-2029-0007,FDA-2016-P-2029,"Attachment 5 Physicians' Desk Reference to Pharmaceutical Specialties and Biologicals - 10th Edition re Citizen Petition from Buchanan Ingersoll & Rooney PC (Virtus Pharmaceuticals OpCo, LLC)"
09000064820a6bf4,Supporting & Related Material,FDA-2016-P-2029-0008,FDA-2016-P-2029,"Attachment 6 Order Business Documents re Citizen Petition from Buchanan Ingersoll & Rooney PC (Virtus Pharmaceuticals OpCo, LLC)"
09000064820a6bf6,Supporting & Related Material,FDA-2016-P-2029-0010,FDA-2016-P-2029,"Attachment 8 Pharma Research Software Solutions re Citizen Petition from Buchanan Ingersoll & Rooney PC (Virtus Pharmaceuticals OpCo, LLC)"
09000064820a6bf9,Supporting & Related Material,FDA-2016-P-2029-0013,FDA-2016-P-2029,"Attachment 11 Izbinsky Dmitriy re Citizen Petition from Buchanan Ingersoll & Rooney PC (Virtus Pharmaceuticals OpCo, LLC)"
0900006482582596,Supporting & Related Material,FDA-2017-P-2674-0003,FDA-2017-P-2674,"ATTACHMENT 1 - Orange Book Approved Drug Products with Therapeutic Equivalence Evaluations re Request that the FDA declare that Empagliflozin and Linagliptin Capsules 10 mg; 5 mg , 25 mg: 5 mg are suitable for submission as an Abbreviated New Drug Application (ANDA)"
09000064825829fe,Supporting & Related Material,FDA-2017-P-2674-0005,FDA-2017-P-2674,"ATTACHMENT 3 - GLYXAMBI (empagliflozin and linagliptin) tablets re Request that the FDA declare that Empagliflozin and Linagliptin Capsules 10 mg; 5 mg , 25 mg: 5 mg are suitable for submission as an Abbreviated New Drug Application (ANDA)"
0900006482582a51,Supporting & Related Material,FDA-2017-P-2674-0006,FDA-2017-P-2674,"ATTACHMENT 4 - NDA APPROVAL re Request that the FDA declare that Empagliflozin and Linagliptin Capsules 10 mg; 5 mg , 25 mg: 5 mg are suitable for submission as an Abbreviated New Drug Application (ANDA)"
09000064825820a3,Other,FDA-2017-P-2674-0002,FDA-2017-P-2674,Acknowledgment Letter from FDA DDM to Foley & Lardner LLP
0900006482582646,Supporting & Related Material,FDA-2017-P-2674-0004,FDA-2017-P-2674,"ATTACHMENT 2 - Empagliflozin and Linagliptin Capsules re Request that the FDA declare that Empagliflozin and Linagliptin Capsules 10 mg; 5 mg , 25 mg: 5 mg are suitable for submission as an Abbreviated New Drug Application (ANDA)"
090000648258234e,Other,FDA-2017-P-2674-0001,FDA-2017-P-2674,Citizen Petition from Foley & Lardner LLP
0900006484d4570e,Other,FDA-2017-P-2674-0007,FDA-2017-P-2674,Citizen Petition Withdrawal from Foley and Lardner LLP
09000064849ea08d,Supporting & Related Material,FDA-2021-P-0035-0008,FDA-2021-P-0035,Reference 3 re: Citizen Petition from Adrienne Samuels
09000064849ea0aa,Supporting & Related Material,FDA-2021-P-0035-0014,FDA-2021-P-0035,Reference 9 re: Citizen Petition from Adrienne Samuels
09000064849ea090,Supporting & Related Material,FDA-2021-P-0035-0011,FDA-2021-P-0035,Reference 6 re: Citizen Petition from Adrienne Samuels
09000064849ea0ae,Supporting & Related Material,FDA-2021-P-0035-0018,FDA-2021-P-0035,Reference 13 re: Citizen Petition from Adrienne Samuels
09000064849ea0ac,Supporting & Related Material,FDA-2021-P-0035-0016,FDA-2021-P-0035,Reference 11 re: Citizen Petition from Adrienne Samuels
09000064849ea0a9,Supporting & Related Material,FDA-2021-P-0035-0013,FDA-2021-P-0035,Reference 8 re: Citizen Petition from Adrienne Samuels
09000064849ea0af,Supporting & Related Material,FDA-2021-P-0035-0019,FDA-2021-P-0035,Reference 14 re: Citizen Petition from Adrienne Samuels
09000064849e9e4b,Other,FDA-2021-P-0035-0001,FDA-2021-P-0035,Citizen Petition from Adrienne Samuels
09000064849ea0ab,Supporting & Related Material,FDA-2021-P-0035-0015,FDA-2021-P-0035,Reference 10 re: Citizen Petition from Adrienne Samuels
09000064849ea08f,Supporting & Related Material,FDA-2021-P-0035-0010,FDA-2021-P-0035,Reference 5 re: Citizen Petition from Adrienne Samuels
0900006484bd235b,Other,FDA-2021-P-0035-0097,FDA-2021-P-0035,180 Day Response Letter from FDA CFSAN to Adrienne Samuels
09000064849ea0b0,Supporting & Related Material,FDA-2021-P-0035-0020,FDA-2021-P-0035,Reference 15  re: Citizen Petition from Adrienne Samuels
09000064849ea08e,Supporting & Related Material,FDA-2021-P-0035-0009,FDA-2021-P-0035,Reference 4 re: Citizen Petition from Adrienne Samuels
09000064849ea088,Other,FDA-2021-P-0035-0002,FDA-2021-P-0035,Acknowledgment Letter from FDA DMS to Adrienne Samuels
09000064849ea08c,Supporting & Related Material,FDA-2021-P-0035-0007,FDA-2021-P-0035,Reference 2 re: Citizen Petition from Adrienne Samuels
09000064849ea0ad,Supporting & Related Material,FDA-2021-P-0035-0017,FDA-2021-P-0035,Reference 12 re: Citizen Petition from Adrienne Samuels
09000064849ea08b,Supporting & Related Material,FDA-2021-P-0035-0006,FDA-2021-P-0035,Reference 1 re: Citizen Petition from Adrienne Samuels
09000064849ea091,Supporting & Related Material,FDA-2021-P-0035-0012,FDA-2021-P-0035,Reference 7 re: Citizen Petition from Adrienne Samuels
0900006484e1b66b,Other,FDA-2021-P-1193-0001,FDA-2021-P-1193,"Citizen Petition from Valisure, LLC"
0900006484e1a32d,Supporting & Related Material,FDA-2021-P-1193-0003,FDA-2021-P-1193,"Attachment A - ACC Resolution - Chemical Variability in Pharmaceutical Products RE Citizen Petition from Valisure, LLC"
0900006484e1b66d,Other,FDA-2021-P-1193-0002,FDA-2021-P-1193,"Acknowledgment Letter from FDA DMS to Valisure, LLC"
090000648119e750,Other,FDA-2012-P-1265-0001,FDA-2012-P-1265,Indicus Pharma LLC - Citzen Petition
090000648119e753,Other,FDA-2012-P-1265-0002,FDA-2012-P-1265,Acknowledgement Letter to Indicus Pharma LLC
090000648132ec6d,Other,FDA-2012-P-1265-0003,FDA-2012-P-1265,Interim Response to Indicus Pharma LLC
09000064839fbdd8,Other,FDA-2012-P-1265-0004,FDA-2012-P-1265,Response Letter from FDA CDER
0900006482f90110,Other,FDA-2018-P-0967-0002,FDA-2018-P-0967,"Acknowledgment Letter from FDA DDM to Fresenius Kabi USA, LLC"
090000648365befa,Other,FDA-2018-P-0967-0005,FDA-2018-P-0967,"Agency Response Letter from FDA CDER to Fresenius Kabi USA, LLC"
0900006482f901c3,Supporting & Related Material,FDA-2018-P-0967-0003,FDA-2018-P-0967,"Attachment A-Current Orange Book Listing of Plasma-Lyte M and Dextrose 5% re: Citizen Petition from Fresenius Kabi USA, LLC"
090000648364f66c,Notice,FDA-2018-P-0967-0004,FDA-2018-P-0967,"Determination That PLASMA–LYTE M AND DEXTROSE 5% and PLASMA
LYTE 148 AND DEXTROSE 5% Were Not Withdrawn From Sale for Reasons
of Safety or Effectiveness"
0900006482f8fd47,Other,FDA-2018-P-0967-0001,FDA-2018-P-0967,"Citizen Petition from Fresenius Kabi USA, LLC"
0900006482190e6d,Supporting & Related Material,FDA-2016-P-2515-0007,FDA-2016-P-2515,Exhibit -5 USP Commentary USP 39–NF 34  re Citizen Petition from Eli Lilly and Company
0900006482190e70,Supporting & Related Material,FDA-2016-P-2515-0010,FDA-2016-P-2515,Exhibit -8 The FDA’s assessment of follow-on protein products: a historical perspective re Citizen Petition from Eli Lilly and Company
0900006482190e79,Supporting & Related Material,FDA-2016-P-2515-0019,FDA-2016-P-2515,"Exhibit -17 Engineering of Therapeutic Polypeptides through Chemical
Synthesis: Early lessons from Human Parathyroid Hormone and
Analogues re Citizen Petition from Eli Lilly and Company"
0900006482190e7a,Supporting & Related Material,FDA-2016-P-2515-0020,FDA-2016-P-2515,Exhibit -18 Precision and robustness of 2D-NMR for structure assessment of filgrastim biosimilars re Citizen Petition from Eli Lilly and Company
0900006482190e72,Supporting & Related Material,FDA-2016-P-2515-0012,FDA-2016-P-2515,Exhibit -10 Structure-Activity Relation of NH2-terminal Human Parathyroid Hormone Fragments re Citizen Petition from Eli Lilly and Company
0900006482190e75,Supporting & Related Material,FDA-2016-P-2515-0015,FDA-2016-P-2515,Exhibit -13 Generic substitution: The use of medicinal products containing different salts and implications for safety and efficacy re Citizen Petition from Eli Lilly and Company
0900006482190e7c,Supporting & Related Material,FDA-2016-P-2515-0022,FDA-2016-P-2515,"Exhibit -20 Effect of Transdermal Teriparatide Administration on
Bone Mineral Density in Postmenopausal Women re Citizen Petition from Eli Lilly and Company"
0900006482190e7d,Supporting & Related Material,FDA-2016-P-2515-0023,FDA-2016-P-2515,Exhibit -21 SA393 re Citizen Petition from Eli Lilly and Company
0900006482190e8f,Other,FDA-2016-P-2515-0002,FDA-2016-P-2515,Acknowledgment Letter from FDA DDM to Eli Lilly and Company
0900006482190e78,Supporting & Related Material,FDA-2016-P-2515-0018,FDA-2016-P-2515,Exhibit -16 Scientific Considerations for Generic Synthetic Salmon Calcitonin Nasal Spray Products re Citizen Petition from Eli Lilly and Company
0900006482190e7b,Supporting & Related Material,FDA-2016-P-2515-0021,FDA-2016-P-2515,Exhibit -19 Contributions of parathyroid hormone (PTH)/PTH-related peptide receptor signaling pathways to the anabolic effect of PTH on bone re Citizen Petition from Eli Lilly and Company
0900006482190a57,Supporting & Related Material,FDA-2016-P-2515-0004,FDA-2016-P-2515,Exhibit -2 Oxidation of Therapeutic Proteins and Peptides: Structural and Biological Consequences re Citizen Petition from Eli Lilly and Company
0900006482190e6b,Supporting & Related Material,FDA-2016-P-2515-0005,FDA-2016-P-2515,"Exhibit -3 Investigation of the Solution Structure of the Human Parathyroid Hormone Fragment (1-34) by 1H NMR Spectroscopy, Distance Geometry, and Molecular Dynamics Calculations re Citizen Petition from Eli Lilly and Company"
0900006482190e6c,Supporting & Related Material,FDA-2016-P-2515-0006,FDA-2016-P-2515,Exhibit -4 Structure of Human Parathyroid Hormone 1-37 in Solution  re Citizen Petition from Eli Lilly and Company
0900006482190e6e,Supporting & Related Material,FDA-2016-P-2515-0008,FDA-2016-P-2515,Exhibit -6 Terconazole I Official Monographs re Citizen Petition from Eli Lilly and Company
0900006482190e6f,Supporting & Related Material,FDA-2016-P-2515-0009,FDA-2016-P-2515,"Exhibit -7 Notice of ANDA No. 208569 Concerning Teriparatide Injection 600 p.g/2.4 ml (250 p.g/ml), With Paragraph IV Certification Concerning U.S. Patent Nos. 6,770,623; 6,977,077; 7,144,861; 7,163,684; 7,351,414; 7,517,334; And 7,550,434 re Citizen Petition from Eli Lilly and Company"
0900006482190e71,Supporting & Related Material,FDA-2016-P-2515-0011,FDA-2016-P-2515,Exhibit -9 Solution Structure and Adenylyl Cyclase Stimulating Activities of C-Terminal Truncated Human Parathyroid Hormone Analogues re Citizen Petition from Eli Lilly and Company
0900006482190e77,Supporting & Related Material,FDA-2016-P-2515-0017,FDA-2016-P-2515,"Exhibit -15 Measuring Parathyroid Hormone (PTH) in Patients with
Oxidative Stress - Do We Need a Fourth Generation Parathyroid Hormone Assay? re Citizen Petition from Eli Lilly and Company"
0900006482190e8a,Supporting & Related Material,FDA-2016-P-2515-0025,FDA-2016-P-2515,Exhibit -23 Combination therapy for osteoporosis: a reappraisal re Citizen Petition from Eli Lilly and Company
0900006482190e8c,Supporting & Related Material,FDA-2016-P-2515-0026,FDA-2016-P-2515,"Exhibit -24 Randomlsed controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture Incidence among
postmenopausal women on oestrogen with osteoporosis re Citizen Petition from Eli Lilly and Company"
0900006482190a54,Other,FDA-2016-P-2515-0001,FDA-2016-P-2515,Citizen Petition from Eli Lilly and Company
0900006482190e73,Supporting & Related Material,FDA-2016-P-2515-0013,FDA-2016-P-2515,Exhibit -11 Addressing the Tertiary Structure of Human Parathyroid Hormone-(1–34)* re Citizen Petition from Eli Lilly and Company
0900006482190e76,Supporting & Related Material,FDA-2016-P-2515-0016,FDA-2016-P-2515,"Exhibit -14 Effects of Oxidation of Human Parathyroid Hormone on Its
Biological Activity in Continuously Infused, Thyroparathyroidectomized Rats re Citizen Petition from Eli Lilly and Company"
0900006482190a56,Supporting & Related Material,FDA-2016-P-2515-0003,FDA-2016-P-2515,Exhibit -1 § 600.3 Definitions re Citizen Petition from Eli Lilly and Company
0900006482190e74,Supporting & Related Material,FDA-2016-P-2515-0014,FDA-2016-P-2515,Exhibit -12 Pharmaceutical salts: a formulation trick or a clinical conundrum  re Citizen Petition from Eli Lilly and Company
0900006481f9a0a6,Other,FDA-2015-P-4224-0005,FDA-2015-P-4224,Interim Response Letter
0900006481d39860,Other,FDA-2015-P-4224-0004,FDA-2015-P-4224,Acknowledgement Letter from FDA DDM to Flamingo Pharmaceuticals Ltd
09000064820ac90a,Notice,FDA-2015-P-4224-0006,FDA-2015-P-4224,"Determination That PARAFON FORTE DSC (Chlorzoxazone) Tablets, 500
Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or
Effectiveness"
09000064820b35a3,Other,FDA-2015-P-4224-0007,FDA-2015-P-4224,Petition Approval Letter
0900006481d42a1d,Supporting & Related Material,FDA-2015-P-4224-0003,FDA-2015-P-4224,Attachment 2 Electronic Orange Book Identifying Active Approved Chlorzoxazone Tablets 500 mg Products re Citizen Petition from Flamingo Pharmaceuticals Ltd
0900006481d39467,Other,FDA-2015-P-4224-0001,FDA-2015-P-4224,Citizen Petition from Flamingo Pharmaceuticals Ltd
0900006481d42a1c,Supporting & Related Material,FDA-2015-P-4224-0002,FDA-2015-P-4224,Attachment 1 FDA Drug Shortages Current and Resolved Drug Shortages and Discontinuations Reported to FDA re Citizen Petition from Flamingo Pharmaceuticals Ltd
09000064840fa89d,Supporting & Related Material,FDA-2019-P-4979-0005,FDA-2019-P-4979,"Attachment-3 Draft labeling for proposed Magnesium Sulfate in Dextrose 5% Injection USP, 1 gm/50 mL re Citizen Application from Andersen Pharma LLC"
09000064840fa89b,Supporting & Related Material,FDA-2019-P-4979-0003,FDA-2019-P-4979,Attachment-1 Approved Drug Products with Therapeutic Equivalence Evaluations (Electronic Orange Book) for RLD re Citizen Application from Andersen Pharma LLC
09000064840fa89c,Supporting & Related Material,FDA-2019-P-4979-0004,FDA-2019-P-4979,Attachment-2 Reference Listed Drug Prescribing Information re Citizen Application from Andersen Pharma LLC
09000064840fa7f2,Other,FDA-2019-P-4979-0001,FDA-2019-P-4979,Citizen Petition from Andersen Pharma LLC
09000064840faae2,Other,FDA-2019-P-4979-0002,FDA-2019-P-4979,Acknowledgment Letter from FDA DMS to Andersen Pharma LLC
09000064849373fb,Other,FDA-2020-P-2134-0001,FDA-2020-P-2134,Citizen Petition from Natural Products Association
0900006484ab33c6,Other,FDA-2020-P-2134-0003,FDA-2020-P-2134,Interim Response Letter from FDA CFSAN to Natural Products Association
09000064849373fc,Other,FDA-2020-P-2134-0002,FDA-2020-P-2134,Acknowledgment Letter from FDA DMS to Natural Products Association
0900006484b2654d,Other,FDA-2020-P-2289-0004,FDA-2020-P-2289,"Interim response to Loeb & Loeb, LLP from FDA CDRH"
09000064849987ab,Other,FDA-2020-P-2289-0001,FDA-2020-P-2289,"Citizen Petition from Loeb & Loeb, LLP"
09000064849987ac,Other,FDA-2020-P-2289-0002,FDA-2020-P-2289,"Acknowledgment Letter from FDA DMS to Loeb & Loeb, LLP"
090000648253b389,Supporting & Related Material,FDA-2017-P-2092-0016,FDA-2017-P-2092,"APPENDIX N - Effect  of the artificial sweetener, sucralose , on gastric
emptying and incretin hormone release in health y subjects re Citizen Petition from Wilson Sonsini Goodrich & Rosati"
090000648253b383,Supporting & Related Material,FDA-2017-P-2092-0010,FDA-2017-P-2092,APPENDIX H - Absorption of Drugs re Citizen Petition from Wilson Sonsini Goodrich & Rosati
090000648253b384,Supporting & Related Material,FDA-2017-P-2092-0011,FDA-2017-P-2092,APPENDIX I - Splenda Alters Gut Microflora and Increases Intestinal P-Glycoprotein and Cytochrome P-450 in Male Rats re Citizen Petition from Wilson Sonsini Goodrich & Rosati
090000648253b388,Supporting & Related Material,FDA-2017-P-2092-0015,FDA-2017-P-2092,APPENDIX M - Sucralose revisited: Rebuttal of two papers about Splenda safety re Citizen Petition from Wilson Sonsini Goodrich & Rosati
090000648253b381,Supporting & Related Material,FDA-2017-P-2092-0008,FDA-2017-P-2092,APPENDIX F - Molecular and Physicochemical Properties Impacting Oral Absorption of Drugs re Citizen Petition from Wilson Sonsini Goodrich & Rosati
090000648253b386,Supporting & Related Material,FDA-2017-P-2092-0013,FDA-2017-P-2092,APPENDIX K - Clinical Pharmacology and Biopharmaceutics Review (s) re Citizen Petition from Wilson Sonsini Goodrich & Rosati
090000648253aef6,Supporting & Related Material,FDA-2017-P-2092-0003,FDA-2017-P-2092,"APPENDIX A - Characterization of the Expression and Activity of Carboxylesterases 1 and 2 from the Beagle Dog, Cynomolgus Monkey, and Human re Citizen Petition from Wilson Sonsini Goodrich & Rosati"
090000648253b387,Supporting & Related Material,FDA-2017-P-2092-0014,FDA-2017-P-2092,APPENDIX L -  Regulatory Toxicology and Pharmacology re Citizen Petition from Wilson Sonsini Goodrich & Rosati
09000064840ff737,Other,FDA-2017-P-2092-0019,FDA-2017-P-2092,Response Letter from FDA CDER to Wilson Sonsini Goodrich & Rosati
090000648253a540,Other,FDA-2017-P-2092-0001,FDA-2017-P-2092,"Citizen Petition from Wilson Sonsini Goodrich & Rosati (Silvergate Pharmaceuticals, Inc.)"
090000648253aef4,Other,FDA-2017-P-2092-0002,FDA-2017-P-2092,Acknowledgment Letter from FDA DDM to Wilson Sonsini Goodrich & Rosati
090000648253aef9,Supporting & Related Material,FDA-2017-P-2092-0006,FDA-2017-P-2092,APPENDIX D - Surge in Expression of Carboxylesterase 1 During the Post-neonatal Stage Enables a Rapid Gain of the Capacity to Activate the Anti-influenza Prodrug Oseltamivir re Citizen Petition from Wilson Sonsini Goodrich & Rosati
090000648253aefa,Supporting & Related Material,FDA-2017-P-2092-0007,FDA-2017-P-2092,APPENDIX E - Modelling and Simulation in Bioequivalence re Citizen Petition from Wilson Sonsini Goodrich & Rosati
090000648253aef7,Supporting & Related Material,FDA-2017-P-2092-0004,FDA-2017-P-2092,APPENDIX B - The Role of Intestinal Carboxylesterase in the Oral Absorption of Prodrugs re Citizen Petition from Wilson Sonsini Goodrich & Rosati
090000648253aef8,Supporting & Related Material,FDA-2017-P-2092-0005,FDA-2017-P-2092,"APPENDIX C - Absorption and cleavage of enalapril, a carboxyl ester prodrug, in the rat intestine: in vitro, in situ intestinal perfusion and
portal vein cannulation models re Citizen Petition from Wilson Sonsini Goodrich & Rosati"
090000648253b382,Supporting & Related Material,FDA-2017-P-2092-0009,FDA-2017-P-2092,APPENDIX G -  open circles=enalaprilat re Citizen Petition from Wilson Sonsini Goodrich & Rosati
090000648253b385,Supporting & Related Material,FDA-2017-P-2092-0012,FDA-2017-P-2092,APPENDIX J - Enalapril re Citizen Petition from Wilson Sonsini Goodrich & Rosati
0900006482b6318c,Other,FDA-2017-P-2092-0018,FDA-2017-P-2092,Interim Response Letter from CDER to Wilson Sonsini Goodrich & Rosati
09000064824a56aa,Other,FDA-2017-P-0662-0001,FDA-2017-P-0662,"Citizen Petition from Impax Laboratories, Inc."
09000064827c3352,Other,FDA-2017-P-0662-0004,FDA-2017-P-0662,"Letter from FDA CDER to Impax Laboratories, Inc."
09000064824a7e37,Other,FDA-2017-P-0662-0003,FDA-2017-P-0662,"Supplement from Impax Laboratories, Inc."
09000064824a579c,Other,FDA-2017-P-0662-0002,FDA-2017-P-0662,"Acknowledgment Letter from FDA DDM to Impax Laboratories, Inc."
090000648448eb5e,Other,FDA-2020-P-1260-0002,FDA-2020-P-1260,Acknowledgment Letter from FDA DMS to Foley & Lardner LLP
090000648448eb61,Supporting & Related Material,FDA-2020-P-1260-0003,FDA-2020-P-1260,Annex I - Orange Book Approved Drug Products re Citizen Petition from Foley & Lardner LLP
090000648448eb62,Supporting & Related Material,FDA-2020-P-1260-0004,FDA-2020-P-1260,Annex II - ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST re Citizen Petition from Foley & Lardner LLP
09000064848d15ed,Other,FDA-2020-P-1260-0006,FDA-2020-P-1260,Interim response letter from FDA CDER to Foley & Lardner LLP
09000064849747f3,Other,FDA-2020-P-1260-0007,FDA-2020-P-1260,Withdrawal from Foley & Lardner LLP
090000648448ef2a,Supporting & Related Material,FDA-2020-P-1260-0005,FDA-2020-P-1260,Annex III - ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST re Citizen Petition from Foley & Lardner LLP
090000648448eb5d,Other,FDA-2020-P-1260-0001,FDA-2020-P-1260,Citizen Petition from Foley & Lardner LLP
090000648494dcee,Other,FDA-2020-P-2175-0002,FDA-2020-P-2175,"Acknowledgment Letter from FDA DMS to Lachman Consulting Services, Inc"
090000648494dced,Other,FDA-2020-P-2175-0001,FDA-2020-P-2175,"Citizen Petition from Lachman Consulting Services, Inc"
0900006484957fb2,Other,FDA-2020-P-1016-0010,FDA-2020-P-1016,"Withdrawal from Celltrion, Inc."
09000064843dcae7,Supporting & Related Material,FDA-2020-P-1016-0002,FDA-2020-P-1016,"Appendix 1 Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (Ropinrole Hydrochloride) re Citizen Petition from CellTrion, Inc."
09000064843dab2c,Other,FDA-2020-P-1016-0001,FDA-2020-P-1016,"Citizen Petition from CellTrion, Inc."
09000064843dc73c,Other,FDA-2020-P-1016-0008,FDA-2020-P-1016,"Acknowledgment Letter from FDA DMS to CellTrion, Inc."
09000064843dc739,Supporting & Related Material,FDA-2020-P-1016-0005,FDA-2020-P-1016,"Appendix 4 Highlights of Prescribing Information (REQUIP XL) re Citizen Petition from CellTrion, Inc."
09000064843dc73a,Supporting & Related Material,FDA-2020-P-1016-0006,FDA-2020-P-1016,"Appendix 5 Principal Display Panel NDC 0007-4887-13 REQUIP XL® re Citizen Petition from CellTrion, Inc."
09000064843dcae9,Supporting & Related Material,FDA-2020-P-1016-0004,FDA-2020-P-1016,"Appendix 3 Email Communication between Globyz and CellTrion re Citizen Petition from CellTrion, Inc."
09000064848219a6,Other,FDA-2020-P-1016-0009,FDA-2020-P-1016,"Interim response from FDA CDER to CellTrion, Inc."
09000064843dcae8,Supporting & Related Material,FDA-2020-P-1016-0003,FDA-2020-P-1016,"Appendix 2 Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (NDA 022008) re Citizen Petition from CellTrion, Inc."
09000064843dc73b,Supporting & Related Material,FDA-2020-P-1016-0007,FDA-2020-P-1016,"Appendix 6 National Drug Code Directory re Citizen Petition from CellTrion, Inc."
0900006483626d99,Other,FDA-2018-P-3176-0001,FDA-2018-P-3176,Citizen Petition from Medefil Inc
0900006483627dd0,Supporting & Related Material,FDA-2018-P-3176-0003,FDA-2018-P-3176,Attachment 1- Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations re: Citizen Petition from Medefil Inc
0900006483627914,Other,FDA-2018-P-3176-0002,FDA-2018-P-3176,Acknowledgment Letter from FDA DDM to Medefil Inc
0900006483a535c0,Other,FDA-2018-P-3176-0004,FDA-2018-P-3176,Agency Interim Response Letter from FDA CDRH to Medefil Inc
0900006482567428,Supporting & Related Material,FDA-2017-P-2528-0009,FDA-2017-P-2528,Exhibit F - Neutropenia in cancer patients - Mayor re Citizen Petition from Apotex Inc
09000064825676b9,Supporting & Related Material,FDA-2017-P-2528-0013,FDA-2017-P-2528,Exhibit J - First and Subsequent Cycle Use of Pegfilgrastim - Vogel re Citizen Petition from Apotex Inc
0900006482567426,Supporting & Related Material,FDA-2017-P-2528-0007,FDA-2017-P-2528,Exhibit D - Predicting Individual Risk of Neutropenic Complications - Lyman II re Citizen Petition from Apotex Inc
0900006482567429,Supporting & Related Material,FDA-2017-P-2528-0010,FDA-2017-P-2528,Exhibit G - Optimizing Adjuvant Chemotherapy in Early-Stage Breast Cancer - Perez re Citizen Petition from Apotex Inc
090000648256742a,Supporting & Related Material,FDA-2017-P-2528-0011,FDA-2017-P-2528,Exhibit H - Pharmacokinetic Pharmacodynamic Modeling - Roskos re Citizen Petition from Apotex Inc
09000064825676b8,Supporting & Related Material,FDA-2017-P-2528-0012,FDA-2017-P-2528,Exhibit I - Granulocyte-colony stimulating factor administration - Tigue re Citizen Petition from Apotex Inc
09000064825676ba,Supporting & Related Material,FDA-2017-P-2528-0014,FDA-2017-P-2528,Exhibit K - Pharmacokinetics and Pharmacodynamics of Pegfilgrastim - Yang re Citizen Petition from Apotex Inc
0900006482567427,Supporting & Related Material,FDA-2017-P-2528-0008,FDA-2017-P-2528,Exhibit E - Risk Models for Predicting Chemotherapy-Induced Newtropenia - Lyman I re Citizen Petition from Apotex Inc
0900006482567638,Supporting & Related Material,FDA-2017-P-2528-0003,FDA-2017-P-2528,Declaration of Dr Scadden re Citizen Petition from Apotex Inc
0900006482567636,Other,FDA-2017-P-2528-0002,FDA-2017-P-2528,Acknowledgement Letter from FDA DDM to Apotex Inc
0900006482567634,Other,FDA-2017-P-2528-0001,FDA-2017-P-2528,Citizen Petition from Apotex Inc
0900006482567423,Supporting & Related Material,FDA-2017-P-2528-0004,FDA-2017-P-2528,Exhibit A - Confirmation of Biosimilarity - Desai re Citizen Petition from Apotex Inc
0900006482567424,Supporting & Related Material,FDA-2017-P-2528-0005,FDA-2017-P-2528,Exhibit B - Chemotherapy for breast cancer - Hassan re Citizen Petition from Apotex Inc
09000064825676bb,Supporting & Related Material,FDA-2017-P-2528-0015,FDA-2017-P-2528,Exhibit L - Neutrophil dynamics in response to chemotherapy and G-CSF - Zhuge re Citizen Petition from Apotex Inc
0900006482567425,Supporting & Related Material,FDA-2017-P-2528-0006,FDA-2017-P-2528,Exhibit C - PEGylation of therapeutic proteins - Jevsevar re Citizen Petition from Apotex Inc
0900006483fbffbf,Other,FDA-2019-P-2123-0004,FDA-2019-P-2123,Agency Response Letter from FDA CDER to Lachman Consultants
0900006483fbbeab,Notice,FDA-2019-P-2123-0003,FDA-2019-P-2123,"Determination That ATROPINE SULFATE ANSYR PLASTIC SYRINGE
(Atropine Sulfate Solution) Intravenous, Intramuscular, Subcutaneous, and Endotracheal, 0.5 Milligram/5 Milliliters (0.1 Milligram/ Milliliter), Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
0900006483c2a1d0,Other,FDA-2019-P-2123-0002,FDA-2019-P-2123,Acknowledgment Letter from FDA DDM to Lachman Consultants
0900006483c294d6,Other,FDA-2019-P-2123-0001,FDA-2019-P-2123,Citizen Petition from Lachman Consultants
0900006481c1a677,Other,FDA-2015-P-0403-0005,FDA-2015-P-0403,"Interim Response Letter from FDA CDER to Lachman Consultant Services, Inc."
0900006481fff842,Notice,FDA-2015-P-0403-0007,FDA-2015-P-0403,"Determination That LEVOTHROID (Levothyroxine Sodium) Tablets, 0.025
Milligram, 0.05 Milligram, 0.075 Milligram, 0.088 Milligram, 0.112
Milligram, 0.125 Milligram, 0.137 Milligram, 0.15 Milligram, 0.175
Milligram, 0.1 Milligram, 0.2 Milligram, and 0.3 Milligram, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
0900006481ffb2e0,Other,FDA-2015-P-0403-0006,FDA-2015-P-0403,Final Petition Approval Response
09000064819f8ea5,Other,FDA-2015-P-0403-0002,FDA-2015-P-0403,Acknowledgement Letter from  FDA DDM to LACHMAN CONSULTANT SERVICES INC
09000064819f8b6c,Supporting & Related Material,FDA-2015-P-0403-0004,FDA-2015-P-0403,Attach 2
09000064819f8b6a,Supporting & Related Material,FDA-2015-P-0403-0003,FDA-2015-P-0403,Attach 1
09000064819f8510,Other,FDA-2015-P-0403-0001,FDA-2015-P-0403,Citizen Petition Request from LACHMAN CONSULTANT SERVICES INC
09000064838edeee,Supporting & Related Material,FDA-2018-P-4454-0005,FDA-2018-P-4454,Attachment 3_Bonumose_D-tagatose as fiber citizen petition_appendix 1 part 3 re Citizen Petition from Bonumose LLC
09000064838edeef,Supporting & Related Material,FDA-2018-P-4454-0006,FDA-2018-P-4454,Attachment 4_Bonumose_D-tagatose as fiber citizen petition_appendix 1 part 4 re Citizen Petition from Bonumose LLC
09000064838edeed,Supporting & Related Material,FDA-2018-P-4454-0004,FDA-2018-P-4454,Attachment 2_Bonumose_D-tagatose as fiber citizen petition_appendix 1 part 2 re Citizen Petition from Bonumose LLC
09000064838edeec,Supporting & Related Material,FDA-2018-P-4454-0003,FDA-2018-P-4454,Attachment 1_Bonumose_D-tagatose as fiber citizen petition_appendix 1 part 1 re Citizen Petition from Bonumose LLC
09000064838ede7a,Other,FDA-2018-P-4454-0001,FDA-2018-P-4454,Citizen Petition from Bonumose LLC
0900006483d3f85c,Other,FDA-2018-P-4454-0009,FDA-2018-P-4454,Letter from FDA CFSAN to Bonumose LLC
0900006484b8203e,Other,FDA-2018-P-4454-0011,FDA-2018-P-4454,Final Response Letter from FDA CFSAN to Bonumose LLC
09000064838ede7c,Other,FDA-2018-P-4454-0002,FDA-2018-P-4454,Acknowledgment Letter from FDA DDM to Bonumose LLC
0900006483cb608a,Other,FDA-2018-P-4454-0008,FDA-2018-P-4454,Letter from FDA CFSAN to Bonumose LLC
09000064838edef0,Supporting & Related Material,FDA-2018-P-4454-0007,FDA-2018-P-4454,Attachment 5_Bonumose_D-tagatose as fiber citizen petition_appendix 1 part 5 re Citizen Petition from Bonumose LLC
0900006484b64ea0,Supporting & Related Material,FDA-2020-P-2174-0006,FDA-2020-P-2174,FR Notice re Agency Response from FDA CDER to Lachman Consulting Services Inc
0900006484b5927d,Notice,FDA-2020-P-2174-0004,FDA-2020-P-2174,"Determination That ATROVENT (Ipratropium Bromide) Metered Spray, 0.021 Micrograms/Spray and 0.042
Micrograms/Spray, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
090000648494d979,Other,FDA-2020-P-2174-0001,FDA-2020-P-2174,"Citizen Petition from Lachman Consulting Services, Inc"
0900006484acb34f,Other,FDA-2020-P-2174-0003,FDA-2020-P-2174,"Interim Response from FDA CDER to Lachman Consulting Services, Inc."
090000648494d97a,Other,FDA-2020-P-2174-0002,FDA-2020-P-2174,"Acknowledgment Letter from FDA DMS to Lachman Consulting Services, Inc"
0900006484b64c7b,Other,FDA-2020-P-2174-0005,FDA-2020-P-2174,Agency Response from FDA CDER to Lachman Consulting Services Inc
0900006482991246,Other,FDA-2017-P-4586-0001,FDA-2017-P-4586,Citizen Petition from Jubilant DraxImage Inc.
0900006482992465,Other,FDA-2017-P-4586-0002,FDA-2017-P-4586,Acknowledgment Letter from FDA DDM to Jubilant DraxImage Inc.
0900006482d51faf,Other,FDA-2017-P-4586-0004,FDA-2017-P-4586,Petition Response Letter from FDA CDER to Jubilant DraxImage Inc.
0900006481df4d1b,Supporting & Related Material,FDA-2016-P-0040-0004,FDA-2016-P-0040,Attachment 3 ASHP Aminocaproic Acid Oral Presentations re Citizen Petition from Troutman Sanders LLP
0900006481de9859,Other,FDA-2016-P-0040-0002,FDA-2016-P-0040,Acknowledgement Letter from FDA DDM to Troutman Sanders LLP
0900006481de9a3d,Supporting & Related Material,FDA-2016-P-0040-0003,FDA-2016-P-0040,Attachment 1 Orange Book Approved Drug Products with Therapeutic Equivalence Evaluations re Citizen Petition from Troutman Sanders LLP
0900006481ed9aac,Other,FDA-2016-P-0040-0005,FDA-2016-P-0040,Withdrawal Letter from Troutman Sanders LLP
0900006481de97cc,Other,FDA-2016-P-0040-0001,FDA-2016-P-0040,Citizen Petition from Troutman Sanders LLP
0900006484841330,Other,FDA-2020-P-1849-0002,FDA-2020-P-1849,Acknowledgment Letter from FDA DMS to FOLEY & LARDNER LLP
0900006484841332,Supporting & Related Material,FDA-2020-P-1849-0003,FDA-2020-P-1849,ATTACHMENT 1_ Approved Drug Products with Therapeutic Equivalence Evaluations_Orange Book RE: Citizen Petition from FOLEY & LARDNER LLP
0900006484973a08,Other,FDA-2020-P-1849-0004,FDA-2020-P-1849,Withdrawal from Foley & Lardner LLP
090000648484132c,Other,FDA-2020-P-1849-0001,FDA-2020-P-1849,Citizen Petition from FOLEY & LARDNER LLP
0900006484a01e53,Other,FDA-2020-P-2028-0007,FDA-2020-P-2028,Response Letter from FDA CDER to Outsourcing Facilities Association (OFA)
09000064848a5396,Supporting & Related Material,FDA-2020-P-2028-0003,FDA-2020-P-2028,Attachment 1_Confidential_OFA CP Sources Relied Upon that are not Readily Available to the FDA re; Citizen Petition from Outsourcing Facilities Association
09000064848a5394,Other,FDA-2020-P-2028-0002,FDA-2020-P-2028,Acknowledgment Letter from FDA DMS to Outsourcing Facilities Association
09000064848a4e34,Other,FDA-2020-P-2028-0001,FDA-2020-P-2028,Citizen Petition from Outsourcing Facilities Association
0900006484dc4727,Supporting & Related Material,FDA-2021-P-1109-0008,FDA-2021-P-1109,Exhibit F RE Citizen Petition from PCCCA
0900006484dc472b,Supporting & Related Material,FDA-2021-P-1109-0011,FDA-2021-P-1109,Exhibit I RE Citizen Petition from PCCCA
0900006484dc46f6,Other,FDA-2021-P-1109-0002,FDA-2021-P-1109,Acknowledgment Letter from FDA DMS to PCCA
0900006484dc4dbb,Supporting & Related Material,FDA-2021-P-1109-0014,FDA-2021-P-1109,Exhibit L RE Citizen Petition from PCCCA
0900006484dc471b,Supporting & Related Material,FDA-2021-P-1109-0012,FDA-2021-P-1109,Exhibit J RE Citizen Petition from PCCCA
0900006484dc4728,Supporting & Related Material,FDA-2021-P-1109-0009,FDA-2021-P-1109,Exhibit G RE Citizen Petition from PCCCA
0900006484dc4719,Supporting & Related Material,FDA-2021-P-1109-0007,FDA-2021-P-1109,Exhibit E RE Citizen Petition from PCCCA
0900006484dc472c,Supporting & Related Material,FDA-2021-P-1109-0013,FDA-2021-P-1109,Exhibit K RE Citizen Petition from PCCCA
0900006484dc471a,Supporting & Related Material,FDA-2021-P-1109-0010,FDA-2021-P-1109,Exhibit H RE Citizen Petition from PCCCA
0900006484dc4715,Supporting & Related Material,FDA-2021-P-1109-0003,FDA-2021-P-1109,Exhibit A RE Citizen Petition from PCCCA
0900006484dc4716,Supporting & Related Material,FDA-2021-P-1109-0004,FDA-2021-P-1109,Exhibit B RE Citizen Petition from PCCCA
0900006484dc4717,Supporting & Related Material,FDA-2021-P-1109-0005,FDA-2021-P-1109,Exhibit C RE Citizen Petition from PCCCA
0900006484dc4718,Supporting & Related Material,FDA-2021-P-1109-0006,FDA-2021-P-1109,Exhibit D RE Citizen Petition from PCCCA
0900006484dc4365,Other,FDA-2021-P-1109-0001,FDA-2021-P-1109,Citizen Petition from PCCCA
0900006484dc4dbc,Supporting & Related Material,FDA-2021-P-1109-0016,FDA-2021-P-1109,Exhibit N RE Citizen Petition from PCCCA
0900006484dc4dbd,Supporting & Related Material,FDA-2021-P-1109-0018,FDA-2021-P-1109,Exhibit P RE Citizen Petition from PCCCA
0900006484dc4dc6,Supporting & Related Material,FDA-2021-P-1109-0015,FDA-2021-P-1109,Exhibit M RE Citizen Petition from PCCCA
0900006484dc4dc7,Supporting & Related Material,FDA-2021-P-1109-0017,FDA-2021-P-1109,Exhibit O RE Citizen Petition from PCCCA
090000648352aeea,Other,FDA-2015-N-3469-0100,FDA-2015-N-3469,Nomination from Outsourcing Facilities Association
090000648352b185,Other,FDA-2015-N-3469-0101,FDA-2015-N-3469,Nomination from Outsourcing Facilities Association
090000648353cb75,Other,FDA-2015-N-3469-0121,FDA-2015-N-3469,Nomination from Outsourcing Facilities Association
090000648353c7ed,Other,FDA-2015-N-3469-0110,FDA-2015-N-3469,Nomination from Outsourcing Facilities Association
090000648353c98e,Other,FDA-2015-N-3469-0112,FDA-2015-N-3469,Nomination from Outsourcing Facilities Association
090000648353c74c,Other,FDA-2015-N-3469-0109,FDA-2015-N-3469,Nomination from Outsourcing Facilities Association
090000648353d17c,Other,FDA-2015-N-3469-0117,FDA-2015-N-3469,Nomination from Outsourcing Facilities Association
090000648347f09e,Other,FDA-2015-N-3469-0094,FDA-2015-N-3469,Nomination from Outsourcing Facilities Association
09000064833a6525,Other,FDA-2015-N-3469-0078,FDA-2015-N-3469,Nomination from Outsourcing Facilities Association (OFA)
090000648353db6f,Other,FDA-2015-N-3469-0131,FDA-2015-N-3469,Nomination from Outsourcing Facilities Association
0900006483abcec7,Other,FDA-2015-N-3469-0255,FDA-2015-N-3469,Nomination from Outsourcing Facilities Association
090000648387825b,Other,FDA-2015-N-3469-0238,FDA-2015-N-3469,Nomination from Outsourcing Facilities Association
09000064838781cf,Other,FDA-2015-N-3469-0233,FDA-2015-N-3469,Nomination from Outsourcing Facilities Association
0900006483859ba7,Other,FDA-2015-N-3469-0225,FDA-2015-N-3469,Nomination from Outsourcing Facilities Association
090000648390f6bf,Other,FDA-2015-N-3469-0245,FDA-2015-N-3469,Nomination from Outsourcing Facilities Association
0900006483859895,Other,FDA-2015-N-3469-0222,FDA-2015-N-3469,Nomination from Outsourcing Facilities Association
09000064838596d3,Other,FDA-2015-N-3469-0220,FDA-2015-N-3469,Nomination from Outsourcing Facilities Association
0900006483786e3d,Other,FDA-2015-N-3469-0202,FDA-2015-N-3469,Nomination from ASPCares
0900006482923e1c,Other,FDA-2015-N-3469-0019,FDA-2015-N-3469,"Nomination from Sincerus Florida, LLC"
0900006482923d9f,Other,FDA-2015-N-3469-0016,FDA-2015-N-3469,"Nomination from Sincerus Florida, LLC"
090000648295af69,Other,FDA-2015-N-3469-0021,FDA-2015-N-3469,Nomination from Imprimis Pharmaceuticals
0900006483b9fa5d,Other,FDA-2015-N-3469-0267,FDA-2015-N-3469,Nomination from Pentec Health
0900006483baa522,Other,FDA-2015-N-3469-0268,FDA-2015-N-3469,Nomination from Outsourcing Facilities Association
090000648353d410,Other,FDA-2015-N-3469-0126,FDA-2015-N-3469,Nomination from Outsourcing Facilities Association
090000648353f3d1,Other,FDA-2015-N-3469-0154,FDA-2015-N-3469,Nomination from Outsourcing Facilities Association
0900006482353ce0,Other,FDA-2016-P-3560-0001,FDA-2016-P-3560,Citizen Petition from Orchid Healthcare  (A Division of Orchid Pharma Ltd.)
09000064823540cc,Supporting & Related Material,FDA-2016-P-3560-0003,FDA-2016-P-3560,Attachment 1 Copies of the Relevant Pages of the Orange Book re Citizen Petition from Orchid Healthcare
0900006482353ce2,Other,FDA-2016-P-3560-0002,FDA-2016-P-3560,Acknowledgment Letter from FDA DDM to Orchid Healthcare  (A Division of Orchid Pharma Ltd.)
090000648253db21,Other,FDA-2016-P-3560-0005,FDA-2016-P-3560,Letter from FDA to Orchid Healthcare  (A Division of Orchid Pharma Ltd.)
090000648253c0de,Notice,FDA-2016-P-3560-0004,FDA-2016-P-3560,"Determinations that Products Were not Withdrawn from Sale for Reasons of Safety or Effectiveness: CEDAX (Ceftibuten Dihydrate) For Oral Suspension, 90 Milligrams/5 Milliliters and 180 Milligrams/5 Milliliters"
090000648228e6e0,Other,FDA-2016-P-2376-0003,FDA-2016-P-2376,Supplement from Latham & Watkins LLP
090000648252ea2a,Other,FDA-2016-P-2376-0005,FDA-2016-P-2376,"Interim Response Letter from CFSAN to Hyman, Phelps & McNamara, P.C."
090000648214f179,Other,FDA-2016-P-2376-0001,FDA-2016-P-2376,Citizen Petition from Latham & Watkins LLP
090000648214f5e1,Other,FDA-2016-P-2376-0002,FDA-2016-P-2376,"Acknowledgement Letter from FDA DDM to Latham & Watkins, LLP"
0900006482433cb5,Other,FDA-2016-P-2376-0004,FDA-2016-P-2376,Petition Denial Letter from FDA CDER to Latham & Watkins LLP
09000064818b8db8,Other,FDA-2014-P-1576-0001,FDA-2014-P-1576,Citizen Petition from Gordon Johnston Regulatory Consultants LLC
09000064818b8f6b,Supporting & Related Material,FDA-2014-P-1576-0004,FDA-2014-P-1576,Attachment 2
09000064818b8f66,Other,FDA-2014-P-1576-0002,FDA-2014-P-1576,Acknowledgment Letter from FDA DDM to Gordon Johnston Regulatory Consultants LLC
0900006483db04ab,Other,FDA-2014-P-1576-0006,FDA-2014-P-1576,"Letter from FDA CDER to Gordon Johnston Regulatory Consultants, LLC"
09000064818b8f6a,Supporting & Related Material,FDA-2014-P-1576-0003,FDA-2014-P-1576,Attachment 1
0900006481a84f76,Other,FDA-2014-P-1576-0005,FDA-2014-P-1576,"Interim Response from CDER to Gordon Johnston Regulatory Consultants, LLC"
0900006483c45460,Other,FDA-2019-P-2240-0001,FDA-2019-P-2240,Citizen Petition from Axinn on behalf of Zydus Pharmaceuticals (USA) Inc.
0900006483c45990,Supporting & Related Material,FDA-2019-P-2240-0002,FDA-2019-P-2240,Exhibit A IARC Monograph (Vitamin K Substances) re Citizen Petition from Axinn on behalf of Zydus Pharmaceuticals (USA) Inc.
0900006483c45992,Supporting & Related Material,FDA-2019-P-2240-0004,FDA-2019-P-2240,Exhibit C Merck Index 15th ed. (2013) re Citizen Petition from Axinn on behalf of Zydus Pharmaceuticals (USA) Inc.
0900006483c45994,Supporting & Related Material,FDA-2019-P-2240-0006,FDA-2019-P-2240,Exhibit E USP Monograph re Citizen Petition from Axinn on behalf of Zydus Pharmaceuticals (USA) Inc.
0900006483c45991,Supporting & Related Material,FDA-2019-P-2240-0003,FDA-2019-P-2240,Exhibit B Golubkina et al Methods of Synthesis and Production Technology of Drugs re Citizen Petition from Axinn on behalf of Zydus Pharmaceuticals (USA) Inc.
0900006483c45993,Supporting & Related Material,FDA-2019-P-2240-0005,FDA-2019-P-2240,Exhibit D Knaeur et al Metabolism and Biological Activity of cis- and trans-Phylloquinone in the rat article re Citizen Petition from Axinn on behalf of Zydus Pharmaceuticals (USA) Inc.
0900006483c459c3,Supporting & Related Material,FDA-2019-P-2240-0008,FDA-2019-P-2240,"Exhibit G Schmid et al 126. Synthesis of All Four Stereoisomers of (E)-Vitamin K, (Phylloquinone), Analysis of Their Diastereoisomeric and Enantiomeric Purities and Determination of Their Biopotencies1 re Citizen Petition from Axinn on behalf of Zydus Pharmaceuticals (USA) Inc."
0900006483c459c9,Other,FDA-2019-P-2240-0009,FDA-2019-P-2240,Acknowledgment Letter from FDA DDM to Axinn
09000064840195b7,Other,FDA-2019-P-2240-0010,FDA-2019-P-2240,Response Letter from FDA CDER to Axinn
0900006483c459c2,Supporting & Related Material,FDA-2019-P-2240-0007,FDA-2019-P-2240,Exhibit F Smith Review Chiral Toxicology: It’s the Same Thing. . .Only Different re Citizen Petition from Axinn on behalf of Zydus Pharmaceuticals (USA) Inc.
09000064836b3867,Other,FDA-2018-D-3130-0002,FDA-2018-D-3130,"Consideration of Uncertainty in 1 Making Benefit-Risk 2 Determinations in Medical Device 3 Premarket Approvals, De Novo 4 Classifications, and Humanitarian 5 Device Exemptions; Draft Guidance for Industry and
7Food and Drug Administration Staff"
0900006483ed972c,Other,FDA-2018-D-3130-0009,FDA-2018-D-3130,"Consideration of Uncertainty in Making Benefit-Risk Determinations in Medical Device Premarket Approvals, De Novo Classifications, and Humanitarian Device Exemptions; Guidance for Industry and Food and Drug Administration Staff"
09000064836af5f9,Notice,FDA-2018-D-3130-0001,FDA-2018-D-3130,"Consideration of Uncertainty in Making Benefit-Risk Determinations in Medical Device Premarket Approvals, De Novo Classifications, and Humanitarian Device Exemptions; Draft Guidance for Industry and Food and Drug Administration Staff; Availability"
0900006483edc73d,Notice,FDA-2018-D-3130-0008,FDA-2018-D-3130,"Consideration of Uncertainty in Making Benefit-Risk Determinations in Medical Device Premarket Approvals, De Novo Classifications, and Humanitarian Device Exemptions; Guidance for Industry and Food and Drug Administration Staff; Availability"
09000064818e0b89,Supporting & Related Material,FDA-2014-P-1657-0003,FDA-2014-P-1657,Attachment 1
09000064818e02ea,Other,FDA-2014-P-1657-0001,FDA-2014-P-1657,Citizen Petition from Gordon Johnston Regulatory Consultants LLC
090000648192c197,Other,FDA-2014-P-1657-0004,FDA-2014-P-1657,Citizens Petition Approval letter to Robert Dormer and Gordon Johnston
09000064818e0b87,Other,FDA-2014-P-1657-0002,FDA-2014-P-1657,Acknowledgement Letter from FDA DDM to Gordon Johnston Regulatory Consultants LLC
09000064816b7e8f,Notice,FDA-2014-D-0331-0001,FDA-2014-D-0331,"Live Case Presentations During Investigational Device Exemption
Clinical Trials; Draft Guidance for Institutional Review Boards, Industry,
Investigators, and Food and Drug Administration Staff; Availability"
09000064816b8001,Other,FDA-2014-D-0331-0002,FDA-2014-D-0331,"Live Case Presentations During Investigational Device Exemption
Clinical Trials; Draft Guidance for Institutional Review Boards, Industry,
Investigators, and Food and Drug Administration Staff"
0900006483d7d25a,Notice,FDA-2014-D-0331-0006,FDA-2014-D-0331,"Live Case Presentations During Investigational Device Exemption Clinical Trials; Guidance for Institutional Review Boards, Industry, Clinical Investigators, and Food and Drug Administration Staff; Availability"
0900006483d7d49d,Other,FDA-2014-D-0331-0008,FDA-2014-D-0331,"Live Case Presentations During Investigational Device Exemption (IDE) Clinical Trials; Guidance for Institutional Review Boards, Industry, Clinical Investigators, and Food and Drug Administration Staff"
0900006481119914,Other,FDA-2012-P-0984-0001,FDA-2012-P-0984,Sheppard Mullin Richter & Hampton LLP - Citizen Petition
0900006481169939,Other,FDA-2012-P-0984-0003,FDA-2012-P-0984,"Sheppard, Mullin, Richter & Hampton LLP - Withdrawal"
090000648111991c,Other,FDA-2012-P-0984-0002,FDA-2012-P-0984,Acknowledgement Letter to Sheppard Mullin Richter & Hampton LLP
090000648225c932,Other,FDA-2012-P-1259-0003,FDA-2012-P-1259,"Citizen Petition Approval Letter from FDA CDER to Hyman, Phelps, & McNamara, P.C."
090000648119d635,Other,FDA-2012-P-1259-0001,FDA-2012-P-1259,Hyman Phelps McNamara PC - Citizen Petition
090000648119d736,Other,FDA-2012-P-1259-0002,FDA-2012-P-1259,"Acknowledgement Letter to Hyman, Phelps & McNamara, PC"
090000648405b43b,Supporting & Related Material,FDA-2019-P-4644-0036,FDA-2019-P-4644,"Appendix ZZZ Redacted re Citizen Petition from Clarus Therapeutics, Inc."
090000648404be07,Supporting & Related Material,FDA-2019-P-4644-0038,FDA-2019-P-4644,"Appendix R Redacted re Citizen Petition from Clarus Therapeutics, Inc."
090000648404be09,Supporting & Related Material,FDA-2019-P-4644-0022,FDA-2019-P-4644,"Appendix S Wang et al (2008) Validation of a testosterone and dihydrotestosterone liquid chromatography tandem mass spectrometry assay: Interference and comparison with established methods re Citizen Petition from Clarus Therapeutics, Inc."
090000648404c457,Supporting & Related Material,FDA-2019-P-4644-0024,FDA-2019-P-4644,"Appendix U Ceponis et al (2008) Accurate measurement of androgen after androgen esters: problems created by ex vivo esterase effects and LC-MS/MS interference re Citizen Petition from Clarus Therapeutics, Inc."
090000648404c45b,Supporting & Related Material,FDA-2019-P-4644-0028,FDA-2019-P-4644,"Appendix W Confidential re Citizen Petition from Clarus Therapeutics, Inc."
090000648405b3ba,Supporting & Related Material,FDA-2019-P-4644-0031,FDA-2019-P-4644,"Appendix Y Redacted re Citizen Petition from Clarus Therapeutics, Inc."
09000064840266ef,Supporting & Related Material,FDA-2019-P-4644-0003,FDA-2019-P-4644,"Appendix A CDC Laboratory/Manufacturer Hormone Standardization (HoSt) Program Total Testosterone - Participant Protocol re Citizen Petition from Clarus Therapeutics, Inc."
090000648402675d,Supporting & Related Material,FDA-2019-P-4644-0011,FDA-2019-P-4644,"Appendix H FDA CDER Approval Package for Application Number 204399Orig1s000 re Citizen Petition from Clarus Therapeutics, Inc."
09000064840266f3,Supporting & Related Material,FDA-2019-P-4644-0007,FDA-2019-P-4644,"Appendix D FDA Briefing Document NDA 206089 Testosterone Undecanoate (proposed trade name Jatenzo) re Citizen Petition from Clarus Therapeutics, Inc."
090000648402675c,Supporting & Related Material,FDA-2019-P-4644-0010,FDA-2019-P-4644,"Appendix G FDA CDER Application Number 205488Orig1s000 Medical Review(s) re Citizen Petition from Clarus Therapeutics, Inc."
09000064840266f2,Supporting & Related Material,FDA-2019-P-4644-0006,FDA-2019-P-4644,"Appendix C FDA Briefing Document NDA 208088 Testosterone Undecanoate (proposed trade name Tlando) re Citizen Petition from Clarus Therapeutics, Inc."
09000064840266ee,Other,FDA-2019-P-4644-0002,FDA-2019-P-4644,"Acknowledgment Letter from FDA DMS to Clarus Therapeutics, Inc."
090000648404c45a,Supporting & Related Material,FDA-2019-P-4644-0027,FDA-2019-P-4644,"Appendix W Redacted re Citizen Petition from Clarus Therapeutics, Inc."
09000064840266f5,Supporting & Related Material,FDA-2019-P-4644-0009,FDA-2019-P-4644,"Appendix F FDA CDER Application Number 022219Orig1s000 Medical Review(s) re Citizen Petition from Clarus Therapeutics, Inc."
0900006484026761,Supporting & Related Material,FDA-2019-P-4644-0015,FDA-2019-P-4644,"Appendix L Transcripts re Citizen Petition from Clarus Therapeutics, Inc."
090000648404be04,Supporting & Related Material,FDA-2019-P-4644-0018,FDA-2019-P-4644,"Appendix O Bagus et al (2003) Important Effect of Food on the Bioavailability of Oral Testosterone Undecanoate re Citizen Petition from Clarus Therapeutics, Inc."
090000648404c45d,Supporting & Related Material,FDA-2019-P-4644-0030,FDA-2019-P-4644,"Appendix X Confidential re Citizen Petition from Clarus Therapeutics, Inc."
09000064843fdf00,Other,FDA-2019-P-4644-0039,FDA-2019-P-4644,"Citizen Petition Denial Response Letter from FDA CDER to Clams Therapeutics, Inc."
090000648404be03,Supporting & Related Material,FDA-2019-P-4644-0017,FDA-2019-P-4644,"Appendix N Transcripts re Citizen Petition from Clarus Therapeutics, Inc."
090000648404be08,Supporting & Related Material,FDA-2019-P-4644-0021,FDA-2019-P-4644,"Appendix R Confidential re Citizen Petition from Clarus Therapeutics, Inc."
090000648404c458,Supporting & Related Material,FDA-2019-P-4644-0025,FDA-2019-P-4644,"Appendix V Redacted re Citizen Petition from Clarus Therapeutics, Inc."
090000648405b439,Supporting & Related Material,FDA-2019-P-4644-0034,FDA-2019-P-4644,"Appendix ZZ Redacted re Citizen Petition from Clarus Therapeutics, Inc."
090000648405b43a,Supporting & Related Material,FDA-2019-P-4644-0035,FDA-2019-P-4644,"Appendix ZZ Confidential re Citizen Petition from Clarus Therapeutics, Inc."
090000648405b43c,Supporting & Related Material,FDA-2019-P-4644-0037,FDA-2019-P-4644,"Appendix ZZZ Confidential re Citizen Petition from Clarus Therapeutics, Inc."
09000064840266f0,Supporting & Related Material,FDA-2019-P-4644-0004,FDA-2019-P-4644,"Appendix B Confidential re Citizen Petition from Clarus Therapeutics, Inc."
0900006483d458cb,Supporting & Related Material,FDA-2019-P-2289-0108,FDA-2019-P-2289,Updated Background Material re Citizen Petition from Contraceptive Study Group
0900006483ca5470,Supporting & Related Material,FDA-2019-P-2289-0014,FDA-2019-P-2289,References for Impact of Contraceptives on Body Mass re Citizen Petition from Contraceptive Study Group
0900006483ca4cd0,Supporting & Related Material,FDA-2019-P-2289-0017,FDA-2019-P-2289,References for Atherosclerosis and Cardiovascular Events re Citizen Petition from Contraceptive Study Group
0900006484112611,Other,FDA-2019-P-2289-0164,FDA-2019-P-2289,Letter from FDA CDER to Contraceptive Study Group
0900006483c59d3b,Other,FDA-2019-P-2289-0002,FDA-2019-P-2289,Acknowledgment Letter from FDA DDM to Contraceptive Study Group
0900006483ca3cb4,Supporting & Related Material,FDA-2019-P-2289-0011,FDA-2019-P-2289,References for Multiple Sclerosis References re Citizen Petition from Contraceptive Study Group
0900006483ca46e5,Supporting & Related Material,FDA-2019-P-2289-0012,FDA-2019-P-2289,References for Interstitial Cystitis References re Citizen Petition from Contraceptive Study Group
0900006484ad694e,Other,FDA-2019-P-2289-0181,FDA-2019-P-2289,Supplement from Contraceptive Study Group
0900006483ca2aa9,Supporting & Related Material,FDA-2019-P-2289-0010,FDA-2019-P-2289,References for Depression Mood Disorders and Suicide re Citizen Petition from Contraceptive Study Group
0900006483cb9ba4,Supporting & Related Material,FDA-2019-P-2289-0019,FDA-2019-P-2289,References for Economic Costs re Citizen Petition from Contraceptive Study Group
0900006483ca4a19,Supporting & Related Material,FDA-2019-P-2289-0013,FDA-2019-P-2289,References for Osteoporotic Fracture re Citizen Petition from Contraceptive Study Group
0900006483d458ea,Supporting & Related Material,FDA-2019-P-2289-0109,FDA-2019-P-2289,Updated Background Material re  re Citizen Petition from Contraceptive Study Group
0900006483c94e5d,Supporting & Related Material,FDA-2019-P-2289-0006,FDA-2019-P-2289,References for Cervical Cancer re Citizen Petition from Contraceptive Study Group
0900006483c943af,Supporting & Related Material,FDA-2019-P-2289-0007,FDA-2019-P-2289,References for Crohn's Disease re Citizen Petition from Contraceptive Study Group
0900006483c92160,Supporting & Related Material,FDA-2019-P-2289-0005,FDA-2019-P-2289,References for Breast Cancer (M-Z) re Citizen Petition from Contraceptive Study Group
0900006483ca4c08,Supporting & Related Material,FDA-2019-P-2289-0015,FDA-2019-P-2289,References for Urogenital Effects re Citizen Petition from Contraceptive Study Group
0900006483cb7cf1,Supporting & Related Material,FDA-2019-P-2289-0018,FDA-2019-P-2289,References for Environmental Impact re Citizen Petition from Contraceptive Study Group
0900006483ca29d7,Supporting & Related Material,FDA-2019-P-2289-0008,FDA-2019-P-2289,References for Ulcerative Colitis re Citizen Petition from Contraceptive Study Group
0900006483c91609,Supporting & Related Material,FDA-2019-P-2289-0003,FDA-2019-P-2289,References for Risk of HIV Transmission re Citizen Petition from Contraceptive Study Group
0900006483c91e4d,Supporting & Related Material,FDA-2019-P-2289-0004,FDA-2019-P-2289,References for Breast Cancer (A-L) re Citizen Petition from Contraceptive Study Group
0900006483ca2a33,Supporting & Related Material,FDA-2019-P-2289-0009,FDA-2019-P-2289,References for Systemic Lupus Erythematosus re Citizen Petition from Contraceptive Study Group
0900006483ca4c53,Supporting & Related Material,FDA-2019-P-2289-0016,FDA-2019-P-2289,References for Venous Thromboembolism re Citizen Petition from Contraceptive Study Group
0900006483c596f0,Other,FDA-2019-P-2289-0001,FDA-2019-P-2289,Citizen Petition from Contraceptive Study Group
0900006481debe18,Other,FDA-2016-P-0031-0001,FDA-2016-P-0031,Citizen Petition from Indoco Remedies Limited
0900006482071491,Other,FDA-2016-P-0031-0004,FDA-2016-P-0031,Interim Response
0900006481debe19,Other,FDA-2016-P-0031-0002,FDA-2016-P-0031,Acknowledgement Letter from FDA DDM to Indoco Remedies Limited
0900006481decb18,Supporting & Related Material,FDA-2016-P-0031-0003,FDA-2016-P-0031,Attachment 1 Orange Book Approved Drug Products with Therapeutic Equivalence Evaluations (Furosemide) re: Citizen Petition from Indoco Remedies Limited
0900006483a653a5,Other,FDA-2016-P-0031-0005,FDA-2016-P-0031,Withdrawal from Indoco Remedies Limited
0900006481f8f70a,Other,FDA-2015-P-3942-0004,FDA-2015-P-3942,Petition Approval Letter
0900006481cef433,Other,FDA-2015-P-3942-0001,FDA-2015-P-3942,Citizen Petition from REGCON Solutions
0900006481cef4f7,Supporting & Related Material,FDA-2015-P-3942-0002,FDA-2015-P-3942,FDA's Orange Book Approved Drug Products with Therapeutic Equivalence Evaluation for Chlorzoxazone re: Citizen Petition from REGCON Solutions
0900006481cef4f5,Other,FDA-2015-P-3942-0003,FDA-2015-P-3942,Acknowledgement Letter from FDA DDM to REGCON Solutions
0900006484763918,Notice,FDA-2019-D-3769-0009,FDA-2019-D-3769,"Providing Regulatory Submissions for Medical Devices in Electronic Format—Submissions Under Section 745A(b) of the Federal Food, Drug, and Cosmetic Act; Guidance for Industry and Food and Drug Administration Staff; Availability"
0900006483fcb532,Other,FDA-2019-D-3769-0002,FDA-2019-D-3769,"Providing Regulatory Submissions for Medical Devices in Electronic Format-Submissions Under Section 745A(b) of the Federal Food, Drug, and Cosmetic Act; Draft Guidance for Industry and Food and Drug Administration Staff; Draft Guidance"
0900006483fcae92,Notice,FDA-2019-D-3769-0001,FDA-2019-D-3769,"Providing Regulatory Submissions for Medical Devices in Electronic Format—Submissions Under Section 745A(b) of the Federal Food, Drug, and Cosmetic Act; Draft Guidance for Industry and Food and Drug Administration Staff; Availability"
09000064847664ca,Other,FDA-2019-D-3769-0010,FDA-2019-D-3769,"Providing Regulatory Submissions for Medical Devices in Electronic Format — Submissions Under Section 745A(b) of the Federal Food, Drug, and Cosmetic Act Guidance for Industry and Food and Drug Administration Staff"
09000064814413c1,Other,FDA-2013-P-0163-0003,FDA-2013-P-0163,"FDA/CDER Response to Teva Women's Health, Inc. (Teva) - Letter"
09000064811f5732,Other,FDA-2013-P-0163-0002,FDA-2013-P-0163,"Acknowledgement Letter to Teva Women's Health, Inc. (Teva)"
09000064839f145c,Other,FDA-2013-P-0163-0004,FDA-2013-P-0163,"Withdrawal from Teva Pharmaceutical Industries Ltd., Teva Women's Health, Inc."
09000064811f56f3,Other,FDA-2013-P-0163-0001,FDA-2013-P-0163,Teva Pharmaceutical Industries Ltd. (Teva) - Citizen Petition
0900006482cbbc77,Notice,FDA-2017-D-5570-0001,FDA-2017-D-5570,Select Updates for Recommendations for Clinical Laboratory  Improvement Amendments of 1988 Waiver Applications for  Manufacturers of In Vitro Diagnostic Devices; Draft Guidance for Industry and Food and Drug Administration Staff; Availability
09000064843b60b4,Other,FDA-2017-D-5570-0020,FDA-2017-D-5570,Recommendations for Clinical Laboratory Improvement Amendments of 1988 (CLIA) Waiver Applications for Manufacturers of In Vitro Diagnostic Devices Guidance for Industry and Food and Drug Administration Staff
0900006482d9d48d,Other,FDA-2017-D-5570-0005,FDA-2017-D-5570,"Request for Extension from Coalition for CLIA Waiver Reform (Epstein Becker & Green, P.C.)"
0900006482e6be59,Notice,FDA-2017-D-5570-0006,FDA-2017-D-5570,Select Updates for Recommendations for Clinical Laboratory Improvement Amendments of 1988 Waiver Applications for  Manufacturers of In Vitro Diagnostic Devices; Draft Guidance for Industry and Food and Drug Administration Staff; Availability; Extension of Comment Period
0900006482cbce4e,Other,FDA-2017-D-5570-0002,FDA-2017-D-5570,Select Updates for Recommendations for Clinical Laboratory  Improvement Amendments of 1988 (CLIA) Waiver Applications for Manufacturers of In Vitro Diagnostic Devices Draft Guidance for Industry and Food and Drug Administration Staff
090000648390cc70,Other,FDA-2017-D-5570-0013,FDA-2017-D-5570,Draft Guidance for Industry and FDA_Select Updates for CLIA of 1988 Waiver Applications for Manufacturers of IVD Devices_11-29-2018
090000648390c0fa,Notice,FDA-2017-D-5570-0012,FDA-2017-D-5570,Select Updates for Recommendations for Clinical Laboratory Improvement Amendments of 1988 Waiver Applications for Manufacturers of In Vitro Diagnostic Devices; Draft Guidance for Industry and Food and Drug Administration Staff; Availability
09000064843b4ec1,Notice,FDA-2017-D-5570-0019,FDA-2017-D-5570,Recommendations for Clinical Laboratory Improvement Amendments of 1988 Waiver Applications for Manufacturers of In Vitro Diagnostic Devices; Guidance for Industry and Food and Drug Administration Staff; Availability
0900006484a64752,Other,FDA-2021-P-0277-0001,FDA-2021-P-0277,Suitability Petition from Lachman Consulting Services Inc
0900006484a64754,Other,FDA-2021-P-0277-0002,FDA-2021-P-0277,Acknowledgment Letter from FDA DMS to Lachman Consulting Services Inc
09000064820ae5c8,Other,FDA-2016-D-1233-0002,FDA-2016-D-1233,"Use of Public Human Genetic Variant Databases to Support Clinical  Validity for Next Generation Sequencing (NGS)-Based In Vitro Diagnostics  
Draft Guidance for Stakeholders and Food and Drug Administration Staff"
090000648313aebc,Other,FDA-2016-D-1233-0040,FDA-2016-D-1233,Use of Public Human Genetic Variant 1 Databases to Support Clinical Validity 2 for Next Generation Sequencing 3 (NGS)-Based In Vitro Diagnostics
0900006482095b9c,Notice,FDA-2016-D-1233-0001,FDA-2016-D-1233,Use of Public Human Genetic Variant Databases To Support Clinical Validity for Next Generation Sequencing-Based In Vitro Diagnostics; Draft Guidance for Stakeholders and Food and Drug Administration Staff; Availability
090000648314e9bb,Other,FDA-2016-D-1233-0041,FDA-2016-D-1233,Use of Public Human Genetic Variant Databases to Support Clinical Validity for Genetic and Genomic-Based In Vitro Diagnostics Guidance for Stakeholders and Food and Drug Administration Staff
090000648313a776,Notice,FDA-2016-D-1233-0039,FDA-2016-D-1233,Use of Public Human Genetic Variant Databases To Support Clinical Validity for Genetic and Genomic-Based In Vitro Diagnostics; Guidance for Stakeholders and Food and Drug Administration Staff; Availability
09000064842df06b,Other,FDA-2020-P-0368-0002,FDA-2020-P-0368,"Acknowledgment Letter from FDA DMS to Crowell & Moring, LLP"
09000064842de8c1,Other,FDA-2020-P-0368-0001,FDA-2020-P-0368,"Citizen Petition from Crowell & Moring, LLP"
09000064845ee523,Other,FDA-2020-P-0368-0004,FDA-2020-P-0368,Final Response Letter from FDA CDER to Crowell Moring LLP
09000064842df06a,Supporting & Related Material,FDA-2020-P-0368-0003,FDA-2020-P-0368,"Attachment 1 Interstate Distribution Under Section 503A of the Federal Food, Drug, and Cosmetic Act—The Five Percent Limit Draft Guidance for Industry re Citizen Petition from Crowell & Moring, LLP"
0900006482908ccc,Notice,FDA-2017-N-2166-0001,FDA-2017-N-2166,"Draft Standardization of Pharmaceutical Quality/Chemistry
Manufacturing and Control Data Elements and Terminologies; Request
for Comments"
090000648290d955,Supporting & Related Material,FDA-2017-N-2166-0002,FDA-2017-N-2166,Pharmaceutical Quality/Chemistry Manufacturing and Controls (PQ/CMC) Data Elements and Terminologies
090000648430fe9f,Other,FDA-2020-P-0513-0002,FDA-2020-P-0513,Acknowledgment Letter from FDA DMS to Foley and Lardner LLP
090000648430faa1,Other,FDA-2020-P-0513-0001,FDA-2020-P-0513,"Citizen Petition from Foley and Lardner LLP on behalf of Romark Laboratories, L.C."
09000064843274f5,Other,FDA-2020-P-0513-0003,FDA-2020-P-0513,Withdrawal from Foley & Lardner LLP
090000648425e54b,Supporting & Related Material,FDA-2019-P-6100-0008,FDA-2019-P-6100,Attachment G- Sterile Decellularized Dermis - Instructions for Use re: Citizen Petition from American Association of Tissue Banks
090000648425e4dd,Supporting & Related Material,FDA-2019-P-6100-0004,FDA-2019-P-6100,Attachment C- The Classic Reprint: The Use and Uses of Large Split Skin Grafts of Intermediate Thickness re: Citizen Petition from American Association of Tissue Banks
090000648425e4de,Supporting & Related Material,FDA-2019-P-6100-0005,FDA-2019-P-6100,"Attachment D- 50 Years of Burn Care at Shriners Hospitals for Children, Galveston re: Citizen Petition from American Association of Tissue Banks"
090000648425e54c,Supporting & Related Material,FDA-2019-P-6100-0009,FDA-2019-P-6100,"Attachment H- Pelvic, Abdominal, and Chest Wall Reconstruction with Allo Derm in Patients at Increased Risk for Mesh-Related Complications re: Citizen Petition from American Association of Tissue Banks"
090000648425e4db,Supporting & Related Material,FDA-2019-P-6100-0002,FDA-2019-P-6100,Attachment A- The Classic Reprint re: Citizen Petition from American Association of Tissue Banks
090000648425e552,Supporting & Related Material,FDA-2019-P-6100-0015,FDA-2019-P-6100,"Attachment R- The use of a cellular dermal matrix in breast reconstruction
evolution of techniques over 2 decades re: Citizen Petition from American Association of Tissue Banks"
090000648425e4dc,Supporting & Related Material,FDA-2019-P-6100-0003,FDA-2019-P-6100,Attachment B- Early Care of Burns re: Citizen Petition from American Association of Tissue Banks
090000648425e4f4,Supporting & Related Material,FDA-2019-P-6100-0018,FDA-2019-P-6100,Attachment U Part 1- The use of acellular dermal matrix in breast reconstruction: evolution of techniques over 2 decades re: Citizen Petition from American Association of Tissue Banks
090000648425e54e,Supporting & Related Material,FDA-2019-P-6100-0011,FDA-2019-P-6100,Attachments J Through N re: Citizen Petition from American Association of Tissue Banks
090000648425e4e0,Supporting & Related Material,FDA-2019-P-6100-0007,FDA-2019-P-6100,"Attachment F- Decellularization Strategies for Regenerative Medicine:
From Processing Techniques to Applications re: Citizen Petition from American Association of Tissue Banks"
090000648425e54d,Supporting & Related Material,FDA-2019-P-6100-0010,FDA-2019-P-6100,Attachment I- Efficacy and safety of acellular dermal matrix in diabetic foot ulcer treatment: A systematic review and meta-analysis re: Citizen Petition from American Association of Tissue Banks
090000648425e54f,Supporting & Related Material,FDA-2019-P-6100-0012,FDA-2019-P-6100,Attachment O- Achilles Tendon Augmented Repair Using Human Acellular Dermal Matrix: A Case Series re: Citizen Petition from American Association of Tissue Banks
090000648425e553,Supporting & Related Material,FDA-2019-P-6100-0016,FDA-2019-P-6100,Attachment S- Market Recap: Q418/FY18 Market Recap: US Surgical Matrices re: Citizen Petition from American Association of Tissue Banks
09000064846dbb88,Other,FDA-2019-P-6100-0034,FDA-2019-P-6100,Response Letter from CBER to American Association of Tissue Banks
09000064846dbb87,Other,FDA-2019-P-6100-0033,FDA-2019-P-6100,Letter from American Association of Tissue Banks to CBER
090000648425e332,Other,FDA-2019-P-6100-0001,FDA-2019-P-6100,Citizen Petition from American Association of Tissue Banks
090000648425e4df,Supporting & Related Material,FDA-2019-P-6100-0006,FDA-2019-P-6100,Attachment E- The US Navy Tissue Bank: 50 years on the cutting edge RE: Citizen Petition from American Association of Tissue Banks
090000648425e4f6,Supporting & Related Material,FDA-2019-P-6100-0020,FDA-2019-P-6100,Attachment V Shuren Letter re: Citizen Petition from American Association of Tissue Banks
090000648425e4f5,Supporting & Related Material,FDA-2019-P-6100-0019,FDA-2019-P-6100,"Attachment U Part 2- Prepectoral Breast Reconstruction with Fenestrated
Acellular Dermal Matrix: A Novel Design re: Citizen Petition from American Association of Tissue Banks"
0900006484568fde,Other,FDA-2019-P-6100-0031,FDA-2019-P-6100,Interim Response Letter from FDA CBER to American Association of Tissue Banks (AATB)
090000648425dfef,Other,FDA-2019-P-6100-0021,FDA-2019-P-6100,Acknowledgment Letter from FDA DMS to American Association of Tissue Banks
090000648425e550,Supporting & Related Material,FDA-2019-P-6100-0013,FDA-2019-P-6100,Attachment P- A Randomized controlled trial comparing a human acellular dermal matrix versus conventional care for the treatment of venous leg ulcers  re: Citizen Petition from American Association of Tissue Banks
090000648425e551,Supporting & Related Material,FDA-2019-P-6100-0014,FDA-2019-P-6100,Attachment Q- Clinical Evaluation of Acellular Allograft Dermis for the Treatment of Human Gingival Recession re: Citizen Petition from American Association of Tissue Banks
090000648425e554,Supporting & Related Material,FDA-2019-P-6100-0017,FDA-2019-P-6100,Attachment T AATB Letter re: Citizen Petition from American Association of Tissue Banks
090000648044429b,Other,FDA-2005-P-0253-0001,FDA-2005-P-0253,"HFA-305 to Antibody Systems, Inc."
09000064804442d9,Other,FDA-2005-P-0253-0005,FDA-2005-P-0253,"J. Shuren, Assistant Commissioner for Policy"
09000064804442e7,Other,FDA-2005-P-0253-0019,FDA-2005-P-0253,"J. Shuren, Assistant Commissioner for Policy"
09000064804442da,Other,FDA-2005-P-0253-0006,FDA-2005-P-0253,"J. Shuren, Assistant Commissioner for Policy"
09000064804442e5,Other,FDA-2005-P-0253-0017,FDA-2005-P-0253,"J. Shuren, Assistant Commissioner for Policy"
09000064804442e2,Other,FDA-2005-P-0253-0014,FDA-2005-P-0253,"J. Shuren, Assistant Commissioner for Policy"
09000064804442e1,Other,FDA-2005-P-0253-0013,FDA-2005-P-0253,"J. Shuren, Assistant Commissioner for Policy"
09000064804442de,Other,FDA-2005-P-0253-0010,FDA-2005-P-0253,"J. Shuren, Assistant Commissioner for Policy"
09000064804442dc,Other,FDA-2005-P-0253-0008,FDA-2005-P-0253,"J. Shuren, Assistant Commissioner for Policy"
09000064804442d5,Other,FDA-2005-P-0253-0004,FDA-2005-P-0253,"HFM-1 to Simpson Woolley McConacnie, LLP"
09000064804442d0,Other,FDA-2005-P-0253-0002,FDA-2005-P-0253,"HFA-305 to Antibody Systems, Inc."
09000064804442e4,Other,FDA-2005-P-0253-0016,FDA-2005-P-0253,"J. Shuren, Assistant Commissioner for Policy"
09000064804442e0,Other,FDA-2005-P-0253-0012,FDA-2005-P-0253,"J. Shuren, Assistant Commissioner for Policy"
09000064804442dd,Other,FDA-2005-P-0253-0009,FDA-2005-P-0253,"J. Shuren, Assistant Commissioner for Policy"
09000064804442e9,Other,FDA-2005-P-0253-0021,FDA-2005-P-0253,"J. Shuren, Assistant Commissioner for Policy"
09000064804442e3,Other,FDA-2005-P-0253-0015,FDA-2005-P-0253,"J. Shuren, Assistant Commissioner for Policy"
09000064804442db,Other,FDA-2005-P-0253-0007,FDA-2005-P-0253,"J. Shuren, Assistant Commissioner for Policy"
09000064804442d1,Other,FDA-2005-P-0253-0003,FDA-2005-P-0253,HFM-1 to Simpson Woolley McConachie L.L.P.
09000064804442ea,Other,FDA-2005-P-0253-0022,FDA-2005-P-0253,"J. Shuren, Assistant Commissioner for Policy"
09000064804442e6,Other,FDA-2005-P-0253-0018,FDA-2005-P-0253,"J. Shuren, Assistant Commissioner for Policy"
09000064804442e8,Other,FDA-2005-P-0253-0020,FDA-2005-P-0253,"J. Shuren, Assistant Commissioner for Policy"
09000064804442df,Other,FDA-2005-P-0253-0011,FDA-2005-P-0253,"J. Shuren, Assistant Commissioner for Policy"
090000648103ca35,Other,FDA-2012-P-0589-0002,FDA-2012-P-0589,"Onco Therapies Limited (Strides, Inc.) - Citizen Petition"
090000648116cd94,Other,FDA-2012-P-0589-0003,FDA-2012-P-0589,OncoTherapies Limited - Withdrawal
090000648103cb1c,Other,FDA-2012-P-0589-0001,FDA-2012-P-0589,Acknowledgement Letter to Onco Therapies Limited
0900006481172df1,Other,FDA-2011-P-0580-0005,FDA-2011-P-0580,FDA/CDER Response to Charles Watson - Partial Petition Approval and Denial
0900006480fa9aba,Other,FDA-2011-P-0580-0004,FDA-2011-P-0580,Interim Response to Charles Watson - Letter
0900006480f146e0,Other,FDA-2011-P-0580-0003,FDA-2011-P-0580,Charles Watson - Supplement
0900006480ed6a9a,Other,FDA-2011-P-0580-0001,FDA-2011-P-0580,Charles Watson - Citizen Petition
0900006480ed6abf,Other,FDA-2011-P-0580-0002,FDA-2011-P-0580,Acknowledgement Letter to Charles Watson
09000064820b6b8b,Supporting & Related Material,FDA-2016-P-2091-0004,FDA-2016-P-2091,"Attachment II Prescription and Over-the-Counter Drug Product List
36TH EDITION Cumulative Supplement Number 02: February 2016
ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST re Citizen Petition from ANDA Consultants Furosemide Inj (Luitpold)"
09000064820b69d4,Other,FDA-2016-P-2091-0001,FDA-2016-P-2091,Citizen Petition from ANDA Consultants
09000064820b69d6,Other,FDA-2016-P-2091-0002,FDA-2016-P-2091,Acknowledgement Letter from FDA DDM to ANDA Consultants
09000064820b6b8a,Supporting & Related Material,FDA-2016-P-2091-0003,FDA-2016-P-2091,Attachment I Orange Book Discontinued Drug Products Listing re Citizen Petition from ANDA Consultants Furosemide Inj (Luitpold)
09000064821c4d75,Other,FDA-2016-P-2091-0005,FDA-2016-P-2091,Response letter from FDA CDER to ANDA Consultants
0900006481cf9674,Supporting & Related Material,FDA-2015-P-3980-0004,FDA-2015-P-3980,"Approval Letter NDA 022249 (Mar 20, 2008) re Citizen Petition from Teva Pharmaceutical Industries, Ltd."
0900006481cf9b2f,Supporting & Related Material,FDA-2015-P-3980-0005,FDA-2015-P-3980,"Approval Letter NDA 022303 (Oct 31, 2008) re Citizen Petition from Teva Pharmaceutical Industries, Ltd."
0900006481cf9b33,Supporting & Related Material,FDA-2015-P-3980-0009,FDA-2015-P-3980,"Approval Letter NDA 50708 (Mar 29, 2006) re Citizen Petition from Teva Pharmaceutical Industries, Ltd."
0900006481cf9b35,Supporting & Related Material,FDA-2015-P-3980-0011,FDA-2015-P-3980,"Package Insert NDA 50708 (Apr 27, 2006) re Citizen Petition from Teva Pharmaceutical Industries, Ltd."
0900006481cf9b3c,Supporting & Related Material,FDA-2015-P-3980-0016,FDA-2015-P-3980,"H R Report No 97-840 Part 1 (Sept 17, 1982) re Citizen Petition from Teva Pharmaceutical Industries, Ltd."
0900006481cf9672,Supporting & Related Material,FDA-2015-P-3980-0003,FDA-2015-P-3980,"Clinical Review NDA 022249 (Feb 26 2008) (excerpts) re Citizen Petition from Teva Pharmaceutical Industries, Ltd."
0900006481cf9b30,Supporting & Related Material,FDA-2015-P-3980-0006,FDA-2015-P-3980,"Package Insert NDA 022249 (Sept 2, 2015) re Citizen Petition from Teva Pharmaceutical Industries, Ltd."
0900006481cf9b3d,Supporting & Related Material,FDA-2015-P-3980-0017,FDA-2015-P-3980,"BLA 103705 Prescribing Information (Rituxan PI) (Aug 12, 2014) re Citizen Petition from Teva Pharmaceutical Industries, Ltd."
0900006481cf937b,Other,FDA-2015-P-3980-0001,FDA-2015-P-3980,"Citizen Petition from Teva Pharmaceutical Industries, Ltd."
0900006481cf9b36,Supporting & Related Material,FDA-2015-P-3980-0012,FDA-2015-P-3980,"Package Insert ANDA 065461 (Aug 10, 2009) re Citizen Petition from Teva Pharmaceutical Industries, Ltd."
0900006481cfa652,Supporting & Related Material,FDA-2015-P-3980-0018,FDA-2015-P-3980,(Copyrighted material) -- NCCN Clinical Practice Guidelines in Oncology Non-Hodgkins Lymphoma Version 2 2015 (March 3 2015) re Citizen Petition from Teva Pharmaceuticals
0900006481cf94ca,Other,FDA-2015-P-3980-0002,FDA-2015-P-3980,"Acknowledgement Letter from FDA DDM to Teva Pharmaceutical Industries, Ltd."
0900006481cf9b31,Supporting & Related Material,FDA-2015-P-3980-0007,FDA-2015-P-3980,"Package Insert NDA 22303 (Oct 31, 2008) re Citizen Petition from Teva Pharmaceutical Industries, Ltd."
0900006481cf9b32,Supporting & Related Material,FDA-2015-P-3980-0008,FDA-2015-P-3980,"Clinical Review NDA 022303 (July 30, 2008) re Citizen Petition from Teva Pharmaceutical Industries, Ltd."
0900006481cf9b34,Supporting & Related Material,FDA-2015-P-3980-0010,FDA-2015-P-3980,"ANDA 065461 Approval Summary #1 Labeling Review Branch (Mar 5, 2009) re Citizen Petition from Teva Pharmaceutical Industries, Ltd."
0900006481cf9b38,Supporting & Related Material,FDA-2015-P-3980-0014,FDA-2015-P-3980,"Package Insert ANDA 200882 (Jan 2014) re Citizen Petition from Teva Pharmaceutical Industries, Ltd."
0900006481ede141,Other,FDA-2015-P-3980-0021,FDA-2015-P-3980,Citizen Petition Denial Response from FDA CDER to Teva Pharmaceuticals
0900006481cf9b37,Supporting & Related Material,FDA-2015-P-3980-0013,FDA-2015-P-3980,"Package Insert NDA 021689 (Dec 19, 2014) re Citizen Petition from Teva Pharmaceutical Industries, Ltd."
0900006481cf9b3b,Supporting & Related Material,FDA-2015-P-3980-0015,FDA-2015-P-3980,"Pub L No 97-414 96 Stat 2049 (1983) re Citizen Petition from Teva Pharmaceutical Industries, Ltd."
0900006484a34a5f,Other,FDA-2020-P-1797-9319,FDA-2020-P-1797,Final Response from FDA  CTP to Keller and Heckman LLP on behalf of Cream Vapor LLC et al.
090000648481ea74,Other,FDA-2020-P-1797-0001,FDA-2020-P-1797,Petition for Extension of Premarket Tobacco Product Application Filing Deadline from Keller and Heckman LLP on behalf of Cream Vapor LLC et al.
090000648481ee32,Other,FDA-2020-P-1797-0002,FDA-2020-P-1797,Acknowledgement Letter from FDA DMS to Keller and Heckman LLP
0900006481cb2a31,Supporting & Related Material,FDA-2015-P-3540-0003,FDA-2015-P-3540,"Attachment 1 Excerpt from Electronic Orange Book Metolazonc Tablets,10 mg re Citizen Petition from  Lachman Consultant Services"
0900006481cb10a7,Other,FDA-2015-P-3540-0001,FDA-2015-P-3540,Citizen Petition from Lachman Consultant Services
0900006481cb2a2f,Other,FDA-2015-P-3540-0002,FDA-2015-P-3540,"Acknowledgment letter from FDA DDM to Lachman Consultant Services, Inc"
0900006481f99d35,Other,FDA-2015-P-3540-0005,FDA-2015-P-3540,Petition Withdrawal Notice From Lachman Consultants Inc.
0900006481cb2b68,Supporting & Related Material,FDA-2015-P-3540-0004,FDA-2015-P-3540,Attachment 2 Label Information Zaroxolyn - metolazone tablet re Citizen Petition from  Lachman Consultant Services
0900006480e50abc,Other,FDA-2011-P-0473-0001,FDA-2011-P-0473,"Acknowledgement Letter to Varam, Inc."
0900006480f81c54,Other,FDA-2011-P-0473-0004,FDA-2011-P-0473,"Interim Response to Varam, Inc. c/o: KVK-Tech, Inc. - Letter"
09000064812984b4,Other,FDA-2011-P-0473-0010,FDA-2011-P-0473,"FDA/CDER to Varam, Inc. c/o: KVK-Tech, Inc. -  Agency Response"
0900006480e50991,Other,FDA-2011-P-0473-0002,FDA-2011-P-0473,"Varam, Inc. - Citizen Petition"
0900006481299dce,Notice,FDA-2011-P-0473-0011,FDA-2011-P-0473,Determination That the OXYCONTIN (oxycodone hydrochloride) Drug Products Covered by New Drug Application 20-553 Were Withdrawn From Sale for Reasons of Safety or Effectiveness
